<SEC-DOCUMENT>0001564590-21-042639.txt : 20210809
<SEC-HEADER>0001564590-21-042639.hdr.sgml : 20210809
<ACCEPTANCE-DATETIME>20210809161232
ACCESSION NUMBER:		0001564590-21-042639
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210809
DATE AS OF CHANGE:		20210809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		211156620

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>fgen-10q_20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-08-09T19:33:35.9525028+00:00 -->
<!-- Version            : 5.0.1.648 -->
<!-- Package ID         : eb9c0c47f0494648af9d850a5814e112 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:fgen="http://www.fibrogen.com/20210630" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
fgen-10q_20210630.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000921299_20210101_20210630">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000003_2" name="dei:DocumentFiscalYearFocus" contextRef="C_0000921299_20210101_20210630">2021</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0000921299_20210101_20210630">Q2</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0000921299_20210101_20210630">0000921299</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0000921299_20210101_20210630">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000878" name="us-gaap:LesseeFinanceLeaseExistenceOfOptionToExtend" contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0000921299_20210101_20210630">2021</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0000921299_20210630" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0000921299_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000153" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" contextRef="C_0000921299_20210401_20210630">us-gaap:ProductMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000154" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" contextRef="C_0000921299_20200401_20200630">us-gaap:ProductMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000155" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" contextRef="C_0000921299_20210101_20210630">us-gaap:ProductMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000156" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" contextRef="C_0000921299_20200101_20200630">us-gaap:ProductMember</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000702" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNetTransferPriceMember_20200101_20200630" decimals="-3">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000706" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenIncreaseInDeferredRevenueMember_20200101_20200630" decimals="-3">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000802" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20210630" decimals="-3">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000803" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20210630" decimals="-3">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000804" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20210630" decimals="-3">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000805" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20210630" decimals="-3">0</ix:nonFraction>
			<ix:nonNumeric id="F_000938" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0000921299_20210630">P1Y3M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000939" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0000921299_20201231">P2Y10M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000940" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0000921299_20210630">P7Y3M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000941" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0000921299_20201231">P1Y9M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_001102" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210401_20210630">P5Y7M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_001103" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200401_20200630">P5Y6M</ix:nonNumeric>
			<ix:nonNumeric id="F_001104" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630">P5Y8M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_001105" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200630">P5Y8M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_001122" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630">P6M</ix:nonNumeric>
			<ix:nonNumeric id="F_001123" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630">P6M</ix:nonNumeric>
			<ix:nonNumeric id="F_001124" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630">P6M</ix:nonNumeric>
			<ix:nonNumeric id="F_001125" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630">P6M</ix:nonNumeric>
			<ix:nonNumeric id="F_001126" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630">P2Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001127" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630">P2Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001128" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630">P2Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001129" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630">P2Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001130" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630" decimals="INF">0.475</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001131" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630" decimals="INF">0.495</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001132" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630" decimals="INF">0.475</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001133" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630" decimals="INF">0.495</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001134" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630" decimals="INF">1.042</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001135" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630" decimals="INF">0.771</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001136" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630" decimals="INF">1.042</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001137" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630" decimals="INF">0.771</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001138" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630" decimals="INF">0.000</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001139" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630" decimals="INF">0.002</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001140" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630" decimals="INF">0.000</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001141" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630" decimals="INF">0.002</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001142" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630" decimals="INF">0.022</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001143" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630" decimals="INF">0.029</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001144" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630" decimals="INF">0.022</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001145" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630" decimals="INF">0.029</ix:nonFraction>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="fgen-20210630.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000921299_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000921299_20210731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000921299_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_fgenSegment">
				<xbrli:measure>fgen:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenHiFiBiOAgreementMember_20210616_20210616">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:HiFiBiOAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-06-16</xbrli:startDate>
					<xbrli:endDate>2021-06-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenHiFiBiOAgreementMember_20210616">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:HiFiBiOAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20090228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2005-06-01</xbrli:startDate>
					<xbrli:endDate>2009-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2005-06-01</xbrli:startDate>
					<xbrli:endDate>2005-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2005-06-01</xbrli:startDate>
					<xbrli:endDate>2005-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:RegulatoryMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2005-06-01</xbrli:startDate>
					<xbrli:endDate>2005-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20090228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2006-04-01</xbrli:startDate>
					<xbrli:endDate>2009-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2006-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2006-04-01</xbrli:startDate>
					<xbrli:endDate>2006-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:RegulatoryMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2006-04-01</xbrli:startDate>
					<xbrli:endDate>2006-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2006-04-01</xbrli:startDate>
					<xbrli:endDate>2006-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-07-29</xbrli:startDate>
					<xbrli:endDate>2013-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-07-29</xbrli:startDate>
					<xbrli:endDate>2013-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:RegulatoryMilestonesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-07-29</xbrli:startDate>
					<xbrli:endDate>2013-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenDeferredApprovalMilestoneMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:DeferredApprovalMilestoneMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-07-29</xbrli:startDate>
					<xbrli:endDate>2013-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-07-29</xbrli:startDate>
					<xbrli:endDate>2013-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-07-29</xbrli:startDate>
					<xbrli:endDate>2013-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:RegulatoryMilestonesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-07-29</xbrli:startDate>
					<xbrli:endDate>2013-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenCoDevelopmentInformationSharingAndCommitteeServicesMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:CoDevelopmentInformationSharingAndCommitteeServicesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenChinaPerformanceObligationMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:ChinaPerformanceObligationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DiscountsAndRebatesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DiscountsAndRebatesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DiscountsAndRebatesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DiscountsAndRebatesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenProfitShareMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ProfitShareMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenProfitShareMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ProfitShareMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenProfitShareMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ProfitShareMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenProfitShareMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ProfitShareMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNetTransferPriceMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:NetTransferPriceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNetTransferPriceMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:NetTransferPriceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNetTransferPriceMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:NetTransferPriceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNetTransferPriceMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:NetTransferPriceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenIncreaseInDeferredRevenueMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:IncreaseInDeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenIncreaseInDeferredRevenueMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:IncreaseInDeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenIncreaseInDeferredRevenueMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:IncreaseInDeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenIncreaseInDeferredRevenueMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:IncreaseInDeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DiscountsAndRebatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DiscountsAndRebatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DiscountsAndRebatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DiscountsAndRebatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:ContractLiabilitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:ContractLiabilitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:ContractLiabilitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:GrossAccountsReceivableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:GrossAccountsReceivableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:ContractLiabilitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:ContractLiabilitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDeferredForFutureRecognitionMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DeferredForFutureRecognitionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDeferredForFutureRecognitionMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DeferredForFutureRecognitionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fgen:APIShipmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fgen:APIShipmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAstraZenecaABMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FibroGenBeijingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">fgen:AstraZenecaABMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fgen:BeijingKangdaYongfuPharmaceuticalCoLTDMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenUSGovernmentBondsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:USGovernmentBondsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenUSGovernmentBondsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:USGovernmentBondsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenUSGovernmentBondsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:USGovernmentBondsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenUSGovernmentBondsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:USGovernmentBondsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenAgencyBondsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:AgencyBondsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenAgencyBondsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:AgencyBondsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenAgencyBondsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:AgencyBondsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenAgencyBondsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:AgencyBondsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:ShorensteinPropertiesLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:ShorensteinPropertiesLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:ShorensteinPropertiesLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fgen:LeaseAmendmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-06-01</xbrli:startDate>
					<xbrli:endDate>2021-06-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_fgenOption">
				<xbrli:measure>fgen:Option</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:ShorensteinPropertiesLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201901Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fgen:LeaseAmendmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:ShorensteinPropertiesLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201901Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fgen:LeaseAmendmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:BeijingEconomicTechnologicalDevelopmentAreaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:BeijingEconomicTechnologicalDevelopmentAreaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201901Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201901Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapGeographicDistributionAxis_us-gaapGeographicDistributionForeignMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapGeographicDistributionAxis_us-gaapGeographicDistributionForeignMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapBondsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BondsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fgen:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fgen:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FalikangMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FalikangMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FalikangMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FalikangMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FalikangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfRoxadustatMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fgen:ManufactureAndSupplyOfRoxadustatMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfPamrevlumabMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fgen:ManufactureAndSupplyOfPamrevlumabMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenOtherPurchasesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fgen:OtherPurchasesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenResearchAndPreClinicalStageDevelopmentProgramsMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fgen:ResearchAndPreClinicalStageDevelopmentProgramsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_fgenPutativeClassAction">
				<xbrli:measure>fgen:PutativeClassAction</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000921299_20210401_20210430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20210501_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-05-01</xbrli:startDate>
					<xbrli:endDate>2021-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenLicenseAgreementWithEluminexMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210719">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:LicenseAgreementWithEluminexMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-19</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenLicenseAgreementWithEluminexMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210719_20210719">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:LicenseAgreementWithEluminexMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-19</xbrli:startDate>
					<xbrli:endDate>2021-07-19</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="line-height:4pt;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="line-height:4pt;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">F<span style="text-transform:none;">orm <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000921299_20210101_20210630">10-Q</ix:nonNumeric></span></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000026" name="dei:DocumentQuarterlyReport" contextRef="C_0000921299_20210101_20210630" format="ixt-sec:boolballotbox">&#9745;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000921299_20210101_20210630" format="ixt:datemonthdayyearen">June&#160;30, 2021</ix:nonNumeric></p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-size:12pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:12pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000027" name="dei:DocumentTransitionReport" contextRef="C_0000921299_20210101_20210630" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> to <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission file number: <ix:nonNumeric id="F_000017" name="dei:EntityFileNumber" contextRef="C_0000921299_20210101_20210630">001-36740</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0000921299_20210101_20210630">FIBROGEN, INC.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:49%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000921299_20210101_20210630" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:2%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:49%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000921299_20210101_20210630">77-0357827</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:49%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporation or Organization)</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:2%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:49%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:EntityAddressAddressLine1" contextRef="C_0000921299_20210101_20210630">409 Illinois Street</ix:nonNumeric></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:EntityAddressCityOrTown" contextRef="C_0000921299_20210101_20210630">San Francisco</ix:nonNumeric>, <ix:nonNumeric id="F_000022" name="dei:EntityAddressStateOrProvince" contextRef="C_0000921299_20210101_20210630">CA</ix:nonNumeric></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:EntityAddressPostalZipCode" contextRef="C_0000921299_20210101_20210630">94158</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000024" name="dei:CityAreaCode" contextRef="C_0000921299_20210101_20210630">415</ix:nonNumeric>) <ix:nonNumeric id="F_000025" name="dei:LocalPhoneNumber" contextRef="C_0000921299_20210101_20210630">978-1200</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code:</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:4pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:5.17%;width:90.83%;">
<tr>
<td style="width:28.83%;"></td>
<td style="width:34%;"></td>
<td style="width:28%;"></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:Security12bTitle" contextRef="C_0000921299_20210101_20210630">Common Stock, $0.01 par value</ix:nonNumeric></p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0000921299_20210101_20210630">FGEN</ix:nonNumeric></p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:SecurityExchangeName" contextRef="C_0000921299_20210101_20210630" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000012" name="dei:EntityCurrentReportingStatus" contextRef="C_0000921299_20210101_20210630">Yes</ix:nonNumeric>&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9745;</span>&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000013" name="dei:EntityInteractiveDataCurrent" contextRef="C_0000921299_20210101_20210630">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9745;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:86.6%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:24.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityFilerCategory" contextRef="C_0000921299_20210101_20210630" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric> </p></td>
<td valign="bottom" style="width:46.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9745;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:25.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated filer </p></td>
<td valign="bottom" style="width:3.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:24.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="bottom" style="width:46.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:25.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller reporting company</p></td>
<td valign="bottom" style="width:3.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntitySmallBusiness" contextRef="C_0000921299_20210101_20210630" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:24.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:46.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:25.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="bottom" style="width:3.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000921299_20210101_20210630" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160; <span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;&#160;&#160;&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2).&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000014" name="dei:EntityShellCompany" contextRef="C_0000921299_20210101_20210630" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9745;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of common stock outstanding as of July 31, 2021 was <ix:nonFraction unitRef="U_xbrlishares" id="F_000028" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0000921299_20210731" decimals="INF" format="ixt:numdotdecimal">92,621,941</ix:nonFraction>.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="TOC">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:95%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:95%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IFINANCIAL_INFORMATION"><span style="text-decoration:underline;">PART I&#8212;FINANCIAL INFORMATION</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_CONDENSED_CONSOLIDATED_FINANCIAL"><span style="text-decoration:underline;">Condensed Consolidated Financial Statements (Unaudited)</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:underline;">Condensed Consolidated Balance Sheets as of June 30, 2021 and December 31, 2020 (Unaudited)</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_OPERAT"><span style="text-decoration:underline;">Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2021 and 2020 (Unaudited)</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_COMPRE"><span style="text-decoration:underline;">Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2021 and 2020 (Unaudited)</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_EQUITY"><span style="text-decoration:underline;">Condensed Consolidated Statements of Changes in Equity for the Three and Six Months Ended June 30, 2021 and 2020 (Unaudited)</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F"><span style="text-decoration:underline;">Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2021 and 2020 (Unaudited)</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA"><span style="text-decoration:underline;">Notes to the Condensed Consolidated Financial Statements (Unaudited)</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:95%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IIOR_INFORMATION"><span style="text-decoration:underline;">PART II&#8212;OTHER INFORMATION</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1A.</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"><span style="text-decoration:underline;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES"><span style="text-decoration:underline;">Defaults Upon Senior Securities</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 5.</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_EXHIBITS"><span style="text-decoration:underline;">Exhibits</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">Signatures</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SUMMARY RISK FACTORS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of the Company will depend on a number of factors, many of which are beyond our control and involve risks, including but not limited to the following:</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Development and Commercialization of Our Product Candidates</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We are substantially dependent on the success of our lead product, roxadustat, and our second compound in development, pamrevlumab.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">As a company, we have limited commercialization experience, and the time and resources to develop such experience are significant. If we fail to achieve and sustain commercial success for roxadustat with our collaboration partners, our business would be harmed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Although regulatory approval has been obtained for roxadustat in China, Japan, South Korea, and Chile, we may be unable to obtain regulatory approval for other countries, or such approval may be delayed or limited, due to a number of factors, many of which are beyond our control.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The negative vote of the FDA Cardiovascular and Renal Drugs Advisory Committee meeting is expected to have a significant impact on roxadustat&#8217;s approvability in CKD anemia in the U.S.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Preclinical, Phase 1 and Phase 2 clinical trial results may not be indicative of the results that may be obtained in larger clinical trials.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We do not know whether our ongoing or planned clinical trials of roxadustat or pamrevlumab will need to be redesigned based on interim results or if we will be able to achieve sufficient patient enrollment or complete planned clinical trials on schedule.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our product candidates may cause or have attributed to them undesirable side effects or have other properties that delay or prevent their regulatory approval or limit their commercial potential.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Clinical trials of our product candidates may not uncover all possible adverse effects that patients may experience.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If our manufacturers or we cannot properly manufacture the appropriate amount of product, we may experience delays in development, regulatory approval, launch or successful commercialization.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Regulatory authorities will do their own benefit risk analysis and may reach a different conclusion than we or our partners have, and these regulatory authorities may base their approval decision on different analyses, data, and statistical methods than ours.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Even if we are able to obtain regulatory approval of our product candidates, the label we obtain may limit the indicated uses for which our product candidates may be marketed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We face substantial competition in the discovery, development and commercialization of product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">No or limited reimbursement or insurance coverage of our approved products, if any, by third-party payors may render our products less attractive to patients and healthcare providers.</span></p></td></tr></table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to COVID-19</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our business could continue to be adversely affected by the ongoing COVID-19 global pandemic.</span></p></td></tr></table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Reliance on Third Parties</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If our collaborations were terminated or if Astellas or AstraZeneca were to prioritize other initiatives over their collaborations with us, our ability to successfully develop and commercialize our product candidates would suffer.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If our preclinical and clinical trial contractors do not properly perform their agreed upon obligations, we may not be able to obtain or may be delayed in receiving regulatory approvals for our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We currently rely, and expect to continue to rely, on third parties to conduct many aspects of our product manufacturing and distribution, and these third parties may terminate these agreements or not perform satisfactorily.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Certain components of our products are acquired from single-source suppliers or without long-term supply agreements. The loss of these suppliers, or their failure to supply, would materially and adversely affect our business.</span></p></td></tr></table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If our efforts to protect our proprietary technologies are not adequate, we may not be able to compete effectively in our market.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Intellectual property disputes may be costly, time consuming, and may negatively affect our competitive position.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our reliance on third parties and agreements with collaboration partners requires us to share our trade secrets, which increases the possibility that a competitor may discover them or that our trade secrets will be misappropriated or disclosed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The cost of maintaining our patent protection is high and requires continuous review and diligence. We may not be able to effectively maintain our intellectual property position throughout the major markets of the world.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The laws of some foreign countries do not protect proprietary rights to the same extent as do the laws of the U.S., and we may encounter significant problems in securing and defending our intellectual property rights outside the U.S.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">Intellectual property rights do not address all potential threats to any competitive advantage we may have.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The existence of counterfeit pharmaceutical products in pharmaceutical markets may compromise our brand and reputation and have a material adverse effect on our business, operations and prospects.</span></p></td></tr></table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Government Regulation</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The regulatory approval process is highly uncertain and we may not obtain regulatory approval for our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our product candidates could fail to receive regulatory approval from the FDA or other regulatory authorities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our current and future relationships with customers, physicians, and third-party payors are subject to healthcare fraud and abuse laws, false claims laws, transparency laws, privacy and security laws, and other regulations. If we are unable to comply with such laws, we could face substantial penalties.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We are subject to laws and regulations governing corruption, which will require us to maintain costly compliance programs.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these, or if we otherwise fail to maintain an effective system of internal control, it may result in material misstatements in our financial statements.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The impact of recent U.S. healthcare reform, its potential partial or full repeal, and other changes in the healthcare industry and in healthcare spending is currently unknown, and may adversely affect our business model.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Roxadustat is considered a Class 2 substance on the 2019 World Anti-Doping Agency Prohibited List that could limit sales and increase security and distribution costs for our partners and us.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our employees may engage in misconduct or improper activities, which could result in significant liability or harm our reputation.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If we fail to comply with environmental, health or safety laws and regulations, we could incur fines, penalties or other costs.</span></p></td></tr></table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our International Operations</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have established operations in China and are seeking approval to commercialize our product candidates outside of the U.S., and a number of risks associated with international operations could materially and adversely affect our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The pharmaceutical industry in China is highly regulated and such regulations are subject to change.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have limited experience distributing drugs in China.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We use our own manufacturing facilities in China to produce roxadustat API and drug product. There are risks inherent to operating commercial manufacturing facilities, and with these being our single source suppliers, we may not be able to continually meet market demand.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">As a company, we have limited experience in pharmacovigilance, medical affairs, and management of the third-party distribution logistics, and cannot assure you we will be able to meet regulatory requirements or operate in these capacities successfully.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our collaboration partner in China, AstraZeneca, and we may experience difficulties in successfully growing and sustaining sales of roxadustat in China.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The retail prices of any product candidates that we develop may be subject to pricing control in China and elsewhere.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">FibroGen (China) Medical Technology Development Co., Ltd. (&#8220;FibroGen Beijing&#8221;) would be subject to restrictions on paying dividends or making other payments to us, which may restrict our ability to satisfy our liquidity requirements.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Any capital contributions from us to FibroGen Beijing must be approved by the Ministry of Commerce in China, and failure to obtain such approval may materially and adversely affect the liquidity position of FibroGen Beijing.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may be subject to currency exchange rate fluctuations and currency exchange restrictions with respect to our operations in China, which could adversely affect our financial performance.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Because FibroGen Beijing&#8217;s funds are held in banks that do not provide insurance, the failure of any bank in which FibroGen Beijing deposits its funds could adversely affect our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may be subject to tax inefficiencies associated with our offshore corporate structure.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our foreign operations, particularly those in China, are subject to significant risks involving the protection of intellectual property.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Uncertainties with respect to the China legal system could have a material adverse effect on us.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Changes in China&#8217;s economic, governmental, or social conditions could have a material adverse effect on our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our operations in China subject us to various Chinese labor and social insurance laws, and our failure to comply with such laws may materially and adversely affect our business, financial condition and results of operations.</span></p></td></tr></table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Operation of Our Business</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Please see </span><span style="font-style:italic;color:#000000;">Part II &#8211; Other Information, Item 1A. Risk Factors</span><span style="color:#000000;"> for additional risk factors related to the operation of our Business.&#160;&#160;</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">There are also a variety of Risks Related to Our Common Stock<span style="margin-left:324pt;"></span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Please see </span><span style="font-style:italic;color:#000000;">Part II &#8211; Other Information, Item 1A. Risk Factors</span><span style="color:#000000;"> for additional risk factors related to our Common Stock. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IFINANCIAL_INFORMATION">PART I&#8212;FINANCIAL INFORMATION</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_CONDENSED_CONSOLIDATED_FINANCIAL">ITEM&#160;1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_BALANCE_SHEETS">CONDENSED CONSOLIDATED BALANCE SHEETS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000029" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">353,361</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000030" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">678,393</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000031" name="us-gaap:ShortTermInvestments" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">153,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000032" name="us-gaap:ShortTermInvestments" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">13,352</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,127</ix:nonFraction> from related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000033" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">24,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,883</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:InventoryNet" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">24,530</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:InventoryNet" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,530</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0000921299_20210630" decimals="-3" scale="3">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0000921299_20201231" decimals="-3" scale="3">889</ix:nonFraction> from related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,458</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:AssetsCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">564,466</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:AssetsCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">755,110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted time deposits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="fgen:RestrictedTimeDepositsNoncurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,072</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="fgen:RestrictedTimeDepositsNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,072</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:LongTermInvestments" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">105,758</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:LongTermInvestments" contextRef="C_0000921299_20201231" decimals="-3" scale="3">244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">30,670</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,647</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_20210630" decimals="-3" scale="3">861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity method investment in unconsolidated variable interest entity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="fgen:EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,083</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="fgen:EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">97,091</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,043</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,617</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,390</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:Assets" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">808,618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:Assets" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">826,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, stockholders&#8217; equity and non-controlling interests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="C_0000921299_20210630" decimals="-3" scale="3">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,118</ix:nonFraction> to a related party)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:AccountsPayableCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">48,988</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:AccountsPayableCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,789</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0000921299_20210630" decimals="-3" scale="3">14</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0000921299_20201231" decimals="-3" scale="3">24</ix:nonFraction> to a related party)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">147,801</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="fgen:DueToRelatedPartiesDeferredRevenueCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">10,699</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="fgen:DueToRelatedPartiesDeferredRevenueCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,907</ix:nonFraction> to a related party)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">25,234</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,547</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="C_0000921299_20210630" decimals="-3" scale="3">23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,330</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">10,718</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:LiabilitiesCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">232,764</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:LiabilitiesCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">163,187</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product development obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="fgen:AccruedProductDevelopmentCosts" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">18,277</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="fgen:AccruedProductDevelopmentCosts" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="fgen:DueToRelatedPartiesDeferredRevenueNoncurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">9,381</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="fgen:DueToRelatedPartiesDeferredRevenueNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,636</ix:nonFraction> to a related party)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">152,865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">138,474</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="C_0000921299_20210630" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, non-current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">94,196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" scale="3">853</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">30,659</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,789</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:Liabilities" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">528,767</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:Liabilities" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">385,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and Contingencies</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000081">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000082">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000114" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0000921299_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000113" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0000921299_20210630" decimals="INF">0.01</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000116" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0000921299_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000115" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0000921299_20210630" decimals="INF" format="ixt:numdotdecimal" scale="3">125,000</ix:nonFraction></ix:nonFraction> shares authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000118" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0000921299_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000120" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000117" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0000921299_20210630" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000119" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_20210630" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and outstanding at June 30, 2021, and December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:PreferredStockValue" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:PreferredStockValue" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000122" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0000921299_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000121" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0000921299_20210630" decimals="INF">0.01</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000124" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0000921299_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000123" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0000921299_20210630" decimals="INF" format="ixt:numdotdecimal" scale="3">225,000</ix:nonFraction></ix:nonFraction> shares authorized at June 30, 2021, and December 31, 2020&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000125" name="us-gaap:CommonStockSharesIssued" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000127" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">92,609</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000126" name="us-gaap:CommonStockSharesIssued" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000128" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">91,441</ix:nonFraction></ix:nonFraction> shares issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; June 30, 2021, and December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:CommonStockValue" contextRef="C_0000921299_20210630" decimals="-3" scale="3">926</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:CommonStockValue" contextRef="C_0000921299_20201231" decimals="-3" scale="3">914</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,443,975</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,399,774</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000921299_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,567</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000921299_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,499</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0000921299_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,179,754</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0000921299_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">974,011</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:StockholdersEquity" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">260,580</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:StockholdersEquity" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">422,178</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling interests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:MinorityInterest" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:MinorityInterest" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">279,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">441,449</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities, stockholders&#8217; equity and non-controlling interests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">808,618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">826,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEMENTS_OPERAT">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and other revenue (includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="fgen:CollaborationServicesAndOtherRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,645</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="fgen:CollaborationServicesAndOtherRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,766</ix:nonFraction>,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; $<ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="fgen:CollaborationServicesAndOtherRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,256</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="fgen:CollaborationServicesAndOtherRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">9,503</ix:nonFraction> from a related party)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,641</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">18,957</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">34,228</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">38,402</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue, net (includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="fgen:ProductRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">11,760</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="fgen:ProductRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630" decimals="-3" scale="3">0</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="fgen:ProductRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">22,167</ix:nonFraction> and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; $<ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="fgen:ProductRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630" decimals="-3" scale="3">0</ix:nonFraction> from a related party)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">13,371</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">15,693</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">28,733</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">20,648</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue (includes $(<ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="fgen:DrugProductRevenueFromRelatedParty" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,974</ix:nonFraction>), $<ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="fgen:DrugProductRevenueFromRelatedParty" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,238</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="fgen:DrugProductRevenueFromRelatedParty" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,056</ix:nonFraction></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="fgen:DrugProductRevenueFromRelatedParty" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,238</ix:nonFraction> from a related party)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">8,648</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210101_20210630" decimals="-3" sign="-" scale="3">168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">24,364</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">42,888</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">62,793</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">67,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating costs and expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="fgen:CostOfGoodsAndServicesSoldOperatingExpense" contextRef="C_0000921299_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,078</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="fgen:CostOfGoodsAndServicesSoldOperatingExpense" contextRef="C_0000921299_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,076</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="fgen:CostOfGoodsAndServicesSoldOperatingExpense" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,479</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="fgen:CostOfGoodsAndServicesSoldOperatingExpense" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,047</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0000921299_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">122,567</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0000921299_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">61,414</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">197,243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">116,315</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0000921299_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">32,554</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0000921299_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">63,535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">63,334</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">113,138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating costs and expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:OperatingExpenses" contextRef="C_0000921299_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">158,199</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:OperatingExpenses" contextRef="C_0000921299_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">128,025</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:OperatingExpenses" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">267,056</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:OperatingExpenses" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">233,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000921299_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">133,835</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000921299_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,137</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">204,263</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">166,212</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interest and other, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:InterestExpense" contextRef="C_0000921299_20210401_20210630" decimals="-3" scale="3">355</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:InterestExpense" contextRef="C_0000921299_20200401_20200630" decimals="-3" scale="3">651</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:InterestExpense" contextRef="C_0000921299_20210101_20210630" decimals="-3" scale="3">856</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:InterestExpense" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,284</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income and other income (expenses), net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="fgen:InterestIncomeAndOtherIncomeExpensesNet" contextRef="C_0000921299_20210401_20210630" decimals="-3" sign="-" scale="3">363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="fgen:InterestIncomeAndOtherIncomeExpensesNet" contextRef="C_0000921299_20200401_20200630" decimals="-3" scale="3">644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="fgen:InterestIncomeAndOtherIncomeExpensesNet" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" scale="3">817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="fgen:InterestIncomeAndOtherIncomeExpensesNet" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,810</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0000921299_20210401_20210630" decimals="-3" sign="-" scale="3">718</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0000921299_20200401_20200630" decimals="-3" sign="-" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,673</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,526</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0000921299_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">134,553</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0000921299_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">205,936</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">163,686</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for (benefit from) income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000921299_20210401_20210630" decimals="-3" sign="-" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000921299_20200401_20200630" decimals="-3" scale="3">169</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000921299_20210101_20210630" decimals="-3" scale="3">130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" scale="3">25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment income in unconsolidated variable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; interest entity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="fgen:UnconsolidatedVariableInterestEntityInvestmentIncome" contextRef="C_0000921299_20210401_20210630" decimals="-3" scale="3">562</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="fgen:UnconsolidatedVariableInterestEntityInvestmentIncome" contextRef="C_0000921299_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="fgen:UnconsolidatedVariableInterestEntityInvestmentIncome" contextRef="C_0000921299_20210101_20210630" decimals="-3" scale="3">323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="fgen:UnconsolidatedVariableInterestEntityInvestmentIncome" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">133,988</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">205,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">163,661</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000201" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0000921299_20210401_20210630" decimals="2" sign="-">1.45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000202" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0000921299_20200401_20200630" decimals="2" sign="-">0.95</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000203" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0000921299_20210101_20210630" decimals="2" sign="-">2.24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000204" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0000921299_20200101_20200630" decimals="2" sign="-">1.84</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Weighted average number of common shares used to calculate</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net loss per share - basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000205" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0000921299_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">92,276</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000206" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0000921299_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">89,451</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000207" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">91,983</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000208" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">88,835</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEMENTS_COMPRE">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">133,988</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">205,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">163,661</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income (loss):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_20210401_20210630" decimals="-3" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,615</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" scale="3">30</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,334</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale investments:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain (loss) on investments, net of tax effect</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0000921299_20210401_20210630" decimals="-3" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0000921299_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0000921299_20200101_20200630" decimals="-3" scale="3">520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income, net of taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000921299_20210401_20210630" decimals="-3" scale="3">57</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000921299_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,744</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" scale="3">68</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" scale="3">814</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0000921299_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">133,931</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0000921299_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">88,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">205,811</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">164,475</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEMENTS_EQUITY">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share data)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="26" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For The Three Month Period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common&#160;Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Controlling</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000241" name="us-gaap:SharesOutstanding" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="INF" format="ixt:numdotdecimal">92,080,399</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="-3" scale="3">921</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,420,471</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,045,766</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">19,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">390,273</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">133,988</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">133,988</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in unrealized gain or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; loss on investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630" decimals="-3" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_20210401_20210630" decimals="-3" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630" decimals="-3" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_20210401_20210630" decimals="-3" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issued from stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; plans, net of payroll taxes</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; paid</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000269" name="fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="INF" format="ixt:numdotdecimal">528,530</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,503</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,508</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at June 30,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000283" name="us-gaap:SharesOutstanding" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630" decimals="INF" format="ixt:numdotdecimal">92,608,929</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630" decimals="-3" scale="3">926</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,443,975</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,567</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,179,754</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">279,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000290" name="us-gaap:SharesOutstanding" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331" decimals="INF" format="ixt:numdotdecimal">88,895,630</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331" decimals="-3" scale="3">889</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,319,354</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">863,068</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">19,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">477,629</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in unrealized gain or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; loss on investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,615</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,615</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issued from stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; plans, net of payroll taxes</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; paid</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000318" name="fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="INF" format="ixt:numdotdecimal">1,332,663</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">7,914</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">7,927</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">17,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">17,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at June 30,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000332" name="us-gaap:SharesOutstanding" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630" decimals="INF" format="ixt:numdotdecimal">90,228,293</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630" decimals="-3" scale="3">902</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,344,912</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,561</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">948,381</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">415,143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (CONTINUED)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share data)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="26" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For The Six Month Period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common&#160;Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Controlling</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000339" name="us-gaap:SharesOutstanding" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">91,440,633</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">914</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,399,774</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,499</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">974,011</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000345" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">441,449</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">205,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">205,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in unrealized gain or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; loss on investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630" decimals="-3" sign="-" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000358" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630" decimals="-3" sign="-" scale="3">30</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000364" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" scale="3">30</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issued from stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; plans, net of payroll taxes</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; paid</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000367" name="fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="INF" format="ixt:numdotdecimal">1,168,296</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000369" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,816</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000372" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000373" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000374" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000375" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">38,385</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000377" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000378" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000379" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">38,385</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at June 30,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000381" name="us-gaap:SharesOutstanding" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630" decimals="INF" format="ixt:numdotdecimal">92,608,929</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000382" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630" decimals="-3" scale="3">926</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,443,975</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,567</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,179,754</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000386" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">279,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000388" name="us-gaap:SharesOutstanding" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">87,657,489</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">877</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,300,725</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" sign="-" scale="3">747</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">784,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">535,406</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000395" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000397" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">163,661</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">163,661</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in unrealized gain or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; loss on investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000404" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630" decimals="-3" scale="3">520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000406" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_20200101_20200630" decimals="-3" scale="3">520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; adjustments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000410" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000411" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,334</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000414" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,334</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issued from stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; plans, net of payroll taxes</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; paid</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000416" name="fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="INF" format="ixt:numdotdecimal">2,570,804</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" scale="3">25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">9,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000419" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000420" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000421" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">9,652</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000425" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">34,560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">34,560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at June 30,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000430" name="us-gaap:SharesOutstanding" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630" decimals="INF" format="ixt:numdotdecimal">90,228,293</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000431" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630" decimals="-3" scale="3">902</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000432" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,344,912</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,561</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">948,381</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">415,143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:ProfitLoss" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">205,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="us-gaap:ProfitLoss" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">163,661</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="us-gaap:Depreciation" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,242</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="us-gaap:Depreciation" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,737</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of finance lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,393</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,247</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net accretion of premium and discount on investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000443" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">767</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0000921299_20200101_20200630" decimals="-3" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on equity investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="fgen:UnrealizedLossGainOnEquityInvestments" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000446" name="fgen:UnrealizedLossGainOnEquityInvestments" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment loss in unconsolidated variable interest entity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="fgen:InvestmentLossInUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20210101_20210630" decimals="-3" scale="3">323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="fgen:InvestmentLossInUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss (gain) on disposal of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000449" name="us-gaap:GainLossOnDispositionOfAssets" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000450" name="us-gaap:GainLossOnDispositionOfAssets" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="us-gaap:ShareBasedCompensation" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">38,385</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:ShareBasedCompensation" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">34,560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense for acquired in-process research and development asset</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">25,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax benefit on unrealized gain on available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" scale="3">138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized loss on sales of available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">258</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,868</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,903</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">7,861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,016</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,231</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">126,874</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="fgen:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="fgen:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">494</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,066</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,529</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,013</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">27,745</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">33,331</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="fgen:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" contextRef="C_0000921299_20210101_20210630" decimals="-3" scale="3">295</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="fgen:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" scale="3">170</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">33,078</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">48,117</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest for finance lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="fgen:IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" scale="3">73</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="fgen:IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" scale="3">115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, non-current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="fgen:IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,388</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="fgen:IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" scale="3">359</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">8,065</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">64,317</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">71,527</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">90,179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,215</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment made for investment in unconsolidated variable interest entity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="fgen:PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="fgen:PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,419</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:PaymentsToAcquireAvailableForSaleSecurities" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">266,647</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:PaymentsToAcquireAvailableForSaleSecurities" contextRef="C_0000921299_20200101_20200630" decimals="-3" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sales of available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">10,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities of investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">10,610</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">201,900</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">254,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">209,864</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repayments of finance lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="fgen:RepaymentsOfFinanceLeaseLiabilities" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,326</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="fgen:RepaymentsOfFinanceLeaseLiabilities" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,992</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repayments of lease obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="C_0000921299_20210101_20210630" decimals="-3" scale="3">201</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="C_0000921299_20200101_20200630" decimals="-3" scale="3">201</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for payroll taxes on restricted stock unit releases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,928</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,858</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">11,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">16,510</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0000921299_20210101_20210630" decimals="-3" scale="3">301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,459</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of exchange rate change on cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000921299_20210101_20210630" decimals="-3" scale="3">446</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000921299_20200101_20200630" decimals="-3" sign="-" scale="3">499</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0000921299_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">325,032</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">303,003</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents at beginning of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">678,393</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">126,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents at end of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">353,361</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000921299_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">429,269</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p><ix:nonNumeric id="F_000515" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000515_dcnt_63098a41-c00f-4e7d-be04-e3c1e5b332cd">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Significant Accounting Policies</p></td></tr></table></div><ix:nonNumeric id="F_000526" name="fgen:DescriptionOfOperationsPolicyPolicyTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc. (&#8220;FibroGen&#8221; or the &#8220;Company&#8221;) is headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#8217;s Republic of China (&#8220;China&#8221;). FibroGen is a leading biopharmaceutical company developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (&#8220;HIF&#8221;) biology, 2-oxoglutarate enzymology, connective tissue growth factor (&#8220;CTGF&#8221;) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat, FibroGen&#8217;s most advanced product, is an oral small molecule inhibitor of HIF prolyl hydroxylase (&#8220;HIF-PH&#8221;) activity that is being commercialized in China (tradename: &#29233;&#29790;&#21331;<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>) for the treatment of anemia caused by chronic kidney disease (&#8220;CKD&#8221;) in dialysis and non-dialysis patients. EVRENZO<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (roxadustat) is also being commercialized in Japan and has been approved in South Korea and Chile for the treatment of anemia associated with CKD in dialysis and non-dialysis patients. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2021, the Committee for Medicinal Products for Human Use of the European Medicines Agency (&#8220;EMA&#8221;) adopted a positive opinion, recommending the granting of Marketing Authorization Application (&#8220;MAA&#8221;) for the medicinal product Evrenzo (roxadustat), intended for the treatment of adult patients with symptomatic anemia associated with CKD. Our partner Astellas Pharma Inc. (&#8220;Astellas&#8221;) expects an approval decision on the MAA for roxadustat by the European Commission in August 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) Cardiovascular and Renal Drugs Advisory Committee (&#8220;CRDAC&#8221;) voted to recommend not approving roxadustat, an oral HIF-PH inhibitor, for the treatment of anemia due to CKD in adult patients. The CRDAC vote was 13 to 1 for non-dialysis dependent CKD patients, and 12 to 2 for dialysis-dependent CKD patients. While the FDA is not required to follow CRDAC's vote, the agency considers CRDAC's non-binding recommendations when making its decision. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 3 development in China for anemia associated with myelodysplastic syndromes. Roxadustat is in Phase 2 clinical development for chemotherapy-induced anemia. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab, a human monoclonal antibody targeting CTGF, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer and Duchenne muscular dystrophy.</p></ix:nonNumeric><ix:nonNumeric id="F_000527" name="fgen:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000527_dcnt_ba76fb98-e93f-4ff1-8d1f-be6fa3b048bb">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation and Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements include the accounts of FibroGen, its wholly owned subsidiaries and its majority-owned subsidiaries, FibroGen Europe Oy and FibroGen China Anemia Holdings, Ltd. All inter-company transactions and balances have been eliminated in consolidation. For any variable interest entity for which FibroGen is not the primary beneficiary, the Company uses the equity method of accounting. The Company operates as <ix:nonFraction unitRef="U_fgenSegment" id="F_000563" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0000921299_20210101_20210630" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> segment &#8212; the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited condensed consolidated financial statements and related disclosures have been prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;) applicable to interim financial reporting and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and, therefore, do not include all information and footnote disclosures normally included in the annual consolidated financial statements. The financial information included herein should be read in conjunction with the consolidated financial statements and related notes in the Company&#8217;s Annual Report on Form 10-K filed with the SEC for the year ended December&#160;31, 2020 (&#8220;2020 Form 10-K&#8221;). </p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000515_dcnt_63098a41-c00f-4e7d-be04-e3c1e5b332cd" continuedAt="F_000515_dcnt_21527bda-4429-42aa-9eb8-4ccd3337b686"><ix:continuation id="F_000527_dcnt_ba76fb98-e93f-4ff1-8d1f-be6fa3b048bb">
</ix:continuation><ix:nonNumeric id="F_000528" name="us-gaap:UseOfEstimates" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue, specifically, estimates in variable consideration for drug product sales, and estimates in transaction price per unit for the China performance obligation (as defined and discussed under <span style="font-style:italic;">Significant Accounting Policies</span> below). On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates. In the Company&#8217;s opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair statement of its financial position, results of operations and cash flows for the interim periods presented.</p></ix:nonNumeric><ix:nonNumeric id="F_000529" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential common shares that would have the effect of increasing diluted earnings per share are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings per share. Diluted weighted average shares excluded potential common shares related to stock options, restricted stock units and shares to be purchased under the employee stock purchase plan totaling <ix:nonFraction unitRef="U_xbrlishares" id="F_000564" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_20210401_20210630" decimals="-5" scale="6">11.4</ix:nonFraction> million and <ix:nonFraction unitRef="U_xbrlishares" id="F_000565" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_20200401_20200630" decimals="-5" scale="6">9.2</ix:nonFraction> million for the three months ended June&#160;30, 2021 and 2020, and totaling <ix:nonFraction unitRef="U_xbrlishares" id="F_000566" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_20210101_20210630" decimals="-5" scale="6">9.4</ix:nonFraction> million and <ix:nonFraction unitRef="U_xbrlishares" id="F_000567" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_20200101_20200630" decimals="-5" scale="6">9.0</ix:nonFraction> million for the six months ended June&#160;30, 2021 and 2020, respectively, as they were anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric id="F_000530" name="fgen:RisksAndUncertaintiesPolicyTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s business is subject to risks and uncertainties, including those related to Severe Acute Respiratory Syndrome Coronavirus 2 and the resulting Coronavirus Disease (&#8220;COVID-19&#8221;) and the risk that we may not get approval of roxadustat in the U.S. for CKD anemia given the fact that the CRDAC voted to recommend not approving roxadustat in July 2021.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, obtaining second source suppliers, <span style="font-size:9.5pt;">regulatory approval from the FDA or other regulatory authorities, </span>the results of clinical trials and the achievement of milestones, market acceptance of the Company&#8217;s product candidates, competition from other products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals.</p></ix:nonNumeric><ix:nonNumeric id="F_000531" name="fgen:RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000531_dcnt_d34d280d-acb5-4853-8da8-a657c1531305">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued and Adopted Accounting Guidance</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span>. This guidance simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step up in the tax basis of goodwill, and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. This guidance was effective for annual reporting periods beginning after December 15, 2020 including interim periods. The Company adopted this guidance on January 1, 2021, and the adoption of this guidance did not have material impact to the Company&#8217;s condensed consolidated financial statements and related disclosures.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000515_dcnt_21527bda-4429-42aa-9eb8-4ccd3337b686" continuedAt="F_000515_dcnt_c2b7e29c-3deb-4e8d-8a02-190ea0e77b66"><ix:continuation id="F_000531_dcnt_d34d280d-acb5-4853-8da8-a657c1531305">
</ix:continuation><ix:nonNumeric id="F_000532" name="fgen:RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000532_dcnt_6d7e39fa-fc0f-49a8-8062-e4eb0898bcb3">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Guidance Not Yet Adopted</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued ASU 2020-04, <span style="font-style:italic;">Reference Rate Reform (Topic 848): </span><span style="font-style:italic;color:#000000;">Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span> (&#8220;<span style="font-style:italic;">ASU</span><span style="font-style:italic;"> </span><span style="font-style:italic;">2020</span><span style="font-style:italic;">-</span><span style="font-style:italic;">04</span><span style="font-style:italic;">&#8221;</span>)<span style="font-style:italic;">,</span> which provides companies with optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform. This guidance is effective as of March 12, 2020 through December 31, 2022. Subsequently in January 2021, the FASB issued ASU 2021-01, <span style="font-style:italic;">Reference Rate Reform (Topic 848): Scope</span>, which clarifies ASU 2020-04 and provides certain optional expedients that allow derivative instruments impacted by changes in the interest rate used for margining, discounting or contract price alignment to qualify for certain optional relief. ASU 2021-01 is effective in the same timeframe as ASU 2020-04. The relief offered by this guidance, if adopted, is available to companies for the period March 12, 2020 through December 31, 2022. <span style="Background-color:#FFFFFF;">The Company has certain lease arrangements that are linked to LIBOR. The Company is in the process of evaluating options for transitioning away from LIBOR and expects to complete this analysis by the time LIBOR is phased out. The Company did not elect to apply any of the expedients or exceptions as of and for the period ended June 30, 2021 and is currently evaluating the impact on its consolidated financial statements and related disclosures upon adoption of this guidance.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Significant Accounting Policies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the 2020 Form 10-K, except for the following:</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product revenue, net </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue, net consists of revenues from sales of roxadustat commercial product to Beijing Falikang Pharmaceutical Co., Ltd. (&#8220;Falikang&#8221;), and directly to pharmaceutical distributors located in a few provinces in China that are not covered by Falikang. Falikang is jointly owned by AstraZeneca AB (&#8220;AstraZeneca&#8221;) and FibroGen Beijing. The Company is not the primary beneficiary of Falikang for accounting purposes, as AstraZeneca is the final decision maker for all the roxadustat commercialization activities, and the Company lacks the power criterion to direct the activities of Falikang (see Note 3, <span style="font-style:italic;">Variable Interest Entity</span>). </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales to Falikang</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang became fully operational in January 2021, at which time FibroGen Beijing began selling roxadustat commercial product to Falikang. Falikang is FibroGen Beijing&#8217;s primary customer in China and substantially all roxadustat product sales to distributors in China are made by Falikang. Falikang bears inventory risk once it receives and accepts the product from FibroGen Beijing, and is responsible for delivering product to its distributors.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promises identified under the AstraZeneca China Agreement (as defined in Note 2, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>), including the license, co-development services and manufacturing of commercial supplies have been bundled into a single performance obligation (&#8220;China performance obligation&#8221;). Amounts of the transaction price allocable to this performance obligation under the Company&#8217;s agreements with AstraZeneca as outlined in Note 2, <span style="font-style:italic;">Collaboration Agreements and Revenues,</span> are deferred until control of the manufactured commercial product is transferred to AstraZeneca.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initiation of roxadustat sales to Falikang marked the beginning of the China performance obligation<span style="font-style:italic;">.</span><span style="color:#000000;"> Revenue is recognized at a point in time when control of roxadustat commercial product is transferred to Falikang. Revenue is recognized based on the estimated transaction price per unit and actual quantity of product delivered during the reporting period. Specifically, the transaction price per unit is determined based on the overall transaction price over the total estimated sales quantity for the estimated performance period in which the Company believes those sales would occur. The price per unit is subject to reassessment on a quarterly basis, which may result in cumulative catch up adjustments due to changes in estimates.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The overall transaction price for FibroGen Beijing&#8217;s product sales to Falikang includes the following elements of consideration: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Non-refundable upfront license fees&#59; development, regulatory, and commercial milestone payments based on the China Agreement allocated to the China performance obligation&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Co-development billings resulting from the Company&#8217;s research and development efforts, which are reimbursable under the China Agreement&#59;</p></td></tr></table></div></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000515_dcnt_c2b7e29c-3deb-4e8d-8a02-190ea0e77b66" continuedAt="F_000515_dcnt_abd7faa1-7917-422a-b175-5b4c8412da82"><ix:continuation id="F_000532_dcnt_6d7e39fa-fc0f-49a8-8062-e4eb0898bcb3" continuedAt="F_000532_dcnt_964f16ba-18d0-482d-aa3f-2e081a7a8554">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:Noto Sans Symbols;"></span><span style="color:#000000;"></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interim profit/loss share between FibroGen Beijing and AstraZeneca from April 1, 2020 through December 31, 2020&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Net transfer price from product sales to Falikang from January 1, 2021 onwards. The net transfer price includes the following elements: </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Gross transfer price: The gross transfer price is based on a percentage of Falikang&#8217;s net sales to its distributors, which takes into account Falikang&#8217;s operating expenses and its payments to AstraZeneca for roxadustat sales and marketing efforts, capped at a percentage of Falikang&#8217;s net roxadustat sales. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Profit share: The gross transfer price is then adjusted for an estimated amount to achieve the 50/<ix:nonFraction unitRef="U_xbrlipure" id="F_000568" name="fgen:ProfitSharePercent" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630" decimals="INF" scale="-2">50</ix:nonFraction> profit share from current period roxadustat net sales in China. The adjustments to date have been a reduction to the transfer price and the related accounts receivable from Falikang.&#160;&#160;</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The non-refundable upfront license fees constitute a <span style="color:#000000;">fixed consideration. The remainder of the above are variable consideration components, which may be constrained, and included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. The calculation of the above variable consideration includes key estimates such as total sales quantity, performance period, gross transfer price and profit share, which require a substantial degree of judgment.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any net transfer price in excess of the revenue recognized is deferred, and will be recognized over future periods as the performance obligations are satisfied.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Direct Sales to Distributors</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells roxadustat in China directly to a number of pharmaceutical distributors located in a few provinces in China that are not covered by Falikang. These pharmaceutical distributors are the Company&#8217;s customers. Hospitals order roxadustat through a distributor and the Company ships the product directly to the distributors. The delivery of roxadustat to a distributor represents a single performance obligation. Distributors are responsible for delivering product to end users, primarily hospitals. Distributors bear inventory risk once they receive and accept the product. Product revenue is recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000569" name="us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms" contextRef="C_0000921299_20210101_20210630">The period between the transfer of control of the promised goods and when the Company receives payment is based on 60-day payment terms.</ix:nonNumeric> As such, product revenue is not adjusted for the effects of a significant financing component.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is recorded at the net sales prices which includes the following estimates of variable consideration:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Price adjustment: When China&#8217;s National Healthcare Security Administration releases price guidance for roxadustat under the National Reimbursement Drug List, any channel inventories that have not been sold through by distributors, or to patients by hospitals and retailors, would be eligible for a price adjustment under the price protection. The price adjustment is calculated based on estimated channel inventory levels&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Contractual sales rebate: The contractual sales rebate is calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. The contractual sales rebate is recorded as a reduction to revenue at the point of sale to the distributor&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Non-key account hospital listing award: A one-time fixed-amount award is offered to a distributor who successfully lists the product with an eligible hospital, and who meets certain requirements. The Company considers this particular award to be an upfront payment to a customer within the definitions of Accounting Standards Codification (&#8220;ASC&#8221;) 606, <span style="font-style:italic;">Revenue from Contracts with Customers </span>(&#8220;ASC 606&#8221;). The non-key account hospital listing award is capitalized when the distributor meets eligibility requirements, and amortized as reduction to product revenue over future sales orders made by the distributor until exhausted&#59;</p></td></tr></table></div></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000515_dcnt_abd7faa1-7917-422a-b175-5b4c8412da82"><ix:continuation id="F_000532_dcnt_964f16ba-18d0-482d-aa3f-2e081a7a8554">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:Noto Sans Symbols;"></span><span style="color:#000000;"></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other discounts and rebates, including key account hospital sales reba</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e and transfer fee discount, are generally based on a percentage of eligible gross sales made by the distributor and recorded as a reduction to revenue at the point of sale to the distributor&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Sales returns: <ix:nonNumeric id="F_000570" name="fgen:DescriptionOfSalesReturn" contextRef="C_0000921299_20210101_20210630">Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product&#8217;s expiration date.</ix:nonNumeric></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The calculation of the above variable consideration is based on gross sales to the distributor, or estimated utilizing best available information from the distributor, maximum known exposures and other available information including estimated channel inventory levels and estimated sales made by the distributor to hospitals, which involve a substantial degree of judgment.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above rebates and discounts all together are eligible to be applied against the distributor&#8217;s future sales order, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible and in the same period that the related revenue is recorded. Due to the distributor&#8217;s legal right to offset, at each balance sheet date, the liability for rebates and discounts are presented as reductions of gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The distributor&#8217;s legal right of offset is calculated at the individual distributor level.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Acquisition Agreement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 16, 2021, the Company entered into an exclusive license and option agreement with HiFiBiO Therapeutics (&#8220;HiFiBiO&#8221;) (&#8220;HiFiBiO Agreement&#8221;), pursuant to which the Company exclusively licensed all product candidates in HiFiBiO&#8217;s Galectin-9 program and will have the sole right to develop them worldwide. The Company has also obtained exclusive options to license all product candidates in HiFiBiO&#8217;s CXCR5 and CCR8 programs. Under the terms of the HiFiBiO Agreement, the Company will make a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000571" name="fgen:InitialUpfrontPayment" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenHiFiBiOAgreementMember_20210616_20210616" decimals="-6" scale="6">25</ix:nonFraction> million upfront payment to HiFiBiO, as well as payments upon option exercise. In addition, HiFiBiO may receive up to a total of an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000572" name="fgen:MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenHiFiBiOAgreementMember_20210616_20210616" decimals="INF" scale="9">1.1</ix:nonFraction> billion in future option, clinical, regulatory, and commercial milestone payments across all three programs. HiFiBiO will also be eligible to receive royalties based upon worldwide net sales. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The acquisition of these licenses was accounted for as an asset acquisition. The initial upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000573" name="fgen:InitialUpfrontPayment" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenHiFiBiOAgreementMember_20210616_20210616" decimals="-5" scale="6">25.0</ix:nonFraction> million related to the license and options acquisition meets the definition of an in-process research and development asset (&#8220;IPR&#38;D asset&#8221;) under the ASC 730, <span style="font-style:italic;">Research and Development</span> (&#8220;ASC 730&#8221;). It relates to particular research and development projects and is determined to have no alternative future uses and thus have no separate economic value. Therefore, this upfront payment was recorded as a research and development expense during the three months ended June 30, 2021. As of June 30, 2021, this amount was not paid, and was included as accounts payable in the condensed consolidated balance sheet.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration payments will be evaluated and recognized when they become probable and reasonably estimable. The related IPR&#38;D asset will only be capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, amounts allocated to IPR&#38;D asset that have no alternative use will be expensed. As of June 30, 2021, all programs were at the early stage of development and the contingencies related to the milestone payments had not been resolved, therefore <ix:nonFraction unitRef="U_iso4217USD" id="F_000574" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenHiFiBiOAgreementMember_20210616" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> contingent consideration was recognized. The Company will reassess the probability of future option payments and contingent payments on a quarterly basis.</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000516" name="fgen:CollaborativeArrangementAndRevenuesDisclosureTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000516_dcnt_57d6175c-e4b8-46d0-9129-be1664ca1eff">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaboration Agreements and Revenues</p></td></tr></table></div><ix:nonNumeric id="F_000533" name="fgen:CollaborativeArrangementAndRevenuesPolicyTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000533_dcnt_0f974974-4435-4d67-b284-1f253583be71">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Astellas Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Japan Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2005, the Company entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (&#8220;Japan Agreement&#8221;). Under this agreement, Astellas paid license fees and other consideration totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000575" name="fgen:ProceedsFromUpfrontNonContingentAndTimeBasedPayments" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20090228" decimals="-5" scale="6">40.1</ix:nonFraction>&#160;million (such amounts were fully received as of February 2009). Under the Japan Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000576" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630" decimals="-5" scale="6">132.5</ix:nonFraction>&#160;million in potential milestone payments, comprised of (i)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000577" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630" decimals="-5" scale="6">22.5</ix:nonFraction>&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of July 2016), (ii)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000578" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630" decimals="-5" scale="6">95.0</ix:nonFraction>&#160;million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000579" name="fgen:CommercialSalesMilestone" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630" decimals="-5" scale="6">15.0</ix:nonFraction>&#160;million in milestone payments upon the achievement of specified commercial sales milestone. The Japan Agreement also provides for tiered payments based on net sales of product (as defined) in <ix:nonNumeric id="F_000580" name="fgen:AdditionalConsiderationBasedOnNetSales" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630">the low 20% range of the list price</ix:nonNumeric> published by Japan&#8217;s Ministry of Health, Labour and Welfare, adjusted for certain elements, after commercial launch. The aggregate amount of consideration received through June&#160;30, 2021 totals $<ix:nonFraction unitRef="U_iso4217USD" id="F_000581" name="fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-5" scale="6">105.1</ix:nonFraction> million, excluding drug product revenue that is discussed separately below.&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000516_dcnt_57d6175c-e4b8-46d0-9129-be1664ca1eff" continuedAt="F_000516_dcnt_304e9279-37df-42e2-8457-c84eb12f12e0"><ix:continuation id="F_000533_dcnt_0f974974-4435-4d67-b284-1f253583be71" continuedAt="F_000533_dcnt_cde6127f-64e7-4ae3-82a1-0c4533b2ffa5">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#8220;Japan Amendment&#8221;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">active pharmaceutical ingredient (&#8220;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">API</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</span><span style="font-weight:bold;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to Astellas </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the roxadustat commercial </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">purposes </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in Japan</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The commercial terms of the Japan Agreement relating to the transfer price for roxadustat for commercial use remain substantially the same, reflecting an adjustment for the manufacture of drug product by Astellas rather than FibroGen. The related drug product revenue, as described in details under </span><span style="font-style:italic;">Drug Product Revenue</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> section below, was $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000582" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630" decimals="-5" sign="-" scale="6">2.0</ix:nonFraction>)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000583" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210630" decimals="-5" scale="6">2.1</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the three </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and six </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">months ended </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respectively</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Europe Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2006, the Company entered into a separate collaboration agreement with Astellas for the development and commercialization of roxadustat for the treatment of anemia in Europe, the Middle East, the Commonwealth of Independent States and South Africa (&#8220;Europe Agreement&#8221;). Under the terms of the Europe Agreement, Astellas paid license fees and other upfront consideration totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000584" name="fgen:ProceedsFromUpfrontNonContingentAndTimeBasedPayments" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20090228" decimals="-5" scale="6">320.0</ix:nonFraction> million (such amounts were fully received as of February 2009). The Europe Agreement also provides for additional development and regulatory approval milestone payments up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000585" name="fgen:DevelopmentAndRegulatoryApprovalMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060430" decimals="-5" scale="6">425.0</ix:nonFraction>&#160;million, comprised of (i)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000586" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430" decimals="-5" scale="6">90.0</ix:nonFraction>&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of 2012), (ii)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000587" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430" decimals="-5" scale="6">335.0</ix:nonFraction>&#160;million in milestone payments upon achievement of specified regulatory milestone events. Under the Europe Agreement, Astellas committed to fund <ix:nonFraction unitRef="U_xbrlipure" id="F_000588" name="fgen:PercentageOfFundingForCosts" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430" decimals="2" scale="-2">50</ix:nonFraction>% of joint development costs for Europe and North America, and all territory-specific costs. The Europe Agreement also provides for tiered payments based on net sales of product (as defined) in the <ix:nonNumeric id="F_000589" name="fgen:AdditionalConsiderationBasedOnNetSales" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630">low 20% range</ix:nonNumeric>. The aggregate amount of consideration received under the Europe Agreement through June&#160;30, 2021 totals $<ix:nonFraction unitRef="U_iso4217USD" id="F_000590" name="fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-5" scale="6">540.0</ix:nonFraction> million, excluding drug product revenue that is discussed separately below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Europe Agreement, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. During the first quarter of 2021, the Company entered into an Astellas EU Supply Agreement (&#8220;EU Supply Agreement&#8221;) under the Europe Agreement with Astellas to define general forecast, order, supply and payment terms for Astellas to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The Company shipped bulk drug product to Astellas as pre-commercial supply for process validation purposes during the first quarter of 2021. The Company recorded the consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000591" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630" decimals="-5" scale="6">11.8</ix:nonFraction> million from this shipment as deferred revenue as of June 30, 2021, as described in details under <span style="font-style:italic;">Drug Product Revenue</span> section below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">U.S./Rest of World (&#8220;RoW&#8221;) Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective July 30, 2013, the Company entered into a collaboration agreement with AstraZeneca for the development and commercialization of roxadustat for the treatment of anemia in the U.S. and all other countries in the world, other than China, not previously licensed under the Astellas Europe and Astellas Japan Agreements (&#8220;U.S./RoW Agreement&#8221;). It also excludes China, which is covered by a separate agreement with AstraZeneca described below. Under the terms of the U.S./RoW Agreement, AstraZeneca paid upfront, non-contingent, non-refundable and time-based payments totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000592" name="fgen:ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">374.0</ix:nonFraction> million (such amounts were fully received as of June 2016). Under the U.S./RoW Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000593" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">875.0</ix:nonFraction> million in potential milestone payments, comprised of (i)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000594" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">65.0</ix:nonFraction> million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of April 2020), (ii)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000595" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">325.0</ix:nonFraction> million in milestone payments upon achievement of specified regulatory milestone events, (iii)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000596" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenDeferredApprovalMilestoneMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">160.0</ix:nonFraction>&#160;million in milestone payments related to activity by potential competitors and (iv)&#160;up to approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000597" name="fgen:CommercialSalesMilestone" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">325.0</ix:nonFraction> million in milestone payments upon the achievement of specified commercial sales events. The aggregate amount of consideration received under the U.S./RoW Agreement through June&#160;30, 2021 totals $<ix:nonFraction unitRef="U_iso4217USD" id="F_000598" name="fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-5" scale="6">439.0</ix:nonFraction> million, excluding drug product revenue that is discussed separately below.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the Company entered into Master Supply Agreement under the U.S./RoW Agreement with AstraZeneca (&#8220;Master Supply Agreement&#8221;) to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The Company shipped bulk drug product to AstraZeneca as commercial supply during 2020, and the first and second quarter of 2021. On July 15, 2021, the FDA CRDAC voted to recommend not approving roxadustat for the treatment of anemia due to CKD in adult patients. While the FDA is not required to follow the CRDAC&#8217;s vote, the agency considers the CRDAC&#8217;s non-binding recommendations when making its decision. The Company evaluated the impact of these developments in revising its estimates of variable consideration associated with drug product revenue. As a result, the Company updated the estimated transaction price, and recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000599" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630" decimals="-5" scale="6">11.2</ix:nonFraction> million as deferred revenue as of June 30, 2021. See details under <span style="font-style:italic;">Drug Product Revenue</span> section below.</p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000516_dcnt_304e9279-37df-42e2-8457-c84eb12f12e0" continuedAt="F_000516_dcnt_441a4c88-453d-4288-8a91-272b289e1d4d"><ix:continuation id="F_000533_dcnt_cde6127f-64e7-4ae3-82a1-0c4533b2ffa5">

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective July&#160;30, 2013, the Company (through its subsidiaries affiliated with China) entered into the China Agreement (&#8220;China Agreement&#8221;). Under the terms of the China Agreement, AstraZeneca agreed to pay upfront consideration totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000600" name="fgen:ProceedsFromUpfrontNonContingentAndNonRefundablePayments" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">28.2</ix:nonFraction>&#160;million (such amounts were fully received in 2014). Under the China Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000601" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">348.5</ix:nonFraction> million in potential milestone payments, comprised of (i)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000602" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">15.0</ix:nonFraction> million in milestone payments upon achievement of specified clinical and development milestone events, (ii)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000603" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">146.0</ix:nonFraction> million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000604" name="fgen:CommercialSalesAndOtherEventsMilestone" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">187.5</ix:nonFraction> million in milestone payments upon the achievement of specified commercial sales and other events. The China Agreement is structured as a 50/50 profit or loss share (as defined), which was amended under the China Amendment discussed below in the third quarter of 2020, and provides for joint development costs (including capital and equipment costs for construction of the manufacturing plant in China), to be shared equally during the development period. The aggregate amount of such consideration received for milestone and upfront payments through June&#160;30, 2021 totals $<ix:nonFraction unitRef="U_iso4217USD" id="F_000605" name="fgen:CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-5" scale="6">77.2</ix:nonFraction> million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Amendment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, FibroGen China and AstraZeneca (together with FibroGen China, the &#8220;Parties&#8221;) entered into the China Amendment, effective July 1, 2020, relating to the development and commercialization of roxadustat in China. While the responsibilities of the Parties under the China Agreement remain largely the same, certain changes were made. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the China Amendment, in September 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Falikang, which performs roxadustat distribution, as well as conduct sales and marketing through AstraZeneca. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the China Amendment, the interim period is defined as the period from April 1, 2020 to the time when Falikang is fully operational. Falikang became fully operational in January 2021. The calculation for profit or loss share related to sales of roxadustat in China has changed for the period from April 1, 2020 onwards. With effect from April 1, 2020, the Parties have changed the method under which commercial expenses incurred by AstraZeneca are calculated and billed. AstraZeneca&#8217;s co-promotion expenses for their sales and marketing efforts are now subject to a cap of a percentage of net sales. Once AstraZeneca has been fully reimbursed for their sales and marketing costs under the cap, AstraZeneca will bill the co-promotion expenses based on actual costs on a prospective basis. In addition, the China Amendment has allowed for a higher cost of manufacturing incurred by FibroGen Beijing to be included in the profit or loss share calculation, subject to an annual cap, among other changes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since Falikang became fully operational in January 2021, substantially all direct roxadustat product sales to distributors in China are made by Falikang, while FibroGen Beijing continues to sell roxadustat product directly in a few provinces in China. FibroGen Beijing manufactures and supplies commercial product to Falikang based on a gross transfer price, which is adjusted for the estimated profit share. In addition, AstraZeneca now bills the co-promotion expenses to Falikang and to FibroGen Beijing, respectively, for its services provided to the respective entity. Development costs continue to be shared 50/50 between the Parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three and six months ended June&#160;30, 2021, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000606" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630" decimals="-5" scale="6">11.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000607" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630" decimals="-5" scale="6">22.2</ix:nonFraction> million, respectively, of net product revenue from the sales to Falikang, as described in details under <span style="font-style:italic;">Product Revenue, Net</span> section below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to sales to Falikang, during the three and six months ended June&#160;30, 2021, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000608" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210401_20210630" decimals="-5" scale="6">1.6</ix:nonFraction> million and <ix:nonFraction unitRef="U_iso4217USD" id="F_000609" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630" decimals="-5" scale="6">6.6</ix:nonFraction> million, respectively, of net product revenue from sales directly to distributors in a few provinces in China, <span style="Background-color:#FFFFFF;color:#000000;">as </span>described as direct sales<span style="Background-color:#FFFFFF;color:#000000;"> </span>under <span style="font-style:italic;">Product Revenue, Net</span> section below.</p></ix:continuation>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">License Revenue and Development Revenue Recognized Under the Collaboration Agreements</p><ix:nonNumeric id="F_000536" name="fgen:ContractWithCustomerMilestoneMethodTableTextBlock" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_20210101_20210630" escape="true" continuedAt="F_000536_dcnt_40657c9e-71cf-47ed-9c45-433c1ee45ce6">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts recognized as license revenue and development revenue under the Japan Agreement with Astellas were as follows (in thousands):&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.68%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.68%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000610" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000611" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000612" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000613" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000614" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630" decimals="-3" scale="3">99</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000615" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630" decimals="-3" scale="3">164</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000616" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000617" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630" decimals="-3" scale="3">327</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000516_dcnt_441a4c88-453d-4288-8a91-272b289e1d4d" continuedAt="F_000516_dcnt_e4ee6117-fd19-4470-98b1-0e30d071ffa2"><ix:continuation id="F_000536_dcnt_40657c9e-71cf-47ed-9c45-433c1ee45ce6">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000537" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_20210101_20210630" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Japan Agreement</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000618" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">100,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000621" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000624" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">100,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000619" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">16,529</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000622" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" scale="3">30</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000625" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">16,559</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000620" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">116,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000623" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" scale="3">30</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000626" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">116,906</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue recognized under the Japan Agreement for the three months ended June&#160;30, 2021 included immaterial revenue resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied or partially satisfied in previous periods. The Company does not expect material variable consideration from estimated future co-development billing beyond the development period in the transaction price related to the Japan Agreement.</p><ix:nonNumeric id="F_000538" name="fgen:ContractWithCustomerMilestoneMethodTableTextBlock" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20210101_20210630" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts recognized as license revenue and development revenue under the Europe Agreement with Astellas were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000627" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000628" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000629" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000630" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000631" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,546</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000632" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000633" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,077</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000634" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">9,176</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000539" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20210101_20210630" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Europe Agreement</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000635" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">487,951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000638" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000641" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">487,951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000636" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">255,039</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000639" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" scale="3">333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000642" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">255,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000637" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">742,990</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000640" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" scale="3">333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000643" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">743,323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:2.5%;text-indent:-2.5%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue recognized under the Europe Agreement for the three months ended June&#160;30, 2021 included an increase in revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000645" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630" decimals="-5" scale="6">0.4</ix:nonFraction> million resulting from changes to estimated variable consideration. The remainder of the transaction price related to the Europe Agreement includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_000644" name="fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20210401_20210630" decimals="-5" scale="6">10.7</ix:nonFraction> million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period.</p><ix:nonNumeric id="F_000540" name="fgen:ContractWithCustomerMilestoneMethodTableTextBlock" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20210101_20210630" escape="true" continuedAt="F_000540_dcnt_c572da03-04e9-496e-baff-c81705315892">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts recognized as revenue under the U.S./RoW and China Agreement with AstraZeneca were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.&#160;/&#160;RoW</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and China</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000646" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000647" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000648" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000649" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000650" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">16,993</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000651" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">13,750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000652" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">27,969</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000653" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">28,305</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China performance obligation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000654" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000655" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200401_20200630" decimals="-3" scale="3">441</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000656" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000657" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20200630" decimals="-3" scale="3">594</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000516_dcnt_e4ee6117-fd19-4470-98b1-0e30d071ffa2" continuedAt="F_000516_dcnt_a506fd36-88d3-462f-b69d-e6a1922dfdc5"><ix:continuation id="F_000540_dcnt_c572da03-04e9-496e-baff-c81705315892">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000541" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20210101_20210630" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement with AstraZeneca, along with any associated deferred revenue as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.24%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U.S.&#160;/&#160;RoW and China Agreements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000658" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">341,844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000662" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000666" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">341,844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-development, information sharing &#38;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;committee services</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000659" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_fgenCoDevelopmentInformationSharingAndCommitteeServicesMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">582,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000663" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenCoDevelopmentInformationSharingAndCommitteeServicesMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,309</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000667" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtProductOrServiceAxis_fgenCoDevelopmentInformationSharingAndCommitteeServicesMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">585,052</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China performance obligation *</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000660" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_fgenChinaPerformanceObligationMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">22,167</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000664" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenChinaPerformanceObligationMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">149,759</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtProductOrServiceAxis_fgenChinaPerformanceObligationMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">171,926</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000661" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">946,754</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000665" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">152,068</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,098,822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* </span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">China performance obligation revenue is recognized as product revenue, as described in details under <span style="font-style:italic;">Product Revenue, Net</span> section below.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the consolidated balance sheets. As of June 30, 2021, deferred revenue included $<ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-5" scale="6">146.8</ix:nonFraction> million related to the U.S./RoW and China Agreement, which represents the net of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000671" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-5" scale="6">152.1</ix:nonFraction> million of deferred revenue presented above and a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000672" name="fgen:SuppliesNet" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-5" scale="6">5.3</ix:nonFraction> million unbilled co-development revenue under the China Amendment with AstraZeneca.</p></td></tr></table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue recognized under the U.S./RoW Agreement for the three months ended June&#160;30, 2021 included a reduction in revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000674" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630" decimals="-5" scale="6">0.2</ix:nonFraction> million resulting from changes to estimated variable consideration. The remainder of the transaction price related to the U.S./RoW Agreement and China Agreement includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_000673" name="fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20210401_20210630" decimals="-5" scale="6">34.1</ix:nonFraction> million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period, except for amounts allocated to the China performance obligation. The amount allocated to the U.S./RoW Agreement is expected to be recognized over the remaining development service period. The amount allocated to the China performance obligation is expected to be recognized as the Company transfers control of the commercial products to Falikang.</p><ix:nonNumeric id="F_000534" name="fgen:ProductRevenuePolicyPolicyTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000534_dcnt_831ed973-d759-41b2-b50b-f480ff1c46b3">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Product Revenue, Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000542" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000542_cnt_1">Product revenue, net from the sales of roxadustat commercial product in China was as follows (in thousands):</ix:nonNumeric></p><ix:continuation id="F_000542_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Direct Sales:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross revenue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000675" name="fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,230</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000676" name="fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,833</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000677" name="fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">7,659</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000678" name="fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">25,205</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discounts and rebates</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000679" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20210401_20210630" decimals="-3" sign="-" scale="3">618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000680" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,095</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000681" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,181</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000682" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,512</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales returns</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000683" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20210401_20210630" decimals="-3" sign="-" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000684" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20200401_20200630" decimals="-3" sign="-" scale="3">45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000685" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20210101_20210630" decimals="-3" scale="3">88</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000686" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20200101_20200630" decimals="-3" sign="-" scale="3">45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct sales revenue, net</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000687" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,611</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000688" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">15,693</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000689" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,566</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000690" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">20,648</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sales to Falikang:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross transfer price</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000691" name="fgen:RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">26,714</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000692" name="fgen:RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000693" name="fgen:RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">51,115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000694" name="fgen:RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Profit share</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000695" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenProfitShareMember_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">9,573</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000696" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenProfitShareMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000697" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenProfitShareMember_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">19,636</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000698" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenProfitShareMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net transfer price</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000699" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNetTransferPriceMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">17,141</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000700" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNetTransferPriceMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000701" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNetTransferPriceMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">31,479</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000702">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in deferred revenue</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000703" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenIncreaseInDeferredRevenueMember_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">5,381</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000704" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenIncreaseInDeferredRevenueMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000705" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenIncreaseInDeferredRevenueMember_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">9,312</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000706">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales to Falikang revenue, net</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000707" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">11,760</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000708" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000709" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">22,167</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000710" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total product revenue, net</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000711" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">13,371</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000712" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">15,693</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000713" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">28,733</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000714" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">20,648</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Direct Sales</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue from direct roxadustat product sales to distributors in China is recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products, net of various sales rebates and discounts. The total discounts and rebates were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000715" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20210401_20210630" decimals="-5" scale="6">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000716" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20200401_20200630" decimals="-5" scale="6">4.1</ix:nonFraction> million for the three months ended June&#160;30, 2021 and 2020, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000717" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20210101_20210630" decimals="-5" scale="6">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000718" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20200101_20200630" decimals="-5" scale="6">4.5</ix:nonFraction> million for the six months ended June&#160;30, 2021 and 2020, respectively, which primarily consisted of the contractual sales rebate calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor.  </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000516_dcnt_a506fd36-88d3-462f-b69d-e6a1922dfdc5" continuedAt="F_000516_dcnt_ab9f0767-9dc9-4c50-ad64-675b018693b0"><ix:continuation id="F_000534_dcnt_831ed973-d759-41b2-b50b-f480ff1c46b3">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rebates and discounts that the Company&#8217;s pharmaceutical distributors have earned are eligible to be applied against future sales orders, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible in the same period that the related revenue is recorded. Due to the Company&#8217;s legal right to offset, at each balance sheet date, the rebates and discounts are presented as reductions to gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The Company&#8217;s legal right to offset is calculated at the individual distributor level. <ix:nonNumeric id="F_000543" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000543_cnt_1">The following table includes a roll-forward of the contract liabilities (in thousands):</ix:nonNumeric></p><ix:continuation id="F_000543_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deduction</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Currency</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Translation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue - Direct sales - contract liabilities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000719" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,137</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000720" name="fgen:ContractWithCustomerLiabilityAdditions" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630" decimals="-3" scale="3">883</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000721" name="fgen:ContractWithCustomerLiabilityDeduction" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000722" name="fgen:ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630" decimals="-3" sign="-" scale="3">183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000723" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">13,793</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021 and December&#160;31, 2020, the total contract liabilities were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000727" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20210101_20210630" decimals="-5" scale="6">13.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000726" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20200101_20201231" decimals="-5" scale="6">15.1</ix:nonFraction> million, which were included in accrued and other current liabilities in the condensed consolidated balance sheet. The rebates and discounts reflected as reductions to gross accounts receivable for direct sales was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000725" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20210101_20210630" decimals="-5" scale="6">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000724" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20200101_20201231" decimals="-5" scale="6">0.5</ix:nonFraction> million as of June 30, 2021 and December 31, 2020, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales to Falikang &#8211; China Performance Obligation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since Falikang became fully operational in January 2021, substantially all direct roxadustat product sales to distributors in China are made by Falikang. FibroGen Beijing manufactures and supplies commercial product to Falikang. The net transfer price for FibroGen Beijing&#8217;s product sales to Falikang is based on a gross transfer price, which is adjusted to account for the 50/50 profit share for the period.  </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The roxadustat sales to Falikang marked the beginning of the Company&#8217;s China performance obligation under the Company&#8217;s agreements with AstraZeneca</span><span style="font-style:italic;Background-color:#FFFFFF;">.</span><span style="Background-color:#FFFFFF;"> Product revenue is based on the transaction price of the China performance obligation. </span><span style="color:#000000;">Revenue is recognized when control of product is transferred to Falikang, </span><span style="Background-color:#FFFFFF;">in an amount that </span><span style="color:#000000;">reflects the allocation of the transaction price to the performance obligation satisfied during the reporting period</span><span style="Background-color:#FFFFFF;">. </span><span style="color:#000000;">Any net transfer price in excess of the revenue recognized is added to the deferred balance to date, and will </span><span style="Background-color:#FFFFFF;">be recognized over future periods as the performance obligations are satisfied</span><span style="color:#000000;">. During the three and six months ended June&#160;30, 2021, following updates to its estimates, the Company deferred $<ix:nonFraction unitRef="U_iso4217USD" id="F_000728" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDeferredForFutureRecognitionMember_20210401_20210630" decimals="-5" scale="6">5.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000729" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDeferredForFutureRecognitionMember_20210101_20210630" decimals="-5" scale="6">9.3</ix:nonFraction> million, respectively, from the net transfer price to Falikang, which was included in the related deferred revenue of the China performance obligation.</span> </p><ix:nonNumeric id="F_000544" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes a roll-forward of the related deferred revenue that is considered as a contract liability (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognized as Revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue - AstraZeneca</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;China performance obligation - deferred revenue</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000730" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">137,338</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000731" name="fgen:ContractWithCustomerLiabilityAdditions" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">34,588</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000732" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">22,167</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000733" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">149,759</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue includes amounts allocated to the China performance obligation under the AstraZeneca arrangement as revenue recognition associated with this unit of accounting is tied to the commercial launch of the products within China and to when the control of the manufactured commercial products is transferred to AstraZeneca. As of June&#160;30, 2021, approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000734" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-5" scale="6">6.3</ix:nonFraction> million of the deferred revenue related to the China unit of accounting was included in short-term deferred revenue, which represents the amount of deferred revenue associated with the China unit of accounting that is expected to be recognized within the next 12 months, associated with the commercial sales in China.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reductions to gross accounts receivable related to product revenue to Falikang was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000735" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210630" decimals="-5" scale="6">10.1</ix:nonFraction> million as of June&#160;30, 2021.</p></ix:continuation><ix:nonNumeric id="F_000535" name="fgen:DrugProductRevenuePolicyTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000535_dcnt_3c96333a-dc35-4a47-a03a-cfd67ace374f">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Drug Product Revenue<span style="font-weight:normal;"> </span></p><ix:nonNumeric id="F_000545" name="fgen:ScheduleOfDrugProductRevenueTableTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue from commercial-grade API or bulk drug product sales to AstraZeneca and Astellas was as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000736" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,974</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000737" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000738" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,056</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000739" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000740" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">6,674</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000741" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000742" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,224</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000743" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000744" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">8,648</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000745" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000746" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210630" decimals="-3" sign="-" scale="3">168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000747" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000516_dcnt_ab9f0767-9dc9-4c50-ad64-675b018693b0"><ix:continuation id="F_000535_dcnt_3c96333a-dc35-4a47-a03a-cfd67ace374f">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During three months ended June 30, 2021, the Company shipped bulk drug product to AstraZeneca as commercial supply under the terms of the Master Supply Agreement. Based on the above-mentioned FDA CRDAC&#8217;s vote on July 15, 2021, the Company evaluated the impact of these developments in revising its estimates of variable consideration associated with drug product revenue. As a result, the Company updated the estimated transaction price, and recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000748" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630" decimals="-5" scale="6">11.2</ix:nonFraction> million as deferred revenue as of June 30, 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended June 30, 2021, the Company recorded a reduction of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000749" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630" decimals="-5" scale="6">2.0</ix:nonFraction> million to the drug product revenue related to the API shipments fulfilled under the terms of the Japan Amendment with Astellas in 2018, due to a change in estimated variable consideration. Specifically, the change in estimated variable consideration was based on the API held by Astellas at June 30, 2021, adjusted to reflect the changes in the estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others. This amount was recorded under deferred revenue in the condensed consolidated balance sheet as of June 30, 2021. During the first quarter of 2021, the Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000750" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210331" decimals="-5" scale="6">4.0</ix:nonFraction> million drug product revenue related to the same API shipments for the change in estimated variable consideration based on the API held by Astellas at March 31, 2021, under the same methodology. This amount was unbilled to Astellas as of March 31, 2021, and was billed and received from Astellas during the second quarter of 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2021, the Company shipped bulk drug product from process validation supplies for commercial purposes under the terms of the Europe Agreement and the EU Supply Agreement with Astellas. The Company recorded the consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000751" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630" decimals="-5" scale="6">11.8</ix:nonFraction> million from this shipment as deferred revenue as of June 30, 2021, due to a high degree of uncertainty associated with the final consideration. The deferred revenue will be recognized as and when uncertainty is resolved.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000546" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210101_20210630" escape="true" continuedAt="F_000546_cnt_1">The following table includes a roll-forward of the above-mentioned deferred revenues that are considered as contract liabilities related to drug product (in thousands):</ix:nonNumeric></p><ix:continuation id="F_000546_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognized as Revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - Japan Agreement</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000752" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000756" name="fgen:ContractWithCustomerLiabilityAdditions" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,974</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000760" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000764" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,974</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - Europe Agreement</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000753" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,984</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000757" name="fgen:ContractWithCustomerLiabilityAdditions" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">11,759</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000761" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000765" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">17,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca - U.S.&#160;Agreement</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000754" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000758" name="fgen:ContractWithCustomerLiabilityAdditions" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">11,171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000762" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000766" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">11,171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue - deferred revenue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000755" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,984</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000759" name="fgen:ContractWithCustomerLiabilityAdditions" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">24,904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000763" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000767" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">30,888</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:continuation></ix:continuation></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000517" name="us-gaap:VariableInterestEntityDisclosureTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Variable Interest Entity</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang is a distribution entity jointly owned by AstraZeneca and FibroGen Beijing. FibroGen Beijing owns <ix:nonFraction unitRef="U_xbrlipure" id="F_000768" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAstraZenecaABMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20210630" decimals="3" scale="-2">51.1</ix:nonFraction>% of the outstanding shares of Falikang. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the guidance under ASC 810, <span style="font-style:italic;">Consolidation</span> (&#8220;ASC 810&#8221;), the Company concluded that Falikang qualifies as a variable interest entity (&#8220;VIE&#8221;). As Falikang is a distribution entity and AstraZeneca is the final decision maker for all the roxadustat commercialization activities, the Company lacks the power criterion while AstraZeneca meets both the power and economic criteria under the ASC 810, to direct the activities of Falikang that most significantly impact its performance. Therefore, the Company is not the primary beneficiary of this VIE for accounting purposes. As a result, the Company accounts for its investment in Falikang under the equity method, and Falikang is not consolidated into the Company&#8217;s condensed consolidated financial statements. Accordingly, the Company records its total investments in Falikang as an equity method investment in an unconsolidated variable interest entity in the condensed consolidated balance sheet. In addition, the Company recognizes its proportionate share of the reported profits or losses of Falikang as investment gain or loss in unconsolidated variable interest entity in the condensed consolidated statement of operations, and as an adjustment to its investment in Falikang in the condensed consolidated balance sheet. Falikang has not incurred material profit or loss to date. The Company may provide shareholder loans to Falikang to meet necessary financial obligations as part of its operations. To date, these loans have been immaterial. </p><ix:nonNumeric id="F_000547" name="us-gaap:EquityMethodInvestmentsTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s&#160;equity&#160;method&#160;investment&#160;in Falikang was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Entity</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership Percentage</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share of Net Income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Currency</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Translation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000769" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210630" decimals="3" scale="-2">51.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000770" name="us-gaap:EquityMethodInvestments" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000771" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210101_20210630" decimals="-3" scale="3">323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000772" name="fgen:EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210101_20210630" decimals="-3" scale="3">32</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000773" name="us-gaap:EquityMethodInvestments" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,083</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang is considered a related party to the Company. See Note 9, <span style="font-style:italic;">Related Party Transactions</span>, for related disclosures.</p></ix:nonNumeric><ix:nonNumeric id="F_000518" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000518_dcnt_ddbfca56-225f-40e2-acdb-4eb369f1c699">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value Measurements</p></td></tr></table></div><ix:nonNumeric id="F_000548" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000548_dcnt_06a600e9-a763-46a2-aa89-44eb46866d57">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company&#8217;s financial assets that are measured on a recurring basis are as follows (in thousands):</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000518_dcnt_ddbfca56-225f-40e2-acdb-4eb369f1c699" continuedAt="F_000518_dcnt_29e55b9e-93b8-4831-a0c4-8c2a600f6c5c"><ix:continuation id="F_000548_dcnt_06a600e9-a763-46a2-aa89-44eb46866d57">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000774" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">220,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000775" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000776" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000777" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">220,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000778" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000779" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">104,483</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000780" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000781" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">104,483</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000782" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000783" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">72,099</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000784" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000785" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">72,099</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000786" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenUSGovernmentBondsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">46,568</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000787" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenUSGovernmentBondsMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000788" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenUSGovernmentBondsMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000789" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenUSGovernmentBondsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">46,568</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agency bonds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000790" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenAgencyBondsMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000791" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenAgencyBondsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">14,284</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000792" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenAgencyBondsMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000793" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenAgencyBondsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">14,284</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000794" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000795" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">12,490</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000796" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000797" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">12,490</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign government bonds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000798" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000799" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">12,151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000800" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000801" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">12,151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000806" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630" decimals="-3" scale="3">233</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000807" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000808" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000809" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630" decimals="-3" scale="3">233</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000810" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">267,428</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000811" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">215,507</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000812" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000813" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">482,935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000814" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000815" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000816" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000817" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000818" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" scale="3">244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000819" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000820" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000821" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" scale="3">244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000822" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">590,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000823" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000824" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000825" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">590,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000826" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">590,591</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000827" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000828" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000829" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">598,735</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Level 2 investments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data and other observable inputs. There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000830" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" contextRef="C_0000921299_20210630" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000831" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" contextRef="C_0000921299_20210630" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000832" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" contextRef="C_0000921299_20210101_20210630" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000833" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" contextRef="C_0000921299_20210101_20210630" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers of assets between levels during the three and six months ended June&#160;30, 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial liabilities related to lease obligations as of June 30, 2021 and December 31, 2020 were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000834" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0000921299_20210630" decimals="-5" scale="6">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000835" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0000921299_20201231" decimals="-5" scale="6">1.1</ix:nonFraction> million, respectively. The fair values of the Company&#8217;s financial liabilities are carried at historical cost that were derived by using an income approach, which required Level 3 inputs such as discounted estimated future cash flows. There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000836" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" contextRef="C_0000921299_20210630" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000838" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" contextRef="C_0000921299_20210630" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000840" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" contextRef="C_0000921299_20210630" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000842" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" contextRef="C_0000921299_20210630" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000844" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" contextRef="C_0000921299_20210101_20210630" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000846" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" contextRef="C_0000921299_20210101_20210630" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000848" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" contextRef="C_0000921299_20210101_20210630" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000850" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" contextRef="C_0000921299_20210101_20210630" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000837" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" contextRef="C_0000921299_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000839" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" contextRef="C_0000921299_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000841" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" contextRef="C_0000921299_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000843" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" contextRef="C_0000921299_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000845" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" contextRef="C_0000921299_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000847" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" contextRef="C_0000921299_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000849" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" contextRef="C_0000921299_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000851" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" contextRef="C_0000921299_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers of assets or liabilities between levels for any of the periods presented.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000518_dcnt_29e55b9e-93b8-4831-a0c4-8c2a600f6c5c">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000519" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000519_dcnt_b7808a9b-ad73-4908-a72a-babdf2c7d5b3">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Leases</p></td></tr></table></div><ix:nonNumeric id="F_000549" name="fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s lease assets and related lease liabilities were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Line Item</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets - cost</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000852" name="fgen:FinanceLeaseRightOfUseAssetsCost" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000853" name="fgen:FinanceLeaseRightOfUseAssetsCost" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">50,477</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000854" name="fgen:FinanceLeaseAccumulatedAmortization" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,146</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000855" name="fgen:FinanceLeaseAccumulatedAmortization" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,871</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets, net</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000856" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_20210630" decimals="-3" scale="3">861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000857" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating:</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets - cost</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000858" name="fgen:OperatingLeaseRightOfUseAssetsCost" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">100,705</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000859" name="fgen:OperatingLeaseRightOfUseAssetsCost" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,934</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000860" name="fgen:OperatingLeaseAccumulatedAmortization" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,614</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000861" name="fgen:OperatingLeaseAccumulatedAmortization" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,891</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets, net</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000862" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">97,091</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000863" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,043</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease assets</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000864" name="fgen:FinanceLeaseAndOperatingLeaseAssets" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">97,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000865" name="fgen:FinanceLeaseAndOperatingLeaseAssets" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,649</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000866" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="C_0000921299_20210630" decimals="-3" scale="3">23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000867" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,330</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000868" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">10,718</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000869" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000870" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="C_0000921299_20210630" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000871" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, non-current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000872" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">94,196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000873" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" scale="3">853</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000874" name="fgen:FinanceLeaseAndOperatingLeaseLiability" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">104,943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000875" name="fgen:FinanceLeaseAndOperatingLeaseLiability" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,762</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s long-term property lease with Alexandria for its corporate headquarters in San Francisco, California, had an initial term of <ix:nonNumeric id="F_000876" name="us-gaap:LesseeFinanceLeaseTermOfContract1" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210630" format="ixt-sec:duryear">15</ix:nonNumeric>&#160;years, scheduled to expire in <ix:nonNumeric id="F_000877" name="fgen:LesseeFinanceLeaseExpirationPeriod" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210101_20210630">2023</ix:nonNumeric>. The original lease was accounted for as a finance lease upon adoption of ASC 842, <span style="font-style:italic;">Leases</span> (&#8220;ASC 842&#8221;), at January 1, 2019. <br /></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 1, 2021, the Company entered into an amendment with Alexandria to extend the lease to <ix:nonNumeric id="F_000879" name="fgen:LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601">2028</ix:nonNumeric> (&#8220;Lease Amendment&#8221;). <ix:nonNumeric id="F_000881" name="us-gaap:LesseeFinanceLeaseOptionToExtend" contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601">Under the terms of the Lease Amendment, the Company has <ix:nonFraction unitRef="U_fgenOption" id="F_000882" name="fgen:NumberOfOptionalRightsToExtendLease" contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> optional rights to each extend the lease for an additional <ix:nonNumeric id="F_000883" name="fgen:LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601" format="ixt-sec:durwordsen">five years</ix:nonNumeric>.</ix:nonNumeric> The lease contract provides for a fixed annual rent, with scheduled increases of <ix:nonFraction unitRef="U_xbrlipure" id="F_000880" name="fgen:PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601" decimals="2" format="ixt-sec:numwordsen" scale="-2">two</ix:nonFraction> percent that occur on each anniversary of the rent commencement date through <ix:nonNumeric id="F_000884" name="fgen:ScheduledRentCommencementYearOptionOne" contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601">2023</ix:nonNumeric>, and with scheduled increases of <ix:nonFraction unitRef="U_xbrlipure" id="F_000885" name="fgen:PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo" contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601" decimals="2" format="ixt-sec:numwordsen" scale="-2">three</ix:nonFraction> percent that occur on each anniversary of the rent commencement date through <ix:nonNumeric id="F_000886" name="fgen:ScheduledRentCommencementYearOptionTwo" contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601">2028</ix:nonNumeric>. This lease requires the Company to pay all costs of ownership, operation, and maintenance of the premises, including without limitation all operating costs, insurance costs, and taxes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company determined that the Lease Amendment was a lease modification, effective June 1, 2021, and thus reassessed the lease classification, remeasured the related lease liability using an updated discount rate, and adjusted the related right-of-use asset under the lease modification guidance under the ASC 842. Accordingly, on June 1, 2021, the Company determined that the modified lease be accounted for as an operating lease, and therefore derecognized the previous finance lease right-of-use asset of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000887" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601" decimals="-5" scale="6">24.6</ix:nonFraction> million and the related finance lease liability of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000888" name="us-gaap:FinanceLeaseLiability" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601" decimals="-5" scale="6">32.6</ix:nonFraction> million, and recognized an operating lease right-of-use asset of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000889" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601" decimals="-5" scale="6">93.2</ix:nonFraction> million and the related operating lease liability of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000890" name="us-gaap:OperatingLeaseLiability" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601" decimals="-5" scale="6">101.2</ix:nonFraction> million. Starting June 1, 2021, the cash payment related to this lease was classified as an operating activity, the impact of which was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000891" name="us-gaap:OperatingLeasePayments" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210101_20210630" decimals="-5" scale="6">1.1</ix:nonFraction> million to the condensed consolidated statement of cash flow for the six months ended June 30, 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2021, after FibroGen Beijing&#8217;s previous long-term lease agreement expired, the Company entered into a new lease agreement with the landlord for the same pilot plant located in Beijing Yizhuang Biomedical Park of BDA. The new lease term is <ix:nonNumeric id="F_000892" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20210331" format="ixt-sec:durwordsen">five year</ix:nonNumeric>, scheduled to expire in <ix:nonNumeric id="F_000893" name="fgen:LesseeOperatingLeaseExpirationPeriod" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20210101_20210331">2026</ix:nonNumeric>, and is treated as an operating lease. Accordingly, the Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000894" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20210331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000895" name="us-gaap:OperatingLeaseLiability" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20210331" decimals="-5" scale="6">3.4</ix:nonFraction></ix:nonFraction> million in the operating right-of-use assets and total operating lease liabilities, respectively. The lease contract provides for fixed quarterly rent payments, and require the Company to pay operating and maintenance costs.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000519_dcnt_b7808a9b-ad73-4908-a72a-babdf2c7d5b3" continuedAt="F_000519_dcnt_8982c7ac-2592-445b-8861-60b85a52e5cb">

<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000550" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense were as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of Operations Line Item</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease cost:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; right-of-use assets</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold&#59;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development&#59;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000896" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0000921299_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,777</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000897" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0000921299_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,653</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000898" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,393</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000899" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,247</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000900" name="us-gaap:FinanceLeaseInterestExpense" contextRef="C_0000921299_20210401_20210630" decimals="-3" scale="3">242</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000901" name="us-gaap:FinanceLeaseInterestExpense" contextRef="C_0000921299_20200401_20200630" decimals="-3" scale="3">534</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000902" name="us-gaap:FinanceLeaseInterestExpense" contextRef="C_0000921299_20210101_20210630" decimals="-3" scale="3">627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000903" name="us-gaap:FinanceLeaseInterestExpense" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,049</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold&#59;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development&#59;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000904" name="us-gaap:OperatingLeaseCost" contextRef="C_0000921299_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,744</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000905" name="us-gaap:OperatingLeaseCost" contextRef="C_0000921299_20200401_20200630" decimals="-3" scale="3">255</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000906" name="us-gaap:OperatingLeaseCost" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,162</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000907" name="us-gaap:OperatingLeaseCost" contextRef="C_0000921299_20200101_20200630" decimals="-3" scale="3">564</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000908" name="us-gaap:SubleaseIncome" contextRef="C_0000921299_20210401_20210630" decimals="-3" scale="3">275</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000909" name="us-gaap:SubleaseIncome" contextRef="C_0000921299_20200401_20200630" decimals="-3" scale="3">306</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000910" name="us-gaap:SubleaseIncome" contextRef="C_0000921299_20210101_20210630" decimals="-3" scale="3">575</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000911" name="us-gaap:SubleaseIncome" contextRef="C_0000921299_20200101_20200630" decimals="-3" scale="3">598</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000912" name="us-gaap:LeaseCost" contextRef="C_0000921299_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,488</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000913" name="us-gaap:LeaseCost" contextRef="C_0000921299_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,136</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000914" name="us-gaap:LeaseCost" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,607</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000915" name="us-gaap:LeaseCost" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,262</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000551" name="fgen:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to leases were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000916" name="us-gaap:OperatingLeasePayments" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,246</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000917" name="us-gaap:OperatingLeasePayments" contextRef="C_0000921299_20200101_20200630" decimals="-3" scale="3">433</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from finance leases</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000918" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="C_0000921299_20210101_20210630" decimals="-3" scale="3">628</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000919" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,010</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows from finance leases</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000920" name="fgen:RepaymentsOfFinanceLeaseLiabilities" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,326</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000921" name="fgen:RepaymentsOfFinanceLeaseLiabilities" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,992</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-cash: Right-of-use assets obtained in exchange for new lease liabilities:</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000922" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="C_0000921299_20210101_20210630" decimals="-3" scale="3">303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000923" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="C_0000921299_20200101_20200630" decimals="-3" scale="3">144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000924" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,498</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000925" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0000921299_20200101_20200630" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-cash: Increase (decrease) resulting from lease modification:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000926" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">24,654</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000927" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000928" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">93,222</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000929" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000930" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">12,587</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000931" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000932" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">9,221</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000933" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000934" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">20,009</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000935" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, non-current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000936" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">91,943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000937" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000552" name="fgen:ScheduleOfLeaseTermAndDiscountRateTableTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease term and discount rate were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (years):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000938">1.3</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000939">2.9</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000940">7.3</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000941">1.8</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate:</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000942" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="C_0000921299_20210630" decimals="4" scale="-2">4.55</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000943" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="C_0000921299_20201231" decimals="4" scale="-2">4.39</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000944" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0000921299_20210630" decimals="4" scale="-2">4.75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000945" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0000921299_20201231" decimals="4" scale="-2">4.74</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000519_dcnt_8982c7ac-2592-445b-8861-60b85a52e5cb">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000553" name="fgen:ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of lease liabilities as of June&#160;30, 2021 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance&#160;Leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating&#160;Leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 (remaining six month period)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000946" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="C_0000921299_20210630" decimals="-3" scale="3">16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000955" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">7,534</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000947" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0000921299_20210630" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000956" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">15,517</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000948" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0000921299_20210630" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000957" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">13,454</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000949" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000958" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">16,798</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000950" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000959" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">18,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beyond 2025</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000951" name="fgen:FinanceLeaseLiabilityPaymentsDueAfterYearFour" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000960" name="fgen:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">53,881</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future lease payments</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000952" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="C_0000921299_20210630" decimals="-3" scale="3">30</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000961" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">125,377</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Interest</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000953" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0000921299_20210630" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000962" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">20,463</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000954" name="us-gaap:FinanceLeaseLiability" contextRef="C_0000921299_20210630" decimals="-3" scale="3">29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000963" name="us-gaap:OperatingLeaseLiability" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">104,914</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000520" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000520_dcnt_44cf3871-2510-4bc9-9c66-fbd88c876f72">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Balance Sheet Components</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p><ix:nonNumeric id="F_000554" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000964" name="us-gaap:Cash" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">130,035</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000965" name="us-gaap:Cash" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">88,046</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000966" name="us-gaap:CommercialPaperAtCarryingValue" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,699</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000967" name="us-gaap:CommercialPaperAtCarryingValue" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000968" name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">220,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000969" name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">590,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000970" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">353,361</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000971" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">678,393</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June&#160;30, 2021 and December&#160;31, 2020, a total of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000972" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000921299_us-gaapGeographicDistributionAxis_us-gaapGeographicDistributionForeignMember_20210630" decimals="-5" scale="6">85.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000973" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000921299_us-gaapGeographicDistributionAxis_us-gaapGeographicDistributionForeignMember_20201231" decimals="-5" scale="6">66.0</ix:nonFraction> million, respectively, of the Company&#8217;s cash and cash equivalents were held outside of the U.S. in its foreign subsidiaries to be used primarily for its China operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investments</p><ix:nonNumeric id="F_000555" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s investments consist of available-for-sale debt investments and marketable equity investments. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#8217;s investments by major investments type are summarized in the tables below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000974" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">104,499</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000985" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630" decimals="-3" scale="3">27</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000996" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630" decimals="-3" scale="3">43</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001007" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">104,483</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000975" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">69,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000986" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000997" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001008" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">69,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000976" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">46,589</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000987" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000998" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210630" decimals="-3" scale="3">21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001009" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">46,568</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agency bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000977" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapBondsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">14,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000988" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapBondsMember_20210630" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000999" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapBondsMember_20210630" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001010" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapBondsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">14,284</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000978" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">12,489</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000989" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001000" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001011" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">12,490</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign government bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000979" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">12,151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000990" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001001" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001012" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">12,151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000980" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630" decimals="-3" scale="3">118</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000991" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630" decimals="-3" scale="3">115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001002" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001013" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630" decimals="-3" scale="3">233</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000981" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">259,534</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000992" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_20210630" decimals="-3" scale="3">146</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001003" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_20210630" decimals="-3" scale="3">71</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001014" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">259,609</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000982" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,147</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000993" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001004" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001015" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000983" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" scale="3">125</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000994" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" scale="3">119</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001005" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001016" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" scale="3">244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000984" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,272</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000995" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_20201231" decimals="-3" scale="3">119</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001006" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001017" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,388</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June&#160;30, 2021, the available-for-sale investments had contractual maturities range from several months to <ix:nonNumeric id="F_001018" name="fgen:AvailableForSaleSecuritiesContractualMaturityPeriod" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_20210101_20210630" format="ixt-sec:durwordsen">two years</ix:nonNumeric>. During the three and six months ended June&#160;30, 2021 and 2020, the Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_001019" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" contextRef="C_0000921299_20210101_20210630" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_001020" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" contextRef="C_0000921299_20210401_20210630" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t recognize any other-than-temporary impairment loss.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000520_dcnt_44cf3871-2510-4bc9-9c66-fbd88c876f72" continuedAt="F_000520_dcnt_0cf6589a-2c38-4275-9c0a-15213da53bd9">

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inventories</p><ix:nonNumeric id="F_000556" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001021" name="us-gaap:InventoryRawMaterials" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,190</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001022" name="us-gaap:InventoryRawMaterials" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in-progress</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001023" name="us-gaap:InventoryWorkInProcess" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">15,541</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001024" name="us-gaap:InventoryWorkInProcess" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001025" name="us-gaap:InventoryFinishedGoods" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">7,799</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001026" name="us-gaap:InventoryFinishedGoods" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001027" name="us-gaap:InventoryNet" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">24,530</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001028" name="us-gaap:InventoryNet" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,530</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes inventory costs for FibroGen Beijing&#8217;s production of roxadustat for commercial sales purposes. The Company started capitalizing pre-launch inventory costs in the second quarter of 2020 prior to regulatory approvals in the U.S. and other territories. As of June&#160;30, 2021 and December&#160;31, 2020, pre-launch inventory capitalized was <ix:nonFraction unitRef="U_xbrlipure" id="F_001029" name="fgen:PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" contextRef="C_0000921299_20210630" decimals="2" scale="-2">37</ix:nonFraction>% and <ix:nonFraction unitRef="U_xbrlipure" id="F_001030" name="fgen:PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" contextRef="C_0000921299_20201231" decimals="2" scale="-2">29</ix:nonFraction>% of the total inventory balance, respectively. The provision to write-down excess and obsolete inventory was immaterial for three and six months ended June&#160;30, 2021 and 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p><ix:nonNumeric id="F_000557" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unbilled contract assets</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001031" name="us-gaap:Supplies" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,256</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001032" name="us-gaap:Supplies" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,147</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues from associated contracts</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001033" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,256</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001034" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,147</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unbilled contract assets</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001035" name="fgen:SuppliesNet" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001036" name="fgen:SuppliesNet" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid assets</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001037" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">7,149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001038" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,353</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001039" name="us-gaap:OtherAssetsCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,309</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001040" name="us-gaap:OtherAssetsCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,807</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001041" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,458</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001042" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unbilled contract assets as of June 30, 2021 of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001043" name="fgen:SuppliesNet" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-5" scale="6">5.3</ix:nonFraction> million related to unbilled co-development revenue under the China Amendment with AstraZeneca. The unbilled contract assets as of December 31, 2020 were related to unbilled co-development revenue under the China Amendment with AstraZeneca. See Note 2, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p><ix:nonNumeric id="F_000558" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001044" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">102,657</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001045" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">102,006</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001046" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,247</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001047" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001048" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,387</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001049" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,312</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001050" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">9,205</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001051" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,545</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001052" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,126</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001053" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001054" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,407</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001055" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" scale="3">760</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001056" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">147,029</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001057" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">144,894</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001058" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">116,359</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001059" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">111,247</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001060" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">30,670</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001061" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,647</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000520_dcnt_0cf6589a-2c38-4275-9c0a-15213da53bd9">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued and Other Current Liabilities </p><ix:nonNumeric id="F_000559" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical trial accruals</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001062" name="fgen:AccruedPreclinicalAndClinicalTrialCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">65,274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001063" name="fgen:AccruedPreclinicalAndClinicalTrialCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related accruals</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001064" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">18,047</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001065" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities to pharmaceutical distributors</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001066" name="fgen:AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">13,793</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001067" name="fgen:AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,137</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued co-promotion expenses - current</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001068" name="fgen:AccruedCoPromotionExpensesCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">20,832</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001069" name="fgen:AccruedCoPromotionExpensesCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,537</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat profit share to AstraZeneca</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001070" name="fgen:AccruedProfitShareCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">7,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001071" name="fgen:AccruedProfitShareCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property taxes and other taxes</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001072" name="fgen:PropertyTaxesAndOtherCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">10,344</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001073" name="fgen:PropertyTaxesAndOtherCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional services</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001074" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">7,471</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001075" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,869</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001076" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,033</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001077" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,900</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued and other current liabilities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001078" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">147,801</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001079" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The profit share liability of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001080" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001081" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-5" scale="6">7.0</ix:nonFraction></ix:nonFraction> million to AstraZeneca as of June 30, 2021 and December 31, 2020 represented the profit/loss share between FibroGen Beijing and AstraZeneca that was calculated for the interim period pursuant to the China Amendment. This liability correspondingly reduced the deferred revenue related to the performance obligation in accordance with the China Amendment.<span style="font-weight:bold;color:#FF0000;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Long-term Liabilities</p><ix:nonNumeric id="F_000560" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued long-term co-promotion expenses</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001082" name="fgen:AccruedLongTermCoPromotionLiabilityNonCurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,205</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001083" name="fgen:AccruedLongTermCoPromotionLiabilityNonCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,424</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term tax liabilities</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001084" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,985</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001085" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,675</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001086" name="us-gaap:OtherSundryLiabilitiesNoncurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,469</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001087" name="us-gaap:OtherSundryLiabilitiesNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,690</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other long-term liabilities</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001088" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0000921299_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">30,659</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001089" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,789</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000521" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000521_dcnt_96227a40-848b-4b74-a7f2-563babfc8fed">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock-Based Compensation</p></td></tr></table></div><ix:nonNumeric id="F_000561" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was recorded directly to research and development and selling, general and administrative expense as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001090" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">10,681</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001091" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">10,780</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001092" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">22,903</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001093" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">21,417</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001094" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,320</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001095" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,864</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001096" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">15,482</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001097" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">13,143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001098" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001099" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">17,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001100" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">38,385</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001101" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">34,560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000562" name="fgen:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to estimate the fair value of stock options granted and purchases under the Company&#8217;s 2014 Employee Share Purchase Plan (&#8220;ESPP&#8221;) using the Black-Scholes option valuation model were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001102">5.6</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001103">5.5</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001104">5.7</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001105">5.7</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001106" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210401_20210630" decimals="3" scale="-2">63.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001107" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200401_20200630" decimals="3" scale="-2">69.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001108" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="3" scale="-2">59.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001109" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200630" decimals="3" scale="-2">68.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001110" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210401_20210630" decimals="3" scale="-2">0.9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001111" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200401_20200630" decimals="3" scale="-2">0.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001112" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="3" scale="-2">0.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001113" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200630" decimals="3" scale="-2">0.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001114" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210401_20210630" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001115" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200401_20200630" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001116" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001117" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200630" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average estimated fair value</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001118" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210401_20210630" decimals="2">11.91</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001119" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200401_20200630" decimals="2">21.72</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001120" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="2">25.38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001121" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200630" decimals="2">17.75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ESPPs</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001122">0.5 - 2.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001123">0.5 - 2.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001124">0.5 - 2.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001125">0.5 - 2.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.5 - 104.2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.5 - 77.1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.5 - 104.2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.5 - 77.1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0 - 2.2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2 - 2.9</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0 - 2.2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2 - 2.9</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001146" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001147" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001148" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001149" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average estimated fair value</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001150" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630" decimals="2">13.60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001151" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630" decimals="2">17.82</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001152" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630" decimals="2">14.69</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001153" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630" decimals="2">18.11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000521_dcnt_96227a40-848b-4b74-a7f2-563babfc8fed">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000522" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.</span></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for (benefit from) income tax for the three and six months ended June 30, 2021 were primarily due to foreign taxes. Provision for (benefit from) income tax for the three and six months ended June 30, 2020 were primarily due to the tax effect arising from other comprehensive income related to available-for-sale securities, and foreign taxes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon the weight of available evidence, which includes its historical operating performance, reported cumulative net losses since inception, the Company has established and continues to maintain a full valuation allowance against its net deferred tax assets as it does not currently believe that realization of those assets is more likely than not.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000523" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.</span></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Related Party Transactions </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas is an equity investor in the Company and is considered a related party. The Company recorded revenue related to collaboration agreements with Astellas of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001154" name="us-gaap:RevenueFromRelatedParties" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210401_20210630" decimals="-5" scale="6">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001155" name="us-gaap:RevenueFromRelatedParties" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200401_20200630" decimals="-5" scale="6">4.8</ix:nonFraction> million for the three months ended June 30, 2021 and 2020, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001156" name="us-gaap:RevenueFromRelatedParties" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20210630" decimals="-5" scale="6">6.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001157" name="us-gaap:RevenueFromRelatedParties" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20200630" decimals="-5" scale="6">9.5</ix:nonFraction> million for the six months ended June&#160;30, 2021 and 2020, respectively. The Company also recorded drug product revenue from Astellas of $(<ix:nonFraction unitRef="U_iso4217USD" id="F_001158" name="fgen:DrugProductRevenueFromRelatedParty" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20210401_20210630" decimals="-5" sign="-" scale="6">2.0</ix:nonFraction>) million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001159" name="fgen:DrugProductRevenueFromRelatedParty" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200401_20200630" decimals="-5" scale="6">8.2</ix:nonFraction> million for the three months ended June 30, 2021 and 2020, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001160" name="fgen:DrugProductRevenueFromRelatedParty" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20210101_20210630" decimals="-5" scale="6">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001161" name="fgen:DrugProductRevenueFromRelatedParty" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200101_20200630" decimals="-5" scale="6">8.2</ix:nonFraction> million for the six months ended June&#160;30, 2021 and 2020, respectively. See Note 2, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s expense related to collaboration agreements with Astellas was immaterial for each of the three and six months ended June 30, 2021 and 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021 and December&#160;31, 2020, accounts receivable from Astellas were $<ix:nonFraction unitRef="U_iso4217USD" id="F_001162" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210630" decimals="-5" scale="6">2.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001163" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231" decimals="-5" scale="6">4.1</ix:nonFraction>&#160;million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021 and December&#160;31, 2020, total deferred revenue from Astellas was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001165" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210630" decimals="-5" scale="6">20.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001166" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231" decimals="-5" scale="6">7.5</ix:nonFraction>&#160;million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2021, the amount due to Astellas was immaterial. As of December&#160;31, 2020, amount due to Astellas was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001164" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231" decimals="-5" scale="6">1.1</ix:nonFraction>&#160;million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang, an entity jointly owned by FibroGen Beijing and AstraZeneca is an unconsolidated VIE accounted for as an equity method investment, and considered as a related party to the Company. FibroGen Beijing owns <ix:nonFraction unitRef="U_xbrlipure" id="F_001171" name="us-gaap:VariableInterestEntityOwnershipPercentage" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210101_20210630" decimals="3" scale="-2">51.1</ix:nonFraction>% of Falikang&#8217;s equity. See Note 3, <span style="font-style:italic;">Variable Interest Entity</span>, for details. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three and six months ended June&#160;30, 2021, the net product revenue from Falikang was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001174" name="us-gaap:RevenueFromRelatedParties" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210401_20210630" decimals="-5" scale="6">11.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001175" name="us-gaap:RevenueFromRelatedParties" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20210630" decimals="-5" scale="6">22.2</ix:nonFraction> million, respectively. See Note 2, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three and six months ended June&#160;30, 2021, the investment income in Falikang was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001167" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210401_20210630" decimals="-5" sign="-" scale="6">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001168" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210101_20210630" decimals="-5" sign="-" scale="6">0.3</ix:nonFraction> million, respectively. As of June&#160;30, 2021 and December&#160;31, 2020, the Company&#8217;s equity method investment in Falikang was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001169" name="us-gaap:EquityMethodInvestments" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210630" decimals="-5" scale="6">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001170" name="us-gaap:EquityMethodInvestments" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20201231" decimals="-5" scale="6">2.7</ix:nonFraction> million, respectively. See Note 3, <span style="font-style:italic;">Variable Interest Entity</span>, for details.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021, accounts receivable, net, from Falikang was of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001176" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210630" decimals="-5" scale="6">10.8</ix:nonFraction> million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021, there was <ix:nonFraction unitRef="U_iso4217USD" id="F_001172" name="fgen:MiscellaneousReceivables" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210630" decimals="INF" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction> miscellaneous receivables from Falikang. As of December&#160;31, 2020, prepaid expenses and other current assets included miscellaneous receivables from Falikang of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001173" name="fgen:MiscellaneousReceivables" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20201231" decimals="-5" scale="6">0.9</ix:nonFraction> million.</p></ix:nonNumeric><ix:nonNumeric id="F_000524" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000524_dcnt_997d8545-edc4-44bb-887e-6b415cbf01f9">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.<span style="margin-left:36pt;">Commitments and Contingencies</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Obligations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021, the Company had outstanding total non-cancelable purchase obligations of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001177" name="us-gaap:ContractualObligation" contextRef="C_0000921299_20210630" decimals="-5" scale="6">81.9</ix:nonFraction> million, including $<ix:nonFraction unitRef="U_iso4217USD" id="F_001178" name="us-gaap:ContractualObligation" contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfRoxadustatMember_20210630" decimals="-5" scale="6">29.6</ix:nonFraction> million for manufacture and supply of roxadustat, $<ix:nonFraction unitRef="U_iso4217USD" id="F_001179" name="us-gaap:ContractualObligation" contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfPamrevlumabMember_20210630" decimals="-5" scale="6">47.3</ix:nonFraction> million for manufacture and supply of pamrevlumab, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001180" name="us-gaap:ContractualObligation" contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenOtherPurchasesMember_20210630" decimals="-5" scale="6">5.0</ix:nonFraction> million for other purchases. The Company expects to fulfill our commitments under these agreements in the normal course of business, and as such, no liability has been recorded. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the Company&#8217;s license agreements provide for periodic maintenance fees over specified time periods, as well as payments by the Company upon the achievement of development, regulatory and commercial milestones. As of June 30, 2021, future milestone payments for research and pre-clinical stage development programs consisted of up to approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001181" name="fgen:MaximumFutureMilestonePayments" contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenResearchAndPreClinicalStageDevelopmentProgramsMember_20210101_20210630" decimals="-5" scale="6">359.2</ix:nonFraction> million in total potential future milestone payments under the Company&#8217;s license agreements with HiFiBiO (for Galectin-9), Medarex, Inc. and others. These milestone payments generally become due and payable only upon the achievement of certain developmental, clinical, regulatory and/or commercial milestones. The event triggering such payment or obligation has not yet occurred.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000524_dcnt_997d8545-edc4-44bb-887e-6b415cbf01f9">

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Legal Proceedings</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company is a party to various legal actions, both inside and outside the U.S., arising in the ordinary course of its business or otherwise. The Company accrues amounts, to the extent they can be reasonably estimated, that the Company believes will result in a probable loss (including, among other things, probable settlement value), to adequately address any liabilities related to legal proceedings and other loss contingencies. A loss or a range of loss is disclosed when it is reasonably possible that a material loss will incur and can be estimated, or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not have material accruals for any currently active legal action in its condensed consolidated balance sheets as of June&#160;30, 2021, as it could not predict the ultimate outcome of these matters, or reasonably estimate the potential exposure. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2021, <ix:nonFraction unitRef="U_fgenPutativeClassAction" id="F_001182" name="us-gaap:LossContingencyNewClaimsFiledNumber" contextRef="C_0000921299_20210401_20210430" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> putative securities class action complaints were filed against FibroGen and certain of its current and former executive officers (collectively, the &#8220;Defendants&#8221;) in the U.S. District Court for the Northern District of California. The lawsuits allege that Defendants violated the Securities Exchange Act of 1934 by making materially false and misleading statements regarding FibroGen&#8217;s Phase 3 clinical studies data and prospects for FDA approval between November 2019 and December 2020. Plaintiffs seek to represent a class of persons or entities that purchased FibroGen securities between November 8, 2019 and April 6, 2021. In May 2021, <ix:nonFraction unitRef="U_fgenPutativeClassAction" id="F_001183" name="us-gaap:LossContingencyNewClaimsFiledNumber" contextRef="C_0000921299_20210501_20210531" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> additional putative securities class action complaints were filed against Defendants alleging the same claims. One of the lawsuits alleges that Defendants made materially false and misleading statements between October 2017 and December 2020 and seeks to represent a class of persons or entities that purchased FibroGen securities between October 18, 2017 and April 6, 2021. The other lawsuit alleges that Defendants made materially false and misleading statements between December 2018 and February 2020 and seeks to represent a class of persons or entities that purchased FibroGen securities between December 20, 2018 and April 6, 2021. All plaintiffs seek unspecified monetary damages and other relief. Motions for lead plaintiff were filed on June 11, 2021 and a hearing on the motion is scheduled for August 19, 2021. Once a lead plaintiff is appointed by the Court, the Company expects to receive an amended consolidated complaint. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 30, 2021, a purported shareholder derivative complaint was filed in the U.S. District Court for the Northern District of California.&#160;The complaint names as defendants ten of the Company&#8217;s officers and directors, as well as the Company as nominal defendant, and asserts state and federal claims based on some of the same alleged misstatements as the securities class action complaints.&#160;The complaint seeks unspecified damages, attorneys&#8217; fees, and other costs.&#160;The Company and individual defendants have not yet been served.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that the claims are without merit and it intends to vigorously defend against them. However, any litigation is inherently uncertain, and any judgment or injunctive relief entered against FibroGen or any adverse settlement could materially and adversely impact its business, results of operations, financial condition, and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Indemnification Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into standard indemnification arrangements in the ordinary course of business, including for example, service, manufacturing and collaboration agreements. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, including in connection with intellectual property infringement claims by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the extent permissible under applicable law. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these arrangements is minimal.</p></ix:continuation><ix:nonNumeric id="F_000525" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0000921299_20210101_20210630" escape="true" continuedAt="F_000525_dcnt_a7e6f58f-25c7-45f7-9bbe-d0e007bd8da6">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.<span style="margin-left:36pt;">Subsequent Event</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Outcome of FDA Advisory Committee Review </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 15, 2021, the FDA CRDAC voted to recommend not approving roxadustat for the treatment of anemia due to CKD in adult patients. While the FDA is not required to follow the CRDAC&#8217;s vote, the agency considers the CRDAC&#8217;s non-binding recommendations when making its decision.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluated this subsequent event and concluded that it required adjustment and disclosure in the condensed consolidated financial statements, specifically to the drug product revenue related the bulk drug product shipments to AstraZeneca as commercial supply under the terms of the Master Supply Agreement. As a result, the Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_001184" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630" decimals="-5" scale="6">11.2</ix:nonFraction> million as deferred revenue as of June 30, 2021. See Note 2, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000525_dcnt_a7e6f58f-25c7-45f7-9bbe-d0e007bd8da6" continuedAt="F_000525_dcnt_c844e30f-8f11-4c34-9597-70c6421de018">

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Agreement with Eluminex</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 19, 2021, Eluminex Biosciences (Suzhou) Limited (&#8220;Eluminex&#8221;), an ophthalmology-focused biotechnology company headquartered in Suzhou, China with a US-subsidiary office in San Francisco Bay Area, California, exclusively licensed global rights from FibroGen, Inc. for the development and commercialization of an investigational biosynthetic cornea derived from recombinant human collagen Type III intended to treat patients with corneal blindness.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, Eluminex will make an $<ix:nonFraction unitRef="U_iso4217USD" id="F_001185" name="fgen:CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" contextRef="C_0000921299_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenLicenseAgreementWithEluminexMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210719" decimals="-6" scale="6">8</ix:nonFraction> million upfront payment to FibroGen. In addition, FibroGen may receive up to a total of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001186" name="fgen:FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments" contextRef="C_0000921299_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenLicenseAgreementWithEluminexMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210719_20210719" decimals="-6" scale="6">64</ix:nonFraction> million in future manufacturing, clinical, regulatory, and commercial milestone payments for the biosynthetic cornea program, as well as $<ix:nonFraction unitRef="U_iso4217USD" id="F_001187" name="fgen:CommercialMilestone" contextRef="C_0000921299_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenLicenseAgreementWithEluminexMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210719_20210719" decimals="-6" scale="6">36</ix:nonFraction> million in commercial milestones for the first recombinant collagen III product that is not the biosynthetic cornea. FibroGen will also be eligible to receive <span style="color:#000000;">mid single-digit to low double-digit</span> royalties based upon worldwide net sales<span style="color:#000000;"> of cornea products, and low single-digit to mid single-digit royalties based upon worldwide net sales of other recombinant human collagen type III products that are not cornea products</span>.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:continuation id="F_000525_dcnt_c844e30f-8f11-4c34-9597-70c6421de018">
</ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form&#160;10-Q, and in our Securities and Exchange Commission (&#8220;SEC&#8221;) filings, including our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2020 filed with the SEC on March 1, 2021 (&#8220;2020 Form 10-K&#8221;).</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FORWARD-LOOKING STATEMENTS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and information contained elsewhere in this Quarterly Report on Form 10-Q contain &#8220;forward-looking statements&#8221; within the meaning of Section&#160;21E of the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;), Section 27A of the Securities Act of 1933, as amended (&#8220;Securities Act&#8221;) and within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; or &#8220;continue,&#8221; and similar expressions or variations. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section titled &#8220;Risk Factors,&#8221; set forth in Part&#160;II,&#160;Item 1A of this Quarterly Report on Form&#160;10-Q. The forward-looking statements in this Quarterly Report on Form&#160;10-Q represent our views as of the date of this Quarterly Report on Form&#160;10-Q. We anticipate that subsequent events and developments will cause our views to change. New risks emerge from time to time, and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. While we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form&#160;10-Q and are cautioned not to place undue reliance on such forward-looking statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BUSINESS OVERVIEW </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#8217;s Republic of China (&#8220;China&#8221;). We are a leading biopharmaceutical company developing and commercializing a pipeline of first-in-class therapeutics. We apply our pioneering expertise in hypoxia-inducible factor (&#8220;HIF&#8221;) biology, 2-oxoglutarate enzymology, connective tissue growth factor (&#8220;CTGF&#8221;) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat, our most advanced product, is an oral small molecule inhibitor of HIF prolyl hydroxylase (&#8220;HIF-PH&#8221;) activity that is being commercialized in China (tradename: &#29233;&#29790;&#21331;<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>) for the treatment of anemia caused by chronic kidney disease (&#8220;CKD&#8221;) in dialysis and non-dialysis patients. EVRENZO<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (roxadustat) is also being commercialized in Japan and has been approved in South Korea and Chile for the treatment of anemia associated with CKD in dialysis and non-dialysis patients. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-right:2.04%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2021, the Committee for Medicinal Products for Human Use of the European Medicines Agency (&#8220;EMA&#8221;) adopted a positive opinion, recommending the granting of Marketing Authorization Application (&#8220;MAA&#8221;) for the medicinal product Evrenzo (roxadustat), intended for the treatment of adult patients with symptomatic anemia associated with CKD. Our partner Astellas Pharma Inc. (&#8220;Astellas&#8221;) expects an approval decision on the MAA for roxadustat by the European Commission in August 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) Cardiovascular and Renal Drugs Advisory Committee (&#8220;CRDAC&#8221;) voted to recommend not approving roxadustat, an oral HIF-PH inhibitor, for the treatment of anemia due to CKD in adult patients. The CRDAC vote was 13 to 1 for non-dialysis dependent CKD patients, and 12 to 2 for dialysis-dependent CKD patients. While the FDA is not required to follow CRDAC&#8217;s vote, the agency considers CRDAC&#8217;s non-binding recommendations when making its decision. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 3 development in China for anemia associated with myelodysplastic syndromes (&#8220;MDS&#8221;). Roxadustat is in Phase 2 clinical development for chemotherapy-induced anemia. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab, a human monoclonal antibody targeting CTGF, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (&#8220;IPF&#8221;), pancreatic cancer and Duchenne muscular dystrophy (&#8220;DMD&#8221;).  </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Impact of </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Severe Acute Respiratory Syndrome Coronavirus 2 and the resulting Coronavirus Disease (&#8220;</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">COVID-19</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 11, 2020, COVID-19, a disease caused by a novel strain of the coronavirus, was characterized as a pandemic by the World Health Organization. The rapid spread has resulted in authorities implementing numerous measures to contain the virus.&#160;&#160; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have taken measures to minimize the health risks of COVID-19 to our staff, patients, healthcare providers and their communities, as their safety and well-being are our top priority. In the U.S., our employees are working remotely when possible, while in China they have returned to work in our offices, manufacturing plants, and are performing medical affairs out in the field. While we have seen some impacts from COVID-19, such as slower enrollment in our clinical trials, particularly our Phase 3 IPF program, we do not know if, or to what extent, these effects will continue in the future, as the impact of the COVID-19 pandemic continues to unfold. The effect on our operational and financial performance beyond those effects described above, including any impact on sales of roxadustat, will depend in large part on future developments with the pandemic, which cannot be predicted with confidence at this time. Future developments include the duration, scope, and severity of the COVID-19 pandemic, the actions taken to contain or mitigate its impact, the impact on governmental programs and budgets, the impact on healthcare systems and operating procedures, the development of treatments or roll out of vaccines, and the resumption of widespread economic activity. Due to the inherent uncertainty of the largely unprecedented and rapidly evolving situation, we are unable to predict with any confidence the likely impact of the COVID-19 pandemic on our future operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial results for the three and six months ended June 30, 2021 were not significantly impacted by COVID-19 relative to prior quarters. However, we will continue to monitor, and to the extent possible, mitigate the impact of the COVID-19 pandemic on our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Highlights</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except for per share data)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Result of Operations</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,364</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,888</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,793</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,288</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating costs and expenses</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158,199</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,025</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267,056</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233,500</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133,988</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,313</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(205,743</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(163,661</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.45</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.95</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.24</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.84</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353,361</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">678,393</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term and long-term investments</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259,609</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,388</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,266</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,883</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenue for the three and six months ended June&#160;30, 2021 included the revenue recognized related to the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$19.6 million and $34.2 million of development revenue recognized under our collaboration agreements with our partners Astellas and AstraZeneca AB (&#8220;AstraZeneca&#8221;)&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$13.4 million and $28.7 million of net product revenue from roxadustat commercial sales in China&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$(8.6) million and $(0.2) million of drug product revenue primarily resulted from the deferred considerations of roxadustat bulk drug or active pharmaceutical ingredient (&#8220;API&#8221;) deliveries to AstraZeneca and Astellas.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a comparison, our revenue for the three and six months ended June&#160;30, 2020 included the revenue recognized related to the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$19.0 million and $38.4 million of development revenue recognized under our collaboration agreements with our partners Astellas and AstraZeneca&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$15.7 million and 20.6 million of net product revenue from roxadustat commercial sales in China&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$8.2 million of roxadustat API delivery to Astellas.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating costs and expenses for the three and six months ended June&#160;30, 2021 increased compared to the same periods a year ago as a result of the net effect of the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Expense of $25 million for acquired in-process research and development asset from HiFiBiO Therapeutics (&#8220;HiFiBiO&#8221;)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Higher clinical trial expenses associated with Phase 3 trials for pamrevlumab and roxadustat post-approval safety studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Higher drug development expenses associated with drug substance and drug product manufacturing activities primarily related to pamrevlumab&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Higher employee-related expenses resulting from higher average compensation level and headcount&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Lower sales and marketing expenses primarily due to a change in the calculation method of co-promotion expenses with AstraZeneca as a result of the China Amendment between FibroGen China and AstraZeneca in the third quarter of 2020. In addition, since Falikang became fully operational in January 2021, substantially all direct product sales to distributors were made by Falikang, while FibroGen Beijing continued to sell product directly in a few provinces in China. AstraZeneca now bills the co-promotion expenses to Falikang and to FibroGen Beijing, respectively, for its services provided to the respective entity. All defined terms referenced in this paragraph that are not already defined, are defined below in </span><span style="font-style:italic;color:#000000;">Collaboration Partnerships for Roxadustat</span><span style="color:#000000;">.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three and six months ended June&#160;30, 2021, we had net losses of $134.0 million and 205.7 million, respectively, or net loss per basic and diluted share of $1.45 and $2.24, respectively, as compared to a net loss of $85.3 million and $163.7 million for the same periods a year ago, due to decreases in revenue, and increases in operating costs and expenses as discussed above. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, investments and accounts receivable totaled $637.2 million at June&#160;30, 2021, a decrease of $91.5&#160;million from December&#160;31, 2020, primarily due to the cash used in operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commercial and Development Programs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Roxadustat for the Treatment of Anemia in Chronic Kidney Disease</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is our most advanced product, an oral small molecule inhibitor of HIF-PH activity that acts by stimulating the body&#8217;s natural pathway of erythropoiesis, or red blood cell production. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our collaboration partner AstraZeneca and we continue to expand the commercialization of roxadustat (tradename: &#29233;&#29790;&#21331;<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>) in China where it is approved for the treatment of anemia caused by CKD in non-dialysis and dialysis patients. As of the second quarter of 2021, roxadustat was listed at hospitals that collectively represent approximately 81% of the CKD anemia market opportunity in China and roxadustat had a 32% value share within the segment of erythropoiesis stimulating agents and HIF-PH inhibitors (roxadustat is the only HIF-PH inhibitor currently on the market in China).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Japan, our partner Astellas continues the commercial launch of EVRENZO<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (roxadustat) for the treatment of anemia associated with CKD in both non-dialysis and dialysis patients. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2021, the Committee for Medicinal Products for Human Use of the EMA adopted a positive opinion, recommending the granting of MAA for the medicinal product Evrenzo (roxadustat), intended for the treatment of adult patients with symptomatic anemia associated with CKD. Our partner Astellas expects an approval decision on the MAA for roxadustat by the European Commission in August 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-right:2.04%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EVRENZO<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (roxadustat) has also been approved for the treatment of anemia in CKD patients on dialysis and patients not on dialysis in South Korea and Chile. In collaboration with AstraZeneca, applications for marketing approval of roxadustat in CKD anemia have been submitted in Canada, Australia, Mexico, Brazil, Taiwan, Philippines, Singapore, India, Colombia, and Thailand.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, the FDA CRDAC voted to recommend not approving roxadustat, an oral HIF-PH inhibitor, for the treatment of anemia due to CKD in adult patients. While the FDA is not required to follow CRDAC&#8217;s vote, the agency considers CRDAC&#8217;s non-binding recommendations when making its decision.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Roxadustat for the Treatment of Anemia in Myelodysplastic Syndromes</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are continuing to enroll MATTERHORN, our Phase 2/3 placebo controlled, double-blind clinical trial to evaluate the safety and efficacy of roxadustat for treatment of anemia in MDS in the U.S. and Europe. This 160-patient trial is studying roxadustat in transfusion-dependent, lower-risk MDS patients, in which subjects are randomized 3:2 to receive roxadustat or placebo three-times-weekly. The primary endpoint is the proportion of patients who achieve transfusion independence by 28 weeks with secondary endpoints and safety evaluated at 52 weeks. We expect topline data from this study between the second half of 2022 and the first half of 2023.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In China, we are enrolling the randomized, double-blind, placebo-controlled portion of our Phase 3 clinical trial to evaluate the safety and efficacy of roxadustat in non-transfusion dependent, lower-risk MDS patients with anemia. One hundred thirty-five subjects will be randomized 2:1 to receive roxadustat or placebo three-times weekly for 26 weeks. The primary endpoint for this study is percentage of patients achieving a hemoglobin response.&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Roxadustat for the Treatment of Chemotherapy-Induced Anemia</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have completed enrollment in WHITNEY, our Phase 2 clinical trial of roxadustat in the U.S. in chemotherapy-induced anemia. This is a single-arm open label study investigating the efficacy and safety of roxadustat for the treatment of anemia in 92 patients receiving myelosuppressive chemotherapy treatment for non-myeloid malignancies, with a treatment duration of 16 weeks. We expect topline data from this study in the third quarter of 2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pamrevlumab (FG-3019) &#8211; Monoclonal Antibody Targeting Connective Tissue Growth Factor (CTGF)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab is our first-in-class antibody developed to inhibit the activity of CTGF, a common factor in fibrotic and fibro-proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the second quarter of 2021, the FDA granted both Rare Pediatric Disease designation and Fast Track designation for pamrevlumab for the treatment of patients with DMD. In addition, the FDA has granted Orphan Drug Designation to pamrevlumab for the treatment of IPF, locally advanced unresectable pancreatic cancer, and DMD. Pamrevlumab has also received Fast Track designation from the FDA for the treatment of both IPF and locally advanced unresectable pancreatic cancer.<span style="font-weight:bold;font-style:italic;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Idiopathic Pulmonary Fibrosis</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are conducting ZEPHYRUS-1, our Phase 3 trial of pamrevlumab in IPF patients, as well as our newly initiated ZEPHYRUS-2, a second IPF Phase 3 study. Both studies are randomized, double-blind, placebo-controlled Phase 3 trials targeting approximately 340 patients, each with a primary U.S. efficacy endpoint of change from baseline in forced vital capacity. The primary efficacy endpoint in Europe for each study is disease progression (defined by a decline in forced vital capacity percent predicted of greater than or equal to 10% or death). Secondary endpoints will include clinical outcomes of disease progression, patient reported outcomes, and quantitative changes in lung fibrosis volume from baseline. We expect topline data from ZEPHYRUS-1 in mid-2023.&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Locally Advanced Unresectable Pancreatic Cancer</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to enroll LAPIS, our double-blind placebo controlled Phase 3 clinical program for pamrevlumab as a neoadjuvant therapy for locally advanced unresectable pancreatic cancer. We intend to enroll approximately 260 patients, randomized at a 1:1 ratio to receive either pamrevlumab or placebo, in each case in combination with chemotherapy (either FOLFIRINOX or gemcitabine plus nab-paclitaxel). Overall survival is the primary endpoint of this study. An interim analysis of event-free survival will be completed in the second half of 2022 for potential accelerated approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2021 the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM adaptive trial platform included pamrevlumab, with standard of care chemotherapy treatments for pancreatic cancer (gemcitabine and Abraxane<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>), in its study for patients with metastatic pancreatic cancer. The combination therapy is offered to patients as either a first- or second-line treatment option, marking the first experimental treatment arm to be offered as a first-line treatment in PanCAN&#8217;s innovative Precision Promise trial. The objective of Precision Promise is to expedite the study and approval of promising therapies for pancreatic cancer by bringing multiple stakeholders together, including academic, industry and regulatory entities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Duchenne Muscular Dystrophy</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to enroll LELANTOS-1, our Phase 3 clinical trial evaluating pamrevlumab in combination with systemic corticosteroids as a treatment for DMD. LELANTOS is a double-blind, placebo-controlled trial in approximately 90 non-ambulatory DMD patients. Patients are randomized at a 1:1 ratio to pamrevlumab or placebo and have a treatment period of 52 weeks. The primary endpoint will assess change in upper limb strength and additional endpoints will include pulmonary, performance, cardiac, and fibrosis assessments. We expect topline data from this study in the first half of 2023.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-right:0.19%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also continue to enroll our double-blind, placebo-controlled Phase 3 clinical trial, LELANTOS 2, evaluating pamrevlumab in combination with systemic corticosteroids in approximately 70 ambulatory DMD patients. Patients aged 6-12 will be randomized at a 1:1 ratio to pamrevlumab or placebo and have a treatment period of 52 weeks. The primary efficacy endpoint will assess ambulatory function, measured by the change in North Star Ambulatory Assessment from baseline to Week 52.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Licensing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Exclusive License and Option Agreement with HiFiBiO Therapeutics </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June&#160;17, 2021, we announced a partnership with HiFiBiO covering three HiFiBiO programs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen exclusively licensed all product candidates in the Galectin-9 program and will have sole right to develop them worldwide. FibroGen has also obtained exclusive options to license all product candidates in HiFiBiO&#8217;s CXCR5 and CCR8 programs. Each option may be independently exercised following delivery of program-specific data to be generated by HiFiBiO. If an option is exercised, FibroGen will have the sole right to develop products from that program worldwide. Under the terms of the Exclusive License and Option Agreement, dated June 16, 2021 (the &#8220;HiFiBiO Agreement&#8221;), FibroGen will make a $25 million upfront payment to HiFiBiO, as well as payments upon option exercise. In addition, HiFiBiO may receive up to a total of an additional $1.1 billion in future option, clinical, regulatory, and commercial milestone payments across all three programs. HiFiBiO will also be eligible to receive mid single-digit to low double-digit royalties based upon worldwide net sales. The HiFiBiO Agreement is filed as an exhibit hereto. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Exclusive License with Eluminex Biosciences&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 19, 2021, we announced an exclusive license of our global rights to investigational biosynthetic cornea derived from recombinant human collagen type III Eluminex Biosciences (Suzhou) Limited (&#8220;Eluminex&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement with Eluminex (the &#8220;Eluminex Agreement&#8221;), Eluminex will make an $8 million upfront payment to FibroGen. In addition, FibroGen may receive up to a total of $64 million in future manufacturing, clinical, regulatory, and commercial milestone payments for the biosynthetic cornea program, as well as $36 million in commercial milestones for the first recombinant collagen III product that is not the biosynthetic cornea. FibroGen will be eligible to receive mid single-digit to low double-digit royalties based upon worldwide net sales<span style="font-size:12pt;"> </span>of cornea products, and low single-digit to mid single-digit royalties based on worldwide net sale of other recombinant human collagen type III products that are not cornea products. The Eluminex Agreement contains other industry standard license terms including related to exclusivity, sublicensing, manufacturing, milestones, royalties, intellectual property, and termination. The Eluminex Agreement will expire on a product-by-product and country-by-country basis at the end of the applicable royalty term.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing description of the Eluminex Agreement is not a complete description thereof, and is qualified in its entirety by reference to the actual Agreement that will be filed with the SEC as an exhibit to FibroGen&#8217;s Quarterly Report on Form 10-Q for the quarter ending September 30, 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Partnerships </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">for Roxadustat</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and future research, development, manufacturing and commercialization efforts with respect to roxadustat and our other product candidates currently in development depend on funds from our collaboration agreements with Astellas and AstraZeneca. See Note 2, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, to the condensed consolidated financial statements for details.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Astellas</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2005, we entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (&#8220;Japan Agreement&#8221;). In April 2006, we entered into the Europe Agreement with Astellas for roxadustat for the treatment of anemia in Europe, the Commonwealth of Independent States, the Middle East, and South Africa (&#8220;Europe Agreement&#8221;). Under these agreements, the aggregate amount of such consideration received through June&#160;30, 2021 totals $645.1 million.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#8220;Japan Amendment&#8221;). Under this amendment, the related drug product revenue was $(2.0) and $2.1 million for the three and six months ended June 30, 2021, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the first quarter of 2021, we entered into an EU Supply Agreement under the Europe Agreement with Astellas to define general forecast, order, supply and payment terms for Astellas to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. We shipped bulk drug product to Astellas as pre-commercial supply for process validation purposes during the first quarter of 2021. We recorded the consideration of $11.8 million from this shipment as deferred revenue as of June 30, 2021, due to a high degree of uncertainty associated with the final consideration. The deferred revenue will be recognized as and when uncertainty is resolved.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">AstraZeneca</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, we entered into the U.S./RoW Agreement a collaboration agreement with AstraZeneca for roxadustat for the treatment of anemia in the U.S. and all territories not previously licensed to Astellas, except China. In July 2013, through our China subsidiary and related affiliates, we entered into a collaboration agreement with AstraZeneca for roxadustat for the treatment of anemia in China (&#8220;China Agreement&#8221;). Under the AstraZeneca agreements, aggregate amount of such consideration received through June&#160;30, 2021 totals $516.2 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the China Agreement, which is conducted through FibroGen China Anemia Holdings, Ltd., FibroGen (China) Medical Technology Development Co., Ltd. (&#8220;FibroGen Beijing&#8221;), and FibroGen International (Hong Kong) Limited (collectively, (&#8220;FibroGen China&#8221;), the commercial collaboration was structured as a 50/50 profit share, which was amended by the China Amendment in the third quarter of 2020, as discussed and defined below in <span style="font-style:italic;">China Amendment</span>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, we entered into Master Supply Agreement under the U.S./RoW Agreement with AstraZeneca (&#8220;Master Supply Agreement&#8221;) to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. We shipped bulk drug product to AstraZeneca as commercial supply during 2020 and the first and second quarter of 2021. Based on the above-mentioned FDA CRDAC&#8217;s vote on July 15, 2021, we evaluated the impact of these developments in revising our estimates of variable consideration associated with drug product revenue. As a result, we updated the estimated transaction price, and recorded $11.2 million as deferred revenue as of June 30, 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Amendment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, FibroGen China and AstraZeneca (together with FibroGen China, the &#8220;Parties&#8221;) entered into an amendment, effective July 1, 2020, to the China Agreement, relating to the development and commercialization of roxadustat in China (the &#8220;China Amendment&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the China Amendment, in September 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Beijing Falikang Pharmaceutical Co., Ltd. (&#8220;Falikang&#8221;), which performs roxadustat distribution, as well as conduct sales and marketing through AstraZeneca. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen Beijing manufactures and supplies commercial product to Falikang based on an agreed upon transfer price, which includes gross transfer price, net of calculated profit share. Revenue is recognized upon the transfer of control of commercial products to Falikang in an amount that reflects the allocation of transaction price of the <span style="Background-color:#FFFFFF;color:#000000;">China manufacturing and supply obligation (&#8220;</span>China performance obligation&#8221;) to the performance obligation satisfied during the reporting period. During the three and six months ended June 30, 2021, we recognized net product revenue of $11.8 million and $22.2 million, respectively. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Additional Information Related to Collaboration Agreements</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash consideration received through June&#160;30, 2021 and potential cash consideration, for upfront payments and milestone payments under our collaboration agreements are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Received for Upfront Payments and Milestone Payments</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Potential</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash&#160;Payment for Milestones</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Potential</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash&#160;Payments for Upfront Payments and Milestones</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Astellas--related-party:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan Agreement</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,093</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,500</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,593</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe Agreement</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">745,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Astellas</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">645,093</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">272,500</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917,593</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. / RoW Agreement</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">439,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">810,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,249,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China Agreement</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,200</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299,500</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">376,700</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total AstraZeneca</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">516,200</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,109,500</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,625,700</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,161,293</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,382,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,543,293</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above table does not include development cost reimbursement, transfer price payments, and royalties and profit share under our existing collaboration agreements. These collaboration agreements also provide for reimbursement of certain fully burdened research and development costs as well as direct out of pocket expenses. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RESULTS OF OPERATIONS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="31" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(dollars in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and other revenue</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,641</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,957</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">684</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,228</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,402</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,174</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue, net</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,371</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,693</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,322</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,733</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,648</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,085</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,648</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,886</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.54%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(205</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(168</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,406</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.54%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(102</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,364</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,888</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,524</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.54%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,793</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,288</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,495</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.54%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenue to date has been generated substantially from our collaboration agreements with Astellas and AstraZeneca. In addition, we started roxadustat commercial sales in China in 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our revenue recognition policy, license revenue includes amounts from upfront, non-refundable license payments and amounts allocated pursuant to the standalone selling price method from other consideration received during the periods. This revenue is generally recognized as deliverables are met and services are performed. We did not have any license revenue for the three and six months ended June 30, 2021 and 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue includes co-development and other development related services. Co-development services are recognized as revenue in the period in which they are billed to our partners, excluding China. For China co-development services, revenue is deferred until we begin to transfer control of the manufactured commercial product to AstraZeneca, which commenced in the first quarter of 2021 and expected to continue through 2028. Other development related services are recognized as revenue over the non-contingent development period based on a proportional performance method. As of June 30, 2021, the estimated future non-contingent development periods range from three to 48 months. Other revenues consist of sales of research and development material and have not been material for any of the periods presented. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is recognized when our <span style="Background-color:#FFFFFF;">customer obtains control of promised goods or services in an amount that reflects the consideration we expect to receive in exchange for those goods or services.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Drug product revenue includes </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercial-grade API or bulk drug product sales to AstraZeneca and Astellas i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n support of pre-commercial preparation prior to the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> New Drug Application</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(&#8220;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NDA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or MAA approval, and to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas for ongoing commercial </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">launch in Japan. Drug product revenue is recognized when we fulfill the delivery obligations.</span><span style="Background-color:#FFFFFF;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received in the future may differ from our estimates, for which we will adjust these estimates and affect the drug product revenue in the period such variances become known. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we will continue generating revenue from collaboration agreements in the form of license fees, milestone payments, reimbursements for collaboration services and royalties on drug product sales, and from product sales. We expect that any revenues we generate will fluctuate from quarter to quarter due to the uncertain timing and amount of such payments and sales.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue decreased $18.5 million, or 43% for the three months ended June&#160;30, 2021 and $4.5 million, or 7% for the six months ended June&#160;30, 2021, compared to the same periods a year ago for the reasons discussed in the sections below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Development and Other Revenue</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="31" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(dollars in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,645</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,766</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,121</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,256</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,503</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,247</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,993</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,191</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,802</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,969</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,899</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(930</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total development revenue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,638</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,957</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">681</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,225</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,402</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,177</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and other revenue increased $0.7 million, or 4% for the three months ended June&#160;30, 2021 and decreased $4.2 million, or 11% for the six months ended June&#160;30, 2021, compared to the same periods a year ago. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-development billings related to the development of roxadustat under our collaboration agreements with Astellas for the three and six months ended June&#160;30, 2021 decreased as a result of the substantial completion of Phase 3 trials for roxadustat.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue recognized under our collaboration agreements with AstraZeneca for the three and six months ended June&#160;30, 2021 was impacted by the increase in CKD related co-development billings in the U.S., offset by the extension of the estimated future non-contingent development period when we were notified of the FDA CRDAC meeting to review the NDA for roxadustat. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Product Revenue, Net</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="31" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(dollars in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Direct Sales:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross revenue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,230</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,833</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,603</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,659</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,205</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,546</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discounts and rebates</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(618</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,095</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,477</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,181</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,512</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,331</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales returns</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(98</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(296</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct sales revenue, net</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,611</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,693</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,082</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(90</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,566</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,648</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,082</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sales to Falikang:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross transfer price</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,714</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,714</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,115</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,115</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Profit share</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,573</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,573</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,636</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,636</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net transfer price</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,141</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,141</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,479</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,479</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in deferred revenue</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,381</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,381</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,312</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,312</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales to Falikang revenue, net</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,760</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,760</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,167</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,167</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total product revenue, net</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,371</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,693</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,322</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,733</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,648</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,085</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, Falikang became fully operational and substantially all direct product sales to distributors in China were made by Falikang, while FibroGen Beijing continued to sell product directly in a few provinces in China. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue from direct sales to distributors is recognized in an amount that reflects the consideration to which we expect to be entitled in exchange for those products, net of various sales rebates and discounts. The gross product revenue from direct sales to distributors was $2.3 million and $19.8 million for the three months ended June&#160;30, 2021 and 2020, and $7.7 million and $25.2 million for six months ended June&#160;30, 2021 and 2020, respectively. The total discounts and rebates were $0.6 million and $4.1 million for the three months ended June&#160;30, 2021 and 2020, and $1.2 million and $4.5 million for six months ended June&#160;30, 2021 and 2020, respectively. The discounts and rebates primarily consisted of the contractual sales rebate that were calculated based on the stated percentage of gross sales by each distributor in the distribution agreement, and non-key account hospital listing award that was calculated based on eligible non-key account hospital listing to date achieved by each distributor with certain requirements met during the period. In the second quarter of 2020, we recorded a $2.6 million as a reduction to the revenue related to accounting modifications of non-key account hospital listing award, when we amended the agreement with our pharmaceutical distributors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen Beijing manufactures and supplies commercial product to Falikang based on an agreed upon transfer price, which includes gross transfer price, net of calculated profit share. Revenue is recognized upon the transfer of control of commercial products to Falikang in an amount that reflects the allocation of the China performance obligation transaction price to the performance obligation satisfied during the reporting period. The variable consideration components that are included in the transaction price may be constrained, and are included in the product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. During the three and six months ended June&#160;30, 2021, the gross transfer price was $26.7 million and $51.1 million respectively, net of the calculated profit share of $9.6 million and $19.6 million respectively. Following updates to our estimates, we deferred $5.4 million and $9.3 million from the sales to Falikang for the three and six months ended June&#160;30, 2021, respectively, which was included in the related deferred revenue of the China performance obligation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Drug Product Revenue</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="31" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(dollars in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,974</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,212</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(124</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,056</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,182</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,674</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,674</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,224</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,224</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.58%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total drug product revenue:</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,648</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,886</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(205</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(168</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,406</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.58%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(102</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended June&#160;30, 2021, we recorded a reduction of $2.0 million to the drug product revenue related to the API shipments fulfilled under the terms of the Japan Amendment with Astellas in 2018, due to a change in estimated variable consideration. Specifically, the change in estimated variable consideration was based on the API held by Astellas at June 30, 2021, adjusted to reflect the changes in the estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others. During the first quarter of 2021, the Company recorded $4.0 million drug product revenue related to the same API shipments for the change in estimated variable consideration based on the API held by Astellas at March 31, 2021, under the same methodology.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2021, we shipped bulk drug product from process validation supplies for commercial purposes under the terms of the Europe Agreement with Astellas. We recorded the consideration of $11.8 million from this shipment as deferred revenue as of June 30, 2021, due to a high degree of uncertainty associated to the final consideration, which will be recognized as and when uncertainty is resolved.  </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During three and six months ended June&#160;30, 2021, we shipped bulk drug product to AstraZeneca as commercial supply under the terms of the Master Supply Agreement. Based on the above-mentioned FDA CRDAC&#8217;s vote on July 15, 2021, we evaluated the impact of these developments in revising our estimates of variable consideration associated with drug product revenue. As a result, we updated the estimated transaction price, and recorded $11.2 million as deferred revenue as of June 30, 2021. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Costs and Expenses</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="31" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(dollars in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating costs and expenses</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,078</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,076</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,479</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,047</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,432</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122,567</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,414</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,153</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197,243</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,315</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,928</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,554</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,535</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,981</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,334</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,138</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,804</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating costs and expenses</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158,199</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,025</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,174</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267,056</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233,500</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,556</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have taken measures to minimize the health risks of COVID-19 to our staff, patients, healthcare providers and their communities, as their safety and well-being are our top priority. We have also seen some reduced enrollment in our clinical trials, particularly for our IPF pamrevlumab trial. However, the overall impact of COVID-19 on our expenses was not significant. During the three and six months ended June 30, 2021, some reduction in expenses, such as due to paused or slowed enrollment for trials, were offset by some increased expenses, such as in patient care.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating costs and expenses increased $30.2 million, or 24% for the three months ended June&#160;30, 2021, and $33.6 million, or 14% for the six months ended June&#160;30, 2021, compared to the same periods a year ago, for the reason discussed in the sections below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Cost of Goods Sold</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold was $3.1 million for each of the three months ended June&#160;30, 2021 and 2020. Cost of goods sold was $6.5 million and $4.0 million for the six months ended June&#160;30, 2021 and 2020, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold, associated with the roxadustat commercial sales in China, consists of direct costs to manufacture commercial product, as well as indirect costs including factory overhead, storage, shipping, quality assurance, idle capacity charges, and inventory valuation adjustments. Cost of goods sold, associated with the roxadustat commercial sales in China, was $1.9 million and $2.7 million for the three months ended June&#160;30, 2021 and 2020, and $4.6 million and $3.7 million for the six months ended June&#160;30, 2021 and 2020, respectively, due to the sales to Falikang that started in January 2021, offset by the overall increase in the gross sales. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold associated with the roxadustat <span style="Background-color:#FFFFFF;">drug product </span>revenue in the U.S. was $1.1 million and $0.4 million for the three months ended June&#160;30, 2021 and 2020, and $1.9 million and $0.4 million for the six months ended June&#160;30, 2021 and 2020, respectively. W<span style="Background-color:#FFFFFF;">e expect costs of goods sold to increase in relation to drug product revenue as we deplete inventories that we had expensed prior to receiving regulatory approvals.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Research and Development Expenses</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of third-party research and development costs and the fully-burdened amount of costs associated with work performed under collaboration agreements. Research and development costs include employee-related expenses for research and development functions, expenses incurred under agreements with clinical research organizations (&#8220;CROs&#8221;), other clinical and preclinical costs and allocated direct and indirect overhead costs, such as facilities costs, information technology costs and other overhead. Research and development costs are expensed as incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites. Research and development expenses also include in-process research and development asset that has no alternative future use other than in a particular research and development project.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses incurred during the three and six months ended June&#160;30, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Product Candidate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Phase&#160;of&#160;Development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 3</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,313</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,332</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,641</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,344</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 2/3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,277</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,320</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,523</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,401</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,977</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,762</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,079</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,570</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122,567</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,414</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197,243</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,315</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The program-specific expenses summarized in the table above include costs we directly attribute to our product candidates. We allocate research and development salaries, benefits, stock-based compensation and other indirect costs to our product candidates on a program-specific basis, and we include these costs in the program-specific expenses. We expect our research and development expenses to increase in the future as we advance our product candidates through clinical trials and expand our product candidate portfolio.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses increased $61.2 million, or 100% for the three months ended June&#160;30, 2021, compared to the same period a year ago, as a result of the net effect of the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Expense of $25.0 million for acquired in-process research and development asset from HiFiBiO&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $21.7 million in drug development expenses associated with drug substance and drug product manufacturing activities primarily related to pamrevlumab&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $8.3 million in clinical trials costs, primarily due to Phase 3 trials for pamrevlumab and roxadustat post-approval safety studies in China&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $3.2 million in employee-related costs primarily due to higher headcount in the research and development functions and higher compensation levels&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $2.4 million in outside services due to higher consulting expenses related to roxadustat in China and higher scientific contract activities related to pamrevlumab Phase 3.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses increased $80.9 million, or 70% for the six months ended June&#160;30, 2021, compared to the same period a year ago, as a result of the net effect of the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Expense of $25.0 million for acquired in-process research and development asset from HiFiBiO&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $22.8 million in clinical trials costs, primarily due to Phase 3 trials for pamrevlumab and roxadustat post-approval safety studies in China&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $20.0 million in drug development expenses associated with drug substance and drug product manufacturing activities primarily related to pamrevlumab&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $7.3 million in employee-related costs primarily due to higher headcount in the research and development functions and higher compensation levels&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $3.8 million in outside services due to higher consulting expenses related to roxadustat in China and higher scientific contract activities related to pamrevlumab Phase 3&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $1.5 million in stock-based compensation expense, primarily due to the cumulative impact of stock option grant activities expensed in the normal course.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Selling, General and Administrative Expenses</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We started to incur sales and marketing expenses in 2019 in China to prepare for commercial operations. Selling, general and administrative (&#8220;SG&#38;A&#8221;) expenses consist primarily of employee-related expenses for executive, operational, finance, legal, compliance, and human resource functions. SG&#38;A expenses also include facility-related costs, professional fees, accounting and legal services, other outside services including co-promotional expenses, recruiting fees and expenses associated with obtaining and maintaining patents. We anticipate that our SG&#38;A expenses will increase in the future as we anticipate an increase in payroll and related expenses associated with an increase in headcount to support the growth of the business in connection with potential commercialization of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SG&#38;A expenses decreased $31.0 million, or 49% for the three months ended June&#160;30, 2021, compared to the same period a year ago, as a result of the net effect of the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Decrease of $34.9 million in outside service expenses, due to the above-mentioned change in the calculation of co-promotion expenses with AstraZeneca as a result of the China Amendment between FibroGen China and AstraZeneca in the third quarter of 2020. In addition, since Falikang became fully operational in January 2021, substantially all direct product sales to distributors were made by Falikang, while FibroGen Beijing continued to sell product directly in a few provinces in China. AstraZeneca now bills the co-promotion expenses to Falikang and to FibroGen Beijing, respectively, for its services provided to the respective entity&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Decrease of $1.8 million in legal expenses primarily associated with less patent-related activities in United Kingdom compared to prior year period&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">Increase of $1.7 million in employee-related costs primarily due to higher headcount in the general and administrative functions and higher compensation levels&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $1.6 million in facilities-related expense due higher repair and general maintenance expenses&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $1.5 million in stock-based compensation expense, primarily due to the cumulative impact of stock option grant activities expensed in the normal course.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SG&#38;A expenses decreased $49.8 million, or 44% for the six months ended June&#160;30, 2021, compared to the same period a year ago, as a result of the net effect of the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Decrease of $59.5 million in outside service expenses, due to the above-mentioned change in the calculation of co-promotion expenses with AstraZeneca as a result of the China Amendment between FibroGen China and AstraZeneca in the third quarter of 2020. In addition, since Falikang became fully operational in January 2021, substantially all direct product sales to distributors were made by Falikang, while FibroGen Beijing continued to sell product directly in a few provinces in China. AstraZeneca now bills the co-promotion expenses to Falikang and to FibroGen Beijing, respectively, for its services provided to the respective entity&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Decrease of $1.5 million in legal expenses primarily associated with less patent-related activities in United Kingdom compared to prior year period&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $3.9 million in employee-related costs primarily due to higher headcount in the general and administrative functions and higher compensation levels&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $2.6 million in facilities-related expense due higher repair and general maintenance expenses.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $2.3 million in stock-based compensation expense, primarily due to the cumulative impact of stock option grant activities expensed in the normal course&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $2.2 million in audit and tax expenses.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interest and Other, Net</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="31" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(dollars in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest&#160;and&#160;other,&#160;net:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(355</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(651</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">296</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(856</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,284</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">428</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income and other income (expenses), net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(363</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">644</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,007</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(156</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(817</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,810</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,627</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(121</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(718</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(711</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.14%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,157</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,673</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,526</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,199</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.14%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(166</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Interest Expense</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense relates to our finance lease liabilities accretion primarily for our leased facilities in San Francisco and China. Interest expense also includes interest related to the Technology Development Center of the Republic of Finland product development obligations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense decreased $0.3 million, or 45% for the three months ended June&#160;30, 2021, and $0.4 million, or 33% for the six months ended June&#160;30, 2021 compared to the same periods a year ago. The decrease was primarily due to the lease amendment effective June 1, 2021, related to our long-term property lease in San Francisco, was determined as a lease modification and classified as an operating lease, as compared to a finance lease before the lease modification. In addition, the new lease agreement effective in February 2021 for our long-term property lease in China was classified as an operating lease, as compared to a finance lease for the expired lease. The classification for both leases no longer trigger recognition of interest on the lease liabilities separately in the condensed statement of operations. See Note 5,<span style="font-style:italic;"> Leases</span>, to the condensed consolidated financial statements for details.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Interest Income and Other Income (Expenses), Net</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income and other, net primarily include interest income earned on our cash, cash equivalents and investments, foreign currency transaction gains (losses), remeasurement of certain monetary assets and liabilities in non-functional currency of our subsidiaries into the functional currency, realized gains (losses) on sales of investments, and other non-operating income and expenses. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest inco</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">me and other, net decreased $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0 </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million, or </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% for the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">three months ended </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and $4.6 million, or 121% for the six months ended </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> compared to the same periods a year ago</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, primarily due to lower interest earned on our cash, cash equ</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ivalents and investments </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">associated with the lower average balances</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and lower interest rates</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, on April 1, 2020, FibroGen Beijing adopted Renminbi Yuan (&#8220;CNY&#8221;) as its functional currency based on reassessment of the primary economic environment in which FibroGen Beijing operates, as such environment was mainly associated with its growing manufacturing and product sales activities conducted in CNY. Prior to April 1, 2020, FibroGen Beijing&#8217;s functional currency was the U.S. dollar. This changed resulted in a one-time $1.0 million foreign currency loss during the three and six months ended June 30, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="17" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(dollars in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(134,553</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,144</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(205,936</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(163,686</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for (benefit from) income taxes</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective tax rate</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for (benefit from) income tax for the three and six months ended June 30, 2021 were primarily due to foreign taxes. Provision for (benefit from) income tax for the three and six months ended June 30, 2020 were primarily due to the tax effect arising from other comprehensive income related to available-for-sale securities, and foreign taxes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon the weight of available evidence, which includes our historical operating performance, reported cumulative net losses since inception, we have established and continue to maintain a full valuation allowance against our net deferred tax assets as we do not currently believe that realization of those assets is more likely than not.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investment income in unconsolidated variable interest entity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment income in unconsolidated variable interest entity represented our proportionate share of the reported profits or losses of Falikang, an unconsolidated VIE accounted for under the equity method, and was immaterial for the three and six months ended June 30, 2021. See Note 3,<span style="font-style:italic;"> Variable Interest Entity</span>, to the condensed consolidated financial statements for details.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LIQUIDITY AND CAPITAL RESOURCES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Conditions</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have historically funded our operations principally from the sale of common stock (including our public offering proceeds) and from the execution of collaboration agreements involving license payments, milestones and reimbursement for development services. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021, we had cash and cash equivalents of $353.4 million. Cash is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Investments, consisting of available-for-sale debt investments and marketable equity investments, and stated at fair value, are also available as a source of liquidity. As of June&#160;30, 2021, we had short-term and long-term investments of $153.9 million and $105.8 million, respectively. As of June&#160;30, 2021, a total of $85.1 million of our cash and cash equivalents was held outside of the U.S. in our foreign subsidiaries, including $63.8 million of our cash and cash equivalents is held in China, to be used primarily for our China operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Capital Requirements</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third quarter of 2019, we started generating revenue from commercial sales of roxadustat product in China. Even with the expectation of increases in revenue from product sales, we anticipate that we will continue to generate losses for the foreseeable future. We expect increase in our operating expenses as we continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. To date, we have funded certain portions of our research and development and manufacturing efforts in China and Europe through outside parties. There is no guarantee that sufficient funds will be available to continue to fund these development efforts through commercialization or otherwise. Although our share of expenses for roxadustat are expected to decrease as a result of AstraZeneca funding all non-China collaboration expenses not reimbursed by Astellas, we expect our research and development expenses to continue to increase as we invest in our other programs. We are subject to all the risks related to the development and commercialization of novel therapeutics, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business, such as from the COVID-19 pandemic or other factors outlined under Part II, Item 1A &#8220;<span style="font-style:italic;">Risk Factors</span>&#8221; in this Quarterly Report on Form 10-Q. We anticipate that we will need substantial additional funding in connection with our continuing operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our existing cash and cash equivalents, short-term and long-term investments and accounts receivable will be sufficient to meet our anticipated cash requirements for at least the next 12&#160;months from the date of this Quarterly Report on Form 10-Q. However, our liquidity assumptions may change over time, and we could utilize our available financial resources sooner than we currently expect. In addition, we may elect to raise additional funds at any time through equity, equity-linked or debt financing arrangements. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements and the adequacy of available funds will depend on many factors, including those set forth under Part II, Item 1A &#8220;<span style="font-style:italic;">Risk Factors</span>&#8221; in this Quarterly Report on Form 10-Q. We may not be able to secure additional financing to meet our operating requirements on acceptable terms, or at all. If we raise additional funds by issuing equity or equity-linked securities, the ownership of our existing stockholders will be diluted. If we raise additional financing by the incurrence of indebtedness, we will be subject to increased fixed payment obligations and could also be subject to restrictive covenants, such as limitations on our ability to incur additional debt, and other operating restrictions that could adversely impact our ability to conduct our business. If we are unable to obtain needed additional funds, we will have to reduce our operating costs and expenses, which would impair our growth prospects and could otherwise negatively impact our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash Sources and Uses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods set forth below (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in):</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,527</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,179</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(254,252</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209,864</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,459</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of exchange rate changes on cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">446</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(499</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(325,032</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303,003</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities was $71.5 million for the six months ended June&#160;30, 2021 and consisted primarily of net loss of $205.7 million adjusted for non-operating cash items of $73.5 million, offset by a net increase in operating assets and liabilities of $60.7 million. The significant non-operating cash items included stock-based compensation expense of $38.4 million, expense for acquired in-process research and development asset from HiFiBiO of $25.0 million, depreciation expense of $5.2 million and amortization of finance lease right-of-use assets of $4.4 million. The significant items in the changes in operating assets and liabilities included the increases resulting from the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Deferred revenue of $33.1 million, primarily related to the above-mentioned $11.8 million and $11.2 million of the deferred considerations of the bulk drug product shipped to Astellas and AstraZeneca, respectively, due to a high degree of uncertainty associated to the final consideration, and $9.3 million of the deferred revenue from the sales to Falikang associated with the China performance obligation. The change in deferred revenue was also driven by the extension of the estimated future non-contingent development period and recognition of revenues under our collaboration agreements with Astellas and AstraZeneca. See Note 2, </span><span style="font-style:italic;color:#000000;">Collaboration Agreements and Revenues</span><span style="color:#000000;">, to the condensed consolidated financial statements for details&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Accrued and other liabilities of $27.7 million, primarily driven by the timing of invoicing and payment&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Accounts receivable of $17.9 million, primarily driven by the timing of the receipt of upfront payments and the recognition of revenues under our collaboration agreements with Astellas and AstraZeneca, as well as the collection from our distributors and Falikang.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increases were partially offset by the decreases resulting from the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Other long-term liabilities of $8.1 million, primarily due to the decrease in the co-promotional expenses with AstraZeneca for its sales and marketing efforts related to the commercial launch of roxadustat in China that are not expected to be paid in the next year&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Inventories of $7.9 million, driven by the increased inventory level primarily related to FibroGen Beijing&#8217;s productions of roxadustat for commercial sales purposes and pre-launch inventory cost capitalized in the U.S.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by operating activities was $90.2 million for the six months ended June&#160;30, 2020 and consisted primarily of net loss of $163.7 million adjusted for non-operating cash items of $45.7 million, offset by a net increase in operating assets and liabilities of $208.2&#160;million. The significant non-operating cash items included stock-based compensation expense of $34.6 million, depreciation expense of $5.7 million and amortization of finance lease right-of-use assets of $5.2 million. The significant items in the changes in operating assets and liabilities included the increases resulting from the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Prepaid expenses and other current assets of $126.9 million and Deferred revenue of $48.1 million, primarily related to the billing and receipt of $130.0 million in regulatory milestones under the Europe Agreement with Astellas associated with the MAA submission in Europe&#59; and the billing and receipt of $50.0 million regulatory milestone under the U.S./RoW Agreement with AstraZeneca associated with the NDA submission for review in the U.S. These milestones were not billable as of December 31, 2019, and was net of the associated deferred revenues of $4.8 million and $50.0 million, respectively. The change in deferred revenue was also driven by the recognition of revenues under our collaboration agreements with Astellas and AstraZeneca&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Other long-term liabilities of $64.0 million, primarily due to the additional accrual of co-promotional expenses with AstraZeneca for sales and marketing efforts related to the commercial launch of roxadustat in China that are not expected to be paid in the next year&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Other assets of $4.0 million, primarily related to the return and consumption of input value added tax by FibroGen Beijing&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Accounts receivable of $1.9 million, primarily driven by the timing of the receipt of upfront payments and the recognition of revenues under our collaboration agreements with Astellas and AstraZeneca&#59;</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increases were partially offset by the decreases resulting from the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Accrued and other liabilities of $33.5 million, primarily driven by the payment of $36.3 million that was accrued at December 31, 2019, related to the change in estimated variable consideration associated with the API delivery&#59; as well as driven by the timing of invoicing and payment&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Inventories of $2.0 million, driven by the increased inventory level related to FibroGen Beijing&#8217;s productions of roxadustat for commercial sales purposes.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investing Activities</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities primarily consist of purchases of property and equipment, purchases of investments, and proceeds from the maturity and sale of investments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities was $254.3 million for the six months ended June&#160;30, 2021 and consisted primarily of $266.6 million of cash used in purchases of available-for-sale securities, partially offset by $10.6 million of proceeds from maturities of investments, and $4.0 million of proceeds from sales of available-for-sale securities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities was $209.9 million for the six months ended June&#160;30, 2020 and consisted primarily of $201.9 million of proceeds from maturities of investments, and $10.6 million of proceeds from sales of available-for-sale securities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities primarily reflect proceeds from the issuance of our common stock, cash paid for payroll taxes on restricted stock unit releases, repayments of our lease liabilities and obligations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities was $0.3 million for the six months ended June&#160;30, 2021 and consisted primarily of $11.8 million of proceeds from the issuance of common stock upon exercise of stock options and purchases under our Employee Share Purchase Plan (&#8220;ESPP&#8221;), partially offset by $5.9 million of cash paid for payroll taxes on restricted stock unit releases, and $5.3 million of repayments of finance lease liabilities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities was $3.5 million for the six months ended June&#160;30, 2020 and consisted primarily of $16.5 million of proceeds from the issuance of common stock upon exercise of stock options and purchases under our ESPP, partially offset by $6.9 million of cash paid for payroll taxes on restricted stock unit releases, and $6.0 million of repayments of finance lease liabilities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three and six months ended June&#160;30, 2021, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021, we had $104.9 million of operating lease liabilities. Our finance lease liabilities were immaterial as of June 30, 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021, we had outstanding total non-cancelable purchase obligations of $81.9 million, including $29.6 million for manufacture and supply of roxadustat, $47.3 million for manufacture and supply of pamrevlumab, and $5.0 million for other purchases. We expect to fulfill our commitments under these agreements in the normal course of business, and as such, no liability has been recorded. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our license agreements provide for periodic maintenance fees over specified time periods, as well as payments by us upon the achievement of development, regulatory and commercial milestones. As of June 30, 2021, future milestone payments for research and pre-clinical stage development programs consisted of up to approximately $359.2 million in total potential future milestone payments under our license agreements with HiFiBiO (for Galectin-9), Medarex, Inc. and others. These milestone payments generally become due and payable only upon the achievement of certain developmental, clinical, regulatory and/or commercial milestones. The event triggering such payment or obligation has not yet occurred.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Guidance </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For recently issued accounting guidance, see Note 1, <span style="font-style:italic;">Significant Accounting Policies,</span> to the condensed consolidated financial statements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no material changes in our critical accounting policies, estimates and judgments during the three and six months ended June&#160;30, 2021 compared with the disclosures in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December&#160;31, 2020, except for the following:</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product revenue, net </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue, net consists of revenues from sales of roxadustat commercial product to Falikang, and directly to pharmaceutical distributors located in a few provinces in China that are not covered by Falikang. Falikang is jointly owned by AstraZeneca and FibroGen Beijing. We are not the primary beneficiary of Falikang for accounting purposes, as AstraZeneca is the final decision maker for all the roxadustat commercialization activities, and we lack the power criterion to direct the activities of Falikang (see Note 3, <span style="font-style:italic;">Variable Interest Entity,</span> to the condensed consolidated financial statements). </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales to Falikang</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang became fully operational in January 2021, at which time FibroGen Beijing began selling roxadustat commercial product to Falikang. Falikang is FibroGen Beijing&#8217;s primary customer in China and substantially all roxadustat product sales to distributors in China are made by Falikang. Falikang bears inventory risk once it receives and accepts the product from FibroGen Beijing, and is responsible for delivering product to its distributors.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promises identified under the AstraZeneca China Agreement, including the license, co-development services and manufacturing of commercial supplies have been bundled into the China performance obligation. Amounts of the transaction price allocable to this performance obligation under our agreements with AstraZeneca are deferred until control of the manufactured commercial product is transferred to AstraZeneca.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initiation of roxadustat sales to Falikang marked the beginning of the China performance obligation<span style="font-style:italic;">.</span><span style="color:#000000;"> Revenue is recognized at a point in time when control of roxadustat commercial product is transferred to Falikang. Revenue is recognized based on the estimated transaction price per unit and actual quantity of product delivered during the reporting period. Specifically, the transaction price per unit is determined based on the overall transaction price over the total estimated sales quantity for the estimated performance period in which we believe those sales would occur. The price per unit is subject to reassessment on a quarterly basis, which may result in cumulative catch up adjustments due to changes in estimates.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The overall transaction price for FibroGen Beijing&#8217;s product sales to Falikang includes the following elements of consideration: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Non-refundable upfront license fees&#59; development, regulatory, and commercial milestone payments based on the China Agreement allocated to the China performance obligation&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Co-development billings resulting from our research and development efforts, which are reimbursable under the China Agreement&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Interim profit/loss share between FibroGen Beijing and AstraZeneca from April 1, 2020 through December 31, 2020&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Net transfer price from product sales to Falikang from January 1, 2021 onwards. The net transfer price includes the following elements: </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Gross transfer price: The gross transfer price is based on a percentage of Falikang&#8217;s net sales to its distributors, which takes into account Falikang&#8217;s operating expenses and its payments to AstraZeneca for roxadustat sales and marketing efforts, capped at a percentage of Falikang&#8217;s net roxadustat sales. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Profit share: The gross transfer price is then adjusted for an estimated amount to achieve the 50/50 profit share from current period roxadustat net sales in China. The adjustments to date have been a reduction to the transfer price and the related accounts receivable from Falikang.&#160;&#160;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The non-refundable upfront license fees constitute a </span><span style="color:#000000;">fixed consideration. The remainder of the above are variable consideration components, which may be constrained, and included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. The calculation of the above variable consideration includes key </span><span style="color:#000000;">estimates</span><span style="color:#000000;"> such as total sales quantity, performance period, gross transfer price and profit share, which require a substantial degree of judgment.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any net transfer price in excess of the revenue recognized is deferred, and will be recognized over future periods as the performance obligations are satisfied.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Direct Sales to Distributors</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We sell roxadustat in China directly to a number of pharmaceutical distributors located in a few provinces in China that are not covered by Falikang. These pharmaceutical distributors are our customers. Hospitals order roxadustat through a distributor and we ship the product directly to the distributors. The delivery of roxadustat to a distributor represents a single performance obligation. Distributors are responsible for delivering product to end users, primarily hospitals. Distributors bear inventory risk once they receive and accept the product. Product revenue is recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which we expect to be entitled to in exchange for the product.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The period between the transfer of control of the promised goods and when we receive payment is based on 60-day payment terms. As such, product revenue is not adjusted for the effects of a significant financing component.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is recorded at the net sales prices which includes the following estimates of variable consideration:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Price adjustment: When China&#8217;s National Healthcare Security Administration releases price guidance for roxadustat under the National Reimbursement Drug List, any channel inventories that have not been sold through by distributors, or to patients by hospitals and retailors, would be eligible for a price adjustment under the price protection. The price adjustment is calculated based on estimated channel inventory levels&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Contractual sales rebate: The contractual sales rebate is calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. The contractual sales rebate is recorded as a reduction to revenue at the point of sale to the distributor&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Non-key account hospital listing award: A one-time fixed-amount award is offered to a distributor who successfully lists the product with an eligible hospital, and who meets certain requirements. We consider this particular award to be an upfront payment to a customer within the definitions of the ASC 606. The non-key account hospital listing award is capitalized when the distributor meets eligibility requirements, and amortized as reduction to product revenue over future sales orders made by the distributor until exhausted&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Other discounts and rebates, including key account hospital sales rebate and transfer fee discount, are generally based on a percentage of eligible gross sales made by the distributor and recorded as a reduction to revenue at the point of sale to the distributor&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Sales returns: Distributors can request to return product to us only due to quality issues or for product purchased within one year prior to the product&#8217;s expiration date.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The calculation of the above variable consideration is based on gross sales to the distributor, or estimated utilizing best available information from the distributor, maximum known exposures and other available information including estimated channel inventory levels and estimated sales made by the distributor to hospitals, which involve a substantial degree of judgment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above rebates and discounts all together are eligible to be applied against the distributor&#8217;s future sales order, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible and in the same period that the related revenue is recorded. Due to the distributor&#8217;s legal right to offset, at each balance sheet date, the liability for rebates and discounts are presented as reductions of gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when we expect to settle the discount in cash. The distributor&#8217;s legal right of offset is calculated at the individual distributor level.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three and six months ended June&#160;30, 2021, we believe there were no material changes to our exposure to market risks as set forth in Part II, Item 7A <span style="font-style:italic;">&#8220;Quantitative and Qualitative Disclosures About Market Risk&#8221;</span> in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_CONTROLS_PROCEDURES"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM 4. CONTROLS </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AND PROCEDURES.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of June&#160;30, 2021, the end of the period covered by this Quarterly Report on Form 10-Q. Disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules&#160;and forms and that such information is accumulated and communicated to the company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of June&#160;30, 2021 because of the material weaknesses in our internal control over financial reporting described below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020, we have identified a material weakness in the risk assessment component of internal control as we did not appropriately design and maintain an effective risk assessment process at a precise enough level to identify new and evolving risks of material misstatement to the financial statements as a result of changes in our business operation. This material weakness gave rise to the following additional control deficiencies, which we also determined to be material weaknesses. We did not design and maintain effective controls related to the timely identification of shipments associated with drug product revenue, and we did not design and maintain effective controls related to the timely identification of changes in estimated variable consideration related to drug product revenue. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of these material weaknesses could result in material misstatements in the drug product revenue, contract asset or contract liability account balances or disclosures in our annual or interim consolidated financial statements that would not be prevented or detected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The material weaknesses described above did not result in any material misstatements of our consolidated financial statements or disclosures, but did result in immaterial out-of-period adjustments to drug product revenue related to pre-commercial shipments of drug product, contract assets and contract liabilities, and related financial statement disclosures during the quarter ended September 30, 2020. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Remediation Plan and Status</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Board of Directors and management are committed to maintaining a strong internal control environment. We have developed a detailed remediation plan and are making progress of what will be a multi-step remediation process to fully remediate the material weaknesses described above. Specifically, as of June&#160;30, 2021, we have continued with the remediation steps that were initiated in the fourth quarter of 2020, including, but not limited to, the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have started a comprehensive annual risk assessment process, and will continue to refine the risk assessment, to identify and design our control activities related to the above mentioned material weaknesses&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have identified and designed new controls and procedures associated with drug product revenue, and where applicable implemented new procedures and controls during the fourth quarter of 2020 and the first two quarters of 2021, and will continue to implement new procedures and controls in the future&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have hired additional resources to strengthen our accounting and internal audit functions.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we will continue to assess risks on a continuous basis to timely identify new exposures or risk categories as business practices change, and we plan to conduct a comprehensive review and, as applicable, update our existing internal control framework to ensure that it has identified, developed and deployed the appropriate business process controls to meet the objectives and address the risks identified. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The material weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. We believe the measures described above will remediate these material weaknesses and strengthen our internal control over financial reporting. As we continue to evaluate and work to remediate these material weaknesses, we may determine to take additional measures to address these deficiencies or determine to modify certain of the remediation measures described above.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Besides the new procedures and controls implemented to date as described above, there were no changes in our internal control over financial reporting that occurred during the three months ended June&#160;30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Limitations on the Effectiveness of Controls</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IIOR_INFORMATION">PART II&#8212;OTHER INFORMATION</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_LEGAL_PROCEEDINGS">ITEM 1. LEGAL PROCEEDINGS</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to various legal actions that arose in the ordinary course of our business. We recognize accruals for any legal action when we conclude that a loss is probable and reasonably estimable. We did not have any material accruals for any currently active legal action in our consolidated balance sheets as of June 30, 2021, as we could not predict the ultimate outcome of these matters, or reasonably estimate the potential exposure.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2021, three putative securities class action complaints were filed against FibroGen and certain of its current and former executive officers (collectively, the &#8220;Defendants&#8221;) in the United States (&#8220;U.S.&#8221;) District Court for the Northern District of California. The lawsuits allege that Defendants violated the Securities Exchange Act of 1934 by making materially false and misleading statements regarding FibroGen&#8217;s Phase 3 clinical studies data and prospects for FDA approval between November 2019 and December 2020. Plaintiffs seek to represent a class of persons or entities that purchased FibroGen securities between November 8, 2019 and April 6, 2021. In May 2021, two additional putative securities class action complaints were filed against Defendants alleging the same claims. One of the lawsuits alleges that Defendants made materially false and misleading statements between October 2017 and December 2020 and seeks to represent a class of persons or entities that purchased FibroGen securities between October 18, 2017 and April 6, 2021. The other lawsuit alleges that Defendants made materially false and misleading statements between December 2018 and February 2020 and seeks to represent a class of persons or entities that purchased FibroGen securities between December 20, 2018 and April 6, 2021. All plaintiffs seek unspecified monetary damages and other relief. Motions for lead plaintiff were filed on June 11, 2021 and a hearing on the motion is scheduled for August 19, 2021. Once a lead plaintiff is appointed by the Court, the Company expects to receive an amended consolidated complaint. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 30, 2021, a purported shareholder derivative complaint was filed in the U.S. District Court for the Northern District of California.&#160;The complaint names as defendants ten of the Company&#8217;s officers and directors, as well as the Company as nominal defendant, and asserts state and federal claims based on some of the same alleged misstatements as the securities class action complaints.&#160;The complaint seeks unspecified damages, attorneys&#8217; fees, and other costs.&#160;The Company and individual defendants have not yet been served.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that the claims are without merit and it intends to vigorously defend against them. However, any litigation is inherently uncertain, and any judgment or injunctive relief entered against FibroGen or any adverse settlement could materially and adversely impact its business, results of operations, financial condition, and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">ITEM 1A. RISK FACTORS </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below in addition to the other information included or incorporated by reference in this Quarterly Report on Form 10-Q, including our condensed consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Although we have discussed all known material risks, the risks described below are not the only ones that we may face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have marked with an asterisk (*) those risks described below that reflect substantive changes from the risks described under Part I, Item 1A <span style="font-style:italic;">&#8220;Risk Factors&#8221;</span> included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Development and Commercialization of Our Product Candidates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are substantially dependent on the success of our lead product, roxadustat, and our second compound in development, pamrevlumab. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have invested a substantial portion of our efforts and financial resources in the research and development of roxadustat and pamrevlumab. While we have received approval of our New Drug Applications (&#8220;NDA&#8221;) for roxadustat in the People&#8217;s Republic of China (&#8220;China&#8221;), Japan, South Korea, and Chile for chronic kidney disease (&#8220;CKD&#8221;) anemia for patients on dialysis and not on dialysis, our partners and we will need to make substantial additional investments in the development and commercialization of roxadustat worldwide and in various indications. Our near-term prospects, including maintaining our existing collaborations with Astellas Pharma Inc. (&#8220;Astellas&#8221;) and AstraZeneca AB (&#8220;AstraZeneca&#8221;), will depend heavily on successful development and commercialization of roxadustat, including obtaining additional regulatory approvals for the commercialization of roxadustat for anemia associated with CKD.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our other lead product candidate, pamrevlumab, is currently in clinical development for idiopathic pulmonary fibrosis (&#8220;IPF&#8221;), pancreatic cancer, and Duchenne muscular dystrophy (&#8220;DMD&#8221;). Pamrevlumab requires substantial further development and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investment and we do not have a collaboration partner for support of this compound. In addition, pamrevlumab is a monoclonal antibody, which may require greater financial resources than for our small molecule, roxadustat</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As a company, we have limited commercialization experience, and the time and resources to develop such experience are significant. If we fail to achieve and sustain commercial success for roxadustat with our collaboration partners, our business would be harmed. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have a sales or marketing infrastructure and have limited experience in the sales, marketing or distribution of pharmaceutical products in any country. To achieve commercial success for any product for which we obtain marketing approval, we will need to establish sales and marketing capabilities or make and maintain our existing arrangements with third parties to perform these services at a level sufficient to support our commercialization efforts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we would undertake sales and marketing of any of our products directly, there are risks involved with establishing our own sales, marketing and distribution capabilities. Factors that may inhibit our efforts to commercialize our products on our own include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our inability to effectively manage geographically dispersed commercial teams&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unforeseen costs and expenses associated with creating an independent commercial organization.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to roxadustat, we are dependent on the commercialization capabilities of our collaboration partners, AstraZeneca and Astellas. If either such partner were to terminate its agreement with us, we would have to commercialize on our own or with another third party. We will have limited control over the commercialization efforts of such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products, if any, effectively. If they are not successful in commercializing our product candidates, our business and financial condition would suffer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercializing roxadustat requires us to establish commercialization systems, including but not limited to, medical affairs, pharmacovigilance, supply-chain, and distribution capabilities to perform our portion of the collaborative efforts. These efforts require resources and time. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we, along with Astellas and AstraZeneca, are not successful in our marketing, pricing and reimbursement strategies, facilitating adoption by dialysis organizations, health care professionals, recruiting sales and marketing personnel or in building a sales and marketing infrastructure, or if the market perception of roxadustat&#8217;s safety and efficacy profile is negative, we will have difficulty commercializing roxadustat, which would adversely affect our business and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Although regulatory approval has been obtained for roxadustat in China, Japan, South Korea, and Chile, we may be unable to obtain regulatory approval in other countries, or such approval may be delayed or limited, due to a number of factors, many of which are beyond our control.* </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical trials and the manufacturing of our product candidates are and will continue to be, and the marketing of our product candidates will be, subject to extensive and rigorous review and regulation by numerous government authorities in the U.S. and in other countries where we intend to develop and, if approved, market any product candidates. Before obtaining regulatory approval for the commercial sale of any product candidate, we must demonstrate through extensive preclinical trials and clinical trials that the product candidate is safe and effective for use in each indication for which approval is sought. The regulatory review and approval process is expensive and requires substantial resources and time, and in general, very few product candidates that enter development ultimately receive regulatory approval. In addition, our collaboration partners for roxadustat have final control over development decisions in their respective territories and they may make decisions with respect to development or regulatory authorities that delay or limit the potential approval of roxadustat, or increase the cost of development or commercialization. Accordingly, we may be unable to successfully develop or commercialize roxadustat, pamrevlumab, or any of our other product candidates in one or more indications and jurisdictions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, for any Phase 3 clinical trial to support an NDA/Biologics License Application submission for approval, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and foreign regulatory authorities require compliance with regulations and standards (including good clinical practices (&#8220;GCP&#8221;) requirements for designing, conducting, monitoring, recording, analyzing, and reporting the results of clinical trials) to ensure that (1) the data and results from trials are credible and accurate&#59; and (2) that the rights, integrity and confidentiality of trial participants are protected. Although we rely on third parties to conduct our clinical trials, we as the sponsor remain responsible for ensuring that each of these clinical trials is conducted in accordance with its general investigational plan and protocol under legal and regulatory requirements, including GCP. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical research organizations</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (&#8220;CROs&#8221;), trial sites, principal investigators or other third parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable. Accordingly, the FDA or other regulatory authorities may require us to exclude the use of patient data from these unreliable clinical trials, or perform additional clinical trials before approving our marketing applications. The FDA or other regulatory authorities may even reject our application for approval or refuse to accept our future applications.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities may take actions or impose requirements that delay, limit or deny approval of our product candidates for many reasons, including, among others:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our failure to adequately demonstrate to the satisfaction of regulatory authorities or an independent advisory committee that roxadustat is safe and effective in treating anemia in CKD, myelodysplastic syndromes, or chemotherapy-induced anemia, or that pamrevlumab is safe and effective in treating IPF, pancreatic cancer, or DMD&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our failure to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our failure of clinical trials to meet the level of statistical significance required for approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the determination by regulatory authorities that additional clinical trials are necessary to demonstrate the safety and efficacy of roxadustat or pamrevlumab, or that ongoing clinical trials need to be modified in design, size, conduct or implementation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our product candidates may exhibit an unacceptable safety signal as they advance through clinical trials, in particular controlled Phase 3 trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the CROs that conduct clinical trials on our behalf may take actions outside of our control that materially adversely impact our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we or third-party contractors manufacturing our product candidates may not maintain current good manufacturing practices (&#8220;cGMP&#8221;), successfully pass inspection or meet other applicable manufacturing regulatory requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may not agree with our interpretation of the data from our preclinical trials and clinical trials&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaboration partners may not perform or complete their clinical programs in a timely manner, or at all.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these factors, many of which are beyond our control, could jeopardize our or our collaboration partners&#8217; abilities to obtain regulatory approval for our product candidates in one or more indications. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or other regulatory authorities may require more information (including additional preclinical or clinical data to support approval), which may delay or prevent approval or cause us to abandon the development program altogether. In addition, if our product candidates produce undesirable side effects or safety issues, the FDA may require the establishment of Risk Evaluation and Mitigation Strategy (or other regulatory authorities may require the establishment of a similar strategy), that may restrict distribution of our approved products, if any, and impose burdensome implementation requirements on us. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The negative vote of the FDA Cardiovascular and Renal Drugs Advisory Committee meeting is expected to have a significant impact on roxadustat&#8217;s approvability in CKD anemia in the U.S.*</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Cardiovascular and Renal Drugs Advisory Committee (&#8220;CRDAC&#8221;) of the FDA voted 13 to 1 for non-dialysis dependent patients with CKD, and 12 to 2 for dialysis-dependent CKD patients to recommend not approving roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (&#8220;HIF-PH&#8221;) inhibitor, for the treatment of anemia due to CKD in adult patients. While the FDA is not required to follow CRDAC's vote, the agency considers CRDAC's non-binding recommendations when making its decision, and there is a high risk roxadustat&#8217;s NDA will not be approved, or if it is approved, it may be for a more restricted use than the Company has requested. We do not know how long it will take for the FDA to make a decision on our NDA. The FDA may give us a complete response letter (rejecting our NDA) or further delay approval of our NDA if applicable regulatory criteria are not satisfied and/or the FDA requires additional testing or information. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical, Phase 1 and Phase 2 clinical trial results may not be indicative of the results that may be obtained in larger clinical trials.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Success in preclinical and early clinical trials, which are often highly variable and use small sample sizes, may not be predictive of similar results in humans or in larger, controlled clinical trials, and successful results from clinical trials in one indication may not be replicated in other indications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we may face similar setbacks.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not know whether our ongoing or planned clinical trials of roxadustat or pamrevlumab will need to be redesigned based on interim results or if we will be able to achieve sufficient patient enrollment or complete planned clinical trials on schedule. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials can be delayed or terminated for a variety of reasons, including delay or failure to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">address any physician or patient safety concerns that arise during the course of the trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtain required regulatory or institutional review board approval or guidance&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reach timely agreement on acceptable terms with prospective CROs and clinical trial sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">recruit, enroll and retain patients through the completion of the trial, including for the duration of the </span><span style="font-size:9.5pt;color:#000000;">Severe Acute Respiratory Syndrome Coronavirus 2 and the resulting Coronavirus Disease</span><span style="color:#000000;"> (&#8220;COVID-19&#8221;) pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">maintain clinical sites in compliance with clinical trial protocols&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">initiate or add a sufficient number of clinical trial sites&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">manufacture sufficient quantities of product candidate for use in clinical trials.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on the rate at which we can recruit and enroll patients in testing our product candidates. Patients may be unwilling to participate in clinical trials of our product candidates for a variety of reasons, some of which may be beyond our control, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">severity of the disease under investigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">availability of alternative treatments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">size and nature of the patient population&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">eligibility criteria for and design of the study in question&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">perceived risks and benefits of the product candidate under study&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ability to enroll patients in clinical trials during the COVID-19 pandemic (particularly for IPF)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ongoing clinical trials of competitive agents&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">physicians&#8217; and patients&#8217; perceptions of the potential advantages of our product candidates being studied in relation to available therapies or other products under development&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our CRO&#8217;s and our trial sites&#8217; efforts to facilitate timely enrollment in clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">patient referral practices of physicians&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ability to monitor patients and collect patient data adequately during and after treatment.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate on-going or planned clinical trials.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we could encounter delays if a clinical trial is suspended or terminated by us, by the relevant institutional review boards at the sites at which such trials are being conducted, or by the FDA or other regulatory authorities. A&#160;suspension or termination of clinical trials may result from any number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, changes in laws or regulations, or a principal investigator&#8217;s determination that a serious adverse event could be related to our product candidates. Any delays in completing our clinical trials will increase the costs of the trial, delay the product candidate development and approval process and jeopardize our ability to commence marketing and generate revenues. Any of these occurrences may materially and adversely harm our business, operations, and prospects.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates may cause or have attributed to them undesirable side effects or have other properties that delay or prevent their regulatory approval or limit their commercial potential.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Undesirable side effects caused by our product candidates or that may be identified as related to our product candidates by physician investigators conducting our clinical trials or even competing products in development that utilize a similar mechanism of action or act through a similar biological disease pathway could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in the delay or denial of regulatory approval by the FDA or other regulatory authorities and potential product liability claims. If we determine that there is a likely causal relationship between a serious adverse event and our product candidate, and such safety event is material or significant enough, it may result in:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our clinical trial development plan becoming longer and more extensive&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities increasing the data and information required to approve our product candidates and imposing other requirements&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our collaboration partners terminating our existing agreements.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The occurrence of any or all of these events may cause the development of our product candidates to be delayed or terminated, which could materially and adversely affect our business and prospects. Refer to &#8220;<span style="font-style:italic;">Business &#8212; Overview</span>&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 for a discussion of the adverse events and serious adverse events that have emerged in clinical trials of roxadustat and pamrevlumab.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical trials of our product candidates may not uncover all possible adverse effects that patients may experience.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials are conducted in representative samples of the potential patient population, which may have significant variability. Clinical trials are by design based on a limited number of subjects and of limited duration for exposure to the product used to determine whether, on a potentially statistically significant basis, the planned safety and efficacy of any product candidate can be achieved. As with the results of any statistical sampling, we cannot be sure that all side effects of our product candidates may be uncovered, and it may be the case that only with a significantly larger number of patients exposed to the product candidate for a longer duration, that a more complete safety profile is identified. Further, even larger clinical trials may not identify rare serious adverse effects or the duration of such studies may not be sufficient to identify when those events may occur. There have been other products, including erythropoiesis stimulating agents (&#8220;ESAs&#8221;), for which safety concerns have been uncovered following approval by regulatory authorities. Such safety concerns have led to labeling changes or withdrawal of ESAs products from the market. While our most advanced product candidate is chemically unique from ESAs, it or any of our product candidates may be subject to known or unknown risks. Patients treated with our products, if approved, may experience adverse reactions and it is possible that the FDA or other regulatory authorities may ask for additional safety data as a condition of, or in connection with, our efforts to obtain approval of our product candidates. If safety problems occur or are identified after our product candidates reach the market, we may, or regulatory authorities may require us to amend the labeling of our products, recall our products or even withdraw approval for our products.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our manufacturers </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or we </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">cannot properly manufacture </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the appropriate amount of </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product, we may experience delays in development, regulatory approval, launch or successful commercialization.</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">*</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Completion of our clinical trials and commercialization of our products require access to, or development of, facilities to manufacture and manage our product candidates at sufficient yields, quality and at commercial scale. Although we have entered into commercial supply agreements for roxadustat and pamrevlumab, we will need to enter into additional commercial supply agreements, including for backup or second source third-party manufacturers.&#160;We may not be able to enter into these agreements with satisfactory terms or on a timely manner. In addition, we may experience delays or technical problems associated with technology transfer of manufacturing processes to any new suppliers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited experience manufacturing or managing third parties in manufacturing any of our product candidates in the volumes that are expected to be necessary to support large-scale clinical trials and sales. In addition, we have limited experience forecasting supply requirements or coordinating supply chain (including export management) for launch or commercialization, which is a complex process involving our third-party manufacturers and logistics providers, and for roxadustat, our collaboration partners.&#160;We may not be able to accurately forecast supplies for commercial launch, or do so in a timely manner and our efforts to establish these manufacturing and supply chain management capabilities may not meet our requirements as to quantities, scale-up, yield, cost, potency or quality in compliance with cGMP, particularly if the marketing authorization or market uptake is more rapid than anticipated or we have an unanticipated surge in demand. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if we are not able to obtain regulatory approval of roxadustat in the U.S. in CKD anemia, we may have excess supply manufactured in anticipation of commercialization. Such excess supply of roxadustat could be wasted, for example, if it expires prior to being used in other clinical trials or prior to being used in other territories where such formulation of roxadustat is approved. We have a limited amount of roxadustat and pamrevlumab in storage, limited capacity reserved at our third-party manufacturers, and, even if we have or are able to put sufficient supply agreements in place for our development and commercialization plan, there are long lead times required to manufacture and scale-up the manufacture of additional supply, as required for both late-stage clinical trials, post-approval trials, and commercial supply. If we are unable to forecast, order or manufacture sufficient quantities of roxadustat or pamrevlumab on a timely basis, it may delay our development, launch or commercialization in some or all indications we are currently pursuing. Any delay or interruption in the supply of our product candidates or products could have a material adverse effect on our business and operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial drug product and the product we use for clinical trials must be produced under applicable cGMP regulations. Failure to comply with these regulations by us or our third-party manufacturers may require us to recall commercial product or repeat clinical trials, which would impact sales revenue or delay the regulatory approval process. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may add or change manufacturers for our products. We, our partners, or regulatory authorities may also request or make changes to our manufacturing processes or to our product or packaging specifications, including in order to accommodate changes in regulations, manufacturing equipment or to account for different processes at new or second source suppliers. If any such changes are made with respect to roxadustat or pamrevlumab we may need to demonstrate comparability to the products and processes already approved or in approval by various regulatory authorities, including potentially through the conduct of additional clinical trials. Even if we do demonstrate comparability, a regulatory agency could challenge that result which could delay our development or commercialization progress. Any such changes could also lead to product having an earlier expiration date, shorter shelf life, or failing to meet specifications. Any of these occurrences may materially impact our operations and potential profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, and even an experienced third-party manufacturer, may encounter difficulties in production. Difficulties may include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs and challenges associated with scale-up and attaining sufficient manufacturing yields, in particular for biologic products such as pamrevlumab, which is a monoclonal antibody&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">contracting with additional suppliers and validation/qualification of additional facilities to meet growing demand&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">supply chain issues, including coordination of multiple contractors in our supply chain and securing necessary licenses (such as export licenses)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timely availability and shelf life requirements of raw materials and supplies, including delays in availability due to the COVID-19 pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">limited stability and product shelf life&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">equipment maintenance issues or failure&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">quality control and quality assurance issues&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">shortages of qualified personnel and capital required to manufacture large quantities of product&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">compliance with regulatory requirements that vary in each country where a product might be sold&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">capacity or forecasting limitations and scheduling availability in contracted facilities&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">natural disasters, such as pandemics, including the COVID-19 pandemic, floods, storms, earthquakes, tsunamis, and droughts, or accidents such as fire, that affect facilities, possibly limit or postpone production, and increase costs.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Regulatory authorities will do their own benefit risk analysis and may reach a different conclusion than we or our partners have, and these regulatory authorities may base their approval decision on different analyses, data, and statistical methods than ours.*</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we believe we have achieved positive clinical results, such as superiority or non-inferiority, in certain endpoints, populations or sub-populations, or using certain statistical methods of analysis, the FDA and European Medicines Agency (&#8220;EMA&#8221;) will each conduct their own benefit-risk analysis and may reach different conclusions, using different statistical methods, different endpoints or definitions thereof, or different patient populations or sub-populations, and regulatory authorities may change their approvability criteria based on their internal analyses and discussions with expert advisors. Regulatory authorities may approve roxadustat for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-approval clinical trials. While we will present to regulatory authorities certain pre-specified and not pre-specified sub-populations and sub-group analyses (for example, incident dialysis), multiple secondary endpoints, and multiple sets of stratification factors and analytical methods (such as long-term follow up analyses), including adjusted and censored data, regulatory authorities may reject these analyses, methods, or even parts of our trial design or certain data from our studies, the rationale for our pre-specified non-inferiority margins or other portions of our statistical analysis plans. In addition, even if we are able to provide positive data with respect to certain analyses, such as incident dialysis, estimated glomerular filtration rate, hepcidin, or quality of life measures, regulatory authorities may not include such claims on any approved labeling for roxadustat. The failure to obtain regulatory approval, or any label, population or other approval limitations in any jurisdiction, may significantly limit or delay our ability to generate revenues, and any failure to obtain such approval for all of the indications and labeling claims we deem desirable could reduce our potential revenue.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we are able to obtain regulatory approval of our product candidates, the label we obtain may limit the indicated uses for which our product candidates may be marketed.*</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to roxadustat, regulatory approvals obtained, could limit the approved indicated uses for which roxadustat may be marketed. For example, our label approved in Japan, includes the following warning: &#8220;Serious thromboembolism such as cerebral infarction, myocardial infarction, and pulmonary embolism may occur, possibly resulting in death, during treatment with roxadustat.&#8221; Additionally, in the U.S., ESAs have been subject to significant safety warnings, including the boxed warnings on their labels. The safety concerns relating to ESAs may result in labeling for roxadustat containing similar warnings. Any label for roxadustat may contain other warnings or limit the market opportunity or approved indications for roxadustat. These warnings could include warnings against exceeding specified hemoglobin targets and other warnings that derive from the safety issues associated with ESAs, even if our Phase 3 clinical trials do not themselves raise safety concerns.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face substantial competition in the discovery, development and commercialization of product candidates.* </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of new pharmaceutical products is highly competitive. Our future success depends on our ability and/or the ability of our collaboration partners to achieve and maintain a competitive advantage with respect to the development and commercialization of our product candidates. Our objective is to discover, develop and commercialize new products with superior efficacy, convenience, tolerability, and safety. We expect that in many cases, the products that we commercialize will compete with existing, market-leading products of companies that have large, established commercial organizations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If roxadustat is approved and launched commercially, competing drugs are expected to include ESAs, particularly in those patient segments where ESAs are used. Currently available ESAs include epoetin alfa (EPOGEN<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, marketed by Amgen Inc. in the U.S., Procrit<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Erypo<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>/Eprex<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, marketed by Johnson&#160;&#38; Johnson Inc., and Espo<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> marketed by Kyowa Hakko Kirin in Japan and China), darbepoetin (Amgen/Kyowa Hakko Kirin&#8217;s Aranesp<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and NESP<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>) and Mircera<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> marketed by Hoffmann-La&#160;Roche (&#8220;Roche&#8221;) outside of the U.S. and by Vifor Pharma, a Roche licensee, in the U.S. and Puerto Rico, as well as biosimilar versions of these currently marketed ESA products. ESAs have been used in the treatment of anemia in CKD for more than 30 years, serving a significant majority of dialysis CKD patients. While non-dialysis CKD patients who are not under the care of nephrologists, including those with diabetes and hypertension, do not typically receive ESAs and are often left untreated, some non-dialysis patients under nephrology or hematology care may be receiving ESA therapy. It may be difficult to encourage healthcare providers and patients to switch to roxadustat from products with which they have become familiar. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also face competition from potential new anemia therapies currently in clinical development, including in those patient segments not adequately addressed by ESAs. Companies that are currently developing </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIF-PH&#8221; inhibitors for anemia in CKD indications include GlaxoSmithKline plc (&#8220;GSK&#8221;), Bayer Corporation (&#8220;Bayer&#8221;), Akebia Therapeutics, Inc. (&#8220;Akebia&#8221;), </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Otsuka Pharmaceutical, Akebia&#8217;s partner in the U.S. and Europe, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan Tobacco, and Zydus Cadila (India) (&#8220;Zydus&#8221;). </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Akebia has completed Phase 3 studies in CKD </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients on dialysis and not on dialysis</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the U.S.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, as well as a Phase 3b, randomized, open-label, active-controlled trial evaluating the efficacy and safety of oral </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vadadustat</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> once daily and three times weekly for the maintenance treatment of anemia in hemodialysis subjects converting from </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESAs</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The study completion date is estimated to be May 2022. Akebia announced an additional Phase 3 </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">study evaluating the efficacy and safety of dose conversion from a long-acting </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (Mircera</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) to three times weekly oral vadadustat for the maintenance treatment of anemia in hemodialysis subjects. The estimated study start date is February 2021</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 30, 2021, Akebia submitted an NDA to the FDA for vadadustat for the treatment of anemia due to CKD in patients on dialysis and not on dialysis.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA accepted for filing the NDA for the treatment of anemia due to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CKD</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in both adult patients on dialysis and adult patients not on dialysis, with a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2022.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, GSK announced positive headline results from five Phase 3 studies of daprodustat for patients with anemia due to CKD. Full results of the studies are anticipated to be presented at a forthcoming medical meeting later in 2021. In Japan, Mitsubishi Tanabe Pharmaceutical Corporation, Akebia&#8217;s collaboration partner, received approval for vadadustat in June 2020 for the treatment of anemia of CKD patients on and not on dialysis. GSK received approval for daprodustat in Japan in June 2020 for the treatment of anemia of CKD patients on and not on dialysis. Price listing for the launch in Japan of both vadadustat and daprodustat occurred in the third quarter of 2020, with pricing in line with roxadustat pricing. GSK is also conducting global Phase 3 studies in CKD patients on dialysis and not on dialysis, and expects to complete those studies by March 2022. GSK and Kyowa Hakko Kirin announced in November 2018 that the two companies signed a strategic commercialization deal in Japan for daprodustat. Bayer received approval for molidustat in Japan in January 2021 for the treatment of anemia in CKD patients on and not on dialysis, with pricing in line with roxadustat pricing. Japan Tobacco received approval in Japan for enarodustat for the treatment of anemia in CKD patients on dialysis and not on dialysis, to be sold by Torii Pharmaceuticals Ltd as ENAROY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>. Japan Tobacco and its partner JW Pharmaceuticals started a Phase 3 study in dialysis patients in Korea in 2019. Zydus started Phase 3 studies in dialysis and non-dialysis CKD patients in India in 2019. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, Zydus received approval from the FDA to begin a Phase 1 study of desidustat for the treatment of chemotherapy-induced anemia, which could potentially be competitive with roxadustat within this indication.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reblozyl<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (luspatercept)<span style="color:#000000;"> was approved by the FDA in April 2020 for the treatment of anemia in adults with myelodysplastic syndromes with ring sideroblasts or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis who need regular red blood cell transfusions and have not responded well to or cannot receive an ESA. It is the first and only erythroid maturation agent approved in the U.S., Europe, and Canada and is part of a global collaboration between Acceleron Pharma, Inc. and Bristol Myers Squibb. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, <span style="color:#000000;">we will likely face competition from other companies developing biologic therapies for the treatment of other anemia indications that we may also seek to pursue in the future</span>. We may face competition for patient recruitment, enrollment for clinical trials, and potentially in commercial sales. There may also be new therapies for renal-related diseases that could limit the market or level of reimbursement available for roxadustat.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In China, ESA is considered the standard of care for treatment of anemia of CKD, and locally manufactured epoetin alfa is offered by 15 local manufacturers including the market leader EPIAO that is marketed by 3SBio Inc. We may face potential competition from other HIF-PH inhibitors. Companies active in the US such as Akebia, Bayer, and GSK have been authorized by the National Medical Products Administration (&#8220;NMPA&#8221;) to conduct trials in China to support its ex-China regulatory filings. A number of domestic companies, including Jiangsu Hengrui Medicine Co., Ltd., Guandong Sunshine Health Investment Co., Ltd., 3SBio Inc., and Hangzhou Andao Pharmaceutical Co. have been permitted by the NMPA to conduct clinical trials in their locally developed HIF-PH inhibitor investigational compounds for the treatment of anemia in CKD. Domestic companies are also in-licensing global compounds to be developed as domestic drugs, including China Medical System which in-licensed desidustat, a compound that is currently in Phase 3 trials in India, from Zydus for greater China in January 2020. In January 2021, China Medical System Holdings Ltd. was granted approval by the Chinese NMPA to begin trials for desidustat in patients with anemia of CKD, including dialysis and non-dialysis patients. Shenzhen Salubris Pharmaceutical Co., Ltd., a domestic company in China, has in-licensed enarodustat from Japan Tobacco and received NMPA approval in the third quarter of 2020 to initiate Phase 3 studies. We will also face competition from generics who could enter the market after expiry of our patents in China, and two potential market players have already started bioequivalence studies, including Chia Tai-Tiangqing Pharmaceutical Holdings and CSPA Pharmaceutical Group. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first biosimilar ESA, Pfizer&#8217;s Retacrit</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (epoetin zeta), entered the U.S. market in November 2018. Market penetration of Retacrit and the potential addition of other biosimilar ESAs currently under development may alter the competitive and pricing landscape of anemia therapy in CKD patients on dialysis under the end-stage renal disease bundle. The patents for Amgen&#8217;s EPOGEN</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (epoetin alfa) expired in 2004 in Europe, and the final material patents in the U.S. expired in May 2015. Several biosimilar versions of currently marketed ESAs are available for sale in Europe, China and other territories. In the U.S., a few ESA biosimilars are currently under development. Sandoz, a division of Novartis, markets Binocrit</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (epoetin alfa) in Europe and may file a biosimilar </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biologics License Application</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the U.S</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The majority of the current CKD anemia market focuses on dialysis patients, who visit dialysis centers on a regular basis, typically three times a week, and anemia therapies are administered as part of the visit. Two of the largest operators of dialysis clinics in the U.S., DaVita Healthcare Partners Inc. (&#8220;DaVita&#8221;), and Fresenius Medical Care AG&#160;&#38; Co. KGaA (&#8220;Fresenius&#8221;), collectively provide dialysis care to more than 80% of U.S. dialysis patients, and therefore have historically executed long-term contracts including rebate terms with Amgen. Successful penetration in this market will likely require our partner AstraZeneca to enter into a definitive agreement with Fresenius, DaVita, or other dialysis organizations, on favorable pricing terms and on a timely basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If approved and launched commercially to treat IPF, pamrevlumab is expected to compete with Roche&#8217;s Esbriet<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (pirfenidone), and Boehringer Ingelheim&#8217;s Ofev<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (nintedanib). We believe that if pamrevlumab can be shown to safely stabilize or reverse lung fibrosis, and thus stabilize or improve lung function in IPF patients, it can compete with pirfenidone and nintedanib for market share in IPF. However, it may be difficult to encourage treatment providers and patients to switch to pamrevlumab from an oral product with which they are already familiar to a product delivered via in-office infusion. Furthermore, pirfenidone and nintedanib may be produced as generics in the near future. We may also face competition from potential new IPF therapies in recruitment and enrollment in our clinical trials and potentially in commercialization.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab is a monoclonal antibody that may be more expensive and less convenient than oral small molecules such as nintedanib and pirfenidone. Other potential competitive product candidates in various stages of development for IPF include Kadmon Holdings, Inc.&#8217;s KD025, Galecto&#8217;s GB0139, Liminal BioSciences&#8217; PBI-4050, and Roche/Promedior, Inc.&#8217;s PRM-151. Roche is enrolling patients in a Phase 3 trial evaluating the efficacy and safety of PRM-151, a recombinant human pentraxin-2 (rhPTX-2), compared to placebo in patients with IPF.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If pamrevlumab is approved and launched commercially to treat locally advanced pancreatic cancer patients who are not candidates for surgical resection, pamrevlumab may face competition from products currently used for pancreatic cancer. These include FOLFRINOX, a combination chemotherapy regimen of folic acid, 5-fluouracil, oxaliplatin and irinotecan, and agents seeking approval in combination with gemcitibine and nab-paclitaxel from companies such as Rafael Pharma&#8217;s defactinib/CPI-613 and Merrimack&#8217;s istiratumab. Gemcitabine and/or nab-paclitaxel are the current standard of care in the first-line treatment of metastatic pancreatic cancer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Celgene Corporation&#8217;s Abraxane<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (nab-paclitaxel) was launched in the U.S. and Europe in 2013 and 2014, and was the first drug approved in this disease in nearly a decade. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If approved and launched commercially to treat DMD, pamrevlumab is expected to face competition from drugs that have been approved in major markets such as the U.S., European Union, and Japan. On September 19, 2016, the FDA approved Sarepta Therapeutics Inc.&#8217;s (&#8220;Sarepta&#8221;) Exondys 51<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> (eteplirsen). Exondys 51 is approved to treat patients who have a mutation of the dystrophin gene amenable to exon 51 skipping, representing approximately 13% of patients with DMD. In Europe, Sarepta received a negative opinion for its marketing application for eteplirsen from the EMA in September 2018. Sarepta&#8217;s Vyondys 53<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> (golodirsen) was approved by the FDA in December 2019 for patients with a confirmed genetic mutation that is amenable to exon 53 skipping, which accounts for approximately 8% of the DMD population. Sarepta&#8217;s Amondys 45&#8482; (casimersen) was approved by the FDA in February 2021 for patients with a confirmed genetic mutation that is amenable to exon 45 skipping, which accounts for approximately 8% of the DMD population.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PTC Therapeutics&#8217; product Translarna<sup style="font-size:85%;line-height:120%;vertical-align:top"> TM</sup> received a conditional approval in Europe in 2014, which was renewed in November 2016 with a request for a new randomized placebo-controlled 18-month study by the Committee for Medicinal Products for Human Use of the EMA&#59; however, the FDA informed the sponsor in a complete response letter in October 2017, as well as in its response to PTC Therapeutics&#8217; appeal, that the FDA is unable to approve the application in its current form. An additional Phase 3 study is currently ongoing. While Translarna<sup style="font-size:85%;line-height:120%;vertical-align:top"> TM</sup> targets a different set of DMD patients from those targeted by Sarepta&#8217;s Exondys 51<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, it is also limited to a subset of patients who carry a specific mutation. Conversely, pamrevlumab is intended to treat DMD patients without limitation to type of mutation. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab may also face competition from other drugs currently in clinical development in patient recruiting and enrollment in clinical trials, and, if approved, in commercialization. Examples of those compounds currently under clinical development are the drug candidates from Pfizer, Pliant, Galecto, and Sarepta. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer initiated a Phase 3 study with </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PF-06939926, its AAV9 mini-dystrophin gene therapy for DMD in February 2020. Pliant&#8217;s PLN-74809 and Galecto&#8217;s lead candidate GB0139, are in Phase 2 development for IPF. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of any or all of these potential competitive products may negatively impact the development and potential for success of pamrevlumab. In addition, any competitive products that are on the market or in development may compete with pamrevlumab for patient recruitment and enrollment for clinical trials or may force us to change our clinical trial design, including, in order to compare pamrevlumab against another drug, which may be the new standard of care.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, many of our competitors have significantly greater resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients, manufacturing pharmaceutical products, and commercialization. In the potential anemia market for roxadustat, for example, large and established companies such as Amgen and Roche, among others, compete aggressively to maintain their market shares. In particular, the currently marketed ESA products are supported by large pharmaceutical companies that have greater experience and expertise in commercialization in the anemia market, including in securing reimbursement, government contracts and relationships with key opinion leaders&#59; conducting testing and clinical trials&#59; obtaining and maintaining regulatory approvals and distribution relationships to market products&#59; and marketing approved products. These companies also have significantly greater scale, research and marketing capabilities than we do and may also have products that have been approved or are in later stages of development and have collaboration agreements in our target markets with leading dialysis companies and research institutions. If our collaboration partners and we are not able to compete effectively against existing and potential competitors, our business and financial condition may be materially and adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, healthcare payors, and others in the medical community. Demonstrating safety and efficacy of our product candidates and obtaining regulatory approvals will not guarantee future revenue. The degree of market acceptance of any of our approved product candidates will depend on several factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the efficacy of the product candidate as demonstrated in clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the safety profile and perceptions of safety of our product candidates relative to competitive products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">acceptance of the product candidate as a safe and effective treatment by healthcare providers and patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the clinical indications for which the product candidate is approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the potential and perceived advantages of the product candidate over alternative treatments, including any similar generic treatments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inclusion or exclusion of the product candidate from treatment guidelines established by various physician groups and the viewpoints of influential physicians with respect to the product candidate&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of the product candidate relative to alternative treatments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adequate pricing and reimbursement by third parties and government authorities as described below&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the relative convenience and ease of administration&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the frequency and severity of adverse events&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the effectiveness of sales and marketing efforts&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any unfavorable publicity relating to the product candidate.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, see the risk factor titled &#8220;Our product candidates may cause or have attributed to them undesirable side effects or have other properties that delay or prevent their regulatory approval or limit their commercial potential&#8221; above. If any product candidate is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">No or limited reimbursement or insurance coverage of our approved products, if any, by third-party payors may render our products less attractive to patients and healthcare providers. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market acceptance and sales of any approved products will depend significantly on reimbursement or coverage of our products by government or third-party payors and may be affected by existing and future healthcare reform measures or prices of related products for which the government or third-party reimbursement applies. Coverage and reimbursement by the government or a third-party payor may depend upon a number of factors, including the payor&#8217;s determination that use of a product is:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a covered benefit under applicable health plan&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">safe, effective and medically necessary&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">appropriate for the specific patient&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">cost-effective&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">neither experimental nor investigational.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor, which we may not be able to provide. Furthermore, the reimbursement policies of governments and third-party payors may significantly change in a manner that renders our clinical data insufficient for adequate reimbursement or otherwise limits the successful marketing of our products. Even if we obtain coverage for our product candidates, the pricing may be subject to re-negotiations or third-party payors may not establish adequate reimbursement amounts, which may reduce the demand for, or the price of, our products. For example, our current National Reimbursement Drug List reimbursement pricing for China is effective for a standard two-year period (between January 1, 2020 to December 31, 2021), after which time we will have to renegotiate a new price for roxadustat, which we expect to be lower based upon historical precedents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reference pricing is used by various Europe member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, our partner or we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available products in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unacceptable levels, our partner or we may elect not to commercialize our products in such countries, and our business and financial condition could be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to COVID-19</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business could continue to be adversely affected by the ongoing COVID-19 global pandemic.* </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic may negatively impact productivity, disrupt our business, and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the progression of the disease, government-mandated restrictions, the vaccine penetration rate (globally and in the U.S.), and the efficacy of the COVID-19 vaccines in preventing the spread and effects of current and future COVID-19 variants.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have taken measures to minimize the health risks of COVID-19 to our staff, patients, healthcare providers, and their communities, as their safety and well-being are our top priority. Despite these efforts, COVID-19 presents a health risk to our employees, including members of senior management. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have seen impacts from COVID-19 on all of our clinical trials to varying degrees, but COVID-19 has most heavily impacted our clinical trial timelines in IPF, DMD, and MDS. There is a risk that any or all of our clinical trials will be further delayed, in particular our studies in IPF, DMD and MDS, due to a new outbreak which could slow or pause enrollment or site initiation and other direct COVID-19 impacts to clinical sites and clinical service providers. In addition, while we are trying to mitigate the effect of COVID-19 on existing patients, it is possible that some patients may not be able to continue to comply with protocols, which could further delay our clinical trial progress.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe we have sufficient roxadustat and pamrevlumab supplies </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for our expected commercial </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and clinical requirements over the next year and our manufacturing partners and we are currently continuing manufacturing operations. However, we only have a limited stockpile of these drug supply products, and therefore, if there is a greater impact from the COVID-19 pandemic than we have expected, or if manufacturing operations are halted again, or if drug product expires due to slowed clinical trials, we could face shortages in our global supply chains. COVID-19 has created increased demand for the limited global biologics manufacturing capacity, and as a result, we have faced competition for manufacturing supplies due to prioritization of COVID-19 related manufacturing. We could face additional competition for such manufacturing supplies, including for vials, reagents, supplements and media, and may face competition to use available capacity at our manufacturing partners. Any such supply disruptions could adversely impact our clinical development and ability to generate revenues from our approved products and our business, financial condition, results of operations and growth prospects could be materially adversely affected. There may be unexpected regulatory delays due to the COVID-19 pandemic including due to travel restrictions impacting pre-approval inspections</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to these and potentially additional business disruptions, there may be delays to any of our business areas including our drug supply chains, problems with our distribution or warehousing vendors, or delays to our (and our partners&#8217;) clinical trials or other development efforts, or commercialization and launch activities. The full extent of these effects are unknown, but all of them could have a material impact on our business, operating results, and financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#8220;<span style="font-style:italic;">Risk Factors</span>&#8221; section.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Reliance on Third Parties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our collaborations were terminated or if Astellas or AstraZeneca were to prioritize other initiatives over their collaborations with us, our ability to successfully develop and commercialize our product candidates would suffer. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into collaboration agreements with respect to the development and commercialization of our lead product candidate, roxadustat, with Astellas and AstraZeneca. These agreements provide for reimbursement of our development costs by our collaboration partners and also provide for commercialization of roxadustat throughout the major territories of the world.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our agreements with Astellas and AstraZeneca provide each of them with the right to terminate their respective agreements with us, upon the occurrence of negative clinical results, delays in the development and commercialization of our product candidates or adverse regulatory requirements or guidance. In addition, each of those agreements provides our respective partners the right to terminate any of those agreements upon written notice for convenience. The termination of any of our collaboration agreements would require us to fund and perform the further development and commercialization of roxadustat in the affected territory, or pursue another collaboration, which we may be unable to do, either of which could have an adverse effect on our business and operations. Moreover, if Astellas or AstraZeneca, or any successor entity, were to determine that their collaborations with us are no longer a strategic priority, or if either of them or a successor were to reduce their level of commitment to their collaborations with us, our ability to develop and commercialize roxadustat could suffer. In addition, our collaborations are exclusive and preclude us from entering into additional collaboration agreements with other parties in the area or field of exclusivity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not establish and maintain strategic collaborations related to our product candidates, we will bear all of the risk and costs related to the development and commercialization of any such product candidate, and we may need to seek additional financing, hire additional employees and otherwise develop expertise at significant cost. This in turn may negatively affect the development of our other product candidates as we direct resources to our most advanced product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our collaboration partners also have certain rights to control decisions regarding the development and commercialization of our product candidates with respect to which they are providing funding. If we have a disagreement over strategy and activities with our collaboration partners, our plans for obtaining regulatory approval may be revised and negatively affect the anticipated timing and potential for success of our product candidates. Even if a product under a collaboration agreement receives regulatory approval, we will remain substantially dependent on the commercialization strategy and efforts of our collaboration partners, and, our collaboration partners have limited or no experience in commercialization of an anemia drug. If our collaboration partners are unsuccessful in their commercialization efforts, our results will be negatively affected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to our collaboration agreements for roxadustat, there are additional complexities in that our collaboration partners, Astellas and AstraZeneca, and we must reach consensus on our development programs and regulatory activities, including for the NDA in the U.S. and the Marketing Authorization Application in Europe. In addition, there are aspects of commercial operations that require cooperation among the collaboration partners, including safety data reporting. Multi-party decision-making is complex and involves significant time and effort, and there can be no assurance that the parties will cooperate or reach consensus, or that one or both of our partners will not ask to proceed independently in some or all of their respective territories or functional areas of responsibility in which the applicable collaboration partner would otherwise be obligated to cooperate with us. Any disputes or lack of cooperation with us by either Astellas or AstraZeneca, or both, may negatively impact the timing or success of our regulatory approval applications.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to conduct proprietary research programs in specific disease areas that are not covered by our collaboration agreements. Our pursuit of such opportunities could, however, result in conflicts with our collaboration partners in the event that any of our collaboration partners takes the position that our internal activities overlap with those areas that are exclusive to our collaboration agreements. Moreover, disagreements with our collaboration partners could develop over rights to our intellectual property, including the enforcement of those rights. In addition, our collaboration agreements may have provisions that give rise to disputes regarding the rights and obligations of the parties. Any conflict with our collaboration partners could lead to the termination of our collaboration agreements, delay collaborative activities, reduce our ability to renew agreements or obtain future collaboration agreements or result in litigation or arbitration and would negatively impact our relationship with existing collaboration partners, and could impact our commercial results.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our collaboration partners could also become our competitors in the future. If our collaboration partners develop competing products, fail to obtain necessary regulatory approvals, terminate their agreements with us prematurely or fail to devote sufficient resources to the development and commercialization of our product candidates, the development and commercialization of our product candidates and products could be delayed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our preclinical and clinical trial contractors do not properly perform their agreed upon obligations, we may not be able to obtain or may be delayed in receiving regulatory approvals for our product candidates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely heavily on university, hospital, dialysis centers and other institutions and third parties, including the principal investigators and their staff, to carry out our clinical trials in accordance with our clinical protocols and designs. We also rely on a number of third-party CROs to assist in undertaking, managing, monitoring and executing our ongoing clinical trials, including those for roxadustat. We expect to continue to rely on CROs, clinical data management organizations, medical institutions and clinical investigators to conduct our development efforts in the future, including our continued development of roxadustat. We compete with many other companies for the resources of these third parties, and large pharmaceutical companies often have significantly more extensive agreements and relationships with such third-party providers, and such third-party providers may prioritize the requirements of such large pharmaceutical companies over ours. The third parties on whom we rely may terminate their engagements with us at any time, which may cause delay in the development and commercialization of our product candidates. If any such third party terminates its engagement with us or fails to perform as agreed, we may be required to enter into alternative arrangements, which would result in significant cost and delay to our product development program. Moreover, our agreements with such third parties generally do not provide assurances regarding employee turnover and availability, which may cause interruptions in the research on our product candidates by such third parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, while our reliance on these third parties for certain development and management activities will reduce our control over these activities, it will not relieve us of our responsibilities. For example, the FDA and foreign regulatory authorities require compliance with regulations and standards, including GCP requirements for designing, conducting, monitoring, recording, analyzing and reporting the results of clinical trials to ensure that the data and results from trials are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Although we rely on third parties to conduct our clinical trials, we, as the sponsor, remain responsible for ensuring that each of these clinical trials is conducted in accordance with its general investigational plan and protocol under legal and regulatory requirements, including GCP. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our CROs, trial sites, principal investigators or other third parties fail to comply with applicable GCP requirements, other regulations, trial protocol or other requirements under their agreements with us, the quality or accuracy of the data they obtain may be compromised or unreliable, and the trials of our product candidates may not meet regulatory requirements. If trials do not meet regulatory requirements or if these third parties need to be replaced, the development of our product candidates may be delayed, suspended or terminated, regulatory authorities may require us to exclude the use of patient data from our approval applications or perform additional clinical trials before approving our marketing applications. Regulatory authorities may even reject our application for approval or refuse to accept our future applications for an extended period of time. We cannot assure that upon inspection by a regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements or that our results may be used in support of our regulatory submissions. If any of these events occur, we may not be able to obtain regulatory approval for our product candidates on a timely basis, at a reasonable cost, or at all.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently rely, and expect to continue to rely, on third parties to conduct many aspects of our product manufacturing and distribution, and these third parties may terminate these agreements or not perform satisfactorily.* </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have operating manufacturing facilities at this time other than our roxadustat manufacturing facilities in China, and our current commercial manufacturing plants in China are not expected to satisfy the requirements necessary to support development and commercialization outside of China. Other than in and for China specifically, we do not expect to independently manufacture our products. We currently rely, and expect to continue to rely, on third parties to scale-up, manufacture and supply roxadustat and our other product candidates outside of China. We rely on third parties for distribution, including our collaboration partners and their vendors, except in China where we have established a jointly owned entity with AstraZeneca to manage most of the distribution in China. Risks arising from our reliance on third-party manufacturers include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reduced control and additional burdens of oversight as a result of using third-party manufacturers and distributors for all aspects of manufacturing activities, including regulatory compliance and quality control and quality assurance&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">termination of manufacturing agreements, termination fees associated with such termination, or nonrenewal of manufacturing agreements with third parties may negatively impact our planned development and commercialization activities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the possible misappropriation of our proprietary technology, including our trade secrets and know-how&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disruptions to the operations of our third-party manufacturers, distributors or suppliers unrelated to our product, including the merger, acquisition, or bankruptcy of a manufacturer or supplier or a catastrophic event, including disruption resulting from the COVID-19 pandemic, affecting our manufacturers, distributors or suppliers.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could lead to development delays or failure to obtain regulatory approval or affect our ability to successfully commercialize our product candidates. Some of these events could be the basis for action by the FDA or another regulatory authority, including injunction, recall, seizure or total or partial suspension of production.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The facilities used by our contract manufacturers to manufacture our product candidates must pass inspections by the FDA and other regulatory authorities. Although, except for China, we do not control the manufacturing operations of, and expect to remain completely dependent on, our contract manufacturers for manufacture of drug substance and finished drug product, we are ultimately responsible for ensuring that our product candidates are manufactured in compliance with cGMP requirements. If our contract manufacturers cannot successfully manufacture material that conforms to our or our collaboration partners&#8217; specifications, or the regulatory requirements of the FDA or other regulatory authorities, we may not be able to secure and/or maintain regulatory approval for our product candidates and our development or commercialization plans may be delayed. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. In addition, although our longer-term agreements are expected to provide for requirements to meet our quantity and quality requirements to manufacture our products candidates for clinical studies and commercial sale, we will have minimal direct control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel and we expect to rely on our audit rights to ensure that those qualifications are maintained to meet our requirements. If our contract manufacturers&#8217; facilities do not pass inspection by regulatory authorities, or if regulatory authorities do not approve these facilities for the manufacture of our products, or withdraw any such approval in the future, we would need to identify and qualify alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our products, if approved. Moreover, any failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us or adverse regulatory consequences, including clinical holds, warnings or untitled letters, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which would be expected to significantly and adversely affect supplies of our products to us and our collaboration partners.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e have entered into an initial commercial supply agreement for the manufacture of pamrevlumab with Samsung Biologics Co., Ltd. (&#8220;Samsung&#8221;). </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, we may experience delays or technical problems associated with technology transfer of the manufacturing process to Samsung and the qualification and scale-up thereof. We have made certain manufacturing commitments to Samsung</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and there is a risk we will not require the quantities of pamrevlumab we have committed to, particularly if we cease some of our pamrevlumab clinical trials</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In addition, our product candidates and any products that we may develop may compete with other product candidates and products for access and prioritization to manufacture. Certain third-party manufacturers may be contractually prohibited from manufacturing our product due to non-compete agreements with our competitors or a commitment to grant another party priority relative to our products. There are a limited number of third-party manufacturers that operate under cGMP and that might be capable of manufacturing to meet our requirements. Due to the limited number of third-party manufacturers with the contractual freedom, expertise, required regulatory approvals and facilities to manufacture our products on a commercial scale, identifying and qualifying a replacement third-party manufacturer would be expensive and time-consuming and may cause delay or interruptions in the production of our product candidates or products, which in turn may delay, prevent or impair our development and commercialization efforts.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a letter agreement with IRIX Pharmaceuticals, Inc. (&#8220;IRIX&#8221;), a third-party manufacturer that we have used in the past, pursuant to which we agreed to negotiate a single source manufacturing agreement that included a right of first negotiation for the cGMP manufacture of HIF-PH inhibitors, including roxadustat, provided that IRIX is able to match any third-party bids within 5%. The exclusive right to manufacture extends for five years after approval of an NDA for those compounds, and any agreement would provide that no minimum amounts would be specified until appropriate by forecast and that we and a commercialization partner would have the rights to contract with independent third parties that exceed IRIX&#8217;s internal manufacturing capabilities or in the event that we or our commercialization partner determines for reasons of continuity of supply and security that such a need exists, provided that IRIX would supply no less than 65% of the product if it is able to provide this level of supply. Subsequent to the letter agreement, IRIX and we have entered into several additional service agreements. IRIX has requested in writing that we honor the letter agreement with respect to the single source manufacturing agreement, and if we were to enter into any such exclusive manufacturing agreement, there can be no assurance that IRIX will not assert a claim for right to manufacture roxadustat or that IRIX could manufacture roxadustat successfully and in accordance with applicable regulations for a commercial product and the specifications of our collaboration partners. In 2015, Patheon Pharmaceuticals Inc., a business unit of DPx Holdings B.V., acquired IRIX, and in 2017, ThermoFisher Scientific Inc. acquired Patheon Pharmaceuticals Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any third-party manufacturer terminates its engagement with us or fails to perform as agreed, we may be required to find replacement manufacturers, which would result in significant cost and delay to our development programs. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur significant delays and added costs in identifying, qualifying and contracting with any such third party or potential second source manufacturer. In any event, with any third-party manufacturer we expect to enter into technical transfer agreements and share our know-how with the third-party manufacturer, which can be time-consuming and may result in delays. These delays could result in a suspension or delay of marketing roxadustat.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Certain components of our products are acquired from single-source suppliers or without long-term supply agreements. The loss of these suppliers, or their failure to supply, would materially and adversely affect our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have an alternative supplier of certain components of our product candidates. We may be unable to enter into long-term commercial supply arrangements for some of our products, or do so on commercially reasonable terms, which could have a material adverse impact upon our business.&#160;In addition, we currently rely on our contract manufacturers to purchase from third-party suppliers some of the materials necessary to produce our product candidates. We do not have direct control over the acquisition of those materials by our contract manufacturers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The logistics of our supply chain, which include shipment of materials and intermediates from countries such as China and India add additional time and risk (including risk of loss) to the manufacture of our product candidates. While we have in the past maintained sufficient inventory of materials, active pharmaceutical ingredients (&#8220;API&#8221;), and drug product to meet our and our collaboration partners&#8217; needs for roxadustat to date, the lead-time and regulatory approvals required to source from and into countries outside of the U.S. increase the risk of delay and potential shortages of supply.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our efforts to protect our proprietary technologies are not adequate, we may not be able to compete effectively in our market.*</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely upon a combination of patents, trade secret protection, and contractual arrangements to protect the intellectual property related to our technologies. We will only be able to protect our products and proprietary information and technology by preventing unauthorized use by third parties to the extent that our patents, trade secrets, and contractual position allow us to do so. Any disclosure to or misappropriation by third parties of our trade secrets or confidential information could compromise our competitive position. Moreover, we are involved in, have in the past been involved in, and may in the future be involved in legal proceedings involving our intellectual property initiated by third parties, which proceedings can be associated with significant costs and commitment of management time and attention. As our product candidates continue in development, third parties have attempted and may again attempt to challenge the validity and enforceability of our patents and proprietary information and technologies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also are involved in, have in the past been involved in, and may in the future be involved in initiating legal or administrative proceedings involving the product candidates and intellectual property of our competitors. These proceedings can result in significant costs and commitment of management time and attention, and there can be no assurance that our efforts would be successful in preventing or limiting the ability of our competitors to market competing products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Composition-of-matter patents are generally considered the strongest form of intellectual property protection for pharmaceutical products, as such, patents provide protection not limited to any one method of use. Method-of-use patents protect the use of a product for the specified method(s), and do not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. We rely on a combination of these and other types of patents to protect our product candidates, and there can be no assurance that our intellectual property will create and sustain the competitive position of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biotechnology and pharmaceutical product patents involve highly complex legal and scientific questions and can be uncertain. Any patent applications that we own or license may fail to result in issued patents. Even if patents do successfully issue from our applications, third parties may challenge their validity or enforceability, which may result in such patents being narrowed, invalidated, or held unenforceable. Even if our patents and patent applications are not challenged by third parties, those patents and patent applications may not prevent others from designing around our claims and may not otherwise adequately protect our product candidates. If the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, competitors with significantly greater resources could threaten our ability to commercialize our product candidates. Discoveries are generally published in the scientific literature well after their actual development, and patent applications in the U.S. and other countries are typically not published until 18 months after their filing, and in some cases are never published. Therefore, we cannot be certain that our licensors or we were the first to make the inventions claimed in our owned and licensed patents or patent applications, or that our licensors or we were the first to file for patent protection covering such inventions. Subject to meeting other requirements for patentability, for U.S. patent applications filed prior to March&#160;16, 2013, the first to invent the claimed invention is entitled to receive patent protection for that invention while, outside the U.S., the first to file a patent application encompassing the invention is entitled to patent protection for the invention. The U.S. moved to a &#8220;first to file&#8221; system under the Leahy-Smith America Invents Act, effective March&#160;16, 2013. This system also includes procedures for challenging issued patents and pending patent applications, which creates additional uncertainty. We have, are, and may again become involved in opposition or interference proceedings challenging our patents and patent applications or the patents and patent applications of others, and the outcome of any such proceedings are highly uncertain. An unfavorable outcome in any such proceedings could reduce the scope of or invalidate our patent rights, allow third parties to commercialize our technology and compete directly with us, or result in our inability to manufacture, develop or commercialize our product candidates without infringing the patent rights of others.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how, information, or technology that is not covered by our patents. Although our agreements require all of our employees to acknowledge ownership by us of inventions conceived as a result of employment from the point of conception and, to the extent necessary, perfect such ownership by assignment, and we require all of our employees, consultants, advisors and any third parties who have access to our trade secrets, proprietary know-how and other confidential information and technology to enter into appropriate confidentiality agreements, we cannot be certain that our trade secrets, proprietary know-how and other confidential information and technology will not be subject to unauthorized disclosure or that our competitors will not otherwise gain access to or independently develop substantially equivalent trade secrets, proprietary know-how and other information and technology. Furthermore, the laws of some foreign countries, in particular, China, where we have operations, do not protect proprietary rights to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our intellectual property globally. If we are unable to prevent unauthorized disclosure of our intellectual property related to our product candidates and technology to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business and operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property disputes may be costly, time consuming, and may negatively affect our competitive position.</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">*</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success may depend on our avoiding infringement of the patents and other proprietary rights of third parties as well as on enforcing our patents and other proprietary rights against third parties. Pharmaceutical and biotechnology intellectual property disputes are characterized by complex, lengthy and expensive litigation over patents and other intellectual property rights. We have initiated and may again initiate or become party to or be threatened with future litigation or other proceedings regarding intellectual property rights with respect to our product candidates and competing products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As our product candidates progress toward commercialization, our collaboration partners or we may be subject to patent infringement claims from third parties. We attempt to ensure that our product candidates do not infringe third-party patents and other proprietary rights. However, the patent landscape in competitive product areas is highly complex, and there may be patents of third parties of which we are unaware that may result in claims of infringement. Accordingly, there can be no assurance that our product candidates do not infringe proprietary rights of third parties, and parties making claims against us may seek and obtain injunctive or other equitable relief, which could potentially block further efforts to develop and commercialize our product candidates including roxadustat or pamrevlumab. Any litigation involving defense against claims of infringement, regardless of the merit of such claims, would involve substantial litigation expense and would be a substantial diversion of management time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may consider administrative proceedings and other means for challenging third-party patents and patent applications. An unfavorable outcome in any such challenge could require us to cease using the related technology and to attempt to license rights to it from the prevailing third party, which may not be available on commercially reasonable terms, if at all, in which case our business could be harmed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend, if necessary, to vigorously enforce our intellectual property in order to protect the proprietary position of our product candidates, including roxadustat and pamrevlumab. In addition, our collaboration partners who have been granted licenses to our patents may also have rights related to enforcement of those patents. Active efforts to enforce our patents by us or by our partners may include litigation, administrative proceedings, or both, depending on the potential benefits that might be available from those actions and the costs associated with undertaking those efforts against third parties. We carefully review and monitor publicly available information regarding products that may be competitive with our product candidates and assert our intellectual property rights where appropriate. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties have challenged and may again challenge our patents and patent applications. For example, various challenges against our HIF anemia-related technologies patent portfolio are ongoing in several territories including the U.S., Europe, the United Kingdom, and Japan. Regardless of final outcome, the potential narrowing or revocation of any of the HIF anemia-related technology patents does not affect our exclusivity for roxadustat or our freedom-to-operate with respect to use of roxadustat for the treatment of anemia in these or other territories. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oppositions were filed against our European Patent No. 2872488 (the &#8220;`488 Patent&#8221;), which claims a crystalline form of roxadustat, and against our European Patent No. 3003284 (the &#8220;`284 Patent&#8221;), which claims photostable formulations of roxadustat. To date, at oral proceedings, the Opposition Division of the European Patent Office found the &#8216;488 patent did not meet the grounds for novelty. FibroGen plans to appeal this decision once the Written Decision providing the underlying reasoning has been published.<span style="text-decoration:underline;">&#160;</span>Final resolution of the opposition proceedings will take time, and we cannot be assured of the breadth of the claims that will remain in the `488 Patent or `284 Patent, or that either or both of the patents will not be revoked in their entirety.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, there is a risk that any public announcements concerning the status or outcomes of intellectual property litigation or administrative proceedings may adversely affect the price of our stock. If securities analysts or our investors interpret such status or outcomes as negative or otherwise creating uncertainty, our common stock price may be adversely affected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our reliance on third parties and agreements with collaboration partners requires us to share our trade secrets, which increases the possibility that a competitor may discover them or that our trade secrets will be misappropriated or disclosed.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reliance on third-party contractors to develop and manufacture our product candidates is based upon agreements that limit the rights of the third parties to use or disclose our confidential information, including our trade secrets and know-how. Despite the contractual provisions, the need to share trade secrets and other confidential information increases the risk that such trade secrets and information are disclosed or used, even if unintentionally, in violation of these agreements. In the highly competitive markets in which our product candidates are expected to compete, protecting our trade secrets, including our strategies for addressing competing products, is imperative, and any unauthorized use or disclosure could impair our competitive position and may have a material adverse effect on our business and operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our collaboration partners are larger, more complex organizations than ours, and the risk of inadvertent disclosure of our proprietary information may be increased despite their internal procedures and contractual obligations that we have in place with them. Despite our efforts to protect our trade secrets and other confidential information, a competitor&#8217;s discovery of such trade secrets and information could impair our competitive position and have an adverse impact on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The cost of maintaining our patent protection is high and requires continuous review and diligence. We may not be able to effectively maintain our intellectual property position throughout the major markets of the world.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. Patent and Trademark Office and foreign patent authorities require maintenance fees and payments as well as continued compliance with a number of procedural and documentary requirements. Noncompliance may result in abandonment or lapse of the subject patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance may result in reduced royalty payments for lack of patent coverage in a particular jurisdiction from our collaboration partners or may result in competition, either of which could have a material adverse effect on our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have made, and will continue to make, certain strategic decisions in balancing costs and the potential protection afforded by the patent laws of certain countries. As a result, we may not be able to prevent third parties from practicing our inventions in all countries throughout the world, or from selling or importing products made using our inventions in and into the U.S. or other countries. Third parties may use our technologies in territories in which we have not obtained patent protection to develop their own products and, further, may infringe our patents in territories which provide inadequate enforcement mechanisms, even if we have patent protection. Such third-party products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The laws of some foreign countries do not protect proprietary rights to the same extent as do the laws of the U.S., and we may encounter significant problems in securing and defending our intellectual property rights outside the U.S. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain countries. The legal systems of certain countries do not always favor the enforcement of patents, trade secrets, and other intellectual property rights, particularly those relating to pharmaceutical and biotechnology products, which could make it difficult for us to stop infringement of our patents, misappropriation of our trade secrets, or marketing of competing products in violation of our proprietary rights. In China, our intended establishment of significant operations will depend in substantial part on our ability to effectively enforce our intellectual property rights in that country. Proceedings to enforce our intellectual property rights in foreign countries could result in substantial costs and divert our efforts and attention from other aspects of our business, and could put our patents in these territories at risk of being invalidated or interpreted narrowly, or our patent applications at risk of not being granted, and could provoke third parties to assert claims against us. We may not prevail in all legal or other proceedings that we may initiate and, if we were to prevail, the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights do not address all potential threats to any competitive advantage we may have.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and intellectual property rights may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Others may be able to make compounds that are the same as or similar to our current or future product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We or any of our licensors or strategic partners might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">We or any of our licensors or strategic partners might not have been the first to file patent applications covering certain of our inventions.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The prosecution of our pending patent applications may not result in granted patents.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Granted patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Patent protection on our product candidates may expire before we are able to develop and commercialize the product, or before we are able to recover our investment in the product.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our competitors might conduct research and development activities in the U.S. and other countries that provide a safe harbor from patent infringement claims for such activities, as well as in countries in which we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in markets where we intend to market our product candidates.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The existence of counterfeit pharmaceutical products in pharmaceutical markets may compromise our brand and reputation and have a material adverse effect on our business, operations and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Counterfeit products, including counterfeit pharmaceutical products, are a significant problem, particularly in China. Counterfeit pharmaceuticals are products sold or used for research under the same or similar names, or similar mechanism of action or product class, but which are sold without proper licenses or approvals, and are often lower cost, lower quality, different potency, or have different ingredients or formulations, and have the potential to damage the reputation for quality and effectiveness of the genuine product. Such products may be used for indications or purposes that are not recommended or approved or for which there is no data or inadequate data with regard to safety or efficacy. Such products divert sales from genuine products. If counterfeit pharmaceuticals illegally sold or used for research result in adverse events or side effects to consumers, we may be associated with any negative publicity resulting from such incidents. Consumers may buy counterfeit pharmaceuticals that are in direct competition with our pharmaceuticals, which could have an adverse impact on our revenues, business and results of operations. In addition, the use of counterfeit products could be used in non-clinical or clinical studies, or could otherwise produce undesirable side effects or adverse events that may be attributed to our products as well, which could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in the delay or denial of regulatory approval by the FDA or other regulatory authorities and potential product liability claims. With respect to China, although the government has recently been increasingly active in policing counterfeit pharmaceuticals, there is not yet an effective counterfeit pharmaceutical regulation control and enforcement system in China. As a result, we may not be able to prevent third parties from selling or purporting to sell our products in China. The proliferation of counterfeit pharmaceuticals has grown in recent years and may continue to grow in the future. The existence of and any increase in the sales and production of counterfeit pharmaceuticals, or the technological capabilities of counterfeiters, could negatively impact our revenues, brand reputation, business and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Government Regulation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The regulatory approval process is highly uncertain and we may not obtain regulatory approval for our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable, but typically takes many years following the commencement of preclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. Except for roxadustat in China, Japan, South Korea, and Chile for patients on dialysis and not on dialysis, we have not obtained regulatory approval for any product candidate, and it is possible that neither roxadustat nor pamrevlumab, nor any future product candidates we may discover, in-license or acquire and seek to develop in the future, will obtain regulatory approval in additional countries.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates could fail to receive regulatory approval from the FDA or other regulatory authorities for many reasons, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disagreement over the design or implementation of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to demonstrate that a product candidate is safe and effective for its proposed indication&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure of clinical trials to meet the level of statistical significance required for approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disagreement over our interpretation of data from preclinical studies or clinical trials&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disagreement over whether to accept efficacy results from clinical trial sites outside the U.S. where the standard of care is potentially different from that in the U.S.&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the insufficiency of data collected from clinical trials of our present or future product candidates to support the submission and filing of an NDA or other submission or to obtain regulatory approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disapproval of the manufacturing processes or facilities of either our manufacturing plant or third party manufacturers with whom we contract for clinical and commercial supplies&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or other regulatory authorities may require more information, including additional preclinical or clinical data to support approval, or different analyses, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program altogether. Even if we do obtain regulatory approval, our product candidates may be approved for fewer or more limited indications than we request, approval may be contingent on the performance of costly post-marketing clinical trials, or approval may require labeling that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. In addition, if our product candidates produce undesirable side effects or safety issues, the FDA may require the establishment of Risk Evaluation and Mitigation Strategy or other regulatory authorities may require the establishment of a similar strategy, that may restrict distribution of our approved products, if any, and impose burdensome implementation requirements on us. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we believe our clinical trials are successful, regulatory authorities may not agree that our completed clinical trials provide adequate data on safety or efficacy. Approval by one regulatory authority does not ensure approval by any other regulatory authority. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. We may not be able to file for regulatory approvals and even if we file we may not receive the necessary approvals to commercialize our product candidates in any market.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our current and future relationships with customers, physicians, and third-party payors are subject to healthcare fraud and abuse laws, false claims laws, transparency laws, privacy and security laws, and other regulations. If we are unable to comply with such laws, we could face substantial penalties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and future relationships with customers, physicians, and third-party payors are subject to health care laws and regulations, which may constrain the business or financial arrangements and relationships through which we research, as well as, sell, market and distribute any products for which we obtain marketing approval. If we obtain approval in the U.S. for any of our product candidates, the regulatory requirements applicable to our operations, in particular our sales and marketing efforts, will increase significantly with respect to our operations and the potential for administrative, civil and criminal enforcement by the federal government and the states and foreign governments will increase with respect to the conduct of our business. The laws that may affect our operations in the U.S. include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">HIPAA, as amended by Health Information Technology and Clinical Health Act, and its implementing regulations, which imposes certain requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information as well as their covered subcontractors relating to the privacy, security, and transmission of individually identifiable health information&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal physician sunshine requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;PPACA&#8221;), which requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to the Centers for Medicare &#38; Medicaid Services (&#8220;CMS&#8221;), information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">foreign and state law equivalents of each of the above federal laws, such as the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers&#59; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources&#59; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures&#59; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the Trade Agreements Act (&#8220;TAA&#8221;), which requires that drugs sold to the U.S. Government must be manufactured in the U.S. or in TAA approved and designated countries. Drugs manufactured in countries not approved under the TAA, may not be sold to the U.S. without specific regulatory approval. We have little experience with this regulation and there is a risk that drugs made from Chinese-made API may not be sold to an entity of the U.S. such as the Veterans Health Administration (&#8220;VA&#8221;) due to our inability to obtain regulatory approval. While there have been recent VA policy changes that appear to allow for sale of drugs from non-TAA approved countries, this policy may change or there may be additional policies or legislation that affect our ability to sell drug to the U.S. Government.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The scope of these laws and our lack of experience in establishing the compliance programs necessary to comply with this complex and evolving regulatory environment increases the risks that we may unknowingly violate the applicable laws and regulations. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs and imprisonment, any of which could materially adversely affect our ability to operate our business and our financial results. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have a material adverse effect on our ability to compete in the marketplace.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to laws and regulations governing corruption, which will require us to maintain costly compliance programs.*</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We must comply with a wide range of laws and regulations to prevent corruption, bribery, and other unethical business practices, including the FCPA, anti-bribery and anti-corruption laws in other countries, particularly China. The implementation and maintenance of compliance programs is costly and such programs may be difficult to enforce, particularly where reliance on third parties is required.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anti-bribery laws prohibit us, our employees, and some of our agents or representatives from offering or providing any personal benefit to covered government officials to influence their performance of their duties or induce them to serve interests other than the missions of the public organizations in which they serve. Certain commercial bribery rules also prohibit offering or providing any personal benefit to employees and representatives of commercial companies to influence their performance of their duties or induce them to serve interests other than their employers. The FCPA also obligates companies whose securities are listed in the U.S. to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) is involved with enforcement of the books and records provisions of the FCPA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with these anti-bribery laws is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the anti-bribery laws present particular challenges in the pharmaceutical industry because in many countries including China, hospitals are state-owned or operated by the government, and doctors and other hospital employees are considered foreign government officials. Furthermore, in certain countries (China in particular), hospitals and clinics are permitted to sell pharmaceuticals to their patients and are primary or significant distributors of pharmaceuticals. Certain payments to hospitals in connection with clinical studies, procurement of pharmaceuticals and other work have been deemed to be improper payments to government officials that have led to vigorous anti-bribery law enforcement actions and heavy fines in multiple jurisdictions, particularly in the U.S. and China.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is not always possible to identify and deter violations, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the pharmaceutical industry, corrupt practices include, among others, acceptance of kickbacks, bribes or other illegal gains or benefits by the hospitals and medical practitioners from pharmaceutical manufacturers, distributors or their third-party agents in connection with the prescription of certain pharmaceuticals. If our employees, partners, affiliates, subcontractors, distributors or third-party marketing firms violate these laws or otherwise engage in illegal practices with respect to their sales or marketing of our products or other activities involving our products, we could be required to pay damages or heavy fines by multiple jurisdictions where we operate, which could materially and adversely affect our financial condition and results of operations. The Chinese government has also sponsored anti-corruption campaigns from time to time, which could have a chilling effect on any future marketing efforts by us to new hospital customers. There have been recent occurrences in which certain hospitals have denied access to sales representatives from pharmaceutical companies because the hospitals wanted to avoid the perception of corruption. If this attitude becomes widespread among our potential customers, our ability to promote our products to hospitals may be adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we expand our operations in China and other jurisdictions internationally, we will need to increase the scope of our compliance programs to address the risks relating to the potential for violations of the FCPA and other anti-bribery and anti-corruption laws. Our compliance programs will need to include policies addressing not only the FCPA, but also the provisions of a variety of anti-bribery and anti-corruption laws in multiple foreign jurisdictions, including China, provisions relating to books and records that apply to us as a public company, and include effective training for our personnel throughout our organization. The creation and implementation of anti-corruption compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required. Violation of the FCPA and other anti-corruption laws can result in significant administrative and criminal penalties for us and our employees, including substantial fines, suspension or debarment from government contracting, prison sentences, or even the death penalty in extremely serious cases in certain countries. The SEC also may suspend or bar us from trading securities on U.S. exchanges for violation of the FCPA&#8217;s accounting provisions. Even if we are not ultimately punished by government authorities, the costs of investigation and review, distraction of our personnel, legal defense costs, and harm to our reputation could be substantial and could limit our profitability or our ability to develop or commercialize our product candidates. In addition, if any of our competitors are not subject to the FCPA, they may engage in practices that will lead to their receipt of preferential treatment from foreign hospitals and enable them to secure business from foreign hospitals in ways that are unavailable to us.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these, or if we otherwise fail to maintain an effective system of internal control, it may result in material misstatements in our financial statements. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting and for evaluating and reporting on the effectiveness of our system of internal control. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles. As a public company, we are required to comply with the Sarbanes-Oxley Act and other rules that govern public companies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020, we have identified a material weakness in the risk assessment component of internal control as we did not appropriately design and maintain an effective risk assessment process at a precise enough level to identify new and evolving risks of material misstatement to the financial statements as a result of changes in our business operation. This material weakness gave rise to the following additional control deficiencies, which we also determined to be material weaknesses. We did not design and maintain effective controls related to the timely identification of shipments associated with drug product revenue and we did not design and maintain effective controls related to the timely identification of changes in estimated variable consideration related to drug product revenue. Each of these material weaknesses could result in material misstatements in the drug product revenue, contract asset, or contract liability account balances or disclosures in our annual or interim consolidated financial statements that would not be prevented or detected. The material weaknesses described above did not result in any material misstatements of our consolidated financial statements or disclosures, but did result in immaterial out-of-period adjustments to drug product revenue related to pre-commercial shipments of drug product, contract assets and contract liabilities, and related financial statement disclosures during the quarter ended September 30, 2020. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed a detailed remediation plan and are making progress to improve our related internal control over financial reporting. For further discussion of the material weaknesses identified and our remedial efforts, see Part II, Item 9A, &#8220;</span><span style="font-style:italic;">Controls and Procedures&#8221; </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Report on Form 10-K</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the year ended December 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remediation efforts place a significant burden on management and add increased pressure on our financial resources and processes. If we are unable to successfully remediate our existing or any future material weaknesses or other deficiencies in our internal control over financial reporting, the accuracy and timing of our financial reporting may be adversely affected, our liquidity, our access to capital markets may be adversely affected, we may be unable to maintain or regain compliance with applicable securities laws, and the Nasdaq Stock Market LLC listing requirements, we may be subject to regulatory investigations and penalties, investors may lose confidence in our financial reporting, and our stock price may decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The impact of recent U.S. healthcare reform, its potential partial or full repeal, and other changes in the healthcare industry and in healthcare spending is currently unknown, and may adversely affect our business model.* </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The commercial potential for our approved products could be affected by changes in healthcare spending and policy in the U.S. and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S., the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (&#8220;MMA&#8221;) altered Medicare coverage and payments for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. The MMA also provided authority for limiting the number of drugs that will be covered in any therapeutic class and as a result, we expect that there will be additional pressure to reduce costs. For example, the CMS in implementing the MMA has enacted regulations that reduced capitated payments to dialysis providers. These cost reduction initiatives and other provisions of the MMA could decrease the scope of coverage and the price that may be received for any approved dialysis products and could seriously harm our business and financial condition. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policies and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from the MMA may cause a similar reduction in payments from private payors. Similar regulations or reimbursement policies have been enacted in many international markets that could similarly impact the commercial potential for our products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Medicare Improvements for Patients and Providers Act (&#8220;MIPPA&#8221;), a basic case-mix adjusted composite, or bundled, payment system commenced in January 2011 and transitioned fully by January 2014 to a single reimbursement rate for drugs and all services furnished by renal dialysis centers for Medicare beneficiaries with end-stage renal disease. Specifically, under MIPPA the End-Stage Renal Disease Prospective Payment System (the &#8220;ESRD PPS&#8221;) bundle now covers drugs, services, lab tests and supplies under a single treatment base rate for reimbursement by the CMS based on the average cost per treatment, including the cost of ESAs and IV iron doses, typically without adjustment for usage. It is unknown whether roxadustat, if approved in the U.S., will be included in the payment bundle or the timing of inclusion. Under MIPPA, agents that have no IV equivalent in the bundle are currently expected to be excluded from the bundle until 2025. If roxadustat were included in the bundle, it may reduce the price that could be charged for roxadustat, and therefore potentially limit our profitability. Based on roxadustat&#8217;s differentiated mechanism of action and therapeutic effects, and discussions with our collaboration partner, we currently believe that roxadustat might not initially be included in the bundle and would instead be eligible for a Transitional Drug Add-on Payment Adjustment (&#8220;TDAPA&#8221;) for a 24-month period. At the 24-month mark, CMS would determine if the TDAPA period should be extended for roxadustat or ended. When the TDAPA period ends, CMS will determine if roxadustat should be included in the bundle and, if so, what changes to the ESRD PPS reimbursement should be made. If roxadustat is included in the ESRD PPS bundle, it may have an impact on roxadustat pricing within dialysis organizations. If roxadustat is not included in the bundle after the TDAPA period, and would therefore be reimbursed outside of the bundle, it may potentially limit further market penetration of roxadustat. We currently expect roxadustat to be granted TDAPA designation one to two calendar quarters after an FDA approval. However, there is a risk that we do not receive TDAPA designation, or when we expect it, in which case, there would be a significant impact on roxadustat revenue from dialysis organizations until TDAPA designation is granted.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2010, the PPACA was passed, which substantially changed the way healthcare is financed by both governmental and private payors in the U.S. There remain judicial and Congressional challenges to certain aspects of the PPACA. For example, the Tax Cuts and Jobs Act of 2017, (the &#8220;Tax Act&#8221;), was enacted, which includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the 2020 federal spending package permanently eliminates, effective January 1, 2020, the PPACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, on December 14, 2018, a Texas U.S. District Court Judge ruled that the PPACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the PPACA are invalid as well. The U.S. Supreme Court is currently reviewing this case, but it is unknown when a decision will be reached. Although the U.S. Supreme Court has yet ruled on the constitutionality of the PPACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the PPACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the PPACA. It is unclear how the U.S. Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the PPACA and our business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, in the U.S. there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals. The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November&#160;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part&#160;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until March 22, 2021. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the U.S. District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. However, it is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional U.S. healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for any future products or additional pricing pressures.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Roxadustat is considered a Class 2 substance on the 2019 World Anti-Doping Agency Prohibited List that could limit sales and increase security and distribution costs for our partners and us. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is considered a Class 2 substance on the World Anti-Doping Agency Prohibited List. There are enhanced security and distribution procedures we and our collaboration partners and third-party contractors will have to take to limit the risk of loss of product in the supply chain. As a result, our distribution, manufacturing and sales costs for roxadustat, as well as for our partners, will be increased which will reduce profitability. In addition, there is a risk of reduced sales due to patient access to this drug. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees may engage in misconduct or improper activities, which could result in significant liability or harm our reputation.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of employee fraud or other misconduct, including intentional failure to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">comply with FDA regulations or similar regulations of comparable foreign regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">provide accurate information to the FDA or comparable foreign regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">comply with manufacturing standards we have established&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">comply with privacy laws protecting personal information&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">comply with the FCPA and other anti-bribery laws&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">report financial information or data accurately&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disclose unauthorized activities to us.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions, delays in clinical trials, or serious harm to our reputation. We have adopted a code of conduct for our directors, officers and employees, but it is not always possible to identify and deter employee misconduct. The precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could harm our business, results of operations, financial condition and cash flows, including through the imposition of significant fines or other sanctions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health or safety laws and regulations, we could incur fines, penalties or other costs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations applicable to our operations in the U.S. and foreign countries. These current or future laws and regulations may impair our research, development or manufacturing efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our International Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have established operations in China and are seeking approval to commercialize our product candidates outside of the U.S., and a number of risks associated with international operations could materially and adversely affect our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to be subject to a number of risks related with our international operations, many of which may be beyond our control. These risks include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">different regulatory requirements for drug approvals in different countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">different standards of care in various countries that could complicate the evaluation of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">different U.S. and foreign drug import and export rules&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reduced protection for intellectual property rights in certain countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in tariffs, trade barriers and regulatory requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">different reimbursement systems and different competitive drugs indicated to treat the indications for which our product candidates are being developed&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">economic weakness, including inflation, or political instability in particular foreign economies and markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">compliance with the FCPA, and other anti-corruption and anti-bribery laws&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">U.S. and foreign taxes, including income, excise, customs, consumption, withholding, and payroll taxes&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">foreign currency fluctuations, which could result in increased operating costs and expenses and reduced revenues, and other obligations incident to doing business in another country&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">workforce uncertainty in countries where labor unrest is more common than in the U.S.&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a reliance on CROs, clinical trial sites, principal investigators and other third parties that may be less experienced with clinical trials or have different methods of performing such clinical trials than we are used to in the U.S.&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential liability resulting from development work conducted by foreign distributors&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">business interruptions resulting from geopolitical actions specific to an international region, including war and terrorism, or natural disasters, including the differing impact of the COVID-19 pandemic on each region.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The pharmaceutical industry in China is highly regulated and such regulations are subject to change. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pharmaceutical industry in China is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new drugs. In recent years, many aspects of pharmaceutical industry regulation have undergone significant reform, and reform may continue. For example, the Chinese government implemented regulations that impact distribution of pharmaceutical products in China, where at most two invoices may be issued throughout the distribution chain, a change that required us to change our distribution paradigm. Any regulatory changes or amendments may result in increased compliance costs to our business or cause delays in or prevent the successful development or commercialization of our product candidates in China. Any failure by us or our partners to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our business activities in China.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have limited experience distributing drugs in China.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have established a jointly owned entity with AstraZeneca in China, one that has a distribution license. It is subject to a new body of regulations pertaining to distribution with which we have limited experience. This new distribution structure may impose higher costs or limit or delay our ability to sell products to our principal customers, and may limit the near term sales of our products. There are operational risks associated with the jointly owned entity, such as working capital funding requirements and regulatory challenges, which could impact our ability to operate in China, including increasing sales of roxadustat. We have limited experience managing distribution of pharmaceutical products, and this new distribution structure may impose higher costs or limit or delay our ability to sell products to our principal customers, and may limit the near term sales of our products. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We use our own manufacturing facilities in China to produce roxadustat API and drug product. There are risks inherent to operating commercial manufacturing facilities, and with these being our single source suppliers, we may not be able to continually meet market demand. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have two manufacturing facilities in China, with one located in Beijing and the other in Cangzhou, Hebei. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will be obligated to comply with continuing cGMP requirements and there can be no assurance that we will maintain all of the appropriate licenses required to manufacture our product candidates for clinical and commercial use in China. In addition, our product suppliers and we must continually spend time, money and effort in production, record-keeping and quality assurance and appropriate controls in order to ensure that any products manufactured in our facilities meet applicable specifications and other requirements for product safety, efficacy and quality and there can be no assurance that our efforts will continue to be successful in meeting these requirements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing facilities in China are subject to periodic unannounced inspections by the NMPA and other regulatory authorities. We expect to depend on these facilities for our product candidates and business operations in China</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and we do not yet have a secondary source supplier for either roxadustat API or drug product in China</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Natural disasters or other unanticipated catastrophic events, including power interruptions, water shortages, storms, fires, pandemics</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (including the COVID-19 pandemic)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, earthquakes, terrorist attacks, government appropriation of our facilities, and wars, could significantly impair our ability to operate our manufacturing facilities. Certain equipment, records and other materials located in these facilities would be difficult to replace or would require substantial replacement lead-time that would impact our ability to successfully commercialize our product candidates in China. The occurrence of any such event could materially and adversely affect our business, financial condition, results of operations, cash flows and prospects.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As a company, we have limited experience in pharmacovigilance, medical affairs, and management of the third-party distribution logistics, and cannot assure you we will be able to meet regulatory requirements or operate in these capacities successfully.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are responsible for commercial manufacturing, pharmacovigilance, medical affairs, and management of the third-party distribution logistics (with AstraZeneca through a jointly owned entity that will perform roxadustat distribution) for roxadustat commercial activities in China. While we have been increasing our staffing in these areas, as a company, we have no experience managing or operating these functions for a commercial product and there can be no guarantee that we will do so efficiently or effectively. Mistakes or delays in these areas could limit our ability to successfully commercialize roxadustat in China, could limit our eventual market penetration, sales and profitability, and could subject us to significant liability in China.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our collaboration partner in China, AstraZeneca, and we may experience difficulties in successfully growing and sustaining sales of roxadustat in China.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca and we have a profit sharing arrangement with respect to roxadustat in China and any difficulties we may experience in growing and sustaining sales will affect our bottom line. Difficulties may be related to our ability to maintain reasonable pricing and reimbursement, obtain hospital listing, or other difficulties related to distribution, marketing, and sales efforts in China. For example, our current National Reimbursement Drug List reimbursement pricing is effective for a standard two-year period (between January 1, 2020 to December 31, 2021), after which time we will have to renegotiate a new price for roxadustat, which we expect to be lower based upon historical precedents. Sales of roxadustat in China may ultimately be limited due to the complex nature of the healthcare system, low average personal income, pricing controls, still developing infrastructure and potentially rapid competition from other products. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The retail prices of any product candidates that we develop may be subject to pricing control in China and elsewhere.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The price for pharmaceutical products is highly regulated in China, both at the national and provincial level. Price controls may reduce prices to levels significantly below those that would prevail in less regulated markets or limit the volume of products that may be sold, either of which may have a material and adverse effect on potential revenues from sales of roxadustat in China. Moreover, the process and timing for the implementation of price restrictions is unpredictable, which may cause potential revenues from the sales of roxadustat to fluctuate from period to period.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FibroGen (China) Medical Technology Development Co., Ltd. (&#8220;FibroGen Beijing&#8221;) would be subject to restrictions on paying dividends or making other payments to us, which may restrict our ability to satisfy our liquidity requirements.*</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to conduct all of our business in China through FibroGen China Anemia Holdings, Ltd. and FibroGen Beijing. We may rely on dividends and royalties paid by FibroGen Beijing for a portion of our cash needs, including the funds necessary to service any debt we may incur and to pay our operating costs and expenses. The payment of dividends by FibroGen Beijing is subject to limitations. Regulations in China currently permit payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China. FibroGen Beijing is not permitted to distribute any profits until losses from prior fiscal years have been recouped and in any event must maintain certain minimum capital requirements. FibroGen Beijing is also required to set aside at least 10.0% of its after-tax profit based on Chinese accounting standards each year to its statutory reserve fund until the cumulative amount of such reserves reaches 50.0% of its registered capital. Statutory reserves are not distributable as cash dividends. In addition, if FibroGen Beijing incurs debt on its own behalf in the future, the agreements governing such debt may restrict its ability to pay dividends or make other distributions to us. As of June 30, 2021, approximately $63.8 million of our cash and cash equivalents is held in China.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any capital contributions from us to FibroGen Beijing must be approved by the Ministry of Commerce in China, and failure to obtain such approval may materially and adversely affect the liquidity position of FibroGen Beijing.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Ministry of Commerce in China or its local counterpart must approve the amount and use of any capital contributions from us to FibroGen Beijing, and there can be no assurance that we will be able to complete the necessary government registrations and obtain the necessary government approvals on a timely basis, or at all. If we fail to do so, we may not be able to contribute additional capital to fund our Chinese operations, and the liquidity and financial position of FibroGen Beijing may be materially and adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to currency exchange rate fluctuations and currency exchange restrictions with respect to our operations in China, which could adversely affect our financial performance.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of our product sales will occur in local Chinese currency and our operating results will be subject to volatility from currency exchange rate fluctuations. To date, we have not hedged against the risks associated with fluctuations in exchange rates and, therefore, exchange rate fluctuations could have an adverse impact on our future operating results. Changes in value of the Renminbi against the U.S. dollar, Euro and other currencies is affected by, among other things, changes in China&#8217;s political and economic conditions. Currently, the Renminbi is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. Any significant currency exchange rate fluctuations may have a material adverse effect on our business and financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Chinese government imposes controls on the convertibility of the Renminbi into foreign currencies and the remittance of foreign currency out of China for certain transactions. Shortages in the availability of foreign currency may restrict the ability of FibroGen Beijing to remit sufficient foreign currency to pay dividends or other payments to us, or otherwise satisfy their foreign currency-denominated obligations. Under existing Chinese foreign exchange regulations, payments of current account items, including profit distributions, interest payments and balance of trade, can be made in foreign currencies without prior approval from the State Administration of Foreign Exchange by complying with certain procedural requirements. However, approval from State Administration of Foreign Exchange or its local branch is required where Renminbi is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The Chinese government may also at its discretion restrict access in the future to foreign currencies for current account transactions. If the foreign exchange control system prevents us from obtaining sufficient foreign currency to satisfy our operational requirements, our liquidity and financial position may be materially and adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because FibroGen Beijing&#8217;s funds are held in banks that do not provide insurance, the failure of any bank in which FibroGen Beijing deposits its funds could adversely affect our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Banks and other financial institutions in China do not provide insurance for funds held on deposit. As a result, in the event of a bank failure, FibroGen Beijing may not have access to funds on deposit. Depending upon the amount of money FibroGen Beijing maintains in a bank that fails, its inability to have access to cash could materially impair its operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to tax inefficiencies associated with our offshore corporate structure. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tax regulations of the U.S. and other jurisdictions in which we operate are extremely complex and subject to change. New laws, new interpretations of existing laws, such as the Base Erosion Profit Shifting project initiated by the Organization for Economic Co-operation and Development, and any legislation proposed by the relevant taxing authorities, or limitations on our ability to structure our operations and intercompany transactions may lead to inefficient tax treatment of our revenue, profits, royalties, and distributions, if any are achieved.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our foreign subsidiaries and we have various intercompany transactions. We may not be able to obtain certain benefits under relevant tax treaties to avoid double taxation on certain transactions among our subsidiaries. If we are not able to avail ourselves to the tax treaties, we could be subject to additional taxes, which could adversely affect our financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 22, 2017, the Tax Cuts and Jobs Act (Tax Act) was enacted which instituted various changes to the taxation of multinational corporations. Since inception, various regulations and interpretations have been issued by governing authorities and we continue to examine the impacts to our business, which could potentially have a material adverse effect on our business, results of operations or financial conditions. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our foreign operations, particularly those in China, are subject to significant risks involving the protection of inte</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">llectual property.</span><span style="font-weight:normal;font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We seek to protect the products and technology that we consider important to our business by pursuing patent applications in China and other countries, relying on trade secrets or pharmaceutical regulatory protection or employing a combination of these methods. We note that the filing of a patent application does not mean that we will be granted a patent, or that any patent eventually granted will be as broad as requested in the patent application or will be sufficient to protect our technology. There are a number of factors that could cause our patents, if granted, to become invalid or unenforceable or that could cause our patent applications not to be granted, including known or unknown prior art, deficiencies in the patent application, or lack of originality of the technology. Furthermore, the terms of our patents are limited. The patents we hold and the patents that may be granted from our currently pending patent applications have, absent any patent term adjustment or extension, a twenty-year protection period starting from the date of application.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property rights and confidentiality protections in China may not be as effective as those in the U.S. or other countries for many reasons, including lack of procedural rules for discovery and evidence, low damage awards, and lack of judicial independence. Implementation and enforcement of China intellectual property laws have historically been deficient and ineffective and may be hampered by corruption and local protectionism. Policing unauthorized use of proprietary technology is difficult and expensive, and we may need to resort to litigation to enforce or defend patents issued to us or to determine the enforceability and validity of our proprietary rights or those of others. The experience and capabilities of China courts in handling intellectual property litigation varies and outcomes are unpredictable. An adverse determination in any such litigation could materially impair our intellectual property rights and may harm our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Uncertainties with respect to the China legal system could have a material adverse effect on us.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The legal system of China is a civil law system primarily based on written statutes. Unlike in a common law system, prior court decisions may be cited for reference but are not binding. Because the China legal system continues to rapidly evolve, the interpretations of many laws, regulations and rules are not always uniform and enforcement of these laws, regulations and rules involve uncertainties, which may limit legal protections available to us. Moreover, decision makers in the China judicial system have significant discretion in interpreting and implementing statutory and contractual terms, which may render it difficult for FibroGen Beijing to enforce the contracts it has entered into with our business partners, customers and suppliers. Different government departments may have different interpretations of certain laws and regulations, and licenses and permits issued or granted by one government authority may be revoked by a higher government authority at a later time. Navigating the uncertainty and change in the China legal system will require the devotion of significant resources and time, and there can be no assurance that our contractual and other rights will ultimately be enforced.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in China&#8217;s economic, governmental, or social conditions could have a material adverse effect on our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chinese society and the Chinese economy continue to undergo significant change. Changes in the regulatory structure, regulations, and economic policies of the Chinese government could have a material adverse effect on the overall economic growth of China, which could adversely affect our ability to conduct business in China. The Chinese government continues to adjust economic policies to promote economic growth. Some of these measures benefit the overall Chinese economy, but may also have a negative effect on us. For example, our financial condition and results of operations in China may be adversely affected by government control over capital investments or changes in tax regulations. As the Chinese pharmaceutical industry grows and evolves, the Chinese government may also implement measures to change the regulatory structure and structure of foreign investment in this industry. We are unable to predict the frequency and scope of such policy changes and structural changes, any of which could materially and adversely affect FibroGen Beijing&#8217;s development and commercialization timelines, liquidity, access to capital, and its ability to conduct business in China. Any failure on our part to comply with changing government regulations and policies could result in the loss of our ability to develop and commercialize our product candidates in China. In addition, the changing government regulations and policies could result in delays and cost increases to our development, manufacturing, approval, and commercialization timelines in China.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our operations in China subject us to various Chinese labor and social insurance laws, and our failure to comply with such laws may materially and adversely affect our business, financial condition and results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to China Labor Contract Law, which provides strong protections for employees and imposes many obligations on employers. The Labor Contract Law places certain restrictions on the circumstances under which employers may terminate labor contracts and require economic compensation to employees upon termination of employment, among other things. In addition, companies operating in China are generally required to contribute to labor union funds and the mandatory social insurance and housing funds. Any failure by us to comply with Chinese labor and social insurance laws may subject us to late fees, fines and penalties, or cause the suspension or termination of our ability to conduct business in China, any of which could have a material and adverse effect on business, results of operations and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Operation of Our Business</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future and may never achieve or sustain profitability. We may require additional financings in order to fund our operations.*</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a biopharmaceutical company with two lead product candidates in clinical development, roxadustat for anemia in CKD, myelodysplastic syndromes, and chemotherapy-induced anemia, and pamrevlumab for IPF, pancreatic cancer, and DMD. Most of our revenue generated to date has been based on our collaboration agreements and we have limited commercial drug product sales to date. We continue to incur significant research and development and other expenses related to our ongoing operations. Our net loss for the year ended December&#160;31, 2020, 2019 and 2018 were $189.3 million, $77.0 million and $86.4 million, respectively. As of June 30, 2021, we had an accumulated deficit of $1.2 billion. As of June 30, 2021, we had capital resources consisting of cash, cash equivalents and short-term investments of $507.2 million plus $105.8 million of long-term investments classified as available for sale securities. Despite contractual development and cost coverage commitments from our collaboration partners, AstraZeneca and Astellas, and the potential to receive milestone and other payments from these partners, and despite commercialization efforts in the China and Japan for roxadustat for the treatment of anemia caused by CKD, we anticipate we will continue to incur losses on an annual basis for the foreseeable future. If we do not successfully develop and continue to obtain regulatory approval for our existing or any future product candidates and effectively manufacture, market and sell the product candidates that are approved, we may never achieve or sustain profitability on a quarterly or annual basis. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. Our failure to become and remain profitable would depress the market price of our common stock and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that we will continue to expend substantial resources for the foreseeable future as we continue to grow our operations in China, expand our clinical development efforts on pamrevlumab, continue to seek regulatory approval, establish commercialization capabilities of our product candidates, and pursue additional indications. These expenditures will include costs associated with research and development, conducting preclinical trials and clinical trials, obtaining regulatory approvals in various jurisdictions, and manufacturing and supplying products and product candidates for our partners and ourselves. The outcome of any clinical trial and/or regulatory approval process is highly uncertain and we are unable to fully estimate the actual costs necessary to successfully complete the development and regulatory approval process for our compounds in development and any future product candidates. We believe that the net proceeds from our 2017 public offerings, our existing cash and cash equivalents, short-term and long-term investments and accounts receivable, and expected third-party collaboration revenues will allow us to fund our operating plans through at least the next 12 months. Our operating plans or third-party collaborations may change as a result of many factors, including the success of our development and commercialization efforts, operations costs (including manufacturing and regulatory), competition, and other factors that may not currently be known to us, and we therefore may need to seek additional funds sooner than planned, through offerings of public or private securities, debt financings or other sources, such as royalty monetization or other structured financings. Such financings may result in dilution to stockholders, imposition of debt covenants and repayment obligations, or other restrictions that may adversely affect our business. We may also seek additional capital due to favorable market conditions or strategic considerations even if we currently believe that we have sufficient funds for our current or future operating plans.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional funds may not be available when we require them, or on terms that are acceptable to us. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate our research and development efforts or other operations or activities that may be necessary to commercialize our product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Most of our recent revenue has been earned from collaboration partners for our product candidates under development.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If either or both of our Astellas and AstraZeneca collaborations were to be terminated, we could require significant additional capital in order to proceed with development and commercialization of our product candidates, including with respect to our potential commercialization of roxadustat for the treatment of anemia caused by CKD, or we may require additional partnering in order to help fund such development and commercialization. If adequate funds or partners are not available to us on a timely basis or on favorable terms, we may be required to delay, limit, reduce or terminate our development or commercialization efforts or other operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we seek to advance our product candidates through clinical trials and commercialization, we will need to expand our development, regulatory, manufacturing, commercialization and administration capabilities or contract with third parties to provide these capabilities for us. As our operations expand and we continue to undertake the efforts and expense to operate as a public reporting company, we expect that we will need to increase the responsibilities on members of management in order to manage any future growth effectively. Our failure to accomplish any of these steps could prevent us from successfully implementing our strategy and maintaining the confidence of investors in us. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Loss of senior management and key personnel could adversely affect our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on members of our senior management team, including Enrique Conterno, our Chief Executive Officer. The loss of the services of Mr.&#160;Conterno or any of our senior management could significantly impact the development and commercialization of our products and product candidates and our ability to successfully implement our business strategy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recruiting and retaining qualified commercial, development, scientific, clinical, and manufacturing personnel are and will continue to be critical to our success, particularly as we expand our commercialization operations. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize product candidates. We may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the intense competition among numerous biopharmaceutical companies for similar personnel.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is also significant competition, in particular in the San Francisco Bay Area, for the hiring of experienced and qualified personnel, which increases the importance of retention of our existing personnel. If we are unable to continue to attract and retain personnel with the quality and experience applicable to our product candidates, our ability to pursue our strategy will be limited and our business and operations would be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may have to limit commercial operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability as a result of the clinical testing, manufacturing and commercialization of our product candidates. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in a product, negligence, strict liability or breach of warranty. Claims could also be asserted under state consumer protection acts. If we are unable to obtain insurance coverage at levels that are appropriate to maintain our business and operations, or if we are unable to successfully defend ourselves against product liability claims, we may incur substantial liabilities or otherwise cease operations. Product liability claims may result in:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">termination of further development of unapproved product candidates or significantly reduced demand for any approved products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">material costs and expenses to defend the related litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a diversion of time and resources across the entire organization, including our executive management&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product recalls, withdrawals or labeling restrictions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">termination of our collaboration relationships or disputes with our collaboration partners&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reputational damage negatively impacting our other product candidates in development.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims, we may not be able to continue to develop our product candidates. We maintain product liability insurance in a customary amount for the stage of development of our product candidates. Although we believe that we have sufficient coverage based on the advice of our third-party advisors, there can be no assurance that such levels will be sufficient for our needs. Moreover, our insurance policies have various exclusions, and we may be in a dispute with our carrier as to the extent and nature of our coverage, including whether we are covered under the applicable product liability policy. If we are not able to ensure coverage or are required to pay substantial amounts to settle or otherwise contest the claims for product liability, our business and operations would be negatively affected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business and operations would suffer in the event of computer system failures.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the implementation of security measures, our internal computer systems, and those of our CROs, collaboration partners, and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, fire, terrorism, war and telecommunication and electrical failures. We upgraded our disaster and data recovery capabilities in 2019, and have continued to upgrade these capabilities. However, to the extent that any disruption or security breach, in particular with our partners&#8217; operations, results in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and it could result in a material disruption and delay of our drug development programs. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We depend on sophisticated information technology systems and could face a cyber-attack or other breach of these systems. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on information technology systems to process, transmit and store electronic information in our day-to-day operations. The size and complexity of our information technology systems makes them vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, loss of data privacy or other significant disruption. While we upgraded our disaster data recovery program in March 2019, a successful attack could result in the theft or destruction of intellectual property, data, or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyber-attacks are becoming more sophisticated and frequent. We have invested in our systems and the protection and recoverability of our data to reduce the risk of an intrusion or interruption, and we monitor and test our systems on an ongoing basis for any current or potential threats. There can be no assurance that these measures and efforts will prevent future interruptions or breakdowns. If we fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to these systems, we could have difficulty preventing, detecting and controlling such cyber-attacks and any such attacks could result in losses described above as well as disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating costs and expenses, expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our headquarters are located near known earthquake fault zones.&#160;&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and some of the third-party service providers on which we depend for various support functions are vulnerable to damage from catastrophic events, such as power loss, natural disasters, terrorism and similar unforeseen events beyond our control. Our corporate headquarters and other facilities are located in the San Francisco Bay Area, which in the past has experienced severe earthquakes and fires, and has been affected by the COVID-19 pandemic, including economic disruption resulting from the related shelter-in-place and stay-at-home governmental orders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After a comprehensive earthquake risk analysis conducted by Marsh Risk, we decided not to purchase earthquake or flood insurance. Based upon (among other factors) the Marsh Risk analysis, the design and construction of our building, the expected potential loss, and the costs and deductible associated with earthquake and flood insurance, we chose to self-insure. However, earthquakes or other natural disasters could severely disrupt our operations, or have a larger cost than expected, and have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, damaged critical infrastructure, or otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place are unlikely to provide adequate protection in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events, such as the COVID-19 pandemic. If such an event were to affect our supply chain, it could have a material adverse effect on our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Common Stock</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market price of our common stock may be highly volatile, and you may not be able to resell your shares at or above your purchase price.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, pharmaceutical, biotechnology and other life sciences company stocks have been highly volatile in the current market. The volatility of pharmaceutical, biotechnology and other life sciences company stocks is sometimes unrelated to the operating performance of particular companies and biotechnology and life science companies stocks often respond to trends and perceptions rather than financial performance. In particular, the market price of shares of our common stock could be subject to wide fluctuations in response to the following factors:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">results of clinical trials of our product candidates, including roxadustat and pamrevlumab&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing of the release of results of and regulatory updates regarding our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the level of expenses related to any of our product candidates or clinical development programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">results of clinical trials of our competitors&#8217; products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">safety issues with respect to our product candidates or our competitors&#8217; products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory actions with respect to our product candidates and any approved products or our competitors&#8217; products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fluctuations in our financial condition and operating results, which will be significantly affected by the manner in which we recognize revenue from the achievement of milestones under our collaboration agreements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse developments concerning our collaborations and our manufacturers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the termination of a collaboration or the inability to establish additional collaborations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inability to obtain adequate product supply for any approved drug product or inability to do so at acceptable prices&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in legislation or other regulatory developments affecting our product candidates or our industry&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fluctuations in the valuation of the biotechnology industry and particular companies perceived by investors to be comparable to us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">speculation in the press or investment community&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">activities of the government of China, including those related to the pharmaceutical industry as well as industrial policy generally&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">performance of other U.S. publicly traded companies with significant operations in China&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in market conditions for biopharmaceutical stocks&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the other factors described in this &#8220;</span><span style="font-style:italic;color:#000000;">Risk Factors</span><span style="color:#000000;">&#8221; section.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of fluctuations caused by these and other factors, comparisons of our operating results across different periods may not be accurate indicators of our future performance. Any fluctuations that we report in the future may differ from the expectations of market analysts and investors, which could cause the price of our common stock to fluctuate significantly. Moreover, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management&#8217;s attention and resources and could also require us to make substantial payments to satisfy judgments or to settle litigation.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our principal stockholders own a significant percentage of our stock and will be able to exercise influence over stockholder approvals.</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">*</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of July 31, 2021, our executive officers, directors and principal stockholders, together with their respective affiliates, owned approximately 40.91% of our common stock, including shares subject to outstanding options that are exercisable within 60&#160;days after such date and shares issuable upon settlement of restricted stock units that will vest within 60 days after such date. This percentage is based upon information supplied by officers, directors and principal stockholders and Schedules 13D and 13G, if any, filed with the SEC, which information may not be accurate as of January 31, 2020. Accordingly, these stockholders will be able to exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of our board of directors and approval of significant corporate transactions. The interests of this group may differ from those of other stockholders and they may vote their shares in a way that is contrary to the way other stockholders vote their shares. This concentration of ownership could have the effect of entrenching our management and/or the board of directors, delaying or preventing a change in our control or otherwise discouraging a potential acquirer from attempting to obtain control of us, which in turn could have a material and adverse effect on the fair market value of our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may engage in acquisitions that could dilute stockholders and harm our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may, in the future, make acquisitions of or investments in companies that we believe have products or capabilities that are a strategic or commercial fit with our present or future product candidates and business or otherwise offer opportunities for us. In connection with these acquisitions or investments, we may:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">issue stock that would dilute our existing stockholders&#8217; percentage of ownership&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">incur debt and assume liabilities&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">incur amortization expenses related to intangible assets or incur large and immediate write-offs.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to complete acquisitions on favorable terms, if at all. If we do complete an acquisition, we cannot assure you that it will ultimately strengthen our competitive position or that it will be viewed positively by customers, financial markets or investors. Furthermore, future acquisitions could pose numerous additional risks to our operations, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">problems integrating the purchased business, products or technologies, or employees or other assets of the acquisition target&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">increases to our expenses&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disclosed or undisclosed liabilities of the acquired asset or company&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">diversion of management&#8217;s attention from their day-to-day responsibilities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reprioritization of our development programs and even cessation of development and commercialization of our current product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">harm to our operating results or financial condition&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">entrance into markets in which we have limited or no prior experience&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential loss of key employees, particularly those of the acquired entity.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to complete any acquisitions or effectively integrate the operations, products or personnel gained through any such acquisition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provisions in our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, and may prevent attempts by our stockholders to replace or remove our current directors or management.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">create a classified board of directors whose members serve staggered three-year terms&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">specify that special meetings of our stockholders can be called only by our board of directors pursuant to a resolution adopted by a majority of the total number of directors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">prohibit stockholder action by written consent&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">provide that our directors may be removed prior to the end of their term only for cause&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">require a supermajority vote of the holders of our common stock or the majority vote of our board of directors to amend our bylaws&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">require a supermajority vote of the holders of our common stock to amend the classification of our board of directors into three classes and to amend certain other provisions of our certificate of incorporation.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because we are incorporated in Delaware, we are governed by certain anti-takeover provisions under Delaware law which may discourage, delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. We are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any provision of our amended and restated certificate of incorporation, our amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in our tax provision or exposure to additional tax liabilities could adversely affect our earnings and financial condition.* </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a multinational corporation, we are subject to income taxes in the U.S. and various foreign jurisdictions. Significant judgment is required in determining our global provision for income taxes and other tax liabilities. In the ordinary course of a global business, there are intercompany transactions and calculations where the ultimate tax determination is uncertain. Our income tax returns are&#160;subject to audits by tax authorities. Although we regularly assess the likelihood of adverse outcomes resulting from these examinations to determine our tax estimates, a final determination of tax audits or tax disputes could have an adverse effect on our results of operations and financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to non-income taxes, such as payroll, excise, customs and duties, sales, use, value-added, net worth, property, gross receipts, and goods and services taxes in the U.S., state and local, and various foreign jurisdictions. We are subject to audit and assessments&#160;by tax authorities with respect to these non-income taxes and the determination of these non-income taxes is subject to varying interpretations arising from the complex nature of tax laws and regulations. Therefore, we may have exposure to additional non-income tax liabilities, which could have an adverse effect on our results of operations and financial condition.&#8203;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state tax laws impose substantial restrictions on the utilization of net operating loss and credit carryforwards in the event of an &#8220;ownership change&#8221; for tax purposes, as defined in IRC Section&#160;382. If additional ownership change occurs, the utilization of net operating loss and credit carryforwards could be significantly reduced.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our judgment in providing for the possible impact of the Tax Act remains subject to developing interpretations of the provisions of the Tax Act. As regulations and guidance evolve with respect to the Tax Act, we continue to examine the impact to our tax provision or exposure to additional tax liabilities, which could have a material adverse effect on our business, results of operations or financial condition.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Tariffs imposed by the U.S. and those imposed in response by other countries could have a material adverse effect on our business.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in U.S. and foreign governments&#8217; trade policies have resulted in, and may continue to result in, tariffs on imports into and exports from the U.S. Throughout 2018 and 2019, the U.S. imposed tariffs on imports from several countries, including China. In response, China has proposed and implemented their own tariffs on certain products, which may impact our supply chain and our costs of doing business. If we are impacted by the changing trade relations between the U.S. and China, our business and results of operations may be negatively impacted. Continued diminished trade relations between the U.S. and other countries, including potential reductions in trade with China and others, as well as the continued escalation of tariffs, could have a material adverse effect on our financial performance and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our certificate of incorporation designates courts located in Delaware as the sole forum for certain proceedings, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that, subject to limited exceptions, the state and federal courts located in the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (1)&#160;any derivative action or proceeding brought on our behalf, (2)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3)&#160;any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated by-laws, or (4)&#160;any other action asserting a claim against us that is governed by the internal affairs doctrine. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the U.S. federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. If a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not plan to pay dividends. Capital appreciation will be your sole possible source of gain, which may never occur.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should not rely on an investment in our common stock to provide dividend income. We do not anticipate that we will pay any cash dividends to holders of our common stock in the foreseeable future and investors seeking cash dividends should not purchase our common stock. We plan to retain any earnings to invest in our product candidates and maintain and expand our operations. Therefore, capital appreciation, or an increase in your stock price, which may never occur, may be the only way to realize any return on your investment.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES">ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">ITEM 4. MINE SAFETY DISCLOSURES.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_OR_INFORMATION"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM 5. OTHER </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INFORMATION.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a press release on April 6, 2021, the Company clarified that certain previously disclosed cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia in chronic kidney disease included post-hoc changes to the stratification factors, and provided additional data from the cardiovascular safety analyses with the pre-specified stratification factors.&#160;&#160;As stated at that time, the Company initiated an internal review to ensure this does not occur in the future.&#160;&#160;We have now completed that review.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s major findings are as follows:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:36pt;">The underlying data used for cardiovascular safety analyses are accurate, with no data integrity issues with the data used to generate such analyses.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:36pt;">In its NDA, the Company calculated accurately and described both sets of analyses, including the statistical methodologies and stratification factors utilized.&#160;&#160;The statistical analyses using post-hoc stratification factors were designated as &#8220;primary&#8221; analysis, and the statistical analyses using pre-specified stratification factors as a &#8220;sensitivity&#8221; analysis. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:36pt;">We believe a number of elements contributed to the fact that the cardiovascular safety analyses designated as primary included post-hoc stratification factors.&#160;&#160;These include a complex data set with data from multiple clinical studies conducted by three companies, and a lack of clarity in the pooled cardiovascular safety analysis plans which identified multiple statistical methods and assessment periods. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:36pt;">In addition, this information was compartmentalized within the organization, which relied on the founder and then-CEO to make key decisions and facilitate internal communication between groups.&#160;&#160;He unfortunately passed away in August 2019 prior to public disclosure of the detailed pooled safety analyses and the NDA filing.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:36pt;">Those responsible for the statistical analyses believed that it was a reasonable and valid way to analyze and present the data.&#160;&#160; </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management is taking steps to ensure the Company&#8217;s processes are consistent with best practices in all respects. We plan to implement and improve a number of processes and procedures, including independent quality unit oversight of clinical data management, programming, analysis, and reporting. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Those directly responsible for the decision to use post-hoc stratification factors in the primary analyses no longer work for the Company.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_EXHIBITS"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM 6. E</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XHIBITS</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporation By Reference</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Description</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SEC File No.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514420380/d824859dex31.htm"><span style="text-decoration:underline;">Amended and Restated Certificate of Incorporation of FibroGen, Inc.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/21/2014</p></td>
</tr>
<tr style="height:2.25pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514380087/d720189dex34.htm"><span style="text-decoration:underline;">Amended and Restated Bylaws of FibroGen, Inc.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/23/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514420380/d824859dex41.htm"><span style="text-decoration:underline;">Form of Common Stock Certificate.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/21/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459017022738/fgen-ex46_97.htm"><span style="text-decoration:underline;">Shareholders&#8217; Agreement by and among FibroGen International (Cayman) Limited and certain of its shareholders, dated as of September 8, 2017.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/8/2017</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000119312514381669/d720189dex417.htm"><span style="text-decoration:underline;">Common Stock Purchase Agreement by and between FibroGen, Inc. and AstraZeneca AB, dated as of October 20, 2014.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/24/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1*</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex101_15.htm"><span style="text-decoration:underline;">Sixth Amendment to the Lease by and between ARE-San Francisco No., 43, LLC and FibroGen, Inc. as of June 1, 2021.</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2*&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex102_408.htm"><span style="text-decoration:underline;">Exclusive License and Option Agreement by and between FibroGen, Inc. and HiFiBiO (HK) Limited (D.B.A. HiFiBiO Therapeutics), as of June 16, 2021.</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr style="height:15.85pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1*</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex211_16.htm"><span style="text-decoration:underline;">Subsidiaries of FibroGen, Inc.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1*</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex311_9.htm"><span style="text-decoration:underline;">Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2*</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex312_8.htm"><span style="text-decoration:underline;">Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1*</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex321_7.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer and Principal Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350)(1)).</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document: the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:90.56%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Portions of this exhibit (indicated by asterisks) have been omitted as the Company has determined that the omitted information is both (i) not material and (ii) the type of information that the Company treats as private or confidential</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TOC"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">FibroGen, Inc.</span></p></td>
</tr>
<tr>
<td valign="top" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:51%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: &#160;August 9, 2021</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&#160;</p></td>
<td valign="top" style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Enrique Conterno</p></td>
</tr>
<tr>
<td valign="top" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enrique Conterno</p></td>
</tr>
<tr>
<td valign="top" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:51%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: &#160;August 9, 2021</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&#160;</p></td>
<td valign="top" style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Pat Cotroneo</p></td>
</tr>
<tr>
<td valign="top" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pat Cotroneo</p></td>
</tr>
<tr>
<td valign="top" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President, Finance and Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>fgen-ex101_15.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex101_15.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SIXTH AMENDMENT TO LEASE</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK5"></a><a name="OLE_LINK6"></a>THIS SIXTH AMENDMENT TO LEASE (this &#8220;<font style="font-weight:bold;">Sixth Amendment</font>&#8221;) is made as of June 1, 2021 (the &#8220;<font style="font-weight:bold;">Effective Date</font>&#8221;)<a name="OLE_LINK5"></a><a name="OLE_LINK6"></a>, by and between <font style="font-weight:bold;">ARE- SAN FRANCISCO NO. 43, LLC</font>, a Delaware limited liability company (&#8220;<font style="font-weight:bold;">Landlord</font>&#8221;), and <font style="font-weight:bold;">FIBROGEN, INC.</font>, a Delaware corporation (&#8220;<font style="font-weight:bold;">Tenant</font>&#8221;).</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="font-weight:normal;margin-left:36pt;">Landlord (as successor-in-interest to X-4 Dolphin LLC) and Tenant are parties to that certain Lease Agreement dated as of September 22, 2006 (the &#8220;</font>Original Lease<font style="font-weight:normal;">&#8221;), as amended by that certain First Amendment to Lease dated as of October 10, 2007, and as further amended by that certain letter agreement dated as of March 21, 2008, that certain Second Amendment to Lease dated as of June&#160;29, 2009, that certain Third Amendment to Lease dated as of May 19, 2011 (the &#8220;</font>Third Amendment<font style="font-weight:normal;">&#8221;), that certain letter agreement dated as of June 20, 2011, that certain Fourth Amendment to Lease dated as of September 8, 2011, that certain letter agreement dated as of November 15, 2012, that certain Memorandum of Understanding dated as of October 1, 2014, that certain Fifth Amendment to Lease dated as of December 23, 2014, that certain letter agreement dated as of December 23, 2014, that certain letter agreement dated as of December 10, 2015, and that certain letter agreement dated as of April 26, 2016 (as amended, the &#8220;</font>Lease<font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;Pursuant to the Lease, Tenant leases certain premises containing approximately 234,249 rentable square feet (the &#8220;</font>Premises<font style="font-weight:normal;">&#8221;) in that certain building located at 409 Illinois Street, San Francisco, California (the &#8220;Building&#8221;).&nbsp;&nbsp;The Premises are more particularly described in the Lease.&nbsp;&nbsp;Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">B.<font style="font-weight:normal;margin-left:36pt;">The Term of the Lease is scheduled to expire on November 19, 2023.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">C.<font style="font-weight:normal;margin-left:36pt;">Landlord and Tenant desire, subject to the terms and conditions set forth below, to amend the Lease to, among other things, extend the Term of the Lease through November 30, 2028 (the &#8220;</font>Sixth Amendment Expiration Date<font style="font-weight:normal;">&#8221;).</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE,<font style="font-weight:normal;"> in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Extended Term</font><font style="font-size:10pt;font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Term of the Lease is hereby extended beginning on November 20, 2023 (the &#8220;</font><font style="font-size:10pt;color:#000000;">Sixth Amendment Commencement Date</font><font style="font-size:10pt;font-weight:normal;color:#000000;">&#8221;) through the Sixth Amendment Expiration Date (the &#8220;</font><font style="font-size:10pt;color:#000000;">Extended Term</font><font style="font-size:10pt;font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;Tenant&#8217;s occupancy of the Premises through the Sixth Amendment Expiration Date shall be on an &#8220;as-is&#8221; basis and, except as otherwise expressly provided in the work letter attached to this Sixth Amendment as </font><font style="font-size:10pt;color:#000000;">Exhibit A</font><font style="font-size:10pt;font-weight:normal;color:#000000;"> (the &#8220;</font><font style="font-size:10pt;color:#000000;">A06</font><font style="font-size:10pt;font-weight:normal;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">Work Letter</font><font style="font-size:10pt;font-weight:normal;color:#000000;">&#8221;), Landlord shall have no obligation to provide any tenant improvement allowance or make any alterations to the Premises.&nbsp;&nbsp;With respect to Tenant&#8217;s surrender obligations under the Lease, all work described in the A06 Work Letter shall be deemed to be &#8220;Tenant&#8217;s Work&#8221; as defined in Section 2.17 of the Lease. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Minimum Monthly Base Rent</font><font style="font-size:10pt;font-weight:normal;color:#000000;">.&nbsp;&nbsp;Tenant shall continue to pay Minimum Monthly Rent as provided under the Lease through November 19, 2023.&nbsp;&nbsp;Commencing on the Sixth Amendment Commencement Date, Tenant shall pay Minimum Monthly Rent in the amount of $72.00 per rentable square foot of the Premises per year.&nbsp;&nbsp;Commencing on December 1, 2024, and on each subsequent December 1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup> through the Sixth Amendment Expiration Date (each, a &#8220;</font><font style="font-size:10pt;color:#000000;">Sixth Amendment Adjustment Date</font><font style="font-size:10pt;font-weight:normal;color:#000000;">&#8221;), Minimum Monthly Rent shall be increased by multiplying the Minimum Monthly Rent payable immediately before such Sixth Amendment Adjustment Date by </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="font-size:10pt;font-weight:normal;color:#000000;">3.0% (the &#8220;</font><font style="font-size:10pt;color:#000000;">Rent Adjustment Percentage</font><font style="font-size:10pt;font-weight:normal;color:#000000;">&#8221;) and adding the resulting amount to the Minimum Monthly Rent payable immediately before such Sixth Amendment Adjustment Date.</font><font style="font-size:10pt;font-weight:normal;color:#000000;">&nbsp;&nbsp;The amounts comprising the </font><font style="font-size:10pt;font-weight:normal;color:#000000;">Minimum Monthly Rent</font><font style="font-size:10pt;font-weight:normal;color:#000000;"> are set forth Exhibit D entitled, &#8220;</font><font style="font-size:10pt;color:#000000;">A06 Minimum Monthly Rent Schedule</font><font style="font-size:10pt;font-weight:normal;color:#000000;">&#8221; attached hereto.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the Minimum Monthly Base Rent payable during the Extended Term, Tenant may be required to also pay &#8220;Additional TI Rent,&#8221; as defined in this paragraph. &#160;Landlord shall, subject to the terms of the A06 Work Letter, make available to Tenant the Additional Tenant Improvement Allowance (as defined in the A06 Work Letter).&#160; If Tenant elects to draw down all or any portion of the Additional Tenant Improvement Allowance, then, commencing on the Sixth Amendment Commencement Date Tenant shall pay, in addition to the Minimum Monthly Base Rent, that monthly amount (the &#8220;<font style="font-weight:bold;">Additional TI Rent</font>&#8221;) necessary to fully amortize the portion of the Additional Tenant Improvement Allowance requested by Tenant and actually funded by Landlord (if any), payable in equal monthly payments with interest at a rate of 8% per annum over the Extended Term, which interest shall begin to accrue on the date that Landlord first disburses such Additional Tenant Improvement Allowance or any portion(s) thereof.&#160; Any Additional TI Rent remaining unpaid as of the expiration or earlier termination of this Lease shall be paid to Landlord in a lump sum at the expiration or earlier termination of this Lease.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Abatement</font><font style="font-size:10pt;font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notwithstanding anything to the contrary contained in the Lease, so long as there exists no Event of monetary Default under the lease  after the application of applicable notice and cure periods, for the period commencing on the Sixth Amendment Commencement Date, and ending on January 19, 2024 (the &#8220;</font><font style="font-size:10pt;color:#000000;">Minimum Monthly</font><font style="font-size:10pt;font-weight:normal;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">Rent Abatement Period</font><font style="font-size:10pt;font-weight:normal;color:#000000;">&#8221;), Tenant shall not be required to pay Minimum Monthly Rent under the Lease.&nbsp;&nbsp;Tenant shall resume paying 100% of the Minimum Monthly Rent required to be paid under the Lease on the date immediately following the expiration of the Minimum Monthly Rent Abatement Period.&nbsp;&nbsp;For the avoidance of doubt, Tenant shall continue during the Minimum Monthly Rent Abatement Period to pay Tenant&#8217;s Proportionate Share of Operating Costs, Taxes and Insurance Costs (in accordance with the terms of the Lease and without any abatement) and all other amounts due under the Lease.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Operating Costs, Taxes and Insurance Costs</font><font style="font-size:10pt;font-weight:normal;color:#000000;">.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font><font style="font-size:10pt;font-weight:normal;color:#000000;">Tenant shall continue to pay Tenant&#8217;s Proportionate Share of Operating Costs, Proportionate Share of Taxes and Proportionate Share of Insurance Costs as provided under the Lease during the Extended Term.&nbsp;&nbsp;Notwithstanding the foregoing, during the Extended Term only, (a) in addition to the exclusions set forth in the Lease, (i) the following items shall be excluded from Operating Costs: gross receipts taxes and costs associated with the fitness center, shuttle, vestibule security guard and security (Visentry AI and remote monitoring), and (ii) Operating Costs shall not include any items which have not previously been included within Operating Costs, except to the extent such new Operating Costs are outside of Landlord&#8217;s reasonable control and/or are consistent with maintaining and/or operating a Class A laboratory/office building in the Mission Bay neighborhood of San Francisco, California, and (b) Tenant&#8217;s Proportionate Share of Operating Costs for the Parking Garage, Proportionate Share of Taxes for the Parking Garage and Proportionate Share of Insurance Costs for the Parking Garage shall not, taken together, increase by more than 2.0% per annum (i) on the Sixth Amendment Commencement Date over the amount payable immediately prior to the Sixth Amendment Commencement Date, and (ii) on each Sixth Amendment Adjustment Date over the amount payable immediately prior to such Sixth Amendment Adjustment Date.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font><font style="font-size:10pt;font-weight:normal;color:#000000;">The limitations on increases to Tenant&#8217;s Proportionate Share of Operating Costs for the Parking Garage, Proportionate Share of Taxes for the Parking Garage and Proportionate Share of Insurance Costs for the Parking Garage set forth in this Section 4 shall not be applicable to the extent any such increase is attributable to Tenant leasing additional parking spaces as a result of leasing space in the 499 Building.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Calculation and Payment of </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional Rent provisions of Section 6.3 of the Original</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Lease shall continue to apply during the Extended Term except as specifically provided to the contrary in this </font><font style="text-decoration:underline;">Section</font><font style="text-decoration:underline;"> 4</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything to the contrary contained in this Lease, if, at any time prior to the Sixth Amendment Expiration Date, any sale of the Complex is consummated by Landlord, and solely as a result thereof, and to the extent that solely in connection therewith, the Complex is reassessed (the &#8220;<font style="font-weight:bold;">Reassessment</font>&#8221;) for real estate tax purposes by the appropriate governmental authority pursuant to the terms of Proposition 13, Tenant shall not be obligated with respect to the existing Premises only during the Extended Term to pay the Tax Increase solely in connection therewith.&nbsp;&nbsp;The term &#8220;<font style="font-weight:bold;">Tax Increase</font>&#8221; shall mean that portion of the Taxes during the Extended Term which is attributable solely to the Reassessment.&nbsp;&nbsp;Accordingly, the term Tax Increase shall not include (and Tenant shall be required to pay for) any portion of the Taxes which (i) is attributable to assessments which were pending prior to the Reassessment or which would otherwise have occurred unrelated to the sale, or (ii) is attributable to the annual inflationary increase of real estate taxes.&nbsp;&nbsp;In addition, nothing contained in this paragraph is intended to excuse Tenant from paying the full amount of any Taxes (including, without limitation, as a result of reassessments) resulting from any construction and/or improvements made to the Complex by Landlord or Tenant at any time.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, the provisions of this paragraph shall not apply to (i) any period prior to the Extended Term or, if Tenant leases the Premises following the Extended Term (i.e. following November 30, 2028), to any period following the Extended Term and/or (ii) any other premises (e.g., Expansion Space, ROFR Space and ROFO Space) that Tenant may lease in the Complex.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Security Deposit</font><font style="font-size:10pt;font-weight:normal;color:#000000;">.&nbsp;&nbsp;Commencing on the Effective Date, the Security Deposit shall be reduced from $2,072,481.00 to $1,657,984.80 (the &#8220;</font><font style="font-size:10pt;color:#000000;">Reduced Security Deposit Amount</font><font style="font-size:10pt;font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;Landlord shall reasonably cooperate with Tenant, at no cost, expense or liability to Landlord, to reduce the Initial Letter of Credit to the Reduced Security Deposit Amount.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Condition of Premises</font><font style="font-size:10pt;font-weight:normal;color:#000000;">.&nbsp;&nbsp;Prior to the Sixth Amendment Commencement Date, Landlord shall retain a third party professional (reasonably approved by Tenant) to conduct an inspection of the mechanical, electrical and plumbing systems serving the Building to determine if any such mechanical, electrical and plumbing systems are either beyond their useful life or will then have a remaining useful life of fewer than 5 years (collectively, the &#8220;</font><font style="font-size:10pt;color:#000000;">MEP Replacement Items</font><font style="font-size:10pt;font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;When each existing MEP Replacement Item requires a capital repair or replacement during the Extended Term, as mutually and reasonably agreed upon by Tenant and Landlord in good faith, Landlord shall be solely responsible for the cost of the capital repair or replacement of such MEP Replacement Item (and with Landlord having the right to approve in its good faith reasonable discretion, the make, model, specifications, cost and contract, as applicable, for such MEP Replacement Item), which work of repair or replacement shall be addressed under the control and management of Tenant, and not included as part of Operating Costs.&nbsp;&nbsp;If Tenant elects to enter into any contract(s) for MEP Replacement Items (rather than have Landlord enter into such contract(s)), Landlord shall be named a third party beneficiary of such contract with the right to enforce all warranties.&nbsp;&nbsp;Once an MEP Replacement Item has been given a capital repair or been replaced pursuant to the immediately preceding sentence, and such MEP Replacement Item would thereafter have a remaining useful life of at least 5 years, any subsequent capital repair or replacement required of such MEP Replacement Item during the Term shall be performed as an Operating Cost, subject to the terms of </font><font style="text-decoration:underline;font-size:10pt;font-weight:normal;color:#000000;">Section 2.6</font><font style="font-size:10pt;font-weight:normal;color:#000000;"> of the Original Lease.&nbsp;&nbsp;For avoidance of doubt, Landlord will continue to be able to include amortized Capital Costs in the calculation of Operating Costs, as permitted under </font><font style="text-decoration:underline;font-size:10pt;font-weight:normal;color:#000000;">Section 2.6</font><font style="font-size:10pt;font-weight:normal;color:#000000;"> of the Original Lease, to the extent such Capital Costs relate to any capital repairs, improvements, alterations and replacements made by Landlord to the Complex and are not with respect to an MEP Replacement Item.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Amenity Utilities</font><font style="font-size:10pt;font-weight:normal;color:#000000;">.&nbsp;&nbsp;Landlord shall review with its asset services team the feasibility of (a) rerouting water and electrical servicing the first-floor amenities located within the Building (Taproot and the fitness center) to originate from 499 Illinois Street, San Francisco, California (the &#8220;</font><font style="font-size:10pt;color:#000000;">499 Building</font><font style="font-size:10pt;font-weight:normal;color:#000000;">&#8221;), which is also owned by Landlord, or (b) separately metering such first floor amenities.&nbsp;&nbsp;If the cost of such rerouting or separate metering is determined to be reasonable by Landlord, then Landlord, at its sole cost and expense, shall either reroute such water and electrical service or install separate meters for the first floor amenities, prior to the Sixth Amendment Commencement Date. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">8.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Right to Extend Term</font><font style="font-size:10pt;font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font><font style="text-decoration:underline;font-size:10pt;font-weight:normal;color:#000000;">Section 34</font><font style="font-size:10pt;font-weight:normal;color:#000000;"> of the Original Lease shall be replaced with the provision of this </font><font style="text-decoration:underline;font-size:10pt;font-weight:normal;color:#000000;">Section 8</font><font style="font-size:10pt;font-weight:normal;color:#000000;">. Tenant shall have the right to further extend the Term of the Lease upon the following terms and conditions:</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Extension Right</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Tenant shall have 2 consecutive rights (each, an &#8220;</font><font style="color:#000000;">Extension Right</font><font style="font-weight:normal;color:#000000;">&#8221;) to extend the term of the Lease for 5 years each (each, an &#8220;</font><font style="color:#000000;">Additional Extension Term</font><font style="font-weight:normal;color:#000000;">&#8221;) on the same terms and conditions as the Lease (other than with respect to Minimum Monthly Rent, the TI Allowance (as defined in the A06 Work Letter), and any provisions which only apply during the Extended Term) by giving Landlord written notice of its election to exercise each Extension Right at least 18 months prior, and no earlier than 21 months prior, to the then current expiration date of the Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Upon the commencement of any Additional Extension Term, Minimum Monthly Rent shall be payable at the Market Rate (as defined below).&nbsp;&nbsp;Minimum Monthly Rent shall thereafter be adjusted on each annual anniversary of the commencement of such Additional Extension Term by a percentage as determined by Landlord and agreed to by Tenant at the time the Market Rate is determined.&nbsp;&nbsp;As used herein, &#8220;</font><font style="color:#000000;">Market Rate</font><font style="font-weight:normal;color:#000000;">&#8221; shall mean the rate that comparable landlords of comparable buildings have accepted in current transactions from non-equity (i.e., not being offered equity in the buildings) and nonaffiliated tenants of similar financial strength for space of comparable size, quality (including all Tenant Improvements, Alterations and other improvements) and floor height in Class A laboratory focused buildings in the Mission Bay area of San Francisco, California, for a comparable term, with the determination of the Market Rate to take into account all relevant factors, including tenant inducements, parking costs, available amenities (including any Complex amenities), leasing commissions, allowances or concessions, if any.&nbsp;&nbsp;In addition, Landlord may impose a market rent for the parking rights provided hereunder.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If, on or before the date which is 210 days prior to the expiration of the then current Term of the Lease, Tenant has not agreed with Landlord&#8217;s determination of the Market Rate and the rent escalations during the Additional Extension Term after negotiating in good faith, Tenant shall be deemed to have elected arbitration as described in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.b, below.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;If Tenant has elected to exercise the Extension Right by delivering notice to Landlord as required in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.a.</font><font style="font-weight:normal;color:#000000;">, Tenant shall have no right thereafter to rescind or elect not to extend the term of the Lease for an Additional Extension Term.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">d.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Arbitration</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Within 10 days of Tenant&#8217;s notice to Landlord of its election (or deemed election) to arbitrate Market Rate and escalations, each party shall deliver to the other a proposal containing the Market Rate and escalations that the submitting party believes to be correct (&#8220;</font><font style="font-weight:bold;color:#000000;">Extension Proposal</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;If either party fails to timely submit an Extension Proposal, the other party&#8217;s submitted proposal shall determine the Minimum Monthly Rent and escalations for such Additional Extension Term.&nbsp;&nbsp;If both parties submit Extension Proposals, then Landlord and Tenant shall meet within 7 days after delivery of the last Extension Proposal and make a good faith attempt to mutually appoint a single Arbitrator (defined below) to determine the Market Rate and escalations.&nbsp;&nbsp;If Landlord and Tenant are unable to agree upon a single Arbitrator, then each shall, by written notice delivered to </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">the other within 10 days after the meeting, select an Arbitrator.&nbsp;&nbsp;If either party fails to timely give notice of its selection for an Arbitrator, the other party&#8217;s submitted proposal shall determine the Minimum Monthly Rent for the Additional Extension Term.&nbsp;&nbsp;The 2 Arbitrators so appointed shall, within 5 business days after their appointment, appoint a third Arbitrator.&nbsp;&nbsp;If the 2 Arbitrators so selected cannot agree on the selection of the third Arbitrator within the time above specified, then either party, on behalf of both parties, may request such appointment of such third Arbitrator by application to any state court of general jurisdiction in the jurisdiction in which the Premises are located, upon 10 days prior written notice to the other party of such intent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The decision of the Arbitrator(s) shall be made within 30 days after the appointment of a single Arbitrator or the third Arbitrator, as applicable.&nbsp;&nbsp;The decision of the single Arbitrator shall be final and binding upon the parties.&nbsp;&nbsp;The average of the two closest Arbitrators in a three Arbitrator panel shall be final and binding upon the parties.&nbsp;&nbsp;Each party shall pay the fees and expenses of the Arbitrator appointed by or on behalf of such party and the fees and expenses of the third Arbitrator shall be borne equally by both parties.&nbsp;&nbsp;If the Market Rate and escalations are not determined by the first day of the Additional Extension Term, then Tenant shall pay Landlord Minimum Monthly Rent in an amount equal to the Minimum Monthly Rent in effect immediately prior to the Additional Extension Term and increased by the Rent Adjustment Percentage until such determination is made.&nbsp;&nbsp;After the determination of the Market Rate and escalations, the parties shall make any necessary adjustments to such payments made by Tenant.&nbsp;&nbsp;Landlord and Tenant shall then execute an amendment recognizing the Market Rate and escalations for the Additional Extension Term.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">An &#8220;</font><font style="font-weight:bold;color:#000000;">Arbitrator</font><font style="color:#000000;">&#8221; shall be any person appointed by or on behalf of either party or appointed pursuant to the provisions hereof and:&nbsp;&nbsp;(i) shall be (A) a member of the American Institute of Real Estate Appraisers with not less than 10 years of experience in the appraisal of improved office and high tech industrial real estate in the greater San Francisco, California, metropolitan area, or (B) a licensed commercial real estate broker with not less than 15 years&#8217; experience representing landlords and/or tenants in the leasing of high tech or life sciences space in the greater San Francisco, California, metropolitan area, (ii) devoting substantially all of their time to professional appraisal or brokerage work, as applicable, at the time of appointment and (iii) be in all respects impartial and disinterested.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">e.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Rights Personal</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Extension Rights are personal to Tenant and are not assignable without Landlord&#8217;s consent, which may be granted or withheld in Landlord&#8217;s sole discretion separate and apart from any consent by Landlord to an assignment of Tenant&#8217;s interest in the Lease.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">f.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Exceptions</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notwithstanding anything set forth above to the contrary, Extension Rights shall, at Landlord&#8217;s option, not be in effect and Tenant may not exercise any of the Extension Rights:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">during the existence of an Event of monetary Default under the Lease (beyond any applicable notice and cure periods); or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">if an Event of monetary Default has existed under the Lease 3 or more times, whether or not the Events of monetary Default are cured, during the 12 month period immediately prior to the date that Tenant intends to exercise the Extension Right.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">g.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No Extensions</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The period of time within which any Extension Rights may be exercised shall not be extended or enlarged by reason of Tenant&#8217;s inability to exercise the Extension Rights.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">h.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Termination</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Extension Rights shall, at Landlord&#8217;s option, terminate and be of no further force or effect even after Tenant&#8217;s due and timely exercise of an Extension Right, if, after such exercise, but prior to the commencement date of the Additional Extension Term, (i) Tenant </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">fails to timely cure any Event of </font><font style="font-weight:normal;color:#000000;">monetary </font><font style="font-weight:normal;color:#000000;">Default by Tenant under the Lease; or (ii) an Event of </font><font style="font-weight:normal;color:#000000;">monetary </font><font style="font-weight:normal;color:#000000;">Default under the Lease has occurred 3 or more times during the period from the date of the exercise of the Extension Right to the date of the commencement of the Additional Extension Term, whether or not such Events of </font><font style="font-weight:normal;color:#000000;">monetary </font><font style="font-weight:normal;color:#000000;">Default are cured.&nbsp;&nbsp;</font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 34</font><font style="font-weight:normal;color:#000000;"> of the Original Lease is hereby deleted in its entirety, and Tenant shall have no right to extend the Term of the Lease except as expressly set forth in this Sixth Amendment.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">9.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Sublease</font><font style="font-size:10pt;font-weight:normal;color:#000000;">.&nbsp;&nbsp;Landlord agrees to not withhold its consent in the event Tenant desires to sublease a portion of the Premises in the Building to The Regents of the University of California (the &#8220;</font><font style="font-size:10pt;color:#000000;">UC Tenant</font><font style="font-size:10pt;font-weight:normal;color:#000000;">&#8221;), solely based on the fact that the UC Tenant is an existing tenant of the 499 Building. For avoidance of doubt, the immediately prior sentence is only applicable to the Premises located in the Building and is not applicable to any premises that Tenant may lease in the future in the 499 Building.&nbsp;&nbsp;All other requirements with respect to subletting the Premises set forth in the Lease remain in full force and effect.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">10.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Right of First Negotiation</font><font style="font-size:10pt;font-weight:normal;color:#000000;">.&nbsp;&nbsp;Tenant shall continue to have the rights set forth in </font><font style="text-decoration:underline;font-size:10pt;font-weight:normal;color:#000000;">Section 35.25</font><font style="font-size:10pt;font-weight:normal;color:#000000;"> of the Original Lease. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">11.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Expansion Right</font><font style="font-size:10pt;font-weight:normal;color:#000000;">.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Expansion Right Generally</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Subject to the terms of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 11</font><font style="font-weight:normal;color:#000000;">, commencing on the Effective Date and continuing for 12 months thereafter, Tenant shall have the ongoing right, but not the obligation, subject to the terms of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 11</font><font style="font-weight:normal;color:#000000;">, to expand the Premises (the &#8220;</font><font style="color:#000000;">Expansion Right</font><font style="font-weight:normal;color:#000000;">&#8221;) to include the Expansion Space upon the terms and conditions in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 11</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If Tenant exercises the Expansion Right, Landlord shall not be obligated to deliver the Expansion Space until after the existing tenant in the Expansion Space vacates the Expansion Space at the expiration of the term of the existing lease for the Expansion Space. Landlord agrees to use reasonable available legal rights to cause the existing tenant to vacate the Expansion Space at the expiration of its term.&nbsp;&nbsp;For purposes of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 11</font><font style="font-weight:normal;color:#000000;">, &#8220;</font><font style="color:#000000;">Expansion Space</font><font style="font-weight:normal;color:#000000;">&#8221; shall mean that certain space located on the 5<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> floor of the 499 Building, containing approximately 44,000 rentable square feet, as more specifically described on </font><font style="color:#000000;">Exhibit B </font><font style="font-weight:normal;color:#000000;">attached hereto.&nbsp;&nbsp;For the avoidance of doubt, Tenant shall be required to exercise its right under this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 11</font><font style="font-weight:normal;color:#000000;"> with respect to all of the Expansion Space.&nbsp;&nbsp;Tenant shall have 12 months following the Effective Date to deliver to Landlord written notification of Tenant&#8217;s exercise of the Expansion Right (&#8220;</font><font style="color:#000000;">Exercise Notice</font><font style="font-weight:normal;color:#000000;">&#8221;) with respect to the Expansion Space.&nbsp;&nbsp;If Tenant elects to lease the Expansion Space by delivering the Exercise Notice within the required 12 month period, Tenant shall be deemed to agree to expand the Premises to include the Expansion Space and to lease the Expansion Space on the same general terms and conditions as the Lease (including the TI Allowance).&nbsp;&nbsp;Landlord shall permit Tenant access, at Tenant&#8217;s sole risk and expense, to the Expansion Space 14 days prior to the commencement date of the lease of the Expansion Space, for the purpose of space planning, construction and moving into the Expansion Space, and, during such early access period, all terms of the Lease shall be in effect with respect to the Expansion Space, except that Tenant shall not be required to pay Minimum Monthly Rent with respect to the Expansion Space, Tenant&#8217;s Proportionate Share of Operating Costs, Taxes and Insurance Costs with respect to the Expansion Space or the increase in Tenant&#8217;s Proportionate Share of Operating Costs, Taxes and Insurance Costs with respect to the Parking Garage which are attributable to the Expansion Space during such early access period; provided, however, after such early access period, Tenant shall commence paying Minimum Monthly Rent with respect to the Expansion Space, Tenant&#8217;s Proportionate Share of Operating Costs, Taxes and Insurance Costs with respect to the Expansion Space and the increase in Tenant&#8217;s Proportionate Share of Operating Costs, Taxes and Insurance Costs with respect to the Parking Garage which are attributable to the Expansion Space.&nbsp;&nbsp;The term of the Lease with respect to the Expansion Space shall be co-terminus with the Term of the Lease with respect to the then-existing Premises.&nbsp;&nbsp;If Tenant does not deliver an Exercise Notice to Landlord within such 12 month period, then Tenant </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">shall be deemed to have waived its rights under this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 11</font><font style="font-weight:normal;color:#000000;"> to lease the Expansion Space,&nbsp;&nbsp;and Landlord shall have the right to lease the Expansion Space to any third party on any terms and conditions acceptable to Landlord.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Tenant&#8217;s failure to timely deliver an Exercise Notice shall not impact Tenant&#8217;s rights under </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Sections 12</font><font style="font-weight:normal;color:#000000;"> and </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">13</font><font style="font-weight:normal;color:#000000;"> below.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Amended Lease (Expansion)</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If: (i) Tenant fails to timely deliver an Exercise Notice, or (ii) after the expiration of a period of 10 days after Landlord&#8217;s delivery to Tenant of a lease amendment for Tenant&#8217;s lease of the Expansion Space, no lease amendment for the Expansion Space acceptable to both parties each in their reasonable discretion after using diligent good faith efforts negotiate the same, has been executed, Tenant shall, notwithstanding anything to the contrary contained herein, be deemed to have forever waived its right to lease the Expansion Space.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Expansion Right Exceptions</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notwithstanding the above, the Expansion Right shall, at Landlord&#8217;s option, not be in effect and may not be exercised by Tenant:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:17.31%;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">during any period of time that there exists an Event of monetary Default under the Lease after the expiration of applicable notice and cure rights; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:17.31%;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">if an Event of monetary Default under the Lease has existed 3 or more times, whether or not the Events of Default are cured, during the 12 month period prior to the date on which Tenant seeks to exercise the Expansion Right.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">d.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Expansion Right Termination</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Expansion Right shall, at Landlord&#8217;s option, terminate and be of no further force or effect even after Tenant&#8217;s due and timely exercise of the Expansion Right, if, after such exercise, but prior to the commencement date of the lease of the Expansion Space, (i) Tenant fails to timely cure any Event of monetary Default under the Lease; or (ii) an Event of monetary Default under the Lease has existed 3 or more times during the period from the date of the exercise of the Expansion Right to the date of the commencement of the lease of the Expansion Space, whether or not such Events of monetary Default are cured.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">e.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Expansion Rights Personal</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Expansion Right is personal to Tenant and is not assignable without Landlord&#8217;s consent, which may be granted or withheld in Landlord&#8217;s sole discretion separate and apart from any consent by Landlord to an assignment of Tenant&#8217;s interest in the Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">f.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No Extensions of Expansion Right</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The period of time within which the Expansion Right may be exercised shall not be extended or enlarged by reason of Tenant&#8217;s inability to exercise the Expansion Right.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">12.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Right of First Refusal</font><font style="font-style:italic;font-size:10pt;font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">ROFR Generally</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Subject to the terms of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 12</font><font style="font-weight:normal;color:#000000;">, the first time after the Effective Date that Landlord intends to accept a bona fide written proposal or deliver a counter proposal which Landlord would be willing to accept (the &#8220;</font><font style="color:#000000;">Pending Deal</font><font style="font-weight:normal;color:#000000;">&#8221;) to lease all or a portion the ROFR Space (as hereinafter defined) to a third party, Landlord shall deliver to Tenant written notice (the &#8220;</font><font style="color:#000000;">Pending Deal Notice</font><font style="font-weight:normal;color:#000000;">&#8221;) of the existence of such Pending Deal, which Pending Deal Notice shall include the material terms of the Pending Deal.&nbsp;&nbsp;For purposes of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 12</font><font style="font-weight:normal;color:#000000;">, &#8220;</font><font style="color:#000000;">ROFR Space</font><font style="font-weight:normal;color:#000000;">&#8221; shall mean all space in the 499 Building which is not occupied by a tenant or which is occupied by an existing tenant whose lease is expiring within 12 months or less and such tenant does not wish to renew (whether or not such tenant has a right to renew) its occupancy of such space.&nbsp;&nbsp;For the avoidance of doubt, Tenant shall be required to exercise its right under this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 12</font><font style="font-weight:normal;color:#000000;"> with respect to all of the space described in the Pending Deal Notice, including, at Landlord&#8217;s option, any space </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">in addition to the ROFR Space that is described in the Pending Deal Notice, which additional space shall be deemed to be included as part of the ROFR Space (the &#8220;</font><font style="color:#000000;">Identified Space</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;Within 10 days after Tenant&#8217;s receipt of the Pending Deal Notice, Tenant shall deliver to Landlord written notice (the &#8220;</font><font style="color:#000000;">Acceptance Notice</font><font style="font-weight:normal;color:#000000;">&#8221;) if Tenant elects to lease the Identified Space.&nbsp;&nbsp;Tenant&#8217;s right to receive the Pending Deal Notice and election to lease or not lease the Identified Space pursuant to this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 12</font><font style="font-weight:normal;color:#000000;"> is hereinafter referred to as the &#8220;</font><font style="color:#000000;">Right of First Refusal</font><font style="font-weight:normal;color:#000000;">.&#8221;&nbsp;&nbsp;If Tenant elects to lease the Identified Space described in the Pending Deal Notice by delivering the Space Acceptance Notice within the required 10 day period, Tenant shall be deemed to agree to expand the Premises to include the Identified Space and to lease the Identified Space on the same general terms and conditions as the Lease except that the terms of the Lease shall be modified to reflect the terms of the Pending Deal Notice for the rental of the Identified Space.&nbsp;&nbsp;If the Identified Space subject to a Pending Deal Notice does not include all of the ROFR Space, Tenant&#8217;s Right of First Refusal shall continue to apply with respect to any remaining portion of the ROFR Space through the Extended Term (subject to the last sentence of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;12(a)</font><font style="font-weight:normal;color:#000000;">).&nbsp;&nbsp;Tenant acknowledges that the term of the Lease with respect to the Identified Space and the Term of the Lease with respect to the existing Premises may not be co-terminus.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, in no event shall the A06 Work Letter apply to the Identified Space.&nbsp;&nbsp;If Tenant fails to deliver an Acceptance Notice to Landlord within the required 10 day period, Tenant shall be deemed to have forever waived its rights under this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;12</font><font style="font-weight:normal;color:#000000;"> to lease the Identified Space.&nbsp;&nbsp;Tenant&#8217;s Right of First Refusal shall be ongoing during the Extended Term; provided, however that Tenant shall have no right to exercise the Right of First Refusal and the provisions of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 12</font><font style="font-weight:normal;color:#000000;"> shall no longer apply after the date that is 18&#160;months prior to the expiration of the Extended Term if Tenant has not exercised its Extension Right pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8</font><font style="font-weight:normal;color:#000000;"> of this Sixth Amendment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Amended Lease (ROFR)</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If: (i) Tenant fails to timely deliver an Acceptance Notice, or (ii) after the expiration of a period of 10 days after Landlord&#8217;s delivery to Tenant of a lease amendment for Tenant&#8217;s lease of the Identified Space, no lease amendment for the Identified Space acceptable to both parties each in their reasonable discretion after using diligent good faith efforts negotiate the same, has been executed, Tenant shall, notwithstanding anything to the contrary contained herein, be deemed to have forever waived its right to lease the ROFR Space.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">ROFR Exceptions</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notwithstanding the above, the Right of First Refusal shall, at Landlord&#8217;s option, not be in effect and may not be exercised by Tenant:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:17.31%;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">during any period of time that there exists an Event of monetary Default under the Lease, after the expiration of applicable notice and cure periods; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:17.31%;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">if an Event of monetary Default under the Lease has existed 3 or more times, whether or not the Events of Default are cured, during the 12 month period prior to the date on which Tenant seeks to exercise the Right of First Refusal.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">d.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Termination of ROFR</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Right of First Refusal shall, at Landlord&#8217;s option, terminate and be of no further force or effect even after Tenant&#8217;s due and timely exercise of the Right of First Refusal, if, after such exercise, but prior to the commencement date of the lease of the Identified Space, (i) Tenant fails to timely cure any Event of monetary Default under the Lease; or (ii) an Event of Default under the Lease has existed 3 or more times during the period from the date of the exercise of the Right of First Refusal to the date of the commencement of the lease of the Identified Space, whether or not such Events of monetary Default are cured.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">e.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">ROFR Rights Personal</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Right of First Refusal is personal to Tenant and is not assignable without Landlord&#8217;s consent, which may be granted or withheld in Landlord&#8217;s sole discretion separate and apart from any consent by Landlord to an assignment of Tenant&#8217;s interest in the Lease.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">f.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No Extensions of ROFR</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The period of time within which the Right of First Refusal may be exercised shall not be extended or enlarged by reason of Tenant&#8217;s inability to exercise the Right of First Refusal.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">13.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Right of First Offer</font><font style="font-style:italic;font-size:10pt;font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">ROFO Generally</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Subject to the terms of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 13</font><font style="font-weight:normal;color:#000000;">, each time during the Extended Term that all or a portion of the ROFO Space becomes available after the Effective Date, Tenant shall have a right, but not the obligation, subject to the terms of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 13</font><font style="font-weight:normal;color:#000000;">, to expand the Premises (the &#8220;</font><font style="color:#000000;">Right of First Offer</font><font style="font-weight:normal;color:#000000;">&#8221;) to include the ROFO Space upon the terms and conditions in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 13</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;For purposes of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 13</font><font style="font-weight:normal;color:#000000;">, &#8220;</font><font style="color:#000000;">ROFO Space</font><font style="font-weight:normal;color:#000000;">&#8221; shall mean that certain space on the second floor of the 499 Building containing approximately 25,957 rentable square feet as more particularly shown on </font><font style="color:#000000;">Exhibit C</font><font style="font-weight:normal;color:#000000;"> attached hereto (the &#8220;</font><font style="color:#000000;">Second Floor ROFO Space</font><font style="font-weight:normal;color:#000000;">&#8221;) and the Expansion Space (if Tenant has not previously exercised its Expansion Right set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 13</font><font style="font-weight:normal;color:#000000;"> above with respect to the Expansion Space), which is not occupied by a tenant or which is occupied by a then-existing tenant whose lease is expiring within 12 months or less and such tenant does not wish to renew (whether or not such tenant has a right to renew) its occupancy of such space.&nbsp;&nbsp;Each time during the Extended Term that all or a portion of the ROFO Space will become available, Landlord shall, at such time as Landlord shall elect so long as Tenant&#8217;s rights hereunder are preserved, deliver to Tenant written notice (the &#8220;</font><font style="color:#000000;">ROFO Notice</font><font style="font-weight:normal;color:#000000;">&#8221;) of the availability of such ROFO Space, together with the terms and conditions on which Landlord is prepared to lease Tenant such ROFO Space.&nbsp;&nbsp;Tenant shall be required to exercise its right under this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 13</font><font style="font-weight:normal;color:#000000;"> with respect to all of the ROFO Space described in the ROFO Notice (the &#8220;</font><font style="color:#000000;">Identified ROFO Space</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;In no event shall the A06 Work Letter apply with respect to the ROFO Space.&nbsp;&nbsp;The Term of the Lease with respect to the ROFO Space must be co-terminus with the Term of the Lease with respect to the then existing Premises.&nbsp;&nbsp;Tenant shall have 10 days following receipt of the ROFO Notice to deliver to Landlord written notification of Tenant&#8217;s exercise of its Right of First Offer with respect to the Identified ROFO Space (&#8220;</font><font style="color:#000000;">ROFO</font><font style="font-weight:normal;color:#000000;"> </font><font style="color:#000000;">Exercise Notice</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;If Tenant does not deliver a ROFO Exercise Notice to Landlord within such 10 day period, then Landlord shall have the right to lease the Identified ROFO Space to any third party on any terms and conditions acceptable to Landlord.&nbsp;&nbsp;Tenant&#8217;s Right of First Offer shall be ongoing during the Extended Term; provided, however that Tenant shall have no right to exercise the Right of First Offer and the provisions of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 13</font><font style="font-weight:normal;color:#000000;"> shall no longer apply after the date that is 18&#160;months prior to the expiration of the Extended Term if Tenant has not exercised its Extension Right pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8</font><font style="font-weight:normal;color:#000000;"> of this Sixth Amendment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Amended Lease (ROFO)</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If: (i) Tenant fails to timely deliver a ROFO Exercise Notice, or (ii) after the expiration of a period of 10 days after Landlord&#8217;s delivery to Tenant of a lease amendment for Tenant&#8217;s lease of such ROFO Space, no lease amendment for the ROFO Space acceptable to both parties each in their reasonable discretion after using diligent good faith efforts negotiate the same, has been executed, Tenant shall, notwithstanding anything to the contrary contained herein, be deemed to have forever waived its right to lease that specific ROFO Space.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">ROFO Exceptions</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notwithstanding the above, the Right of First Offer shall, at Landlord&#8217;s option, not be in effect and may not be exercised by Tenant:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:17.31%;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">during any period of time that there exists an Event of monetary Default under the Lease; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:17.31%;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">if an Event of monetary Default under the Lease has existed 3 or more times, whether or not the Events of Default are cured, during the 12 month period prior to the date on which Tenant seeks to exercise the Right of First Offer.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">d.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Termination of ROFO</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Right of First Offer shall, at Landlord&#8217;s option, terminate and be of no further force or effect even after Tenant&#8217;s due and timely exercise of the Right of First Offer, if, after such exercise, but prior to the commencement date of the lease of such ROFO Space, (i) Tenant fails to timely cure any Event of</font><font style="font-weight:normal;color:#000000;"> monetary </font><font style="font-weight:normal;color:#000000;">Default under the Lease; or (ii) an Event of Default under the Lease has existed 3 or more times during the period from the date of the exercise of the Right of First Offer to the date of the commencement of the lease of such ROFO Space, whether or not such Events of </font><font style="font-weight:normal;color:#000000;">monetary </font><font style="font-weight:normal;color:#000000;">Default are cured.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">e.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">ROFO Rights Personal</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Right of First Offer is personal to Tenant and is not assignable without Landlord&#8217;s consent, which may be granted or withheld in Landlord&#8217;s sole discretion separate and apart from any consent by Landlord to an assignment of Tenant&#8217;s interest in the Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">f.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No Extensions of ROFO</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The period of time within which the Right of First Offer may be exercised shall not be extended or enlarged by reason of Tenant&#8217;s inability to exercise the Right of First Offer.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">14.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Third Amendment</font><font style="font-size:10pt;font-weight:normal;color:#000000;">.&nbsp;&nbsp;Commencing on the Sixth Amendment Commencement Date, Section 2.6(a)(20) of the Lease relating to &#8220;Administrative Rent&#8221;, as added to the Lease by the Third Amendment shall be deleted in its entirety from the Lease and shall be of no further force or effect.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">15.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">California Accessibility Disclosure</font><font style="font-size:10pt;font-weight:normal;color:#000000;">.&nbsp;&nbsp;For purposes of Section 1938(a) of the California Civil Code, Landlord hereby discloses to Tenant, and Tenant hereby acknowledges, that the Complex has not undergone inspection by a Certified Access Specialist (CASp).&nbsp;&nbsp;In addition, the following notice is hereby provided pursuant to Section 1938(e) of the California Civil Code:&nbsp;&nbsp;&#8220;A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law.&nbsp;&nbsp;Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant.&nbsp;&nbsp;The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.&#8221;&nbsp;&nbsp;In furtherance of and in connection with such notice:&nbsp;&nbsp;(i) Tenant, having read such notice and understanding Tenant&#8217;s right to request and obtain a CASp inspection, hereby elects not to obtain such CASp inspection and forever waives its rights to obtain a CASp inspection with respect to the Premises, Building and/or Complex to the extent permitted by Legal Requirements; and (ii) if the waiver set forth in clause (i) hereinabove is not enforceable pursuant to Legal Requirements, then Landlord and Tenant hereby agree as follows (which constitutes the mutual agreement of the parties as to the matters described in the last sentence of the foregoing notice):&nbsp;&nbsp;(A) Tenant shall have the one-time right to request for and obtain a CASp inspection, which request must be made, if at all, in a written notice delivered by Tenant to Landlord; (B) any CASp inspection timely requested by Tenant shall be conducted (1) at a time mutually agreed to by Landlord and Tenant, (2) in a professional manner by a CASp designated by Landlord and without any testing that would damage the Premises, Building or Complex in any way, and (3) at Tenant&#8217;s sole cost and expense, including, without limitation, Tenant&#8217;s payment of the fee for such CASp inspection, the fee for any reports prepared by the CASp in connection with such CASp inspection (collectively, the &#8220;</font><font style="font-size:10pt;color:#000000;">CASp Reports</font><font style="font-size:10pt;font-weight:normal;color:#000000;">&#8221;) and all other costs and expenses in connection therewith; (C) the CASp Reports shall be delivered by the CASp simultaneously to Landlord and Tenant; (D) Tenant, at its sole cost and expense, shall be responsible for making any improvements, alterations, modifications and/or repairs to or within the Premises to correct violations of construction-related accessibility standards including, without limitation, any violations disclosed by such CASp inspection; and (E) if such CASp inspection identifies any improvements, alterations, </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="font-size:10pt;font-weight:normal;color:#000000;">modifications and/or repairs necessary to correct violations of construction-related accessibility standards relating to those items of the Building and Complex located outside the Premises that are Landlord&#8217;s obligation to repair as set forth in the Lease, then Landlord shall perform such improvements, alterations, modifications and/or repairs as and to the extent required by Legal Requirements to correct such violations, and Tenant shall reimburse Landlord for the cost of such improvements, alterations, modifications and/or repairs within 10 business days after Tenant&#8217;s receipt of an invoice therefor from Landlord.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">16.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">OFAC</font><font style="font-size:10pt;font-weight:normal;color:#000000;">.&nbsp;&nbsp;Tenant is currently (a) in compliance with and shall at all times during the Term of the Lease remain in compliance with the regulations of the Office of Foreign Assets Control (&#8220;</font><font style="font-size:10pt;color:#000000;">OFAC</font><font style="font-size:10pt;font-weight:normal;color:#000000;">&#8221;) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the &#8220;</font><font style="font-size:10pt;color:#000000;">OFAC Rules</font><font style="font-size:10pt;font-weight:normal;color:#000000;">&#8221;), (b) not listed on, and shall not during the Term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons List maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">17.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Brokers</font><font style="font-size:10pt;color:#000000;">.&nbsp;&nbsp;</font><font style="font-size:10pt;font-weight:normal;color:#000000;">Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, &#8220;</font><font style="font-size:10pt;color:#000000;">Broker</font><font style="font-size:10pt;font-weight:normal;color:#000000;">&#8221;) in connection with the transaction reflected in this Sixth Amendment and that no Broker brought about this Sixth Amendment, other than Jones Lang LaSalle.&nbsp;&nbsp;Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker, other than Jones Lang LaSalle, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this Sixth Amendment.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">18.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Miscellaneous</font><font style="font-size:10pt;font-weight:normal;color:#000000;">.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">This Sixth Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions.&nbsp;&nbsp;This Sixth Amendment may be amended only by an agreement in writing, signed by the parties hereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">This Sixth Amendment is binding upon and shall inure to the benefit of the parties hereto, their respective agents, employees, representatives, officers, directors, divisions, subsidiaries, affiliates, assigns, heirs, successors in interest and shareholders.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">This Sixth Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.&nbsp;&nbsp;Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.&nbsp;&nbsp;Electronic signatures shall be deemed original signatures for purposes of this Sixth Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">d.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Except as amended and/or modified by this Sixth Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Sixth Amendment.&nbsp;&nbsp;In the event of any conflict between the provisions of this Sixth Amendment and the provisions of the Lease, the provisions of this Sixth Amendment shall prevail.&nbsp;&nbsp;Whether or not specifically amended by this Sixth Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Sixth Amendment.</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-align:center;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">[Signatures are on the next page]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">IN WITNESS WHEREOF, Landlord </font><font style="font-weight:normal;">and</font><font style="font-weight:normal;"> Tenant have executed this </font><font style="font-weight:normal;">Sixth Amendment</font><font style="font-weight:normal;"> as of the day and year first above written.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:36.62%;"></td>
<td style="width:63.38%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware corporation</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ Enrique Conterno</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its: <font style="text-decoration:underline;">CEO</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">ARE- SAN FRANCISCO NO. 43, LLC, </p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware limited liability company</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:ALEXANDRIA REAL ESTATE EQUITIES, L.P.,</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:35.75pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware limited partnership,</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:35.75pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">managing member</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:35.75pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:35.75pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:ARE-QRS CORP.,</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:71.75pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Maryland corporation,</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:71.75pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">general partner</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:71.75pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ Kristen Childs</font>____________</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:71.75pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its: <font style="text-decoration:underline;">SVP of Real Estate Legal Affairs</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT A</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A06 WORK LETTER</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS A06 WORK LETTER dated June 1, 2021 (the &#8220;<font style="font-weight:bold;">A06</font> <font style="font-weight:bold;">Work Letter</font>&#8221;) is incorporated into that certain Lease Agreement dated as of September 22, 2006, as amended by that certain First Amendment to Lease dated as of October 10, 2007, and as further amended by that certain letter agreement dated as of March 21, 2008, that certain Second Amendment to Lease dated as of June 29, 2009, that certain Third Amendment to Lease dated as of May 19, 2011, that certain letter agreement dated as of June 20, 2011, that certain Fourth Amendment to Lease dated as of September 8, 2011, that certain letter agreement dated as of November 15, 2012, that certain Memorandum of Understanding dated as of October 1, 2014, that certain Fifth Amendment to Lease dated as of December 23, 2014, that certain letter agreement dated as of December 23, 2014, that certain letter agreement dated as of December 10, 2015, that certain letter agreement dated as of April 26, 2016, and that certain Sixth Amendment to Lease dated of even date herewith (the &#8220;<font style="font-weight:bold;">Sixth Amendment</font>&#8221;) (as amended, the &#8220;<font style="font-weight:bold;">Lease</font>&#8221;), by and between <font style="font-weight:bold;">ARE- SAN FRANCISCO NO. 43, LLC</font>, a Delaware limited liability company (&#8220;<font style="font-weight:bold;">Landlord</font>&#8221;), and <font style="font-weight:bold;">FIBROGEN, INC.</font>, a Delaware corporation (&#8220;<font style="font-weight:bold;">Tenant</font>&#8221;).&nbsp;&nbsp;Any initially capitalized terms used but not defined herein shall have the meanings given them in the Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">General Requirements</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Tenant&#8217;s Authorized Representative</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant designates Catherine Sharpe and Martin Quan (either such individual acting alone, &#8220;</font><font style="font-weight:bold;color:#000000;">Tenant&#8217;s Representative</font><font style="color:#000000;">&#8221;) as the only persons authorized to act for Tenant pursuant to this A06 Work Letter.&nbsp;&nbsp;Landlord shall not be obligated to respond to or act upon any request, approval, inquiry or other communication (&#8220;</font><font style="font-weight:bold;color:#000000;">Communication</font><font style="color:#000000;">&#8221;) from or on behalf of Tenant in connection with this A06 Work Letter unless such Communication is in writing from Tenant&#8217;s Representative.&nbsp;&nbsp;Tenant may change either Tenant&#8217;s Representative at any time upon not less than 5 business days advance written notice to Landlord.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Landlord&#8217;s Authorized Representative</font><font style="color:#000000;">.&nbsp;&nbsp;Landlord designates Greg Gehlen and Jeanevy Abata (either such individual acting alone, &#8220;</font><font style="font-weight:bold;color:#000000;">Landlord&#8217;s Representative</font><font style="color:#000000;">&#8221;) as the only persons authorized to act for Landlord pursuant to this A06 Work Letter.&nbsp;&nbsp;Tenant shall not be obligated to respond to or act upon any request, approval, inquiry or other Communication from or on behalf of Landlord in connection with this A06 Work Letter unless such Communication is in writing from Landlord&#8217;s Representative.&nbsp;&nbsp;Landlord may change either Landlord&#8217;s Representative at any time upon not less than 5 business days advance written notice to Tenant.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Architects, Consultants and Contractors</font><font style="color:#000000;">.&nbsp;&nbsp;The architect (the &#8220;</font><font style="font-weight:bold;color:#000000;">TI Architect</font><font style="color:#000000;">&#8221;) for the Tenant Improvements (as defined in </font><font style="text-decoration:underline;color:#000000;">Section 2(a)</font><font style="color:#000000;"> below), the general contractor for the Tenant Improvements (the &#8220;</font><font style="font-weight:bold;color:#000000;">General Contractor</font><font style="color:#000000;">&#8221;), and any subcontractors for the Tenant Improvements shall be selected by Tenant, subject to Landlord&#8217;s approval, which approval shall not be unreasonably withheld, conditioned or delayed.&nbsp;&nbsp;Landlord hereby agrees to approve Hathaway Dinwiddie as the General Contractor, if requested to do so by Tenant.&nbsp;&nbsp;Landlord shall be named a third party beneficiary of any contract entered into by Tenant with the A06 TI Architect, any consultant, any contractor or any subcontractor, and of any warranty made by any contractor or any subcontractor.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Tenant Improvements</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Tenant Improvements Defined</font><font style="color:#000000;">.&nbsp;&nbsp;As used herein, &#8220;</font><font style="font-weight:bold;color:#000000;">Tenant Improvements</font><font style="color:#000000;">&#8221; shall mean all improvements to the Premises desired by Tenant of a fixed and permanent nature.&nbsp;&nbsp;Other than funding the A06 TI Allowance (as defined below) as provided herein, Landlord shall not have any obligation whatsoever with respect to the finishing of the Premises for Tenant&#8217;s use and occupancy.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-1</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Tenant&#8217;s Space Plans</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant shall deliver to Landlord schematic drawings and outline specifications (the &#8220;</font><font style="font-weight:bold;color:#000000;">Space Plans</font><font style="color:#000000;">&#8221;) detailing Tenant&#8217;s requirements for the Tenant Improvements.&nbsp;&nbsp;Not more than</font><font style="color:#000000;"> 10 </font><font style="color:#000000;">days thereafter, Landlord shall deliver to Tenant the written reasonable objections, questions or comments of Landlord and the TI Architect with regard to the Space Plans.&nbsp;&nbsp;Tenant shall cause the Space Plans to be revised to address such written comments and shall resubmit said drawings to Landlord for approval thereafter.&nbsp;&nbsp;Such process shall continue until Landlord has approved the Space Plans.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Working Drawings</font><font style="color:#000000;">.&nbsp;&nbsp;Not later than 15 business days following the approval of the Space Plans by Landlord, Tenant shall cause the TI Architect to prepare and deliver to Landlord for review and comment construction plans, specifications and drawings for the Tenant Improvements (&#8220;</font><font style="font-weight:bold;color:#000000;">TI Construction Drawings</font><font style="color:#000000;">&#8221;), which TI Construction Drawings shall be prepared substantially in accordance with the Space Plans.&nbsp;&nbsp;Tenant shall be solely responsible for ensuring that the TI Construction Drawings reflect Tenant&#8217;s requirements for the Tenant Improvements.&nbsp;&nbsp;Landlord shall deliver its written comments on the TI Construction Drawings to Tenant not later than 10 business days after Landlord&#8217;s receipt of the same; provided, however, that Landlord may not disapprove any matter that is consistent with the Space Plans.&nbsp;&nbsp;Tenant and the TI Architect shall consider all such comments in good faith and shall, within 10 business days after receipt, notify Landlord how Tenant proposes to respond to such comments.&nbsp;&nbsp;Any disputes in connection with such comments shall be resolved in accordance with </font><font style="text-decoration:underline;color:#000000;">Section 2(d)</font><font style="color:#000000;"> hereof.&nbsp;&nbsp;Provided that the design reflected in the TI Construction Drawings is consistent with the Space Plans, Landlord shall approve the TI Construction Drawings submitted by Tenant.&nbsp;&nbsp;Once approved by Landlord, subject to the provisions of </font><font style="text-decoration:underline;color:#000000;">Section 4</font><font style="color:#000000;"> below, Tenant shall not materially modify the TI Construction Drawings except as may be reasonably required in connection with the issuance of the TI Permit (as defined in </font><font style="text-decoration:underline;color:#000000;">Section 3(a)</font><font style="color:#000000;"> below).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Approval and Completion</font><font style="color:#000000;">.&nbsp;&nbsp;If any dispute regarding the design of the Tenant Improvements is not settled within 10 business days after notice of such dispute is delivered by one party to the other, Tenant may make the final decision regarding the design of the Tenant Improvements, provided (i) Tenant acts reasonably and such final decision is either consistent with or a compromise between Landlord&#8217;s and Tenant&#8217;s positions with respect to such dispute, (ii) that all costs and expenses resulting from any such decision by Tenant shall be payable out of the TI Allowance (as defined in </font><font style="text-decoration:underline;color:#000000;">Section 5(d)</font><font style="color:#000000;"> below), and (iii) Tenant&#8217;s decision will not affect the base Building, structural components of the Building or any Building systems (in which case Landlord shall make the final decision).&nbsp;&nbsp;Any changes to the TI Construction Drawings following Landlord&#8217;s and Tenant&#8217;s approval of same requested by Tenant shall be processed as provided in </font><font style="text-decoration:underline;color:#000000;">Section 4</font><font style="color:#000000;"> hereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Performance of the Tenant Improvements</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Commencement and Permitting of the Tenant Improvements</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant shall commence construction of the Tenant Improvements upon obtaining and delivering to Landlord a building permit (the &#8220;</font><font style="font-weight:bold;color:#000000;">TI Permit</font><font style="color:#000000;">&#8221;) authorizing the construction of the Tenant Improvements consistent with the TI Construction Drawings approved by Landlord.&nbsp;&nbsp;The cost of obtaining the TI Permit shall be payable from the TI Allowance.&nbsp;&nbsp;Landlord shall assist Tenant in obtaining the TI Permit.&nbsp;&nbsp;Prior to the commencement of the Tenant Improvements, Tenant shall deliver to Landlord a copy of any contract with Tenant&#8217;s contractors (including the TI Architect), subject to commercially reasonable confidentiality requirements, together with a copy of certificates of insurance from any contractor performing any part of the Tenant Improvement evidencing industry standard commercial general liability, automotive liability, &#8220;builder&#8217;s risk&#8221;, and workers&#8217; compensation insurance.&nbsp;&nbsp;Tenant shall cause the General Contractor to provide a certificate of insurance naming Landlord, Alexandria Real Estate Equities, Inc., and Landlord&#8217;s lender (if any) as additional insureds for the General Contractor&#8217;s liability coverages required above.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Selection of Materials, Etc</font><font style="color:#000000;">.&nbsp;&nbsp;Where more than one type of material or structure is indicated on the TI Construction Drawings approved by Tenant and Landlord, the option will be within Tenant&#8217;s reasonable discretion if the matter concerns the Tenant Improvements, and within Landlord&#8217;s sole and </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-2</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">absolute subjective discretion if the matter concerns the structural components of the Building or any Building system.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Tenant Liability</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant shall be responsible for correcting any deficiencies or defects in the Tenant Improvements. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Substantial Completion</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant shall substantially complete or cause to be substantially completed the Tenant Improvements in a good and workmanlike manner, in accordance with the TI Permit subject, in each case, to Minor Variations and normal &#8220;punch list&#8221; items of a non-material nature which do not interfere with the use of the Premises (&#8220;</font><font style="font-weight:bold;color:#000000;">Substantial Completion</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;color:#000000;">Substantially Complete</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Upon Substantial Completion of the Tenant Improvements, Tenant shall require the TI Architect and the General Contractor to execute and deliver, for the benefit of Tenant and Landlord, a Certificate of Substantial Completion in the form of the American Institute of Architects (&#8220;</font><font style="font-weight:bold;color:#000000;">AIA</font><font style="color:#000000;">&#8221;) document G704.&nbsp;&nbsp;For purposes of this A06 Work Letter, &#8220;</font><font style="font-weight:bold;color:#000000;">Minor Variations</font><font style="color:#000000;">&#8221; shall mean any modifications reasonably required:&nbsp;&nbsp;(i) to comply with all applicable Legal Requirements and/or to obtain or to comply with any required permit (including the TI Permit); (ii) to comport with good design, engineering, and construction practices which are not material; or (iii) to make reasonable adjustments for field deviations or conditions encountered during the construction of the Tenant Improvements.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Changes</font><font style="color:#000000;">.&nbsp;&nbsp;Any material changes estimated by Tenant to cost in excess of $100,000, which are requested by Tenant to the Tenant Improvements after the delivery and approval by Landlord of the Space Plans, shall be requested and instituted in accordance with the provisions of this </font><font style="text-decoration:underline;color:#000000;">Section 4</font><font style="color:#000000;"> and shall be subject to the written approval of Landlord, which approval shall not be unreasonably withheld, conditioned or delayed.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Tenant&#8217;s Right to Request Changes</font><font style="color:#000000;">.&nbsp;&nbsp;If Tenant shall request changes (&#8220;</font><font style="font-weight:bold;color:#000000;">Changes</font><font style="color:#000000;">&#8221;), Tenant shall request such Changes by notifying Landlord in writing in substantially the same form as the AIA standard change order form (a &#8220;</font><font style="font-weight:bold;color:#000000;">Change Request</font><font style="color:#000000;">&#8221;), which Change Request shall detail the nature and extent of any such Change.&nbsp;&nbsp;Such Change Request must be signed by Tenant&#8217;s Representative.&nbsp;&nbsp;Landlord shall review and approve or disapprove such Change Request within 2 business days thereafter, provided that Landlord&#8217;s approval shall not be unreasonably withheld, conditioned or delayed.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Implementation of Changes</font><font style="color:#000000;">.&nbsp;&nbsp;If Landlord approves such Change, Tenant may cause the approved Change to be instituted.&nbsp;&nbsp;If any TI Permit modification or change is required as a result of such Change, Tenant shall promptly provide Landlord with a copy of such TI Permit modification or change.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Costs</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Budget For Tenant Improvements</font><font style="color:#000000;">.&nbsp;&nbsp;Before the commencement of construction of the Tenant Improvements, Tenant shall estimate and deliver to Landlord a Budget for design and construction of the Tenant Improvements (the &#8220;</font><font style="font-weight:bold;color:#000000;">Budget</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;The Budget shall be based upon the TI Construction Drawings approved by Landlord.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">TI Allowance</font><font style="color:#000000;">.&nbsp;&nbsp;Landlord shall provide to Tenant a tenant improvement allowance (collectively, the &#8220;</font><font style="font-weight:bold;color:#000000;">TI Allowance</font><font style="color:#000000;">&#8221;) as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.  a &#8220;<font style="font-weight:bold;">Tenant Improvement Allowance&#8221;</font> in the maximum amount of $25.00 per rentable square foot in the Premises, which is included in the Minimum Monthly Rent payable during the Extended Term; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.  an &#8220;<font style="font-weight:bold;">Additional Tenant Improvement Allowance</font>&#8221; in the maximum amount of $50.00 per rentable square foot in the Premises, which shall, to the extent used, result in Additional TI Rent as set forth in Section 2 of the Sixth Amendment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-3</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the TI Allowance, Landlord shall pay the TI Architect up to $0.15 per rentable square foot of the Premises for the preparation of test fits.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before commencing the Tenant Improvements, Tenant shall notify Landlord how much Additional Tenant Improvement Allowance Tenant has elected to receive from Landlord. Such election shall be final and binding on Tenant, and may not thereafter be modified without Landlord&#8217;s consent, which may be granted or withheld in Landlord&#8217;s sole and absolute subjective discretion The TI Allowance shall be disbursed in accordance with this Work Letter.&#160; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant shall have no right to the use or benefit (including any reduction to Minimum Monthly Rent) of any portion of the TI Allowance not required for the construction of (i) the Tenant Improvements described in the TI Construction Drawings approved pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 2(d)</font><font style="color:#000000;"> or (ii) any Changes pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 4</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant shall have no right to any portion of the A06 TI Allowance that is not disbursed before the last day of the month that is 18 months after the Sixth Amendment Commencement Date.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Costs Includable in TI Allowance</font><font style="color:#000000;">.&nbsp;&nbsp;The TI Allowance shall be used solely for the payment of design, permits and construction costs in connection with the construction of the Tenant Improvements, including, without limitation, the cost of electrical power and other utilities used in connection with the construction of the Tenant Improvements, the cost of preparing the Space Plans and the TI Construction Drawings, all costs set forth in the Budget and the cost of Changes (collectively, &#8220;</font><font style="font-weight:bold;color:#000000;">TI Costs</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, the TI Allowance shall not be used to purchase any furniture, personal property or other non-Building system materials or equipment, including, but not be limited to, Tenant&#8217;s voice or data cabling, non-ducted biological safety cabinets and other scientific equipment not incorporated into the Tenant Improvements.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">INTENTIONALLY DELETED</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Payment for TI Costs</font><font style="color:#000000;">.&nbsp;&nbsp;During the course of design and construction of the Tenant Improvements, Landlord shall reimburse Tenant for TI Costs once a month against a draw request in Landlord's standard form, containing evidence of payment of such TI Costs by Tenant and such certifications, lien waivers (including a conditional lien release for each progress payment and unconditional lien releases for the prior month's progress payments), inspection reports and other matters as Landlord customarily obtains, to the extent of Landlord's approval thereof for payment, no later than 30 days following receipt of such draw request.&nbsp;&nbsp;Upon completion of the Tenant Improvements, Tenant shall deliver to Landlord:&nbsp;&nbsp;(i) sworn statements setting forth the names of all contractors and first tier subcontractors who did the work and final, unconditional lien waivers from all such contractors and first tier subcontractors; (ii) as-built plans (one copy in print format and two copies in electronic CAD format) for such Tenant Improvements; (iii) a certification of substantial completion in Form AIA G704, (iv) a certificate of occupancy for the Premises; and (v) copies of all operation and maintenance manuals and warranties affecting the Premises.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, Tenant shall be responsible for the cost of the Tenant Improvements to the extent that the cost of the Tenant Improvements exceed the Tenant Improvement Allowance and any portion of the Additional Tenant Improvement Allowance elected to be used by Tenant</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Tenant Improvement Progress Reports</font><font style="color:#000000;">. Upon periodic request by Landlord, Tenant shall deliver to Landlord a Tenant Improvement progress report in the form of </font><font style="font-weight:bold;color:#000000;">Schedule 1</font><font style="color:#000000;"> completed to provide all of the most up-to-date information regarding the Tenant Improvements.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-4</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">6.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Miscellaneous</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Consents</font><font style="color:#000000;">.&nbsp;&nbsp;Whenever consent or approval of either party is required under this A06 Work Letter, that party shall not unreasonably withhold, condition or delay such consent or approval, except as may be expressly set forth herein to the contrary.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Modification</font><font style="color:#000000;">.&nbsp;&nbsp;No modification, waiver or amendment of this A06 Work Letter or of any of its conditions or provisions shall be binding upon Landlord or Tenant unless in writing signed by Landlord and Tenant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">No Default Funding</font><font style="color:#000000;">.&nbsp;&nbsp;In no event shall Landlord have any obligation to fund any portion of the TI Allowance during any period that an Event of Default exists under the Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Infectious Conditions</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant shall require the General Contractor, TI Architect and any consultants, contractors, subcontractors and all other service and materials providers entering the Complex during the construction of the Tenant Improvements to perform services or provide materials in connection with the Tenant Improvements to comply with all criteria recommended by the Centers for Disease Control and Prevention and applicable governmental authorities). </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-5</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Tenant Improvement Progress Report</font></p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building Address: _____________________________</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification Period: ______________</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. Original Project Budget&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$__________________</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Net change by Change Orders/Update to budget&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$__________________</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Current budget to date (Line 1 &#177; 2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$__________________</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. Total costs incurred to date&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$__________________</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. Remaining balance to budget (Line 3 less Line 4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;">$__________________</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification signature: ______________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-6</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT B</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXPANSION SPACE</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000019.jpg" title="" alt="" style="width:538px;height:767px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B-1</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT C</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">SECOND FLOOR ROFO SPACE</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000021.jpg" title="" alt="" style="width:539px;height:758px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-1</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT D</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A06 MINIMUM MONTHLY RENT SCHEDULE</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000023.jpg" title="" alt="" style="width:306px;height:194px;"></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-1</a></p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvgjwefnhf2j000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>fgen-ex102_408.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex102_408.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.2</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;"><a name="TOCHeading"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:11pt;font-variant: small-caps;font-style:normal;text-transform:none;">EXCLUSIVE LICENSE AND OPTION AGREEMENT<br /><br />by and between<br /><br /><font style="font-weight:normal;Background-color:#000000;color:#000000;font-variant: normal;"><br /><br /><br /></font><br />FibroGen, Inc.<br /><br />and<br /><br />HiFiBiO (HK) Limited (d.b.a. HiFiBiO Therapeutics)<br /><br />Dated as of June 16, 2021</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">TABLE OF CONTENTS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:93.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 1 <font style="font-weight:normal;">DEFINITIONS</font></p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:93.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 2<font style="font-weight:normal;"> LICENSES AND EXCLUSIVITY</font></p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License to FibroGen</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License to HFB</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublicensing</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subcontractors</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Implied Licenses; Retained Rights</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party In-Licenses</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Technology Transfer</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exclusivity</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.9</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen License Options</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:93.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 3<font style="font-weight:normal;"> GOVERNANCE</font></p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alliance Manager</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joint Steering Committee</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Resolution of JSC Disputes</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dissolution of JSC</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:93.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 4<font style="font-weight:normal;"> DEVELOPMENT</font></p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development Plans</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work Plans</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen Development Responsibilities</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development Diligence Obligations</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HFB Development Responsibilities</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development Records</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development Reports</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:93.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 5<font style="font-weight:normal;"> REGULATORY</font></p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory Responsibilities</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory Filings; Ownership</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interactions with Regulatory Authorities</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option Programs</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:93.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 6<font style="font-weight:normal;"> MANUFACTURING</font></p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:93.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 7</font><font style="font-weight:normal;"> COMMERCIALIZATION</font><font style="font-weight:normal;"></font></p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization Responsibilities</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization Diligence Obligations</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization Report</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:93.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 8<font style="font-weight:normal;"> FINANCIALS</font></p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront Payment</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option Exercise Payment</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone Payments</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublicense Revenue</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upstream License Costs</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Books and Records; Audit Rights</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.8</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxes</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:93.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 9<font style="font-weight:normal;"> INTELLECTUAL PROPERTY</font></p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Background Technology</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ownership</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prosecution, Maintenance &amp; Enforcement</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Defense and Settlement of Third Party Claims</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enforcement</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.6</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trademarks</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.7</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CREATE Act</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent Right Extensions; Regulatory Exclusivity</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:93.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 10<font style="font-weight:normal;"> REPRESENTATIONS, WARRANTIES, AND COVENANTS</font></p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual Representations, Warranties, and Covenants</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Representations and Warranties by HFB</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HFB Covenants</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual Covenants</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NO OTHER REPRESENTATIONS OR WARRANTIES</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:93.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 11<font style="font-weight:normal;"> INDEMNIFICATION</font></p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.1</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnification by HFB</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnification by FibroGen</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnification Procedures</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.4</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Limitation of Liability</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.5</font></p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:93.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 12<font style="font-weight:normal;"> CONFIDENTIALITY</font></p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidentiality; Exceptions</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized Disclosure</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior Agreement</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.4</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Residual Knowledge</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Publications</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:93.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 13<font style="font-weight:normal;"> TERM AND TERMINATION</font></p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.2</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination by FibroGen</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.3</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination for Cause</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.5</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination for Patent Challenge</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.6</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effects of Termination</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.7</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Survival</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:93.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 14<font style="font-weight:normal;"> DISPUTE RESOLUTION</font></p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dispute Resolution</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Injunctive Relief</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:93.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 15<font style="font-weight:normal;"> MISCELLANEOUS</font></p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.1</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entire Agreement; Amendment</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.2</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Force Majeure</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.3</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notices</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.4</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Strict Construction; Headings</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.5</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interpretation</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.6</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assignment</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.7</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change of Control</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.8</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance by Affiliates</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.9</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further Actions</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.10</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Severability</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.11</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Waiver</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.12</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Independent Contractors</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.13</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Counterparts</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.14</p></td>
<td valign="top"  style="width:83.58%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Choice of Law</p></td>
<td valign="top"  style="width:6.42%;">
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXCLUSIVE LICENSE AND OPTION AGREEMENT</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIS EXCLUSIVE LICENSE AND OPTION AGREEMENT<font style="font-weight:normal;"> (this &#8220;</font>Agreement<font style="font-weight:normal;">&#8221;) is entered into as of June 16, 2021 (the &#8220;</font>Effective Date<font style="font-weight:normal;">&#8221;) by and among HiFiBiO (HK) Limited (d.b.a. HiFiBiO Therapeutics), a limited company organized and existing under the laws of Hong Kong, with a registered address at Room 303, Third Floor, St. George&#8217;s Building, 2 Ice House Street, Central, Hong Kong (&#8220;</font>HFB<font style="font-weight:normal;">&#8221;), and </font>FibroGen, Inc.<font style="font-weight:normal;">, a Delaware corporation having its principal place of business at 409 Illinois St., San Francisco, CA 94158 (&#8220;</font>FibroGen<font style="font-weight:normal;">&#8221;). HFB and FibroGen are referred to herein individually as a &#8220;</font>Party<font style="font-weight:normal;">&#8221; and collectively as the &#8220;</font>Parties<font style="font-weight:normal;">.&#8221; </font></p>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BACKGROUND</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, HFB and its Affiliates Control certain Patent Rights and Know-How relating to the Gal-9 Licensed Program;</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, HFB and its Affiliates Control certain Patent Rights and Know-How relating to, and are conducting research and Development with respect to, compounds and products directed to CCR8, CXCR5, and other targets.</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, HFB desires to grant, and FibroGen desires to receive, an exclusive license under such Patent Rights and Know-How to permit FibroGen to Exploit Licensed Compounds and Licensed Products directed to Gal-9 in the Territory.</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, HFB desires to grant, and FibroGen desires to receive, an exclusive option to receive an exclusive license to Exploit (a) Licensed Compounds and Licensed Products directed to CCR8, (b) Licensed Compounds and Licensed Products directed to CXCR5 or, (c) in the event FibroGen does not wish to exercise such option with respect to (a) or (b), Licensed Compounds and Licensed Products that are directed to a target that is the subject of another program Controlled by HFB and selected by the Parties.</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW THEREFORE<font style="font-weight:normal;">, the Parties agree as follows:</font></p>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;color:#010000;font-family:Times New Roman Bold;text-transform:uppercase;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref401171744"></a><a name="_Ref401171902"></a><a name="_Ref431666561"></a><a name="_Toc74552545"></a><a name="_Toc74553427"></a>Article 1<font style="color:#000000;font-family:Times New Roman;text-transform:none;"><br /><a name="_Ref401171744"></a><a name="_Ref401171902"></a><a name="_Ref431666561"></a><a name="_Toc74552545"></a><a name="_Toc74553427"></a>DEFINITIONS</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref22391284"></a><a name="_Ref22391368"></a><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Acceptance</font><font style="color:#000000;">&#8221; means, (a) with respect to an IND in the United States, the later of (i) the occurrence of [*] following the FDA&#8217;s receipt of such IND if the FDA does not place a clinical hold with respect to such IND filing in such [*] period or (ii) if the FDA places a clinical hold with respect to such IND during such [*] period, the FDA&#8217;s notification of the lifting of such clinical hold and (b) with respect to an IND in a country other than the United States, the clearance of such IND in accordance with applicable law such that the Clinical Trial may be Initiated based on such IND in such jurisdiction</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref504655369"></a><a name="_Ref504655369"></a>&#8220;<font style="font-weight:bold;">Accounting Standards</font>&#8221; means International Financial Reporting Standards (IFRS) or U.S. Generally Accepted Accounting Principles (GAAP), as generally and consistently applied throughout a Party&#8217;s organization.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Additional Third Party IP</font>&#8221; has the meaning set forth in Section 2.6 (Third Party In-Licenses).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Affiliate</font>&#8221; means, with respect to a Party, a Person that controls, is controlled by, controlling or is under common control with such Party, but only for so long as such control will continue. For the purposes of this definition, the word &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221;, &#8220;controlling&#8221; or &#8220;under the common control with&#8221;) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of more than fifty percent (50%) of the voting stock of such entity, or by contract or otherwise.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Agreement</font>&#8221; has the meaning set forth in the Preamble. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Alliance Manager</font>&#8221; has the meaning set forth in Section 3.1 (Alliance Manager). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Arbitration Forum</font>&#8221; has the meaning set forth in Section 14.1(b) (Dispute Resolution).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Arising Know-How</font>&#8221; has the meaning set forth in Section 9.2(a)(i) (Arising Technology).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.9</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Arising Patent Rights</font>&#8221; has the meaning set forth in Section 9.2(a)(i) (Arising Technology).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.10</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Arising Technology</font>&#8221; has the meaning set forth in Section 9.2(a)(i) (Arising Technology).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.11</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Bankruptcy Code</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 13.4 (Termination for Bankruptcy).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.12</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Bankruptcy Event</font>&#8221; means, with respect to a Person, such person makes a general assignment for the benefit of creditors, admits in writing its inability to pay its debts generally as they become due, files or consents to the filing of a petition for bankruptcy or insolvency, the appointment of any receiver, liquidator, trustee or similar officer to liquidate or conserve its business or any substantial part of its assets, or files a petition or answer or consent seeking under the laws of any jurisdiction any proceeding for its insolvency, bankruptcy, reorganization, adjustment of debt, arrangement, dissolution, liquidation, or any case or action is taken against such Person by a third person in furtherance of any of the foregoing and such case or action by a third person is not dismissed within [*].</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.13</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Bankruptcy Laws</font>&#8221; has the meaning set forth in Section 13.4 (Termination for Bankruptcy).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.14</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Biosimilar Product</font>&#8221; means, with respect to a particular Licensed Product in a particular country, a product on the market in such country commercialized by any Third Party that is not an Affiliate or Sublicensee of FibroGen and that did not purchase such product in a chain of distribution that included any of FibroGen or its Affiliates or Sublicensees, that (a)&#160;is approved by the applicable Regulatory Authority, under any then-existing laws and regulations in the applicable country pertaining to approval of products with no clinically meaningful differences as a &#8220;generic&#8221;, &#8220;biosimilar&#8221;, or &#8220;interchangeable&#8221; version (or terms of similar meaning) of such Licensed Product, which approval uses such Licensed Product as a reference product and relies on or references any information in the approval application for such Licensed Product, or (b)&#160;is otherwise recognized by the applicable Regulatory Authority as a &#8220;generic&#8221;, &#8220;biosimilar&#8221; or &#8220;interchangeable&#8221; product (or other term of similar meaning) with no clinically meaningful differences to such Licensed Product. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.15</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">BLA</font>&#8221; means a Biologics License Application submitted to the FDA pursuant to Section 351 of the Public Health Service Act, 42 U.S.C. &#167; 262, and 21 C.F.R &#167; 601.2 as these provisions may be amended from time-to-time (or its successor statute or regulation), for purposes of obtaining Regulatory Approval for a biological product in the United States, or any equivalent filing in a country or regulatory jurisdiction other than the United States.<font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.16</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Business Day</font>&#8221; means a day other than a Saturday, Sunday, or a day on which banking institutions in San Francisco, CA or Hong Kong are required by applicable law to remain closed.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.17</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Calendar Quarter</font>&#8221;<font style="font-weight:bold;"> </font>means a period of three consecutive months ending on the last day of March, June, September, or December, respectively, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the first to occur of March 31, June 30, September 30 or December 31 after the Effective Date, and the last Calendar Quarter shall end on the last day of the applicable Royalty Term or the Term, as applicable.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.18</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Calendar Year</font>&#8221; means a period of 12 consecutive months beginning on January 1 and ending on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs, and the last Calendar </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>2<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year shall commence on January 1 of the year, end on the last day, of the applicable Royalty Term or the Term, as applicable</font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.19</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">CCR8</font>&#8221; means [*]. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.20</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">CCR8 Option Program</font>&#8221; means the program of Development of the Option Compounds and Option Products Directed To CCR8.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.21</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">cGMP</font><font style="color:#000000;">&#8221; means applicable current Good Manufacturing Practices, including, as applicable, (a) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Parts 4, 210, 211, 601, 610 and 820, (b) European Directive 2003/94/EC and Eudralex 4, (c) the principles detailed in the International Conference on Harmonization&#8217;s Q7 guidelines, and (d) the applicable laws the Territory corresponding to (a) through (c) above, each as may be amended and applicable from time to time.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.22</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Chairperson</font>&#8221; has the meaning set forth in Section 3.2(a) (Joint Development Committee). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.23</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Change of Control</font>&#8221; means, with respect to a Party, that: (a) any Third Party acquires directly or indirectly the beneficial ownership of any voting security of such Party, or if the percentage ownership of such Third Party in the voting securities of such Party is increased through stock redemption, cancellation, or other recapitalization, and immediately after such acquisition or increase such Third Party is, directly or indirectly, the beneficial owner of voting securities representing more than 50% of the total voting power of all of the then outstanding voting securities of such Party; (b) a merger, consolidation, recapitalization, or reorganization of such Party is consummated that would result in shareholders or equity holders of any Third Party immediately prior to such transaction, owning more than 50% of the outstanding voting securities of the surviving entity (or its parent entity) immediately following such transaction; or (c) there is a sale or transfer to a Third Party of all or substantially all of such Party&#8217;s consolidated assets taken as a whole, in each of (a) through (c) through one or more related transactions. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.24</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Claim</font>&#8221; has the meaning set forth in Section 11.3 (Indemnification Procedures). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.25</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Clinical Trial</font>&#8221; means a study in humans to obtain information regarding a product, including information relating to the safety, tolerability, pharmacological activity, pharmacokinetics, dose ranging or efficacy of such product, including a Phase I Clinical Trial, Phase II Clinical Trial, and Phase III Clinical Trial. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.26</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">CMO</font>&#8221; means a contract manufacturing organization. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.27</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref58504101"></a><a name="DocXTextRef32"></a><a name="DocXTextRef34"></a><a name="DocXTextRef35"></a><a name="DocXTextRef36"></a><a name="DocXTextRef37"></a>&#8220;<font style="font-weight:bold;">Combination Product</font><a name="DocXTextRef32"></a>&#8221; means a Licensed Product that is sold for a single invoice price and is either (a)&#160;approved by the applicable Regulatory Authority to be sold in the form of a combination that contains or comprises a Licensed Compound together with one or more other therapeutically active pharmaceutical agents (whether coformulated or copackaged<a name="DocXTextRef34"></a> or otherwise sold for a single invoice price), or (b) together with any (i) [*] or (ii) [*] related to a Licensed Compound, but excluding any of (i) or (ii)&#160;for which [*] of an independent Licensed Product<a name="DocXTextRef35"></a> (such additional therapeutically active pharmaceutical agent and each of (i) and (ii), an &#8220;<font style="font-weight:bold;">Other Component</font><a name="DocXTextRef36"></a>&#8221;); or (c)<a name="DocXTextRef37"></a> defined as a &#8220;combination product&#8221; under 21 C.F.R. &#167;3.2(e) or its foreign equivalent. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.28</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_9kR3WTr1AIGC9KFwvoutlkoxCD21"></a><a name="_9kR3WTr19HGCCNFwvoutlkoxCD21"></a><a name="_9kR3WTr19HGCBMFwvoutlkoxC9"></a><a name="_9kMHG5YVt3BJIEDOHyxqwvnmqzEB"></a><a name="_9kMHG5YVt3CKIEBMHyxqwvnmqzEF43"></a><a name="_9kMHG5YVt3BJIEEPHyxqwvnmqzEF43"></a>&#8220;<font style="font-weight:bold;">Commercialization</font><a name="_9kR3WTr1AIGC9KFwvoutlkoxCD21"></a><a name="_9kR3WTr19HGCCNFwvoutlkoxCD21"></a>,&#8221; &#8220;<font style="font-weight:bold;">Commercializing</font><a name="_9kR3WTr19HGCBMFwvoutlkoxC9"></a>,&#8221; or &#8220;<font style="font-weight:bold;">Commercialize</font><a name="_9kMHG5YVt3BJIEDOHyxqwvnmqzEB"></a>&#8221; means any and all activities directed to the marketing, promotion, medical affairs, distribution, offering for sale, sale, having sold, importing, having imported, exporting, having exported, or other commercialization of a pharmaceutical or biological product, but excluding activities directed to Manufacturing or Development. &#8220;<font style="font-weight:bold;">Commercialize</font><a name="_9kMHG5YVt3CKIEBMHyxqwvnmqzEF43"></a><a name="_9kMHG5YVt3BJIEEPHyxqwvnmqzEF43"></a>,&#8221; &#8220;<font style="font-weight:bold;">Commercializing</font>,&#8221; and &#8220;<font style="font-weight:bold;">Commercialized</font>&#8221; will be construed accordingly.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>3<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.29</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Commercially Reasonable Efforts</font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8221; </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">means, with respect to the efforts to be expended by a Party or its Affiliate with respect to any Development or Commercialization objective, obligation, activity, or goal related to a Licensed Product under this Agreement, those efforts and resources that a </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> would normally devote to accomplishing such objective, obligation, activity or goal, based on</font><font style="font-size:12pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the specific product and conditions then prevailing and taking into account efficacy, safety, product labeling, profitability, supply chain considerations, the competitiveness of alternative products sold by Third Parties in the marketplace, the patent and other proprietary position of the product, the likelihood of regulatory approval given the regulatory structure involved, and all other relevant factors, including technical, financial, legal, scientific and/or medical factors and, in any case, that such Party shall assign a budget and responsibility for such task or obligation to employees or contractors of such Party who are held accountable for executing such task or obligation and for monitoring such budget and progress on an ongoing basis. </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.30</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Competitive Activities</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 2.8(a) (Exclusivity Covenant)</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.31</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Competitive Product</font>&#8221; means, with respect to HFB, any [*], and, with respect to FibroGen, any [*], or in the event of the Replacement Option Election, the [*], <font style="font-style:italic;">provided</font> that if (i) FibroGen does not provide an Option Exercise Notice in respect of a given Option Program prior to the expiration of the Option Term for such Option Program or (ii) a Licensed Program becomes a Terminated Licensed Program, then &#8220;Competitive Products&#8221; will cease to include any [*] that is the subject of such Option Program or Terminated Licensed Program. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.32</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Confidential Information</font>&#8221; has the meaning set forth in Section&#160;12.1 (Confidentiality; Exceptions).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.33</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Continuing</font> <font style="font-weight:bold;">Technology Transfer</font>&#8221; has the meaning set forth in Section 2.7(b) (Continuing Technology Transfer).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.34</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref67744561"></a><a name="_Hlk17799977"></a>&#8220;<font style="font-weight:bold;">Control</font>&#8221; or &#8220;<font style="font-weight:bold;">Controlled</font>&#8221; means (a) the possession by a Party (whether by ownership, license, or otherwise other than pursuant to this Agreement) of, (i) with respect to any tangible Know-How, the legal authority or right to physical possession of such tangible Know-How, with the right to provide such tangible Know-How to the other Party on the terms set forth herein, or (ii) with respect to Patent Right, Regulatory Approvals, Regulatory Materials, intangible Know-How, or other intellectual property rights, the legal authority or right to grant a license, sublicense, access, or right to use (as applicable) to the other Party under such Patent Right, Regulatory Approvals, Regulatory Materials, intangible Know-How, or other intellectual property rights on the terms set forth herein, in each case ((i) and (ii)), without breaching or otherwise violating the terms of any arrangement or agreement with a Third Party or incurring any additional payment obligations to a Third Party <a name="_Hlk17799977"></a>unless the other Party agrees in writing to be bound by the applicable portion of such payment obligation; and (b) with respect to any product, the possession by a Party of the ability (whether by sole or joint ownership, license or otherwise, other than pursuant to this Agreement) to grant a license or sublicense of Patent Rights that claim such product or proprietary Know-How that is used in connection with the Exploitation of such product. Notwithstanding the foregoing, a Party and its Affiliates will not be deemed to &#8220;Control&#8221; any Patent Rights, Know-How, or product that, prior to the consummation of a Change of Control of such Party, are owned or in-licensed by a Third Party that becomes an Affiliate of such acquired Party or that merges or consolidates with such Party after the Effective Date as a result of such Change of Control. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.35</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Cover</font>,&#8221; &#8220;<font style="font-weight:bold;">Covering</font>,&#8221; or &#8220;<font style="font-weight:bold;">Covered</font>&#8221; means, when used to refer to the relationship between a particular Patent Right and particular subject matter, that the manufacture, use, sale, offer for sale, or importation of such subject matter would fall within the scope of one or more claims in, or is otherwise claimed by, such Patent Right.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>4<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.36</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">CPA Firm</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; </font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">has the meaning set forth in </font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section </font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.7(a)</font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (Books and Records; Audit Rights). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.37</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">CREATE Act</font>&#8221; means the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. &#167; 103(c)(2)-(c)(3).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">CXCR5</font>&#8221; means [*]. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.39</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">CXCR5 Option Program</font>&#8221; means the program of Development of the Option Compounds and Option Products Directed To CXCR5.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.40</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Defaulting Party</font>&#8221; has the meaning set forth in <font style="color:#000000;">Section 13.3(c) (Disputes Regarding Material Breach).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.41</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref524455014"></a><a name="_9kR3WTr19HGCDP6vwny3"></a><a name="DocXTextRef58"></a><a name="DocXTextRef59"></a><a name="_9kMHG5YVt3BJIEFR8xyp05"></a><a name="_9kR3WTr1AIGCAM6vwny3yxw"></a><a name="_9kR3WTr19HGCDP6vwny3"></a>&#8220;<font style="font-weight:bold;">Develop</font>&#8221; or &#8220;<font style="font-weight:bold;">Development</font><a name="DocXTextRef58"></a>&#8221; means all internal and external research, development, and regulatory activities related to pharmaceutical or biological products, including (a)<a name="DocXTextRef59"></a>&#160;research, non-clinical testing, toxicology, testing and studies, non-clinical and preclinical activities, and Clinical Trials, and (b)<a name="_9kMHG5YVt3BJIEFR8xyp05"></a>&#160;preparation, submission, review, and development of data or information for the purpose of submission to a Regulatory Authority to obtain authorization to conduct Clinical Trials and to obtain, support, or maintain Regulatory Approval of a pharmaceutical or biological product and interacting with Regulatory Authorities following receipt of Regulatory Approval in the applicable country or region for such pharmaceutical or biological product regarding the foregoing, but excluding activities directed to Manufacturing or Commercialization. Development will include development and regulatory activities for additional forms, formulations, or indications for a pharmaceutical or biological product after receipt of Regulatory Approval of such product (including label expansion), including Clinical Trials initiated following receipt of Regulatory Approval or any Clinical Trial to be conducted after receipt of Regulatory Approval that was mandated by the applicable Regulatory Authority as a condition of such Regulatory Approval with respect to an approved formulation or indication (such as post-marketing studies, observational studies, implementation and management of registries and analysis thereof, in each case, if required by any Regulatory Authority in any region in the Territory to support or maintain Regulatory Approval for a pharmaceutical or biological product in such region). &#8220;<font style="font-weight:bold;">Develop</font><a name="_9kR3WTr1AIGCAM6vwny3yxw"></a>,&#8221; &#8220;<font style="font-weight:bold;">Developing</font>,&#8221; and &#8220;<font style="font-weight:bold;">Developed</font>&#8221; will be construed accordingly.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.42</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Development Plan</font>&#8221; has the meaning set forth in Section 4.1 (Development Plan).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.43</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Diligence Milestone</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 4.4 (Development Diligence Obligations)</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.44</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Directed To</font>&#8221; means, as used with respect to a given compound or product and a given target, [*].</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.45</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Disclosure Letter</font>&#8221; has the meaning set forth in Section 10.2 (Representations and Warranties by HFB).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.46</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Effective Date</font>&#8221; has the meaning set forth in the Preamble.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.47</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">EMA</font>&#8221; means the European Medicines Agency and any successor agency thereto.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.48</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Exclusive Target</font>&#8221; means each of (a) Gal-9 and (b) after the Option Exercise Date with respect thereto: (i) CXCR5 Option Program, CXCR5; (ii) CCR8 Option Program, CCR8; and (iii)&#160;in the event of the Replacement Option Election, Replacement Option Program, the Replacement Target, except for a target to which a Terminated Licensed Program was Directed To. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.49</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Executive Officer</font>&#8221; means (a) in the case of FibroGen, the chief executive officer of FibroGen,<font style="font-style:italic;font-weight:bold;"> </font>and (b) in the case of HFB, the chief executive officer of HFB, neither of whom will be a member of the <font style="color:#000000;">JSC</font>. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>5<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.50</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Existing Nondisclosure Agreement</font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means the Amended and Restated Mutual Confidential Disclosure Agreement entered into by </font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FibroGen</font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">, HFB, and </font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HiFiBiO</font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> Inc., effective as of </font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.51</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Existing Patent Rights</font>&#8221; has the meaning set forth in the definition of Licensed Patent Rights.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.52</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_9kR3WTr26DGDIcBj4xecwFEzm"></a>&#8220;<font style="font-weight:bold;">Exploit</font>&#8221; and &#8220;<font style="font-weight:bold;">Exploitation</font>&#8221; <a name="_9kR3WTr26DGDIcBj4xecwFEzm"></a>means Develop, have Developed, make, have made, use, have used, offer for sale, have offered for sale, sell, have sold, export, have exported, import, have imported, Manufacture, have Manufactured, Commercialize, have Commercialized or otherwise exploit. &#8220;<font style="font-weight:bold;">Exploiting</font>&#8221; will be construed accordingly.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.53</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">FD&amp;C Act</font>&#8221; has the meaning set forth in Section 1.76 (IND).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.54</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">FDA</font>&#8221; means the U.S. Food and Drug Administration or any successor agency thereto. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.55</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">FibroGen</font>&#8221; has the meaning set forth in the Preamble. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.56</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">FibroGen</font> <font style="font-weight:bold;">Arising Patent Rights</font>&#8221; has the meaning set forth in Section 9.2(a)(i) (Arising Technology).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.57</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">FibroGen Background Technology</font>&#8221; has the meaning set forth in Section 9.1 (Background Technology). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.58</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">FibroGen</font> <font style="font-weight:bold;">CMO</font>&#8221; has the meaning set forth in Section 2.7(a) (Initial Technology Transfer).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.59</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">FibroGen</font> <font style="font-weight:bold;">Indemnitees</font>&#8221; has the meaning set forth in Section 11.1 (Indemnification by HFB).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.60</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Field</font>&#8221; means any and all uses. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.61</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">First Commercial Sale</font>&#8221; means, with respect to a Licensed Product in a country or region in the Territory, the first sale to a Third Party of such Licensed Product in such country or region after receipt of Regulatory Approval and, [*]. First Commercial Sale excludes any sale or other distribution of a Licensed Product for promotional or advertising purposes, Clinical Trials, preclinical trials, or other Development purposes, free samples, named patient use, compassionate use, patient assistance, expanded access, or charitable use.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.62</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">FTE Rate</font>&#8221; means beginning on the Effective Date, [*] per year. The FTE Rate is subject to annual increases beginning on January 1, 2022 to reflect percentage increase in the Consumer Price Index for the US City Average (all items) for the prior Calendar Year and similarly calculated year to year for each subsequent Calendar Year. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.63</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Gal-9</font>&#8221; means [*]. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.64</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Gal-9 Licensed Program</font>&#8221; means the program of Development and Commercialization of the Licensed Compounds and Licensed Products Directed To Gal-9.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.65</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">GCP</font>&#8221; means all applicable Good Clinical Practice standards for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of Clinical Trials, including, as applicable (a) as set forth in the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Harmonized Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) (the &#8220;<font style="font-weight:bold;">ICH Guidelines</font>&#8221;) and any other guidelines for good clinical practice for trials on medicinal products in the Territory, (b) the Declaration of Helsinki (2004) as last amended at the 52nd World Medical Association in October 2000 and any further amendments or clarifications thereto, (c) U.S. Code of Federal Regulations Title 21, Parts 50 (Protection of Human Subjects), 54 (Financial Disclosure of Clinical Investigators), 56 (Institutional Review Boards) and 312 (Investigational New Drug Application), as may be amended from time to time, and (d) the equivalent applicable laws in the region in the Territory, each as may be amended and applicable from time to time and in each case, that provide for, among other things, assurance that </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>6<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.66</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">GLP</font>&#8221; means all applicable Good Laboratory Practice standards for nonclinical studies, including, as set forth in the then-current good laboratory practice standards promulgated or endorsed by the U.S. Food and Drug Administration, as set forth in 21 C.F.R. Part 58, and the equivalent applicable laws in the Territory, each as may be amended and applicable from time to time.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.67</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">HFB</font>&#8221; has the meaning set forth in the Preamble.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.68</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">HFB</font> <font style="font-weight:bold;">Arising Patent Rights</font>&#8221; has the meaning set forth in Section 9.2(a)(i) (Arising Technology).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.69</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">HFB</font> <font style="font-weight:bold;">Arising Technology</font>&#8221; has the meaning set forth in Section 9.2(a)(i) (Arising Technology).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.70</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">HFB Background Technology</font>&#8221; has the meaning set forth in Section 9.1 (Background Technology). For clarity, HFB Background Technology includes [*].</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.71</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">HFB Screening Know-How</font>&#8221; means Know-How owned or Controlled by HFB prior to or during the Term relating to HFB&#8217;s [*].</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.72</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">HFB Screening Patent Rights</font>&#8221; means all Patent Rights owned or Controlled by HFB prior to or during the Term claiming, in whole or in part, any HFB Screening Know-How.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.73</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">HFB Screening Technology</font>&#8221; means HFB Screening Know-How and HFB Screening Patent Rights.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.74</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">HFB</font> <font style="font-weight:bold;">Indemnitees</font>&#8221; has the meaning set forth in Section 11.2 (Indemnification by FibroGen).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.75</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;[<font style="font-weight:bold;">*]</font>&#8221; has the meaning set forth in Section 14.1(b) (Dispute Resolution).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.76</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref68119559"></a>&#8220;<font style="font-weight:bold;">IND</font>&#8221; means (a) an Investigational New Drug Application as defined in the United States Federal Food, Drug and Cosmetic Act, as amended (and any successor regulation) (the &#8220;<font style="font-weight:bold;">FD&amp;C Act</font>&#8221;) and applicable regulations promulgated thereunder by the FDA, or (b) an equivalent application or other authority pursuant to the laws and regulations of equivalent Regulatory Authority in any other regulatory jurisdiction, which is necessary to initiate or conduct Clinical Trials of a pharmaceutical or biological product in humans in such jurisdiction.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.77</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Indemnified Party</font>&#8221; has the meaning set forth in Section 11.3 (Indemnification Procedures). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.78</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Indemnifying Party</font>&#8221; has the meaning set forth in Section 11.3 (Indemnification Procedures). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.79</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Initial Technology Transfer</font>&#8221; has the meaning set forth in Section 2.7(a) (Initial Technology Transfer). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.80</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Initiation</font>&#8221; or &#8220;<font style="font-weight:bold;">Initiated</font>&#8221; means, with respect to a Clinical Trial of a product, the first dosing of the first human subject pursuant to the applicable protocol for such Clinical Trial. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.81</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Joint</font> <font style="font-weight:bold;">Arising Know-How</font>&#8221; has the meaning set forth in Section 9.2(a) (Arising Technology).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.82</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Joint</font> <font style="font-weight:bold;">Arising Patent Rights</font>&#8221; has the meaning set forth in Section 9.2(a)(i) (Arising Technology).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.83</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Joint</font> <font style="font-weight:bold;">Arising Technology</font>&#8221; has the meaning set forth in Section 9.2(a)(i) (Arising Technology). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.84</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Joint Steering Committee</font>&#8221; and &#8220;<font style="font-weight:bold;">JSC</font>&#8221; have the meaning set forth in Section 3.2(a) (Formation; Composition). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.85</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Know-How</font>&#8221; means any data, results, and information not generally known to the public of any type whatsoever, in any tangible or intangible form, including trade secrets, practices, techniques, methods, processes, inventions, discoveries, developments, specifications, formulations, formulae, </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>7<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">materials or compositions of matter of any type or kind (patentable or otherwise), software, algorithms, marketing reports, clinical and non-clinical study reports, clinical and non-clinical data, regulatory filings and regulatory submission documents and summaries, technology, test data including pharmacological, biological, chemical, biochemical, toxicological, and clinical test data, analytical and quality control data, stability data, studies and procedures and any other know-how, and any physical embodiments of any of the foregoing</font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.86</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">License Option</font>&#8221; has the meaning set forth in Section 2.9(a) (Grant of Options).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.87</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref58492388"></a><a name="_Ref65086315"></a>&#8220;<font style="font-weight:bold;">Licensed Compound</font>&#8221; means (a) the compound designated by HFB internally as [*], and any other compound Controlled by HFB or its Affiliates that is Directed To Gal-9, (b) after the Option Exercise Date for each Option Program, all compounds that are Directed To the Exclusive Target that is the subject of such Option Program, and (c) any [*] the compounds set forth in the foregoing clause (a) or (b) that is Directed To the applicable Exclusive Target. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.88</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Licensed Know-How</font>&#8221; means [*].</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.89</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref531617418"></a><a name="_Ref65693626"></a>&#8220;<font style="font-weight:bold;">Licensed Patent Rights</font>&#8221; means any and all Patent Rights, [*], Controlled by HFB or any of its Affiliates [*] that are [*] to Exploit any Licensed Compound or Licensed Product in the Field in the Territory, [<font style="font-style:italic;">*</font>]. All Licensed Patent Rights existing [*] are listed on Schedule 1.89 (Existing Patent Rights) (the &#8220;<font style="font-weight:bold;">Existing Patent Rights</font>&#8221;). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.90</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Licensed Product</font>&#8221; means any product that contains a Licensed Compound, alone or in combination with one or more therapeutically active pharmaceutical or biological ingredients, in all forms, presentations, compositions, dosages, and formulations. A Licensed Product will be deemed the same Licensed Product if it contains all the same therapeutically active pharmaceutical or biological ingredients. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.91</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Licensed Program</font>&#8221; means the Gal-9 Licensed Program and, after the Option Exercise Date for each Option Program, the CCR8 Option Program, CXCR5 Option Program, and in the event of the Replacement Option Election, the Replacement Option Program, as applicable, but not a Terminated Licensed Program. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.92</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Licensed Technology</font>&#8221; means Licensed Know-How, Licensed Patent Rights, and HFB&#8217;s and its Affiliates&#8217; interest in the Joint Arising Technology. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.93</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Loss of Market Exclusivity</font>&#8221; means, on a Licensed Product-by-Licensed Product and country-by-country basis, (a) one or more Biosimilar Products for which such Licensed Product is the reference product have obtained Regulatory Approval and are being legally marketed in such country; and (b) such Biosimilar Products sold in such country achieve, on an aggregate basis, at least [*]. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.94</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Major Market Country</font>&#8221; means any one of the following countries: [*].</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.95</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Manufacture</font>&#8221; or &#8220;<font style="font-weight:bold;">Manufacturing</font>&#8221; means activities directed to manufacturing, processing, packaging, labeling, filling, finishing, assembly, quality assurance, quality control, testing, release for distribution, shipping, or storage of any pharmaceutical or biological product (or any components or process steps involving any product or any companion diagnostic), placebo, or comparator agent, as the case may be, including process development, qualification, and validation, scale-up, pre-clinical, clinical, and commercial manufacture and analytic development, product characterization, and stability testing, but excluding activities directed to Development or Commercialization. &#8220;<font style="font-weight:bold;">Manufacturing</font>&#8221; will be construed accordingly.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>8<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.96</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">NDA</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means a New Drug Application submitted to the FDA pursuant to section 505(b)(1) of the FD&amp;C Act, 21 U.S.C. 355(B)(1), and 21 C.F.R.&#167; 314.50 as these provisions may be amended from time-to-time (or its successor statute or regulation), for purposes of obtaining Regulatory Approval for a pharmaceutical product in the United States, or any equivalent filing in a country or regulatory jurisdiction other than the United States.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.97</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Net Sales</font>&#8221; means, with respect to a Licensed Product and [*] </p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the avoidance of doubt, [*] </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the case of any [*]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If, on a country-by-country basis [*]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If, on a country-by-country basis [*<font style="font-size:12pt;">].</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.98</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">New License Agreement</font>&#8221; has the meaning set forth in Section 2.3(b) (Survival of Sublicenses).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.99</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Non-Defaulting Party</font>&#8221; has the meaning set forth in Section 13.3(c) (Disputes Regarding Material Breach).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.100</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref58503295"></a><a name="_Ref65077016"></a>&#8220;<font style="font-weight:bold;">Option Compound</font>&#8221; means (a) any compound Controlled by HFB or its Affiliates Directed To CCR8, (b) any compound Controlled by HFB or its Affiliates Directed To CXCR5, and (c) following the Replacement Option Election, any compound Controlled by HFB or its Affiliates Directed To the Replacement Target. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.101</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref58501435"></a>&#8220;<font style="font-weight:bold;">Option Data Package</font>&#8221; means, with respect to each Option Program, the information and materials set forth on Schedule 1.101 (Option Data Package).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.102</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66189661"></a>&#8220;<font style="font-weight:bold;">Option Exercise Date</font>&#8221; has the meaning set forth in Section 2.9(e) (Exercise of a License Option).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.103</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Option Exercise Notice</font>&#8221; has the meaning set forth in Section 2.9(e) (Exercise of a License Option).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.104</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Option Exercise Payment</font>&#8221; has the meaning set forth in Section 8.2 (Option Exercise Payment).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.105</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Option Know-How</font>&#8221; [*]</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.106</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Option Notice</font>&#8221; has the meaning set forth in Section 2.9(c)(i) (Delivery).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.107</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Option Notice Delivery Date</font>&#8221; has the meaning set forth in Section 10.2 (Representations and Warranties by HFB).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.108</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Option Patent Rights</font>&#8221; has the meaning set forth in Section 10.2(f) (Option Technology).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.109</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Option Product</font>&#8221; means any product that contains an Option Compound, alone or in combination with one or more therapeutically active pharmaceutical ingredients, in all forms, presentations, compositions, dosages, and formulations.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.110</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Option Program</font>&#8221; means the CCR8 Option Program, CXCR5 Option Program, or following the Replacement Option Election, the elected Replacement Option Program, as applicable. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.111</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Option Technology</font>&#8221; means Option Know-How and Option Patent Rights.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.112</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Option Term</font>&#8221; has the meaning set forth in Section 2.9(e) (Exercise of a License Option)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.113</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Other Component</font>&#8221; has the meaning set forth in Section 1.27 (Other Component). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.114</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Party</font>&#8221; and &#8220;<font style="font-weight:bold;">Parties</font>&#8221; have the meaning set forth in the Preamble.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>9<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.115</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Patent Challenge</font>&#8221; means any challenge to the validity or enforceability of a Licensed Patent Right or HFB Screening Patent Right used to generate any Licensed Compound, including by (a)&#160;filing a declaratory judgment action in which the applicable Licensed Patent Right or HFB Screening Patent Right is alleged to be invalid or unenforceable, (b) becoming party to an interference with the applicable Licensed Patent Right or HFB Screening Patent Right pursuant to 35 U.S.C. &#167;135 or (c) filing or commencing any re-examination, opposition, cancellation, nullity or similar proceedings against the applicable Licensed Patent Right or HFB Screening Patent Right, or petitioning for any form of administrative or judicial (or arbitration) review of the applicable Licensed Patent Right or HFB Screening Patent Right, including post-grant review, <font style="font-style:italic;">inter partes</font> review, or opposition proceedings; <font style="font-style:italic;">provided</font> that the term Patent Challenge shall not include a response to a claim or allegation that FibroGen, its Affiliates or Sublicensees infringes or may infringe any Patent Rights owned or Controlled by HFB, any of its Affiliates, or any of their respective successors or assigns, including in <font style="font-style:italic;">inter partes</font>, post grant review proceedings, oppositions, nullity proceedings, reissue proceedings, reexamination proceedings, and other similar proceedings before the U.S. Patent &amp; Trademark Office or other agency or tribunal in any jurisdiction, or in any arbitration or litigation.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.116</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Patent Right</font>&#8221; means (a) any national, regional, or international patent or patent application, including any provisional patent application, (b) any patent application filed either from such a patent, patent application, or provisional application or from an application claiming priority from any of these, including any divisional, continuation, continuation-in-part, provisional, converted provisional, and continued prosecution application, (c) any patent that has issued or in the future issues from any of the foregoing patent applications ((a) and (b)), including any utility model, petty patent, design patent, and certificate of invention, (d) any extension or restoration by existing or future extension or restoration mechanisms, including any revalidation, reissue, re-examination, and extension (including any supplementary protection certificate and the like) of any of the foregoing patents or patent applications ((a), (b), and (c)), and (e) any similar rights, or any importation, revalidation, confirmation or introduction patent, or registration patent or patent of additions to any such foregoing patent application or patent.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.117</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Person</font>&#8221; means any individual, partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, Regulatory Authority, or any other entity not specifically listed in this definition. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.118</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="DocXTextRef121"></a><a name="DocXTextRef120"></a>&#8220;<font style="font-weight:bold;">Phase I Clinical Trial</font>&#8221; <a name="DocXTextRef121"></a>means a clinical trial in humans conducted under an IND that generally provides for the first introduction into humans, whether healthy volunteers or patients, of a pharmaceutical or biological product with the primary objectives of evaluating safety, metabolism, pharmacokinetic properties, or clinical pharmacology of such product, in a manner that is generally consistent with 21<a name="DocXTextRef120"></a> C.F.R. &#167; 312.21(a), as amended (or its successor regulation), or, with respect to any other country or region, the equivalent of such a clinical trial in such other country or region. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.119</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="DocXTextRef123"></a><a name="DocXTextRef122"></a>&#8220;<font style="font-weight:bold;">Phase II Clinical Trial</font><a name="DocXTextRef123"></a>&#8221; means a clinical trial in humans conducted under an IND that is intended to explore the safety, dose ranging, or preliminary efficacy of a pharmaceutical or biological product that is designed to generate sufficient data to commence a Phase III Clinical Trial for a particular indication(s) in patients with the disease or condition for which such product is intended, in a manner that is generally consistent with 21<a name="DocXTextRef122"></a> C.F.R. &#167; 312.21(b), as amended (or its successor regulation), or, with respect to any other country or region, the equivalent of such a clinical trial in such other country or region. Notwithstanding anything to the contrary set forth in this Agreement,<font style="font-style:italic;"> </font>treatment of patients as part of [*]. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>10<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.120</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="DocXTextRef125"></a><a name="DocXTextRef124"></a><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Phase III Clinical Trial</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef125"></a>means a clinical trial in humans of a pharmaceutical or biological product conducted under an IND that is performed to gain evidence with statistical significance of the efficacy of such product for particular indication(s) in patients with the disease or condition for which the product is intended, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of a BLA by a Regulatory Authority and to provide an adequate basis for physician labeling, in a manner that is generally consistent with </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef124"></a> C.F.R. &#167; </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">312.21(c)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, as amended (or its successor regulation), or, with respect to any other country or region, the equivalent of such a clinical trial in such other country or region. Notwithstanding anything to the contrary set forth in this Agreement,</font><font style="font-style:italic;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">treatment of patients as part of </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.121</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Pricing and Reimbursement Approval</font>&#8221; means the later of (a) the approval, agreement, determination, or governmental decision establishing a price for a pharmaceutical or biological product that can be legally charged to consumers, if required in a given jurisdiction or country for the Commercialization of such pharmaceutical or biological product in such jurisdiction or country; and (b) the approval, agreement, determination, or governmental decision establishing the level of reimbursement for a pharmaceutical or biological product that will be reimbursed by governmental authorities, in the case of either (a) or (b) if [*] of such pharmaceutical or biological product in such jurisdiction or country.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.122</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Product Marks</font>&#8221; has the meaning set forth in Section 9.6 (Trademarks). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.123</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Regulatory Approval</font>&#8221; means all approvals necessary for the sale of a product for one or more indications in a country or regulatory jurisdiction, which may include satisfaction of all applicable regulatory and notification requirements. Regulatory Approvals include approvals by Regulatory Authorities of [*], NDAs and BLAs and all [*].</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.124</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Regulatory Authority</font>&#8221; means, in a particular country or regulatory jurisdiction, any applicable governmental authority involved in granting Regulatory Approval or, to the extent required in such country or regulatory jurisdiction, Pricing and Reimbursement Approval of a product in such country or regulatory jurisdiction.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.125</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Regulatory Exclusivity</font>&#8221; means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a Licensed Product other than Patent Rights, including rights conferred in the U.S. under the FD&amp;C Act, the Public Health Service Act, and the Biologics Price Competition and Innovation Act, including pediatric exclusivity and orphan drug exclusivity, or rights similar thereto outside the U.S.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.126</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Regulatory Materials</font>&#8221; means regulatory applications, submissions, notifications, registrations, or other filings made to or with a Regulatory Authority, and documents and records required by such Regulatory Authority to be maintained or held for inspection, that are necessary in order to Develop, Manufacture, market, sell, or otherwise Commercialize a Licensed Compound or Licensed Product in a particular country or regulatory jurisdiction. Regulatory Materials include INDs, NDAs and BLAs (as applications, but not the approvals with respect thereto).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.127</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Replacement Option Election</font>&#8221; has the meaning set forth in Section 2.9(g)(i) (In Connection with FibroGen Non-Exercise). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.128</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Replacement Option Program</font>&#8221; has the meaning set forth in Section 2.9(g) (Replacement Option Program).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.129</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Replacement Target</font>&#8221; has the meaning set forth in Section 2.9(g) (Replacement Option Program).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.130</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Royalty</font>&#8221; has the meaning set forth in Section 8.4 (Royalties). </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>11<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.131</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Royalty and Net Sales Report</font>&#8221; has the meaning set forth in Section 8.4(b) (Reports; Payment).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.132</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Royalty Term</font>&#8221; means, on a country-by-country and Licensed Product-by-Licensed Product basis, the period commencing upon the First Commercial Sale of a Licensed Product in a country, and ending upon the later to occur of (a) the expiration in such country of the last to expire of any Valid Claim of a [*] of the Licensed Compound contained in such Licensed Product in such country; (b) [*] after the First Commercial Sale in such country of such Licensed Product; or (c) expiration of [*] for such Licensed Product in such country.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.133</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:11pt;">[</font><font style="font-weight:bold;font-size:11pt;">*</font><font style="font-size:11pt;">].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.134</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">SEC</font>&#8221; has the meaning set forth in Section 12.2(b) (Disclosure to SEC).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.135</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Standby Letter</font>&#8221; has the meaning set forth in Section 2.1 (License to FibroGen).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.136</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Sublicense Revenue</font>&#8221; means, non-refundable sublicense upfront fees and sublicense milestone payments made by Sublicensees to FibroGen or any of its Affiliates in consideration of a grant of a sublicense under the rights licensed to FibroGen pursuant to Article 2 (Licenses and Exclusivity) hereof. Notwithstanding the foregoing, and for the avoidance of doubt, it is understood and agreed that Sublicense Revenue shall exclude (a) royalties, (b) amounts received from any Third Party for the purchase of equity (except for equity premiums), reimbursement for research and development performed by FibroGen or by FibroGen&#8217;s subcontractor or delegates (specifically designated in a plan for research and/or development by its agreement with Sublicensee) or by Sublicensee, (c) [*], debt financing, (d) reimbursement for patent costs or other patent related expenses, and (e) [*], (f) [*], and (g)[*].</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.137</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="6736-2-MO-01_PB_3_191933_5335"></a>&#8220;<font style="font-weight:bold;">Sublicensee</font>&#8221; means any Third Party granted a sublicense by FibroGen under the rights licensed to FibroGen pursuant to Article 2 (Licenses and Exclusivity) hereof.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.138</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Technology Transfer</font>&#8221; has the meaning set forth in Section 2.7(b) (Continuing Technology Transfer).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.139</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Term</font>&#8221; has the meaning set forth in Section 13.1 (Term). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.140</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Territory</font>&#8221; means all countries of the world and all territories and possessions thereof.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.141</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Termination for Convenience Notice Period</font>&#8221; has the meaning set forth in Section 13.2 (Termination by FibroGen).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.142</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Terminated Licensed Product</font>&#8221; has the meaning set forth in Section 13.6 (Effects of Termination).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.143</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Terminated Licensed Program</font>&#8221; has the meaning set forth in Section 13.2 (Termination by FibroGen).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.144</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Third Party</font>&#8221; means any entity other than HFB or FibroGen or their respective Affiliates.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.145</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Third Party License</font>&#8221; has the meaning set forth in Section 2.6 (Third Party In-Licenses).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.146</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">United States</font>&#8221; or &#8220;<font style="font-weight:bold;">U.S.</font>&#8221; means the United States of America and all of its territories and possessions. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.147</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Upfront Payment</font>&#8221; has the meaning set forth in Section 8.1 (Upfront Payment). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.148</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref70341149"></a>&#8220;<font style="font-weight:bold;">Upstream License</font>&#8221; means any of that certain Sub-License Agreement [*]. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.149</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Upstream License Costs</font>&#8221; has the meaning set forth in Section 8.6 (Upstream License Costs).</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>12<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.150</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="DocXTextRef145"></a><a name="DocXTextRef146"></a>&#8220;<font style="font-weight:bold;">Valid Claim</font>&#8221; <a name="DocXTextRef145"></a>means a claim of (a) an issued, unexpired, and in-force patent, which claim has not been held invalid or unenforceable by a court or other government agency of competent jurisdiction from which no appeal can be or has been taken and has not been held or admitted to be invalid or unenforceable through re-examination, <font style="font-style:italic;">inter partes </font><a name="DocXTextRef146"></a>review, post grant review or disclaimer, opposition procedure, nullity suit, or otherwise, or (b) a pending patent application that has not been finally abandoned, finally rejected, or expired; <font style="font-style:italic;">provided</font>,<font style="font-style:italic;"> however</font>, that if a claim of a pending patent application has not issued [*] after the first substantive patent office action considering the patentability of such claim, then such claim will not constitute a Valid Claim for the purposes of this Agreement unless and until a patent issues with such claim.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.151</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">VAT</font>&#8221; has the meaning set forth in Section 8.8(e) (VAT).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.152</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&#8220;<font style="font-weight:bold;">Work Plan</font>&#8221; has the meaning set forth in Section 4.2 (Work Plans).</p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;color:#010000;font-family:Times New Roman Bold;text-transform:uppercase;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref24725935"></a><a name="_Ref24725956"></a><a name="_Toc74552546"></a><a name="_Toc74553428"></a>Article 2<font style="color:#000000;font-family:Times New Roman;text-transform:none;"><br /><a name="_Ref24725935"></a><a name="_Ref24725956"></a><a name="_Toc74552546"></a><a name="_Toc74553428"></a>LICENSES AND EXCLUSIVITY</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref24719038"></a><a name="_Ref46577924"></a><a name="_Ref46593611"></a><a name="_Ref46773276"></a><a name="_Ref54433198"></a><a name="_Ref70059430"></a><a name="_Ref72504970"></a><a name="_Ref73526091"></a><a name="_Toc74552547"></a><a name="_Toc74553429"></a><a name="_Ref22234111"></a><a name="_Ref401172460"></a><a name="_Ref24725864"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">License to <a name="_Ref24725864"></a>FibroGen</font><font style="Background-color:#FFFFFF;font-size:12pt;">. Subject to the terms and conditions of this Agreement, HFB hereby grants to FibroGen an exclusive (even as to HFB and each of its Affiliates), transferable (as permitted in accordance with Section 15.6 (Assignment)) license, with the right to sublicense (as permitted in accordance with Section&#160;2.3 (Sublicensing)), under the Licensed Technology, to Exploit the Licensed Compounds and Licensed Products in the Field in the Territory. FibroGen acknowledges that, subject to and except as set forth in the Standby Letter entered into contemporaneously with this Agreement by and among FibroGen, HFB and [*] (the &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;font-size:12pt;">Standby Letter</font><font style="Background-color:#FFFFFF;font-size:12pt;">&#8221;), termination of the Upstream License will result in the automatic termination of the license under this Section 2.1 (License to FibroGen) with respect to the Licensed Patent Rights that are licensed to HFB under the Upstream License. FibroGen may, within [*] of termination of the Upstream License, provide written notice to [*] of its willingness to continue Exploiting Licensed Products. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552548"></a><a name="_Toc74553430"></a><a name="_Ref47444955"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">License to HFB</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Subject to the terms and conditions of this Agreement, FibroGen hereby grants to HFB, a non-exclusive, non-transferable (except as permitted</font><font style="Background-color:#FFFFFF;font-size:12pt;"> </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">as permitted in accordance with Section 15.6 (Assignment)) license, with no right to sublicense, under the Licensed Technology, solely to perform the Development activities that are allocated to HFB under each Work Plan, provided that HFB shall have the right to subcontract Development activities as permitted in Section 2.4 (Subcontractors). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552549"></a><a name="_Toc74553431"></a><a name="_Ref65692115"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Sublicensing</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref527619"></a><a name="_Ref66456261"></a><font style="font-weight:bold;color:#000000;">Sublicensing Rights</font><font style="color:#000000;">. </font><font style="color:#000000;">FibroGen may grant sublicenses of the rights granted to it under Section&#160;2.1 (License to FibroGen) through multiple tiers to any of its Affiliates and to one or more Sublicensees. Within [*] of entering into any sublicense, FibroGen shall provide a fully-executed copy of such sublicense; </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;"> that FibroGen may redact confidential terms of such sublicense that are not necessary for HFB to monitor compliance with the terms and conditions of this Agreement. <a name="_Ref527619"></a><a name="_Ref66456261"></a>[*]</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref70159398"></a><a name="_9kMI3J6ZWu8GDCDB"></a><a name="_Ref46568269"></a><font style="font-weight:bold;color:#000000;"><a name="_9kMI3J6ZWu8GDCDB"></a>Survival of Sublicenses</font><font style="color:#000000;">. Upon termination of this Agreement for any reason, for each Sublicensee not then in breach of its sublicense agreement or the terms of this Agreement applicable to such Sublicensee, HFB will enter into a direct license with such Sublicensee on the same applicable terms as this Agreement, taking into account any difference in </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>13<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">license scope, territory, and duration of sublicense grant (each a &#8220;</font><font style="font-weight:bold;color:#000000;">New License Agreement</font><font style="color:#000000;">&#8221;). Under any New License Agreement between HFB and such former Sublicensee, </font><font style="color:#000000;">HFB will not have any obligations under the New License Agreement beyond the obligations contained in this Agreement, </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;"> that HFB will receive the same amounts in consideration under a New License Agreement as HFB would have otherwise received from </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"><a name="_Ref46568269"></a> pursuant to this Agreement based on the former Sublicensee&#8217;s Exploitation of the Licensed Products.</font><font style="font-weight:bold;font-style:italic;color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref65141317"></a><a name="_Ref67933675"></a><a name="_Toc74552550"></a><a name="_Toc74553432"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Subcontractors</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Each Party may perform any of its obligations under this Agreement through one or more subcontractors; </font><font style="font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:12pt;">provided</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> that (a) the subcontracting Party will not engage any subcontractor that has been debarred by any Regulatory Authority; (b) the subcontracting Party remains fully responsible for the work allocated to, and payment to, such subcontractors to the same extent it would if it had done such work itself; (c) the subcontractor undertakes in writing obligations of confidentiality and non-use applicable to the Confidential Information that are at least as stringent as those set forth in Article 12 (Confidentiality); (d) the subcontractor agrees in writing to assign or grant a sublicensable license to the subcontracting Party to all Know-How and Patent Rights developed or invented by the subcontractor that are necessary or reasonably useful to Develop, Manufacture, or Commercialize any Licensed Compound or Licensed Product; and (e) the subcontracting Party will be liable for any act or omission of any subcontractor that is a breach of any of the subcontracting Party&#8217;s obligations under this Agreement as though the same were a breach by the subcontracting Party, and the non-subcontracting Party will have the right to proceed directly against the subcontracting Party without any obligation to first proceed against such subcontractor.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552551"></a><a name="_Toc74553433"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">No Implied Licenses; Retained Rights</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Except as explicitly set forth in this Agreement, neither Party grants to the other Party any license or other rights, express or implied, under any intellectual property rights (whether by implication, estoppel, or otherwise). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46660666"></a><a name="_Ref46588531"></a><a name="_Ref46589181"></a><a name="_Toc74552552"></a><a name="_Toc74553434"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Third Party In-Licenses</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. During the Term, if either Party identifies any Patent Right or Know-How owned or controlled by a Third Party that it reasonably believes may be necessary or reasonably useful to Exploit any Licensed Compound in the Field in the Territory, or absent a license or agreement with such Third Party to such intellectual property, would be infringed by the Exploitation of any Licensed Compound in the Field in the Territory (&#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">Additional Third Party IP</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">&#8221;), then it will so notify the other Party. As between the Parties, [*], to enter into an agreement with a Third Party to obtain a license, covenant not to sue, or other similar rights under any such Additional Third Party IP within the Territory (a &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">Third Party License</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">&#8221;). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref67828112"></a><a name="_Toc74552553"></a><a name="_Toc74553435"></a><a name="_Ref404365909"></a><a name="_Ref404929756"></a><a name="_Ref259817415"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Technology Transfer</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66181875"></a><a name="_Ref25047767"></a><font style="font-weight:bold;color:#000000;">Initial Technology Transfer</font><font style="color:#000000;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66186121"></a><font style="text-decoration:underline;color:#000000;">Gal-9 Licensed Program</font><font style="color:#000000;">. Within [*] and in accordance with the Technology Transfer plan to be agreed by the JSC and thereafter automatically deemed to be attached hereto as Schedule 2.7(a) (Initial Technology Transfer), HFB will transfer to FibroGen </font><font style="color:#000000;">or, at FibroGen&#8217;s direction, a</font><font style="color:#000000;"> CMO designated by FibroGen (a &#8220;</font><font style="font-weight:bold;color:#000000;">FibroGen CMO</font><font style="color:#000000;">&#8221;),</font><font style="color:#000000;"> </font><font style="color:#000000;">electronic copies of all material documents, data (including </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>14<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">Manufacturing process data), regulatory correspondence, clinical and pre-clinical data, or other Know-How included within the Licensed Know-How existing as of the Effective Date, including but not limited to documents</font><font style="Background-color:#FFFFFF;"> and information (including any </font><font style="color:#000000;">CMC records and information), data (including Manufacturing process data), other Licensed Know-How, or activities, in each case, that are in the possession of HFB, its Affiliates or subcontractors and necessary or </font><font style="color:#000000;">reasonably </font><font style="color:#000000;">useful to Exploit and Manufacture Licensed Compounds and Licensed Products Directed To Gal-9 and to enable </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> or such </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> CMO to assume the Manufacturing activities of the Licensed Compounds and Licensed Products Directed To Gal-9.</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;color:#000000;">Other Licensed Programs</font><font style="color:#000000;">. With respect to any Licensed Program other than the Gal-9 Licensed Program, within [*] with respect to such Licensed Program and in accordance with a plan to be agreed between the Parties no later than [*], HFB will transfer to FibroGen</font><font style="color:#000000;"> and/or, at FibroGen&#8217;s direction,</font><font style="color:#000000;"> a FibroGen CMO, electronic copies of all material documents, data, regulatory correspondence, clinical and pre-clinical data, or other Know-How included within the Licensed Know-How with respect to such Licensed Program existing as of the applicable Option Exercise Date, including but not limited to any documents and information (including any CMC records and information), data (including Manufacturing process data), other Licensed Know-How, or activities, in each case, that are in the possession of HFB, its Affiliates or subcontractors and necessary or </font><font style="color:#000000;">reasonably </font><font style="color:#000000;">useful to Exploit and Manufacture Licensed Compounds and Licensed Products for such Licensed Program and to enable FibroGen or such FibroGen CMO to assume the Manufacturing activities of Licensed Compounds and Licensed Products for such Licensed Program (the transfer described in the foregoing clauses (i) and (ii) with respect to each Licensed Program, the &#8220;</font><font style="font-weight:bold;color:#000000;">Initial Technology Transfer</font><font style="color:#000000;">&#8221;). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref24715794"></a><a name="_Ref68770174"></a><a name="_Ref68770202"></a><a name="_Ref24715701"></a><font style="font-weight:bold;color:#000000;">Continuing Technology Transfer</font><font style="color:#000000;">. [*], HFB will promptly notify FibroGen of and transfer to FibroGen or, at FibroGen&#8217;s direction, to a FibroGen CMO (if applicable to the Manufacture of Licensed Products) any additional documents, data or other Licensed Know-How, in each case, that is in HFB&#8217;s possession or Control and has not been previously transferred to FibroGen or a FibroGen CMO and is necessary or reasonably useful to Exploit and Manufacture Licensed Compounds and Licensed Products for such Licensed Program (the &#8220;</font><font style="font-weight:bold;color:#000000;">Continuing Technology Transfer</font><font style="color:#000000;">,&#8221; and together with the Initial Technology Transfer, the &#8220;</font><font style="font-weight:bold;color:#000000;">Technology Transfer</font><font style="color:#000000;">&#8221;). Notwithstanding anything to the contrary in this Section 2.7(b), [*] HFB will provide to FibroGen or its designee any documents, data or other Licensed Know-How, in each case, that is in HFB&#8217;s possession or Control and has not been previously transferred to FibroGen and [*].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46592750"></a><font style="font-weight:bold;color:#000000;">Technical Assistance and Consultation; Costs of Technology Transfer</font><font style="color:#000000;">. HFB will reasonably cooperate with FibroGen to facilitate the Technology Transfer to FibroGen or a FibroGen CMO (as applicable). In the course of any Technology Transfer, HFB will provide FibroGen or the applicable FibroGen CMO [*] involved in the Development or Manufacture of the Licensed Compounds to provide FibroGen or the FibroGen CMO with a reasonable level of technical assistance and consultation in connection with all Technology Transfers. [*] </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref535945138"></a><a name="_Ref56633300"></a><a name="_9kR3WTr7GBBIHOFwynmBH1kp1BJ445p4JF2r37"></a><a name="_9kR3WTr7GDFJEMFwynmBH1kp1BJ4"></a><a name="_9kR3WTr7GE7CEKFwynmBH1kp1BJ4"></a><a name="_9kR3WTr7GCBHF47sstds73qfrv"></a><a name="_9kR3WTr7GCBHG57suykm0Ay0Czn3ADASXED6CB3"></a><a name="_9kR3WTr5DCDDF85nk3wjw"></a><a name="_9kR3WTr5DCDDG95nk3wjw"></a><a name="_9kR3WTr269CB9eOr7v0ZL24tsHN"></a><font style="font-weight:bold;color:#000000;">Third Party Vendors or Contractors</font><font style="color:#000000;">. On a Licensed Program-by-Licensed Program basis, at FibroGen&#8217;s<a name="_9kR3WTr7GBBIHOFwynmBH1kp1BJ445p4JF2r37"></a> request<a name="_9kR3WTr7GDFJEMFwynmBH1kp1BJ4"></a><a name="_9kR3WTr7GE7CEKFwynmBH1kp1BJ4"></a>, <a name="_9kR3WTr7GCBHF47sstds73qfrv"></a><a name="_9kR3WTr7GCBHG57suykm0Ay0Czn3ADASXED6CB3"></a>HFB will use Commercially Reasonable Efforts to<a name="_9kR3WTr5DCDDF85nk3wjw"></a><a name="_9kR3WTr5DCDDG95nk3wjw"></a> transfer to </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>15<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> HFB&#8217;s</font><font style="color:#000000;"> relationships with Third Party vendors and contractors that HFB has engaged in the Development or Manufacture of Licensed Compounds and, if any, Licensed Products, by, at </font><font style="color:#000000;">FibroGen&#8217;s</font><font style="color:#000000;"> request, introducing </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> to such vendors or contractors. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46563471"></a><a name="_Ref68869033"></a><a name="_Toc74552554"></a><a name="_Toc74553436"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Exclusivity</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46589679"></a><a name="_Ref66813683"></a><a name="_Ref46491659"></a><font style="font-weight:bold;color:#000000;">Exclusivity Covenant</font><font style="color:#000000;">. Subject to Section 2.8(b) (HFB Change of Control), Section 2.8(c) (FibroGen Change of Control) and Section 2.8(d) (</font><font style="color:#000000;">Acquisition by Either Party)</font><font style="color:#000000;">, during the Term, the Parties will not, and will ensure that its Affiliates do not, independently, or for or with any Third Party, directly or indirectly, Develop, Manufacture, or Commercialize any Competitive Product in the Territory (or license or otherwise authorize any Third Party to do any of the foregoing) (the &#8220;</font><font style="font-weight:bold;color:#000000;">Competitive Activities</font><font style="color:#000000;">&#8221;) unless agreed in writing by the Parties. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46490617"></a><a name="_Ref46590254"></a><a name="_Ref46490627"></a><a name="_Ref46492473"></a><font style="font-weight:bold;color:#000000;">HFB Change of Control</font><font style="color:#000000;">. If HFB or any of its Affiliates undergoes a Change of Control with a Third Party, and such Third Party is (either directly or through an Affiliate, or in collaboration with another Third Party) [*], then </font><font style="color:#000000;">it will not be in breach of the restrictions set forth in Section 2.8(a) (Exclusivity Covenant) due to such Change of Control with such a Third Party, and such Third Party may [*] (ii) HFB and its Affiliates institute [*] technical and administrative safeguards to ensure the requirements set forth in the foregoing clause (i) are met, [*]<a name="_Ref46490627"></a><a name="_Ref46492473"></a>.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref68772121"></a><a name="_Ref48639355"></a><font style="font-weight:bold;color:#000000;">FibroGen Change of Control</font><font style="color:#000000;">. If FibroGen or any of its Affiliates undergoes a Change of Control</font><font style="color:#000000;font-size:12pt;"> </font><font style="color:#000000;">with a Third Party, and such Third Party is (either directly or through an Affiliate, or in collaboration with another Third Party) [*], and:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_cp_text_1_102"></a><a name="_cp_text_1_104"></a><a name="_cp_text_1_106"></a><font style="color:#000000;">[*], such Competitive Products [*], then it will not be in breach of the restrictions set forth in Section 2.8(a) (Exclusivity Covenant) due to such Change of Control with such a Third Party, and such Third Party may continue to [*]<a name="_cp_text_1_102"></a> after such Change of Control; as long as: (x) [*]<a name="_cp_text_1_104"></a> and (y) FibroGen and its Affiliates institute [*]<a name="_cp_text_1_106"></a> technical and administrative safeguards to ensure the requirements set forth in the foregoing clause (x) are met, including [*]; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref57798122"></a><a name="_cp_text_1_108"></a><a name="_cp_text_1_112"></a><a name="_cp_text_1_114"></a><a name="_cp_text_1_115"></a><font style="color:#000000;">[*], then it will not be in breach of the restrictions set forth in Section 2.8(a)<a name="_cp_text_1_108"></a> (Exclusivity Covenant) due to such Change of Control with such a Third Party if it does one of following: (x) [*]. FibroGen<a name="_cp_text_1_112"></a> will notify HFB of its intent to select option (x<a name="_cp_text_1_114"></a>) or (y<a name="_cp_text_1_115"></a>) within [*] of such closing of the Change of Control.&nbsp;&nbsp;Until the divestiture or termination is complete, FibroGen shall ensure that (A) [*], and (B) FibroGen and its Affiliates institutes [*] technical and administrative safeguards to ensure the requirements set forth in the foregoing clause (A) are met, including [*].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_cp_blt_1_116"></a><a name="_cp_text_1_117"></a><font style="color:#000000;">For clarity, the same stage of Development means with respect to the Competitive Product and the applicable Licensed Compound or Licensed Product: [*]. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_cp_text_1_119"></a><font style="font-weight:bold;color:#000000;">Acquisition by Either Party</font><font style="color:#000000;">. If either Party or any of its Affiliates merges or consolidates with, or otherwise acquires a Third Party (whether such transaction occurs by way of a sale of assets, merger, consolidation, or similar transaction), and at such time such Third Party is [*] or is engaged in activities that would otherwise constitute a breach of Section 2.8(a) (Exclusivity Covenant), then such Party will not be in breach of Section 2.8(a) (Exclusivity Covenant) if it does one of following: (i) divests, or cause its relevant Affiliates to divest, </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>16<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">whether by sale, assignment, exclusive license or otherwise, its interest in such </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> or (ii) terminates any further Competitive Activities with respect to such </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"><a name="_cp_text_1_119"></a>.&nbsp;&nbsp;Until the divestiture or termination is complete, the acquiring Party shall </font><font style="color:#000000;">ensure </font><font style="color:#000000;">that (A) </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">, and (B) such Party and its Affiliates institutes </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> technical and administrative safeguards to ensure the requirements set forth in the foregoing clause (A) are met, </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.9</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref74129615"></a><a name="_Toc74552555"></a><a name="_Toc74553437"></a><font style="font-weight:bold;text-decoration:none;">FibroGen License Options</font><font style="font-weight:bold;Background-color:#FFFFFF;font-size:12pt;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref70709073"></a><a name="_Ref67918072"></a><a name="_Ref57922207"></a><font style="font-weight:bold;color:#000000;">Grant of Options</font><font style="color:#000000;">. HFB hereby grants FibroGen, on an Option Program-by-Option Program basis, the exclusive option during the Option Term for each Option Program to obtain an exclusive license to Exploit the Option Compound and Option Products that are the subject of each Option Program in the Field in the Territory (for each Option Program, a &#8220;License Option&#8221;). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref70709786"></a><a name="_Ref66779195"></a><a name="_Ref48523823"></a><font style="font-weight:bold;color:#000000;">Data Sharing</font><font style="color:#000000;">. During [*], to assist FibroGen in conducting thorough due diligence to decide whether to exercise the License Option for such Option Program, HFB will provide all material data and results in the possession of HFB, its Affiliates or subcontractors from non-clinical and pre-clinical studies for Option Compounds that are the subject of each Option Program as soon as reasonably practicable [*]. In addition, [*], HFB will provide a summary of all material data and results in the possession of HFB, its Affiliates or subcontractors from all non-clinical and pre-clinical studies for Option Compounds for each Option Program. If reasonably requested by FibroGen, HFB will provide to FibroGen and its representatives an [*] in connection with JSC meetings or more frequently as mutually agreed by the Parties. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref70528615"></a><a name="_Ref66779500"></a><font style="font-weight:bold;color:#000000;">Option Notice</font><font style="color:#000000;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66780767"></a><a name="_Ref58962078"></a><a name="_Ref48682438"></a><font style="font-weight:bold;color:#000000;">Delivery</font><font style="color:#000000;">. On an Option Program-by-Option Program basis, HFB will deliver to FibroGen [*], and with respect to any Replacement Option Program, [*] pursuant to Section 2.9(g)(ii) (Replacement Option Program Election) (collectively, for each Option Program, an &#8220;</font><font style="font-weight:bold;color:#000000;">Option Notice</font><font style="color:#000000;">&#8221;):<a name="_Ref48682438"></a> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.08%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(A)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66818293"></a><font style="color:#000000;">the Option Data Package for such Option Program, which shall include the information and materials identified in Schedule 1.101 (Option Data Package) whether or not such information and materials have been previously provided to FibroGen pursuant to Section 2.9(b) (Data Sharing);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.08%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(B)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">electronic copies of all submitted filings to a patent office related to the filing, prosecution and maintenance of any Option Patent Rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.08%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(C)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref72329635"></a><font style="color:#000000;">a Disclosure Letter for such Option Program; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.08%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(D)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref70002021"></a><font style="color:#000000;">a proposed [*] pursuant to Section 4.2 (Work Plans) for such Option Program; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.08%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(E)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">a list of all Third Party vendors and contractors that HFB has engaged in the conduct of Development or Manufacturing activities for such Option Program; and</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>17<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.08%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(F)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46432986"></a><a name="_Ref47104636"></a><a name="_Ref65668009"></a><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">, the provided information is accurate, and a statement that subject to the disclosures contained in the Disclosure Letter for such Option Program, the representations and warranties of HFB set forth in Section&#160;</font><font style="color:#000000;">10.2</font><font style="color:#000000;"> (Representations and Warranties of HFB) are </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> with respect to such Option Program </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"><a name="_Ref46432986"></a><a name="_Ref47104636"></a><a name="_Ref65668009"></a>.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Additional Information</font><font style="color:#000000;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.08%;white-space:nowrap">
<p style="margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(A)</font></p></td>
<td valign="top">
<p style="margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66779902"></a><font style="color:#000000;">For [*] following receipt of an Option Notice for an Option Program, FibroGen will have the right to reasonably discuss and request that HFB provide additional data and information pursuant to Section 2.9(c)(i) (Delivery) in its possession with respect to such Option Program. Within [*] following FibroGen&#8217;s request, HFB will provide FibroGen with such additional data and information. For clarity, the Option Term with respect to each Option Program will expire [*].</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.08%;white-space:nowrap">
<p style="margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(B)</font></p></td>
<td valign="top">
<p style="margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66261728"></a><font style="color:#000000;">During [*], upon FibroGen&#8217;s request, HFB will provide to FibroGen and its representatives [*], in each case, as FibroGen may reasonably request related to such Option Program to conduct customary and reasonable due diligence of such Option Program.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref70508579"></a><font style="font-weight:bold;color:#000000;">FibroGen Option Decision</font><font style="color:#000000;">. If FibroGen makes a final decision not to exercise a License Option for a given Option Program, FibroGen will provide notice to HFB within [*] of such decision and such option shall terminate pursuant to Section 2.9(f) (Termination of a License Option).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552556"></a><a name="_Ref46691172"></a><font style="font-weight:bold;text-decoration:underline;color:#000000;">Restrictions</font><font style="color:#000000;">. During [*], other than with the prior written consent of (i) FibroGen, which may be withheld in its sole discretion, HFB will not grant to any Third Party any right to Exploit any Option Compound that is the subject of such Option Program in a manner that would conflict with the License Option granted to FibroGen<a name="_Ref46691172"></a> hereunder and (ii) HFB, which may be withheld in its sole discretion, FibroGen and its Affiliates will not engage in any [*] that would conflict with the exclusivity set forth in Section 2.8 (Exclusivity), with respect to such Option Program or the rights granted to FibroGen if FibroGen were to exercise such License Option. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref65266783"></a><a name="_Ref65153703"></a><font style="font-weight:bold;color:#000000;">Exercise of a License Option</font><font style="color:#000000;">. FibroGen may exercise the License Option for a given Option Program [*] following delivery of an Option Notice with respect to such Option Program, or that the Parties mutually agree upon (the &#8220;</font><font style="font-weight:bold;color:#000000;">Option Term</font><font style="color:#000000;">&#8221;), by (i) providing HFB with written notice of its exercise with respect thereto (each, an &#8220;</font><font style="font-weight:bold;color:#000000;">Option Exercise Notice</font><font style="color:#000000;">&#8221;) and (ii) paying to HFB the applicable Option Exercise Payment set forth in Section 8.2 (Option Exercise Payment) [*]. From and after the Option Exercise Date for an Option Program, all Option Compounds and Option Products that are the subject of such Option Program will thereafter become Licensed Compounds and Licensed Products, as applicable, for all purposes under this Agreement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552557"></a><a name="_Ref65153954"></a><a name="_Ref57917530"></a><a name="_Ref57797411"></a><font style="font-weight:bold;text-decoration:underline;color:#000000;">Termination of Option</font><font style="color:#000000;">.</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">If FibroGen (i) provides written notice to HFB pursuant to Section 2.9(c)(iii) (FibroGen Option Decision) or (ii) does not provide an Option Exercise Notice prior to the expiration of the Option Term, in each case, in respect of a given Option Program, then FibroGen&#8217;s right to exercise the License Option for such Option Program will terminate. Following termination of any Option Program, including pursuant to </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>18<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">Section </font><font style="color:#000000;">13.2</font><font style="color:#000000;"> (Termination by </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;">) or </font><font style="color:#000000;">13.3(b)</font><font style="color:#000000;"> (By HFB), HFB will have no further obligations to </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> with respect to such Option Program and this Agreement will terminate with respect to such Option Program, including all Option Compounds and Option Products.</font><font style="color:#000000;"><a name="_Ref57917530"></a><a name="_Ref57797411"></a> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66989219"></a><a name="_Ref65153680"></a><a name="_Ref65156475"></a><a name="_Ref65160290"></a><a name="_Ref65677917"></a><font style="font-weight:bold;color:#000000;">Replacement Option Program</font><font style="color:#000000;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66784275"></a><a name="_Ref67945640"></a><a name="_Ref66784279"></a><a name="_Ref66893321"></a><a name="_Ref67036851"></a><a name="_Ref66989224"></a><font style="font-weight:bold;color:#000000;">In Connection with FibroGen Non-Exercise</font><font style="color:#000000;">. Notwithstanding Section 2.9(f) (Termination of Option), if FibroGen, in its sole discretion, elects not to provide an Option Exercise Notice with respect to either the CCR8 Option Program or the CXCR5 Option Program, then upon FibroGen&#8217;s written request prior to the expiration of the later of the CXCR5 Option Term or CCR8 Option Term (&#8220;</font><font style="font-weight:bold;color:#000000;">Replacement Option Election</font><font style="color:#000000;">&#8221;), the Parties will work in good faith to identify one additional program of a [*] that is Controlled by HFB or its Affiliates for inclusion as an Option Program under this Agreement. For clarity, FibroGen may elect [*] for inclusion as an Option Program under this Agreement pursuant to this Section 2.9(g)(i) (FibroGen Non-Election) [*]<a name="_Ref66784279"></a><a name="_Ref66893321"></a><a name="_Ref67036851"></a><a name="_Ref66989224"></a>.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref68773351"></a><font style="font-weight:bold;color:#000000;">Replacement Option Program Election</font><font style="color:#000000;">. Any program identified by the Parties pursuant to Section 2.9(g)(i) (FibroGen Non-Election) and elected by FibroGen pursuant to the Replacement Option Election for inclusion as an Option Program under this Agreement will automatically become an Option Program for all purposes under this Agreement (each such Option Program, a &#8220;</font><font style="font-weight:bold;color:#000000;">Replacement Option Program</font><font style="color:#000000;">&#8221;, and the target to which any compounds or products under such program are directed, a &#8220;</font><font style="font-weight:bold;color:#000000;">Replacement Target</font><font style="color:#000000;">&#8221;).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_cp_field_47_122"></a><font style="font-weight:bold;color:#000000;">[*] HFB Screening Technology</font><font style="color:#000000;"><a name="_cp_field_47_122"></a>. Notwithstanding anything in this Section 2.9 (FibroGen License Options) or otherwise in this Agreement to the contrary, after the Effective Date, [*], any HFB Screening Know-How, HFB Screening Patent Rights, or any Confidential Information relating thereto.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;color:#010000;font-family:Times New Roman Bold;text-transform:uppercase;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref401866397"></a><a name="_Ref431733404"></a><a name="_Ref431733831"></a><a name="_Ref45121083"></a><a name="_Toc74552558"></a><a name="_Toc74553438"></a>Article 3<font style="color:#000000;font-family:Times New Roman;text-transform:none;"><br /><a name="_Ref401866397"></a><a name="_Ref431733404"></a><a name="_Ref431733831"></a><a name="_Ref45121083"></a><a name="_Toc74552558"></a><a name="_Toc74553438"></a>GOVERNANCE</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46593711"></a><a name="_Ref401866069"></a><a name="_Toc74552559"></a><a name="_Toc74553439"></a><a name="_Ref401173223"></a><a name="_Ref359242852"></a><font style="font-weight:bold;text-decoration:none;">Alliance Manager</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"><a name="_Ref359242852"></a>. Within [*] of the Effective Date, each Party will appoint an individual (from the Party or from any Affiliate of such Party) who possesses a general understanding of Development issues regarding pharmaceutical and biological products to act as the facilitator of the meetings of the JSC and the first point of contact between the Parties with regard to questions relating to this Agreement or the overall business relationship and related matters between the Parties (each, an &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">Alliance Manager</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">&#8221;). Each Party may replace its Alliance Manager at any time upon written notice to the other Party. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref405396512"></a><a name="_Ref46590301"></a><a name="_Toc74552560"></a><a name="_Toc74553440"></a><font style="font-weight:bold;text-decoration:none;">Joint Steering Committee</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref401172343"></a><a name="_Ref65691363"></a><a name="_Ref46594947"></a><a name="_DV_M187"></a><font style="font-weight:bold;color:#000000;">Formation; Composition</font><font style="color:#000000;">. No later than after [*] after the Effective Date, the Parties will establish a joint steering committee (the &#8220;</font><font style="font-weight:bold;color:#000000;">Joint Steering Committee</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;color:#000000;">JSC</font><font style="color:#000000;"><a name="_DV_M187"></a>&#8221;) comprised of an equal number of representatives from each Party (or appointed representatives of any Affiliate of such Party) with sufficient seniority within the applicable Party to make decisions arising within the scope of the JSC&#8217;s responsibilities. The JSC may change its size from time to time by mutual consent of its members, </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;"> that the JSC</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>19<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">will consist at all times of an equal number of representatives of each of HFB and </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;">. Each Party may replace its JSC representatives at any time upon written notice to the other Party. If agreed by the JSC on a case-by-case basis, the JSC may invite non-members to participate in the discussions and meetings of the JSC, </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;"> that such participants will have no voting authority at the JSC</font><font style="color:#000000;"> </font><font style="color:#000000;">and are bound by written obligations of confidentiality, non-disclosure, and non-use provisions at least as restrictive or protective of the Parties as those set forth in this Agreement. </font><font style="color:#000000;">The </font><font style="color:#000000;">JSC</font><font style="color:#000000;"> will be chaired by an HFB representative prior to the first Option Exercise Date with respect to any Option Program, and thereafter by a representative of </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Chairperson</font><font style="color:#000000;">&#8221;).</font><font style="color:#000000;"> The role of the Chairperson will be to convene and preside at meetings of the JSC. The Chairperson will have no additional powers or rights beyond those held by the other JSC representatives.</font><font style="color:#000000;"> The Alliance Managers will work with the Chairperson to prepare and circulate agendas and to ensure the preparation of minutes.</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Specific Responsibilities</font><font style="color:#000000;">. The JSC will: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">facilitate the provision and exchange of information between the Parties with respect to the Development of the Licensed Compounds and Licensed Products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">oversee the identification and Development of Option Compounds and Option Products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">oversee development of the Option Notice (and all components thereof) for each Option Program;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">review, discuss, and determine whether to approve any </font><font style="color:#000000;">Technology Transfer plan </font><font style="color:#000000;">pursuant to Section </font><font style="color:#000000;">2.7(a) (Initial Technology Transfer) or </font><font style="color:#000000;">Work Plan pursuant to Section 4.2 (Work Plans);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">review, discuss, and determine whether to approve any update or amendment to a Work Plan pursuant to Section 4.2(b) (Work Plans);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">review and discuss any Development reports provided by HFB pursuant to Section 4.7 (Development Reports); </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">establish such additional subcommittees as it deems necessary to achieve the objective and intent of this Agreement, including as necessary to manage the preparation and prosecution of Joint Arising Technology pursuant to Section 9.3(c) (</font><font style="color:#000000;">Joint Arising Patent Rights)</font><font style="color:#000000;">; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(viii)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref401173297"></a><font style="color:#000000;">perform such other functions as appropriate, to further the purposes of this Agreement, in each case as agreed in writing by the Parties.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref432165377"></a><font style="font-weight:bold;color:#000000;">Meetings</font><font style="color:#000000;">. During the Term, the JSC will meet on at least a [*] basis, [*] the JSC will meet on at least a [*] basis, unless otherwise agreed to by the JSC. No later than [*] prior to any meeting of the JSC, the Alliance Managers will jointly prepare and circulate an agenda for such meeting; </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="font-style:italic;color:#000000;">however</font><font style="color:#000000;">, that either Party may propose additional topics to be included on such agenda, either prior to or in the course of such meeting. Either Party may also call a special meeting of the JSC (by videoconference, teleconference or in person) by providing at least [*] prior written notice to the other Party if such Party reasonably believes that a significant matter must be addressed prior to the next regularly scheduled meeting, in which event such Party will work with the Chairperson of the JSC to provide the members of the JSC no later than [*] prior to the special meeting with an agenda for the </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>20<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">meeting and materials reasonably adequate to enable an informed decision on the matters to be considered. The JSC may meet in person, by videoconference or by teleconference. In-person JSC meetings will be held at locations agreed upon by HFB and by </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;">. Each Party will bear the expense of its respective JSC members&#8217; participation in JSC meetings. Meetings of the JSC will be effective only if at least </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> are present or participating (including by videoconference or teleconference) in such meeting. The Alliance Managers will be responsible for preparing reasonably detailed written minutes of all JSC meetings that reflect material decisions made and action items identified at such meetings. The Alliance Managers will send draft meeting minutes to each member of the JSC for review and approval within </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> after each JSC meeting. Such minutes will be deemed approved unless </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> members of the JSC objects to the accuracy of such minutes within </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> of receipt. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref401173318"></a><font style="font-weight:bold;color:#000000;">Decision-Making</font><font style="color:#000000;">. The representatives from each Party on the JSC will have, collectively, [*] vote on behalf of that Party, and all decision making will be by consensus. Disputes at the JSC will be handled in accordance with Section&#160;3.3 (Resolution of JSC Disputes).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref401173282"></a><a name="_Ref401866310"></a><a name="_Ref401866383"></a><a name="_Ref401867194"></a><a name="_Ref401867590"></a><a name="_Ref401867596"></a><a name="_Ref404378279"></a><a name="_Ref431733846"></a><a name="_Toc74552561"></a><a name="_Toc74553441"></a><font style="font-weight:bold;text-decoration:none;">Resolution of JSC Disputes</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref401173799"></a><font style="font-weight:bold;color:#000000;">Within the JSC</font><font style="color:#000000;">. All decisions within the JSC will be made by consensus. If the JSC is unable to reach consensus on any issue for which it is responsible within [*] days after a Party affirmatively states that a decision needs to be made, then either Party may elect, by written notice to the other Party, to submit such issue to the Parties&#8217; Executive Officers, in accordance with Section&#160;3.3(b) (Referral to Executive Officers). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref401173823"></a><a name="_Ref404417087"></a><font style="font-weight:bold;color:#000000;">Referral to Executive Officers</font><font style="color:#000000;">. If a Party makes an election under Section&#160;3.3(a) (Resolution of JSC Disputes; Within the JSC) to refer a matter to the Executive Officers, then the Executive Officers will use good faith efforts to resolve promptly such matter, which good faith efforts will include at least [*] in-person, video or telephonic meeting between such Executive Officers within [*] after the submission of such matter to them. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46660134"></a><a name="_Ref66352385"></a><font style="font-weight:bold;color:#000000;">Final Decision-Making Authority</font><font style="color:#000000;">. If the Executive Officers are unable to reach consensus on any such matter within [*] days after its submission to them, then:<a name="_Ref66352385"></a> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66352265"></a><a name="_Ref65218654"></a><a name="_Ref46496952"></a><font style="font-weight:bold;color:#000000;">No Changes</font><font style="color:#000000;">. Neither Party will have final decision-making authority with respect to approval of a Work Plan pursuant to Section 4.2(a) (Work Plans).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">HFB Decisions</font><font style="color:#000000;">. HFB will have final decision-making authority with respect to any such matter relating to an Option Program prior to the Option Exercise Date with respect to such Option Program.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">FibroGen Decisions</font><font style="color:#000000;">. FibroGen will have final decision-making authority with respect to any such matter [*], </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;"> that FibroGen cannot require HFB to perform any activities or incur any costs or expenses that are not included in an approved Work Plan (including any amendments made in accordance with this Agreement). For clarity, such final decision-making authority does not apply to any technology transfer pursuant to Section 2.7 (Technology Transfer).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66352232"></a><font style="font-weight:bold;color:#000000;">Limitations on Decision-Making</font><font style="color:#000000;">. Without the other Party&#8217;s prior written consent, neither Party may unilaterally make a decision (in exercise of its final decision-making authority on any such matters) that (A) amends, modifies or waives </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>21<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">compliance with any term or condition of this Agreement, or expands such Party&#8217;s contractual rights or reduces such Party&#8217;s contractual obligations under this Agreement, (B) conflicts with this Agreement, or would be reasonably likely to result in a violation of applicable law, the requirement of any Regulatory Authorities, or result in the </font><font style="color:#000000;">infringement or misappropriation of intellectual property rights of any Third Party,</font><font style="color:#000000;"> or (C) is stated to require the agreement or consent of the Parties under Section </font><font style="color:#000000;">3.3(c)(</font><font style="color:#000000;">i</font><font style="color:#000000;">)</font><font style="color:#000000;"> (No Changes).</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref65234201"></a><a name="_Ref46660173"></a><a name="_Toc74552562"></a><a name="_Toc74553442"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Dissolution of JSC</font><font style="Background-color:#FFFFFF;font-size:12pt;">. The JSC and any subcommittees shall be dissolved on a program-by-program basis upon: (a) with respect to any Licensed Program, the date on which [*] with respect to such Licensed Program, (b) with respect to any Option Program, the expiration of the Option Term for such Option Program without an exercise of the License Option for such Option Program. The JSC and any subcommittees shall be dissolved in their entirety upon FibroGen&#8217;s election in accordance with Section 15.7 (Change of Control of HFB). Once the </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">JSC</font><font style="Background-color:#FFFFFF;font-size:12pt;"> is disbanded with respect to any program, the </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">JSC </font><font style="Background-color:#FFFFFF;font-size:12pt;">will have no further obligations under this Agreement with respect to such program and, thereafter, the Alliance Managers will be the points of contact for the exchange of information between the Parties under this Agreement and any references in this Agreement to decisions of the </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">JSC </font><font style="Background-color:#FFFFFF;font-size:12pt;">will automatically become references to decisions by and between the Parties in writing, subject to the other terms of this Agreement and consistent with the terms of Section 3.3(c) (Final Decision-Making Authority). </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;color:#010000;font-family:Times New Roman Bold;text-transform:uppercase;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref401868096"></a><a name="_Toc74552563"></a><a name="_Toc74553443"></a>Article 4<font style="color:#000000;font-family:Times New Roman;text-transform:none;"><br /><a name="_Ref401868096"></a><a name="_Toc74552563"></a><a name="_Toc74553443"></a>DEVELOPMENT</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66191346"></a><a name="_Toc74552564"></a><a name="_Toc74553444"></a><a name="_Ref66214590"></a><a name="_Ref66211014"></a><a name="_Ref46580378"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Development Plans</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. An outline of all major Development activities to be conducted by FibroGen with respect to the Gal-9 Licensed Program is attached hereto as Schedule 4.1 (Development Plan). Following the Option Exercise Date with respect to any Option Program, FibroGen will provide an updated Development Plan to HFB reflecting all major Development activities to be conducted by FibroGen with respect to the applicable Licensed Program. Additionally, prior to the first Regulatory Approval of a Licensed Product for each Licensed Program in a Major Market Country, FibroGen will provide an updated Development Plan with respect to such Licensed Program to HFB within [*] of each anniversary of the Effective Date based on the currently available information.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66737958"></a><a name="_Toc74552565"></a><a name="_Toc74553445"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Work Plans</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66738087"></a><font style="font-weight:bold;color:#000000;">Initial Work Plan</font><font style="color:#000000;">. HFB will conduct certain Development activities until IND filing with respect to each Licensed Program in accordance with a written plan that includes [*]. [*] prior to the approximate delivery date of an Option Notice with respect to each Option Program, HFB will submit to the JSC a proposed Work Plan to become effective upon the Option Exercise Date for such Option Program. The JSC will review and discuss, and determine whether to approve any such Work Plan in accordance with Section 3.3(c) (Final Decision-Making Authority). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66738058"></a><font style="font-weight:bold;color:#000000;">Updating Work Plan</font><font style="color:#000000;">. At least [*] (or more frequently as may be required) prior to dissolution of the JSC with respect to any Licensed Program, the JSC will review and update HFB&#8217;s activities under each Work Plan based on the currently available </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>22<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">information. Each such update to a Work Plan will become effective and will supersede the previous version of such Work Plan upon approval thereof by the JSC. Additionally, from time to time prior to dissolution of the JSC, either Party may provide to the JSC a proposed amendment to any then-current Work Plan. The JSC will review and discuss, and determine whether to approve any proposed amendment to the Work Plan in accordance with Section </font><font style="color:#000000;">3.3(c)</font><font style="color:#000000;"> (Final Decision-Making Authority).</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66210988"></a><a name="_Toc74552566"></a><a name="_Toc74553446"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">FibroGen Development Responsibilities</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. During the Term, FibroGen will have the sole right and responsibility for, and will have sole control and authority over, at its sole cost and expense, the Development of the Licensed Compounds and any Licensed Products.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref72331937"></a><a name="_Ref67759709"></a><a name="_Ref70436563"></a><a name="_Ref70433912"></a><a name="_Ref70529689"></a><a name="_Toc74552567"></a><a name="_Toc74553447"></a><a name="_Ref72306688"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Development Diligence Obligations</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"><a name="_Ref72306688"></a>. FibroGen will use Commercially Reasonable Efforts to Develop in accordance with the Development Plan, and obtain and maintain Regulatory Approval for, [*] Licensed Product Directed To each Licensed Program in the Field in [*] Major Market Countries. FibroGen shall use Commercially Reasonable Efforts to [*] (each of the events as provided in the foregoing (i)&#160;through (iii) are a &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">Diligence Milestone</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">&#8221;). If FibroGen makes a final decision to permanently cease Development of all Licensed Products for a Licensed Program, FibroGen shall give HFB written notice within [*] of such decision and such Licensed Program shall be a Terminated Licensed Program pursuant to Section 13.6 (Effects of Termination).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46576809"></a><a name="_Ref46653723"></a><a name="_Ref74005306"></a><a name="_Ref65266722"></a><a name="_Toc74552568"></a><a name="_Toc74553448"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">HFB Development Responsibilities</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Subject to the terms of this Agreement, on an Option Program-by-Option Program basis prior to the Option Exercise Date with respect to such Option Program, HFB will conduct the Development activities with respect to each Option Program, [*]. On a Licensed Program-by-Licensed Program basis, HFB will conduct solely those Development activities allocated to it under the applicable Work Plan for such Licensed Program, [*], subject to any agreed budget set forth in such Work Plan.</font><font style="Background-color:#FFFFFF;font-size:12pt;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref53909166"></a><a name="_Toc74552569"></a><a name="_Toc74553449"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Development Records</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Each Party will, and will cause its Affiliates, Sublicensees, and subcontractors to, maintain reasonably complete, current, and accurate records of all Development activities conducted by or on behalf of it and its Affiliates, Sublicensees, and subcontractors, respectively, pursuant to this Agreement. Each Party will maintain all such records relating to the Development of Licensed Compounds and Licensed Products for a period of [*]. HFB will document all non-clinical and preclinical studies in formal written study reports in accordance with GLP, cGMP, and GCP in compliance with ICH Guidelines, as applicable, and in compliance with applicable law. Upon FibroGen&#8217;s reasonable request, HFB will, and will cause its Affiliates, Sublicensees, and subcontractors to, allow FibroGen to access, review, and copy such records (including access to relevant databases).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46592973"></a><a name="_Toc74552570"></a><a name="_Toc74553450"></a><a name="_Ref404364864"></a><a name="_Ref404273525"></a><a name="_Ref405396169"></a><a name="_Ref404365299"></a><font style="font-weight:bold;text-decoration:none;color:#000000;"><a name="_Ref404364864"></a><a name="_Ref404273525"></a><a name="_Ref405396169"></a><a name="_Ref404365299"></a>Development Reports</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. At each JSC meeting for [*] during which either Party is performing, or having performed, Development activities for any Option Compound, Option Product, Licensed Compound or Licensed Product in the Territory, such Party will provide a report to the other Party (through the JSC) summarizing such Development activities performed during the period since the preceding JSC meeting, such Development activities as are in process, including a summary of the data and results of such Development activities. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>23<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">Following dissolution of the JSC pursuant to Section </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">3.4</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> (Dissolution of JSC), </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">FibroGen</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> will provide to HFB a Development report no later than </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">[</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">*</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">]</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> during the Term</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">summarizing the Development activities performed by or on behalf of </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">FibroGen</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> and its Affiliates and Sublicensees in the Territory for the Licensed Products since the prior such report provided by </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">FibroGen</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> or, in the case of the first such report, since </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">[</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">*</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">]</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> prior to the date upon which the JSC was dissolved pursuant to Section </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">3.4</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> (Dissolution of JSC). HFB will have </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">[</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">*</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">]</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> following receipt of such </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">[</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">*</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">]</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> report to reasonably request additional information and a reasonable and prompt opportunity to discuss. Such reports and any additional information provided by a Party regarding Development activities for the Licensed Compounds and Licensed Products, in each case, will be the Confidential Information of the providing Party and subject to the terms of </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">Article 12</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> (Confidentiality). </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;color:#010000;font-family:Times New Roman Bold;text-transform:uppercase;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc74552571"></a><a name="_Toc74553451"></a>Article 5<font style="color:#000000;font-family:Times New Roman;text-transform:none;"><br /><a name="_Toc74552571"></a><a name="_Toc74553451"></a>REGULATORY</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref55553427"></a><a name="_Ref59028308"></a><a name="_Toc74552572"></a><a name="_Toc74553452"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Regulatory Responsibilities</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. During the Term, FibroGen will have sole responsibility for, and sole decision-making authority over, all regulatory activities and associated costs and expenses for all Licensed Compounds and all Licensed Products in the Field in the Territory. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552573"></a><a name="_Toc74553453"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Regulatory Filings; Ownership</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. FibroGen will lead and have sole control over and decision-making authority with respect to preparing and submitting all regulatory filings related to the Licensed Compounds and Licensed Products in the Territory, including all applications for Regulatory Approval in the Territory. FibroGen will own any and all Regulatory Approvals and Regulatory Materials related to the Licensed Compounds and Licensed Products in the Territory, which will be held in the name of FibroGen or its designees. FibroGen will keep HFB informed of receipt of any Regulatory Approvals with respect to any Licensed Products in the Territory. HFB will reasonably cooperate with FibroGen in its efforts to prepare and submit any regulatory submissions to obtain, support, or maintain Regulatory Approvals for the Licensed Products in the Territory and all regulatory activities related to the Exploitation of the Licensed Products in the Territory. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552574"></a><a name="_Toc74553454"></a><font style="font-weight:bold;text-decoration:none;">Interactions with Regulatory Authorities</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. FibroGen will have the sole right to conduct all communications with Regulatory Authorities in the Territory related to the Licensed Compounds and Licensed Products, including all meetings, conferences, and discussions (including advisory committee meetings).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552575"></a><a name="_Toc74553455"></a><font style="font-weight:bold;text-decoration:none;">Option Programs</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. During the Option Term for any Option Program, HFB will not submit any regulatory filings related to the Option Compounds or Option Products for such Option Program or conduct any communications with Regulatory Authorities in the Territory related to such Option Compounds or Option Products, in each case, [*].</font><font style="Background-color:#FFFFFF;font-size:12pt;"> </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:11pt;margin-top:0pt;text-indent:0%;color:#010000;font-family:Times New Roman Bold;text-transform:uppercase;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref46579767"></a><a name="_Ref46595186"></a><a name="_Toc74552576"></a><a name="_Toc74553456"></a>Article 6<font style="font-weight:normal;color:#000000;font-family:Times New Roman;text-transform:none;"> </font><font style="color:#000000;font-family:Times New Roman;text-transform:none;"><br /><a name="_Toc74552576"></a><a name="_Toc74553456"></a></font><font style="font-family:Times New Roman;text-transform:none;color:#000000;">MANUFACTURING</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46608628"></a><a name="_Toc74552577"></a><a name="_Toc74553457"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Manufacturing</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. During the Term, FibroGen will have the exclusive right to Manufacture and supply the Licensed Compounds and Licensed Products itself or through one or more Affiliates or FibroGen CMOs for Exploitation in the Field in the Territory. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>24<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:11pt;margin-top:0pt;text-indent:0%;color:#010000;font-family:Times New Roman Bold;text-transform:uppercase;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc74552578"></a><a name="_Toc74553458"></a>Article 7<font style="font-family:Times New Roman;text-transform:none;color:#000000;"><br /><a name="_Toc74552578"></a><a name="_Toc74553458"></a>COMMERCIALIZATION</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552579"></a><a name="_Toc74553459"></a><a name="_Ref46585407"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Commercialization Responsibilities</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. FibroGen will have sole control over and decision-making authority with respect to the Commercialization of all Licensed Products in the Territory, including the right to determine the price of the Licensed Products sold in the Territory.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref68117983"></a><a name="_Ref72331949"></a><a name="_Toc74552580"></a><a name="_Toc74553460"></a><a name="_Ref431783938"></a><a name="_Ref25510622"></a><a name="_Ref405396186"></a><font style="font-weight:bold;text-decoration:none;color:#000000;"><a name="_Ref431783938"></a><a name="_Ref25510622"></a><a name="_Ref405396186"></a>Commercialization Diligence Obligations</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. [*]. If, with respect to any Licensed Program, FibroGen</font><font style="font-weight:bold;font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:12pt;"> </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">ceases all Commercially Reasonable Efforts to Commercialize all Licensed Products within such Licensed Program for [*], such Licensed Program shall be a Terminated Licensed Program and all applicable Licensed Products shall become Terminated Licensed Products; </font><font style="font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:12pt;">provided that</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> (a) if such cessation is a result of a safety concern, regulatory issue, clinical hold, Force Majeure, or injunction or other operation of law, such [*] period will be extended for [*] any of the foregoing listed in this clause (a) caused [*] and FibroGen is diligently seeking to remedy such issue, such [*] period will be [*] as is reasonably necessary to resolve the [*]</font><font style="Background-color:#FFFFFF;font-size:12pt;">. If FibroGen makes a [*] Commercialization of all Licensed Products for a Licensed Program, FibroGen shall give HFB written notice within [*] of such decision and such Licensed Program shall be a Terminated Licensed Program pursuant to Section 13.6 (Effects of Termination).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46593124"></a><a name="_Ref509919663"></a><a name="_Toc74552581"></a><a name="_Toc74553461"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Commercialization Report</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Within [*], FibroGen will provide to HFB a report summarizing the Commercialization activities performed by or on behalf of FibroGen and its Affiliates and Sublicensees in the Territory for the Licensed Products since the prior such report provided by FibroGen or, in the case of the first such report, since [*] prior to the date upon which the first Regulatory Approval for a Licensed Product in the Territory was granted. HFB will have [*] following receipt of such report to reasonably request additional information and a reasonable opportunity to discuss at a time mutually agreeable to the Parties. Such reports will be Confidential Information of FibroGen and subject to the terms of Article 12 (Confidentiality). FibroGen will provide updates to any such report at each meeting of the JSC.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;color:#010000;font-family:Times New Roman Bold;text-transform:uppercase;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref401171917"></a><a name="_Ref401171940"></a><a name="_Ref401172167"></a><a name="_Ref401866556"></a><a name="_Ref401867575"></a><a name="_Ref401868110"></a><a name="_Ref401868270"></a><a name="_Ref404944507"></a><a name="_Ref404967481"></a><a name="_Ref431887298"></a><a name="_Ref432165760"></a><a name="_Toc74552582"></a><a name="_Toc74553462"></a>Article 8<font style="color:#000000;font-family:Times New Roman;text-transform:none;"><br /><a name="_Ref401171917"></a><a name="_Ref401171940"></a><a name="_Ref401172167"></a><a name="_Ref401866556"></a><a name="_Ref401867575"></a><a name="_Ref401868110"></a><a name="_Ref401868270"></a><a name="_Ref404944507"></a><a name="_Ref404967481"></a><a name="_Ref431887298"></a><a name="_Ref432165760"></a><a name="_Toc74552582"></a><a name="_Toc74553462"></a>FINANCIALS</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref54447653"></a><a name="_Toc74552583"></a><a name="_Toc74553463"></a><a name="_Ref431879541"></a><a name="_Ref25092022"></a><a name="_Ref24716794"></a><a name="_Ref22192203"></a><a name="_Ref22192296"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Upfront Payment</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. No later than [*] after receipt of an invoice from HFB, which invoice may be provided beginning on the Effective Date, FibroGen will pay to HFB a one-time, non-refundable, non-creditable payment in the amount of twenty-five million dollars ($25,000,000) (the &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">Upfront Payment</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">&#8221;) [*]. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref65159236"></a><a name="_Ref65153255"></a><a name="_Toc74552584"></a><a name="_Toc74553464"></a><a name="_Ref54517730"></a><font style="font-weight:bold;text-decoration:none;color:#000000;"><a name="_Ref54517730"></a>Option Exercise Payment</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. No later than [*] after receipt of an invoice from HFB, which invoice shall be provided as soon as reasonably practicable after FibroGen&#8217;s delivery of the Option Exercise Notice for a given License Option for an Option Program, FibroGen will pay to HFB the corresponding one-time, non-refundable, non-creditable payment for </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>25<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">such Option Program set forth in Table </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">8.2</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> (each, an &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">Option Exercise Payment</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">&#8221;): </font></p></td></tr></table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:17.4%;"></td>
<td style="width:25.99%;"></td>
<td style="width:26.38%;"></td>
<td style="width:30.12%;"></td>
</tr>
<tr>
<td colspan="4" valign="middle"  BGCOLOR="#BDD6EE" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Table 8.2 &#8211; Option Exercise Payments</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#DEEAF6" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#DEEAF6" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">CCR8 Option Program</p></td>
<td valign="middle"  BGCOLOR="#DEEAF6" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">CXCR5 Option Program</p></td>
<td valign="top"  BGCOLOR="#DEEAF6" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Replacement Option Program</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option Exercise Payment</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:108pt;;text-indent:-112.5pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref65249343"></a><a name="_Toc74552585"></a><a name="_Toc74553465"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Milestone Payments</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref58698305"></a><a name="_Ref72346333"></a><a name="_Ref55554455"></a><a name="_Ref55647807"></a><a name="_Ref52458212"></a><a name="_Ref53845086"></a><font style="font-weight:bold;color:#000000;">R&amp;D and Regulatory Milestones</font><font style="color:#000000;">.<a name="_Ref55554455"></a><a name="_Ref55647807"></a><a name="_Ref52458212"></a><a name="_Ref53845086"></a> FibroGen will make the one-time milestone payments set forth in Table 8.3(a) upon the first achievement by FibroGen or its Affiliates or Sublicensees of the corresponding milestone event by the first Licensed Product for each Licensed Program.</font></p></td></tr></table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:6.78%;"></td>
<td style="width:73.23%;"></td>
<td style="width:19.88%;"></td>
</tr>
<tr>
<td colspan="3" valign="middle"  BGCOLOR="#BDD6EE" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Table 8.3(a) &#8211; R&amp;D and Regulatory Milestones for each program</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#DEEAF6" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="middle"  BGCOLOR="#DEEAF6" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Milestone Event</p></td>
<td valign="top"  BGCOLOR="#DEEAF6" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Milestone Payment</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:108pt;;text-indent:-112.5pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:-0.8pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:108pt;;text-indent:-112.5pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:108pt;;text-indent:-112.5pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:25.85pt;;text-indent:-30.35pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:108pt;;text-indent:-112.5pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:25.85pt;;text-indent:-30.35pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:108pt;;text-indent:-112.5pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:25.85pt;;text-indent:-30.35pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#5B9BD5" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maximum total milestone payments per program</p></td>
<td valign="top"  BGCOLOR="#5B9BD5" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:108pt;;text-indent:-112.5pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:25.85pt;;text-indent:-30.35pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Maximum</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:108pt;;text-indent:-112.5pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:11pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:11pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:11pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref65249000"></a><a name="_Ref58698425"></a><font style="font-weight:bold;color:#000000;">Sales Milestones</font><font style="color:#000000;">. FibroGen will make the one-time milestone payments set forth in Table 8.3(b) upon the first achievement by FibroGen or its Affiliates or Sublicensees of the corresponding milestone event by the first Licensed Product for each Licensed Program. </font></p></td></tr></table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:6.78%;"></td>
<td style="width:73.23%;"></td>
<td style="width:19.88%;"></td>
</tr>
<tr>
<td colspan="3" valign="middle"  BGCOLOR="#BDD6EE" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Table 8.3(b) &#8211; Sales Milestones for each program</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#DEEAF6" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="middle"  BGCOLOR="#DEEAF6" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Milestone Event</p></td>
<td valign="top"  BGCOLOR="#DEEAF6" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Milestone Payment</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:108pt;;text-indent:-112.5pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:108pt;;text-indent:-112.5pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:108pt;;text-indent:-112.5pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:25.85pt;;text-indent:-30.35pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#5B9BD5" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maximum total milestone payments per program</p></td>
<td valign="top"  BGCOLOR="#5B9BD5" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:108pt;;text-indent:-112.5pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk24716774"></a>Each milestone <font style="color:#000000;">payment</font><a name="_Hlk24716774"></a> under this Section&#160;8.3 (Milestone Payments) is non-refundable and non-creditable and payable only once for each Licensed Program, upon the first achievement by FibroGen or its Affiliate or Sublicensee for a Licensed Product Directed To an Exclusive Target in the Territory that is the subject of each such Licensed Program, notwithstanding whether a Licensed Product achieves the milestone event more than once or whether more than one Licensed Product Directed To an Exclusive Target achieves a milestone event.<font style="color:#000000;"> If any of R&amp;D and regulatory milestones events 2 through 5 are achieved by a given Licensed Product prior to achievement of any of the preceding R&amp;D and regulatory milestone events 1 through 4 for such Licensed Product, all preceding milestone events not previously achieved for such Licensed Product shall be deemed to be achieved and payable upon achievement of the applicable R&amp;D </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>26<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:12pt;text-align:justify;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">and regulatory milestone events for such Licensed Product. </font><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If </font><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</font><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> events are achieved in the same Calendar Quarter or the same Calendar Year, then </font><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</font><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:15.38%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen will provide HFB with written notice of the achievement of the milestone event in this Section&#160;8.3(a) (R&amp;D and Regulatory Milestones) no later than [*] after the achievement of the applicable milestone event by FibroGen or any of its Affiliates, or within [*] after FibroGen has knowledge of the achievement of the applicable milestone event by a Sublicensee. HFB will invoice FibroGen following receipt of such written notice as soon as reasonably practicable and FibroGen will pay the associated milestone payment no later than [*] after the receipt of such invoice. Such payment will be made by wire transfer of immediately available funds into an account designated by HFB. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref431873469"></a><a name="_Toc74552586"></a><a name="_Toc74553466"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Royalties</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref57925134"></a><a name="_Ref431869826"></a><a name="_Ref411565536"></a><a name="_Ref410096450"></a><font style="font-weight:bold;color:#000000;">Royalty Rates</font><font style="color:#000000;">. </font><font style="color:#000000;">On a Licensed Product-by-Licensed Product and country-by-country basis, FibroGen will pay HFB royalties on aggregate annual Net Sales of each Licensed Product in the </font><font style="color:#000000;">Territory</font><font style="color:#000000;"> in a Calendar Year </font><font style="color:#000000;">at the royalty rates set forth in Table 8.4(a) until the expiration of the Royalty Term for such Licensed Product on a country-by-country basis (&#8220;</font><font style="font-weight:bold;color:#000000;">Royalties</font><font style="color:#000000;">&#8221;).</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:86.31%;"></td>
<td style="width:13.49%;"></td>
<td style="width:0.09%;"></td>
</tr>
<tr>
<td colspan="3" valign="middle"  BGCOLOR="#8DB3E2" style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Table 8.4(a) &#8211; Royalty Rates for Licensed Products</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#C6D9F1" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Calendar Year Aggregate Net Sales of a Licensed Product in the Territory</p></td>
<td valign="middle"  BGCOLOR="#C6D9F1" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Royalty Rate</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td style="border:none;padding:0;"></td>
</tr>
</table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:11pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]<font style="color:#000000;">. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref53845060"></a><a name="_Ref46595344"></a><font style="font-weight:bold;color:#000000;">Reports; Payment</font><font style="color:#000000;">. FibroGen will deliver a written report to HFB showing a calculation of the Royalties and whether a Sales Milestone has been achieved, providing Net Sales in sufficient detail to allow HFB to verify Royalties and achievement of Sales Milestones due in a given Calendar Quarter no later than [*] after the end of each Calendar Quarter (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Royalty and Net Sales Report</font><font style="color:#000000;">&#8221;). All Royalty payments will be payable concurrently with the delivery of the Royalty and Net Sales Report for the applicable Calendar Quarter. All payments under this Agreement will be payable, in full, in U.S. dollars, regardless of the country(ies) in which such sales are made. For purposes of computing the Royalty of any Licensed Product that is sold in a currency other than United States dollars, such currency will be converted into United States dollars at the median of the buying rate and the selling rate of exchange reported by the Wall Street Journal on the last day for the month in which such sales were recorded.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66814484"></a><a name="_Ref48643847"></a><a name="_Ref46587075"></a><a name="_Ref410748061"></a><a name="_Ref46616796"></a><a name="_Ref46588738"></a><a name="_Ref411362922"></a><font style="font-weight:bold;color:#000000;">Reductions</font><font style="color:#000000;">.<a name="_Ref410748061"></a><a name="_Ref46616796"></a><a name="_Ref46588738"></a><a name="_Ref411362922"></a> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66270983"></a><font style="font-weight:bold;color:#000000;">Reduction for Loss of Market Exclusivity</font><font style="color:#000000;">. If, on a Licensed Product-by-Licensed Product and country-by-country basis, a Loss of Market Exclusivity for a Licensed Product in any country has occurred [*], then the Royalties due to HFB pursuant to Section 8.4(a) (Royalty Rates) with respect to such Licensed Product in such country will be reduced by [*] of the applicable Royalties that would otherwise be owed on the Net Sales of such Licensed Product in such country under Section 8.4(a) (Royalty Rates) in such Calendar Quarter.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>27<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref65252786"></a><font style="font-weight:bold;color:#000000;">Reduction for Additional Third Party IP</font><font style="color:#000000;">. With respect to any Third Party License entered into after the Effective Date pursuant to which FibroGen is granted rights under any Additional Third Party IP that is necessary to Exploit a Licensed Product in a country or jurisdiction in the Territory, FibroGen will be entitled to deduct from any Royalties due to HFB pursuant to Section 8.4(a) (Royalty Rates) with respect to that country or other jurisdiction [*] of royalties or other amounts paid to such Third Party under such Third Party License to the extent necessary</font><font style="font-weight:bold;font-style:italic;color:#000000;"> </font><font style="color:#000000;">to Develop and Commercialize a Licensed Compound and allocable or specific to the Licensed Products.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Cumulative Reductions Floor</font><font style="color:#000000;">. In no event will the Royalties due to HFB under this Agreement in a Calendar Year be reduced by more [*] due to HFB pursuant to Section 8.4(a) (Royalty Rates) that would otherwise be due in such Calendar Year for the Licensed Products as a result of the foregoing reductions.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref72492853"></a><a name="_Ref73004235"></a><a name="_Toc74552587"></a><a name="_Toc74553467"></a><a name="_Ref410308528"></a><font style="font-weight:bold;text-decoration:none;"><a name="_Ref410308528"></a>Sublicense Revenue</font><font style="Background-color:#FFFFFF;font-size:12pt;">. FibroGen will pay to HFB </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;font-size:12pt;"> of any Sublicense Revenue received by FibroGen under any sublicense to the extent the sublicense is directed to a Licensed Program for which </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;font-size:12pt;">. No Sublicense Revenue will be owed to HFB by FibroGen with respect to any sublicense to the extent such sublicense is directed to a Licensed Program for which </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;font-size:12pt;">. Notwithstanding anything to the contrary set forth in this Agreement, to the extent that any payment is made to FibroGen under a sublicense in consideration for both (a) a sublicense under the Licensed Technology and (b) a license or sublicense under intellectual property rights or materials not licensed to FibroGen under this Agreement, </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;font-size:12pt;">. The Parties will discuss in good faith any dispute by HFB with respect to such [*] and will resolve any issues in accordance with Article 14 (Dispute Resolution).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref54360169"></a><a name="_Ref65692027"></a><a name="_Toc74552588"></a><a name="_Toc74553468"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Upstream License Costs</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. [</font><font style="Background-color:#FFFFFF;font-size:12pt;">*] responsible for all upfront payments, milestone payments, royalties, or other payments due to the licensor under the Upstream License, as well as any rewards, remuneration, or other amounts payable with respect to inventions and technical achievements required by applicable law to be paid to any Persons for the development or invention of any Licensed Technology (collectively, &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;font-size:12pt;">Upstream License Costs</font><font style="Background-color:#FFFFFF;font-size:12pt;">&#8221;). Without limiting the foregoing, if [*] fails to pay any Upstream License Costs or otherwise fails to maintain the Upstream License as required by Section 10.3(b) (Upstream License) and </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;font-size:12pt;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref54518002"></a><a name="_Toc74552589"></a><a name="_Toc74553469"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Books and Records; Audit Rights</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref410748076"></a><a name="_Ref54518246"></a><a name="CPA_Firm"></a><font style="color:#000000;">HFB will have the right to engage, at its own cost and expense, subject to this Section 8.7 (Books and Records; Audit Rights), an independent nationally recognized public accounting firm in the United States chosen by HFB and reasonably acceptable to FibroGen<a name="CPA_Firm"></a> (which accounting firm will not be the external auditor of HFB, will not have been hired or paid on a contingency basis, and will have experience auditing pharmaceutical companies) (a &#8220;</font><font style="font-weight:bold;color:#000000;">CPA Firm</font><font style="color:#000000;">&#8221;) to conduct an audit of FibroGen for the purposes of confirming FibroGen&#8217;s compliance with the payment provisions of this Agreement. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">The CPA Firm will be given access to and will be permitted to examine such books and records of FibroGen as it will reasonably request, upon [*] prior written notice having been given by HFB, during regular business hours, for the sole purpose of determining compliance with the payment provisions of this Agreement. Prior to any such examination taking place, the CPA Firm will enter into a confidentiality agreement reasonably </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>28<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">acceptable to </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> with respect to the Know-How to which they are given access and will not contain in its report or otherwise disclose to HFB or any Third Party any information labeled by </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> as being confidential customer information regarding pricing or other competitively sensitive proprietary information.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref67742500"></a><font style="color:#000000;">HFB and FibroGen will be entitled to receive a full written report of the CPA Firm with respect to its findings and HFB will provide, without condition or qualification, FibroGen with a copy of the report, or other summary of findings, prepared by such CPA Firm promptly following HFB&#8217;s receipt of same. No other information will be provided to HFB. In the event of any dispute between HFB and FibroGen regarding the findings of any such inspection or audit, the Parties will initially attempt in good faith to resolve the dispute amicably between themselves, and if the Parties are unable to resolve such dispute within [*] after delivery to both Parties of the CPA Firm&#8217;s report, each Party will [*] internationally recognized independent certified public accounting firm which will resolve the dispute, and such accounting firm&#8217;s determination will be binding on both Parties, absent manifest error by such accounting firm.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">Within [*] after completion of the CPA Firm&#8217;s audit, FibroGen will pay to HFB any deficiency in the payment amount determined by the CPA Firm and, if the deficiency is at least [*] of the total payment amount, then FibroGen shall pay all costs and expenses associated with the CPA Firm&#8217;s audit and any dispute thereof pursuant to Section 8.7(c) (Books and Records; Audit Rights). If the report of the CPA Firm shows that FibroGen overpaid, then FibroGen will be entitled to off-set such overpayment against any Royalty then owed to HFB. If no Royalty is then owed to HFB, then HFB will remit such overpayment to FibroGen. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46587755"></a><a name="_Ref411580292"></a><font style="color:#000000;">HFB&#8217;s exercise of its audit rights under this Section&#160;8.7 (Books and Records; Audit Rights) may not (i) be conducted for any Calendar Quarter [*] after the end of such Calendar Quarter to which such books and records pertain, (ii) be conducted more than [*] in any a Calendar Year period (unless a previous audit during such period revealed a material underpayment with respect to such period), or (iii) be repeated for any [*]<a name="_Ref46587755"></a><a name="_Ref411580292"></a>. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.8</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref54517777"></a><a name="_Toc74552590"></a><a name="_Toc74553470"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Taxes</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref509919687"></a><font style="font-weight:bold;color:#000000;">Taxes on Net Income</font><font style="color:#000000;">. Each Party will be solely responsible for the payment of any and all taxes levied on such Party&#8217;s net income.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Tax Withholding</font><font style="color:#000000;">. The amounts payable pursuant to this Agreement will not be reduced on account of any taxes, unless required by applicable law. If applicable law requires the withholding of taxes on a payment by FibroGen to HFB under this Agreement, then FibroGen will pay the amount of such taxes to the proper governmental authority in a timely manner and will [*]. FibroGen will promptly (as soon as reasonably available) submit to HFB appropriate proof of FibroGen&#8217;s payment of the withheld taxes as well as the official receipts in respect thereof. Notwithstanding the foregoing, to the extent there is an increase in the applicable rate of withholding tax on any payments by FibroGen to HFB, which increase is solely as a result of a change in form or domicile of FibroGen, FibroGen shall pay HFB an amount so that after any such additional withholding tax has been taken into account (including as a result of any withholding tax imposed on the additional amounts payable pursuant to this sentence), HFB shall have received an amount from FibroGen equal to the payment HFB would have received had no such additional withholding tax applied. If HFB delivers to FibroGen or the appropriate governmental </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>29<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">authority in the applicable jurisdiction the prescribed forms necessary to reduce the applicable rate of withholding or to relieve </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> of its obligation to withhold taxes, </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> will </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">, as the case may be, </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;"> that </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> is in receipt of evidence, in a form reasonably satisfactory to </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> (</font><font style="font-style:italic;color:#000000;">e.g.</font><font style="color:#000000;">, HFB&#8217;s delivery of all applicable documentation) prior to the time that the applicable payments are due.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref71285740"></a><font style="font-weight:bold;color:#000000;">Tax Cooperation</font><font style="color:#000000;">. The Parties shall cooperate and exercise their reasonable best efforts to ensure that any withholding taxes imposed on payments to HFB are reduced as far as possible under the provisions of any applicable law (including any applicable income tax treaty). If withholding of tax is required from any payment, both parties shall use reasonable efforts to provide sufficient time for the Parties to review the applicable law and establish any available reduction or exemption from such withholding. For purposes of properly determining its withholding tax obligations (if any) in respect of payments to HFB based on sales (such as royalties), FibroGen covenants to maintain records, available for HFB&#8217;s review, that support the apportionment of such payments to U.S. sources or non-U.S. sources, as determined for U.S. federal income tax purposes, and as otherwise may be required under the income sourcing rules of other jurisdictions that may impose withholding obligations in respect of such payments. Each Party will cooperate and exercise their reasonable best efforts to enable the recovery, as permitted by applicable law, of withholding taxes, VAT, or similar tax obligations that were paid in respect of payments made under this Agreement, such recovery to be for the benefit of the Party that bore the economic burden of such withholding tax or VAT. Furthermore, the Parties shall reasonably cooperate and provide each other with such forms and information as reasonably may be needed to comply with any applicable tax reporting obligations.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Certain U</font><font style="font-weight:bold;color:#000000;">.S. Tax Matters.</font><font style="color:#000000;"> The Parties intend that, for U.S. federal income tax purposes, the license under this Agreement (and the rights transferred upon exercise of the options under this Agreement) represent a sale of intellectual property (i.e., a transfer of all substantial rights in respect of intellectual property as determined for U.S. federal income tax purposes). </font><font style="color:#000000;">[*]</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref53846726"></a><font style="font-weight:bold;color:#000000;">VAT</font><font style="color:#000000;">. The Parties agree to cooperate with one another and use reasonable efforts to ensure that any value added tax, sales tax or similar payment (&#8220;</font><font style="font-weight:bold;color:#000000;">VAT</font><font style="color:#000000;">&#8221;) (in respect of any payments made by FibroGen to HFB under this Agreement) does not represent an unnecessary cost in respect of payments made under this Agreement, including use of available VAT exemptions, zero-ratings, reduced-ratings, suspensions or other reliefs. All sums payable under this Agreement will be exclusive of VAT. If any VAT is owing in any jurisdiction with respect to any such payment, then FibroGen will pay such VAT and HFB will provide to FibroGen tax invoices showing the amount of VAT in respect of such payment in addition to any amounts otherwise payable by FibroGen under this Agreement. Where the prevailing legislation requires the recipient to self-account for VAT (for example, but not limited to, the reverse charge mechanism), then FibroGen covenants it will correctly account for VAT in respect of the transactions under this Agreement upon which VAT is due. HFB agrees that it will raise a tax invoice (or equivalent document) to support the charge to VAT.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.9</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref53908723"></a><a name="_Ref411580294"></a><font style="font-weight:bold;color:#000000;">Late Payments</font><font style="color:#000000;">. Any payments or portions thereof due hereunder that are not paid on the date such payments are due under this Agreement will bear interest at a rate equal to the lesser of: (a) [*] in which such payments are overdue; or (b) the maximum rate permitted by applicable law; [*].</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>30<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.10</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">No Other Compensation</font><font style="color:#000000;">. Other than as explicitly set forth (and as applicable) in this Agreement, neither FibroGen nor any of its Affiliates will be obligated to pay any additional fees, milestone payments, royalties or other payments of any kind to or on behalf of HFB or any of its Affiliates under this Agreement. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.11</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_9kMH1I6ZWu57789BbHxArt9"></a><font style="font-weight:bold;color:#000000;">Other Amounts Payable</font><font style="color:#000000;"><a name="_9kMH1I6ZWu57789BbHxArt9"></a>. With respect to any amounts owed under this Agreement by a Party to the other Party for which no other invoicing and payment procedure is specified in this Agreement, the payee Party will provide an invoice, together with reasonable supporting documentation, to the paying Party for such amounts owed. The paying Party will pay any undisputed amounts no later [*] after receipt of the invoice, and will pay any disputed amounts owed by the paying Party no later than [*] after resolution of the dispute.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;color:#010000;font-family:Times New Roman Bold;text-transform:uppercase;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref401172006"></a><a name="_Ref401172096"></a><a name="_Ref401866958"></a><a name="_Ref401868221"></a><a name="_Toc74552591"></a><a name="_Toc74553471"></a>Article 9<font style="color:#000000;font-family:Times New Roman;text-transform:none;"><br /><a name="_Ref401172006"></a><a name="_Ref401172096"></a><a name="_Ref401866958"></a><a name="_Ref401868221"></a><a name="_Toc74552591"></a><a name="_Toc74553471"></a>INTELLECTUAL PROPERTY</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref67908071"></a><a name="_Toc74552592"></a><a name="_Toc74553472"></a><a name="_Ref46557349"></a><a name="_Ref53908800"></a><font style="font-weight:bold;text-decoration:none;">Background Technology</font><font style="Background-color:#FFFFFF;font-size:12pt;">. As between the Parties, (a)&#160;HFB will retain all rights, title, and interest in and to any Patent Rights, Know-How, and other intellectual property rights owned or Controlled by HFB or any of its Affiliates as of the Effective Date or generated or obtained by or on behalf of HFB or any of its Affiliates during the Term outside of the scope of performance of activities under this Agreement (the &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;font-size:12pt;">HFB Background Technology</font><font style="Background-color:#FFFFFF;font-size:12pt;">&#8221;), and (b)&#160;FibroGen will retain all rights, title, and interest in and to any Patent Rights, Know-How, and other intellectual property rights owned or Controlled by FibroGen or any of its Affiliates as of the Effective Date or generated or obtained by or on behalf of FibroGen or any of its Affiliates during the Term outside of the scope of performance of activities under this Agreement (the &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;font-size:12pt;">FibroGen Background Technology</font><font style="Background-color:#FFFFFF;font-size:12pt;">&#8221;). Other than as set forth in Sections 9.3(e) (Licensed Patent Rights) and 9.5 (Enforcement), each Party has the sole right, responsibility, and discretion to file, prosecute (including the defense of any oppositions, interferences, reissue proceedings, re-examinations, and other post-grant proceedings originating in a patent office), maintain, and enforce all of their background Patent Rights as follows: (i) FibroGen shall control the Patent Rights within the FibroGen Background Technology, </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;font-size:12pt;"> and (ii)&#160;HFB shall control Patent Rights within the HFB Background Technology, including HFB Screening Patent Rights, </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;font-size:12pt;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref74060849"></a><a name="_Toc74552593"></a><a name="_Toc74553473"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Ownership</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46595422"></a><a name="_Ref22232809"></a><font style="font-weight:bold;color:#000000;">Arising Technology</font><font style="color:#000000;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref58937119"></a><font style="color:#000000;">Ownership will follow inventorship for (A) any and all Know-How developed, created, conceived, or reduced to practice during the Term solely by or on behalf of a Party or any of its Affiliates in a Party&#8217;s performance of activities under this Agreement with respect to a Licensed Program (&#8220;</font><font style="font-weight:bold;color:#000000;">Arising Know-How</font><font style="color:#000000;">&#8221;) and (B) any Patent Right claiming, in whole or in part, any such Know-How described in clause (A) (the &#8220;</font><font style="font-weight:bold;color:#000000;">Arising Patent Rights</font><font style="color:#000000;">&#8221; and the Arising Know-How and Arising Patent Rights, the &#8220;</font><font style="font-weight:bold;color:#000000;">Arising Technology</font><font style="color:#000000;">&#8221;), with inventorship being determined in accordance with United States patent laws (regardless of where the applicable activities occurred). Arising Know-How invented solely by or on behalf of HFB or any of its Affiliates, and all Arising Patent Rights claiming any such Arising </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>31<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">Know-How (the &#8220;</font><font style="font-weight:bold;color:#000000;">HFB Arising Patent Rights</font><font style="color:#000000;">&#8221;) will be solely owned by HFB or any of its Affiliates (&#8220;</font><font style="font-weight:bold;color:#000000;">HFB Arising Technology</font><font style="color:#000000;">&#8221;). Arising Know-How invented solely by or on behalf of </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> or any of its Affiliates, and all Arising Patent Rights claiming, in whole or in part, any such Arising Know-How (the &#8220;</font><font style="font-weight:bold;color:#000000;">FibroGen</font><font style="font-weight:bold;color:#000000;"> Arising Patent Rights</font><font style="color:#000000;">&#8221;), </font><font style="color:#000000;">[*]</font><font style="color:#000000;"> will be solely owned by </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> or any of its Affiliates (&#8220;</font><font style="font-weight:bold;color:#000000;">FibroGen</font><font style="font-weight:bold;color:#000000;"> Arising Technology</font><font style="color:#000000;">&#8221;). Arising Know-How invented jointly by HFB or any of its Affiliates and </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> or any of its Affiliates (&#8220;</font><font style="font-weight:bold;color:#000000;">Joint Arising Know-How</font><font style="color:#000000;">&#8221;), and all Arising Patent Rights claiming, in whole or in part, any such Arising Know-How (the &#8220;</font><font style="font-weight:bold;color:#000000;">Joint Arising Patent Rights</font><font style="color:#000000;">&#8221;) will be jointly owned by both Parties (&#8220;</font><font style="font-weight:bold;color:#000000;">Joint Arising Technology</font><font style="color:#000000;">&#8221;).</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">HFB will promptly disclose to FibroGen any (A) HFB Arising Technology that is Licensed Technology or (B) Joint Arising Technology, as applicable, developed, created, conceived, or reduced to practice by or on behalf of HFB or any of its Affiliates during the Term. FibroGen will promptly disclose to HFB any FibroGen Arising Technology or Joint Arising Technology, as applicable, developed, created, conceived, or reduced to practice by or on behalf of FibroGen or any of its Affiliates during the Term. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_DV_M410"></a><font style="color:#000000;">Each Party will have an undivided one-half (1/2) interest in and to the Joint Arising Technology. Each Party may exercise its ownership rights in and to such Joint Arising Technology, including the right to license and sublicense or otherwise to exploit, transfer, or encumber its ownership interest, without an accounting or obligation to, or consent required from, the other Party, but subject to the licenses hereunder and the other relevant terms and conditions of this Agreement. Each Party hereby [*] is required to effect<a name="_DV_M410"></a> the foregoing regarding Joint Arising Technology. Each Party, for itself and on behalf of any of its Affiliates, licensees, and Sublicensees, and employees, subcontractors, consultants, and agents of any of the foregoing, hereby assigns (and to the extent such assignment can only be made in the future, hereby agrees to assign), to the other Party (and the other Party hereby accepts such assignment) a joint and undivided interest in and to all Joint Arising Technology. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_9kR3WTr2664BKRFy0ruru363aV34n14vu15miy2"></a><font style="color:#000000;"><a name="_9kR3WTr2664BKRFy0ruru363aV34n14vu15miy2"></a>Notwithstanding any provision to the contrary set forth in this Agreement, neither Party may invoke this Agreement as a &#8220;joint research agreement&#8221; pursuant to the Cooperative Research and Technology Enhancement Act, 35 U.S.C. &#167; 102(c) without the prior written consent of the other Party. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref401173242"></a><a name="_Toc74552594"></a><a name="_Toc74553474"></a><font style="font-weight:bold;text-decoration:none;">Prosecution, Maintenance &amp; Enforcement</font><font style="Background-color:#FFFFFF;font-size:12pt;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref73533870"></a><a name="_Ref401175117"></a><font style="font-weight:bold;color:#000000;">FibroGen Arising Patent Rights</font><font style="color:#000000;">. FibroGen will have the sole right, responsibility, and discretion to file, prosecute (including the defense of any oppositions, interferences, reissue proceedings, re-examinations, and other post-grant proceedings originating in a patent office), and maintain all FibroGen Arising Patent Rights and at its sole cost and expense. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">HFB Arising Patent Rights</font><font style="color:#000000;">. HFB will have the sole right, responsibility and discretion to file, prosecute (including the defense of any oppositions, interferences, reissue proceedings, re-examinations and other post-grant proceedings originating in a patent office), and maintain all HFB Arising Patent Rights at its sole cost and expense, </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;">, that (i) any HFB Arising Patent Rights that are Option Patent Rights will be subject to </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>32<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">Section </font><font style="color:#000000;">9.3(d)</font><font style="color:#000000;"> (Option Patent Rights) and any HFB Arising Patent Rights that are Licensed Patent Rights will be subject to Section </font><font style="color:#000000;">9.3(e)</font><font style="color:#000000;"> (Licensed Patent Rights).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref67775837"></a><a name="_Ref70609561"></a><font style="font-weight:bold;color:#000000;">Joint Arising Patent Rights</font><font style="color:#000000;">. FibroGen will have the first right, responsibility, and discretion to file, prosecute (including the defense of any oppositions, interferences, reissue proceedings, re-examinations, and other post-grant proceedings originating in a patent office), and maintain all Joint Arising Patent Rights, in the Territory using counsel mutually agreed by the Parties (such agreement not to be unreasonably withheld by either Party), which may [*]. The Parties will use good faith efforts to agree on a mutually acceptable strategy and will coordinate with each other for the prosecution and maintenance of all Joint Arising Patent Rights. If FibroGen decides it is no longer interested in the prosecution or maintenance of a particular Joint Arising Patent Right in any country the Territory, or [*], then it will promptly provide written notice to HFB of such decision. HFB may, upon written notice to FibroGen, assume the prosecution and maintenance of such Patent Rights in such country in the Territory. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref65260341"></a><a name="_Ref401866882"></a><a name="_Ref401866888"></a><a name="_Ref405396219"></a><a name="_Ref405404347"></a><a name="_Ref431872275"></a><a name="_Ref431873284"></a><font style="font-weight:bold;color:#000000;">Option Patent Rights</font><font style="color:#000000;">. [*], HFB will have the sole right, responsibility and discretion to file, prosecute (including the defense of any oppositions, interferences, reissue proceedings, re-examinations and other post-grant proceedings originating in a patent office), and maintain all Option Patent Rights [*], </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;">, that, HFB will provide to FibroGen [*] provided by FibroGen with respect thereto. HFB will provide to FibroGen electronic copies of all submitted filings related to any Option Patent Rights as part of the Option Notice in accordance with Section 2.9(c)(i) (Delivery). For the avoidance of doubt, upon the Option Exercise Date with respect to an Option Program, the Option Patent Rights with respect to such Option Program will automatically become Licensed Patent Rights for all purposes under this Agreement, including without limitation Section 9.3(e) (Licensed Patent Rights). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref65260785"></a><font style="font-weight:bold;color:#000000;">Licensed Patent Rights</font><font style="color:#000000;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref431872195"></a><a name="_Ref401866022"></a><a name="_Ref405413247"></a><font style="color:#000000;">[*] If FibroGen declines to file for, prosecute, or maintain (including defending or prosecuting office actions, prosecutions or interferences) any Licensed Patent Right in the Territory, then it will give HFB reasonable notice thereof and thereafter, HFB may, upon written notice to FibroGen and at HFB&#8217;s sole cost, control the filing for, prosecution and maintenance of such Licensed Patent Right in the Territory thereafter in accordance with this Section 9.3(e)(i) (Licensed Technology), </font><font style="font-style:italic;color:#000000;">mutatis mutandis</font><font style="color:#000000;">. </font><font style="font-weight:bold;font-style:italic;color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">No later than [*], HFB will (A) provide FibroGen, [*], with electronic copies of documents (including file histories and then current dockets) for the applicable Licensed Patent Rights that are in the file maintained by HFB&#8217;s in-house or outside patent counsel for such Patent Rights in the Territory or otherwise available to HFB, including any communications, filings and drafts as well as written notice of any pending deadlines or communications for such Licensed Patent Rights (</font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="font-style:italic;color:#000000;">however</font><font style="color:#000000;">, that HFB will provide notice of pending deadlines as promptly as possible after the Effective Date so as to ensure adequate time and coordination with respect to such deadlines), and (B) execute and deliver any legal papers reasonably requested by FibroGen to effectuate transfer of control of the filing, prosecution, and maintenance of the Licensed Patent Rights in the Territory. In the event HFB assumes control of the preparation of, filing for, and prosecution and maintenance (including the defense of any oppositions, interferences, reissue </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>33<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">proceedings, re-examinations and other post-grant proceedings originating in a patent office) in the Territory with respect to any Licensed Patent Rights pursuant to Section </font><font style="color:#000000;">9.3(e)(</font><font style="color:#000000;">i</font><font style="color:#000000;">)</font><font style="color:#000000;"> (Licensed Patent Rights), then </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> will (1) provide HFB with electronic copies of any relevant communications, filings, drafts, and documents not previously provided to HFB as well as written notice of any pending deadlines or communications applicable thereto (including file histories and then current dockets), and (2) execute and deliver any legal papers reasonably requested by HFB to effectuate transfer of control of the filing, prosecution, and maintenance of such Licensed Patent Rights.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">Each Party will reasonably cooperate with the other Party in the filing, prosecution, defense, and maintenance of the Licensed Patent Rights. Such cooperation includes promptly executing all documents, requiring inventors to be reasonably available to discuss and review applications and other filings, and requiring inventors, subcontractors, employees and consultants and agents of such Party and any of its Affiliates, and for the prosecuting Party and any of its Affiliates and Sublicensees (with respect to FibroGen), to execute all documents, as reasonable and appropriate so as to enable the prosecution and maintenance of any such Licensed Patent Rights. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref410098659"></a><a name="_Ref72497600"></a><a name="_Toc74552595"></a><a name="_Toc74553475"></a><a name="_Ref410099465"></a><a name="_Ref410098954"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Defense and Settlement of Third Party<a name="_Ref410099465"></a><a name="_Ref410098954"></a> Claims</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. From and after the Effective Date, if a </font><font style="Background-color:#FFFFFF;font-size:12pt;">Third Party </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">asserts that a Patent Right or other right owned by it is infringed by the </font><font style="Background-color:#FFFFFF;font-size:12pt;">Exploitation</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> of any </font><font style="Background-color:#FFFFFF;font-size:12pt;">Licensed Compound </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">or </font><font style="Background-color:#FFFFFF;font-size:12pt;">Licensed Product </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">in the </font><font style="Background-color:#FFFFFF;font-size:12pt;">Field in the Territory</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font><font style="Background-color:#FFFFFF;font-size:12pt;">Each Party will </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">give the other Party</font><font style="Background-color:#FFFFFF;font-size:12pt;"> </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">prompt written notice of any allegation by any </font><font style="Background-color:#FFFFFF;font-size:12pt;">Third Party </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">that a Patent Right or other right owned by it is infringed by the </font><font style="Background-color:#FFFFFF;font-size:12pt;">Exploitation</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> of any </font><font style="Background-color:#FFFFFF;font-size:12pt;">Licensed Compound </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">or </font><font style="Background-color:#FFFFFF;font-size:12pt;">Licensed Product in the Territory and then the Parties shall confer</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font><font style="Background-color:#FFFFFF;font-size:12pt;">FibroGen will </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">have the first right, but not the obligation, to defend against any such assertions at </font><font style="Background-color:#FFFFFF;font-size:12pt;">FibroGen&#8217;s </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">sole cost or elect to settle such claims </font><font style="Background-color:#FFFFFF;font-size:12pt;">(except as set forth below)</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. FibroGen will promptly inform HFB if it elects not to exercise its first right under this Section 9.4 (Defense and Settlement of Third Party Claims) to defend against such assertion and, following discussion with FibroGen, [*], HFB will have the second right, but not the obligation, to defend against any such assertions at HFB</font><font style="Background-color:#FFFFFF;font-size:12pt;">&#8217;s </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">sole cost. The other Party and </font><font style="Background-color:#FFFFFF;font-size:12pt;">any of its Affiliates will </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">assist </font><font style="Background-color:#FFFFFF;font-size:12pt;">the defending Party </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">and cooperate in any such litigation at </font><font style="Background-color:#FFFFFF;font-size:12pt;">the defending Party&#8217;s</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> request. </font><font style="Background-color:#FFFFFF;font-size:12pt;">The other Party </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">may join any defense pursuant to this Section&#160;9.4 (Defense and Settlement of Third Party Claims), with its own counsel, [*]. </font><font style="Background-color:#FFFFFF;font-size:12pt;">The defending Party or any of its Affiliates may </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">settle or consent to the entry of any judgment in any enforcement action </font><font style="Background-color:#FFFFFF;font-size:12pt;">hereunder </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">without the other Party</font><font style="Background-color:#FFFFFF;font-size:12pt;">&#8217;s</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> prior consent; </font><font style="font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:12pt;">provided</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">, </font><font style="font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:12pt;">however</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">, that any such settlement or consent judgment will not, without the prior written consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed), impose any liability or obligation on the other Party or any of its Affiliates. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref54519183"></a><a name="_Toc74552596"></a><a name="_Toc74553476"></a><a name="_Ref410099436"></a><font style="font-weight:bold;text-decoration:none;color:#000000;"><a name="_Ref410099436"></a>Enforcement</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref54519162"></a><font style="font-weight:bold;color:#000000;">Enforcement and Cooperation</font><font style="color:#000000;">. If in the Territory, (i) </font><font style="color:#000000;">HFB </font><font style="color:#000000;">or </font><font style="color:#000000;">FibroGen </font><font style="color:#000000;">becomes aware of any actual or suspected infringement of any </font><font style="color:#000000;">Licensed Patent Right or Joint Arising Patent Right</font><font style="color:#000000;">, or (ii) any such </font><font style="color:#000000;">Licensed Patent Right or Joint Arising Patent Right </font><font style="color:#000000;">is challenged in any action or proceeding (other than any interferences, oppositions, reissue proceedings or re-examinations, which are addressed in Section 9.3(e) (Licensed Patent </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>34<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">Rights)), then such </font><font style="color:#000000;">Party will </font><font style="color:#000000;">notify the other </font><font style="color:#000000;">Party </font><font style="color:#000000;">promptly, and following such notification, the </font><font style="color:#000000;">Parties will </font><font style="color:#000000;">confer. </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> will </font><font style="color:#000000;">have the first right, but </font><font style="color:#000000;">will </font><font style="color:#000000;">not be obligated, to defend any such action or proceeding in the Territory or bring an infringement action with respect to such infringement in the Territory </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">. </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> will promptly inform HFB if it elects not to exercise its first right under this Section </font><font style="color:#000000;">9.5(a)</font><font style="color:#000000;"> (Enforcement and Cooperation) to defend any such action in the Territory or proceeding or to bring an infringement action, and </font><font style="color:#000000;">HFB will thereafter have the second right, </font><font style="color:#000000;">but </font><font style="color:#000000;">will </font><font style="color:#000000;">not be obligated, to defend any such action or proceeding in the Territory or bring an infringement action with respect to such infringement in the Territory </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;">. HFB will keep </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> reasonably informed of all developments in any action or proceeding. Regardless of which Party exercises its right </font><font style="color:#000000;">this Section </font><font style="color:#000000;">9.5(a)</font><font style="color:#000000;"> (Enforcement and Cooperation), </font><font style="color:#000000;">the other Party and its Affiliates will </font><font style="color:#000000;">reasonably assist </font><font style="color:#000000;">such enforcing Party </font><font style="color:#000000;">in any action or proceeding being defended or prosecuted if so requested, and </font><font style="color:#000000;">will agree to </font><font style="color:#000000;">be named in the filing or join in such action or proceeding if requested by</font><font style="color:#000000;"> such enforcing Party</font><font style="color:#000000;">. If </font><font style="color:#000000;">the other Party </font><font style="color:#000000;">elects to be represented by legal counsel, then </font><font style="color:#000000;">the enforcing Party will </font><font style="color:#000000;">bear all of </font><font style="color:#000000;">such Party&#8217;s </font><font style="color:#000000;">related and reasonable legal costs and expenses if </font><font style="color:#000000;">the other Party </font><font style="color:#000000;">is required to be named in the filing or joined in such action or proceeding or is joined in such action or proceeding at </font><font style="color:#000000;">the enforcing Party&#8217;s</font><font style="color:#000000;"> request.</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46590613"></a><font style="font-weight:bold;color:#000000;">Damages</font><font style="color:#000000;">. In the event that either Party</font><font style="color:#000000;"> </font><font style="color:#000000;">exercises the rights conferred in this Section 9.5</font><font style="color:#000000;"> (Enforcement) </font><font style="color:#000000;">and recovers any damages, payments, or other sums in such action or proceeding or in settlement thereof, then such damages or other sums recovered </font><font style="color:#000000;">will </font><font style="color:#000000;">first be applied to all out-of-pocket costs and expenses incurred by such enforcing Party</font><font style="color:#000000;"> </font><font style="color:#000000;">in connection therewith (</font><font style="color:#000000;">including </font><font style="color:#000000;">attorney&#8217;s fees). <a name="_Ref46590613"></a>[*]</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.6</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46675313"></a><a name="_Toc74552597"></a><a name="_Toc74553477"></a><a name="_Ref410849909"></a><font style="font-weight:bold;text-decoration:none;color:#000000;"><a name="_Ref410849909"></a>Trademarks</font><font style="Background-color:#FFFFFF;font-size:12pt;">. FibroGen will have the sole right to brand the Licensed Products in the Territory using trademarks, logos, and trade names that it determines appropriate, which may vary by region or within a region (the &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;font-size:12pt;">Product Marks</font><font style="Background-color:#FFFFFF;font-size:12pt;">&#8221;). FibroGen will solely own all rights, title, and interest in and to any Product Marks adopted for use with the Licensed Products in the Territory, and will be responsible for the registration, filing, maintenance, and enforcement thereof at its own cost and expense. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.7</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref68879013"></a><a name="_Toc74552598"></a><a name="_Toc74553478"></a><a name="_Ref54519139"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">CREATE Act</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Notwithstanding anything to the contrary in this Article 9 (Intellectual Property), neither Party will have the right to make an election under the CREATE Act when exercising its rights under this Article 9 (Intellectual Property) without the prior written consent of the other Party, which will not be unreasonably withheld, conditioned or delayed. With respect to any such permitted election, the Parties will use reasonable efforts to cooperate and coordinate their activities with respect to any submissions, filings or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a &#8220;joint research agreement&#8221; as defined in the CREATE Act. Notwithstanding the foregoing, HFB&#8217;s consent under this Section&#160;9.7 (CREATE Act) will not be required in connection with an obviousness-type double patenting rejection in any patent application filed by FibroGen or its Affiliate claiming a Licensed Compound, Licensed Product, or uses thereof. In the event of an obviousness-type double patenting rejection in any patent application filed by FibroGen or its Affiliate claiming a Licensed Compound or Licensed Product where such rejection is due to any Patent Right within the HFB Background Technology, HFB will discuss and consider [*] such Patent Right to FibroGen.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>35<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552599"></a><a name="_Toc74553479"></a><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;text-decoration:none;color:#000000;">Patent Right Extensions; Regulatory Exclusivity</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref22242335"></a><font style="font-weight:bold;color:#000000;">Patent Right Term Extension</font><font style="color:#000000;">. If elections with respect to obtaining patent </font><font style="color:#000000;">term </font><font style="color:#000000;">extension or supplemental protection certificates or their equivalents in any country in the Territory with respect to any </font><font style="color:#000000;">Licensed Product </font><font style="color:#000000;">becomes available, upon </font><font style="color:#000000;">Regulatory Approval </font><font style="color:#000000;">or otherwise, then </font><font style="color:#000000;">FibroGen will </font><font style="color:#000000;">have the sole right to file for patent term extension or supplemental protection certificates or their equivalents and to determine which issued patent to extend. HFB and any of its Affiliates will reasonably cooperate with FibroGen so as to enable FibroGen to exercise its rights under this Section&#160;9.8(a) (Patent Right Term Extension). Such cooperation includes promptly executing all documents, requiring inventors to be available to discuss and review any filings, and requiring inventors, subcontractors, employees, consultants, and agents of HFB or any of its Affiliates to execute all documents, as reasonable and appropriate so as to enable FibroGen to exercise its rights under this Section&#160;9.8(a) (Patent Right Term Extension). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref411565647"></a><a name="_Ref410836061"></a><a name="_Ref46595590"></a><font style="font-weight:bold;color:#000000;">Regulatory Exclusivity</font><font style="color:#000000;">. With respect to Regulatory Exclusivity periods (such as orphan drug exclusivity and</font><font style="color:#000000;"> any available pediatric extensions), FibroGen </font><font style="color:#000000;">will </font><font style="color:#000000;">have the sole right </font><font style="color:#000000;">to seek and maintain all such Regulatory Exclusivity periods that may be available for the Licensed Products in the Field in the Territory.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;color:#010000;font-family:Times New Roman Bold;text-transform:uppercase;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref401172032"></a><a name="_Ref401868182"></a><a name="_Ref52788416"></a><a name="_Toc74552600"></a><a name="_Toc74553480"></a>Article 10<font style="color:#000000;font-family:Times New Roman;text-transform:none;"><br /><a name="_Ref401172032"></a><a name="_Ref401868182"></a><a name="_Ref52788416"></a><a name="_Toc74552600"></a><a name="_Toc74553480"></a>REPRESENTATIONS, WARRANTIES, AND COVENANTS</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552601"></a><a name="_Toc74553481"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Mutual Representations, Warranties, and Covenants</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Each Party hereby represents and warrants to the other Party as of the Effective Date, and covenants, as applicable, as a material inducement for such other Party&#8217;s entry into this Agreement, as follows: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Corporate Existence and Power</font><font style="color:#000000;">. It is a company or corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement, including the right to grant the licenses granted by it hereunder.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Authority and Binding Agreement</font><font style="color:#000000;">. (i) It has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">No Conflict</font><font style="color:#000000;">. It is not a party to and will not enter into any agreement that would prevent it from granting the rights or exclusivity granted or intended to be granted to the other Party under this Agreement or performing its obligations under this Agreement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref71210627"></a><font style="font-weight:bold;color:#000000;">Consents</font><font style="color:#000000;">. All consents, approvals, and authorizations from all governmental authorities or other Third Parties required to be obtained by such Party in connection with this Agreement have been obtained.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>36<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Bankruptcy; Insolvency</font><font style="color:#000000;">. It and its Affiliates are not subject to any action or petition, pending or otherwise, for bankruptcy or insolvency in any state, country, or other jurisdiction, and it is not aware of any facts or circumstances that could result in such Party or any of its Affiliates becoming or being declared insolvent, bankrupt, or otherwise incapable of meeting its obligations under this Agreement as they become due in the ordinary course of business. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">No Debarment</font><font style="color:#000000;">. </font><font style="color:#000000;">Neither it nor any of its employees nor to its knowledge, any of the agents performing hereunder, has ever been, is currently, or is the subject of a proceeding that could lead to it or such employees or agents becoming, as applicable, a Debarred Entity or Debarred Individual, an Excluded Entity, or Excluded Individual or a Convicted Entity or Convicted Individual. For purposes of this Agreement, the following definitions will apply:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">A &#8220;</font><font style="font-weight:bold;color:#000000;">Debarred Individual</font><font style="color:#000000;">&#8221; is an individual who has been debarred by the FDA pursuant to 21 U.S.C. &#167;335a (a) or (b) from providing services in any capacity to a person that has an approved or pending drug or biological product application.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">A &#8220;</font><font style="font-weight:bold;color:#000000;">Debarred Entity</font><font style="color:#000000;">&#8221; is a corporation, partnership or association that has been debarred by the FDA pursuant to 21 U.S.C. &#167;335a (a) or (b) from submitting or assisting in the submission of any abbreviated drug application, or a subsidiary or Affiliate of a Debarred Entity.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">An &#8220;</font><font style="font-weight:bold;color:#000000;">Excluded Individual</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;color:#000000;">Excluded Entity</font><font style="color:#000000;">&#8221; is (A) an individual or entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in federal health care programs such as Medicare or Medicaid by the Office of the Inspector General (OIG/HHS) of the U.S. Department of Health and Human Services, or (B) is an individual or entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in federal procurement and non-procurement programs, including those produced by the U.S. General Services Administration (GSA).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">A &#8220;</font><font style="font-weight:bold;color:#000000;">Convicted Individual</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;color:#000000;">Convicted Entity</font><font style="color:#000000;">&#8221; is an individual or entity, as applicable, who has been convicted of a criminal offense that falls within the ambit of 21 U.S.C. &#167;335a (a) or 42 U.&#8211;.C. &#167;1320a - 7(a), but has not yet been excluded, debarred, suspended, or otherwise declared ineligible.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46858504"></a><a name="_Toc74552602"></a><a name="_Toc74553482"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Representations and Warranties by HFB</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font><font style="Background-color:#FFFFFF;font-size:12pt;">HFB further represents and warrants to FibroGen (I)&#160;with respect to the Gal-9 Licensed Program, </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;font-size:12pt;">, except as set forth in Schedule 10.2 and (II) on an Option Program-by-Option Program basis, </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;font-size:12pt;"> in accordance with Section 2.9(c) (Option Notice) (the &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;font-size:12pt;">Option Notice Delivery Date</font><font style="Background-color:#FFFFFF;font-size:12pt;">&#8221;), except as set forth in the disclosure letter delivered to FibroGen </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;font-size:12pt;"> (the &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;font-size:12pt;">Disclosure Letter</font><font style="Background-color:#FFFFFF;font-size:12pt;">&#8221;), as follows:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref54442769"></a><font style="font-weight:bold;color:#000000;">No Conflicts</font><font style="color:#000000;">. Neither HFB nor any of its Affiliates has entered into any agreement (other than agreements with subcontractors) granting any right, interest or claim in or to, any Licensed Technology or Option Technology to any Third Party that would conflict with the licenses and other rights granted to FibroGen under this Agreement. The Licensed Technology constitutes all intellectual property rights Controlled by HFB and any of its Affiliates that are necessary or reasonably useful for the Exploitation of the Licensed Compounds in the Field in the Territory. All Existing Patent Rights are exclusively owned or exclusively licensed by HFB or any of its Affiliates, and are free and clear of any (i) </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>37<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">liens, charges, security interests, and encumbrances or licenses and (ii) claims or covenants, in each case that would conflict with or limit the scope of any of the rights or licenses granted to </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> hereunder, or would give rise to any Third Party claims for payment against </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> or any of its Affiliates.</font><font style="color:#000000;"> </font><font style="color:#000000;">HFB is entitled to grant the license granted to </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> under Section </font><font style="color:#000000;">2.1</font><font style="color:#000000;"> (License to </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;">), and HFB has taken all appropriate measures under all applicable laws to grant such licenses. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">No Notice of Infringement or Misappropriation</font><font style="color:#000000;">. (i) Neither HFB nor any of its Affiliates have received or is aware of any written notice from any Third Party asserting or alleging that any Exploitation of any Licensed Technology, any Licensed Compound, any Option Technology, or any Option Compound has infringed or misappropriated, or would infringe or misappropriate, the intellectual property rights of any Third Party, and (ii) no claim is pending, and HFB and any of its Affiliates and, to HFB&#8217;s knowledge, any Third Party collaborator, has not received from a Third Party notice of a claim or threatened claim to the effect that any granted Patent Right rights within the Licensed Technology licensed to FibroGen under this Agreement, or the Option Technology, is invalid or unenforceable. To HFB&#8217;s knowledge, the Exploitation of the Licensed Compound, and Option Compound as contemplated hereunder will not infringe, misappropriate, or otherwise violate the intellectual property rights of any Third Party. Additionally, to HFB&#8217;s knowledge, there is no unauthorized use, infringement or misappropriation of any Licensed Technology or Option Technology by any Third Party as of the Effective Date. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref54443052"></a><a name="_Ref54446702"></a><font style="font-weight:bold;color:#000000;">No Misappropriation</font><font style="color:#000000;">. To HFB&#8217;s knowledge, no employee, consultant, agent or independent contractor of HFB, any of its Affiliates, or Third Party, has misappropriated any Licensed Technology or Option Technology. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref431832413"></a><a name="_Ref46672724"></a><a name="_Ref398123207"></a><a name="_Ref408752592"></a><a name="_Ref46525606"></a><font style="font-weight:bold;color:#000000;"><a name="_Ref398123207"></a><a name="_Ref408752592"></a>Licensed Technology</font><font style="color:#000000;">. All Existing Patent Rights are listed on Schedule 1.89 (Existing Patent Rights). All Existing Patent Rights have been and are being diligently prosecuted in the respective patent offices in the Territory in accordance with applicable law, have been and are being filed and maintained properly, and all applicable fees have been paid on or before the due date for payment, and the Existing Patent Rights that have issued are subsisting and not invalid or unenforceable, in whole or in part. The Existing Patent Rights represent all Patent Rights Controlled by HFB and any of its Affiliates that are necessary or reasonably useful for the Exploitation of the Licensed Compounds in the Territory.<a name="_Ref46525606"></a> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Option Programs</font><font style="color:#000000;">. (i) HFB has the right to use all Option Technology to Exploit the Option Compounds in the Territory as contemplated under this Agreement; and (ii) the Development, Commercialization, or other Exploitation of the Option Compounds as contemplated herein will not conflict with any other license or agreement to which HFB or any of its Affiliates is a party.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref47474563"></a><a name="_Ref46525526"></a><a name="_Ref47116244"></a><font style="font-weight:bold;color:#000000;">Option Technology</font><font style="color:#000000;">. (i) Schedule&#160;10.2(f) (Option Patent Rights) sets forth a complete and accurate list of all Patent Rights existing as of </font><font style="color:#000000;">[*]</font><font style="color:#000000;"> that are Controlled by HFB or any of its Affiliates that are necessary or </font><font style="color:#000000;">reasonably </font><font style="color:#000000;">useful to Develop, Manufacture, Commercialize, or otherwise Exploit any Option Compound in the Territory (the &#8220;</font><font style="font-weight:bold;color:#000000;">Option Patent Rights</font><font style="color:#000000;">&#8221;) and (ii) HFB does not own or hold rights to any Patent Rights that would otherwise fall within the foregoing clause (i)&#160;but for the fact that it does not Control such Patent Rights, HFB exclusively owns or exclusively licenses all rights, title, and interests in and to all Option Patent Rights. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>38<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref68874903"></a><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;color:#000000;">Licensed Compound</font><font style="color:#000000;">. HFB has disclosed to </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> all compounds that HFB or any of its Affiliates owns or in-licenses that are the subject of the Gal-9 Licensed Program or each Option Program, as applicable.</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref68120707"></a><font style="font-weight:bold;color:#000000;">HFB Assignment</font><font style="color:#000000;">. For the Existing Patent Rights that are owned by HFB or its Affiliates, all employees, consultants, contractors, and other Persons who have contributed to the development, creation, conception or invention of any of the Existing Patent Rights have executed a written agreement assigning to HFB or any of its Affiliates all rights to such developments, creations, conceptions or inventions, or Existing Patent Rights, and neither HFB nor any of its Affiliates has received any written communication challenging HFB&#8217;s ownership or right to the Existing Patent Rights. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">All Material Information Furnished</font><font style="color:#000000;">. HFB has furnished or made available to FibroGen or its agents or representatives (i) all [*] requested by FibroGen, (ii) all material safety and efficacy data, (iii) all material regulatory filings and other correspondence with Regulatory Authorities, and (iv) [*], in each case ((i) through (iv)), concerning the Licensed Compounds, the Option Compounds, the Licensed Technology and the Option Technology. All such material information and data, regulatory filings and other correspondence with Regulatory Authorities is [*]</font><font style="color:#000000;">.</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Conduct of Research and Development</font><font style="color:#000000;">. HFB and its Affiliates have conducted all Development of Licensed Compound and Option Compound in accordance with all Applicable Law.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref54360068"></a><font style="font-weight:bold;color:#000000;">Upstream License</font><font style="color:#000000;">. The Upstream License represents a complete and accurate list of all written agreements pursuant to which any Third Party (other than pursuant to Section 10.2(h) (Representations and Warranties by HFB)) has a license, covenant not to sue, option or other similar right that would be necessary or reasonably useful with respect to the Exploitation of any Licensed Compound, but not including [*]. The Upstream License remains in full force and effect. HFB is in compliance with all material terms of the Upstream License, and no circumstances exist which could reasonably be expected to result in a breach or default of any Upstream License. All consents or approvals required under the Upstream License in order for HFB to grant the rights granted to FibroGen under this Agreement have been obtained. Subject to and except as set forth in the Standby Letter, this Agreement is consistent in all material respects with the terms and condition, and meets all material requirements of, the Upstream License. HFB has provided FibroGen with a complete and correct copy of the Upstream License. HFB has not waived any of its material rights under the Upstream License, and, to its knowledge, no such material rights have lapsed or otherwise expired or been terminated. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(l)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref65876822"></a><font style="font-weight:bold;color:#000000;">Government Funding</font><font style="color:#000000;">. (i) To HFB&#8217;s knowledge, no Licensed Technology that is licensed to HFB under the Upstream License is subject to any funding agreement with any government or governmental agency, and (ii) no Licensed Technology owned by HFB or any of its Affiliates is subject to any funding agreement with any government or governmental agency.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(m)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Downstream Licenses</font><font style="color:#000000;">. Neither HFB nor any of its Affiliates have granted to any Third Party a license, covenant not to sue, option, or other right with respect to any Licensed Compound, or Option Compound in the Territory.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(n)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref53908871"></a><font style="font-weight:bold;color:#000000;">Consents</font><font style="color:#000000;">. Without limitation to Section 10.1(d) (Consents), each Party and its Affiliates have obtained all consents, approvals, and authorizations from all governmental authorities </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>39<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">required to be obtained by such Party or its Affiliates in connection with this Agreement and, as between the Parties, the Party responsible for obtaining any such consent, approval or authorization will be </font><font style="color:#000000;">[</font><font style="color:#000000;">*</font><font style="color:#000000;">]</font><font style="color:#000000;"> to any governmental authority for the failure by such Party or its Affiliates to obtain any such consent, approval or authorization. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552603"></a><a name="_Toc74553483"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">HFB Covenants</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">No Conflicting Grants</font><font style="color:#000000;">. </font><font style="color:#000000;">Following the Effective Date, HFB will not, and will cause its Affiliates not to, enter into any agreement with any Affiliate or Third Party that materially conflicts with or contradicts the terms and conditions set forth in this Agreement, including any agreement that would limit the grant of licenses or rights hereunder to the Licensed Technology or Option Technology.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref65692985"></a><font style="font-weight:bold;color:#000000;">Upstream License</font><font style="color:#000000;">. During the Term, HFB shall fulfill its obligations under the Upstream License and will not, [*]. HFB will provide FibroGen promptly with notice of the occurrence of any breach, amendment or termination (or HFB&#8217;s receipt of notice of an allegation of any such breach or termination, and a copy thereof) of the Upstream License, and if HFB fails to cure such breach in a timely manner, will permit FibroGen to cure such breach on HFB&#8217;s behalf. HFB shall furnish FibroGen with copies of all notices and correspondence that HFB receives in connection with the Upstream License related to FibroGen&#8217;s rights or obligations under this Agreement or that could reasonably be expected to adversely affect FibroGen&#8217;s right or obligations under this Agreement, [*].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Control of Licensed Technology</font><font style="color:#000000;">. HFB and its Affiliates will (a) maintain (i) ownership or Control of all Licensed Technology owned by HFB or its Affiliates at any time during the Term and (ii) Control of all Licensed Technology in-licensed by HFB or its Affiliates at any time during the Term, and (b) not assign, transfer, encumber, or otherwise grant any Third Party any rights with respect thereto, in the case of either (a) or (b) that would conflict with, limit the scope of, or materially adversely affect the rights granted to FibroGen under this Agreement;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref524455256"></a><font style="font-weight:bold;color:#000000;">Control of Option Technology</font><font style="color:#000000;">. HFB and its Affiliates will (a) maintain (i) ownership or Control of all Option Technology owned by HFB or its Affiliates at any time during the Option Term for each Option Program and (ii) Control of all Option Technology in-licensed by HFB or its Affiliates at any time during the Option Term for each Option Program, and (b) not assign, transfer, encumber, or otherwise grant any Third Party any rights with respect thereto, in the case of either (a) or (b), that would conflict with, limit the scope of, or materially adversely affect the rights granted to FibroGen under this Agreement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref71620726"></a><a name="_Ref72440521"></a><font style="font-weight:bold;color:#000000;">Negative Events</font><font style="color:#000000;">. During the Term, [*] will provide prompt written notice to [*] if [*] reasonably believes that any of the events set forth in Schedule 10.3(e) (Negative Events) have occurred or are reasonably likely to occur. Upon occurrence of any of the events set forth in Schedule 10.3(e) (Negative Events), (i) the Parties will cooperate and exercise their commercially reasonable efforts to agree on and carry out remediation plans with respect to such events and (ii) except to the extent required by applicable law, [*] will not take any action that conflicts with, limits the scope of, or materially adversely affects or diminishes the rights [*] under this Agreement. This Section 10.3(e) (Negative Events) is without limitation to any other remedy available [*] under this Agreement.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>40<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552604"></a><a name="_Toc74553484"></a><font style="font-weight:bold;text-decoration:none;">Mutual Covenants</font><font style="Background-color:#FFFFFF;font-size:12pt;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Compliance with Applicable Law</font><font style="color:#000000;">. Each Party will comply, </font><font style="color:#000000;">and will ensure that its Affiliates, Sublicensees, and subcontractors will comply,</font><font style="color:#000000;"> with the applicable law, including as applicable GLP, GCP, and cGMP</font><font style="color:#000000;"> and any applicable anti&#8209;corruption or anti&#8209;bribery laws or regulations of any governmental authority with jurisdiction over the activities performed by or on behalf of such Party or its Affiliates, Sublicensees, and subcontractors in each case</font><font style="color:#000000;">, in the course of performing its obligations or exercising its rights pursuant to this Agreement. </font><font style="color:#000000;">Neither Party nor its Affiliates, Sublicensees, and subcontractors will knowingly engage any agent to perform activities under this Agreement that has ever been, is currently, or is the subject of a proceeding that could lead to it or such employees or agents becoming, as applicable, a Debarred Entity or Debarred Individual, an Excluded Entity or Excluded Individual, or a Convicted Entity or Convicted Individual.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Assignment of Inventions</font><font style="color:#000000;">. Each Party will ensure, and will ensure that its Affiliates, Sublicensees, and subcontractors ensure that, any and all Persons involved in or performing any activities under this agreement by or on behalf of such Party have an obligation to assign such Persons&#8217; rights, title, and interests in and to any Know-How and Patent Rights to such Party prior to any such person performing such activities. As between the Parties, each Party, Sublicensees, and subcontractors will be solely responsible for the payment of, and such will pay, any rewards, remuneration, or other amounts payable with respect to inventions and technical achievements required by applicable law to be paid to its and its Affiliates&#8217;, Sublicensees&#8217;, and subcontractors&#8217; employees, consultants, contractors, or other Persons for the development or invention of any Know-How or Patent Rights; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Debarment</font><font style="color:#000000;">. In the performance of activities under this Agreement, each Party will not knowingly employ or use any Person that: (i) has ever been debarred or is subject to debarment or convicted of a crime for which an entity or person could be a Debarred Entity or Debarred Individual; or (ii) has ever been under indictment for a crime for which a person or entity could be so debarred. Each Party will inform the other Party in writing immediately if it or any Person that is performing activities under this Agreement is debarred or is subject to debarment or is the subject of a conviction described in Section&#160;306 of the FD&amp;C Act, or if any action, suit, claim, investigation, or legal or administrative proceeding is pending or threatened, relating to the debarment or conviction of such Party or any Person or entity used in any capacity by such Party or any of its Affiliates, Sublicensees, and subcontractors with respect to this Agreement or the performance of its other obligations or exercise of its rights under this Agreement. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Consents</font><font style="color:#000000;">. In the event that either Party determines that HFB would have been, </font><font style="color:#000000;">[*]</font><font style="color:#000000;"> in breach of Section 10.2(n), but for the [*], such Party will notify the other in writing and provide all relevant information with respect thereto. The Parties will thereafter work together promptly in good faith, </font><font style="color:#000000;">[*]</font><font style="color:#000000;"> to take all steps necessary in order to remedy such breach (including, if required, obtaining all consents, approvals and authorizations from all government authorities and paying any amounts required by applicable law to be paid to any governmental authority for the failure by such Party or its Affiliates to obtain any such consent, approval or authorization).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref65250180"></a><a name="_Toc74552605"></a><a name="_Toc74553485"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">NO OTHER REPRESENTATIONS OR WARRANTIES</font><font style="Background-color:#FFFFFF;color:#000000;text-transform:uppercase;font-size:12pt;">. EXCEPT AS EXPRESSLY STATED IN THIS Article 10 (REPRESENTATIONS, WARRANTIES AND COVENANTS), NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. all materials are provided &#8220;as-is.&#8221; EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>41<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"></p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;color:#010000;font-family:Times New Roman Bold;text-transform:uppercase;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref401171994"></a><a name="_Ref401172059"></a><a name="_Ref401866946"></a><a name="_Ref401867014"></a><a name="_Ref401867022"></a><a name="_Ref431900307"></a><a name="_Ref431900409"></a><a name="_Ref46563913"></a><a name="_Toc74552606"></a><a name="_Toc74553486"></a>Article 11<font style="color:#000000;font-family:Times New Roman;text-transform:none;"><br /><a name="_Ref401171994"></a><a name="_Ref401172059"></a><a name="_Ref401866946"></a><a name="_Ref401867014"></a><a name="_Ref401867022"></a><a name="_Ref431900307"></a><a name="_Ref431900409"></a><a name="_Ref46563913"></a><a name="_Toc74552606"></a><a name="_Toc74553486"></a>INDEMNIFICATION</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref401172886"></a><a name="_Ref46595796"></a><a name="_Toc74552607"></a><a name="_Toc74553487"></a><a name="_Ref401175176"></a><a name="_cp_text_1_167"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Indemnification by HFB</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Subject to the remainder of this Article 11 (Indemnification), HFB will defend, indemnify, and hold FibroGen, its Affiliates, and its and their respective officers, directors, employees, and agents (the &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">FibroGen</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> </font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">Indemnitees</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">&#8221;) harmless from and against any and all liabilities, losses, costs, damages, fees, expenses, or other amounts payable to a Third Party claimant, as well as any reasonable attorneys&#8217; fees and costs of litigation incurred by such FibroGen Indemnitees, all to the extent resulting from claims, suits, proceedings, or causes of action brought by or on behalf of such Third Party against such FibroGen<a name="_Ref401175176"></a> Indemnitees that arise from or relate to: (a) the [*] of any Licensed Compound, Licensed Product, Option Compound, or Option Product by or on behalf of HFB or any of its Affiliates </font><font style="color:#000000;font-size:12pt;">[*] </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"><a name="_cp_text_1_167"></a>with respect to such Licensed Compound, Licensed Product, Option Compound, or Option Product, (b) any activities performed by or on behalf of HFB or any of its Affiliates under this Agreement; (c) a breach of any of HFB&#8217;s representations, warranties, or Development or other obligations under this Agreement; (d) the willful misconduct or grossly negligent acts of HFB or any of its Affiliates; (e) violation of applicable law by any HFB Indemnitee; or (f) any claim or demand from any employee, consultant, contractor of HFB or its Affiliate or other Person who is an inventor of any Licensed Know-How or Licensed Patent Right with respect to the ownership thereof; excluding, in each case ((a), (b), (c), (d), (e) and (f)), any damages or other amounts for which FibroGen has an obligation to indemnify any HFB Indemnitee pursuant to Section&#160;11.2 (Indemnification by FibroGen). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref401172395"></a><a name="_Toc74552608"></a><a name="_Toc74553488"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Indemnification by FibroGen</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Subject to the remainder of this Article 11 (Indemnification), FibroGen will defend, indemnify, and hold HFB, its Affiliates, and each of their respective officers, directors, employees, and agents (the &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">HFB</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> </font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">Indemnitees</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">&#8221;) harmless from and against any and all damages or other amounts payable to a Third Party claimant, as well as any reasonable attorneys&#8217; fees and costs of litigation incurred by such HFB Indemnitees, all to the extent resulting from any claims, suits, proceedings, or causes of action brought by such Third Party against such HFB Indemnitees that arise from or relate to: (a) the Exploitation of Licensed Compound or Licensed Products by FibroGen or any of its Affiliates or Sublicensees in the Territory </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">; (b)&#160;a breach of any of FibroGen&#8217;s representations, warranties, or obligations under this Agreement; (c)&#160;the willful misconduct or grossly negligent acts of FibroGen or any of its Affiliates; (d) violation of applicable law by any FibroGen Indemnitee or (e) any claim or demand from any employee, </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>42<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">consultant, contractor of FGEN or its Affiliate or Sublicensee who is an inventor of any Patent Right with respect to the ownership thereof; excluding, in each case ((a), (b), (c), (d), and (e)), any damages or other amounts for which HFB has an obligation to indemnify any </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">FibroGen</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> Indemnitee pursuant to Section&#160;</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">11.1</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> (Indemnification by HFB).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref401172436"></a><a name="_Toc74552609"></a><a name="_Toc74553489"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Indemnification Procedures</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. The Party claiming indemnity under this Article 11 (Indemnification) (the &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">Indemnified Party</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">&#8221;) will give written notice to the Party from whom indemnity is being sought (the &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">Indemnifying Party</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">&#8221;) promptly after learning of the claim, suit, proceeding or cause of action for which indemnity is being sought (&#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">Claim</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">&#8221;). The Indemnifying Party&#8217;s obligation to defend, indemnify, and hold harmless pursuant to Section&#160;11.1 (Indemnification by HFB) or Section&#160;11.2 (Indemnification by FibroGen), as applicable, will be reduced to the extent the Indemnified Party&#8217;s delay in providing notification pursuant to the previous sentence results in actual prejudice to the Indemnifying Party; </font><font style="font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:12pt;">provided</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">, </font><font style="font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:12pt;">however</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">, that the failure by an Indemnified Party to give such notice or otherwise meet its obligations under this Section 11.3 (Indemnification Procedures) will not relieve the Indemnifying Party of its indemnification obligation under this Agreement. At its option, the Indemnifying Party may assume the defense and have exclusive control, at its own expense, of any Claim for which indemnity is being sought by giving written notice to the Indemnified Party within thirty (30) days after receipt of the notice of the Claim. The assumption of defense of the Claim will not be construed as an acknowledgment that the Indemnifying Party is liable to indemnify any Indemnified Party in respect of the Claim, nor will it constitute waiver by the Indemnifying Party of any defenses it may assert against the Indemnified Party&#8217;s claim for indemnification. The Indemnified Party will provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party&#8217;s expense, in connection with the defense. The Indemnified Party may participate in and monitor such defense with counsel of its own choosing at its sole expense; </font><font style="font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:12pt;">provided</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">, </font><font style="font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:12pt;">however</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">, the Indemnifying Party will have the right to assume and conduct the defense of the Claim with counsel of its choice. The Indemnifying Party will not settle any Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money. The Indemnified Party will not settle any such Claim without the prior written consent of the Indemnifying Party, which consent will not be unreasonably withheld, conditioned or delayed. If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (a) the Indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to the Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (b) the Indemnified Party reserves any right it may have under this Article 11 (Indemnification) to obtain indemnification from the Indemnifying Party.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref401175197"></a><a name="_Toc74552610"></a><a name="_Toc74553490"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Limitation of Liability</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font><font style="Background-color:#FFFFFF;color:#000000;text-transform:uppercase;font-size:12pt;">IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, EXEMPLARY, OR INDIRECT DAMAGES OF ANY KIND ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT OR ANY CLAIMS ARISING HEREUNDER, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>43<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#FFFFFF;color:#000000;text-transform:uppercase;font-size:12pt;">(WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE), REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION&#160;</font><font style="Background-color:#FFFFFF;color:#000000;text-transform:uppercase;font-size:12pt;">11.4</font><font style="Background-color:#FFFFFF;color:#000000;text-transform:uppercase;font-size:12pt;"> (LIMITATION OF LIABILITY) IS INTENDED TO OR WILL LIMIT OR RESTRICT (A) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION&#160;</font><font style="Background-color:#FFFFFF;color:#000000;text-transform:uppercase;font-size:12pt;">11.1</font><font style="Background-color:#FFFFFF;color:#000000;text-transform:uppercase;font-size:12pt;"> (INDEMNIFICATION BY HFB) OR SECTION </font><font style="Background-color:#FFFFFF;color:#000000;text-transform:uppercase;font-size:12pt;">11.2</font><font style="Background-color:#FFFFFF;color:#000000;text-transform:uppercase;font-size:12pt;"> (INDEMNIFICATION BY FIBROGEN), (B) DAMAGES AVAILABLE IN THE CASE OF A PARTY&#8217;S FRAUD, GROSS NEGLIGENCE, OR INTENTIONAL MISCONDUCT, OR (C) DAMAGES AVAILABLE TO A PARTY FOR A BREACH BY THE OTHER PARTY OF THE CONFIDENTIALITY OBLIGATIONS UNDER </font><font style="Background-color:#FFFFFF;color:#000000;text-transform:uppercase;font-size:12pt;">Article 12</font><font style="Background-color:#FFFFFF;color:#000000;text-transform:uppercase;font-size:12pt;"> (CONFIDENTIALITY), MISAPPROPRIATION OR INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS, OR THE OTHER PARTY&#8217;S BREACH OF ITS OBLIGATIONS UNDER SECTION </font><font style="Background-color:#FFFFFF;color:#000000;text-transform:uppercase;font-size:12pt;">2.8</font><font style="Background-color:#FFFFFF;color:#000000;text-transform:uppercase;font-size:12pt;"> (EXCLUSIVITY).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552611"></a><a name="_Toc74553491"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Insurance</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Each Party will maintain during the Term and </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> of any Licensed Product for which it is responsible hereunder, and at its cost, reasonable insurance with a reputable solvent insurer against liability and other risks associated with its activities contemplated by this Agreement in an amount appropriate for its business and products of the type that are the subject of this Agreement, and for its obligations under this Agreement; </font><font style="font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:12pt;">provided</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">, </font><font style="font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:12pt;">however</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">, that at a minimum, each Party will maintain, in force beginning at least [*] prior to enrollment of the first subject in a Clinical Trial, product liability insurance policy providing coverage of at least </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Each Party will furnish to the other Party evidence of such insurance upon request. Notwithstanding the foregoing, such obligation may be satisfied by a program of self-insurance. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;color:#010000;font-family:Times New Roman Bold;text-transform:uppercase;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref401171848"></a><a name="_Ref401171859"></a><a name="_Ref401171880"></a><a name="_Ref401171889"></a><a name="_Ref401172018"></a><a name="_Ref401172078"></a><a name="_Ref401172241"></a><a name="_Ref401866970"></a><a name="_Ref401867059"></a><a name="_Ref401867707"></a><a name="_Ref401868081"></a><a name="_Ref404340764"></a><a name="_Ref404355021"></a><a name="_Ref404381919"></a><a name="_Ref431479812"></a><a name="_Ref431900575"></a><a name="_Ref46580441"></a><a name="_Ref46585423"></a><a name="_Toc74552612"></a><a name="_Toc74553492"></a>Article 12<font style="color:#000000;font-family:Times New Roman;text-transform:none;"><br /><a name="_Ref401171848"></a><a name="_Ref401171859"></a><a name="_Ref401171880"></a><a name="_Ref401171889"></a><a name="_Ref401172018"></a><a name="_Ref401172078"></a><a name="_Ref401172241"></a><a name="_Ref401866970"></a><a name="_Ref401867059"></a><a name="_Ref401867707"></a><a name="_Ref401868081"></a><a name="_Ref404340764"></a><a name="_Ref404355021"></a><a name="_Ref404381919"></a><a name="_Ref431479812"></a><a name="_Ref431900575"></a><a name="_Ref46580441"></a><a name="_Ref46585423"></a><a name="_Toc74552612"></a><a name="_Toc74553492"></a>CONFIDENTIALITY</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref410748122"></a><a name="_Ref46595912"></a><a name="_Toc74552613"></a><a name="_Toc74553493"></a><a name="_Ref401172479"></a><a name="Confidential_Information"></a><a name="_Ref410249622"></a><a name="_Ref410249632"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Confidentiality; Exceptions</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, during the Term and for </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"><a name="Confidential_Information"></a> thereafter, the Parties agree that the receiving Party will keep confidential and will not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any information and materials furnished to it by or on behalf of the other Party or any of its Affiliates or generated pursuant to this Agreement (collectively, &#8220;</font><font style="Background-color:#FFFFFF;color:#000000;font-weight:bold;font-size:12pt;">Confidential Information</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">&#8221;). For any Confidential Information that constitutes a trade secret of either Party, the foregoing non-disclosure obligations will continue for as long as such Confidential Information remains a trade secret. Confidential Information of a Party or any of its Affiliates will include all information and materials disclosed by such Party or any of its Affiliates or their respective designees that (a)&#160;is marked as &#8220;Confidential,&#8221; &#8220;Proprietary,&#8221; or with similar designation at the time of disclosure or (b)&#160;by its nature can reasonably be expected to be considered Confidential Information by the recipient. Know-How disclosed orally will not be required to be identified as such to be considered Confidential Information. The terms of this Agreement and all Licensed Know-How will be deemed to be the Confidential Information of both Parties. All reports delivered by FibroGen to HFB hereunder will be the Confidential Information of FibroGen. On an Option Program-by-Option Program basis, all information and data regarding Option Compounds or Option Products with respect to </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>44<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">an Option Program whether generated before or after the Effective Date, including pursuant to activities contemplated by this Agreement, will be considered Confidential Information of both Parties, with both Parties deemed to be the receiving Party of such Confidential Information during the applicable Option Term, and</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"><a name="_Ref410249622"></a>the exceptions set forth in clauses (a), (d) and (e) below will not apply to such information and data during the Option Term. For the avoidance of doubt, Notwithstanding the foregoing, Confidential Information will not include any information to the extent that it can be established by written documentation by the receiving Party that such information (a) </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">was already known to the receiving Party, other than under an obligation of confidentiality (except to the extent such obligation has expired or an exception is applicable under the relevant agreement pursuant to which such obligation was established), at the time of disclosure, (b) </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"><a name="_Ref410249632"></a>was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party, (c)&#160;became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement, (d) </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">was independently developed by the receiving Party as demonstrated by written documentation prepared contemporaneously with such independent development, or</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> (e) was disclosed to the receiving Party, other than under an obligation of confidentiality (except to the extent such obligation has expired or an exception is applicable under the relevant agreement pursuant to which such obligation was established), by a Third Party who had no obligation not to disclose such information to others.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46818221"></a><a name="_Toc74552614"></a><a name="_Toc74553494"></a><a name="_Ref411530799"></a><a name="_Ref411565687"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Authorized Disclosure</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46566002"></a><a name="_Ref46817876"></a><font style="font-weight:bold;color:#000000;">Permitted Disclosure</font><font style="color:#000000;">. Except as expressly provided otherwise in this Agreement, each Party may use and disclose Confidential Information of the other Party solely as follows: (i)&#160;under appropriate confidentiality provisions substantially as protective or equivalent to those in this Agreement (but of shorter duration of no less than five (5) years from termination or expiration of the Agreement; provided, that in the case of the Third Parties described in the following clause (C), such terms of confidentiality need extend for no more than two years from the date of disclosure): (A)&#160;in connection with the performance of its obligations or as necessary or reasonably useful in the exercise of its rights under this Agreement, including the right to grant licenses or sublicenses as permitted hereunder, (B)&#160;to the extent such disclosure is reasonably necessary or reasonably useful in conducting Clinical Trials under this Agreement, or (C)&#160;to actual or </font><font style="font-style:italic;color:#000000;">bona fide</font><font style="color:#000000;"> potential (sub)licensees, acquirers or assignees, collaborators, investment bankers, investors or lenders </font><font style="color:#000000;">(including in connection with any royalty factoring transaction)</font><font style="color:#000000;">, or; (ii)&#160;to the extent such disclosure is to a governmental authority as reasonably necessary in filing or prosecuting Patent Right, copyright, and trademark applications in accordance with this Agreement, prosecuting or defending litigation related to this Agreement, complying with applicable governmental regulations with respect to performance under this Agreement (including any disclosure to any securities exchange), obtaining Regulatory Approval or fulfilling post&#8209;approval regulatory obligations for the Licensed Compound or Licensed Products, or otherwise required by applicable law; </font><font style="font-style:italic;color:#000000;">provided, however</font><font style="color:#000000;">, that if a Party is required by applicable law or the rules of any securities exchange or automated quotation system to make any such disclosure of the other Party&#8217;s Confidential Information then it will, except where impracticable for necessary disclosures (for example, in the event of medical emergency), </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>45<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">give reasonable advance notice to the other Party of such disclosure requirement and, in each of the foregoing, will use its reasonable efforts to secure confidential treatment of such Confidential Information required to be disclosed and will only disclose that Confidential Information that is required to be disclosed; (iii)&#160;to advisors (including lawyers and accountants) on a need to know basis, in each case under appropriate confidentiality provisions or professional standards of confidentiality substantially equivalent to those of this Agreement, or (iv)&#160;to the extent agreed to by the Parties.</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46566007"></a><a name="_Ref46818077"></a><a name="_Ref66991119"></a><font style="font-weight:bold;color:#000000;">SEC Filings and Other Disclosures</font><font style="color:#000000;">. Either Party may disclose the terms of this Agreement to the extent required to comply with applicable law, including the rules and regulations promulgated by the United States Securities and Exchange Commission or any equivalent governmental agency in any country in the Territory; </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;">, that such Party will provide the other Party a reasonable opportunity to review such disclosure and reasonably consider the other Party&#8217;s comments regarding confidential treatment sought for such disclosure, including redaction of financial terms and milestone events. The Parties will use Commercially Reasonable Efforts to conform their respective disclosures made pursuant to this Section 12.2(b) (SEC Filings and Other Disclosures) to the extent allowed under applicable law and the rules of any applicable securities exchange.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref65689680"></a><a name="_Ref46818190"></a><font style="font-weight:bold;color:#000000;">Press Release</font><font style="color:#000000;">. The Parties shall issue the mutually agreed press release set forth on Schedule 12.2(c) hereto (Initial Press Release) on a mutually agreed upon date following the Effective Date. Other than public disclosure permitted by Section 12.2(a) (Permitted Disclosures), Section 12.2(b) (Disclosure to SEC), this Section 12.2(c) (Press Release), and disclosures required by applicable law, the Parties agree that the portions of any other news release or other public announcement relating to this Agreement or the performance hereunder that would disclose information that is not already in the public domain, must first be reviewed and approved by both Parties (with such approval not to be unreasonably withheld or delayed). After a disclosure or other public announcement has been reviewed and approved by both Parties under this Section 12.2 (Authorized Disclosure), either Party may make subsequent public disclosures reiterating such information without having to obtain the other Party&#8217;s prior consent and approval, </font><font style="color:#000000;">so long as the information in such disclosure or other public announcement remains true, correct, and the most current information with respect to the subject matters set forth therein</font><font style="color:#000000;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref411580308"></a><a name="_Toc74552615"></a><a name="_Toc74553495"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Prior Agreement</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. This Agreement supersedes the Existing Nondisclosure Agreement. All confidential information exchanged between the Parties under the Existing Nondisclosure Agreement will be deemed Confidential Information of the disclosing Party and will be subject to the terms of this Agreement. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;color:#010000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;color:#010000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;color:#010000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref48699180"></a><a name="_Ref524455276"></a><a name="_Toc74552616"></a><a name="_Toc74553496"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Residual Knowledge</font><font style="Background-color:#FFFFFF;font-size:12pt;">. Notwithstanding any provision to the contrary set forth in this Agreement, use or disclosure by an authorized representative of a receiving Party of Confidential Information that is knowledge, technique, experience, or Know-How retained in the unaided memory of such authorized representative of the receiving Party that had authorized access to such Confidential Information (&#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;font-size:12pt;">Residual Knowledge</font><font style="Background-color:#FFFFFF;font-size:12pt;">&#8221;) will not violate the confidentiality, non-use and non-disclosure obligations set forth in this Agreement, </font><font style="font-style:italic;Background-color:#FFFFFF;font-size:12pt;">provided</font><font style="Background-color:#FFFFFF;font-size:12pt;"> that such authorized representative did not intentionally memorize such Confidential Information for use outside of this Agreement. Any use made by the receiving Party of any such Residual Knowledge is on an &#8220;as is, where is&#8221; basis, with all </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>46<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;color:#010000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#FFFFFF;font-size:12pt;">faults and all representations and warranties disclaimed and at its sole risk.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref431900838"></a><a name="_Ref432165388"></a><a name="_Ref46593181"></a><a name="_Toc74552617"></a><a name="_Toc74553497"></a><a name="_Ref524455280"></a><a name="_9kMHG5YVt9IE8BJD1rv3Dxqy6IEYTAC10P"></a><a name="_9kMHG5YVt9IEDKOE1rv3Dxqy6IEYTAC10P"></a><a name="_9kMHG5YVt9IGDGDcKpwky8uq66s3pT2MUYJ9D"></a><a name="_9kMHG5YVt9IG99ID1rv3Dxqy6IErc5L9E"></a><a name="_9kMHG5YVt9IGACIB1rv3Dxqy6IErc5L9E"></a><a name="_9kMHG5YVt9IGCHHxnfkkdn3D0s0sl3C8EFK"></a><a name="_9kMHG5YVt9IEBBC64mmBbM20qhwD03C8E"></a><a name="_9kMKJ5YVt4887DEVKifr6ykJP68BHH13IupL8FF"></a><a name="_9kMH3K6ZWuAJEEMHNIz14AAuwBjVtq2H9v"></a><a name="_9kMHG5YVt9IGDFGgKpwky98vsH"></a><a name="_9kMHG5YVt9IGEHJiKpwky98vsH"></a><a name="_9kMHG5YVt9IGFE9cKpwky98vsH"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Publications</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"><a name="_Ref524455280"></a>. </font><font style="Background-color:#FFFFFF;font-size:12pt;">FibroGen will be the exclusive owner of any publication rights with respect to the Licensed Compounds and Licensed Products in the Territory, and will have the sole and exclusive right to publish on such Licensed Compounds and Licensed Products in the Territory without the prior consent of HFB, </font><font style="font-style:italic;Background-color:#FFFFFF;font-size:12pt;">provided</font><font style="Background-color:#FFFFFF;font-size:12pt;"><a name="_9kMHG5YVt9IE8BJD1rv3Dxqy6IEYTAC10P"></a><a name="_9kMHG5YVt9IEDKOE1rv3Dxqy6IEYTAC10P"></a> that no such publication may include the Confidential Information of HFB.<a name="_9kMHG5YVt9IGDGDcKpwky8uq66s3pT2MUYJ9D"></a> Prior to </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;font-size:12pt;"><a name="_9kMHG5YVt9IG99ID1rv3Dxqy6IErc5L9E"></a><a name="_9kMHG5YVt9IGACIB1rv3Dxqy6IErc5L9E"></a> with respect to an Option Program, neither Party will <a name="_9kMHG5YVt9IGCHHxnfkkdn3D0s0sl3C8EFK"></a>make any academic, scientific or medical publication or academic, scientific or medical public<a name="_9kMHG5YVt9IEBBC64mmBbM20qhwD03C8E"></a> presentation related <a name="_9kMKJ5YVt4887DEVKifr6ykJP68BHH13IupL8FF"></a><a name="_9kMH3K6ZWuAJEEMHNIz14AAuwBjVtq2H9v"></a>to such Option Program, any Option Compound or Option Product<a name="_9kMHG5YVt9IGDFGgKpwky98vsH"></a><a name="_9kMHG5YVt9IGEHJiKpwky98vsH"></a><a name="_9kMHG5YVt9IGFE9cKpwky98vsH"></a> with respect to such Option Program or any activities conducted pursuant to this Agreement with respect to such Option Program, in each case, without the JSC&#8217;s prior written consent.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;color:#010000;font-family:Times New Roman Bold;text-transform:uppercase;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref401172111"></a><a name="_Ref401172288"></a><a name="_Ref401867421"></a><a name="_Ref401867448"></a><a name="_Ref401868235"></a><a name="_Toc74552618"></a><a name="_Toc74553498"></a>Article 13<font style="color:#000000;font-family:Times New Roman;text-transform:none;"><br /><a name="_Ref401172111"></a><a name="_Ref401172288"></a><a name="_Ref401867421"></a><a name="_Ref401867448"></a><a name="_Ref401868235"></a><a name="_Toc74552618"></a><a name="_Toc74553498"></a>TERM AND TERMINATION</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref401173132"></a><a name="_Ref401866225"></a><a name="_Toc74552619"></a><a name="_Toc74553499"></a><a name="_Hlk54470451"></a><font style="font-weight:bold;text-decoration:none;"><a name="_Hlk54470451"></a>Term</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. This Agreement will commence on the Effective Date and, unless earlier terminated pursuant to this Article 13 (Term and Termination), will expire on a Licensed Product-by-Licensed Product and country-by-country basis at the end of the applicable Royalty Term (the &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">Term</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">&#8221;). Following the end of the Term for the Licensed Products and in such country by expiration (but not termination), the license granted to FibroGen under Section 2.1 (License to FibroGen) will become perpetual, irrevocable, fully paid-up, and royalty-free. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref401175367"></a><a name="_Ref57925002"></a><a name="_Ref46492110"></a><a name="_Ref67731549"></a><a name="_Toc74552620"></a><a name="_Toc74553500"></a><a name="_Ref401173149"></a><a name="_Ref404412076"></a><a name="_Ref405310094"></a><a name="_Ref431877024"></a><a name="_Ref403473417"></a><a name="_Ref404351779"></a><font style="font-weight:bold;text-decoration:none;color:#000000;"><a name="_Ref401173149"></a>Termination by <a name="_Ref404412076"></a>FibroGen</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"><a name="_Ref405310094"></a><a name="_Ref431877024"></a><a name="_Ref403473417"></a><a name="_Ref404351779"></a>. FibroGen will have the right for any or no reason to terminate this Agreement in its entirety or on a Licensed Program-by-Licensed Program basis (&#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">Terminated Licensed Program</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">&#8221;), which for the avoidance of doubt, terminates FibroGen&#8217;s license and rights for any Licensed Products Directed to the applicable Exclusive Target, upon </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> prior written notice to HFB (&#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">Termination for Convenience Notice Period</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">&#8221;). Effective upon receipt by HFB of such written notice to terminate from FibroGen and upon written notice to FibroGen, HFB may elect in their sole discretion to have such termination be effective on a Licensed Program-by-Licensed Program basis at any time during the Termination for Convenience Notice Period. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;color:#010000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;color:#010000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;color:#010000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref524455314"></a><a name="_Toc74552621"></a><a name="_Toc74553501"></a><a name="_Ref401175472"></a><a name="_Ref404420803"></a><a name="_Ref405136859"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Termination for Cause</font><font style="Background-color:#FFFFFF;font-size:12pt;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref524455315"></a><font style="font-weight:bold;color:#000000;">By FibroGen</font><font style="color:#000000;">. In the event of a material breach of this Agreement by HFB, which material breach remains uncured for </font><font style="color:#000000;">[*]</font><font style="color:#000000;"> measured from the date of written notice of such material breach by FibroGen that identifies the material breach and the actions or conduct that FibroGen considers would be an acceptable cure of such material breach, FibroGen may terminate this Agreement in whole or with respect to those Licensed Programs (and all Licensed Products that include such Licensed Compound) to which such material breach relates at any time during the Term of this Agreement by written notice of termination to HFB. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref524455316"></a><font style="font-weight:bold;color:#000000;">By HFB</font><font style="color:#000000;">. In the event of a material breach of this Agreement by FibroGen, which material breach remains uncured for </font><font style="color:#000000;">[*]</font><font style="color:#000000;"> measured from the date of written notice of such material breach by HFB that identifies the material breach and the actions or conduct that it considers would be an acceptable cure of such material breach, HFB may terminate this </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>47<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">Agreement in part with respect to those Licensed Programs (and all Licensed Products that include such Licensed Compound) to which such material breach relates or the Agreement as a whole at any time during the Term of this Agreement by written notice of termination to </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;">.</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref68778242"></a><a name="_Ref524455317"></a><font style="font-weight:bold;color:#000000;">Disputes Regarding Material Breach</font><font style="color:#000000;">. In case the Party (the &#8220;</font><font style="font-weight:bold;color:#000000;">Defaulting Party</font><font style="color:#000000;">&#8221;) alleged by the other Party (the &#8220;</font><font style="font-weight:bold;color:#000000;">Non-Defaulting Party</font><font style="color:#000000;">&#8221;) to have committed a material breach under Section </font><font style="color:#000000;">13.3(a)</font><font style="color:#000000;"> (By FibroGen) or Section </font><font style="color:#000000;">13.3(b)</font><font style="color:#000000;"> (By HFB) disputes occurrence of such material breach, then the issue of whether the Non-Defaulting Party may properly terminate this Agreement on expiration of the applicable cure period will be resolved in accordance with Article 14 (Dispute Resolution). If as a result of such dispute resolution process, it is determined that the Defaulting Party committed a material breach of this Agreement by a final written determination of the arbitrators, then such termination will be effective as of such final determination. If the Parties in good faith dispute whether a material breach has been cured prior to the final written determination of the arbitrators, then such dispute will also be determined in such arbitration in accordance with Article 15 (Dispute Resolution). This Agreement will remain in full force and effect during the pendency of any such dispute resolution proceeding and the cure periods set forth in Section </font><font style="color:#000000;">13.3(a)</font><font style="color:#000000;"> (By FibroGen) or Section </font><font style="color:#000000;">13.3(b)</font><font style="color:#000000;"> (By HFB), as applicable, will be [*], such proceeding will not suspend any obligations of either Party hereunder, and each Party will use reasonable efforts to mitigate any damage. If as a result of such dispute resolution proceeding it is determined that the Defaulting Party did not commit such material breach (or such material breach was cured in accordance with this Section </font><font style="color:#000000;">13.3</font><font style="color:#000000;"> (Termination for Cause)), then no termination will be effective, and this Agreement will continue in full force and effect. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.4</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref72505420"></a><a name="_Ref_ContractCompanion_9kb9UyCCC"></a><a name="_Ref67779215"></a><font style="font-weight:bold;color:#000000;">Termination for Bankruptcy</font><font style="color:#000000;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Bankruptcy</font><font style="color:#000000;">. Either Party may terminate this Agreement in its entirety upon providing written notice to the other Party upon a Bankruptcy Event of the other Party.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Bankruptcy Laws</font><font style="color:#000000;">. All rights and licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the United States Code, as amended (the &#8220;</font><font style="font-weight:bold;color:#000000;">Bankruptcy Code</font><font style="color:#000000;">&#8221;), or similar laws of any applicable state, the U.S., or foreign jurisdiction (collectively, the &#8220;</font><font style="font-weight:bold;color:#000000;">Bankruptcy Laws</font><font style="color:#000000;">&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined under the Bankruptcy Laws and are to include trademarks and trade names. In the event the Bankruptcy Laws in a jurisdiction outside the US do not have provisions similar to those in Section 365(n) of the Bankruptcy Code, the Parties acknowledge and agree that it is the intention of the Parties to incorporate such rights and remedies herein and the non-bankrupt Party may elect for this Agreement to be treated in accordance with Section 365(n) of the Bankruptcy Code in such jurisdiction.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">If a Bankruptcy Event occurs with respect to a Party during the Term under any Bankruptcy Laws:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">unless and until this Agreement is rejected as provided pursuant to such Bankruptcy Laws, such Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a trustee under the Bankruptcy Code or other applicable Bankruptcy Laws) shall perform all of the obligations in this Agreement intended to be performed by such Party. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>48<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;">if this Agreement is rejected as provided for under the Bankruptcy Laws, and the non-bankrupt Party elects to retain its rights hereunder as provided for under the Bankruptcy Laws, then the Party subject to such Bankruptcy Event (in any capacity, including debtor-in-possession) and its successors and assigns (including a trustee under the Bankruptcy Code or other applicable Bankruptcy Laws), shall provide to the non-bankrupt Party copies (or complete access to, as appropriate) of all Patent Rights and other information necessary for the non-bankrupt Party to prosecute, maintain and enjoy its rights under the terms of this Agreement. All rights, powers and remedies of the non-bankrupt Party as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including the Bankruptcy Laws) in a Bankruptcy Event of the Party under the Bankruptcy Laws. In particular, it is the intention and understanding of the Parties to this Agreement that the rights granted to the Parties under this Section 13.4 (Termination for Bankruptcy) are essential to the Parties&#8217; respective businesses and the Parties acknowledge that damages are not an adequate remedy. The Parties acknowledge and agree that the payments made under Section 8.4 (Royalties) shall (A) constitute royalties within the meaning of Section 365(n) of the Bankruptcy Code or any analogous provisions under other Bankruptcy Laws, and (B) relate to licenses of Intellectual Property. In the event that this Agreement is rejected or deemed rejected under the Bankruptcy Laws, the Party subject to such Bankruptcy Event (or its Representative, assignee or trustee in such case or proceeding) shall provide written notice thereof to the other Party. The Parties waive all rights to object to the application of Section 365(n) of the Bankruptcy Code or similar provisions under Bankruptcy Laws. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552622"></a><a name="_Toc74553502"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Termination for Patent Challenge</font><font style="Background-color:#FFFFFF;font-size:12pt;">. If FibroGen, its Affiliates or Sublicensees directly or indirectly and voluntarily commences or participates in any Patent Challenge, HFB shall have the right to give a written &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;font-size:12pt;">Patent Challenge Notice</font><font style="Background-color:#FFFFFF;font-size:12pt;">&#8221; to FibroGen. Within [*] following FibroGen&#8217;s receipt of the Patent Challenge Notice, and, unless FibroGen or its applicable Affiliate or Sublicensee withdraws or causes to be withdrawn all such Patent Challenges within such [*] following receipt of the Patent Challenge Notice, at HFB&#8217;s sole discretion, HFB may convert the licenses granted pursuant to Section 2.1 (Licenses to FibroGen) with respect to such Licensed Program to non-exclusive licenses and terminate FibroGen&#8217;s obligations under Section 2.8 (Exclusivity) with respect to such Licensed Program, or terminate this Agreement with respect to such Licensed Program, if permitted by applicable law. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.6</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref404968746"></a><a name="_Ref46571175"></a><a name="_Toc74552623"></a><a name="_Toc74553503"></a><a name="_Ref401175672"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Effects of Termination</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Upon termination of this Agreement with respect to a Licensed Product or, with respect to a Licensed Program, all Licensed Compounds and Licensed Products that are the subject of such Licensed Program (each a &#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;">Terminated Licensed Product</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">&#8221;) shall terminate, and (in addition to any other rights and obligations under this Article 13 (Term and Termination)): </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46568593"></a><a name="_Ref404968701"></a><a name="_Ref46570468"></a><font style="font-weight:bold;color:#000000;">Licenses and Options</font><font style="color:#000000;">. As of the effective date of termination of this Agreement with respect to a Terminated Licensed Program, all licenses and all other rights granted by HFB to FibroGen under Section 2.1 (License to FibroGen) with respect to such Terminated Licensed Program will terminate. In the event of termination of an Option Program, all </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>49<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">outstanding License Options granted by HFB to </font><font style="color:#000000;">FibroGen</font><font style="color:#000000;"> under Section </font><font style="color:#000000;">2.9(a)</font><font style="color:#000000;"> (</font><font style="color:#000000;">Grant of Options)</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">for such Option Program will terminate and, if this Agreement is terminated in the entirety, all outstanding License Options shall terminate pursuant to Section </font><font style="color:#000000;">2.9(f)</font><font style="color:#000000;"><a name="_Ref46570468"></a> (Termination of Option).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref71283035"></a><font style="font-weight:bold;color:#000000;">Reversion Rights</font><font style="color:#000000;">. At HFB&#8217;s written request, FibroGen hereby agrees to [*] which FibroGen will and hereby does as of the effective date of termination: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref72430569"></a><font style="color:#000000;">grant HFB, with respect to each Terminated Licensed Product, a non-exclusive, royalty-bearing, worldwide license (with the right to sublicense in multiple tiers) to all FibroGen Arising Technology (with reasonable and customary comment and step-in rights for HFB), and FibroGen&#8217;s rights in the Joint Arising Technology, [*] for the Exploitation of such Terminated Licensed Product and, if not terminated by HFB for FibroGen&#8217;s material breach in accordance with Section 13.3(b) (By HFB), [*]; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">effect a technology transfer to facilitate HFB&#8217;s practice of such license; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">[*]</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref72332737"></a><font style="color:#000000;">[*] </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-weight:bold;font-size:11pt;">*</font>]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref70061488"></a>In addition, if HFB reasonably believes that HFB requires a non-exclusive license under FibroGen Background Technology in order to Exploit such Terminated Licensed Product and provides a written request to FibroGen, FibroGen shall (to the extent it is permitted to do so) negotiate in good faith with HFB for commercially reasonable terms under which FibroGen will grant to HFB such license. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref67734798"></a><font style="font-weight:bold;color:#000000;">Ongoing Clinical Trials</font><font style="color:#000000;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Transfer to HFB</font><font style="color:#000000;">. If, as of the effective date of termination of this Agreement with respect to a Licensed Product, FibroGen or its Affiliates are conducting any Clinical Trials for such Licensed Product, then, at HFB&#8217;s election on a Clinical Trial-by-Clinical Trial basis, FibroGen will either (A) reasonably cooperate, and ensure that its Affiliates reasonably cooperate, with HFB to transfer the conduct of such Clinical Trial (including any data, trial master files and clinical and safety databases) to HFB or its designees, or (B) subject to FibroGen&#8217;s approval, continue to conduct such Clinical Trial, at HFB&#8217;s cost (unless this Agreement is terminated by HFB pursuant to Section 13.3 (Termination for Cause) [*] for the conduct of such transferred Clinical Trial for such Licensed Products after the transfer date. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Wind-Down</font><font style="color:#000000;">. If HFB does not elect to assume control of any such Clinical Trials for any Licensed Product, then FibroGen will, in accordance with accepted pharmaceutical industry norms and ethical practices, wind-down the conduct of any such Clinical Trial in an orderly manner. FibroGen will be responsible for any costs and expenses associated with such wind-down (unless this Agreement is terminated by FibroGen pursuant to Section 13.3 (Termination for Cause), in which case HFB will bear all such costs and expenses).</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>50<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref401173180"></a><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;color:#000000;">Return of Confidential Information</font><font style="color:#000000;">. As of the effective date of termination of this Agreement with respect to each Licensed Program, each Party will promptly return to the other Party (or as directed by such other Party destroy and certify to such other Party in writing as to such destruction) all of such other Party&#8217;s Confidential Information relating to such Terminated Licensed Program and the Exclusive Target to which such Terminated Licensed Program was Directed To </font><font style="color:#000000;">provided</font><font style="color:#000000;"> by or on behalf of such other Party hereunder that is in the possession or control of such Party (or any of its Affiliates, Sublicensees or subcontractors), except that such Party will have the right to retain one copy of intangible Confidential Information of such other Party for legal purposes. </font><font style="color:#000000;"><a name="_Ref401173180"></a>Notwithstanding any provision to the contrary set forth in this Agreement, the receiving Party of any Confidential Information will not be required to destroy electronic files containing such Confidential Information that are made in the ordinary course of its business information back-up procedures pursuant to its electronic record retention and destruction practices that apply to its own general electronic files and information.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref401173140"></a><font style="font-weight:bold;color:#000000;">Other Remedies</font><font style="color:#000000;">. Termination or expiration of this Agreement for any reason will not release either Party from any liability or obligation that already has accrued prior to such expiration or termination, nor affect the survival of any provision hereof to the extent it is expressly stated to survive such termination. Termination or expiration of this Agreement for any reason will not constitute a waiver or release of, or otherwise be deemed to prejudice or adversely affect, any rights, remedies or claims, whether for damages or otherwise, that a Party may have hereunder or that may arise out of or in connection with such termination or expiration.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.7</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref401172378"></a><a name="_Toc74552624"></a><a name="_Toc74553504"></a><a name="_Ref66818376"></a><font style="font-weight:bold;text-decoration:none;color:#000000;"><a name="_Ref66818376"></a>Survival</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Termination or expiration of this Agreement will not affect rights or obligations of the Parties under this Agreement that have accrued prior to the effective date of termination or expiration of this Agreement. Notwithstanding any provision to the contrary, the following provisions will survive and apply after expiration or termination of this Agreement in its entirety: Article 1 (Definitions), Section 4.6 (Development Records), Section 8.4 (Royalties) (but only with respect to Net Sales made during the Term), Section 8.7 (Books and Records; Audit Rights) (</font><font style="Background-color:#FFFFFF;font-size:12pt;">but only with respect to payment obligations accruing during the Term and only for a period of three years after expiration or termination</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">), Section 8.9 (Late Payments) (but only with respect to payment obligations accruing during the Term), Section 9.1 (Background Technology), Section 9.2 (Ownership), Section 10.5 (No Other Representations or Warranties), Article 11 (Indemnification), Article 12 (Confidentiality), Section 13.1 (Term), Section 13.6 (Effects of Termination), Section 13.6(e) (Other Remedies), this Section 13.7 (Survival), Article 14 (Dispute Resolution), and Article 15 (Miscellaneous). In addition, the other applicable provisions of Article 8 (Financials) will survive such expiration or termination of this Agreement in its entirety to the extent required to make final reimbursements, reconciliations or other payments incurred or accrued prior to the date of termination or expiration. For any surviving provisions requiring action or decision by the JSC or an Executive Officer, each Party will appoint representatives to act as its JSC members or Executive Officer, as applicable. All provisions not surviving in accordance with the foregoing will terminate upon the effective date of expiration or termination of this Agreement and be of no further force and effect. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>51<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref53832281"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</font></p>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;color:#010000;font-family:Times New Roman Bold;text-transform:uppercase;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref401171976"></a><a name="_Ref401172127"></a><a name="_Ref401172219"></a><a name="_Ref401867480"></a><a name="_Ref401867672"></a><a name="_Ref401868139"></a><a name="_Ref401868148"></a><a name="_Ref431482692"></a><a name="_Ref431901190"></a><a name="_Toc74552625"></a><a name="_Toc74553505"></a>Article 14<font style="color:#000000;font-family:Times New Roman;text-transform:none;"><br /><a name="_Ref401171976"></a><a name="_Ref401172127"></a><a name="_Ref401172219"></a><a name="_Ref401867480"></a><a name="_Ref401867672"></a><a name="_Ref401868139"></a><a name="_Ref401868148"></a><a name="_Ref431482692"></a><a name="_Ref431901190"></a><a name="_Toc74552625"></a><a name="_Toc74553505"></a>DISPUTE RESOLUTION</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref431879512"></a><a name="_Toc74552626"></a><a name="_Toc74553506"></a><a name="_Ref127343006"></a><a name="_Ref383350034"></a><a name="_Ref401175882"></a><a name="_Ref404948982"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Dispute Resolution</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">In the event of any dispute between the Parties under this Agreement, the Parties will first attempt in good faith to resolve such dispute by negotiation and consultation between themselves. In the event that such dispute is not resolved on an informal basis within fifteen (15) Business Days, either Party may refer the matter to the Executive Officers of the Parties for attempted resolution, whereupon the Executive Officers will confer and attempt in good faith to resolve such dispute by negotiation and consultation for a thirty (30) day period following such referral.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref59046198"></a><a name="_Ref410248695"></a><font style="color:#000000;">If the Executive Officers do not resolve such dispute within such thirty (30) day period, either Party may at any time thereafter proceed within thirty (30) days thereafter to binding arbitration in accordance with this Section 14.1 (Dispute Resolution). If a Party so proceeds, it shall submit such dispute to arbitration with [*] (the &#8220;</font><font style="font-weight:bold;color:#000000;">Arbitration Forum</font><font style="color:#000000;">&#8221;), and notify the other Party, in writing, of such dispute. Prior to the arbitrators being selected, each Party may seek from any court having jurisdiction a temporary injective or provisions relief necessary to protect the rights of the Party. The right and obligation to arbitrate under this Section 14.1(b) (Dispute Resolution) shall extend to any claims by or against the Parties and their respective Affiliates and any agents, principals, officers, directors, or employees of either of the Parties or their respective Affiliates. Within thirty (30) days after receipt of such notice, the Parties will each designate in writing an arbitrator to resolve the dispute. Both of the designated arbitrators will elect a third arbitrator; </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="font-style:italic;color:#000000;">however</font><font style="color:#000000;">, that if the designated arbitrators cannot agree on a third arbitrator within twenty (20) days after both arbitrators have been designated, the third arbitrator will be selected by the Arbitration Forum. Each arbitrator will be an individual with biotechnology and/or pharmaceutical industry legal experience, and will not be and will never have been an Affiliate, employee, consultant, officer, director or stockholder of any Party. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref59029933"></a><font style="color:#000000;">Within thirty (30) days after the designation of the arbitrators, the arbitrators and the Parties will meet, at which time the Parties will be required to set forth in writing all disputed issues and a proposed ruling on the merits of each such issue. The Parties will have the right to be represented by counsel. Except as provided herein, the arbitration will be governed by the [*] Arbitration Rules. The arbitration proceedings will be conducted in English.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">The arbitrators will use their best efforts to rule on each disputed issue within thirty (30) days after the completion of any hearings associated with the arbitration. </font><font style="color:#000000;">Either party may apply to the arbitrators seeking injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. </font><font style="color:#000000;">The arbitrators may enter early or summary disposition of some or all issues, after the Parties have made reasonable submissions on those issues. The determination of the arbitrators as to the resolution of any dispute will be binding and conclusive upon all Parties and their respective Affiliates and any agents, principals, officers, directors, or employees of either of the Parties and their respective Affiliates. The arbitrators will issue a written award that contains a reasoned opinion setting forth the findings of fact and conclusions upon which the award is based, including the </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>52<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">calculation of any damages awarded. </font><font style="color:#000000;">A judgment on any award rendered by the arbitrators may be entered in any court having jurisdiction thereof.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">The (i) attorneys&#8217; fees of the Parties in any arbitration, (ii) fees of the arbitrators and (iii)&#160;costs and expenses of the arbitration will be </font><font style="color:#000000;">allocated among the Parties as determined by the arbitrators, who shall have discretion to make this determination equitably, taking into account (A) which party prevailed, in the view of the arbitrators, (B) whether any party caused unnecessary delay, burden or expense, and (C) the reasonability of the attorneys&#8217; fees, costs, and expenses requested</font><font style="color:#000000;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">Any arbitration pursuant to this Section 14.1 (Dispute Resolution) will be conducted in [*].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">The Parties intend that each award by an arbitrators in an arbitration pursuant to this Section 14.1 (Dispute Resolution) will be rendered in accordance with the United Nations Convention on the Recognition and Enforcement of Arbitral Awards and will be enforceable in accordance therewith. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">The arbitrators will take appropriate actions to prevent, remediate, and/or sanction abusive conduct or other actions that threaten to undermine the fair, speedy and cost-effective resolution of the matter.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">Except to the extent necessary to confirm an award or as may be required by law, neither Party nor an arbitrator may disclose the existence, content, or results or any arbitration without the prior written consent of both Parties. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">In addition, during the pendency of any dispute under this Agreement initiated before the end of any applicable cure period under Section 13.3 (Termination for Cause), (i) this Agreement will remain in full force and effect, (ii) the provisions of this Agreement relating to termination for material breach will not be effective, (iii) the time periods for cure under 13.3 (Termination for Cause) as to any termination notice given prior to the initiation of the proceeding will be tolled, and (iv) neither Party will issue a notice of termination pursuant to this Agreement based on the subject matter of the proceeding (and no effect will be given to previously issued termination notices), until the arbitrators have confirmed the existence of the facts claimed by a Non-Defaulting Party to be the basis for the asserted material breach.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref431879132"></a><a name="_Toc74552627"></a><a name="_Toc74553507"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Injunctive Relief</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Nothing in this Article 14 (Dispute Resolution) will preclude either Party from seeking equitable relief or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any proceeding if necessary to protect the interests of such Party or to preserve the status quo pending the proceeding. Therefore, in addition to its rights and remedies otherwise available at law, including the recovery of damages for breach of this Agreement, upon an adequate showing of material breach, and without further proof of irreparable harm other than this acknowledgement, such Non-Defaulting Party will be entitled to seek (a) immediate equitable relief, specifically including both interim and permanent restraining orders and injunctions, and (b) such other and further equitable relief as the court may deem proper under the circumstances. For clarity, nothing in this Section&#160;14.2 (Injunctive Relief) will otherwise limit a Defaulting Party&#8217;s opportunity to cure a material breach as permitted in </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>53<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">accordance with </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">13.3</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> (Termination for Cause)</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;color:#010000;font-family:Times New Roman Bold;text-transform:uppercase;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref52788469"></a><a name="_Toc74552628"></a><a name="_Toc74553508"></a>Article 15<font style="color:#000000;font-family:Times New Roman;text-transform:none;"><br /><a name="_Ref52788469"></a><a name="_Toc74552628"></a><a name="_Toc74553508"></a>MISCELLANEOUS</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552629"></a><a name="_Toc74553509"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Entire Agreement; Amendment</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. This Agreement, including the Schedules hereto, set forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings between the Parties existing as of the Effective Date with respect to the subject matter hereof, including the Existing Nondisclosure Agreement as set forth in Section 12.3 (Prior Agreement). In the event of any inconsistency between any plan hereunder and this Agreement, the terms of this Agreement will prevail. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein. No subsequent alteration, amendment, change or addition to this Agreement will be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref432138496"></a><a name="_Toc74552630"></a><a name="_Toc74553510"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Force Majeure</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font><font style="Background-color:#FFFFFF;font-size:12pt;">Neither Party will be held liable to the other Party nor be deemed to have breached this Agreement for failure or delay performing any obligation under this Agreement to the extent that such failure or delay is caused by or results from acts of God, embargoes, war, acts of war (whether war be declared or not), terrorism, insurrections, riots, civil commotions, strikes, lockouts, or other labor disturbances (other than strikes, lockouts, or labor disturbances involving a Party&#8217;s own employees), government actions, fire, earthquakes, floods, epidemics, pandemics, or quarantines (&#8220;</font><font style="font-weight:bold;Background-color:#FFFFFF;font-size:12pt;">Force Majeure</font><font style="Background-color:#FFFFFF;font-size:12pt;">&#8221;) and for so long as such failure or delay continues to be caused by or result from such Force Majeure event. The Parties agree the effects of the COVID-19 pandemic that is ongoing as of the Effective Date may be invoked as a Force Majeure for the purposes of this Agreement even though the pandemic is ongoing to the extent those effects are not reasonably foreseeable by the Parties as of the Effective Date. The affected Party will notify the other Party in writing of any Force Majeure circumstances that may affect its performance under this Agreement as soon as reasonably practical, will provide a good faith estimate of the period for which its failure or delay in performance under the Agreement is expected to continue based on currently available information, and will undertake reasonable efforts necessary to mitigate and overcome such Force Majeure circumstances and resume normal performance of its obligations hereunder as soon a reasonably practicable under the circumstances. If the Force Majeure circumstance continues, then the affected Party will update such notice to the other Party </font><font style="color:#000000;font-size:12pt;">[*]</font><font style="Background-color:#FFFFFF;font-size:12pt;">, to provide updated summaries of its mitigation efforts and its estimates of when normal performance under the Agreement will be able to resume. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref431873649"></a><a name="_Toc74552631"></a><a name="_Toc74553511"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Notices</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Any notice required or permitted to be given under this Agreement will be in writing, will specifically refer to this Agreement, and will be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section&#160;15.3 (Notices), and will be deemed to have been given for all purposes (a) when received, if hand-delivered or sent by a reputable </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>54<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">international expedited delivery service, (b) five (5) Business Days after mailing, if mailed by first class certified or registered mail, postage prepaid, return receipt requested, or (c) by email, if confirmed by the intended recipient. This Section&#160;</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">15.3</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> (Notices) is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td style="width:34.52%;"></td>
<td style="width:45.48%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to HFB:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#000000;"><br /></font><font style="color:#000000;">HiFiBiO Therapeutics<br />Room 303, Third Floor, <br />St. George&#8217;s Building<br />2 Ice House Street, Central, <br />Hong Kong</font><font style="font-weight:bold;font-style:italic;color:#000000;"><br /></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: <font style="color:#000000;">[*]</font><br />Email: <font style="color:#000000;">[*]</font><br /></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With a copy to (which will not constitute notice): </p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HiFiBiO Therapeutics<br />237 Putnam Avenue</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge, MA, 02139</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: <font style="color:#000000;">[*]</font><br />Email: <font style="color:#000000;">[*]</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foley Hoag<br />Seaport West<br />155 Seaport Boulevard<br />Boston, Massachusetts 02210-2600</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: <font style="color:#000000;">[*]</font><br />Email: <font style="color:#000000;">[*]</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to FibroGen:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">409 Illinois Street </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, CA 94158</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: <font style="color:#000000;">[*]</font> <br />Email: <font style="color:#000000;">[*]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With a copy to (which will not constitute notice):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">409 Illinois Street</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, CA 94158</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: <font style="color:#000000;">[*]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: <font style="color:#000000;">[*]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ropes &amp; Gray</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1900 University Avenue, 6th Floor</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">East Palo Alto, CA 94303</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: <font style="color:#000000;">[*]</font><br />Email: <font style="color:#000000;">[*]</font></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>55<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552632"></a><a name="_Toc74553512"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">No Strict Construction; Headings</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. This Agreement has been prepared jointly and will not be strictly construed against either Party. Ambiguities, if any, in this Agreement will not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. The headings of each Article and Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552633"></a><a name="_Toc74553513"></a><a name="DocXTextRef472"></a><a name="DocXTextRef473"></a><a name="DocXTextRef474"></a><a name="DocXTextRef475"></a><a name="DocXTextRef476"></a><a name="DocXTextRef477"></a><a name="DocXTextRef478"></a><a name="DocXTextRef469"></a><a name="DocXTextRef470"></a><a name="DocXTextRef471"></a><a name="DocXTextRef479"></a><a name="_9kR3WTr23AGFExw3yif"></a><a name="DocXTextRef480"></a><a name="DocXTextRef481"></a><a name="DocXTextRef482"></a><a name="DocXTextRef483"></a><a name="_9kR3WTr2CJGGFcLcszv1G"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Interpretation</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font><font style="Background-color:#FFFFFF;font-size:12pt;"><a name="DocXTextRef472"></a>Except where the context expressly requires otherwise, (a)<a name="DocXTextRef473"></a>&#160;the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa), (b)<a name="DocXTextRef474"></a>&#160;the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; will be deemed to be followed by the phrase &#8220;without limitation,&#8221; (c)<a name="DocXTextRef475"></a>&#160;the word &#8220;will&#8221; will be construed to have the same meaning and effect as the word &#8220;shall,&#8221; (d)<a name="DocXTextRef476"></a>&#160;any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e)<a name="DocXTextRef477"></a> any reference herein to any person or entity will be construed to include the person&#8217;s or entity&#8217;s successors and assigns, (f)<a name="DocXTextRef478"></a> the words &#8220;herein,&#8221; &#8220;hereof,&#8221; and &#8220;hereunder&#8221;, and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g)<a name="DocXTextRef469"></a> all references herein to Sections or Schedules<a name="DocXTextRef470"></a> will be construed to refer to Sections or Schedules<a name="DocXTextRef471"></a> of this Agreement, and references to this Agreement include all Schedules<a name="DocXTextRef479"></a> hereto, (h)<a name="_9kR3WTr23AGFExw3yif"></a> the word &#8220;notice<a name="DocXTextRef480"></a>&#8221; means notice in writing (whether or not specifically stated) and will include notices, consents, approvals and other written communications contemplated under this Agreement, (i)<a name="DocXTextRef481"></a> provisions that require that a Party, the Parties or any committee hereunder &#8220;agree,&#8221; &#8220;consent,&#8221; or &#8220;approve&#8221; or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (j)<a name="DocXTextRef482"></a> references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, (k)<a name="DocXTextRef483"></a> the term &#8220;or&#8221; will be interpreted in the inclusive sense commonly associated with the term &#8220;and/or,&#8221; and (l) references to any Sections include Sections and subsections that are part of the related Section (</font><font style="font-style:italic;Background-color:#FFFFFF;font-size:12pt;">e.g.</font><font style="Background-color:#FFFFFF;font-size:12pt;"><a name="_9kR3WTr2CJGGFcLcszv1G"></a>, a section numbered &#8220;Section 2.2&#8221; would be part of &#8220;Section&#160;2&#8221;, and references to &#8220;Section&#160;2.2&#8221; would also refer to material contained in the subsection described as &#8220;Section&#160;2.2(a)&#8221;).</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>56<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement will be construed against the drafting Party will not apply.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.6</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref431879660"></a><a name="_Ref58747226"></a><a name="_Toc74552634"></a><a name="_Toc74553514"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Assignment</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. </font><font style="Background-color:#FFFFFF;font-size:12pt;">Neither this Agreement nor any interest hereunder will be assignable by either Party without the prior written consent of the other Party, </font><font style="font-style:italic;Background-color:#FFFFFF;font-size:12pt;">provided</font><font style="Background-color:#FFFFFF;font-size:12pt;"> that (and notwithstanding anything in this Agreement to the contrary) either Party may, without such consent, assign this Agreement and its rights and obligations hereunder in whole to (a) to the successor in connection with a Change of Control of such Party, or (b) to a Third Party that acquires, by or otherwise in connection with a merger, sale of assets, or otherwise, all or substantially all of the business of the assigning Party related to the subject matter of this Agreement. Additionally, FibroGen may, without such consent, assign this Agreement and its rights and obligations hereunder in whole to any Affiliate of FibroGen. Each Party will promptly notify the other Party of any assignment or transfer under the provisions of this Section 15.6 (Assignment). This Agreement will be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein will be deemed to include the names of such Party&#8217;s successors and permitted assigns to the extent necessary to carry out the intent of this Agreement.</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> Any assignment or attempted assignment by either Party in violation of the terms of this Section&#160;15.6 (Assignment) will be null, void and of no legal effect. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.7</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref66789953"></a><a name="_Toc74552635"></a><a name="_Toc74553515"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Change of Control</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Each Party will notify the other Party in writing promptly (and in any event within </font><font style="color:#000000;font-size:12pt;">[*] </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">following the execution of a definitive agreement by the Party, its Affiliates or its equity holders that results in a Change of Control of the Party.</font><font style="Background-color:#FFFFFF;font-size:12pt;"> </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">Notwithstanding anything to the contrary in this Agreement, if during the Term HFB undergoes a Change of Control with a Third Party, and at such time such Third Party is [*] or is engaged in activities that would otherwise constitute a breach of Section 2.8(a) (Exclusivity Covenant), following the effective date of such Change of Control, at FibroGen&#8217;s election, the JSC and any subcommittees shall be dissolved (to the extent then in-effect). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.8</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552636"></a><a name="_Toc74553516"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Performance by Affiliates</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">.</font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:12pt;"> </font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">Each Party may perform any obligations and exercise any right hereunder through any of its Affiliates, </font><font style="font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:12pt;">provided</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;"> that such Party will remain primarily responsible for the other Party hereunder. Each Party hereby guarantees the performance by any of its Affiliates of such Party&#8217;s obligations under this Agreement, and will cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party&#8217;s Affiliate of any of such Party&#8217;s obligations under this Agreement will be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party&#8217;s Affiliate.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.9</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552637"></a><a name="_Toc74553517"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Further Actions</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Each Party agrees to execute, acknowledge, and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.10</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552638"></a><a name="_Toc74553518"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Severability</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by the arbitrators or by any court of competent jurisdiction from which no </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>57<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">appeal can be or is taken, then the provision will be considered severed from this Agreement and will not serve to invalidate any remaining provisions hereof. The Parties will make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering into this Agreement may be realized.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.11</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552639"></a><a name="_Toc74553519"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">No Waiver</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Any delay in enforcing a Party&#8217;s rights under this Agreement or any waiver as to a particular default or other matter will not constitute a waiver of such Party&#8217;s rights to the future enforcement of its rights under this Agreement, except with respect to an express written and signed waiver relating to a particular matter for a particular period of time.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.12</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552640"></a><a name="_Toc74553520"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Independent Contractors</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. Each Party will act solely as an independent contractor, and nothing in this Agreement will be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein will be construed to create the relationship of partners, principal and agent, or joint-venture partners between the Parties.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.13</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552641"></a><a name="_Toc74553521"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Counterparts</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. This Agreement may be executed in one or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.14</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc74552642"></a><a name="_Toc74553522"></a><font style="font-weight:bold;text-decoration:none;color:#000000;">Choice of Law</font><font style="Background-color:#FFFFFF;color:#000000;font-size:12pt;">. This Agreement will be governed by, and enforced and construed in accordance with, the laws of the State of Delaware, without regard to its conflicts of law provisions.</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Signature Page Follows]</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SWStart"></a>58<a name="SWStart"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF<font style="font-weight:normal;">, the Parties have executed this Agreement by their duly authorized representatives as of the Effective Date.</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:49.99%;"></td>
<td style="width:50.01%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HIFIBIO (HK) LIMITED (D.B.A. HIFIBIO THERAPEUTICS)</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">FIBROGEN, INC. </p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:/s/ Liang Schweizer</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:/s/ Enrique Conterno</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:Liang Schweizer, Ph. D.</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:Enrique Conterno</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:Chief Executive Officer</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Signature Page to Exclusive License and Option Agreement]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 1.87</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 1.89</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Licensed Patent Rights</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 1.101</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Data Package </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.78%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:6pt;line-height:13.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:18pt;">&nbsp;</p></td>
<td valign="top" style="width:2.78%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:6pt;font-family:'Times New Roman';font-size:18pt;line-height:13.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:18pt;line-height:13.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:6pt;line-height:13.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:18pt;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;">[*]</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:5.56%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Package for Replacement Program </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To be determined by the parties in reasonable. <font style="color:#000000;font-size:11pt;">[*]</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 2.7(a)</p>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Initial Technology Transfer</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 4.1</p>
<p style="text-align:center;margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Development Plan</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 4.2</p>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Work Plans</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 10.2</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Disclosure Schedule</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><a name="_cp_text_1_205"></a><font style="color:#000000;font-family:Times New Roman;">[*]</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 10.3(e)</p>
<p style="text-align:center;margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Negative Events </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 12.2(c)</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Initial Press Release</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FibroGen and HiFiBiO Announce Transformative Partnership to <br />Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;line-height:13.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:18pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:18pt;line-height:13.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:18pt;line-height:13.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;line-height:13.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:18pt;"><font style="font-style:italic;font-size:12pt;font-family:Times New Roman;">FibroGen Exclusively Licenses HiFiBiO&#8217;s Galectin-9 Program, and Obtains an Exclusive Option to their CXCR5 and CCR8 Programs</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;line-height:13.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:18pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:18pt;line-height:13.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:18pt;line-height:13.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;line-height:13.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:18pt;"><font style="font-style:italic;font-size:12pt;font-family:Times New Roman;">Transformative Transaction for FibroGen&#8217;s Early-stage Pipeline </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;line-height:13.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:18pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:18pt;line-height:13.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:18pt;line-height:13.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;line-height:13.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:18pt;"><font style="font-style:italic;font-size:12pt;font-family:Times New Roman;">HiFiBiO to Receive $25 Million Upfront, and Up to a Total of $1.1B in Additional Milestone Payments Across All Three Programs, Plus Royalties</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SAN FRANCISCO, CA and CAMBRIDGE, MA, June 17, 2021 (GLOBE NEWSWIRE) &#8211; FibroGen, Inc. (Nasdaq: FGEN) and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science announced a partnership covering three HiFiBiO programs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are very pleased to add the HiFiBiO drug candidates to our pre-clinical development pipeline,&#8221; <font style="color:#000000;">said Enrique Conterno, Chief Executive Officer, FibroGen. &#8220;With the addition of up to three programs in the immuno-oncology and autoimmune space, we have the potential to transform our early development pipeline</font>.<font style="color:#000000;">&#8221;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;The FibroGen partnership represents significant validation of our Drug Intelligent Science (DIS&#8482;) approach and deep expertise in disease biology and translation science,&#8221; said Liang Schweizer, Ph.D., Chief Executive Officer, HiFiBiO. &#8220;As another successful showcase of our open innovation approach, we look forward to working closely with FibroGen, an exciting, growing biopharmaceutical company.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, FibroGen will make a $25 million upfront payment to HiFiBiO, as well as payments upon option exercise. In addition, HiFiBiO may receive up to a total of an additional $1.1B in future option, clinical, regulatory, and commercial milestone payments across all three programs. HiFiBiO will also be eligible to receive royalties based upon worldwide net sales.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen exclusively licensed all products in the Galectin-9 program and will have sole right to develop them worldwide. The lead product candidate in the Galectin-9 program is expected to enter clinical development in the first quarter of 2023. FibroGen has also obtained exclusive options to license all product candidates in HiFiBiO&#8217;s CXCR5 and CCR8 programs. Each option may be independently exercised following delivery of program-specific data to be generated by HiFiBiO. If an option is exercised, FibroGen will have the sole right to develop products from that program worldwide. The lead product candidates from the CXCR5 and CCR8 programs are expected to enter clinical development by the middle of 2023. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We look forward to a productive partnership with HiFiBiO, a leader in the field of single-cell science for antibody discovery and translational medicine,&#8221;<font style="color:#000000;"> said Mark Eisner, M.D, M.P.H, Chief Medical Officer, FibroGen. &#8220;We are excited to bring the Galectin-9 antibody program into the FibroGen portfolio. As Galectin 9 plays a role in suppressing the anti-tumor immune response in both myeloid malignancies and solid tumors, we believe this antibody candidate from HiFiBiO can advance the treatment of cancer in combination with chemotherapy or other immuno-oncology agents. The exclusive option to access projects directed to CXCR5 and CCR8 provides additional opportunities to expand our therapeutic area focus on oncology and immunology. These are both important biological targets playing clear roles in autoimmune disease and cancer.&#8221; </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">About&#160;FibroGen</font><font style="Background-color:#FFFFFF;font-weight:normal;"><br />FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and idiopathic pulmonary fibrosis (IPF). For more information, please visit www.fibrogen.com.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">About HiFiBiO Therapeutics</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">HiFiBiO Therapeutics is transforming the field of immunotherapy by combining proprietary single-cell profiling technologies with advanced data intelligence and deep knowledge of immune system biology. This approach enables the development of novel antibody therapies that are paired with biomarkers to predict patient response. HiFiBiO Therapeutics is working actively to address unmet medical needs around the world through its own innovative pipeline programs and open-innovation partnerships with world-renowned industry and academic researchers. The company&#8217;s strong global footprint features cutting-edge laboratories on three continents, in Cambridge, Mass., Paris, Shanghai, and Hong Kong. To learn more, please visit www.hifibio.com.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements<font style="font-weight:normal;"><br />This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development and commercialization of the company&#8217;s product candidates, the potential safety and efficacy profile of our product candidates, our clinical programs and regulatory events, and those of our partners. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as &#8220;may,&#8221; &#8220;will&#8221;, &#8220;should,&#8221; &#8220;on track,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">uncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and our Quarterly Report on Form 10-Q for quarter ended March 31, 2021 filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contacts:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investors:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Tung, M.D.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate Strategy / Investor Relations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">415.978.1434</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mtung@fibrogen.com</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Media:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GCI Health</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGenMedia@gcihealth.com</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contacts:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HiFiBi<font style="color:#000000;">O</font> Therapeutics</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investors:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vincent Tse</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">617.395.1212</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">media@hifibio.com </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Media:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vincent Tse</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">617.395.1212</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">media@hifibio.com </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">[*]</font>&#160;= Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>fgen-ex211_16.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex211_16.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1</p>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">List of Subsidiaries of FibroGen, Inc.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:73.02%;"></td>
<td style="width:26.87%;"></td>
</tr>
<tr style="height:26.05pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Subsidiaries</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Incorporation</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beijing Falikang Pharmaceutical Co., Ltd.</p></td>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen (China) Medical Technology Development Co., Ltd.</p></td>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen China Anemia Holdings, Ltd.</p></td>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cayman Islands</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen Europe Oy</p></td>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finland</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen International (Cayman) Limited</p></td>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cayman Islands</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen International (Hong Kong) Limited</p></td>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hong Kong</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen INTL LLC</p></td>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware, USA</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Skin Sciences, Inc.</p></td>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware, USA</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>fgen-ex311_9.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex311_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Enrique Conterno, certify that:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Form 10-Q of FibroGen, Inc.;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 9, 2021</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <font style="color:#000000;">Enrique Conterno</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enrique Conterno</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>fgen-ex312_8.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex312_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Pat Cotroneo, certify that:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Form 10-Q of FibroGen, Inc.;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 9, 2021</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Pat Cotroneo</p></td>
</tr>
<tr>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pat Cotroneo</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior<font style="font-size:11pt;"> </font>Vice President, Finance and Chief Financial Officer </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>fgen-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;), and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Enrique Conterno, Chief Executive Officer of FibroGen, Inc. (&#8220;the Company&#8221;), and Pat Cotroneo, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended June 30, 2021, to which this Certification is attached as Exhibit 32.1 (&#8220;Periodic Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: <font style="color:#000000;">August 9</font>, 2021</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">In Witness Whereof<font style="font-weight:normal;font-variant: normal;">, the undersigned have set their hands hereto as of the 9<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day of August 2021.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Enrique Conterno</p></td>
<td valign="top"  style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Pat Cotroneo</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enrique Conterno</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pat Cotroneo</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer </p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President, Finance and </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of FibroGen, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gvgjwefnhf2j000023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvgjwefnhf2j000023.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )? [X# 2(  A$! Q$!_\0
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MX#)SP1TSD>OW_P#\%!OV8M(T_P#9DT75M-T^*ROM"L;+4$=8A&\<EJL<Q((
M((*GGMSZDU^3O_!+'Q[\&/BI^V=\2/BQX]\5Z6;I/%-U86WVF\@+06]E<LFQ
M=[C;EBQR/TQQ_3M^V)\1?V=_'GP.\4:%/X[\/EH])N8[1+:^@ "B!P$*EQD]
M-I R>A-:3?)A8PBO?<O:::NTDOGUOOLGIM>UKBKU-(*/(TUO96U7FUM?JN^G
MA7_!)+X[Q?$+X7:5X<DO5N9]+L_LCJ)-V)+9!&1U]4_SR3],?\%&_%[>&/V>
M?&;(=K-HE]("#@G$$G'_ ([7\UW_  14_:/\.^%_VD?B9\*M*UZWU'2]"\67
M=K;O'<*Z(EQ-YR0MABN5CF0@<$ CBOZ1_P#@HOX>M_%7[,_B^_WCR6T*[VM[
M26TAX[<<X]>1[48J[ITZBC9/DB_6*7ZV_JQ%#D52<7K:,FK:]OP23\_N/Q%_
MX-_94UK4?&^M70\RXOO$^KS;VRQVM>S[,D\Y']>,5^LW_!7RVAG_ &7?%1=%
M+C2K_:Q SQ#)CGKP:_)'_@WPN=/@N_&^F13JTECXIUFV*[N08[Z<8.3D]N?7
M\J_6_P#X*]W$4/[+WBH,P#G2K\*I/7,,F.,YY/\ GK4UK^SP][_Q%Z;1V^>Y
M-%OVE7_!'_TH_-3_ ((O_%:?2_V?KVSD=BT5K?6W)/9Y4 '3' 'L<?A7P?XJ
M\=Z=X9_X*-'QQJMTKB(2K;VSN&W$7&_Y4)Y/ &0.^.>WW5_P1?\ A9<:G^S]
M>W<D9S+;7]ST(P&:5QV[;N_)^A-?FWXK^"VJ^.?^"IVE:-<3R)H^GEY);;D1
M3,UZH&X'@X3=_P!]'/O>GMJ?2])7?6,N;?KMJ_\ (F/\*HWJU4=UW7+%?*WI
MJK6/VK\2?\%K-&^&FLZ9X<U[X?:T-(7[!9C7O[+NCIZI*ZVZ,]RB"-%7&2S$
M  C)[U^OG[/W[2G@7X_>%;'Q!X=U*S::[ACE^RQ2AB Z*V,;BP8;N0?TKPKX
MM?L=?![7O@%J>DW7@[2I=3MO# E6\:V@,OGK;AMQ8QYRK,&!SNR/7D?SJ_\
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M;EI0HV:J*LKK^[+E].C[;=S\N_V(](LM"_X*2>+[*QA6&)Y[-G15"C<LS9X
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MI_8,^*.C_"G]H&_O]8L-3U!--LO$-Z)/*FDR(]DQ<D*[C<3GY6]!SFU\)/\
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M3K74K3)/D7<8ECR1@_*?4=?6L.#PCX9\.:5J2:%HEAI:-979*V<(B!/D2'.
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MM[N]+B._5'\GS8VD_BWX) .1GOFLK2O^"OW[0J:'9Z;%^SKXME)L/LT4W]D
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M\7O"5G=R2:SH=]I,]_;F"94ABU*:^-L1,R^2Y?[-,2B.710C2*BR1%_Z9?\
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MO+,Q_P![G/KL?M'>//V"OVL]-ATSQ]XL\,:W:1*BNEY<VDD<@C^YNC=W4[0
M,<\*#@]*UKSC4E!Q32C&*:>^G+?7_MW>WR*I5(PJN;3Y==+ZV;6E[-7MUMOK
M:VAP/_!%'5+35_@!X<O;)S)!/X?M)8V*E<H\4;*<'GD'I7P+_P '$7B_1/!W
MP]U'6-<N&MK"SN[26XF6-I/+C%S'N8JN3@9YP*_6CX&_'O\ 8@_9L\-Q>%?"
M'C;P[I=C#$EO&D%W:[(XDZ1H@=5 X'*GH,=S7!_M&>+?V _VK[1+7Q[XI\+Z
MS;JT<C)=W5F\<C1D%6>-V=205SWYY[XJ:\HU*T9Q3Y%*#:;L[)Q;UM:^C6V_
M1HG#25*4G*[3C)::-WLM[.VW9V\]A?\ @C'J5KJG[-&AW=HY>&;1]-D0E2IV
MLD>"0<$9^E?B/_P7P\;Z!X1^(7@&36KEK=+OQ_H.GPL(V<-=WFI0VUM&=H./
M,FD1 QP 3SQ7[_\ P2_:+_8F_9S\*1>#?"7CGP]I>G1+%''%!=VVU8XE(2-5
M\Q0J@8/'H*\3_:!'_!/3]I[5[+7O''B+PIJTVGW<=];FZN;.0)<1,'25%<L%
M8,,J1RO !'6BI)2KPJ*_(JD)M=;1<6U>V^FCL]>C0Z,XT_:<UWS0:5M+NR6N
MC2V/IC]A"ZBNOV2+:>(DQMX71P2,?*VE3$?IZ]*_E%\5>._#R?\ !62P\+/<
MR#6)8;R]2#R7*M;Q:C;Q2/O V_))-&N"03NX'6OZL/AW^UA^QG\*_!T'P_T7
MQYH%KI<-LUD;=+VWV20M"8-A/F *!&64$*>6)]*^1[OP3_P3EO?BNOQJEU[P
MFWBE)3,NHFYLS=*K.)"OFY+[<C)&<=.#51G%8E5M>333JK7_ "OZV7=F;?[J
M</M2M;M=-/S[/_@GZQ6\BGX!SR?P_P#")R-^'E*:_B5^'OCWPY/_ ,%7/$'A
M>.Z<ZQ;0V]_-;^4X"6TVI7,$3[R-IWRV\J@ Y&PD@<9_KK'[=7[(:Z&?"H^(
MFA_8#8MIWV7[9;;#$R%"-WFYSGYL[?O=L5\,:=X$_P""<>E?%2;XSP:[X33Q
M3-+YTFHK<V0NG&\RA6ER)",G.W..O HA-1Q"J->[JO/6Z_4I22H5*;3<Y<O+
MK9*TH-WT=[J+5KK6SONG^L/BYP/@'.YSM'AB,GCL(6K^*3X$^/O#ES_P5=\5
M^&8KJ1M8LQIUY<6_DR!4@NKZZCA?S"NP[GMY 0"2,<XR*_K@O/VZ?V0]0T.7
MPK+\0]">PELO[/-J;RVVB,(% #^9G<, YVC)SV)KX;T'P-_P3E\-?%2;XSV6
MN^$XO%%Q,L\VI)<V8NI K%PIE!WL 2<*3QR>.IFFXPKNI*[BXS6FCN[6[Z::
MEPG%8>5-WYFXV[*W+=O371-;K6SZ6?Z/_M1^$+WQQ^SG>Z/I\;27$WAZ$(H7
M)(?34'0<]A7\E?\ P3<^*WAK]DW]KSQY\//C'JD/AV34_%5WJNCM?G[*EW:2
M2JTGE-*55S&^X,$)*@J2 #7]5?\ PW_^R2UJ-+?XC:"]JL"VGV:2XM7B,21B
M(1G,W(VC;D@'OP>*_.'X\_!K_@FS^T+XJC\:ZSKOA6+6(I)98+^&[M8KF(S9
MW&.9&$BY!QPW/?-3"4J=64U9QE!Q=]]6M?73\_(E2BZ/LI7NI*2:]+?YO[CU
MK_@I[^U;X"7]F;Q%J?@K68M=/]AZC>(UGB8NK6K.BJL32$DJF>.YQ7X3?\&T
M'QAB^,^H^+/%<]O/97]SXWU83VDZ_-%NN_.C&\%HW)@FB8E'=59C'G<K8_:S
M2O"_[ MCX0'@C4O'&B:KI@@%MY5[J<%PIB">7M(D=LC'!!Z=ZZG]GH_\$\_V
M5]7O-<\ >(/"6B/>SO<RK8SV4*-.Y+&5HXRH9MW//WCW[UI1E"'M>9-N<8J,
M[_"T[R35M4^FNEEO=@YITO9V][GNI7NN7E<;6MN_==[Z6:ZW/D?_ (.(O%&C
M^$O@QJ&L:W.UM866FQ7%Q,(WD\N**)'=B%!)PJD\"OIK_@B/JUEK/[/7A2]L
M7:2WGT&UEB9E92R/;!E." 1D,.O^%>J?M&?$;]@[]K#2(M&\>^+?#.LV<:!)
M([NYM'CE53P'C=W4[1@=\A5XR#73? OX[?L/_LU>&H?"G@_QKX<TJPMH4@@C
MM[NT"1Q+\H1$5U"CL,'A<CN:5&4:=.M&6\XI1:]>I%1\RHJ/V+\WSY;6^:U[
M^26OY*?\'&'BW1?"/@^#5-;N&M[.WN=-::18VDV!IX #A03C)%?IE_P1QU*V
MU3]GGP_=6C%X9- T]D8@J2I2'!P>1G^5,_:/\5_L!_M:06T/C_Q3X6UJ"W,;
M;;RXLY(W:$@QL8W9EW#8#GDDC=W->E_!7]HK]B;]G;PQ#X2\)^.?#^F6,,44
M$:07=MM6*( +&J"155>%Z9Z#'>BE-1I582^*3CRVVLDE]_7\O.JLE.-%1O>"
M:E?_ +=:MITLT]7?3;4_%O\ X.(O&>A>#M$CU'7;AK:T3Q'I432B-GP\^IP6
M\8PH)^:61%ST&<G&*_8G_@D7?V^H_LU^'+JV9FBETC3Y$+*5)5HHBIP?45PO
M[1FO?\$_OVKA"?'OB?PMK,44L4^V\N;21&EB8.)#'(S#=N ;OALXQQCV#X.?
MM,_L5_L_^$[;P7X7\=^']-T^U6....&[MB!'&H5$ \Q0JK@<#/8=N9IM1HU(
M/XI5%)6VLE%:Z;Z7WU[(JK*,U2Y;WA#EDWL]MET:MKJUVVU_3FN*^([!? OB
MACT&D7)/X 5\J_\ #Q']E'_HIVC?^!5M_P#'ZJWW[?\ ^R7J]E=:9<?$G1)X
M+V"2WEB:ZM@KI*I4C/G'!'4<'D"H:NFC-;KU1_(OX.\?>'I/^"LE_P"$Q<O_
M &M'Y5Y)!Y38%O)J$D"R;\8P71EXZ<9ZBOWR_P""M_P-LOBE^QKKR3(3"?"]
MPKLJ[V4-8MSCKD<XZ^U267@G_@G+8?%=OC7#KWA-?%33&=M2%S9"Z(W^;M,N
M=Y&<D#.!R<5]=^._VL?V,/B;X+O/AYK/CGP]=Z5=6OV+[,]W;;(TV>61N,AW
M!E)4@@9)SQBM*DN;"PI1^-3N[[-;:.VFFVN_X:4YJ&)=:SY>5)6?517SM==K
M^9_G>?\ !OA\'-2\9_MV_$;5+S[?K=KX%U6'PQIUY?1SSK#:6NLZHJ6\<\VY
M(RL5M;R2VR%6A+K*_P TX9O[M?\ @K(]CX5_8TUMKA3;Q67AJ\:;:A)58[1B
MV%7K@#L/?VK"_9\\-?\ !-[]E_Q-J?C#P-J?@O2=0U:ZDOKR:S>QA:>YE8LT
M\WE;/-D).2S$EL'+&OHGXU_M%_L2_M$^#KOP+XL\;^'=3TR\C>"6&:ZM0C0R
M+L:-D\QE9".F<<9'2C$S]M1PT$K2HQI0D]E)4H1@GYN5G)]O-BI3Y:E:4]54
MYW'R<Y\W36R7N]=>R/R;_P"#=+Q5X>^)_P "AJ&CW#W>F:A%?M!++#+"71GF
M7+13*LB'((9'4.K#:5!%?*W_  53_9J^/_PI_:Y^&G[1OP?T?[5HVA^(F_X3
M"W6VF>:ZT"=9/.:UDB952XM[@039D$B-"DT6T2,DB_N1^S5XT_8&_9&TNYTG
MX>^*O"^AV5P9&6*RN+2.*-I&W2%(HW106R1CCKT'&/?/%W[9'[%'Q$TRXTCQ
M#XQ\+ZQ%<1R1XNFLMZ&08RLOF,<CT8,!S@9YI-I.G.*3E!:W6DK._+K^=_\
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M&2:^R_'O[7G[%/Q5\/7OACQ%XT\,ZK;WD3Q;9WLPT)==NY9/-8GC@J05QSU
M(VK2A*HJU-6EI>#LTDFK1;:2:LM6DK]D90=E*$D^1WMKM?KTU7Y[61Y!^RK^
MUM^QMK_PQTJVU6\\&:1K.F6<*:C!J%O8M+O2)58%93N1U8,I7;SGDC%>%_%_
M_@IK\(]*^)VE_#SX(>!+?QQ/=WB6MQ/H>G1W$$"E]AFF>!'CA4_>"[CCD D
MFO$M<_9*_P""<FLZQ?:S9^/-+TQ]0E:6>.QUE;9&WG)!$$R*<Y/!&,&OHO\
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M@\6DW"I+Y>P7SH(5EQ@['=20<C/(K]46_P""AO[)TBF.3XF:(Z."K*UQ:NK
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M^PG\"/#UKX=\+^*/"6F?9HUC-Q";"25PBJ%&_>NS&W.5&XY.21Q7K-S_ ,%
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M^I/_ ))IZ?\ !$W]EN,YC?5D/JKR@_I=5]V;?B]_SUN?_'Z-OQ>_YZW/_C]
M'PW_ ,.5_P!F7I]KUW'IY]Q_\EU7?_@B;^RW(<R/JSGU9Y2?UNJ^[-OQ>_YZ
MW/\ X_1M^+W_ #UN?_'Z /A#_AR3^RQ_U%/SD_\ DFC_ (<D_LL?]13\Y/\
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M5^RP.1_:@/\ O2__ "35C_ARI^S%MV_:-:V_W?-GV_E]JQ7W/M^+W_/6Y_\
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MG=5]U;?B]_SUN?\ Q^C;\7O^>MS_ ./T ?"'_#DG]EC_ *BGYR?_ "34Z?\
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MF<?Z#$/\GMZ9.:^@J^>/"O\ R5#5O^O#2/\ TBBKZ'H **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7B'QU_P"14?Z/_*O;Z\0^.O\ R*CGMAQ^E &/X5_Y*AJW_7AI
M'_I%%7T/7SSX5!_X6AJW!_X\-([?].4-?0U !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBC_A67A#_H'+_P"._P#Q% '(?\+PT#_GUG_7_"C_ (7AH'_/K/\ K_A77_\
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M>&@?\^L_Z_X5U_\ PK+PA_T#E_\ '?\ XBC_ (5EX0_Z!R_^._\ Q% '(?\
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M  O#0/\ GUG_ %_PH_X7AH'_ #ZS_K_A77_\*R\(?] Y?_'?_B*/^%9>$/\
MH'+_ ..__$4 <A_PO#0/^?6?]?\ "C_A>&@?\^L_Z_X5U_\ PK+PA_T#E_\
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M_K_A77_\*R\(?] Y?_'?_B*/^%9>$/\ H'+_ ..__$4 <A_PO#0/^?6?]?\
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M?]?\*/\ A>&@?\^L_P"O^%=?_P *R\(?] Y?_'?_ (BC_A67A#_H'+_X[_\
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M_"C_ (7AH'_/K/\ K_A77_\ "LO"'_0.7_QW_P"(H_X5EX0_Z!R_^.__ !%
M'(?\+PT#_GUG_7_"C_A>&@?\^L_Z_P"%=?\ \*R\(?\ 0.7_ ,=_^(H_X5EX
M0_Z!R_\ CO\ \10!R'_"\- _Y]9_U_PH_P"%X:!_SZS_ *_X5U__  K+PA_T
M#E_\=_\ B*/^%9>$/^@<O_CO_P 10!R'_"\- _Y]9_U_PH_X7AH'_/K/^O\
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MI;/5=;L[*Y<[5BGD5&8^@!/-=)8W]IJ4"W5C.EQ _P!V6,[E8=001ZU^+?\
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MGFVO.W],'[%7Q/O/B?\ "73-6O96FFBM[=7=\DEM@!Y/)SU/->_^+/BU\/?
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M<(\UN_I??Y TTDUM?7R2[]O(_=77?$>B^&K1K[6]0M].M44LTUPX1 HZDDX
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M/HY724?376W_  _Y:_MS>/\ ]HOPC^VMH,WP;T(ZW?&XNOM$<C.FPI*GD%6
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MU?25?-?P0FMX[O6B\\2'S)-@9U7=^\.3DG'0^O\ 3/T9]KM?^?FW_P"_T?\
M\50!8HJO]KM?^?FW_P"_T?\ \51]KM?^?FW_ ._T?_Q5 %BBJ_VNU_Y^;?\
M[_1__%4?:[7_ )^;?_O]'_\ %4 6**K_ &NU_P"?FW_[_1__ !5'VNU_Y^;?
M_O\ 1_\ Q5 %BBJ_VNU_Y^;?_O\ 1_\ Q5'VNU_Y^;?_ +_1_P#Q5 %BBJ_V
MNU_Y^;?_ +_1_P#Q5'VNU_Y^;?\ [_1__%4 6**K_:[7_GYM_P#O]'_\51]K
MM?\ GYM_^_T?_P 50!8HJO\ :[7_ )^;?_O]'_\ %4?:[7_GYM_^_P!'_P#%
M4 6**K_:[7_GYM_^_P!'_P#%4?:[7_GYM_\ O]'_ /%4 6**K_:[7_GYM_\
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M@'^SC&*\8U_X!?#SQ)X@M_$NJ:7'/JMM()8IVC0LC!@W#$9'(]>*]D^UVO\
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M%8_$'_H,R?\ ?9_^*KZFHH ^6?\ A6/Q!_Z#,G_?9_\ BJ/^%8_$'_H,R?\
M?9_^*KZFHH ^6?\ A6/Q!_Z#,G_?9_\ BJ/^%8_$'_H,R?\ ?9_^*KZFHH ^
M6?\ A6/Q!_Z#,G_?9_\ BJ/^%8_$'_H,R?\ ?9_^*KZFHH ^6?\ A6/Q!_Z#
M,G_?9_\ BJ/^%8_$'_H,R?\ ?9_^*KZFHH ^6?\ A6/Q!_Z#,G_?9_\ BJ/^
M%8_$'_H,R?\ ?9_^*KZFHH ^6?\ A6/Q!_Z#,G_?9_\ BJ/^%8_$'_H,R?\
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MRS_PK'X@_P#09D_[[/\ \51_PK'X@_\ 09D_[[/_ ,57U-10!\L_\*Q^(/\
MT&9/^^S_ /%4?\*Q^(/_ $&9/^^S_P#%5]344 ?+/_"L?B#_ -!F3_OL_P#Q
M5'_"L?B#_P!!F3_OL_\ Q5?4U% 'RS_PK'X@_P#09D_[[/\ \51_PK'X@_\
M09D_[[/_ ,57U-10!\L_\*Q^(/\ T&9/^^S_ /%4?\*Q^(/_ $&9/^^S_P#%
M5]344 ?%GC#P]K?AZSL8M<NGNI9-0MI(W+$X1'^8=3A<'G&<FOK3PNRMH&EL
MO0VL9'Y=_>O$_CJQ)T0=A<1@?C(&_F>^:]H\)?\ (N:3_P!>D7_H(H \V^!W
M_(L-_P!=%_D:]LKQ/X'?\BPW_71?Y&O3O$/B32?"]A)J6L726MK&KL7<@ E%
MW8R2.OXXH&DV[)7;-QW6-6=V"H@+,S' 50,DDGH *QK'Q'H>I7+VECJ5M=7$
M9P\43[F4].1UZU^!W[>__!13XV_#V"_T_P"#?@K5/%&GN)XC=:=&VQ4 (#,X
M !'7UJY_P23^-_Q(^,=Y>:_\17NK75[RXD,NEW+/NM2S?<*MT(SZ8]/:Z4?:
MJHTU:$4UYW=ON"HG3<(O5R>MM4MOQU/Z ****@04444 %%%(3@$G@ 9)]AUH
M 6LC4]>T?1S&-3U"WLVE_P!6LSA6?)QP/J#7RM^TC^TK:?"WPS?OX7_XFWB6
MWAG>/3X5WRF1 P5 B[FSN7KCO[5_-/KG_!0;]J7XJ?M!Z!X4\5^$]:\(>&'U
M81_;[L.D=Q&L^U @!SAAR=P'TYITTJE2---*[U?;2_\ 7Y;%3BX4W-_)==UT
MWZ_\$_L2M[B&ZA2>WD66&0;DD0Y5AV(-35Y=\&;N6^^&_ABXFD,TKZ?#OD8Y
M+-Y:$G/XU\@?MM_'_P"-WP9T:6Y^$G@Z[\5WQC/EV]K&6;>5R,,%.,'WX/UX
M)+E;3Z.W^0H)S[+2^K]/\S[;USXB^"O#5]'INN>(M-TV^E(5+:YN%25B<8 4
MG))STKK;2[MKZVAN[29+BVG02131G<CH>A4BO\\7]N#2/^"ZG[2WQJT+XE_"
M>&'X>^#_  ZL%['H4]_<PW.KZDMXT]PNMJ^@:H)=-%M%!!!!875E-FXOFE=W
M%G):_LY^P=_P52^-^A>-_#/[-_[1_A.^\.>-(;*Q@FN9TD?3[Z556&XELKB5
M4W+YBD[6"N%(RO85"#G'=*>ONW[6_.[MZ:I;BEI.RUCW_K^M3^J:BLS1M2AU
M?3+'48&#1W=M#."/62-7/ZFM.H"]]@HHHH **** "BBB@ HHHH **** "L+Q
M-_R =4_Z])?_ $&MVL+Q-_R =4_Z])?_ $&@#PKX'?\ 'YK/_727_P!&-7TE
M7S;\#O\ C\UG_KI+_P"C&KZ2H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "O$/CK_R*C_1_Y5[?7B'QU_Y%
M1_H_\J ,?PK_ ,E0U;_KPTC_ -(HJ^AZ^>/"O_)4-6_Z\-(_](HJ^AZ "BBN
M4\;^)K?PAX9U7Q!<L$CT^VDF)/3Y%+?R!Z\4-VU&DVTENVDO5Z'17<DD-M-+
M$N]XXW<+_>VJ3@>_%?'.E?M0RZA\5O\ A6_]G@3^>(2^Q<\MC(;'^?UK\E?C
M/_P5'_:'U#Q;K7@WX(?#'5/%UO:RW%I+J%G%M@C*[DP90.<]PI/N.#7YY:1\
M:O\ @I3I?Q<_X6=-\$9)++S_ #3;H\QO" ^[O"%S_P "]JJBX.3E.[@X/E2W
MY[Z/5;=PJ1E%**LIJ?O/^ZTOQO\ F[WV/[1AGOU[XHKXR_9$^,/Q1^+7@^RU
M?XE^'+CPYJLMNCSV5Q&R/'(4!*DE1D@]3W]:^S:3323[ZBOOY,****0!1110
M 4444 %%%% !1110 4444 %4K_4K'2X#<ZA=0VD ./,F<(N?3GK_ )]17E'Q
M:^+N@_#?0[^>>[3^UXX6:TM.-\CA25P,Y)) 4  ]3Z5_+W^V#_P4I_:INO&L
M?A'1? 6MV7A*;5H;;^WPDD=M':R3JAD &,C9SP,8SV')%\TXP6[E%/RO^MMB
MN1\CGLDM//Y73MYZ_B?ULZ=JEAJL'VC3KJ*[ASCS(FW+GZC@_A5^OB/]@_Q%
MJ?B3X+:1J.K73W=[<6]M-/)(Q9O,:,%@<Y[DU]N5=2/).4;WL]_D0G=)A111
M4#&LRHK.Y"JH+,QX 4#))/H!61:^(=%OIWMK74K6>=#AHDD!<$<$8^HKY<_:
MZ_:#TOX)?#K6[@W"KK-SI\Z6,2L/,,[1DQA%!W;B<>G7%?SC?L6_MP?M+ZG^
MU!KVA?$W1+_3/!VL:IN\+WDQF*75I++U97 ", <8&<CVYITU*I44(K2[YF]+
M)*^G?^NFI4ERT^=Z-VY5T=W;7L?UZU0U+4['1[*;4-2N8[2SMUW33RMM1%]2
M37)ZGXUTWP[X)C\6:M,L-JFFQW;NY !8Q!SDL1[G_P#77XH_$']KSXH_M*?$
M34O@E\-M-O%\+2SR6E_XCMD<0Q*Y,1"RQ@ NHW$8/RG/XK>3BM6K^7D$8MQ4
MWI&Z3[]+G[5>'/BEX \6WCZ?X=\3Z9JMY&YC>WM9UDD5P<%2!WSQ]:[^OYO?
M'_[/?QS_ &$;"7XN^!M8UWQM)<N-2U'1Y+B6Z8;CYLJ1+N8(1R-AP!QGUK]-
M/V)/VS8_VC?!3ZCXDMWT;Q';1?Z1IEROE7,<T8Q(DD;88'<#R1COWJDE+X&Y
M-)N2MM:U[=];_=W)E[EK[-KE?\U[6>FV_<_0ZBOPG_;+_P""G?Q%^!GCY/ ?
MP\\$:EXPU>>5HXK;3K83,,-C+MMVJ,^I_+I7SC;_ /!3;]O:\A2YM_V=M=,,
MHW)F%0<'V*U":>VNMOGV*G"4&E)6;2:]'L?TS45^;W[$W[1OQT^-EHL_Q:\$
M7?@^X.,VMS%M9>O!;: >W(SQ^GZ0U<HN+L_735?>2%%%%2!7NKNVLH7N+N9(
M($^])(=JCZGWJK8:QIFJ*6T^]@NE!()B<-R.M?DW_P %+/VMM3^&7@#5_"?P
MY,E]XWN()5L;2U8M+)<;&"@^7E@ V,\' R?K\4?\$C?VM_CE\1[Z\\*?&S2[
MO1_$4.J3(UK<,[ P&4B)T9\;E9,>X/!SC-52BZDI):1C%MM[WV5EUO=??YHJ
MHN2,6_BD[VZ<MK_?T]?Q_I-KE?%'C?PKX+MTNO%&M66CP29V27DHB5L''!;C
MKD?45\U_M?\ [3FE_LT^ ;KQ1<E7NXX)988."[L%_=JJ]2S'@#UQCM7Y)^!=
M4^-7_!371+NYUR'6_ GA3=*FES*9K*:YA!;RI PV;$90&7GCJ<9Q4I.5^77E
MU?IY/:_EY,?+9)MV4M%WZ:M=M3^@?PYXM\.>+K3[=X<U:TU:UX_?6D@D3!Z'
M([>]='7\T,OQ<^.W_!.GQQH7P]OK36?%W@G4KR.P36)!-<FV5R$#7#MN#*#C
MYL]<9P!FOZ!?@S\2+?XG>!]&\2J56XO[6*>:$$90O&C8('0@L01VI^[)<T&W
M&VM]T_3MV9+4HNTU9O;K?Y_UT/6:R+W7M'TV=+:^U"VMIY,;(Y7"L<]./?(J
MMXH\16'A71+_ %O4I5AM;*%Y79R #M4MCDCL":_DW_;\_;Z_:#/QRT*Z^">C
MWNL>"M*UV&#Q'=6S2+';60FQ(Z% 4<J!RIQPWXU-Y.481C>4FDKZ+5I;_,J,
M4XRG)VC'MO?3_,_KDBECF19(G61& *LIR"#T(-25\=_L6?%C4/BU\)M'UW4]
M_P!L:QM3.'SN$AC7>#GH037V)5SCR2<=[6_),SB[JX4C,$5F8A54%F)Z!0,D
MGV &:BN)X[:"6XF8)%"C22,> JJ,DFOR"_:P_;XU_P *^*X/AC\)M,E\0:[J
M\ITV9;)?-:S64F*2:1H\E% )SD\],G%3U2ZO[NF_WEJ+:<NBM?O\C].6^,'P
MV36/[ ;Q;I*ZQO\ +^P&X7[1OS@C9USGCZUZ0DB2HDD;!XY%5T=>596 *L#W
M!!!%?ST:Y^Q#\99=-/[1\'BW6U\7QVQU4Z!]JF^SL^TW'DFUW?WOD+;>V,\U
M[#^Q)_P4%\9>-O&%Q\)_B_H=UX;U+09FTU)[]&C%XL3-&DT+R ;U;&X 'C-4
MDI-03O4YFG&STT3WV>]_3\%)6]Y:P>TNK?IY:_@]M7^W%<-XH^)7@?P9/';>
M)_$>FZ/--M\N.\G6-FW?=P">^17RQ^UE^UUHOP&\&OJ>DNNHZW/'FPLXMKRW
M,C@>5''&-S,S,0!@'G\*_,G3?@A\:O\ @H!I3>/O%^I:WX'$#F]TNRAGFLY'
M5#YL._!7<7^4!.1R%Y)&(3NF^D7:3?3S7?\ K8KEM;FT4E>+6NKM;\_Q/Z =
M'UO2M?LH]1T>]@O[*7[D\#AT;N,$>HZ5JU_.'X)_:V^-?[('Q5TOX&^.M'U/
M4_!\]S#8VWBB9'DME".(QYTKY"OM& QQG)YYY_H)\!^--+\=^'-/U[2ITFBN
MK:&5]C!@KR(&(R/Q_E5VNG.%W!67-ZK_ #,W=/EDK2WM^7X'9T445(SYR^.O
MWM&_Z^8O_0A7M7A+_D7=)_Z](O\ T$5XK\=?O:-_U\Q?^A"O:O"7_(NZ3_UZ
M1?\ H(H \V^!W_(L-_UT7^1KJ_B-X!L_B)H;:'?3O;PLQ+.A8$YQQ\O/;_\
M77*? [_D6&_ZZ+_(U[91OHQIN+NG9KJ?!WQ=^"/@CP'\*]30:19ZE(EK<#S[
MB!'D+%#R6<9/6OS^_P"";0MU^+GB=;6!+: :K.%AC4*BXF/15XK]7_VH2?\
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M_&C]N'1/#NA?%/PE::5HME92+K$"^=;P1QMQ*.20 3_G/H?Z)Y?]5+_US?\
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M_BF)/^NZ_P#H1J'I4I6TYJT&_/5(T3O"K?5QI/E\E>*?_ [=+'T9_P $\O\
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M#KD<E[IEK).]K;W2%XBD98A@KC&#@<_F>:F^!EAI6F?M97UKI5E!91PNL3I
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M^:)(E,B,I89X_O _7UKP'_@FE\1-5\4:;JFC7C-]FTLW%O ,_(%AW!0HSCL
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MH:SIEK\3[G2O#5Z\R6\<4<CSI$[OCYGDVY"D <8R.<]_F3X._P#!);_@H/\
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MISQZC:3.RVZ^6D\98#8QW$;L]0!T^N.,_;/B+Q+IOAG39=4U&55M80S.X=0
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MJ-I%+F=F9MS!&/+$\]>Y[_A]XU52$85>:$F[1Y;^J3?KK<B,W*DH22UDI/\
MQ))?H?RR>+?#G_!70:#>K/J-@MNL!!"K=GY4C8=-WIW/Y8K\OO@_H_\ P49/
M[3/E6]_:'6%U6W^W;?/W&'[2OG;>00=H<C/3C&>W]Y.L0RW.EWUM"BR27%M+
M"JL-PS(C+G!!!QGC(X//:OS3^&?[(_BSPE^T%?\ Q1NBKV-W<F41-&"BKYFX
M<;<>OY9%52:YI\S<4H:/^:3?P_=Y_=:X27NQ:LWS/1]$N76_??3RVLSZZ_9T
MC^(5IX!LE^*$X_X2'R;<7!F?!+^7^\(WD87=GUSFO>FN;  LT]H H)+-+"
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MW_P4V_\ \BT ?8_VVS_Y^K?_ +_)_P#%4?;;/_GZM_\ O\G_ ,57QQYV@_\
M0R^/?_!3;_\ R+1YV@_]#+X]_P#!3;__ "+0!]C_ &VS_P"?JW_[_)_\51]M
ML_\ GZM_^_R?_%5\<>=H/_0R^/?_  4V_P#\BT>=H/\ T,OCW_P4V_\ \BT
M?8_VVS_Y^K?_ +_)_P#%4?;;/_GZM_\ O\G_ ,57QQYV@_\ 0R^/?_!3;_\
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MVVS_ .?JW_[_ "?_ !5'VVS_ .?JW_[_ "?_ !5?''G:#_T,OCW_ ,%-O_\
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MBT ?8_VVS_Y^K?\ [_)_\51]ML_^?JW_ ._R?_%5\<>=H/\ T,OCW_P4V_\
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MI9->O];L+@J@9M+MUN)R@7$>Y7C?@J!CJ"!^?I?G:#_T,OCW_P %-O\ _(M
M'V/]ML_^?JW_ ._R?_%4?;;/_GZM_P#O\G_Q5?''G:#_ -#+X]_\%-O_ /(M
M'G:#_P!#+X]_\%-O_P#(M 'H/QR^%[?%2VM["/5TAM%"B2)4WC"G)PR@ALGG
MVSCMSW?PJ\&Z9\-_"MMX>@O8'$95F)VQ<A=O.[:6/4^WYUX7%J&D0C$?BGQ^
MH_[!-O\ _(N*9+>:+,VZ3Q/X^9O4Z3;_ ,OLN/\ ]9]::;BI15U&;YI+HY+9
M^?X:CD^9IO5QCRKRCII_6W<^POMMG_S]6_\ W^3_ .*H^VV?_/U;_P#?Y/\
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M_P#0R^/?_!3;_P#R+1YV@_\ 0R^/?_!3;_\ R+0!]C_;;/\ Y^K?_O\ )_\
M%4?;;/\ Y^K?_O\ )_\ %5\<>=H/_0R^/?\ P4V__P BT>=H/_0R^/?_  4V
M_P#\BT ?8_VVS_Y^K?\ [_)_\51]ML_^?JW_ ._R?_%5\<>=H/\ T,OCW_P4
MV_\ \BT>=H/_ $,OCW_P4V__ ,BT ?8%S<6<]O-"+V%#)&Z!TE0LI(.& !).
M#R0!R*^(/$'[*FD^-_B):^,?%.K&]CL;D36J2!F6/#;@0&XSP,'Z<UT GT($
M$>)?'H(_ZA-O_P#(M6O[4TO:4_X2KQ_M(QC^R;?^9M:%HU+JMOU\MO)C3>U[
M)M7_ *W]5UZGU=ID>E:186FFVD]O';V<$<$2^9&/EC4*"0"!DX_IVJ]]ML_^
M?JW_ ._R?_%5\<F?0223XE\>\G/_ "";?_Y%I/.T'_H9?'O_ (*;?_Y%H$?8
M_P!ML_\ GZM_^_R?_%4?;;/_ )^K?_O\G_Q5?''G:#_T,OCW_P %-O\ _(M'
MG:#_ -#+X]_\%-O_ /(M 'V/]ML_^?JW_P"_R?\ Q5'VVS_Y^K?_ +_)_P#%
M5\<>=H/_ $,OCW_P4V__ ,BT>=H/_0R^/?\ P4V__P BT ?8_P!ML_\ GZM_
M^_R?_%4?;;/_ )^K?_O\G_Q5?''G:#_T,OCW_P %-O\ _(M'G:#_ -#+X]_\
M%-O_ /(M 'V/]ML_^?JW_P"_R?\ Q5'VVS_Y^K?_ +_)_P#%5\<>=H/_ $,O
MCW_P4V__ ,BT>=H/_0R^/?\ P4V__P BT ?8_P!ML_\ GZM_^_R?_%4?;;/_
M )^K?_O\G_Q5?''G:#_T,OCW_P %-O\ _(M'G:#_ -#+X]_\%-O_ /(M 'V/
M]ML_^?JW_P"_R?\ Q5'VVS_Y^K?_ +_)_P#%5\<>=H/_ $,OCW_P4V__ ,BT
M>=H/_0R^/?\ P4V__P BT ?8_P!ML_\ GZM_^_R?_%4?;;/_ )^K?_O\G_Q5
M?''G:#_T,OCW_P %-O\ _(M'G:#_ -#+X]_\%-O_ /(M 'V/]ML_^?JW_P"_
MR?\ Q5'VVS_Y^K?_ +_)_P#%5\<>=H/_ $,OCW_P4V__ ,BT>=H/_0R^/?\
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MP=&_Z!MI_P!^A1_8.C?] VT_[]"M>B@#(_L'1O\ H&VG_?H4?V#HW_0-M/\
MOT*UZ* ,C^P=&_Z!MI_WZ%']@Z-_T#;3_OT*UZ* ,C^P=&_Z!MI_WZ%']@Z-
M_P! VT_[]"M>B@#(_L'1O^@;:?\ ?H4?V#HW_0-M/^_0K7HH R/[!T;_ *!M
MI_WZ%']@Z-_T#;3_ +]"M>B@#(_L'1O^@;:?]^A1_8.C?] VT_[]"M>B@#(_
ML'1O^@;:?]^A1_8.C?\ 0-M/^_0K7HH R/[!T;_H&VG_ 'Z%']@Z-_T#;3_O
MT*UZ* ,C^P=&_P"@;:?]^A1_8.C?] VT_P"_0K7HH R/[!T;_H&VG_?H4?V#
MHW_0-M/^_0K7HH R/[!T;_H&VG_?H4?V#HW_ $#;3_OT*UZ* ,C^P=&_Z!MI
M_P!^A6-XAT+1ET34V&GVR%;24AEC4,"!Q@^M=A6%XF_Y .J?]>DO_H- 'S_\
M%=,TVYN]9%Q:Q3%))!&'0,!^\.?TSC'M7T-_8.C?] VT_P"_0KP3X'?\?FL_
M]=)?_1C5])4 9']@Z-_T#;3_ +]"C^P=&_Z!MI_WZ%:]% &1_8.C?] VT_[]
M"C^P=&_Z!MI_WZ%:]% &1_8.C?\ 0-M/^_0H_L'1O^@;:?\ ?H5KT4 9']@Z
M-_T#;3_OT*/[!T;_ *!MI_WZ%:]% &1_8.C?] VT_P"_0H_L'1O^@;:?]^A6
MO10!D?V#HW_0-M/^_0H_L'1O^@;:?]^A6O10!D?V#HW_ $#;3_OT*/[!T;_H
M&VG_ 'Z%:]% &1_8.C?] VT_[]"C^P=&_P"@;:?]^A6O10!D?V#HW_0-M/\
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M?XE^&?BK/X5_:3\,7G@C0+F^6#1M4U%3%97L<DFU,3L%16(*X5B#D\>_[M>
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M=)?_ $8U?25 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNS%N@PD['G/I7TO9WD%_;0W=J_F03H'C?^\IZ'O7\=?[%G[#>EZ9^UGXCN?
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MC9-+9<S23]&W\D?T5_%?]HCX6?!>UEN_'_B&WT6*)68F=XXU.T9QN=U ]/\
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M^*^>]D?K;10#GFBLAA1110 4444 %%%% !6%XF_Y .J?]>DO_H-;M87B;_D
MZI_UZ2_^@T >%? [_C\UG_KI+_Z,:OI*OFWX'?\ 'YK/_727_P!&-7TE0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>(?'7_D5'^C_ ,J]OKQ#XZ_\BH_T?^5 &/X5_P"2H:M_UX:1_P"D
M45?0]?/'A7_DJ&K?]>&D?^D45?0] !7&?$#PA9^.O"FK>&KY0T&HVTD3!AD$
MM&R@?CN/;GVKLZ:SHOWF5?\ >8#^9H>J:[Z#3LT^S3^X_EL^/7[.O[8G[)GC
MG5?B%^SJ9KKP:^H_;M7T4>=&)8#)OG:W:,8$AC4X###8QD=1]C?L^_\ !8CX
M1IH-OX;^-M[/X;\:V30VEY;:DQM91=LRPNF^=2KJ93\NWZCK7[>ZKI=AKFG7
M.F:C!%=V5Y$T4T4BK(C*P(R P(R.<'ZCH37Y4?M9_P#!,;]FWXD>!_$FM/X7
ML;'7E62^74%ACBE\\?O$9)8]KB19%##GGGTH4N2'++6"LV_M.UMGTV^]]BU^
M]E?7VDY):64;:6;\]_D?I)\,_BAX5^*_AVV\3>$KZ*]TVZ2.2-XY8Y25D7<I
MRG4>^/3U%>BU_.S_ ,$X?B!XM^&WQ O_ ((W%W<ZAH6CWS6EE<-,TJ_9HY-D
M0+$G)50!U/;-?T2@Y /J ?SK2<.51DOAG%2CW2:6_GJ97]Z4?Y9.+[77;^NP
MM%%%9C"BBB@ HHHH **** "BBB@ HHHH 0JI.2H)'<@$_G7X\_\ !3EC_P (
MP^,C$R# /'#'^9Y/OS7[#U^//_!3B.3_ (1=SY;X,RL#M.""QP1QR#_+GI4/
M^)1_Z^P_]*1<?@K?]>G_ .E1/HG_ ()Y?\D6L/\ KE!_(U]^U\"?\$\T=?@K
M8,58 QP#)4@9P3C/TK[Z+!1EB%'J2 /UKHK_ ,6?K^B,X[+T0M?-'[3/QDT[
MX4>![^6:95O=0M)H+9 W[S?(K(H"@YR3C''>OHV:XC\F<QRQNZ12L%5U)RJ,
M>BDGJ*_FE_X*2?M>O\/?B3H.F>*?#FNZKX=M=5C2:2PL[B[BB19A\TJQ*V%
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MRNGJEKY:J_0^[_VM_A[?_M'?!F2V\"7!>YN[69K*>$ARLCH6B(*Y&<D$8_\
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M\9_X8]_9T_Z)EX>_\ K;_P",U+;;;>K;;'[J223OW?\ 7^1^ 7Q@_:A\:?\
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M_P! 27_OS_\ 84?\+KUO_H"2_P#?G_["OH3^P]'_ .@=:?\ ?E?\*/[#T?\
MZ!UI_P!^5_PH ^>_^%UZW_T!)?\ OS_]A1_PNO6_^@)+_P!^?_L*^A/[#T?_
M *!UI_WY7_"C^P]'_P"@=:?]^5_PH ^>_P#A=>M_] 27_OS_ /84?\+KUO\
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M'H__ $#K3_ORO^%']AZ/_P! ZT_[\K_A0!\]_P#"Z];_ .@)+_WY_P#L*/\
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M\+KUO_H"2_\ ?G_["N"^(/Q+U3Q'HS6%SITEM$Q)+LFP9X]0/3'J<^U?8/\
M8>C_ /0.M/\ ORO^%>,_&[3-,MO"KR6]G##,"V&CC5>,#K],'W'&* /%M'^(
MFJ67BV\UE+&22:XMK.)X0A)"P0)$N1C.&" ],8Q7I?\ PNO6_P#H"2_]^?\
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MO6_^@)+_ -^?_L*/^%UZW_T!)?\ OS_]A7T)_8>C_P#0.M/^_*_X4?V'H_\
MT#K3_ORO^% 'SW_PNO6_^@)+_P!^?_L*/^%UZW_T!)?^_/\ ]A7T)_8>C_\
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MN,G'[D\CMU4]J3_A=>M_] 27_OS_ /85]"?V'H__ $#K3_ORO^%']AZ/_P!
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M^:S_ -=)?_1C5])4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"OXV> _C'I,.M>!]374[":-98YD*LC*R[@5920>.]>MU-FN@7"BBBD 4444
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M-_B-\5_!7PLTF36?&&K0:;9Q*69I)$4@ $\[V7TI7_'0->VVIZ117X4?'/\
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M*QPF0*2X^5>,DD#(S7[\_!?X7MX1_9^TKP0D9CNVT$6SKC!\PQ*BYZ'L>_\
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M&*_1IO\ @C3^QQLPG@ZV5_\ GM]@MQ+GUWA]V>W4<?2OSA_:-_9$_:X_9O\
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MFOB5_P %K?V9)O!^KVUC)<RS7%K-%MFAF<?,AP5'E#G/&>3SP,FOD[_@G/\
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MM;5,39WX\GG.>>HK^7[_ ()%?M'>-/\ @H=K5C\3?V@/"=_X'ULZA,L?AWQ
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M.!2UFU=IZZ.Z&I-)KNK'\VGA']C?_@IC8>(](O-;^+MW>:5;WD4E[;"*93+
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M8').2.@/49^4O^"?/P:\+^$?B-J>H^!;"*#PV=0?R&MHU6 A9.-NP;>W;O\
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M^_G^@X-5J3CLD_:>]ILEIZ[?\.?OCI4BRZ9ITB$,CV-HRL.00T$9!S7Y+_\
M!3GQEITWA"W\,QNCZ@9XXU@S^\)$N[H,G/7UQVKXK^%W_!;>]T3PE8Z/XT^#
MWC./6-+B2QD631+YF_T8&)B&BCQ(N5!4Y.1TZXJ?X9:IXZ_;Z^+L'C'6?#.J
M^'_"<=XLUO;:C;RV[R*7R"T4BC QS@CCT%*S]K!P]Z,)WETO%-:V_P""*$HQ
MA)R]V?+[BW][M]WW'6^)/C-XV^&O[,OAVQ\'7!T_5;E;6W^=_+SYBK&V1UZ.
M?QK[7_9R_95^'WQ8^&.A>-/B]H%CXFU_58%FFENK>&8EV1)';?*CG[SC&/\
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MJ .IHKEO^$U\,_\ 06MO^^J/^$U\,_\ 06MO^^J .IHKEO\ A-?#/_06MO\
MOJC_ (37PS_T%K;_ +ZH ZFBN6_X37PS_P!!:V_[ZH_X37PS_P!!:V_[ZH Z
MFBN6_P"$U\,_]!:V_P"^J/\ A-?#/_06MO\ OJ@#J:*Y;_A-?#/_ $%K;_OJ
MC_A-?#/_ $%K;_OJ@#J:*Y;_ (37PS_T%K;_ +ZH_P"$U\,_]!:V_P"^J .I
MKQ#XZ_\ (J/]'_E7HW_":^&?^@M;?]]5X_\ &?Q)HFH^%W@L[V*XF)? 1AZ#
MCU]>* '>%?\ DJ&K?]>&D?\ I%%7T/7S+X:\0Z)#\1]5O)+N)+62PTQ8Y2PP
M7CLXE8YY. P(/O\ F?<?^$U\,_\ 06MO^^J .IJK>V5KJ-M):7L*7%M,-LD4
M@RCCT([]:P/^$U\,_P#06MO^^J/^$U\,_P#06MO^^J /S:_;0_9J^$WBW3'T
M^V^'.F7^H7Q'GR)I\3@NYYY,9)X/.3U]1BO2OV.OV4?A-\-/ EJ;;P'I-CJR
MO&XD-C%%)&-N[*E45L[NO.!Z<U]G7&O>![]@]W=Z7,P((:=5<Y'H=I.?>K$7
MBOPC:KY=OJ-C$@Z"'"K^@'ZU4'RPG'?FES1EUCJKI>3"7O2C):<L.5K^;;5]
MW>[_ $[=5%%'!&D,*+'%&H1$485548  'M4E<M_PFOAG_H+6W_?5'_":^&?^
M@M;?]]5-P.IHKEO^$U\,_P#06MO^^J/^$U\,_P#06MO^^J .IHKEO^$U\,_]
M!:V_[ZH_X37PS_T%K;_OJ@#J:*Y;_A-?#/\ T%K;_OJC_A-?#/\ T%K;_OJ@
M#J:*Y;_A-?#/_06MO^^J/^$U\,_]!:V_[ZH ZFBN6_X37PS_ -!:V_[ZH_X3
M7PS_ -!:V_[ZH ZFBN6_X37PS_T%K;_OJC_A-?#/_06MO^^J (O$O@/PEXP3
MRO$FAV6K1]"EW$)%(Z=#Z]ZX*']G3X*6Y)B^'?AQ"3DXL8^2?7BO0O\ A-?#
M/_06MO\ OJC_ (37PS_T%K;_ +ZH"[. 3]GCX+QW"74?P]\/)<1L&25;*,,K
M#H0<9XKXG_;-T;Q!XQT.W^&/@?2I;;3GE6WD>WC*HL&[:P 4 8V]NWX5^B__
M  FOAG_H+6W_ 'U6?)K/@.XE^TS7&DO/G/F2(IDS]=IHUO'7W4[RCTDNS_IE
M1ERW:^+[+_E?<\$_9*^"&G?"3X<:59O9+%JIC0S2%0'W;06). <D_P N<GI]
M:5RJ^,?"T8")JEHJKP A 4#V  _E2_\ ":^&?^@M;?\ ?5.3N[VLNBWLNB)U
MW>[U?J=00""",@\$5S-YX,\,7]VM_>:-9SW:-N6>2(&16ZY#=<YYIO\ PFOA
MG_H+6W_?5'_":^&?^@M;?]]4O/J'ETW-/4=#TK5[ Z7J-E#=6!78;:50T97&
M-NT]L5Y)+^S;\#YY7FF^'/AR265B[NUC$69F.22=O)->D?\ ":^&?^@M;?\
M?5'_  FOAG_H+6W_ 'U0!SGAGX._#/P=="]\->#]&TBZ4Y$UG:I$^1T.5 S7
MIE<M_P )KX9_Z"UM_P!]4?\ ":^&?^@M;?\ ?5%V!@^)/A'\.?%\AE\2>%-*
MU>0G):\MTE/OU'?O7/1?L[_!:%=L?P\\.*O3 L8_\*[_ /X37PS_ -!:V_[Z
MH_X37PS_ -!:V_[ZH"[9P=I\"_A#X=EDU?3/ NAV-W;*9EGMK.-)0R#(P0IY
M) Z@U^9/[2OPZ\8?'WXH^'])@TZ>'PQI%_"\R"-A&Z1N,#^[C"CVK]<6\9^%
MV!5M5M64@@@L""/0COFJ$>L> H93<17&CI,>2X1?,S_O;.OXT)OFC=MQ6\>C
MVMZ6L4I.*=M)/:79=5;2][%/X7^!M+\!>$='T;3K5+<P6,"3;5"DML7(.!VP
M/3Z5V&L:)I6OV4FGZQ8P:A9R@A[>X0/&V1@Y!]167_PFGAG_ *"MM_WT*/\
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M6$7^%>E?\)KX9_Z"UM_WU1_PFOAG_H+6W_?5 7+7A_POH'A6S%AX>TNTTJS
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M  FOAG_H+6W_ 'U1_P )KX9_Z"UM_P!]47 ZFBN6_P"$U\,_]!:V_P"^J/\
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M?]]-_P#$T?\ "BHO^@M)_P!]-_\ $U]#44 ?//\ PHJ+_H+2?]]-_P#$T?\
M"BHO^@M)_P!]-_\ $U]#44 ?//\ PHJ+_H+2?]]-_P#$T?\ "BHO^@M)_P!]
M-_\ $U]#44 ?//\ PHJ+_H+2?]]-_P#$T?\ "BHO^@M)_P!]-_\ $U]#44 ?
M//\ PHJ+_H+2?]]-_P#$T?\ "BHO^@M)_P!]-_\ $U]#44 ?//\ PHJ+_H+2
M?]]-_P#$T?\ "BHO^@M)_P!]-_\ $U]#44 ?//\ PHJ+_H+2?]]-_P#$T?\
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M+2?]]-_\31_PHJ+_ *"TG_?3?_$U]#44 ?//_"BHO^@M)_WTW_Q-'_"BHO\
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M^&7V[QC?:(UXZ"VM;&;S03N(GMTFP2.N V,8Z=,]*]1_X45%_P!!:3_OIO\
MXFCPJ3_PM#5N3S8:1_Z10U]#4 ?//_"BHO\ H+2?]]-_\31_PHJ+_H+2?]]-
M_P#$U]#44 ?//_"BHO\ H+2?]]-_\31_PHJ+_H+2?]]-_P#$U]#44 ?//_"B
MHO\ H+2?]]-_\31_PHJ+_H+2?]]-_P#$U]#44 ?//_"BHO\ H+2?]]-_\31_
MPHJ+_H+2?]]-_P#$U]#44 ?//_"BHO\ H+2?]]-_\31_PHJ+_H+2?]]-_P#$
MU]#44 ?//_"BHO\ H+2?]]-_\31_PHJ+_H+2?]]-_P#$U]#44 ?//_"BHO\
MH+2?]]-_\31_PHJ+_H+2?]]-_P#$U]#44 ?//_"BHO\ H+2?]]-_\31_PHJ+
M_H+2?]]-_P#$U]#44 ?//_"BHO\ H+2?]]-_\31_PHJ+_H+2?]]-_P#$U]#4
M4 ?//_"BHO\ H+2?]]-_\31_PHJ+_H+2?]]-_P#$U]#44 ?//_"BHO\ H+2?
M]]-_\31_PHJ+_H+2?]]-_P#$U]#44 ?//_"BHO\ H+2?]]-_\31_PHJ+_H+2
M?]]-_P#$U]#44 ?//_"BHO\ H+2?]]-_\31_PHJ+_H+2?]]-_P#$U]#44 ?/
M/_"BHO\ H+2?]]-_\31_PHJ+_H+2?]]-_P#$U]#44 ?//_"BHO\ H+2?]]-_
M\31_PHJ+_H+2?]]-_P#$U]#44 ?//_"BHO\ H+2?]]-_\31_PHJ+_H+2?]]-
M_P#$U]#44 ?//_"BHO\ H+2?]]-_\31_PHJ+_H+2?]]-_P#$U]#44 ?//_"B
MHO\ H+2?]]-_\31_PHJ+_H+2?]]-_P#$U]#44 ?//_"BHO\ H+2?]]-_\31_
MPHJ+_H+2?]]-_P#$U]#44 ?//_"BHO\ H+2?]]-_\31_PHJ+_H+2?]]-_P#$
MU]#44 ?//_"BHO\ H+2?]]-_\31_PHJ+_H+2?]]-_P#$U]#44 ?//_"BHO\
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M7_\ @G%JO[4?PH^/.J:%\9=;N]3T_P 4:M_:&CF8R*+>TN)=R6Q#,<^6&'.
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M9B ,D8ZU^=>A_M&>*K[X[_\ "OY+V Z<+I8O,^T)L*E]O4MT^G<=:_([Q?\
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MGUM>,>K6FJ[I7_#Y']@OA/QAHOC331JNAW"W-H2 LBL&!SG!!7CM74U\'_\
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MW#-(QD17"H,LQ!.0!ZXQU]#63X[MO&<WPLEM] 9U\6?V?$(V7.X7(AEW=/\
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M/?Q&RAC>80*AE7(VR$DMSSV]!4T$JU1QO9*,FM/B:VL^W]="JL7"*:U;:O\
MW5I=-=]>_P NI_8,C!T5UZ.JL/HP!'Z&G53T]MUA8M_>L[8_G"AJY4B"LW5]
M7T_0]/N]4U.YAM;.S@>>:6:18U5(U+'EB,DXP ,D^E3WXF-E=B#/GFWF$6.O
MF&-@G_CV*_GX_;5^#?\ P4/^)^NZUX?^$OB9]"\)ZG!=6AN?*FEFA2=2BR1
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MT^[YVZ=#\9/^"S-RGC+Q;\//#6B&&_O3KVDHT=J5DF40S1!V;;\V 5).>
M.*_9#]DGP=/I/P$\)Z-JR/Y=QHUJDD4F=V#"BLN#[=37XW?LG?!CXA?M3_&B
M_P#C#\3+6Y3PY'>R7/A^TNP[(D"R%TEQ(-H+  C/0=.*_HMT/2;;0M)L=)M$
M5+>QMXX(U48 5 !P!]*I15.FEK[2HO?3_ET<7UWUT>H3DI248MRA3UB^SLKZ
MV_X?38\PNOAAX/\ "VCZW?:5IL4-Q+!--([(C;G()/&WJ<^_OW-?@W%<M/\
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M!."/K7Y,?\%4OVF_A?;_  ZM/"FC:OI?BG6M18VMM86,T=S(]Q<'"+&J[G)
M*Y.S .2.!NKPZ3_@BAX[26<V?Q[\8V\$L\TR0IKUP$C\UR^U07X"@@ #@ <5
MZ'\(?^"+^D^#_&]CXQ\>>.-4\=SV,\<T,>N:A+?I$8\<QQ2LR*>.2 "<G.:?
M*IVC)\J;U:Z+\RHS=.7-'5K:^E_/R=CZ$_X)<^#/$NA_#73]4UNSFL([^R\Z
M*VD#+Y:R1DHN& Z;AV]1Q7TW^V=\;?#OPP^%OB*SOM3M[/4M0T^6*W2254=F
MD1E55RP.2S*![^^*^J/"GA32/!^BV&B:/:16UM8V\<"") @(10.V/P]J^*/V
ML?V*[3]IS4M.GU/5Y+2QL9X9FMEF:-9?+96VLH(R,KWQ55I.HU;HH1]5&R??
M=+R)HJ,=9WZR7=2;3776S/AO_@EQ\'KG5-2\3?$OQ!$9IM7O[B_MIY06S$\N
M^+86Z Y&-OJ:_=\ * H& H  ] !@5XM\#_@YH_P8\)67AG24C$=K;16Y9 !N
M$849R!_LBO:JJ;CI"'\./PKM=*^MWU1-Y2<IS^.5N9][=>OI\@KA?%?PU\$^
M-XS#XHT"RUB)N"EW&LBD=,88$5W5%9_(=W]^_F> V_[+WP(M)H[BW^'/A^*:
M)@\<BV<89&'0@[>"*]LTG2-.T.SCL-+M8[2TB $<$0PB <  #T'%:5%%P*6I
M6IO;"[M <&X@DB!Z8+C%?@I^U7_P2#\0?'SXA)X_T7Q[JGAC5+:Z:ZM9M.U%
MK8JV\N ZA\.IX^4KCKZFOWXHI<J<E*VJV?8KF?*X?9;3:]#^:'4?^"1O[5L6
MFRP6_P"T7XH>*&#RH84OT=C&@ 50 23P #QT]#7Y*:U_P3I_:"L?VF=*\+W?
MQJ\0OJC7:;9VN?WV5G7/\L$<@]N17]XLJNT3JC;792%;^Z2,9^H]>W6OAG6?
MV-].U;XNVOQ5?4<:C:SK,HW<X#[R.?H./S-:4FO:>_I#E=FM^?HFGI;O=$R^
M#2W-SK>_PK5_C:WS/RZ_:/\ @1\7?@3^S2L'BG6+[QG%#8QM=&6229V1(5W[
M\%L-L7E3@CJ?6OL#_@F9\=O@[+\"[*P'B+1-"U2(QB[LKJXBMY$>/>LJ,I^8
M,'89#*!P>0>#^E'Q(^'&B_$OP9>>$-?MXKNUNK7R#YRA@&,/E,V#Q\W>OPU\
M8_\ !$QKOQ3J>N^!/B=KO@RUU">69]/TC59K.US*^XGR$<(&Y/(4=3ZTE4G:
M4&E:3YN?9[JT=[VMI_PY347%23M+9QWOY^6NOW*_?]8OCS\8_@C)\-_$%IK?
MC'P]>QW5C<1VT"7L$C-.8R%&&(&""1@9)[#BOQZ_X)N>!O$5I^T'XR\3:7;R
MP^"M1UFXGT]UW^0\;2D[U &S:P.1M_48J:#_ ((C>*+J^T^7Q!\;_%NKV5E>
MP7365QKMP\,PAD5RDB^9\RMMPRG@CUK]M?@-\"O#GP2\':;X<TVWADN;.*.-
M[P*#(QC0+NW]26.22<]L=354FJ?M9:MU(J-O2VO]7%*3E&$>D)-_?O\ \#S;
M9[S11168@HHHH **** "BBB@ K"\3?\ (!U3_KTE_P#0:W:PO$W_ " =4_Z]
M)?\ T&@#PKX'?\?FL_\ 727_ -&-7TE7S;\#O^/S6?\ KI+_ .C&KZ2H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "O$/CK_P BH_T?^5>WUXA\=?\ D5'^C_RH Q_"O_)4-6_Z\-(_](HJ
M^AZ^>/"O_)4-6_Z\-(_](HJ^AZ "O+?B3\1[?X>Z?)JEY$#:0KNFE;[J+@DD
M^@XY)/ S7J5>=_$_P#9?$7PCJOAJZ5%_M"!H1*>J;D=.#V^]G\!2=^F]U^>O
MX%1M>TMGI?MJM?D<!\/_ -ICX3>.[&6XMO&&B6US;L5N+>:]A1D.<8QN)!!X
M(('KD\X\Y_:<_:-^&'@WX5>(;@>*-&U.\N+62*"PMKJ*>6;"ME0F<EF8J%V@
MGJ>,<_@I^UK_ ,$M/B=\-I/$'B[X8?&GQ/X6GUFYDNTM+347>T#.V0$@=R@&
M>" %P>N37:_L5?\ !++XG^++32O'?QG^+GB#QHEI/&PT_5+MA92_.)#_ **"
M$8X4<[3@=,9Q5./M(RE:T$U&5KM1>FEP3]C4BK\S24X]')=&O\_QZGKO_!/?
MX>>(O&WQ5UGXL_V-/HVE7^IO-;HT3Q+)"96*R;2 /G!W< 9ZGBOZ(5R  >P
M_2O/?AU\-?#/PV\/V.A^'].MK2.UACC9XHU4LR*!G@#TZ]?PQ7H=7.5U"*VI
MQY$^Z22_3L0KMRDU;FDY6[7_ %_2RZ!11168PHHHH **** "BBB@ HHHH **
M** ,'5_%'A[0%WZUK%CIBCDM=S+$/S-?BW_P4W^,7P</A3 \<Z,9UE03!;Z
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M9]EV7RMV(2LXKI=)O33;7S/;O'/Q/^&VDZ-JUOKGB_1K(K:S*\4EY&DZN%;
M",1SD<Y[9Q7\Z-E\8/@^W[9\13QOHY0WT?/VZ#H)^O\ K /R]\<"OMK]H_\
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MO^%'E1?\\H_^^%_PJ2B@"/RHO^>4?_?"_P"%'E1?\\H_^^%_PJ2B@"/RHO\
MGE'_ -\+_A1Y47_/*/\ [X7_  J2B@"/RHO^>4?_ 'PO^%'E1?\ /*/_ +X7
M_"GE@HRQ 'J3@?F:8LT3G"RQL?174G\@: #RHO\ GE'_ -\+_A1Y47_/*/\
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MY47_ #RC_P"^%_PH\J+_ )Y1_P#?"_X5)10!'Y47_/*/_OA?\*/*B_YY1_\
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MD!'Y47_/*/\ [X7_  H\J+_GE'_WPO\ A4E% $?E1?\ /*/_ +X7_"CRHO\
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MS@#GH.![]U3;J5%1:W4I1:TY8IKXN[?SUT\PG%*'M8]9*,D_YM+V\M;Z_P#
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M3 EV8D_Q C'.<U]M>$?V/?V8M#U&'6_"7@GP_'?6S!X[O39;*8QD'(^>WC;
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MKGPKKEXTNJVTKQ/;P,TD@9"0<H@)'3/T]Z\TB_X+>_LV32QQ)9ZJ6ED2-?\
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MX1Z2=FNZ>F_3U-8).%23O>"336VZTU^?],]IAO?VXX?%DOQJFU&Z'PK0M?\
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MPKX'?\?FL_\ 727_ -&-7TE7S;\#O^/S6?\ KI+_ .C&KZ2H **** "BBB@
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M?#C4O!_@^SO+=XX[]&8S("K8VXV(B?W?PX&:_I;/A+PL>3X=T4G_ +!MI_\
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M<B5DWS-=WIKZNVI+NVFVVTK?+2WW6"BBBI ^<OCK][1O^OF+_P!"%>U>$O\
MD7=)_P"O2+_T$5XK\=?O:-_U\Q?^A"O:O"7_ "+ND_\ 7I%_Z"* /"?A7XVT
M7PYX:BAU.5HFN"DL0/4J%*Y^AQD_AU[>E_\ "VO"/_/TWY5#<?"/PU<6]G;.
MK[+.%8D*@*6VC!9N>2>23[U2_P"%*^%/[LOZ4 :?_"VO"/\ S]-^5'_"VO"/
M_/TWY5F?\*5\*?W9?TH_X4KX4_NR_I0!I_\ "VO"/_/TWY4?\+:\(_\ /TWY
M5F?\*5\*?W9?TH_X4KX4_NR_I0!I_P#"VO"/_/TWY4?\+:\(_P#/TWY5F?\
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M"/\ S]-^5(/BMX+'S"Y(;U$2#_QX-GK[>]9O_"E?"G]V7]*/^%*^%/[LOZ4
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-H1 !C"CH,#TZ4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gvgjwefnhf2j000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvgjwefnhf2j000001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_X0F217AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    >    <@$R  (    4    D(=I  0    !    I    ,0 9     $
M  !D     0  061O8F4@4&AO=&]S:&]P($-3,B!-86-I;G1O<V@ ,C P-3HQ
M,3HQ-R Q,3HS,3HP-@   J "  0    !   $0Z #  0    !    \
M   & 0,  P    $ !@   1H !0    $   $2 1L !0    $   $: 2@  P
M  $  @   @$ !     $   $B @( !     $   AG         $@    !
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M?O\ ;Z:2G1265>[J7VJRMF72TVLL=CU%P:YH!IJW[358ZWT'-=O?_I,ST?\
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M        86-S<$%04$P     ;F]N90                    $  /;6  $
M    TRU!1$)%
M               %8W!R=    ,     R9&5S8P   /0   !G=W1P=    5P
M   48FMP=    7     4:U120P   80   (,=&5X=     !#;W!Y<FEG:'0@
M,3DY.2!!9&]B92!3>7-T96US($EN8V]R<&]R871E9    &1E<V,
M#41O="!'86EN(#(P)0
M
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\
M]_HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7B"JBMT9LJ>!7MU% 'G_ ,)=3LV^'&GVYF1)[*-Q<1N0K1#>QRP/0$<YK"\
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M=Y9'& <\G&:[/Q!\4?#%KIYN+/S-3OX<O:PI:R<2%2H.YE 7AB"<YP37H=%
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MW/H:SKOQ?X;\3:S8^%X)$U#[86EE"[E$0C'F*<X'.Y17,?&3_D;O '_7^_\
MZ,@H [9OB)X6BGC@N=1DLWD^X;VTFMU/_ I$4?K7212QSQ++%(KQN 5=2""/
M8U!J.FV>K6$ME?VT5Q;2C#QR+D&O*OA5<W>A>./$7@=YWEL;/?/:;SRBAP,?
MB'4_7ZT >PT444 )7)2_$7P^;R6TT\WNJS0G$HTRSDN GU91C]:YSXX^(;G1
MO!L5G:2-')J,WDNZG!\H*2P'UX'TS7;>%?#UKX7\.6>EVL:H(HQYC#J\F/F8
M^I)H I:;X_\ #VK:O#I-I=RG4)2P-O) \;IM&X[@P&.*ZBL&^\-6UWXLTKQ
MN([NR62-SMYEC=2,$^Q.1^-95KXQU+7[B_\ ^$7TFWO+.QE,#W=U=F%9I%'S
M+&%1L]1\QP* .SHKB]#\?Q:[I.I2P:5=+JFF.4NM,+H)$8$]&) (X//MTK#M
M?BAK&K>%)=>TGPE)+;VPD>X:6["*JJ>B<9<[>3P .G)H ]/) &3P!U-<<?B/
MH(N["(F\^S:A,8+2^\@^1,X;;@-UZ\9QC\*J:SXFNM;^%=QKFC6:-%=:=.\A
MDN/+:W 1@Q&%.\@@\<9QUJO\-Y]4?P+HZW&AV\ME#;"2WDCN@\KL"<?(RJJG
MKSOXH ZCPSXKTSQ;:7%UI;RM%;SM YDC*G< #QGM@UI7]_;Z;927=T[+!&,N
MRQLY ^B@FN9\%>,+;Q+IVJW8T]=+AL;IXG5W4\A0S,V.!U/K]:K0^+-8U[0K
MS5]'T.*32@)!"9[DI/<*N0S(FP@=. 3S[4 =%X=\1:?XITH:EICN]J9&C#NA
M4DJ>3@\XK8KRKX9ZY:>'?@O;:E>;S%%+* D:Y>1C*0JJ.Y)XK6U?Q[J7A>YL
M)O$FA16FF7LHB%Q;WGFM QYQ(NT#IG.TGIWH [^BN%\1_$"?0/%VGZ"OA^ZN
MC>@F*6.5<R8'15^O!+%<=>E+HWCC4)_&K>%]=T,:9>26YN;9DN1,LB GC( Y
MX/\ WR: .YK#B\5:9+XNF\,*TO\ :4-N+AQL.W8<?Q>OS"N%\.Z[XJO_ (IZ
M_'<6=K(EHD-NUN+QE2WC8[MR_(=[8SG.W\JZ.S\7BZ^(TOAQ]$DM9TM#,UU,
MZ%G4$8 "YXY/4_A0!V=4-4U6TT6PDO;UW6WC&79(FD( &>B@GM7.KXNOM2\4
M:OH>B6%O))I2(9Y;J=HPSL,A5"JW'J32Z1XHA\7^ +W5([<VS^3/%+ YW>6Z
MJ<C..1TYQ0!M>'?$%CXGT:/5-.,IMI&95,B;2=I(/'U%:U>>_!3_ ))?I_\
MUUF_]&-70^,?%-MX/\.3:M<PR3!"$2)."S'H,]A[T =#17&R^+M0TKQ-HND:
MWI]K$NL!Q!-:W+2;9% )5@47@[@ 15?7_B!<:)XPL?#X\/W=PUXK-#(DJ9E(
M!P%7/3< "6*X'- '=4UF"(6;H!DUQ.A^-[^[\:3>%];T3^S;T6_VF!DN1,DB
M9]0!S_@:M#Q7>ZKKE_I?AVQM[H:>1'=7=U.T<0EY_=KM5BQ&.3VH T-"\7:3
MXDO]1L],EEDDT\HLY>%HP&8MQA@#D;#VK3O]0M],LWNKGSO*CY;RH7E8#_=0
M$_I7FWPON)[KQUX]EN;8VUPUS;B2%G#[&'F@C<.H]#WKU2@#C;?XH>$KJUDN
M;?4+B:"+AY8]/N65..Y$>!6_H^NZ7X@L_M>DWT-W#G!:)LE3Z$=0?8UY?\"M
M5T[3O 5_]MOK6VQJ,CGSIE3CRH^>3TK,\"7LEIXU\9>)-%TVXN/#X63RX[=5
M197#A@5W$#  <X'(#=.U 'NU%>::)\2M9\0V^F7>G>#[J6RN;HP7$XF!6$;L
M9'&6P.2< =LULP>,-1UV_O[?PQI=M=V]A*89KN[NC#&\HZI'M1BV/4X% '94
M5Q6B?$!-;L=5$>DW2:QI9*W6F>8F\$$\JY(5EX//Z=,XNG_$K7]?\.G6-#\&
M2W,<;.)MUXJCY3T08RYQR<#V&: /3Z1B$4L>@Y->=GXKVTO@(^*+/1KJY2)S
M%=0K*BBW<%1AB3D@[A@JI]\58TKQUKNJ7MDT7@R];2[NU$R7:S("3MST8@ $
M\#<02.<=J .@\+^*M,\7Z9)J&DO*UO',T#&1"AW* >GIA@:W:XKP=XWL==\,
MZIK+V0TJRL+J2-U9@<*JJ[,<#&?F/ S5/4O'^K:7H47B2;PW_P 2%]C%OM8^
MTK&Q 60Q[=HSD<;L^N* /0:*\H\>^+-5:^\&#1!"^EZK>V\R/YQ1K@AT98VX
M.U.5R>3[<<]-K7C"[T--%M+K2XAK&K7)MX;=+DM#&00-S2;,XPRG[O\ *@#L
M:*Y#3O%MV_C"[\,:EI\4=[%:B\A>VF\Q9DSC'S!=K9]>*P1\4=4O+[6M/TSP
M=>W%_IA4& SIG&6W%B,C(PN%4L6SQTH ]-HKSN;XA:M9^(]#T>^\-QV;ZQ$L
MD4L]^RJC%>8V B)W \8]QT[='J6O7EIXKTO1+73X;D7L;S2RFY*- B$!F*;#
MD?, .1D\<=: .AHHHH *H:GJEKH]D]Y>>>($Y=H;>24J "<D("0 !UZ5?JAK
M?_(!U'_KUE_]!- '/6WQ-\)WEL]S:WUU/ A(>6+3;EE!'J1'BMG1?$^B>(HV
M;2-3M[O9RRQO\ZCW4X(_$5PWP%_Y)Y)_U_R?^@I67\8M+'AN?3?&^BG[+J<5
MV(IVBX$P()!8=_NX/J&H ]DHKD+SQLGVG2M-TJS^VZKJ5N+F.%I?+CABQG?(
MV"0/3 )-0P>-Y[+Q7;>&_$>FI87=V,V=Q!.98)S_ '02JE3VP1_,4 =F3A23
MV].:YNT\=^'+W7O[#BU!TU3D?9I[:6%L@9_C4#..?>NFKQ'QSX0N_%'CS7KC
M3)GCU;3+2TN+4*V-Y^?(]CP,'UH ]AU/4[;2+&2\N_.$$?+M% \I  SDA 3C
MWQ530O$FF>);4W6E2SSV_:9K:6-&YQ\I=0&Y]*YKX;^.X_&FD/:7ZB/6+0>7
M=P,-I<=-X'H>A'8_A3/".N67AKX-Z5JNH/LMK>T!;:,LQ+$  >I- 'H%%<%?
M>--?TG1%\07OAJ(:40KR1QWQ:YAC;&'9-@7Z@-Q^!K'^(_BW47\,:)>^'WB;
M2]4NH8VG\PK(Q8EA'C'R@["&/7MCK0!ZK15+3IM0FM ^I6D%I<9(,<,YF7';
MYBJ_RJ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'G?Q5;[%'X7U@\1V&MP/*WI&<[OY5U-S?75]<O9:3\IC;;/>,,I">
MZJ/XW_1>_P#=)XMT"+Q/X7U#1Y"%^T181C_"X.5/X,!6-\./$KZYH'V+4 T>
MLZ6?LE]"_P![<O <_7'YYH Z;3M-@TV$I"C%G.Z65VW/*W]YCW/\N@XIVJ7/
MV+2;RZSCR('DS_NJ37$>-/B0_A3Q-;:0(+%_M$*2JT\TJD;F9?X8V&/E]:N>
M,?%N@/X1UNTMM?TEKV2TFA2(7T0?>RE<?>X.30!\FU]5?!FX\_X7Z8I.6A>:
M,_\ ?QC_ "-?,G]D7/\ STLO_ Z'_P"*KWCX-:_I.B>#)K#6-:TNTG6\=HXY
M;^+)0JG/WO7=0!ZY<6\-W;R6]Q$DL,@*O&ZAE8'L16-NNO#W$AEO-)'1SEYK
M4?[7=T]_O#ON'(Y>Z^)Z)X[M_#MJNG3PSRPJDZW$C%ED"D$;8RIX;CYL5V'B
M/7[+PQH5SJU\^(8$R%S@NW91[DT <CH\B:E\<=;NX&5XK+2(K5F7D%G99!S]
M!7HM</\ #+1KNRT*YU?5%QJNMW#7MP",%0WW%_ <^V[%=Q0 4444 %%%% !1
M110 4444 %%%% !1110 5XUXQCMKS]H3PU;W$<<T+6 22-U#*>9^"#]17LM<
M_-X)\+W%T;J?0;"2X9MQE:$%B?7- 'ELZ7?P6\9"YB\V;PAJDF'C&6,#?_%#
MM_>7CJ*[_P"(=W;WGPLUFZMYDE@FL]\<BG*L"1@BNEO=*T_4=/\ [/O+2&XL
MR /)E0,N!TX/I6<?!?AHVB69T.P-LK%EB\D; QZG'2@#A]!T%O%7[/=MI5N4
M\^6V<PDXQYB2E@,]N5Q5GX1>)(6\/Q^%]0;[+K.ENT+VLWRNRAB00#UQG!_^
MN*[O2O#^D:('&EZ=;V8?[P@0*#^50:QX3T'7W5]4TJUN95X65DPX'LPP?UH
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M>?%BY-QXA^'<TR^3*]R9'B)R4+-!Q^'(S7H@\ >$ 01X;TL$<C_1E_PJQ?\
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MC<???38669QZ&8D.1[$D4 <7JWAGPYX9U_3]7N?$>J1R6ODM%&^E;)':$*$
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MJ$MX^\DK$*B_BQ% &I%/%<*6BD210Q0E2" 0<$?@>*=++'#&TDKJD:C+.Q
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M+:6:*&8SQ,C\G &P\Y/IBJ=MXRL)=7M-+NK6_P!/NKU6:U6\A"";:,D @G!
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M<;2VX=RJ %CD\GU- '944TD(I9FPHY)/05R<OQ$T..T>^47\NF1OL>_ALW>
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M44R2-)8V1U#(P*LK#((KRV6<?##QC=E;26;2-<3=9I$"S1W2](1Z!\\?_6-
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M*\M\:Z[>67C"TUFWD_XE7AV:*&_ S@_:00Y]]B^4?J] 'J5%("",CD'H:6@
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M+((V3*_RCG&,+G<2#QCUH O>#IX_$.K:MXL0[[:X=;*P8C'[B+.YA_O2%_\
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M_P"P.?YM6=X(@FUGQ?XTBDU[4M.U%-3=FBMC"-T0)53\\;$A<8X.,8]:[)_
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M<V4#J]L\TB>9 5! "D(,C!(Y!J"?X4Z1=)8/<:KKDE[92"2*^>^+3#'1<D$
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MW$.K:%XQG\*VL&F:2&N?M5R^Z2:\F$>Y]JDXC7!')SUX KH/@X2?A5HN>?\
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MF6^H7UW:1C$*71C8QC)X!5%)'/?- ' ^ /#T'B;X9VD"^)-72TEBDM[FTA:
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M!]*[5T61"K@,IZ@C(I(X8HL^7&B9Z[5 S0!6U/4[/1]/GO[Z=(;>%2SNQ X
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MT ;]1^;'YOD[U\S&[9D9QGKCTK*U3Q)IFE745I<2RR7DPW1VMM"TTI7/WMB
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7EEM86=Q^T/J1FMXI"NC"4;E!PVZ-,_7:
M2/I7J=<5!X&NH/&DOB@>()FO)8O(>,VR>68N/EQG/\(.: .8U")U^-=GHUE=
MIH\,&DM_9ZPVT94,S[GVJ1@$@-D@9^6N@M/!L6E>.H/$^H>()9]0N ;4(84B
M$YV' PHY("Y_X#[5<\9^ ;'QC):71N[BPU*S/[B\M^&49S@^N#R,$8-/T'P@
M-#N&U/5=8OM9OXHRL<]T<B%,<[$'0GN>2: .5\+RS^%?&GB_3M4L;N\BOKG[
M9'/:6SW(*N6PCA =A(/1L#KVQ6_\*_#M]X:\&+:7Z&.6:X><0$Y,*MC"'WXR
M?K7'>&]#D\8)J7B'1?&NHZ/%J%Y+.]DDP=HN<9?!&TG&<=EVC)QFNH\++KPO
M-6T@^*AJT,,:&/4?LZEH)2S;H^I#G:%/)X].: ,/X8V-M>_";7K"YF^S6LUQ
M=Q22C@1(4 +?0#FJEGK6M^"9=*\-^-M.CN=&BGBCL-5@R A0@QY^F!P<'&?O
M5U_A_P"':Z#X:U7P^-8N+BPU&*56$D:AT:10I8'Z=CWJQ-X*FU*"QL]:UJ?4
M-/LI4F2%H51Y63[OFN/O >P&>] &/8?\G#:I_P!@)?\ T9'69X5_M/5_B!XV
M$.M2:?>17JH8_L\<I:%2RI@L,@8';^]75:SX!74O%L?B*TUF]TVZ,'V><6P7
M,J>Q.=I]\&J.O?"^#4==BUS2-8O='U-8Q')/"2QE   W9.2<  \\]Z (M.\'
MV?A7_A)<ZL]Y=:M:2W,UO)&J#C=E@J\ 9?'\JI?"'3;&3X765RVGV\UPD\TZ
M-)"&;S59@K=,Y  &1S736O@PV>C7MM%K%Y)J-\NRYU.Y"RRNN"-HSP%&3@=J
MD\&>$G\':9_9D>IR7=DI9HTDA560DY/(ZCZT <+\,+'4?$7@:>2/Q&\)N;B<
M7L/V6*0F1C\Q8L,DE2.M97C+2;3P3X"M?#=OJ\MW9OK4?V[S, QHR;O+.WH#
MMW>M=A/\*$M_$%SJF@>(M1T1;LEKB"VP58GKM].IZYQVK>G\!Z+<^$Y?#TZ3
MRV\S&62>23=.TQY,I<]7SW_#IQ0!A_&B.-?A;>A44*DD.P # &]1Q^%=MHG_
M " =._Z]8O\ T$5PTOPKFOM"_L34O%NK76GHR>3#M10BJ1P3@EN.!DX'IQ7<
MZ1IJ:1ID-C%/<3I"H57N)-[D =S0!Y]X]_Y*QX"_ZZS?^RU%\6K>&Z\3^ HI
MXTDCDU41NK+D,I>+(^AKJ?%W@J/Q1>:7?1:E/IU]ILA>">%0QP<9!!^E4-:^
M'<NLSZ1*_B&]4Z5()K=VC5W,N0Q=F/7)&<8P.@&* &_$6V\*6/AUFUC3/,%W
M=Q[8K,".6YG .T%AC/&>2>E8'B?^US\2O -SJGV2&66XG"6]MN8Q+M3(:0GY
MSSV51]:[/Q7X,@\8:#;Z=J-[,DUO*LT=U  K!P",XZ=#6/>_#!;ZZTR^G\2Z
MN^I6#;DO&=68CC@*1M7IUP<YYS0!G_#V\%_\2O'DUV<WT5TL$6[J($9U&WV^
M52?PJKYDEA\7O&]U:#%PFB"5<#/SA$QQ^ KH-6^'$-SXB77M'UF]TC5#&(YI
MH0KB< 8RP;@G _KC-3Z1\/+32_%$WB!M8U2ZO9T"2^;, LN ,[@ ,C(& , =
M,4 <MX T2\\2?#&W@C\2NEG<QRQ7-N+6)B&9FW@L1G)SG)YYJYK&B6?A[X+Z
M]H=K?M?QV22(6D S&Q97V\>F[-3Q_"5-/U2YGT#Q-JFCV5R^Z:TMB,?\!/;'
M;(.*W]3\%6]UX0/AJRNY;*R<%9G""223)RQ+'N3R30!QNK6T _9L0+$@']GP
M28"@?-O0[OJ3WJ;QM:6\'[/2I#!&BI9V;HJH  Q>/)^IR>?>NANO <UUX(C\
M*MKDHLT18C(MNN]HU(*KZ=NM+J/@6XU3P3%X7N-<F-JBI&\HMEWNB%2BDY[%
M>O4_S ,2[O=.;4/!)33WOO%#62R6<8F:.*)&C&YY#@_*,''!)Q5?PR;]/C[K
MT5_/#),VDHSF"(HN08L8!)/ .,YYK6O/A@MY-H]X-?O;;4M*A%M#>01JC&(
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M<?O"N26;CCG ["J=_P"!;J^\9VWBC_A()XKRU0Q0(MLI14.[@CO]\\T =M7
M>.IK_5M;TGPYI-O#=21.NIWD4TQC0QQL!&K$ \,_.,?P5WJ!@@#'<P')QC-<
MIHOA"[TGQ-?:W-KLUY+?!1<1RP(H(4$(%(Y4#/;KWH \Z^)<7BJRO=*\:7&D
MV%K+I,JJ\EM=-*74L-H;*+A<Y'_ Z]ETO4;?5]+M=1M&W6]S$LJ'V89JCXIT
M%O$NAS:5]M:UAN!MF98PY9?3GI]:H>%/"-SX3T*32;;6I[B 9^SF:%28"22<
M>HR<X- 'G_A"ZN;+PW\3;JS8BYAO+IXV'56 ?G\.M:/A#PS<^)?A;86D?B21
M--N;8QR6\=G"=K9.X;L9SNR<]>]=/X3\"?\ "+3ZB?[5EOH=1D,MS'/ HW.<
MY.1ZYZ5BVGPD_LJ\N!HOBO6-,TZX;<]G;OC'^ZW;TSC/O0!OZ1HFBV'@"70+
MF^%]I=I'-;W$TQ PH9BP)Z#;G'MBO._A/<QZ=XL_LG5OM)D-J6T&2[7;NMF9
MF.T=BPP?HI':O1M6\%17WA^UT&RO6L-,AV[X$C#^<H.=K$G)!/)]>]1>+? B
M>*;[2[P:E+87&FG=!+;QKN#9!ZGMP.* */B>XTP?$'0X[33WO?%"0R&W!F:.
M&"$A@7D(!X^]@ 9/Y5C>$?ML?QS\5Q7L\4LYL86D:&(HA.V+& 23P#CK70:W
M\/1K.M6&NKK=Y9:O:0^2UU;(J^:O/53D#[QI+3X<PZ=XHEU^QUS4TN9H1',)
M'$GG,,89R>2,A3M&!QC@<4 87PBMX/[7\9S^2GF_VK)'OVC=MW,<9]/:N0L;
MB;2_@;XQ6Q)C4:U);\?PQL8E(_$''XUZAX:\"W'AB75);3799'U&0S2F6V4X
ME)/S#'UZ4SPY\.K70]%U+1KF^EU'3M1=I)HIXU4[V !8$?0?CS0!%K*6H^"%
MPMJ$-L-%!CQTQY0(/]:X[Q/;(/V;=-S\Q2&VD0GL68?T8BNEA^%,T.C7.B#Q
M;JIT:1&6.T(3Y,^K=2,\X&!5F_\ AA%=^$H?#,.NZ@FFQD%A+MD9L'(&>  #
MV H Z*#1]-M='66WT^UCE2P\A76$!A&%^YGKCVKSWX9RZ9%\#[QM98KII-PM
MP1D'8>"!CG/.!BO15TK4!X?_ +-.KL9]GEB[-NN[;C'W<XS[_I7/Z/\ #>VT
MWP?>^%Y]2GNM,N@V T:H\9)!R&'N >: .!\;->2_!BTDMK2+3]#5H?L=O*S2
MW#H2=KN^0JY'. &^HZ5[Q7F\GPDM[GPQ_85]XBU:ZMX]OV4,X"P8/9<<\9')
M.!TQ7<Z38R:9IL-K->W%](@^:XN""[G/?'% 'EGQS3S+OPBF67=>N-RG##F/
MI[UA:_I__"'?$:UF\8?:M>\.W+$6MQ?3/+]F)/=<[25[@CD<CGBO1O%_P\?Q
MAJ-K<W6O7,$=FQ>VBBA3$;';DY/)^Z.M;6J^&8/$/AF31=;F-X) =TX0(P;)
MVLH' (H Y+XR7YB\ 6AMI5^PW5] D\B .IA(9L^A&57ZU8\1^ 9O%&DPKJWB
MR5[*W87$<B6L,87"GYMPQQ@U;TWX=0VWA.Y\,:AJMUJ6ER)MBCE0*T!!R"K#
MG@\C/\JI:1\*S8I'9WWBC5;_ $>(@IIKMMB(!X5N3N7_ &1@4 2:_?:3+XR\
M.&QM6U+Q(UL\EDS3&.&.%E.9).#QC=@ $G\JR?"/VV/XZ^*X[V6*2X-C"9&A
M0HA.V+&%))X!QUKI?$?P_M]>\0V.O6NJ7>F:E:1^4LUKMY7G@@_[Q'TXJ&S^
M',6G>*9->L=<U)+F6$1S"1Q)YS#'+DC)&5!(&/08'% &=\/_ /DI7Q#_ .OJ
MV_E)7I5<;X<\$3^'O$&HZLNMSW+ZG()+N.2!0&(W8QCIC<:ZB^BN;BSDCM+K
M[+.V-LP0/MY]#P>* /$OA7X9TKQ!J7BIM1AG<PWP">5=RQ8!+Y^XPST[UZ)H
M_AS2O!&L:E?PSM#9:F;2"..65Y'\\,ZXRQ).=ZXY/?M6;H7PROO#4EV^D>+[
M^W:\</<$VL+[V&>?F4XZGI6A%X%O)_$&GZMJ_B>_U,6,IEBMI8DCCW[2 VU
M!D9SG% '):BWB3P'K.LZ[HT$.N^&;Z[DN+V!6R\$@)$O(Z8((Z$#;R!C-)XN
MO]-U/PG\/KG1U9-/.K6R0(WWD5 5VGW&W%=FG@V]MEU6WL_$4\5IJ=Q-/+$]
MNCF(RDEA&>,=>X/K4.L?#C3=2\(:?X>M;B>QCTV19;6>/#.CC/)]<[B3TYH
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M,/1MI&1['BHM$\.Z9X<MFMM*MS;6['=Y0E=U!]0&) _#K6M10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gvgjwefnhf2j000021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvgjwefnhf2j000021.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" ;*!-8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *AN[6.[@:WFBW*ZE64]P:FHH \]U_X'Q)JK>*?
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MN^#[[^+;C]RP[>]>I? Y&;X->$"0/^17T\\?]>Z5Y;_P4X_Y,#^*W_8GW_\
MZ U>J? S_DC7A'_L5=/_ /2=* .L&<<T444 %%%% !1110 $9&*YGXA_#'PU
M\0]-:SUNS!D"XAN59E>)ARK#!'(('7BNFHH \H7_ (6K\%XECE%QXMT=6R'B
MC$=U:(.-N!D.H&,<Y/-=KX.^(WA+QI"KZ1JL/G*O^D6<D@$L#?W67L:WI(B[
M[LCCU%8-W\*_ MUXDM_&#:'''J5MN*W5OF,N3U+A<!_^!9H Z%7#=*X3]H._
MUC1_AIK&MZ+\T]G9R3*OV?>0!&V2O&-WUXKJM4U>#P]8->72[8HQF1U0G8O=
MB!VK@?C+JUC\2?@SK4?@[48;Z*^T^:*3R+DJ?+9&4]#N4Y&.E 'C/_!.'XY>
M.OC5K'C"\\0^+]0U;3[5;4:?]MLXHA#EI0RC8 3RIZU]86CQ^7E3\O:OB?\
M9'GM_P!G;0/B!HWPWT*\O+/0=+MYK/[6Q6:X8++(^?-W-PW').>U>X?LU_M4
M67Q^\2:IIFAV$D5KIT999)(RHE^[R 5&.7]3G!Z57,JUZB=O(A>Z[+8]N!R,
MXHID,A=3D=&(I]26%%%% !1110!\3?\ !3.5E_;,_9-12PW?$:[#8;@_+:U]
MJVV0-IY/][UKXI_X*:?\GG_LD_\ 92KO_P!!M:^UH/O-_GL* )**** "BBB@
M HHHH **** "BBB@ HHHH **** ,'QK\/O#/C^P;2_$VDQW$;9V,S,&0XQD8
M(KAY-#^*?P;M5'A=Y_$VCQMM32R1'-;1CG"L0VX 9 &<FO5B,C!J.6W5QU/Z
M4 <SX(^*_@[QC_H]A??9[S&9-/O%\N=!TY4G./?H:ZB.59%W _\ UZY;QI\(
MO"'C25=1U'35COHE_<ZA QCF4@8'S*5) ]"<5I^$])U70]'CT_4]8DOID9O]
M(F7!*YR,X/:@#8HJL=3MA-]G6>-I.OEJWS8]<5/&^\9QQGCWH =1110 4444
M %%%% !1110 $X&37R3_ ,%0MQ\9?LVQ ?ZW]HC1$^\1U2;'3W&?PKZU?[A^
ME?)?_!4#_D>/V9_^SCM!_P#09Z /K&V7;']3DU)38?\ 5BG4 %%%% !1110
M445'=74=I"T\OW54L?PH DHKE_"/QH^%_CNZFL/"7CC3+ZXM9-ES;PW:^9$W
M]UEZ@UTR2;CC% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-?K1^R9XW\%?$;PE?_$OPMXKTW5O^$@U)[NXFT^X5]@/^K5L<J=O8]J_"/\
M:F_9K_:7_P""87Q/O/ UQXBD;P_XE::/1=69;?[+XDMX1&&E>S\Z81LIDP/,
MPW4J>N.I^$G[>DOPRLFTK3)O$7PQ\9:7#)$?[#N)5TF[NXT8!+NU?<\+D@QG
M;N"L03@ D<^"XNP<JWU?'0=&HM+/5-][[)=CVN(OH\\14\KAG/"U>.98.HG*
M,J>E11ZJ5-OFO':2C=IIW2>A_08MS%MR3@5+7YV?L(?\%2_CQXD^$N@>(OVK
M/A/:R0:A;QR2>*_#-^+J&)=I+23)#YNSMNRPP22> <?;GPO_ &BO@[\9+);K
MX;^/=-U5]BM+:VUVOG0Y_OQMAE_$5]9&49Q4HM-/JG='\_XC#XC"UI4:T7&4
M79Q:LTUT:>OWI/R.WHIL;[QG%.JC$**** /G_P#X*<?\F!_%;_L3[_\ ] :O
M5/@9_P D:\(_]BKI_P#Z3I7E?_!3C_DP/XK?]B??_P#H#5ZI\#/^2->$?^Q5
MT_\ ])TH ZRBBB@ HHHH **** "BBB@ HHHH @OK."[C\N:%65AAE9<[AZ'U
MKSKXB^"_"G@WP1XBU#0+BR\.R7FGR1_;)F;[/'(RY#F/.T<Y)VX)ZGDUZ802
M>M>4_M?ZCX8TSX*:U/XML3+;-;2+&JACF3RG*[M@W <'GFB+DI:?Y?F!X)^S
M/\)O&_AWX%>.-:\?>.]/\576I:1(L.M65UY$=QM$PV<$[".!]?6H/^"7[>.U
M\1^)1\6+=M)\0+&V[PZMNGEP6^(MCJZ(BL&Z_='X]NC^!FA^$_AU\ _%%G?-
MHMN1IL@GM+.^EEB63]\1EF=L!L]>./2J/_!.[0OC/%X=\2^+_B;%83>)I/-M
MK.XM;N*6W:-$B\M 4D; )W=^_M4^TE*5DW;SM^A7+.*VLCZ_MF AP2,C[VVI
M*\Z\-?'%(8EM?BGH$GAB^\S8PO)"UO(Q.!ME V\Y'!(Q7>V]]%<HDULZR1R+
ME760%2/J*HDL44BL&Z4M !1110!\2_\ !33_ )//_9)_[*5=_P#H-K7VM!]Y
MO\]A7Q3_ ,%-/^3S_P!DG_LI5W_Z#:U]K0?>;_/84 24444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !@9SBFG/./_ $&G44 <7\0/A:/$LRZUX=\0
M76BZK&JK%?V\C$!1_"4W!3D9ZY[5>\ MX\L+&33O'B0S31/\E];859@0/X<#
M!]:Z21/,7&['--: $[@Q!]: &^<JR^6R$#^%O6I0ZL<*:Y7Q[X6\7:M);ZIX
M.\8/IMS:YS#)%O@G'HP!!_(BL+PY\:M4TB=]-^+?@^7P^ZS-'%J#R&2UN<#A
MPZJ1&#C[K'\: /2**JV&KV>IVZW5C,DT<GW9(VW*>/6K"/O&<4 .HHHH ***
M* $?[A^E?)?_  5 _P"1X_9G_P"SCM!_]!GKZT?[A^E?)?\ P5 _Y'C]F?\
M[..T'_T&>@#ZSA_U8IU-A_U8IU !1110 4444 %1W$8D&T@\C' J2FLX3EJ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAOQW=72V%S9SRHCW,\*VQ8N\?S869'0[5X896O<OAU\>]3^!&JZE_P $M?\
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M!Z&BN;\&?$_P=XZ20>&]626:W?R[BUVE9(G[J0>XKHHWWC)'>@#XG_X*:?\
M)Y_[)/\ V4J[_P#0;6OM:#[S?Y["OBG_ (*:?\GG_LD_]E*N_P#T&UK[6@^\
MW^>PH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9X<?.NY6+ D$$';C@YKWD $9VU2U[0M-\0Z=)I6JV*3V\T;))&W<$8(ZC'%
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M_#G6VM+OPOXVT6\/EWD)43Q-%>A!(K2QOO"W""7"\ ;9%'UMX;\5>'OC2_\
MP[2_X*NZ0ND^)-*']G^"/C)#:AYA';$W=T[:MJA8D2"&&+>B!7$FUADBJUAX
MBU']C?5YOV&_VY]&3XC? KQ9(UY\,_'-Q;_VW-I"W)^Q:9Y=W=$6EMY5K#++
MMB3]V92R?*Y%<5'!0PU=U\)4=.+TB[_#+^6I'I&^TK:]6?1YAQ%B>(<+1R_/
M\)3QU114YTY*_MZ/3$8*NO>51Q_B4>9I2C*T8W:-;]BW_@H9IOAO0M+\+_L]
M_%43?9_+C_X0GX@3;;AHU"AGCEZ2N5R=J.<;"3C! ^[?A)_P4(^''BV_M_"/
MQ#L[KPUKTPS]CO+4F-P1P5=&=>6W=2.!7X[?MT_\$\/!/[+'CS2_%/PZ^(FH
M:Y\(=<CD>P\?:0L>M7%A-;QHKQS^08+= ]S+%&N7#8!/)78VWKUA^W3^R;X1
M\W7K72?B]\+;2\9O[<\/WRZE:6_EJDCB2YM\S6;K$RLJW V)@E5=5->Y@N*<
M=AI.CF=+X=Y05[+NXK6WGL?EO$W@7PGG-"CC^#,R2CB%)TZ.(_=MM.SIQJ-<
MKG!^ZZ<FIK?9IO\ >O2M3@U&WCO+*59(I%#+(K<$$9%7J_#_ $;_ (+0Z!^S
M?\$M6\??!_7]76\T9?,C\!:OIB7)NF+JI='7&\9;@*ZL &)4#%?7/_!+W_@O
M;^S[^W7\,8=:^(-K=>#?$27S6<]K>:>\=K.P&[,;"20'([$Y!&*^OP>88+,:
M/M<--2CW7ZKIZ,_G7B+A/B7A''/!YSA9T*BZ2BTGYQ>J:\TVC]!Z*IZ;K6F:
ME9I>V-Y'-%)RLD1W*?\ .:M+-&S; W-=A\^.HH!STILA5HSS0!0\2ZOI^@:3
M<ZYJLR1V]G;R3SRR=$15R6]>!Z5\E?LO^%;[]JO]I7QY^U!\1- LM4\%IYFC
M?#JWO;6.2-X4E$5S.R,"0Q:U7:W7:S>HQK?\%*/BAXWU"P\,_LH?"7RYM8^)
M&J'3-:8Q@_9=)9 EPY)^ZV9XL$ D9Z=:]\_9Y^$>C_ GX*>&OA)HJ?N=!TF*
MUWL^YG<#YV+=R6).?>@"C:_LN_L\V=U]IMO@[H"LO"K_ &<A4#(. #P!D#@5
MVFDZ#H^DV(T_2]-@MH%Z0V\*HOUP!BKV!Z4  =!0%QL<:0IY<:;5'84ZBB@
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M?/VC]4\>Z]<^ ?B%IITW6XU,MK#-&8VEA ')5CG=USQP,5[)&<KUH =1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%#9*X!H @U.ZBL=/FOKAU6.&)I)&;LH&3
M^E>!?LN:;J7Q#^+_ (T_:-OY6:QU:==/T%68_)#;L\3D#T8J#D=<"MS]LWXA
M:[X2^&%OX4\,2>9J'BJ]&CQ#9N8).AC9\>Q<'.#C%=S\%?AYIWPM^%^B^!=.
M.$T_3XXV8L3N?&6;/NQ/84 =:<F$A>/EX]J\I\?WIU_XQVF@7WEMHNCZ<U_J
M4;_PR+DH_P!!D?G7J5Q<06MG)/<2JL<<;,[,V  !R<]J^9%^+WA+QMH&J3Z/
MXFT^\U+7=>73/,648%CA4?H2.#GGVHUZ![NS/./^"A7QJ7X'?\$V?'WB_P 1
MQ0VFN_$"WGT&UMI&_P!;+>!K;,:E@2R6XEE 7<0(RVU@K _"G[%.M?%+]@?X
M V7Q7^-?@?\ X2;X!_''3?[&\6:/8WT<$UA<3RS1^>3$)+AE73H)90%:,,+E
M5R'3->F_\'#/Q)M_&'Q;^$_[(NC>+K?3X;.U_M#4+K4-4DAL(I+J06UO<7'R
M[0L2QS,9?F*I+)P,X>O\,='^,'_!)Z34/V/?VM-+77/@G\5K5K*]\5^';9X;
M6RU34MEHVZ]F"B,1V5M-(R*,X(< G=7YSFF*^L\23G=J%**BI=%*2^TEKR]'
MZ:G]E<#Y+3R7P9PV&DHU,1F55UYX=MQJU:%*\5[&=FHU(22K0M[S;26ETYO!
M/@G7/^"<,LW_  4/_8SUB'QI\$?&$8?7/AZH%K>6FG2GRM/1I[CS[G>MQ/NR
MJJQ$;!LY!$?AS]FK4/A)?O\ \%*_^"1'C^&3P7/"8-3\ W=N@O(-$M<-J(\[
M4I)78//9#&%#J)LH<( SO"O@?Q1_P1Z^(<G[6GP<O+7XA?L__$"1X[V3PZIN
M[BWL &6Q>2Z<)%&S7$Z#<"5;:P')Q4,_[-/C+_@GQX\_X>$?\$V-?L?'WPNU
M+R](N-/TQ7UB]M]*41S:C-))M"*BRV+IYF?D+ID_>K!4O94X*5.W(^9QB[RA
M?7VM)K_EV]W':_4]:KC)8JM5KTL;[5XJ"IPJUH)4<9&"2>"QL'I3Q=%Z0KM\
MTHJ_5,6\^%?P\_X*-^+9/VW/V#]>A^'OQE\+7 UCQ9X9U;S;Q;W5Y,?9%CFN
MV2 8%L2=L14^8I9>1E->T/X"?\%AM=C^,GP>DD^%WQYT%4U/7K;5FGO8M0A@
M ALD1I6AMD+,L9)5,]%;<,Y=\3/V?_#'[8VL6_\ P4^_X)Y>+K)O'&@LWB;Q
M=X%U"X.HZA%J"D?985MX 5!86\I\LD;\K@X%6/BG\'/A7_P5JBM_VSOV2O%]
MCH?Q9T>07WB7P7KVH"YN7@L0$MREO &VF1HT(SPX( QFKE3E43YJ49N3YG9V
MC52L^>G:W+45[M)N]S&GCJ>$J4:T<;6P\<-!T5.<>>I@9RU>#Q2?\?"U+/V5
M26D4HZ;H;XSU>Q_;ZDL_^"?/_!0*W_X17]H3PGFT\*_$2>0W-G=/)MO;W=;V
M0M[1!]DMX8U+,WSN"NUAAG:YK'A"[\/:?_P2._X*&6#3ZQH@&F_!?XFV]S)]
MFWW"BST9GMK(HK(L+H[+-*W VN23O$GB.?2O^"N/@"W_ &:OVA\_#_\ :4^'
MJ+!HL/BB;^S[74I;F9;FZ"62[I6V65DA((^4R*W(R0^S3PE^T3\,1_P25_;=
MN%\*_$/X9V\EA\+O$E]>+IVG:O/&@TW2=BG]Y=*X=)!@ R+TYXH?[Z3J1:ES
MKE4I67M+6_<U([1DOYWJS./+@\/3P]24Z/U>;J5*-*[>%E)Z8_ R6L\+.Z<Z
M$6H+F>MK-5_[5U?_ ()Y>$&_8,_X*!6X^('[//C#Y?"OB;19%M/L"6\AO;IM
MEF&N9"]Y<6\8#S#B,E3@E"GA_P $ZU_P2I\/W6E^.M;A^)O[-?QHB;2O$5KI
ML8LIM):_4[G.TRW4ACT^*8;5>,,6!R'PU3?#K5-1_99T.Z_X)(?\%'XA:_"O
MQ RQ^#_B#8_\2_3QY;-JMT_VN;!D N9K>(87Y7.W@$55^'/@OQ'_ ,$LM4U+
M]FS]HFZM?$/P&^/%JVFR^+/#RF*WTU]0(MEDEO)@JKY=FD\C!<G'SC@4>[&<
M9I<JBN5-N\J;ZTY)ZSI/H[V2U151RK4ZV'E4]M+$3]LZ=/2CF%---8J@_P#F
M'QT$FZE.*O*<4GNTY_!7PL^+O_!..1OV[OV(?&-OXW^"7BMAK/BCP2L,5I=V
M>DL2--MFEN?M$[,/M;9= CDQ?.&S\L&A_"KX>7WB/_A[-_P3:US[!%X-9[GQ
MO\,[J.22^O)$!N-96*XOG? -M.R+LAX*YC )P(?#7@?XT?\ !&_QU-^T=\$O
ML_Q ^ _Q"N)+W5+CPY9O?26NCPEOL'F73A8XW?[: ),D2>6?2K6L_L_>&O@;
M\0K/_@K1^P-XNL_$O@G0Y(;OQSX8M[IM2U.![AF;5H]R 1Q>7:7.>6 C(\PY
M !K.,(TZ*@Z7+R-R<+M\G:I2>[CU<5H:5,9*OB*F,6-]K]9A[&GB'!*&+5N5
MX''PVA73?)"NWS<MI7M9J.V^#7@W]OSQ8W[>?_!.7Q1'\/\ XN>';C^T/$?A
M/4T:\DO]?G/F@12WSB#"IYGW83&2.5!IOB[PO\)O^"QNHV_PU^)5Q_PKC]H;
MP';C3_$&N:@LE[9ZQI%@6AF*(K06J-)?7CL H+*L6 2A(#_'O[.-E^T!X@M/
M^"I__!,[Q-97WBS2\^(?%'@:\G.I:E!JTS;TME@A4JAVEB5)]0..C_B7\*O!
M'_!;K0;#Q-X8\2V7@OX_>#(X]!\5>'O$UX(6N["S1FN;F*TB#M&#?7NP,WW3
M&R'D"G*,JD9QG",G4:E:_N54MIQ?V*BMJM=5\RJ>,IX>>'Q4,95HT\+'V:JR
MCS8G+IW_ -WQ$='B,)*[Y)2LDI))?9;/%.L^"O\ @HH]G^PK^VG;_P#"'?M#
M>$XVTKPSX[EFDN;2X=#]LOF:"U\BU4&"V6-=[,-TBD'=@-+K'BU/ 7AFR_X)
M;?\ !5#0GU;2XXTN/@[X_P!/G\N&WMPATS2D:#3@A8#9<2GSIF(5E63/#5-X
MEC\)_P#!8#X>6_P!^->H)\/OVD? 4::;I=CXFN5M(=1DD<7%Z$LT!E)2VM6Z
MCY2RL011X<\4Z3\4O ,G_!)[_@I7:S>%]:\)%F^%OBNZ*Z387T%G$-,TXC>
M\ZRR?:'5@O[Q5P#\E:RES3E.R]]<JF_@GT=.JK^[-;*5]7]QRTHJEA:6%GSQ
M6'E[6IAZ>M;#-ZK&9?4WG0G=5)48VBO>6WO*$6VG?\$X_"4W["/[?I7X@_ #
MQ\1=Z)XDT)FM!ILMK+]KGS':;KJ1FO)+-<-,H7;E<@LA=X:\'_M!_P#!'#3)
M;RZU^S^*7[/OC!FBURSTF*WL6@U*]01,<XGNALM8(B KA6+]%90Q/ASX>L/V
M1?#UU_P2;_X*/W 7X:^+Y(+[PK\0M+G_ +.TV%H"=1N=UU, 9/WXM(\*ORLV
MT\-FJ_PU;]H/_@B_JLGP7^-^AQ^*O@GXZB:XU#Q%X9L76VMK^\"VB(UY,$"N
ML%J)&3GY75N?F-9QC[/V<VG34$XWW=)_R5$_CAV;^R_F:8BI+'K$T/:0Q-3%
MR55T^54Z&916JQ.'DO\ =L9#55(1U=1*]WH>,_M>?\$\_@[_ ,*GF_;J_8^\
M5G5/A3J%U&8_"=K'+#J.E6P;[&93)=RR239NQT* [921P U<3\%M _:A^!_P
MINOB)\&?#&E_$[X20ZC=OJEC#I+R0Q,N'N)YK?"W-LZJ2[RKNA# LS2*M?3V
MB?"V'_@E!\3I/V__ -FS7;7XA? 7Q!G2+R'P[,;^[M[1TV;Y+AE6)?\ B80Q
MJ'W?Q;,9.#7\1?LJ^+?V<_',?_!1W_@ECXITWQMX>9!;W6AV:OK5[!-< M>;
MA&H3:@.,9RON<5PO+_8XCV])>SGO-4Y:*^U2"VG%_P O2UCZG_6^EFF4K+,S
MK0QV'E:.'J8NFE&<TES87$S5IT,33T4:_,^=-RE%V37/_L:?\%%/#OA/5K.R
M^%_Q6E\$7TDS&\\)>/M1\[2)V7@".\8*( 4. K!,-\J@X4M^@_PG_P""F?P_
MU+78O!/QX\.7/@O5;B3;:WUYC^S[Q0#NECG+ ;,C@GJ'4YYK\_\ ]H']DGX/
M_P#!4GP)J7[;G[$.H6>C^*K/2K^_^(WP\O+KS[_S84\FQBM[:V4K$\ZV4Y4$
M_.9%/7<*^<?V=]5_;%\+^$]:L_@9<'QAH]@UP?$WPWNIA=7]I:VABC>=K ,)
MX8BTZH9+8G:4 =OE4GW*/$V8Y?55+&4_:0EK&I!7<EWMMIU2U3T/S+./!+@W
MBS 5,?P[B_J&*I-1K83%.RIU'M'VO\LO^7<I)J4;.ZO8_HE\.^*=#\2V*:AX
M?U>UOK>2,/#/9W D5E/3YAQ^M>'?'W_@IM^QQ^S1\6;;X*_&7XQ:;HGB"ZC:
M2WL[Z[BC,@$8DVC>X^8JRX'&2:_'K]BS]N23]F^;Q]XFL_B!JWAOQ=>7TE_I
M?AZ^LTFTJ9HBV+%V:/S(3N9U!)3A1ELKD_"G@W6O'?\ P56_X+$Z?XO_ &GK
MM4T.X\>1/XBNK2%[:WM+./C[Z@F-2MN,%FZ'J*^PP&98',Z;EAIJ72W6_FGL
M?SOQ5P/Q5P7C/J^<865)O52M>$EWC-7C)>C/Z,_V"/#/B7XV_'3QY^W'XCNH
M[K0_%<@M/AVJY(CTV&4PF0]1EVM8V&"1C!SS7V!$H1-JFN$_9OTSX3^$_@[X
M<\"?!K6;6Z\.Z+HL%GI'V>\$W^CQKL4[LG.<=:[OS8@N[>N*[CY,=10"#THH
M **** "BBB@ HHHH \-_:8_:[B_9Y^-?PF^$S^$I-0/Q.\23:6ETLP7['Y8C
MRY!//,@Z5[=;[L89<5\F?M__  D^(/C_ /:K_9K\7^#?"M[J%CX8\>7-UK=W
M;PL\=G"RP -)A2%!VGJ1]WVKZRM6=E(=>A_.@"6D (/+4M% ",H;K6%XT\">
M'?'5BVE>)=/ANHCRGF+EHFP?G0]F'!![8K>HP.N* /+;71_BM\)G9-(U"7Q'
MH$2EUM;IMU[$!RP!QF3CITKI_ WQ0\,^/K59],N6MINDFGW8V31D=F4\BNIE
M7Y=P7ISTKC_&OP;\&>.Y%OM3L[BWNH>8;JSF:.1,'/T_2@#KH9%=1Y;#%25Y
M3?\ B/XK_">^:7Q);-KF@*%2*;3;'=>1L1_$%"J4&#GC/(YKO/"/CGPSXNM5
MFT77+>X8 [HUF!=<8SD9)!&: -JBD#H>C4H8'H: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ****  G SBO(?VH?VF8_V=M7^'.F2>&FU!O'W
MQ#L?#$;K.J?9VN5D82G)Y"[.@KUYL[3BOF7_ (*(?#KQQX\\3_ 6\\%^&+K4
M$T'XY:/J>K/;PLRVEK&LV^9R%.U5!ZG 'K0!]+6S;X]^?P]*>5W+M)J.T9C&
M0PY5B..GM^F*EH Q_%?@_P /^,M+ET'Q)IR75O.@#JR],&N!A\#_ !)^$LYD
M\":M'J^BK&6FT?4)"LR'H/*E & !_#WKU8@'J*3:O3:/RH YOP)X^L/'.C+J
MEOIU]8L#MDM]0A\N13@=B>G-%=$((U.5'6B@!]-D1FZ''O3J0\'<6H XKX;?
M +X??"76M6U_P593V\^M7C76J&2Y:03R'/)!Z8!.,5U5OJVG:E-+9V&I0220
M\3+#,&:(]@0.AX/7TIEAK^C:RUQ;Z3K%K<O;R;)EM[A6,3>C8Z'VKGO OP9\
M#_#OQ)JOBOPO83P7FLRB347>Z=UE8%CG#,0/O'H!UH C\$_ 3X<_#SQGK/C[
MPII#6^IZ_<>?JEPTS-YTG/."<#KV%=3#J^F7-S)IEOJ$,EQ"=LT*S LGU Y'
MXU!IWBOPYJVH76E:7X@L[BZM6VW5M;W2N\+<\, <J>#U]*P?#OP>\#^%_'FI
M_$;1=.FCU;69 ^H7#3EED(R!\I.!@,>@H \%_: _9_\ AAH_[2?@WQ'H6ES)
MKGBSQ8L^LW4EPS++'%'P-IX SMZ5]26,2V]I';)]V-0@_ 8KP?XBR6GB_P#;
M4\'Z-INJQS2>'])N+V]MXI0QBS)$!N /RDYXS7OD7W>O\1_G0 ZBBB@ HHHH
M **** !@2,51UWPYI7B;3I-(URT6XM9@!+ ^=KX.1^N/RJ]10!Y3XG^#_P 0
M?".F.?@3XNCL8XXF_P")/JJ^9;L>B[7*EHP!]35/X/>.-%^&C_\ " ^/=*N-
M)UJ^N&GNKRX7%O?3,,O*KG'&1U.!7L!1"""@^;KQUK/\2>%O#_BG39-(U_1X
M;RWF4K)%,F<C^8_"@#A_B;J>H>)/B+X6\(:=/')I<LS7>JQ?*=RQD/$X(.<;
MAU'I7HQ18;98P JHH ]L5Y->? +Q%X,\61^,_A)XA:,1VWE3:+JUP\L$BC.%
M1CGR0 S= <UG>/OV@K^6*/X8:IX<U30=6UB7[$NI7,86U1<J))EE.,+M)PV
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M;R22_P!I>+-:EU"\<N22IEF)8@=AF@#N?M< X+T?:;?_ )ZK7A_QR_8B\/\
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M<Z.)GBJ<7%)<M''PBN5RI.Z]CF%)^Y4BFN9N3]G?=/$OPC\367Q<_P"&Y_\
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M ^/OB>W\2:M\9?B9X?>&-E^Q^#_&UWIL#Y5%RR1,%/\ JP>?7UH ]C&H0/\
MZIU;_=85()U,8D8%<_PFOG[X6_L#^&/A+XPM?&>F_'[XM:K+9ME;/Q#\0KR^
MM9.0<-$[$'I7NE]I[:EI,FGM+)#YT4B^9 Q1EW#J,<@\]>N: +:W<);[ZX]=
MU+]IM_\ GJM?+=O_ ,$M_!L:DR?M5_'9MSLP6/XKZDJKDDX ,IP!DBI/^'7O
M@K_HZ7X\_P#AV]0_^+H ^G'DB;[LH[]^OZUAV/@/P9IOB5O%]CI4<6H21^7)
M<1LPWKZ$$XKY]/\ P2Y\$'G_ (:D^/7_ (=S4/\ XNE'_!+KP0.G[4GQZ_\
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M;4-'NVM[F -_%'(A#(WN#7SZ/^"7_@MD4/\ M3?'IF50&;_A;FH<X ']X>E
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M_P">JT?:;?\ YZK7R_\ \.O?!7_1TOQY_P##MZA_\71_PZ]\%?\ 1TOQY_\
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M/B3XM_%7Q>PW/+XCBMXV]$B61,8^JU[G0 4444 %%%% !1110 4444 %%%%
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MJNN?L_ZA#-<?:O!N@K=Z:TU\-L.-2NXH,, N743 #.0,5:^!>K^.K+Q'<_\
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M4)Q_$S'@#/0!0HP !6'X],/Q2^)UC\-8YF%GH<L>I:M)&>"XQY<+CNK9;/\
MNUZ9;(L<6Q% 7^%0!Q[<4 24444 %%%1M<!1N88'J: )**ACO8ILB"1'Q_=8
M&IE)(R: "BBB@ HHHH ***&8*,F@!&=4&6-()HS_ !5SOQ1^(^C_  O\$7WC
M/6@TD=G"S);QG#SR!25C7@\MC ]ZX'X"_MA?#?XX%M)F\S0=>MT5[CP[K3&*
MZC5C\C ,!N!&&&,\.OK0![%131(3CCK[T[/.* "BBB@ HHHH **** "BBB@
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MVTSX@%C;ZMJFH%RU^&T^W6SW2&VA*LI9S&LA8 $','P4_:)\,?MGW\G[#O\
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M3-'_ ."EGP+U;]M']E;P+IW@GXC> -UAX@^%NAZ?%X@'B6T?RTM)9;5T2!%
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M]S7YW?\ !0']IOXD_LI_\%"K[Q/\&?&OAV35=>^'>DQZEH6J^%=2OY($AFU
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MWA+P>-#UG4A9Z?<0M/K-UO*^1:H1\V1ZLNW_ (%CO0!X-XOT35_VG_VE-/\
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M[YJG\&)_V9?^"O>N3>+9/#>I>#OVH-/TU_$<WB'09I1I-PVGLMO91;+F6>(
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M6J_#W]I#PFL.M^(9FFSH]YK.I;C,ZK>O= 1+LNR@1(Q\XX/!7,^'OQ0^'?\
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MD:Q>T5E6WCO6<%6;?(N21M 4JT^1UG5LXOE4VM5_T[K+I;[,M7JC3ZC[3'+
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M#\,;'P1^TI8:/<>(;CQ]I.BV^FV.J>1)]@AM)KP-<7LL1M;FW#QE1EH?E(5
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M.E[18C"*+AB8)+]_1I\J531\TX)1J15TN:SM^H'PC_X*V_!>_P!3T_P+^TG
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M_AG_ ..WAT+=P:Y-:P:-_:TA41V%LSW1>Z<A3$V/;*<;10I5)I--2<GRJ_\
MR]27PU.U6.C5];I]R?JN"HR]C.G6P\**]JU3;E4P%63_ (V$:;=3!UKWE&'/
M&-X7U2;M>&=0NOV+GN/^"8W_  4NT^36?@EKTB6_@KQE"HTRWM([/.H3./LP
M-Q*'N7MHL%\@@C[A.9-%^(%U_P $\-:N?@?X[T]O%G[(_P 9E\KPMJUFWV.W
MTVRUEA*\GGD/=RF*S=R?G5F*[AM;%1^-=:_M::R_X)O?\%:]+6S6TW6_@/\
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M3=_X*>V>_25W)\,?VB)E#NEK(%O[DKJ&HD@J%>SLOW"XP A& N)-<\3>/?\
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M?>'?[6^!=SKWA7Q*LBP+X=_M@MH,D9;#3G#HZ/G&5/&"?F.#7TCIWP^\8_\
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MPW\/E,NQAR1DCGI7F?[&R6.L>(_B-XTA@C5]1\8R'*J <)E!GCZT >\4444
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M8SOG(\Q(TR1U[U17X]_'7X%6RP_M*^!8;W3<E4USPO'YZ[%'S/(CR"3T_AH
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MR/GD0R\9Q^Z%>>_#K4=*^%/CO7_B?^QU?0ZTC7"WGCSX?:Y*WVC1QM;>EO\
M=12/W[XWL#M^@KU3]D?2_$-[IGBCX@Z+=V-QK5]-;QZ-#< XATY2Q3(P,,?,
MEZ'G:,UG_M>?!;X<Z7I6M_M"?#G3M+TGXM6,-LL=_I<:6\EU=EHT6.>2,!Y$
M.XI\S=&(H I_"IOAO^VE^T9#\2-*L+BUC\%P1W&I*1LWZH3&/)=6!RJ%)ER/
M^>?4YK[ AB54"\_+POM7$_L\:7J=K\+-$U;Q1X?T^QU_4-)MYM>^PVZH)+HK
MER2.3\V3SZUW5 !1110 4444 %%%% ",H<;6%97B3P=X:\4:<VDZ[I5O/ P^
M[+&IQ]/2M:B@#S*/X>^/?AS"!\)-<^U6N\L=)UA]T:^R,,,/;)(J[:?';1M.
MN8]&^(EM+H>H./\ 57"YC. 22'&>/E/6N_9@JECV&:\H_:]UFTL_@IK.DK80
MW-]JEJ;'3894!S+*\<0(STP9 <]>* .1^#EZGQ]_:(UWXL7T,<VF^$6&EZ#-
MY>TM)NE9Y1GU5U''85]"!0IZU\\_ 7]F[Q5\&OA=I-Y\/-::'4KBWCN]4T^]
MN'^SRSLJ[S@ <]1T_.O1H_C,OAK4K70?B5HT^F7D\>8KD!9+:3U;>C-MYZ!N
M: /0)&PK8/\ #7EWQRTG3/&^LZ'X*U1VDMUN)-0NECZ@0^7@?CYOUKT6#4+6
M\B2[M9TDADCW(Z,""#WS7A_BW56@\2^+O$)DN(Y-7FBT+2V7)59=KIN!'0;@
M,L.<&@-.IY/\>_#WPF^#O[-?Q0_:P;7;W2X8;.\ETU5N-DAN!N@@MXV9&*&2
MX:)5[ D$\5^:7_!-K]BOX,_MU>#?%7@JY^+>H:#\5-+U9-<T]ETWSHY-.BB"
M?(YV)$\ES<+O)9F(@3"8#$_6O_!?WXFW?@']F?X<_LKZ;>+)JOB34$NK^QMA
MYK21VJ $G^(;IYH]I*G=L8C!2OG/X._LE?L^?M]_"GP=X0_9+U^3PW\:_ 6B
MP#Q?H'B^2Y^QW-O;9\^XA94D3=+>W&X RC:'(VH, ?G/$&(CF&>*ARJ:I1^!
MNSDY-:1?225GIKTZG]E>$.!K<*^$=3-GB:F$GCJZMB(052%"G1NHRK0?Q4IU
M.>G+I?K=6?KGA:?X2_\ !5"U;]C3]K?R_!7[0'@60:''XLMXY-1FOX],!%[(
M[+Y=NK/,9L@,3DDC@BJ?ASQUJUUJ%Q_P29_X*E:;(S:L=WPO\<7$PO;FSOKC
M;IVE^7#:YB0*DD\H,CX4XWA=PJ'XT:/\,?\ @KUK5A\&=:U2;P/^T[X+LAX?
MUK2=>W_V3<M9LQU&2.2T2>/ F\T)F0,0HX(()U/B?\1C\=OA_9_\$M?^"DNE
MR>"_BA9W"3?"K6]'C!TN]NVB;3M*BN#:_:) LC32.[.B*%7+%#M!SES-RDFF
M]E-Z1J+9TJB^S.^BD]?+H=D8T8TZ>%<9TX1O5GAXINM@I/7ZY@IZ2K8:=N:5
M--QC%/7:15_MSPE_P3>\277_  3H_;M@7Q=\"?$+KJWAWQ5>;]]JJ)]H?9:6
MIDD4&^:7)9@?E+=":-9^&_Q+_P""+VMKHWB;43\2OV=?B)&FA>)AJ$L-K##J
M%^3]ID^S0M)/(R6%FX'(5O,91R!B.WO_  7^R!\&)/\ @E7_ ,%1KVXM?!-U
M-_:7@_QMX*8RVTD0F-XPDV*]PO\ I<C0_-"O SROST_X;^%OC/\ \$C/AUJW
MP _;1T:UUKX#_$_S].OO%'@N827-IJNH1+ ^[S&6=4CLK65SL@899=I9\J7R
M>R2;O!05E+>5%NWN3CO*#Z2VM]X5*TL13G&4E7EB9MSI)<M+,HIV6+PLMZ.+
MCK[2G#>2C?5M$OBOX=WG_!.BWM_^"G?[#.JR^*OA/XN#7'B+P9.HTV&VL;@^
M18QLTC//(!/<[EQ&I4QC=[R>)_V6E\#Z5#_P5!_X))>-)I-#EGQJ_@FUM1I\
M=OHEFK?;_P!Y=MYC*\]FH,80-B1BH8**H_!3P5XG_P""5UYJ7[<7P8DL_'?[
M-WC95%XUBP_MJSTX@II[.MZ(")&N9U#!0WR[LA21FI\(/V;?'W[)'BF3_@HQ
M_P $OM;TWQQ\)[RQ:POM-U=I$U:#2861]3E9+U;5<K/8R*F"SX=<*REF$*G'
MEC"=*UGS.,7K!_\ /ZFUJX/5N*T3T-*V.J>TJ8BGCE4E)*C&M6ARTL7%)?[!
MCHNRHXFE;EA6;YI07HS7'PI^%?\ P5.\.S?MG?LA:LW@7XZ>#8VU7Q#X?TFS
M8K?:TXW6O^EW9CCW*(#\ZJRKYGS#L32]&^ __!:S15^)7A">/X??'WPPIU/5
MK6SLY;C[?%;GR[%6GF,<2Y=4;*Y*G.1U-8NN?!OPK^WI\66_X*'?\$TO$T+>
M/_#-\GB+QMX)\9>;'+'J9(-I! 2BV[;A;R%AYQ7)7+"G_$CP!\'/^"OGQ,C_
M &C/V+?%,FB_&+1VAU#Q1X5\:-(D'D6BK';^2T<3VY:1XTX\[ #9.WFCEE6C
M=TXS<NB:2K);3A_+-/626NK[$^VI8.M!PQ57#+#QM&<X.=3+I2^+"8A/^-A*
MM[TZLOA48V6K1I^%]6L/V]G/_!,3_@H=9_\ ",_&SPHRVOA#QU)(=2O)9&+:
MC>[Q!BV3_1;:&/F0[@6 P5I^FZUX-L=:G_X(Z_\ !032S-'IURVF?!GXB7!:
MZN(WNI!8Z1(D%OF.(+"ZNOF2?*0%?!YIGQOU/3O^"G<.E?L8_M+";P'^U1X)
M$MOHMO?*IT._DG*75XI>R^TJI2QM4PSNF7==N\[E$?CZ]\%?$?X::)_P27_;
MVN[CPQ\3O!,4>F_"?Q%I:YT?5;AH1I^C^:;99I DJNCMYBQ\<$(QVER^)RBT
M[KE4I?;CUH55TFNDWKL%%4XTZ=":G2BFZTZ%%.3PTW:V98&6]3"U-'.BO<7-
M+WM$TZ>XU7_@E]XI_P"&&_VW83XV_9Q\=\>&]6OL#[)':*+RYDBL[0R2@M?W
M4"G)!^3>#TI=8\"7?_!([7+/5I==?X@?LY_&:%=+\46UXHM8]/\ M[9D801-
M)<2O'I\,H7&T$,5R&I;?5KO]A_X,O_P3-_X*C0"U^$OB10/!OCSP/^\!\FX_
MM&\:79ON0/M,]O$/W S\_P#!R*_PY\%>)?\ @E7X'USX8_M1M;:U^SS\<K6;
M3V\5>$9#)>:=+?1^4KR+($G&RQ2:1A%#(=V NXC;34>5I6Y5!?$]94;_ &)+
M[5-])/2S(E4CBH352:KRQ$KRA37+1S*$6K8FBT_W..AK*I3BFY3@DU=M.3Q/
M\%?B/_P3H%K_ ,%%/V _%<WBKX0>)5?Q!XJ\+2-%IL%GI\A!TZW82LTTB@WD
MNW$89-@WC))JYJ7PD^&'B_0/^'OW_!/#66T_5/ 8CO/&GP_AM6MXKJ6W'VK5
M@UQ=$,4-O,R-LC.Y4PA#$XH_!#X:?'+_ ()837_[8/P/BTWQU^SKXZ:/4=8N
M+&1!JMGHJ-)_9Y=+W[.1+)]K&=JMC8V0O&[/\$?!CPWX&^(W_#VS_@G3X@C\
M1> ?"L\UUX^\.:_YL>KQLP>;65A^T1PQGR[2X!3:[#<#M+D %1C[JA[*RO=P
MYM8/_G[2?VH]7%:&OUKFJ5,3'&^U;C[*&)<.6.*BU9Y?CX?\NZV\(56^;E:E
MLDUO#X,^ _\ @I3H'_#=?[">L'P1\:O"N+S7O"]C:L%N]<G+2#;=73QID+YA
MWJI4\]":@\+^%_A+_P %D[5O@1\=M17P+^T!\."=/U+6H;5]1FU72;!5AD,L
MO[NW0R7UX[%4+'*94%6R,N/X :9^UY\7&_X*._\ !*[Q'#<>+M#U)M9\6>"O
M&S21W,>LSX=(8/,1+<IY>_)68J#P&/2G_&?P-\._^"T6O:?I'A#7O^$._:,\
M$Z>FD^--$\3++'ITVFV+.+FYMVMDFCR;^\\M%\TL55_EPH>CD;A+F@JCJ;J]
MH5DMI0>T:D5NKMNP>VI86I24<74P\,*O=J2@WB<LFW?V%>+]ZOA)-^Y)Z)27
MH[_A/6_ G_!0N%_^"=7[>EHOACXZ>$?^)5X5\;1QOJ5Q,8S]KOBS1[;>,-%;
MK'S(=PDPI+<4FD>,[?X)ZU/_ ,$J?^"G.EKJWA>Z9[OX3>-+N8W-S;0LQTO2
MMD%KN6,;8[B4"1_E)(;&>(_C+J/@G_@J9!H_[)7QSN)O O[4?@N-]*TNUU M
M_8M_-D75\0]F)U 2VMFVEG7YV&-W(J?QCXFT%_A;IO\ P2J_X*DVTWAGQ%HJ
MPS?"7Q3X>VO87]M#"=,TLS&V\^7][*L[MOCC^4#<$88+O*\IQL[:*;^&=_\
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MF#C@4_PSHWP&_P""T=D?AA\49O\ A7WQZ\%,RZIJEG:2Z@VHZ388MF5I&\N
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MOAW#)IWA(R2-_8>I?: ETQ+V@G "Z=:P',A3YW^7)+*-+Q'\4-/^&7PIM_\
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MZ]XP\%>-_,3,]F(HM+CMRL?V;,OV$D_OMOSKN*'<!:^,L_@#_@JW<Z?^S?\
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MBWB[3([FZM54M*K;<OMYZ'D9YP:Y>6^ET;]HVU\.6-MMM;OPZ9I %^4,C.%
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M\YB3\FQ6#;F)D"C&235S]C3X=W'A;X3:?XX\2VRIXE\81KJOB62/(62XD+N
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MX*6>.].T&'3M)\=:7\5-#L809+:R9X=>LX%9=SRP3!'EP/E#A=K/P#SQ]K?
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M0R^5*C?*V?G_  KZ6L($MK&&VB&%CA55'H ,4 34444 >;_M F()X2\U6/\
MQ6MEMQVZUZ#(76$M@' R%]>*YSXH?#6/XD:7:Z>^LW5C)8ZE'?6MS:N0RRH&
MV_498?E6;>>$/C (O^)7\1;<MDAOM>G9&,>U $?[/LYU7P./$3NNZ^O)F"KV
MVN4_]D_6N^" '/I7,_"3P!+\-_ =GX0EO%FDMWD=Y8U*JS/(SG /(^]744 %
M-,:GK]<8%.HH 1U++M!Q7G7QEAN-"\5>'?&ED5C\F6:"^N&7I$RX _[Z->C5
MS/Q=\(+XX\"7OA\S-&9/+=77KE'#8_2@#HBX:VWQ\@QY7WXKY+@\/>!?$7_!
M4GQR/&.GZ?-Y?PQ\-&'[7(-V/-UC=CD<9V9Z\D5]*?#+Q='XO\#V&KDJL[V<
M?VB!6!,4FP$H?0@GH:_.W_@H5^Q'XC_;J_X*&:AX5\'Z#X"MKKPQ\.])DNM8
M\41WYN+@3S:@4B7[+*F43R&^]GF0XZT >A?MB>&? 7A__@IG^R7)X)TRS3_B
M9>)#.MG(#G%I !D;CV+_ *U],?M\ML_88^,#,OW?ACKA*G_KPFXK\O? 7_!-
M/QY^Q#_P5>_9CU_Q?J/@FX75M0\0)"OA>'45D41V:J2WVJ5P1F5>@!K]0OV]
MG5/V'?B^SGA?AGKA;:<<?89LX]Z /GW]E7P-\*9?^"1GA^YNM,TL7I^$%T7D
M:8#]Z;69CQN^\&QU%>J_\$M]'TZ']@SP$--A2W62PO%5X5P0OVVXVX/< =,U
M^77P7_X(P?$WQO\ L36'[0MMJOPMN-/OO!=SK2V6I6>LM<20^4TOE2&.Y5-Q
M"[2551\QXZU^IW_!+)+:#_@G_P##*RM/#>FZ1':Z&]M_9^C[OLL1BN)8SY>\
MEMI*EN23S0!WNHZ'\9/"FH-?^%_$4.M:>7+M8ZIM68<YVHX"J%QP,YKJ-(\6
MJ_AJ/Q!XDM?[-9A^^AFD!\L@D8R./QZ5M;$Z;:K:MI.GZS92:9J-FLT,\926
M-UR&6@ L]4L]1@%S97$<T;#*R1N&4_B,UP?C+8?CCH+#K]A'_HZB'X'S>$$;
M_A5/BFXT.,S>8UB2TT#,3R2'8GGT! KF_C'XX;P-\8/#NJZEH5]J"C3]L[:7
M;F1D/F/\Q7J!T_2@#V>W_P!4OTI]<CX"^-OPN^(NH3:-X-\;Z7?WEN@>YLK7
M4(I)H%POWT5R5^\O7'4>HKKE.5!% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %-*9;.?TIU% '.^._A?X)^(FB2:%XOT&
M&]M9 P:)V9.O7E2#7C<_[)?BWX17<FM?LQ?$:71-S>9<:/JV+BVN-HX3)3>/
MP:OH8C/!IIC0]5Z<B@#YY7]LGQ-\(;I?#_[3_P .+_29MP0:YI%J9K"0D\$-
MG*@#&<]#FO:?!'Q#\*_$*Q35O!_B"UU*U8G]]:R!E'U[C\JT]4T;2M6LY+'4
M]-AN(9/]9%)&&#<8Y!ZUXOKO[%WA_1M0?Q?\"=?G\#ZVW+-IS/);/D8(,9(4
M$@G) H ]TH8X4FOG1OC3^TW\ YEM?C;X%D\5Z;P%USPQ [2#/=XA'M &#_%W
M%>D_"S]HSX8?%VU+>'?$D<-QEM^FW\T<5S'C^]&6)Q^% '2>/O%]EX-\,7&O
MWS?+#M558_><D  >O7]*Q/@YX,O/"WAE[S59%FO]8F^V:A(W5I'4''MCI6;\
M=/#/B#Q(NG-!H,>L:5:W22WVC^8T;S$*^UUD4'D$J<'@X'M61XN_:6\+V?A&
MX.F1WEKK$FU;72;F,1W3#C=(L9.YE SR!@X/I0!X[^T_XXUWXJ^-X_ 'PYU@
M6^J:A,UEIMP!F.&.)]\LK=<9&Y<^XXXKW#PMX;M/#/A/_A"/@'J>DVMUI@@M
MM0,^^159<#)'7.-W3UKPK]DG3+;XR:_XD^+GPXU#3[;5M"U0Z18F\43"(J7^
MTRE5P )<Y!]N^*]G^.GQ1B\ _"+Q5XV^%OB/0K74M#C,FIS21HX:8<!2 3\S
M-E0#SD^M '$^.]2T_P",/[4.@_"+P[JNFR+X;\C5_'4,>?,>5)7-H%X(XEMI
M21D'!%?1UE;I;K';H2 J85?0#H/RKQ']B;X<:IHG@S4/BIXQBAD\0^-+I-2O
M9EA(^5DWK&,@80%W('0;N.M>[JBJ %7ITH 6BBB@ HHHH **** &R2",%B>%
M&6]A6?I'BG1M>++I.H0S,C[756^8?A]"*O3PK*N"*\[\4_L]^&]3\1OXY\%W
M=UH&ONOER:E8S.H=1@8,9)0\ <A0>.M 'I%!&1BO'[_XH?&+X1:<7^*7A>X\
M06:R;3JWANS<R+GIF#;R,#E@X^AKN_"7Q-\&>,;#^T/#GB:WNE_Y:*EPC/&P
M4$J5!.",\CJ* /'/VQ]>NO%^O^'?V:M(GDBF\6^:]U-"<>7!&RN<GDY.Q\<=
MJ]V\,Z3:Z!H]KHMG'MCM+>.!!_LJ,#]*\+_9P-A\;?C-XH^.FJV*R?V/JC:1
MX?N"WW(5$I9EQ\I#"8<CJ*^A L8/ 'K0 ZFS?ZIJ=D8SFN?^(FNRZ%X,U35+
M2Y"31V3?9V+=)#\J?^/$4 >7^(KRZU+6O%WB6ZN5D2.3^RO#JR'E9BWDS!?K
MT-?%O_!?#XJ6WP;_ &,O!/[,NA;K:3Q=J"27<.YF#6UEY<[HQVXXN9+=@,@Y
M7." PK[,T72'\0:IX2\(ZI8K+);S/JNN31G/E7.X3(Y]-[>O6ORM_P""CGQ)
M^''[8O\ P6%TGX.?%'X@S:;X'T+5[/PE=:CI;+*L+%RTZCY_+1GN93 \IYB
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MGQ=H/@]0+>WTS1=BW45Q-<%F(E;^T/F &WYLG@4_XR? 'XA:EJMO_P %!/\
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MSO@YI'_!0/\ 9ANCHGQ[^'L\2_%+PY&QTV&ZM[&)M0N9$LD_?7.Z>6U4Y.)
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M7/$/[<7A7Q!^P7^W7(NB^._AG;;_ (4>(+?.FFZN[!7L6CDOY\M<!YI+5OD
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M$-,TKQY\9/\ @E;\:9/@Y\2K.+Q=^SGXNU22]\Z2!M>=-"&Z*V ?B&,X$1V
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M^('@FUO+?S]6:9G;3+C8NP-=0L5CG97&$N Q;)^[EB?K#XO>%OC=_P $S_B
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M?OG&/2K4'Q"^*%H/+\1_">:%F^[]EOXYLCZJ!B@#XN^#O[#/_!7K0OV4M)^
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M?VD;?]GOQ7>_\$_O^"M?A.U\;:3:0C4?"NNWD3:U?6]Q.1#:C]Z=D:+"9<$
M%3@8^:NSFBH*<:BY;VC4?3;]U576W3FU^>_@K#SCC)X6>"DW&"J5<)!V<TV[
M8[+9+X$_MQI\JMNFMH_B]XN^(?\ P3=\4P^'/'^C2?'K]F/Q+:-JWA?1M4T_
M^U-)TNU=BFEVL=]>)/&HCB$914958#(&&!K2^+GA6X_9'\(:;^UY^P?XK7Q;
M\#?$TT%A\2_@]ILQU[3(;>6$W6J&X5O-MK5?(A6V=RB&-9,$A6(-2+XOZA_P
M3I^)+?L1_P#!1K2(?B+\&[XR:EX,FUI6U>ZM=-@9K?3XTB)$40Q"I,8 "$DC
MM4_COP=XQ_X)1^+--^*FA:M_PF7[,OQ2FATS6/"_B.Y\R.$:GFYNG33X]L>]
M;*V:-2V00Q0\-5<[49MMI0LG_P _*$GT[RI/S;270RIX>M4^K15.-:K7BW&W
M^[9G32^%)>[3QM/JU%3YK>]>S<&LW'CG6?@K%_P47_X)6/=>")+BX-KXT^"?
MA6$ZDINS.UFDSZ="IMT_<*)P# #\P?KDFWX-?X,_MC?"K5/VI_\ @G+I>F_
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M_:,\-R+:PZQH.IKI=_J\N-^HW M+/R)'9@)E8E24W'. .8?'OBK3?!FD6_\
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M'[.'CZ:+2+C1?$ET;EHH)E$M^Z6416,2[/,49!# @'@\-^(GQ$UK]C2]T_\
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M8>(]%D\N&#QMX5O$N+6:0DD1D%$"NJ%68'!&<XQ7PI^UA^S!\(_V?_&/A_\
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M /@?2_"UC\5?"D:V-A%#*(]=ML&1452?O]3CUKH1\=?@L?\ FKOA?_P?V_\
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MQL^T?MV_\$EKVYL/C!I*C5OBUX*N%9K59M6+3W")-J'EP%86BO$'DJVX/QM
M7*WWPU\1_P#!.;Q!;?M&?L6>+F^+W[.NL2+IGC31K"ZD\1/:6:D7&JS/' J6
M< \J)D$LCX4OM;KRNO>&]!^%5W:_\%!_^"2VM3>*)=:\S4?BA\,!/_:USI:Z
MCB6WA;3M/!6%8 UXI61\1[ J[@K%:E&5/W)14>764$MGTJ4>RZM?@14K4\1&
M6(IUI575?)2KU;)5%I?!YI%VO-)<L*CY+2L[M6:9X+TW]G3_ (*>W\G[2?[+
M^HWG@?\ :GT6-O%\WABS2>[L[@Z81!9VRRSK#9KYS)I[%LG:6(96 <B.T\0_
M O\ X*5>)9?V<?VT_,^'W[1_AV:3PQX?U32_/N8[R\AS)=7$BVBI:J=Z2C#2
M%1NRK$8!O>(OAA\#/VH[<_\ !07_ ()@>-U\.?%?29O^$AUKX2W6J0QW,FEZ
M8"AMH],TT-(WGSVMIB,OY<OF@%@S@4ZYT;]G_P#X*?Z NL0>(5^$'[47AR$:
M6ND7U];:!_:FM@^9=3"V3S+Q\?OES@2#(W#%3RUI6C:$G4][1?NZR7;M56ZV
MU9JZF#P]256$\11IX=<D92=\3EM2UE3J:?O<#)OE?NOW+ZI[U-0^*GP^_:U\
M7G]B7_@K7HA\(_&;PS)'I?@WQ)I+/<&[U+52K0>;%IR^0!%&U@/GDV-SDK\V
M%\5^.-7_ &4;NU_X)P_\%2=&CU7X,ZHFWP?XZMYE2YBTZR/F0NL&GB:X/F7"
MPJ0[!E!.<C-6M/UWX)_\%,/#B_#7]K6)?@[^TIX/\X:;?:A]G\.KJ^K7AVZ6
MIBE+7DYCCCLLK@,/,_=EE=34?AOQIH-_;7'_  32_P""N/A^;1FCG6Q\&_%M
M[6.Q@:TLAYTDIU+4@KR)+)%'&)$CVOO"G!/ Y2G>2DGS>[&I)?'T]G7_ +R^
M%.W0488>G*.$JT)QC17/5PM*5Y47;F6-RNI=^Y_R]E3O-6;6UK5_$'CZ^_8D
MTBS_ &<OCKH<?BS]DWXF?\B#XGFD$%Y9:;=!;ZXE2*+S;URANA'^]\MCY? &
M>;5_I_C;_@F%X3C_ &TOV(+G_A8G[.OC:-;[Q)H6LP)9BUCW_9+"+S+LO=.Q
MN+DME8A]P!P <U'X>\;>'O@7/>_\$[?V\]&EUKX-ZX5M_A'\7+>&-X(+.[?[
M1]H&K7A6(B.&:*,M"IVF/"@J%:H[>_\ &G_!+3Q,NM?8_P#A<G[*?C>1KA;B
MQMWU]=.LX%9+0&>01V5N\EY/&<9*N(\*2P&'[]-N7PJ"WM>=&79]Z7;^[8(T
MU6C'#J'MIXCWY4V[8;,J=])P=U[''Q6LK23]K!VC=V<NF:+X0_9J\-WG[>/_
M  1]U!_$GPSTE6TWXM^%]<A:)%AM$6]N'$NIXFVO%+ F((V(V[@6)90G@_X2
M?#K]I^WF_;M_X)/^(+W3/CEX=DBUCQUX'GA>2T?4=8)2XA2?43%;+' C:B08
MPRMM&W;\@8U'POH7_!-[7+3XW?L.^*%^,G[/^N*NG_%;2[.8>)/L#Q'SKV1C
M!MM;?=:FW4-,W!R&&TKAOB;X3Z=X->'_ (*-_P#!'WQM)K^K;VUSXA?"V+4#
MJ5S;2:KA;2S.EZ<NT"W%S?,8Y7Q%Y.5SL8A^]S*,HQ]W648Z<O\ T\H>CUDE
M?2ZL'MJ-2$\10KU$ZUJ='$U]8U4M'A,TB]+V]RG4<8/6#O9757POXD^!'_!3
M36#\7?@]!)X#_:N\.J-7T/0[22>XM;YM,PT$>^58K.,S2>4"S'C/S!@#B2QN
MOV=O^"HWBR3X"?M87<OPY_:<T&Z?PI8ZEI*W%[%=2Z>6FO9Y$M@EH&9UO4*F
M0@ 91R-F;7BG2OV?_P!K:T'[=_\ P3ZUQO"/QN\+RKJ,GPMFOH+>74+?30))
MXX]*L-]Q,T[J@"$@2%PK;2U2:EX'^ ?_  5$T=/%W@GQE_PJ']J+08X="NM#
MU;4(M"^WZM%MFU2Z6U@\V[.0]XNX@2?N]C@!&-3RU:L5&T)N6K5K1JQTUCM:
MK]UV_N/;8'!UI5(?6,)"A[L97YZ^7U7O">C=7 2>EFG:TM=7S4?$?QZ\+:YK
M?_#"'_!:7PX=.;PY$NJ^$_&.ES,]Q,V/LUG$\6EH_P ODO.^YG/W0&PVTEWB
MOXI-^S_-#_P3E_X*OZ$+WX6PH)? OCJW<)=#2;$F*R_<Z<LLV)&C4D2.'7?A
M@<9.AH7Q$^!O[:VC+^RA_P %0M"D^&?Q,\(R&^TSQE<1VWAY=0AB'V:UMVGO
M6-Q.6,LD@P@5_++J>,5#X>\=?#_XB6DG_!.C_@KCH[>%]5\.R"Q\(_%:2WBT
MN&ZTW3P4$PU#42))Q/)&V'1 KAQG!;%+]Y4BVJB=WRQ<E\5O^75=?^D/3KJR
MHT\+3E"G5PM2/LOWM6E0EI#K'&Y8[MJWQ5J?O*SBK)+2/Q9I'CK_ ()CZ)#\
M//'+)X\_9/\ C \=E<:M>".TN--;58MLKHJF6]D>'3K>1@ $#;L##*H+6\6Z
MK_P3T\'-^V%^P38+X\_9A\72*^N:#K3):-:7J'[ D>^\W7C9NO,ERL0'\/*X
M:DT2[\9_L77]Q^Q3^WC8-XT^ OQ&ADB\'_$BQC:^AT>ZU)A;VLG]IWX2"'R+
M)+B4K&K,@8,@8;LK8>++7_@F3XGFD\,Z(WQ@_9)\6*;N'4-/MTUX64T:"'RS
M=-LLHF;43(P568L #]X$"^9T8N6E-0V37O4I.V_>D][>:^6,:<,5RTIP6*J5
MWS/E?+0S"DKNZV]EF$/L/1\Z^%M^\[1OA)X ^#>@W7_!0?\ X(Q^,Y/$7AOP
MW(^B?$CPCK-H\:+8PQC4;^7SM4*OS&EE&5BC9L-N4DA@(_".E^!OVN'F_;G_
M .":&HS:5^T9H:C5_%_@H0R26<DE[FTDC6:_\JT"I \\GR9S\N &P"[5OA5=
M_P#!/#6[7]J'_@GA\0X?BY\$[QH] ^(GAFSU)_$4EKO)N]0FDAM%6V@"VD%L
MGF2G*F7Y\)("5\3^$_!)@7_@I=_P27\1-J/BZ-CJGC3X/B87]Q!!> 6<4!TK
M302JQF628H[X0)O&0.)Y9QE&E**7+[TH1Z=JM'\VEKY&BQ%&O3GB:=>=3VEJ
M='$5?M+9X',XZ)QE:T*EH:N+YM-(/"&F?LN_\%;;YOC!\%-7N/A_^TM:1MK]
MQH5BMS=6ES;Z<1!;Q*\HAM5\UOL9)!)4M\RG+&FW?Q ^$W[<GC"3]C[_ (*9
MZ6_@?XZ>%IET'P?X@TEY;K[=JM\0"\J6"BW4Q^7:8WR%#N/(PU7_ !5\*?@'
M^VK8?\-I?\$VO'T?@OXMPL-1U3X9S:U#:S'3-/7RY$33]-5YBTTD-L0I.V3S
M.<%QA#J7P'_X*=^'_P#A&?C1-)\'_P!ISP7;M;Z>NI-;^'4UO6[LYM_W3;[R
M9H_(A&"JR+Y@ !W8J>:<DE[KE+5NW[NLO3I5^[WOP)5,+1FZB=>E3PZY4KN6
M*RVIM9.W[W R;]FTT[1L^:^KIZW\<O"GQ>\1)^P__P %G?##:!XO\/A;CPWX
MJTJY:::6[N5"VL4D6E*T>U(Y WS2%3M&['6K7BZ;6/V%Y[;_ ()V_P#!1N,^
M)OV=_$^\>#_'JJL-W;QVFV_F=(;+SKKYKV:UC(=@0!N7*Y DLOB%\#?^"@VA
MQ_L]?\%$='G^$GQL\+E[FS\1:I;6WAV/4Y#^ZL8&>Z+7$I^9'V@8/)1F[U_#
M>I)X6CNO^"7W_!6VT:WT.7:G@'XQK";>&+R,ZE>2#5M3*EU9OLEOB., ',;\
M,,5S.7--33O[L9M:/O2K_P!U_HM;[D*="DHX6=&<?9VJ5L-2EI'JL?E<^CC_
M !'33FG&5N5Q7NO\1>+=5_X)^>'K+P!K>GQ^-/V/?C(J0Z+JNH8MKK2K/6(Q
M)(R*/,OG>"Q\S[RH7."JJX"DDTG5?V ?!/\ PWM_P3BNSX[_ &>_%P/_  FG
MAO6-MF;-;.8V,">9?%KE_,O9KELQQ#'EA3E"K4ND^+[#]DC5KK]AW]J_1/\
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MC_@F)_P3][_LB^!__!)'1_P[$_X)^?\ 1HO@?_P1QU[Q10!X/_P[$_X)^?\
M1HO@?_P1QT?\.Q/^"?G_ $:+X'_\$<=>\44 >#_\.Q/^"?G_ $:+X'_\$<=-
M;_@F'^P!GY?V1O __@CBKWJB@#R?X7?L3_LK_!3Q*OC'X3_ 'PSX?U3R&B^W
M:;IJ12!2P8KD#H64'\!77?$OX1?#[XR>&G\'?%'P78:YI<S9FT[4(?,A;@C.
M#[,P]P37544 >"?\.P_V 0F!^R+X%S_LZ%&!^5>F_"GX+_#?X&^$8?A_\(_
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M#8S:E]IUEV+6D:W-^T-M'Q;D[DB9/F&X#:,NG\'_ +/_ /P6CA/QW^#NL?\
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M%X#_ &^K1O\ @HC_ ,$X/%+>%/C!X:!U;Q1X+:REO_/UV=BX5;G47BMU"J9
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MSF2WCMGPT=N'CN5O)&'VI^)%R.<));?%.T_:@5?^":G_  5?T-_#OQ/LRP\
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MBYRJ4(8%-3A9O$Y9-NRG2;;EBL$V^9KFJQ]E):+K1^(NO^ I?!.@_P#!.O\
M;XT.:XL]-C%E\(OVA[%"^C&"YC66&Z8R26T/EPVC6\;F.2<!D(#$?,VK?:SX
MA_8*^"4?P3_:QT>3]H+]F;Q;!')X?\2>"+AF71+6UE#1;_+5(%::[EAQF\*X
MC8AW/R-4L[CX8?'VW_X=(?M[NVA_$;X?S'2/A/\ $/\ ?2K=M.<6<ALM/$<$
M06R%K@3SMDG#$.3E5\9ZM^PW.W_!-S_@IUIC>*/@-XCF\KPAXP6=;'[+:V.;
MO>MMIBR7;B2Z^S*1)*K*03\RY!IR7M75YK6]V,W]E[>RK=TGHINZ:L[ZW,5'
MFP]/ 2BYRYOK$\-'W?;0?O+&Y;55G"JTU4="$H^\IQ]G:\4G@CPR/^":'PNU
MC3_"_C"U_:2_9W\<&6P\?6_@W FT&[\I/ML\BP&5%'V-;<#?<Q\]=F [.^"_
MPU\2?LC+J'[=/_!-WXHZ?\2_ VL-;ZOXX^!NEXCU:QM;UI%TNQ<6WVQRUJ;R
M9GW&)A]D<_/\P4E\#:Q_P1TN?^&9?VAK\_$;]G_XP1K!KFMQPC2/[+O)SY%X
MPBMS<7DQ6T@B;"/&I\P!/G6EN_AK\2?^"1K1?MX?L@Z[_P +!^ OCYCJOB+P
MREO%I@MM,E.W18&NKMKB[?#:C_K(XUD/E?O1\XVS&$:,8ITW%4KW2=Y4&].9
M/_EY!O=7DDO)::5J_P#:2K1HXB.(ECFO9SG#DP^9J+M[.KI&.&Q=.SC"2]E*
M4XQ?->2D\;X4_#WX2^(O&LW[?_\ P3'\>P^&?$'AN)[K6/@!K0C&K:C8VAWW
M\,/E37<S-<; B#RARXPRG@R^'/A%\.?VWOBX_P"TS^Q;\5+'X$_'S3M2N;?5
M/A]XQ\N.;4->EWRZE=P,TLL[)Y5Q,O\ QZ@DPG='%EMNC<?L_P#@?X([/^"L
M7_!+GQLNI>$M#N%;Q+\/SITD9.GP_OM57[9JCLZJPAVY2#<N[,6< %T_[->C
M?M9+)_P4X_X)4^-6T+XGV)6[\2> 8].:Z=?$-\3+J2B\U61(!Y<5[)]V'RF,
M?R[2P"J-"II!TU+[3C%VYE_S]IRO=26[A?JM"I9KA%5EBHXR=./(J$*]>GS>
MQG9WP./@XRYZ3O[M>496NWSZ-+-^*-[^SY_P4>\=Q_#/]IK1KC]GOXY>&H4G
MN_&7BH)]BUZSM_W$,$1N9K9@\LTWG#$'*QG#-SBY\:O$'PS_ &OM5T_]C_\
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M(K/_ (*<_P#!-;Q-)J7@F69O%'BSP/\ V@NFPVR6Y00VILK?#,CA)3L(R >
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M%T*S^*'[.'CV1+FZUK1TEU#4;/18"PL)#YOV:WBFE^U1[N'1BAV;=JYA\+_
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M^,_"L4E]<6=]>1BUBA\^Z:&--D4#RNOE.?FR"=Q C^%6B+XP\*ZE_P $F/\
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MO"&$JN=2G!7KX";?-]:PTM?:X23:FHVG:+:Y]I%#P%X67]B;X8ZU_P $V/\
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M8:K[6I0I^]/"2=[8S"SLW4PK;5X>^N62?/HF0_#C5_BM_P $\/ -_P#L!?\
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MKRUZFF-IUJWUW#U'"K/%6J2ITM*6/@FG]8PDE?V5>"3G*%Y7:MR*[B5/A/\
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MH$AANXR5-P67:WSLJ*&DF^!GQ%_X)<_%>S^/'@[Q WQ$_9UU22'3=>M;V_\
MM<<5K>$->NVGP,8F,<228+J03P<Y8$^(?P@^+G[)?C^'_@I?^P/KTWBGX5ZH
MQ\4ZMX0EU)H(;:YU5I$6S:PM2/EA2[A(!&4V\X5!DY%&FH2IN/*^9QB]8?\
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M5&^Z5T&Z(_\ 1=>S2Q0^6Q:)2,=,5P?P&F\G0]2T27:)['5I$F4?P_*O^!H
M/AI^TS\'?B['?2>"?&<,G]G3+'=+>1-:LK$9Z2@$BNL_X3+PI_T-.F_^!T?_
M ,57"Z3X$\+W_P 5M>?Q+X=M+IKM8FMWFCW':#,2#Z5U/_"I/AU_T(^F?]^1
M_A0!H'QIX5'3Q3IO_@='_C5"?XJ^!X96B;Q#"Q4X_=L&7\".M)_PJ3X=?]"/
MIG_?D?X5=MO!'A>SMUM;7P]:QQK]U$B&!0!1_P"%L>"/^@['_P!\G_"C_A;'
M@C_H.Q_]\G_"M+_A$O#_ /T!+?\ []BC_A$O#_\ T!+?_OV* ,+5/CG\.=%C
M66]UXLK-C]U [D?@H-5/^&E/A)_T'KC_ ,%MQ_\ $5V%CH.E:?)YUGI\43?W
MHU _I5R@#@_^&E/A)_T'KC_P6W'_ ,1576/VIO@WHFG2:I?>(;A88UW,1IL_
M'YIBO1JY7XQ?\DVU3_KDO_H0H \WC_;[^#%[:?:M$L=<OMQQ&MOI+X;\3BF+
M^W3X689'PT\3_P#@N_\ KUUW[)H!_9\\,Y_Y\Y/_ $=)7HX '2@#PL_MT>%A
MS_PK3Q/_ ."T_P"-1G]NWPJ)%C_X5IXH^;_J%G_&O>** /!Q^W;X;WE&^%?B
MK_?&GC!_\>J3_ANCPM_T33Q-_P""T_XU[I10!X2?VZ?#6=L?PM\4R$_=VZ>.
M?;EJN1_M<Z[/"MQ;_L_>+&C==T;?9X^5/0_?KVJB@#Q5?VM/$;'!_9]\5_\
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M_P#!0CX9:-\6OAIK<7AW]JSX/PK)XNTV_D:;6M3O-&B\L%8$ A1Y+V-"J[
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MK+#<>(M-BT;QUX7\*Q_;]0L=2N6DU*]>5Y]\: %[575-HW!2O#<UH++X_?\
M!)[X_CXG_ Z>\\1_LT>+-8;7M2_X5MI?]N6PTA"R1)/?3PE8&VL "+G#<G>2
M0*B_:+^''Q2^'GC.S_X*,?\ !'=EGTWQ?IJZ5XNT?P?&_B;5;34KJ234KO[7
M 8[J*VC7%H'".NR7:H #G)K&C*'+)<LK\D?BA?[=)[N#[>J\C2G4J8C,<-C(
M5:51UJ7LXXBI&U'%1V^K9C3UY,1"S4:B;O:+\UJ?&3P/9_M=Z;I?_!2?_@F#
M/'H_Q0T6'[1XU\+Z1F^UAKR^9;<$ART2LD'VAFPI!3=M!8 U8\1Z;X9_X*F_
M"C3KG363PI^U-\(VBL]876I#)J>K0Z5#OE:."/$2%]0N6QE.'1UZ<5!^T5\/
MI_C6-(_X*H?\$I+FWC\:Z;%->^.M!TZ5M8\0"]OF2T0?V<!=PPL('G9DPF$!
M(&:L?$S1=$_X*G?!?0_BE\,[NVT7]J+X30VUEXJL?&5W]CU.^32X6GN6MM,@
M,J-NO[E0I>!#N!C8J JG:I^\J5:<5>4DFXIVC52VE3>O+475:Z]>IPX6M]7P
M>"Q*J>RCAYNFJLES8C!-M_[/BHZ>WP<K^Y-M-1GMIRMFBZ9J?_!13X/:A^Q+
M^VY>?\(Y^TEX8N/-\$Z]XW)AN+J"ZF^UW"16L 16 M+-<AP2 ZGC!S-\'/VA
MM8\9^&+_ /X)\?\ !8OPSJ$&K:L\NM^$->\:2+:16@$:VEC$B6P1G/VA+AE;
M.WKR<#%6PTK6_P#@J?\ LY3_ +,_[3UPNB_M1^#;C=X5N?B8#X?:ZM[NY2YE
M6WL8%62XVV=D0Q>U(&]&SAF(O? C]H-/VEOAEJW[!'_!733=8TOQC>74NL>"
M=8\>6L?AFPACCA6WM%WQFVDD8W'V@I^[97 ."Q7 SIRY:L)QE\2Y8RE\,TM.
M2LNE2+T4M>_D5C,/; XK#5*,4J%95)TJ+_>85R=_K672^WA:B7/*DU'EY;7U
MYC*^$7AGXB_L4>.9OV'_ /@I&EWJW[.NL1-INBZW=+]BT=+Y=NJI,LT>V=CY
MD3I@.?G;T&*K>#=4_:H_X(]_$IM-\:V^I>,OV?=261_,T:U2WTYIKX8CQ/(I
MDWJ@&>>>.@)IW[/%G\2/V;_&-Y_P38_X*D_:9/@3>6;:?HFLR6ITSPZE^KC5
MU==7*6LL@WQ2KCS'+2$*5"DYK_!CQ[^U)_P20^*LGPI_: TS6M<_9_OO/FCF
M\)>'UGTF22^.R _VC<PP$.$ +()SM/3>,M1_!C2?OP4&U%[SI]7&?\U-[IZ:
M'76^L9AB,9AYJAB98B$9RI1]RCC59VQ&%DD_8XY7_>P2:;DM=+.]X^^&_P 4
MOV(OBS#^V?\ \$S-5E\0_ /Q->6VJ>)M)\&V_P!IAM],T<1BZBN9[E791(QO
M\,N-H\S.2%Q'\8_@3X]L-?@_X* _\$=/%<<D?B2WCT7Q+X<\'0MJ%Y:W$VZ]
MO'F:8.H3>MLK 8^8KCK3?&O@[XP?\$V?C]'^TG_P3[U"37?V;_&>L65]X@C^
M&5FWB00:5I(B%]'=W4\<JV^]I+_8XN !^\W-&4&(_CY\&OBO\"?'T/\ P4 _
MX(]ZU!?>&_%EG'HOB"U\#*?$^J6EY<,U]=M<0M'<P0(#% '/F+L?RU(4.36=
M2G[M2+C*T6FU%WY+Z\]%]8O5RC96O8>$Q52KBL'6IXBE4=:FZ<:M>-HXE1T>
M%S.-VH5Z=E"G43DY*-[*]UM?&?0O#O\ P4;\.V/_  4)_P"">\5OX;^-GA=I
MKSQ?X6MYOMNL73[EL;#C/DH?)MI)!A1E'Y!8&J^L^%[G_@HI\&K"_LYF\.?M
M9?!:?=J\6H[CK&KVVEQO+F.WC A0O>W<87<F=Z%2<'%6OVC/#.A?MK:=HW_!
M3_\ X)F>3I_Q.\/R3:AXZ\/M<-?>(]R!+&SV:9&;J&-S';S,JE$+IM;!.X"A
MX[\,:Q_P49^!6A_&KP%+#I?[6'P<FA/BZQ\43&UUB]MM+ADN7:VTF!9%R;V[
M@"%X(R7!1BH(5MY_O:U12CS.:O[ND:L;*TH/7EJ))::ZK?73BP<EA<'A)PJ^
MPCAZCIIU5SU\#)\R^KXE.WML#/F:C-I-1G'3W;/0\&_$7P]^WC\([K]@/]OZ
MT_X1WX]>&;64>%?$GC*;R7EO[Z0O"JVT 3E;;R%PP(*[?[QS3^%%IXO_ +,U
M[_@G+_P5*FN;?2Y+<P_ OQ/XH;['IZ75B&TZW-LMN%>8.MY&ZAF8!57(#<U?
M\,^-] _X*:_L\S?L??MGB31?VCO"-O.WAN^^) 'AWSKZ^E)@2.V@*/*ZVWD9
M1K5N&5@&W$G,^"47C7XK>$/$W_!.+_@J///ITVCVNSX&:SXNA_X1[1EOM/CD
MTV(6URJ6TM\&-U 4#+,&12Q&[:&4?WM2%2_.VN52>TFO^7===)16TEUUL56B
M\'AL9A905%4JBJSHTWS2H-R36+RR;LY4IOWZE+1*GS)/JE^#_P 1_C)_P3Y\
M1W7[&/\ P4'TK5O$7P.\21IX7\/ZO<*MEI=O#(^^>Y215$S($D;)#Y S@@BJ
MT/ASXU_\$U_C$WBKPA=77B?]DSQE?3Z_J4/A^W":9'8ZMYEE:0RW,BF7='&U
MBVX,"P"^I)M_LY_%;XL_L8^(=5_X)Z_\%-]*UJ_^$>LVT?A/PYJL&CKI^@1^
M=)F:<:K(EK*\(CD.YE=F09; P2,OPO'\<_\ @F=\?KCPV_V_7/V2O'6J7FMS
M77@[2_[0T@Z;JBRV>G^=JTT2>5*JBR9MESC;L8,_FFLX2]G1A4O)*$K7>LJ3
MW<9:^]2;]-#IQ,:F(QV*BX4:DL324VH^[A\?%+^-A]+T,?%.[BKWJ<WH[7CC
MX8_&']A7XJ1_MD_\$Z;VXUSX"^+;Z'6?$FE^#81-#!I.EE#-!<7%R'95??>X
M8$$?O.N!B3XR_"?Q)\7KNS_X*6_\$E=9^R^(M6LHX_&WA3PROV[5(=7U!FO+
MTR-/NC&WSHD95 &1\H 8 4_%7@WXU_\ !,W]H*/]HW]A2[DU_P#9U\::O:ZE
MKT7PYLV\1"'1=+*_:8[J[GCD%N6\V^"L+@ $-N==NT6/VAOA;X]/BBT_X*A_
M\$A-0@F;Q'8X\::+X;SX@UZTU;4F>[NEGLA'=PP,BR1*Z*R^600%VE<DH\M.
M<'"2L^:48_%'K[2C+K'KRV7:X87$5)8[!XN-:G)U8>SA7JKW*^G+]4S.#=HU
M4E[-5;MOE4K.]U?^+/AG5?VX/#6C_P#!0?\ 8.N1H?QV\%QR#XA^&+%C>ZS=
M7#[--MI?+(:"/_1[:>3 3YHW_O#-7;^+X<_\%:?A/%\%OB"+?PC^TSX!AMM#
MEOO%4K/=:BUDN^_*V\&V,;IA("K)PP..%XH?M >%=4_:8TSPY_P4_P#^"<-Y
M':_%SPW:R-\3O#D+_P!I>)?M1$.EVS#2HA=0Q$1073;2L9,;;L%P5%OXA:-\
M._\ @KO^S_8Z*DEOH_[47@+3[31M6C\?WW]F7=Y);*LNHM#IULSEE,HD'S6Z
ME6W+M3&T5*TJE2._/%.STA45OBC_ "U;+5:ZJ]]=..G/ZO@\+6NZ,<+4<%4:
MYL3E\[_P:\7I7P%W[DGRODG:VEG0\#:'XA_;?^%>K?L2?\%$YI-!^/=G-]J^
M%&N>-E\B3[/>,N](8+?8K[5L6R7!/[P8QSFS\#OCMKOPW2^_8!_X+ >'-0?P
MIKC_ /%-:[XFVV-G:V>GJ3 5\D))(C211;3N)W.JGC-4_!UEXJ_X*5_ ;6OV
M8OVZY&T3]H_PU(TOPKN/B1 _APS6U[Y99(K2!8FNRHLI=Y:W<)N3!(+&M#]G
M7]H.[UC1=3_X)T_\%C]-UNST6^G5/"NM>*-/C\.Z3#9Z<ORG[6/LLCHTD*[&
M <., G!(-TY6JTY*35URJ4]I+I3KKI+726O?R*Q-'FP>,P\J,+4JGM9T:#:J
M4'H_KF63?QTG93E2=DI1DKI.ZS/A%I/QG_X)[?$";]CG]NNYN_$G[-.M6I\-
MV6M20K::(+R],6H&=90OG-MVWBE=W4/V %0:7-^T[_P21^*I^*GP]?5/&7[,
M^K33^*+V'PK"B:?(FHK):64#7,P9_,0"P?<6 8;1W.9/V>1\</V*?'-U_P $
M[O\ @I MY=_ '5M-?0--UBSTL6?AO^T+UTU 2_VQ+':R[5!NU9?-+!PV%PHJ
MOX'\3?M,_P#!('XY/_:-AJ?B+]F37+N[\4W)^'NBC4M/DM[Y9+:Q1M1N8H]L
M^8[(E1<$%2I!<L341Y:,83?/#DE9M^]*D_Y9+:5%O;5:'96]ICL5B*;]AB7B
M:2FX)<E',(V_C4GK[#,5=N44I>^X[M6=KXG_  /^(W[+/Q%C_;@_X)5:TVK?
M"7Q!-$VN:-X)@-T+>QL%4WB2RW0?8CR)<'<",9QGI1\8/A7\0?B#>V/_  4O
M_P""0FIRVNH>)=.BL/'7A;PW U_J%KJMTSZA?/,9MR+CS+6-U0!05& !D53^
M*/PD^+?[ _QG7]K;_@F5?QZQ\#_%5S:Q:I:?#N.3Q+-!8V:1O>K<R3QSK IE
M6X^<3C'0M'MP'?M$_#SXFZ/XLL?^"GW_  2!O&ELO&FFQVWC;2?"]N_B#6;+
M6KYY-0O!=6QCNXK8!'M1(@=1$^U0H5\T2I_NYPY&K2ORP=VGUJ4?+JX]-M>L
MX7$3JXG!5H8BE/GI^RA5KQLJB27^QYE'958VY*=9.[<;^G2?%JR^&?\ P5+\
M$6/[7O['UW:>%?CYX+F.KZMH<MR][JU['8H%M%2,#R0S2)&4^7;EAG.3FC_P
MK;_AXQ\&[?X<?&;68/"O[5_PWNC!/<>)MW]I:AIMNS7\6RVB"Q+EKV-%)3<3
M'R3D8O?M"Z'\/O\ @HIX2TO]OO\ 8)OK+2_C9X-N?[5\0:#J6H^?K\T.GKLM
MS#I<+7,9=I$7RP8T#G;D]5K,USX<:M_P4V_9\TO5?%&IVNC_ +6_P[F^S:Q9
M^.Y3I.IW>GVSR7Z-#I,*G<I%W$@9[52Q1@2/E)<E[:I.T>=S6EM*=5=^O+57
MSZ_+EPU;ZC@</^^>&CAJW+[ZY\3E\W=*G.[_ '^7RNXW=FKQTZ._\./C*?VK
MOAQJ/_!.K_@I]H=UI?Q6FM[FY\ ^*O'$PM1'JUXOV33T2" (6=6FW@,&5@,$
M9Q6?\&=;\5?"/5=6_8!_X*RV%U-\.[Q3I_PL\1>(E%EIUO\ V47A22 P;99$
MD$MHR;F)"JF[#$UJ?#SXPV?_  4 ^!>J?L-_\%&-/U+1_CE!!>ZG\/\ 5/B-
M;CPU;-J-PAMM.B2*'R)IWW39\LP,2F3AB 3E_L\>(/$L,>O?\$X/^"NL-];^
M%[&.'3OA-K7B&W70-#!TD30EX;X+:RW4<@-D8R/-R -V-^&<*GM*E*K&7-=.
M*E);]J=:/??EET?0,51^JT<=AYT(TN6:JSHT7>4-4UC,KGI[CT<Z6BY$]6M5
M6^%.M?M _P#!,3X@R?LK?MGVNJ>)OV=?$-K_ ,(C:ZIM2TT>-]5:.:XN1.5$
MK+'%)?!P'W#$FW[HI;C0OCY_P2]^,/\ PT9^SE<W?BS]FKQ-?2>)-2M?"4*&
MR339,Q6T,US.K.K!'C(;(!'2H?V>/&_[0/\ P3T\<7?["/\ P4"M]6U#X#ZQ
MI[^$[/4-)T=;?0%N]7=)I9O[6FCMI?*2*:],I$A:,"1E4",$&DVG[17_  2=
M^/W_  L#X6_:O$'[,GBW5IO$=\OPZTT:S:#26+PVT<^H74(6)]C0G/VD*1DA
MR*S_ (5&$H\\52=M=:E)O>+VYZ3VZ61V5HUL1F6(IM4*T\72;:7NX7,(I7YX
M67^SX]?$DE).H[.W6SXS^&'Q-_8G^*$/[:W_  31\1OKWP.\1WD&H>*M&\&(
M;F*VTO2C']KCN)[H.55W%\=RD8^?G(&+?QJ^'47[4\>F_P#!2O\ X)87*Z7\
M0]+C\_QKX4T@/J&IIJ%\VQN)=T496&28LJ*!@L< YK+\>?#_ .,?_!-[XZ)^
MT]_P3\U5=:_9Y\9:C9SZW%\-[=O$Y@TO3%B^W)<W$\4JP!I&OL2"X^7#[F0J
M%6]^TI\.[[XHZGI/_!4G_@DA<)'XHM[>2[\;:'H\KZUX@@U#4&\K#6"K>0QD
M122ET!0(H+*#CC2I3Y:=6GR[--PB[I=54HO1-:W<;;Z7[XX;$.IC,%C56A+V
MD'2AB:L;1J*RB\'FE-72EI[*-6[?NJ=GT?X\^&'_  W!\-M'_:H_9JU6/1_V
ME_AS%O\ B;I+;KC6+[4+-5L(F^SX,,;LUJ7"J@'SC@\YOPZCX3_X*C?"9OV,
M_P!J:2'PC^TGX,6.PT'6O&,Y^T7DCS?:KW;;6^U,_9[0J=P.,@C&"*R_C#\,
M;[]K_P"'/AG]O/\ 8^N[6S_:)\$6_P!K^*VBWLC2^()KVQ2.RC9-'C%Q#&QE
MMI"J&*,$,N02"HU-0G\)_P#!7']G:/X _%=K?0?VI/ ]K#8Z1)\2+L:')>S2
M3+<7GDV-N=\Q6UMF# VP"$@[5&2'*/-5DK7=2.STA6T7KRUOOU1STZBHX'#U
M^=TH82K;VD5S8G+I.3LFFTL1@).6EVOW4TMU:5'X:ZSXK_:A^&NM?L(?\%1(
M;S0_BU>-+JGPH\0>.&%H8WO(DL[>.."UV>;B>&=AN!!Y'5>'?!#XH^.?V;=8
MOO\ @GO_ ,%;-#U+4OA/X@EBT;P3XBUK98:7;6>B"619HFB"3212NNGJOS%A
MNCW9!?)\,=?\3_M^_ [Q!^QW_P %)7N-#^-UFTVI?"34/B5:KX9B8W,,=K;0
MPQ1""2Z87"3MS;R [L#<5VA?V;OC-XI\&PZU_P $V_\ @KYI6LMX%U#[-H7@
M#6=;TU-!T""#1A*\DL>H%;2:>%VCL!$X,A),8;:7(:*,ESTY*3V<>:75ZITZ
MZVO>ZBUU:?D],=AYU,/CL'4HP?).-6>'H.SIWLUB\KJ=5ISU*5DK1FK]5G?#
MSP[\>?\ @F=\18_@-^T@]YXL_9F\61OI&HZE9VXMM'0ZIA6E>4CS_P!W'YI;
M:V2.A&W(CAC_ &AO^"4OQ?;XZ?!07_BW]F?Q%>3>*IK/PO;I_9Z6=\TD-A;O
M<3*S[D1K1MV0"!'RQ+9K_!*'X^_\$Z_B=+^QU^V3;WFI?LZ^,(I=(NM5T32B
MF@H^K%4$CZM+';O$B1M(92LY:,9*[BHQ:\-:S^T=_P $B/V@I/%WA:TU+7OV
M8/$FK77BC=\/=&_M:S.G77FP:?'+J%S$-DP LF/^D;6!!!8-RHU(TZ4)24X<
MDM&]72?2_P#-2?RLOPZ:WML=CJ\+X?%2Q-%.UN2CCXI/WEI^XQ\=7I>\FM5]
MJ;XO_ ?X@>!/$B_M[_\ !'O7Y)M#\10Q:1X@\/>#8OMMU:DYN[PRO<!U"[XX
M5.,8.T#CK:^-GPIU3XYW&F_\%*/^"2^KQV?C"XLQ)XX\+^&BU]JL6JZ@WF7)
M?S=T:LJ2D.J+C@X&  ,OXX_!/XJ?LU?$>']O#_@DCK<&H>#?%D<&E:[I_@2)
M_$^J6K.?MEW]HCDCN8X4!CB5B)048J,(*N?M'_";Q7KVMV/_  5(_P""1UY;
M/J>J6OG^,]#\/2-K_B"WU34G:2<2V(CNX865) )$4H$PV%( (52E+]Y"49;J
M347\U5H.VF]Y1MY7'@<9*5; UX8J#YE*C"I7@O>=DG@LTC?5.RA2K7>TG;MK
M>/-1\)_\%2?AG:?%CX,V$?AW]I[X3S)>W=C=7!FU35K71X"<10K^Y5I+^>/9
MN0D."#P<&GI'@ZS_ ."D?P8F_9%_:QNE\.?M2>#G^SZ;JOB_<ES=V;S&_8+:
M0;8\"S9(_G7< <\9.;WQI'@__@I/\+](_:G_ &5/)TG]I3X2W%M=ZWI/B&^"
MZS?V^D0-,[6NE0M-')NOYH%1GA4%MRE@"%;+?PJ/^"IW[-O_  ISX[W"Z1^U
MMX-E^S67_"P)6T.XN[26X:^;R=/@&7 L=@+M: @X884[CM[U;FE93]I#7I"K
M%;K^[65O.]ON\[#5/[/P=!<SPT<-7TO[V(P%1MZ]/;Y?*Z<T^6T9=?M6/A-\
M6_$/Q[\#ZM_P3N_X*V:;=Z3XVU19]=^&WB3QH/L<<-[+$-/T^-8K8(TK"62[
MD!;(.QAC*@B#X-:E\0?V4?$%]^P-_P %05N-0^!WB!/[*\*^(]646.D0M8_Z
M<LL<B!9I%:2.)1\Y.2N<@$5:^$'QBU']M?X/^(/V%?\ @JG#JFC?%";[5XA^
M&>L_$FP3PO:Q7!@33]/C58C;RS2?:)KI@AA<.-PRY515;]G;Q%X\^#FL:M_P
M3._X*O/?Q_":_MX]*\(:UJ5FNC^'(Y+!VOMZ:LZ6DDR,T42J59R78 @ FHC*
M4I491G)_94I;W>U.O'^7727333OOB*+HT<PPTZ,(6<:TZ%)MQ7*U_MN5ST]^
M/Q3I62<4_>2^&G\+=>_:5_X)*^-)O@;^TW!J/C;]G_5+7^P(+K3X%L])-YJ)
MCGFE65U\P^7&;O<N[/#X/RC">-?AG\8?^"?_ ,6(_P!K_P#8*OI/$G[/OBB\
M77/$&D^#;42V\&DV)56@N)[@.5#A[K:PP1ALDG:*9^S_ /$+]I+_ ()>^.YO
MV1OVX]-U;6/@7J-C)HUG>>'M"5=#-YJ;)-YJZI<16TA1(FN=^)24^?@[%--\
M1^#?CC_P2^^/:_M _L?W#Z]^S?XXUB'4]8C^'-F=?CCT.QV"1+F\N(W6#<)K
MC;(+@+@.2XQQ$>6-&,7SJ,).ZWG1>RZI2I6NEMIJ=52-;$YI4E^XJ3Q5&ZE\
M.%S&*7-[R7\#'Q^-6;O-.+M>[M?%SX$>//@!XTA_;C_X)+Z^;_X?:V\5IKNB
M^"HWO#:P6JK)>"5[H2;59XV!8'(+8!S6A\9K2S_;@T33?^"DG_!,MTT/XS>'
M?-G\;>$=+F^W:Q(]VRZ?;N%?,*8M8;J0X7+1Y'#"L7XP?!3XL?L3?%6#]LC_
M ()7ZE#J7PJ\3-;V&IVOP_23Q/=6T$ 26^%R9HITA3<C L)05;@[!P-C]I+3
M?^&DET7_ (*J_P#!*YHK3XC:-]HN/'WA^UD.J>)$DNC%IEMC2T^UP1_N([IC
MPF8CO&Y@<54C[M6G)-:J;@GVU=7#ONMW%^E^^6'KR]I@,9"M&5X^QAB*D=7H
MH_4<TI[.,K>S5:[:<5)1['B_PC;?\%#/A9H_Q.^&^HKX=_:P^#<:R>+-.OI&
MFUK5+G1HM@*P*!#&\EZJ$*4P'P",9!FT'4=+_P""COP<F_89_;5+>&OVEO!*
M^7X7\2>-)&CGNWO;AKYU2UMPBMML;>W4AU/#(PP228?BAX#D_;[^#GAO]J3X
M$ZA;Z?\ M4_"6&"Z\?Z1X@N"FNWMQHL'[PP:1")45WOE3RU:WB#-A6"YV&:"
M]TO_ (*H?LVG]F']I_?H?[4_@& KX?OOB4W_  CQO9;ZY-R4AL;<JTQ6PM80
MVZV)7*.HP[$UR^TK.-K\\=%M&M'?7^6JM'=7U_#G53ZO@Z<K^SCA*Z;<5?$9
M=-M^]&_^\9=)O6+Y;0E'JO>H?"_4/&?Q1\+:[_P3<_X*?Q75GXBU2SFF^"?B
M;Q8OV.VM]05#IE@(8X%1I29+AW4,6!5#P>"%^"OQ6^*/[('B"^_8+_X*>:%J
M&K?"/Q,R>'O"NL:RJ6.EV]G8$^9-&T:K++&^;3!W' *@D\@Q_"36_&?[3WPR
M\3?\$Z/^"F*7VE>.K>SN+GX(ZOX^M?\ A'=.%]'#_9VGI$\:V\MX6GN257R9
M@ZAL[FPAL?LU_&WQS\";C6O^"<?_  5>TW6G^'&L+;^&_!.L7VFQZ1H<-M8E
MS+*NHR"U>6%A]EQ)ND()4-MWX,TZDFX34I+>*E)72?6G67X1EYK3O>,H2G1Q
MV&G1IS2<:LZ-%M::6QF63TM))<U6ELW%ZVVX7XL^!?VI/^";GA_Q=I'@S5K[
MQ7^SSXZ\,ZM>&X\-V:KID,VL6LUC:!YY49]\8-JY^;YAM !)(/U%_P &VL8'
M[%?C7YV'_%SKP^__ "#=.[U\J^.K']K;_@F9IGC;X1RB\UK]GWQ[X:UN_L[[
MP3HO]J:1&^JV=Q9:?YNI3P(1(K+:,R"9LILVB0N<_57_  ;8'/[%'C8C_HIE
MY_Z;=.J\B4:?$E.G%2CRPDN26JB]/@?6+Z:+6YGXG2J8KP7Q>,FZ57VM?#-8
MBDN5UTE5UK4]H8B%[5+-W3AKI=^0_L&QG^S/V35R5#?'?QMO5?E4J(M8P,>E
M?KU9Q*L0(')ZU^0_[!O_ !X?LD?]EX\<?^B-9K]?(ON_C7Z/'X4?Q6.HHHJ@
M"HKE79<1M\V/E^M2TA*]#0!XUXGM/B7\)/@9XTUOX@_$0ZY<,MQ+I\DD**+6
M)_E2(;$3.,]\GIUKS']FSP;\2/ G[+^E>&+#X<S:E-J%V-4DFL[R) 2X1^DC
MJ<DY_*O5/VX+R*/]F[Q#;1LN^X\B&/#<EFF0?_6KN/A#HDGAOX>Z+H4D?_'K
MID*9]/D Q^E &39_$_QY#90H_P $=8W"-0P74+3@X_ZZURK^+_&C?&=/%'B+
MX4:M:Z=;Z;MMY!-!+B0[MW"2'MBO:*,#.<4 <#/^T)X+MU:'4=/U:WF53OC.
MERMMX]5!'ZUQOPH^/7@C1K35(+ZTUE6FUJYE3_B23\J978'[OIBO<" >"*38
MF,;!^5 'A_QA^-/A#7(O#2Z=)?*$\569N%N+)XQY>XYW9&=OK7I\7Q.^'R1>
M8OC/3 O0;KQ16W=:=87^#>6,4A4Y7S(P<5G2?#[P+,Q>;P=I;,W+,UC&<_I0
M!YG\5_B?X$TKXB>$=3TWQKI?G7VJ"UNMM\G^JQGUXY%>G6OC7PQJ2R'3_$5G
M+L&6\NX5BH]>#TJG??#?X<Y6XD\":3))#\T.[3X_E;V^7BO _!'['\W@?X_Z
MA\:=?L_[0A\66[6=]I-C(\<5B0J[9%7A>D>#C'+Y]: /:/@E,L^B:I>0/YD=
MQKDTD;_WEV1C/Z5<^,5DNI?#S4HGM_,:.'?&JKD[@1@_K6#:?LN_"FTMQ9VE
MIJ<<:ME5CUB=1^C5))^S'\,9@PEBU5E9-C*VM3XQ_P!]T ==X/OEO?"VG7?F
M+E[*+=R/O;!D<=\UR7BR\6Z^..C:)$A\Z/2II]W;&&&/S%0Z#^SQ9>%-)71O
M"?BO4K&%79X=]P9BA)_VZJ3? #QK<>-(?'+_ !KU#[9;V+6R#^RH"I0Y['OS
M0!Z-XBLS>^'[ZW5=S2V<BA?4E#@5RWP$EC'@:/3O,S+8R>1<)NSL=54$?G5=
M/A=\3H073XXWC'.0C:/ !]*P?!/PG^-?PX&K3Z!XLTN^DU35)+QH[^$QKN<D
M]44GCTZ4 :WQ0AFN/C3X%,$880O=F0]URJX_D:]'&>]>07W@_P#:9NO'%OXM
M9?![K:6GEP1M=7 .\[MQXCQW6MU)_P!IF'Y[NP\(R1AOF6"ZN-Q'MF.@"U^T
M!!(G@"37+./-YILPN+-MN2K@'G\JZ3P/>3ZAX-TJ_NGW2S:?"\S#NQ0$_KFN
M-\3^(?B-=:%>:1JOPZ:[^U6KQQBQF+;'(X8[EZ"J7P]\;^/?#7@VST34/A)K
M$DUK&R;E8<C<<=O3% &WHQ_XOQJ@\S/_ !)U_P#:-=QCG.:\?TOQIXMLOB9>
M^+-3^$>M6]K-IZPK+M#'=\F1C' ^6NBNOCQX=T]L:KH&M6P8?*?[/9LT 0Z9
M=V^A?M":EH6',FKZ6M[NQPN-L?\ [(/UKO-4*#3YM_3RF_\ 037@_CGXY>#]
M,^(NC_$33=-U^9I"NF7$<>CR$I$6+ESV S7>R?M!^ KNPNE']H1[8&($]F4S
MQZF@!?V7BA^#>G^6./M%Q_Z.:IO$^FQ:1\9]#\5J5\Z_A?3F]TV2R_S0?K6/
M^SCXV\&Z9\*K.RU'Q5I]O,DTS/#<W21LF9">06_VA3?CS\2/!&@>'K/QO9>+
M]+DGTW48VB6/4(V)WYC[-Z.: /3M1G%O9/<G^!=WY<UQ_P "=&2T\(RZQ@@Z
MO>/?,<]3( ?Y5J7WC7PAJ.@3/#XKTU]UOR4OHSC(]C[C\ZK_  8N+9/A9H*M
M=1G&DVW_ "T'_/)* .K;)7BO._ASILGA+XF>)M*OK@,^L72W]NOI&3(O\UKT
M%[JWVY$\?_?0KS[Q9J5GH7QN\/W!EW-K%J]FNTCY3'O8_P#H= &C8_\ )5+C
M_KW'\I:[2N)L'7_A:ES_ -< ?_1M=M0 4444 %%%% !1110 5ROQB_Y)MJG_
M %R7_P!"%=57*?&5@GPSU:1C\JP@M_WT* ,3]DS_ )-\\,_]><G_ *.DKT:O
M.?V3OD_9_P##2-U6SD!_[_25Z,#GI0 4444 !.!FLV+Q7H,VJMH<.LVKWB?>
MMEF&_(Z\9S5C5;.2^T^XLXI&C::%E5UZJ2.M?,_BKP7XL\#W3VNB^%HUUNQU
M.2\M?%GG;LH6R5E&,G(R.>F>V* /IY9B6V,5SZ"O._B_^T!:_"S7+;0;C1S(
MTT+2M-),D:[ 5&U2[KE_FX'/2L.V^$-_#X.?XBZAXWN&\5-IQNGU+[4XM4?'
MF*OEY*[%P%SCD#WKKOA]_9/Q1^'NDZSXR\/6=Y<^2!(]Q:JX:5< R+D="1N&
M.V* ,6;Q_P",/'_B\^'O VJPZ;:VNEK=W=Q<0XF+R+F)0&##;PV_C/ QBL7P
M[\7/'_BR6'X;V\]N-<AU">'4]9MH1Y"PQ<ET4Y)+9 !VD9STKNOB)\&/ ?Q'
MB3_A)["9?+5D#V=X\#%#U4E""1[=*P=5^&X\!OH?B/X9Z6K6^BQR0WFGJQ9[
MF!NP.>6!R03GF@";PQXV^(WAKXC3>"_B?/IMQ9WT?F^'[VPA99&"E R2Y.-V
M7R-H'"GK7HGFO_L]_P"=>9:;%XU^+'B;1]>USPI)H>EZ7*TWV6^.;B2?/!XP
M -N[U^\/2O3'4!?N_I0!'?7Z6$$ES<2*L<<9=F;H  23U] :^?\ X&6?_#0/
MQ[U']HR\A?\ L73X6T[PW;S\.K*BAY<#*D'?*O7M[59_;=^-=QX.TK2?A-X4
M1KC7/%]^FG+';J':W@E5U,CKG<!GOBO5OA'\.M+^%'@?3? 6CPA;?3XV16!S
MN)8L3S[L: .H1!&, G\:=110 4444 %%%% #9G*1EA7RU_P4*\6?$?2-)TO3
M?!/PWU+5DOI#!<:G:VL<D-AN9%\QU+;MH#\X!^Z:^I9ON5\C?MJ>)OB[X0^-
M7A:Y\!^*UBBN[@".S56F\O!3<9(USE6Y].":<9.+NG;Y7)E[WN]_.QYI^W/=
M:/X0^$WPW'Q-F2ZDN-'6#3Q'97!QJ!AC"LS)C;&".0W&>U?7O[*$6JQ?LX>"
MTU&VAAF.AV[-#"VY44KD $'G@BOFG_@H9\5[CP1X,\&ZAXE\,R:]/XDMVT^Z
ML8X)6BM9)(D)G 0<8QU;@9]Z^E_V7M.DT;]GOP;IWV18=FB0'R5?<(PR[MN>
M^,XIRE=+;^O(KEC%777\/F>D4C$JN12TV1U53N/:I X/]H/XEV_PQ^&.I>()
MGQ+);R06:;<EYF1MH R.IK-_9-^&<_PM^#NFZ!?R.UY+--<WC28W%Y'SS@#L
M!VKSGX_6=_\ ';]IC0O@QIS1MIOAR2SU?5_WF.DIW)WY*2+QQ7TE#$(@%"__
M %N* )**** &RYV<&O/OCY+<:CX;A\$VI/F:U<I;^8I_U2C+EOI\@%>@3@E.
M!WKYL^+G[2WP^\&_'P77B6ZN(XM!TMXY(X5$ADG:0QC:O? 9ORIKS#?3[_0[
MCP3XF\/SWOB;Q]K&K6D.F^&(6LEN[QA"MHMNCO-(SMA50(P)8X  R:_#7PK\
M5/VI/B!^U%X^_P""G'P \!+<V?@WQ--KFJ37]RD4-G:SEQ%%+&+E9'5H3AXX
M78D,X'#8/Z7?\%.?VA/"GP9_X)C>((-.\2Q?VYXXM[?1F2RN/W\UQ=I^^W;5
M.,V\4Y(8*&"E-V< _"O[.'PA_:*_9&_96\!_\%(_V9=?U/6[.^FU"Y^*'A]-
M0CM]-AL[*]DB@CF4,DDJL=^Y0K$,&(R""?S_ (JQ$L1F%*A&]J*=23CK)=(N
MVM[/5JVVI_7'@)E\,DX+S#.*JI>UQ\XX.C&OS1I5$HNI5IRG=*/M8KDA)M)3
M23O>Q[+KW@WPE_P4X_9YA_:W_8WDDT;]IKPG;P'Q'I_PY5?#L<E_>SB.X>:Y
MN LD["T2?:ZW)[@E\A:K^!/&\W_!:+X'>(O'.L066A_M)?"]IKKP)'\/83I4
MUY9B&)K-9[R[:4X%W)<D!+B(H3OPN=[6?%7@30O^"B?P?M_VY?V"W_X1W]H3
MPE'')XH\.^!\V'FWM]+Y4K/=W*Q[MMJ+@AD<@C*9R0#5T7Q?'_P62^%6L_&S
MPEIUOX1_:&^%;R7/A33_  :K)-J-JL<;V9:ZN-J(/M4EP  ^5/S$#<#7+.T\
M1RWYW.-[1TC5M]J/\M2/5:MOMT]ZG&6%P#G#]Q]4J\JG4]ZOETJC2]C5BDO;
M8&O>T)I148RE=NSO/^SG\7O!'_!12UU?_@F]_P %*[;3=)^('A-K?P]X&\1:
M5IKSZ_)/8>8VI^9J4_VN)9V^P1>;-^Z$N]\;B0%P?@/\8_BTOC]O^"2__!5.
MTM&TW7K:2+2=:UMI-;UZVU2]95LG@NQ+=01%1*QB9H@(<+EEY%=#\&OB;\.O
M^"G.DZA_P3W_ &[=.TSPI\6O!X@T/PCXDM;1[S5KN^M YU1VGPT*R,+!!(=R
MA@[;2W&,/X5?&KX@>-?$<W_!*7_@J/I$=M>:[')'HWBS6I?[2U6UU*[*1Z?Y
M;1-)""%F.QC@)@9*BIIU.>-*I&HW>\5)JW/K_#K7V=]$W:ZZ&F*P?L)8W!_5
M(TO9J%:5"$^:6'O&ZQV736E2E)>]6HKF:DK<RZ'@_P#:"\>_\$ZOCW<?L ?M
MRZ;IFO? '5]4O+S2[[X@1S>([I-!A66+2?*C@EDBBB\VSMV$/V?Y'+L%3Y64
M^,;?M#?\$:/B;_PG7[/<D_B3X%>-X+>QL$\>:F+VP%U=?Z3.T5A:2P-%((XL
M*[0_<)4[C@";P7^T+XI_87^+%U_P3E_X*'>%K#Q!\'M0U6ZDT?Q%XV+:A+!X
M>MA)%IC10VOF!8FDLH66,J&1G;@8%-\>ZC\??^",7CS^UO ]O<>-O@1XQAC@
MTU?$UTHL([R[_P!(F>*VA<2+(L43*"44%6;.2%%1*?+AW)3<?9R6MO?HWM>,
MOYZ;>S5EY]NFGAY8C-(0>'HU7C*2DZ?.EALR47I5I2VP^,A>\H2<F[KW5=IR
M?M$VOQ1_X)I^+=-_;U_X)XSW>I?!KQ[IYUN\TW7M06/08+S468P1IIEN]K*L
M:P-$(MT;-&-JLQP0-?XX^#/!_B_X5:7_ ,%6O^"7,T]GXH\,W<+_ !,T#PWY
M>AZ*;2S@DO\ 43/;,MM-=*UPL*RJ)7\Y. &90ZY7Q7M/BC_P2V\7VW[:7[%O
MVCQ5\"?'%N=;DTW4;Q+/2K>XU%G-M"+162;"0F+8Q0$# ;!%:'Q;\"^'X_"6
MG_\ !6;_ ()DZI+]JT>ZA'Q/\(^&X?[.T^.QMXFU'4A-YWE33JTD=O'(J;MX
M/RY*C&D^6,JM**:M:3@MXO\ Y^49:IKJXI7.2C[2I3P.-C.$W-RHQQ,](5[:
M?4LQIW3A42LH592BG?9VNJMQH'B7_@J!^SG'^W#^S3?7&A_M.>&YO[/\26'P
M[NAH,,JFY:-999[@B:9_[/$9W+<L-J[2!@1BU\+?B7X&_P""T7P9U[3?B#::
M)H7[1_@O[3KG@:?P!I#Z;>7-K96ZI913:A=B95C^W7;$QK/&P*I(H0!F-36]
M#\5?\%'_ (,_\/"?V.'F\+?M!:!,=.\2^&_ \RVJ2;[AH5F>YN2F\FP2-OE8
MC!VU;\)_$3X:_P#!9CX7:IKJ:%I_@W]H[P"9]<\'0^$;5A>7]C80J;6-[JX
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MCVPT?PSXJO(Y-2U9]:N6VAS*GF0K(J2+A]P7Y1ENN*'@_P",?CG]EGXH7O\
MP2>_;QT.'4OACXFOKJ+PYXL\62&_O+30U5[?1V@BMS(@7[190LL;+E&=B0J@
M8FC5]VG4C4;L^52:U6O\*LNU]%)^IT8K!2^O8W"/!P7-35>6'IS7(_=O]>RV
M>SE;WY45SRN^6_:#Q/XV^,__  2!_: 7]G;QK&/$7[-WQ%U:ULK&X^)%T=<"
M:"GE_P!I-;VMK*JPY^W2;U>W(DVIA'VMNG^/?_"WO^"97C:U_;A_X)\S7&L_
M!/Q]IZZM+8^(;X)HL>H:H[R11PZ7;R6LJ(MNL BWH3&H"LY(X=<_$+XN?\$C
M_BZ?V4/CIHG_  FGP \>:C;:7H>I>-+KSX;;159#JDUM;VQ<J?\ 3V+HR#?Y
M2D _-3OBQ+\7?^"5?C.+]KK]CN.3Q;\ OB+9_P!LPZ;J5Y]ETF"[U-V>WA2U
M0I-F.V2 (SID X;#*0<Y2C3P\XN4H^SEVO.B^MOYJ7R6G4UP]*IBLQPT_9T<
M1+&4[7E+EPV9I=)WUP^.BMU*3_>)^ZKV=C]H"'Q!^S]I_AO_ (*[_P#!,I_.
M\(Z_;S7?Q/T-9AI_AV">$1:="ITU&M;B9#<27CX9I,2XD&%;YM#XA?#3PQ^W
MS\"K']N?_@GS>7^C_'S1[.RC\>:-\/9AX;MWU&9?/U)Y))A%)<.&E<;Q<N&7
M@L^XEL[XMP:_^RE+HO\ P53_ ."=Q;6/AGXNAEO/B/X9B86&BVLMNL>GPQ/"
MY2>4&\FNV^XVUP6^ZP)O^/?AAI7[8WPHLO\ @H7_ ,$UM6FT/XP:?:V\7C_P
MOX*4:9&-0NQY^H.\UR8S(X#L"59@R]SFMG_$J4TGLI."ZWL_:47W>[5G9WU.
M&E+V>'PF-YTN6;H1Q%7:-KQ6 S.GH^6-G!5[P3BXNUEIE^&]4\1_\%B?@)K7
MQY\-7"^'_P!I/X7R/'X?A^&LC:*;ZUN#&MN9[RZ9V9E$=[L"7,>PE\@;P6U/
MV=_C!\+_ /@JMH.H_L6_MZ6FC:1\4=%F73/">L>&]&E.L/!9+YEP'U&Y%U&I
M9X/WGS(),G +,#67INK:Q_P5L^$^H?M4?!6/_A$_VA/A+(T&FZ3X*Q;R:G:7
M#1BW=[FY(4%0MZ557X^8$#<,Z7PA^)GP;_X*V^'+K]D7]K?2M'\(_%W09(],
M\,:UI=C+<ZI=I:)YMXQN'5H5+-"^[YP&W';DXJJ<N:K!<W-[167-\-=;6?2%
M1.ZU^[H/$8=X7!XA2H.BL'5YOW<N;$99)M/F@K-XG!3NI^ZERQ<ES75WC_L\
M?%OXB_%?QA-_P1W_ ."JVFV4?EZ8\>A^(+PMJGB)-<NI$N;4B_:2[MU86EW<
M!9-@V1A4+ [LP_#S]I7XE?L'_&R;_@GG_P %$M%T_6?@GJVI7>I0WOQ"AD\1
MWR:,BO#I0B6"6:*.$3V4!$+0 QNSL%3*5:^#7QD\:?M#:O<?\$C/^"GFCPZ7
MXC@L7?1_&.H,=2UD:W-)'/:+O0R0+BTNY%5\@!%56(8D4SX??M)^,/V+_B)+
M_P $X?\ @I3X/L]2^%NL7EQ?6/B'QE,^IS6VA0QO%IACAM3+MA-Q8)MB*[D:
M1B0HP:QI5HTZ<*KJM.,G%3DKI6=O95EH[+92=M?QZ\5@95JV*PDL'3GST_;R
MP]&:2J:7>89=/5*;7O.A:<KI+TK_ !*U+X\?\$9_C6/!?A.:X\1_L[>-9[73
MM/?XB:E_:MO]F=8Y=2,5G:2Q")\RS@[H-K@ $.3\TO[0FM?&#_@EKXYM?VP_
MV![Y]:^!OQ.TM=1CLO%-V?[%@U;4I);@1Q:9;2VLD(6UM[<1L\99$8HS$\*>
M(M?^.7_!&?XF2?!K7[6X\<_ +Q>UOIFCWGC*^5K9895CEU&6*VMF)1P9I5*E
M &VG&<\R?%OQ)\6/^"3GCBW_ &F?V2+:;QA\ OB9IW]JZ;I6L7 M=*M-3U%Y
M)HXH[9&69#'9V\"JSQC"DJW( #E^[C.+<H<CV2O*CYQ:MS4Y>6B7X1AZ=7'8
MK"R4*&*>+IM*3DH4LQC%+W:UVW0QU-W=Y.\I\UHWWV?VBOA9H>B^%](_X*J?
M\$E)KB/3M.N/M?CC0]%V:'H<=AIT?F2B2QVVDT\;RQ?O8PS"0,2!C##,\3>'
M?'W[>GP$TO\ X*8_LGK<Z;\=]#NO[*^(^C^"+I="TYHK=Y+B660S.LUQ(UL;
M/<1<N"@1 N4P-#XU?"G3/AC9Z;_P5!_X).W<UQX5@NO-\>>&=%C72])33].3
MS+E9(Y?+EEB>2/YU"L3DD9X-4?%.B^._VP_A7I__  55_8C$^C?%;2;A=)^(
MOA'PE,+"W6.!I)I9))IBCR[K7[&K!68%=N,%64.JN:K.#3;E'GY8;/:U2DUI
M==8ZMW9C@:E2G@\+BHU(KV=3V$:V(7OTFTTL!F$/=;INW+&O[D4XQTZ+2\"^
M-OA=_P %D_@1JOB'68=/\/\ [4'@NVO-;\-R?#W36TFXNFM4*:;'+?70E_=F
MXDC.U+A65MK#9M)K/_9[\=Q_\%)8=:_X)^_M_K::;\0OAG##8^!=8T.U:77I
M[JS$L>H"?4KDW46XR6UL9'0Q^:V2"^%*:.B^(/A!_P %@OA)J'Q-\%PV/@W]
MI?P/#=:]HVG^#[,Q7-[]AC*Z?$UW<#8$:Y= ") 58!L+@UG?"3QO9?\ !432
M=0_8/_;%M+;PK\5_A;'':>&?$EBINM6U*\M1)%J:RSN&A5VDMK;>0X#LQV_=
M%5&7M.22?/[16OM"M9/27\E1=+WN^A.(H1P.'Q=+V,L,L)44G'FYZ^6MM?O*
M&WUC!S>C48IJ+OS=7G_LX_M&^+_$GC:;_@DQ_P %9M(TEH4TV33]%US5K.36
M_$$7B'49(_L16]:2[@29(;Z;RIS&%A"JID&U@[=&^,WQ:_X)E_'>X_8?_;"T
MRUUK]G_Q7K$PTV\^(3-K\R>'X-T=LT$-O,\<292(M";?()W"-0/EM?!#]HO4
M_B_K-Q_P2F_X*O>&K&SUK[!-9Z/XPUSS-3UA/$.H2(-.(>/S8=ZP7[[)"0J"
M) S?>PWPS\:OB+_P3V^*DW[ G[=N@6^M?!7Q+J4MOHGB#QI=M?-;^'[=GBMY
M(8+<OY:%HXV\LKE3VP,UE[;DIPJJH_=?*I27O1=_X=9:-IZ)2T74ZJF!J5,=
MB\$\#3?M:?MI8:E->SK)+F^NY;4U2JQ^-T?WDFK1\E!XMU[XX?\ !&WX[_\
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M##=Z@Q%O&FEP/:RB-8FC$6Y&,?RAFX.(_'U[^T'_ ,$9?'?_  EWPY@F\:?
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M2"+W@SXC?#'_ (+2?#K5M8U'2M/\%_M#>!'FUGP='X1M7^V7^GV,"FUC:ZG
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MPTFP\9>'HX?#G@76K726OM?^W(T@OF.HRF[@28BVAWRC8K[CRQX1GA#Q\O\
MP5J^&VK>%==T^U\)_M%?!NUEU7P*WAI6_M'6'T^':L<EW-^[AW7\T.2LBMO
M8?*&(L_!'XU^!/V_;>__ ."=?_!1'0M,\/\ Q*\,K#H'@_Q4]O)?:O<:FK.+
M]GDP\*2?Z-'E]X5]_!Z54:DI5*<N?F<URKF5HU;7]VIMRU%LFWKVZ%XW!^PP
M^,I2POLEAI1J.G2ES5L VXM8C"O55\)/252,5>*YO?5KOS+QU\?_ -H;]C70
MO&W_  3C_;6T>QO?!.N>&]<U+PGJ'C*637=3A7[)/#HGD2PSRQ6Z"ZM(&53$
M#$[,_P"[R&'HO_!$;]O3X!_LG?LO>)/ /Q7A\5-?:IX\N;ZU_L/P?>ZA'Y+6
M5G&-TD,;(&W0.,9S]TXPPKA_&_[2'QJ_9<\#^-O^"</[=WA2WU+0]0\,ZU>^
M#?$7BF^>_OH8DLYHM%6)8#(D:&ZM(MBL%\MI"QVBNT_X(D_\$_\ ]GK]JW]F
M?Q+\0OBJWBQ;_3_'EU86YT'QA?:?"(5L;)PS103*C/ND/S$$XV@]!BLCE_QD
ME*G&;:C&:M)>_#6/NONE]E];LCQ,PZI^#6/KU,/"$JM?#3]K1E?#XBZJ?OH+
M7DG))JK!R;BU#17.;_X)V_'7POK/Q-_9;^!6H^&?%6D>)M-^*WC#6);77O"M
MW8H;>>VU22-P\R!3F*4'&[.?RK]L(CE?^!5^)/\ P3I_9\\$^&/BA^RQ\=;;
M7?%&H>(M0^+/B_2IKC7/%-Y>1_9X;758T58YI'4$)$OS<'K7[:P*%CPHXW&O
MT>/PH_BD?1113 *BNEE>-EAEV-M.UMN<'UJ6D8+]YATH ^2_B=\)?BK\-_AG
M:^"_B/\ %7_A+[C6_'PN;1CI@@,$+2;UA&"2^W'7CZ5]6:<I2WAC(QMB7CTX
MZ5XG\==7?4/VHOAKX-)#6K237DB[<J64,O7VX->Z!%7H* %HHHH *YOXF?%;
MP=\)-%3Q!XVU);6UDF$,<C,HW2$$A1DCG@UTE>(_M>VMGJOBGX7^'[R&.6.]
M\?6RW$+#.Y K=1Z<_K0!T.F_M=? W4IO)'BZ&'_:N)HT7\]]:L/[2'P.G@DN
M/^%I:%&L:EF\[585X'_ JVKCX;> )X-D_A*Q=>/O6X-<.W@GX%^/_%.H> U^
M&^FWPLX%^WW4,:E(&8?ZLE>0QP>.M &+X2^+WP^^,?C7_A8Z_%+2E\.:?F/1
M[/\ M)%,MPKKNN,@C*X!7!)'\J]07X@^!]222'3O&NF-)MP/+O8V*^^-U<;=
M?L;?LWWFU9/A;:KL4*/*FD0$#Z,!VJG-^PW^S/*FW_A7&SU:'4)US]<24 ;7
MPU^*$TOB^^^&/B;4X[S4+5?M%OJ43*(KF%L$*N/XE^;(YX&:[X7D;#<I!7^]
MN'^->$^)?^"=G[->JZA;:U8>']1T^[L_NW%KK5SGR\?,@S(< ]Z;IW['WPN\
M06KW/A;XBZTENLQ5H[?4B^R0=5)SP>G'6@#WI;J%A\LB_G3T=7&5;/TKQBR_
M9$GT=,>'OC/XELBWWV61)"?^^AQ5B3X"?&[3T$7A[]J'78XQ_P L[K3+60_G
MMH ]@HKPZ^^$O[8D<K+I'[1MHT:_ZMKO24W-]=J8S20_#[]N'3V"0?&[PW=1
MXRQN]+;.?^ I0![E17ADP_;ST4^2]_X)U3=S'-#;SIM'H1M'-4)?B+^W3:.8
MY/A'H]QLX,D-PP$A]0#T% 'T 4SWH\L]WKPBU^-'[7=H@AU/]F][F102TMKJ
M"*I]@&JRG[4/QHM$\G5OV0_%$<R\2>5?0R*?H0* /;A'SEC0T*-U_6O#7_;(
MUV!_+NOV</&:N/O*+7=M/IP.1[UHV7[8?A^2!9-:^&'C"R9OOQ_V)*^S\0O\
MJ /7C:H>R_\ ?-0:A9V36KO?+&8U7+&1< *.N3Z5YS'^U_\ !T\22:U"VW++
M<:#<(5'N"O%<1\<OVW?@8GA-?#6E^+7DGUNX%@PCMVW1)(I4RX/9<CF@"7P!
M\%M,^'/[1.L7^LZ@NKZ;XIB^T:<9(R%M76% T?4@@^0[YR.6QCO7LTWPS\!W
M<'D7/AFUD0X.UE)'\ZX-?V@_V:UT:&*;XC:'(UD@:!9;](6& 1W(QQGKUR:U
M_!/[47P%\<Z)%K>B_%OPZT4DC(L;:U!N#*VTC[WM0!NZE\(/ &JQ^5=Z#'M_
MNJ[*/K@&L>3]FKX3RC#:/<J.@6/4)0 .@'WO2MJ/XN_"R7_5?$G06[?+JT)_
M]FK4L_%?AB^(2S\1V,K,,JL=TA)'KUH Y'_AFGX3\'^R;O@8_P"0E+_\56?J
MO[+_ (*?5['6M!NI[.;3Y'DM6>1Y=CL,$\MZ=J](&HZ>>E]#_P!_!3A=VIX%
MS'_WV* ..\#?"_6?#>O2ZYK_ (T?5I-OEVH:T$7D1X;Y>&.>6ZUVM(KHQ^5@
M?7%&]0,EA0 M%&1ZT;AZT %%&:-R],T %%&>U&<=: "N7^+EG=W_ ,/-3L[&
MV::9H0$BC4DL<CC KJ-P]:\]^)_BS6[S7K'X8>"KZ:'4[^19;JZC0-]EM@&R
MY[#)"@?[P]: /F7]D_\ ;'^(OA#4I_A;\5O@WXGTW3='LRECMTLL\Y,F=X!5
M>/F8]6^[[U[];?MF_"USLGT3Q#"V?NW&EA"?IEZ[+5?!CR^--)\:7&M-'_9M
MK) 8W(592ZL,GW&:Z0V-I<[9+FW#L.A<<B@#S%/VS/@;L9IM?DAV\,)55<?^
M/5K6O[47P+N/++_$K1X1(N[_ $C4(DP/?+5U4_@3P=<LSS^&[-V<Y8M".:J2
M_"?X;3AA-X*T]MWWLVXYH I6WQZ^"MX,VOQ9\.2!NFW6(?\ XJO)_B%\,_AI
MX]\0WU]:?$_0K>'4FDEN+K^U\S([C&U5#8V^@SU.<5Z;J'[.?P5U*5GN/AUI
M_P PPWEQE<_D:YZ;]B+]F6;=O^%EO\S9^6ZF&/R>@"EI?@OQWKGA?3_A_??%
M;1O['M84M[B:RD$DU[ JA1$PPNSY1C<&/6O5="TW2/#VDVNAZ-$L=M9PK%;Q
MA\[54 8SGT%>677[!W[,=X"LOP_G]-RZQ=+@>@_>U6;]A#X+6X9='75[/;_J
M3'K$[>7]-SGI[YH ]*^)6E:GXJ\$ZAHFAW\5K=7%NR0S28*ABI';//-8'P*\
M#^(?!.F7EMK,B1Q37!>"T\TR%#@ MN8 \XSCH*XZ']B#PU9DM9_$GQ)&Q;</
M]*)P<^]:47[-/CO24,N@?M&>)[61%Q$&AMY%'U#(: /6D&'X7'XU7\1:C;:-
MHMSJVHSB.WMK=Y9G9@,*%)KR2^^#_P"U!%;AM%_:7F:;_I\TN J?^^8J\B_:
M%LOVL=)GT/X6ZE\<+75F\577V.\L[/3!E;<D!V?"91<'&[C&: -S]E?1[[]H
MGXX:]^UMXIM&_LZ5AI_A:VN00\,<14[AC"L-_F')SUQQ7U5Y?S;L]\US?PT\
M :+\,_ VE^!= LUCM-.A,<2QL=J9)8_>))Y)ZUTVY<XS0 4444 %%%% !113
M9&*+N S[4 $W^KYKQKQ]^S5X.\7?&%?C!XF\0M#Y=KY'V7>T6!L"YWK)CT/3
MO2?MA_M5V?[.7@R&UT#3SK'C3Q$PM/!GAJ'#27MXTB1J2 =WEJ9%9S@X4$]C
M7A<'_!/3QU^U'X.C\<?M_?$K5M=N=4MWNY/!>EW#:?8Z0K;F6W22V\N9\!8<
MEFZJW]ZI:OU:]'8+V/7_ (I?L]S?%#4]+N?A[\9K?3%L]/\ LEQ:QVJW8GCW
M1C=C>"#E ,]\UZ]X$\.3>%O"6F>'[O48[J:SLTADN%CV+)M&-P7G&?3-?G!^
MQA_P2Q_8RG^ R_&7[3K'A'Q5;>,/$EEI_BO_ (3:\)MTMM;O;:W_ '<TQBDV
M)!$-K##%26)SFO8O@W^TK\:OV6?BYI?P+_:2\<V_C#P#X@D^Q_#_ .)D+PCS
M9Q,BK;W1B58_,VRMT.,6K<G)-$:>\G?YZAS<VC/MQC@9K)\7^(+?PQX=O/$-
M](JPV5K)/)\P&0BEL<\=JO6]Y;7$44T%W'+%,BF.1) RN#R"#WR*\'_;B\3^
M(IM#\-?#+P?:RW5SXFUY;6\^RX9XK4KM9B.PS(G/N/6J ?\ L.:=K'B7P=>?
M&WQ;N_M7Q)J,S;IH=L@@011JAZ#K$3^->^UE>%?#>G>&-"M= TR+;!:Q[8\_
M4G/YFM6@ HHI&.%)/IVH K:SJ$6EZ?)>SOM5?XJ^>3\/M-\7Z':^'?%-K#=Z
MEXLU1M0;$ACE73V1F R#P0P'..]>G?'^[U>^\(+X0\+WRPZKJEPD=F9,'H2Q
MX/\ LJWTQ7/^ 8;?Q!\1+WQ48T>'P_:MIMA=)]U$4G<O')XY]>PQW4G&,7)]
M UE))?UHS\C_ /@OS>_#GPK\>O#OP%^&+"W70=):_P!8MEF$BQ7=RP$88[V8
M-Y4>_:P7"RJPSYG/8(WBW_@G)J>@_MA_LN:;)XB^!?Q.M[:XUWP9:6[ZH=(L
MX((WG@GN6\R.%A<RSKNR"NW9SL-?.4/[3WP?\;_\%%/$7[5W[3WPYOO'?@"^
MU[46U"PL[ 7'VBW,4D%EQ,\:X51!@.X(2-<#*@#Z=\>>.O$_[ $6C^*-,T^#
MQQ^R?\756YT_X?ZI"VH7FB6CHEW=VZQ*T5K;L9[F7'[QQA0IR5+'\FIXI8C'
M8G,.;[=HR2U@HZ1;7VH2V:5WIL?Z"8[):W#G#>1\(JASVH2E5IS:5+%3JI5*
ME*$K^[B:32G2<N7164DY-.Y\5_ ]KXB\.Z;_ ,%9O^"9NHQZ?XLM@]YXO^']
MD_\ ;%Y'>7S"R5?LD&Y(]D,L[[2G0%AR*=\0/%&B?\%#?"7_  \$_8RTA? _
MQ-^$-PRWGA!I%N[G5[2U1;JWECL[<%3NFNG7+J=QCQS@4[QIX8\3_LT?#"S_
M ."F/_!+77VTSP3JT(U#QG\+_$5\9$#W$@L[6%;"R39Y<?G2R8>?*E0P9\!:
M:NH>%/'/PRO_ /@H=_P2'T63X9_\(%-)9?$#P'K#BUBUNVM(X[M'6SLC+Y^]
MKC8=\L88(!P5S7H2YHU'3?VDI.,>MM54I2Z=Y1=GMIW^/HV>%ABJ.KIU'0I5
MZRUII^[+ 9@K24HM>[0J6J))[P2M&SIE]\*?^"R/PQE^&?B73X?AK\>_ %G:
M6MKJFL7Z6?\ :^H2L&U5ELH]LLC!;*4%&4M&9EW8PU9W@#]HV;_@H5X*N/V!
M/VV/ [>%_BHT<UYX<\8ZQ&FCA-03$=A$8<))+S,I"<F38<9(4U:^&GACX2_\
M%,_#=Y\7/V0=*?X.?M*>"H;:?6=662/2;#5]6U$D:E*/)$]U( L-ZJ<(P\\;
MQ\S%<OX5?%WX=_\ !3F23X:?$'X<KX)_:?L89=6\,_$32;&/3+4W5EM73XY;
MB1YKG&YXF;;#N.PE=N%!4:DI2I^]&3J)J^T:R7V=;<LUM]^I5?#T*%+%4E0J
M4J>$E&:@VW6RVI)<WM(N[=7!U=9N*E:-]8?S:/PC_:$\*:A>3?\ !*3_ (*9
M^"I&T^SU&30M%^(=RJ:';Q:3I*_Z-()Y0LCI++8L1)NPPF49SG-3PS\:_BI_
MP27\?WW[+W[2'A6X^(WPCUB)Y=!U2WTW9#'=WC AUOKE3O*6XDW*&)Y4@#!H
M\"?$WX*?M>_$*X_8$_X*9?#UO^%J:7JLWAC2/BWX=LHX7%CI6Z4R27M[(TC&
M>:WNAY@A <7' 4LQ6+Q#^T!K7[+'CZ3]BC_@JIX0A^+W@Z&".[\)ZWI]BVH7
M-M=7!\NW<W-Y) BJD'G?*L9*EA@L :7M;T_;1J?"^6,W]GI[.JNOD]>YO_9]
M*MC)Y?/!\ZJP56KA82TK.^F,R^>T9-)\]->S?+T:VDE\:_$'_@CQ\3KB*WL9
M/B5^S]XV\_7M'73[3[7:Q0S,\>GQ?;IE>/>L2Q'A@'Y;G<#5WXD?#Z7]ASQ#
MI7_!1O\ 85UJ#Q1\-_$T]MIOQ \%Z66UJ2WMYC]OU'S'&^*W CMDA+D*8R>V
M[#5/B3\3?%G_  3I\<0_LN_MM:/;_&3X :M"VI>"[>-&U:^LM/B9H=-@,D[6
MUO&R)'&S*@9<EBK8*J;_ ,5?"7B;_@FAI6G?&KX"^(E\9?LR_$:6#3?%WPYU
MV8ZA<6_]H(;J^*6T"PV\;"TM_)5WE8J9"&#[MPJ7[MU%*3BJ=FNLZ/FNDZ;Z
MV;LNAE'FQ4L+5:C5JXQ.+GMA\QIQ^Q-6_=8RG?XG'633Y[V;H_$:X\5?$GP_
M:_\ !7__ ()RQ?V1KREK#Q=\/(+7^U+J.X,ATY)#;0!DC0VZ";#)DAEDK3\<
M2?"O_@IK\.YOVV?V2=/C\#_&3X8W/VH^%_MR3W.I:9ID9O!Y5C"?F+W=S @9
ME*LT94Y!6LSQ#XG\6_!3X6?\/-?^"7TT6@_#77-T'BGX2^(@61+WSCID;BPL
MR4"8C,VY[ACEBP&#@7M.\(?";XS?#&^_X*"?\$E;6[^%WBCP#*]OXJ\'ZM<1
M6-MJFC6,/VZY"6EF)GF,LKVB;7D17\K;\A"LSN_:.G/6ZYIQ7VGO[6D^_>-U
MT,^6GA\/#%1YJ;I570HUZFOL8WL\!F$=>:&MH5+37*WLE9.TWQ?X<_X*_P#P
MUN/V?_B)HZ_#WX_> [.&6VU_59%L&U.\DE!OE6TCV3,PMX6.TC*"3)&,BD^&
MG[1G@+_@I3X0;]BK]OKP@/!OQ.TFSGUG3?&>L-%HOF:IO\BP@,6(Y&;R;Y"(
M\Y=8]PSE35;X8ZKX(_X*::%?>-_V<- _X5)^U+X/MX[[4_$T&W2+#6+JY.R\
MPT7VBYDVVXN-N5!W2?-D'<#X0^._@%_P5?N+CP)\6OA_)X!_:2TBQE\0+X^T
MFUATJTN;FT=;?3[=Y97GG*XFM691'G,1*GY5!5*I5K.$N93=1-:Z1JI:6?\
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M^5Y?B#\*]>D'DOY=P--M$33[+<-H=KN=M\X^^''5@L6CWW@OXZ_#C4/V^?\
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M)_&7_!,KQ-IWP-_:'L[/XN?LP^-/-N-)T6YWZO?:=8VN&ME4N;:UAD-W)"Q
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M3M#%V7NXO .T53JQO>M"U-\S:UU2T/&FA:S_ ,$G?B-:_'S]D^[C^('[/_Q
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M7%<L<1/$WIJM/W:>.I1NOJ^(BT_9XR'*E&;3NX)J>J;N?$3PKX2_:R\(6O\
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M;M*M9-:TKQGJB)I'VC4EE\JUMOLV$F=S:7@Q&1AC%OQ]VF_!S]H_P]XY1_\
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MWC9(VP22+^/_ ![FBR\;_M2VDI?5OAQ874:CA;>^D5B?K]GKV78OI0$4'(%
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M\J,P)&Y2P('^(K&^%7[5,7Q%^)+^ -3^&6MZ#_Q+?M=CJ&IH%@O3G!CC/\3
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M?^Q]^W-X?L_B3\$_%%VVGZ)\9=0C\O6-'DO%S<7< F:]D9[:)V" 1H24X.,
MU=4\;P_L+?!ZQL_!/A.U^-W[)GCB<3Z+KWB[;'>:%?S,]JT41F5R!%]FEG&V
MS3YIC@YRQ4N:C*RFZ?LU=7UG2;Z6M>5%];7MIK9$T8_VC2IU)TEB9XJ3C+ED
MH8?'PWYXW:5',E9-)N,VU).#<FG-X@^#>F_!&9O^"F/_  1[\0?VI\.M/Q;^
M/O!\-DUD#I-B/M>HAY]68S,)?*5-L4!9=Y*@\T:MI?@C]I>TA_;B_P""2);0
M_C1X?4ZK\7O"EG'*3--JK>=/_I.J^7;,(V@O!^X0[Q)T085IO"'PNO\ ]D#X
M5W_[6'_!.#XBWGQN^"4MO=V'CKP'XTA>."VTZ%?M&I7'[YH$W,D7EY%JY"S,
M<3#@YWP6\/\ AJ--2_;2_P""2WB&XUCQC*J:A\4O@IK$;-I.G?VCYDOV>)\6
M43QVI%W''@2@@+MV@'=<8K2*BHW7,X1>W:I0?ENXQ;=]&N@5*RY:F+C5G5E2
ME[*G7KQMSQ=D\'FT6EK;2%6:@N:S4FE=7@G[-?\ P5=LO^%[?LO!/A]^U5H*
MMXQN-'MH;J^^U_V9_H]G )[KR+&,R2?V>WF8(3HRL S4FD>._@+_ ,%*-/F_
M9%_;9TU?!_[2F@QCPIX;\32-<ZDUS>P$O<3LED(K-"TB2C8\NT[OE;%9?P8\
M,? C]L?Q3<?M7?L"^.+SX9_'K3;.3Q)=?!?2E:31[FWTYEBBT_=#%9QB.[EC
MLGD)D90T[@H3N*MT@_ +_@HM\7F\)_&#4YO@%^TIX=U*31M/_P"$,C#6^L:H
MI=[NZE6")65]R2Q\W>2!GS&Q\TRYIP4_<DZF[VI5?[R;^&MV3LVRY4Z.$J5H
M06)HPP<>:#;<L7E\FOA>E\1@':SM&45"^JO=[&C_ !D^''[3,<G_  3^_P""
MO'AW^Q/C#X=W:5X+\8332ZA,^J:NW[AS%I4:VJ^6DECCS)&1\?,4.\5'I/Q"
MN_V(-4_X=V?\%4] _P"$D^"NL,5\'^++F8QFWTZQ^>%TM-,6:YQ).D *R2[E
MQD@KD#,\3>*?A=^VM\7U^ G_  4.T=/@9^T!X9OK6VT#Q'X+52VN:K?B+[#]
MH$,,K?N$6QVYN@3YC;6CQA;?QK\7R^!+[2_V ?\ @K/X2B_X1&6-H/!OQWL\
M?VVEA:-YHFV%;Z4F>6.*-P3'A9&R&'-3=P@ZD9+1\JE)6NMN3$1T][HI.W?U
M<<+1GB88&>'J*,XNM/#49I\DDN?ZWE%173BF_:2I0E/1N/+II):?$6X_8%U#
M_A2'[0'AP^,/V1OBQ)GP+JLEW]ECTW3;LB^G=+> 2Z@Y076S$A1FV!@5+;1-
MJND^,O\ @FI*G[?O[!^HMXW_ &=_&,C7_B7PRRKIT=O'G['8QM+>^;>2_O[A
MGW+$""F&&&R*?Q(\:V_[-?@[0?V2/VL_"T?C?]G/Q="L'PM^-5T0FM:7872)
M=23Q!ENI&,,<T<*XB@)$2@)C:*T-4C\=?\$X_@XOQC^""6_[0O[+_B^..XO]
M*\;*(QH\$<OD6,<;3LRC?=3!BRV8'[E?E4@/3E[LI0<N54U=6UG1>]FK>_2[
M6NN7R,E^]A1;A[66+?)*$FHX3,8)N.]TL/F,4KR<G"3K0O:\K2-;T?P;\$?+
M_P""A7_!&NY-]\-_#[?V9\7?!\,4EI&\=G_ITS-+JV9B'BE@CQ;QL0$!4G)
M35OAG\,?VS-.C_;B_P""2NJ_\([\>/"42:MX^\)V-O,S3ZEK+;9D6ZU5HK5?
M) U'YHT*R XPO[L54\'>'O#O['/PKUK]I#_@F=XGE^.'P5D:33/BOX-\<Q[8
M;,01+<7,ZF001Y>W>WCXMIL 9)<$*)/@E\,_#GBQ-0_;D_X)&_$W5KSXAV+0
M:Q\0/@??1L=)2ZU0R*MDAQ81&&T$E_LSYH_<)M"D8=\O,XT9<MG>3C%Z1ZJI
MA_3=Q3>E]+[U4J1P].IC*52HG!JE3KXA74TVD\)F]-K1:\E.K.,$DX2YK*\7
M#QG^S_\ \%2M"_X61\(](7P/^UKX8D_MG1[2W^TWTFH-I9W6\7VB806$1DE$
M?S/D+\PP5+T[3M9_9R_X*B:>_P"RO^UG9P^!_P!J+0W'A+3?$DEO=:HUY-II
M,U]<,EJ(+)3))'>J4,A W95F^4''^%D?P'_;0\=2?M,?LA:C-\+_ -HK0(WU
M/3_A'H2[])U9-.82&&0Q0VB(+R01+)NG889LJV"PD\.>'_V?O^"C/QCDT'QI
MXINOV>_VH-)U2XT!;7P7$9;75+ZU\R74+^7[/#'LF<_;(RINR<(/GE ^8CS5
M(IWA/GT<=HU5IJD](U?5IM[+0JI1H9?4JQC'$X585*497<Z^ F[Z:)RKY;*R
MT2E%:^][WO:6D_M ^#[%YO\ @GS_ ,%L/"K))X?7^U/"7BZYO)+AC(P^RV<?
MV;1HSM7RFF?=)*?1AR&"Z9\6#^R7JS?\$Z/^"M>@OX@^%+'S/ OBNXN"&72K
M'=#8E+32DEG =HP<22;UW?,"!SE_%+XG_#3XZ>-U_9(_X*\>"K3X6^+/#<,>
MHZ+\3O"NUKW58TS;6MM.%ANGV,LDEP6,P!:,9"_Q6?C1X]TC3M9L_P!@+_@K
M;X,CTS1]/M?*\'?'/20O]L7.E619+>1U*7LK&Z>,,XW(1O.5.-QF527O2C47
MN^ZG)='_ ,NZR:T2VA)I+S[U2P-&K.C2J86HO:IUJE+#RV:LXXS*9+3FC?FK
M48N;^%."MI8DT?QK_P $K-1CT/QQ'_PL+]DOXP8L[B2>2*QAL'U8AY9/)4S7
M\S1:? X"_('#8RK@47WC*\_X)_7H_;O_ ."?UD_C#]E_Q<-VM>&)IO[/BM[R
M/_B6K&TE\);Z4FY62;<L2@'Y22N&J;XG1>//V(? %A\!/VFK8?%;]FOXC7,-
MOH_Q0UEMFJ>%[C4H7C2:U\YKI\VMC'-*@6",EG."I!C:I)XHU#]@'X)O\3?V
M<] M_P!H#]E/Q/)YMU;>-T\IM*NDF-L(8S."/FO-\IVV7WN.O[PUS2I2:B^1
M05[._-1??^]1EN^5M;:I(YZ">94:56I#ZS+$RY)6?)AL?#56:LE1S*"7N.3A
M.4U=1;E[US6_A1X'\!(O_!1[_@BOK8F\,^$]NB?$?P?;V,EKYME!NU*^E-SK
M#[R&3[%&5CB9L %&)!4.U"W^'?[<VG)^V=_P3+/_  B_[2OAK.L>,O#MC#+*
MTTE\?L<J?:M2$5H-D!F;,:'=RN%+9JM\-_AAH_[+7PZU;]K;_@E?\3;[XQ_#
M*UDFT?XE?#WQK;R+:V\(@2[O[[,AMH]XMH[6$?Z/*V)V/S@,JP_!#1_"?Q"N
M[S]NK_@E?XDNK7XO6$*ZEXT^ \T9;1%BNBUI]D5@EC&T<"O-.O,@W1K@ C!/
MM1@TK/WG&'_IS#O6[ZRBKORN4ZC5&KBHU*DW2:I4Z]?1VDTG@LU@[/V4KN,*
MLU",7R^_9:6A%^RW_P %AM$C\>_!>.'X?_M.6&?$5Y806MYJ/VB#3@(+>$33
M_9[)"[?8VW#)0CE3EB8].^*7P>_;4T^3]AO_ (*=>'U\+_'CPXP\/>"?%4LD
M^H2W&IZ@<F1H]-5;1#&1:C$DK1MC[XP2<[X0>!_V??V^O%,_[0G[%7Q$O_A%
M\=H+.35;SX5^'MTFER6%@R1K;JT,-D@%S(+1WS,P'F,"C9W*FK:]\'/VZ_B^
MWPD_;1LS\!_VB_#.H1V&@:QX'"R#7]9O"NQ[G[/"S P>7;;";H$^:VUUPP6?
M:2Y5.\&ZCLWM3K)=^D*JZ7:N]$C6=&C0K5,(HXBG#"QYXPNY8O+YO2]-V;KY
M>[\DE'F2@U)RZO3TSX_^$_''F?L!?\%J?"GV'Q1H :?PKXLFO7NG-Y=_N[2,
MPZ.GEX6)U.YY-K8PP4YP6=YJW_!.W7%_8 _X*/P'QE^SMXLVIX2\37'^CI:K
M99OYG2RT_P Z[.^^N+5"KR KLW LN5K*^(?Q(^&G[3OQ%C_9P_X*I>"K7X-?
M$[P^D-SI7CSP?Y;7.J7$FV.SMIEBBN7*JC+)G[1@LN!LQQJ?'._U+X''2?\
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M_$[]EGXD0PP^!/BEJP"ZMX<M]3A_=SP"5;AM]I8L[(%MXLL!M"?<-B&PUO\
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M6-M'T4K;=3-1C[.GA9PE'>K4PT-94>JQN73O:=.6\Z<9-I1:<;:J%O%&A_\
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MG_:__9!\11_"WXZ>$[I-7\0>%M95[Y-2UEMOV%(KB\>.%0OV5ONVY4^:-R9
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M%W]DC;K@C[P/4?XT 7/A_H^L:)X1L]/\0WC7-\BDW$SMN+,2>^3VK;IL8*H
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M FO1*X?XQ:1H^F:=)\55\.6M[K/A^V>32GN(Q\K$%2,_> (8]"* -/P]\,/
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M_P"$NT&$V=IIMY<XM;@R7$N&!2&VA=E ^59%/5CB];^,?"_Q2^#I_P"">/\
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M']O7_@D=XWEU[1X]0C\1^//A?X>U!=.:Q2S,;6]D]A:.)9?M(@O-L31DN2<
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M^.W_  11\4?\)Q!8+\0/@3XT634]0U#PU8[EC216CL4>YF'RN?,A/4[E5NY
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MTN;;PM\7/$22:LEAJFH1^3&4O)@T$1MXS)(7$@:,*2VT9JC\%K?QI_P3_O\
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M"1 >9.L@D$BY WH#CK3? FIW7['>E:A_P2<_X*0VK-\*=>$<7@WQY8XTVPC
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MCX&_MH_!74-1UGXHZQJ.L13:])&JV\FF2LD"QY7Y21D9QDCZ5] ?$;Q1X?\
M!L6GB]T"*ZDO[Y+6*(0*Q^;J><<#^M;EOX6\.)#Y,/AZQ55^ZJV:!<?E0!Y[
MI_[9/[/-^RH/B%#"6Y_?V\BA?K\M:MK^T[\!;QBMK\4M,D(&2HE(Q^8KI[WP
M!X+U.(PZCX4TV53_  M91_X5BWW[/OP8U.7S[_X9Z+(^,%FTZ/)_("@"&#]H
MOX*7$GEP_$;3V.<?Z[O^5;VF^/\ P=K,RPZ7XDM9FZ[4DSD5SLG[,GP&E7RI
M?A1H31G^$Z<G^%4=2_9+^!E]&([7P1:66ULJ;.%$_#ITH ]"75-.<X2\C/\
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MO+$UU',8+XX^S-M+N0L@D!>3X]?LZ^*/VI[.U_X* ?\ !(3Q5=Z+?7@@\/\
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M[GPWH^M#P[I<$>JEHK2S:R\QV<1+<6FQC;<!47:A0E:_P,@^/O\ P3Q^)_\
MPQ_^VFE_?_L\^+HY])NM4\.Z;CP_YNKD)YCZO/#;RQ*B&3S"LP9 68!BH(=X
M,U_]H7_@D1\?KCQ1X3LM3UW]E_Q'KEUXF,GP^T4:M9MIMUYMOIL<FH7,2A9\
M"T/%P5?*D._F8:$J<*2YHRA&,M'UI3_F3^U1?3?_ "WE4S#%8ZK^\P^+JUZ2
M35N2CF-'^6ZUH8^"N[QU<I)/5>]K_';]FKQ3^T&MK_P4+_X)%^,+C3X]0:+2
MO%7@_P "PGPNUHL*&>\E>X>6W^T*91"K 1$.VU_F"@!WQB^%%Y_P46\*:?\
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M=EJUL]EJ-I'-#(N&CD7((Q0!):7EK>P+<6ES'*C+E7C8,#^529KS.Y^"VM>
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MC/I^FWT8DM[/0%,,D'!4J9]QW\C(^45ZA?64=_936-Q&SI-&R,K8Z$8KY_\
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M&!QA<&K7PY^,9_X*5_![6/V4?VW;"?PG\:M/^T>(/AQJVJZ<N@V\LD<*VEA
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ML_'>AZI<+ILU[]@A-W?30V$ >27=>7"H"ZJ6*LC8*X-?XI:+XR_X)PZ]I/\
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M*?Q>_P""3_Q6F_8U^/\ 82^+_@)XZU"'2=&U/Q7-B"#1SM_M2:"" NV/]/\
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MTW.&GS4\/A,53GR1IS=+#XJ?Q4)WL\!F$79JE%W@JDK1<)1?PZ*CX3A\5_\
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MFV%O>W9#L\=T\=S)))'!&XQY@!#LW!YK4^&7QB^#_P"V!JDW_!,7_@H5\/\
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M>G0:E.%-R=;+JLU?ZQ1E?FJ8*MI-T^9PC)JT5HWCZ;\8?&W[&?Q(F_X)^?\
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M-3U3-**W^$?_  4H^&5U^US^RC;V/PG^/G@6.XUA?"/AG4)-6O-5M=.CW6D
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MC!8VYU"9;QOEEE1U8!/,95!!ZA/ OQ^M?AYXKNO^"5'_  5#\(V?CB_CFM]
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MC]I\0?BW+\7%T"[@D6U\QT;3TLOW31!&*RB8_,#D*,=*]<M\^7@^M $E%%%
M&?XCT"T\1Z+>Z)J#2&&]MVAE"-@A67!P?6O&;C6K;4?'&C_LU>$[FXDTW3E_
MXGDTR!B(4.Y(MXZY,3 D@?>KW:J=MIUC;7\FIQ6FR:9 LK]V R0/S)_,T /L
M-.M;"SCT^UA\N.&-4C7^ZH& /R%/O85:UDS_ ,\S_*I@1T%1W2LUM(JCDQD#
M\J .3^#4*#PM<Q#.$UJ^"]_^7AQW^E;WB>&'^P[SS55E^R2'#*/[IKS7P?\
M&?P'X 34/"OB74;J"\M]8NFD0VCD;7F=E(.WG((-'Q!_:8^'!\)7RZ5JEW--
M);NB*EB^3E2/[OO0!K?LW:?ITWP9T8R:<O\ RV'[R,9_U\GM1X_TS3U^(_AE
M%L8=IO!E?*&/^6E9O@WX[?![PIX;M=!M=6N-L*\8L7&-Q+'MZFL/X@_'CX<7
M_B'1]9T?4+V::SO4)CCL';Y27R>GN* ._P#BYX8\*7_@BZ?6=$@E4*H&8\9;
M< .F.YKD? ?[*WP1U'P5I4_B#P!#-=+:XD?[5,N<,W4*X!JM\>?BE<>)?AA=
M6'@SPWJTMU--"(C':GH'!/3/8?RKK[/XNZ);6,5E%X7UB-5C53_H9^7UH ^+
MOVBOV:O@EIW_  5^_9[\+6G@:--/NO!^O/<6JWDX21EMK@J2/,Y(..OI7UY?
M_L:? &[G^T6OA.:R;;AA9ZC,BM]1N(-?/OQQT7QSXO\ ^"F_P6^/NB_#_6)?
M"_A7PSK-OK-\+4@PR3P2H@QW!+COD&OII_C1;2IC2O!FN74QY$,=K@G\VH \
MCU?]C;X<7'Q0M?"&F^+_ !9:6JZ>;N>WM]<(7YG=0%RI(Y3M5O4/V1?A+9?$
M"T\,'Q+XP,UY:R3^=_;8P0I/RGY.:ZV#QGXQE^)[^*F^"_B)88]*6V0LBY+"
M1WS_ ./XKB_VD/VE1\)O$W@_QAXB^%GB6UA?5_LMQ<168?,3% 5Z]]WZ4 8N
M@?"^X\%> _'OB"W^+>M16F@ZM?0VHO9(9-@CC'EJ28>I9L8R*Z3_ ()Y?"CQ
M-X5^&]]\4/B!?S7&N>-KUM1N'F4(R1DD(I4*H^[@]_K7 Z7K'CCX[_%M_@MI
M/A74M*T=?%\FN>++B[1=LEF[(\=ME22"_E,",@@,/4U]?V%E!IUK%8VD*QPP
MQK''&O15 P!^ H \)_;T\-+J_A+PWJE_&S:7I?B"&YU;]XZ@0AT_ND9_&N@^
M)=IX9NOA'I?C_P #&UMVT=H=2T0SS!8\C!^;YAN&PMD9["O1/'G@O2/B!X7O
MO".OVYDL[ZV:&958J1GN#V(.#7">$OV2/A7X8\&Q^")[6_U*RCC=?+U2^:0?
M-U/&,=3Z4 >@^'?$5CK^@6OB#3[R&:VNK=98IHW&UE(SD$'%<-\?O'W@UOAM
MK.BC7;:6^O+.2VTV"WN$=FO-C&)< YSO X'-<1X_^%\GP@TO1;G5O&-[)X1T
M^\6T72X2L$=C;D?>9^K*H4@Y..:ROC5\5_V?/A%X5U#P]\.-.6_U^Z,$T-CH
MH$TMV5=9 >&YSMQ0!UGPD_9Z\+>+O >B^)?BQI.H:EK$L<=S<1:I>/\ N+A<
M@$(NW;P!QC\*]FM;..U15CXP,5F>$=8N/$&B6>NW.E7%F]U$KFSNN)(>HPWO
M6S0 4444 %%%% !1110 5'= F(X&?0'N:D)P,UPO[1GQ%'PT^#NN>*8"?M4=
MDT=DBL-S3281,9]&<'O0!YC%$WQP_:[M]:MIF;2O L)B:.1>'N7:8,5(XXV1
MG!KZ%2-EQTX[5X]^QO\ #2;P+\,I-;U 2?;O%%VNK7WF')#31JVWH.A8U[&I
M)4$CM0 R?I_P$U\:_L8?\I5OVK/IX:_](!7V5<?ZL_2OC+]C&1/^'K/[5T9;
MG;X9.UN/^7 4 ?:-(XRI%+4%_,((&F96PJDG;_*@#R;XGSVWB;XN6>@7D<ZV
M_AFU37&FBSM9XV.48_[O.#ZUP_Q>^..E_LS?L1>-OVB/$.H,LUKIMQ=Z:TFX
M/)>2[;>T@8JC;0]P8DR5*J&RPVAJUKSQHNM>&+CQ1HMRUK?>,M?_ +/LXIOF
MQ%L6':WL61FR/7%?&_\ P<3?M"Z=X*^ OA/]E?PUJ,0N?$U__:FJ6=O/DI86
MQ^0R*'W!'G<,A9'5S;L0<QYKRL[QRRW*ZV(?2+M_B>B_$^[\,N%9<:<>Y?D]
MKPJ5(N?E3B^:;]5!.Q\H?\$QO@Q\8?B7X8\=_M$_LI_%"?0_C#X'U*&6X74T
MM5TNZTB[CE>7(:"0M,7MI@0,!0RXY)KV?X$ZI^SS_P %6_$-U\3/#/A34/ _
M[5VAV+^+(_$FA,ZZ'<WU@R0:8C17DMR@08L6D"Q*2T<A#'D' ^$GP>\*:/\
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MHUH4*F'JKV,>:>&I/WZ?_49E4U:]&2M*=*#BK\UU;54_CCXQ\0?\$^=1TO\
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M]TJZ<-LC$2$CE<O1X:^.'@C5;63_ ()Y_P#!:OPPWE^&RVM>#/%E_<M9F6-
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M"_L!?\%D?"UOXPUS0YH+;PCXN\$^='<07FHJA628Q26\,D<<4T6,P, 4R0[
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MQ%.C4P<FX1]I.GAYVC5CTQN5-64:T?CJTX<K=XI[61\9/#GB;_@F!X$TW5?
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M,AM8[3.HSNHLMUU)ONYK:/#R#:>F48J)YVXNI&2WY5-[Q?\ S[KKK"6W,]M
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MT<_B-*G3\%L=AU3JX>4,3A^;#U+NG2;52\L/.[4L/4W@E9)QE9:W?DO[!O\
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ML^]26\R,-D]^#GI7M6BZUI^K6WFVE_#(P_UB),K&-L#*G'0@\$'D4 7J***
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M6/MOK=&OSXBEBYIU[4J5>LO=J.-E/!9A%W491>E&HXIN*O[2UFJ-CX:^!?\
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M=WRF"UFCO;\F"+[+9BXE 2/<N<ID!@6^'M3^%'_!3;3YOV+_ -LN"+P;\=O
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MG858I\XW U%X;T_PK^R_IUW^VE_P3MOH_B5X.\80^7\9O@_,R:C;>';.]!O
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MH1)ZFJ\'AWX,_ML^*)_VC/@_XD_X4O\ M3>%;R:QNOAS831::=>UBUW7>JW
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MK6^FQ7US!TIO%QQ-6%.E'V,:LE_M&"J/3ZMBXM7J866M-3G&=FE[R=[YVO\
MBWX)_M]>((_A+^WYX5C^ WQL\.QK>1>+5A@TF36'PL=C \ET);B3"LC@;NV5
MQQF?QC?3V\]K_P $W_\ @K/;1_8-K1?#_P#:&F0_:$2,C4+R1=1U3S"X<_9+
M,F) <'9)P5(GTRT^ ?\ P62T6/Q!-<+\.?V@/"ZMJ&IS6-B\AU&. ^39QM<3
M;(^7"=,D8Y'7!X>UJU_;1^U?\$Q_^"DVW0?C%X91+?P3\0F_XF5W([EM1O0[
MIBV0?98+>$$O\P<CAE&=%&I=\MFYZ1D_AJ_].IK2TGLG:]U:^Z%'V.&Y*-15
M*<<):=:A!N5;!OIC,%*[=7#1;YIPYYQ]G)>Y9)J'7?$UC^S=H5E^Q%^UUX9C
M^(7[/_B\B#X4_&>YMQ=RZ'!J $=G<17MWFWB%I9,\F((P(P,H/+!4S/!K/\
MP3B\&R:QX*W_ +17[)7C11]HAOF;6(=#2TEVMM!*6-N9M1N6Z)\YMQGYUR&Z
M-XB\+>&M7N/^"17_  4*L(;[3$$EC\%?B)<1F^GMFNW%CI$L:0?NX56!_,&]
M_D( ? YI/MNJ_P#!+CQ8O[(/[6TL?Q"_9G\<;ET+6KZ;SQ:QVRFZN62UM2[K
MF]ND0AB,B,-ZX(RY?WK?*HKE4MY4I?R5%]JFWI=WMO=;B<?;+ZJDZLZLO;2H
MK2ECJ4=?K6$>GL\;%>]R0E!\RG'E>L7!HOA?PU^Q?I-W^U'^POXM/QF^#?B*
M%[3XS?#&>8:E!H]I<+]KNY'MK41VT9BM(#;AYPX43;2-A.9O _PATS3&E_;U
M_P""2GQ;FNM84KK_ (\^!<.H&2.-;AS]ET\V&EJ@9(_,N/W<C''EDI_%1J'@
M=_\ @E+JEGXRT/7O^%A?LX?&8?V3XRTO4 (H+ 7[;Y&^S0EYI'CT^&4#.T'>
MRG#$"G>)/@QX[_83:'_@HM_P3I\8S>)/A?XBW>(/%G@MI(]/M[;36(-E;-&[
MM.ZAKJ0 !=RA!D#@TY0]FDJD.7D^))N]-])TGNX=6KOKIT#VU/$.<\/BG4EB
MO<HU:RM2QBC92PF-35J>(C9QIRM"3?))3VD<7\6O"O[*O[;WPT\7?M(_"#Q-
M#\%_C3X9\,ZI::_\-=-N;;2DU;[):2W.JW @MT\]_.BENH3N?#"/;)D!C7+_
M /!+7X"?%WXO_!'6K[P-XHN+"S@\87$!W?%S4_#T)G%G:L?W%M!)&QVO_K&(
M)#!=HVY/H7QR_9T^#O[5_P "?$W_  4-_8*\6-X9US2?#%S8^-/!=I;&UCED
M:W:76I!+<,'<&TNY5.%(=4 7#9%>Z?\ !N1H6D>(?V&_'&D:W8QW5I)\4+KS
M+>3[K#^SM-/.*O)83CQ-2E.*NX2?-'X9[6DELFUOHNACXAXRC/P3Q]&C5J6I
MXC#P="LG[;#22J-TG)J\J:T]DW*7V];W/F/_ ()Z_#<67[27[,OQ7\#^&;SP
MYX-OOB-XFM+/1[CXL:CKJM>)9ZDDT@BN(41=Y1FR&SSG'-?N#;[R&$C9^:OQ
M8_8:\%>)]'L_V5]8\ ZLJW#_ !N\:JMC?L?(SY.J#.0&(X7 ^4U^LVB?&6[T
M2\_L'XH>'+C190S;=2E8-:R<9X< 8';Y@*_1(_"C^+ST:BJNF:UIFKVRW>GZ
MA!-&PRLD,P93^(-%4!:HHHH **** .7^,L7B6;X::U'X/$AU/^SY#9K#C>7]
M!^&:\1DOC%!H=_\  SPYJ?\ PD5GIMPVK(+"6)9+@0YVRM(JK(2^X C(STR*
M^E&C5SDCVIB65I'DQP*NXY;;QF@#R3]GOQ5\7->UZZ@\<:S<ZE:BQA>>2?15
MLA97?&^W4;1Y@'S?/TX]Z]>1LYP>]-AM;>W!6")4!.3M&,GUJ0#'04 %%%%
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ME#@\<$\UYYXAN?&GQ@^+^@^%_&WA*#2;?3KA-5T];B6.:4,A4'C '?KU]NU
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M''P%^,OF6^E>)_").H7=G91,XTV6>=Q;V<1E@O2Q*%P_E,8P M4_#7P!\?\
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M:&7RSAL9@^#5E\5_^"6^FZK^PE^W!X?2?X4_%2TFC_X6-X%LYY(=.U;4]ED
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MP36_X*A0;?A)XH!7P-X]\&NK1QK!/]ONW=8RUUC[3/:QJ#"#G?@;6)JC\/\
MP1KG_!*KP7K7P\_:0NK?Q'^SM\<+:339?%7A7Y;K3)K^,Q!Y%D"W.$L4GD/E
MQ,=Q 7+X6K7PXUM_@C\-M2_X(S_\%)X(?"OA._V0>"_BIX:C^Q:>^V9]5NC)
MJ.I[(I%666V@'EP?*SM&_P!Y7-3X0>!_$7_!,6;7?V/OVNOLMY\'_CW92V6G
M_$?P8'E73+F^ LXWGO[L06\*I:>=.V$D90N\ H"M.'[OEG#117+S2U=-_P#/
MNIMS4^D=M-;O<*TI5J%?#59*<L14]O*E2]VEC::::QF$>KHXF*BY5*:<DY12
MY%K$E^#OPU^,_P#P2UO[_P#;,^ +V'CS]G;QILU+7'LI$CU&TT92XTY9([TP
M2>8YO/F"(<;&#[!MS3\(?!;PMX2^(;_\%;/^">/BB+Q!X'\+S2WGQ"\*ZPLL
M>JP;E:;65A:X2*(A+.<E2C8+9VECU=\*_"?QC_X(K_$"Z^,/AO1=/^)_P!^(
MEP+FX\2>%[>?5[JUT>U#?8999U6WLX99?MB8;<T<FQ]F, 4X?LZ6/[+/QAL?
M^"L7[%/C.Q^('PQT^9;OQQH_]H#4M;L%O7<ZI%'%9QI!%Y%M<K)B6;]VV6D)
M4?,>S]C3C3E!QY'S.+?O4K_\O*;V=/JXZZ:&U3'2Q6*KXI8J-66*A[*G7:M3
MQL4E%X3%P7\/%*ZC&K>+U3L_B&O\!](_;$^)3?\ !1;_ ();>)[>3QOH6H-J
MWBKP1XM1DG769RTB00M*L=LXV-)DB4K_ +1( #?C#X*^%/\ P6<UVUT+PYXF
M_P"$*_:(\$V*Z7XPTKQ)#+]ANM/LF9+J:W>UCDB5C?W@51YF_:K?+M^8.^(/
M[-A^(GQ#A_X*Q_\ !,WQ7:^+M0L9W\3>*/ 7B2Z%_J=CJ,[ADM$LM-C+*?+W
M$QO.6^48)'(F^/'P8\#_ /!;G3=-^*_P5\7V?A/XW>$[2'0?&'@#QI?Q6,7V
M6U1Y;J[@LX4NKH*+N]6%9)"JX1D8;Q\RJ4_=J4?9J3FU+D3]VJO^?E-_8EU:
MO;0JCCZ=&OA<9'%2I0PT72C6E%2KX&=W_LN,A9>WP\M>2<HQM%I7=FB3XN:A
MX#_X*@C2?V0OV@]1?P#^T]X-232]-34%=](OYMPN;T;K%9HTVVUNVW?(OS$8
M#9P;'BWQ#HL/POTO_@E9_P %3+:XT'7-&2&X^$/BSP^HDT^\M(HFTO2_.^R>
M=*0\B7,A\U4(7;O",!EOQ.L/"W_!9WP%IOP]\4ZPWPZ_:2^']J+"W\(^+98]
M'L=3EFE$EV8[5_M%\_EVUO(2 %*%QNRI-)I_B#P[^TO\((?^"4?_  4&>3X;
M>-/A_,%^'/B8*FDZ3KD5C"--L09]1WS7/GSO,X>&%1+&@*;2K*VE1*I7E)N[
MFK*7V9I:.%1+136REO>VG0Y:7)1P.'PU3FA'"S=2I1@[UL%*336*P=35U,-4
MYHR=*TDKRUVD)9Z-HW[!GPJN/^"</_!3>X\[X3>.)%NO!_CGP9(7CBDMYOME
MTL@C#7>?M+6<7^I .YC]W<RV/A5H_P"T5_P1E\+7WA3X[:7I_C#X!>-))?[6
MU[PG)%]IM]2O(5@1<7#K<<6]N7(6)E&[AV.0*OPW\.Z?^SO\.=4_X(W_ /!2
MJZB\-^%_$TT5]X1^)WA5Q:::61FU*[6;4-3"1M^\CM8@J6YPTI1CED:CX$:U
M\:O^"-D]Y^S)^U7X,L]?^$GQ CEU&[\;>!=/N;C[+J%\%LT1KRZ^SVT9$=L\
MSKM9@&5^0V*B/LZ<H3MR*%TF]72;WIS_ )XM_#+HOO*Q$ZF.HXK"J4,34Q-1
M5I44N2GCX+6.*P;7^[XA*_M::<KS2]U-.)5^%/PRTG_@G/XIE_X*6?LMZW#X
M\_9]UJ%M-OM.3=#K-O8NRP"1UO5@/_(22,8 +!">-K,U0^!/V4/&/A3QN_\
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MB"I"L!D'B/X.^!_^"AOQ7D_;]_X)K>*1;?$3PK?1^(/&7@GQ=YJ2C400UC%
M[(MJX86LF[$S)RN7'>+1OV;_ (C_ /!,KXF?\-W?L):WI?Q>^$^I>7HDWV&6
M77M2MK%]DU_<.MC'#;H(Y+29!(9"B;D#@DMML?&#]GC2?VG_ !_!_P %6/\
M@G1XOLM>\0:3>MXJ\:?#[Q-?+<ZA97ENR_9+6.QTZ-W5I1;S?NY)@S!AM89:
MJ]C-4U1=.UI<TH)ZK5-U*+?3JXZJSL;_ -I1>-_M"&-3C.E["GBIP7O.W^XY
MC2T3ERKEC6]Q\Z3L^C?B5X'^!_\ P6!\=K\=OV3?$TGAOXS:'''=>)?"OBZ&
M<0R6]JHCA\EHXC;[Y) G!EW 'YMO.-#XMW.E?\%+;72_V(?VJ"_@/]J+P4DL
M6BO=MNTC4)9V2]NP6L!,AVZ?;1@-(PR\GRAOF A^.OP)^''_  54O;3]M_\
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M\:?">_U-?$7B[X>^ ;S_ (1R"PL[;:(K&XM!,)+E) +C:OV7@9_=D'F7XM_
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M)XIOOB1\&;[4F\2>)O W@S4AH-I90L?W.GW%D)7DE.QR1FU!4#!C!.:D^/\
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M/@&Z'AN'3K/21&AM+BV,BRW"W)@OR%%J3]_$<N]2SOCS\$+C]J#Q+:_M@_\
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M>Z9$=-US5);LQP(?[5G%EYAAL;:>8[0Y$<A0[-R[JWQ@^ 'C7X<>([?]O_\
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M6 *G'J/Y&NS5U;[IKR+XJ_L@^ O&>H_\)EX0U&Z\)^((U8QZMH"I#([%LY?
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MY2;3PQ42J>0<5Z7^TG\0/&OPL^#&J>,?AMI%C>:Q:^6ME:Z@SK"Q+ ?-L(.
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M<?ZZ&0'$D81F;@''S =* /9?@WX^LOB=\-M)\<6$@>.^M59F52 SCAB,\XW
MX]JZ>N)_9T^&>I?!WX.:+\-]6U1;RXTNV\J2X7HW)/H/6NVH **** "BBB@
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M^)/V>_%>K3_V;/XXW>(+@:!"&AM1!''*T,*[DA8Q>1\I(.Q,#$GBCQ'\:?\
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M7Q9^SCKNI7&N6=W!IS:YC2'$L.EHMQ+MA1@UO:,8QE5# @G>#2?%?P)\=/\
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M+^#-7_X*J? %OB$FH#PK^U#X/G-A?6BR?V"+RV>=I-ZQ*&GD=;'8I;LRXP0
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MVOKCY[D/+-;N-H_>;-_)4"M'PU/X#_X*Y? 2X^+?@&RM_#?[4?@>VFU2:X\
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M^ )&?P$9,>'TO[2[*; V[=-.R+:W)^4 +O']XD:'P(^.OA[]K?1]0_X)^_\
M!3_26T;5HI([/PIXB328]- MK!-S[[ZZ.XAWBQN ^<'!Y;C/\'ZCXE_X*^_!
M#6/C9H$K>%?VE?A?+L\.K\/9CHHU&SN&18#<75PSRNR^3>E/+G01[WX^<AKG
M[/7Q>^%?_!4C2-2_8>_;]T;2-+^*6DS#3?"?B+P_H?\ Q./)LU,ERLE_="X"
MF0P'?@H)%8X!+"G3J2=2#4K\ZT<_AJVWA/HI]%?RT>PL5AUAL'BXU*#I1PE5
M3E"FTZ^72;4O;8=_\OL)/2I9<EO?5_M/-^!_BWXP?#;Q7<?\$J?^"FL*W'P^
MNK%M-TKQ1#:M((M6O'2]BD74[GY<"">Y4L!E,%0,)FH?!OQB^.'_  2V^+\W
MP!_:#T4^*OV>=:OKKQ#_ &E:::VN8L)DD@TY5N)<0J0]K:$Q@XYW@DN*E^ G
MQ4^)?Q-\;W7_  1W_P""IMK:S1QZ>T.B^(KH-JNO1:W=/#=VK?;Y9;B%<6MS
M.BR"-65 J;@0V:_@O]H[XJ?\$_?C*/V!_P#@H)HUAXF^".J7MWJ<-UXZMY/$
MEZNCHKP:8L(CD>%(Q<6-L_D>3\C.S 1EEVY1G3IPIS=24+2Y5.2NJ?:E46GN
MK92VZVZG9B,+7Q5?$X5X>G6=6DJTJ-*5H8F+3MC\%))J.(=FW2Y9>]9-MW2=
MX\\*?&[_ ()8_%,?$?\ 9,OU\8? ;QA-;VK1M(_B#RK.)8WO\HF(HB9#.-Q.
M.@(R":=\<M#^+7[*'BNQ_P""AW_!,;4/[6\#_$738[C6O#\DC:A)8ZMJ#R7L
MT;6%O\D&R%;9 "2R9*G<,5'\1[OX\?\ !''XN+X(\(7EQXM_9Y\92VVEV$/Q
M!U :M";1HTFU$PV=K)%'&Y,DX;,&'5?NL!R_X^:G\8/^"8GBVT_;/_8"U-M6
M^"GQ/T]-271?$EZ?[)MM5U-WN0D.F6KVYBV6L%LD;.I**=C,?E =3EIQJ1ES
M4_9R3:WE2;^W3>EZ;WMIH+#>TQF(PE2#HXAXFFX1G-J-/'1BHKV&)3O[+%T]
M$I7DY2O;I?>^.W@SPE^T5X:T[_@I?_P37OVTOQAX=N#J/BKPK+<K:R-;Z:.,
M:?;9:0/)&/D8[9.G1B*S]=\#^*_^"D/P.L?VIOA_J*^&_P!I7P7<_P!G>+-)
MDNO[)%Y:6SR7OF):K^]E)BN+9"YQG9CC:N=#X\?#71HO">E?\%3/^"35Y>:;
M::;=^?XZ\,Z2T>B:*+/38_,E$MA&MO+.CR1_O(]S>8&) &<C-U?PWX^_;V^!
MMA_P4D_99U&YT/X]:#<?V5\0--\(W@T*PN(+=I+E[B7<4GN&:W:T5B+AE95V
M!?D(%U(WG.$H<W/'F<8OW*B5OWE-V]V2W:UO=Z]3#!UOJN7X:O"JJ4:-5T8U
M*RO6PS=U]2QD';FPSLTJCY4K1:AK9:7@OXF^%_\ @J?\'=4^"/[3FG/X7_:$
M\/V]WK7@_4I+5-!BNKOR_)TV ROF:0^;,&$8&<+N496LWX#^+M7_ &DHM3_X
M)S?\%-K5M*G\*PKIOPW\2+:_V?YLVFF6&X)U"Y.Z82&.T8.HS)@MD;E-:/P_
M\;_#3_@LA\&-6U3Q%9V?AO\ :<\&6MWKGAW4? 6E+I<MTULI32[>;4+@2,4^
MT/&=BSHRLH=2F,C._9_\>2?\%%?[;_X)X?\ !0F*'3?'?PZMUL? _B+1[?.L
MS7%DLD>H>?J5U]I4F1[>S9V78)C\PR -M1DZDZ=1S4W.+2DU[M56MRS6T)K9
M;^G0SQ6'^H8?'4)4)8=86HJDZ<9<U7 R;2]O@W=>VP\M.:-H)0UYMFZWP&^,
MGQ@_9X\977_!-#_@I?HK7WP_U#3Y/#^F>(H]+-R(=4U9XV2X&HW.%"Q17ESF
M0 F/;@#$9RFD>+OCI_P2C^,DGPY\7V8\7?LY^*M2EU-KFSLVUTKHJF2&U3S6
MQ"C8$/RYP>V>*9\ ?VCO%^N>-KK_ ()2_P#!6#2K*^ADL9-,T'Q)JEHVM>(+
M/7]2,?V.9;V62Z@CD2WOY#%,$'E ("RA64IIOQD^+W_!,3XZG]C+]K73;7Q1
M^SWXJU:86$OCK=X@E/A^$&* 011RF&)=PC9HC#P<'8N!6$?X$&IRBHOE4G\5
M+7^'4V;B]KZ*W?<]"MA:U;,,7A/JM*I*O2]I.A"7[G&12;^MX*=GR8B/Q^SY
M9.]HWZ$GBK2OC7_P2<^,T?B#]G[44\7?LZ^.-0M4N-LS:^8M*M!&=3+% (;<
ME[B[Y)(;'S$;2*O?'[P=K_PYU;3?^"IG_!+C46?3-0C?4?%WA>:?SY+:[O6\
MB*-M-MQM"K'-(=K$E" <G:!6?XMU[XY_\$:?CC'\'9+AO%7[.?C_ %"UL+/_
M (6!=_VN$TM1%)JQ@M;:6..%V:\N-P,&V0*I*L Q:Q\?/#_BK]AW4-)_X*1?
M\$S=:NKKX7^(X6U3Q+X8U"\%KH<$ETXMK2(:7;&V=HU$^45MQC?:<@#%-SIQ
MIU(M2C&,K\J^.EWE3>S@W[SLMM/(QP\JV(QV"Q473K3Q5-PC6GI1S"-K/#XM
M._LL2K>SC)N7[R-UNF/^*'@7Q1\5/ GA[_@I_P#L0ZG]E^)6GPB_^+/A)KCR
M#]LLU2W(73(<OM>XAG8([9?<&R,L*TM2L?#/_!6;X$G4/#)_X1']ISP/!%;R
M+,R>'X]1FN9@UPPC7,TI6TMY?="<]#D9GQ;\-^.O#_P_\-_\%>OV!=2NK.^U
MB,ZK\8?#6GW@TSP_%=6:)#<*UDC0SS1M=)<,XDDE+,2V>0:U-1\+:#_P5%^
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M+S_A%_VI/!LWV*Z@:;^P1?0R7#2;UC&Z>5ET\*I;H&&,$8-:'Q@\/^&/B/\
M"W2_^"J7_!-&XN-(\7>$KJ'_ (6EX=\.Q+H>C36MG"^I:C)-:J()[P/<"%7
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M_P#RT&\'#9/!KUPC(Q6!XW^&G@_XAZ>VG^*]&AN%*X6;:!)&,Y.Q_O)T[$4
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MSI8&CBM+=B?WTKO@)Q[9/TKN-$TBR\-Z7#HFFQ;;>WC5(8]WW%'&*\'\0/\
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M7TQ7J?P8^!?@?X%Z)<:+X)M73[=<_:=0N)&S)=3[0ID?CK@"@#M  .@HHHH
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MQ#H5]\3/@;XFMU_LB^ETW^Q=.CN[UA(S)=^5</*Z01N-GF\ABV%QRSPK\6?
M.J?&.;]A'_@KO\*+76KRWU*ZTGP_\;/&2QZ'/#HFGJQMI$O)(TGDAFGMW;S3
M<?O#=$%G+,K,^)?Q$^*O[ GQ)/P,_;>\%W7[0'P<O(HIO!^L>+-+$EE97UP/
ME>WO[V.<LT5L)%VB485\C:,YF5:4:/M54:Y'RQFU[T-OW=1?:CVEJ="R^-;,
M)8&>"A/ZU35:KAHSM2QC5[8O!3_Y<UTK\]-ND[:*+V5S7/$?Q7_X(N_$]?B5
M^S[:77Q)_9_\>++X@M=.T^R^SZ7:-=NZ6<']K.ET\K1PK%M;<GFC!V\DFY\5
M_ &D?LKZAI/_  5:_P""9WB!=5T.^GM[7XF>!?#,7]L);V;(=3U,W%_*;@VR
M?N(8W985,>Y2"G(;+^,_B+Q__P $Z?%%GI7C/1[KX_?LN^);/^UO#6AZGIXU
M'1=,MY&*:7:17UVERBB*%8FB5&56'(7D$['QF\#7G[+'@33?VQ/V O%G_"6_
M!7Q#=06OQ.^#.AROX@TR*UEA:[U5KG+3V]L#!"EO(YB4QK)U =D:I<L/:TW>
M,:;34=Y4K_;IO[5-]8W\K=#&G*5;ZIB6H5*F+3I.J[QH8^FO^8?%0T='%4]E
M4Y(WDT_::<Q1^)<?C/\ :F\#I_P6%_8)EN/#GQ:MY&T[Q;\/?#MG_P )%>F7
MSFL%E<N"L ^QQ(^U;8 J0^21O.AKOB#X8?\ !87X;WO[4WPNTNU^'G[07PPN
M&OM)T/3M4?7-1UC3=,A^U0*EF?)1%DO+M%$WD2$.@0EPVRLW4W\8>+?@A'_P
M49_X)1W=QX#U#S1:>,O@CX(B_M5?M0F^Q132V$*FWBQ;1K* UL.") >KF]X'
M7X*?MJ?"S5OVFO\ @G?H6E_ ?XR>!?.N/^$-\$:@3<^(M'LHOM'EC3;/R%DC
MFO)H(BS0NK-%Y9+9"C6'-4J.D_?YX\SAIRU.U2F_LR7576OWF'++"X..)C%T
M?JM5T:=:7O3P:;:>"QD/>]MAW>T*JC5]UM::Q2>$/'=I_P %AO <W[$'[6FE
MQ^ ?C/X!LXQH7B?6;@F^U"^)WWR?V2HM%WFW@;<N7\L-N XP4^#O[3EE^W1H
M/_#N#_@J5X2_X1CQ1H]G<:EI?C;QEJ7]BW/]M2$1:?#_ &?%':AW%O?Y6,N5
ME$(;82VY*_P7U[PG_P %$(M0^%VK>&(?@A^U#X6MXI5^(MNPTC6M;OI"?M^Z
MTM4M99)/L\;!D.X*)22!SFO\#OBO\)OVV?$-Q^S)_P %"OA'8?#WXZ6-A)J%
MG\6O$7E>'-6GU8,J:9;;$BMIW9(;F)XX6D8NMN&"M@,N5&?M/9S=7F<_=O)>
M[4BM/9S7V:D=E*VJOJ;XS!T\+3Q=#ZFZ,<-RUE3I3YJN!J32;Q>$E=>VPE;2
M4J2DW&5OW:M<?X+^/OQ$_84\6WW_  3#_;6\-77BOX.^)+R/PWX;\9:\H\-V
M=II9/^E743)$7N(_](0LQN!MV@!QFH-*^*7QW_X(\^.+C]D3XMZ/??$;X(Z]
M'%8Z/K%Y:#0=/CDO2LEW)'<B*=YB@D=60S#&"<IBHIOBG?\ PA^,3_L+_P#!
M4_P##\2/#ESJD6@^"/BUXVLX]-&FV<A'VR\@O[B(S2*?,A+2"X^4PCYAG ;X
MQ^(WQ-_8B^*"_LO?\%#_  C-\>OAG<&"/PEXQ\7:6%M[*ZNT4S74&H7<4SLT
M44C(=LW[M1QMX GVRHKVBJ.#IOE3DKN'_3NHOM1:5E+75;FWU&6.Q3H5<%"N
ML325>I3ISY88QQT6,PLKKV.)BF_:T7[-RYI>Z]EK^/--O_\ @D1\4+']L']A
MB=O'WP%\?++-XA\.Z+&9M/M$M8Q:VB3:Q+]K<%KN[E9"/++.AC._A1#\1H/&
MOP2O]!_X+ _L'--?:3\0&AU'XN> /#EK_:BZ:KJNI:M#<ZC()3;JTBM&[K!%
MY).0% V&3X[6>K_\$\-6T?X@_#.^G^-W[)_C".5KKP%SK>AZ5;0*L=K']MN?
MM,,*R7]P9!M*;WM]GS$#$?Q#E\:? 7X>^'?VV?V*)[C7O@;X\C@G^)'P)T>W
M.LZ3HUM-"+O5[6X!$MM9KP]L^(HQ%N*D*"4-5.6E*<&W%4_>M'5T_P#I[3?6
MD[N\=]7H887VF,IX3$M0KSQ*=!UJC<8XRG'_ )@\5&W[K%T[+EK62DXQ?M7H
MW:^(VF:=^V5\.+/_ (*N_L(W?_"*_';PZS3>+/ 7AUCXEU&X>6=-+MBT<F%@
MVVD$THQ:C>KDG[IDINI^.[7_ (*U_#BZ^.WA/38OA_\ M"_ >'^TM"TVVN#K
M.I^((]/B-PJ1V)$"1E[Z2(;O)FP^U"&!VTE[I-E\2/@D?^"AW_!)W5E^'/C>
MQ7=X^^"_@>3^TY;O-R;"Q$VG6^84"Q)=7"![;#>:S\%2X@\ ZKX*_;,^&NN_
M'[]A[PW:_!+X[?"VWFN]4T#PNR_;_&%K:PM<SQ-IMF(1,LU\8E820RJ7'EL&
MSMK24I2JJ+:E[1<SC%6C5Z^UA_+.Z3:TNU\S.,?J^%]O2@Z?U6JZ-.I5;=7
M\S47@\3'7VV%ES.-.JE4M&;?NZI:O@;XD?#/_@L9X,F_93_;%TNU\ _&CP!8
MQ:9X7\4:UJSB\U#4I68:@PTN/[&A<?80&A._9YF1M ^?(^%_QT\??%>QO/\
M@CE_P4$\-7%A)KTMS9^"?B)XFB_L=K$1(8M)*6*0P_:U-S "F9\2F382XQNG
M^!>I_ /_ (**V>J^!?$_A/2?@?\ M,^$XX4L_&T.HIHNK:]KMP6_M&X^QVPM
MI9K@?9FW(QD9///0$[\SX;?%6^^.7Q#_ .&(/V^_AFFD_&"ZFGM?AW\=O%&F
MIHVIZ=]F4C23"PBANI@UY&73$^96G*Y8G!FG6C)4JDJB;FW'FY?=JK^2I'I)
M;*5OGT-:F!IX66+PD<(Z4,-^^]@I\U3 U.52^N8.I=^VP[TG*ES-W37)LS0^
M%W[1'C;]E;Q5=?\ !+#_ (*!^#I]=^%NLZL-#\/>-/$DO_"-VMMHT'RFXBV1
M;IHBX5MQN20<+O(.:K:C\2OBQ_P0^^(-Q:?#+3+CXH? 7QU9G7-%^RPKINFV
M^I7DF(8DU Q74ES(EG9* A<!TE\PJ",TS2OBQ%X6^,LG["G_  5B^%O_  G>
MG3ZH="\(_%[QQ:II<EEID?#W4-[/$)IDDD",TOV@DL?O=J3XS>./'/\ P3E\
M<6_@'X_>#V_:*_9[U[3UUKP*OB+35U#2])O)I'CLX8-0O([G<\-C;N$1' *7
M+.  2U1[3V='F]HX>SERJ35Y4O[DU]JF_LO6U_F;_4?K&.CA98*%7ZY256I0
MA/EP^.:VQ.&EI['$Q7Q4VJ5W%JSO9V_&2^-?^"/_ ,0+']J/]C>]N/'WP%\>
M-+J?B'0='M<Z99QHOV:R@DU=Q=N?WUR&5@4+LNTAAG#_ (M>%=1\(V^A_P#!
M7'_@FI>L;[Q!';I\5O /A6W;7FL[JZWZIJAN+N3SOLV!Y$3H((_*RK#9N"5'
M\:1XP_X)V:EI/BOP3</\;?V4_&<4UW=>");7^U]%TRSBPMG;F]N1=11 74L<
MRE-H9H<;3QB7XBZ%X@^$'POT?]N?_@F9KEQ>?#OQ0MJOQ2^"OA9FUZQL+JZB
M-YJ/VF$>9;VA2W%O;,ODQF)-H^16V%U.6FJM!MJ,/><%O3?2=-_:B[MVOI=J
MW0YL+S5%@L:N2=3$7HJO-6I8RG'W?JF,I_\ +K$4](1J\OO6A+VEK2'?$K4]
M9_;>\"1_\%8?V'+:;PE\</!$S6GB#P#X;_XJ74KJ.>5=/@E,;*%@ M?M3\6K
MAUWG.4#C4N;GX(?\%M? %U\4;8:=\,_CIX%F^RZ'8Q:R=8OM3TZQB^U*R66Z
MW3:]S<LN_P MR&3;N((VX4^I3?%+X*3_ /!0?_@E/IB?#'Q;H,JVOC7X->!4
M&HMJB/,+.SDETZW7R5"1&]G3?;'.'<'*EAI?"S0?V>?^"@WP\U/XQ_L86VE_
M 'XW>%;B:"/2_"^K".^UK3[>(74SBQLF@\P333"-F,;Y,6TDX4"N:=:IR2:G
M[2/-)6M&KI?GIO>$[*S6EY+YDUJ?]GX25:,)8;ZG5]C2JM\U7 )O7"8I*[Q&
M&;?[NI^]M"36FL2EX ^*OB7_ (*G^$?^':_[;6D7'@GXM>'86U31?'7B!O+N
MY]0699&@_LF..U0L;&1UVEW&P&3:?O4_X._M;+\8(T_X)I_\%7_ 36L,$DU[
M9>.?&&IGP^T0A3;8J+:** L,@[6,PW]P:H? [QI!_P % =5N/V<_BMX/C^#W
M[4&EVYU.T^+S6HT;6]2O$8 VYM[=;:XD?^S)'CVEV_=CS N!D)\)/C'\)/VB
M/'C_ +*7_!5/X-:;I/Q$C666S^,/BY8?#>H+!!Q81^9Y-O,R,VXH3*"[-T/:
M8UN:4)JM>53W;RC95%MR5%TG&]N:W7<TQF74Z$<9AJF ]G3H6KNE1J7JX2I)
M/_;,%)R2J8>I9-TN9N+C'W%HRSX.^,/Q&_X)C^-[S_@F=^U+X?N?''P5\:75
MOX?\/^,-83_A'+"VTZ_ ?5[F*5(I&G5#J/[S-P#&8?E9-V$KK\4_CA_P1 ^(
M]_X;T30[SXH_ _Q98&\T,_V>-*TQ=2O&WH$U%HKII72UM&789,,K^9M7:,MU
MOQ[K/[,_QB_X89_X*B>!9?C!X0U#4+/1? WQ6\:V8M5T>WOMCZG>6^H7<;RN
ML9N80[K< PBR4*R;1MC^*GQ(^*W_  3P\>K\,/VL/"=Y^T+\"-4M8[WP7-XE
MTL76FV&I3M_HP@O[R&Y+O!9PSA8TD^Y.S!>]'MO8Q;IU'!4Y<L6U=TM?@G_/
M!O9ZZ6U.B&!_M#$0I5L'3Q/UVFJE2$)<E/,+;8G#-J/L,53N_:4VJ7--RLI&
MM\2_#6H?\$M_B#IW[:'_  3GUZ3QI\%?'$K-XH\-^&K?[=865OIZQP".;5I/
MM3+YES+<-N_=D.KQY;;D0_$/4O$7ABUT/_@LY_P3^,JW7B2XAM/C'\.?#L(U
MHV2.7U+46N;R02?9%*PVL;;;>+RPZN"F[:;'Q[\/^(?V 1I?Q/\ V9=?F^,'
M[*_BQG?6/A[9@Z]HNF6=JL8DC>[G^U0PI-=RSR%E"Y>,@DE0*I^/;[5_A7\*
M]'_X*#?\$_) WPP\57$=M\6O@9X=7^V-.T[S(Y;O4WN4VR6UD#;0V]N[&",Q
MQR#E5?:;J/V,ZE+6')[RA'7D;WJ4WU@VVW#S>G0Y,)*IC*&#QC4:\Z[=#V]7
MW5BJ:NOJ6.C_ ,N\1!)1A6M9N$7[1Z2-3QMX3\!?\%#_ (;1?\%+_P!D*YA\
M&_M!>&/.U;7O!>AW3^)-0NVMI/LEFOV=VC2$E+<."+7Y@^"K8W&K'XUO_P#@
MK[\.I-*\0:0W@+X]?L_VL5]I\DCF_P!2\1201-]K0::$MDMV:]AM2QV2^6[*
M@4;MILVOA;P5\<_@H_[='_!+*^_X5/\ $C18I;SQ=\(? M\;R6^AMG^S6=N^
MEVQ2) XB:15:V(<R9P>6.?\ #+7[?]N/PAK'BS]G7PX/@C^T=\++5;[Q1>:#
M&+75/'&Q)6U&.73[18&DWW\4!<2))L>0(0-Q#*ZE*,=U4C=J.D:UM5*'\E2.
M[VUT0H4_JF#J5:<'2^IU.2G.J^:MESE)1="NM?K&$J7<(22J\L)7M'8T?AI\
M;O!O_!4+PE-^PM_P4)\.0^"?BEX5TWRO#7C#Q)JIM;RYUJX8Q+C2HTM5:149
M/W)9MVW[HR*H_#OX^^)]%U;4/^",/_!0/PW+<>&=1U.ZTCPI\1O$MP=#CMM)
ML%9-*E2WBCC-Q&]SIZE9#<_O#+L+R ?.WX&>,O@=_P % ;J]^"?[3'P^TOX1
M_M':+;K)IOQ-U"2+0]7U/Q$[;(6-O MM-+<(/+(BRS':, <5G^%?B3I'B3XM
MW7_!/C_@I5\-;;4/& U*ZTCP5\>O%]K'I%[::;8EO[.E2Z>*.XFCEO;5V243
MYEDNF&Y]WS%.HZE*G4512<_=4K:36WLJJZ32NE+T=RL5@:=&IC,#]3<(T(JN
M\/&=WAIM<WUW U+^_1;]^5&ZLM.332YX/^.WQ-_X)R^.;S_@FE^V%X7NO&OP
M7\57EMX:\-^+-5C'AZQM-+N7QJ-S%+%"[W" WZ[V-P#'Y60T>[(77O&GQ6_X
M(L_%.3QG\"-.NOB1^SWX^@?Q!IUI8V7V?2X&O'*V4 U5H[MI7BM88BI+J)59
M6V+R32U#XH:W^SI\9W_8>_X*F?#]?BOX3OM0@T'P1\5_&VGBQ_LFUN]JZE>P
M:C=1O*X N;</(LX,?V=?G4$;;'QE\5_$;_@G7XNA\.?$+PU<?M!?LPZY9_VO
MX6TW5-/&IZ+I8D9X].M8M1O([E/W-O$C(J.H8.6"C=4RJ*E1YXU''V3Y8NUY
M47_+-?;I]GKH;T\']:S*G2EA*=9XV"G4I*7+0S%:/VU"3M]6Q2?O.+5/WN9+
M>SN>-]3\1_\ !,OX@:=^WI^Q#%-XR^"?Q,A:]\:>%M#A-QI^F-:Q);I#/J[K
M=.I-]=W#*0L6'C:(A@/DD^+7PFM?$_A73_\ @K!_P3#U_P"Q_$"\MHKCQ[X#
M\*0GQ)=0ZGJ3&XO?,DF:40-&)65D%NH4<X3@"M\8KO6/V&TT'XP_!BV?XM?L
MK>/HI+O6OAG#&VLZ'H:VZ(! UU,MS#;[M0N)9/D$8+VP3_EGQ=\>>!?$/A'X
M.V7[>'_!)?QQ=:99ZO:VMSXX^#/@R5M=2UU"]4M.);-#)! T$;K'L\A=@CP%
M4* !QIIU*.MH^]RKXHO?VM*3WC+?E>VJMT,,/*4HX/'Q<74JMT%B*FE/$P5X
M_4LPA;W*\5^[=9Q::Y)>T=N95_&/BW7?^"D7@C_AY1^R_:OX)^-GP?D:S;PA
MH>?$E_J]LQC6UF$3*BPA1)>$'[,_F /D_NQMU-)UKX*_\%O? -Q\-/C+96'P
MW^.'@V*'2=%U.^UI[Z]U%8P)KYETU3:1Y)CD#<-Y><@@ J,32-4_X: ^$.I?
MMQ?\$N]$C^#_ (T\"LUIXL^%/@6'[5)XBA!C%I,^GVJI$0OG7A5GMWW;6QG9
M@7_@GIG[/7_!1WP]J$?PFLM._9__ &BO#\BVMOJVBZR-.U35Y@C/J,XLK,VK
M.[@3*Y(;8)&R0,BJIRE6G&#:G[17<;6C5MM*+^S-65UI=KYF=2C'+\'/$4Z,
ML+]2J\M*HGS5LNE*2;HUXZ_6,)*3<E)*K:$Y*WV2M\,?CSX@_P""D7A=O^"7
MW_!0;PHWA'XC:59RZIH?CSQ-<&QN_P"V#(OV2#^RDCM0S_8[UMJ&0B14W["3
ME%^$7[5-WX7U*?\ X)/?\%1_ 4EUX-O-2GMM/\?>+KP^&X[;1M/BW:<RQ1Q1
MM) \^G_)-]H)<RE2[A2M4?@=\2-$_;LURX_9>_:=^&D/PO\ VE;.Q;5--^,M
M];1Z'K=SJJ21Q6-MY4*6UPT@LKA0D9<[EMPX7A<1_#KXQ?#WQW\5/^&%/^"M
MOP<M=0UR;4+JRT;XT>-HX=!N8-#LXV:T*W,D4<[Q37%I,RR^<?,:Y(W-AA44
MZTOW=55+\SY>>2]V:Z4JJ[K;FM\SJQ.6X>E+%86I@>2%*/UB5&C/WZ%1KF^O
MX"I>*E1E92]ASJSBE[,L>'OBY\:O^"27C?4/V'?CCI%_\1/@GXB6'2M%\1:A
M9KH%C$M]LDOIXYTBF>;9]J=6'VC*E6(*X)5^M_%7XI?\$3OBA/J/PAT>Y^)G
M[/OCZP;Q#H=O9VHL],M;N_ED%O FIF.Z:X>.SM(\#S!YBOYFP<%Z7C3XC?$#
M]CKXM?\ #)O_  4C\&2?''X=W4T%GX-\?>+]*6&#3Y;Q$>ZNK?4;R.61S%',
M5)6;*+'P4"_+)\8/'7B;_@G+XUM_!?Q9\(K^T)^S3X@TU-;^']CKFGKJ&D:1
M+/(\>G6UMJ-W%<KF&SM\1I'(%99F<*N_+#G[&#<)N'LW9-J\J+VY9[\U-[)Z
MI(*>%GF.,IQJ82GB7C:?/4C&7)3S%12M6IM\OL,7"_-*+5/FDY+6[3TOBG\*
M?^'?WBO2O^"@/_!,/6G\3?#759H[?QEX2\+V[:K:6VGVB":[$VIRM=-'&[H5
M+A%,9)P3C;5?XE7/Q!^*FBZ7_P %GOV#Q=Z7XPU"9-*^(/P\\-Z?_P )!-;.
MCOY\\TSAA;A[.&SW(+9-@9&W_,2=#XT>#/$G[$VD:7\?OV%_&5U\1/V==>N/
MLOB[X7Z-))X@T>VT^- ^HK-+*UU! LI5XW<(I7?MSV.?XDU3XB0_"+3O^"A/
M_!,ZWOO#_AO6)OL?Q$^!7@^W;5[6TN=\B75S-;(KVUONM(;;+&W4A7WD_/DW
M6BHU*E*2<$ESN$>C7_+VD^U]X];[&>"E4K87"XR+A5E.7U=8BM[JJP::> Q\
M+>[4]U*->TE>$7[7J;'BRQ^%?_!5CX;7'[<?P)DL? ?[0OP]\[7;7PMIFH'7
M]2U.'2XB]G&MF6C6/S;@Q;7$#[F"J1(&Q5'0/&.G_P#!:'P6W[/7QYL(?A_\
M;O@[!"FEZY?77VB^UJ\^8:DHTQ1:QQR>;8PEUQ((FD  4 [[?AG0/@W^UK\'
M+_\ ;'_X)MR:?\$_BUX/CN=0U3X<^#=2\ZYUBQL$:2&V.FVGE(R3SB/&Z%E<
MX!W;B*S/@U?^$/\ @HC9:IX=\&Z'9_ G]I/P!;PSZGXJTV9=-U?Q9?3!VU9I
M+*T6VD=VEM@SAQ)Y?GD';N8,2:J2C&4E+VJN[*T:UNJ_DFOE=V,)1^HX>M4H
MPG06!J)4Y3?/6RQR:BZ<U>7UG!SNXW7M+1;;2V=CX3?M(P_\%#-!D_X)K_\
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M_:.^*'P,GA\._M9Z/;QPS2.+7Q9X?MC)9OD$JLB9\Q&^5@244$XQUY]P\/\
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M5_AYK6^&UM+Z9WM[IETVW98R1;V*D2,227<'(P!H>./A%X7UOP5'_P %6O\
M@E-=7GA'3?#,SW/B[P7(5T>PGTW2E^TW"-;VN'G65H@'0OB0-G(XJGJ'Q$N?
M^"?'AR#XJ?LR^'AXP_9%^)_[R;3]6_T>73M1NBUI,%,@:^)2*QWJV%4F3C&S
M)GT_X0Z5^SSX6F_X*0?\$A?$D^K^!(4F3Q_X2UJ#RPNE6 -S>9FU!C,?,,07
M,:[UW;D) Q7=*,9>Y-622FXQ^*+_ .?E+?FIOJD[+3T/DY1C1HQQ%*34JD_8
MTZM5?NL136GU+'Q_Y<XNFDHQJ27O--\VTB(WGA+_ (*(^!E_:7_8%TM?AO\
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M%_P4YUD_&;X0Z1+X'_:QT!6UW1]-LC/<6EZVF?\ 'M$6N!'9H))##ECDKWW
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MM!X4D\*W/@J+P9^T9HUG-XED\4^%]+2S6[^PG[-9P/>R[Y2I\ZS9@,$&(,I
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MT"SCBT*SNH(4-]=2XM09)F=9H$^^H94&0"G.:?$6G?L$>$F_;Y_X)JQ-XG^
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M)1115 %%%% !1110 4444 %%%% !1110 4444 %%%% !102!UIOF+G% #J*
M<C(ILDBQ+O<_+W/I0 ZBJ=AXAT35)I;?3M3AFDADV2I'("5;TJX#0 4444 -
M\M2,?Y%<Y\0OA;X+^)&F#3/%.FM(JOOCEBF:.17P0&W*03C.<'(S72T8!ZB@
M#QK1OA]\2O@C>W%YX-O5U_3)I UQ_:3&2]Z*"05"J5 4 #DUOS?M)?#P>&;K
M5+Z^^PWT"-MT?4&2.[=P#M58BVYMQ&%QU)KT4CC %<Q\0/A%X'^)UI':>,="
M6Z$,PFAD$C(T<@'RL"I'(_*@#*^#W@?4HH)?'OCE WB+4F;[0Z'Y8XLKMC4=
M ,*#Z_,>:Z_6-2LM&T^:_OIMD,:Y9O;I7GTVC?&;X7NTN@W\/B+181G['>;5
MO%]6#JJJY'88&?>L#7?BEX7^.OB&S^#4,.H:;<21_;]7M=2MS;S+;INQC)/)
M94Z=5;/2@"O;_LY>$_C_ .%;K7?CEH(N)]2O_M6FM:7!A>&#AX3N7!S@Y*\C
MDY%8]UXJ_:5_9FU<-XIM/^$P\"P0F.&73=-:;5+?'RQ[@BQH^ OS$^N<U]#6
ML<-M#'%&#M1-J]\C _PKSGXP>(#XXU>/X*>%+UH[V^C\^^O(X]R6]NI;<"V#
MM8L%'3/S4 =-\,_BUX&^+>@P^)/ 7B>RU.UD $C6MPCM"Q4'8X4MM89Y!-=1
M7B/CC]D'3;&*;Q7\"O$5QX1\2+;A/MT,GFP7(!S^^C=6W<-)C:%.7K(\#?MC
MR>$/'=O\%/VD+2'2_$$C)''KVG)G3+N0EDPTA(\F1FC8^6PX#+R30!]"T57M
M=0L[J!9[:Y216P0T; CG'I]1^=6* "BBB@ HHHH :85.??O7!_&7]F[X3_'&
MQ2V\=:$TDT+*]O>6UPT4T;+G:0RGG&3@'(Z5WU'X4 <+\!?@'X)_9^\!CP%X
M)GOI;;[1)-)<:A/YDTC/CEC@9QC XX KNJ** "BBB@ HHHH **** "BBB@ H
MHHH **** "FRDA/E([?>^M.ILHRA&/SH ^?_ -L#6[GQWJN@_ #0KHQWFKW:
M7=PI4%?(C61R&ZD#*?G7N'A_0=*\-Z3!H^EP^7#;K^[16X&3G^=>#? O1XOB
M+^U/XP^,NH)(LUC:KI,%NTGR;0D+;@/JQZU]#K&=P(7B@"2BBB@ HHHH *Y_
MXE^(;CP_X$U35M.>/[5#:,;59?NM*1A%]\G'%= 3@9KPW]JSXGZAX,U3P[X?
ML-"^W6MU?";4BTFQ;>.*1)-[MD8'RGIS0!)X>\,IXEU?PCH5[#+#)HD,FNW#
M1L1NNI&#-&PP<#_2"0#SQ7Y._P#!7_XB_$;]K?\ X*.VO[)5QXDT/3=-\/ZK
M;Z/X9OKF5HX4DO8+5W:Y9"W(E^7A0PX&*_2[X8?M.?"G3KCQE\1?&&NS:79+
M#)<-<7FU8(H+=&6381RX'E[N,D]AC-?CK\#-'\ ?MN?M>>+OBA\3_P!I:/X8
M^(-8\4+JG@N:^TW[:;C4)KHFV@RI0!D(B ;!!QT%?%\95I5*-# PWJ25U>UX
MQUW\WH?TQ]&O*Z>'S3,^**_,H8&C)1FH.?+6K)PC+EBFVHQ<G)).R]YJQ]6>
M$/$WPC^-6F_\,!_\%<=)D\%^)/ K^=X3^(UVT.B1ZGI%BHL;=/M5[F6Y$LIN
MI@VT+(!NZYS!X8\2>._V3;QO^">7_!3?PPOB/X;>)(_L'AKXFV]N_D6-QJ#;
MI9QJ=^% $,<C!MJ[T"$D$ 5B?M:WOPT_:#^)MC^S-_P46M%^%/C[PEHD2Z?\
M:[YFNQXETJUFGMHR;4%1&MS,\]R#DA?+*],&NJ_;#\2>+_AKX3T?]CC_ (*2
M>#V\8:'?736WA']HBXN#;QZ;<7<6YK@6H'[P6L3X*%OF\LY/->3*4DIRNFX>
MZIO6Z>GLJWZ2MR]>8^_I4:=>6%PTJ<E'$)U98>#LH2236+RVI?E;6OM*"FJF
MO+[-V?+33QYX?_X)_>(IO@OK/AP?$S]E'QXIO/"OBVVB35(["\NA]C,?]H2[
M;>)HS;3R[4R5\W<N?G AU7X9^(_^"=OBQ/VE?V&_$R_%O]GW5E73_&&EZ?*_
MB(VNG1XN-4E<Q!;6#,<;()&; +C<,=8/&^O^&/V6OV7=#^ GQ9\%K\>/V?\
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M U+]L'_@G!\7(?!_C&QT=]3U?]G:&U,TMSI=C+&LNGF[+$8O)K>!MVT&/[4
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M8-@C=%6!@W(/3K5C]K;4/AQ\>/B5I_[,/_!1/3Q\,?'OA718HK+XY7C-<_\
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MZ6C7%PT]Y-L@NYU!"(2$_>_,R"I_^&=[S]E:X3_@J5_P27\;CQ!\,IFW^(/
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MV\3XA?LS_$!CH=]JD:V^E+9S:B?]/G$=M]HOI#';+-\@9%;C85/(A;P3K?\
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M1110 4444 %8?Q#T+4/$G@[4M%TV0+<7%N5@9NS<$=QZ5N$@#)--W(?XA^=
M'D.D>'OB#XCOO#VDZQX'ATR+0T#3:@9 YD9860!/E'!//?%5_'GP^^*;_%!=
M?\(O<1Q_*+.2&Y$=M"H+;A+'C]XQ!X)(Q[U[-L3KMH**3G% "6_F"",2G+;!
MN(]<4^@<# HH KZAJECI<+7.HW<,$2_>DFF"*/Q->7^//%OCO7?&7_"/^"/B
M7I.@VUO 9))+J&*8W&4W!E+,-H'<\UO?&_X3:I\5M(ATW3O%)TX1[A)&\'FQ
M39QC<F1G&#^=><^(?"WP^T22T\*:A\--2\9ZKI-J8+R^TM,>4CC.QOWF5RO
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M SW_ (2UBUMA:+JCV4'V.SADOI]TI\RZN-Y$>3^ZW+@J:H?&+X8ZI\>Y=/\
M^"D/_!)?7ET_QM?6FSQMX2\,1FZU%-6OF,]VSO-\F5$NTJJ@<9&WH-+QSJ/P
M_P#^"I'PS@^)'P<L[?P?^T]\+)/[0N+6\9KK5-6@TF)@J1*NV)#)?2PE,@D,
M.0<\7.,N>:FO>FDVE\%:*^U%[1J+MI=G'3JT:.#PTX572HX>;5.4M<1EM5VO
M"O%)^VPDG=1FD[)O9Z.O\,/"GAOQUX*N_P#@DI_P4*O/[!\>:/>"?PQ\0(W2
MZ:6V8G5'1]0NR?ES+Y(51C"[#DC-9_P>UKX@_LGG5O\ @G%_P4VT<WWACXAV
M$DN@^-(F;59M-U34/+T^W"W-P?*B"11W,N?O)P>C&KFB^#-/_P""C?P=D_9'
M_:\OH_"O[4'@V;R+'Q!XLWO>SV;2F_.V&#9&F+5D7)R> PZ8#OA9\7?$?QY\
M&ZM_P3G_ ."LVEWFE^-M:AFUKX;^*?&?R1V=[/&NFZ?%'#;[6D/F2W3@LP4@
M.I'"M2NG.,XW3M:,FNFWL:JZ/M+7U*Q$O]DQ-#$*+@JGM*]&G\<)MZ8_+I;3
MHSLI3IJ[7+:UGI#X)T?Q?_P2>^(UT?CTZ^/OV=?'S2VFGZ@TIU=[6UM0\EM,
ML (AB+320+S@8'R\J,TXOA5\;_\ @D9\3/\ A>_PGUL?$SX#ZU)'X<5+[4GU
M'R[>X5+F^G-G;D1(R&UN$#<*2P!R7.;?PBU[QI^R/XAU']A+_@I_'=ZU\$=:
MVZ7X+\2:Q_HFC0C3\W2SQB(&9U>00(/GR&V C&:J_#G7OVDO^"2'C:3X&?M/
MP:CXZ_9YU:S_ .$<L;Z")+/23/J)2YFE0D-)F-/MJNF[G#$$;0#C&%.%.'+&
M4%%NSWE2EUC+O2ENFKJUCJK5,5BL1B5*I1Q56O3BYP7NT<QHI652C+_EUCZ2
M?)4B[-MWLW>\_P 6?@'KL?B:S_X*A?\ !-KQ7_:GAG[4WBCQ;X#N-1%BMOY&
MWR;/[#:X9T<)-E6))'0X)S/\:?V>]#_:QN+?]O\ _P""8_BR33KI9EF\4>!T
MN8])6"SL% )6VM_WC>8\7W6ZYR,$YJEXN\!_%[]@GXGK^UW^P3JD_B3X >*[
MP:[XCT3P?#MM[;2K,J/(GFN-[X8-/M8   -WQ4GQ2^!OCWX$>+8/VY/^"2/B
M-;OX<:^T5OKGAOP/"TGV6UM%5KOS9;G>-K/&^2%!'09(%:RIWC)3I/=2DHO5
M2TM5I=XO1R6]WL31Q-3ZS0K8;'4[NFZ5"K6C[LH)^]@<P5O<K0M^ZJ62:AI+
M:VAXKMM'_P""O?PRM?$_PMN%^'_[2G@%?]/T6U4:/;ZI+?3*K?Z0^9IC'96;
MOP<KOPWR.*=:^&_"7[<WPG'[&/Q7UC_A#OVCO@[;RVVBZM:A;==>N=.0V%BK
MZA-F20RS;6+1X)'S+T%1_%RTTK]N;1--_P""C?\ P31NE\/_ !H\,JTOC+PG
MH[?:]6GDO76PA;<^(1MM8KJ3 7+(2,!@M-\3>"[/_@H)\+=-^)7@+5XO"_[6
M'P>C6;Q997BM/K&LWVC1>2H55VPI+)>A"HVD!S@Y7--^]-RY>>4H[KX:L-KK
MM5779W1ST98?#86A&%9X:G1JOE4ES5LOQ#LG"KO[7+ZE_=G&]N?5W3NOPLU,
M>*/"5_\ \$AO^"D5LNC^(+<11>"/B/&%NIMS,^JW6Z^NB54!5M8/D'S!MC<[
M<5OA5X=\5_L?:AK'[ G_  40A34_!/Q;L98/!?C:.Z_M632KR\*Z?:R)-.?)
MM0D)FF+ 94J"#C@V]!UO2_\ @HE\))OV"_VWK9?#/[1OA!=GAGQ1XR+/<7+7
MDYO9U2WM]B96Q@@C^<MPZ'J6!K?"_6?&OQ(\.:U_P3?_ ."I4-U9^(-8M9I?
M@KXJ\8*8X;6^:/\ LVP$,5OM:3]Y+)(-S8(0@YX-4G^\A*-V[<L92TVWIUNS
MZ)ZZA6A[.CB</B+0C[15<10I.[YKIQQ^736DJ4O=G4I;Q4&K6VK^"+KXS?\
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MDUWX(^)KR#4/%'A_P9;YCL]+TD1K=17$USO;;(ZWV&505&X<X&;7Q@^']O\
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MW5[B1]:DM-+T_P S[#*L61#$TSWEIN4C:0IV?<%6OASXE\4_M,_#S6OV#/\
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M<^8^T9;/?FM&L+X::3K.@^!=+T?Q!</->6]G&EQ)(VYBP'0GOCI6[0 4444
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M-F&Z-E(Z\4 ?*W[1/B?XO>'_ -O+X;VOA+X?V=YH5[I$\>KZL=2>*6WPMR0
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M(V&O?\$UO^"LT5Y%X3LHTTSX0ZUXDLAX?T59-*\VVWPW@6UENXW#VC1\REE
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M%:.V5OG'EMM7"JQ+.\9^*/C%_P $;OV@X_V>O$J#Q1^SA\1-4L;*WD^)$_\
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MU[<!GD @@CQMNLIE@"O &9\%/$7B3_@I_P"#?%'[(G[4!ATWXS_!6V-Q\/\
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MMGCNHK; :T5U##RVP BJ27C^*5[\??\ @C/\9X_ OAF>?Q1^SQXTFM=/T_\
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MAOE^'NEC6+7^R7+Q6L<VHW46(I-K1?,+D!AR'.:=^SY^T3XV\2>-[K_@DO\
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M!^L^.8%\/:>M_'$=.LDC\I;>6]+3SLR+Y<PD16.&.T&S^SA\<O&_P'U#5O\
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M5I5:2J5:-.:C#&TU?DQ^%E;]SB:32]K3>LDGI9M$?QPT/Q]_P3IU_3/V_O\
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MJ+PW^U+I/_#N[_@I[X)FT?6K>:2>Q\:^(GCT&()!Q8QE&6)WW%25RW[S_:/
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M#O7)X?#7A;QE<6_]DVMK9W1;^T+Q+N5-TL:_;8]S^8/*\H_,I(%*WC[XD?\
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MIWPU+%U,13O;FY*69TDE^\6O[C&4TU*5W>4G+KO=^-_PRM? .EZ7_P %2?\
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M:V$E]:Q.%JX"+FX>TKX2$U[.:W_M# 5-.6:?O.E:[@W'O;/^(%[^T!_P1?\
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M._"S'":U WKM8G^E &#<L_\ PO)%V?+_ &/%\WXW%=HWW*\SA^(7@[4?C?\
MZ'XAM9/+TB,2;),[3F;CIQU_2NT?QUX2>/RQK]M\PP#YE ')_"U9#\9O'DWD
M@1M-9A9!_$1%@_E7=:V,:7<X'_+N_P#Z"U<!\(O&?AIY=:U2ZUBW$UQJTJG+
M'YE65PO;^[BNCU;XC>"YHKC3$\1VK3M P6)9/F/RMVH ;\&D\OP%;C=G_3+K
MK_U\25:^)EQ':^"]2+*N)+&6,Y.,90UA_"?QCX:M/!<-O-K-NK+>71QN.?\
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MCOXP\(Y_LZWM%M]NG6T;R7A>[E+WD]S)\D/RE,-\I5J37;;X?Z1]G_X*6?\
M!)"TD-MX39!\9O!=JDEG'+91C^T]0+7&I$,Z,L4496WB9CG>F2-M:2E+VG+*
MUTN:45V_Y_4FMD]W%:[IZ[S%0J456HWDI3=.E7JZ*-FD\NS&#^W'^'3JU.:+
MYHN+27NV/A5I/P,_X*AZ!>>,O@=HTOP?_:4\$0PWFH>(K=HM&MM8UJ\<_:I"
M(#+<2[?L]QC*B13+S]YL9GPZ^,OAO]MO79OV5/VH?!/]A?M(:;)<6OP[^+MC
MIZV:VTFFQF:P:2XF9KD[KN&4L4C);S %PS5HZM\*O@U^W_HO_#9?_!,W5O\
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MVZ&NB?&[PZO]@> _%UY)-J$SZCK?S0R-'IR"UC\D-IP7S)"C;?F*8<TGA_\
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M$ZM:;QYX&TS_ (33]D'XY1B 6=PQLH-+FU-L2$1,);Z=X["S?EE17\W;\K@
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MM\ OC_H__"(_M<>#T'AGP_K42W-_-?3Z*/M-Q*SH([*)IIH;]-KNP0DL"XV
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MF\EM;O4-KM/]MOVB.V-)D4,D892F,$*"7_$/XIW/_!//QJG[*/[</A:/XT?
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M-X$D^'O[3VDZ?/XBM/B!I\,.CVUSJMNXM]*B:8M+=%0LUD654W9@)3.U 6>
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MC7GP[\,XT[XL>$X87LHY8K/_ $Z8M+J?[XK)%-!'MAB.-N02<@3ZO\,?A/\
MMM:(W[;7_!*'5_\ A&OCMX1C&M>./#-A;2YNM2UGY9E6\U/RK?\ = :CAHT(
M<-@"/<A(_;.HE*TFU?E5K372=%])+XFE9[BE+#4Z,L1!U,/%2Y*6(JIRGA9-
MV^JYE#64J4_@A.:E'EFNB:65\+_B[\.O^"DVI3_!SXT> _\ A#OVFK&&:_\
M"_Q,M;&+2X%NK+Y=.CDG=I+GF5HV*I'N.T[,$"IO 'Q0^#/[3WQ!F_X)^?\
M!3GP"\WQ(TW5I_#.A_%S2;:&!DL-+#L)7O;Y_-8RRV]P?,$6)!/D@%V(L?\
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MHH,&E?&;0-1^(]Q_P3M_X*O>!5\:ZW#J$/AOP'\2=/MC(^GR79S=737U^Z.
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M1S^M6A^QY^S^!@>!HO\ O\_^->G44 >8_P##'OP _P"A'C_[_/\ XT#]C_\
M9_7YCX$B;_9\Y^?UKTZB@#@]$_9N^!_AZX^U:/\ #+3X9=FTRK&=Q7T)SS5O
M4/@5\)=5A%OJ/P^L)D60.JR1G 8=^M=C10!R[?![X:L<GP7:?BI_QJ.7X(_"
MJX97N? 5C(T9S&60_+].:ZRB@#DY?@K\*YF5Y/ MC^Z;<A:,G:?4<UYUXL^!
MG@GXK>._^$6;18;?0=+C1[R.S7RY+N<EB$+YW!5\L=.NXU[BW2O(?C!XYMOV
M?/$S?%[Q-J%C9^$IK>.+7;JZO8X?L;*2!(#(0""9!G&3QTH I^+/V,?@\]JF
ML^"_"T6GZUI\7_$ON/.;RW<=/-4Y# \YSZGUKH/AEX&^'OBSPC::K?\ @NT^
MU*SPW68< S0R&)R,'H70D5P6F?\ !0K]FOXV7Z_#C]G+XP>'O$WBC4LQ6=G9
MZG"QB?J792X9@J[F.W)P/>O9/AGX5N/"/@VQT:](-UL:6]*L2IF=VDD(]B[&
M@#SKXL_"OPU?7^F_#?P'X4L+&35-TNJW8@^>*RR$=H\D_O-T@(X/X5(W[#_[
M/UWX5;PW<^$Y&:2$I)??:G$[$CD[@>.2>@ %='\:/#_BBVFTWXB>$+B$7&BN
MS7T,S[1/:##R("> ?DSSQQ7F[?\ !4']C'3+L^$M8^.GAN'Q-#-]FN- ;6[<
M2I<]#%N+[<[ACKGVH W_ (0?"WPEH&O:E\*-;\&V+P:1"AT:XVEI9[7UE.[&
MX$CL,]:Z+XD> _A[X3\*W&J67@JS^T;62VS'D"0HVTG+8P"*F^"^EZIJ]]>_
M%?5M0AF7Q%''-IL<,@=8;;;E!N7*MD;3\I(KH_B3X6E\8>$[K1K:39.T3-;-
MN( D"G;G';/6@#B/#'[+_@G[$^I>.[9M4U:Z5OM=PTA5%/;RU7 7 [UF:/X)
MLOA'X^LO"%A8"Z\.ZAEX_P"T&\V2VN2P& _#%3MZ'(!/!YK(U3_@H'^S]\%9
M3X&_:B^+OAGP?XJMEWSZ;?:I&GF1L3L=5#%@&&<9 S@UK?"?Q7I?[3GBNU^-
MO@?Q)87WA*UC^SZ?)8Z@EP)IHWW.Q,;,O&[ YSZ@4 >FZEX:\)6]DUQ<Z/;M
M'$I<9CSCWKS;X<?";0OB)-_PLOXBZ)'-=2-)#;V$+8MHXU(4';_$QQDDGCH!
M7L$UFL]LUM+@AUVM^5>'ZE\:?"W['NG267QY\56>E>%S?$6/BK4+U(H/,D.?
ML[[F#;]RO@ '@4 ;7Q%\(6'P:B'Q4\#)- MK(L=YIOF9ADB<[>$/1MQ4YR.,
M^M>I:<(;NRCN7A'[Q PW#H",X_SFO$-*^-?@S]LN"/0O@OXETO6/"JW&[5M:
MT_5(IED5!D1IY;%E;)C/('%>Z64*VUK';I]V-0JY]A0!YE<:);?&SQ??6E[=
M20:+HMP;62S@;RVGG!)?<1U7 CX]<U:\;_!/1+/31X@^'MA_9^M:=$TNGB!]
MD<TB@$+*O1E)'4\^G6L?XF^,]._9FU'4/BCK]_96_A:ZVS:FUUJ$-N()-[J9
M-\S(G)DC'7/'TKFX_P!N7X$?M S+\*OV=OB[X=UK7M5'D#[-K,+&VSR_R*V]
MF"+(?E!&5H ]7^%?BC_A,?"D-QJ5O'_:%J?L^J+''\GVA1\^T]UST-=2;:W)
MR8%_[Y_SZUB?#SP?'X/\*6NC^9YDXC!O)O\ GK-@!G_$BM^@!@MX!TA7_OFG
MCC@444 %%%% ";%/:E*@\$444   '04444 %%%% !1110 4444 %%%% #9IH
MX%WRR!5'7-9>H^-/"^F1M)>Z];QA%W-F0< #/\N?I7GO[:43-\!-6N/M$T<<
M*^9-]GD*.RA6X!!'/2OGO]F'X+^!]+_;>\?>']4L)-2TZ\\(Z7=V-IJDOVE(
MB40L-L@(&<^G(H ^KO\ A=OPN=XX_P#A.;$&09 \PC^E<[\1/VO/@%\+/#\W
MBCQE\08[>QM\F6:*WEEQCG^%3Q711_ [X,J59?A)X7]%_P"*?MN/_'*XW]JG
MX7_#F+]FWQA%;_#O0OW.@7$D*#28<*0AY V]: ([[]N7]G[3(H99/$VI2QRQ
M[XY(="N7WC\$INF?MP_ [Q!(+70;W6KB3^[_ &%<)CC/\:BO0OAII&F0^"--
M-OIT$?\ HBKM6%1^%;PLK=3E(47Z+0!Y#XQ^.]EXJ\%:G8:1\-O$6H1S6+JB
MPPP)OX[^9,O'^<5#^P9K5]K'[-F@R7\+0R0O<))#)MW(1,W#;25S@CH3FO6O
M$43#1+I8%7<UNX7Z[:\A_8*@DA^!*VUXN)X]:N1*O]T_)Q^5 'MU%%% !392
MP7Y3]>,TZFRR+'&7:@#\O/\ @O;\7O\ @H)X0\'_ !%\!_LY?LY^'_$GP\U;
MX3D>,O%&H:O%#<Z9F6X7]VCW$>?EPW"/]*_.S]IW4_VU=7^!OP9O_P!K7]F_
M0_!MK9>%4M/!OB#2M:2XFUVW6&%RTL4=Q((R@:(@[4)\P]UVU^R7_!5_Q#I-
MI^RC\<M$GN]MU>?">0VL/3S,>?N[]J^#_P#@L^K)^Q3^RBRL%W>"),,&Q_RX
MZ=U.?UKYKBZ*EP_6OTL[]K21^W?1SK2I^,66)?:=2+UM=.G.Z^>WS-KP;H_[
M,O\ P4W^)RZ9=^+[[X!_M+6<UQH-OIW@^!Y[&^-G&UQ>7[&WAA5990UY&0UU
MN B0[I!A7/&_Q&^%7[6OQ2_X9O\ ^"GG@Y?@W\;/#TT":/XN\(R"9]6U.[5!
M9+/';0S$"*(VQ&;O!RP#1X^7:B^#?P#_ ."B.@K\??V._'LOP4_:,T?;HUQX
M1M]4M_#4=[J$8$VIWZ6UHLMZ^]+BYC\W?N;R=L@&QFIFCW_[//\ P4WBF\/_
M +3VCR?!']I7PK&]TNJK9VOAQ-;OGQ'I<;R77G7TK)&EKV1U.=G!5:^9C&=2
M*Y>5RF[ZZ0K+IS6^&JGK96NE;4_:I8C#T:CJ?OZ5/#QY7%7>)R^I)_%3>LJV
M!FO<:DZD4W=6;3>=\8_'OPZF\26?["?_  6#\,-X;3PK8I<^!_C!X=8-JNL:
M1;NUE913Q)#>R;9RMU<,QE4AU4%5;YFW/C!JWQ$_8=T2P_8[_;MT*U^)7P-\
M42-8:+\8+O;!JVEM>+YEU=0H[WTI>W1V5%"H3M&&/ JGHU_\%OVP7_X8M_X*
MIV\WP_\ B=X#39HWQ2CBM],_MW1K'-G$KZAJF^:X$\[W4_"*DNS>,,K 1:?X
MO\6?#"\A_P""<W_!730%\3>'=2D^Q^#_ (R0PR:@^G7]\-SW*:MJS!(T@BDQ
MN2(O'LYRHP'*3;E45G?W5)[KO3K+MT4GKYWWBG2IQC1PE2DW[.]6KAX-M-.S
M6-RZ2=U-:RJ4XS<7?^&TK)=>\<6O["WP?L;'P7X/M_C)^R3X_N/M.DZ[XLVP
M7VA:A<%K22&/S5D?]REI+,-MI&"\V <Y)N>#_AIJ7[(WPMOOVPO^":GCR]^,
MGP5FMKJQ\=>!?&UNT,-EIELIFU*97G>%2[B,QY6U<@.2!*/E:O-XL\(_L,:J
MW[)?QD\-?\+>_9A\52&_\#>-FM4UR71[NY(LD1;R8Q:?;M#+!>2E(D+(9-X
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M2]QJ\42^+'_8%^";_%+]FGPG:_';]E'Q=*)KBS\:-]EETR[69K18$>X#,/\
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M_P",XF'B#P_XY3[.-'CM9S:QK&UR>?.OKB=F*V?_ "P0'C;(*WPXTOP5\"/
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MZ[FDZ].3J8NE6J<MO8TZLT_:X>;5GA,=&W[W"R;LJDXMJ%_?LFEGQ:E\!O\
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MF.(0Z= SW$DHW$NK^7A@&!Q)J>C^#_V.[>W_ &U/^">=]'\0OAY\0HPOQ?\
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MA^)G[*/Q,CC3P7\2M4C$&K>';;5(<K-"CB>1FM+'>546\)9ONA2?+,XAU?\
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M<=+=BJF+>,J5YT\9[5XM*$*M6%J..4$KX7%PVI8JDURTZS3E+?FUN1:;\%/
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MI2K1Q-;#QH0]@ISCSSR^<GKA<2M?K&"JV_=5)7Y4HV2O9M^(&IVG[<UW8_\
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M"64]U^Q!^V!9GQ)\"?B%"VB3>)-,@^Q6MI<:FP2YD^T-\^(K<RLR*03C*XP
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M/[.FF_'W68O^"HG_  3)\2V2^,=-SKGB7P.Y;5-0CUJZ.Z2%5/[M65)7!4#
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MNCL1*,*F'>$ES5'[3ZQ.A#15HIW_ +0RVI9>SK1NINA&R?OK5)I5=%\"3?\
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M^=>=_ OX]:!\8K"YA6RFTW5+"80WNF7CKYJMC[P P=N5;M7HFY6BW,W##J*
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MD:I<?LMKH/COP_=BZ_X3[P1JC)<33",K )1]E,N$ RO[\'<IP%(!K]\S\-?
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MPV74I9[:.Z07$8F-O;)\KXW?-P2N>>#7](S?*J9.,L-N>WM7Y]_ ']I+X!_
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MK*!"1*ET;2$O!%_I\7DB0X4,_P#>Q5?PG\'?V@_V(?B$?VI_V$]=F^-7P?N
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M;R^(?A+XX\ZR^&NO>+KP:W8VT>ENT4$MKI<9NC;>8MW:MM;RS'L0')&54/\
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MRUC48])MQ>ZEI@ ANI1$H,B <!3MXQZT ?('_!3+X?\ BW]I/]LWX,_L@_\
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MW;P#XSX;X-XCQD\[K*E2KX>=)3=-U8J4G%V=-)\R:336FEU='ZD:7XI\)_\
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MWG-N5"X /<8Q3]%\,_\ !3U--6?P[_P38^,B6EPJW"M9Z;?B.0, 5?Y;;!R
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M\OY>A:=.7C*P-O;)"D!@1(.&!Y%?0$BY@V_[/YTL44,:".&-55>%55P!BG$
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MFOG#Q)-XP_9)^-UUXQN=$OM;\*^)I'N-4U"%9)&TQ@S\$L6X^88 ('L*^H0
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MS;805RPP>&P>M5_VO/"GBI_%'@KXJ>&-.FU"3POJCRR:7%*L8N0YC5078@*
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MY4B;I_HTL4AQZ[1G/M0!]G>%M5_MK1+'5$DW"XMUDW=CGG^M:CGY:\]_9?\
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M'?Q\8?\ 1*F/_I16;\8'V_\ !"[7N.O[-\O_ *9C6A_P53_Y,Y^/G_9*&_\
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M/V8-8U+5OB+82_9-&N+K0F33;F3S(@\L-P599-L9=MVTC( [YK[&\)?M&_\
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MORMWO^/-3G*G0PF.BXP<9NC#$S5U%)N/U',J:U<%_"C72:<>26U[-T;QNO\
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MO7KCC.*ZZ%=D>STH =1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!CX%?%[X)_%;X[^&O#_BSQ1\*2/#N@:MJ:0W&H9>X0>4K$;OFXX[UYO\4?\
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MP6_:P_X6Y^U7\5/V:9/!GV-OAC_9O_$V^U;A??:X/-^YCY2O3J<T >XT444
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MD/P3\4_B9^QWX-\1>(M4\"Z9<ZCK6K6<D]U/-) CO(TC.6+%W=B<]30!Z?\
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M8NK1;CQLL%]%;7!C6X00S'8X4X<9['(Q7]D5 !1110 4444 ?/\ _P %./\
MDP/XK?\ 8GW_ /Z U>J? S_DC7A'_L5=/_\ 2=*\K_X*;#/[ GQ6'_4GW_\
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M(_VC_*@#XCB^*/[$ZAD/_!*_Q3@?=)_9VNB"/48L:/\ A:G[$O\ TBP\4?\
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MI[T 245'YV?N@^^10MRCRA$:@#XI_P""FG_)Y_[)/_92KO\ ]!M:^TE_UO\
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M*>)E[&,YNV'QU--Q6&Q*_P"7.+BER<]I7J03Y]5(3XBW_A']HWP*_P#P4O\
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M %%%% &;XM\4Z5X+\-7WBK7;I8;/3[=I[J5OX(U&2:\YNOVG=-U?X;7/Q'\
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M$*_$&X#<W[-<I"^_]C&@#Y9_X-Q#M\,?#5C_ -$0UX?^7+%7U-^QOIM_9_\
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M<Z;HMK:7&U@WSQQ*A.1[BOYA;[_@\7_X*P2W<DMMX:^$ZP^8WEQOX3NF(7/
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M&9+HW$YX8=/+Q@D?0 _I[_X77\'/^BL>&O\ P?6__P 71_PNOX.?]%8\-?\
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MMR5;Y<]NM:6I:!\8[#1)_$=AXOAN=1CC^T)I#696*3OY.?,SZC/3FOD74/\
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M6T_80_X*@^&8?'WP]UJ3['X6^-<UM)+=:5=7RC?<QWNHF5%-M&SX*1AD"C/
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M+\#OCAX?2.XL_&&FPP:2^K3$".R@E-RL]PX 9) !(!QE#P#5OQI??V/=6O\
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M+X4_&"Z@$]QX?M]03R[2XBN[O=;1_8['=(!!"NTC*+MRI?<0ZO\ \$YO _\
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M[1KFHPZ5H]UJ5U(D<=O;O(SR-@* ,Y->?_LSW>DZSX%C\?0W44FH>(F:XO\
M;.IRR.R*?^^0* ,/XG^/OBCH7PWUJ]^(WPQA^P0Z?*]PVG3)<,D04^8VUW'1
M<XY[FO-O@UK7[-.ON?B)XMT"-]+OK**+PZ==TD-*+<* =H4$*"P;CZ^M>O\
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MM4>)=#TW2/#?A;7[Y8[3Q!XHM;"ZMGC9A<6[Y#I\H/!X_2L2]_8.^"OF?:/
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M8_"2-ZY#X=?LY_M:_LW^'IO#/PA^(/A_7;.XU2>^DA\10[9 \K98;XHTXXH
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M) )K]>?V=M3\"ZU\#_"^K_#6[NI]!NM$MIM-FOHV6:2)HU*F0$!@V#R",@T
M?(G_  4=\ :Q^T7^W?\  G]FC6OC5XV\,>%O$5IXCDURU\&:Y]A>\\G3HIHE
M=MC9Q(HP,?Q-7A?C3_@EE\'/^"?_ /P4 ^#GB?\ 9T^,OQ2M;WXF:]</XZDU
M+Q<)_P"U8[";3S LH\M05_?R C!)&*]=_P""LWC+Q-X'_:D^#.K? 1_%=S\6
MXK7Q$G@K3]#TRRN+.8_V?")OM)N>%41G(.X8YSVKYV^&/QL_:7\7_MM_"F+_
M (+ :9XD\-O#K<L?P=72=,L4@O-3:YL?-CN3:>8VT!;?'*J0S9/!% '[*R1!
M0"<-MY45^9>M?L?:-_P40_X*8?M*?#;X\_'KXG6?AWP'#X67P[X?\,^+#96D
M/VK3Y3.Q38PW/Y:\\?>:OTQN&(BV X/3)[5^27[3/Q0_:U^'7_!13X\2_P#!
M-?1_%FL>,[J?PVOQ&M[K1]*?3+:)+.4VWD23LDA9D+9Y;TH Z?\ X)9?L=^#
M?V"_^"LOQ2_9)^!WQ*\;/\.?"OP^TN_T7PKKWB(W5O%=WVV2XFQL3+%LGIQN
MK]1->D:+1[F5&VLL#E6SC!VGG/;Z]J_+?_@D+\0]8\<?\%'OB1J?[9$_B/3?
MVCKOP7IXU;P_<6-G%IJ:0A3R)(_LH*>9L\O.7).[@"OU*UH@:;*7!*A265<9
M(P>.>,_7B@#\5?AM_P $S_A9^W'_ ,$K?%'[77[4'QY^*VO>)DTOQ5=_8V\;
MN+%6T^ZO/LP$7E9P! ORYY+&OLS_ ((:^!=4^'W[)_A4:A\4O%GB1M<T>.];
M_A*M6%V;5@JIY<&%'EQ;5R%]Q7YZ:'\;O^"@GA/]C?6/!/["_A;QAJW[/YT_
MQ"FH:MXFT/16O5B>XNS?@'>'VKNEVMLR,#K7Z,?\$/O&?[)/C/\ 9-T5OV5_
M&/B35H+"UCM]5_X2:%HYXIQ''O !C3*\K@C(.: /MNJ/B'_D%W'_ %Q:KU4?
M$/\ R"[C_KBU 'S;_P $=_\ E'I\.?\ KPF_]'/7KW[67_)LOC[_ +%#4/\
MTG>O(?\ @CO_ ,H]/AS_ ->$W_HYZ]>_:R_Y-E\??]BAJ'_I.] '\B__  06
M_P"4U/P+_P"R@-_Z)GK^RJOXU?\ @@M_RFI^!?\ V4!O_1,]?V54 %-G420.
MA_B4C]*=2."4(![4 >7>#]5_X5GXTO/A[KD<<.EWURUSH=XW.]V.9$;T.X\<
M8P*\3_X+F31'_@E'\<$:7_F0=0+[5]8'_P#KU](?%G3OA_JO@Z?_ (64\<>G
MP2>9),S,K1$ X9=HSD=1@'GM7P7_ ,%?M:^)MS_P2Z^,FD_#]Y-0\-6_@F\!
MN_$$(20P>2^?+=0'<X)^^!UQVH _ /\ X(/^*O$G@O\ :I\=>)O"FK2Z?J%C
M\$?$T]I=P'#Q.L4>&![<U_7G\&+B[U3X6^&=4U2X:XN+CPW8RS2S<LTC0JS'
MIZFOX_O^"))S^T5\13G/_%A?%//_ &SBK^P#X&_\D=\)?]BKI_\ Z3I0!U7E
MQ_\ /-?RH\N/_GFOY4ZB@!OEQ_\ /-?RH\N/^XOY4ZB@!OEIG.*=110 4444
M %%%% !1110 4444 %->*.0;70,#US3J* &B&)1A8E'_  &CRX_^>:_E3J*
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M.&UC\I[":-9FD\M"421<\T[QO^S=>ZW\2+?_ (*Q?\$Q_$EAXW:SFE\3^*O
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MC#X9> YU\,WMG#$#-=7$DCRV[S(9_)C.("'9@<OCBU^T)\-[#]O6[L?VH_\
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M?AFVUVTAF\.Z/H]JMYH>BZ9)<74[10!07)6-HB",D9?GUK9^&O[3'[0?P?\
M TD-]\-Y/#_AJ:,2VEG-IK2W,JLJX)\R(;#C9QN.,&@#ZOTS]J+P!^T7\5?#
M_@7X0:A'J%K;7$=_JMRQ9 (P=^W SDD*>#BNF^./B+PO-\9_!/PI\5-YFGZY
M#=>=8E3LF*A"@;'/WAZXK\^?A7_P40\9^";6\^)LWCO2],TBQN O]F2:5;M>
M78) 4>8#D*2<=#CG@XY]Q^*W[3WPB^,GPWMOBSXJU6\\/^)K.UA.G6EC-%)<
M7B\.#$C/'N))(QB@#Z7U;]A_]FS6+C^T+3P)_9]UN)^TZ;>21-G/U(_2N%\;
M_L)?$6[\?:/X[^''[1VJ:>/#\C2:58ZK91WB1.0 #RHST[UXE\(/VO\ XYZ?
M:EM0^,UK967F9L--\9Z'!I\\R?PA74R%N-HS@U[=JW[97Q?^''AJ#Q+XZ^ %
M]JUEY*R_;?#5Z9EN%(4ADW0H#]Y>"1UH Z;3[O\ ;D\#1,=9TWPGXNA7EIDN
M'M;EL#LBIMR?3VK1_9?\3:OXTU+Q5XN\6>#;C1M6?4FANHYNR([* /8*H[5R
M5U_P42\"3>"KC75\ >(M,U+[&9;+3=8LQ"9I-I*QY&[DD#H#C^?;_#;Q"NG_
M  "OOB_K^G&UDU739M4O[99-QB),C8!('8CL* ,_0_CA\--4_:-UO0+WQA90
MR:59+;M'=7"QA928_NEC@_=[5ZE>>*= &DW6K1:O;36]M \MP\$RL H4D]#7
MFOPL\!?"KXS?"32_$&O>&(KV&\>YGC:9FW@//(>60CU[UA^./^"?OP7UW1M0
ML_#5QJVC-?6<L,HLM0DVE61A@J6Y'/2@#"_9%\>Z)?\ A]?#7BS3YM2\0>*+
MJYO[B40C:]F76)6?' YCQ@#H!7M?Q9>R\._"[4-,TM%@::QDMK%%Z"1D(4<^
M]?-G[-_[('[7_P $](FU#1/C7HLC22-''IM]H@79"-N%\W:QY*_W3]XFNJ^*
MGC/X\S>)/"_@;Q]\.[6:/_A(;.:35M)NW>+B0_PM"G;WH ]RT[^S/ O@-7FS
M##:V^9-K%L,2<GG_ &C7F7@'X1_$C4-$_P"$ZTSXI75CX@U*63SKVXM4NH_)
M#!4548 #Y54?A[G.Y^U?\5O#_P -/ASY&M;V.J7D5LJQ*&8 L6W8R,#Y#S[5
MK?#KXR?!JXT&VT;1OB-H[&&/;Y+:C%YG&<G;N)H \[^/6I_M >!-!T!!)HGB
M"X;Q D=K<2.UM+)(;>?C8@V],GKVKH/ASX]E\ ^%(]%\:?"G7[.5H_,UK4EL
MLVLEP5"R/NSDY(/:L[XQ:]'X\_:1\&_!8,JV]O:R>(EN5Y#,D5Q !D>TF?3%
M>X91SY>T_P"ZR\#VH \._9GA^"?B'XJ>+?&_PLTE;.9I(;:^C:-D:5U:9O-P
MQ.0?,QD>E>\5YU\+;N#Q1\1/$WBF*T$)M+F/2MI4#=Y)D?<,?]=37HM !111
M0 44TN!UIRG<,XH **** "BBB@ HHHH **** "BBB@ )P,XKY;^,+3?#W]J3
M3Y?ASXLUS3]:\2V+S7>CZ;HL=S'>2+GYW+'Y<#(QTKZC<G:<'M7SM\0O$%EX
M4_;0\+SZS*(+6;3;@BXFX <HZ[0Q_/% ',>%M0_:DUCX]:MHOA'Q#]B\S14G
MN9/$>DI&[OE0K*J9&!DYZ=>E=S=?![]M:^@:9_VLM/M5D7,L$?@VW8)D<J&/
M7'3-:^@^/?"UW^TOJCQ:_:^7'X=0,SW"+_%&>YKT>3X@>!6A=%\9:7N"XV_V
MA'G/YT >3_L':;XIT'X4ZSX=\8^)O[9O['QIJL4^I+:I")<3?W5X'Y5S'Q^L
M[=_VN-(\,;OF\4^ ==M9$/\ RT5+90 /IO[5O_LO^.?#%CXM\?:9=:]:1QQ^
M)IYEF:X58F\QR>#G&>*P_BKXJ^'?C[]LOX9:AX<UNSU"ZT'^U[2^:SN$D-OY
M]L@VG:3C.,4 >,^,)Y](^+_[,;Z?+Y<-KJ4^D2JO.09HCCG_ *YU][Q9SDGJ
M2:^!OB!=6JR?"7Q+>-M;2_C%);PL3]T&:?'Z 5]\1DE\]NU $U>.ZM;V^B_M
M=6&O; LNH>&?L.[U57>7'Z?6O8B<<FO'OC=<_P!D_&WX:-;IAM1U:]MI,>BV
M,[C_ -!H ]@5L]Z'4,N&J*$YD/\ GN:F;[IS0!X/;@Z/^WOF-=D>H^"/F4'A
MW$C,3^@KW9"2,DUX;KMM<0_MU:#J4K,(YO#,T2+Y9VD@3'.?H#7N41SDXH =
M36Y.#3J#TH ^ ?\ @M!^R-^S;\8?@'\8/B_\3/A'I>L^)/#?PJW:'JUX',EF
M0]PXV@,%^]SR#7G/Q._X);_\$_='_P"".NN?%_3OV7O#L/B2W^ <FIQZPK3"
M5;M=*\P2Y+D;MW/3K7T9_P %4_\ DSGX^?\ 9*&_]N*H?&+(_P""%GB+#?\
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M4?50(2T61VYP:M^,?@Y\+ETO4-:D\*6\=PEO)+]HC8JY8*3USZU9^ G@_3/
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MQ+"0J%,97'E^]:>J_MU?M$:SX]O/$WAOQU-\/[=;<?VBNN>'[9Y[D( 25CD
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M'=6TP5HIU8-]TJV<TX2(>AH =12!U)P#2T %%%% !102 ,FF^8G9J '4444
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M_P#CC]L[XS?$SP'K7AS5O$%UXGMX/[4TV^BGN);)=&TP8RC',8D4#/3MQG%
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M3C*]*^1_^"Y01/\ @E)\;"T?3P)??^B'H _F-_X(CC;^T1\1AC_F@_B@<_\
M7.*O[ ?@?_R1_P )_P#8KV'_ *3I7\J'_!K-\-_"'Q@_X*A/\*_'^G-=Z+KO
MPPUZSU"W20J7C9(MRY'(R"17]9'AK1;#PYH]GX?TB#RK.PM([:UB+;BD:#:J
MY[X  _"@#2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ^(_\ @IL<?MF_LE'_ *J3=_\ H-K7V<TBJ5('\7]*XCXK_LX_"GXS^._!
MOQ%^(&A27>I^!-4DO_#4ZW3QBWG<*&;:I ?[@ZY%=RB@NK]?FI/_ "_,4O\
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M[4(+5I*G*,ZE/>\;R@MI=JM)[<W5I];HYZ<N6CA,53DJ:C-TZ&)FFW3G=Q>
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M//$\W]F3VNH,/*TL#3H(K?SR"^51IL2[,-NW$BQ\-_VG-5^$OB>X_P""4?\
MP4R\%KK/PY.J2:;H/CCQ)<_\([##H&FKMT^1$MHT>2&66QCVR&X)(DVLSA2&
MF,TZ<'&JU9VC*6MGTI5;?9T^)-]3;%8?%5,1B:&)P-.?-!5:U"A))5(J]L?@
M)-V556;E2:O9+SY<_P"+>G?'_P#X)%^/H_CA^R;>-XH^"_CFUBLK6Q\7:@=0
MM([RZ_TB8I8V;P>4RQVX57*9",RG<2NV;X[^'_B1^P/K.G?\%"?^"=E]-J_P
MM\968UC5O#VMWP_LFVO-18^3&FFVC6[+&D3H(PP9H\*"W' ?BI\??^"*7CNX
M^&,NC7WQ(^!?BB#S-%N#8II.GI>WK!R5N_*N))9$@A8%?,^8.6PI'-CQ/KWQ
M8_X(S_$7_A;'[.-O-\1/V??B KZ_'IEE9BWTVT-R62R@;4WCNY)2D7EE6W+Y
MG!*DL6$RC1BI1DY0Y'=K=T6]I1_GIRZKI8VP_P!=QE?#2IPHXJ>(C)4Y2;C#
M,Z:6M&M?^#C*2:4'+24V]=$W<^,/A?PC\7_AOIO_  5-_P"";,TVE^./!]Q#
M)\3?#.EE-%TN>VL(FO[]I;51%/=A[@01N#*PE08Y90PJ'P]K?_!5+X$?\-7?
M!"^D\)_M0>%9OL.M6/@NZ70+>[C>;8LDDDN;B60:>JX(GX7Y,!<)4WQ-\%Z5
M^S5+I/\ P5<_X)F:[]NT74'@LOBIX#\/J=6CAMF']J:I]HO[AI_LT9\BWC?;
M$AC!4JR [3#XWM/%O[6'@:/_ (*[_L&W<WAGXR:>QT_Q5X"T&W_MZ\$CR_V=
M'*WG#RX0+*,2;5MEROS$YW,=:C:YN>[DUS2C#:2T7M:3M\:TNN]SAPLN6AAJ
MV&DHTX5/94:]=/GHS=T\!CH)ZX>;O%55[JC9]TK/PU^+/@S_ (++_"_6/!/Q
MPT/2?"7[0/A&2XUOP!?^"M+;2YKFVM;=8[.">^N_/(4WUW(QBCD0_(KKM*L3
M1^!'Q!NOVKKS4/\ @E)_P4KT^UTWQ!H<::?X1\5:3;&XUHW]L3>76[4KIKB$
M%H8%4NJ+O3*@[BI&EJOB7X7?\%D/ %S^TE\,=&M/AS^T#\+[DZAH^DV>HR:U
MJ&KZ5IL/VB$1VI,"1B2^O542>5(=\84^9NV+#X.^(2?\%<?!%U^PG^V-IEOX
M#^,W@ZSC_P"$>\7:O+NO-0O@XEO5_LN(6B;C;P.I7<VP,7&W!4J\I5J<>=3<
ME9-Z1KJVL9;\M1+9O2]O0IT8X7#8JF\/+#T\/-3J4T[U\LJW25?#M:5L+)M<
M\4W)1D_)O*^!O[2/CSX9>*YO^"9W_!6GPUI>HZ#%8N-/\0WUE+KFK6^KWS1F
MT=+N1YX@4ANY@C^6#'M52V-P+=8\6_&'_@D?\;?^%)^,/*\8_LZ?$#4XK:PF
M\;7#:[)#H=NP%XT$-O(D4#M]J?<K0D.8U.T[3G4^%7[55M^V9I+?\$YO^"JO
M@G^P/$UC;S7^F>./%VHMI=Q_:[_)I\?V&".VW,L5YE4,F)!&<@[B13\*_'GX
MG?L >,;[_@FA^VMH$WC+X,^)+R'P[X?\5:O"GA^UL]+?_C^NHGBC>2= ;I-Q
M-P63R^'&[-9QJ/V<)*;M%\L9M>_&6WLJJU]V_N\QM6PM;Z[B,+5P4)5:E/VE
M;#0E:CB*:U6-P$[KEK+^(Z<E=P;26Z4'Q/L_CE_P1R^)D.O? S49/&/P'\8+
M!IUG%XXU+^U(09%66]9+.U>!(Y.'!8QX*G'/.-;X]:3%^SG)H_\ P5F_X)8M
M(W@G4O/F\<>$;S%EHL&0FF68&EV_V>5X_-FNI/F+[7"RC:N<Y]G\5OCU_P $
M=_'5Q^R_\2M(N_B7\#M>5+;1]0O-/CT.QCDOBKW,B7"Q3O(R(SJ4\T+QE0F!
MBYX_LM1_X)-^/;/]L[]A2X7QU\!?B#YS>)/#>CPE]/M5M4%I9QS:M*+J7!O;
MR=UX0EU9"'[4Y4XQJ:RC&#3:WE0ETJ0_FAWVWVZ%4XXJMB,+.,:=:MB8<E.H
M_=H9I1LN;#XE/^#C%&W+*32]HGK>S9\2O"VN?&/X6^'_ /@K7^PQ+)IGQ$T=
M8=2^,7A?3)ETG27>Q@%YJF^T4I<7*R7<:"0&9S,O0EOF%B"VT7_@K?\  )OC
MG\*T_P"$1_:L\!QF34(? X70([\W5R88#-<3AIYBFG6N5VSC8789V.%JG\1(
M/%_P8N=$_P""P_[ WG7.G>-Q#=_%OX?^'[?^T8[#</[2U>.YOI1+Y"&6,1N5
MAC,7\)0?(;7CK3[7]N/P!;?\%5OV&7_X1'X\>%5DN/%O@7P_N\07UV[S+IEH
MS)*1'!BTMYI% MCO20\$IN:EK*<'[S:O4@MIK=5:;Z26C:=M?O.6G+V6&PV(
M@U2A3J^RH8B6LL-4U7U#'1O[V&E[T%5CIR\KM:Z5#X:^/=0_X*H?#O7_ ($_
M'6VM?#OQ\^%]O-J7PQU3PO$VGWE_+90FW@BN-1N3,Q5KZ=&8121L60.I&TFI
M_P!GOXZ>'_VJ[O4/^":'_!4#1]/L_$6B^3X<\"^*K'2?M.L+=Q,PO7.HW)N(
MUD86T.Z554-N/)^7:ZX\=+_P5@\ W7Q<\*:3'X"_:)^ \8U;0H;:4ZMJ&OKI
MT33;%L<01QE[YX5SY<NU]J8924-SP)\4/AY_P5W\)W'[)'[:&D6G@7XR>";*
M/2_"/BK6=5?[5>ZI,2+Y_P"S(3:1LX^Q@-&2P0N2NP@YJ$W.4'"?,Y*RYE:-
M9?RS_EJ=%_2*Q6'CA\/BHXC"^PIX>:G4C2:=;+JDK.-?#ZVK8:H^64U'51<E
MHTF_,?'WQQ_:,_89T'QO_P $^_VN-,L->\!^(O#.MW_A?5O$TDNMWUJDEG/;
M:/Y4RRF&%1<6MNP0Q?NV=F&W@CWC_@V;_P"29_%H<\ZWIG7_ *X3UX[X@_;$
M^)'A7X,^./\ @FE^W_\ #NXO%M_#NK3>#O&'B*4:.T45C9.='CCMH84,RO=6
MB[7:5B[2E#Y@7GQ?_@G!XJ_X*!>'O#7BB/\ 8N\5>+M/LYKZU.O+X9^'MGK:
MO((Y/++R3D>2<;L*!AN<UR9;*$^),*H3;2C4TDO>@^5MP?=+=/K=GL<=8>M3
M\#<\J8C"PI59U,')U*+O0Q,?:KEKTUO&<_>52+LU:.USZ<_8+8M8?LD9_P"B
M[^-__2?6*_7Z+[OXU^!/_!+C7_CMK'[67[-EC=^)O&UQ\-8?'_B>;38O%?@.
MUTU1J1LK[[21/#*[%O.:7"L3CIA>E?OI;1M'$4+[OF...WI7ZF?PB244#I10
M 445C>/]0\3Z3X/U/5?!VB?VEJ=MI\TNGZ?YWE_:9E4E(\]MS #/;- &S7EO
M[;7_ ":/\1/^Q3O/_19K\V?&'_!83_@OM\/=>\-^%_&7_!&[0;'4/%FJ-IV@
MV\GCA<W5R(C)L&'./E5CS@<'FN/^+O\ P5G_ ."X?Q9TOXA_LUZY_P $FO#^
ME7>EZ# OBR9_&B-_9-G>^8L5R^7VE=L4C'!/"'I0!]Z_\$]_A?I7Q@_X)1?"
M?P-K%T\,-UX+LV\R/.496+ \$=Z],\2?!#XUCP>OAO0/C EZEO/:F&TU*S$<
M?DQ.I:,N@+'*C'.2>]0?\$X/A_=_"S]A?X7?#W4?$.GZM<:3X/M(;C4-*F$E
MO+)LRYC8$@@,2.">E>W;5_NT >:V/Q4\?:#LTG5_@OJ/EVRK')>VLRF':!C<
MHV[B/P%<S\2/B[X8\5>/O"NE2:=JUO#I]]_:4US)I<GEJT?RA&.,#.\\^U>W
MA5'11^5-EM[>>-HIX$=6&&5E!!'I0!\S_&SQ;H'QE_:1\ >#_AUK5M=7WA?5
MH]1U15=7VPG:<<98=^H%?2\//(K&TCX:^ - UR3Q+HG@C2;._F7;)>6NGQQR
MN/0LJ@D?C6Z !T% 'S_^W+JFM>)]$TSX)^%IE,_B*[6'4X]H+BU<%"5'4\FN
M6U[]ESQC\/)/#'A2T^/NM7^DWFHK:7.DR*S1&-4:4';YAV@,G8=37HGQL^!'
MQ"\6?&?0/B]X!\06<4FCQ+'-I]] 2DZABWW@PQR!4%YXP\?6'QHL]0^)W@"Z
MM]'LM'=5U*QB:XMVNF?C:J!GW!2>3Q0!ZY<:5'=6$EC&[0E]P$D+;63T(QBO
MF;]H?XL>.?@IXS\+^%/B)X8U'QUH,]T9KJ?1+3=<696.9HY)4P!L!CQG)))%
M>_:=\8?AU?0>=<>)[>SRWW=2S;,?^ R!37(> /$?AWQU\;M<\;Z-XBLYK*UL
M5TQHDNE;$L;J[' /^T/SH \E\<_'+PO^U9\=="^!_P /H+R>WT__ (F.IWZQ
MX%FR)* LH[99D7KU:OJ^S4QPB+'W>!7R3\+?"$GBS]JWQ?\ $'X*:C;V,8M9
M(1?6<*/:W4HE5FC;;T./?.<&OH/P)\2M:U;4CX2\:^$[O2=65"QVQN\$P'!=
M7 VJ,@\$YQ^% '<,,C%1_9ESNW<^]+%+&Z#;*&[=:>#GI0!FZGX3\/:RLB:M
MHUI="9-DGVBU5MR^AXY%>-_&KX1?LC_#+2O^$O\ %/PHTFSNKBY1+>\T>W^S
MWI9G5,QR1E74_,.A%>[5\V_M/>)]'M?VF/AUX7\6:[8V^DW-S+)<6]](JJS)
MY; _-P?FQ^- ')ZI\.?AC8:U:^./A5\;O%'@[7-0C6V2^U*&YU"68, PA47<
MC \H#@=< =JP/BY^SE\?/BOXK\(ZE#^UKX=U^+POKL6J?V+KA^RR7DL8&T/#
M"A4-G/4'K7T;XW7P[X\\<^$= TJ_M[B*QF.K07$#*ZE8V2( 8X_Y:5K^._!'
MPGM-#U#Q;XB\):?$1"TT]Y';*LQ[Y#@;L_K0!\R?%SXI?&_Q3?:3\,/BQ^RO
MJFL0^'M2;4;W5/#]WO@D5,;=BA8SC9*."/X37>:%^V%X!^*'AO3[WQ=<>(OA
M;=6M^9KC3_$%H+<R*C, FXL%(*@'\16EX%\&ZOJGC=;SX5>--2T&%M,%W-#<
MR?;5N5+*40F4_NP0<\#@ @5J^"O&VL?%?XP^)/@9\9OA]X;U"UT&UCFAN/+\
M[S]X7(:.0%5X<=* -/P[\5?AO\<_#\7C7X!^*_"FH++J)35+FXD3<T2#;)_"
MQ+ 8Z\>]8OQ.^#_[/.NSK\1[/]G[2_']UJM_#8:A)8003+"@PIE;)VX4=<<\
MUJ>)?V'/V??$$OVG3_"DFAR,OS?\(]=26:GZB)@#_6N=\-_L:?$GX0Z3-H?P
M'_:,U/1],:62:/1[S28KB/S&'+>8S;LG _*@#B_C!_P3D_9>\^3Q%XFMY;?1
M[J2*"PTF&.>2UMICT?RTEV<[?[HY-?.?Q6_8V^)7AG]K+2O@3X4\>#6+.YT=
MM5L+-_-MT@39(")(HR58%@V"0>6!)KZT\&67[:GP7\,?V)XR\(:9\1XQ>-*+
MJ&[\NY;<>%VR$J OO^%>"^&?C/\ M/\ @#]JG4?VD/VDOV6?$D$D?A_^QM*T
M_0;=KQ?*:2-@^Z)6Q_'D4 8NC_ #_@H9\&97\51:YJFM:;=6V]?#^AXM4ME?
M!*.0J[MF,'(.<"O.9_&WQ^\%:1)XV\4^ O&6H-(OFVNA^&;B\AAVOC!8X1"0
M2<]1P/6OO!OVEO@EINO2_$?Q'^T3#:Z1):BW/AO4K?[/LE=@=Q60"3<"<= !
MZBNX&MR:[JYTZ]?PVW@N;3U$,\=^%F,I8;5P#M"[<$8P: /C_P"$7_!5%?AY
M\.QHWQ%GNM?UZ\_>:59PR1O):QA%_=2E >5R1D@G(KK](_X*EZYX8N+72?&7
MPXM=<U;4-ICT?PSJZ/<0*?[XD1#Z]L?*:]8O/V4/@#J]U-\.]-^"$.E6]K8Q
M36OBBSM47S6=VRN]?F+#RE)R>1(/6O%M4_X)7_"'2([KPSX ^*=_9^,GTUY%
MU2YTWS)YLJX3YV;Y1E9#@'^(GO0!],>%?VJ?AUJ_@"/QOXFNX=$E\E9+C2;J
M\1[F#(&0RKW&?T-:NC?M'? _Q*\=EI/Q5\/M=38VV4NK1)/TS@QEMP/U'%?"
MUI_P37_:2^$/A#7=0\)?$/3KS7)[>6XD9I'DO9-JG AW,0"><#[O)KP6?]G7
M]HCX@Z9:?%3P[\1M/\"Z;X-UBZM/BO-KFC0-?ZJZJF%@D5<QL&ZXP2&SSF@#
MZD\#W7C_ ,>?\%&_'WQ"D^&4GB/2_"=XL&BW%K(C$AX6B8*67'\)'4]*^F#K
M7P:U2<77C/X5S:5J4WS2^9II8QD]_,3C\J^=?V /@S\>+#X/WWC3X=?$:UF;
M7]3F>WUC5;</.]LMS<",DYP_R$<GDFO<+3QK^U+X1O8] U_X>_\ "06:R!=0
MU67RXU:,]61$Y_/- '2QZ/X#UEC;_#7XO7%C?_W(];DNM@]/)EE(7\A6GI7A
MCXU^'HR;7XBV>O,W##4K40;?<>4K9KA_&WC?X$Q7*PM\+)K?SDS?:K:Z6UHT
M)]#*44G\#47@;5/AAXFN5TOX,_'34]/G49D:2.2Z5AG[NZ;Y>OI0!W.H_$[X
MH>&+I=.U#X/7NJ*I!DO-'N 8E'7@. 3QV]:TK'XZ^"[B=;34%O+"3&7^VVC(
MJ>H+=./K6:T_QF\//_9UKKV@ZPJKGSK[]S,P/)X0A?H?6HY/BEXCO)WTOQE\
M%M473]O[^]WI-"WK\B@L1^= '8Z-X_\ !WB*1H]!\3Z?=LO\,%XC'/T!S^E:
ML<Z2C,9#>ZG(KR&^TW]F[Q);FW2WC\/[3_KHK>72]W_ ML>[\ZT-*^'4RV,:
M_"[XY7=G99YC:2.^#GV>1B1^% 'IT^<<"O$?@=\9/&GQ2_:#\;:,;MF\.^&G
MDTZ.%8P5^V++G=N X/E\8)KIO$GB?XT?#[1+C6M8;0]1T^QCWR7$C-',XSC/
M!VBO(_\ @E3XPA^)OP9\0_$X>';C3IM>\537DZW'5V:-#N!P,C!/- 'U112;
ME]:-R^M "T4FY?6C<OK0 M%)N7UHW+ZT +0QP,TFY?6D9EV]: /BO]KK2/[+
M\+?M':B\0=]0\/VEQ;GNOE6Y!/ZU](?LGZXOB;]GOPGKZRLWVK20VYFW$_,P
M_I7D_P"UWHEI>7OC3PPT"[O$'PYU*X,>T?.(4BC/_HW-=I_P3T>$?L<^ 8@N
MQHM%*-&>JXFD']* /:J\5_;ET>\U7X RVMG&TC0ZWILV%;DJEU&Q/Y"O:JX'
M]I'2CJ?P>UD$';;Q+/G']Q@^?TH [33IX;N);JWD#))RGTZ?TJPXW+C-<C\%
M=>;Q-\.M)UE+O[0MQ;M(+A6SO_>.,9_"NN8[$Y:@#Y;_ ."E7P:\'^+?!GA7
MXJ:F+J'5O"OBZUEL;VSU2>W=5E6:%E_=N@8;+B3ALCFOIG296DMUD+[M_*Y8
M'"]N17C?_!0*-'_9TN6*CY-8L6''3]^O_P"JO6_!4HF\*Z7,RX+Z= WXF,&@
M#6I#ZTM(Q '- 'R5_P %49'3]CSX]N&/'PI)P&/8W%9OQAR/^"%?B 'G_C&V
M4<_]@>M#_@JE\W['7Q\"C/\ Q:ENGUN*S_C$?^-%GB _]6W2_P#IFH ^5?\
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M>/?^"I'PXUF_\5_%*3X*-\,;PZSJ'P]EUJ33&OP=3,'F'301Y@?[,03VV^U
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M9E7\:O\ P05CQ_P6H^!*QG:L?Q")V^O[F88%?V54 %%%%  >E?(W_!<P;O\
M@E)\;E_ZD.^_]$O7UR>E?(__  7*_P"44WQM_P"Q#O?_ $2] '\U/_!OK\2/
M%7P?_;-\7?%'P+J'V/5M%^"WB2[T^X8 [)$CB(/((X/M7]=7PJUG4/$'PS\.
M^(=3F\ZZO]$M;BYDP!ND>)68\ =R:_DA_P"#=+X0Z]\?OVY?$GP7\-WD5O?>
M(O@[XBL;2XFC#+$TB0@,1D9 )R>>F:_KE^''AZZ\(>!=%\*W\ZR2Z9H]M:22
M*N%=HXU0L!V!(SCM0!NC..11110 4444 %%%% !1110 4444 %%%% !1110
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M  [\1AI8K"SU;%[>10:5&4M8BML&A0-N '[MMP8FKGQ.T6Z^"_A6Q_X+&_\
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M<^Z-5M\@+EU[#-?:_@/]HG1Y/@]?^-=>U>\74-1LI;N.QO[62-8BQ9DBC9@
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M]K<*TMBS^(H602*#E2PY&?2OKK]C#(_X*K?M69]/#7_I *^2_P#@VN\(>&-
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M7O\ P0N\?^'_ ![^RMX9BT/0]0LY-'T6*VO/MNFR6HD<I&P90R*)!AL;N^*
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M/0!_/%_P:P?$?PA\(?\ @J3_ ,++\?ZN-/T71?ACK]UJ5ZRDB&)8XBS$ $D
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M:^+/B;X4^!.K1?\ !-7_ (*\:+_;7P[\-P_VK\-?$FGR,MZ--@+:?ID;PZ8
M0&BAN9#YAW L P. :^;_ /@FO\(?V2_C_P"'O&GPN_:"^),/A7Q,WV.Y^'FH
M76MI91RZ@5FB6(GEI"7>([%&?ESR2,?3OAOQM\*_B?IW_#NK_@K;92>&]8\#
MW!D\(?$:98]'CU#2K)?L-J%N+D>=<++)]JE5\;9!@]5.?R7)XU(Y:G#D3FVD
MVKQE9V]G5[-[QET6A_H7XB8C#XCC*I&JL14IT(TW.$96JT?W<''%8!V^S?EK
MP5W)V?FI?&T7Q6_X)2PV_P"S;\;;J/QS^S'X\_XE/]H3+%:W5K'>#?J$R"UW
M7>]4:10&<*0%VD,21!J7Q&UO_@GSX8M_CW^R'!'XB_9-^)LC&XT76I/(ELM2
MF+64Y5I0]\<1V>Y3D(2^,# )3PYXG\=?L07,W[ W_!1;2&\6?"3Q6O\ 9OA[
MXB6]B5ALI]0P99QJ%[C:(89&R5&4VG!.#4UC\1=#_P""<VOR> +?07^)/[*'
MCQ6O=#\16D::A'I][<$6/E&^F @1HWMKB5D0Y D4X4DY]"4O9MS3<.7376=*
M7W>]2:WWZ:]OAXT8XA1A4HK%U*[YWRRY,/F-/7]Y!-_N<PC\71MJ:Y;NS;IO
MP<T'X!^')O\ @I1_P1]UB>\\$Z:DMOX\\)ZU;E$ETFQ475ZIDU!FG)?RD4"-
M0XW$KGFJ_@[1?!O[0\5W^W#_ ,$JKRXT/XY:$@U7XL>'YMTEK--JFZ6Z6.34
MLQ;(WAN541*"RE=NW %27WPHUC_@GUKD7[7'[ ?BU?BE\![QETWQQH-C(^M&
MVTZ(_:-3ED.!;Q+Y<.SS&^[YAR "<M\1^&?#7A&>T_X*$?\ !)35Y-:UF]D?
M4/BK\.89O[5GTX:FWG)"UE;@K"L7^FJ58[5* */EP*<)1M2E%1LKRC'6W55:
M+[7^)/97)JUJ.*YZ]&O.JZC]G1KUK+F6E\'FD7]JWNTZCY5S.+OII7\%6_[-
MG_!4K4I_CK\"8[CP+^U9I,+^+I+'3UN;BSN)=,*V]A"&NRMJ@=A8$OL(!W@A
MN318>+?@5_P4I\7-^RK^WUI4OA_]H'P_,WA3P[KVC^=-'<W,1+W4DB0;+12\
MD<@PV5P1M[5>\0^ ?@/^V7 W[=W_  3D\50^&/C+IDW_  E.K?#-]0#W#V.E
MJ8Q;QZ?:*WS3S06953\K^=SS)BII;3X!?\%3/#RZ?XOU2/X5_M/^%[=-&M;6
M\OH])&I:L/WMS,MK#F<G(D7)&]3C@XS1+V]33W)RJ>]LN2LENUMRU5Y6U?4T
ME4P-&4JO^T4*>'7(FY.6)RVH]%%]:V!;]UI)V@MTWKG77Q6\%?M,^+9/V#?^
M"P6B?8?BMX?GCTOP3XIT6261I-2U?;Y;S1Z?LMOW:/8[=^5.#G:=PI?&'C?6
M/V+M2@_X)U_\%+M.7Q#\"]44CPCXBAD\F_M-.LB9+=A%IW[WY[A80=[;@ <Y
M&ZK>E>,?@]_P4C\.GX)?MM_\6M_:,\(1O%H&I:E(F@_VKJU^<:>OE?Z^8QK'
M8\8##S/E^\*9X<\>:9HT4O\ P3'_ ."L^B36.E1S+:>#?B8UJFG0BUL=TQD%
M]=XDE266*%0Z AB^TXS\KG.4KU%)/F=HSDKW6RIUT[.[U2ET_.)4Z%.:PM7#
MS2I+VE;"TI_PW\2QN5SL[0VJRIJ^DFME=5/$/CW5OV%M$M/@7\7=*A\5?LC_
M !8VGP;?7#>7=:?IMULO;EE6#-XS@W14"1\L%!&-Q O:GHGC7_@FUX+3]O+_
M ()[:Q_PE7P#\9A;WQ9X9UQ4@$2^9]DL5$MQYEV^)KEV++@\#?D8(KZ!\0-"
M_9QN;W]@+]M#1IM>^!/B5OLGPH^)D*(MO;V-VWVPSKJ5QA7"0W$:%HLA#'@9
M &)8;CQE_P $I_$B_$;P6J_%K]EOQPSW5TNFPG55L;:!3#9JUQ,!;PN]U<HV
M0?F$.,Y"TI2<:CDW90TOO*@^JLU>='JK="8QCB(PI*G[6KB7SNG)VPV94[[I
MW_<X^*5V[J]6#LKNS;I&B^$/@=X:OOV_/^"-$\TW@70=^F_%KPOKBL!<0V:K
M>R_O-2+S_/'+$F( ",9!R3AW@_X8?#']KZWN/VX_^"66LWOAW]H/PEY>L^-M
M!FWR6=QJFM%TN5274R852)?[0V^6H# J/E^3$=_X;\-?\$_=;M?VE/\ @GKK
MO_"SO@3J172OBEHMK-_;K6K0-]HNW=D @@#6K6Z!G.1CG@J2[Q9\(] G>/\
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M:-5=K?9J^=P4L#A*DJB6(PD:"4%+F<J^75.W>K@)]K/1-7UUI^)OCYH,&O\
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M[2XU:_8Y19-0/D*J[;G!5=C< @8&$UCPYX+_ &2=9L_VY/\ @G/K+>/OAOJ
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MA%_:$2C+7EC?!5/T0EFS^->B8%1W"L(&,)"MM^5MN<&@#X%T_P />'_VA?\
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M#-8\#?LEZ#H6L_%WPWXT6UM+:*RU;PQ:F.W^S"WB,:_-+)\WS;NO1AP*VO\
M@IGI-O+\!+?QB/BCX;\)7'A?7M/U>SU3Q83]A$MM?6UPJR8=#AC$$X.<N* /
MA_\ :O\ ^"3GC3]CJ\L_^"@.@_MK^-/%WCCPOXHTO^R_^$HT^VD0K?:K;VDL
M)=2'6,I=2<*1^IS^G?P4\1:]XG^&FCZKXG=6U!["'[7)"I =_+0LP!)(!+'C
M)Q7XP?'3_@L7\1OVH_BMI/["'Q/_ &A?@SIFD^)O$EJ[^*M$TK4 L,=A?17B
MY9[AHT9VM HW$']Z.#UK]EOV?HM.M_A!X=:P\26VLPW&E0-'JEC\T-SF)/G4
M@GY3C(SB@#Y._P""C-E\</C'^U[\(?V/?AY^T=XB^'?A_P <6OB >(=0\-QJ
MUQ(MOIT<T:IO.!\P()(/#'&._AW@3]BCQ[_P2@_;I^&]S\*OVBM<\<R?&B^N
MK+QLWC*UB62:*UN+ QRAX"A:0"XD'S$CI7L?_!5W6;KX$?'+X9_M?>&/V@?A
M[X5USP79ZY]AT3QY'(T>IFXLHH66/RY4;*@^_++7R9^R[_P49U?_ (*>?MX^
M%=#^,W[27PR\-W?P=U)9M+M- TF[@/B"XOKBU!@CDN)RLFTVRC]WN/[T9% '
M[47 =H\H.0W3O7YD_%W]G7XY?\%+OV]_C]^SIX@_;%\:>!?!_P -6\-/HN@^
M%=A607NGR-,9?-9@W,?W0 #N.:_32XN!'$MPKX'][;G(_I]:_*']MK]J+Q/_
M ,$U?VU_C!^T#\-/VEO@^U]\2&T%=<\%^*X)WU'3$L[&14?%O< G?O)Y4<$4
M =U_P2=^&/CK]AC]OKXF?\$U?#GQ1N/$WPZ\(^$=+US26U*S2WGM[N\ DEPL
M)$>TEST4'@=:_275WEBTZ::#[Z1LRCU(4D?K7Y4?\$//VC-)_;I_:[\;?M\>
M)?CUX)N_%'C3PW!HTWP_\.VD]M/9PV#B);IH[AS)M8#/( .>,U^JVL1O-IDT
M*/M+Q,N[^[\IYZB@#\5K?]@CXK_\%'O^"?VO?MW?'[]NWQ[=ZA8Z)XDGM_"L
M,$,FFH-.GO/*0*Y+?\L1N.<^E?H!_P $B_BG\4/B%^R;X-?XGS:?-<2:##):
MR6,31YA6-$7*LS9/';''Y5^7GQ@_X*'>-?\ @G-^S!KW[%?A7]I+X+^+/!]U
MI6M12:Q::9>SW\*W\]UYL7EP3%2Z^:W..H (YK]*?^"+Z>!KC]ECP\?!_P ?
M/#_CG^S],BM6N/#O"6V45_*==[%7 Z@X- 'V;5'Q!(HTFY5SA?)/-7JJ:U:/
M?:;-;1,0\D952I (_.@#^>+_ ()P_L@^&?CY^Q3\;?VG/B'XUMM+M_A7XVU>
MVBTZS\%:=</>6\:I(=\LT;,6W-_=_/I3O@]^P]\8/BM\1?!/PW^//PEC\!>&
M_C9-+'\,?%%KHNBW3+ U@;G=.D<>[)79C!A(SGV!\.;O_@IO_P $S_@W\=?V
M&?BA_P $]M:\4:/\6[S4M6T77O"MXEX;=IY#$OF& R)M*QJV&*GGOTK-^%G_
M  4=_P""M4_Q _9^;XW_ /!,G7IO#OP&5(;-="T>[ANK]$T\68WM(S+DA%)V
MK@9/K0![S_P3Z_X-(]'_ &>?VK=!^.O[1'QJM_&&B^&M0^W6_A>3PM;?9M1E
MVN/+N%>256095L!0<CK7ZN^&?V /V*_!'B*P\8>"OV2?AIH^K:;>1W5CJ6E^
M";&">"9>DB.L.Y64X8$$$$"OD?\ 9>_X+@_'?]H+]HOPA\"?$W_!,KXB>"[7
MQ1J7D'Q!K-P_D6L>S)D;=;(I X_B%?HU0!#%;&-MW%3444 !Z5\B_P#!<W_E
M%'\;O^Q!O_\ T2]?71Z5\B_\%S?^44?QN_[$&_\ _1+T ?S&?\$1_P#DXCXB
M?]D%\4_^BXJ_L!^!O_)'?"7_ &*NG_\ I.E?Q_?\$1_^3B/B)_V07Q3_ .BX
MJ_L!^!O_ "1WPE_V*NG_ /I.E '64444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?$G_!34X_;._9)/_52KO_T&UK[(U9A)ILZ]-T+_
M /H-?&W_  4VP?VSOV2@?^BE7?\ Z#:U]/?M&^+=7^'WP \<>.?#S1B_T3PA
MJ5]8F9-RB:*TDD3([C<HR.XJ:LE&DV^S_(Z,'1EB,73I1WE))>K:2_$_ /\
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MH+8? _P7_;R^*C?'3]FWQ]!^S[^TAHFH21WW@;Q5<16DFL>(),RW,L.9)+K
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MX$_LUKAF\27I,NH%;O598[?Y(;Z4'9$8F,?R88A01C5Y5"5-2;?,XP>LD_\
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M** "BBB@ HHHH **** /B7_@II_R>?\ LD_]E*NO_0;6OHC]L;_DT[XH<?\
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M+%T\3*C3P=Z4:LX\U?+IO3V&*C9>VPTG[JERPM!QUTUH?$2V\!?MA_"W0/\
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M-X/SYV*[X!>%OC+_ ,$;-:UC]H?1M'T_QY^SG\1YX[ZZ\1>'\WFK6>E+YO\
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M; @CUSZ4 ?*W[4?_ "DR_9[_ .Q?\2?^CM-KZPKY._:B.?\ @IC^ST?^I?\
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M'[9:QS>8EO)Y8W(K\!@#C![BOS>_X*1?\$4_^">'P;_9@UCXH_"[X;:QX?\
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MY)Y2)W=RV\+C#8&[&!FOU'UX;M(N 1_RQ;^+;GY3WH _$'Q;^V#^V=_P2_\
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MQ.\2:EX?N98=4BTWP6^V,QOL;YG=0?F_'%>B?\/=?A9G'_#,WQD_\(U/_C]
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MV^B_''P;,VLZWH-]JCW>LSQZ<NVV\G3HVFC#M(B;,QKYF5#9^[5'5/AO>?\
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M_!2S2[_1?C5;VEYJ'@'7?'@30+=M2N4^RZ;&L-OY+3MOF#!&B=7 R-Q'%'X
M>(O$^C2ZQ_P3<_X*V0WT7@>&--+^%&L^((?[#T;.D>;!YD%X@MI;I7#6ACR7
M)4Y;&]B:A*-:5.2FY<T6N:2M?_IW77?I&2M9DXS#RH4\=A:E&-.TE5G0HN[6
MJ?US*ZEOATYITG9<EUJMJOP_3]HK_@EG\0V_9X_:RAU#QE^S;XAA_P"$1AU
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MZ]BU'Q5X=\%P^5'::=I/EK=0SO<%I"))$OC\J97+@9.VI/B]X%M_VQK/3_\
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MLOPMXBU5A'I-LM@QO$GCCC#RD-*L$8!889D))R15CX4?&#7OVQ_A?J_[!_\
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MOCMY+?52KG*@8*RJW7.#TK]MK=RR<KBOTT_B(DHHHH *CN!GD ]/2I*1_NT
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M/(O\?<?G0/\ @JY_P3N<A4_:[\$'=TQKD7^-?,?[3.K?MV_ KX=V_CBQ^/\
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M&5AC/I0!T6E_$/XG_$JT_M?P#X;_ +*TZ53]FOM<C^9R#@GRLAL9SWZ"N/\
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MGL2T11=HA4[E$,8R6QUP!7V7J$!N;9H-S+N!!9>HX^E8P^*7PV^ZGCW16/\
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MH58GY>.2<_C0!U8]J*C68 <)_P"/4>?_ +'ZB@"2BH_/_P!C]11Y_P#L?J*
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M&G&%1591:?*I27P[6IU;6]WHI;>ITXC U,1BL3@Y8.E5]K35:5&A-*-=*_\
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M5_$2Y_X*S?#3Q+\(?B_%9:#^T/\ "6TGU+X::EX)A-CJ%X]A$88HKC4;II@
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MM\X7:<_]=*]C^)O_  4Y^%\O@'5;:U_X)@?'VWDGL9(O.F^#Q54RIY)W=.E
M'XC']L7]C:!"RZW<1QKW;X,W(4?^3U6K3]K7]DB^MUO;6[OI(6^[)%\%;QE/
MT(OC_.OU2\$_&3]FSQC^R!XD^&K_ /!./XJ6&I2^!=98>,O$OPR:WL8Y#%+M
MD>;<0NT,O;H#Z5];?\$K/!'@0?\ !,_X6>(M0\"V-])'X/\ -D6/3(VFF*R2
M' &.6/0#UH _G=^)?[0?['/C3P3J'AO6M;UBPM[J':]Y:_!JYADCP=PP[W;
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MJ^*;3]ECQ-X%^RWT<?V'XA>#!I]Q+E)\LJMGC*]>P(]:\U_X*Z_%CX:_ _\
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MN (>02Y10N3D>@K]0_\ AYY\(_\ I%C^T)_X9D__ !5'_#SSX1_](L?VA/\
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MGX3_ +3OP?\ B9\9_$WEMJ'_  EWPI^%;KI0MW&8[<XD.)%Q\QQSZ>@!P'P
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M[=I[NZG\'Z@B11J,LS$P   9)SQQ0!_2;^P.[O\ $+]D%6<G/[+,9Y]X(O\
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M2>/K3_@J3\.S^T#\)-!7P;\?_@2JZO:Z.)1?7VO1:=&;AA#IJA.7OC;KDQ,
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MWX!M\1_BI^S#X7US7M2\9^(I-0U2^MG:69AK-V 6(<9.!^E 'V)_PT'\!?\
MHMGA'_PI;7_XND/Q_P#@&QW'XU^$<_\ 8R6O_P 77D7_  Z%_P"":?\ T9KX
M-_\  63_ .+H_P"'0O\ P33_ .C-?!O_ ("R?_%T >M_\+\^ .03\:O"/R],
M^);4_P#L_P!/RIMY^T!\"GMI$A^-/A-F:-@-OB.U/;_?KR;_ (="_P#!-/\
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MJ7[;/_!(_7+RY^(4074?BU\(]65_[,M?[2WSM%%/.+.!TM62\C78)<AEP%&
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MT^;<RNT0CM5:26.[&W>5!?*L=R XGPWU#X'?M\>-3\?/V6M1NOAK^TQH,/\
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M RH';&/X.]<K_P $);N[N_ GQM-W=22[?C7?*OF2%MJ_8[4X&>@R3^=?._\
MP2\NKH_\'%/[96FFZE^SQZUIYC@,AV*?LUP>!T'- '11_P#!8+_@M;Y@\_\
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M'VB?$+25D2UUS2;?4+59EPZQS1K(H8=CAAF@#<IDL1DZ.5I^1G&:* $50!C
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M_P#!2N?X8C]GUT^(NA>(-0D_M.R_L&W\*W5U#J!U$WMLMMY#6O[P2>>82".
M <UY'_P05^.^D_'3]AW3=1T;P?JVDQ^'&M]$"ZI T1NS%:Q$2QJZJ0C!P1Q7
M>?\ !57QQX7^%GPB\*_$KQO>R6>C:#X^T+4-6OEMI9OLUM%J]BTDC+&"=JKD
MG@\ GM0!^9/QN\$_M>GXG:3XK_:*U7]I2W^#*Z];?\))X9U_5-7FBN)&O(Q9
MGS=V]2+AK;;MY#+R.U?L_P#L[2:*GP7\,0>';'48;9=%M0MOJDTDEU$/+4!9
MGE_>%\#DMDD]Z_/[_@H+_P %C/\ @GI^T7^SY-\&/@#^T%:>*?&6J>*]!^P^
M&=+T^\^U74D.LV,SQJDD*\A$8]1C83VS7Z ?LXS7-W\&=!U74=,N+&2\TV&Y
M6SNAB2$-$ORD=CGJ* /DO_@K/<?"F?XG_#O2=/\ #7Q U'XN26^M?\*]3X=Z
MMJ%K=H_V.(W!)M6"LHB^8[\<*<=Z^1?V;?#GQDTC]MKPK?\ [=MK^T!>K?21
M_P#"N+'Q5K&JR1V-PL]L+R1B'(:/<;?>) 5( P17U-_P4;_:.^#G[)W_  4>
M_9]^-7QW\2-H/A>SA\3I>:U)I]S-#;^9I<<2[S"C;06=>2*XGXO?\%+/V2_V
MQ?VV?@;I?['_ ,2E^(5SHLVL#Q!!X?T^8?V9'<RZ8D<T[21C"'RWQC'W#Z4
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M9LK*:Z4;C&F[:6(_E0!.R* 3BLCQ5XQ\.^#-.;5/$>JPV4"J6,DSXZ<].I_
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MGW+*PC@F)!)V]!]:_16P_P"#O#]IC4/%UY\/K#_@EMXBN-?L5WWNAQ:U,UY
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MMJ>?"G'$484\12E.==^TJ4:#_=5XJ[^OX"2:BJZWE27+)IR7)ND7'P]\>?\
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M7X6_\%&M>M_V4_VS[.3X8_'WP?$VBQ?$J\G>[TW5H;$G[9.(@]G;)YTJR;0
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M[X6_8*^&P_82_;7TQ_BQ^SWX@D74O#/C;PO,\"V*QN;EXS#:$NS-J#%</=]
M2./W5:*U.TH/EY-I/>$OY*B>]-]U?IZF-.,L5RPK4W5G7ESSHT7:GB8*_P#M
MF"G=*&*A:[I>[-M-<FZ))OAAK?\ P3>G7XY_L*_$^/XV?L^ZNRZ#\1O"<VI/
MXB-I)*#<:A</:6"Q6<96RMX8Q+.25\[;)B-URRX\+>$? 4'_  \F_P""0WB7
M^T-5D87_ (V^!TES%.MI:W:BUM[9M'T<!@D3RO-L>8A-@=2P!%3>%_ /Q&_X
M),>";[0[OQI9_'/]G+QYOT?Q9;^'5CL+BPU*]B N;H^1]IGQ'86>W GC1FF
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M=&C*GA9^THPI+VM2C&[K8":2?UK!M-^VPW-[TH0E-^S=W'9ID?B?1_V<I_\
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M)^/'[.=M;2KK&A_#NUU:XDY\LPS7D2*.G7D'K73?\$+,?\.H/@M@?\R38?\
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M5\C?\%S#C_@E+\;CC_F0KX_^07KZY/2OD?\ X+F#/_!*7XV@]_ =\/\ R ]
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MW=L7DC3S<P*R1ROQM*#8>"!BLSX;?##XR?\ !-KX@2_'SX,W\WQJ_9EUB/\
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MG\.O#.N:E!:?:[J;7[4,8(CN&Y"2,'V[UX/\"=(U'1_^"Y/CJUU'0]-L9/\
MA0NF,5TV/8K?Z;U(]?QH ^[I#A<D5\'?\$5];\.V'[(/CZ#4+VWC?_A;WB@2
M+)V/G=\U]XS?ZLU^<_\ P1_\,>)K_P#9:\>ZEHW@CPKJ 'Q@\3E6U2U#M+BX
MSACD?RH ^HO^">]YIMS\#7FTO:T3:Q,%:,?*WR1]*]K\0M<)HUT;6(/)]GDV
MJW0G::\L_8O\>3_$?X/Q:[<>!=)\.R1WS1/INBQ!+=2J)R.!UR?7@#FO5]7Q
M_9\VX<>2_P"/RF@#YP_8I\.>#X].^)$^G:9"UP?%5R;II(0663:>!G/%5_\
M@DHNS]DXVZ'IX\\6\KT_Y&34_P#&L'X2Z+8?$*[\=S_#?X?W^DQ6NMW<5_)!
MXA2-;JXP?WF%C']>O6M3_@CS;SVG[&]I:7$;+)'XU\5JRR/N88\1ZEU/?ZT
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M-/6_FCB@>4QW3Y1FE7.T,0#TKKOV.(OV_P#]G[]HSX\?LY?L6>#/!WBKX?\
MA'Q5:)I,?Q*\;WRW-DTXNI9=FQ"IWR^8QQC^'U.,/]IV-4_X*>_%8)N7;XB^
M'0'S'_H(::/ZU]3_ /!/X$?MJ?M41ELC_A--*';G]W>4 /\ ^%A?\%M/^C:?
M@'_X6FH__&J/^%A?\%M/^C:?@'_X6FH__&J^O/)C]/U-'DQ^GZF@#Y#_ .%A
M?\%M/^C:?@'_ .%IJ/\ \:J*\^(7_!; V[)-^S;\!%1E(=AXVU+ICG_EE7V#
MY,?I^IJ&^C5;23:/^6;=_:@#XU_X('S>([C_ ()]6LWB^SMK?5&\>>(OM\%G
M,9(HY?[0DW*C'DJ.V><5]I'I7QW_ ,$-<_\ ##<G/_-1?$G_ *<)*^Q#TH _
M+W_@JI_R-_[4G/\ S0C1_P#TX05]#?\ !"S_ )1/_!7_ +$?3_\ TFBKYY_X
M*J?\C?\ M2<?\T(T?_TX05]#?\$+/^43_P %?^Q'T_\ ])HJ /KRBBB@ HHH
MH *\%_:Z_P"">OP0_;&U'0_$GQ#LI+76O#=U-/HVL:?M6:$R1^6PRRG.5QGZ
M5[U10!Y7^R-^R'\)/V,OA+IOPA^$6BQV]CI]N8VNGB7SY_G+9=@!GECV[UZI
M110 4444 (P++@5\I?MQ_P#!(_\ 95_;U\7:)XZ^,6DRPZEHNH0WB7-C''^_
MDC#*H<,IW##>O! KZNHVCTH YCX6?"_P=\)_"L7@OP7I$5C96[,ZV\,:J-S<
MEL #D_TKIZ,<YHH **** "BBB@#XO_;-_P"4L7[*G_7GXJ_])(J^Q]9_Y!-S
M_P!<&_E7QQ^V=_REB_94X_Y<_%7_ *215]CZS_R";G_K@W\J /SP_P""6G_)
MW&H_]BSXT_\ 4O6O2?V,_P#E*Q^U9_N^&?\ T@%>;?\ !+3_ ).XU'_L6?&G
M_J7K7I7[& W?\%6?VK,_W?#/_I * .9_X+/?&O\ ::^$^F^&$_9Q^-DG@Z2U
M\/ZYKFK/'IXN/MZV7V0);X)^4'SV.17VK\/-3O=<\-VFJWLBM))#E]HQSD\]
M2?SKX1_X+G#;I>ED'_FF/BW\>=._PK[L^%(Q\/M,_P"N)'_CQH Z$<5'<8\O
M!/>I*CN2PC^5<G<!_3- 'QY_P3[^(7PO\.VOQ0TWQ7XBTV.^;XF2EH;K!D*_
MV98 <XYQ_(>U97_!/R;P5JO[5_QD\1Z#;6;7DWC.VA:]MU"NT8T73_E; !QN
M7Z9XKYK_ &E_V+/B]_P5$\6^,KKX?_!+X1Z#H^D^)(],FUG^Q0VJ7TD=I!(S
MRR"5>09PN""=L?7T]0_X(<?#?XI_LW:CXG_97\4?!_P3INE^![^2S?Q1H5LL
M=_J5W<0VU\IG^=BV(KCRP>0!&HX/% 'W!^U,<? 'Q*=S+_H(^9<<?O%YYKQC
M]FWXF_!:T_80\ 65]XCTF.>/X<Z49 R!2-MM'DDE>F>?QKWOXX^)/^$1^%>L
M>(_[(M;_ .RVX86EZ!Y4AW #=GL"<_A7XG_M(?\ !$W]K3_@H5X&T3]HC1M0
M^%OPUT+7=#LM3L_#WA'P?M$2R RINE%VI8XE53^[P1'GT% 'Z.?\$7_^$2/[
M$WA*7PG%9JDFCV?VLV:@*9S I8DXY/(S]175?\%++S3-/\ >#+[6KF.&SC^(
MWAUKJ25P%6,:UI^2>N1SZ=*Y_P#X) >,=<\<_LCZ/XE\2?!+PCX!;4(K>YM=
M+\$V0AM98'MXMLS@?\M#@\'D  =JZK_@I/XPU7P]\#(="T+X6^$_%U]XBUO3
MM)L]+\:6PET\R7&H6MNKNIZ[#,)![QCTH \Y_P""K?Q ^"'B7]C;5-%M=>T:
M=[KQ5X9C\C ''_"0:<6'3/W5(..V37TA^SM#96GP@T6UT40_9(;");58UPBQ
M",;<>WYU^0/[2W_!,/\ :(_9D^)6B_M\ZQ\%O@[??\(GKEI&O@ZQT,06-XU]
M?1VB%U\Y\F-[E7!PI_=KTQ7[ ?L\:SJFO?!SP[J'B'P]8:3?_P!DVZW^F:2?
M]%M9?*7?'%Q]P$X!':@#Y9_:\\1>$_#/_!5O]FV^\::C:V]NUEXJVO=L-I8:
M2G0$$Y].E8O[>_B'X7>,_P!MW]E^WTRXTV\^S^(-5=UAC&8Y/M&E;7Y R>#C
MZ]*O?\%0]6\7?$KX_?"_]D?P+^SQ\-_%6H^.+37%AU[QYI?VIM'6"QCF9[<9
M7YF7<#EAT6OD?X$?L8_'7_@E_P#MZ^#]:U'X$_"KQ--\;=;CM))5L?);P]'9
MW%OYDUF/,DV.WVI,C(SY(]* /VDD7(X'3I^5?!/[*WC;X=>&O^"M?[7L/C#6
M[."0KX,*QW(#,?\ B7SG^Z>W7'MGC%?>3RL4V.=K@<K^%?E?^V!\'_B?_P %
M#OVT/C-^S=\-OV>/A+;?\*W?P_+J/C+7-#$VK:HM]8.P623?&,( P7&[C% '
MI7[,&J^!O$7_  7W^.&K^';RRN=OPK\.K;7-O&/N^6@9<X]37Z":\2-)N-N[
M/DOM"]3\IXZBORN_X(D_#/XD_L3?MD>-/^"=/B?X+?#]1X0\,1:[J'Q#TJV6
M/5KUK^198K61@S;HD#-M&>-H'%?JGK$OD:=-/L#;(V;:W1L*3B@#\P?V!OB)
M\([;_@A;XHT#4/$NFKJ+>'_'*- R[9#(UUJ"H#N7JV5QZY'->S_\$1],\'Z3
M^R;X)'@>PL[:"X\/1R7_ -A55668@?,V /F[U^?7Q9_8T^+O_!1_]D;7OVS-
M)_9W^#?@/P[;Z-KAETOP_H(AGD&GW%SOG\WS0!(_DG)\O@]<U^AW_!$SQ[X^
M\8?LK:$_C3X*>"_!-O-8PR:/9^#8RJ7$"QJOF39S\^[?SQG"G^*@#[8JCX@)
M72[AD"[O))^89%7JS_$C,NDW)&/]0WWN* /Q)_X-\_\ @HS^QO\ L8_!?XL>
M"/VD?BXOAO5-6^+^HWVGVTVBWL_GPE%7=F&%P,%#U([5WW_!=;_@J]^P3^U'
M_P $QOB=\&/@;\<EUOQ-J^DQ#3]-BT&^B:79=P2.2TD"J $1CR>U?;G_  1_
MT71[S_@GK\.99-(M9#]AN#N:%6Y,SY/(KU+]L/P]HL7[*OQ$=-'M4*^#=1*L
MELH(/V=^>E 'Q_\ L"Q2?\)Y^QZ7&"O[+*!@?^N,5?HU7YW?L-EE^*7[)"*?
ME7]F'@D<\11BOT1H ****  ]*^1_^"Y7_**;XV?]B)??^B)*^N#TKY'_ ."Y
M7_**;XV?]B)??^B)* /Y@_\ @B@?^+\_%#_LW[Q9_P"DR5X3^Q;/;6G[67PW
MO+Y@L$/C#3I)F;. @NDR3@'C&<^U>Z_\$4R1\=_B@1_T;[XM/_DLE?+WPFT7
M5/$/Q.T'0-$LQ<7EQK%O#:V_FA#*[2@*@)X!+$#/;K0!_:)X+_X*/_L0>-?B
M/%\+?#GC6WDU":\:TM9O[#E2WDE'\ <KC)Z#. :X_P#X(P+"/@+\0_LJJ(U^
M.WBE555  7STQT'08KPV?XN> /&O[&FB?L>>";>_\4?$*.^L;>:UO]%>U:RD
MAGCDE;S779A1P&#X;)]*]H_X(C6MW8?LV^/+"^E:2:'XZ>*DF8]F%RN>>] '
MV91110 R<XC)Q7YU?%+_ (+>_#WX7_MQ?%?]CWXU:]I'@/3? K:6=)\3?8;V
MZN+\7-L9WRD,;JN" @^I]J_1:1=RX_I7R3\<?^".?[+'QU^/?B+]H_5O%'C;
M0/%'BI;<:Q<>&-<CLUN/(C6-"<0EC\J@'+&@#A_ ?_!7W_@E!X1NI->U3]K<
M:MK$D8$FK77A35#(%_N+_HIP >GM7AO[9W[:/_!+O]HK5KCQQ\'/^"BVI_#?
MQ+)I<ME>:CX;\*ZFK7BR$A97;[*#O0/(5/8N?K7LGQ*_X(__ +./AA+32])^
M/'Q;DU34M1@2SMY?&WRLOFKO.!"!@ \Y('N*Z#X__%[XU^'[E/V4OV0/ &GZ
MU=>'?"7D:MK.J7"QWUK,D;I%Y<CM&K.WDOF0G&?K0!^7O[;6L_\ !-CQ!_P3
M;^)&@?$7_@HMXD^.OQ&T_P .,_@&\\1:)J$,UC< )^Y#O!@J77<2S 9'8U^$
MK\OP/R^E?T?_ /!53]K;]H+]G#_@FC\1/V>_VQ? RSZM\2/"MPGA_4I9DFN+
M9F$:,C/ \R%58J<DIRYK^<!SND8Y[F@#]+/^#<CQU^P+X/\ 'WQ2C_;GURQT
MM;KPY:IX/U2XT6:\FM+L3DF2+RD8J1\IYP"0M?>UKXK_ &"E^.FH^*]1_P""
MWGQ U#P'J]I' _P_O-!U)M.BME$:F!(F@V*K(KKPH/SFOD'_ (-7/VH+']E;
MXE_&#QKK'PT_X2*QN/#=C#,OVZ.%K<BX9MP#JV_A3P!FOZ5_@/X_\ ?'WX1Z
M#\7O#.@016>N6*W$<%Q9[7A.2&0AE4Y# CH.E 'ROX;_ ."RW_!'?POX'A^'
M/A_]HFR71;> Q6]J/"FJ;=I+$XS:]?F/-<M_P^=_X)Z?#V2:[^'/[9]KJ%JE
MOMM= U3PKJNU7&3\L@MQ@L0!R2.>W?[^/AK0SUT&S_\  5?\*#X<T0' \/V?
MU^S)Q^E 'D'_  3X_:?U[]L7]E/PQ^T1XF\'0Z%=>(&N6;3+=V98UCG>-6!?
MGYA&#CWKW&H;:RAMXA%"BHO]U% 'UX%34 %1R_?;C^&I*BE^\W/\/>@#XXUK
MX\?"O]G[_@H'\5_B%\7/%$>EZ3;_  W\*^9<&%Y#_P ?FN+@! 3U8#TKYW_X
M+M_MC? ;]J3_ ((Q_&R+X0>*)+JYT^#3$N+2XL9(9%W:C;$'##G[K=#VJ_\
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M6/;]IY4#N-E2?&63P1_P4G^$VD_M.?LPV,>D_M)?"6Z@O==TK7+O;K=_::1
M\LC6NDPF:.1VOY81'OA3+_NV*@A&HGP<O_!4[]G1?@E^T#<+HG[6G@PBULIO
MB#(^BS75I+<F\/E:= %WXL6C4LUL&4\\9+&N5U*C_P"7DI1WO:-6/\K_ ):L
M=D_)_+FA)83"12;PE*A6YG'2=?+ZSVJQ;_CX";UG&6T96W2;;\"_B=X\\#V>
MK?\ !,[_ (*YZ+/)JGCRWEU+P3XP\:Z@?%5QIU_=K'IUG' BFX6$HPNY5D\U
M-A#?<#AB?#^U\=?\$P?BO>? +_@H'+>>,/V?/&&_2_#>M>*+XZII]M':*US'
M-#I"-=&/?-Y*["J[20V6(%6_@[\9K_\ ;4^$VM?L'?\ !4VTU/1?B@_VK7OA
MCK7Q$LU\+VB3F%;&PAVPFWDFD-Q-<LJF)U<*V-[(H%#]G+Q%XZ^#NIZI_P $
MT_\ @JPMXWPGU*V31_".O:E9KH_A^"2QS?[X]39;6::,O%$H;<^6*JX )%$'
M&3I3@V^D)2W7>G675/92-L1'$1CCL/7I03DE4Q%"D[QJQ3NL;EL]U4A92E2^
M%J,D]&TJ]MX-_:2_X(N?%EM0\=OK'Q'_ &>=66/PU;R:OKZPZ2)+X1W%Q-_9
M:RW!#(L5TN/+'F?-\WS@&U\8_@5\2O@%XKT__@I7_P $W_$&H:M\&]6N6\4>
M*O"'ANZ'AC3K33[#R]MK-;^:AN8G"W/RBWX&<(P;FG\ OB-^TK_P2\\>7'[*
M'[;6FZOX@^!NJ6#:-;ZAH.AB/0S?ZF\<S2+JMQ%;L56.2Z\S$I93OPN4&&>)
MO"?QN_X)E?'G_AH#]C>ZD\1?LX^-=8BU36H_AY8G7XDT6R*"5+F[GBD2 L);
MG8XG&<-F087$QC35)<JE&$9:K>=*71QVYJ5]U;X3:I4QU;,7.-6C5KUZ5E5M
M;#9C1M?V=2-OW&-BK33BU>::>NKU/CC^SEXD\>S6G_!1_P#X)->)[BU\.ZA<
M+%XF\)>!8QX6AM;>Q4-<L[-) 9D>2,[D$626+8;O;^(,5A_P5F^%=G^UE^P[
M'_PAG[0'@.-F\4>'_"<?V"^U"2]ECMHW?6&^R^9Y=G:SR AG.UFC)4L W/\
MQ?\ @M\3OV+OBU'^V/\ \$J+Z'5OA7XB^S6&IVWP]27Q/<016Z+->+<--%<1
MP1YC9?,$V58[?E/ V_VD=/'[2XT;_@JI_P $JWCM?B3I4<]WX]\-V=Q_:GB)
M7N"FFVW_ !+$%U#&WD+=N5(1C'\RAG!VJ45.-6,J;UUG3B][/2I0?1K=QO\
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M I9]Q+ $Y-?L=:AEBPP_B-?)?[<3%?V[?V5U!X;QYJ88?]P74#_,5]:P*%3
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M.0V(FZ ^]?*__!OEX<T'P9_P4E_;P\*^%M$M=,TO3?BI#!8Z?8VZPPP1K+>
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M=#_&?:@#]'J*^8?^&2?VT_\ I(_XG_\ "+T+_P"0:/\ ADG]M/\ Z2/^)_\
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MINA:3;IIWPM\3ZC:C1=+9]*\V%W34)A#)<(_^ALC*K[AR=N]0VGI'B?X/_\
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MJ+P+;QV=F?&EPNAKJ<TTPENVBM8"\TNVUMG!!A!1B#@ DC/^)&F^/?AYX?\
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M@&P6*!:B^"?BOQCX.OM2_P""77_!56"ZM_AW-&FD^#?%TUJNFZ/'/9.;TO\
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M>&[UE^-_^"8'PM_9\'PM\'_'K0O[1\2^-M;OK+5+CPKXVU9;.&.&T\U#&)Y
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M=:I%;?!M]4\:1Z[::3?Q74!EC*0RR21*=]KEB,$)RW''V[_P4:^-_AW]E_\
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MQQI/P2A\+_\ "*:AX?M3K'_"*W'G!8Q?GRFN-I*+(1G'/(QTH ^?_P#@UU^
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M&R%RWHW_  ;)9'PU^+&5V_\ $[TSY=N,?N9^W:O/_A]^T#X?_;*\+:I^P/\
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M[.[E,DFVZV&'R%. !NR#CJ.M 'Z,_L"_LO6'Q5\6_M0>//"FLS:/XPA_:/\
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M?\#?\%"/C&=0^+'P)\$?$[Q*+R;R-2U[PUHM[>+),D8'EO+#&P+*K]"<@$4
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M;&VO;.\^&_A8/:S3A=^V[ULG^('(PF>?3/6OG[_@X*^!WP:^"'_!%_XS:?\
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MU[X<MHX=M:T^S61['389)5DLXOW<$$V]=K_/(,.1BM6+XX?#_P#:.63]@_\
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M#N7YC2^*$6YQDIO23TIUDMU/^6KII=7<D;5/9T:U1NA7I1P\?>HIMXK+Y/\
MY?8::NZN ;]UJ,U%0DFX[7QOB%^T)?>$/BH/V!?^"O\ X8L/B5'IR6[^%?$G
M@R&07UI=7N$BDDE::UB:..*0C'DL01SOP<['[0-]JO\ P3!U;2?V3_VF OQ/
M_9;\:K<)H7A^=A-KUBEB$NAMEA-E$'?4;B)CEWRB#!0@[G6?QX\%?&&U/[!7
M_!:'P6=)\:>'5:Y\+^+IM1E=VO+K]W:QFWT:-8\)%(K;I)"K ?,%).&VMWJ/
M[ E[_P .Y/\ @I3:KXP_9W\4;4\(>+LC3UM([+_B83.EOIXDO) ][/:QE7E!
M7;D;D)4'->,I\Z7V>>2U@WHJ=?O"6R;NMK]"88>4:U+#/#MSY>>6'I/]WB8I
M+_;<JFK*->.E7V4.63NTMI(C^*7BO7_^"?WP]\._$KX821ZY^R?\;(81??#7
MQ%^_U/3;/583=7\</D^5Y;K:J\,1:YDP3\V\_O!<O=,?]F'X #_@J7_P2MNG
M\-_#?68I)/'WPU^($RS1RK:W1TVV6*.$228\Y[N9]UVO,BD$#*"$^*]2_P""
M=>I+X*U_1QXQ_8S^-C!-"N6D%@NDV6L8FDD#*LVI3-#8@_?:,N>1Y;X%%WI^
MI_\ !/6]?_@H/_P391?&7[-WC(;O&/A/(LQ;1V7^@0QO=:GYUZV^]GNW!CB!
M79M.Y"I$^]&+;5HP2NMYT7>RG!_:I-[I;+INB5>M3IJ'[R6(G[DZC2P^/BKW
MPN)NFJ68I:1G-.7M(.T[R4G5\ 7?@SQK\,_$'_!1;_@EIH=U\._&'P]M9&^*
M>C>)FSI.NV$<!U*]6*(-=3$RRQ0J )8#L# %&^>IOV>_!?P1_P""F%EJGQ]_
M9+TK5OAI^TCX/AAU?5M:69(=#U;5[\MYL@25KV0QJ(IR@54P91D.,;7:I9_#
MGX?W%O\ \%+?^"19:>QT&/ROCAX)"S8;3_\ D)Z@6O-7SL7_ $>.(_9HBPW[
MT/&PR3_"?X._MN6J_MQ_\$O=3_X13X\^&8_^$@\;>$8;>YO_ #]4OR L:SZF
MT=HACVW1S'$4;/*J0M:6UBI.,G:[2T53JIT6MFMVM+M;A.I"G&KB8RK8=.2I
MPKUDW+#RT7U3,XO65";]VG4DYQ491=K)Q6#X#^,G@#_@H1X_NO@G^T!X0_L_
M]I_PRUY9>!OB9X75[?3X&T=&N;8W9GEE#L]U',SLEKS&Z@!&X'J/_!L@"OPS
M^*RE=O\ Q.M+XQT_<SUQ%Q\2O@C_ ,%*=&N;[5M"'@W]L#P/&;7PGMFNKUM3
MDT8"^+;%6+3HS-.MU'\^[8?FW.-HKN/^#9$@_#3XKE6W#^V]+Y Z_N9ZSP/O
M<086::E>-2TUI=<NTUTFNOE8TXT2I>#>?8?V4\.X/!J6'F^94Y.O=SP\]5+"
MU=Z:BU&,HSLM;OZ5_;C_ .3[_P!E7_L?=3_],>HU];Q?=_&ODC]N/_D^_P#9
M5_['W4__ $QZC7UO%]W\:_3#^)1U%%% !1110!PO[3G_ ";OXX_[%>]_]$-7
MXJ_\&6O,/[1&?^AETS_T"[K]JOVG/^3=_''_ &*][_Z(:OQ5_P"#+3_4_M$_
M]C)IG_H%W0!]=>(_CA\4?C7_ ,$__P!N2R^)GBEM2C\)^//$^A: IMXX_LMA
M#%%Y</R 9QD\G).>M?=O[+*@_LQ?#G/_ $(>C_\ I%%7YT>$/^3"?^"@W_97
M?%W_ *+AK]&/V6?^38OAS_V(>C_^D45 '=A0.12T44 ?./Q_^+7Q"\(?MY_!
M?X7>'O$;6^A>)='UR?6K#R487+P26*QG<02,"1^A'6OH755#6,@/_/-A_P".
MFOEC]J/_ )29?L]_]B_XD_\ 1VFU]4:F";*3 _@;_P!!- '\\/\ P38OKVX\
M=_#>PGN6>&W_ &S;@0QMR$'V&(X'IR2:^T?^"70_XV,:;V_XM_XH.%X'_(;2
MOBC_ ()I<_$3X>L.W[9UQG';_0(:^UO^"73 ?\%%M..?^:?^)QQ_V&H_\1^=
M 'U__P %A/\ E'!\4/\ L%V?_I?;5[Y\-/\ DG'A_P#[ EK_ .B5KP+_ (+"
M.O\ P[@^*'/_ #"[3_TOMJ]^^&H(^'6@*1TT6U'_ )!6@#:HHHH *^9O!W_*
M4GQ__P!DR\,?^C=:KZ9) &2:^,_$W[1'P+^!/_!43QK-\9_BSH/A=;[X8^&S
M9G7-2CMO."S:R&*[R,X++GZB@#O?^"H__)JUO_V4/PM_Z>;2OBKX#C/@_P#9
M+![_ !R\7C@_]3%/7O\ _P %'/VX_P!CGQS^SC#H'A']IKP7J-X/'7ANX:"Q
MUV&5Q%%J]J\CX5CPJ@L?0 FOBC]F/_@JI_P2P\%_#OP3X=^/OQ"\7+XD^%'Q
M&\2:II9\.^&[BZM)GN-:NIT)= 1(C(8V^7^\.] 'IG_!37]H#XS>+#^U-\&-
M6\;-)X=\.^)/#-AH^G?8H\6T%UIKRS)N #'<_/)^E?0P^&'B#X;?LA?"?Q9'
MXR$VCP^%]+;4;%M.C5Y ;*)E"OG(QM/>OS3_ &A/^"P'["'Q,\:?M5KIOC;6
M8V^*DWA^'P3<:AH,ULBW$-CY1DD=\>5M8G&_'&>#BOT5^ OP]\5?MB?LJ?"7
M3/!GQYTOQ5X)L=#TR/Q FDZE%+N9($22%Y(QD%2LD9 P<J1UH ^QOV;O$<_B
MOX,:#KL[,WG6K>66Z[ [*OZ 5W=8W@/P;IOP_P#".E^"M#@$=CI5E':V\8;.
MU$4*.>I_&MF@#F?B;\4?"OPJ\-W'B3Q5J4<,<:$PPLP#3OM8B-,]6.TUY1X#
M_:M\?7]P/%?COX2:AI/A6[9(K34,$O"_ 9I044",?,=V[VQ2?M2_!#Q)XI^(
M&D?%I-=GN=(T-H9+[0 N5D6-V=V'U7(/(ZUOW/CF;XZ0Q^&OA2Y;0;B/%]KG
MD_NFCSMD@0X^_ANHZ<T =>/C;\/S-<0KXHL_]'CW%O.0AN,X4AN3C''7FO*]
M;_;'UWPCKG_"3>,?AAJ6G^#99!%!JEP@4HY'WW4J-H+*ZCYCG(-=_KG[.GP\
MNO!-IX/T;1?L*6$PEL7CE;=&X)R<YYR&;CWKC_$WQDTW3-*O/A7\;/#DDFI.
M -.B2$B/4Q\I'ED8PR_-D'_GDW% 'M.AZYIOB+38-7TB[CFM[B)9(Y(V#!@1
MD=*N5Y1^R3\'/&/P:\ 2:)XO\5#4)+BZ>XA@CCVK:QN%Q%SSE<$9S@\5ZO0!
M') A^<CYAZFN9\8^&OA9K%S%+XYT[2YIA&1"VI2)N"Y[;CTY->9_%?Q5\3M6
M_:@\._"[PKXUN-'TBXTF2XOC!&A:1B90,;@>GEBO!?CY^QQ\#OVBO^"DNA^"
M_P!H_0KSQOI]G\,;>:QM]4U&:)8)&NM1W,OV9X^OEKG=GH,8[@'9^(?^"6/_
M  3[U_\ ; T?]M-O#.B1^*-&MY(XHUU1_)DD;S3YC)YVW/[UN-N#@5P7_!'[
MX<?"[Q#KO[3$<WA;2;N.']I/7%M_W*/LC\BVVA>3@<G\ZZN__P""5_\ P1OT
MSQK:_"[4?@MX9A\1WUNTUGH4GC+4!=SQKNRR1?;-S ;&Z#^$^E?+'_!NKX0\
M,_"[]O\ _;A^$_@33?[/\.^'OBA!;:+IL<[R+;1"2\0 ;F8]$7YF)/'6@"']
MHSP)X/T?_@I[\3AIGA^WA-GXD^'AM61>8BVH::&P??)SZY->^?LI_M4_LT_
MC]NG]J/0/C#\=O"7AF[N/&6EM;V>M:U%;2MB.ZSA789 #IT_O5XQ^TZP;_@I
MY\5G'\7B'X=,O_@QTS_/X5]%_L2?#7X?>,_VW/VJ+SQ9X1L=0F3QMIBI)=6Z
MN57R[OC./8]Z /;_ /AY#^P7_P!'??#O_P *RU_^+H_X>0_L%_\ 1WWP[_\
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MM;/><!Y#(_+,3RQR>: +/[5"EO@!XE"QLS?8EVJL>YL^8O0>OI7S+^S_ /\
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M_ _BSP= I\-?&RUACM;[7-&M-UI;":XOEN99Q<3&ZN2P*JS+G8&4LVKIEO\
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M@?\ !.3P"NIVT,/[1?[)WBQ4N/(\00OJ,6C6D+^79K&96%I#YEY+&Q"P%3Y
MVJK?,(_#GB#X>ZU=7?\ P2C_ ."@=FA.AM_9?PA^)7V4WUPJ73>9!()B?)A$
M=JUN!MR%5=O\)HL/$?B;_@FOXD_X9?\ VS+:/XE_LU^,&9M$U"^SJGV*ULU\
MR)HH(3LC+WDD&4)Q\F5^88JYRY9.JWRI>Y&?6G+_ )]U%]J':4NEO4SC3]JH
MX)T_;5*C]K.@FU3QM._-]9P4E;V>*2]^482A><91Y-XAI/AG2?V"/ UY\6OV
M%/%7_"_OV?\ 5B^G_%CPMX@QJ4.G21QK+>3;(5AMHR]J;9-\D4G0[LJP / /
MPNL_"%E=?MV?\$??BK?:]K!\C5_B)\"WN&N+.&34B4MK'[)8BV7R[03WA19&
M<)]G7:?E<,7W@UO^"1VO6_A;3M=/Q6_9W^)*I9^-%U$+<+93LQ%[)]GMCM+_
M &.*W&YN&# '@#,GB/X5^+OV 3#_ ,%%/^"<GCJ7Q7\/?$1;7/&7P^N)EM8;
M6TO/ETRU:SA)E80_;I2$(W1F'G W5-.,J<DI0Y?9KWE'65*_VZ:6KALWJU;F
M\S2>(IXOGG0Q#JRQ5HTJM:RHXU+?#8U6Y:>(C9PIR2IOFY'S;2,WP/X?^ O[
M2NM-^V+_ ,$^M<?X;_'#0=VH'X+:3<106NJ0:?B6:$VME'%(XNY$C1U,I60,
M01SN"Z!X)^!G_!0[QU)XN\+^.V_9[_:ETF^DTB?1?#LL>F+JNKQ;IM3OFCMX
M_M/F/OO(RQG+@1@,7"L6O^(?@_\ "G5=+;_@J%_P3"\3R:7J'AEEN]>^'D4:
MZ9#-8V(,U^GE@^:ZRF,*R#[X.!VS)<_ KX>?\%!="_X;4_83\7S?#WXZ:3!#
M;ZSX2T[R]+2Y\03'S=3G6>0B9R$NYU\SG/E],ELTJ<N5)QC*_O.*M:I#^>':
MKW2=_P "7C,'3KRKPQ%;#P@O8QJU5S5,)4=U]6Q<6I.>$E=)3G&5DI>]\1F^
M*O&_P<_:^\2-^S=_P5+\(V/P=^)GAF%;[3?B5I=I%I]UK$,7^CVUM++=)<32
M!S)),3O"EHMPQ@[IO'WC'PG\0-;M_P!@S_@K?X6A\.:CHL36_A/X[0VZ6^H7
MVF66565[N_6XDD^TRQDDJ%5RV<9.XW-"E^ /_!6_2Q\,_P!H&&'X;_'+PBS3
MW6N6=CM;4K&U'V:&)[JYP#OEGW%!@@QG&X FCPOK/PR_;YBD_8;_ &^;&'P?
M\8_!SKHVG_$*.S%Q<7=OIX_TB1[J<A"99$ER1\I+'H< YN,Y1;BXOGTBWM-+
M>G4[372]GV;V*A]7P=2$*].M1^JWG5A2;<L&VO=Q6";<I5*$M95(ISA;E]U:
M#?&\_C[]D_P[:?LD?MPV;_%'X!^.)HX_"/Q:U)GN;KPS=7Z-;V\UO=WIDBA%
MK9+/,JQQ;D+[E.-R&K=^(C_P3[\ K'X1T&+]H3]D/Q)-]ICF\06QU$:5<(YB
M\A)&*VD9:_WR'%MR01]_]X9O#_B+6O >K7'_  2Y_P""G,C:OX9\2!C\,?B!
M,S:I-IEY=D:?IK1R9\J 10M<2@Y^0MDC!IUMXC\-?\$U/%LO['O[3UJOQ(_9
MJ\4*=1T/7KR,Z@;0QIYK;+:$^6@;42V<]^<<UM)^\YI\BBE%.6LH2=K1J7WI
M/H^FAC"G&?+AJD?;U*C]K*G1;5'&4E=O$85IKV>-@M>2'*VXR3BW=-/"WPRN
M_P!AOPA=_M&_\$Z/BA)\<O@I=R/HWQ.\ ZW,VI06BM"+C4+UXK<06RL+2&WA
MWO'(1]H.\.K86#X<>&?#]FEU^WY_P28\7R3>-Q"+_P ;? #(DT]+>[8VL=I]
MCL1; I 7EN &=@IA!&.07:C\,_&O_!(C6H=9\ ^+F^*7[//C-8M&\;:??72S
M0P7ET=UW.UM;GETL+15W-P1)M;@+5CQ/X#@_8[6'_@IU_P $U_$[ZYX+UK=<
M^*OAM.BVL$%C<D6MK$UK%^^8)-/Y@[KY:GIFL_9RIRC:"AR:N*U=/_IY3OK*
M+^TGHM=#25:CBX5*E/$.M]:M"E6G[M/%J+3^IXY*RA6LK0G:$N;E?.]&4_ /
MPR^ W[6>H2?M:_\ !-7XIW'PJ^+T<#W^H?!_1;Y+6V?2[(A'A6"PBA?%Q+':
MNRF0H_F,",N"([JX^!__  4)\>OHWQS5?V??VFO"EPD-A=^'H8M+/B/7;H_Z
M.TB['NG> 0VV#YRN//\ E;.0FIXG_9P\&:YIB_\ !1G_ ()&>/9M%N?,SJ7@
M&U:/2HXM)L@/M@$:DR.LDMK'F/H_FY&2%J,>"/@Q_P %4?#G_#0_P<U=OAG^
MT-X*MVO=7TW3;46"ZIK4O-D1<7!$CN@M1@CE?..1R*(TY\JCR1;EK;[%:._-
M#K&HG9V5@GC,'3J2Q,:]:G2I1=*-22OB<#4?N_5\2K7J827\-2FIV=FI)WOG
M^)/&OP9_;>\7K\&O^"C?@ZW^!OQJ\.QQW=IXWTFWATV;5Y&VQV-M,9TGN' #
M(^/,'S#*[<<7/B!?W?AVZL?^"<O_  5NM%N/#TQDB^'_ .T1)$1J,*1!;Z\?
M[;J)N&=9'^QV9\M$^5MK%N"EC2Y/V??^"P.AI)X^C@^&/Q^\+JU]<W=C8K N
MI)#^ZLXVN;D@L2Q1L#D'GL0(?#6IP?M/M-_P3+_X*=E='^)&@[+?P+\3F3^T
M+EF+?VE>EKN4^4N8(;2#(Z[MIP0N3WI0YX-/VFD9O2,U_P ^ZJZ2WL]VTO0J
M*HX7DHU8U*2POOUJ$&W5PCZ8S 2O)U,.G[TH<TX<DM8-)-1^)_$,?[,WA?2O
MV/OVKM M_B3^SAXS5+7X7?&#4;47-YX?@U%-EI/!=77F0Q&SL69U\J%0I *
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MB&K\5?\ @RT_U/[1/_8R:9_Z!=U^U'[3CI_PSQXX4M_S*]]_Z(:OQ7_X,M&
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MKG@SPG\,?"GBG2KBPU+3_@CK5O>V-W"8Y;>2/Q'"KHZGE6#=J^G_ -C"4?\
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MP?\ B1\<H= U"QO%O-%O+?1?-CM9&*%XV"O&9!A ,G'6NR_X(Z_\$O\ 2O\
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M\3&U7AD0$<$C\:^D_A8 /^"F?Q2P/^:;^%O_ $K\05XM_P './\ RAF^+?\
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M7P5\7)L\#^-_#3JJ0+!,=0O9&2'S+LXNKFVC 9!]UB,H20?9_"W[5?P8M?\
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ME-6KTN6NV\-7T7/*E?FC4:3DIM?9T^EOVXG>/]NC]EL1MC=XYU('W']CW_\
MA7UI%&JIM3@>@%?)7[<G_)]W[*O_ &/NI_\ ICU&OK>+[OXU^G'\3C7MHW.6
M+?G14E% !39'9",+Q2AT;[K _C39N0 /7^E 'X9_\' 7_!Q%^T?^QI^U7KG[
M%7P5^%/AU])C\+A=:U37))9Y+IKD.NZ-491&% Z$-D^E?FW_ ,$,/^"SGQ8_
MX)A?$3QC8>%/V<IOB5IGC?R[O4M#TB9X;U)H5E"/&RQR?(/.Y&P].M;/_!UD
M"/\ @L+XM;!V_P#".Z=_[5KZN_X,U_@1\!?'K?&+XJ_%SX=^']6U#P[=:=;Z
M;J.O6,,JV<4T-QY@!E4A=Q5<_2@#Y(\??\'#7[4NB:3\>O@QX0^#.@Z+X;^,
MWC+5-8U;2]>BFFO]*>\"*\._*!BNP<L@Y)X%?N3_ ,&V/_!0CXP_\%"_V,;[
MQ%\8-$T73YO!.H6>@:6NBPR(LEO#;*%9][L2QV@G! Z\=J_%'_@ZQ^!WPE^"
M/_!3)[3X1> ]+T&UUSPO#J>H6^DV:0Q37+S2AI-J #)"CM7Z:_\ !EUD?L(?
M$#/?QVG_ *(H _9">3RDW[<U^5?_  57_P"#F>W_ ."8?[4VH?LW:O\ L:ZE
MXHCM+>*2#7AXH^PQW.Z&.1MBO:L"%\P*2&/(K]5G56&'%?*W[8/[+G_!//\
M:?\ VCO"/PA_::^!/A_Q)XNOO#]]J.ARWWA^&8_98YH(YMTK1-SN>/ )Z?2@
M#\8?BO\ \'='AOXC_M-_#G]H9?V(K^S7P+I^I6LNEMXW1VO/M3VS;@_V4;-O
MV?&"#G?U&.?IKX2?\':WQI^/$^FP?!S_ ()(^+O$CZQ=-:Z6ND^-%E^TSKUC
M7%GRPKJ?^"X__!(#_@E/\"/^"=GC7XGZ;\,]!^'NO:58S3>%=2TG3[2WDO\
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MWB($&!6+X.\1KXC\*:7XG>+[/_:6GPW31;LB,R1A]H/&<9QTK6^TJ&V%N?\
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M?P-KUQ\1%TPSZ18_&6P=M/%I (#DIN)R<<[1R<4 ?J117QN?VJO^"ORC+?\
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M_!7W/S_\$Q/#/_AWK7_XW0!]D45\:']J_P#X*]9S_P .S?"NW.-P^+MMD?\
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M>,O!^L>$O^&$+"W74]+N+-9O^%@2MM\U&CW8^P\X#9Q^%?/?_!)7_@YDN?\
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MPW)KEEK)N] AL[ITGU'4#I5M)>X6W\J^BD!11(2X+CS,"&#X=_%S]FSXX_\
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MUK+*B=XSBH\]2BVTW"4>1I\JR?A-\-OBW_P3S^*'_"=0:YJ'QH_9:U"-M/\
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M16WT?3DU(/%-!=:1%/.\KVMK-;3-^X&45581A1CU/_@V1_Y)I\5^/^8UI?\
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M^Q@_[4.HZ7J(_:<^*G@+^S%E"Q?#WQ4-/2YWA03*/+;?C;\O3&3ZU[9DX%%
M'P/\:_\ @D)X$TOPI=^.O%_[=/[1VHW&BQM>:=<2?$!'D@F12RL#]GW8![9
MYKG_ ( ?\$</%WQ!\!:7XT^/W_!0GX^ZEX@^T22V<UE\1@\=K&'^15+0\D$9
MS@<U]1?M-?M%IX2\>:-\!-.TB.2\\331P7-W=,RQP6LVZ)G!VX9@3]W(JOIO
M@_Q)^Q_IT*^";BXUKP@C-)?V]],/.L 2&EE7&-RA4W;=F06/)S0!YK<?\$?8
MKJ VUU_P46_:7EC8C='+\2E96P<CC[/Z@5Y;\7_^"3>I?!RQL]1\+_\ !1G]
MHO3_  RUR(=2TZ+Q^&=I'W8D4"%<DD+D=<9.<FOMSQI^T'X \%_#F/XD7FNK
M-97#K%9^2A+3R,<*H&,@D@]0!Q7$ZA\/_%OQ5\/?\+/^*6JW'AN^@!:QTNSF
M$L%HH.!(>N7<'MC /? H Y_]D?\ X)U^'_V5/&*>./"_[3OQ:\46\FGO =!\
M:>*DO+ %]I\X1+"G[T;!AB2>6SUKW'XD?#X_$;P3?^"QXMUC1/MR*JZIH-X+
M>[M]K!@8Y"K;3D>AX)KEOV9/CM!\=O!\FNKI4EK)9S&V=BQ99BJH3("5& =P
MP.:],H _,?XE?\$[/#/PZ_:M\.Z'XI_X*(_M'6\-YI+/!JD_Q$_>HRF8;0X@
M/RYQQCO7K7P?M? ?PW_;^\/^#M(^,6N>+(M+^$MI$VN>*]8^U7LS"?4AF21@
MN20N3@#DUZY\7W\4>)_VLO#?@*Q\0MI^F_V.\TYBCW-(S&7CDCIL'.#_ #KQ
M3XD_L=_ GXG_ /!3'1_#/QI\(P>,K:W^%=N]K'XBA6;[/NN-3W;, 8'RCUH
MX3]KCXD_L[?$_P#X*)>&_P!G5OVZ?C%X7OO$VBS%U\$>/&LM-L9XWN6$?E>2
MPWMMVDYZ%><FOSM_8ML/V??V</VF_P!LWQG\>?VU?CIX7\/>%?BA9:9!K'@'
MQ08]0UQYKZ2W6:[81-Y[[I8_GPN,D]J_2SQ/_P &X_[!>N_M@Z'^U1!IEQ9V
M6CK(UUX%AT^W_L^]E8R'>YV!@!YB\<Y\L<^GR?\ \$9/V$?V/OC;_P %!_VX
MOAY\6OV=_"OB'1?#'Q0BMO#^F:OH\=Q#81":Z^6-7!"CY5_*@#S/Q!^SO\/?
MBC^V%XGUWX>_MH_&G5M)U&[\!W.F:WJGC#_B8W4=W>6!7SI#$"7CWDH",*Z@
MYXKTCX?_ /!)W]N3XM?MH_M!:3^S+_P5A^*'@?2=!\3V$-W-?:A)?7VJNR7.
M)+B8/&)&4J^&V\^8WI6G\7/V0_V:?A#_ ,%.O'%O\,?@SH6AQ^&?$OP_;08]
M-T^.)+$R:CIP<Q@ !<AF''K]*^[?^"?RJO[:W[5050/^*TTH<?\ 7.\H ^3_
M /AQ?_P5Z_Z3O_$S_OB3_P"/UWW[.O\ P2J_X*^_L[^.)O&H_P""QFK>,!-8
M/:G2?'>@27]HNX@^:L9N1AQC@^YK]-,#TI"BGDB@#X$^/W["_P#P5]^/?@-_
M J_\%/=(\'E[R.?^U_!?@N2SO@%# Q^;]J/R-NY&*\'D_P""&7_!7B-?-D_X
M+O?$W:OS,OER\X_[;_SK]<MB^GZU%J !LY 1_P LS0!^<7_!)KPUKWA#_@BS
MJ?A3Q-XEFUK4K'Q5KT-YJLX;S+J0:HV9&SDY-:GP6_8&N/VC?V+_  /\0[?]
ML/XR>"9&\&PVL>B^#_&_V'2XRDTG[XP^4_S,&^;!&<5V'_!'?PAI'CO_ ()X
MZAX.UGS/LM[\0/$:S)#@,P&I.< D$ \8Z=ZCT3_@B9I/A3PC#X'\-_\ !0O]
MHBRT6WA\NUTJU\:0);PH6+;%3[/@+D\"@#\G_P!G#1/#6C_MW>!O _Q)_P""
MP7C.U^'?A#X<7$NO:UHWQ-N3<6VKRW4X%M9MY!W1$%&;*G:V\9X%?=D>H_\
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MI3_PZ"__ !BO$/\ B%0_8G_Z.)^,O_A36W_R+39/^#5']B=%W_\ #17QF_\
M"HMO_D6@#V__ (=>^&/^DG7[2G_ATE_^1Z/^'7OAC_I)U^TI_P"'27_Y'KQ%
M?^#5K]BK;Q^T;\9O_"JM_P#Y%I?^(5K]BO\ Z.-^,W_A50?_ "+0![8W_!,#
MPJBY?_@IW^TH/K\4A_\ (]>V_LO_  0T']FCPM-X3C_:'\;>.S<7KRK>^//$
M2WURFX+\BML7CY?UKXF'_!JW^Q4.1^T;\9O_  JK?_Y%J;1O^#6?]C/0M5M]
M9TG]H_XS0W5K,);>9/%-ONC<=&'^B]10!]U_M*_L^']IKP/#X%/QD\<>!VM]
M02Y_M?P%K:Z?>L /]69=K?*<\CVKX+_X*B_\$Q)/AE^PAX\\;0?MU_M":\^G
MK8S?V-X@^(GVBPN0;^V0K+%Y(# *2V<]17O'_#HG72V5_P""E?[2GOGQ]%_\
MCUB_$/\ X(DZ+\4O!M[X#^)/_!0#]H;6M%U! E]I>H>-H)89U# X96ML$9 -
M 'U1\-/%GA=OA3X9>77H5$GARR*LLW+9MTP0?;KFOG6Z_P""7FC^+M=U'6=.
M_P""CG[1T;37;3M:Z7\3A%#;+(S-L5?(.% SCGH*_)?XN?\ !/#]B+P/\:[[
M2O WC;X]:QX#\!:Y?:+\0M>7Q-#']ENX8WB6.(?9!D"=K8<*^ _&!7Z>?\$P
M_P#@G!\ ?V&?BM<>)/@G\3/'OB*W\:>#M.U$+XNU2.X6*,QS,FW9#'ABLHSG
M_P"L #L6_P""1[;"/^'C/[3W3H?BMG_VWKC_ (T_\$N-,\/_  ^OH+C_ (*+
M_M(37%PB&WM;GXH+^^;S$! S!_M"OO"0((=RXZ=17YS?\%'/@79_M#_\%B/V
M7_"&L>.-?TFQT[PSX@U%H]'O/+2YFB:.1!*A!#J&B'!'3IB@#TGPY_P24FN=
M T^=?^"B?[2\>ZQB/EQ_$H;5RH./]17EGQS^!O[('[,GB^'P3\?O^"R'[07A
MC5+B/S8;&]^)["5T #9&VV; P0?I7W98_#36]/TZ'3H/B7J'EPQK'"V.=JCC
M)W<FOG+]I_\ X)">"_VI_C+9_'/6/VD?B!X9URULS;B;PK<6\*RQ^6(_F\V-
MVSM Z'% '!?!S]LW_@FM^SW\,?$GA.Q_X*,ZI\4)M8LI(HK;XD^*)[QG;;*1
M )1;+Y:L7*EO[N/2OSO_ &6O'?[*'Q0_X*-_&GQE\2/VCK[X$^';>&T30;KX
M4?%"X19MRH74XMW$H;'FME1M;(Y K]&I/^"$>@87=^WK\</E;/\ R%[+/_I/
M7P/\2?\ @GCJ_P +?C)^U5/X/_:V^)ZZGX%L]#ET^]?5+<R7K/I[.OVC;".%
M8%1MQP!0!]9^ ?'7_!-?P/XXT?QA!_P6S^,6M-INI07*Z3K7Q$GFL[S8X/E3
M)]D7=&V,,,C(-?I;!/::QI[265V6AGC(6:WDP1GC*D=/\1[&OR?^"'_!);P7
M\<_@WX=\-?M#?MO?%JQU3Q-X0L;Z^LUURR,%XMQ;I(X&ZW;"_O4X+9YKZ T_
M_@D7/I=O'967_!6+]H6.*-2$B3Q];JJ>P'E"@#MO$7_!*Q]>URZUV3_@H'^T
MA9_:I"XM['XC"." 8 VHIA) P.F355?^"2^X )_P48_:8^9<X;XEC _\E^M=
MC\#OV4)/@=\/M4^'LO[;7CSQ=_:;3%=:\6^(XKB^MC(FS$3@*%*XW*<'!)KR
MG5_^"3'B/P_I5QX@O/\ @JI^TDMK;PRRLR>,XV  W.<8B.>F * .E;_@DI-$
MPQ_P4:_:;88_A^)B\_G!3O\ ATH7+-'_ ,%'OVFN?7XECC_R7KF_"_[.?A/X
M3^!=>\(^(O\ @H?\9M275% .J>(/$R37EAF2%D,+B,;"3&%Z<>::KVG_  2E
MU"[MHYXO^"M7[0[0R+N!_P"%@6X;GI_RRZ?A0!U _P""2ZJR@_\ !1W]IIFS
MN6/_ (6<H)P>O^HZ5]#? 3X)-\"?AW!X C^)WBSQ=Y+9_MKQKJWVZ^?$:IS*
M$7C"@XQU+'O7A?A?]@:^\,_!S6_@V/\ @HI\6[Z;7+E;E?$M]XLBDU2Q V92
M"4* J'81R#]XUR__  Y^\7LJ@_\ !4G]I+YCD.WC2,Y[_P#/*@#VS]J;]C=/
MVH=6T?43^TI\4/ )T>.96B^'?B?^SUNO,(.Z4>6VX@C _&N'^'7_  3'7X<^
M/-)\<_\ #>7[0FN?V3?1W7]CZ]\01<6=WL;/E31^0"R$XR 15'_A@FZC^"EQ
M\$_^'AGQ:W3:@;MO%2^+H5U:/Y8P(UFV$;,Q],=7DKRSQ=_P3/UO1M:T?PUI
MW_!5;]H2XO-6N=L:-\08>(P1N.1#C(7<PSZ4 ?<_CCPG'XP\&ZEX.A\1ZAIK
M:A8R6XU#3;HPW-N70IYJ2 '#@'(/8@5\PW'_  2:CEW-_P /%_VG$=N?+7XI
M;D7+%C@&WZ<G\ *T/%G_  3ZUGQ5\*]!^%:?\% OB]ILFANQ;Q!IGBF&/4;W
M*(O[^0J0P&SCCJQKCY/^"2FNJA9O^"K/[17_  +QS#_\:H W#_P25\QRB_\
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MT8HRON7@8K1N_'WCOXQ74GAWX>:7]@T>93'=>(I)&$B<X(CC.W)((YY ]*]
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M^+G1_P#R)36^/G_!(!U*I^PW\0XR1]]/B9&2OO\ \>E?U-1_\$8O^"6FW/\
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M>)/&;7'DG26T7Q4NGBWQNW[@T#[L\=^W%?5W[-W_  4C_P""0/[.%M>1Q_\
M!)>#QU)>/NW?$+Q-%J"P?<X0-;@#[G;U-?TB#_@C+_P2T9F/_#!7PO;=][_B
MC[0?^TZ<W_!&7_@ELPPW[!/PQ]?^13M/_C= '\\?QH_X*[_\$A?C-\/YOA__
M ,.6O#7AA9G++K7AC7(K:\BRC)PZVO\ M$C)X(7TKP%_C]_P1\/3]A7X@_7_
M (6='S_Y*5_4TW_!&+_@EFWWOV!_A?\ ^$C:?_&Z#_P1D_X):'K^P/\ "_\
M\)&T_P#C= '\LJ_'_P#X(^CK^PK\0?\ PYT?_P B4T_'W_@CZ?\ FQ;XA?\
MASH__D2OZG/^',7_  2S_P"C!_A?_P"$C:?_ !NC_AS%_P $L_\ HP?X7_\
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MDU[]*[^"HM.:#VOL=]3#5Z^88K#3PU*<\12]K*C!VH8V*C?ZUA':U/$Q7O\
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MO=7+?;&OK%$M 8M*@#[ \UO,?+?9N!RP#%@-35K#PI_P5P^!*^&V*^%?VHO
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M;_LU^';^U\/^+-,AT2&2.0+9(]JS,L>'&W+#)[T ?J8OQJ^% &#X_P!+_P#
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M19-/U>#3KZV9@;F5KO2\94YP?KC\Z\B^%%OYLW[>R74>Y6T*!67&%;_B5W]
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MP1\:?LC?"SQ=XH\.+>:GJ7P_TBYO[J949YYGLXFD<L5RQ+$DD\DFO4&_8?\
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M6<XR< <_A5_1]5L?$FDV^L:-=K/;W<,<]M<!3M>-AE6&>>17AO\ P4ZB1_V
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M#+>ZU.X^'_@74SJ%[K-CI\>^WMCIT#0Q^7/<"( M;.'("D.&Q6?\$-9\,?\
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M4;+1_!_Q&\=6/]FP:;#>B-M1O;:^FBEEDV?;%5V6ZS']F&'CX5;'QXD\>?\
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M!_&3P99J/#GBS6KQI[Z_U'S/-O%&FHMM&6^S6[!E+-M0LPVX-+\/1\'/V_\
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M^"G_ &4CP[_Z)TNOU3_8F_Y2@_M:?]?WAC_TUU^5G_!7'_E:!^"G_92/#O\
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M:? 7_@I[\5N/^9C^'6/_  8Z97U+_P $_P#'_#:_[56/^AVTO_T7>U^5D?\
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M^F2.: /I;_AD_P#X)7_]$6^!_P#X(-&_^-T?\,F_\$L2,CX*_ __ ,)_1O\
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MWP UC_@IY\"O%GQ#\6Z9I7[,5[)X^\;S>(KB.3XC7*_9W>VMX3&, 'I;@_\
M C7)?\$R_A[\=]/_ ."]WQG^-7[0-]X#&M>.O@W979T_P'KTE];VJQW-M;J&
M9P-K'R"Q&2?F% 'ZR4444 %%%% #7"[&R!^5>/\ QJN;+2_BCH.I:SJ4-O9_
MV+J*'[1=+&&8Q\ !B/45[!)GRVQ_=KR7]IWP!X-\2:!IWB;QSX;L]1TW1=0C
MEO([Z,L!"94W8 Z\>O% &/\ ##]HOX/^#/"ECI.M^,%^T3._EK!:23*V%7/S
M(".WKSVJ_P#LY>,=+\7>-/'ESI]G-"DVM(T!N(MAFC*G#J.N,4?L_P"F^%_!
M.IZIX#TK3+.UCO'CU#2([>$ &VE#A,_18AG P.*O_$O=\.O'>E_%.%MMI<7*
M0:U&\O.TXB0HO&<;R: +_@T_VC\9O%%UJJ@36T,<-FO_ $PPNYOSQ^=?$7[-
M-I;>)_\ @I;^V1<^,]8N+&XT^;0_[+DM9#"RXLF\LC'WC@#\Z^W/B#X8\27L
MUC\2_AM) -06'-S!<9VWEN0I,>!_%P*_)_\ X*'>&/\ @K)^SM^T7\3OVX/V
M3K+P'H_A_P 3+I[ZK:^.-)::\WVMHD7[J-HR -R.1EN00>] 'UI^T=#-JGQ6
M^ NI^+)#?7]KX<U^:UN+B/=(TRW6F^6_/._;_%W'M7GOP.NKJX'[>4UP[-(_
MA^W;,@X)_LR__F*\;^!'[-W_  <"?M@_%CX*_M/?M/?$7X6P^$O#]_9:Q#9:
M/&UK=2:?<O;S2J8E@PQ,<2X!8 &OM+PA^PY\5O#-Q^U!>S:IH^[XP:2EOX78
M7;,L+K9W4),^5&P;YEZ9XH ^<?\ @H</B3IW@/\ 9)U3X%:/HUUXL7XKZ6FG
MQ^(-PLV_TB9@K%2KJ"^ Q!Z'M7EWQ<T?_@JAJWQZ_:"\4:5X,^%^FZU#X5V>
M*+&WUB]^QM:#2[;<T,?F;6<H%Y?)Y KS;5/V3_\ @X"^*_Q0\)^$]?\ VC/@
M;'J'PFU:VU#PJOVQHH#<QNLR-S;?OC^]YXYY':NZ^('[*/\ P<IZ=XH\2>)=
M;^,?P)DU3XFQQZ5XBCM820D+Q);^8B_9OW8V1("W/2@#R+_@CY:?M!^*/VO/
MV?\ PYK^E^'[*TTSX7Z[>>&?L=Y+)]I7^T=25O.RV-P+S@8P-H7ZG]/?C3^P
MA\9OC!^S=\=?A6)M-M=6^('BS3=4T!X;HQH(X;+3HG#MR4):VEX[C;7R+_P1
MO_X)<?\ !37X ?M1>#/BS^TGXY^'NI>!? GAS5-%TL:!=.]XWGM-)CF! R^9
M<2_-NXZ8XK]C(D;Y2S?P<T ?.<O[-WQ+$?[/:^58^9\-[VS/B1A<?PQZ->VC
M>5Q\P\V=,>Q/I5/X0_LO_%GP3^TA\5_B9K"Z>VF>+HS_ &1Y4_SDFY\P!^/E
M&W.:^F]H[4%1VH ^!_B5^P9^TWXI^ G[//PFTBT\/7"_#NQA7Q?!=7 VR,BP
M!?))X/\ JGX/&34Z?L!?'V']F[]K/X96MOH_]I_%SQ5JE]X)C2ZVPF&:%%C$
MW V'*].U?>"H ,5'*K1IE3]U3SB@#YW_ &5_V??C9X=_9]^'OPW^,VNVNGMX
M1\(Z9IUQ9^'[R0)/-!;QHQ=B3N7<@XX!QVS7T)9VB6-K%:1'Y8XU49[XKP?X
ME_%?X]_#7X^>#_"US>Z/-X=\3:K);*BV_P"_4#D?3J*]\A)FC5CP< M[4 4_
M%Z@>%M2PO_+A-_Z :\S\, ?\,MR-CDZ3?9/K\\M>F>,/^16U+_KPF_\ 0#7F
MGAC_ )-:;_L%7W_H<M '"_'\#_A7/PCX_P"8UIG_ * *]=_:"C>7]GSQQ#$N
M6;P;J@557<2?LLF !WKR/X__ /).?A'_ -AK3?\ T 5[5\6=;D\,?"7Q-XHB
MA65M-\.7UTL+G ?RX'?!/H<"@#QG]C**:V_X)SZ+!/"\<D?A+4MZM&4(R]QC
MBLS_ ((N_P#*-;X:_P#7+5?_ $[7E=C\ ?B#+\5OV';3XB7.F1V+ZEX8U!_L
MMNQ*)M,Z<9_W<_C7'?\ !%W_ )1K?#7_ *Y:K_Z=KR@#ZEHHHH **** "O-?
MVQ_^34?B-_V)6I?^DSUZ57FO[8__ ":C\1O^Q*U+_P!)GH \A_X)T?\ )M?[
M/_\ V1S3_P#TG6OJBOE?_@G1_P FU_L__P#9'-/_ /2=:^J* "BBB@ IK2*I
MP3VSTIQ.*\@_;,_:Y^&W[&OP,UKXV?$R^VPZ;:2'3]/C9?/U*Z$4CQVT",Z^
M;(PC;"*2Q )QP:F4HTXN4G9(VH8>OBJT:5&+E*3LDDVV_)(YS_@IRZ+^P'\5
M@S ?\4=?GK_L-7JOP,D0_!KPB0?^96T_M_T[I7\_7[2/_!SW^VG\?O@WXM^"
M\W["UG:V?B32[C3UNOL=TTB12*RA\>9C=@],8K>\%_\ !U[^W%X3\*:7X7MO
M^"?^GR0Z5I-O9+/):WRE_+C5,G]Z .E<_P!>P-K^UC_X$O\ ,]C_ %5XHT3P
M-97V7LIW?HN4_H3#*>]+N'K7X(C_ (.L?^"@& 1^P-X8Y&?FU*0'\OM7%.'_
M  =7_M_GG_A@CPK^&JR<?^3-8RS?*HNSKP_\"C_G]QZR\.?$!JZRG$_^"*O_
M ,B?O9N'K1N'K7X2V'_!T=^WW>VPN9/V*? MOEB-LVL7&>/I/C\B:G'_  =!
M?M[?]&<?#_\ \'5QQ_Y&K&6?Y)%_[S#_ ,"5CT:?A'XH5(J4<GQ&O_3J7ZKS
M/W3W#UHW#UK\,=/_ .#GK]N^\F\JX_9'^'=JNW/F3:Q=D?3Y)6/Z5>/_  <R
M_MPY_P"3;/A;R0!_Q--2Y/?\OZ].U82XFR".^(C]YZ&&\#_%K%P4Z>3UK><5
M%Z=U)IG[@;AZT;AZU^'J_P#!S-^W*S;4_9J^%;>NW6-2.W\AGU[=O<5J_P#$
M2K^UPT9D3X#>  ORC>WV[:I()&3Y_L3[X/H:RJ<6</4W9UU\KO\ 0[\+]'_Q
M>QD;QRJ<>W-*"OZ7EJ?M;N'K1N'K7XL'_@Y#_;,%A_:J_LX^"6M>3]H6&_\
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MPA^T;'\+?&MY_P $R/\ @JWX0L?B%<:?Y-CX4\7V=K_;6IV-WJF'68WFHO\
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M;%4%AJU".&@JZC3DI5\'-IMU\.W**K8-M*\.:,DE\-]2SHW[1LW[%WQ OOV
M/^"I'A:Q^*'A*VM_[5\*ZC<6[>(M3M+JX816W[S49%CCC2 3X6.,&-G 7*DB
MI=9^*VM?\$L/BA)^QQ^VQI=I\5/@;XB,VJ>$[36MVNZA9:= S0V**ERT5O"!
ML0M&B;5.=A'&*/QT^.NI_";XA+^Q#_P6 \-)\4O!>E0PZCX-UGP' ]O?6\\F
M;>U66>*2PBD2.W,P9/+=BS*26VXJY^T;\1?$W[&6LZ3^QC^W[I=O\5?V>;FQ
M%UX+C\.QE-:LM,MF,.FPR74#6$1<;(VDR9-Q/#XP*F=:5&,VIN/LVE&ZUA?[
M%7>].72U[=D5A<MI8RMAJ=7"*HL9"52I"E)*&(Y$FL1E\FH^SQ$+N52E+D4G
M))-E_P"*?A+7O^"5NM:'^T-\*]5'B?\ 9Q^+,EMI7B;P#XNN3<B(:D3=7IAT
MZ'R;17%G:F%'<OC>R,&4DFE\4M<UW]G_ ,+6/_!7;_@F^D>A_"_5E:/Q-\,O
M$3-96"W@E.E1[--T\QQ;=R&;<\C$.V\8R5.A\9/#7BS_ ()T_!_2_$WP@UV'
MQE^RK\4;J"Q\5_#WQ !<ZW:G4;<R7K02VL<#PLMC;&%&:Z8([DE3\K+336O$
MW[+7[.:_\% O^"6HCTOX1:]<?\59\+?B%#_:%U]M2X;38VC6/S)DCRKS9-Z#
MELX*'RZVE>C*<(-PY$IVCK*#=O?AWAJTUH]=CCPJGF&'PV,G%5ZE>I[!U)OE
MI8J&O^S8E6O1QFB5.HE--I-SZFEXA\$?"S]H/X;S_P#!3+_@E);77PRU;X=W
MK6/B[PKMBT/3M1TVQA_M*Y4P:<I:=I6:U0H9 KI'@@%%S5T'5_ O_!7'X<7'
MQ _9D\.R_#/]I?P9:0ZGJ_B;PS&FAV6HW%T_D7&ZZ@:6[D46PG*Y<$LV"Q!.
M)/A#\/OA5JGPF\0?\%!?^"-+:K\.=?\ ",=SI/C+PG\0KR.]@U?2;:"/4+HP
MH_VV;S)'^R1AA-&NU)  CG>:G[-J^ OV]=<U+X]_LCZ9=?#']K#PQ;C4]7\1
M:I(!X?U.>[+072I;7#WS;!;&?:%B3#N"2P&1*E3E."]U^T3;C!Z3:UYJ3Z33
MU<79OH$HK#X7%8B#J1^IS5.G4JV]KAE)J+P^813?M,+*[BJD74<>L%L7?A%\
M3?V??^"TWAN?P'XV^'\?@SX_Z59S^(HO&OA#2;>P2Y-FWV:R@>^D,UT5Q-;%
MEP#NARI&Q5K/\ _'SP9XT\3WG_!+G_@J%X%M?$WC+3;J+PMX+^(&CV*:GJ5G
M-?$^;</?:@S%&#/!MDCB&-GW/E7.?\!M5_9K_P""J_CR:3XD> ]9\#?M-6&G
MOKJ^--)F^R:++)9-'#8PF&ZGN<#YK8OBW#/Y;8;&5,/B3XH^$OCQ\?F_8B_X
M*X>$IO$7Q TO5(?#W@GXB?#O?91VEU>;/M%Y<L\MO#(%)M=K?8R%$;9C.0M3
M"K*<(5.>+E)\O,]IK;EJKI.VSY=UOJ=-7+Z-/&8G+_J]6%*A35?V,6G6PD_^
M?V$G>U;"-NS@W&7LVGRMHN>%?VC[O]G;Q;<?\$XO^"JGA73?B99VL,;^&O$4
M%FVN:G9W=\5VRBYU*3:BI'(=I6/<F.K '.EX\N=2_P""/GQ3M_@3\>D'Q1_9
MI^(S2-I'ASQ3-_;5]8PV$0N"8K9S#:0LU[=1.V$(*Q*^ ZBL7XR_&Z^TGXQP
M_L3?\%E?"UO\3+72_(D\*>*/AW%):W$-Y=X6*2619+.%XXX9,8\AB&&3OQD[
M7[1KZQ_P3J@T/]EC]HJY3XJ?LG^+EF.CZ/9(K>(+"&S,=T2UW:K8QAI-1N(F
M)>60&*$JIC).6ZG[N<XRM[-V4I7;IWWA52O>G+ND]+.W45/!JOB\+AJE#F6-
MA[2I2@TJ6):5_K& F^7V6*C?G5.4::;<H\W0K_$?Q#X@_P"">7B+1?VIOA@(
M=8_9C^.C6IU3X;>),SK86NJ 7M[#;Z;$8K.)EMA)#&&+C!V,74DBU\3]#G^$
MO@FS_P""QG_!,:9O"_@>\,TOC3X<ZVPT_37^SRII-LB:=IVQ9%,QN9V$DQ^9
MU=<%FJ'XF>(?$O[#'P7\-^-?@]/#KW[(WQBCC;4/AOJ\?VC7-)M=4A-S?QI-
M!Y30R+:[H8V>\E"-RV\_O!8L="E_9P_9ME_X*/?\$E[_ /X1_P  :XAD^(/P
MO^(NW4)IEMKIM/LQ"D8FF4>;+>SN6O5R&0@[ 4#LI2E"[7*N9)?%!_ST^]/N
ME9VZ&,7_ ++A\8DI3KU?J_/.RH8JE=KZMC(ZNEC+1BE5Y9QYHJ7/]HCUW4_!
M/[2'PWD_X*3?\$XO#:_#OQ?\)=MW\2-$2&/1M+UZRMH&U.\1XK$F6\\R6*)2
MDDB*Z9#<A7J[X0T/X+?\%=?A]>?%+]F_0KGX7_M#>!=/@U#4-9\+6\.AV.KZ
MM??ZV9IX1-=S*IMYMI9PX\P@EM[8R/A*O@3Q1\-?$W[?O_!*;3]0^'OCGP/:
M7#_%;PUXXF%SIVOZ>D7]HWZ6\3M>3!I)H847;+!A-R@HQ#B?]F7P/\!_V_=3
MU+XZ?LI:3K'PH_::\)+%J^J:MJ%RJZ#JFM7WF><Z6]TU\_E+LN-JK&FTR#<'
M& *A5=:I"+<9^TBY2BMIV^U!])*UVG8G$4(Y;A\5B*2JT?J<XTZ=2I:53"\S
M5Z&.A=^TPU2[C&I'G:B_@^R5OA_^T#X"_P""@&@ZG^R!\?? %KI_[1.A_:M/
M\#_$_P -V"K)$=&A,]NT^I7$DMV"]S#/YAB R)?E"LQ:NX_X-IM+TG4OAI\6
M)M3TRUN2FM:9M::W5L?N)^F0<5YKX'^*/@+]NGXPW/PJ_:8\%W>C_M1:#-<V
M?P_^)7AM6M-%632E>YM6NHIIY$<27D<^XBT^=74*$8#;ZA_P;+C/PL^+0!_Y
MC&F?^B9ZQR^?ML^PM1RY[*I%2ZV4-(R7\RZ]#JXVPU/+O"//L'3IRH*^!J>Q
M;YH*4ZWO5,/.^N'J<JY4U%QE&5XJZ;Y']@:TTV&/]DN[@L88Y'^.GC=&D2(!
MF40:Q@$XSC@<>U?L F-O%?D%^P8NVP_9(.?^:\>./_1&LU^OL7W?QK]./XC'
M4444 %%%% 'PO_P<E?\ *%WXW?\ 8'L__2ZVK\3?^#47P]??#_\ ;5M?VEM6
M*MH?]K0^"6MX<FX^WZE%(+=\<#RE*'<<D^W6OVR_X.23_P :7?C=_P!@>S_]
M+K:OYN_^""GQ;U_P=_P5&^"?A+4/'*Z7X7OOB-9WNM0W=TD-M))#%*8WD=N
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M2UW7/&'BW]H7XR>++[4M<\7ZC?:6/#_BJ>WAMK&6Y=H(3&$"J5C,8./3@]:
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M[51)KMRMD'Q<ZD2 )MN[[R],]1ZU]+G]H[]G8\GX]>"0W_8T6G'_ )$KR?\
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M_LJ^BD:)MUPB[UC)VY5>^.AJA_P1=_Y1K?#7_KEJO_IVO* /J6BBB@ HHHH
M*\U_;'_Y-1^(W_8E:E_Z3/7I5>:_MC G]E+XC?\ 8EZD/_)=Z /(?^"='_)M
M?[/_ /V1S3__ $G6OJBOE?\ X)S$M^S3^S^WK\&]/_\ 2=:^J* "BBB@ /2O
M@O\ X.&O NG^*/V Y?$EY/+')X:\7:9?VBQCY97=I+4A^,[0MRQ^7!R%]Z^]
M#TKXK_X+WAF_X)M^*\'IK&CGZ_Z=%7D9_&,LEQ%U]B3^Y-GZ)X1U:E+Q2R5P
M=F\517RE-)KYIV/SK_8R_9=_X)\?MD? FZ^'.F>(+CP=\:_)M[#06\2^*!]F
MU?4'&YY8+9 2\8P1MQG)%'[+7[(7[&W@'XH^)_V:/^"E&@Z]X*\36OVK4?#O
MBC5-=&EZ;>:>DL5M L:R*'D,DB7,J2 89$(/*FMC]E?X(?LV?M:_#_P7J'[,
M'QIL_@]\=? NFV]A9V^M7EK9_P#"6ZNZ[OM,)$LD\@"JR_+$#_L]Z[KXG7_P
M;_;9O;']F7_@HM'_ ,*8^+W@N)0GQ3\0"&UM?$FCVA:W5%FU!X6D:XNIY[A=
MD04K"6##+)7YSA<!AY8>E/V=)RVC*W[NHNJE_+-=W:^A_96><39OA\XQ^ AC
M<93P[DY58-R^M822?NU:33_>X6:LY1@YVNTXIJYY=\&/V/?V9/V;_CYJ_P"S
M'_P4J^'.HV<'B"\(\&_%-=4FTW388+:*22:5&9@LR2N88@2C8+\8.#4OC;]C
M+X$?L8?'RUU;]H;X4+\0O@=X\C2;P=X[T#4KN"'3EOKEA9I)>"6.)VBM8GF=
M=IR'5LL#@>L?$GQ%H7Q?@TW]@'_@JKX<D\(>,-.5K#P3^T#>0[;">& BYNY_
MM6H&W!2;R8[<%$;)EYVG!J3Q'XBF_94\"6?[&O[>7AO_ (6M\%_$B1WGPK^+
MFD;[VST9)XC9Z8AFE\FU0Q6T4MP5223:LF5WH<UO_9^!IPE&$(J,'>,I*[BW
MO"HMW&ZM>UK-:]3Q_P#6OBG'8B$JV)K3JXB*]K0A4DH5Z<4E'$X&::C&JE%.
M=+GC+G4ER:M+SWXU_LL?LN?L>_&7PW^UU\-OAG9_&C]G6>60Z@UE<RZ@=-N(
M$2 1SS[UMR)+R>,A)0ZLL31XYYWOC'^PM\*_AK<V/[8G_!.;0O#'Q<\!Z?Y6
MG>+/"-Y91^)GM[DLUQ=2[)(VBC5+<P $_,I8\8>N@M_[&_X)T_#B;P)XN"?M
M&_LJ>-&W3ZUX:;^T%T"YMI=S"3RV6SB,E]/!C=< GR6_C 4W/A]\,_BI_P $
M]-!N/C)^Q)\6+7]H+X+:D9;7QOX-T"Z-Y/!?SQC[1-)#8K)%^[M4A!9Y$.9<
M%0"E:?4\,FU[&-EJTDG*G)=8+7FA+?3F^1QRXDSJI3A6IX^I6J.]*G*K*?L<
M?23?[K$7LJ&+IW<+R5/F;BTWI)\K\0?@U^R?^TK\/H?VRO\ @G3\+- N/B18
MW']HZ]\#[K2[?4XX[%V.G?+I4<;0KAGCN<D8 7><$DULZU\!_P!C_P#X*C^"
M;?Q5^SP-)^&_QFTN..P'@74+A(8OLNGKF3R[&V7"AAA5Z8Q@@= [X:Z%X$\"
MZ[-_P4>_X)7Z\NKW<JL?$G[.5NR?VI#I;,MD0;6Q>XE;%QY=U\VU0OS9!^6J
MGA+X)?"+]J;Q2O[4_P#P3/\ C%IOPG^*$*R6]Q\*M6NH;&\>.)=UW-'' ]Q.
MPDR O[O#?Q;0<5I'#QJ/E=.$G+648V2:7_+VF^DEUCW6VU^>698C!RE5HXW$
MT5A_=HUZG/*>'DU[V$QL-7*A=+V=10E%KFM-ZI7-#D^ _P#P4-\$3?L[?MO>
M'K'X6_'_ ,&VTNF^%O[06/1;?5=3U4L;-?LD:[Y-@BL=RE=Q\WY<ASF;X:^.
M_@I\5_#-Q_P3Y_X*I^#(?A]JGAFZ.MZ#XE\N+08=2B@'V&TC)P'F:03W4@8C
MY@"0>*KZ_9_!S_@I'\1H_%WBF^M_V:?VG/"%U#*VG^)#'II\3:Q.$&CHAN'^
MU%HEMK4';#N'VI-BR QDQ_$C6/@-^WUK*_ 7_@H#HY^ _P 7O"ELEQ/\2/$=
MO':VNNZ9:YMHX/-OY(78S2SR3@>5M*P,RMP:(^]*\>6<I>ZG+158[6J+[-1=
M-(_<3S4(N.&J>WH4Z?[Z4*3<JF7U7[RK8-QE+VN%JN[DH.IRIQNDUK=^&_B/
MQ/\ L4:9=?\ !++_ (**:2TGPC\1,MGX7\>:7;G3[ *[&_O9?M4N&E59;B*,
M@ [6!7H14GA+Q'9?\$XO$VK? W7+:3Q-^RG\:C,NC^,-&.Z&SDU3;:8DU"0#
M)CL[221E7^]O&>34?Q,\27^HZ?8_\$]/^"MWA^4:M"[VGP__ &@_(,EB)+@I
M<W,@N[X6R%(D>VM245CN3#88*3%KM[X>_9X^'MG^PU^V58_\+)^!OBBX23X0
M_&W1U^V6>@W%W$UE9'SY&BM8_)A6\N6$<DI4/E0RG(TO**3C*RC[L92UE!O3
MV51=8.VDNS3OU./ECCH*.)I.I+%/VE:G1M['$I;8W![*.*C9.=/W9\RFN3=)
MMCX3\0_\$MOB%_PV/^PS>V_Q ^ GBV6./Q NCQG4;BRT^Q0+/YERP$<9-QYP
M#[N!P1\E7O$S>$_A%XCL?^"F/_!+VX/B6\UAVE^-GA>.;^U[W1[?49%U*?>@
MPML$^RRQDD_*[#MFC1K+XD_\$Z?AE);1ZC;_ +1W[*?B^WDM&;PO-)J"Z/;)
M+YE[*ZPK]EB#7$DJ FX*DQD,58$"IX%TGPU^QUIVJ?M5?L6:Q#\9/A7\0[7R
MOBE\*=(F6ZN_"=G>*UW$;B"R:5$%O;I=6[--(B@L%R1E@N6%+E@H>SY?>Y=W
M2D_MT^\+ZN*4M'ZHTGB)8KGQ<JKQ-2I:C"K*ZIX^E%I/#XU2Y73Q-.+Y82J*
M-ZD8M3>C+/Q%^$'PB_;/D@_X**_\$^O$UNOQ@TBZ_P"$N\2>!;N__M"\62'B
M&)+2(, S/&N >#N'M3_%S?!'_@I_X*C\:^(-0;PC^U9X'M;;0K/PWK=\(VU*
M]TLK?7C1Z?&"Q#LUXJJ1E67! V9JE\.OA'INEZM=?MX_\$FOB[:RNZKK?BSX
M#I>(NHP:9"WRV'V6Q-Q(6ED0@*Y4$2<')%5M/\&?";]KCXB7'[8/[)OC2U^#
MO[0GAF[GBU7X/ZM+':7FN:W%YESK$T,2/+=OYD=Q=PC$.YFMRK*GSD*,9?:B
MKS=Y)?#46ZJ4_P"6HNW=;"K5*5.HW#$U8PPBY*%6:?M\*VK/!XR-KRPS=XJ:
MC.')]I)LW;[QG\(O^"H'@Q?V<OV\&F^'W[0'@.UGTOPK_;]ZNF0:AJNIDF%5
MM5!>0)Y%EN4C)#C&=YJ/P!\4?"$_A=O^"57_  5@M[CPWHOA6X7_ (0WQA),
MND65SIFF*MI:.CO\\HE:*5D<C#*5YR&K)UC2_@G_ ,%(_B+'XJN=2A_9Q_::
M\'W<4T^G^)?*T[_A)==F9?[.$9EE-TQC^RPY(@WC[2-H?(%.^(VL?"O]JS5H
M_P!C[_@ICI[?"OXL>$[<6&F_&S5(HX;37-.L&,1D6XU!H"RW<[3.C)&48<JV
M<@/FJ.+JNTI2]WF>U2.WLZB=K32TNU'7J5&CA:=2.#G&M1I4OWTJ-.[JX"J]
M?K.":O&IAI-\]J<IOE:O'1,T/ OB6#]F*SN?^"57[?=LX^"OB21?^$ \?:>W
MV"Q-NK-JL\GVN7YIAYT]M%D;@K94_*15?PKK7Q)_X(]>+;_6O#VFGQU^S7\1
M)7U>TUCP[:F;RX+H-'8(][)A!)Y*QL<'#C./O"HOB%>Z%XITG3?^"=/_  4]
ML(]/U"SC:#X4_M&31AM/-O)MO[B07=\8(V00BRL\Q!P&(5MI"L;^J^-O&'[#
M_@.'X _ML^&IOCQ^SIK]O%=>"O''A_=J%OIEBH\K3(_-<06R,55)-HF< 'Y6
M8 $GPOF3UI_!/7FIO^2HMW3Z)V:M]KJ3_O-/V%6'M?K;<Z^'C_"Q<;?[[@Y?
M##%M+FE3;C/GBTX:N)#;W_AS_@F+\0(?VGOV 2?B#\!_$5O';?$<:/\ \3*:
MPFL]P5)+HX2W+F]CQDY8JV15?QQ^SSIOA;6;;_@I#_P2-\8V?B+7--C>;Q1X
M561M;OH;W4<^:HC4;(Q''-*6SG&S/(SF+PO#X=_X)S> [[PUHMS'^TC^S)X\
MS_PF5]X9"Z@GAZ[MV7S1*MN?LT;2F:SV^9,I/DG@$#=;^%OPQ^(7['%K+^UW
M_P $U?BW8_&'P3=M]K\6_"/1[IKB^@N+Q=L$+VNG+,/W$<P8EG4KY><%<FCV
M*E^[DK<OO-1>M)VNIT_YH/=I<SO]PHXCDYL71KN=6I^YC4JK]UCZ2?+]7QNG
M[K$0NZ<95.16Y&I62D6OB$/@U^VP\?\ P4;_ &$M5^S_ +1&F7J>(]1^'>H:
M@+Z\:SL8SIP"V48.TN192 _=*ODX+T>.?"G[.'_!93P1]I\1>(H?!/[2VD6L
M/A.UT'Q!J@@6\>PQ=7LZV,89MA$MZJCDJT1!^YD97PW\'_"L>)I?^"BW_!*7
MQE:Q:]#;_:=9_9R,L<>I?V);F.WN(UM;)KB=O.N8;:<!@%*S [A\@,.A_"7X
M1?MO^.9OVE?V,?BW:_ GX^Z3-+IS?#?7+R&QN;S5@K3:I>QHKS715H;FXC_U
M08FW^=4&XEJ,L1&U2$9.>LH)V4_^GE-NR51[M;^74TYJ&!G[7#UZ]!81<E&M
M-.57!RV>"Q,4FYX2]E&HHSAR\WO:M&[%\7?AI_P4!\%K^R;_ ,%-[2\\ _%[
MP=!,WA^ZUJYCTB"ZO;T[;2-;<9=CL,!(QDCD'DBF^#?'OP^\2>$U_P""7G_!
M6.&[\,V_@:Z-SX)\833+H]C=Z781KI]H4+C=*)/])=7QAE[_ "@5D>*K[X&?
M\%)/&0M_C9IG_#./[1?AMHKV:Z\31QZ>NNW15(].@5KJ07#,%2W/$.X9&W=Q
MN7XF-\'_ -L'5[?]DK_@I/"OPE^+W@>Q2UMOB]KD44%IXDT>Q:2W1UGOY(6E
M%S<O=SKMCV,$+ G#*#FJ.]2+4F_=C*6U1+1PJIV]Y;7=M=K&'U?"TYPPU2%6
MA"'[V=.E[TL'5=G]9P/+=3P]1MN<82DU'ENM$6_AMXF^(_\ P3FAN?\ @GG^
MVEI3:K\$?'4+:3I_C30[4V=G"^HD-<S&[F )2.*1]P&2NTG'%6?#WQ,@_P""
M7_C.[T3X903>,OV4OB8ANK+Q%HN)T@O+E%L&CDOW"KO3['([*O167C[U1_$3
MQAXK\&^'K/\ 8'_X*S^#FUZQU(M:^"?C[;1O<:?IU]?1[5N!<WJVT6RVB<EB
MNXJ$Y4J,U7O_ !'X._8Z\"6W[*/[1_AIOC=^SGKUS]O\"?%+1%^W6ND7,[-;
MK;F0M':(\-REW*RK,S@."1R0$I2HZTWR*FO<<M94_P#IW/2[IM;-72TNS516
M9:XJBZ\\6^:M3INU'&Q6JQ>&;Y5#&1LI.G+DG?G7)=M#;OX,W/\ P3V\>V_[
M>?\ P3;U>U^('P@N?+TWQE!I:'5KJVTV!EN=1D:;B.$!8-HDSA&9<@#.9?%W
MA;PM;Z[IO_!27_@E-?\ ]N^.;B6XU7XI^"X[G^V+ZP?5V\]E,*@I!L;[8K9)
M ( 7(7A_A7P7\2O^"<_@G4/$OPF\;6W[1G[,OB*.XTKQAI/AV1KXZ?!(OF:G
M>2QVRM @2%7CW/.%S+\^,Y%?X8>%8?V78[W]MG_@FQXNA^*'A7Q9BY^(7P3T
MV59K_0;:\$DEC;2VVG^=@6R274;>:R%3#]YSYA#453I\EN1+WG%:NG+5J5+H
MXO[27-\@J8AXB4L5'$/$3D_8TZM1.,,93T7U7'I\KA6BOAE-0BY6]_1,M_$?
MP-\ O^"A4D/[?7[$?B==-^/FCWZ>+M2\!ZMJ7VR\>#1U,,<<=G$IQ)+)!9%,
M\,' /+5/XAE^!'_!7OP0O@?XZ:LO@7]I3PGIZ>&].TO7-1%C%?ZBI$UPRV<>
MYRH82J%^\IZ]*Q/AQ\)/AYXL\13?M]_\$D?BS9Z'XBM;=M5UC]G^XNXH-2;0
M[!E%S:+;6;74KF[GM(-JE0K_ &H?,K%5*GP1\%?V_O'LGQJ^ OC&U_9]_:+T
M"Z>"\\%^(IX=/FUG7W+274L2M(]TW!E0YAWD@!D7YL3[_*U*$7[3WI17P55_
M/!O::WLVGY!&IAL+4YJ.(KTH816HUI1?UC S:M]6Q,;.4\)+X.:*G%1N^9)M
M&TGQ*^&/_!2_P*/V7_\ @H>S?#WX[>";>>T\*S:Q=+I,%[J6J,?L<8M1EI-B
MI9;EZMORO#U'X$^(-M\*]#F_X)0_\%3]&OM(\#2R):^#/'$972]/%KIY,PE\
M^0!I5>6*,!\<D@<9&<OQ ?@I_P %'_B&NM>-YHOV;_VE_"MQ#<2Q>)1%IW_"
M1:M((TTF%&N'%TS1I!:DXAWCSQM#@H38^(WB'PI\<[FR_82_X*G^'I/ OCS2
MXVT[PG\>M1AV6%S!;-Y\\RW5^\&5F,(B5E0AFDQP>KC[2-ZR:E-KE4GM5CMR
M54[6E;2]D$J.%A&& G3J4:,;U9X>FW*K@:EU)8G+Y)M5*#?[R482F^633CI=
M3>"/B)9?L@OJ7_!/S]J;2+C4/V<?'4S6GP[\=:?BWLULKQS?O,;Z0#S0B72J
MS+G!5NM5_#,_C3_@D!\19/V@_@%&OQ _9P\?.UYJEUH,)NY+>UB5K>S$EY(
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MR>"C*^I? S4I(;6\\0W5L&N=4>*&*2:ZD$\<LT"XC7<T+*VW#$>+_P#!*_\
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M?\%-->\2? [XZ>,]4T'X*W/AWQ-X9O-0L4M_[2DD2.XQ)N090L>"H&5 Y.:
M/Z(!T6EHHH **** "BBB@".Z3?%M_P GBOS7_P""CW[-OQ"^ WQJ\;?\%%K_
M .&/@?QUX5LO!::?-HNN:Y<V5U%(^HQN&39;2(5&0,E@?F/3O^EE?+__  65
M./\ @G!\3#Z:?:GCVO8* /S#3_@I)\)S^T7X1_9SD_8<\"K=^+O#JZQ;ZT?%
M%W]GM4*RGR7069<M^[/(X&1Z&O8S\8/  8@_LS?"_P#\*#4/_D*N_P#VT?\
M@D;X]_;,\0? ']J[X(1^$%\0>%?AQ!IFMQ^+-5U.VCO;=K:,P*AL3E2ADG)/
M!.X#GMQ*_P#!&3]N0<GPM\$O_"Y\6_\ Q5 %;_A</P__ .C9_A=_X4&H?_(5
M97CC]HSX5?#[P9JGCG6_V9OA3'9Z39R7EPTGB:]B!"(3@N]F%&[[O)QDBN@_
MX<R_MR?]"O\ !/\ \+CQ;_\ %5Y/^W!_P2#_ &S/#W[(GQ U7Q+H7P?M[)-!
M*33:?XN\333H'D1-R).3&Q!;.'&.* ,W]FW_ (*-?!O]I/6KO2/#?[$OP_TR
M.UT^&]6\N?%=U+'*LF-JAH[(Y^4!L],=.:^GO^">G[17P:_9-\2_$SQ;X\"V
MB>/M<MK^QT/PG8R3V^G)'Y_RF241EBWGKT4#Y>G>O7O^"(__  3+^$_["G[*
M?A#QCIVD02^/_%G@72SXRUZVU*YEBOL1F6+9',Q$6U90N$51\O2OMB.V5$5-
MWW1CY>!0!\S?\/9/V6?[GBC_ ,$J_P#QRC_A[)^RS_<\4?\ @E7_ ..5]->0
MO]YO^^J/(7^\W_?5 'S+_P /9/V6?[GBC_P2K_\ '*9<_P#!5_\ 9;G@>)(?
M%#%D8?\ (%7CC_KI7T[Y"_WF_P"^J@U&!#92!OF_=M][GM0!\<_\$%=<LO$O
M[ $/B#32WV>\\?>(I8=ZX.TZA)C(R<&OLZ9BL3, 3@9P.]?'O_!#5G/[#<F\
M_P#-1O$F.>W]HR5]AN=JYQ0!RFF_%'P/?_$W4?@_:Z]')KVFZ;%?WE@I'F)!
M(=JN>>A)]!751%BF6KY<^&TJ_P##VCXD/@[1\*=*Y_[;C_"OJ-""O% #J***
M /$3_P GL1_]B_\ _'Z]NKP]F _;9C7_ *EW)_\ (]>X4 %%%% !1110 444
M4 %%%% !1110 4444 %&,]J** #I0  <@444 ,G4-$P:OE[_ (*4_LF^&_CS
M^S1XNT?PW\-X]2U_5-ES&T*R&6:YCA>-'7RR2"JL0.,9/KS7U!<E@F5'\)KY
M%^%O[3GQGUW]LK]HKX5:_P")H9O#_@"/1/\ A%[,6JJUJ;BSWRY8#+[G/<\<
MT =)\)= ^/W[.W[,?A/PSI]A)KT=EX.T^RCTLPF.XTN9;10^X[&:8*RD'=M/
M3FK'PFT'5?B!%<6&B+>:;"T>WQ+K6HVI674E8D>5&I)6, ;OF# \*<'MZJWQ
MA\,:+H5G]LU 7FJS643O86GSREV1"!M7)7.5ZX'/6M/Q/X8N?B-HT%A>WEUI
MUNS9OK96&^1>1MSSC\!0!S?@"Y^"OPJ2'X7?#2VAM[.'=*R6L_F10ALEF:1F
M./<9XX[8KS?X]_&7X$:+XGFU+XC_ !AAU2QLX5DMO#.ASQ>>) "<LR2AFW8;
MY>OS5TWC_P#8K\%_$76(4U#Q)JEGX=BLUB;PYI]QY4<L@<DNS@;SD'!Y' Z5
MJ:9^R7\%_AYX#O/#O@'P-'9EK63]]O=Y7;:<?,6R30!QOP _:IUOXH_$J/X<
M>'/@#KGA70K6S:1=0UY#"9\ ?ZM-AW=3R6['TKF_^"Q/[$&N?M__ +!_B;]F
M[POK$=C?WUY97UC<31NR>9;W"2%2J?,<J&Z=Q7K_ ,-GN_'UAH/Q0U>WQK%F
MLMG=01GY47YE^8=CR#^->DS[7@^SE>HQBLZB;@U>Q49<O0^%_P!AC_@JM^SZ
M/A/H?P=^/EU-\-O%'@_2;?1M1T_QC-%9"XDM88X7EC\THQ5G5]N5&0._6O3/
MB[_P5;_8O^&GA&;Q/HWQ:TOQ1/'@1:1X5U2VO;RXR>B1I(2<<GH>WK7K'Q@_
M9=^ _P =;9+7XL_#2PUN-95<+<HPPPS@C!']X_G6'\-?V&/V5O@]J_\ ;GPW
M^#.CZ3>!&VW$ D+@D#IN8@=/2B.(GI^Z3DENI67_ (#O^)$J.%E[SJM7Z<J_
M.]SY0_X()?LR?$[X;7'QL_:T^*OANXT*Z^.OQ"/B'3]!O89$N+.U822QB4,J
MX;_2&' Q\HYZ5^BMPP2,N>P->%_LK?M+?$3XY_$KXB>#/&GP)UKPC9^"?$0T
M[1M4U:W*1:Y#F0>? <_,O[L<^XKW2?&S)'Y=N**</9KEYE+TU6NMA\W/KR\O
MEU_IGF/Q0N]FJ:'\4-,FD*:/>)!J%G#&&DE2618Q_NA?,8GVS7HUA=0W4<-S
M$XVR+N0;AT*BOF?XU_&3P1^S]\0]>\'_ !B\6V.G^'_&VGM<KJEY<(@M'S*@
MCPQ!9MWE\ $\UQ_AC_@I9HUGX.M_ WPA^%6O^)KNUNI--T[45B$=O<B,#;<@
MDJ98R#D[ 3@'CUT ^P?%[PMX6U'=(/\ CQE_] ->$ZA\:?A;\-?V7)4\7>/-
M*LKA=)U 1V=Q?1K,V#)D*A;<3R.W?WKQ_P 1ZI^W;^T'X;OAKOB"30]'O;65
M9+7PUI&T)"P.4N&N4W !0,F,YZ]>*S?A+^P5\*?"_P"SQ%XF\=:S:K?7MC=!
ME:\+FXD=GP 9>0Q(7[OI0!=UK]K/PY\>+CX8_#;X?^ ]>:#3+_3;FZUR\A2.
MVV@1*=IW'.>>!U XK["^,/AZ;Q3\)?%'ABRNECN-0\-WMK#*Q("M) ZAB1VR
M0:\;U;X7_#GP+\"_!=KINBK#-%/IGE^=(7F!"C/\73\*]6^/4T]O\!O&%Q;3
M-&8_".HLLBC+!A:.01D=1B@#\\_^":?P%T3]FK]J#]H;X3Z/96L!L/@[H+W$
MFGL_V>21XKR0E=['^_ST'':O8_\ @C_^U+^S9X/_ ."=WP]\/>*OV@/!NFZA
M:KJBW-G?^)+:&6'.JW9 9&D!'!!Y[&O)/^"4FLZO=?M,?&#5;F]FEO&^$/AH
M27#,&8L6O0",C&0 !TQ[5](>&O\ @FC\!M=T6'5+_P /Z3+)/YC22?V';@DF
M0GLH&,Y[<T >P_\ #9/[)I;:/VG/ .6. /\ A+K3D_\ ?RC_ (;)_9.QN'[3
MO@#_ ,*ZS_\ CE?!O_!1S]A/XP?#>X\'W/[)?PDU#6M,FU95\6KX/\+V$VH+
M 8I^8Q<KY2_,(N>O->%3_LX_M5EL1_LR?M%;?^Q+\*__ !J@#]9C^V9^R:!D
M_M._#_\ \*VT_P#CE/7]LC]DTE5/[3?@#<WW1_PEUGS_ .1*_)1/V;/VI]^)
M/V8OVB\'C_D2?"O](JQ?B+^S9^W//X*U+_A5O[,?QN;Q(UJ%TL>*/!7AK[%O
MW8Q((8UD*XSWS0!^PP_;(_9,.<?M-> /EZ_\5=9\?^1*\Z_:Y_:Z_9:U+]E_
MX@V&F_M(^!9YYO!^H)#!#XJM'=V,#  *),DYKGO '_!,[X,7_@S1;WQ5X4TV
M'6+C2X'U9?[$MUS<&)3)QMX^8FM'6/\ @F3^SY:6,UROAG2V:.%G4/HD+#(!
M[8&?S% %+_@G%(I_9H_9]^?K\&=-V\]?]'6OJRO&_AA9IIOB+P3HJ6BK%I_A
MN>UMV@A"(L<?R+A<\   ?A7LE !1110 'I7Q7_P7NPO_  3<\6$-S_:^C_\
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MEY-E$3;VWE_-*P'F95BWRE;3Q3I_@?'_  2@_P""KNG&;2X!]H^#GCN2X?\
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MQC;:9!#* P"DT/@SX)_X=6:!XF?XR7,?B3]G7X]V[6.@^+O!DWVC4-/$R/\
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MK4Z3J4IGDF\00:5NC-[<-"\=G"&2]M'B5@S'#IE3ER(/#/[,GC2]^-7_  ]
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MX8:WI^U="UZ9(/[.TA9IL7$[+.S"1R(83M&0$/R&QH^H7G[(OP$F_P""5_\
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MMY[$KL&W!..IKVK_ ()8?\G_ /Q/_P"R,^ ?_3)9T ?HQ1110 4444 %%%%
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M>_LW]YOSIEQ):[CU^81NNX>QX- &#X,F'@WXLZE\/U3R[+4+<:A:[OXY,*'
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M/3U'_@;"?Z5]<'I7R-_P6YE*?\$WOB#D<"&Q;CVO(B:\_-E?*ZR_N2_)GUW
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MC/QDT:)H?"?C;Q?,][-+?WSM,HCCA544I;F 9:7!7^YC%4_A99>)/ \>N_\
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MO[/_ /V-6K_^FXT ?75%%% %?5/^/";_ *XFO@WX(9/_  1H^,0 ZZ?\2O\
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MP]: "O"?^"F Q^PK\1C_ -0>,X*@_P#+S#ZU[MN'K7A/_!3)T'["GQ&RP_Y
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M37Y:X=#Z@R%L&@#R7XI:#XN^,&G2>/M8T&:/1]!Q>>'M%GC/FW,\>"MRX.,
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M\;_\%/?B7\2_$-OXT^(EMXY\0:Q9Q1Q6>J:YX@GNKF*-'+HB2RAF55=F8 $
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M#_\ !6OX[_"WP^WA'X::U\2O#>DS2--+IV@^*[JSMVD;[S&./:I8]SC)Q1+
MYK\,<).*^))3C^[E_P!.W_(^L=$$>*. 8N%>?$&'JU8VIU'4P]9QQ=#:*Q<>
M1J=:"24:EG);WOJ?LK\;/#_AG]NNQT__ (*8_P#!-.!-#^+GA>234/&WAO[:
M^H:W*RF.PL2MD3-;QGRK:5P/+4.I#L&855\1^&=1_P""C?P;TWXF^&95T/\
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MPS>+K-+'QQX?\.VQUS4K/6+POJ%ZTT4ZSQ0X#VJNB;=C8"JNXY9\19/V@?\
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MZA($F\O,0"*3@,"RP^+_ ,7_ /@EW\;9/V1OVI;&U\4?L^^*-4GDL;OQMO\
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M-O\ \)Q>-K$:Z4JQ-JYCM;>2.*%BUW<!@80LF%R' .;G[0?A[QM^Q;J.G?\
M!3;_ ()H:O=7/PS\2QOJWB3P]J5V+?1[::Z/V>UA_LRW:V<QJ)V*!PY1@I)Q
MP74Y8TZD91E'D=Y0CHZ<MU.E;:'5VWN9X>6)JXK!8FC4IUJE>$H8?$U$O98Z
M%N5X7,(RT==1_=QE.[4XI]F1_$7X<7/[9_@+0OVW_P!D^]73/VE/A]$MS\4M
M*N/,N-9O-0LHTLHF330)+>!F>W9U3RD4[AN!88K4>[\%?\%</@M'^S+\>XX_
M"_[3G@RWCLM)U3QO<'3Y+R:2875[Y5E;%"S"UMRK;X<IN#87)-9OQ/\ "_Q
MM/A_X=_X*^?L$:I=6^J:A%_:?Q=\*VM\-.T-)K-4CF7[ AAN)HWNUN697DD+
MLQ?/SDG2U/PSX>_X*C_ C_AI+]ET2^%?VF/!D<0UVW\$HOAV._NKV<"5I)Y0
M)IBMI!/@K<$C)4L<U7(Y5I0^*4XW<5I&M%KXX=%.V[W;^\Y(U8T<'0KQFZ-+
M#U7"G7T=;+ZW,T\/B.LL&Y-QCS-14)QLM'$H^ ?$WB[]NKX6:S^Q5_P4]MKG
M1?C&TTNI?"'6/'4(T%5:ZB2SMH8X;40M=,+B.X;#)(&!QR5IWP)^,'BKX7W.
MJ?\ !-[_ (*_:1JMY\,]0EAT+P)KVL6J:)I-M:Z(9&\U+N(6\\T,C16"H=SE
MB4W9$C9;\.O&5S_P6:^$&N:_XX6U\+_M$?#E9;WP'/X)M3I+W=J(D^QI+>71
ME<@7DMPP1)DQG<,$EC/\!/C;H/[>[:U_P34_X*8:1I^G^-/#/D^'_ _B;1]/
M:;68[FQ\TZHTFIW1N45W%A KR#8)]S@[MR[<X2@ZE.<*C;FFHR>U1;.G53^U
M;1/77S-<91JT</C<-BL,J<*$HU*]"A95,%)M..+R]K_ET_=G4C#E5N;6VJQ_
MAA#\?O\ @G!\06_9+_:V2\U[]FWQ=%)I6H:AI>EBWTA6U8[&E?46CCFC6.)I
M2^V8%1N*\J")=(U?]HW_ ()%_&I_B!\,X+[Q/^R]XFU&X\6-%X/TU+VQ-A>^
M;!IT+W]U$TBR*OV(Y$P5EVDEM[9K_!SXR_%[PCX]E_X)/?\ !3!8;KPSXIB:
MTTOQ-JK2:SK%E>Z@5@T^6&[EDFAB9/-)20Q#RB%SCD4[0/CS\4?^":_QOF_8
MC_;*TC3?%7P"U;5I[W2[KQO#)XBG7083+%I8B59##$@DM+=A (,1EB0%.&#B
MZ=&G"HIRIJ$K*6MZ4OY9IVO2?F[61O6IX_&8RO2JT*&)J5Z2G4I025+'45?_
M &G#\OP8V/O7Y4YW:\TYOBQ\%?B/\!?%\?[?O_!'O7H[KPQXIB32=>T/PC;/
MX@O+5SF[O&F^TI.D:"2*)2%8%"RK\JDYL?&_X5:OXRU2Q_X*A_\ !)+4$B\1
M7=FLWC3PSH*R:YK%OJ^IL9;D202+<0Q,J389% 5 IVJ% (J_%VU_:%_X(_?$
M&'XT?LJWTWB;X*^-HXK2"R\9:D]Y90WEU_I,NRPLG@$;+#!M#M&2%RIW9-6?
MCSHWQ,_X)_:W9_\ !0[_ ()R:E/J?PK\:6G]KZOX?U:\V:/:W6I,QAC33+5[
M9E1(FC"!U8I@9;Y>7.G3IJLIQE#EM*2C]AWTJTM-I?:2MZDX.OC,16P53"5:
M55U8RI4*M91Y<5%)*6"S!-_Q(JT:4YW=^9Q\M'XC2>"?^"F?PXL_VB_V<;-?
M#_[3_P )9X;_ %+3]4G9]3U&#2(GE/V?3HVD@W27\\&UFA&7!1CM.TT[3P?;
M?\%3O@C_ ,,]_M+W*Z#^U;X3F^SV.I>-&?3;FYLWF:^81V%ML5L6912SP\$;
MLC(:K7Q;\/>&_BA\,M._X*I_\$V;Z;2?&OA"XA/Q,\-Z&$T/2)K2SMWU+43+
M;(L,UTKSB /^]83*<$' 853X;\2?\%2O@%_PV#\"KRX\,?M.^$9/L&M67@>0
M:#%>I)<&-97FE_?S2KIRJN1<D ?N^1A1;7-.2<>:4X\S47I6CI[T5TJK357>
MYQX>I]3PM&I1G]6I4:W)"=2SK8&M+F_<5KVE/ U'=-2M!1DKK=.;X7?&K7_V
MO/AMK'[!'_!6*PU+2OB+=M-K_P ,]>\:V<>A6]K=/#'IUA$J6OD/<2?:)KMP
MNUE=2RD,47%?X'>(O''P U2__P"";W_!5>QO+OX-7T*Z-X-US4K==)T2V>P+
M7N]+U5MYYHV=(5#;VW,RJW!(,WPJ^*GA;_@LW\,-<\)_&6RTSPS^T)X,6?7?
MA_JG@G33IL]S:VMO&EI#)?W0F;RS>WK,8TE4Y1' 4JQI/@3\1]7_ &O=7U'_
M ()0?\%*;2TLO$.@QI9>#_%EG$]QKD=]:$WER7U&X>YB5F@M]K. H=6* G(Q
M$9QG[.<9<S:M&3VJ=Z59O1M+9OKL:UJ53#T\=AJV&5"-)QJXBA3^/"NZ:QV7
MM6M!/E<XP:O&^MM51^$OC+]I+_@E1XPE_95_;,L=6\5? &_L'T6TOM'T=+;2
MVOM3:.9YA?R1QSX1'N]R^;\I#;>8U-1>(O!GQK_X)J?%R+]I/]B*>77_ -G7
MQUJ$6J:]9^";7^UHTT;3V4-#<7EVDC0EO.NMKB8#_6%GX&#X)_M/?$#X>>,+
MC_@F5_P5DT73=2T./3G33=8UJSDUW5X=6OF3[&ZW3R3Q*4BN9=D@C!C&WE<,
M"W7_ !C\:_\ @D=\<&_9\\<B/Q=^SIX]U6.TM9/'5P^NM'H4.W[88;>"1(82
MWVMB4,!$A )4[>5'V7U:,XRDHQE92UYZ,KZQEU]FWIOL=-:GC:F:5:<Z-&KB
M,32YI0BE]6S&CI+V])6M#&Q_B+E3E>ZNG=.3XI_!3XE?L?>.K?\ ;=_X),ZE
M'J7PQ\3+!8:QIO@N%]>N+:V@VRW8FDNTGV+O0C>'W*6P2J\#2^/6GV'[5=OI
MG_!4[_@F RZ3\5/#K23^//"]FS:MKK2W;Q:9;_Z'^_@BQ;Q7C<(H,;,P#,NX
M8_Q1MOVA?^"./Q/AU3X+:A<>+/@9XP\FPMK?QQJ1U2W7S0)KYDL[22%(WVB0
M;FC^89!W$Y.U^T#I=W^S3#I/_!6/_@EI.[^!]8:>;QMX7E9;+1(>8=+LU_LJ
MV^S2.HEEN7&=X1R)!@4YQI1C5C)-)6<XQTE"VU6E?MN[=&S+#3Q%:M@,51G"
MHZJ]EA\3424,5&W*\#F*3:=244H1G-M\T;VMJH_'7A"'_@H'\+-#_:.^#EY#
MHG[5OPACBN?'&GZD[-J^H7.C0[6\K3(\PH\E^$"*T*C=\C<':;&E:AI7_!4;
MX(M^Q_\ MBVIT#]J#P2K)X:UCQOG27N7O;@WC+'96NSS=MC;0(V^$]5<8+EC
M7^(OAWQ3\6?A9H/_  5S_87U">P^(&EK!?\ QF\.Z-=#2=(D>P@^V:F7MD:.
M>[1[E%#JTTGG D9))86+6&S_ ."MGP(?]H;X5RCPM^U1\/8]^H0^!5&@IJ$E
MW<>3!YMU.//F=-/LVV8N!L+LI)5U OXJKCO*<;M7M"K'HU_T\M9Z7UW,>:6%
MP=.MS*C3P];EC5M^^RW$-M>QJ_:G@)-RBT[1Y)1TNK.C\-?$'C7]H;P3KW_!
M.#_@I[:WUCXP,,DOP-\0>+K4:+91ZA'#_9M@L8MUA>\S+<LZHZRJZH=P9L"I
M/@5\:OB#^S7?:I_P3L_X*LZ#JE_\,=5$7AWP5K>I6::3I-O:6)<R3K=A8)I8
M6 M<-O9O[Q&XYA^%_C[6_P#@JO\ #CQ%\#OC:;?0?C]\++.;5/AIJ_A6'[#?
M7CV$7DP0SZC<M,2IOIXV*I+$2RB0%=F1-^S[\=M,_:XN]4_X)I?\%.=!TV/Q
M-HRQ^&O!/BB'27O-8CO(G?[=(VI7!N$61OLT(:1=@?+#G (5-PC*G5A-IR34
M9R^VMG3JK^9ZJ+;9IBJ%2-/&T,5AH*--QJUZ-&RGAY.SAC<O<=53^&=6,+)V
MDF[--9WASPO\</\ @FO\3IOA!XXOIO$7[*_Q#^T7FO7'A_3RVD1VNL1R6$ F
MU*5%EA,<8MI&*3#Y "N2Q:O2?^#9@L?A?\7"W7^VM-SC'_/&?TXKR_P?\3/C
ME^S;\3+C_@EM^V_9PZQ\,?'\ETNBZYXBFDUC5;6VNU>TTIX)Q))!;!)X(F3]
MSB)]TF%R*](_X-HM3L+/X5_%@WE]#&9=8TTQ^=*$W_N)^1FL\NY5GV'A!-)>
MT]V6\'R:Q7]SK'IJS3C;V]3PASS$8E0E4J_4I*O2LJ>)A[=J-:<5HL1>\:MW
MS-*%SF_V#?\ CP_9(_[+QXX_]$:S7Z^1?=_&OQ]_8%O;.73_ -DZ!;F,R+\<
MO&K*GF L5,6K8('7D']:_8&%E93M;/S5^G'\0CZ*** "BBB@#X7_ .#DK_E"
M[\;O^P/9_P#I=;5^'O\ P:"D#_@J_;Y./^*+U+J?^F+5^X7_  <E9_X<N_&[
M'_0'L_\ TNMJ_&K_ (-,OVW/V>OV7/CMXT\$_'?3=)T>/Q):Q7%GX^U:1(TT
MSR89=UL',18>9N QO&<=#0!^L_[%%[\&M+^#/[:6I?M%6$=SX%A^/GBA_$\,
MRNR/9A(?,!$?S'CTK[X^%<_@ZZ^&'ANY^'4:IX?DT&S;0EC5E5;,P(80 WS
M>7MZ\^M?D]\"OC=\*?C!^PE^WY'\+?']CKLU]\2O$^HVD>ER>8TMK/%&8I5
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M?\%)/B5\.]!;QQXON3HNCK9&RTN%->U$.RM,A.T;&DR3P6/I7Z9ZI_QX3?\
M7$U^:O[*WP@_;D^-_P"Q1XV^$/P\\>?#S2_!_BSQ%XWTJ&35O"=W=7MO!<:W
MJD3L774HHV8%G(Q$!QSF@#OO^"7]M;V?[=G[2EI;?$:X\8+%;^$T/BFZD5GU
M4C2\?:"4^0ENI*\9K:_9=_Y31_M,?]BOX9_](8*XG_@CI\';_P#9Y_:J^/OP
M)U36HM2N?">F>$=.GOX;?R5N'32OF<1[W\L;L_+N-=M^R[_RFC_:8_[%?PS_
M .D,% 'VU1110 4444 %%%% !7R[_P %F5W?\$WOB<0<?\2RUPPZC_3(.?\
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M@=HUYX=_X)]6VAZAKEQJ<]KX]\11S:A=X\VX8:A)\[8XW'OC S7VD>E?'?\
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M/\-_@'X+T#4(]:TI([_1?"MG:SINO80<21QAAQD$ \YK]::_,W_@[,_Y0_\
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M /QFC_AB']C3_HTSX:?^$+I__P 9KU&B@#R[_AB']C3_ *-,^&G_ (0NG_\
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M /"?CJ?VJ4VG&-9>[%6;TT5KX8_%'P+_ ,%I/A!K6D>.['2_#O[17@=[C7?
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M&<.6G/VFB=HS:UB]E2JQWM]GFOV9TXC"5I8S%86I@8^TE#VM;"0FO9U8VO\
M7\!4VC.+]]T6F^5M+K;,^)4_[0'_  1>^+RZ?X%EO/%'P'\7K;Z?9?\ "<:H
M+VRW3 3WGE6-K+'Y<@42?.T&&7Y264@5M_M"Z;>?L?ZCH_\ P5<_X)?>;>?"
M_P 1+<3^,?#NX:;X?MU0)IEFKZ:C6TTR_:)[AP"K[)!YGR [FH^%OB[\;O\
M@D!XSN_V1/C7X=OO'WP7UZW6WT?5%TO^QM/CFOBLES(EX\4C2E%=PR^<0,%B
M4QDV_&%E??\ !(3XNV/[5W[(3MX[_9]^(323:]H_AEOMUC:K:1"VM%GU>3[1
ML=KV[D9&#+O:-HOF( $\T849>\TH.[T]^B[Z26W/3[I6T?57'3IXBOC*$E3A
M7K8F#C"=^7#YK1LKTZL6V\/C%%)PE)V]HFM[7C^)_A_Q5X[^&?AO_@L1^P))
M<6OBJWCM[[XS>'?#LPT?10UG ;[51/$S0S7<;W,:B0;Y?.7D%C\XL7MCI/\
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M]-:;?,$;QPJ=I8$ \^E?UH>"_#-IX,\,Z=X3T^YDEM]+T^&TA:4Y8K&@0$X
M&<#TK^1/_@W2^+NM? #]N;Q-\9_#5I:W&H>&_@WXBOK*&\5C$[I%$VUMK ]O
M7O7]<'PM\17_ (K\!:+XEU41I<:IH]K>S11L2J-+$K$#/.,D@9SP.M '1444
M4 %%%% !7YF_\'9G_*'_ ,6_]A[1_P#TNBK],J_,W_@[,_Y0_P#BW_L/:/\
M^ET5 '\_/_!!SXW^$OV=O^"H/PW^*OCOQ)INCZ79R7\$^J:M<F&WMS-92QAW
M<=,%O4?45_3E\+?^"C'_  3/\&17>L^(OV^/ NJZMJ<S337-YXAC8VH;)\F(
MY.$!9\=_FK^0G]FC]G?XH_M6?%[2?@/\&M)M[[Q%KC.MC#<72PI\B,[$NQ
M"@]>M?;UI_P:K_\ !9+5;2'4+3X+>')HIXUDB9?&UG@J?^!<4 ?T'_$O_@IA
M_P $VY-<M/B/X-_;?\ QZQI<3O\ 9X-=C\N]4<LLF!SP6QSGFOY</^"B_P 5
M/"GQN_X*K_$;XL^!M7MK_2=>^)WVFQO+.4O%+&98AN5NZG'%>]:O_P &L7_!
M8KP_I<VK:G\%?#B6]NA>5O\ A,K0[?;@\GZ5\4^(_A#X\^ _[2(^#?Q,TE+'
M7O#OBB&SU2UCF618I5E3(#*2".0: /[7/V ?^3(OA'_V3?1?_2..O7J\=_8%
MGCB_8D^$<;SKN7X;Z+GG_ISCKUS[6G:>/\7% $U%0BY+@;&7WP:E0DC\: %H
MHHH **** "BBB@#Y_P#VX/@C\,_$%KH/[4_Q#U#5E?X*QZAXEL;+2_+!N_+@
M61T;>.X@ &".IYK\;/\ @EO;?L:_%C4=;_9-_:C\"+'<^/KB%]#\=--:6[:"
M+2&:X=?M$OSP"7RTCPN=Y;!QFOTW_P""S_[4WC[X%_#O1_A1X4TBPN+'XD:'
MXATW6)KU7+01)8<,FU@ <R=PWTK\U_\ @F=^SS^QO^UIX"U[]FOXG^,9])^+
M'C+6!'X'O!X>DN#I]G:0B\E9) PC5I5CN8V5FX"<<MS\'Q1SU<ZPE./*[*3Y
M9[2O9<J\Y6LNQ_5O@7' 87PUX@Q>(E6A>IAU[2@I.5'DYY*M)1^Q2;<YK[25
MNQ[7=?&/Q)^S=\1YOV$_^"I_A!?BUH&Z&S\(^/)M/%T]E<:@JR2W*7^H\D1)
M.J[DP4$8 X3%2^-?B;>?\$X?'1_9W_:Y\*)\<O@#J5C_ &]\/_M%B=8&FK*[
M6^FV\=S> 0H8[2VD_=1$@>:67 >K'AO]H/PQXMBD_P"">7_!7_PA$WCS0XA!
MX5\7332ZI<IJ&HX:!L6H\I1''-%M8M@[>=O-26/QG\,_LBZY-_P3C_X*R>&(
M_$7P_P!.5]:^'OB2^EDNYTTZ,G3].C6VLP=BF*WN7VLQ9=Y!%<$9>ZW&HEK9
M.2OR/_GW6ONGK&+=]CZWZG*6(C3JX%U).'M*E.C*T<3&R:QN7M)<LTO>J4X<
MK]ZS6C2D^+W@[QC_ ,$UI]+^(GP"\7S?$C]FOQ=<II_B#P#)<R:W#;V6T2ZC
MF/'V2$OB5-_?=M;VJ>,_$'C+X3>!=/\ ^"B7_!.VUDTOX4^+F6R\8?!FW)NT
MM;QGDAN96L+7-M"#;6T)WL2W[PDX#5/J=M\2?^"0/B2+X*?&.6;XA?LT^/EC
MT=IM6F2&.&.Z >_E6UMV>4LL?F @XW9P"20 _7/B-J?[!.KVO[7?[(^D/X@_
M99^)"[+SPW<2_8[>RU"8M97 \@[KAF6.S+[B@4^8PR,<Q4Y:?-S-TU'5QWG2
M?2<>OLWLUMJM- P].MBXT:M*$<7*NVJ=:5HT<?"VN'KQ?NT\=&UXSG[[E%VD
MVTW;/@CX6?'[X:W7_!0G_@EE-_PJSQEX.$UWX@^'MO<K;C5-.T^,S>0+#3QB
M<3R)&-CG8_3()JAX!G\&?\%(] NO$W[.6AI\%OVC/A[##>>*M>L]NC'Q'=70
M,FI$QV8^T3L9;5CB3[HN#N^\14_BGX.Z!\/=/C_X*B_\$C]4F7P;HLSCQMX1
MCA_LV%M*TX?:[[>]TWFNLIA161$)8-E>F0R\TSP7^V/X?@_:^_X)<6O_  B?
MQH\+PC5?BMH.DHUJMU<:KF:X)N;LHDFQX;O!0'?YC-QP&T]Y/E5FY*[C':HO
M^?E)_9:ZI;F,YX=T95J#G&G"?)3K5TW/!SOKA,?%W<Z4G^[A.IS17-?:Z5;X
M/_$;X)?\%-X[CX-?'3X<K\./VEM.T^?7+'XEV\$.@O=:O"PATJ$R#_2VVI<6
MC",#<?(W)T6F^$/C)X.^)/CR;_@GQ_P5.^'*ZUXHM[Z3PSX5^+D]A%#-:V=L
M#NNOM]Y^^;S)8L^:O+E_4Y&A8:S^SG_P5ZT63XB?!/2X_ 7[46AVTOBUK?2[
M663[=)IW[BQ@-U<;(5#.VGMO RAVY4@$TWP?\2O@=_P4(#?L0?MUZ&OA_P"/
MVC2?\(CX?\71QS:A<S7%OEIYW>/;;JS/%(,%MOSM@YHYY.,9*HFY[2:7)57\
ME1;*HNCWNS6K1P]"M7C4PE6C"@KU*,9.5?+I_P#01AY)\U7"-ZN,'R<JU6J;
MH6?Q=O?A!\4)?^">O_!5OP5_PL^R-U:Z)X)^)=U8K<2:>^I%9+F[74=0PY\E
M;J!=Z9,8ML$?*HJ7XCZ_XR_X)B^+[7X??%)X_C9^S#XM#WMCHLT!UJ/3K*'Y
M;*$270%K ?/>)]J':VQ2,$"I/"/QL\#_ !C,_P#P3?\ ^"MGAF.'XI:&PT?P
M5XTD9]2O$U#6&#1RG[.OD(8DELMI9MK>6-VW:P#H/B#J_P#P3O\ %;_L'_\
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MJW@&/QY-'=P^&_ OQ0N+$>98"Y.+J[&H7_[PX$EN?-3D>4<\XK5TK4OV9?\
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MZB?VCOVA$\)?&^U^%FF>,;F'Q VEVUY9:;9NPC\EIBIEFR,!3C:.>I KGO\
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MVIOBG^U3^V!XY\#ZMK'Q"TO3+.&V\%+<I!;BT0)DI.HY(1.03SFOJ3PY\0/
MOB'Q7K'@OP_XIL+O6-#\K^VM/M[I6FL_,7,?FH#E-RC(SU K>H **** ,7QS
M\0_!?PT\-WGC#Q[XAM]+TO3[=Y[R]NFPD4:*69CCT"L?7@UXBO\ P5D_X)S-
MT_:T\+?]_9?_ (BOB_\ X.W9[6']A7X>0:E=F&QNOC+IL&J9F,<<MJUM<B1)
M,$ H5+9!XQ6A:_LN_P#!KO\ 9XI+O0/V?][0J9,ZU9CG'_73KS0!]A?\/8O^
M"<__ $=KX5_[^2__ !NC_A[#_P $Y^W[6OA7_O[+_P#$5\A?\,P?\&M?_0O_
M +/W_@]M/_CE(W[,7_!K6JEO[!_9]&!G/]O6G'_D2@#[G^"_[>?[(/[1'BQO
M GP4^/.A^(M86W>=M/L9'$GEH0&<!U&0-PZ=C7G/_!9-Q)_P3<^)K ?\PVU_
M]+(*_+SQQ\//^";OPS_X+5_L\VW_  3E'@>SL;K3;P:TG@34HI%D;['J6[S/
M*9A_!#U_V:_4+_@LC_RC:^)Q9O\ F&VWS'M_ID'- 'N'[.O_ "0'P-_V*.F_
M^DT==I7RO\!_^"EW[!>D?!'P;I6I?M5^"8;BW\+:?%/#)X@@5HW6W0%2"_!!
M!!KK_P#AY]^P!_T=GX&_\**W_P#BZ />:\*_X*8_\F*?$?\ [ T?_I3%4?\
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M/[5Q[?\ %,M^/V 5]G3MM3.:^,OV+Y&'_!5?]JX,>WAKYB,?\N H ^T:***
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MW&I._'EZ]#'.H7T&U5/ZURNL?!KXJ:#;_P!G>&H/)C;!>X\-ZI]D8#TVRYH
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MS?\ !1?PP^M?"N[D^R_!KXY)9QW7V6SN\3K<?VQJ1$ $5M+!$6MH2L>S;@J
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M/AK^T]X=4ZMI_@#3=]QI>JC33N6 RB&UMHQ<2>6K$RD -\P8 &G:1;_LX?\
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M"T_4+R[-X+>>WD=A)'YC3L/F]@#[T =3_P 0D?\ P1K=B6^)/CA>?^A\MO\
MXU7GGQ"_X-PO^"8O[//[07PJT[X7ZIJ7B!/$GB:XL-4L?%GC!7M3"-+OYLEH
M!'(I#P1XPP'3.<C/Z$Q_\$0/^"8 R3^RY8<G/_(:O_\ X_7S?^VW_P $N_\
M@F]\$?C#\';BV_9::XTW5/&,UIJVGZ7?7LTUS$=*U-U4+YV<"2*-N,=/0T :
MWPL_X)>_L??LF?M:>#/'_P *?@UX,MEMUG8ZKI_B2]N+FWF,,J B-[A@01P2
M5(^;I7T)_P %CBH_X)M_$YNW]FVV>O\ S^0''Y=J^??AG\ ?V,OA+^V)X/L_
MV>_V8]0\&W&IZ?/'-J&H272SLACE<H$FE8 'RQR!FOH+_@LE H_X)L_$Y<?\
MPNV7G_K\@'Y4 =_^S_H/[/:_ ?P2;O1O!GF#PGIWF;K>T+9^S1Y[=:[^S^'7
MP:U"W6[L/ /AN>)N5DATFW93[@A:^2_@;_P15_X)GZW\%_!^MW_[,EB]S=>&
M;">:0ZQ??-(UNC%N)_4YKZO^#OP0^&GP"\!6?PP^$WAQ-(T/3T5+2PCFDD$:
MA54?,[%C\J@<F@"*]\+? #39_LNI>&/"-O)MSY=Q86J-CZ%1_D5X;_P4?TCX
M$Q_L0_$-]$TOP@MT-)C\IK>&U# _:8NA KI?CI_P2^_8>_:5\>-\3/C;\#K7
M7-<>#RGOI-1NHB5W,V,1RJOWG8].]?.'[>7_  1Q_P""<7P\_9$\<>+_  C^
MS=9V>H66G1/;7"ZQ>L4)N(E/#3$="1TH ]Z^'LW[-WA_]B?PU>>(+?P;;R_\
M*RL][2VUMNW_ -G1^V<Y/ZUYG_P3B^*_['EA^RM;CQ+J_@U9E\5>(?EN+2 L
M$_M:Z*]5Z;&7';'3I7YQ_P#!%[_@G[^R+^T9_P %#_VDOA/\9?@];:UX=\&Z
M7X=;PWI<U_<I'9M-;EI<%) QW,,\DX[8%?IMJO\ P0T_X)9Z;HEW)9?LI:=$
MT=O*\>W6K\?-@G/^OZYYH ]R^'?BO]D+XI^'?^$M\"#P5?:<UQ- +E;"W13)
M$Y1U^=0>&4CI@]1D$&M[^Q/V>&.$T#PA(W]V.QMG/Y!2:_/7]D7_ ()2?\$[
M-2_9FU_QGXJ_9PL[S4+3XA>*-/T^9M4O?D6+4[J*%2%G&5"HH/J!7TY^R%_P
M2K_8]_9N@C\>^#_@[:6/B;4+!HM2O(=2NI$,;G<8T621@J\+CC(]: />+OP3
M\#[.U-W>>#?"\</3S9-,MPN?3)7&?:OB#P[HWP9D_P""]?B"%M&\+_V7_P ,
MYJ54P6WD>;_:=J,XQMW8S[XKWO\ :1_9-^"7B/0K'P1XZ\)+JG@75M4BAU7P
MS<74JQM<'Y8I49&5P1NER-Q!W#BOB/P__P $J?V"KO\ X+9:]\$+C]G^S;PS
M:_ 9=5CTS^T[S"WAU"W3S0WG;L[&*XSCGI0!^B?[3/\ PC=G^RYXH'A'['#9
MK9?NO[-5!&#YRYQL^7.>OO7Y,?\ !,3]J3X=?LI?LZ_%C]H;XYZA=0Z+X=TS
M1WNH[.W1[IXC]GC4QP[@7^9ATY_*OU$^(WP'^%7[,W[$_B#X3_!7PFNB^']/
MM9)+33X9I)!&TEP'<[I&9CEB3R:_!F__ &;/AK\>?^"=OQU^*WBWX?\ F^,?
M#OAW0;3POJNH7DD9ME:XM.R,%*D2/U!/- 'ZG?!O]O7]GG7?VR]2_:FL?$5P
M/"OCKX:Z#9:"TD:+<F6:X8*)(]WR$&)R6YP,>M?15]X5U<>+=0UNVUS1R/\
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MGP3-<:!?%#=V%O?R1>9M8.!N!W#E1T/:@#A;FU^$7Q*U?R?"?QE\)WS %O\
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M /I9_'O@<#GQCI7_ (,8O_BJN6.JZ9J<"W6FW\-Q&W"R02!U/&>H]J^6IO\
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MM65\&O\ @E3^P;\ ?B7IWQ5^$OP L]'\0:7,TECJ$6I7<OE,3R0'E*Y]<@T
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M6H?'7[-7QUA.DZMJ=C&;.#2VU%O+$CS'?,WEV"3L50KN'S9WC-.L/AO\7O\
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M]LW_ (*Z_L_> E\<:;_P3V\,^/I6O(X/[!\"S:A=7NUB<R[&1?D7N>>HKEO
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M^+MKJP_;K^&_V5/%#S/<?\)1;[!']G9=^=_3)KUS_A^5_P $C!P?^"@WPO\
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MRKC]GRZ@M'MM"\6W#.YS_P 3*V61<^IVX_*OSA_X:H_X+5?] /XX?^(\6/\
M\<I1^U3_ ,%JA_S ?CA_XCS8_P#QR@#] /\ AFKQAIETU^MWHMXR\K';P2VS
M-[;MYP??!^E0O\-?BCI+#46M=0VJWF>7#K7F@$= $\H<>V17P)_PU3_P6JS_
M ,@'XX?^(\V/_P <IMQ^U7_P6G6W=GT/XX* ARP_9WL3CCKS)0!/_P %C/\
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M%?I</^#6?_@BP[(3\7=0W''W?'2G/_D6OMQO^")/_!+]A@_LH:+CT_M&]_\
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M /E-0!]*UX;_ ,%)R#^P[\0A_P!0N'_TJAKG/^%A_P#!4K_HWCX0?^'+U/\
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M'KF/0=2\*^!K*RU*2!Q%+<1W:EHP2NTX ]>U>R?\$3O^"1?[/NK?\$YOA_\
M$KP_\2OB/X=O?&6B6>KZ];^'_&$D-O->/;QAI A4[>.,#BN9_P"#DK]I?X*?
M%7_@C#X@^%_@?QW97FO:#K'A634=-69?-2-RC*X7.2N&'-?:7_!"P@_\$H/@
MKC_H1]/_ /2:*@#S7XZ_\&VW_!/?]I[6[/Q+\?\ 4OB-XLOM/M?LUC=:IXXG
MW0Q;BVP;-O&XD]*XNT_X-)?^"05C<I=V?@/QI#-&P>.1?'%WN5AT(YK].J*
M/C^X_P"".7P/N=$D\-S_ !W^+S6,EJ;5[5O'3[3"5V[/N=,<?2O!]0_X-*_^
M"0VJ7\^IZAX#\9RW%S,TT\C>-[O+N223U]2:_3BB@#\P?^(1O_@CUC'_  KO
MQC_X6UW_ (TG_$(U_P $>?\ HG?C+_PN+S_XJOT_HH _$?\ X*;?\&S?_!+S
M]EK]ACXD_'KX4^!?%$/B#PSX4OK[2IKSQA<RQI-%;22*61SA@&4<'@U\D_\
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MD7=_KE("Y/!X&* /J+.>E&:_*^/_ (.G?@+MS%^P!^T?C/5O!,'/OQ<4YO\
M@Z;^!++@_L _M&_^$3#_ /)% 'ZFEU'!85\P_P#!6AA_PRN!D8;Q/9C_ ,<F
M/\P*^8? /_!SO^S=XY^)GA?X:WO[&OQXT*;Q3XBM-'L=1\1>&;>UM8IYY!&A
M9VN.@)R<9. >#7T3_P %9/\ BK/V)W@L[V\L5U;4K58KB&0QSQ"2&;Y@5.%<
M Y!&1D#GO0!^=_[9OQ?^%%C_ ,%F[CP;<^/-'CU&\^-G@2ZAM3J<99UAM75W
M^]V,T8P!T8YKW+_@BXBQ_P#!3/\ :HB 3Y=>AX5< ?Z!I/\ ]:OS#_:R_P""
M0/CO1?\ @K^?#5M^T+JFH6/_  L_PSIUYXFNFN&U6*:^B21&+M*SDJ(G^?S<
MC"8'7'Z.?\$-?#\GPR_;U_:DTNYU^_UIM+U)6DU/4+AYKBX46.E,2SR,S$]>
M2Q[>E 'ZX(%V\TZORGLO^#K3]EK4Y;J#P;^QM\=-?M[&\:VEOM#\+VMU") 1
ME=\=SM!^89'7^MK_ (BG?@3_  _L _M&'W_X0B'_ .2* /U.IK[&!4GMZU^6
M3_\ !U!\!D^_^P%^T8/^Y(A_^2*^D?\ @G-_P5T^#W_!277M=\/_  _^#?C[
MP?J&@QL]W:^-M/AM9&0&)20B3,WWI549'56SC R ?A_^WNW_ !0O_!0?G[OQ
M2TH?^5J]_IBO1/\ @RR./C=\5,_\\]+_ /1-_7CW_!0SP7>7R?MU^+(/%NK6
ML&F_%"P\S2K6\>.SNC)K%Y\T\:L%D(ZJ2K'K7L?_  9@3Q0_&;XK32RQJB0:
M5\V<+_J]0Y]J!I<VAZ3_ ,%B-"US5?VA?B-J6E:9/<6^G^*5>^FCA9EA4SOA
MF(!P.#]<&G_\$]/VGOVI?V#/"7AKXFZMH/B?6_V>]<^W:QXNL_#_ (7@EA6[
MD>?2HXY;R6,>1-YUM:2;!,H*,G'+5[]^T_\ %GX0VS_ME^"M4\2Z5_:^J:59
MOHL;3Q%I62[O"XC;KN QD#)^85X#_P $]OVK/VDOV$_!?AOQAXW\'^(-:_9W
M\027VM>*(_#_ (72Z6*9C-ID:/=3JB02_:K6W;RQ.!L93R[L#^=\1U(T>)*5
M1S<+4_B6J7OOXUUB]FC^OO!S#3Q_@GF.&C0I5^?%V]C5?*ZMJ&JH2L^7$*UZ
M36O,K=3U+XF?"KXK_L(_%A?VP/\ @F%?0ZM\%O%TUM'J^G?#^W;Q(]OI]D(V
MO1<3W$<ZQ*TBW&'$H()QE0IVN_:!\"?$;2O$EC_P4Y_X)#WRPKXTT]++QAX?
M\,P/XBUBTUB]>74+UKBVD2YB@"JUHKQJ5$;8"J V6;\0?AC\6/\ @G/\6C^U
M'_P3FU.U\2? WQE/;P:E#X+$GB6:"QM!$U]]HE='CAW2+<*L@F/*X8J1\KOC
MGX(^)_P\\8VG_!3;_@D3/'?Z3XXTQ;/Q9H.E1MKVK6&LWKRZA=_:;1(YX;8(
MIM4=1)F-_E"A6W-SRIQI4ZBY))1ES-0>L+_;HOK![N-E9:'T.$Q%3$8G"5XU
MJ-3VM-THU*T>6.(244\+F47S<M>%K4ZK<VY1NK7NMOXXZ7\.?^"C7A+3/V]O
MV$;RST7XV>!I?[:UK0]3U W>N7<>G1[;7R=-C>>$NTJ1[,QCS"0K9)(-#5OA
M[>_\%,O@?ILOC;5;7P_^UQ\.[@6NK+XTF:PU&_TZV:2^0PZ7;J%(87<2B0VX
M+.&4L1C-[X]>&_AM_P % -&T[_@H)_P3QU:UTSXO>#+AM:\2>&=8O@VMSP:>
MFR PZ7:FX4L\J+L#!5DR 3DE:HZ]\/\ 5/\ @I[\#]-\6:AJ=EH?[6'P_O/L
M^N:9XTN&TN[O+"T:2^5K?3+=79QMNH$$CP(6*,K'&UC4HJI6EHI.I&Z4=(55
M_-'^6LNE_O.3"U98'+\/)UOJ_P!6J\C=2+EB,"W=>QK7:]ME\KV;;25X^X]G
MH_#[XT:;^WQ\&=3_ &$_^"EFC7^C_&Z&"ZO?A_KWCZV3P]$-2N4-KIB+#;F!
M[A]TNX1M"RNJMPW&,[]G_P 4^); :U_P3D_X*W07D?@F&---^%&M^(+5=!T:
M,Z2)8#)!>1BVENHW#6GEY:3*[2<;R&TO!WQD\.?\%%?@QJ7[&7[?MA>>&/CU
M9PW=]\/]4\<0)X:LY-1GC-MI<*K&4FF<R2EA'Y#[DW$;R!G.^ WBS6M2@UC_
M ()M?\%:Q=6'AK2UBTGX4^(M6M?[#TAY-,\V!BNH/]GEN8Y"UF8F"R&1>6QO
M^::<I5)TY<S;:<>:6G,[?PZZ_F6R>OH+%47A,/C<,Z,:+IS565&D[RHW:?UO
M*YKEO2;UG2]Q<J>KW5#X">/?V@?^"=GC>Z_87_;XLM4UO]G_ %C3I/"5GJNG
MZ0MEH:7>K/'/-,-4DB@F\I(Y;[S")BR$.57Y%*NT]/V@/^"3?QU;XA?!Q[GQ
M-^S-XOU.7Q%?1_#_ $U=6M%TE]T5K'+?W$1\MPK0\B<"0<[V).7?L^_$#X[?
ML!^+;S_@GY_P42TS4-0^!NK:;)X6L]<T71Q'HZ7FK21S-<?VM<);.(8XKF\$
MK!BT9!VI^[!+=&?X^_\ !)/XUOK_ (1@D\4?LP^,M4F\0W\W@/26UN!=%8O%
M;+->W$:QQ2;6B)(GVL#D,<XI*7)1C./.N26[UG1>W++^:D^NNRO8[*E&6(QV
M(H\F&J?6Z7-R1]W"X])7]I1TM0QT=TE!MS=N9;-WC3P'\7/^"=WQO7]JK_@G
M3J0US]G[QGJ%I=>(+#X>V9\1?9])TM8_MR7%S<QS"'=(;X*ZRC'S LOE@"U^
MT%X ?XMW.F_\%3O^"3MU#:>+[6)[GQ=X;TV1]8UYM0U!_*(-B1=0PD12S%HP
M JJI8#Y1MI^*? _Q<_X)J_&^/]HS]A#4H_%G[//C;4K1]8C\"POXDD@TC3A%
M_:"SSRQM%;[I&O0KB?!P0S)L^6Y\?OAU<^*=5TW_ (*K_P#!)*XA_MJ"-[GQ
MKX7MYFU;7(;^_80!'TV);F&,K%*[.C.NU5++G;FE.GRPJ45"2Y7=PB]8=7.@
M]/=OJXZ;VN31Q,JN,P./A6IS=:#I1Q-6/N5].7ZKFE-\UJME[.%1NH[Q4K=5
M'\3_ (?7/[8'PY\._MY?LC:A'I_[1G@.%;GXJ:/>2//KUSJ%I''91E=)3S8H
M69[9V6/R8@P=2PSNK1OKSPE_P5O^ L7[.OQNEA\,_M/^!+>*QT_4/B%<G29+
MN:2<7%]Y%A;[3,1:VS!@;?,>X, N6:L_XJ> ;S]J[P3X=_X*%_L;ZK:P_'KP
M3"MY\5O#5[,TNM27UFL=HGDZ1")ECWRV\LBQLD6\$$A69@-'69?!/_!7SX"+
M\(?'CV_AW]J?P3##9V8\<7*Z(FH32S>=>&"SMV:6;;:6\F0UN#&SJ<!2S#:4
M/:5I0MS<\;J*TC55OBC_ "U5UW][KU.6-;ZO@\/B%/V2PE7E55*^)R]N37LZ
MJNO;X%N3C%N44J<U[FG*Z?PZ\7^)?V]O@YKG[&O_  4P%SH7QJC,VI_"/6/B
M-:CP[%_I4,=K:Q1PVZP-=M]H2X.UHI P)'S%2HD_9X^,OB?X?3:K_P $V/\
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M%,/V>YX[F-E_X1_Q)SO7_GMIO^?PKZP^U1B/SVGC\L\ALC'YYKY=U;_@E-\
M/$?BG3?'&N?$7XI76L:-#/#H^IW'Q:UUI[&.8J94C?[9E0Q1,X/.RO8K[]GK
MP[J/P:M?@M/XU\6)9VT01=67Q9>#5&^9FRUZ)1.Q^<\ER< #/% '?#4[(\_;
M(?\ OX/\:<UY"B^8\R*I^ZS,,&OG?_AW'\-I(=DGQT^,2_[GQDU_'_I97?\
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MMA4>1%A1Z@'\Z /&/^#G7X;^#],\'_&+5M)TF.T;3?"?@V*TCMUVQJAOPN,
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MR>*M%<K\#/BWJ'A&%CDV<B/>V\1!X\N*20K&-ORX48Q7C_P<L_\ @H%\.O\
M@H<O@KXS?&^T\4_#'5_#;7.DVZZ'9VLD-RGVK?S&3(<@0'GCCZT ?8U%%% !
M1@'J*** $"X[]:7:,8Q110 TQJ>2:AE@RZ[D8X/#<<?UJQ10!C^(/!_AGQ+;
M_9?$.CPWD;+M9;@$Y'I6#+\"OABT7E:9X7M["3^&:R4QN/H1C'X5VV .@HH
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MYY9F))/>O6?V'/VN]1_8O^+<OQ7TSPM'K$DFDW%E]CFN!&/WJ%=^2C<C)[4
M?LCJ'[;/AW]EGX;Q_#[QOI-K;^'_ !C\:_#MYK7BF^U)DCT:WT^[L9I)"@C.
MX,KYQGC::]W_ ."BW_!<C_@FQH_C/X!?&#X?_M%Z)XZB\!^();O7]&\+S-+<
MA#]D X9 ,Y5SR0/DZ\U^"'[6O[??Q&_:B@;P]/:KI7A]Y!.VDJZ3%KC" R>9
MY:MSY:<9Q\M> HK2'"=_4@?SH _L2^'/_!8C6OBWX'TOXC_#K_@FW\<]:T/6
M+..ZTK5+7PRACN8'4,CJ2PX*D$=N:VG_ ."H7Q/QA?\ @EC\>O7_ )%F(?\
ML]?S-_LY?M._\%G/$WPQM+#]G;]K3Q]9^%=%$>GV5C:_$R"QBM%1%V1+%+<(
M54)M XQ[UWUO\</^#@Z2Y%O'^V)\1-Q.-W_"YK,8Y_Z_* /UM_X*Z_\ !5[P
M^GA?X0^#OCK^R;\1OA;9W/QCTN^77_&VGQP6JP6PE\\Y5BQV^8K'']VM_P#X
M*7_\%LO^";7B?]A>XT_X,?M:^#_%/B328[>[M?#-C?2+->-%;2_N1F/C<Y"Y
M[=:_G9_:Z_:H_;D^+^LK\*?VQ/VA/%WC";PS=.+:Q\0>*CJ$5G*X&61ED=#D
M8Y!(KQ4F,-GRS\K?=;T]* /Z$OCG\='^('[<-U^T2_APV+7/Q7\"ZH-+^T&3
M)BL;K]UO"@<F/ /O7&?\$1O^"P/[)UG\;_C_ /'[]J[XI>'?AC>>//,;3])U
M6_=E9EM;&$*C!,MGR7Q\O_U_SVO/^"R7BB]UW^VYOA)!N_M?2;[:FH*"/L4,
MT07_ %/\0ES^%?%-]*9[EI2Y8L<EF8DF@#]Y/^#>7_@LA\$OV<?@SJO[&NA_
M!'QMXZ\9:IX^U'6]/M?"6GK.L]O.+:)<%@"#O3&#_?%?J,G_  5$^*+LV[_@
MEK\>6_WO#,0/_H=?R,_LKZ]^T=X;^*EKJG[+?C74/#_BM=OV34M+UV/3Y4_>
M+@>=(Z*OSA3@D=*^OA\<_P#@X,;D?MA?$([N0?\ A=%E^?\ Q^T ?T0:G_P5
M2^(VE6LFH7W_  3%^/%K;PQ[III/#L02-1DEC^\'8>O:OC3]B/\ X+R_\$[O
MB%^WI\0OV@OB-\9(/ASI%[X8DTVU@\:9@G><7D,FT*@;(P7YR!^[Z5^2'Q%_
M:=_X+K^!_!5_K_C_ /;$^(BZ2D86\5/BQ;W)D#,$QY45T[,"7 .%/&>P-?"]
M[<3WMW->SNTCRR,TDCMN+,3DDGN: /N[_@H)_P %"? >J_$O]IOX3?"2TL/$
MWAWXN>.%O['Q9:Z@P2"*WU"XFC,:[/WBNL@/7BOLK_@S'LX-4^,GQ6L[[;<0
M26^EK-&P.#F*_P".:_$'!%?K9_P:I?MO_LI?L6?%;XB:S^U%\:]+\&V^L16"
M:;-JGF8N&2.[#!=BMT,B?]]4>8'Z+?\ !QA\'?AC\./#?P[USP+X%T_2KS6=
M4U,ZI>6L2JUPR_9]I;/7&YCVZFO&/V OVUXOV<?!GAO]D#]M_P  :--\$_'G
MVGQ$MUXKTZXOV@LF,HMS!;IYF(&O[$L 8Q\SO*!M97/K_P#P5X_X*(_\$L_V
MV?V:6T3X*?M,>'?%_P 0M$O(Y/#&GZ?-<"14EGM_M9V[%4XAC;);D <8KSK]
MA_\ ;4T3PY\/?"_[#7_!1'X;V=Q\,_%MFVJ:9XJ\1Z@\0L=(CB>2TCB2"/>\
M7VRR?#&0'=*^1@8K\ZSR7L>*%44^1\BM=7BVW\,WT3[]S^RO"_#_ %KP%JTW
M@_K$8XF<I*,N2O!0I<RK8>_QU*5^90^U9KTZSQGKOQ[_ .",/Q;/PUE^T>,O
M@#XODM],TV;QQ=BXM_)D59=2>*RMI 8GS+,#F'#[<;6SFI?BYXB^,'_!*+QM
M:_M6?L8L_B+X"_$[3UU2TTW6KH6VDP:EJ3/.D<6GQO%*A2SMK<(6CRJ-L)W#
M:6WOC7X\_P#!(CX@3?LG_&/2[SXC?!/Q,D&FZ/K7B!5L;6&*Y"27\\2QK(Y9
M#/(&^<#CC'%3?$#X@?%C_@C_ ..%^)7P-L+CXB?L\_$?3_[=T73;I4M-)M+S
M4)':"&.0B61C%9VT(4G 99,X!XK"4H8>G-)RA[-KSE1OY?#.G+IY?AZ]&A5S
M#%8=NE1Q3QE)ZN7)2S.$4OBNV\/CJ>N]^:?-_P!O:GQT^&&G>"=+TO\ X*F?
M\$G[V?\ X1NUNOM'C7PUH:KHNDI8Z<H>X66V;R)98WDB(=0'9L\ \$9_BG1?
MB)^W%\']._X*B?L=&XTCXQ:1)_97Q(\/^#;H:9:E('DN)9I)I6CDN&:U-H&V
M2L"NU0,JRBQ\8?AI)^RQ<Z?_ ,%%_P#@EQK+:I\.;B=1XS\&Z! 18PV%DH>\
M$T\[.VQVBVL0@*\\G 6HO&-K\1?VAO >G_\ !6K]@SSM$\<+(-)^(WP_\+0>
M>JM"SO/-)-)P-UHEIE5BX7:01\U54C3O.FXO6/,X1=T]OWM)]U?6#?7RUY\'
M4E'"87%PJ1TG["%?$)J459KZAF%-;Q:34:ZLKQCM?31\,>,/AG_P6.^$NI>,
M],M[#PO^TUX%M[GQ!H<?@O36M+B]6S7&GQ/?7*F,*;B2/@391@&PH!-9OP5\
M?1?\%.[#4?V!/VUUM]!^*/PR@CMO!WB#3XFO-8O+JSWQ:FLU[)YL*L\EO;&3
MYU#LQY8+D:8O/A/_ ,%8/A=>_M+_  4&G_#_ /:+\ QW&OV_A_PZS7MUJ$&G
MH391_O#''&'N?*P^UBK #D<C/^'7C&T_X*U:'=?LI_M"6MKX$^,WPIMXX=(\
M3<W.HZO>1JZ:F&A7RHT<O9Q;\EL%\+\H;=2E[:4+M3]K%V>T:R2T3_DJ)KIO
M:S,ZE%8'#XJ"I2PT<'53:;YZ^5R;7O4VK_6<'/X7:UDV_-T_@?\ M(^(O'WB
M.?\ X)0_\%7-"LUU!K&:QT3Q1K4<NL:Y;^(M2D1;!UG1KF)9$@U"3RYCM6,1
MQJ6 )PSP[\9/BA_P3;^+\W["W[;6B1Z[\#?$NI2KINH>-)GUF2'0+?=';O;V
M]L\H12\<1$ AW9(PN0:N_!S]I$?M:23?\$S?^"GG@R#1?'$-C,-!\?:[,S:D
MOB*[81:</L\*HID6'4 4!?:PA&0-P-0>"OCMXT_9"^(<O_!-_P#X*&>#F\1?
M"W5-0DT[1/%WBB3[,MKH=N62"6&.!6<QL\,;?ZS(/<G.,8U+TH5(U7O:,Y*S
M3V=*K'ST2D]#JJ8&I+%XK RP,?>I^VGAJ<URSLN;Z]EM392C_$=!W;24;]H]
M<\4?&S_@CE\9S^SMXZM&\7?L[>.[VUTS2YO'%\+V!=,81MJ\D%G;/\AW7LP=
M6B'FE5/S!BU6/CEI/CO_ ()^>(M+_P""BO\ P3QO[S6O@QXIC;5M<T2YG&FZ
M+"UR?LUI";$-!,5!N"R!D8QM@MC'$=M\1OBS_P $H_B7+^Q-^TOX>D\?? OQ
MA<V^CZ'KWB;;9V=M87!6359H8T61W"F^E$BEQ_JQMQG F^*:>/\ _@EGXTL_
MVKOV.]1N/'?P#\;>=J^K^'85%OI5NKC[/9P--)YLK8:=65B!DJ 1TI-PC&;3
ME&-.6W_+RCUT:TE2ZM+6WX.C&MBL=AFH4J\\93:YFW'"YI%*S4UH\-C8VLG+
M1UDWUUA^)>C_ !%\%>%/#W_!7[]@J]NI+7Q)$NK_ !=\+Z7,-,T2VDM8UCN8
MVMW:">YC:\6Y9@=Y=BS X()U/$GAGP__ ,%,O@;'^V-^Q3"WAO\ :.\%PH?$
MVD^ H_['^U75],L,DCWER(S(5M([@AEG)^\I)R!67X]7XA_L\6>C?\%4OV&S
M>:AX'^(>S4_B9X!TF-?[/TYH$0W4,MS(&9D:Z^TAB(U(?=CY<"M#QMX&TO\
M;&^&T/\ P4._X)VW">$_C=X8"R^+?!?A.)[JYFO+V3[-\\DQ5$*6WVE@JQ'(
M9N%SDZMJK4J4[7YES."WE?7VM![+NXO6]^IRT9.C0PF,C-4W";HPQ4TVJ>KB
M\#F-)7YJ=_W<:VW(HRM;10^%_&T?_!9WX1:S\1;:UM?#/[1'PP:6\\&Q^"8F
MM;G4+*.%&LQ)?7'RJ/M<\^%65"I&["Y)$GP,^+OA+_@I38W_ /P3>_X*!:;I
M^@_$SPF+;0O _B.PLY+[6IKRQ+OJY>Z830Q2.-/B$C[U63?)M+X&&IXML/\
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MS-)JF@VFA2/?7VJZ;80^9%&-WE1Q"2^O0,X8AD&0P8@5?AIX_B_X*=:#>?\
M!/?]LS1;?P9\8_"=JL7AOQE<;KG4[V_B/GWH-NGE('-K"ZG+D!6)Z_*1/VE2
M$_:*;DK7M:%96^&7\M1+9O2_W%RP\<#AL53]A+#1PDU-T^;GKY9-M6KT6O\
M><'-NU2"U49-]$W1^!_[4OB<:_/_ ,$R?^"NGAVQ9$M)#IFN>(HY-<U:'6;Q
MX_L6V6)KB)2L-Y)LDP%0*JDIAA3;_P")7QC_ ."2WQNN/V4OC]:2^*/V?_&V
MI1:=IMUXXN&U)(M%C;%[);VEL[;,_:CO5HOFV)PQ-7/A%^U$GQZDD_X)S_\
M!63P=;Z7X@L[66YTKQUXFO&%\-7G8)IZ>3"B!B(KPE/GPPCY^\2*FG_%SXF?
M\$Y?B5>?L(?MB>'CXV^#/BK4(=%\.^*/%+"RAM=+R!?7,*1!W92;M=P,@;]V
M,'G-0JD?8PGSO1\O/):QZ*E675?94UN[-^?16P$GF&(P53!0;JTO;3PT)I4J
M_58W+ZE[0JKXW1:OR<R\E%\1;O\ : _X(N?%)="\,377B[X$^+(H;#3?^$RU
M 361:<":[,=I;2*4<('!=HOF7*C=QG4^.6G7G[&U_I/_  56_P""9K2WOPI\
M3+-+XP\.(QTS0X539IEDC6&;>>4&YN+B0#8P61=W ;<<_5O&GQT_X(\^.V^"
M?C.QO/B1\#?$D45IH]YK:I8V<;W062Y:/8)6+I&74C*C'3;P*T?BM9ZA_P $
MW_%6G_M^?L%,WC#X$^-1*?$_A>SB\G2K9(56QLHY+B7S964WEU-(N%!#@CG.
M:<I1C&I=N*IM22M[]%_SKI.F^J_E(I>TQ&*PM9QIUYXN')SMN.'S.-E>A73U
MPV-T]R;O^]3?6[/B=X;\4^*?A[X>_P""P/\ P3_N)K7Q)''#?_&CPSX?F73=
M)1K2'[?JXE$C127<;W"[)=K2>8,L"S+D3W,6G?\ !5OX&G]K_P#9E"^%_P!I
M[P$CR>(-+\"6YTQKM[FX-I;-+?703S2MA:2,NV8[,LA(W+FK\1M.\3>%=&T3
M_@KO^P0EW]EU]8;[XQ?#_08Q]DM51/[0U9+BXFR?*>51&Y6,;0<J1]VK'B;3
M=*_;_P#A(G_!1;]AZ0>"OC]X+5[CQ9X-\(QF[N+II9_L-H7DFVQIMLK6:0;8
MSD,1U7)/=E*=-J_-'F<.DUO[6D^DEH^5[;&,>;#X>ABTU3]E6="&(G9N@VVO
MJ&/A=<]"6L%76BBHMJSLJG@'X@W?_!6GX:ZU\.?&EE#X?_:*^#]I-JO@.Z\+
M0M'J&I?8(2D<<U_.6C0&_GA)Q,A+J)!@ D3_  ,^//A+]NRVU3_@G!_P4BTC
M2])^(GA^WA\/>"?$C:?+J6L/J2%A>L]Z1/#'(1;1;I,H'WD#)7-0Z5XZ'_!5
MKX?ZEX@\/Z1;^ _VBO@K"VJ^'4TAC=ZAKJZ?$6$;*1&D>^^EA&?F(<+U4D&U
M\'_BE\.?^"FFA7?[%'[:WA^P\%_%[PK!'H_A'QA?32W&H7NJ,S?;F,$0AC\T
M?9%# L0-YVD$&KC44W3?/S^T3LWI&K:ZM+^6:V7=VT#%8586CBJ<\+*A'"3C
M-QI24Z^72DT_;47_ ,Q&$J74IP2O&,GKI=XO@3XJ_&'X(>/;S_@DO^W]I2W7
M@WQW)=1>&_$7B6\_M?4[.WF0VFD/;"-YH80MQ;1,@= (W8DJ@P3Z3_P;+DGX
M7?%HG'_(9TS[IX_U$]><>#?C-\1K74[S_@DG_P %#/#C?8_$?VJU\'^/?$3B
M.ZLX!&8-(,$$2@.OVJ!60-)@NY!R!D[7_!O!\>O@A\&_A[\3--^+WQ?\,^%[
MC4=8TUK"'Q!KEO9M<A89PQC$KKN )'3/6LLN_P"1[A8W;Y542YE:<+0^"7>V
MZ>[N;\<494?"+/92IQIRJ_4JC=)\V'KWK-+$TOY)5$N6I3^RX1?6R=^P;_QX
M?LD?]EX\<?\ HC6:_7R+[OXU^+__  3I^+7PN\5ZE^RCX1\-?$31;[5;/XU^
M-+JZTVUU.)[B&%K;5=LC1AMP4^8F"1SFOV@B8%,CN:_3C^(AU%%% !1110!P
MO[3G_)N_CC_L5[W_ -$-7XJ_\&6HS#^T1_V,NF'_ ,<NZ_:K]IS_ )-W\<?]
MBO>_^B&K\5?^#+3_ %/[1/\ V,FF?^@7= 'V-XW_ &@OB?\ 'K_@G[^VU8_$
MG6A=Q^#/&GB;P_H(6%$\FQA2,QI\H&<%CR<FON+]EG_DV/X<_P#8AZ/_ .D4
M5?G/X0)/[!/_  4&R?\ FKGB[_T7#7Z,?LL_\FQ?#G_L0]'_ /2**@#NI1E<
M^]?@/^Q[KGQ<^)/_  44_;*U&\^#_P </B9+9?%I;..Z^'7CZ;3$T^"-[M8H
M)0MS%O 0!4Z@!/>OWXE#$# [\\U^$GPQ_8X_:[_9V_;?_:,^(7Q)_92^-DVB
M_$[XK27?@G4OAM\0(-*CO8?,N6#RJGF,V0ZE2VT@$\'- 'I&HZ;\7]2_;;^#
MOP?NO@3^T]X+T'Q6NH0ZU!K'Q>NY!,!-;8N<K>DA(@S;L$$^:N.AK[C\8_\
M!-[X=>&O"FI^(M&^)OQDUBZL;&6>VTFQ^*VLB:\=4+")"UX%#-C R<9-?FK\
M??"7QBT/]JOX6W.N?LQ_M,V<D.B:U+#;WWQ@2:\E1'MMSP2K%^[5=WS#'.4X
MXK[H^#7[<O[5?PR\'Z;\*/#O_!,CXJ:O_9=CF.ZUSQE;W5[-&7)\R69H\N?F
M R>0 !0!X['X6^++1*[?L#_M=!F&=O\ PNBXX_+4#2KX4^+1./\ A@;]KO\
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MN@M6BB6%856-1CR]HX],8[59"J#D*/RH \._X=K?L$*X(_9$\ D[>O\ PC<
M_P#9:;=_\$V?V"[VQET^Y_9 ^'\EO,I62%O#4&&'?^'/3BO=** /P+_X*!?\
M&>_BGXJ_M :A\1?V(OBIX9\+>%=8D>XF\-ZQ:S(MA,6)V0["WR<]#C'85X?_
M ,06G[>7_1Q_P^_[\W/^%?TQA%4[@HR>O%+0!_,W_P 06?[>/_1QWP]_[\W/
M^%==\!?^#,#]HO3?C%X?U#]H3]H'PG<^#8=2CD\06^BPS_:IK=3N9$W8&6QC
MJ.#7]&U! 8889H ^:?A/_P $F?\ @GC\*_A[IOP]\/?LB^!YK;2[6* SW&@Q
M--<LD:KYLCMDNQQDDDFND?\ X)O?L&L-\G[(7@'@=_#D)(_2O<@JCHM&.,8H
M _*?_@L1_P &SWP)_;=\-:3XH_9$T+PK\,/&FGW<AOIK?2/+M=4@:)5"RB+!
MW*T:8;!.';/:OSQ3_@RV_;OD7</VC/A[_M?N[D\]^U?TS%5;[RT  =!0!_,W
M_P 06?[>/_1QOP]_[\W7^%(?^#+']O \G]HWX>_]^;G_  K^F6B@#\=_^"1W
M_!K1\+OV.=;G^*/[:6I:!\2/$8E>+3='6PD;3;5-\+1S8=LO*&1NJD -U]/T
M8'_!-?\ 8'+9/[(7@'_PG8?\*]OVJ?X12T >!Z]_P3#_ ."?>NZ;+HVH?L>?
M#Z2WF7#QR>&H&!]>"OZ]1VP:_%O]J_\ X,SOB[K?QLUC7?V5OC_X:M?".HW<
MUU8:7KUK+')I_F2NRVZ["=Z1J44$\G'-?T0$ ]1361,9V#\J /YF?^(+W]NL
M$"3]H[X?!NBJT-U_,#BN/G_X-2_C5I\TMK=?\%!?@3#+'(T4T+^)-KHP."I!
M88((QBOZAO$5K>7NGR6^GWYM9F7$<RQ[MI]<9&:_'VZ_9C\<^(O"WBBXU?\
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M\$WHTT/1;[_1?$GPQU"%G(N0_P#9:,-.L?W2IY:&7YWZD2#KBKOQK\'>*_\
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M;9S33R-=0X1$$A+,>P S7K/_  [C_P""?O\ T9)\*?\ P@-/_P#C->._M_\
M["_[$_PZ_8Z\=>-? _[(WPWTG5M-T^&>QU+3?!-C#<6\BW,.'218@RD>H(-
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M?DS^Q+^W#\$?^&;_ (K?M!^#=>;7/#_A'P/I.E:Q-%&\'DWD<]NKP_O .GF
MY'RXK];/VEO+/P+\2"4_+]A[#/\ &M?R;? SXL>.?AG_ ,$8?CLOA#5A;QZ]
M\6-/TW5%\L-YENWE2[>O]Z%>U ']</PP\8Z%\0/ &A^,_#>HP7EAJFEV]S:7
M%O+YB,CQ*X(;N,$5T5?.'_!)<L__  3;^!KE%'_%LM&\YMQR6^QQ8-?1^:
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M,^#SCD^%]/\ _2=*\O\ ^"G'_)@?Q6_[$^__ /0&KU3X&@'X-^$<C_F5=/\
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M9W_[;/\ P24\1W/BC5-007GQ6^!VI-]IL=-34-\L=ND-JMJ@6U_TR-1(9-H
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M;="J^:5"4JVL:-37GPTDDZ34I)24];MW^B?V"BSV'[)8*XV_'CQO^/[C5_\
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MPK\)O#UVNDP:E<2OK$MPEO:RW"VZ2MY-RQ8&4A=JC=\V<8H _;FOEW_@LO\
M\HWOB=_V#;7_ -+(*\C_ .")G_!4W]H?_@HGJ?Q-\,_M!>!_">DZA\/_ !9?
M:*)O"JW"PW#6SPH6 F=C@L[^G 7CFO7/^"S)(_X)N_$YCG TNW)VKDC_ $R
M]/7B@#V[]G7_ )(#X&_[%'3?_2:.NTKXM^!O_!77]C?1/@KX/TF^U3Q8LUKX
M7T^*15\&WC ,MN@/(CP>1UZ5U7_#XO\ 8O\ ^@MXL_\ "+O?_C= 'U17A?\
MP4P!;]A;XC*/XM'C')Q_R\PUQ?\ P^+_ &+_ /H+>+/_  B[W_XW7E?[;?\
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M  4-_9D^#GQ%7X*?$S2&U6>/RSK$+Z7+/'9QR;0K$"-@?O\ 8_PFOE?_ (+
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MMCY>",UO>"_V]/V%_!_A32_"VG_M.:#-!I6FP64,LMPQ9EBC503\O4C!/UH
M^A@<C-%>(Q_\%'OV'MO_ "<CX=Z_\_#?_$TO_#Q[]A[_ *.2\.?^!#?_ !-
M'MM%>)?\/'OV'O\ HY+PY_X$-_\ $T?\/'OV'O\ HY+PY_X$-_\ $T >VT5X
ME_P\>_8>_P"CDO#G_@0W_P 31_P\>_8>_P"CDO#G_@0W_P 30![;17B7_#Q[
M]A[_ *.2\.?^!#?_ !-'_#Q[]A[_ *.2\.?^!#?_ !- 'MM%>)?\/'OV'O\
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M*Q=CM"XSEJ.OW?F*7PL^>/\ @XR^,OPJ^*/A'X5V7P]\=Z;K$EKJ6JO<K8W
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M6S2'&G2J4XT,12GS5'[6IAZ%W":L_P#A1R^2LN:.\J*LK2FK:62ZOX-^)/\
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M&IW/P_TKX6R_\%UM);0]&U*WO]/L6\!^(ML-Q Z/$_\ QY\[6C0_A0!^_?\
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M]R_X)V>(/VL_^&18=.TSX8Z%>02^(/$:MMU)582'5;L$9,F,!LCIVKPWX?\
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MK<,DUI%;3-!*LD38=&5IHP%[C%?U>_# ;OA[H#LK*?[%M?E;_KDM &_1110
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M$D-GXBM-+O3K6K6UD^V34FQ:HD$8B6-AO>4+&?\ 6#&31\0_V;/$7_"R(/\
M@KA_P3!UO2_&DCLVN^(/!%Q<-K6K6>M:LS?:+,VFGJVPPQWP+1&0-'L<DE0,
MY_PA^&'Q<_8'^)G_  GNA^(+KXU_LJZA&VG^)M0T?6$N-"MK:](^W7$^D6\U
MR62WC63?NAVLNY25W?,_3? 'QY_9;^.4G[:G_!.N_P!0^+GP5U'5+OQ!JW@G
MP1K":?:6-Q?F6.+3)=,AE>;?!%-:L,VP:,(N](_+.V?9T_8J,J;BE+FM'XJ<
MO^?E-;RAUMJMC1XS'5,;*O2Q\*TYTO91JU;1I8NG_P! 6+YN54\2E\+FXRO+
MT9M_&3X&?"G_ (+%:=9_M%?LV>.+/P[\8M):*W\6>"?&NKQ0M]ALT8//#96J
MS3KNGFC56<C()!VM4GQ/\#^ ?^"T7@73X+;7X/ W[17@>PM]!U;PGXRU---@
MNI(OWE_)%9J)KK8CEP"RJ5*[7 .ZL?XZ?!>V_:-\9P_M7?\ !(?XJ1V?BB:.
M&U\:?"[P/=)X9O-.BB!EN[F42S6LLR&X\F-L1$.^TY;'%S]H?X?^'?VZ+S3_
M -H__@GMXTA\#?'G3[)+3QQ\*_#L@\.ZU)JLI,NHN]U/)9R7#P[W61PK;MI^
M89*U4XPE[12IJ7-9RL]*JZ2@[^[./5+>YG@\1+#O!>PQDL.J#DJ,JD;SRZ<M
M)4<6G%-X6L_=C.5HJ,6T][WD\?K^W+\(;C_@F;^W79S?#KXI>$Q+>?#/5-4A
M_L+2]7N((O[,TR F\W3W+327$C8CB_>I&Q3E<&/X4IX6^#_@"^_X(T_\%)M0
M_P"$=\-_:A?^%?B%I%PNG:1+&#_:CYOKX()/W[^1^[C(#*R$[@2)OBOXAT+]
MO?X0:?\ ##XB:3#\(/VI/ -Q%<>&?[<M_(UCQ2ME;M!9P0ZK=+;*IN;Z<%%6
M5SNC\P*PRRU=)TCPO\8OV>G_ ."?W_!3;6(/AK\8](E5_#'Q0\?1_P!IW.H6
M+7)U"54U.0^0B",I;D"[89 7EQY=4[2;<;3DX\JE+W5-?\^JB^S+^5NS:1RJ
M7L<+&C4YL/3C656="G[U3#5%>V/PC2;J8=/WYQ@Y))[VLU7^"5K\6/\ @E!_
M:G[%/[:7A>/4/A#\5X)([CQQX,LYV@L]3U)4LL/?W8AAC$=I:2RNBHS(&63D
M9%'@+P%XG_X(X_%*Z_:>\"26?Q$_9W\>.]M<:MX3;^UM0@T](R+.1[C;#:H[
MW4R*#YA5UW!>>*M?!_Q%\5_A=\,-8_8E_P""Q_@[4K+3?%@GO_!/Q2^(%PWB
M:WTC5[F%;&SMXGC^T0V[QJEY<JWVB,Q@L2$#F0U_V?M+\>?L#:_JG@C]L*QN
MOB9^ROXLB73]&\;ZE=#7=!M+:WS+:W4>G6[7@A26Y\B- RIB3##<14Q5.G*B
MX7C&+M&3^*B[:QJ)[TWLF]M[V.BM/%8CZ[&M*G6J8A)UH4VO8YE"+TJX62NH
MXN'Q<D;R;BURWNG3@_9H^('_  33^)H_;R_X)[:SIGQ.^$^H)%HDBZ5)-K^I
M0V!\N;4)I/LL<<*K'):2+YAD*H657'+;;GQE^ .@_M8>*[/_ (*J_P#!.SQ5
MINI>+M#NF\4^-OA_KVI"]U2UO(&0V=O'86*R/&\GV:7]U(X9CC!&#BC\&O!/
M[37_  3=\>S^,O"\FJ?'K]FN^LVT;^T=&UU;G1!'<M')?7?]G6LMV5\DI=(^
M^-5;YP7RZAX_%/PF\9^$/C;'^W1_P2:\7OXT^'MQJT>N>,OAQX"U"/14TZUM
M=@AL;BP259IDG NBJ?9L@;L(VX9GV:5'DE!J*E=T]W"5_P"+3>\HWULKI(VE
MBL7/,%BHXV$ZDJ7LZ>*DE[/$4[?[ECD]*=>RTE/E?M%;LS9^.GP2^&7_  5A
M>S_;5_8U\<6%A\4M-F6Y\4>!?%>M1?:8[>P0)')#96BSR?O9$4*68*V1M()P
M9?'%U:_\%D/AA:_!#XPS?\*[_:8^'4;)I6A^*PFC6.J->2K-<HEJ_G7DACL;
M-&8[$V-*CG<K$#'^,OP43XK_ !,C_;%_X(\?$R"YFN#"?%7PT^']Y%X9N;&V
MM0#+))"TUO+-'-,FS:(2'=_XNM:G[0UII7_!1.PTKXJ_LO-#\*_VJ/"*W \0
M_#6S4Z)KVK2792)1_:%T;)Y&BTZVFF^7>5CDV$ID%KE[TJMZ:;FO>BG[M:*Z
MP?2HND5J]?4QP];V,<"Z6)=*&&?[FK-?O\LG_P ^<5%I2EA)-^S]HXJ%K-R5
MVG):P>$OVI/@^G_!*']LR^;P/\5/A=;S67PVUR\F32=&UR>VB_LO2U#3YGNA
M.7\P".)3+&I:,=B_X4:K=?LW^#+_ /X(W_\ !2B!]"\!ZP8X_!OQ(T&,V&FR
M'S7U:\=M0O\ 8CHL\T$.8X_E8LIX((J?$/1?#?[8WP5\/_!KXCZS'\+?VM/A
MC;QPVJ:S&%UKQ?/8P&VLDCUB8PQN]U=%)(REQ,-PWJ7 WBQH-_:?$G]GR;_@
MG9_P58MV^'?Q&T^%H_A_\7OB!"VM27K371OKH0:@^8(A%"+2W<B[PV^-"59-
M@<-)J4?B4>52EI&:?_+NI?:2V5[._P!QC*+^I^PJW4%6]K4H05ZN'J7NLPP-
MKNI0^W*,%.*C)W=ES+.^$/@GQ%_P3(U/6OV5OVI1:ZI\#?C]:RZ;:^._",C/
M%ILFH$6D4EQ?W"PP0JMF)YGVJY &\9132?#[P=\9O^",_P 4)OCO\-K&S^)'
MP%^(=TUS?:UX3M9M8N;/1K9F:UDEN52*UBDE-X-K;RDFU@N2#E?A'I7CGX2^
M!/$O[%G_  5)MKH>$/']C-'\*/BMXRNQXBL-*U"6/[%8?9RC3P69$;RW2LTT
M(18SDJ,N)OV=]6^-_P#P3[U+6OAY^U_X.U/XG_LX^,_*L]-\:ZE?-KVAZ?HM
MJ7,=XMG;?;$BBG\VWQ&WEY*C&\H<.,8TU3?*X<ND7O*BW]F2W<)?S/1)[]3?
M$5L5BGC(RJ4\5*O9U:2:5+,8*UJN&EM'%45K*$6YN<+<K;<76\0_LXZ5\!OB
M39_\%8?V%/%-CXT\ :>!?>./#Z7PU;6;.6^9VU./R[1!##Y%I<JY624"/#%S
MM )O?\&^'[1?P2^!?PZ^)UE\5OB1I^ARZAJVGR6*Z@Q'G*D<P8_*#T) Z]2.
MM8OAOX3?$?\ 9!^+\WQ^_9_\='XL?LO:A)<3^.[/P_J2+I&F1ZDIAN8;K289
MI9':VM9H)V#6_$2A6$87CF_^"*'_  3@_8Y_;K\!_$#7/VH_@QI_BBZ\.ZA9
M6^DR7\:LUO')'*SJ,CNRJ>,=*SP$?9\0X>+CR/\ >.44[IMP^./E+[M"^-*D
M\1X,YU.6(6*C%8*$*UK5(P5=VP]>+LU5HMMOF2;C-=$C?_X)Q_&+X;>+M8_9
M7\#>&O&%G>:M9?&CQE<W=C#NW1PO!J95^1C!WKW]NO%?M'!RN0/E/K7X8_\
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MDEHYX/[47B[_ ,)7PY_\K:^LO#FO:7XET:'6M$NX[BWG7,<L;9#<X/Z@U>H
M^/C_ ,$D=&)R?VH?%W_A*>'/_E;0/^"26C@8'[47B[_PE?#G_P K:^P:* /C
M_P#X=)Z1G/\ PU%XN_\ "5\.?_*VC_ATEI'_ $=%XN_\)7PY_P#*VOL"B@#X
M^_X=(Z/U_P"&H?%W_A*>'/\ Y6TH_P""2>D#I^U%XN_\)7PY_P#*VOL"B@#X
M_P#^'26D9S_PU%XN_P#"5\.?_*VO%?\ @H!_P3%TSP+^RQK>OP_M%^*+XIJF
MDQ_9;CPUH*(^[4;=.2E@K#ENQ'OQ7Z55\\_\%/UW_L9Z\A_BUS1A_P"5>UH
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M'W_#I'1AT_:A\7?^$IX<_P#E;7S]_P %1O\ @F9H_P ./V%/B!XO;]HGQ1J
MLK"W86EQX;T*-)-UU"I!,5@C 8/8U^H5?+O_  67_P"4;WQ._P"P;:_^ED%
M'F_P2_X)3:1K/P;\(ZL?VF_%D?VKPS82^6OA;P\0FZ!#@%M-).,]R3[FNI_X
M=(Z/_P!'0^+O_"4\.?\ RMKZ-_9U_P"2 ^!O^Q1TW_TFCKM* /C[_ATCH_\
MT=#XN_\ "4\.?_*VL?XB?\$A[#4/ .MV-I^TQXNN)I])N(XX?^$7\/#S&:-@
M%RNF[AG..,'TQ7VS39L>4<T ?D7_ ,$H?^"7'A)O!'CCP /V@O$VBZIH7C;4
M(-0TR/0]$ED4_P!H7A21EN+*1TW*!Z#L. ,?6J?\$E-(*+C]J/Q?C^'_ (I7
MPY_\K:\N_9<U^W^ 7_!:3XX?#/Q'>M_Q<A+&]\/JS AG2!II%YQT\P\#/UYK
M]$(SE : /D$_\$E-)/)_:D\7_P#A*^'/_E;5?4_^"4WA_2;.;4+S]JCQ:D<,
M322,WA;PX,  GOIN.U?8TC[%W5YG\2KZ[^)_B^W^$V@71CCLV6Y\02+C A^7
M]SG!P6!;TZ=: /YTO^"U'[/:>$K_ .-VN/\ $C7-0MM/TKPO)I_]HZ#IMM)<
MQR"<-YBVUO$%VE>"F,KC.XU]^?\ !##_ ()O:%\:?^"9WP^^(<OQW\0Z6UY)
MJ>ZSM?#>AS+%MU"X7A[BPDD.0O=C7@7_  <OP);^*?CY;QJ J>&?!ZJ%[86X
MK]$O^#;S_E$+\,_^NVK?^G.YH Z;_AT1X>QC_AIGQ5_X2/AS_P"5M0W'_!)?
MPK:QYG_:F\41+TW-X5\-CO\ ]@WU%?95?'/_  7&T*SC_P""='Q$\90230ZE
MI]G9_8KJ"=D:+_3(1V.">3U'>@#\]?\ @X5_9;^&'P7_ .":'C+Q9\/_ -J*
M?Q7J6F^)=)M=1T%M/T%6ACFF"[W%E:13)P1@[@/K7"_\&O\ _P /(6_8I\7'
M]DGQG\&K#0E\??Z7'\0&O1=B?[!;C*?9T*E-FSAN<J:;_P '$_PG\*^&O@S\
M3-:\/6TMJMIX \"EK>.4[)7:[C4N^<Y.#CMT%;'_  :P_P#!.G]DS]K3]B#Q
MAXY^.7P^NM4U*R\??98)K?7KNU C^P6SX*PRJIY=N2,_E0!^C"O_ ,%S0P,W
MQ6_9?9<_,I.J\_E%FOGW_@G4_P#P6&/PS\;CX7_$S]GF"U7XL:X-076_[0#F
M[WQ>9Y>R/'E=-I/S8ZU]3_\ #CS_ ()Q#E/@[JBMV8>,-2X_\CU7TW_@A+_P
M3.T>&2WTOX'7UO'),TTB1>+M14-(WWF($_4X&3U..: /@+_@NA+_ ,%,O^&=
M_!__  UAX[^"NH>&!\2M#WP>!&OA>>9_:5KM.9D5<!]I/L*_8O\ 9_DCD^"'
M@WRY%;_BD]/&5.1Q;1 \_6OSE_X*R_\ !!O]B[4_V$/B)XF^"?PE\5?\)GX=
M\.S:GX5M=&UZ\O))[R+:Z)Y,C2>9NVX*@9P*^G/^"(GASX@^$?\ @EI\%/#/
MQ4T'4M,\06/@N&+4K#5K1[>X@8,WRR1N%96 QU% 'U7<7EI:+ONKA(U R6D;
M  ]SVJ'^WM$_Z#-K_P"!"_XUXG_P47^ ?AG]I?\ 9AUKX/\ C'7M8TW3-8FM
M8+R\T.Z6&XCC:XC#,KLCA<*22<=*^-[?_@UM_87NH4N;7X^_&9HI%!B:/QI;
M%6';&++I0!]"_P#!;[5M*N?^"6GQH@MM2MY';P%JH5(YE8G_ $*;L#7RE_P9
MW*5_X)<72D=/'VH?S%<'_P %!/\ @W(_8\_9_P#V3O%GQ9\/?%[XK:A=Z/8-
M/'8ZQXM@DM9]JLVR1%M%+*<8(##BONG_ ()!_L\_"/\ 9E^ VN?#+X*>%1HV
MAP^)C/'8K=2S!9)+>%W(:5F;EV8XSQF@#ZYHH''%% !2,-R[:6D8_+0!0U?P
M[X?\0Z7)H7B/1;2_LYL>99WMJLL3X((RK @X(!Y'45S$W[-_[/SR_:&^!?@]
MGQA2WAFT./\ R'6SX_\ B#X,^%_A:Z\;_$/Q=IVAZ/9!3>:IJUXD$$ +!06=
MR% )..O6N;\$_M3?L]?$?PHOC'X>_&SPOKVFO,\,=]H^N07$;RJ,F,,C$%P"
M/ESF@"6Z^ /[/$,#/-\#_!B!5):0^&;0*/K^[Q6%^RQX4\(Z#H>M:WX%\(6.
MBZ?K6M27$=II^FI:J.!EL*H# ]CW%5+K4?&7[1&W2=)TV]T#PONS>R:A;^5=
M7+JVX*F V%^ZV<C(R :]6T:PM]+LX-.LXF2&")(X58=%50!_*@"\N=HR.U+1
M10 4V3.SBG4V3.P[30!^"'_!SZT*?\%0/V59KAD5?^$N@+NQ"X476G<D^U?=
M_P#P3*\4>'M3_;\_:%72M9M[A8=%\'0RR17"NOF?V5&#@J<'D=*^1O\ @XR_
M9K\?_M _M^? WQ%X.L8[C3O VH0ZCXGDFD;;';&[T]<KL4\Y]2*Q/%?@'2=)
M_P""CVDPZ-/)8V=U\6OAY97EG"V%GB?0G9E/7JPSG.: /W0MK@3*&)^]T]ZF
MK/T'1-/\/:?#I6EQLD,.5C5F+''U/)K0SSB@ HHHH **** .%_:6!;X&^(@)
M%7_1%^9FQC]XM?S0_P#!,B:?2_\ @B]^UY=HC+)'JD$BM(H_Y_--Q\IZ@YS^
M%?TL?M2R2Q? +Q+)"S!ELEV[>I_>+Q7XE_''4?A[\//^":/QRL[?5=.TF+5/
MAKX>6W62946ZNWO+8E5SRTF$^Z.< GM0!XK^TC_P2.^"_P =]9_8OL_A]X"N
M='NOC%\+Y=9^(FL:;<2#[7>BTBG#*'#1Q.6+84!<Y[U[U_P2A_X(#?LGV_[5
M/Q4\ _M!?"+4O%'A_3(].OO!DFK:A<)):H9[Q6BG:(1JS_N8LK@\,/6OO3]D
MC]ET_M"_\$T/V<_$6@:Z='\2>'_AGH\FCWS_ .K3=:0!RPV/NRJD?\"]J^D/
MV2/V9#^S?X1O-,U3Q;=:UJVJWOVO4=0N&!!?:%VH B87()QCOUH V/"'[(W[
M,G@SPKI_A'P_\!_"*6>EVB6MGYWA^VD<1H-JY=D+,<#DDDGO7S)^T1^SG\&=
M;_X*,> /!6F_";PK:QZE\,]:A\N/P_;+&'9+A5<@1D<<=CTK[C4;1BOEGXKK
MO_X*M?"E<_\ ,@:M_*>@#P?6/^"?/[17A..;X-^'_AG\/M0L+];BWTCQ<WAV
MW:72K=V)PX6W52VU@@+*>5)KH(/V._AA\#?C9^S'\(_$OP^\+ZI?67A_Q+'K
M%\-#MF%]*)]*.YOW2[O]8P&0,;F'<Y^^# L8.P&O$_C=\'_&GC?]J_X2_$C1
MEB_LGPK8ZXNJE]^\-<2::8]N%(Z6\O4CH* /G/XU_L.?%GP/\:?$WCKX:?!G
MP'XB\.^*+Z'^R=)'AR!GTB18]OFD"W "YY(RW3O7D_[6W[*S_LY?"7X2W_C'
M2/#_ /PF&J?$.[FU2]T?288%"/%*ZP@K&AVJ&"D8 .*_5(6Z)D@]?O9YS7Q#
M_P %H%SHOPE)_A\=R8_\!7_PH [_ /X)Q_ 7X&WG[%W@6^O?@YX5GN)K&=I)
MYO#ULTC_ .ES]6*9/' ST%>YQ_ #X$K\H^"GA/'I_P ([;?_ !NO.?\ @F[G
M_AB?P!G_ *!\W_I7/7NU ''_ /#/GP&W?\D2\(@>WANU_P#C=-;X ? =%R?@
MKX3^7G)\.VW'O_JZ[*D=0ZE&'#<&@#\>O^"^G@*T^&?Q4M[_ .%/[-FO7RZS
M\&]1TR/_ (0'P.;A6NVU&&1$E\A5P2(B<DDCCCFNX_9,_P""_P#XS^)OQ&\"
M_ ;Q+_P3O^-OA>/5KB#2)/$.O_#Z6UL;=U@^_),UQ\@)4_PG.17ZD_9$#,P/
MWCD]:XSXX:-?7WP]NI]&LOM%YI\L=Y9PB/=ND1O[O.3R: .P\YV& O5<_CZ5
MYG^V#^U=\-OV*OV?/$?[2/Q?FN(]!\-6/VF[%FB/*^71%"J[HI)9P.6%=QX-
M\26OB_0+77+"[AFCFMU:1H) P60CE3CN*^)/^#E=VC_X(Y?%XC_H#VX_\GK:
M@#3_ .";/_!8:U_X*"^)M'L[;X,ZUX<TGQ-HMSJ7AG5-0MT1;M;>4K*#B=NV
MWH#U^N/N2OQ;_P"#<-/^*%_9OC#;57X?^*"JKV)GAR?QW5^TE !1110 'I7R
M/_P7,(7_ ()2_&PM_P!"'??^B'KZX8X'-?(W_!<E+F[_ ."5'QLAM;.:9V\!
MWX6.%-S-^Y?H* /Y[_\ @T]UG3/#O_!5T>(-?U6VL;*U^%OB"2ZNKR=8XXHQ
M'%EF9B  ,<D],5^>7Q:GAO\ XJ>)KJVFCEAF\07LD4T<FY74S,001U'3\ZV/
MA%\4/C3\!=8U37OAM<7FF7.K:'=:1J4BV8;S+*X7;-%\P. R@C(P:XF65UVM
M@_*<JWOCG]: /[C/^"?_ ([T3X@_L:?#/7_#TDIA'@O38<2J =R6L:GCGTKV
MBO*/V(='T_2/V0OAE9:?;1QQGP+I3L%7JQM(B37J] !114=Q/Y,32$<*I- #
MA(A.W=3MP]:_$WXM_P#!X_\ !SX2?%GQ-\+]1_94\374OAOQ%?:7//'-;@.U
MO</"6&;@==F>@.#7/_\ $;+\#<X_X9$\5?\ @1;?_)% '[H%U7J:%D1NC5^%
MI_X/8O@<"1_PR/XK[];BVX_\F.:=_P 1L?P+++M_9%\6_=^96N+7[WM_I'2@
M#]T=ZCJU&Y0,DU^%O_$;)\#0S;_V1_%@_NA9[7C_ ,F*!_P>Q_ T*HD_9%\5
MY_BQ<6W_ ,D4 ?N=)<HF<-]W[W'2O-OVO[N:W_94^)>H6=PT4\/@/56AFC8J
MR,+64@@CH00*_'%O^#RSP-XY\2:7H'@3]C_Q==7=Y?)%!I\:P32W;.0JQHJW
M!+.6( 4#)S6/^T!_P=B:+HGPX\;?LV?%?]C#QMH/B+5M%U"PEL]6MX[::S:Z
MBD,7FQO.&4!)4;I]T@C- '(_\$Y?^"?O[,WQA_X(<7/[2/Q!\-:Y=^+I(M0D
M:^C\6:A&K,EQ?*O[M)E0G:@S\O/-?6WQI_X)'_L.:'_P4@^'OPXL/ OB!=-U
M3P4MQ>QMXVU,LSF_=#AS<908SPN #BORO_9#_P""]/@3]F+_ ()D-^P3JGP5
MU?4-0VW:G6K62-86\V6YD&090W_+<?P_PU[[\1?^#JGX1>,_VM_"/[3$?[./
MB2*T\,^'TTN;3Y)8/,F*W33;Q^^V\@D<D'(- 'VCX1_X)%?L/:C^SW^TIXFG
M\!^(#?>%M8UI-%D_X3C5%6(1>'K*9 RB?#_.YSN5LC Z#%0Z)_P22_8C;6OV
M;K<^!?$07Q+JU_%K&/&VJ?OE32=5DPN;@[,M"@^7:.3ZU\;:'_P=5?"#0OA7
M\9/AP_[-OB)I/B9J&I7%G-YT&VT6YTFVL5#_ +_/RR0%CC/#?A532O\ @ZA^
M$5IJ?P@O+C]F_P 2;?AG?7EQ=+Y\'^D^;9WUNH7,QY!N@><<(: /U^M_^"%'
M_!.9H5,GPZ\4-U.?^%D:SSDY[75?C;_P=:?L)?LX?L:V7@&7X$>&-4L?[4DC
M6Y.I>);V^X(O2<?:)7QDHO3W]:_8'_@CU_P6(\'_ /!6;PAX@\5^#_A3J7AB
M#0=0DM6CU*:)VD*I V1LD?\ Y[>V,5^;G_!ZKYATSX9-*^3]IAX_#4* /H7_
M (,SD1/^";GB_:@'_%S9]V!U/V&TK[U_X*M22Q?\$V_CO.C[/+^$^N%9%ZAO
ML,V/UQ7P7_P9H_\ *-WQA_V4ZX_](;2OOC_@J7:_VE_P3N^-FD-)'&MU\,=8
MB,LC86/=:R+N/L,@T!?E=WT/P/;Q-?Z]_P $JO@NNHZ])>7=IXOUP+]HN]S0
MQC3M(VCDDJH)/L"3[U]L:IX'_:6_X)3_ !!L_P!KCX$WNI>/OV<]15O$VH:1
MINJ1:)I:/JF^UMK=K9Y)9"T2R6+"3R0#A 54!B/S,^'OP?TSX+?!:'0M+^,.
MB>,H[[7Y-16Z\.ZAYT5@TD$8-FW VS*(PS*>Q3!&,5^EO@/XB_M _P#!(;XM
M_P#"#?$/1Y?%W[-^N37'B>ZN/!NCC58#;7<<MM81?;+A(HTF4P6;%/,";64A
MF+BOS3,>6/$6*G.\;.G::VB_[W>#^TNWWG]N\'QQ%3P7R;!X=TZWM(XSGPM3
M3ZQ#GAS*E-:PQ$$_W+2WD_1Z'Q9_9T\>>$O$5O\ \%'/^"2GB26X^'.J3)<^
M(/"/@^,Z!#:6.FJHN$D:XDC>9))(I\KY!QN)VL<$M^+?P3\8_M@Z3IO_  46
M_P""3NMW&B^++ZWAT?XA>"O">=.N+;5)4;4+^66^N'MOM!#3VL3%(R)-BL"<
M,@H_$'X?_%C_ ()L?%Q?VA?V M0C\4? _P 836\%_;^'%?Q'/!96JH;X7#M&
MT41,GGA7\PC.=S+AL2?&WPU\2?@[XHLO^"EO_!)NY74/#_CK34A\2>&;-FUS
M4;'5]09[^Y$UE$LL%N$C%JC!9,HV% ((8Q-)1J<\)I)WG&/1O_EY1[)O5K\.
M[P]?$5,1@ZF&Q5*;E!T\/4K))5())/!9E%+^)%6C3J*SO%MO5-;OB:Z^&W_!
M8/P''\8OV=9+7P+^T9X#\[6;O2+&%KF^U#[)^YLD74G%M$A:14*ON?8>2O&:
MA\.?#*']O+X8K^Q_^T5XA_X1/]JKX9S.8=<U>U.JZIJFG0AKV%/MD;)#"/,O
M1&%%PY79N(^?:)_CMX4^'_[;6A:?_P %#?\ @G;?0Z/\3O!]Q_;/B3POK%]C
M4Y8--7$7E:7:F<$O+& JD*)/NDC<16?K7@#5?^"F7P7T_P")RZO:^&_VJO -
MQ]C\2:;XFN&TFXO;&U,MXLD.G0([OE;F!/,,2[V5UX 5CI)>TKR4H<[DM4M(
MUH[Z=JJ\K=?ESX>=/!X*E[.N\+2H5;1YTI8C+J^JY*C?\7 2O*+YM=8O?>3X
M5_%?5/&^AZE_P2W_ ."J^@RZ;X^UBWE?P%XZ\5WW]O7-OJ^I8M+%4BMPZQ%/
M.9ED:X51@J3'G-0?"A_&W[%'C*]_8W_X*H6<NN?"7Q8DFG_"_P 0>);P:A:6
MD>E%HH9+;3K;[0\0E6YM2%<QL@50<MDKI^!OBUX:_P""D_PCOOV3?VXM'OO#
M7Q^TZSNM2\ ZMXHLXO#MK/?R1>1IT0V%9I7$LP;RQ#RN2NYA6;\!_%VH^.(=
M8_X)M?\ !56*;3-'T=(M+^%_B:ZMAH^G-)I0E@E*:A,(9;A)3]EV-M8R=2!O
M&9IRYG3FIMNSC"<NJ:LX5?-='W\]S%4_8T\9A\11C32DJF)H4M7!W5L9EDMU
M#:4Z;;BXIK9Z5/#&C?M'_P#!(/XHGX?_ +2,FH>.OV:_$;+X/6\OM72#2=NH
MF.XN[L:<C7<I,<2WZF(*OF!I/F!=!4OBSX8_'3_@G[\0(?V\OV.=<O/&G[/V
MM7$GBS5-#T>^70M.CMIRT5M:2PN[R.H26+]X+<D ?<R2*B^ WQ,^,_[%OBZZ
M_P"">/\ P4<T.ZU#X,W^FR^&;'Q#I6C8T^&_U:2.7[0-4N%@Q#'%=78D<$M&
M5&U<(26:7JWQN_X)-_&:1-(@;QE^S7XPU.;7+H^#M/\ [;"Z.2\5HCW<ZI'%
M*5,6,2[3C.XC I>[3HJ_/&,96U^.A+L^]*7GT1V5%CJF85E/ZO6KXBE>2BK8
M;,J*6LH6UI8Z*O).-E[1I6[WOB9\#?B#\'?%EO\ \%)?^"6WBFXU7X0ZI>+J
M_BKPCX40:#:VFFZ-L2>*47$BR3I,\-Z<+;DC<P ;<K&Q\3_AY;?\%$O#-G^W
MM_P36OO^$3^,/AV&/_A,O!WAF%H+R;4;U@LC?VE,UJCF.#SLL$;> 5^4D Y?
MBGPC\7/^"8OQJC^-_P"QQ=0^+OV=_&FI6KZI;^$X'\120Z/8+&=1665T,,&Y
MI;S8PE ."&*[#B]\>O LU[JNE_\ !5'_ ()07JFZ6*2\\9>%1=-J>JV][?OY
M"H=-@6>&,K'+*67<"JJ6&<&G6BHQJ0J4Y*SO.G'[+Z5*#W23U<7W,\/5J>WP
M>)H8B#<HNGA\3424)Q>DL%FD-8N;BO91J*TM%+K=2:M\+8/^"B/PFL?'/P2U
M9?"W[4WP?A9/'6G6\)FU;6;ZU_T" R:HQMX1(WV8R;E:39YF,C&XV/!WB/PM
M_P %!OAY)_P33_;1AA\&_'[PBT>F^&?&FO*VO7UU(DGVZ](>-8XX&\BV5#FX
M.X2 @DC!S?BGX!U/]I/P)X?_ ."CG[&UW#9_&[PE"M]\6/#-W,?[3>^LXTM%
M\G2HEEV;YH)&5'";T;) )8#0U2/PA_P5R^!:^ O$=]#X3_:A\#116T)\73#0
MH]0GFF5[MH;:#=-*5M+>0'="IC9TRH#$C5\TJLE9-S5W'[-:-MT_LU4M&U]J
M_0Y5*-'!TI.;I4L/4LII?[3EM?F::DMJN!<V[*>OLZBUNM:OPJN/&'BGP[JW
M_!-W_@J^MQI_Q \81G4?A5XN\870UZ>SFOU2PACA2V+I$$E@G<,T\8))&%!!
MH^&'C?XB_P#!/3QE??L>_P#!4;1;KQ1\$_&4YTKP=XA\3ZDMY866GZ+YC0S0
M:=;_ &J0+,SV&(B4:,K'DOL;;)X'\8ZS_P %+/A!K7[.'[>T+>$_CEI+3:A\
M*;_Q1:+X;M[D3Q1P6L2K\LMRXN1.2HA8%2,%B&%.^ ?QGNK^/4/^"8O_  5P
MTB^M_"[-!X?^'_BN;3UTO3(DT?S&GE_M*?R)9HY#;68215<R%EW;!*,Y1G;V
M<X2DKJT)R^U_T[K]V]EYV-\91J<F-P^+HTW&+C4Q.'H/6&J<<7E<]7HK3J0:
MY7::>CTS='^%OQV_X)2?%"&T^+>IW_CK]F'Q-)'I&M7$]\EII21:H1YTK:>L
MEQ+)Y40ERHC4RC(!4D4>*/!7[1/_  31^(Z_MR?LLW^H>-OV<]>G?Q;-HFEZ
M@FA:;'#JC/#96TD#R23/Y2369$A@& J[E4JVV#X0:E\;/V&_'S?L(?MS6\FL
M? KQ8DFFW'B#0K(R:;;W&J%8XYCJETL)B5$>4N0Q9 N0&ZF7PWXU^.O_  2-
M^.-QI][I=QXP_9I\1:I=^(?/\)Z7_;$:Z5.)+?3(GO+E8XHY0J6IVK-L(P0Q
MWJ"6I4::D^>FHOI\5*79]Z+Z[Z+[MZDLRQF-J4^;#XNK7I*\?AH9A12=G&UG
M3Q\==8VU:ZK71^+G[-7BSXJ&V_X*%?\ !'OQG<1QZGY>F>*/"'A"W&AM:;$-
MU=N]Q<R0B93*L*,!$=QVD9PU2_$_X.W'[=_ARQ_;\_X)<>(?^$?^)EG:10>-
M_!?A6$V%RFJ7I,UV[ZC</;"5U60AF",'Y(/S8&3\8?A=\6?V+OB!%^VQ_P $
MMM7L_$7P_P#%T*:3J&FZ#O\ $-W;7$I^U7GVB$1O'"BF%%)\P,A^3C<#5SXZ
M?#CQ'X3URQ_X*D_\$G-7M;J/6K0W/BCPO;R'5M7L]3U)V>6-["))HH2B2@/'
MO CVG . :52,5&HI0:ZS47HK[5:/IO*/F8X/$UISP4\+C*;NI4\/4KQ6J=E+
M YFE96:2A2FM5RR[Z7[_ %OPG_P5A^%W]D^#;&'P+^U)\)6:_B\N'[=J6KP:
M1$T4:#4&%O#;^;?3Q,,R.4==^&7#+7\#^#[7]MWX:S_\$V?VX+Y?#/[2?A6Z
M6/P_XL\01MKFH7=G(QU1U$T>V*)1:LD.#<DLH!^]\M3_ !:A\!_M^_#G3_VS
MOV.HI-%^/WPLNK>\\4>']8F$-]J-OI4#7,S6NEVQF,I>\EA5-ZIYARC8RH-(
M>%%_X*L_ )?#GQ OH?"O[5G@R;[&R^*+G^PA?6SSM<$QVD(:67;8A5+/"/F!
MQE3NK67-*3DX\SE'TA5BK:+M52ZK_AN:ERX/#T_9S>%IT*R:4DIU\OKN]I._
M\3+YOXE--I-=5[R?"3XD>-8=*U;_ ()J?\%?-+N+7Q%XMMY=8^'7C+QAJ0UV
M2QU&Z6/3+!(H;<2K'M<WDBR-,J@[@=H8$2?#^V^('_!.3QW=?LJ_\%'%N?%7
M[/?BLG2?"_B#7;P7&FVL=CNNX[B/3(#=2C=,(8]C;=A*ON."*G^&?QL_X>'?
M"S6OV/O^"CFE7GACXN0R3^(/AMK/B6Q3PW:EE@CLK"%GW)+,[75S<$1K&P91
MU+( 8?@3XG\4^'=0U+_@EO\ \%54GA\!R0KH_@KQ0MG_ &;I,=Q9,;UW_M2=
M879'\N-%*AM[LJ84-DS%QC*E*$V[Z0G+5O36G76B:;^%K75?/7$49THXW#XB
MG"-N6IB:%'5633CCLKD]5*/Q3IOW7%2Z/3-T31OVGO\ @C+X]?1_BT^H?$?]
MGO6H5\-6]U=:PEEI1EO_ "YYYEL%>YDWQI'>*4V*'&[##>%JS\2_@K\6_P!E
MGQY;_P#!17_@G#KEUKWP2UZX'B'Q1X9\..- LK?3; @"UF6:3S)D8?:>!!E1
MORIRN:_P6^*WQZ_X)[^+)OV(_P#@H1H-[K_P?N[%]-MM9\-Z)YVG+J&I.LOF
MC4;M8#Y:1RW.[#,R8X#;33=8TGXP?\$L/C>WQ%_9WF_X2[]F_P >ZA#>Z@OA
M.W?7VBT.RVB42SRH(H"WGS[667#;<DC;6=J=.BK*48QD^MYT9>KWI=-4_=?W
M=%2.-K9E.3E0JXC$4OBM;"YE126DE_RZQRTFG&UYW7K>^+G[-/C"34;7_@H5
M_P $B_&$TGA34F6+7O"O@^'^P196]FF^Y9WN)(C*KNFTIY) /(#'.;GQ LX/
M^"HO@6S_ &U?V 95\'_'[P3&S^,/">@934+R2^F2RA)U27[+'E+*WN'& Q*L
M4." 3C_$[X:?%3_@GM\5+?\ :G_X)KZO;>*/A'XO\G3[ZT\.L_B.XABB EO3
M-^[>.*,,C+D29!^7Y>M:GQ_TRP^(\FE_\%:?^"5UU'!XHTW[1+XZ\&W4@OM8
MAFN#'I=JHTNW$\:'9]J<AF4;/W@W%2*J?+&-5.#6TIP73M5HOI)/6WKH9T:U
M2=3!8FA7@U9T\-B:JU]Y6> S2"]UJ<4Z:FM4XWO9Z.N_!^F_\%(/A7:^$M"U
M!?"?[67P1C;^V&6$W>K:]<:-$+:,MJ&Z&"&26^V,")I1&R@Y=<L'?#S5(/VQ
MO E[_P $M?\ @H+ OAGX]>'2D/@OQOXF9M>OKF:[E?49@IA58[?;91V\63<?
M.KKR&0J8_B+X-/[;_P +O#_[;_[,MW;Z3^T9\-DAO/B9X>U.0P7]W<:1"'G-
MOI-N)2S27JJ$61$WG*$*3BI(K_P__P %7_@*WP>^-P;PC^U7X%@9-+N/%,@\
M/0Z@U]<F51'!"6GG9-/M8E<-"H#." 5;<+DN:I9*\I+K\%:/5/M67?35=MN?
MFIT\#'FE[.E0K+6+OB,MQ%W[ZW57+G-NZEKR2C;57=+X767COPRFL?\ !,7_
M (*F)=0R^.+67_A3?C3Q/=#6OL.HR8TRQ^SVT!E\GFXEE#-/$$V%#M!W!GPT
M\=?%S_@FKXUN?V5/^"C6BWOBWX'^.)O[%\*Z]KVKK+8V>GZ>3FYATZ'[4P5_
M,MOW9*;=BGG#$.^'7BWQ+^VC\/->_8*_X*!VMUH?Q,TJUFG^"^N:]9_V%8RW
MD$7V"SB\XJDMTS3W(946)]Z*3RP"F7]GWX]Z_P"!;K4O^";?_!570]0A\(W7
MD^&_!7B9M,33].ACLBWGS_VC/Y+O"VRWVR*&+?Q!0PS%-Q7LY0<E:\8RETOO
M3K+SVB[=M>^V*HUZD<91Q5.E4NXU:]"C[MTK-8W+9;J27O5(.\6XR5K.RK7?
MP;^,_P#P3=^)-K\6-%\27GC;]E?Q<K7GB2&&1=/TFU@UHM9^6^G&2::X,,4E
MNV!$-X 7"$$UZ#_P;+#;\+?BVN>FLZ;Z?\\9_2O,O!2?'#_@GS\2YOV4/CD%
MU[]FSXB274]YJV@6;7EE;6NJHUA9F34[A(UMRFRV=]KL%3YEWLV#Z;_P;+$G
MX7?%K/\ %K.F=O\ IA/4Y?'DS_#PBG%+VEXRWB^351?6'9O6]RN-)5JW@]G=
M>O.%:4E@N6O37+&M3]N^5UH[1Q4&Y*K;1Q<.UWRG[!O_ !X?LD?]EX\<?^B-
M9K]?(ON_C7Y"?L%KNLOV25ST^._C@_\ D#6:_7N,86OTX_B,=1110 444$X[
M4 <+^TW_ ,F\>-O^Q8O?_1#5_-__ ,&XO_(5?_LY_P )?SN*_H\_:;FQ^SWX
MV1E_YEF]'_D!OSK^9'_@@Q^T-\"_@?JLG_"WOBYX>\-E?VB_#&I-_;6JQV^V
MTB,_FSG>0?+0L S8P.] 'Z-_LD)))_P5ONHXDW,WQK^*ZJJ]6)TZ( 5^;W_!
M&/PIXI\%?\'-&G^&_&6@7VFW]O\ $/Q49K/4+5XI8]T5ZRDJX! *D,#CD$$<
M&OM+]E/]N;]D/PM_P5&E^)VL?M*>";718_C!\2M0CU2Y\16ZVQ@N;&);:;S-
MQ79(RE4;HQZ>E?)/_!*;]H?5/VK?^#HJP^/&KSV<TFO^./$$D4]BRM!+!'9W
M,<+1E0 5,<:$'OG- ']2U13JQ#!5/W34M-DE$?WA0!^4O[-?P_\ &W@;_@J=
MI$WC/PI?Z6NK>,_%]UIGVZSDB^TP&ZL\2)O W*01AAD<BOU9DMX)4*2Q*RD8
M(8=J^-/CE\1_ GC_ /X*<_ N'P7XLT_5)-)TKQ-::I_9]ZDOV2X$^FYAD )(
M?@\=L5]G4 0V5C9Z=;K:V-LD,:_=CC7 %5-"\3Z)XC22;1M3AN!#*8Y?+D!V
M,!T('0\C\ZT:\U\4?#/6/!GB&X^)?PK58[BX ;5='4L(KX 8R ,JLF N"%YV
MX/7- 'I0(/0T5ROPS^*&F?$31_MR6$^GWBY^TZ7?$+/#CN5SG!XP<#K75 Y&
M: "BBB@ HHHH *^>_P#@IY_R9OKO_8<T7_T[VM?0E?/?_!3S_DS?7?\ L.:+
M_P"G>UH ^8_V3O\ DL_[9'_9.?#O_J-U]2?\$OO^3$_ /_7K>?\ I=<5\M_L
MG?\ )9_VR/\ LG/AW_U&Z^I/^"7W_)B?@'_KUO/_ $NN* /?**** "BBB@ H
MHHH *^7?^"R__*-[XG?]@VU_]+(*^HJ^7?\ @LO_ ,HWOB=_V#;7_P!+(* /
M;OV=O^2 ^!O^Q1TW_P!)HZ[2N+_9U_Y(#X&_[%'3?_2:.NTH *;*-R8_I3J*
M /SS_P""C_AVP^ W_!1W]FG]I;P]I$SW6M>,+G1O$$Q!9/)FMX;6,G/"X,@Z
M]:_0J,Y2OD[_ (+,^"=5UC]C#6OB1X8LMVL^!YK77--NU4E[;[/>6\TCKC_8
MC:O7_P!DGXRV_P 5_P!D+X?_ !IU35EN#K?@FPU&^NWF3F1[9'E).<<-NS]*
M /3[D&:)H8WY;*Y7^'CK6)X*\!:7X0EOKRW9IKG4+IY[JZFYD<LQ.,^@["LO
MX5^*O$OC6[U+Q+<K$NAS3!-#79^\95+!I"0,%6.".>E=I0!^ _\ P<S\>,?C
M^/\ J6_"'_H-Q7Z'?\&WG_*(7X9_]=M6_P#3G<U^>/\ P<T?\CC\?_\ L6_"
M'_H-Q7Z'?\&WG_*(7X9_]=M6_P#3G<T ?=5?(O\ P7(_Y1@_%#_KSLO_ $M@
MKZZKY%_X+D?\HP?BA_UYV7_I;!0!^:?_  <@?\F__%C)_P"9!\ _C_ID=?7G
M_!KC^REJW[,W_!,_3_$NI^*K74U^)%]!XFMX[:"139QRV-NGDMN)W,/+[#O7
MR'_P<A?\F^_%C_L0_ /_ *5I7Z5?\$+?^447P7_[$FP_])HJ /KRD9U7[S ?
M6EKY3_X*9?M"_M%?"76OA3\*?V9]:TG2O$'Q*\8'1EUC6[99K>S7]VV]D,;%
MN">F/Q[ 'U45B?DA: (P=P S7QJGP5_X+4LNY?VS/A: >1_Q1_\ ]IH_X4G_
M ,%JO^CS?A;_ .$?_P#:: /KKQ5H>G>*-#O/#FIQ+)#>6KPR*W<,I''OS7GO
M@'Q?-\)YK?X5>/RT4-JPBT766P+>6WSA$9B!M=5*KR3N()XKY1^.OB?_ (*W
M_LI>'M*^+7Q+_:0^'OB;0X_%&DV.JZ/IOAH033P7-_!;OL<PX! E)[=.M?=_
MB#PGH/BS2VTGQ!IT=U;R#)CD'W3CJ".0?<<T ?.W_!7BZMKK_@GI\0I;6XCD
M4Z+-AHW##_5/Z5L?\$^P5\">(E;K_;T9P?\ KT@KRG_@LK\,Y/A[_P $T/BW
MJ_@7Q3>:;;V'@W4+F&R5FD42);2ON)=CZ5Y#_P &LW[07QA_:2_X)YW_ ,3O
MCAXXN=?UR?QM>0MJ%U&JL8XPJ(OR@#A0 .E 'Z<44V,L44E,<?E3J "D?[M+
M2/\ =H ^)/\ @X9 ;_@D=\5"1G]QI_\ Z7P5X7_P:+:)I&H?\$A["[OM.ADD
M_P"%C:U^\D0$@X@%?07_  7TT.3Q+_P2U^(7A>"X6%M2N=)M4ED7<J&34K=-
MQ [#-<E_P;M?LT:O^Q]^PAJG[.FN>*;?6+KPY\2M4$VIV<;)#/YD-I,-H;D8
M#@?A0!][B*).GTI41%.=V:\^_:+_ &A/#'[.?@1/'7B?2[R\BFU*&R@M[$*9
M&ED.T?>(XK@KO]M'Q1H]O-JNO?LX^++73[;(N+Z2#"  XW<@#!^M 'T#03CK
M6#\/?B!HWQ%\*:?XLT-'%KJ%K'-#YC#(5D5AG!QG##I5[Q3KMGX8\.WWB346
M9;?3[22YN-O78B%CC\!0!H9ILC@1E@W3TKY^T;]N"_\ %]H=8\$_L]^*M6T]
MI7CBO+>$;6VD>@;L0>O?I7;? 3]I#PQ\>CK&FZ5H]_I>HZ#=BVU2PU';OBD)
M;@8)_N^U 'P?_P %8OB+X%\&?M6VV@^*?%&GZ9=^(/#=M:Z/;W5U&CWTPO[!
MMD:L<N>1PN37@'CI&7_@HYHKYZ_'#X:9&>/^1=DS_*N+_P"#GZ(#_@I[^RF%
MC4EO%D'\/7%UIU>H?%KX:^/_  G^WGX/\?\ B+PS?6FC^(?C=\._[#U"ZM72
M*^6'0I8Y#&Q&UL-Z'B@#]G%/_H5.\Q-WWU_.HG8B/*G^*OCK]H;XL_MQ_$+]
ML:X_9;_9.^)7AKP>FC>&3JVI:KXCTD7@NP?LBK&JB,E3NF8[LT ?9FX>M&1Z
MU\9+\&/^"U!7(_;,^%__ (1I_P#C%*/@O_P6GW?-^V7\+\?]B=C/_D&@#[+:
M1%^\X'U-+FOB#X-?%K_@H'\,/V]?"?[-W[4WQ8\(^*M%\4>%;W4;>3P_I?V6
M2WEC$A0']P"1B%\_,/OCTK[=CW>6NXY.WD@=: .%_:;1)/@5XBCD'RFS7/\
MW\6OY(/#VJZWXE_X(U_%JZU.ZGO)+7XSZ6(Y),N8X5C4!?8#-?UP_M,?\D+\
M1?\ 7FO_ *,2OYIO^"5'A;PUXM_X(]_M6:9XH\.V>HPP^(;>:-+RW5MCK<V
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M1,A/IN&*_/;_ ()G#Q!\)O\ @I?^T]^S<\W^A7%S:^(-/G>W";Y)Y9I7(_O
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MF_[8I7-?&OXZP?"ZW@TG2-*DUKQ)J$9_L?1+211)<'<%R2>%').?]FNB^&A
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M_8C\.V_P3^,'PS:7[1X'\!W']H7'B6PMH8[BW+V$0MX]KW,TD>6MI=QB"G>
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MX*M?":S\5:''K%SI>@_%[X@%?#L]MHEBL@M98YA"LTD,LMHQ$YNBSF?YF?+
MW/A9\;?AO_P5I\-S_!?Q9X!MO"O[2NE1W&K>'?B1X5TF'3T\VPXLHYM0>2>^
M7#LF\HH^[F,H5P+'PE^,?PB_;5\0W'_!,S_@H+\/8KWXKZ1JDWA'1/BAX3T6
MVEO$MM)7S'D?4-0>28R336LY9EA"NLV2J%RPBG4E*-/V=52<GRIR7NS76E4T
M^)=&U?<VQ>#CA:V+AB<!*C&E'GJTJ4G[3"RL[8W!RNOW,G9RIQ:C:*35K-9/
MQ,^)GQK_ ."9_P 2_P#A3_Q\\(W'Q[^"&L0QS>%[SQ;I26^F6%]<ME6M]0N(
MKMG>*UCE4()@-LC-A,58^.7B+XH?\$QO%UKJWA.SNOC?^S5XLM6U33?#.J:=
M]IT'3896*:=:IJ=Q'>Y$48C9,,@<;3L.[(;IW[1T_P"Q1\1KW]@K_@J)X8L?
MBYX1@M1J?A6]%I_PD%_974[B&V&_4GCC18X%E7$<8*NV%R&(%C6_B_J__!*[
MXL-^R%^VKIUK\7?@3X@$VJ>%M+UJ,Z_J-E80%H;&!4O&AM8=I16>-$*KSL(
MX)SA!2DIN*@[)O5TI/>,OYJ<O.Z2.BCA,17Q%*$L)#$SK0<I1A[M/,:45_&P
M^B]EBZ2?,W%1E*4GJW=/0^-7A>']EWP5HO[?'_!.CQ$=<^&NM36MI\5_@[X=
MSKVEQV\D37^J_:II6N8K56BBBMY&$"&)9%PR!RK9^L2^+/BK\ E_X*=_\$TW
M?X>>-K63['XP^#?@:U_MU9)FN#8Q32VH!BBQ:H)@HL@=C;^#ES?^+'@[Q)_P
M2BU31?VE_A?K\GB;]G'XI7%M8>)?AYXKO6NFC&I!KR[:+3XA!9B06EL(8WD9
MR-S(^Y6W+2^)NKZW\!O!EG_P5U_X)RPVOA_X9ZTS1>(/A3XD9K.Q>Y60Z.K)
MI>G%867<AER\[,'8L!EM@TERPYH3]UQ7,XQUY&WI5IOI'^:*LM[HX,+&IB*>
M%K8=JNZTW3I5ZOPXE:WR_&0=TZS^&-67,U:+4DK-6_ 4_P )_P#@HU\)M;_:
M1_9&\/:9\"?CI\/)+BYL_#?@35/MU]K^DV5NMP(OL$)MD\N:\N8D,A@DW&!$
M)=6""M\"_&.D?\%*HM2_9U^,/A"Q^#W[17A>WCFTOXG17!T[7=6O]Y-]G3[=
M+)GD^QQ2J49G**V_"D<Z'B/P/\-OVE/AA>?\%*/^"5FG:C\*-8^'-T;'Q5X6
M_<:#INJZ78P'4[DB'2P[7#3/);1E7E176-E(4J&-?PEK'@O_ (*X_#B;QK^S
M1HA^%O[3'@NQAU36O&7AVVBT"RU2:ZD\FX+7=JTU]*HMUF"AF4EI,,2I.%[T
MZD(2DI.2N[+W:T5NX):1J+HU9W6Y<XTZ>!KU*<9TJ=":A&=1N5;+*KDDJ6(;
M;=;!U+\K4W*%I7Y;W3S/V?OCUX"_;%\03_LB?\%+/@_IWA'XGVMG/J%E\7/%
M$R>'M8;5-R1:;";:&*U=F6*X0I&9B'\E#M.5989_C%XS_9G^-LG[ W_!1_X?
M_P#"TOA_J6JPZ!X1^)?CVS31AI=A)C[;>V]T\3S2J/M$99_M>4\I0'7-;/P9
M^)WP"_X+1^'/^%9>-OAQ_P (7^T)I.GS^(E\>^$=%MM/CN'LV^SV4$E[(\]V
MRJ)[=FX!#1Y1UVJ#5\!?'K0?%OC&^_X)8?\ !3[P-9^,O&&GWL/A3P3\0_#^
MFIJ&HV$U[_KKI]1U.4R*X:2V*RQP[@(B65B%-3S>[3FJJ=W:-1I-36_LJJZ2
M6R;UOKN;UL-&EB<5A:N!G'V4.>MA(R?/AW_T'8"=]*-[<U.#C'V;LXN-K9OC
M_P")7QE_X)U?%$?LQ?M=>%+CX]?"/4C;Q>'?$'C/25L+2UN;Q5,\]O?S0W,C
MR1Q,Z%1. %&?W8'&O\?%U#_@FWJ^C_'#]F.>;XO?LR>-?/;5?AWM.I^'M-AM
MQ'!;1OJ<_P!N6+=?W+RC:(R\D/EG?M&*>B?M'7'[-7CR[_X)S?\ !5GPEI_Q
M0LK6.-O#/B2UM?[=U&RO-0P(Y/M.IR(J)&CE5\N(,A7 W 5=\=RZE_P1X^+5
MG\#?CY(OQ2_9I^(C3?V;X;\2'^VM0LH;"(3XBMI?L]E SWUW&[;5<,L>[Y77
M+-RC[.4E)I0:2;^.A+I%K>=-O=.ZM^#^KUJF,H8>6'C5JUX.;IPTH9G2LOWV
M'6BHXR,??3BH3Y^;6]U*'XI?\)I\$?AWX:_X*+_L+^=J'PW\;K;W'Q7^!WAV
MW.LZ/ID4D/VW6(;B603Q6B?*8)"MM!Y*N0 @PE7-2TNQ^/'[/W_#R'_@FE=1
M_#/XI:+"TWCSX1?#]SKTE_FX_L^R\VR4B&';;Q74ZI]C/F"5VP60L:OQ,\3>
M)/\ @GIK>@_M7_":\CUO]F?XZ-;27_PL\1,;C[!::JOV^\CM],B\JRA(ME:&
M,%Y!@E&+ EA:^*&AR_"GX>Z?_P %BO\ @F-,_A'P/J'FR>,_AEK\G]G:=/\
M9I5TFV5-.TW;%*GF?:YRKS'YI%D3EBE/W/:U%+HN:45\47_S]I?W=;M1MI]Q
MS0C4]CAJU.UZLW3H5YJ].NE>^78^+TE5LN2-6:D[PB^;:2S_ (?^)])_;Y^&
M&N?&W]G3PK:_!?\ :$^$=K/J/]G^#V%UJ7C"WLXC<2PMID2VRL)[]K<,6@G'
MF!8R'#;*N? #Q?\ !W_@I=::M\%?CQX-T?X._M!>%(X(-%^(2ZF--U?6=:E+
M"^N#86XLB\P%M\R-YFSS>-O(*Z[J/@S]IOX:77_!2'_@FWH'_"L?&7PC5;GX
MD:,EO'H>EZ_:VT+:G=QF+3BTMX9)8H5VRRQAX\JQ'4V?!NA_!G_@K[\.[OXE
M?LX:#<_"WX_^ -.AU#5_$GAV&WT*QU35;X[9)7N;<3WDRI]FGV,2CCS"#NW.
M 4XRE4C#GC-S5[)+EK16TH_RU(^5F[+46(A2PN'K572J86%&I&"FVY5<MJ2:
M_=5KMNMA:C:M&3DE&3M&]T^9\!?&WQ%\2/'UW_P3L_X*#?#//C"Z:]L_A_\
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M/^&>OV*UX^]_PM+3_E]_^0;ZXKI/^(.;_@F/_P!#Q\2/_!U;?_(]>0_MZ_\
M!JY_P3S_ &:/V._B+\=O OC#Q])K'A7PI>:CIR7FJ6[Q-+''N4,!""1D=B*
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M''W_  2._P"D>GPQ_P#";CH =_P^^_X)'?\ 20?X8_\ A1QUQOQT_P""[_\
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MV^ GB'Q;X^71/AS=:+'H,L&KVZRR+=V8FE\QC 0V') P!Q7V!^SQ_P &K/\
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M&3QFO _B'_P36_8&TO\ 9 _9/\8Z9^R5X(AU/Q=\7-+T[Q+?QZ.OG:G:/<W
M:&9NKH0%R#Z5L?M"_P#!,C_@G]X<_:0_:F\+:)^R#X%L[#PE\ [C5_#MK!HJ
M+'IU\+%76XB ^Y('RV<'\* /L'Q+_P %>?\ @F#<>)+/XD^&/^"AGPCL]:CM
M?(U"RD\41M%=)AOW7FXX =D(;:/NBJOBW_@L%_P36^+%O'X=\7_M^_"71]+\
MY9+IM,\;1W$DY7E4W!5VC=SU_A->4W'_  26_P"":Z?M(? OPQ#^Q)\/5L/$
M&EW;ZQ:#04\NZ*V%](AD7/S$/'&WU7-9#?\ !*+_ ()P#QM^TEIO_#%7P_\
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M6K_'8LV0/^,7+0\XX_Y:^OT^M?KJ5MPN\HN.N=M17:1-#NB13W7"]^WTY[T
M?B_X9_X*<?\ !0OQMJ.JZ;X7^/7Q4N;C0]2DTW6[?_AG#34DL;Q!\T+AIQAL
M\?A6]:?MW?\ !4O5)5M-$^)/Q?OIG^6.*V_9QTQG=O0 7&3]!7T!\#_V=O\
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M-?\ P\4G_P KZ^A?^%*_#7_H3K+_ +Y;_&C_ (4K\-?^A.LO^^6_QH ^>O\
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M.<GN#0!_+A_P_._X*[_])!?B'_X-5_\ B*/^'YW_  5W_P"D@OQ#_P#!JO\
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M5?WJ3_5#IT8XJG"#I+%3KOGNGR8?,J>MYI-_N<QA\2N[MQDK-O6;2?@UX?\
M@Y\/[S_@I=_P1XUN[L_"NEQSQ^.O"/B0J8Y](L(_M5ZNZ\\Z?=(8T4A&5U&0
MA4\53^'^C>"?VH+&Z_;0_P""7:3>$OCWX?CCU+XJ:?>;Y-.NI=4626Z\I]1\
MV/:CP76T1JH*R#A1L =JWPDO/V&?$$7[;G_!-GQ2WCSX*7,BV'CGP]8R-JDD
M.G0M]HU-G>7]W$I2+9OQD;AVX)XA\+^%I3:_\%$/^"3FKM>>-))&U'XK> ;=
MVU*YM'U5O.$1B \J)8F6Z5EQCC:N "1IR2A'DG'EY5>4(]%_S\HOHE>\DO\
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MF_$M=1N?%WB*^A^T7'BKQ!)]HNC(S$ML+#,2[N-H/&T#/%<S_P %B[J/3_\
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M)@,IYR<<<\U[)5?5K-+_ $NYLGB#^=;NFT@'.5(QS0!\Q_\ !&WQAXB\5?\
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M'6^JZQ-XB_:.\ C6[=+B'S(5NK;4M2>15:.(;$\I<C<2<]Z_8S]HD%O@'XZ
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M:*MO#K-Q$8_L=HMO'+B.UDSYW##. ,]3UKQ+_@Y2CD_X?-?&B1$./[6L.?\
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M5&NJ\\;*]-U%RT,S@G9QG>WU?&1=Z=_W4G)0=VVI.'P#X1^$+Z])_P %$O\
M@E1XOAM_%%K']KUC]G-IHH[TZ-;E+:>);73FGF;S;B*WG"M\A6;D@E146C_"
M3X.?MX^.?^&@OV*?BS8_ O\ :&TV>33)/A[K-U!I4M]JJ*TVJ7RI$T]T0T5U
M<QY\O)^SE7V8;&C<? _PY^Q\Z_\ !7;_ ()D^+/^$@^&=PPM=>^'RV;V!@T2
M/$5[NN]1>2X8->V:' @$G[P%247+1W?[+^G_ +3U@_\ P4X_X)->.6T'Q]IJ
MI#J_@2'3-[G7[D%M3<7FJ2)$-MMJ#?=B,9$'R<L5#]E+^'*DG-/G<$_B3_Y>
MTG=-/KRWMY=]99AAXR>,I8N=./)["G7K0;=&I:W]GYA!Q:=-?"JTXRO%R?.T
MGRT_%^K_  #_ ."DGB*.T^/.D2?L[?M&>'O+N9;GQ!%%IL>NWA58]-@#W4GV
MIV"+;D_N=P!^3?@4[X@W7P;_ &NM0L_V2O\ @I3;_P#"I_BMX%M1;6?Q>U2*
M*WM/$>CV):W1OM6H/%)(+FY>YG!6/8P4N&S5R\\%_ 7_ (+-6O\ PT=\ -4C
M^'?Q]\*QG5/$FAK;7.I_;A;9ATY!/.UM:Q,WDQ'<JOMW8D4@9HL/ WPD_P""
MQ4%O\#OCQKI^'/[2GPUB&A:]JDEK-JS:MI^FDQ7,A$1@LH2]_<3':KR,NP[2
MR,""<)8CX%&;JWY>BK1726W+4BMWIK^&-'$87+Y4G5E6PJP2:J1BG.IETY67
M/2UDZ^#JOI>HHQ<>ZN[QOXV\3_#O2+;]@#_@K1X1F\1:7J#?9O!OQTLX9;JT
MT^^OA\MQ]KOU@B"6T;%F9-S($SLP-QANO$O@K]C+P/;?LJ_M ^')OC1^S;XD
M;^T/ OQ1T>W^VV^EW%P6MH[?S6:.RC>*XCNY2BRL5$H.&)(#K#XH#]H.R7_@
MF)_P5B\.R:'\3K==O@7QM<7WVYH]1U ^79$VVF 0!420<RS[&V'<0?F$T<_P
MZ_92O;C_ ()&_P#!0JW'B#P'<32:U\-O'[+-%Y8G79!&+*PWR86Z-X29)AD@
MY549!2]I&53VBFK6Y%*7Q1?_ #[K)K5.VDM7HO>[G+;#K"5*3E4<O;U*-!OV
M=>FO^8_ 35N6JKIRHQ:5G->SLFE'X<\$^._^"<WAB[\8_!WQI%^T3^S'XDMY
MM(\6:3H5Q)J+:;"X\S4[IX+4?98P((Y(]\DRK^\VOMS4/P]\.Z?^R[=WG[;O
M_!,OQ7'\3/"_BR$W?Q"^"-NPFO\ 1+:^)DL;>6TTWS0!;))=H?-=2OEX!?YV
M5TVE?&;_ ((\:C)^SU^T!/)\1/V:_B!%_8-[J#-!IL=K)J'_ !_S""W,]Z[1
M6JS97*AQ]W::=/X)U;_@DE>0_MM_LYZR/B!\"?BUYDVL>'_(&EC2[*=]^E1&
M6=I[J8K#=SC(C0_N_P!Y@D W&,:<H*4'!4T^:+=Y46UO#^:F]VO>TZ(FM4_M
M"525.M'$RQKM1G91H9C%--TJ\?=6'Q<4KII4Y.=O>NTW5\"_"OX4>-?$+?M\
M?\$EOBE'H/B:RA.KZY\ KFZCM[^71+!E%S:+;6#3S.;J>TAVH2%?[2,LK;5H
MMO!7P-_X*"^.?^%M_ CQE;? /]I/0[F2WNO!NM7,.ERZUKS,9;N9 '>\X#3+
MN$0D!P2J9)JU=?LRS_LU7,?_  59_P""4GC5M=^'9D$FO>!4L18M!X=LL2:H
MK76I2-,Z//I^/DA\T>:"@95&77/P#\%_MTV4_P#P49_X)J>+O^$4^+'A^(:C
MXC\$V]@]RTWB"X8RS*MWJ,D-NI5)9!N6,Q$KG@D5G[&<8^QG33=^9P3TFMW5
MI/2S6ZCIZ&W]H85UI8ZGC9PIJ/L88FK"]2A-KE^I9A!KWJ4OX:K3C.RNU/1V
MKZO+\"O^"DOC5+[XD21_LY_M,>%[B*18];2'35U_5)2B:2B_:)/M;-''#:Y"
MQ @3_)O!1B?$'Q-X5^-<]E^P;_P56\.2>"_&6CJVF>$_CM<1@6<UO;'S[BX-
MYJ1@WK,\2QAT0JQFP2">+Q^'7P@_X+!Q']L/]EC5Q\._V@/!N_6O$7AV.WGU
M$ZA?0'R])C%U=&WM8R?L*?,D;!3)B0$K\T>GZC\/?^"J4,?[$O[:A/@7]H[P
M:#HVC>*6674S>O"?M%^S16GDV49*PLH!E?&_<A)&VB/-4YK6DZNL6_AK*UFI
M+[-1)66VIG&M1P=2G&I[2A#!)^UII.6)RR3>E6@[N5?!N7O-<U2*IR2MLW7\
M4>(_!7AOPY9?\$\/^"@GAZ34O!VW[+\'?VA+6,3V*VMWMECN/MEV\4&V*V>W
MC/D^9@Q8&Y0&,TVJ>+?^">G@'_A7?QQT@_M!?LK^,E$NFZYH?FZI'I-G;O\
MZ.6)$=G%)->2P_+YQ1O*^5F;Y:CTVX^&WQUMS_P2&_;WG71?B!X#F;2/A3\0
M)$FNFNWN.+23[)8[8446?V7B:=ACAV#AL26WBO6_V!IF_P"">7_!3K2&\5?
MGQ1(8_"/BQKC[.MK:V.9]Z6>GB:Z/F73VZ[7E##K\P#U3DJ<O;)J*MRJ3WB]
MO9U5LXIZ)N^EM>I,8RK48Y=*+JSD_;SPT=%B*?QK&Y?/>%=Q_>2I1E#53C[/
M>";X:\/:9_P3>\)WWB'X&^+8OVD/V=?%P>P^(UKHK#4&T6X55>]ED6T/V6/-
MH+=0TLB<G#;1AJ/AY\,]7_9[:?\ ;N_X)3_$Q/B!X?OF35_'WP)L[GS+ZQCO
MLKIU@]CIJRL3;"ZN697=?+^RG&X!R)#X&UC_ ((VW(_9V^/6H?\ "S/V>_C
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M%?H,?^"4G_!.,G<?V*?AB?KX$TW_ .,4G_#J+_@G#C'_  Q1\,?3!\":;_\
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MO_KT ?J-0WW37Y<_\15W[%?_ $07XL?^$U_]>@_\'5W[%8&?^%"?%C_PFO\
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MUI#%&3N*>] 'X-_#O_@C]_P<0^$?&%IK?CK]NCX@>*-)AW?:M&7XG-:&4E2
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M%VN0?$K]G'62OAZ\2.^_MF^CL956XNKDQP)#9HR75F\8E9BJ[@I&Y^*WC?\
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MDG_!)#]OO49O"?CKP=/+J'@WQSIUS#:VFHVX3S;>-KZ_!>3=<74Z;8XP"(L
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MW^$/B']BW_@H/;PS?"WXO^<;7QY\.G^V/97]U$EO<>8]R(V58[>!)?DMI>9
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MXM^!;>*P^%>L:1&!H>MSI;G3M(6>8+<3%)BZN[>3"=@)Q&?W9L:#K.I?L:_
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ME_L7P'?37%FRF\C_ 'FZ;YMQQSVX%?IMY_\ P12+*(_VR_VD"=W3^VO$//\
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MP=&/M986.&JJZDN?$9?-W5F]?;Y=)NSOJE*%]?BD^&_Q8UKXC^!=2_X)M_\
M!5_PK-H_C?4K6XG\!^/_ !I<'4GM]6U!?LUD%C@4K&4\UV#&95 !4E<YJC\%
M[OQC^ROKFJ?L@_\ !4B"XUWX/^((WL/AEXI\13BZTZUBTTR1030VMOYK(DR7
M%JP#NNP*@.XYQI?#[XPP_MH?"_4OV /^"FVC7VD?& 0W5[X!\2>-I!I2+JUT
MOV73HDM[?RFE96FW!61U91@ACC-#X*ZQXH\#3:M_P3V_X*V6M\? ,T0TWX4^
M(-?B&EZ5'_9.^!7AEA$4LZ2"2T*%F<[0N[!8TX5.9TZBFY:.*G+ST<,0NBZ*
M6]^Y.*HSI4L;A:M&-.\U5J4*+OS:JV+RN;N[?:G2O9QBUMM7^&MI^T7_ ,$J
MOB))\+_VAAJ7Q$_9IUZ+_A%4U7^T$ATF--0:.>\O!:PM<2'RD%^&3@OB3YQN
M7"ZI\/\ XY?L!?$]/VROV*-:NO'_ , =8NI/$^L>'_#=TFEV5K;3,Z6]G(KN
M\AVI)$0WDC& 2J\X;\'O$?[0W_!-7QO=?L=_MN:5J^O?L^^)+-O"-OJ,=NME
MI$<NJM'-/<B^*1S%$BEO=^),KM?;RBX<FF?M _\ !*KXT+\;?@)-=>*OV9_$
MVHR>(]0M?!MFMU9+ICYBMHIKNXC9D8*\9W!P']34:>PC'WHJF[?WZ+_]NI/S
M6RW[=E;V^,S&M+FP]:>+HNS2Y<+F,$M=$[X?,%>Z4;7J:6[R>/O@MXR^"/Q%
MM_V^/^"4GBR;Q%\(]4O(]3\6>#O!T?\ 9T=GI^D^6LT4PF<2R+,T=[]V$8RX
M"N6#&U\8O 6E_MU:=I_[=7_!.37(_"OQDT>$-XM\!Z!E-3DU"\?$SB\F:!7*
M0M/DJC!@6QM)!JAXS^&'Q1_8/^+<?[87_!-[4Y-<^ ?BF^@O/$FF^"$;4TM]
M*TOROMD=Q=7*2F,._P!N_>!P1AQD%5"V_C7\.%_: DTW_@IY_P $HKG^S_'F
MGJ9_&GA?2_,U35EU"_81G,+B6&,K \NY0H 7) !7-3.,?9U*;@]7S.$>G:I1
M>[_F<=5K8C#XJI/$8/'QQ$7:#I0Q-6*=[KE^IYK#;6WLHUDD[)2ZW3O%WPYM
M/VZ_A?I7Q.^#_B1/!_[57PLC9/&VD^7OU?6M0M@ME;DWCF&'S6^S>8-N\*)<
M'.T,;.DZ]X4_X*"?">3]@K]MQ8? ?QX\+[-.\,>-O%2MJEYJ#AS=WS918XHS
MY%LL;;ICD2+@D_*:7Q$^&<_[:7PYT7]LK]E^^CTW]I3X=Q^=\4-*D9KK6;K4
M+-5L8F%B \$;,UL[*BQJ"''!YK0-]X1_X*M?!^/]E']H\6_A/]I;P3''8:'J
M_C2[^SS7DTDOVB]V6=MM5F%M:LI#1G;D$!<$UMK*I):2=1)6>E.LK=7]BJMF
ME;5;')'_ &? TJCDZ<<)4;<HJ^)RZ;DW=+_F)P$F[I2NU2J6O=:TOAA/XJ^(
M/@K6/^"?W_!6N.ZT?Q]XA5K_ .%OC;QG/_:CVLMXBV4,42V^Y$V20SR;FF49
M9L[<[B?!WX@?$K]B37-5_8X_X*?>&[WQ5\#_ !45TKPCXM\077G:79:;I)E,
M$\-G;B9A%.7L J%E,?[O[^UC2_#WQ%XH_;*^%>L_L1?\%0K:ZT7XPR--J?PD
MU[QTBZ3L>ZBCM+:*.WM1$9R+B*X;YD<')')7 E^!WQ7\:?!:^U#_ ()P?\%=
MM'U2Z^%NM-#HG@?Q!K:KI.E6MKH@D<2QW$?E3RQ2/'IZHV]FRT98_,^<Z;_>
M4I<\DK<L927_ ))671/:+=GL[FN,HU*M'&X6K1ISU56IAZ#M=)IK%Y5/5W5N
M>I2=U[LD]'ID>#/ /QU_X)E_$>+P]\3M2OOB'^R[XHVZ/KEU:W$<&E(FILJW
M$S6L;3S,8(O-+*J@.,@;,YIU]X;_ &@_^"<7Q6;]KK]DK4K[Q]^SKK5Y)XIN
M]!\/7B:981QZAYD5I9RQLTLQ:));)M_E G"@JN&P?#31/CS_ ,$V_B(W[-'[
M48NO$G[-?C".31M4U33;%;;18VU7"-(UTR),JI$92^Q^!RI&W(-*D_:+_P""
M2_QF;XP?"2#4O%7[,?B*^N/%#Q^%;%9K%;&]+PV$$EY.C.'6/[(=WF , G+%
MFR75*E&_/",)[K6=)^6_-2?6Z:LONZ*E2MC\952J8?$RQ-)6NO9T,?%)Z/\
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MGQ9JTWF:3:1V6;N&>*SMS/(%DF6WC"DJ0S*26Z5)\)OB[KW[3OP[UC_@GO\
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MZ%2,$5-10!^4?[=?[+&G_L>?MX^"?VW?"MC=+9_:Y+.X:.=O)M$E>W;SG50
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MS^UXW[!/[97B"QU*?Q<QU/X>:QIL>81#B;S+5G;:Q9?+B_A/W^O-?H$C[^E
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MO^$6\)KW^7X_^*,^W;UK];/LZ_WC39;9=OWFZ=<T ?AG_P $4OV=_%?[,/\
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MD<FI^,O#-]=>3I=O-<,MC:Q+I=L8'=0;AR%?=L9=X(QS;^(WA2#]LGX5:/\
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M8D59Y?.0A0&92PN<.:I4IM-W7-RPVGU]K2\^\=SBP=1K!X+$*4;*<J$:M?\
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MOAGX:_;P^!5C^W+_ ,$]KZ]T?X\:38V<7C[1/AW,/#EN^H3KY^I/)+,(I)Y
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M_GV[0"3R?X#7M@M% VJ[#TPQ_P :/L:9/SMUR,G.#^- 'S+_ ,-[?'S;\_\
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MX>A^V6%D;6%;>*&XU=UN2F;^\N&!'ED,C18;!59_C/\ #&:]\+Z=_P %9?\
M@F!XECT_QE?VL<_CKP3X/M_^$HN[?4M3;SKSS?,,RVY1)2K1^0H7&0$'"Q?$
MW7]8_P"">FJZ3X@\+6O_  M+]E+XD*UY-X#O(_[;L]%CMU1Y(09LVMLS:C>.
MYVX#&#:?GC6KGQ.\%^*_@-\/[+_@H3_P2\\5FS\*>(K.VO?%WP?L[Q]0BM;[
M4!O>-]/MB;>,0Q,$VL,IL^7 &#?*DYTK64?>Y5\4&_\ EY2>J<6];75M?=Z'
M'AZDVL'BXR4IUVZ*K37[G%TUI]3QT/L8B*]QU7&=[0ES_:,_Q[XMU3_@HEX
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MJU]I6AV7F:=%%@VUE!+J\@NCG?.C*R,GF>6HPV6S73XNZY\#_B9)_P $^/\
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MHACF.)F&%;*#OP:O_%&:[_X)F^*K"2&9OC'^RCXX\YO^$+O)CX@M-,AM%41
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MHKZ.[CUG[)IRJ)X\!'\D6WEGIDY7!/M7BH_X/3/V-3R/V9O&0^NIP_TCI?\
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MBC_@YO\ C-K#> M4U+PVWPXT^VUS4=-ADD&E6[QV#&\F5%=BB\[F[5ROP_\
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M1;C]N#_@C%\2+[Q=I>ALVE>-/ ?B*W>%-Y07-Y<"2_>W0X@-NF%B<D%B&;)
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MX6_:"T'6;ZX_X)T?\%?O!\-]XRT5%M?#'BYV?5KN*^U'#0MNA^0>6DT(#$@
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M]NLZ+Z]M-ELJ-.>80I5W2CBI8E\KDFJ>'S""\F[4,R5DTI6G)J7NMO6[XO\
MA/H'A/2O^'HO_!(W6+JP\)Z&6_X3GP?#"-+M7TK35^UWB/Y[>;(LIB16103@
MDCD5')9^$/VU/#,/[7/_  2_L/\ A#?C9X0CCU#XHZ7H\9L8KV?5/WUUFZN"
MHD"/;W(R@W/O)X)&8_#?PJ'[,'A"X_;O_P""57CJZ^(WPEAAFL_'O@GQ):-:
MK%I=J@N=1F\R^>,LSK$L85+9F7S&(##*U5^'&A>%OB%/??MP?\$D=7O)/B=I
M\?\ :GQ8^&.H;_L4#ZH6E>*.>\%K;O';F.[51&D@*[=HB& ^E.-G&+2LTY.,
M7HW;^)AWT\X[O;=F-2HHPGBJ=2<O925*G6KQLXIM+ZGFT':ZLW&%:5E>UKV]
MW2\/Z]^SQ_P5Z\,-XV^$>EKX%_:GT&WF\6_:-#T]U^V2Z>3;V4!O)ML2AF.G
MON'*%1UV-3/ WQ2^#'[?<<_["/[>&A0Z/\?-#F_X1+PSXTM;.2_NFGMB7GF:
M9<1(YDB?V^?*^^;\/M#_ &>_^"B7B.;]IC]C;Q1=?#W]I;2;8^*[WX=V\,UQ
MI]U#IK+;V]DLS)9VR"XD2P9F+,J^8P9&P7"PZW\ _P#@I)X^?X(?M2FX^$_[
M2V@7+^'='N_#GF7-OJ>H1DO=7$@M(EAC9G69,-<XP00[8Q6<92J*+E*,G-Z]
M(5EWM]BJM>SO^&\J.'PM2M04,10AA%S).\L5EU1K>/VL1E[T4K1<5!-W5[NU
MX0^-WA+XI7]W_P $W/\ @K)X<BF^)FDR)HG@GQE(KZG>QZAK'S1R^9#^Z0QK
M+8[26V_(,X*D!$\>Z]_P3H\9-^PS_P %%-#M_&_P,\3R-)X9U+5IS=S6MC9
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M:.XT#QKX?F%U)>7,X$=G#)%I\,HVJCA]S3@< '8<XN?$>YU?]D*&S_X)Y_\
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M@G'XB@#Y?_X(_?\ (R_M/?\ 9S7B'_T&&OM8=*^*?^"/W_(R_M/?]G->(?\
MT&&OM8=* "BBB@#Y/_:C_P"4F7[/?_8O^)/_ $=IM?6%?)_[4?\ RDR_9[_[
M%_Q)_P"CM-KZPH *Q?'_ ($\-_$7PG?>$?%6F1WEG?0F.:&925/IG!'>MJCK
M0!^7OPEU3Q?_ ,$W_P!LF7X1ZU=2/X-U:UWZ3(MNL2!G0$IRI!+.AV*&/.[I
M7WS\9]1^&^M?"T^)/$WC*PTRS55N;'6+JZ")#)U5@=P['WXKS#_@I'^R&G[2
M/P@EO?"W^A^*-)D6ZTW4K6#=.K(#@+@C)Y(^;. 3CG!'RK_P30W_ +4>N_\
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MD?#KP;XH\2>(V^*/Q$MVBN9% TC2)BK?V;&<Y''&\Y&3UX[4 ?,UE_P;B_\
M!%V.RABN?V$_#DDBQ*LDG]K:C\S <G_CY[U)_P 0XO\ P14SG_A@WP[_ .#C
M4O\ Y)K[;0%5P:6@#XC/_!N1_P $53S_ ,,&^'/_  ;ZE_\ )-'_ !#D?\$5
MO^C#O#O_ (.-2_\ DFOMRB@#XC_XAQ_^"*O3_A@[P[_X.-2_^2:_,'_@X=_X
M)K_L.?L#?$K]FO6?V2OA7IOPMGU[XG10ZQXBL;J>;[-'');LLY%S*RCRR2_8
M'') K^AJOQI_X.K+&PU3XS?L?Z7JEG'<6UQ\9HH[B&:,.LB&2U!4J>""#@@T
M >G>;8Q+'(O_  <EQ+\N"VS1AYA]_P!Z,5](?\$Y)8FUKQ08/^"H0_:%#1VP
M%LK6/_$GR&^?_1W.=_OZ5[4W[&?[(3?NW_96^')S_>\$V!S_ .0JZ+X>_ SX
M,_"2>YN?A5\(_#'AE[S;]L?P_H-O9F?'3=Y2+NQVSTH Z9_-:)DC;G!VU\?_
M /!;B&2X_8<>%(FEV_$+PT/+5=VY1J=N>F#TZ].U?8@^1<5X'_P4.^)/C+X2
M_LVWGC;P/\"U^(U[:ZYIHD\,OI+WVZ%KI%>9841V=HEW2#"G&W/&,@ ^$?\
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MH]S:9[IY.FVS27]S%]X,T@@_A= 377X*^-_V$KK_ (:A_P""9WQ2D^,GPAE
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M3HX?#RITZDJV&A0CSR4+SJY;4EKS4K.7M\'5NY^XZBBG&]NNI!XBNO \3_\
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MZTN!:*N]=RM@XD;ICK7,?\';+PR?\$;/$T<.,CQIH9( _P"G@U[Y_P $+?\
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M.* "BBC<,9S0 44A=!_$*4'(R* "BBB@ HHH# ]#0 4CG"$D]J6FNP",2>U
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MYAIT6SR?M&^?B?EMP''3WKV8?\%3?@;C_DEOQ(_\)F/_ ./UP7_!(':WB?\
M:?Q_T<UXA^7L/EAK[3$:8^[0!\T_\/3?@;_T2WXD?^$S'_\ 'Z/^'IOP-_Z)
M;\2/_"9C_P#C]?2WEI_=H\M/[M 'PG\3O^"R_AKPM^TG\//AQX>^%_BQO#_B
M*PU.?6OMGAO_ $P/#+ L7DCS\$8DDW9_V:]6'_!4_P"!IX_X5;\2/_"9C_\
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MM8$DC\M@P"9).<@YKZ+=(3%T'3@;J /Y.O\ @X^_;)^-W[7_ ,4_ 6N_&O\
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MP4$GS> ,\GM7OVL7\6AZ/-K5Q',T=O%O:**/<Y'H!W-7FBC=MS+DT[:-NW%
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M2F_;BL[?4/@[XKU2\'AO7O&6_6+ZUT7$MKH[6R0R2101^?90E(C"/*=BVU
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M7BJQ_;[_ & +^XUKX,>-[5M8O-+U:^^S:)!<Z@3]GB33HI+>;:D3Q^660E,
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MG@K3S:WEY8V=N/LD<E_<AU2,WUZV4$R%6"MA1N)H_ /XDW/[=<M[_P $IO\
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M^SG)^S=^TKYGAS]JSP'"\>B3?$23_A'EOWO;IKDK!:0$23E=/MH@X:V.TLC
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MW[#_ ,%'/^CY/@__ ."^'_XS1]A_X*.?]'R?!_\ \%\/_P 9H ^PO-']UO\
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M/6N1\!_"_P#X*7:=XUTN_P#B-^T7X'U#0H;Q'U:QLM!V37$ /S(C>0-I([T
M?2?F+W% E4C.#^58/B^U\2W?@^^@\*ZC#:ZP]C(FFW-Q"S1PSLA"LR@9(#=L
M=*^<YOA+_P %8)),VW[4'P]"[CM5O#O1<G'_ "[\\;: /JKS%]_RH\Q?7]*^
M5S\(_P#@K#GY?VH_A[_X3O\ ]STG_"H_^"L7_1T?P]_\)W_[GH ^J?,7U_2C
MS%]?TKY6_P"%1_\ !6+_ *.C^'O_ (3O_P!STH^$?_!6#^+]J3X>_P#A._\
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M_P )W_[GH ^JO,7U_2CS%]?TKY6_X5'_ ,%8O^CH_A[_ .$[_P#<]'_"H_\
M@K%_T='\/?\ PG?_ +GH ^J?,7U_2@S*.H/7%?*C_"/_ (*RXP/VH_AYS_>\
M._GTM_2OH?X=:;XYTWP;IMG\2-6M;_7(;-8M2O+*/;'/+_$ZC VCGH10!T@E
M4C(-,EN(PC \<=Q7AOQZ\#?MU>)/&)O/V=_C1X3T'0_*0?8M:T<S2[@H!.XP
MMP3D]:R/A)\-_P#@HEI?Q%T_4?C)\??!6L>&XY&.H:;IN@F":7G^%_*6@#\T
MM*^-&L_L]_\ !T1\>/B!9>"+[7M(3X8Z<GB%;*%I9[.U:.P9YUC&"VTJ?H#6
MK_P5 L/A1^U-_P %6OAMX<N?&%O'X<\<>!=/TR'68U$R02W,FH00R85AN9)V
MC.W</F7DC!KJ/V<;Q9_^#I_]I"Q@O8K6ZO/@Q:V]D;Q05:4I8;3@@Y //T%>
M$_M;?L:_$[2O^"F?AWX >-?B1I(\0>,M/CNM%U;2T:UM=/O)_M7V51\BL@%S
M$KG@D[B 22,?*<8?\BR'N\W[R&CV>KT9^^?1TJ1H\;8JI*LZ*C@\2^>*O*%H
M+WDNKC\5NMK'L7@[XT>._P!@SXEW'_!/C]NWPHGB+X/^(]0&F:'XF\43&".U
MT. %!);Q0ASY9(1L%@1R,TWQSXK^*O\ P1B\<K\1O@C:2?$?X#_$?3O[3T2"
MY866F6VIZA(TL:P[/,D9TLK- K-@,CG."M7OA1^T!HL.I7'_  2V_P""E/@)
M=4;[8/"WAGX@65C';^19Q$K).;Z[/F,KN@;S O3&<DBJL7QA\0_\$DOB)??L
M]_M->&(_BK\&?$5O+XC\(W-E8C49+66>7[/:1?:KLI&"EK:.2D?_ #U#+PQ%
M?/*2IT[JJXJ#LIM7G1;^Q-?:@_LN[T9^Q2PM2MC/JTL%"K6KTU*I0BVJ&84U
M\.*PS5G1Q$;>]&*BFT]-6@^)>C>*/^":GB;3?VZ_V(7F\7?!'Q7YFH>)?#T,
M*VFEVX8?8K*!I6W2N/.NBR84'>BCH6S-\1_!!\7^%-'_ ."KG_!-6=K?Q(Z6
MT/Q:\%>&8\0Q3NAU35&FGG(8C+V\;[4(*[2#D8$.KZ[XN_X)$_$Z$2P1_$K]
MG'Q\TE\NDQ0MJ\EI:6RF.U1IIMMM"YN9T8XR&\L ?, :D^)VC:]^R'J6B_\
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MT;QMJUP;C4AKDLBRVB>2FU _V&\E"L7QL3GEJ;\,_P!IK5_V<_&!_P"":?\
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M$UT\M^FKW#+'8KY< V9$5\P4[]I"X.-W%6Q^+'Q)_P"":7Q*N/V%/VL/#_\
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M^[GN+2QN_ L%PRR3$F0[W3)!)^Z>!7I7_##'_!:+_I*AX>_\-S;?_&Z^^J*
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M\7/^"8W_  5P^.'PM\0?!OXB_P#!4'0[K0/%&DS:;K%M#\/;>-Y+>5=KJ'"
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MC!/!_C+[8;7[/IUC\\++:Z4)+HA[A(1^\EWKSNRI(J>:48NLJB6ME4EO!_\
M/NLO/2*=K)6^9##/ZU3PDL-*4HQ=2>&HR]RLDK_7,IFK)22M6E3AR-MR7=*O
M\4OB#XE_X)\:-X>%W;6?B[]E/XR(MUI?P]US=/J^D6$\:7MW!''&UO#"_FW+
M*H,LP"J 6)YK0\8:#KW[&/P1M_\ @IS_ ,$R-;_L?X<^((TOO&GPS\;2++"S
M2S+8V4,<%HH)2-[F63#7600I#-C;4*?$>?\ 80=?V=_VAO#[>+OV1/BK(Q\
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M4IM#\>_#^\\%?M%6&F2^(H_'?A=4L]-N#9.L%C YN);I]G[VV+A8@286*NN
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MDC2UABTU@=/96L+/]ZX%R(I]C$@G]X.<59U_]G?X7?M8Z6O[;/\ P3 \?R^
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MF?XH'P+_ &EK*/XM_LP>,I&?1[S4F;7/L%I:*S0>5"&%M 7O)+?*XV_)E<,
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MX>/_ +2?_2*3XU?]\67_ ,<H-#Z]ILFW;\]?(G_#Q_\ :3_Z12?&K_OBR_\
MCE(W_!1_]I$?>_X)2?&S'^RMG_\ '* /J7PKJO@+6&U&'P5J.EW#6>H20:LF
MF31L8;H<.DH0_+(.X;##O6R.!@5^3'_!,;]N+XX>!=;_ &@I- _X)T?%;7O[
M6^/^MWUTNEK:YT^9UBW6LNYQB1<#.,C!%?5(_P""C_[29&?^'4GQJ_[XLO\
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M.4 ?7M%?(7_#Q_\ :3_Z12?&K_OBR_\ CE'_  \?_:3_ .D4GQJ_[XLO_CE
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M_#'_ &H/VH?BC\!-2TVS\!_LA^//B3'?+*9I_"*0;;/8%P)/-8?>W'&/[IH
M]JHKY"/_  4?_:2R=O\ P2F^-1^8C.RRY]_]91_P\?\ VD_^D4GQJ_[XLO\
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M?[$7Q$^'-G#I[7":UXK6V%O*X8 0KY;EMY!R.,8!YH ][#J1D,*7('4UY_\
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M;BME@>_WZ^F/AMXQU7QUX#TSQ?K/@C4/#]U?VJ33Z+JQ3[1:,?X)-A(R.^*
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M_"8?L^^-E;3?#/B/1)H;=K99'%S?2^5 'NV"R7&S:Q4DK\GRD"J_ASPK8?\
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M^,M)F"HNFV8,%DWDZ<KS-O:+)\Q@XW88$9Q%K>B>'?\ @J3\,;+]DOX[7[>
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MJ;/6O!MQ&\-]%HB%8[TM-J&YVS?6:@;4\S#KM.P-F+3OV8Y_CYXA_P"'F_\
MP2,\9PZ?XHT^:2/4O!NKV[R7"^(+I&DU'9/J#+ 56UOP!A3$?+;9AF!#M$^
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M:P*B26;KYI?:A9 P'.+WQ=_9]\-_M>^*+;_@J3_P3O\ &EC=>+M#E;Q1XP\
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M^U=?ZE<WUE_P4W\16D,UP\D-JGPQT9EA4L2$!*Y( XR>>* /YMS\7/\ @XK
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MW9VLA^=C]V% O1E7Z(* /YQ#_P %9?\ @Z:3F6P^*WW<_P#)'X?_ )!IJ_\
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M9K7:%)93QS\@KQK_ (7_ .!_^DN7Q._\1TB_^1* /-'_ .#DK_@K(./^'/\
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M:>^UR2\6S$1OF^%&HK))($QYQ3['@$GYMO3/% 'P2O\ P<E?\%8]@9O^"/\
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MXD6Y2[73;=[I(B-0B\@,57]ZV[<6P*B^&?A']I+]@CXG_P#"]OV3-7U;XZ?
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METW2[3PUX;N;6\ETW[1=*UW(QBE$;JD(S&0I_*OJCQ3\"_\ @BO\4M'MM5^
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M(/A'\=M)\5?%3X,ZQ9QV%KH?BX17#:9#"S30R)ID]Q):*[3^4&590 %W LP
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M0QJK8097 #=#G-?8OP1\!_L=?M2_"BQ_9@^''_!1_P 26MKJDUNMUH7A_P"
M=M EGJ2PI)EIH+9=DH3 \PMDJ0<\UKEW">)P.,IU9XKFC!MI<EM7OKS.R\CS
M.+_'K(^)>&\;EN&R7V%7%4Z=.57ZQ*;<:<U.+G#V2C*:=[R?O/K)GA'_  36
M\*>!O"'_  7B_9_7P#K^AZY'JECXDOK[Q!X?L&MX]0EE^W2'=N W,A^3(_NX
M.#Q7]*$ :09)7I7\V?PN_P"";'[6O[&W_!<;X#_L?>)_VM6M;S_A&]6N_ _C
M7P]H-O)<66GM]N=D>.7[\CL'+%LX+\5^RUM^P5^W>MNH7_@KAXY7Y1A5\ :3
M@<?2OM-S^:G\3L?6SQ[/]4I_X"V**\?_ &:?V?OC[\&+;5$^,G[76N_%!K]H
MS9R:UX=L[,V(7=D+Y&,YR.OI10![11110 4V7_5M]*=39?\ 5M]* /BO_@C]
M_P C+^T]_P!G->(?_08:^UATKXI_X(_?\C+^T]_V<UXA_P#08:^UATH ****
M /SA_P""O7[/NN?M!_\ !1[]CB32M8CL%\#^+M0\5WSS1AA+;V<UB7C'S*0S
M<8(!QGH:];U'_@N[_P $P-$U2XTG4OVD8TGMIFBF0>&=4.UAC(S]FY_E6G^U
M(/\ C9C^SV,?\P#Q)_Z.TVOJ0^']!8[FT2S/_;LO^% 'DOP%_;W_ &9/VFOA
MCK'QB^"WQ(CU?P[H/G#5M0_LRZA%OY4?F/E)8T=L(0?E5L]N>*\9B_X+]?\
M!+&>)9(?VE5^;HQ\+ZI_\C5]C6^FZ?:1F*TL(8E;[RQQ!0?R%0CP[X?' T*S
MX_Z=4_PH ^?_ (1_\%5?V)OCIX,\2?$#X9?&*._TKPC:BXU^Y;1KV/[-&2H#
M;7A5GY<?=!..>U<#_P /]?\ @EGLW']I5!QGGPOJO'YVHK[!AT;1[>)H(-)M
MHT<8=$MU 8>XQSTIG_".^'_^@%9_^ J?X4 > ^&/^"J7[$WC+X":Q^TWX<^,
M*7'@K0-16QU76#HM\GDSEXU""-H0[<RIRJD<UY__ ,/]/^"6FUB?VDU!'8^%
M]4_^1J^P5T?2$@:U32K81LVYHQ NTG(.<8ZY4?D/2F?\(]H'3^PK/_P%3_"@
M#P'_ (>G_L4#]GL_M4-\98_^$%&I_P!GMK7]AWW%SE!Y?E^3YF<R+SLQSUKS
MV7_@OM_P2U5"5_:5C_'POJG_ ,C5]A_V/I'D_9_[*MO+_P">?D+M[=L>P_(4
MS_A'?#XY_L*S_P# 5/\ "@#Y_P#&O_!5?]A_X>_"'0OCOXL^,\=MX6\2,RZ1
MJ7]BWK^;M6)B"BPEU($T?51G=]:\_D_X+\?\$LDC,@_:50\<?\4SJG/_ )+5
M]B/I.E21QPR:9;LL0Q&K0KA.G3CCH/R%1_\ ".^'\Y_L*S_\!4_PH _+WX#_
M /!47]B;X _\%"?VA?B/\4?C*FGZ/X\A\,:AX5O!HE]*M[;_ -EQG?B.!F3A
MUX<*>>G%?0]M_P %ZO\ @E[=W<=G!^TBC--(L:?\4OJGWF.!G_1NF2/I53]B
M?2M*NO\ @I]^UFMUIMO)LOO"X020J=H_LP<#(XK[&_X1[0 <C0[/_P !4_PH
M ^??C9_P5;_8@_9XM] N_B[\98])C\3::M_HY;1+^4W-NT<<BN/*@;;\LJ'#
M8/)'4&N/\/?\%UO^"9/BKQ%8>%= _:*6XOM3O([6RMU\-:F&EFD<*B\VV!DG
MJ3@5]:S:/I%R%%QI5M)L7"[X%.T>@R*8OA_04(9-$LU(.01;+P?RH \8_:G_
M ."C/[)/[%^M6'A_]HSXIKX?NM2M_/LXVT>\N!)&2P!S#$X'*,.2.E>?>!?^
M"WG_  3:^)7C+2_ '@O]H2.[U76-0ALM/M?^$<U)/-FE<1HN6M@HRS#DD #D
MD5]67&DZ5=R>;=Z9;RMC&Z2%6..>.1[G\S3$T#0HG$D>BVBLIRK+;*"/TH \
M$_:9_P""I/[%/['WQ!B^%O[0OQ>&@:Y-IT=]'8MHUY<9@=F57W00NO)1N,YX
MK,^ /_!7?]@G]I[XIZ?\&/@I\<X=9\1ZHLK66GKH=_#O$:%V^>:!$! '3/)X
M&:^D;K2-*O9/.O=+MYGQC=+"K''U(I(-&T>UD$UMI-M&X& T=NH(_(4 ?.G[
M0'_!6W]A#]EWXD3?"7XW_&^+1]>MX!++8C1+^8A2Q7.Z*!E^\I'6G?LY_P#!
M6?\ 85_:P^*MO\%O@/\ &N/6_$=S9RW46G_V)?0$Q1@%VW30(O /KFOHFXT?
M2+M_,NM*MI&_O20*Q_4>Y_.D@T71[63S;;2;6-MI&Z.W53@]1P* /F'XK_\
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M4T>GZ?#"UO%8PK&V=T:Q *<]>* /CO\ X?[?\$LMF_\ X:7CQC.[_A&-4_\
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MFF1Z#H<+B6'1[5&7[K);J".<^GK0!^6'[1OC>/\ 9.^(J_"3]H#_ (+C>*-
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M09-,A7$,FH:)=RR1+M50J_\ $U&U0$ "CH#Q69XW_P""4/\ P6W\:?%3P_\
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M9\/;BP\2^$9?"]M+;W^GQ"4QQQR!B%5D(SAW&" <<&OH'X8?\$U_^"[OP?T
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M ,%$_$7ABZ\(-+:^(_!D_@NTN!;^8H5F63?M=&9& P3@J<DUT'CO]A_]O/\
M8;TW1K/PO_P46\477PR_M#&MZE_PB=JT^AQ/*/WFT3Y,(9CPB$@9Y'6LCQI_
MP2R_X+B>-/'VA_%&]_;N\,V^N>'YFDM;RQ\-W,33Y_@E;^U"70<X7/4FNMOO
MV&?^"^FMZ/<:'K'[=OA"6VNHFCN(9O"]W(LBGJ#NU8@CV.: .I\;_P#!)O\
M:*^/=AHGQ>L?^"IGB>\OM-S?>%]7L/ ]I!)N)^52YEW>60 K D''<=:\*\0?
M\$P/C3^WO\4]%^"_[:/_  4/\06OQ ^%>N_\)#X=T_2_!MOY$FV13%<AB[B0
M;5CW1^8V#GL<5U'PJ_X)G?\ !=GX*Z;=^'O ?[>GAJ'3KJZ>>.S?P[<F*W+,
M25B4:HHC7YC\H&*K?%O_ ()9_P#!<CXQ+IMWXH_;O\,1ZAH^H1WFGZE9>&;A
M+A67_EGYC:FQ$;<;@.N!TQ0!T_Q2_P""=W[>W['N@7WQ%^"W_!0SQ/JVD7VK
M&[\5:6?"EK''I\&"TMS;1"8*H'+. K,QZ8Z5YG^WK^Q1\?/C;X.^ NH0?\%+
MO%OB+2?%7QCTRUTC5M-\)6]A-IDK+-BZ1O,W,T>TC:00V>>U>I1?L4_\' [Q
M[KO]OKPD/EVM&WAJ[==OXZM7RM^T7_P32_X*Q?L]_$GX8>(-1_;*T6:?Q7\9
MM(BT+3[/09X[/3M4VR>7<K%_:#!1@,6 *[L_>[$ ];^//_!-#X_?M?:Q)^PK
M^W]_P41\116MQJ<&J^$QI_A&WV:LL1(A<L9'PX)E+!F!.W@"NU^+W_!);]NK
M]DOPYK_Q\_8\_;S\3:EXDGM;:'4/#*>%;.SM;N&-4C:8()E'GA(T^8YRH("^
ME#XO?\$Q?^"X7QV\+MX7\>?MR^#;B/<KVM['X3N!<6SJ<AXY&U1F0@YZ<\UT
M^E?L2?\ !P)INEV]DO[>WA/%K'&BF7PW=L7"K@%C_:O4^N/PH ^1O@7X]U7X
MC?\ !PS^S#XM\0?M1:C\4+JX\#ZLMY/J>D_8YM&G$%\'LV7HV&!;<!@YK]^8
M8U:)<C^$#]*_)W]E/_@B-^VKX4_X*>>!_P#@H5^TU\>O"^O77A>PN;6ZM]#\
M,_97N%D@EC#,SWDQ+ R?>QDCM7ZR0*R1 -U]Z  0(#G)HI]% !1110 4V7_5
MM]*<2!U--E93&0&[4 ?%?_!'[_D9?VGO^SFO$/\ Z##7VL.E?$?_  2*O;:R
MUS]J&[NKA8XD_:8\0EI&;@#$/-?;%M/#<V\=Q!(K)(@9&7N".#0!)1110!\G
M_M1_\I,OV>_^Q?\ $G_H[3:^L*^3?VHG5O\ @IE^SWM8<>'_ !)G_O\ :;7U
MED'H: "BBB@ HHHH **** "BBB@ HHHS0!\:_L0_\I0OVM?^O[PO_P"FP5]E
M5\8_L3-C_@J#^UL0W2^\+YY_ZA@KZ^TK7M+UEYETO4$G-O(8YA&2=K X(^M
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M040G)6EW#UHW#UH 1U+# .*3RQV8CZ4[</6C</6@ QQ@TWRU["G;AZT;AZT
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M )Q+^)1_W.5C7VL>P_ST-.7K_P !H ^*/^'B/_!1/_I$SXF_\+*QH_X>(_\
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M_AXC_P %$_\ I$SXF_\ "RL:^V:* /B;_AXC_P %$_\ I$SXF_\ "RL:1_\
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M+_I%%XF_\+.P_P :/^'B/_!1+_I%%XF_\+.P_P :^VJ* /B7_AXC_P %$O\
MI%%XF_\ "SL/\:/^'B/_  42_P"D47B;_P +.P_QK[:HH ^)?^'B/_!1+_I%
M%XF_\+.P_P :/^'B/_!1+_I%%XF_\+.P_P :^VJ* /B7_AXC_P %$O\ I%%X
MF_\ "SL/\:/^'B/_  42_P"D47B;_P +.P_QK[:HH ^)?^'B/_!1+_I%%XF_
M\+.P_P :/^'B/_!1+_I%%XF_\+.P_P :^VJ* /B7_AXC_P %$O\ I%%XF_\
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4?ZS</6I*:@ / [4Z@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gvgjwefnhf2j000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvgjwefnhf2j000019.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" ;>!-(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$7QJ_P"#7;_@DU\?/C'XL^.OQ&\"^,9-?\:>);[7==FM?&D\,3WEY</<3%$
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M;92ZX))XZY%<G_PZZ_X-HO\ I(U=?^%Q:?\ R-7V[\1_CK\6],^(>O:;I_\
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M ,&Z?ACXA>$?^"+7P%TSXGQ74>I2>&;N[MUNF)?[!<:G=SV'7^'[)+;[1V7
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M-X/2D#J1D4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB223DU^&&L:SJOB#5KC7-=U.XOKR[F:6ZN[J8O)-(QR79B22Q/)))S7[@?\
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M/_ACWX$V'@G_ (2W[&/$7V'4+N?[9]E\_P"S[OM$TF-GVF;&W&?,.<X&/<:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS_PP3_BVWA\@_P#,%M/_ $2M=!0 4444 %%%% !1110 4444 %%%% !1110
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MAU\6/#D7AG5KJ2WNYO#_ (V#3QQW,K1_9QIFLH5E@,>IWI:+RY-\ERI5(@A
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MA6_E6UT%HI[9?L,-N6=<F/6(H&FW!V72X=P/2/\ 9V@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *&;%%>3^+?'GQI^)/BC
M7/A_^S])H>AIX?:*#4?&_BC39=1M!?EHI&LH+&"YMI+@K;LWF3&>)(GFA5/M
M#K<1P 'K&:*\;U+QM\?_ (!> ;WXA_&O7?#?CBQTRX:YUZ[\(>&Y]$?3-+"K
MYEPMM<7MY]J,/[R:0+-&[0HPBCEE"12^P1W*31+-#(K*PRK+R&'8\=C0!)11
M10 4444 %>"?\%5?^47W[2'_ &03QA_Z9+NO>Z\#_P""JN?^'7W[2 _ZH+XP
M_P#3)=T >]1_<%.IL?W!3J "BBB@ HHHH **":* (;EY%A9XQ\P^[7R5X%_X
M*D>$O"OC?XC?!W]M3PT/ACXF\!Z;J6NQQSR/<VNM>'K:*6X:_LY%3=.4MXG9
MHU4N?+<A04ECB^N2@/6O)_C[X(\*>,/B)\.XYOAS::IJL/B5KM?$,5Q;PWWA
MVSMX7GDN8C(K.\4T\=I831Q88QZ@<G:&K&K&LW%TY6L]5W7;R\CTL#B,OIT:
MU/%4N;FC[LD[.,EL^S3VDGK9W3NCP[P_X<_:I^%WB'2_ .D66C>*K[PKI%IX
MRURYA0RXUK4[W6A?BTLI)+7"S^;=E99+YXX2D:):JIW#Q;]M+]I7_AJS]M+X
M0_LGZSX.70[GX>>*-1\>:QHGBZSO;+3YKBRO/[+\*WJW<PM&NV;6[C3XGM;=
M;BVE%\0ES+Y*._W#^S7:6_B*U\4?&U[[79!XV\57$]C;:Y.LD=I8VBIIML+$
M@?)87"69U&-<D,^IS2@_OL#X-\.7OQT_:)_;+\<?M6^#?BE\1?#]]-X@UWPG
M\*;?P/XLF\2>"Y].LUBT&UU?4+.&X:W,S:CK#7YMFA @'AV_9\O$\E;'FGV_
M^Q-X"\.>$_@[_;W@S5Q=Z%XBO(KOPRUOKTNI6JZ/;V=KINF202R@-MFL+"TN
M9!R//N9R&?.]O5/$?A+P[XNTN31/$^CV]]9S8\RVNH0Z$@Y!P>X(!!Z@@$8-
M'A/P[HGA+POI_A7PYH5II>GZ78QVNGZ;I]ND4%I!&H2.&)$ 5(U4!550
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MGAVQ\3R>&]6\/QP^*["+5[Z[BMXKO29)_.'V>/3_  1#*SI$@32;ZX9Q)&J
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M3 [RWL[?:$E3=:P[[E%D90 ?H<([G;DS_P#CM.\NX_Y[_P#CM?+OP$_X*L_
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M'5QU^)NO?]_8/_C5;&B:;<Z78"RNM5GO&5B1<7&WS&&<C)4 9_ 5>P#U%&*
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MG,Q^T2))<W<DEQP7>X8#<J*[??- !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<5^T5X@^#WA3
M]GSQUXI_:&MK.3P#IO@W5+KQQ'J6FM>6[Z/':2O>++;JCM/&;=9-T01RXRH5
MLX/:UP?[3GP4M/VE?V:_B%^SCJ.OR:5;?$#P3J_AJ?5(K<3/9I?6<MJ9@A90
MY02EMI(R1C(ZT =Q; K%@U)4<'"X# C^'%24 %%%% !1110 4444 >6?M+ZI
MI^L0>%_@SJ%AK4D7C3Q1;V^H76DPJ\%I8VJOJ%Q_:!+#987*69TYVPP:34H(
MB,39%OX!ZU_PG%YXP^)"ZU)>6UYXOO-*TJ&\\.BPN-.MM+D;39;9F+%KJ)K^
MVU&ZBG(4-%>H%4J [^)_M:?#/PO^TEXF\?:_K+:/K"?#WPS#X8\&Z)<76Q3X
MKU$0WCVU_#=+)8W,<HD\-_9S/#)Y,DDT@VL498O!O@SQ+\.?B/XX\/:5^U%X
MAN]!TWQ/X<TRST[09EFU:#7[B"&2ZL;PWQN8O*-M/I]TJ6L5JD5O<RDJ=@D
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M^TM(UO3->LUU'1=3@NH&D=!+;S!UW(Y1UR.ZLI4CJ&!!P010!<HHHH ****
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MQLB7 &0HZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1>*O"?C&;0;^W^,_CK_A67AJ.&WO89[[2+*SNCJ]C<R(%,5U";3Q5)%,I6+
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M#_:<_9.U\Z_^QQ\6-0TB.[C2,:7;QO?Z3<7Q18$NKRQGEW0QO=ZGJVISFWD
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MS$MMMO<2Q1L #[USGI17P_X5_P""MOB3X8W?B2]_;#^!-WI/@C1=5N&7XK>
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MVC?V.OBQ^SSX3U*SLM5\>?#37?#NFWFH,X@@N+W3Y[:-Y"BLP0-*I;:K' .
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M?M2S3),&2*5I=\9! -;_ ()%>)_VKO@S^TM??\$^/VT9[S6O''@OX9S:E/\
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MVC4=)CNY$L[F3_B>Q?/) (W/[M.6/RKT'(?\-_\ _!WM_P!(FO@W_P!]2?\
MS0T ?:G[$?[;?Q?_ &@?^"D'[77[*_CB+3E\-_!/4O!]OX/:UM=L[+J6GW=Q
M<><V?G^>%<>@S7U[7YD_\$%_@I_P4;TC]J3]JK]K3_@HY^SCI_PY\1_&"\\'
MW%C9Z/>126<[V%MJ5O,(D6ZN)(PBO;D^8Y),O!(&!^FU !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;!'.23N=+97/;<3C P*[BO)_V,/^20:Q_P!E6\=_^I9JU>L4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %!.!DT4V0%HF51GY: '9'K1
MN'K7Y1?M"_\ !$3_ (*M_%7X_>./BA\/O^"RFO>%_#_B;QAJ>J:'X:@T^=DT
MBSN+N26&T4B3!$4;K&,#&%KAM6_X(.?\%>="T^XU;6O^"[VO6MG:PM-=75U9
MSQQPQJ"S.[-* J@ DDG  S0!]+?\$TOBA\2_%W_!8;]O[P!XL^(>N:IH/A?6
MOA^GAG1=0U::>STA9]*OWF6VA=BD D<*SA NYE!;) K] *_+O_@WN_9T\$?
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M3^"=0CTS4]26R2?^T?#-_/$FI64J-(F^./;#J"E2TBR:< @(ED1^W\(_LB_
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MWQ'EU734:3,4\MM)YPAA2=V =4.UC'&O\(% 'PKX+_X*$Z)_P5"_X*$?L?\
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M ,% =5&H>/K;XE:9J/@W4_#:W%BRW$]]YT%I:I:C*V;V-U9*Z1A(/*:_M_\
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M-WBB'7OB1^T#XPU35-4U&.SMHPEM%?SQ2.K0Q*2;F[CFNFVNT+(T+1HA:4R
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M$1T2\O\ 4_B1X'T.2[@O;O1H39JVMK-87<%XMMI\TL*3K$MQ&8]3+RP.(59
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M** .7^,C2)\)/%$L;,&7P[?%6'!!%N_2NHKF?C.1_P *A\5?]BW??^D[UTU
M!1110!Q_P;\+>!/"/A2\TWX<:['J6GS^*-;O;FXAO$F5+ZYU2ZGO(MR< QW4
ML\93JAC*-\RFNPKR7]B]%3X0:P%7_FJGCH?EXLU:O6J "BBB@ HHHH ****
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MF%C%)%%']ES;9AG$*"XC*7 &9B2 ?0L%Q%<1B6%PRL,JRG.1ZT^HTC,8VHN
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M\0^(+R+PGI%BW N+.UNC=6<5W+:P9C.J2/,AE7=Y?DVAF41B6WW_ *&_"O\
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MG@/3(Q+J>@ZY<2:QHATVW(9;>W@/^E:6\=A81V\;(98(S<L,2,0U>C_LT_\
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M#_LX?#GPMJ-U9>4NM>$?"-C8S36TFURGG6\2LT;;4;;DJ2JGL#7I= !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)O7UH 6BF^8O6G4
M%%%% !1110 5Y?\ MH>%OB[XX_8[^+'@SX 7EY;^/-6^&NO67@FXTW4OL5Q'
MK$NGS)9M%<%T$$@G:,K+N78P#;EQD>H5Y7^W!\7?%O[//[%GQ?\ C_X"BM'U
MWP/\+_$'B#1EOH3) UW9Z;/<1"10REDWQKN4,"1D CK0!Z?; K'C9MJ6F0AO
M+RYR>?YT^@ HHHH CE=A$Q4<A:_,N#QMX=^/G_!1/XR_'73KJ^\=ZQX2TIM
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M-KXW\3:1&+:,JOD6&NWUC!D$GYO)MH]QSRVX@ ' [R@ HHHH **** "BBB@
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M(G_":?VWPH_M1K#[%]D\GKE?,\[S>^W9_%7T=0 4444 %%%% !1110 4444
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M@=\#O!7PCG^(TFK_ /"*^&;'2IKN'1[:R@O'@MTB,R01)B!692XB5BJ9"C(
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MRVXV\<39/H=ZMTH U*,UC_\ "/:__P!#UJ'_ (#VW_QJAO#WB#;@>.M0_P#
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M *))K9Z>NGW=:O[+D:M\,]43M_PL;QA_ZDFI5\E_M,_%KXBW'PC^,FN>)?V
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MK&#CT^10/TS[T :E%8QT+7%'/CK4/_ >V_\ C5+_ ,(]K_\ T/6H?^ ]M_\
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M5UWXT^)/A]\9?V._V>=>\1_&KPC=6_B6/XD:DLK6T=NFI6&I,NH:2RM,;/\
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MK)_X1[7_ /H>M0_\![;_ .-5>TVPNK. 17FIR73C.9ID16;DGG8 O P. .E
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M3BD9K74/&MY:;;92T#JJ6MA;6MH622 .D[PM<*9)%$H1M@],"D4ZB@ HHHH
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ME!2Y^R?*2XQ]GPV^R)4Z8&* )J*** /-?VH-:>T^&L7A2RO;2&Z\4:U:Z/\
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M_N?!6CW_ (FNHIK+3))W:WA=%TYPK+&54@,P![FN#_X=]?\ !WI_TD;^&_\
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M?ACX1U"]G_M#4?$P=9YM?T._N$5%LXML"M&D;/,Q3?(QJWX?_9Z^%W_!+O\
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M'5I>Z;#-J&O7/_%-6@DM6^U)>LYBMG@MA+#''%$;V[FGCE#+Y=W=Q<)^S?\
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M).0![UJ_A+PUKMS:WVKZ%9W-Q8LS6-Q<6J/);$XR8V(RA.T9(QT'I7E_C_\
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M ++^N?LMZ3K&MV^D^(M'U>TU#5Y]4>?4GFU(SO=7C7#'>T[2W,DF\GAB,8
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M7PW?Q]?S6'A>'QMJ">+M81&\G3=-N/"VO6CW$\H!%O"'N$5IWVI&'W,R@$@
MUO\ @F./^-;7[/?/_-#_  G_ .F>UKW&OCS]@#]LO]G7X9?#+P-^P)\1?BEI
M6F?$;X9^#]*\+ZA932LMOJ#V%M9V#7=O*P \A[F2*!&E\LR2NJQAU>)Y/L 2
MCT[XH Y?X2>$/"7@CPQ=:)X,NFFLYO$FL:C+(]PLI%W>:G<W=TN5X 6XFF4+
MU4#:<D$UU=<)^S]\.M9^%G@>_P##.N30R377C3Q)J\;P9VB'4-;O;^)>>XCN
M44_[0.,CFN[H :81Z]:/+'<TZB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'\(_"'X=:_\ %CX@ZF;'0?#&BW6K:W?+;R3&WL[:%III/+C5G?:B,=JJ6.,
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M=72'[4]VULD2W8DN);FY"3*ZP27++ (88X8HG^/O^"=/[*7Q+^.5Q^T=XM\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6TQ+BTN&N[16MW=]4M]LJ"4;!(=FY )/G+_@JS9?\%B?C!^R-JGP=^('P3^
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M&C8J<J2* /H?XB?"B'QA\;/$7Q-L?B1X9CM-8L_A_#!#-J>)%.@^([_5+DL
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MN'@?_P ):T_^-T?\,C?LK_\ 1N'@?_PEK7_XW0!UW_"=^"O^AQTG_P &$?\
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M5?'6H7,UUX7/@J*VFN=)70]=NOM4-Q%<R!3%>:9;HZD<K<+_ 'L@ ^V****
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M:>T&S\.>,_AE?MX-_:$\0>(O&\^F>'=-U2"_01W]G/IEK-;W#WWV2XVI=O!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M32Q<2:;!X4UN]U1EAUGSH87_ +6DE73F5;&[EM;*'[!OEF N6V@'[H02QL@
M?H!UK\XOVLU4_P#!R-^R^P'_ #3G5O\ TV^)*N_M/_M5?L,?LX_'SXE:M^WE
M^TM\7O#!U3XBKIW@NQ\)>,O&B6<5G:^%O#%Q<(MOH4ODP 7&J>86=5,C7#8+
M$''(?%OPGX?\#?\ !P'^R;X:\):KK5]IT/PTUF2SNO$7B"]U2\D66P\32_O+
MJ]EEGDP7(&]V*J%0850H /U#HHHH **** "N=\0?%3X:^$_%&C>!O%/Q%T/3
M=:\2?:?^$>TB_P!6AANM3^SQB2X^SQ,P>?RD(=]@;8K M@8-6O&VH>+-.\(Z
ME>^!=)L=0UN.QF;1[#5-0>SM;FZ$;&**:X2&9H(F<*&E6*4HI+"-R I^,?V9
M_#\O_!37X+GQ?\1-4USPIX=O]-TNV\2:;;ZBMAXQUV.;3(M3$&I7UC-YFD6A
M?5IBFFVQCE\M(W-P(+N:R(!]N&:SQO:6/Y6^;YAP:_,/]LC]I?\ :K\41?&?
MPWX2_9VMKCX.?'#X37=AX-^,5QJESYMB);673HY$;3;>^/V'8\FJP;TA4I?R
M.TJ,7C7U34OASXDLO!7Q-_X)[V'QBT[POX=FTZ/2H]8\*Z/.UKX5\-BU\VZN
M;F>[=XK:]N(;FWT][3[3YY(DUB,1+<M!;_'?[#_[<'QY^%O[7>J?\$ZOA;\3
M+'QE)I$EY;>!?&7B;Q=>1^'M:;2[?4[3_A&I[![2Y_LRXEN["\N0(QI_DQQL
ML!O;"SL(K\ \9^-/QP_X*/\ B3_@G_X<_P"">OP1_;<^&/QC^(GQV\7:QH?_
M  AOPMNK&ZDTWPT8=2N]13[0S1/;0N)5B$<RY$-LRQN%W*?OC]CS_@K5^S[X
MD^&'A/\ 8L_8P^&>I0^+/A_X5M[#5O!UYI,B7.@16+FS73VLWE68WSE(%*R.
ML%LUUFYN@T31R?*?[ 'Q_P# 7QATW3_^"HO[1?PZ^('AZX\/>&XM1B^*/@_X
M3ZQ>K=6UIX>N+3Q S7&EG[##)+KOVJ[\N[LWC$%BL<K20O9)9^Y_L^?L#?MZ
M^$OBKXJ_X*2?LD_'GX'ZWXZ^)VGVVI>))IM9?5/"7B.[N+)$N;>Q2QTJ&XT>
MSMKCRI$D6YO[C4AIUJ;B2V:24D /$O[+'Q[^*'_!0?P+??"/2;LS^$I-0OOB
MQHOB37&E\*BSU?6/[2FM-YBCN-4N'O"]^(K<1V44FG);N2XD5?IS7/\ A&]*
M^)/@G]EW]MC4U\2ZI?'2]0\.Z[I\ T_29KFV8PF6>VD?RX'-R+2 >26#3:Q:
MP"./S%+\%X#L_BYIDGP$_;)_8:^"TVK^&/BIX?LK37O^%C:U=_VMX<TG481J
M<^L745HUS%>2S"WAE*>9%LNY[ALM+JMS-%TUQ\ /'O[6?QU^$O[3.L^)/%6I
MW/A'46GN!XJ\$OX8\.P6/G^9<6R:!>J=5N;M[FRT>YC:[G\BVN;"UOX9#]G:
MPN@#[8HHILK%8F*G^'B@#X__ ."K'B/]L;0;3P1IO[)7Q&T3PG>>(;RXT7^W
M/$&M&*&'4KJ>RBM$BLT0OJ%R83?M'#N2-#&TLA54WI^9?[?_ /P4(_:/^-_[
M)FK:7X[\9_#/7#H?C*#P1XJ\%SV-]'<>"Y=-FT_^V-5U:-KFX:^C6>]CTVX6
M-;J*2"5GC8&:9*^B?VC/^"D__!2?PA\&M8_;;^$W_!/C2Y]&M=7U;3=#\7?%
MB?\ XGVCO+JRV-MHC>&;*7S[>26]M[6PWPWLK3LUO>R)&JFWCYOXQ_\ !.G_
M (*?_"3XVZ=_P7,T73?A?XX^,NCZ7 ?&7[/OPGT.ZL]+\4Z(;::"^$5\TIEU
M'4##)%<0^;#(RR01QI]L$%O#( >X>!OV]OAAXE^!>F_&"_4_#[Q=X'^',VL_
M$#PK8ZA;Z[;OH-H(Q;S:AIZS1ZB(Y(OLEW!<-"C117*K+*J22@]_^SW^WO\
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M^*K/_9R_Y$'4O^QZ\4?^GZ_J]\2&/]F1KGC^V=#X_P"XG%5']G+_ )$'4O\
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M?@;5[76O%$GAB]MK.QG.FZ[MCD>XB3!8W$(7@Y,@'6@#]+** <C(HH ****
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M_!-_PU8?&KQ;J?BCXA1^-+G4'\0:=80GS-0\5:;:3^)=(DBA3>8+4'1[ZR(
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M)!H?/X5ZS7$:!\$] \/:PNM6.NZL\IN%GF6:Y0K-(%5=SX0;CM51DG(VJ.@
MKM44HH!/3B@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%><ZG\7/%VM_%Z3X4?#+P:MU;Z0MO+XL\4:C,8[*Q$JNRVD(4,
MUS>X\F1HOD1(9U=Y%+1I( >C45YK\8?BYXN^!EI:^-/$_AB'5/",<RKXCUS3
M93'/H<;2(IO)H'R&LHD\R2>99-T2@-Y31K(Z>C0W$<Z>8AXH DHHHH ****
M/&/V[]:^)T?[-NN?#_X&7>DQ^/O&WE^'?!JZS>30PFZNB5EE#0.DP-O:+=79
M,3;T2U9P#L(KXC_:(_9A^)_P _X)B?%30_%.A^/M>TWPO^SEXMT^-M?N-&NH
MX;BW\(V^C6>H0RK>"6!!:6>I7,T*QR%KC7KUE+?*&^N?VJ?B#XFD\0:Y9^ =
M"MO^$@\$^%[=_ NK>(/#,=WIT?B_79I])TJ2*;(DCDM@9H[I4*'[+K"Y<*["
MN/\ VI_V68_&_P"P)\2/V;_@Y^R,9O$&K_!_5_#7A6_UF^TR:Z>\FTJ:UMI9
M[V>X:623S&0O/([.S$NS$DF@#V\_M!W.G^+_  OX-\4?!7Q=H[>+-:FTO2]0
MOI-,>W6XCL;N^Q)Y%Y)(JF*SF (1OFV@X!)'I8)(Y%?('C)E\*?M?>!U\-_!
M*;15A\1:3+'HMC]AB^TR/H'C97E7RI?+!"JF2S D( ,D 5](CXA>-SR/@EKG
M_@RT[_Y)H ZZBN1_X6%XW_Z(EKG_ (,M._\ DFC_ (6%XW_Z(EKG_@RT[_Y)
MH ZZBN1_X6#XX_Z(EKG_ (,M/_\ DFC_ (6#XX_Z(EKG_@RT_P#^2: .NHKD
M?^%A>-_^B):Y_P"#+3O_ ))H_P"%A>-_^B):Y_X,M._^2: .NHKCI/B7XOB;
M9+\&M85O[K:KIP_]N:?_ ,+"\;_]$2US_P &6G?_ "30!UU%<C_PL+QQ_P!$
M2US_ ,&6G?\ R33OAE\4M-^)5YXDTNWT6\TZ^\*ZZNDZQ9WIC9H[AK*UO%VM
M&S(P,-Y"<@G!)!Y!% '65^(/_!T/\-K_ %K]J'P3K/\ ;.N:%=^)_ABO@_P5
MJWAWPQ=S0W^L7>L_O-.UN=+"5;G398#MCM89I)TN) QM3',9*_;[(]:_*?\
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MM(<%@->\\)>&_%G[5OB:#Q=X8L]6L8?A[H#-;WUBEQ&LQOM9V.$=3\VWS!N
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MH)_!WA2]T?74\F>3Q9KUX@5@P:&XU:[N(6R,CF*1#CJ,X.""* /S[_X+:?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-I^NWND7;Q,\4;L5FL[ABBJ5$-LTN[!('T1X$_X)Z_\ !6>Y^+O@[Q]\4?\
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M)O@KP1\(?$GA[Q?K?]GZA'\;/B1+):W5O(KB.7QMK<D;?=Y5HW1U/0JP(X-
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M< =A_+\*K>'?#VA>$=!L?"WAC2+73M-TRSCM=/T^QMUB@M8(T"1Q1HH"HBJ
MJJ     !5]_NT ?.?PG_ .3E_!O_ &!_BM_ZEVD5]&U\Y?"?_DY?P;_V!_BM
M_P"I=I%?1M !1110!PNO$?\ #0_A?G_F2-?_ /2O1J\6_P""87Q-\'Z#_P $
M[OV4_AG?ZG)_;?B'X ^%?[/L;:UDF<1P^'[622>78K>1 ,!/.DVQ^;+%%N\R
M6-&[?XY^(_B%8_M#>!/"WPR\&_VEJ&K>#_$2R:E=2!+/2(4NM'8W$QR#(=VQ
M5A0%G+$\(CL*_P#P3^_8\L/V+?V9?!?PDU?6!KOBW1_ NAZ'XH\4R2M(U\VG
M626T44195,=I#AQ#"%4*'=V#2RS22 %KX)_"7Q'^S1#XC\7_ !/^,.K^(M/O
MFC%FNHZC?WB>'K..>Y:.W#W$TKRQQQ3(TU[,6GE=97D>.UCM+2Q]&\:ZK8:Q
M\+];U'3;N.>WFT&XDAGAD#+(K0,0P(X((Y!K>+9PH/M7B'Q5^&/C'X/6FJ>,
M?@I87>I>&[W39(?$G@&W=I##F,(M]IBD_NWBC #V28CG4!H@DRE;@ Z7X$Y_
MX6A\:O\ LIEK_P"HOH->A:[X>T3Q3HUUX;\3:-;:AIU];M!?6-] LL-Q$PVL
MCHP*LI&001@UYW\!)0_Q2^- S_S4RU/_ ):^@UZE0!R&E^,O$J_%#4/ &M^!
M[RWT]=/AN]!\0PXDM+Q=Q2:W<CYH;B)MAVN LL<R-$TC1W"P,\6GXCZ;\3?#
M6H^'56Z\-W4-_9>(;".WB#P7#QQS6M^TSRJPBC-M-;&&-)'=]0B<[4@<G>\3
MZ>-5\-ZAIB:[=:9]HLYHO[3L619[3<I'G1F160.GWE+*RY R".#X;^S-\4_%
M'QPU^Q?XC7TEJ?#EJ]QX9O;.:2SB\96[[X1K0M'&X6Y1U"QL[*LDKN0RFUE<
M [JS\8_$WQ7\*+SQPOP@LU\5P2WTWA#P[JVJ&-"P:6*QDNIQ"6M#-$8Y90L3
MO;B=XPDK1X>G\8+*6U^('P3CNKJ2YF7XB7"RW4RJ))B/#&N_,P154$]3M51G
M. !Q7*_LO3^._$OQ,UK3?B!/JL4?POAF\(Z#<WFJM+_PD]N[02-K4P"(DKLM
MM#;;]BF.ZM]41,QLCMVWQV_Y*=\%\?\ 12KK_P!1C7: *_Q'_P"3*?$'_9+[
MK_TVM7)?L<22O^T/^U:DDK,(_CYIJ1AF)V+_ ,*_\'L0/3EB?J:ZWXC$?\,4
M^(!G_FE]U_Z;6KD?V-3_ ,9$_M8?]G :;_ZKWP;0!]!4444 %?A3_P '+?P9
MTGQU_P % --^)FGZEXKM=>\(_L]VUU;^(/ NK:U:2>"8_P"T]77^W=9-IHFH
M1MI:!IN+>6WNF\FY1B5DB9/W6K\>?^#A;]F?2_C?^U7X;U'Q7^VK\-/AYHZ_
M#[3X-6\'>)(V@U;Q)IXU6^BN[6*6+3YY)XYGO+%(H][K!<PK,L!D*2  _27Q
M!X5^''QF\2^(/^$"\<>)O"_C+P?JBZ5K&O>$G>&6UOI-/ANHUEBFBDLM1"VV
MI)(@N8+B*-Y]RJLJ93Q;XH?MT?'7X6_\%5/@=^P+HUMH.I>$O'G@V^O_ !'K
MFN:7+_;+W%M9ZM(CQM#)%;Q[GT^%G'D$8>0*%!79\[_M[_\ !0OXW?\ !/3]
MH+QM\1/ASHKZSX6G^)>H7GC/1[;2HKB6Z6U\*^ ?)/G2W,(MH]L]RCRJ)G7S
M5<1,$8CJ/VH;O[?_ ,'&G[+-[C'F?#75FQZ?\2WQ)Q0!^E0SWHHHH **** &
MM(B+N9P!ZFHK'4]-U.%;G3=0AN(VSMD@E#J<'!Y'O6+\1-"\'>)/#:Z3X^NA
M#I[:I82HW]I26NZYCO(9;9-Z.A;=.D2F(DK*&\IE=79&^(/VM/BQ\%O^":G[
M87PYU/X+_"A[>SU'X.^)-/E\ ^!U^RZ<MQ+XF\+PZ;</I\)%O"S7&H7L23+$
M)IY;D0*9&9$ !]:_M%?M,^!?V;=,\/S>)]/N-1U3Q9XFM] \,:%9:C86MQJ=
M])%+,8XWOKFW@RL$,\I#2JS"(J@=V1&B\9_M,>%/A;XC\)Z+\7-,E\,VOB^2
MTL=)U?6M<TJ&"35[@D1Z4J_:_.FNR5.!#')&1T<X./F']MS3_$OB'X^_!;XE
M_M2_L_\ @Z\^'/@+6-?_ .%@7FI>$7\00-:7NGP6UG<6LAC(MHUO)$6=)HPY
M$ D0;(]QN?MZ?%;X/_'G4OA_H?P?U+2?$WBB^TK5SIMG'\/[G4M173=2T6]@
M-U;W")YED@&2P"GS6$4;!>& !]P+(K#.:CNX@\39!['@]P<C]:^7[[_@H]I_
M@?\ :N@_95^)'PZGTO4)/!+>,;@1S^9)I/AM-0?33JEXV!$D?V@1,T:.TD44
MQDD51%+M^HFFCFMV>-\C!% $E%&<T4 %1W-U;VD#W-S,L<<:EI)'8!5 ZDD]
M!4A8#J:^0_\ @H=K'Q2?X\_"GX<:&^AR>$O%VFZ[IFOVOB2.>6PAO+BZTBRL
M[ZXMXAC4$C6\NX!8RLL,SWJ-(46$RQ 'TIH'QI^$GBKQI-\.?#GQ'T6^UZUB
MN);C1[74HWN8T@E2*9C&#N CDEC1CCY6D4'!(KJ P/0U\?\ [27[&^J>%)H_
MVIO"GQZU+4OB)H\\=CIVO?$?7GATO3--NKY9)(%2S-LD=NEV-/NY%82/<II,
M5M(Y261JY?\ ;L_X*2?%[]DFX^'W[4UI;Z&_P'U._P!2T_Q1'?V+QZO*?*06
M-]!YDB-]G^2^O) D<CM:62E 7F"J ?<^Y>F:7</6OA?]NC_@L_H7[#7PPEG\
M7_!:\U3X@06G]H2>$[.^7R+C25U"RL?[4MKC!^TPRRZA;"*.,&9F=T9%,$NW
ML_V8/^"JF@_M8Z;8^(/A[^S#\2K/2;./58?B!J6M:*L$7A+4K$HDNFRY;-U<
M^8S)LMP^T(SL0O- 'UK5+6/[76QD?0[6":Y^7RX;JX,4;9/.7".1QS]TY(QQ
MG-4_ /C[PG\3?"&G^.O VO6^IZ5J5OYMG?6K[DD&<$>H8$%2IP58$$ @BMF@
M#YA^"'P\^('Q<^ D_A2ZMM(TVSMOC_K6LS7<>I27$@_L[X@W>H-$L?V= =[6
MQC#%AM#!R#C96?\ \%7F'_"$?!#G_FZKX=?^GJ&O5?V-"/\ A3VL<_\ -5O'
M?_J6ZM7SQ_P5G\4_%N#QW\!_!UM\*HYO!$W[1'P]N;CQDNL1+)!J7]OH!:&U
M)\QE,85O-7(!< ]#0!]P4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME6;XD^!O#W@N2S\3K/XDT"R@@EFGO$>)$UN2ZMY"1);2REM,D8+;Q".5V)6
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M;FXTC49X<3K#;1?VA&"H#1PQ@!_+!?[8_P""C7[0'QND^ OPV_91_9^_8O\
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M_@E3_P $Z-6O[C4[_P#8S^'[374S2S,OA^-%+,<DA5PJ\D\  #H,"N:^)O\
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M"'_H!W__ (4-]_\ 'Z/^&;/A#_T [_\ \*&^_P#C] '@!\*_MP+R?C/XP_\
M RT_^9:N=\#?LK?%6U_;!\(_M6_$>_US6-0T..]MKZ6^D-R1!/83P>9!#!HE
MHJ7#-]E223S )8;>)95E-M:>1]?>"O OAWP#I<FD>&H)XX);@S2+/>2SL6*J
MOWI68XPHX!Q[<FMW;_M&@#QCQ#XAE\6_LIZAX-T+PMKLU]JGP_EL[*+^PYPK
MS2V)1%W%0!EF')XYZU'^R_=,_P :_P!HC9G'_"X+$_=_ZDSPS7I?PT _X5IH
M''31;3C_ +9)7G7[,2#_ (73^T1\O_-8K'_U#/#- 'K_ -I?U%'VE_45/10!
M!]I?U%)YS'Y?E./\_G5BOQG_ .#BS]N;]N[X!?M9:1\)OV0?B#XA\/:1IOPC
ML_%GC35/#_BRR@DTZP&J7Z7$XLKN/;*WD6SA75F)*XV#8-P!^R'VA\9XKX9_
M:F^"]C??\%KOV;_VBD^+&E176GQW7AV3P2J;[V>*?P]XON1?,2P,<*M;"-=H
M82,9-VS8N[[JC8&)64@@KP1WK\V_VMM.LI_^#D[]EN^FMD>:'X<ZP89F7YH]
MVF>) P'^]QGZ4 ?I11110 4U_E4MCH#3J:ZEU(/=<4 ?%_PL^.?Q6_X*0?&#
MQ_\ #2SL_"NB_"7X>^*[G1M<M=2T66ZUW5=1M)UEL+NUDF*PV:+)##?1W*QW
M 97@$3QSI,;?SWXLZ3^UE\-_CYI7@"U^)UP)/#_AF\L=)UR31[J\NO$4-S;"
M]M;>-$O3)?7-E)HVIWMM#,L]Q-%:W%G/*@NOMFH>M_%G]GSXK_ ?Q%9^/_V=
M_#.K:UJ^DZ3'IOA*ZT^Y7?+;K.@@\/ZN)6S<:=B6=DOB3-9 ,_[P_+)?\":*
MG[&WPYUS]KK]NGXR3&WL/"VBKJE[KRB^_P"$?DBDOVEN#-!%RYEUJ>UWQKL6
MVMX<GF0T ;OPY^%OP#_:^BC^*?B]FUZW76!=^(_ VHB/4-"?7(;.*W6^CCOK
M;SC&;86TUN5,4$L3V]T(?,E,C?&__!/G_@F%^SA\5_@?\3+'X>_!SX8Z'JG@
MW]KSQY%H]SXB^&MMK=E/96&IZOI]K97=LTD+7,4-O?S"',P,;K$<LJ;#QGPY
M_;Y_:)\1_MG^,-4_8"\">'K?]G_6M/LIX_BCXN,^D:+:-=7-B4+O=;?-<3G5
ME0P_?M[^TC3:+2!*\E_9^_:*_;!_8)^!WQ-\?? _]IO2_BC=?\+>^*%IJGA/
MQ1=V5C<WK:?=:ICQ)&[%(VDFOKG3Y+B/<&*+&L*X9V !]R?M_?M9>&?!.CZ?
M\$/"USXJU^'PK9ZE;ZI<>'(=0:_:33]-7[0_VFWD@A%U(US:Z99M(S(-6U*.
M95\W2]ADO?A9^W#\ O!4G[57Q+U?X8V?AOP=X7U;5M/\ V^BI"OPPLK33[E-
M.M[%Y+M=.N1;VLLL5U*!8.Z23*EV8%C@KQ']EW]MGX2>/'^&_P )]*^*6I>#
M?&7BCQ]J6H_$[^UY+2"XAT.;0/%3:?*U\L0@F$6HII\SW*91]3N9)5):X(;Z
M:\4I^WV-.\,?"GXW?#&U^('AMC=CQ/>>&[>**77[F*5AI]I=1NWDVUA<&)I+
MB0;S'&L,,B-]HE*@'T9^S=\;[+X]_#6+Q1+I,VEZQ8R+9>)=%N+>>)]/OQ%'
M*T>+B..0QLDL<L3LB^9#-%)M < >A5Q7P&\"^,/A_P##>TT+X@>*FUK79II[
MW6M2VD1O=W$K3RI$#RL$;R-'"IR5A2-225)/:T ?&?C;XA?L>?%GX'?%KQU^
MV,\WA_5H_">KZ7X\\%^(K])=5\*Z5'8WD+PVD" [9I[.:YF$]N)6N!=JJ33P
MI;*OPU^PQX3_ &]OBK^T1H?_  4J^+>G-XL^".H>)-1G\*^'?B1JTLD_@'PF
MMQ<ZRDIEBD$<EPER-+VK)#=(DVE1Q2SVKZ;:R+^L?QO^ _[,/BZ]@^-_QP^$
M?A/5;SP?;M?6_B'7-!@N)]/BACF.\2,A;8BS3,%Y 9BP&[!KQWX"?#7Q5\<O
MA9K/Q$^'VO:Y\*X]8U'[!_82R37&I:?+I]ZT6HP237,CHK27<%S LD2%/LZ1
M2)DR$  [KQ_\=O!/QB^$>I:-X6L;754CNX+7QOX/U;PI-JMW-H\TPBGB&F+@
MW,=S"VU)#NA\F<7 $R*(I/S9\8_LL_#7_@F5XE_9S_;5^..EWVN_#/6);SX;
M_')?B):^9(NGWMM>V/AS7KZT,<<</D6ES<V,OVTS2VEAJ?V %U3CZF^&'[/G
M[0_A/QSXB\87OB[P_>^)8-#L;+P3IO@MH+/3[&XTR\G-QIR3?,]L)[;]T+>1
M3 T<*L5BECE8^*_M3?MU/^V[+X@_X(E^+?ACKA^('C&[M] \0ZK#X:6X6#2Q
M.IN]1>%SY5E/;6YMKT,[LC)-&\)#O"A /M?]I?P;^S1\"/V;=<\0^-Y[VQTV
MW\46_CZ\\O6C+J.NZMHDZ>(5B$]X[M,Y31UC$;-A+:W$*&*.)-F1\'++P[^R
M/\6M2_9\^"/[-&CZ'X!O?$FERPZ?X'5?,T5KZP:(:A+I\%O'':Z>\^GR0F9)
M))#<M-+(BQEG'YJ_LS?"'XE?M<?L[+^PO^U%_P %)?$VD_$GP3\2?%&CZGHN
ME>%K'6;CQ+?PZ9?F1K6[F=Q)#<:'?\(PBRID13NCDQ^AW[$F@_M+?L_2V\/[
M>7[6.CZYYFBPZ=X3N->DMK#4-6NGF:YN[B1=RYV+-96J0X+(UO,V2LR4 4?V
M!U^-7[0?B[Q)\;?VE_V3]9\#R2?&36/%O@Q?$<WV6\T^./1[7P_8N]M',^^2
M6Q&H*^\E =LBIB6)E^RJY;XG?%WX9?!?P9?>/?B;XTT[1-)L;:XGFNK^X6,$
M0P2W,H4'EV$,,TFU<G:C'& 32> _C)X#^(DES8:)J<D.HV,ABU#2=0MGM[JW
MD5(F=2C@;@OG1J70LFX[0Q((H X_]C5,_![6#G_FJWCO_P!2W5J^:?\ @KA\
M:O$FG_%CX!_ >+X(>++C2[O]H'X>:O)\0(;6+^Q;:4:^J"QDD,F_[3\@?:$(
MVR*<]:^E/V-;B%?A!K"&09_X6MX['_EVZM_C7E7_  5>7;X(^"! Y_X:J^'?
M_I[AH ^L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@XPHP,DYZVB@#SO_ (5/\9/^CI/$'_A/:3_\BT?\*G^,G_1TGB#_ ,)[2?\
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M-=TE]$^"?AE+^(W\?[3GPZO)+3>/,6W_ +>AC\TKUV[_ )<],GWH ^N:***
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M=X1::XTH07FM_:"8I)41IH#%</(LBJ65;6;S%4X!]A_9>_X)B_$S]N&'P?\
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MXDA_;&\9:+KL7A/1[1KZSM=>T34--N;^:,,H46AL(;AY0T8\E/[/BS+MED0
M^HO^"*G[3GQ-_:VU'XM?%;XQZII<FK:;K5CX6T>WTG19=,C_ +'L'O?L\GV2
M9R\1:6XNSE@IXV$9B('I7_!5U#_PA'P1.?\ FZKX=?\ IZAKT#]A#P9X2\(_
M!G5K3PUH5M9[?B=XXA!C3YS&OB[6&5"Q^9@"[D9)Y<GN:\__ ."KL@/@?X(D
M<C_AJKX=<C_L-0T ?6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!\IZ/;7MW^WC^TG:65K)
M+-/\(?!$4$<499I'*^*,* .23D<#GGWKR;XN?LR_$#]F7_@FE^WH?'VK:3>-
M\1M+\;>)]%719II?(M9?!EI8K%-YD4>)?-L9CA=R[63#;B57U:T?49_V_OCS
MJ;>(-54^%OA7X3O]!M%U>X%I:W5Q'XD2:?[,'\AY'6W@4LZ,2(D_NKB#_@N=
M+J.E_P#!)KXV>(="UW4M,U+1O":ZII.I:3J4UG<V=Y:W4%S;S130LDB,DT4;
MC:PSMP<@D4 >\?%70/B5K>J^"]2^',>ALVD^+#=:S+KE]+'Y-DVGWMNSPI#$
MWVB8//$!$S0KM+L9 4"/:^&OPBT#X>VZWEUJ-UKFO36J0ZIXIUJ1)M0U#$CR
MDR.J(JIYLDC+#&J0Q!MD4<<85!YA)_P3)_96N9&N6N_BLK.S,PC_ &@O&:+R
M<D!5U8 #/8# [56U#_@FM^R)I=I)?:GK'Q4@@AC:2::;]HKQHJ1J!DLS'5\
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M_D>I9_&6A6MTUC=:C;13+,L30R:A"K"1FB4)@MG<6GA4#J3-&!]]<WGN[B(
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M 1&VO,O&\Q6.WW.Y'S-3G_:J_8XLRZ7'PR_:5C:.2:*1'T_QBI62(9E4_O\
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MKR;]I;X=Z=.L.L7*6\UO_;T$FR2W600R?.JL&9"P95.?E7 !]@4444 %%%%
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MB7QA:YN!'N"DPW%I8SO(<LEO%=;02P4^L5\-_P#!4+_@L=X7_P""<_Q6\/\
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M@C*R CJJGIU4'M47@_X:_#SX>PRVW@#P+HVAQS/OFCT?2XK99&P!N81J,G
MR><"MNB@ HHHH **** "BBB@ HHHH 8\$<B[77*^E*8P>].HH :(P#NS3J*Y
M7XO_ ! U;X<^"?\ A)-"\/1:I>2ZMIVG6=C/?&V226[OH+12THCD**IG#'",
M<+C'H 4_@GIGP]TCPE?VGPSU*2YTUO%FO374C2%L:C)K%Y)?H"0.%O&N$QT
M7 ) R?!_^"KW'@CX(_\ 9U7PZ_\ 3U#5[]E'XB?&SPW\++JYUCX2^'UTNY^,
MOBBSN[JW\:2230/<^,]0@=EB-BHD"22DC+KN5<_*3@9O_!5IY?\ A!O@?Y@&
M?^&JOAUG'_8:BH ^LJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M &&8/_BZ .AHKGO^%M_"S_HI6@?^#B#_ .+H_P"%M_"S_HI6@?\ @X@_^+H
MZ&BN>'Q:^%O5OB7X?_\ !S!_\71_PMKX6=_B7X?_  UF#_XN@#H:*Y;4?C;\
M'=)LI-1U7XL^&;6WA&9;BXUVW2-!GNQ? 'O4X^+?PK9<K\3/#_\ X.8/_BJ
M.BHK+T/QKX3\3220^'/%&FZ@T6#*MC?1R[ 3P3M)QG!Z^E:E !1110!X1XJT
M3]H'6/VLO%#_  :^)WA+P_:Q_#WPXMY%XC\$7.K/,_V[7,,C0ZE:", <;2K$
MGH1TKB/VG? /[3_BWX<PV_C3]I'X7:A8^'?'7AO7[_2;7P!>:7<7AT?5[#6C
M:1W#ZO<B.:1+0!087SO4?*#O7V#37UA/VIO%RZ9#;L/^$!\-[_/9AC_3=<Z8
M%>'_ +>OP8\1^-=5^&?]O:)X+O=)7X\V7B?5/^$AT^YNC;6-AX=O7G-J(W39
M>;+218I&W(OF'*DX( /*?^"(O@7XQ>#_ (D>*]?^-MYX?FU3Q/\ LY_"/4[/
M_A&7G^SI8+#K]G;*ZS@,LWE6BF0 NI8L5(#;%_12OC;_ ()GC=X_L2W_ $9W
M\'C@?]=O%=?9- !7*_%SXIZ=\)/!5QXNOM)O-2F^U6]GINDZ>B&XU"\N)D@M
M[:+>RH&DE=%WNZ1H"7D=$5F7JJ\?\5>*/!5U^U5:Z=X_\7:;IUOX+\)0ZGI-
MEJ-]!&ES>:E+=6QNL2899((+*>%&5L%=1N P.%( +OA[X"W7C22#QA^T??)X
MBU9;S[7:^'8;R8Z#I.)[2XMXDM"5BO9;:>Q@GCOKF-KA9S-)#]E206\?I\5I
M! BQQ1X"C KG3\7_ (/D8_X6EX=_\'D'_P 75K1_B5\/_$-ZNF^'_'.C7URR
ML5MK/5(I9&P.3M5B<"@#\=?^"_O[*?Q@_:#_ &_O[1T'XV>+O GA5O@SX:TB
MXN-#CT#[-K%_?7OB[2OLSMK.M:9F4VVKSVP6$S$KJ;!_++1E_5/^#DZ.Y\7>
M%OA+^SVO@KQ)XO7X@76KVMUX8T?QAK&GPQ6\$FFSRZW)::;97#:G+8*/.CAE
M:01 R3?8KX1MY'A?_!R[X<^&%]^VGHY^*O@?PA9OK7P433?"?C+Q5KD%C#]H
MQXF66 F;=N,5W<:*_P JJ5M[J^"DRR6\EO\ L)XS^&_Q.\5ZC))IOQ/TFTTM
MMIM=-OO!T=YY'[O:WSM,N[.7_A& Q7GN =)\/K>"S\)V5K;R(\<5K"L<D,@=
M640I@A@J@@^H5<_W5Z#P+]N?_62?]C_\&O\ U84%?0?@[2=?T308[+Q1XCCU
M:_\ ,8SW\5B+=9,GC$89MN!@=3G&>^*^>/VYYU\R0A_^9^^#9_+XA04 ?3^:
MY_Q[\1O#GP^T>;4=:O6\Y;:6:UL+6W>XNKSRT+&."",&2>3 P(T!9FPH!+ '
MF?&OQIOK_6]0^&GP4TVUU[Q5;Z3)=;IY'73=.;S##&MW.@)1FD$G[I TA6"0
MX&%W2?#GX!Z1X1\2S?$3QAXANO%7BJX1X_[=UB%,V<#E6>ULXP,6L!=0Q4$L
MVV,2/)Y<>T _(?\ ;8_9%U?XA?\ !8#3/BY^T?\ &;X2^&?"'Q#\1>#]0OO@
MGXD^*5P+S[.C:2;Y=;TQIFL+U;E=$MK?RK;SHY;O3=%9]\$%U*_HVI?"#]KG
MP7_P6KL_BW>? ?POJFGR^--;TWX'>(=>^*,]Q8V\-_X?U+4M26331?W#Z5<S
MM816\=U:6,:"*:Z:YANI)(77N/VPO^"=_P"VIXO_ &ZO%OQA^''A>'Q+\._%
M'BS2M;U#PW'=:?!#J<,,/A5+FPO#=3*SK(?"T4)Q&ZBUU"\C^;[1(H]&^$'_
M  3$_:.^'7_!4'7OVV-6\=?#*^\'ZWXECU.WTF'P;$FN:1#'H=_I_P!EM[T0
M!O+DFNXY')?+);(O3*D X/P5\.?$WQ9^-OP:_:!\2_'+XB>&?$7PITO1;K1_
MA?KG[-J7%WX<TQ[%-/URR6[-O]IWWTMDT0O$E:*.,S"-)M\,T7W9^R%H.O>$
M_P!D_P"&'A7Q-I-Q8:EIGP]T6TU"QNX3'+;31V,*/&ZGE65@5(/(((K9^(GP
MB\-?$B**\OI+C3=7L]/NK72O$FD[8M1TU9PGF&"4JP +10N496C9X(F9&,:X
MY;5/C;J7P7UV/0?CM;>3I$D%G!I_CN&$K9W=VZI')'<1J6^Q,9B&4L3&4?.\
M>6YH S_&_P#R3#X__P"]>_\ J-V%8_\ P2C_ .46O[-?_9 ?!O\ Z9+.M7QQ
M*!\,/C^P/R[KW_U&[#-8W_!*&3/_  2V_9K&X?\ ) O!OX?\22SH ^@J***
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M@_P_XAB\":[8^(+*(3_VEI<EK<Z;/(78QVMU^Y29T'F!$.TC)SZ=;_#3X]^
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M>JZ]##JFEZ98ZA?0SRI"D5O>27<=LV^1E5B[6-V H)(\DD@ @GSS_A?&F_\
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M2-=32V66!H$DB$BF,-%&'#(NV@#K/V6/VP_B=\1OC3\0?@U\:/"/A[3E\/\
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MV>M#6K[Q)XQU>UN);J[TN*Q5S]G602^=#!#:33.1)';1JJ;P/+KP']LSQ?X
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MTC49-:U/Q%\#[#6!/=QO;FVMXD%Q:[&:(WLC<N2L&<*%).0/^"7_ ,2",_\
M"6?LV^__ !B3:?\ RVKZ7^+WP^OOB'ID<.C:K_9NK:;>6>HZ'JPA5S;7,,C%
MEY'"2Q-);28P3#<2*"-U0?!CXYZ?\4;>ZT#7="G\-^+M%98?$GA349 TUG-@
M?/%)@+<VS@AH[B/Y75@"$</&@!X;\+O^"<_B;PSXMCD^(OQ*^'-WX2F#'Q!X
M!\%_ G3=$TWQ(1&XMSJ(DFNFG^S3%9X-ACV/NW;PV%]@7]B']B_'/[(?PO\
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M_P ,0_L7?]&A_"__ ,(#3O\ XS1_PQ#^Q=_T:'\+_P#P@-._^,UZA10!Y?\
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M'?:MK5PDD\AN[77])?1HX8PJ%))=0>W9V8,D4-K.2<E#7@_[-/AC]F_]F/\
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MY\1:#'X#\-:Y)XF\3> [E3J;::]N@N8 =KK]D-S%!F/_ %MW>:<+:, 07)4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KY#_:GE\=@>,%BM],;P]_POWX?D2&:07G]
MJ_;O"_V)2,%/LQN_L@E.=XB,Q0%@N?KROEW]J/\ Y$OQ=_V<]\+_ /T]^#J
M.;^,7A[QU^S0GQ?_ &[_ (^M975K-IO@R6ZT;PC&93!9Z%J-S<O(KSO'YDLO
MVZ11'A57R5.\F0A.>T/XW:O^SAX'_:B_:-T71+>^U#P'\+]=\26>FWS$1W$U
MEXG\?72PN4.=K-$%)4YQD@]Z]5_X*_ ?\.SOC,<?\R9-_P"AI7R-^U'XHTKX
M:^&OBW\5/'W[0/B#P3X$TV2"P^(]GI?A[1]4M=7T*]^('C"VO4N;;4=.O3-B
MW:54CC4!S,RNDN54 'ZCP%C%F3&[I4F0>AKXTB?QXD>&_;0_;"_#X)Z)T_\
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M(P2*_1.OS'^&,TTW_!2W]G26XD9I&F\4^8TA.XG_ (5[X,SDGJ<]>^:_3B@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9!\,=8\8Z3XBO/&=J-+\0>"[^\MYM,>WL[Z\9YFM2',4L=M):!6^3SKN G&
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MFT3Q;H\.H:1>>'[R'5+&XA66.YMV@=9(F1P5=60D%6&"#@\5-\,/^2;>'_\
ML"VG_HE*C^*4'VCX8^)+=M0N+3S-!O%^U6;%9H<P."Z$$$,.H(/4=: /QG_X
M-KO%OQ-^ FD_M">+/B_XKU7XB>++KQ!X.T;38O\ A.X]7C@TU_$FOZ#:0+=R
M2,R;+V'4)BC85H)()4R)^/U>\=_M%>//AE8:9KGC;X&W-OI^H>*]$T-[JW\1
M6TQ@DU/4[;3XI"@Y95DND9@.=N<5^6G_  1CU_2=5A^-MKHOQOM?B-&WQ(^&
MES!XDM[&XMOL4 \>ZK9P:7Y<LTH:.-++[9%-GS)(=4C,A)4 9_[%/[4GC'XD
M?M,_$;X(^/OVE]2\<&Q\;?#/4_#.B#XB7NL6.D6G_"8>&!<K'YX+22K<3^5(
M;D03PM&5194G=;4 _;>BBB@ K\W_ -K3/_$2-^R__P!DYU?_ --OB2OT@K\W
M_P!K3/\ Q$C?LO\ _9.=7_\ 3;XDH _2"BBB@ H90PPPHHH ^6_BI\ 7_9V^
M/WC#]KKX(_$F\TW7/'EG'_:7P]32S=6?B?5;33ID20HG[Q)WB@L8Q(A 5;9E
MPS7 *?,_[;'PP_;/\?\ [27A/Q3HOQ?DTGQO)YL,/@/2;&"XM9M)O(_)73)+
MN6)_)-Q-;W=PYB! LM)O)I-T@BB7ZL_X*,_LL7_[1_@_P9X@T#QQK7AW5/ '
MCJR\2:?K'A^W:XNK5H0<.+?=Y=RJ2>5(\,D<HDBCD1(S(T97\T?#'[2-W_P1
M3_:0UW]K/_@HO\5]*^-%I\1X=/3X>^/O!NMVMU>3:/+"H\Z*SFN?/D"+"(_.
MS-')"01<0OOBN0#]/OV:;+4OV4OV>_%5[\>&N-%T7PMJ6J:S>>(M>U>&\GO+
M62,:C?:E<O H4%KJ:].P*"J1J ,;:^8_^"'W[:?P/\?7'QB^!:ZGJ6A^,M;^
M-7C;Q_IOAGQ-ILEC=R:-J?B*Y^SMY<F/WJYB\R+[R?:(LYWBK'@GQO\ \%)_
M^"NFB3&X\#K^SM^SSK\N^"XU+$_C;Q;I)CX4)S%I<%RLJ-N(,Z>4Z#*NLC?,
M_P"SO_P11^)=O8>*/VAOV'?VA[[P_P")O$7PZTU?">O:UF^T?QKH-[!._FW9
MFF>ZL]0N#!;R231!$A)@FB#.TJ1@'K'_  46_8/^*OQA^(G_  G_ ,5-0\>0
M^!=4U74D\1:!X;\70J=7N9IHK6VAA 0F W.EI'!&CY4WUCI:J%DF>9?>-,TW
M]LK7M%M/V<?VG_C!X5U3X>^(-)FT;2_B)HVEAYO&EM=E(8C=^8KP6-TT$Z[4
M5)8KEUF^Z@Y^(?VAO^"R'QD_9XM]0_8(_:Z_9UU3PS\5/&]X()K;QCXOBOO#
MKZ:UFT+:SINJ7%U 84>:U8002R1F*=O->9&#(-[]D?\ X)A?MH6_[6'PU\ ?
MM0_M6^%]8T'P"_\ PGO@WP'X7NVFD\+?\5#'=F&4)%'#);S6\:11LPB!EGD:
M"$BR9U /U<_9Z^!WA_\ 9_\ A?9_#W3-0;4KYD2;Q#X@N(5CN=:OQ%'%+>3[
M>-[")%"CY8XTCC3"1HH^*_A/_P $7O$WPF_X*JW'_!0>VU[P5>?;OB7X@\1Z
MIKC6,T6MW&GZCHUS91:0L4:"UCC@GGCD,XS-,(2TC%I7!]@^'D6F? C_ (*#
M:7\*OAI\3?&7BK1?&OA;6'^(5CJ&I3:Y'H7B*P@T(:;)=7+,QTQ[C39+K]U(
M5%SY<;@%ERWUI^% !^%'X444 %'X444 &!Z48'I110 4C,J_>-+7/:[\0O!>
MB^+])^'VKZZD>M:Y#<S:7IH5FEN(;<)Y\H"@XCC\V)6<X4--$I.Z1%8 X7]C
M5T'P?UC<P'_%UO'0_P#+MU:O+/\ @J]_R)'P1_[.J^'?_IZAJWX:\2:[X3_9
M6DUCPWJT]G<3?M.7=E)-;L59K>Y^*$EM/&?]EX97C8=U=AWK _X*N>*=$%K\
M%/!4\UU'??\ #2WPZOH6;2[AK>9?[?A0QB=8S$LHY?8[*2J\9)4, ?85%%%
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M0071\E2BSX>2WCC?\I_@C^SU^S)\)?@G#X_U3_@CQ\1O$WQ0^+'ABRU+1/\
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MSXF\-^'VT/2[C7M=>Z5=-%RES:VT@9=TQM9!(89Y"T^+F<22R^9Q[X  , 4
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MWT_7);K6&A>5I(Q#_9GG-N"QL9H'4J%,+Y^J?^"KQ_XHCX(_]G5?#K_T]0T
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M'_X(L?L/^'K^UU30/V3?!-C=6,T<MG<6>O:U')!(ARCHRW *,I (((((&.E
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M;C;]HU#4?$FMSS2[5"KN=[DLV% 49/  %7O^'2O[+?\ PA7_  K?_A0/A_\
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MA_:9UO\ ;3_9YUOP_P"']#^+/BSX@7VO6M[<QV_@KX0V,[VD=LUNCM+YEZF
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M'RS7%WJZ2MGJ<K;1#VV^]=Q7G?AG_D[#QK_V3WPQ_P"EVOT >B4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 V9 \94T0\1K_NBE?[M)%]Q
M?]V@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\3_ +9WP%\'
M>+]2\7?%:[U/6K/6/^%Z?#_P\9=-U:2!&L;W4/#-I<H47C<\%[<)NZC<,8*B
MOMBOEW]J/_D2_%__ &<]\+__ $]^#J /.?\ @H?^QY\*?V>OV)/B7\:?AGJ/
MB.VU_P .^&9KO2;BYU^:9(I@54/L<E25W;AD<$ ]JX_XB?M(67[(/A'XV_M
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MW7_IM:N7_8_O[R\_:"_:FM;F7='9_'C3H+==H&Q#X!\(R8X S\\C')R><9P
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M *I]X8_]+M?H ]%HHW#UHW#UH **3>M+0 4444 %%%% !1110 4444 %%%%
M!1110 4444 (_P!VDB^XO^[2O]VDB^XO^[0 ZBBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *^7?VHF!\%^, /^CG/A>?P_MKP=S7U%7Q;^V'X/\
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M4 ?)_P#P1G_Y.'^)O_9O?P3_ /3%J-?H57YZ_P#!&?\ Y.'^)O\ V;W\$_\
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MY..\%?\ 8#^*G_J6Z17TA0 4444 %%%% !1110!\+_MK_P#(N_%K_LIFO?\
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MG>'4@$;,L2!@$XH ^\?BUJC:9\.]6O\ 3=1:WFCTNZ>.:.8JRLMM*5.0<\$
M_45TJW%LXW+/^;$?UK\T?A3_ ,$W/V??V[/V?=)_:7C^*7Q6\%^(_B=X/M/$
M\VEZ=XXU*;3-!U#5=/BU 0P6WFQQRVT)O558P$1D7;A02!VWA+_@AE^SUHGA
M'2]+\8?M+?&[5M4AT^&+4M63X@ZK:K?7"QJ))A"MP1&'8%]@9@N< D#- 'WS
MYD/_ #V'_?S_ .O3)I;01MMF49Z'=TKX93_@B%^RU*=L7QT^.3'T7XGZO_\
M'Z9_PY(_949L-\>OC@?]G_A:&K?_ !^@#[CLWMEW@W>[YNN[I4QN[0-M^T=.
MOS'C]:^!_"O_  0Z^"6D:2^G>//VH?C1K#)J=])I-Q!XVU2R>&QFNIKB&VD*
MW+&X>%9O+\YL,Z(@VJ% J;1O^"5NF_ ;X_\ PP^)/P ^(7C?Q1I.G^)M0_X3
M[P_X\\3W>J6LME)H&JPVLI6XE?*IJ$MGF-48G<LG'D T ?>GFP8SYX_[^?\
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M5XN(_P"CGOA?_P"GOP=7A8_X*Y_\%!",C_@G+X+_ /$@-)_^)KRWXK?MO?\
M!0KXAZ%JVDM^P7X+M1K'Q0\+>+UD;X[:2P1=(O='NC;].?,_LK;N[>=G!QR
M?:W_  5^8?\ #L[XS #/_%&S#C_?2OGGXE>!/"/QB\#?'GX$>,])CN+'XDV\
M?@Y+UXT<Z5-JOCOQM81:BB,"&>V><3JORY:,89<[AH>&?^"A/[0/QZU6U^'W
M[3?[)O@?P+X1DUK1[F_U9OBE9ZV\[1:M9N($M;>)BQQF0LY5%2)SDMM5O&?V
MXO$WPJO/V!/VDM:^'_[17A7P_JC>'M:?PSIT&IM;7D4ND^)O%VHQ_9UC4%&E
M2=1!M(.^!_NA,T ?K1:EVB#OU[>]>.^$[ZSM/V_OB5]JN4CW?!_P/MW,!G_B
M:^+*Z?1_VH/@)JUY9Z3I_P 4M):XOKB*WM(O/VF6:1U2.,9'WF9E4#J20!7Q
MK^U[^S?X:^('_!=O]GSQY\4_"GA_Q%X:\2?";Q)I$.@ZYIJ7BBYTWSIVE>*5
M&C(*ZG%L/+ H^<<9 /T%CO;:9@(90V1D,O2IJ\R^(7PG\?:%8QZU^S?XQMO#
M][93--'X7U"U#Z)J9/D;H9553+9[DA9$EMR%C>XDF>"Y;Y&Z?X3_ !-L?BIX
M*M_%4.ERZ;=>8]MJVCW-Q%)/IE[$VR>UE:)F0O'(&7<C,C !D+*RL0!/B7\:
MO@]\%],M]:^,/Q3\.^%+.\N/(M;OQ)K,%E'-)@G8K3,H9L G .< GL:P?!G[
M7W[*'Q&\36O@OX>_M,^ ->UB]+"STG1O&%E=7,^U&=MD44K,V$5F. <*I/0&
MNAU2(?\ "U=$&!_R+^I=?^N]A5/XW3> [/X7ZI>_$GPBNO:/;K'--HYT/^TF
MN94E1H5CMMK&:7SA&8U"EMX4KSB@#K$N891F-MP_O#H?QI^X>M?)_P"R]J/Q
MP\<S>)/BQ\ OB\VH?#B?6-0L?"_@#XA>'-1BO[.[LI'M+Y)]5N;B6ZC*ZI'?
M Q2V\FQ(4CCV1JM=C\2O^"B/P,^ &L>'_"'[1>GZ[X*UGQ%?VMKI]CJ.EO/&
M6F;#2"X@WPO%"3$)Y5<I";B$.5+B@#WZ2>*)#)(V%7J?2N<^(GQE^$GPAT.'
MQ-\5_B=H'AC3;BX6"WU#Q#K$-E!)*59A&KS,JERJ.0H.2%)Z UY-\7_$_C?X
M[_"O5M.L=+O? /A/4-%AED\7>)YKZPOHG:6-PB6EG/;7D)&UXY"\]LPWH5\U
M=X'YN_L/?#?X<_#G]M?]B70_AQ\<4\=:;_PK73YGNM3U7Q%>7D-TWA/Q29)(
M!?2&RM+)D\E([=(XIT$*@HJAMP!^J.B?ML_L:^)M9M/#GAS]K'X:ZAJ&H74=
MM8V-EXXL)9KB:1@B1HBREG9F(4* 220!S7I:7,4GW"3[[>/SKC?CSHNC>(OA
MXV@>(=*MM0TV_P!:TNVU#3[RV6:&Y@DU"W1XW1LAU9205((()!ZUX5X"M_C9
MJ/Q!TOXA_LL>+]4L/ ^S4;+Q%\*_B1X9OK>6VU%HKZ\2Z%W=2FYL8S-)80I;
M)!)#%;-F&)5*A0#ZI\Q<XH\Q??\ *O _B[^WK\*?V4_"$WB/]K6RU#P3':R1
MI]NDM9+RSOF/VIV-M/$I$H2WL[F[D0A9(+6,RRI&M=!XL^*/Q>\5Z/J=U\./
M#=OX5TS3X[U+KQ=XUMI-L/DI=Q_:(+!"LMS&D\43G?);)+!*LD4K<"@#U6XU
M&UC_ '33#>QVHO<M@G ]^#7F'@&P^-\?BG4?'/B;XJ6GV+4?$$V?"%_:VLUM
MI^EP+=06QL9X%@F2:Y/V2[F:Z:Y"?O88UC#!T^4?VF?%?AR7XX?".P\._'O0
M?&$FH>(+8ZI=>*-#N+O49)+?6[.2T73)8#'8Z9,([^\$D@A6>ZMK=49I!"73
MZ2E_X)C?\$W+R>2\O/\ @GU\#YIII"\DLOPGT=F9B<DDFVR22: /2+GXW_"[
M3_B#;_"O5/%L-IKE[;1S:;:WD,D,>H;Q<'RK:9U$5S,B6LTDD$3O+%&%DD1$
MDC9J/Q&_:@_9L^#VNQ^%_BW\?_!?A;4YK5;J'3_$7BBTL9W@9W1952:16*%H
MW7<!C*,.H->7^/?^"=_[ 7P^\#ZUX^\!?L._!_1-=T+2;C4-$UG2?AGI5M=:
M?=PQ-)#<02QVX>&6.15='0AE90001FM+X<P)'_P4E^+'EHJ_\6-^'G0 ?\QG
MQI0!OG]O7]AL#)_;)^%?_AP-._\ CU>JV]S#=0I<6[[HY%#(P[@]#0S(ZY4=
MQ_.JOAX?\2&Q'_3G'_Z"* /-D\.:SK'[57BR73/&VH:6L?P_\.!H[."V<.?M
MVN<GS8G.?H0/8UO6'@3P_P##+7/$7QCUKQ)?7U_>>'[6UU34K]4^2RL&O)XE
M"0QJ/E:\N6)"EFWXR0J@0>&_^3I/&7_8@^&__2W7*=\<?%-I8V>D?#.[TK49
M/^$_N[[0(]2M+7S(-+8Z5?79N;DY&R';:-&&[R2Q+_%0!\:?\$8M-\7VGQK\
M=:_XK\$WVB0ZU^SK\&;G1UOKFUD:[M8],UBU^T#[/-*$1I;>4*KE9,+ED7(S
M^A-?&O\ P304MX_L1GI^QW\'/P/G>*^*^RJ "BBB@ KRG]HG_DJ_P,_[*M=?
M^HIX@KU:O)_VBV ^*_P,S_T5:Z_]13Q!0!X1\-!Y?_!!W0Y2Z[7_ &.[-?O?
M,"/"_P#]?]*]]\9^*K;XU^)M<^ G@/Q5<0II=O%%XZUG1[BXADTQ)PKK8PW<
M)00WTMNWFDQ2?:+2*2"8K']IM9&^7_@#\4M"G_X)T^$?V//C#\ ?CMH][_PH
MG2O!OBAM)^$^IM<V,_\ 9/V.Y,+M;21ED;?M<JZ$J"0P&#TWP]\?>#OA1X,L
M_ 7@0_M5V6F6".88V^#LLLDDCNTDLTLLFDM)/-)*\DLDTC-)+)(\DC.[,Q /
MH[X2:'I.G_ 31_#]IIT*V4?A>TMX[41#RQ$+.,;-N,;<<8Z8KI1\/_ 0 _XH
MG1__  6Q?_$U\D>!/C/=Z5X$T[P_J^H_M31SPZ;!!/%%\&BZ*RPHC#/]DG@$
M$=>G?O6__P +_P#^HU^U=_X98_\ RGH ^F[OPIX=NM!E\*S:):G3)X9(+C3Q
M !#)&ZD2(R8P58,V1WS[UY9\%_'</PAL_!WP!^)>MS>?JVF^5X#UB^FN)AJ\
M%O;!_L4MS.\A?4HH5:0I)(9;J*&:YC#^3>"W\RN/C_(%^36OVK.O_1%3ZC_J
M#^QKE]8\<>%_B%\+(OA[\1$_:DN;>2SM1-#_ ,*7.ZVN(&CDAFB?^R"8YH9H
MTFBE4AXY(DD0AE#4 >F_!P@_M'>"?^P'\5#_ .7;I%?2-?(ND_$G4/A1\0/A
MW\6=<^#'Q&O-)OM%^("M#H_@.^O+RP.H>(=,O;1;JWBC,ELTD$4C!7 (*,#R
M"*]('[>/@L]/V??C=_X9K6?7_KA0![E17AW_  W?X,QG_AGWXW?^&:UG_P",
M4G_#>/@L#<?V??C=C_LC6L__ !B@#W*BO#1^WGX)(R/V?OC;CU_X4WK/_P 8
MH7]O+P4S%%_9^^-N1P?^+-ZSQ_Y H ]RHKPT_MX>#!Q_PS[\;L^G_"FM9_\
MC%!_;P\%CK^S]\;/_#-ZS_\ &* /"/VUG7_A'OBT,_\ -2]>_P#5/SU]+>(=
M6\:_$_XSV_P_\/:5=:?X1\-^1J'B;Q,;Z2UEOM05TFMM,LUC=9&10JS7<LFV
M$H\5JHN3-=BT^;/BEJ2?%;1]?\9>(O@E\5E\*^)/C==Q7]I8_#^^76$TR?X=
M-I+WB6AA,HB^TL8A(4*[_6M?X;^//!7PH\%V/@#X?']JJQTO3T9;:)O@]+-(
MS,Q>2666726DFFD=GDDFD9I)9'=Y'9V9B ?98A=45-V=HQENIJ2OE#_AH/\
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M?LQ>"M2DUOX8^,[[6#J6@VUQ]LNAJGADBXD,R-YDN9I?G/S9E?GYCGJ/$O\
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M-7L$T;2::[LUL8D96"HS0S2(W2C_ (*J?M"Q?(/V%M1P!@$Z7X_&<?\ <DT
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M@_L[QQXKL/&\'@[1_%'AS0YETH:AJ&JW-A"]Y':SSPINNTD9HY'DC\QBIW*
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M_8^\:_&:Q_9%\#_%+XF^"?$&CV]EXD6S\-_$2[@CE:YENUC^>XDD:2>6*QU
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MKWC>)M'^U,^E:=8^9IUM$-I:2UM'DO9<^4(DF=1Y"E?#_P!C[_@G3XH^-7[
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M9(7;3U:0(SH&]'_9A^ ?QX_:0^)NF_M1_M8?L8^.FTCQ-IE_XC_?>-]*DO\
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M]3T32O%%A;WPDU"ZT:>&=!=S0PM$HTR99,RAP98MJ.I=D^H/*C_N"D\B/L*
M/B_1_P!MK]FCX2_$3Q9\3-+_ &?6T7Q%X_OK6_\ %>I7'Q"\*+/J4MM:0V=N
MQ,NLG8D<$"*(TVH"7?&^21G\N\9_ S]EOQW>Z3XC\'_M4ZM\*X?BUXA,/Q&\
M.^"O&&DZC:WFF)J/BKQ1&ET][:72L+F_UB87<"N]I(D[V8$ML3YN=_P7T_X)
M:?&K_@HW%I&E?!_X4V.K7EFVD-#X@FUNWLY--AMY[YKN!?-8,WGI=1$8RNZ
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MG>4G]V@#Y_\ BWJFC?&[XM? 'Q;\&+R'Q'I'A+XT7T_B2_T0B>'3(V\%>(X
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M[P]\"/A7X8T"Q\-^%_#LVG:;I]E':Z?86&K74,%K;QJ%CBCC64*B*H"JJ@
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MC:O\9O!-K>6DSPW5K<:]:))#(IPR,I?*L"""#@@T =#_ ,+6^%__ $4C0?\
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M9M'\'K87$(M?^$@\9>'9C<QO$7)7^S]2NL;".=VT$2)MW8?8 >R_\+5^%_\
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MY5/P6\5*5; ;!!TT'.&'YU9C_P""AG[,OEJ/.^('W1_S1GQ1_P#*VOGO3/\
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M^*?#-G*@Q:7"[9(YY8I)6V&",O,FYHP* /2O^'AW[,V,^;\0.O\ T1CQ3_\
M*VO$/^"E_P"W?^SWXL_X)P?M >%=%?QQ]MU3X(^*[6T^U_"7Q);1>9)H]TB[
MY9=/6.)=Q&7=E51DL0 37;>*/V[?BU\.?VB=+_9[^(_PR^&=OKUY:Z+?WF@Z
M/\3-4NM0ATK4==M]%74(UET&&"94N9QNB\Y6P.2H92>H_P""J63_ ,$P/VD
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MBOX[^)7Q2\4Z+\0/AG#X9NO!_P"S;\(-$ACM]<%_'J-N;?7[V*[#B*,QEDO
MIB*DJT;?,P(->E?\%K/V<?B]^U'^QPWPP^"?P4T?QYKK>(([JST;7[>PELXY
M8[.\\J>9+V)U:-9V@#"/9*5<A7 +9\T_X(T*#^T/\3L_]&^_!/\ ],6HU^A(
MB &,T ?+?[!_['&D^&_V1OAQX+_:'^%,D/B3P;I^K6&FV>J7\$LVCV-QJ+RK
M91-9)%"MNL,-DL<:* D<$*<E"3]!>!_A)\/OAO-=3^"?#L=@UXJ"Z\N5V\S;
MG;G<QZ;CT]:Z+RP>M.H *^<?^"DO_(A>#\_]!KQ%_P"H-XFKZ.KYQ_X*2_\
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M^*/AU?:_#8ZMHNIVMU8R0I_8MY:1FX@OG+R))Y8DC6%A#O=A/M9#$TI'S_\
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M6KZTG[+7Q*^&%K=-HOA[^W3X?UBVB+6*Z:@T@2?,,HMCY:Q>D84< 8J]J?\
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M@9\-?'NBW&DZYX>^#_AC3-7TN]AVSV5U!I5K'-!(.SHZLA]"M>G^#_A3\/O
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MZ'KYD_X*3W5Q86GPEO+2X:&:/QYK[QR1L59&'@'Q858$<@@@$$=",T >XR^
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M(\,^,_VG_&VIZ'X@URYL]>F\.^,[I+C3;9-,O;A+K]]%M*FY@MH#P3FZ7ZT
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M]4U'39(]0LGMYX+NPOY["[ADB<!D>.YMIHR".JUV5<W\+OA'\._@MX47P/\
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MT77+ZWM1;PW>H6*R2+"&9A'NZ[0SNP'0%B>]=Q10!Y1_PPO^Q_\ ]&[>%_\
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MZ\4:/"+"TL%C:WT[7K_3[=OFMF)9H;6-F.<%RQ 4$*.__P"$$\2_]%C\2_\
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M9W*R><6F+A@#]9OAHZ_\*]T%%*Y_L.S^I/DC_/TKY%_X($_\F16O_8%\ _\
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M[3+"8P5< _1#_AR=_P $D/\ I'3\(?\ PB+3_P"(KZ*\">!?"'PR\$Z3\.?
M/AVSTC0= TR#3M&TG3[=8K>RM((UBA@B1>$1(U554< *!VKX?_X*Q_\ !1KQ
M#X7_ ."&/BS_ (*+_L!_&=;6ZNM(\.ZCX,\50:9;W#1PW>N6%K,'@NXI(P_E
M331.DD>Z-]PPKKQ]*?\ !/#XF>.OC7^P)\#_ (S_ !/U]M5\2>,/A#X9UOQ!
MJ36\47VJ^NM*MIYY=D2JB;Y9';:BJHS@   4 >R4444 %%%% !1110 4444
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MOBE\-/B2UTOP]^(^CZXUFRK=+I.J17'DEP2H;8QQD*V,]=K>AH Z2BH_)/\
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M3(+.#3D@$MJ(XR&B"%ML>P^'_M6>-+#6O$/A+0/@%H'Q"^+'['W[-=SH-_\
M'+7-8UJ29O$&H02R7EA9R6L["86]K'J,"3.T*XCB8RAUM$S^D?AW_@HG8?\
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M]S>7<UY<RM),[R,TEQ/-(26/+GH,  'A7A7QG^VQ<_$O59=<^)NAZ?X1L_%
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M?VT/C%?:Y-XRN=1M_&-OXX>.^@TS[4?L]@!Y7D86U"*[&$LTQ=@P4A0 :/\
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M\FTF&]M;R*\M[X1NYD:=984X>5HB!S&3S6;_ ,%4E5/^"77[2"J/^:!^,/\
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M!1CC)]'OO!EOJD]K=:E<-/)87!GL9)HXW:WE,;Q%T)3Y&,<DB;A@[9&7HQ!
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M?B#Q!:PSRWL=TM_9220LZB$BTTF5H_,+_-J!B:(7"0LGE_[6'_!4OQM^S?\
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MFMKW0]7DL]2T6\_X233K:\M#- ZNCHQFA8J0'0Y&4<9^UO\ @E_XA\0>+_\
M@FK^SUXO\6Z]>ZMJVK? [PG>ZKJFI73SW%Y<RZ/:O+-+(Y+22.[,S.Q)8DDD
MDT >ZT444 %%%% !1110 4444 %%%% !7Q+_ ,%/@/\ ALS]DGC_ )FCQ]_Z
M@6MU]M5\2_\ !3]@/VS/V23G_F:/'W_J!:W0!Q?_  4"\>I\,/\ @H#^PAX[
MO8K?[#8WOBB'4;F^;9!:076EV-F9I'X5,&X&TD@%]H_B /V['^T%\"9$5_\
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M-(R1E4+CZ#W2_P#/(4X1H'W[>:=0!'ND/6$4;I.ODBI** (]\O\ SRHWR_\
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MX*%3#J$ISU#*N*]4H_"@#Y__ .&<_P!M_P#Z2(7G_AK=(_PI#^SC^VTPV/\
M\%#[QE/WA_PJW2/\*^@:* /!=9_9S_:UF\1ZEK'A/]NV]TFUU"XCF.G_ /"N
M-+G6-A!'%P[C<<^6#[9KH/!/P>_:5\/:5):>+?VN+C7+E[@NMX_@?3[<JF
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M<Q7EO9^ =3M+RXL_%/BR70=B3-J\L<<MND)F\PQ,LA;;L0#)^R* "C ]***
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M>WLNIWDDUL\P V27@QY@9Y0#Z_\ V?/^"INO_M'?MY_$O]C^U\':?!H'@_\
MM_3%U-+2=)7OM.F6%@EQ)(([L96;S5AA MG,<;R,2K2^Z_\ !1WY/V"OC).K
M,K+\,]:&5[J;*0,/H1^=>-_#6P_8&T#]HNX^.?A;_@H7X5\4^*M6M]<TW1]"
MF\<Z#<R%=6U)K[[# T:_:G1;B4I%")&#*(58/Y$'E]Q_P5;LOC%<_LD>*+OX
M?:MI=KX:L_!_BB7XA17IW3WVGMX<U.&VMK=?*8!AJ$UC<-)OC*I:,@W>810
MW]DSQ#KWBS]K3Q-XI\4W$TVJ:E^S/\+[K4I;C338R27$FH>+VD9[=B3 Q=B3
M$22ARO:OIZOFO]F?QE<?$?\ ;/\ &7Q#NM-M;.77OV<_AGJ,EI8:M%?P0-/J
M7C&7RTN8?W=PBEL+,GR2 !EX(KZ4H **** "OG'_ (*2Y_X0+P?C_H->(O\
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MI+J.@^'[<VTJ".2,3S"8302QI$()E3RW*.TD<BY,<,B_/\'_  3T\)?MO1?
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M@I\'OAY>>(O%'A7P^8DM?#?B[2H=4AN[BWMGAD:WO+JW^SQ!+OS5F:0!A:7
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M-X-^#,GAO3M2TGQ1J>FPVNJ:SJ^L:3>6L%\=/^S/&MO;SR7"K;[CYES'#=[
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M1]R+W% !115#Q!?7VFZ'?7^DZ:;VZALY9+6S^T+'Y\BJ2L>]N$W' W'@9R:
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M4R#P/?>.)->NH;4^#<26=WI#P1>6)5V*HD\QKA"N""BJ226-?2'X44 ?@_\
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MJ*YW2[3P</B7K%]9"/\ X2&31=.BU,?:"9/L:37AMB4SA5\Q[S:V 6(<$G:
M(?\ A*/B3_T2W_RN0_X5YWX:\2_$)?VI?&++\,]TA\ ^&P\?]LQ?*OV[7<'.
M.<Y/Y>] 'ME%<O\ \)/\2?\ HEO_ )7(?\*3_A*/B1_T2[_RN0_X4 =317+?
M\)1\2/\ HEW_ )7(?\*7_A*/B2.OPM_\KD/^% '445R__"4?$G_HEO\ Y7(?
M\*/^$H^)/_1+?_*Y#_A0!U&:*\Z^)/Q>\<_#7X=Z]\1M5^$4LUIX?T6ZU*XA
MAUR'?)'!"TC*N1U(4@5Z% 96B!F^]0 ^BBB@ HJ.:XC@C\USQ1%/')N"'[M
M$E%&:,T %%&:,T %%&1ZT4 1S\Q-\I/L*6+9Y2^6/EVC;]*<Q^6DB^XO^[0
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M !]^!_Q:U&XTGX5_&#POXFNK6-9+J#P_K]M>M"C$@,XA=BH)!&3@9KL,CUH
M**,CUHR/6@!LLGEINQ_]>OF'6_V\?V2OC:GQR^!_Q-T"\E\%^ ?#^IV?Q&U3
M5(4;3;BQ2"[CU."01N98C'';SY298VFC_>0^8GSU]//''*FQQD5\@?\ !1;]
ME+X!_"S]A#]K#XS?#_X?PZ7XB\4? OQE-KEY#?3F.XD;1[QVD$#.8HV9RS,R
M(I9G8L26;(!]=V_EB']TFU?[O\ZFS7B/QU_;4\#?L]>/7\$^.M/DBC^PZ;+:
MWX9W^T3WAU+;;I%%&\C.J:7<2$XQM^AKMOV>/C-I'[0GP5\.?&30=/N[.W\0
M:9'<FQO[>2&>SER5EMY%D56#1R*\9X )3(R""0#N*,T9[US?PL^*?@#XW?#W
M2?BQ\*/%%OKGAS7K)+S1]6LR3%=P.,K(N0#@CV% '29HS4-U,+>W>X;HJEC^
M KY3^'O_  5L^ 7C[P)HGCF#2M3M8]8TFWOX[:33;YFB66,2!6*6I4D!L$@D
M9Z$\&@#F?VYS_P 7W\4?]AK]G7_U:5Y7VQ7Y_P#QQ^+/@7X^:AX@^+_@OQ!#
M)O\ B%\!-'NM(DMYX[BV-O\ $D3+.RS11GRY?MA52 1NMY.>*^_MZ=-U #J,
MTW>G]ZO+?C5^V?\ LS_LZ:G>Z)\9OBK:Z'=:;H,6M7T,EC<3&&QDNTLXYV\J
M-@ UPZQ@=2<\85B #U2BO 5_X*=_L4L./BGJ7_A$:S_\B4[_ (>=?L5?]%3U
M+_PA]9_^1* /?*,]Z\#_ .'G7[%7_14]2_\ "'UG_P"1*Z;X6_MG?LY?&C5X
M]"^'/CJZOKJ2^CLXX[CP[J%KNF>WN;A4S/ @YBL[ALYP/+P2&9 P!ZM1FFK(
MCJ&SCO4;W4,9PQ]!^= $U&::)%(SFN&^.G[1GP9_9K\+0>,OC7XU71--NM06
MQMKAK.><RW!BDE\L)"CN?W<4KG"X 1B< 4 ?E]\!?@'X\\#?\'"EY\4M6_8S
MUK1-&UK4M?ET[XL^-M%MK2UN9'M]7D:QT6/1H([:2ZN%E%PU]J+RW<EI:3(Y
M61ANA_X(O_M"_M _M2_M[V'B_P"/.E_$JXNO#7PU\4:=IMYXITW2[2PTV.34
MM"@NX8FL=(L?M,C:AINHV>6=_+.BNP'[_C[T\/?\%7/V _'?AVW\2>$OCK+J
MNEWT.^SU#3/">K3P3I_>21+4JP]P2*^>OV3/#O\ P2%_8M^)$/Q$^"/Q8\<P
MKIVFZOIOAO0=3T/6;C3_  _9:GJ,6HWEO9QFP#1H]Q#&V'=R N,\DD _0[[-
M"8_+V?*&! ]P<_SKQG_@HI9M??L#_&BV1U5O^%6ZZZ[^^RPF?'UPOYUG?\/.
MOV*?^BIZE_X0^L__ ")7D_[<W[>?[*WQ7_8P^+G@+P1\1=0NM5N_ACKTEO;O
MX5U2W#B/3YY7&^:V5!\B,>6&<8&20" >@_LUZKX)US]M+QEK7PRTF.Q\-WG[
M.?PSGT"QBT_[(MM9-J/C PQB#:ODA8RJ^7M79C;@8P/I.OF_]G+0?#_AC]MG
MQMX;\):Y<:II>G_L[?#2VTW4KJ^^U2WENFI^,5CF>;)\UF4!C)GYB2>]?2%
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M  F^&UKX533]/MKRXO+O5M=72S-]GEU:_NI;[4)X_.9G5);RXN90I/RB0*
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MV@^,O&?AS[=X-FM[B*]L[ZVAM;R9WEDC(^SL$L)2%8$DLHSUH ^GJ*!G'-%
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M/2/^"9WB3XZ?L(^#/!ME;_"35O&VD^+OA_X9U2&2YFTW1!;QS^(+%[4/*((
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MPMFES'=20P2-:SRZG!;7@G,;"<S2)N+F5D\^_9'_ &//VW/^#B+_ (*C:?\
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M;^>\\=P^$+[3]3U*RM7359].-];6L6-AEGE#6X2-=V_SMH!<8'YZ_P#!*?\
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M(TN;S4^UIJT4>YB'VO\ 9\(&7*N5);F_VC/C;_P5*\,_'C5/"_P"_9/C\2>
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M]XY^(;>(]$T72[5[G4]8UCXK:E;6MI"H):2662X"QH "2S$  <UQGQ*\?_\
M!5;XKIXGT#Q5^S1J::'KFAZIHMC;6/@+PK'=VEC>@*XDF;XCNDTRQH@$@BC4
MMN8QX8*OR7^V]8_\%>OB;I?AO]BGXG_%KXO>)'^,US?:=:^&O$OPM^%*6]W%
M8V,NH2RC[+JTH=HW@@8Q2R6ZLC.1(758Y #UC_@B%^W78^$?V65TIO#^CQ2>
M(]6TJ;3[76/%-U'-<W4/A;P;9WTD:I9S@"?4]2MV +@M-J:HJLQRWU)^U5\:
M[WXO:#H/[-GQ-^&.FV47BCQ5X;N;[3YM7U#S;G3(?%>@V]T566P@5U$E[:QN
MOF [;C.& (KXM_8"_P""7O\ P49_9\\->&?!-SI&@>';[3=2N)]%O/&'@2#4
MI[.UANO *&:>33=?:W0R#1))1;+<!Y4L)<;6F00>X?MJ? G_ (*G:A^UMHGQ
M2\ R^&_B!#H_P_CFT/3=#\!RZ=:K/;>,?"U_-9L;WQ!Y*74D5F;@2// )8;2
M2)5+KYJ 'KNJ?\$>?V&/BGX^\2:CX@\'ZM9QV>IQ6NGZ9X=\37>G06\(LK:3
M&R"1?,8R2RL9&W-B0+G:B <%\3_^"1_[!GA?]G/QA\>/A-H/BK^T-!\*:IJO
MAZZU#QIJ5S;M<VL$LD4CP33&.>(R1JVUU*2(1D%6YI^)%_X*%^-_AKXZU:]_
M89^*7@OXK>*E"6?C#X:^)_#^GZ?&R6\4,5W<:>WC-HKJ^6-#$+B0/^[BM5=)
MDMTBKR_2?A'_ ,%9AX!U?X3>*_V5/'NK>&]:L1ITEGJWB#2+Z*QL&LHK.2WC
MM9/'8M[J)A'),T-VLRO)<RHW[C9!& ?=T'_!-;]A<P*6_9T\/R?[7ER?_%UC
M^!?V:/@7^SU^VEX3/P7^'-AX=_M;X7^*/[2^PAAY_E:CX?\ +SN8]/-?_OKZ
M5\_^!_CC_P %UO _@[2_">K?LR77CJ^T^P6'4/%.N>#_  KIMWJ,H)_>R6]G
MXX-NC%<9\H(I8G"(,*-35?BW_P %8-8LHOBA<?L(:];_ !*T71]6TKP[-'9^
M%I-">TO9--F/VFW_ .$T%P95ET_&^.904E VY&Z@#[X=5="I/WABOF7_ ()T
M? GX2^&M(\9_'#0O ]G;>+-<^+OQ'M=4UN/=YUQ$/&VK#8V3C'[F+L/N"O _
M@_\ MD_\%I5^*\W@GX[?LN:/-_9VD6U_J&@^%?!>@0WDD5P;F.-UN+GXALD:
M"6#KY4A90P(CRC'4T;XB?\%._A5X>NO"?[/_ .RUKVF6-YXIUC79?^$Q\&^$
M]6E$^IZE=ZE=(&MOB'9+L%Q=N(\J2D:JK&1LR$ _01AE<8KY!_9<_8B_92^+
MO@7Q1\1/B5\$-'UC6M0^,GQ!^V:E=+)YDOE^,-8C3.& ^5$5>G05YT?VB?\
M@N)V^ ^C_P#AF_#W_P ]6N>^''QC_P""KO[/G@>T^'&B?LT3ZOJVN>+]>U:)
M;_P?X8LQ<W.HZA>ZM<I&(_B%,0B-<R*H()VHNYBW) /K/]G'X3?"_P ;> =6
MU_QI\-O#^K7S?$;QA&]]JFCP7$S*OB;4U5=\BDX"@ #/ &!7H/\ PSW\ ?\
MHA_@_P#\)FT_^-U\H_![XD_\%+/ WP-LO"K?L6>(-/\ %S^+-?U37K[[#X:U
M#39X[W5[R\C2"'_A,+:6$A)X]VZ609# ;AACZ7HO[1_[:\'P_DTWQ%^PAX^N
M_%36<ZQ:Q9KX3M]/6X)?R9#9MXLDD,:@Q[T^TAG*MAXPP" 'L?\ PSU\ O\
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M]+\;1^&Y9H8E>6VDO[;[+]K21[.Z^SJ'MVN" 4@DW-+;Q2* >B:S@Z1=#/\
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M4++QU\"O'.N>'=1V-?.D3Z9?>))XI)()5@F,DENHWR6I21V@80]E\.OV(_\
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MM_V<_AOH<FGM,T>K?"_]D#7O"VO6Y>%XR;75+:\DFM=P<J^Q?WD321$A9":
M/L[X9RI_PK_08@WS#0+)B/3]R*^1?^"!) _8BM,G_F"^ ?\ U6/@VO1O@=X6
M^+DF@P0_ 7XA7GANWAT.SCUJS^+?@CQ+K$S70\T;[66\UBWC6+;@&.%&QM4N
MQ#(J>+?\$NH?C#^S]^QF/AIKO@?Q5X/\7'1? QM)M<^$NL:M:Q>1X \*65RD
MD-KY)9TGM+NW91,C1RQ,&!V%" ?H'17S7_PMK]JS_HK&C_\ B*'BS_Y<4?\
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MZ@'OGPG/_%??%[_LIVG_ /I@T*O4 0>AKY$^$'A']O\ D^(?CX/\</A7&O\
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M+!+=K:>;YOV<3,A<1>82_EYV[N<9YJ7_ (5!\*1T^&GA_P#\$L'_ ,371T4
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M,CBM@)CG]*QOAY>7FI^!]'U/4+AI9KK2[>::1OXF:)23^)-;= #=@HV"G44
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MOG&6Y'V;RA(ZN)(_JLJIX*^]($51A%V_A0 1J5C4$?PBFFWC,WGD?-MQ4E%
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MK:Q'X5.FV,GBN]O6\9:C-::>&BT[3/)$\T5K<E(VG:./F)MSR1H-N[>OV?\
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MHGP_T6P\%ZVUXEQ]OTF&QACM+CS41%E\R%8WWJH#;L@ '  /2J*** "BBB@
MHHHH **** "BBB@ KXF_X*??\GF_LD_]C1X^_P#4"UNOMFO@G_@L=XVO/AK^
MT'^S#\2;/P'KGB9=&\3>-'FT/PS%!+J%RLW@[5+7,$4TL0F*-<+(ZJQ98HY9
M,$1M@ ;^WCXA\32?M;?LE?!SPQ:W8?XB:=K6D7VI:;="&[TNUM;GPYK,EU"Q
M!&\#2=I!'W))".0*^G+']E"2QL(;"P_:2^*$,$,2I##%XAMU5% P% %M@ #
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MWH,C/(K"^)'P"U?XF30&\_:$^)6@W%HS-)-X+U2"QBN-P4#*O#)T"COU)/?
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M'P"^&%]\7-1^%_PT\2:?HMS:R:QIFAMJ4=TFGM<Q)=72M*=F+>!Y+A@>2L+
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MS38_[7\ZSG:WM[H*RGL8+J!]PR/WJC.>*_"_X'?!#]JWXM-8>$_C9^Q[\?/
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M +]ZO_C1_;7_  4:_P"@9\'?^_>K_P"->]8'I1@>E '@O]M?\%&O^@9\'?\
MOWJ_^-<3\6K;]M/XA:/=^$/$7ACX":UJ LKC['I6H6MY<R>8]K-%A8KC*Y:&
M>6,[AAHY65LHS _6&!Z5^,.H:;X\\4?\'56F^)?LGB+2O[+$\,G@Z'3)XKF\
MTG_A&EB'BB>>&T:UGT9YU^PQF2Z^T)=[$(3)@0 _0>X^$W[8'AGQ)'XE\(>*
M/A_XIDN)8+^Z;Q=X%_L^>UU*.PCL7OHI;)F9YIH1)&2_,<6V%24R*P/#_P"U
MU^TG\/\ ]JKX=?LK_&^/X=W%YXNN$@N5T1KV*^2-])UV]CNHUG.V10^AR1R
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MZ4T-UHVJ6>GH^F7YVF.5F@E?<5+*SH\J,<2-7 _\$XO^"D?@+_@HI^R=K'[
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MP+7O^#0;]I;PQHUWXAU__@LM<V5C86SW%Y>7GAF\BB@B12S.[OJH5%"@DL2
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M=X<\*>'/!_AZQ\)>$]"L]+TO2[..TTW3=.MU@M[2WC0)'#'&@"QHJ@*JJ
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MHFBN-+75I'2V:>&59465HPS!"R!25!(!R 2*\S^W?\%'O^A3^"7_ (46K_\
MR'0!\.?&'P_HWP?_ &1_VR/V8=1^/+>//&'@GX%?$.X\3ZC?FTAOVAOO">AR
MV<TMK;(B6\9C1X4^4^8;5VW$Y ^RO^"4OP-^)G[,O_!.3X._ 'XS: FE^*_"
M/@FUTW7M/CO(KA;>Y3(91)$S(X]U8@^M?/'[=/P:\:^!/V7/VJ_BK\6]#\(0
M>,?'W[-_Q%O-5NO"<<CJ;6U\/:79VT#SS1I+*$\F:10PVH;F0+C<Q/OW_!(C
MXN?$CX]_\$S_ (*?&?XO^*Y]<\4>)? =G?:YK%U&BR7=PX):1@@503[ #VH
MZKQS_P I"/A?_P!D;\=_^G7PC7LU>,^.?^4A'PO_ .R-^.__ $Z^$:]FH **
M** "O _^"JJG_AU]^TA_V03QA_Z9;NO?*\#_ ."JK_\ &K[]I 8_YH+XP_\
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MBBR\.Z7\1O%S6.JZSJMQ=:3'JTUUK(81/+)#%!*S:O,T$$<4VW^U;T9#2ER
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M_$#2-,_9SUG4Y(?#NK:=>:Q]HC:'?#?Z;X@$,;H3GE]-DE4,,/&UO*N5D0T
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M_P /[[X >#_ >L>/M.\&^,KFQ7QG)JLDECI,(TB\U"ZM;:PBDCF=1:01_O\
M W31QQ[I)54_&'_!6&[^,GQF\9_ 7P)^S5\']2\::;KG[(=K>V:V^F^9>VBW
M=E>V5K>#['.(XY(IKJUNE",R>9;(H)5J]0_X.W?'7[/?A'Q;^SCI_P"TK-\0
M;?PWJ2^*1)=?"UM.@UC/VSPY#<K]HO(VQ =,N-2(@4JL]REF)"$4NGS_ /\
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MZ5X;K_[*G[0FLZ]?:QI?_!2;XN:/;7=Y-/;:1IWAOP9)!8H[EA!&T^@22LB
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M_48]+MUU"QTC/V2WG$2^9'#D ^6&R%R!\H%;6T'^.DV+_>H ?11N'K1N'K0
M5POQ6A'_  G'PU!_Z':?_P!,>JUW6X>M</\ %>0?\)Q\->/^9VG_ /3'JM '
M1>&K'2;31+.'1722S2TB2U=>C0JN$QZ_+C\Z\3_8T./VB/VL!C_FOVF_^J]\
M'5ZI#KNE?#72--\)ZI'JET]GIL$2W%AX?N[A75%V;B88W52=N=N21D>H)\__
M &5=+M;'XY?M)WEJFUK_ .--A-<?,3ND'@CPO'GD\?*B# ]/<T >W4444 %?
MCKHWB'P]!_P<\^(/@/J'B^QGCMO$MGXZL;.6S1-4;5I_!!T\P"ZC@FDELX;2
M)I3;RRVJ*\T!57"%I/V*KA_BMXH\$?";2)/'^H>$9K_5+BXALM,M-)T]9K[4
M;R9UBAMHLE0K.Q ,DC)%$FZ262.*.210"U?_  =^"M_/-JNK_"OPQ-<7#F2X
MN+G0;=FD=CEF9F3))/)).2:^,_B3\=/V?->_X*Z_"CX2?#GXH>%]0U2QU;2H
M/[#T'4H9VL_L'AOXD17,+)"2(6A:YMD:-MI7S5&*^G/#7P/M_'L-OXV_:>NM
M+\0:W]I-U;^'H+HSZ)X=D,: 06J.D?VEXA'(?MT\8G=IKDHMM#(MK%Z19^%_
M"D=Y_;-AH-BL[.9/M45NF]F;JVX#))R><\T :V<]** ,# HH **** "BBN9\
M;?&'X??#[7-*\*^)-;;^U]<;_B4Z-86<UY>W48GM[>2=;>!'E,$4EU;B:?;Y
M4"RJ\KHAW4 =#]K@\UH1(NY>JYZ5\J_\%,OV\/B7^R5\(M>\6? +P?H>O:KX
M8N="37FUYIUM+=M5UFRTRUM0\8"^>_VN2<_,QACAC,D>+F)J^;/^"G&A?M._
M&?XS>%/%?Q.T74/A?X#TVZT6_P#!-K'I=AXCU#5;R-WCU+2-2@%[;6J+>)?Q
MVO\ 9=K<ZA<W_P!BCDME/D3PM\9_\%Q?^"A_Q.T']FV__P""2W[07P NO"OQ
M$UB\T"37M0\->(I]2M/B!9VKZ.;6^M=6N]/^T-/-):W$+12PB1)+%&>[<1-:
MW8!^I$4?Q^_9V_:VU_XUZA\.->\=>'?&MG<?VQIOP_O[)XK;4XDTR"VO1;WL
MT#Q>9:6A@D FD&^S5@J^:0L?@OXF_$W]K#]J?X=?M2?!7X<^+M,\(:7X/U[0
MM6M_$4EC#!/--KD%I>6\R"2:6UN;1]*,VV,$W!"Q.\/E,']"_9P^ \&K?L3^
M%],T3XLZA8^(-<^'\$]QXO\ "GBLZA;1ZK=VOG3:C:E0MK<*;F:2=,0K X(_
M=A#LJC^RK^R1J_A+P[J\_P 9/AMX=\/S7E_NAT?3_&$_BD'8H#WTM]J-C;S>
M?<M^\E4JQ:4/<22RS7,Q !YO\>?^"@GB+X+?\%,/A#^Q]\2/A])J?A_7_!-W
MXFOO&'AC2[R^;2[^%+JTF2:"!)&ALBTUNHF;.V2=%<@9:OHSX6?%SP/\3/C+
MXL/A*;4MNFZ+I-I<MJ>@7EBK2[KR;;$;J&,3@)-'DQ[@I<*2&R*_(G]J[6?V
M4_V6OVX]0^!O_!%OX,WWQ ^.7B7]G/Q9\-_$&B?"C5/*3PK?3:GH4%AJFIWW
M_'O:2VQCU%YIB_G^=]F6Y>(2I,GTY\!?V/?VSOB=^U)IOQ]\6_M VWPLUKPG
MK]QJ^L?""'P3'<6L$UY!JUQO^WW$D[:K"9M8EB:2TGBB\M[D1FQN2]M: 'Z5
M>;S@K3J\/\1^)OV]_ ?B*<V'PQ^''Q$\/BZ>[:XTKQ1=^'-8@L_/8BQ@L+FV
MO;6^NQ /EN)=0L(9Y6"LEF@,U>O>%-<U#Q#X6TWQ!JWA:_T.ZOM/AN+K1=5D
MMVNM/D= S6\QMI986D0DHQBEDC+*=CNN&(!R7[0OP%LOV@O"^B>&;_QKK&BK
MH?C;0_$D4FDS*HNY--OX;Q+:=6!62"1H0K*>0=KJ0R*1\\?MZ?!W]M_]J+]D
M_P 3_LBZ;X"\#?VAXUMX]/O?'#3-/IEO:*?M,[-ILZM(2ZQ"T3]\Q5YA."HC
M"'[&IHBP<YH _*O_ ((V?\$]?VJ_V9G^,?Q^^*?P4^R^/O$&M3V%E9>*M0@M
M;/Q'I"R!TCCM;5ITTY3#%;(K/)-MDDN 8V15WI^QA_P3V^)'[ _[?WCCP5^S
ME^R]#_PK?XP75_J5CX_O8ECO?ABD,T\4=HL)D:&2"6(7:VDD),P2>T6Y1$B(
MD_57RQG-'ED'@T ?#O[$7QX\%? []IOXK?LC?%\:M'\2/$'CVZ\0Z-96W@^]
MEB'A^:[GL-,,E[#"\19X=/%Y+-(R1^;J3 L9Q<!=S]E*PUJY_P""A/C;Q(_@
MK7O"=KJWA2?Q%J6CZ[XC@O;J^O-0_LBS6>XMX#(MAY,.A+##$965T>1HVD(F
M$/U>_P /O!4OB74/&3^%=/\ [6U;2X-,U/5/LB?:+JR@>>2&WD?&YHT>ZN65
M"<*T\A !8Y9X(^&W@/X9Z'#X9^'?A#3=$T^W79!8Z79I#%&I=G(55  &YW;'
MJ['N: *7PLTOX?Z7X:NX?AI/#)IS^(M7ENC;R%E&H/J5S)?#_>%XUP&'9@1V
MKY\_X*L1RW/@CX+BWA:3[/\ M1_#J>XV+GRH_P"W8$WMC[J[V1=QXW,HZD"O
M>_@S\,#\(O!U[X4.N?VA]L\6:[K2W'V?RO+_ +2U:[U'R<;FSY?VKR]W\6S=
MA<[1X#_P5<39X(^"94D;OVJOAT&P>H_MN'CZ<4 ?5]%%% !1110!^4__  4'
M_P""J7_!;G]GO]L/QI\'OV5/^"8=MX^\ :-<6B>'?%TEA>.VH))902R-F.55
M.V9Y(^ /]7SSDUXS_P /N?\ @X__ .D,EG_X+=0_^/U^WGEGKFG4 ?B"W_!;
MO_@X[09D_P""-%FO8;M-U#DYQC_7U^IG_!.7XW?M(?M'?L9>#?C-^UQ\&4^'
MOQ"UC^T?^$@\(1PR(+#R=1N8(,"1F8;[>*&7DG_6<<8KRO\ X+[_ !3^)OP.
M_P""1OQF^*OP;^(.L>%O$NCZ-8R:7KV@:A):WEHS:G9HS1RQD,A*,RD@@X8C
MH:R?^#<_XP?%?X_?\$;/@Y\6OC?\2-<\7>*-6_X2#^U/$/B/4Y;R\N_*\0ZG
M#'YDTK%GVQ1QQKDG"HH' % 'VY1110!^2?\ P78_:[^$/["/_!7#]B3]JSX[
MR:DOA/PKI7Q!;5CI-F+BX_TG2H;2/9&64-^]N(\Y(P,GM@_#O_!QO_P7<_85
M_P""H'[#_A7X ?LPOXN_M[1_BG8Z_=CQ!H*6D(LXM-U.W;#+,^6\RZBP,=,G
M/&*_HH\;_";X6?$J:WNOB)\/-%UQ[-66U;5M,BN#"&^\%+J=N<#./0>E>#_M
M2?$G_@E-^Q3X6;Q?^U1<_"3P39^1<3VL.L:?9K=7XMPK3+:6RH9[R10Z9C@2
M1\L!MR1D ^3_ /B,!_X)$I_RV^)G_A'1>G_7U7Z0? CXS^$/VB/@IX0^/GP^
M%U_8/C;POI^OZ)]MA$<WV2\MH[F'S$!.Q_+E0E<G!R,G%?BY\=?^#CO]B;QI
M\3(?@;_P2\_X)5WWQO\ $E]<WMM8ZA-X-2SANVB17CFLK*"WGO+R-HQ/(RRI
M:/&(U)4AF*?L1^R)KOQ!\4_LK_#?Q/\ %SX>6OA'Q5J7@'1;KQ1X3LK![6#1
MM1DL(6N;*.%V9HDAF9XEC9F90F"3C) /2:*** "BBB@ HHHH **** "BBB@
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M3\)OAG\8/^%*^$_&5O-?ZQJ[Z]H7A;0[2&<W6K7US/HT\5I;-%I=]Y4\LUG
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M;B@"UXY_Y2$?"_\ [(WX[_\ 3KX1KV:O&?'/_*0CX7_]D;\=_P#IU\(U[-0
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MQZSX;T6VUJP\+W5JI5!;&Q\'3R ' W?Z3+<9)],=J[$_LC_M+GG_ (;$TO\
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M"<#T+P5_P2<^)%[X-TJ^\??'?5['7)-+MWUBQL=!DFAM[HQ*98XW^WC>JON
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M%_PB_BS4]&N/-'@CPVHW3:;<02LF&;,;,4)"D@E5(YG_ (;Y_:P_Z-I\.?\
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MBG7M#AT?6[BWMO#'P^FUN2SU7=90078D@C>2UD%K/J,(*X\R.ZF4Y&0?)_\
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M#X-\!_VE_P!J_P#X*M>/=>T3]L7]N_\ X4_\ ;K3=5AU+P7\._$5DVN7MW8
M17-E)J:6J2+!_HKZB9(8]KVUU'"^5N(R/UU_9>N_#OC'X$-X;\1:8LDZWFI6
M7BWP[J,@NTTZ\EN9GNM,.]1YD$?F>7$64+);>2X!1U)^(_\ @A5\+/ /Q&_X
M(J?"GXM_$;XCZIX7U+3F\=7&J^.-/U>.SO([677]3CN3<7<BM^ZV6MK(S.<!
MK&W).(@* -+_ (*&_P#!+3]D?X7_ +#"?"K]A_X+P^#?B)I^EWP^$6I^#=<;
M3;RVOI&M+N>\GOVD#E6_LVT62YD<RE5B@C=6F5&J?L0:U_P4)^!O[27P-_98
M_;7UY?B9KE]X5\07E_X\T/0[$ZCX7M8K=7.EZQ=(\FZVG\[2MTL0A9[W3K<9
MNXV:<=#\1?B'^UOX]^)?A+QC^R_\)M)?1]<UB'PY87FO0L;KPA9^3;26:_9G
M51*(XGEUBX^<A98+.T;,MH2.V^*WP'^+/[%_PWTOQ[\$OC=KOB'6M0U;2]/U
M:RU*S6>X\5^(;W4(;?\ M"5H@)#$OVJ[N)H ?*CACW#9';XH ^V/+R,,<XH$
M0'>N+^ /Q8U7XS_"ZR\>Z[X&N/#=]->7EI?:/<7*S^1-;74MLY25 %FA=HB\
M<H $D;HX W8KMJ "BN7^)WQB^'/P<T6'Q#\2O&.GZ+9SWJ6L=QJ%P(U:1E9L
M<]E17D=ND<4<DCE4C=AR<?[:?[,[_ BT_:6D^+>FP^"M1CE?3=<NEDA6Y6-9
M&D98Y%$A")#-(QVX6*)Y3B-2X /5*;OKS+X>_MB_L\_%/X<V7Q>\!?$-=3\,
MZAH^K:I::M;Z7=^6UKIEP+>]8@Q!E>.4[?+8"1]K%%8*Q'BNB_MS_M&W_P 1
MO$\_CS]G'_A7_@BQBTR;PMXJ\77!:UU*+[1/_:45U+"Q&GW$<,:%3(#!&PE+
MRLB L ?7-%<A\'OBJ?BEX>N+K4O#5QH>M:7=+9>(="NI!(UA=^5'*465?EFC
M,<L;I*O#HZG"G<J]?0!Y=^R3JVKZ]\*M6U'7-6NKVX3XF>-+99KRX:1EAA\3
MZG##&"Q)V)'&D:+T5$51@ "O(O\ @J]_R)'P1_[.J^'?_IZAKU3]C5@OP=U@
MD]/BKX\_]2S5J\E_X*L:A;7'@GX)K;SH^W]JKX=;MK=#_;4/% 'UI1110 44
M44 ?D'_P4E_X.5?VF_V&/VV?'7[*O@3_ ()KWWCK2?"-U9Q6?BN'7+V%=0$U
MC;W)(2.QD4;6F,?#M]SMT'AO_$85^V5_TA^U#_PI-0_^5M?O9Y:GJ*/*C_N"
M@#^:G_@HC_P<>_M:_P#!0/\ 8Q\<_L?ZS_P2\UCPQ;^-;&WMI-=M]4O[I[3R
MKJ&XW"(V"!\F';C<,;L]L5^L7_!LCH.O>$_^"'WP2T+Q/H=YIU]!_P ))YUG
M?6S0RQ[O$NJLNY' (R&!&1R"#WKTK_@MI^T1\5_V1_\ @E]\6/VBO@9XA72?
M%7AC2;.;1]0:$2")Y-0M86.T\'Y)''XUE_\ !!G]IWXQ_MG?\$HOA3^TI^T#
MXE76/%WB3^W/[6U%8%B$OV?7=0M8OE7@8B@C7WQ0!]@4444 ?E3_ ,'.^D_\
M%>M2^&7@5/\ @FE?>.(_#,WV^#XDQ?#J18]4WA[>>RD$D0%U#$HM[@,T+HIW
MA)-P=17Y\?\ !/3P5_P;0^)/$L,__!0#X@?%G4/BIK=Q=3>))/CTUUI5K-,7
MDF%Y-):2$1M*I'^MNI"[#) W[:_I9>WCD^^-WUKQ+]K+_@FY^Q%^W!HTND_M
M,?LY^&O$DTC;UU:;3UBOHY!"\*.+B/;(2B.=H8E1@<<"@#X _P"#- 6'_#J[
MQ&\(A^T'XRZL9Q'C=C[!IN-WX#C-?K8 &YS7X\^//^#7'Q[^SUXP_P"%@?\
M!)[_ (*&>.OA+<+JD=W#X=UB\ENK"+;;>6[9C(\V5I%4[I4("DCG"U^IO[,F
MC_&+0?V=/ >C_M#ZI;WWCZT\%Z5#XWOK20-%/JZVD:WDB$  JTXD8' X/2@#
MO:*** "BBB@ HHHH **** "BBB@ KX3_ ."NGAF#QU^T=^S%\-]4U;5+73-?
M\1>-8=4&DZI-9S31P>#M4O(T\V%E<+YUM"Q /.S!R":^[*^)O^"GW_)YO[)/
M_8T>/O\ U M;H \>\ >._P!M+QU_P5,^%OPH\7?&C4/'?A'P'\5/$=SK O\
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M>=)+"QA^T1%[-3&P61BK+)&-CLQP?@^BG]ISP:?^H-\6_P#U,M(H ^E****
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MW^Q_"_@W2](TG[=\(KR2?[+;6D4,7F,FN(K/L0;BJ*"<X '% 'G_ .WD@/\
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M!]_<16O@?X@:AF:YMY7<1QZ5JSG):8EE6WOV.+G_ %4Y6Z$<E_L?\$S+AO\
MAWE\ [0_=7X&^$F7CC/]DP9_E7M7B#PWH/BS0KGP[XETBWU"QO;5[>\L;R%9
M(;B%U*O&Z,"KHRDJ5((()!&* ,-/@Q\)7&Y? &FD?[,%/_X4E\)?^A TW_OQ
M6?::EX;^ 7@W0O#/B+7]6N;)M073;35-4D>Z-JK;V@2XN2,[% 2W2:9B[NT0
M>2260LW;I()%#C^( B@#F/\ A27PE_Z$#3?^_%<_\3M!_9P^#O@J\^(/Q$\.
M:5I^EV31))+]C>626:65(8;>&*,-)<7$TTD<,4$2O+-++''&CNZJ>M\<>/=&
M^'^A/KNM^9)E_*M+.WCWSWDQ!*01)_'(V" H_EDC#UGX+:%XH^,>E_&'Q7>7
MVHS:!I[0^&M)NKA#8:/<R"9)]1AB503>RP2_9S/(TC10"2.#R5NKP7(!\I^-
M?AGXXB_:U_9E^.WC;1IO!LFL_&+4M-T?X=6-TGEZ7IS^!O%=P3J#0NT5YJ$C
MV\#2;6>"UV"&W:3]]=77L&A_"KQ?;:-JGQK^!+65OXTM_%&O)<:;?S-#I_B6
MW35KO;9WKQJ[1D9/E7:H\ENS$A)8FE@ED_;!C6/]H7]E)%[?'K4O_5?>,*]"
M^"^HV6D_#_5-0U&ZCAMX?%WB!YII& 6-1JUV2Q)X  ZGI@9H ZOP[KEQK?AZ
MRUO4?#=YI%Q=6<4\VE:CY1N+-W4,89#$[QET)*MY;NN5.UF&"?/M7^'NO_';
MQ3*/BSX<^R^#]'U3.F>%;P13#6+B"6-X=1N=C,/+25-\%N3QA991YFR*WD\0
M^&=;^-/B#P;\4OAK\9Y+?P@L5MJ5WI^FO-Y?B.$M'/:LMQ'.GDQ $NRHI%R"
ML<I:$/$_=^'O%GASQ3'<2^'=5AO$M;R>TN&AD#".:&5HI(SZ,KJRD=010!SW
MPN@C'C/XB8'_ #.,/_IFTRNVP/2N-^%W_(Y_$3_L<H?_ $S:9794 &!Z4WRE
MQ@>N:=10!\PSH#^U(5_O?M- '_PV%>M7/Q&\7^#_ (QVW@?QUH:MX>\1,L?A
M/Q%I\;MY5XL#22Z??ISY3,L4DL-R"(I,M XBE6 WGDT__)TO_=S0_P#585]!
M^,_!/ASQ_P"%[OPIXIT>&^L;R/9-;S9QURK C!1E;#*ZD,K*K*00" #4R2,H
MR]*?Y;^HKCO#?BRU\&:[X?\ @EXE\0ZMJVL2>&?.MO$&KQ6RRZRUJ8H;F23[
M-'%$L^Z6&1E2**-O/)B0+&ZQ]I0!"[&-=[$8QFO&-4_:(\4ZQ\</".@?#E-%
MO/!.H>,-2\+:YJSDS2W&IVVGWMRZV<L4WE@6TVGSVMPKHS>>7C_=M;ONZ?Q1
MXC\)_')/%'P2\-^--?T^XTUK2W\1:GX=::UD@$Q,CV<5\J'RIW@4;S ZW-O%
M=PRH\+R02UC_ !/\+>'O!/B?X$>#_">AV>EZ5I7CZ6STS3-.M4@M[2WC\+:X
MD<,4: +&BJH554    =* +GQ9TN?1?V/_%6BW<>V:R^&][!(!G&Y-/=3C.#C
M(/I65^S&%_X73^T05'3XQ6(_\LSPS_GZ5K_%S5+W6/V0?%6K:DVZXNOAO?2W
M'R[?WC:>Y/ Z=>G:N3_8_OKN]_:#_:HM[J;<MG\>-.@M_E'R1GP#X1DQ[_-(
MYYYYH ]\HHHH *_&*?P3X3U7_@Y_M_B3XJL]$A\<Z=XH?3;/15^(FGR0_P!B
MGP:)(]8%N=0COAJ<K".!K+[";9;=C,&D=?M#?L[7Y.:=^QI^T/I__!P9JGQ>
MM;2WL_@9%XJA\1Z=I.F^-K9;:W\6R^&/LUU=MHPU6-4FN4NYI);S[%)<.ZIA
M5266Y8 _4V'Q5X<@@6.76[*-T3F-KM,J0.1UKY"^*OB;PYXU_P""D_P;\9^$
M==L]4TC5;SPQ>:7J>FW23V]W;R^%OB>\<T4B$J\;HRLKJ2K @@D$5U?CO]N?
MQ3\'OVQ_#_[.WB_3_!,/A7Q#=:3I6DZAJWBF73M8N;^[2X_=VD-Q!]FU(J5M
MM\<5RMQ&LVXPN&C+_/7[*0_XK7]BT_\ 5+?AG_Z@/Q&H _2VBBB@ HHHH *1
MD#KL;I2T4 ?*'[7/P@_; \.7D.H?L3>'M!U+6KKQM#XAT*X\1:LUC8^'[HO%
M_:EI=K&CM/INHV8U $QH\T.HW4,P1U?S['S3]K;PO^U3\(/'NB?\%"O&G@74
MOB-<>';NUTFQ^%OAF\AAMM!M9+#7[*>]>YN76.&UO;F^T.:]>19?L,5DSM)<
M0VOFC[X\M>U(]O'(NQ@<?[QH _&_]G/]BKQS]KUKXI?M,_MRZ+X!^$/Q8OM0
M\1>'_@?\/-<&H7OBC1[& R!H1:7%PCSQ6"V=L\>EI=2Q1Z=8M%=--F5OCC1/
M$?[0W[$G_!-GPW\)? O[??AWPWJ&K_$J;PO\1_A:(TDO-'O;77M1N;LZ5?Q2
MPV-U)#%=Z?/>F:X6,?9X+:2\6.:*UE_H6_::^"FH?'GX(:W\*= \:7'AJ^U"
M&.72]<M;6&<V=Y!/'<P.\4J-'/#YD2K)"ZE98B\9X?(^2?\ @F7_ ,$\/BS_
M ,$K5DT^\N]1\:>&O%4&GZ!!IL.LP:G<^!+&UNM0NK:/[6;&QEU6UDN]5U&2
M25HUEM?M$$20R0K-<H 7O^">/QB^&W[>'["GAOX<_#;PUX\6W'P[\C4/B)KU
MJRH?$,EO8W#W\>H(UN][>F_FNI9+BV5&CNK&Z\W[,YA63H;C]DO]OKQG\:]&
MUOXH?M#:'<:%X+T;5K?PAJFGV;"[@U;4AL.N"V9/)66PLFN--M89FN2RWLUS
M/,Y+0/V?[&CP?%3XL>)OVH?A&/$6F?";QIX9T6]\*Z5J5XT-GJ^I3^?=WVL1
M:;-&9M.WK-;1L"8//N$NY9+<LRW,OTL(U!S0!G^$O"7A_P #>&]/\(>%-)AL
M-,TNSCM--L;9 L=O!&@1(U'9550H'8"KSSE$+D=!GZTK2;1N)KYDM_VH/CO^
MT!K?B'P]\)/V9;>]\%6.DZ>=7D\7^*)-%U?4;>_MC<8L;/[+(I8VLD0474]I
MB9GBD,1CD*@&/^UM\-+[_@I/\-K?X8^ /#%NWP_U:'58;[QMJ6M20V^J6\VG
M300BU@LP+F]L)9I/WDJ75@72W1HI+BWF_>?ES\3=!_;L\6W/C'_@WNCO%C^)
MT.H6</@7XA7FB"#2;_X36UCLM+:+")B3S?W-Y< .'B2]M_,N)(XX)OHYO^")
M?_!.']HOX#>!_@)\.?V7_!\&H_##Q\-#\;:U:Z3)8:MJQT?7M.BU#[7<QRPW
M#&^TIKN=5DEE"QWB/"'98)%[C]MS_@E;\(O^"=_P'T7]N+_@EY\+3X3\;?L\
MZKJ'C.;01K]U=+XJT5]/@M=7TJXFOI)WV-864)B W>6;8K"L<DWFJ 6$^)GQ
M*_9E_87M_A3_ ,%'K[1/AWX@\)?VI!X/\?6MQ!-;6.Y]<L;.Y9&2UM]7QID2
M3/;VI.H7"W9#:?$^'D]4_8,_X*#^'OVH?V O"/BW1_@FNCZWK6EZAH&B:+I_
MA^_U#PZ+ZQMO+*32Q0%M*LRX,.W4!;L&CD6,SQ^5<3]QX*^.'[-O_!5OX#>#
M?%/P#^+_ (7U"W>XTW7M<T'5M-M]7D2PFA:'4=(O;/SA'')-:7-U8R;Q((7E
M8A&9%KCOVT/V</'G[,O[)?B3XL_LS?M*W'A?Q7X1\.*^AWWBY(9X+JZ0:B([
M4-$;9<W5WJ8CAM;@7&F6K"W%MIT1CBV '2?LBZA^R[^P]\-O&WAWQ]\<_ _A
M&Z;73XG\3:'JGCJTCM_#MI<^5I]EA9IB;.WE6TBVQ,S1QS2O#%(Z*E>Y_!3]
MJ/\ 9L_:2MKZ\_9X_:#\#^/(M,\O^TI/!?BRSU1;3S"XC\TVTC[-QCDV[L9V
M-C[IQ^5?_!/C0OBG\2KCX._\%9?V\?#7A*'QC^T=\9[6UUF"\\!Z?!#H7@VR
MTW7[GP["TLMKYR22:ZN@RQ7;2M)(+;0U\PM$N?UB\.7WP>U+XFZMJ'A)]!N/
M%4GA_3AKEYIZPM>R::)[[["LTJ_.T"S'4?*5B55WN"H!9R0#+_9W^'_B'X<?
M#O4O"_B=(5N+KQSXHU2)H9-R_9[_ %Z_O8#T'/DW$>1CALCG&3\K_P#!4+]G
M_P 'Z!XH^#OQNL=;\0C6K[]ISX>VEW"WB*Z:RDB;6X#@VI?RN"JX.WC:,=*^
MH/V;/BEJ/Q*\%:M=>)]:M[C5-/\ '?BC36AA"*\5K::_?V=JK(/2WAB&XCYL
M;CG->,_\%7F_XHCX(<_\W5?#H#_P=PT ?6%%%% !1110!^0O_!2'_@Z_\,_\
M$\?VUO'/['&H?L.W_BN;P5<V<+^((?B"EDMWY]C;W>1";&39@3[/OMG;GO@>
M'_\ $<EX,_Z1LZI_X=:/_P"5E?6/[=__  =(?L0_\$__ -K+QA^R%\5?@1\4
MM6\0>#;BUBU'4?#^GZ:]G,9[2&[3RS->QN0$G4'*#Y@>HP3Y%_Q&K_\ !-__
M *-E^-G_ (*M'_\ EC0!\:_\%,?^#L/PQ_P4&_8>\??L>Z?^PWJ'A6;QM86U
MLNOR_$)+Q;/RKN"YW&$6,>_(AVXWKC=GM@_J_P#\&NC%?^"%7P-"_P#4S?\
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M@>E&!Z4 <[XR/BQ+G2;[PQI5K>+:Z@9+Z&:<QNT)MYT_='&W<)&B)W8&S?\
MQ;0>"\/ZQ!'^T-XKU/2O@4\?BZ;P;H,>MZP-9B_TO3DN]8-E;D;L?NI6OVR
M"?M/)( QZ[Y:BO._#" ?M7>-%'_1/O#'_I=K] &O\,+#Q-'%KWB'Q9H:Z7=:
MUKTERNG_ &E9C#%'!#;(2Z\$NMN)0!RHD"GD&NO'2FF-&ZBG#CB@ HHHH :8
MT;J*JZSKFE>'=*N==\0:I;6-C96[SWEY>3+'%!$BEG=W8@*JJ"2Q(  R:XGX
M^_%/XK_#?P5?:M\'_@%?>/M<AMQ+::+!K4&GQS_O &0SRAMC[-S+\A#, I*Y
MW#C-,L_!7[3GBW4/#'Q"\?R7T?AZY@FO?AK-8O9+;M'=7)@N;N&4>9=QNR*
MY+VDLFGLT.X"04 =;^SQ<Z_XCT[Q%\3]8GNUL?&7B :KX;TV\^_8:;]CMK:
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MU235/&%]K*>(_$'A>2S\F&TT:\26W:;38# D;+,RE'3SI!-*R%A R@ ^AO\
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MI4<EQJ>F37%[90VT\I&]+6WNM12^9BP6,02-P&?.+_P4;_Y-^\._]EX^%O\
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M:-J6I:?X^&JG^T])N-/BN(?+%G#B-AJ,;++N.=A&P9!KW/\ :G_:2\%?LC?
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MX8U2-Y[R/QA-=ZC>)9Z5XKL[618/LD:1>:WB%&="[;/)(#-W /L*B@'(S10
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M:]AN-1C::^AG-TD1MYY)71W\Y71.8_;)_;BNO^"C?[8W@;]E3]I[X<ZYX?\
M@'\*/B):#XX6T&DVDJZOXI,%S=:9X>N(X+^Y-P@6RN&DAMS-+)(XMS")A#D
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MDWX=_P#!U3_P1M\=ZW)I.J_'G6?#$<=JTOV_Q%X3NA [!E'EC[.LS;SN)&5
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MWB7]D[X"_#?2_A5X ^.VB-I6CVHM[-M:^(0U"XV@D_--<SO(W)/&[:HPJA5
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M'@3X7^"]#\-ZU>6?AS5/&OC]H9=?AM]8U72VF6..%O*Q)I;,5)R!,G7OV/\
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M:7=+;7RF-E\N0PQ3 <CG]W-&<C(R<<$$#YU^ L:C]H7P'U^;P_\ %<MENO\
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MS))(Y+.Q[DDF@#Z/M/#>@Z?+Y]AI%O Y7:6AA5<KD'' ]0*\/E_X)C_L;O\
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MOQ^S;\8+B22_0^#8;[X8:@D'E#3[<!)&CA9T0W?GECAF .0"-HJE\;?VE?\
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MV]^U_P"/-8TKX^_LN7GB/P;<Z?;M\?+BVCFDNH9 TLW@OQ1 BXC8D9:0')&
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M75]HEQ:Z'KM]$H1E?S8?L^C6T6975@9"0TIWA #[#HHZ#FC.>E !11D'G-%
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MM0!UM%%% !1110 4444 >)>&A_Q?3Q%Q_P UHC_]0JUKVVO$_#>?^%Z>(O\
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M2-%)[99@,]J .U3[M?-WP>S_ ,-.>#?^P+\6_P#U,M(KV5/BA/MP?AQXI_\
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M;,7_ !-++]UUX_X]?FZCTZ4 =G_PT]^S[_T5S0__  -6C_AI[]GW_HKFA_\
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M^F^/IM-L_BY;V,GAMM-6TTIKTSB[8 W.X6H@"]29>^W(!]__  L^/6H_$/\
M:<\7?"G2)M+NO"VD?#/PKXET74K/+274VIZAXA@E;S-Y1X3'I5NT8501O<EF
M#*%]>KX0_P"".1\-&W\+GP9-J$FC_P##%?P9_LAM65%NC:^=XL\HS!"4\S9M
MW;25W9QQ7W?0 45@_$+XA^$/A5X.U#X@^/=9^P:/I<'G7UYY$DGE)D MMC5F
M/)'0'K47@+XJ_#/XJ:?)JGPQ^(NA^(K6%E$UQH>K0W:1L1N 8Q,P!((.#U%
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MYO O[0"6+R>!?CF-/\+^+M/LYKK4+=KE_L-U;QAF-Y:S2 !X2B2/L8B2-8I
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MX%UC6Y;'35DM(M3C_L_9""JJ8M5N(T=]WFS0PSOLPJIXW_P3M_X);:K^SO\
M$/Q%^U1\6]!NO$_QFUYKT^&KC7+8V^@^!]/D:>2WTRQ@5F$$:27,JL(1A$FD
M2+"9W@'SKKO_  <-^$/BC_P3[^%:K\.=4\<?$9M3\*)KU[KZW6AV6K:W8QO>
MC4[;[%;R/+;OKVDQ6AC\J*$-<JLIAC;)^RKSX0?!SX_Q:#\-_P!E?XU1W'B-
MOA'9Z,OQ>M?%5Q>ZC866@ZMITL=C(]A>6EW*M^;FZ%S)'>1;VM4W%R!7Y_\
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M\?:YHWP2^'7A#PQKEUI5A-X@T_PSI%O9226OF72VDDR0JN5WK>*C$=5D /!
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M-->:AXR\%W6N6[VZ@*8D@MM2L&20LZ,)#*P 1E\LE@R\%_PK_P#X*:?]';?
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MH= FLX&,4>+I([A9Y-CMY2@HV1*_[/;AZUY*/V)?V8KC]HJ3]J_5OAA'JGQ
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MX:>/-+\7?'OQ!>_VTL+75H)=0TS0-2^UV%BMC#)]AENI1=IL9(HYHW$EN(Y
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MOX\_$_\ ;M/C[4+KXA:3\,['X8_#OX8V,T<&I6VI_;XUM[:6WB:.SN;"SDU
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M,9]Z^:?V4(/C?%^UWIUQ\3-;\-WF@S6/Q6D\(+H]E/%>0P'QEIA=+QI',<C
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MU;3H[BZM['P?X<M](GMK:#3T>'?.D3PVB;7.^1[F>4E0!&OBW[//[?7@J_\
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M)/G8QKC)&#]Q^&M?T[Q5X<L/%&C3M)9ZG9Q7=I(RE2T4BAU." 02#G!&1WH
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M\?:YH^H:=86FDR>#=-URY+ZS;RPO')/J<:Z<X@N(,?:K+S RQDO[9_P2Z_;
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M4;V2^\9>%YO "Q:+X;T9KBQU*ZFMCHM[)<WMQ;"2..Y2X@6WD>0S7&J6\:@
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M%_Z,6J?A,C^RY #_ ,Q"\_\ 2F2K6K,1:*<?\MXO_1BUY;X+^.7B:Y^(6G^
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M_P / _V>?^@+\5/_  PGB_\ ^5='_#P/]GG_ * OQ4_\,)XO_P#E70!\S_\
M!;G]GBS^,'B7X1^/M:^)?@K3=+\+WU[%>:'XQ\,:CJBZFTFH:)>LJ+80RR1J
M]OIES:2,0!Y>I$@[PE:?AC]ACX/?\% /^":?PG^#]U\5?#/B71?#_P *K3PQ
M#XP;X=1S/+=0Z?#92W]C]K6*6U5GA\Q%"A6 C." M>9_\%4Y_%G[6WCOX7?%
M[]E#XV?$3P3JGPYO;B;4-)N_V>?%_P#Q/(SJ>B:I#&+AM(E2W9;G0X!O:"92
MDS*R.F])/;?V!/VCO!W[,W['?P[_ &>/C'>^.M:UKP-X3LO#YU30/V>/&D$%
MU;V4*VUO(RRZ<[>:T4<;2-G!<L5"C  !ZQ\/?V3?BU\([6ZTSX=?M,7,-O?1
MZ:U\VK>%X+V:XNK;2K+3FN&E>0'=(EE&[#GYF;DYKO/@G\(]>^%<?B74/$_C
MM_$6J^*O$0U?4;XZ:EHJNMC:621K&C, !'9QG.<DDUQ__#P/]GG_ * OQ4_\
M,)XO_P#E71_P\#_9Y_Z OQ4_\,)XO_\ E70![917B?\ P\#_ &><X_L7XJ?^
M&$\7_P#RKKM/@A^T9\)OVB=/UK4?A9K&I3_\([K1TC7;/6/#=_I-U8WOV6WN
M_)EM[Z"&92;>[MI02FUDF4@D&@#/_:F_:*T+]E+X$^)?CUXG\+:IJ^G^%]%N
M=1NK/28E:4QPPO*<EB JG:%W<X++Q7C/[3^K?%?XJ_#7PQ8_%_X-> /"*R^.
M98A8_$C5H-7TB11H]ZT,TX11'@2%MJ.,^9'&>XPS_@L9J_BC4OV'/B=\+_A_
MXKTC3=8OOA/XGUN]BUOP]=WL5UH^GV:_:TBDADBCM[CS+FS"&5VR&D*Q2!':
M/V[XQZ58:UXG^&^EZ[807<$GC6;S8;B)71R-%U0\J1@\@'GH?I0!\_\ _!)G
MX,> _AY\-/\ A(].OO@OK'B._P!!TZ+6_$_PG@ACDO)-US(R7"Q#;$BN[+%&
M,D+&59F*;JZ$?\$[/$^C?M_:K^W;X#_:#71[C7)?+UCPW_PA-K-]LLY+;0X)
M[=[LN)&RFA0>4Y!,!NKK:#YIS[3\#?!/@WPAX T0>%/"^GZ:LNAV9D6PLXX0
MQ\KJ0@&3ECR1W/K7;EU!P30 ZB@'/2C</6@ HI-RXSFC<I&0: %K,\4^-?!W
M@?3UU?QKXLTW1[5I1$MUJE]';QF0@D(&D(&X@$XSG@UIY%? ?[=OP=^&OQL_
MX*@?!7PC\6/"%KX@TF;Q!HMI-I.I@R6TD,GA?XF7+JT9.TYFT^SDR1G=;QG^
M$4 ?80_:'_9T X^.W@D#K_R-%IQ_Y$K@/VG?C/\ !/7?@OK%_P"#?C/X7NO$
M>@PKK7A>WTWQ99)-<:C9G[1!;!FDX29XQ;R#(WPS2(2 Q-(/^"7G_!/,#_DS
MSP'_ ."&/_"FK_P2X_X)Y*S./V/? GS=O[#CH ]XMIC-%O,>WV-?C+^QM\7_
M -HN]_X+S>(M \;_ !Z\6:YX6U3XJ>*M/TCP'<'4H[70K>(^+D+N7A^SSQJN
MD6$@&\*JZQ9;"Q5@/V:MK=;:!8(\[5&%W'/%?DO^PG\&/VR_@5_P6S^)FKVN
MC^(+?X=_$#XA>)KCQ-H=YX.DVV5C'-J=]IVL2:U)8K:74=Q<ZG)%%:V<YNXH
MI;.*=G6RG10#ZTTO]EW]E>#X\VW[9MW^Q)XD_P"%N0V?R^+FTES<)*=,&FDA
M?M'E@FT'DG"\KC.2 1];ID* 12XXP:* /DW_ (*6_"?X&_%H>%?!OQY\<+HN
MAZO/-:MJ6FWJP:CIE^ICEL]0R20UF@6ZM9T='B9-2!E"Q*[#\S?@5^UCXE_X
M('^--2_9@\1^*-&^.1^('C#4M<\.^./!^M1ZMXAOEC.CH;&YL8M[*TD+R2/)
MDS3/'+("P1*^J?\ @H9_P3E_:7_;(_X* 7'ASX%_M17O@_0;GP_'J/Q0M[?5
MKNW:+2KZ"#3K*."%4,<\A;2=8=V$L9)>U$JO'$%D^./V:/C;XA\.?\%8)/!/
M[#G_  3$T.&+X':/K5E\3/#WA.:S2_\ $&L))?6(G2XNWMHA#]LBTU/-42/;
M8E5/,1W5@#Z(_:E_:._X+!?M_P#P5TGQ3X"_8FD^#?PIT:33O%/BZ?QQK,4V
ML^(K"*VFFFL(M.",L\+_ +B40R8+20K'(C(SQGQ?_@E3\1?B=_P0KT ?$+]I
MCX >)&_9Z^*7DVFE?$;2XUN)M \B[OY[.YUFTA_U-Q-]LFAF?:I2.SLT.#&5
MK]+OBI^VQ8V"^)/!'QG\)ZSX(.AR:7/X?UBQU*>P>]O9);)XK>*]U:UL=+EE
M$DVUK5;V<S)',A1L21KT7P]_:;_8[M/@CX=\+7\]Q)I.L:M9Z3)IEU$/$4D>
MI:A=;$CU*?3GO((YI;V1XVEFEVO<;OG8D$@'GG[:?CC]D?X&? VQ_P""B/PZ
MU7P?%I=O>1QMXJL]3N&L3%?:C;2*\8LWVB,ZQ:Z9<WNQ2SV]M>%PS%@?./@/
M_P %+?V(OC!\>_@?\3/@+K5G<R?%WPQ?ZKK7AVWTA-0_X1.1T1+J7= K2Z?>
MMJ$UG9W*A5AN1()B082[_#?PG_X)'+\<?A[I/_!1S]A*'3?'WP5\4>)-:U/Q
M9^S7X@U>[T[2+C3+/5;ETL=,$;&.6:.2W,2I,5MY9U+YCA(C'TI_P3<^/W['
M3?MM:?X>_96_9\T>X\<6?@.;PSXV\-^ =#M[%/#&CVNHLOG*MU)"+/RM5%W]
MJL-]S.ZZQ82+<7$=JJJ ?H?\.?VO/AOX\_:"U+]F"[\+>)_#?C*Q\-CQ#:Z;
MXFT5K9-4TP3+;RW-I(&9)EBEDBCD&0R--'\N'!KUVO%=.^"OQ<\<?M-^#_VG
M/'6O:3X?3PKX)U;0E\*Z+&+QKHZE/:37/G7LL:,8E;3K!HUBBB8-'+O:1754
M]J;..* &F6,=7%?F_P#M)?\ !4CX9ZEJ/CI?CQX(^,5O\(?"?Q,N? -Y;^$O
MAK+/!XBU*.XCM)+2ZG=B9[6>8SVXCA39,EQ&OF"0%3[A#XA^*WQK_;&\"^&/
M$7C_ %NQ\)MI/CW5+C2_#^H-8(-0T+Q%HVF6*N\1$MQ#)!<7CRPRL\;,R\ !
M0.3_ &JF^ _P$\4:9^SK\=OB?I>B^'?'#>%O%UCK7B?4K6(ZEJWAC7M';4KB
M[GN"I>>2W_LB0D%MR6=Y+^Z,9>0 _+O]M7XI_"R+QU<?MD?L'7WQ&\-_ /XI
M:'H/A3]I ^-O#-Y'IBZ?JTXFL=0BFN6:6X@E5);2]>-V:."98XFS/'L_2CP1
M_P $_?!G_!-SX.^(_C-^Q1\2]:?P?I_A_P#M>W\(WFJ12626]OIVH,\D#A1'
M/YS2V4A\[@BRC/FX^4^S?LXZ/\ /VR?^"=OA?X">)[&UUCP]KWP=T73_ !+X
M=DC>!XK.\TF+8#&ZI)%E&W1OM4@IN7!7C\\?^"8G_!6WX=_LA^!O$_\ P3B_
M;ZU6-_AWX \1ZIX:^'?Q2\6:];QS>(_"W]MWNCV9EL9V26X@BEM+FV>6W$@A
MCCC#Q)'%), #V7]@SXW?M.? CQEXX\!>./#>A^#_  ^WC"\UFW\"OILDPT>S
MDANKF_FC%LS8*FP:?R;82H+C5)4*1B.,-?UG]MCX+_\ !,CQ':IHO@*\^,M[
MK/POUWQEXD\:^ W^T""QLI2TMTTDCNK1S:A(EL_ER,UM']B23,-M%M^@O%?[
M;'_!'V[^&X\*3_M;_ '4]-TRQ!TW18?BAH:N?+V/''$7NT"L6BC RR@D#<PY
M-?E3\!M9_8P_9B_85_:1^)+?M-?#:Q^)O[1MGJ'AKP3X#USXUV'B:X\%Z%=V
M):Z@GN;#=L ;[?<,R+(TZVNGQ*+B[=(90#],/V'/VI_C-:6GACP%\3/V3[[P
MUI7Q"^,GCG3[#7'\66MT]E>C4?$&JO!/;HNY=HLYX"P)!=0>AJ[_ ,%8/!?A
M]E^!_P 01:S+JR_M,?#JP-Q'>2JK6W]O12>6T88(PW_-DJ2"!SP,?,G_  3L
M_P""J7PH_;1UGX2Z!H_@K4_#\WA;XL>,O'?CK7M0NH+C0=(@OQXF@@M!J%NS
MJL\EQJB"-;I;7S(X'D7_ %ENDWU3_P %2=5TS7/AK\"=;T:_AN[.\_:D^&\U
MI=6THDCFC;6865U8$AE((((."#D4 ?6]%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %?$O_  4^8?\ #9O[)/\ V-'C
M[_U M;K[:KX1_P""NS^,4_:-_9BMOAO9Z6WB2;Q%XT70[C6II%M+9QX/U-IW
MD6-6:3-JMQ&J\ /(C$X7! +'[5?P>T_XW?M\_LDJWB]M)NOASX8\0^-8X9-+
M>2/4TAET"U:U$NY5C8BY+;OG(*QJ5'FAU^X;:;S8UQ_=!/%?GK^WQ\(?&OC/
M]O;]C#QMX&O=8B@T>/4W\81V.J2I;S:5Y^APQF: -LD5+RZM6Z??\MCGRD*?
MH3;0)$OR'^%: /"?^";G_)O/B+_LO?Q5_P#5@>(*]\KP/_@FY_R;SXB_[+W\
M5?\ U8'B"O?* "BBB@ KY1\9^/\ ]N#]G_X^_$D_"#]@+5/B9X=\7>*+/6[#
MQ%IOQ$T33%7&B:;8/ T-[<)(&62R<[MN"&&,U]744 ?$_P 9/C?_ ,%#/C7\
M-M6^&VN_\$CO%MBFIVNRUU:Q^,'A)KK2[I6$EO?VWFW#HES;SI%/$Y1MDL,;
M#E01S?CG1_\ @I#X4_;,\(_M2^'OV&+WQ1HNK? ?P]:>+/!N@_%+2[-]%\6V
MMQJS&W>YGNH%OK>W@U>]C ,3PRR213KLDMXBOWY10!\G_P##8W_!2C_I#]XD
M_P##Q^%__DRM3_@FO^SY\3OA!X1\4?$#XP>%[GPSX@\<>*-<U6\\(WDUI<2:
M2MYXHU_640W%I/-#-\NL! 5(XA#$*SM''].5QNAZ/XIA^.?B/7;UI_[%N/"N
MC0:>C3$Q_:H[K5&N"J] Q26V!8#Y@$!^Z, '94444 %%%% 'RQ^V9\-C\?OV
MP_A3^SY'X_\ %'@>2]^&OC7Q"/''P]U5-/UZ!;+4/#%L=/2Z:.3;97']I"6>
M$+^\EL+-MP\G#5/^'4US_P!)+_VL/_#L0_\ R%78_$C_ )2F_!O_ +(!\2O_
M $^>!*^@: /EO]ECX*R? /Q7KWPZD^+OC;QN8?CD9O[>^(&N#4-2??X+M3L:
M98XP47^$;>!7U)7B?AC_ )+GXE_[+1'_ .H3:U[90 4444 %9L/_ "-5Y_V#
M[7_T9/6E6;#_ ,C5>?\ 8/M?_1D] &E7S7\&_P#DYWP?_P!@?XM_^IEI%?2>
MX9Q7S9\&V'_#3G@\_P#4'^+G_J9:10!]*4444 %%%% &'HK%+_677&X:DNW/
M<_9(*^?_ /@J;X-\&?$3]F_0_"'Q!^%>H>.M'U#XE>&4NO!VDV]I)-K?_$SA
M9+3_ $RYMH%21U16>290B%F^8J$;Z T3:U_K V;O^)DGR_\ ;K!7B'_!1WQ#
MHOA3X#Z#K'B+XO:M\/;&/X@: EUXJT&W$EY8(]XD;)$#%* T@?R<F-POF9(P
M* ,SXN? ?X4>))?C0FO?\$T]2\6CQ<V@GQ+)!>:"O_"Q#;2(;<QBXU*+;]AP
M&/VO[-G8?*\TD9X_QC^RQ\ ];U_QI?ZO_P $=-8UF?5?!.D:=J6I+?>%_P#B
MI;2!M+\K25\S6$8-:_9H&S,(XL:4?+DD)A$OH7Q3\6_#"S;XM+K?[97CSP_]
MCDT5==_LP0?\4<791"+'=82<71PLF_[1PQQY74<MXS\;_!>UU[Q=%J'_  4+
M^*&ER0>$=,EO[.S6VV:-;LVG>5?P9TMOW\^^$/DR+B^FQ''\IB .2^(W[,_[
M/%MH\VNZS_P2=\1::MA\%-0TAO$>GW?A@S:7IATJZA?P^G_$U9S*T+R6RE$>
MWW3C,P3<Z_)G[ GP9^ _QP^"_P"SI>>(_P!ECQE\<]+\)_!OQXOA'PE\4K'2
M)-6M%C\9VEC'9RQ:C>)9,]K;9ABE9HU-O8@I';M)';C[+^(?C[X._P!@W45O
M^WS\5)+QOA#?W%KIMJMO_IEF-+N6_M?_ )!RG[8J!IUPZ+YD2?NL94_*_P#P
M3Q\/K\>O@3\%[2]^/'QJU1;WX'^-K?\ X2Z-FM_%3"/QWIQVS;_-(GC,'V8M
ME@T*RD'# @ ^@HOV9/V;5F*3?\&YNEE3)S(OA/X:C.>K'_B;^OMS3E_9H_9F
MV[1_P;B:;]WK_P (I\-,9_\ !OZUT6L?L/3R7^O->_M=?M62R26D0NWM=<M-
MERHDAP+?;8@!@P5FV;3M5P3C<#.G[$+IJ,SI^UK^U5O_ .$=5)&;7+7RVMQ"
MG[E?]!Q]HVX4D8DWALMNRU 'S#^W!\'_ (1?#[7OV?M:^'W_  2=L_@3=R_M
M6?#F"3Q?!H?A"W-Y&?$%NWV'=HU]/<$.RI+M91%^X!9MP13[+_P2#_9W^+?P
M^_;$_:T_:+\5^&DM_"/Q$^($]IX1U-;Z&1KR;3/%?BZ.]4Q*YDBV-<PC+JH;
M=\N[!QY1^WK^SE#\(;W]FSQ(OQJ^.7B99OVG_AS9V]C\2]4BFLK9#XFC<N52
MWC/VK<C;2S,1%(1T*[?0/^"./Q9^(_BG]N[]L;X2^(?&%Y=>&_"7CL3^&]'F
MDS!827GBGQ@URT8QP9##$6Y.=HZ4 >R?\%Q](\1:]_P24^.^D>$I[&/4)_ \
M@MY-0FACC'[Z+)#3G:LFT'RSG>)-FS#[:^*O^#0#XC?&KXK_ +.OQP\>_'WQ
MKXA\3>)-2^)EG)?>(O%UU-=:C?%-*MX%,ES<9FF58H8T7<Q"JH"@<Y_8"YLX
MKV%K:[@22-OOI(H93^!J.STFPT^,Q:?8PVZL<L(8PH)_ 4 >9_M1_$3PQ\'-
M-\+_ !;\<7[6FA^%]9U+5M:NEA>5H;.V\/:M-,X1 6<JB,=J@DD8 S7%^)?V
MU_C)X%\*ZAXZ^(/_  3N^+6C:'H^GRW^N:O-X@\(SQV-G$ADFG,5OKDDL@1%
M9RL:.[!<*K-@'._X*V'?^Q9XP4#YCX-\7;?K_P (?KM;_P#P4.T/XI:W^RK\
M0Y? 7Q%L-%L;;X:^('UBWNM!^V/=C[#)M16\Y/*XW@G#=0<<<@'C_P#P0:T*
M;PU^POI?AN8R-)I]GX:MI&DCV,VSP;X?7=MY*D]<9./6OMMSA<U\R?LFZ1XO
M^'?P[\>:-XG\=R:7J'AW7]&C\1:YXF\FZE4V_@S05GEN94=(O,+*6>4-LR"1
MP<CU236]?*L$_:$\-[LXQ_9<7_R30!YK\7)+6']H;QI)?RHL T/X7--),V%5
M?^$JU;))/&,5X;\#=:@U?]J?X/W7C*\GEMY?%E^?V?6UJ&T:X;P*-!UX.\4J
MIYS2/*+%I?WC[K!?#[W %XURS?1WQ1^"/PL^,*:Y%XS^)/A^\M?%GA33-"\4
MZ9J$,<UO?0V4]W/&=HF5DS)>2[EW$$!1T!SH>)/ FC>+O$'AWQ3XC^,GA6ZU
M#PGJTFI^'+J32XPUA=/9W-D\J8N>K6UW/&0<C#],A2 #UO5KVUT_3Y;Z]GCB
MAA7S)I9&PJ*O)8GL *\^^!^@ZWXGUS5/C_XVM;B'4/$2"#P]I]PUY'_9.B(Q
M,$36MP$^SW4S;KFY_<Q3!I(K:5IEL8'%?Q182^-/#>H>#O$WQU\-76FZI8RV
MFH6S:;&HEAD4HZ96Y!&5)&001V-<7_PSK\/QT^/2]?\ H9M2_P#EG0!ZI\:_
MADWQ#\-V]UH]Q8V?B3P_?KJG@_6+W3TN!INHHCQA\,-PCDAEGMIO+:.1[>ZG
MC22,OO'PWI5CX'_;F_9U_;"\$>*EU?PSH_Q$^/F@^&_%%N[0K?Z&TWA7P3I^
MH6Y8&6'[1;2BXB8@R1"2$D%TP6^C9OV?OAO 8TE^/T8:>>*"%6\3:B/,ED<)
M'&,ZGRS.RJJ]2Q &217G'[4?[''B'XP_\$Y?CO\  W]F7[+>>(_B)#?VUO)<
MM):/<ZQ;R+822S7-Q/*[D+911AV;A($ XQ@ ^SK9G,7S')J2HX-WE\IMJ2@#
M\]?^"VWP&_X)U_&_QM\-I?VV?COJOA+Q'X;\.>(=7^'NCVK>'DM]?6WNM$GN
M+9G\0V-Q9>>9XM/C2-WA66*:XCE+V[3J.7_;C^/G[!?[/G[,WAK]L+]JO]B?
M3_CUK'B:XT71M'U+7/!?AW5M9FA/AM=4:6>XC46JQB.&YD86>8#+*QACV.2N
M1_P<5_$WXD?![7?A[XR^#NJ:QI7B34OA[XQ\-+KMC87;0Z9I^JW7A^RO+H3V
MCK)%=V\+_;(0P,>VTN)#B2&$CO7^$W@G_@H3^QG\&O$WC#]L.;P3XB@E\*^-
M_P#A,M0TW2EU[4(KGPK;1S[5D)CL9YQ=%S/ #Y4L0,?W00 ?4G[!5G^S=>_L
MQ^%OBC^RI\#M$^'O@_XC:'IOB^Q\.Z+X>L],V?VAI]M.K3PV8\K[1Y1B1V!;
M/E@!F !KVBO,OV1/!OA+X7_L\^$O@OX+^(ECXJM/ GAC2_#9URP$*K=M96%O
M!YA2 F.%F"!S&IPN_ XQ7IM %762?L&1_P ]HO\ T8M?!/P9^//P?\/?MJ^&
M_AOX,D^&.FPP^(/B=8W5K_PL*\EOAJ-YXUL))P\-Q9*8[N>Y,\R6P+1Y+I%+
MY2(S_>VJC-H 1_R\1?C^\6OCO_@K9_P4%U7_ ()H_LN^&?VC=.TJUO;6Z^*W
M]A:Q;S0*TK6ES'J3DQ%G0(RRPPR$DD;(W&.00 ?9N\8JIKBDZ+=J1_RZR?\
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MDMH9"B2M(F!^T*G[4#_8&^',DD>AR7%Q;>(%\-PPOJR6<B%5NH'NF5(YH>9
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M4.G_ /1D'QN_\-C^SE_\K*XWQO\ L'> O ,&J7WB#]A/]HE;?1[62XO;BU^
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M5I$ Y^/WC'YO^Z@ZE_3'Y#TKTSQ@L?VCQDN%_P"1.@_A][[_  H _&=/@?\
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M3M4#)[U\6_M.?\I8O@C_ -C=X?\ _4.^+%?:E?%?[3G_ "EB^"/_ &-WA_\
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M/X@^#-)UVSCUB[FCL]8TV*ZB603S*'"2*0&VLPSC."?4UT>JG%H#_P!-XO\
MT8M<!X%_:0^ NJ:_%\/-*^+GA^ZUJZU+7$M]/M=3CD=I+'4S:7D7RDA9(;B1
M87C)#A]RXRC  '7>#?A_X+^'6D_V#\/_  =I.AV+3-,UGH^GQVT)D( +[(U
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M7[^RMQ@=Q#;Q@GJQ!)Y->)?\%7O^1(^"/_9U7P[_ /3U#7JW[&G_ "1[6/\
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M'Q$L(ACU:2WBA%VC(/EAFWN95B4D-%O*\0N0 >C44!E8;@>** "BBB@#Y_\
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M \1VNGW$C)'=265[JMRL3,O(5FBP2.0#F@#W^&17BROTI]1VZD1=1U/W:DH
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M6L$%REH)6,20(\8C=8 $%VEYN'FF4GNM\O\ SS- $E%1[Y?^>9HWR_\ /,T
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M_: TOX@>)O%GAZZ6RBF\.+?>(1I]MJTLL4ML9F,EI8H%0'9'(BE H+Y^T?\
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MUXVO;S2;KPSJ>F:J;B:]MHD\G^UX)RU_-'N<LH9&9&"E%7T+_@GM_P $H?\
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M=^'M%N72VU/7+R3S/-EL"2#<7&I,J[B4] -H/V#XEED31;S"G_CU<!O<J?\
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M[6O'&IV5G?:Q-::_XJDGE>.&."+=LO;9R8HHXSYPVJ!P #]+OVE_$/B#PCX
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M[JR56U.W\,^(K)+#Q#96=Y$EU!<K!>1I(JS0S)-#( PP&25$=6 RK(K+R 0
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M;-W!<(XDQF%<J<@CYY_:E_9]^,__  3C_8_U+Q[^S=XPT75-/\)IX6L8=/\
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MJ<ERR,UWNC<1K)@J0Q("\J2I^G$_86_9R>,.-(\4<KP?^%CZ[_\ )M<;\?O
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MV^%?!/[(O@=M<\075]>V]_;R7]G;P_8Y! )5D-W=11LLB*T>WRY20YP8R 6
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M?X1_YY7_ /X.+K_XY2?\*O\ ".,>5??^#BZ_^.5T5% '._\ "KO".,>7??\
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M (Y1_P *N\(_\\K[_P '%U_\<KHJ* .=_P"%6^$3_P L[_\ \'%S_P#'*/\
MA5GA#_GE?^O_ "&+K_XY7144 <[_ ,*M\(?\\K__ ,'%U_\ '*HWOP(^&6H^
M)-!\77^A2W&H>&=4DU'0[BYU"XD^R73V=Q9-*JM(5W&WN[B/D'B4]\$=A10
MBC"XH Q2T4 &,# -(1GK2T4 >>_';]E/]G?]IG2$T;XZ_"+1/$B11B.WN+^S
M'VFW031S%(IUQ+$K20QEE1P'V -N'%>>?M8^+[+]E^WL_B/\,/ -G+XF\?>*
M-+T"\9=02QM[F;RY$M3.VT@SRLL.GPOMR9KJS60B&+,?T+7A/[</[)/AO]J+
MPQHM_KW@[3?%4W@^^;4],\(^([Z6'2]3G^7F1H^8;A55A!=88P/(S;'5F1@#
MYQ_;F_9!_:5\&>'[C]K_ %?]HNZ^(&G^!=,U+4O%'@G^Q;;2Y[[11H=_:WMM
M93J)%D8B5;I+.[62WDN;:)G("A3Y]^VU_P %*OVKO^";7PC7]H7P7X+3XI>!
M=?UB^TE-*O$DM-4T/7&M8TM;9[7#RP@7T-PLL9,B@2(R2%IXHA[[\4/A5^V?
M\0?&GA3]GOP4)X_AZU[=:AXS\2>/?(U&33Y[1-)NK%+*17$E^K74]V1]I11O
ML75U, 6.?I/C7_P2V^#GQ;^*_P -_BM9^(-2TJ;X9[&TO1)/+O=/NYXOL'D7
M<L%P&4W,0TVT59N7 C7G*@T ?DC\>/V*O!W[&%S\)_VT?^"C5]>>-O%/Q/FO
M-0_:/\(ZEXGF%W:)<S74NGO;20-%(+FSAG6$QD^4UOIUX8UVQCR_IW_@GM_P
M34_8^^)/[4\[>"==;_A5/A+P[I?B_P %_"2[U2"ZF@OK^ZU:.>#4'1!*UO;E
M2HLFDGA>.XMC(S*%1_I/_@J[^P-\!_C;^R-I_P *?$\UY'JFM?%#PK:1>)+C
M4@]_/=7MY%H+SRO*&^UM%8:G>%87!4D9X.6KVC_@GU_P3T^!/_!.SX :+\#_
M (0Z3%<7&FVYCU'Q3=:?#'J&K/MC027#QJ 6\N"WCXP"(5.,\T =Y+XY\0V?
M[1=O\-H_]/TN^\&R:E+]GBB T2X@NTB7SFW^8WVU+A_)78%7^R;GYF+$+WU4
MX_#^CPZI+K<6GQ+>3PQQ372QCS)(XV=HT9L9*J9)"H)P#(V/O'-R@!IB4_>Y
M^M?.W_!0GQS\'/@Y\,(?'%_X!\,ZM\4=4NET7X,+JGAN+4+J7Q+-@V(C!4ND
M4<Z17$L@95BB@:5F4(#7T77CWQ:^#GCG5/VAO!_[1GA6RT?5V\'^%=;T:#0=
M1D,#L^JW^BN]['<[9!&8+;3KE=@3,GG[=R DD _._P <?\%:/B-\5?B?I'AS
M]AW]@?XB>,O _P -_'%UI7CN\3PG$9[J=-3TR]2XC#RQ-%YL,=S=%G0N\TUL
M^#B2N+_:2_X* >$O^"OW[<W@7]A#XA_"_P 7>!_@-X%\>6S_ !B;Q!9,C>(O
M$"1O-IF@7)A<BWM_,BFEF5\_\>^\F/RU:O7/^"H\7QY_:.\;:%KW[#/P$\=>
M%OB1\,M-N]6UKQ!>0WFCK-J.M:--;V6E(;57MM6NQ)'#YLK2-:VACB5YBDT@
M''?LR_\ !*[2]2_X(QZS^SC\:/#GB?PW/\0+1?%^G^.+KPS)'XFTCQ3.D]LU
M[=VEDSW+1E5MVVEY)V@U&>"81A&P ??'[07Q]^!O@37&NKVXDU35+6.&UUBU
MT^ZV6\%NK3W6R[;[GRK;7)$(#2ODH$Q*,_-]A\7?A!_P4/B?P7^T+\5+6YT5
MKJ[MM6\%PWL^GS+=:;<RV33VL&Y&,2:G'?(9+IF9_P"S[-OLX67>?%_^"7_P
MDT;PG^R/=_"*+P3KGBCQMX!BUN[^-6N:E>2ZO'YYAMYIM'TVZC5H5N;P[=AM
MA<RPV]L_F>1<7$:#ZC_95^,'[!ES^R[9^ _!_P ;_A[KWCS1]/O;7Q5?>$X+
M?6M6/B)KF1=5U%+-(Y+BX\W41<W7F&(QRJ?.YB(:@#PSPI_P3^\0?L,_MU_!
MOQ%^RE\./&4WP'T74K5_&6A?8Y;JZM=:.A^(M.BUELX$F\W[-=W )D#309 C
M2%4^RO@CX5\(>/?VBOBSX\U?X4ZQI>I7-UHMG;^))+.[T^+6--BL \,>X.$N
M)8;J;4 SJN526%"3M 7F?^"3_P 1OBM\1O@=XHF^*J^,XWT7QLVBZ+%\18XD
MUPVEIIFGP&>\6.63$MQ.D]WSMRMTI0-&8Y9/J0Q C!- '@_['7PW\*R_"769
MGCOB?^%I>.%7&K7(  \5:JN.)/;Z]S1^WE;6]I^S_P"'[2W;<D7QJ^&4<>YB
MQVCQQH6.3DD^Y.>]>F_";P]X'\-^%;S2_ %S'+I\OB36+V=HKP7 ^VW.IW-Q
M>C<"<%;N6=2G\!!3 VXKXJ_X*7?L7_ +P!\3_@[^T]X+\/:AIOBK4OVG/ =K
MJ36VN7/V.Z\_Q!%-++);&0Q-(SG.[;QM7&,"@#] J*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^+?^"FVFO?_ +5_
M[,&I6^O:3:WFG:WXZGL=.U22Y1M5D;P9JD+6\+P6\RI(L<LEQF;RHREM(H?S
M&CC?[2KXE_X*?J/^&S/V21_U-'C[_P!0+6Z /0/V@M#\52_$7]F[XC>'K2UN
M+3P;XK6[UJ">\,+/;7^FOH:F/"-O9)]6MY=A"@K&WS @5],1CY%!'\/0=J^6
M?VE/'DOA#XM_LL^'KW7!:Z/XJ\;2:5K5NT:LMYLT.YO;.,D@E3_:%G8R J5)
M:)03M+!OJ*"53"O/\&<T >.>$_!9\5?M!_%*5/%^OZ;<6L]@FGR:;J\BQ6TL
MVE)&T_V9RUM+( %(,L4BY1<@XQ3W\>?%[]G$6\/QF>/Q?X)5[6U?XA6-JL.I
MZ6#'L:ZUBSA18&M_-3?+?V@BCA-XI>RMK6VGO%U/A-+N_:"^*KH=VZ^T<C_P
M7)7I&JZ-I6MZ?<:3K&G07=K=0M%<VUU"LD<L; AD96!!!!(((P1UH FCN%FB
M$J=#T-.\P@XQ7SKX*N/B7K>NZY^R!X0\1>+-#M/ ,RQ7GQ FM1)<SV,T<-QI
MUO9S7C7 NI$@E>WGNIO,D+V#.Z;KE&7V?P'X-T3P9-K2Z/<ZC)_:>K+=W7]H
M:Q<WFV3[-;PXC\^1_)3;"O[N/:A8N^W?([, =+12;E]:-R^M "T4FY?6C<OK
M0 M?EC_P<[6^M?#_ /9"U7XN36>CWECJFN>&=)LK/5-"LM3C,]NOB"21V@O<
M1 A;J$HP;<74J!R ?U-W+ZU\L?MM?LLZW^WAKFN?LYG]H'Q5\/[70+'PSXFT
M?7/"4BQWEG>F?78)&1^&4LJ0\[OE,*LN#DD _-;X,)X1^*O[&GP[L/BY\2/@
MA\%]/^)GA#XL7&AKJDFF+X7MHKCQGX0U.'1B+*[C^SRO:02P%HYUO[-E:8$7
M%L"/NO\ X)'R?#?PQX;TSX.^"_VC/A/\0K[P[8:O<ZI-\)[W2'M;074NF%7E
MBTJSLX(6FEAN9$7R RK\AEN#&TK_ %?\!/AYX^^%WPUM?!OQ.^-.I?$#5X)Y
MFF\3:MIMM:3S*SDHACMU6,! 0H(&2!SD\UVA2(G<>OKZ4 /HI-R^M&Y?6@!:
M*C\T_D>?:I* "BBB@#\;/^"&'['WPP_86_;WN?AQ\*_"O[1FBR?$+X0Z]J_B
MN?XW:=H]I#J5SIFKZ+%:2645D99"R+JMSYADEQ^\C(5MV$_3&^_:X_9^\9>*
MK[X4_!_]H;PAK7C30=?LK7Q#X9T?Q#:W6H:=&-6MK.[2>W1V>+8TIB<LH*.X
M'RMBOR%_X-O_ (:_$73?^"KGQF\>>,/"FL?V;%X'U73O#]Q,KV5MH,+ZII%X
MNG-:2M.QEEMY;24.+F3REMV1FE+JZ?>OPN_9/_:S^$/[7_CKXS?$_P >6&K>
M O$OC:1_#]HOBK7;N>UCN/$6BW-DOD7=_)9Q%0=0B98;6+REA@$;LDCJ #[G
MJ&:>. %IG"J.<L< =>M35X]\7_V-/!/Q?UO5/%%W\2_'.CZAJUO]GN'TOQ1+
M)9K 8?)DC_LZ[\^P=9(MR.)+=\[V;A\. "S\:?B!XU\:V5U\(?V=+^3_ (26
MZOK>QU/Q3:K"]OX2@E7S9KUVF5XI;J.WPT%KY<Y>:XLS-$+9I9D[[X>_#_PO
M\+? VD_#?P58&UT?0]-@L-+M6D9_(MX8UCC3<Q+-A5'+$D]S7F_A;7M<_9OT
M[1/ /Q%\/:+#X;;4(M$\-ZQX1T@V>GZ?$8X5M8+BT&X6*M(TL$91GA AAW-&
MTZQKZ\)L\ YH DHHHH **** &39,3?)N_P!FB(,(U#CY@OS4DZF2)ESCT-+$
M"(ERW\(H ?1110 4V7?Y?[M>?>G44 >8?!?XS?%[XAW<6D_$7]DKQMX#DAT]
M9;G4_$>I^'YK2:?Y0T4*Z=JMW-DEBP+HJ[5.6!P":'\7/C/X@^*L/@B7]ESQ
M5H6AVNIW2:EXTUS4M$>PNK6..41R6L=KJ<MV#++Y++YUNA$>\.L;8%>F^6OO
M^= C4'I0 ZBBB@ HHHH *_/O_@OIK_B;PG\+_ WB#PA^Q78?&K4H[[48[/2=
M0_9_/CN.TF9("A?;JMD^G1R;2K3+'<[RJC8A4;OT$K\P_P#@Y8U7]E$?#;X3
M^$OVF]>U^W?6?%$R>'[/PWX%TO5KF:2.XT]RWGWZ'[)&)_L<;K&Z^>LY20/&
M&  /GWQ=XU^(_P"QS^PW<:U\+_C###-X5_9+^!,&I_$;X=^)(UDM-.75O&HG
MOM+BO5B@U:1T'EQV-Q):^=YQV2+.D,;_ %Y_P1$^,R_'_2+;XHIXGUC7!>?L
M[^!K0Z]XBU"6XU+56L]?\:V;7EX9))3%=3& S2VXFG2WDD>!)[A(EFD],_X)
MN_#O1_$'AG0/VM?A[J=G?>"/B!^SE\/]$\/V,VBPZ=<(NG3:]>/)):VT:VT"
MO'K4"B.(;5:*0 !=N?:O!?P;U#PK^TIXH^,4 T^'1]<\ >&_#MCIMHA5K9M-
MN];G=B-H41LNIPJH!_Y9MD 8R >F4444 %%%% !7F7[97P6U_P#:3_9#^*O[
M._A75+.QU3Q]\-]<\.Z;?:@7^SVUQ>V$UK'))L5FV*\H9MH)P#@$UZ;7C?\
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MZOHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_A;3;QK#4O$NGV\T>/,AFO$1ER >03D<$'\:T+@H(_G; K\4?@K^SA_P2?\
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M?^&6/VFO^DEWQ-_\(WPC_P#*:@#W7[2/[C4?:1_<:O"O^&6/VFO^DEWQ-_\
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M*WT07$FGW$EVFHZ=%>PH"EP8X[22.XV*8A<8D@9N  ?NQ_PL3P/_ -#?I?\
MX,HO_BJ/^%A^!O\ H;]+_P#!E%_\57YUK_P4-_83(_Y6%7_\)GPC_P#*.KGA
M_P#;O_8D\3ZO#H>E_P#!PS;1S3;MCZAI7@NTA7:I8[I9]&2-.!QN89. ,D@$
M _0AOB+X'49/B_2O_!E%_P#%59T'Q/H?BO0['Q/X7U>UU'3=2LXKK3]1L;A9
MH+J"10\<L;J2KHRD,&!((((/-?(/P>U;P!^T7XJF\!_L_?\ !<F'QWK5O8M?
M76C^#6^'^J74-JKHC3M%;:8[K$'EC0N0%#2("<L 4TW]G/X@_L:?!?4/"/\
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MU<:1.;.2^1_@]-JS(&BVF)3>V=O)A-H_=[?ND@_36LQ_M+?!^[U3Q5H.HO\
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M#H_X9(_X*(?])7/$/_AJ/#7_ ,AT ?4?VD?W&H^TC^XU?+G_  R1_P %$/\
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M;%&1EEBNU\L;GB#>+?\ !43X-?M-:I\(_B?KW[/G[1_AGPS\(OACH<UA\2/
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M8?"WQR^][Q+N3S82F!Y!B'SJ'W_PU^AW_#9O[./3_A.;C_PG[_\ ^,5\/_\
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M1/J5TEKIMLM[(^XD2,FGM++]XS7-]<SL0\AR ?GS_P %[E'_  RM^TXV.?\
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MG_P74_:$\5?!CX[Z;+I'[6&I^!=,T7X73>)-:\*0ZM>6*^)[6&[FM);6V/\
M:ME#=7(6]%WY%N&NBFF;&;;/#%)UW_!07]IOQA^QSXL\;?%CPY\%_ .O:5?_
M !,M[7Q)JGBWPSJ%]+#,VD>$XK6WCDM+:183+'/>HC7#1H;@6L8.)'Q\4?\
M!UY\7]<^&'[9G@WPW91ZCK=EXN^%,=M=>']/UJT06C8\1Z8UU)'=:=<+;^9:
MZY>1I.LJDO&&VJUK')7Z ?MH?L=?&W]K3Q)XPN_@5;>![K5_#/Q4:1+?QPRP
MQQ^?X4T.,744K:?J,,I1H_+:TN+.:"43>:##<VEK-& ?0O[(^BZ)H7Q7_: T
MWP_HUKI]K%\6[(0VMG;K%&F?"'AQCA5  R22<#DDFO<*\9_9C@NH/C'^T ]U
M'(ID^+=DZ,<X8?\ "'^&QP<#< 01G';%>S4 !4'J**** "OBO_@MXJCX&^""
M!_S&O&O_ *JWQO7VI7Q7_P %O/\ DAG@C_L->-?_ %5OC>@#[4V@# %>=>&0
M/^&L/&G_ &3WPQ_Z7:_53PE^UG\+?&GBF_\ "VC6/BS&FZG>V%WJ]SX"U>WT
MP3VETUK.JWTUJELX6>.1<I(RD(6!*@L(?AAXL\->./VCO%'BSP;XAL]4TS4/
MAIX3N;'4-/N5FAN(9;O7)(Y$=20RLCJRD9!# C((H _+_P#X*.?$GQEH/_!8
M&\U;PWXU\06>C^'_ !/\.K#Q1X@T>.WA/A9+VZA\JT%L;^)]5&HG,$CF%A;1
M%VPXC&/TV\%_ME_"&]^&W_"ROBKXRT+P):7'Q$\0>#M+7Q1X@@M4O[[3-9O]
M+"1/-L#RSFP>9(5W,%8J-VTL?S-_X*6?!C]D;QQ_P6;\-_%WXZ?\%,9-%U;P
M?KWAMK'X*:O\,?$.I62RM)IJVT27=EJ4$2>;=W%E<@I'M69E:99HXW2O-_VR
M?#=AK_[0GP=UKP=XUO\ PMKWA_\ :*\67.O^(]-N/"&ES-I4OQ.\30M9V^LW
M]_:ZI9W4UK_:_EV>R>UO5601(&MKL@ _<+P=XI'BS1Y-6C@,:IJ5[:8W;LFW
MNI8">@ZF/..HSCMFMBN1^#'E_P#"&7'ER^8O_"2:UM?(^;_B:77/'%==0!\N
M_P#!0GXM:G^Q3\$M-^*_P>TFVMUT?6/%WB*]T4,T=KJL\/A/Q-K;1SA""R2W
M]NDSX()?YL@UI>+?AU^TO\%/"&J?&7QO_P % ]<OM(\)Z?<:QJUCK'@_P_:V
M4]M;(TTB3SI:HT,12,[Y%92BDD," :X+_@N'#-/^QW=6\$3222:/XY$<:KEF
M/_"N/%N  .237LW[5_@;X4?$[X#ZQXB\3>+=4MK74M)C@TN^\/\ C2^TK[=-
M<"2"R@$EE/$9UFFNTC6$LRS/)&-K,$H X+]GCXG:O\3/VA/BDS^-FUS0]'_:
M(L[3PG-'=B:W@TV;X9Z+?;;=E.TPO/>7$X*D@M<,P^]7U)7R!^R'I6J:#^T1
M\9M#U[Q VK7UG^TOIL-YJKVL<!O)E^$WAQ7F,<8"1EV!;:H"C.%P *^OZ "B
MBB@ HZ\&BB@#P7QM^U]\*OV9]1^'W@'XC+=?;OBK\6-3\+>&/L]Q:1QB_>]N
MY5\TW%Q$0A5&QL#LS[(E5I98HWX&YU7XBW7Q)\&^ O!6IW0L]2UKQY>ZUIL-
MP$CN+>W\>Z0DSON(!"VEQ?+UR4ED !SBO _^"J^F:9+^T1^QWJUQ\3I?#,[?
MM.2V)6U^V+)JT)\2V5V=/?[-;RK)!)/9VS-'.\,?FQ02ER8=I]HUKQ'K7A/X
MX_#G5_#FH&VN+C6O'EA-)Y:/NM[CXBZ!!*F&4XW1RL,CD9R,&@#[(B"^2NT<
M;1UJ2FJ B?053L]>T;4+K['8ZQ;32^6)/+AN%9MA (; /3D<].1ZT )IGAS1
MM&N[[4--T^.&;5+I;G4)$X,\PB2(.WJ?+BC7/H@%<E^TI:^/K[]GGQQ9_">2
MZ7Q5/X0U2+PN;.=8YAJ1M91;;'8A482[,,Q !P217>8XQBO._P!J_P :>)/A
MS^R[\1OB+X.U#['J_A_P'K&IZ3=>2DGDW4%E-+$^UU96VNJG:P(..01D$ \,
M_;<C^**?M%_")_A?K6CZ?>?V/?17DFM6<TRNA\3^#UV@0RQG[Y ;)(*Y7&2"
M/8UTS]M01X'CKX7_ '?^A4U'_P"3J\%_X*3?#7Q+\7_%G@?X6^%/BYXF\#ZI
MX@\*W5I;^,O"5^]OJ.FLWBOP9NDA<$$;ERC#(RCL,C)-?94(*0J&ZA0/TH \
M)_X)S#7(_P!G#4D\1W%K-J"_&'XC#4);&%HX7F_X376_,:-69F5"V2H+,0."
M3UKWJO$OV  /^%%Z\<?\UL^)7_J<:Y7MM !G'6BO-/VK/B5XU^%7PEA\2?#R
M73$UB]\:>&=$MIM8LY;FV@74]>L=-DE:**:%I-D=V[JOF*-RKDXR*7_A$_VN
M_P#HNGPY_P##67__ ,O* /2J*\U_X1/]KO\ Z+I\.?\ PUE__P#+RC_A$_VN
M_P#HNGPY_P##67__ ,O* /2J*\9^&;?MA>/?AQX?\<7/QI^&]O)K6B6M])!'
M\+]098S-"KE0?[<Z#=6Y_P (G^UW_P!%T^'/_AK+_P#^7E &M\9/V@_@C^SQ
MHFG^)OCU\6O#W@S2]3U)=/LM4\3ZO#8VLET89IQ#YTS+&K&.WF8!B,[#CG .
MI\./B=\/OB_X/L_B%\*?'6C^)=!OO,^QZUH.J0WEI<>7(T4@2:%F1]LB.C88
M[65E/((KXE_X+(?M<_MZ_P#!//\ 8YG_ &EOA_K?P?\ &5UINO6]O>:)KGPB
MU^2-[=XIR75K+5)O)<,B?/<&*#!93(':-'\<_9C_ ."X'C?X%?L9?LR?$;]L
MS0_!M[XB_:.\7>(-5U'6-/\ $EGH^A^#?#J:YM<LXDN6NKFW74;...R4+-M6
M6.YDBFM99)0#]7:^??\ @IO\?_B9^S)^R'J/Q>^$FIP6>N6_C;PAIL5Q<6:3
MH+?4/$^EZ?<KL<$$M;W4R@]5)!'(!'M'@/QUX3^*'@G1OB3\/O$EKJ^@>(=+
MM]2T35K&8207MG/$)89XV'#(\;JRD<$$&N3_ &H_V:_ G[6WP>NO@E\2M5U:
MTTBYUO1M4DFT6>..X$VFZI:ZG;@-)'(H4SV<:O\ +DHS!2K$, #F_P#@G%S_
M ,$_/@23_P!$9\,?^FJVKVJOGGX>?L]?M@? _P" _AOX%_!_]I'X=Q0^#_#.
MG:'H>H^)/A#J%\6MK2&.%6G6'7[?S)&C3!*-&H8YVX&VG?\ "M_^"J/_ $>/
M\ ?_ !&O6_\ YLJ /H2BO,?@A=?M&VOC/7?#/QR\:^$?$%O9Z+I,ECJ7A/P7
M>:.AOG:[%XKBXU&]!&V.U9(E8-&),L\GF*5].H 3:OI2[1TQ110 ;5]*\#_X
M*J@?\.OOVD./^:">,/\ TR7=>^5X)_P55_Y1??M(?]D$\8?^F2[H ]YC^YFG
M4V/[@IU  5!ZBDV*>HI:* "D**>JTM% ";5]*6BB@ HP#U%%% %?5-)TS6["
M32]7T^&ZMIE*36]Q$'CD4]593P1[&N>_X4=\%_\ HDGAG_P0V_\ \174T4 <
MM_PH[X+_ /1)/#/_ ((;?_XBNAT[3[+2;&'3=.MHX;>WC6*"&)0JHH& H X
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M!]C5XC\<?B)\?[?]J3P!\&_@SXG\/:=::YX \5:UJ_\ PD&CR7<<DEC>Z!!
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M\:7%U??$+XE:EHMI:22V0C:7[#I6G6EW<R;I'AM8S%-=(\\A>[N;NXGC6.8
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M3WUW<Z3I^JM;WVM:T;>&]2WL[HS"2S4)I=Q<L;1$NF3[7&\S6[K%;^?^)/\
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M(/CS\58P\DA8A5^('B!57)[!0 /0 #M6_P"(_@UI&F?$KQ9\0/V>M5TOP_\
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MPD4T=]%^]7YP5..,Y[;Q+\#_ (T_%3XK>))/B?XW:7X<Z]H%G9VG@N"*U/\
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MX]^*[^+;-]>U:33=4AN+7PG!X6,#0S1B,PN]F;J.828>&1"!\P!_5JCWQ10
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MS?@-X&_:"L?VF+R":Z\0V_AVTTZXTVU46>C7%['(DLFJG3HL6Z74DD-LP95
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OA?\
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M1:7$^5QHHYW0J.<C!/&<$?4&:YGQVI;Q1X-959MOB24M@?=']FWHR?Q('XT
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M^"LWPWLKC6?@7\5?^$H\0+<1?M)?#S3CH\>N3C3)%.NHWFO:!O*,X+$"7;N
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M/ % 'V%XO\07/A3P9JWBRS\/WVL2:;I<]W'I6F1AKF]:.-G$$2D@&1R-J@D
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ML\=S?W>M>$[2UBDFV.88VGFB#R".0HA9@CD;6N1?%[_@HC##&/\ ABKX:\J
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MIS/X2T^%$M(K"TG4J@GDDD\UHR%52F_#@?2?[$O@_P"!/[:O[)/P[_:Y\>_
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M,6@JRRC)D,<Y$X:3;*VX$T ?HED'D&BHK<R&!3/'MDVY90V<''3-2T %%%%
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M4H_Z-Z\._P#B0]Q_\S] 'U;N'K1N'K7REG_@I1_T;UX=_P#$A[C_ .9^C/\
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MIGYXA(O.[!S#K7_!1'HO[(_A/_Q)2_\ _E%2?VU_P43_ .C1O"?_ (DI?_\
MRBH [OQUH?[12?M3>'_%'@_5=.F\%_\ ""ZC:SZ??0R(MKJ9O;-Q,[QG,ADA
M^1%*_)Y$IS^\P.SW_'C^[X1_[ZN?\*\1&L_\%#V;$G[)/A-5_P"SD[\\_P#@
MBJ3^U_\ @H5_T:9X4_\ $DM0_P#E%0!Z)^RS\-OBK\,/".M:%\3K_26^V>,-
M>U33[72=[!([W7-1OP[.W)+1W4(VX^7RSU)./)_^"KQ'_"#_  1Y_P";JOAW
M_P"GJ&L/X-^,_P#@I=K_ (1O[WQ/^RQH$EVGBK7+>%K_ ./%_8NMM%JEW%;@
M1_V(=\8A2()-_P MD"RX'F8'BG_!3#X<?MN^-?#WPAUCQWXVTWP'HLW[0_@;
M3%\#Z3KDFN-+>/J\?EZD-5-O9W,!!<+]GC  \@.) TA"@'Z:DXZT9SR*^4?V
M=/@O\<-+^,>O:CXN^.FIZEI_@OQ9'I<VGR^(=:G6]6;2[.Y#M'<W\L7#7P&&
M1O\ 5Y&#@CZM084"@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!-RYQFC>O3=7-?$#XC:=\/K>S%QI&H:A=:GJ,-CINGZ;:F66>9\^G"HJJ\CN
MV B1LQZ8K)\/_$#XEWW@[0?$'B'X+WFFZCJ%X4US0O[9M9I-(@_>XF:1&*3Y
M")\D9+9F']UL '>452T+Q#HOB2R;4-#U2WNX8[J>WDDMY@ZK-#*T,L9(_B21
M'1AU#*0>0:NT %%%% !7YU_\%N_VC?@]^S)^T-^RS\5/C1XH;3='TOQ)XVEO
M&M;">\G6.;PCJ%@L@@@1Y647-]:1LP4A3,I; Y'Z*5Y_\5?@%IGQ7\1V/BJ\
M\8ZYI%W8:+J6DQ-HMQ"@>UOFM&G5Q)%)D[K./:1C&6ZYX //_#'[;7P*G\3_
M  G^$'P^\=^'?$VK>-M4;2)(=+UZ)YM.2#0[_4&N&C3<77-B(3RH!G!SQM/L
MGCKQ#J'ASPGJ>JZ%8VEYJ5MI\\VGV5]>FWBN)DC+*C2+'(8U) !<(Y4<A6Z'
MYK^,VGPVG[1_[(<D<DS--X_UB21YKEY&9CX'UC/+,>O7'3.3U)J?_@HO^Q]\
M;OVB_&/PE^*7PB^.R^$K'X<>*FU+QKH\C3JOB#2!+;73VRO&V%<36%O@%<.C
MRH75&DCF /=?!GB+QL?&>I^%/&L>FR1V>FV5S:W]B)8_,>9ID>-HI"VT*T *
MN';?YI&U-F7;X>^-?AKQ=KEU9^&["\OM*L]4FTJX\16JHUD-1AG-O-: AM[/
M',KQ.X7RDDCDB9Q*C1CY1_X+/^!_B]XA_85^,/A'X(_%N[\.^+[ZW\'2:/XF
MEUPZ>VELWBD,Q^T1!3%$D>]<]TR&8@DUS_\ P0.N_BK>?\$M/AC/XM\96?BB
MQDU[Q%)>>*KJ\N'U'5M0/CC4LW#"5.8Y$^<LS>9N;!'>@#]!**3<OK2Y'K0
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MZ;96<K6GA?XQ?$^PM?A_?VI;_A"+Z:UE:;6$U)4+:C)>QQ!7BF<K$+]0K,8
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MPMXTD\71>'/#]KIJB?1[.^UNRU+3H9;MXQ<3M&@OHRC.T40,8BPK%5 /;/\
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M^T\1>)KA966#2T'Q-N+JV"I#<J7NH[<V2L]I>^6]VDD=K//'"*^_?V /B7X
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M+_XW?#;4(/$]GX:MHKZ0W/C?1"\WGB,2[I%D<,Q.YA(P/4B@#U[X3_\ (_\
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MSMIKZUN[>[T_[0JZA(9PM[;6VV,([N6*(K,X4_=$=S:2(N^2/[WRC<*^6/\
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MX%% &+X@3QZ=&B3PK+I2:A\OFR:A%(T/3YL*C!N>W/'?-8/V;]I#_H,>"?\
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M/?#FSAFM8G@M9O&VG(\2%00I43$*0#C )QBM#_AMG]C7_H[+X:_^%S8?_'J
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M^@QX)_\ !=>?_'JR?^&V?V-?^CLOAK_X7-A_\>H_X;9_8U_Z.S^&O_A=:?\
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M.OQ.M_%EWJ=]JMG>>)/$5XFG+=M;B)H8E:\DBBBE(9E#1,JO,[ *-H ![QX
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MBV:6NGP(?(D7S[OR//BRR^7!&S$-Y# @'V9^S9X1_8^U7]G#PKIG[-WP\?\
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M'[(@O/\ AE#X8C4FB^T?\*^T;SO(SLW?882=N><9Z9YQ7AW['+8MOV40<?\
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M#%C_ ,(KH+>%W\5:Q)X^NM/N'BL->GN);5+.'"2J+>ZDG9I-_G>4MOA%D=J
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M8;/QO)I[:HUQ<S7ATO?]G!EN'D 7S/FX5@.>^:Z"@"/[3'Z-_P!\TK3J(_,
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M"/O5XK^USXFTOQA\+]$T+PS%>7EV?BKX&G\F'39B1'#XKTJ:5S\G"K&CL2>
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M2^OTKS'Q?XQ$'[7_ (%G70]4:'_A7/BA6 TQ\J3?^'^<=2/< XQSUKV:-&5
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MM0WFEVVFQK<S._SO"FL+)&K-M-HN\(P&\ [OXWR"/XC_  D 4LW_  L.X_\
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M?ASI^DZ%XBB:*ZT'4_[+3R4NX)%EA2Y10#-:NZA)HP0SPO(JLC%77T^C';%
M'Y!Z7\;]4_8F^-.A_'D^(-8UCX"W6N:Q9?$OX=ZW"/$MYX;O9=1^RW-S%<S
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MZ.*]Y ('2@!:*** "BBB@ HHHH **3>,9I<\XH **** "BBB@ HHHH ****
M$*Y^\*3RQZ"G44 %%%% !4;PB5&CEC5E;AE(Z^M244 51I.GXP=/M_\ OR*Y
M#Q1K7B*T^)&D^!O#'A.T^QWNC:A>7NM7&FR2PVTL$EDD=N=A4!I5N97&6R1;
MM@'#$=S3#""<D#KZ4 ?GQ^WMXOMOA9^VM\"K/6?'7Q%TF&VU*Q6.X\(_!Z^U
MZ%_*\.>,XGD1X--NQ)< RQJ;4%G6&9IC$%0RKW1_:?\ !AX/[1/[1'_B(>M_
M_,S7TA\6O@_/\2?B'\+_ !G;ZS%:K\/O'%QK\UN\.YKQ)=!U;2Q$#GY"&U(2
M$G/$)'?([[RQ[?\ ?- 'QG_PT]X(_P"CBOVB/_$0]:_^9FOF+_@I7\3_  ;\
M7=2_9M\'I\3OBIXCCN/VM_ ,5UIOCSX&ZEX7LVMYM1-O-BYN=(LEE=HY6B\G
MS&+QRRG855BOZT^6/;_OFOA__@N F- _97(_Z/>^&H_\J,G^% 'HW_!'Q2O_
M  3K^#__ &2?P;_ZBNCU].5\R_\ !'[_ )1V?!__ +)/X,_]171Z^FJ  G R
M:^>_C#-KVJ_M9:!\0?@W:S>(/$?@3P9J_AO5M"&F,MG!_;D^E7D4\]\\D<<?
MDC15\V"(3W*QW\$IA"/&9/?KR^LK.'S+ZYCACWJF^1PHW,P51D]RQ  ZDD"O
MD[PA^TM\<YOAK\2OVW;O7/ __"M?">J>-Q+X)TGP=</KE^OAR]U#3!<_VO\
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M%UI.BWBV0M]+AC\.SQN+0P01S21NY$KM/).P>;",B%8U]PH ^?Y/V8]2\/\
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ML^(]!L]!_LGQE/XAO]$:XUC3TMM1\?>&X)I+5XXTEN(\71\J3RU)&QVC'*4
M>*_M'?MO?M.> ?\ @N+??""[_:#M8_A2_P 7OAWX+D\'VWB2"RNH+G4+*UU&
MV"P"Q>Z=3/\ :Q=21R".X34=,MWD2*&X"?KZJ[1C%?&UW_P2\^(C?\%2I/\
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M_P""G3__ )'K /[/?BE_'-G\0[CX\>()=2T^QO+&Q=]-T_;%:W3VSS18%O\
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M(@R*/#7[4@/_ $>Y\2R/I_:24 ?1GPG3_BO_ (NY'_-3M/\ _3!H5>IUY?\
M"?\ Y'_XO?\ 93M/_P#3!H5>H4 %%%% #=YHWFFT4 .WFC>::#30ZD9% '/^
M-_BQ\.?ATUNGCKQOI.C?:8Y'MO[5U**W\U8P#(5\QAD(""V/N@Y.!6UI.LV6
MN:7;ZSI=TD]M=1++;S0N&61&&0P(.""#D8ZUX7^U?^RQ?_'3Q!I_BG0_'0TN
M;3[$0S6\UC#/%-ME+H3YJ.NP;I1+'M'GHXC9T3>']2^#-GI^F?";PUIND:Y!
MJ=G;Z#:QVNI6]N(8[J,1*%E1!D(K !@H) !P":NT>5,QA*I*HT]CK-YIU1U)
M4&P4444 %%%% !1110 4A;'45S?Q,^*?A;X6:1:ZEXBGF:;4=2@T[2=/M(&F
MN;^[F;;'!#&H)=OO,QX6.-))9&2*.21<RR^+FM2> M+\>:I\(_%%C_:$P%YH
M]Q:V[7NEQ_.3+<)%.ZE%" D1-*YWKM5CD  [BBJ.A^(-*\0Z;#JFCZE;7D,T
M8>.:SG62-QDC*LN01D'FKU !1110 4444 >7_'73_B/=?%CX,W'@1+_^R[7X
MC7<GC3[&^(QIA\-:XJ&<9YC^W/8@#G]X8S7J%>>_&/XMZO\ #?XD_"CP9INE
M6MQ#\0?'UUH&H33EM]M#'X>UC5!)'@XW&33HTYR-LC=\$>A4 %?#/_!<ZXO+
M?P?^S+J%CHMYJ#:?^V1X#U*:UL(1)*T%I-<W<VU<C<WE0OA1RS84 D@5]S5\
M._\ !<!#_8'[*Y)_YO>^&O\ Z<)* /2/^"/QS_P3L^#_ /V2?P9_ZBNCU]-5
M\R_\$?O^4=GP?_[)/X,_]171Z^FJ /G?_@J5^R9\4OVW_P!B/Q9^S7\%/B+:
M>$/%6LWFC7F@^*;QI FFW.GZQ9:BDO[H%PP-I\N!][;G KYB_P""=_[,FL_
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MA,^+M8O-$N86O7N=)MYT;[9)&L5^V!\S1R2^4?E8H3M-[_@G'X[L+#_@F#\
M/'WQ%\70VZW'P3\(3:AJVLWP4//-I-FH9Y)#R[R. ,G+,X')- 'T)17+_P#"
M\/@Q_P!%;\,_^#RW_P#BZ/\ A>'P8_Z*WX9_\'EO_P#%T =117+_ /"\/@Q_
MT5OPS_X/+?\ ^+H_X7A\&/\ HK?AG_P>6_\ \70!U%%<O_PO#X,?]%;\,_\
M@\M__BZ/^%X?!C_HK?AG_P 'EO\ _%T =117+_\ "\/@Q_T5OPS_ .#RW_\
MBZ/^%X?!C_HK?AG_ ,'EO_\ %T =117+_P#"\/@Q_P!%;\,_^#RW_P#BZ/\
MA>'P8_Z*WX9_\'EO_P#%T =117+_ /"\/@Q_T5OPS_X/+?\ ^+H_X7A\&/\
MHK?AG_P>6_\ \70!U%%<O_PO#X,?]%;\,_\ @\M__BZ/^%X?!C_HK?AG_P '
MEO\ _%T =117+_\ "\/@Q_T5OPS_ .#RW_\ BZ/^%X?!C_HK?AG_ ,'EO_\
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M ,'EO_\ %T?\+P^#'_16_#/_ (/+?_XN@#J**Y?_ (7A\&/^BM^&?_!Y;_\
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MCQ:L6GM,643HMY!!/)L0%RKM;*9,+E4!8IPO_"_OVS=F[_AD[P#TSC_A=O\
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MGZ!H^BR?LO> $6.U@@:YE^,SJ% 0 NR?V27 XR1MW=L$\5P _P""6G[/6/\
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M6\>:]?Z#H.A_% >3'<Z_8>$O]&GMQ#IUI<0>?<K!:1F*14ERD:JT"22^R_\
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MZ;KFFP7^GSJV1)!+&)$;Z%6!I2A."U5A0J4ZDM&F;-25'4E2:!1110 4444
M%%%%  ..*;L%.HH /:BBB@ HHHH **** /$?VJ?^2]?LT_\ 9:M0_P#4'\4U
M[=7B/[5/_)>OV:?^RU:A_P"H/XIKVZ@ KX__ ."R/@?PE\2_@)X7\"^.M(CU
M+1=0U[7GO]+N&;R+IK?P5XEN[?S%! <1W-O!,H.0)(D;&5!'V!7)_%WX%?!_
MX^>'[?PI\:/ASI/B?3+6\^UVUCK5FL\<4_E21>8H;HWES2IG^[(PZ$T >(Q?
M\$A/^"9$D>^3]B'X?[LG@Z*OK]:L1_\ !)+_ ()L1:=-HT7[&O@5;.XFCFN+
M-=)Q%))&KJCE<X+*)9 "1D!VQC)SV)_X)_?L5L2S?LS^$3GGG2EI?^'?W[%/
M_1LOA'_P4K0!P_\ PY__ ."8O_1D?P^_\$@_QIK?\$@O^"8H''[$GP]_\$J_
MXUW7_#O[]BG_ *-E\(_^"E:3_AW[^Q2?^;9/"/\ X*5H X_2O^"3G_!.#1;A
M[S1?V//!%C-);36[S6>E^6YAFC:*6/*D'8\;O&R]&5V4Y!(J#_AT!_P3&[_L
M2?#_ /\ !(/\:[C_ (=_?L5=OV9O"/\ X*5H_P"'?W[%/_1LOA'_ ,%*T 4_
M G_!/[]D'X6Z=+HGPR^"NG>';":Z:YFL-"NKBSA>8JJM(4BD52Q54!8C)"J.
MPKY__9&^ OPP\1_\%!/VM/#&O:1J%U8^'?$G@^UT.VF\07Q6SMY/#=M</&G[
M[(4S32R8Z!I&(Y)S]&?\._OV*?\ HV7PC_X*5KSSPM^P'^Q='^U%XUTV/]F?
MPBL/_"$>&[DQKI" &9[O6HVD/JQ2&)<GG$:CH!0!ZJW[)GP%967_ (1"X^8$
M?\AZ^XS_ -MJ\WN/^"0__!,^\N)+R]_8N\!S32-EY9M'#,Q]R3S7;?\ #O[]
MBG_HV7PC_P""E:/^'?W[%/\ T;+X1_\ !2M 'SO\6O\ @F1^P#X1^,GAOPSX
M:_9.\&Z=INNZ#-#K%G9Z?Y<=^B^(O#9"2J&'F(-S$*01GG&0"/5/^'//_!,/
M_HR+X?\ _@E7_&O1/!_[%/[)WP_\5V?CGP5^S_X7TW6-.9FL-2M=+19K<D8)
M5NHX_D/2O4* /FS_ (<]?\$PO^C(O '_ ()5_P :ETW_ ()%_P#!-31M1M]8
MT?\ 8R\#6MW:S++:W5MI/ER0R*<JZLI!5@<$$<@C-?1U% 'S7_PYZ_X)A]_V
M(_ '_@E7_&C_ (<\_P#!,/\ Z,B^'_\ X)5_QKZ4HH ^:_\ ASS_ ,$P_P#H
MR+X?_P#@E7_&E/\ P1[_ ."8K *W[$W@%MN0N[15XYSZU])T4 ?-?_#GG_@F
M'_T9%\/_ /P2K_C1_P .>?\ @F'_ -&1?#__ ,$J_P"-?2E% 'S>G_!(7_@F
M>EI)8+^Q;X$%O+(LDD(T<;&=0P5B,X) 9L'MN/J:C_X<\_\ !,/_ *,B^'__
M ()5_P :^E** /FO_ASS_P $P_\ HR+X?_\ @E7_ !JUI/\ P23_ .";6@W3
M7VB?L;^";.9[::W>6UTORV:&6-HI8R5()1XW>-EZ,KLIR"17T510!\U_\.>?
M^"8?_1D?P_\ _!*O^-=Q\,?V$/V2_@KI-QH'P@^"NF>&+"ZN?M%Q8Z#)-:PO
M,5"F0I&X4N555W8SA5'85ZY10!P[_LZ_"+;QX;N/_!O=?_':;!^SK\(Q"JGP
MY<-\N"S:O=9/_D6NY?[M)%]Q?]V@#E="^"?PY\,ZK%K>AZ--!=0[O*E.I7$F
M-RE3\KR%3P3U%=6$4#&*6B@!HB4'BG444 %-\M>HIU% !1110 WRUSD4>2M.
MHH *3;Z4M% #?+'K3J** "F^6*=10 4444 -$8!S7@O_  540#_@E]^T@<_\
MT%\8?^F6[KWRO!/^"JO_ "B^_:0_[()XP_\ 3)=T >H^)O@Q\.?&NNCQ3XCT
M%IK[[&ELUQ'>31%HD9V1#Y;KD R.1GIO;UJG_P ,[_"+_H6I_P#P;W7_ ,=K
MM(_N"G4 <3_PSM\(O^A:G_\ !O=?_':R_&?[(/[.WQ%\,7G@OQU\.H]6TG4$
M"7VFW^H7,D-P@8-L=#)AER!E3D'H:]*HH ^;6_X(^?\ !,1FW']B/X?]<_\
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M_!,/_HR/X?\ _@E7_&OI2B@#YK_X<]?\$P_^C(OA_P#^"5?\:L:E_P $C/\
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M";>'4K86VHPP:7M2ZA$L<HCD .'42112!3D!HU;J 15_X<\_\$P_^C(OA_\
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M6H_^"3/_  3:35;S08?V-/ _V5HK2>2U_LD",N'N%#$9P2 S@=P&/8G-T_\
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M,LI8%,;7Q^I_PJS7'?"G]G[X*_ S[<?@_P##/2/#O]J>5_:']E6@B^T>7O\
M+W8Z[?,?'^\:[&@#R7]C*,'X0ZP<_P#-5O'G_J6:M7K B [UY3^QA_R2#6/^
MRK>._P#U+-6KUB@ HHHH **** (Z*** /'?VPOV)_@I^W#X6\.^ /CYX=_M?
MP_H7B1=9;2VE9%N)Q:W%NFXKSA1<,PQW KQK_APS_P $MR,?\,R6/_@PG_\
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!53_D,S?\
M7O%_Z%)5JJJ?\AF;_KWB_P#0I*M4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 8/PP_Y)MX?_ .P+:?\ HE*WJP?AA_R3;P__ -@6T_\
M1*5O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X9_P %#_\
MD@6@?]ER^&'_ *GF@U[G7AG_  4/_P"2!:!_V7+X8?\ J>:#0![G1110 444
M4 %%%% !1110!Y/^QA_R2#6/^RK>._\ U+-6KUBO)_V,/^20:Q_V5;QW_P"I
M9JU>L4 %%%% !1110!'1110!P/[17[27PA_94^$^J?&SXY>*(]%\.Z/&K7=[
M(C.2S-M2-$4%G=F(554%F)X%> _L[_\ !:;]D;]H+Q+;^&(['QAX2DU"81Z+
M=^-/"\^GVNHD_=$<[CRPS$@!&96)/2H?^"LWQ$^$GPKTCX*^._CSX5U+7?"&
MF_&:.?6-&TG1WU":Y=="UAK;_1T!,JI<B&3&."@)Z&O)_CU_P6H_8D^)'P<\
M2_#V?X)_%75H]6T&[M(],O/A5?\ E3LT#!%)*$+\^T!OX3@\$"NVAA_:4K\C
M=^M]CS\1B94ZC2DE;I;5G4_M?_\ !2_XC?$[Q]>?L5_\$P?#<7C;XF7$;6WB
M#QD2&T+P.K':9[J891YUY*Q#)#8W D"-_KW]G;X<WOP>^ O@OX3ZGXAFUFZ\
M+^%['29]7N,^9>M;P)$9V]W*[O;-?G?^R-_P53_X)Z_LB?LXZ#\.?A_^SK\3
M-$DLM&MWUJ.P^%=\OVJ^$ \Z:20KF5B^XEV)X/IQ7Z&?LY?%9/CI\ _!7QJ3
M3GLU\7>%[#6$M)!AH5N8$F"$=B-^/PI8JG4IP45&R77JRL+*-67,Y7;_  .X
MJ2HZDKC.X**** "BBB@ HHHH **** "BBB@ HHHH *C>?8NXU)7"_'5]6O\
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M8O:VUQY5T[_?DCGFGC1AR;=;?>6D#NP!W5%%% !1110 4444 %%%% !1110
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M^(K/2[]@T]G%>VD5RL,A7@NBRA3CC(H [BBBB@ HHHH **** "BBB@ HHHH
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MI&G6]K:6<*PVEK;0K''!$H 5$50 J@       =JN444 %%%% !1110 4444
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M ! (P17D\?@G6_@7_:EM\/\ X?PZSX3UC6YK^XT'35CCN-.N+VYENM1N@)&
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MP_\ A'\(? FN:A'X1^$&BPV&CV%TRR7%^UMI_P!@MGN90 '$<3RL4"#=,8I
M4$6U_8U54&U1TH"*. M+0 4444 %%%% ".@==IKR+QKX#U_X3:[XE^)'PL^'
M2>)X?%VH0WOBCPO]LBAFNK\6]K9+>12W+B) +6UA5XOE!$(9?G9MWKU(44]5
MH \<UCQ9\4/%5E=>'OV?/A&OAN>ZC,+>*/%VEBVMK*59(U+?8P5FNR(I7EC
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M_#.*SK>V<>:HM>[1M1]C&K:F_N=SV2I*CJ2N<[ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK7_[(?AZ\UN/Q3_P7(O?CQXRN+(;Y=49#>> K>3.-\2Z&'EM8^^Z[B@0]P,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.D>$[^]L?V%?VF)IELY#"M]\)Y+:#=L)&^5I3L7CD@,0.<'I7TY_P3?9Y/\
M@GY\#]\7EM_PJ/PZ'CQ]TC3H 1CMS14P]6E3YJBMK8FCBJ-:IRTW<]NJ2HZD
MK$Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9]5;I;8G"QIQEUYNMSM*DJ.I*Y3N"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ****  J#VINP4ZB@!OE)W7/UH\F/^X/RI
AU% #?*CSGRQ^5 B4=!3J* &[!3J** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>fgen-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-08-09T14:56:03.0123524+00:00 -->
<!-- Version            : 5.0.1.648 -->
<!-- Package ID         : eb9c0c47f0494648af9d850a5814e112 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:fgen="http://www.fibrogen.com/20210630" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.fibrogen.com/20210630" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.fibrogen.com/20210630/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" id="Role_StatementCondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical" id="Role_StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited">
        <link:definition>100050 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited">
        <link:definition>100060 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" id="Role_StatementCondensedConsolidatedStatementOfCashFlowsUnaudited">
        <link:definition>100070 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPolicies" id="Role_DisclosureSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenues" id="Role_DisclosureCollaborationAgreementsAndRevenues">
        <link:definition>100090 - Disclosure - Collaboration Agreements and Revenues</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntity" id="Role_DisclosureVariableInterestEntity">
        <link:definition>100100 - Disclosure - Variable Interest Entity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100110 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100120 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>100130 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100140 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100150 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100160 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100170 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEvent" id="Role_DisclosureSubsequentEvent">
        <link:definition>100180 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" id="Role_DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>100190 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables" id="Role_DisclosureCollaborationAgreementsAndRevenuesTables">
        <link:definition>100200 - Disclosure - Collaboration Agreements and Revenues (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityTables" id="Role_DisclosureVariableInterestEntityTables">
        <link:definition>100210 - Disclosure - Variable Interest Entity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100220 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100230 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>100240 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100250 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100260 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail">
        <link:definition>100270 - Disclosure - Collaboration Agreements and Revenues - Astellas Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail" id="Role_DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail">
        <link:definition>100280 - Disclosure - Collaboration Agreements and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail">
        <link:definition>100290 - Disclosure - Collaboration Agreements and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail">
        <link:definition>100300 - Disclosure - Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail" id="Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail">
        <link:definition>100310 - Disclosure - Collaboration Agreements and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail">
        <link:definition>100320 - Disclosure - Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail">
        <link:definition>100330 - Disclosure - Collaboration Agreements and Revenues - Summary of Product Revenue, Net (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail" id="Role_DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail">
        <link:definition>100340 - Disclosure - Collaboration Agreements and Revenues - Product Revenue, Net - Additional Information 1 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail">
        <link:definition>100350 - Disclosure - Collaboration Agreements and Revenues - Roll-forward of Related Contract Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail">
        <link:definition>100360 - Disclosure - Collaboration Agreements and Revenues - Deferred Revenue - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail">
        <link:definition>100370 - Disclosure - Collaboration Agreements and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail">
        <link:definition>100380 - Disclosure - Collaboration Agreements and Revenues - Drug Product Revenue - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail" id="Role_DisclosureVariableInterestEntityAdditionalInformationDetail">
        <link:definition>100390 - Disclosure - Variable Interest Entity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail" id="Role_DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail">
        <link:definition>100400 - Disclosure - Variable Interest Entity - Summary of Equity Method Investment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" id="Role_DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail">
        <link:definition>100410 - Disclosure - Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>100420 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" id="Role_DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail">
        <link:definition>100430 - Disclosure - Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail" id="Role_DisclosureLeasesComponentsOfLeaseExpenseDetail">
        <link:definition>100450 - Disclosure - Leases - Components of Lease Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail" id="Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail">
        <link:definition>100460 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail" id="Role_DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail">
        <link:definition>100470 - Disclosure - Leases - Schedule of Lease Term and Discount Rate (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" id="Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail">
        <link:definition>100480 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2" id="Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2">
        <link:definition>100490 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail">
        <link:definition>100500 - Disclosure - Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" id="Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail">
        <link:definition>100510 - Disclosure - Balance Sheet Components - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" id="Role_DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail">
        <link:definition>100520 - Disclosure - Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfInventoryDetail">
        <link:definition>100530 - Disclosure - Balance Sheet Components - Schedule of Inventory (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>100540 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail">
        <link:definition>100550 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail">
        <link:definition>100560 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail">
        <link:definition>100570 - Disclosure - Balance Sheet Components - Schedule of Other Long-term Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail" id="Role_DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail">
        <link:definition>100580 - Disclosure - Stock-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" id="Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail">
        <link:definition>100590 - Disclosure - Stock-Based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
        <link:definition>100600 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100610 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail" id="Role_DisclosureSubsequentEventAdditionalInformationDetail">
        <link:definition>100620 - Disclosure - Subsequent Event - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" name="CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour" name="FinanceLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_RestrictedTimeDepositsNoncurrent" name="RestrictedTimeDepositsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" name="EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_AccruedProductDevelopmentCosts" name="AccruedProductDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_DueToRelatedPartiesDeferredRevenueCurrent" name="DueToRelatedPartiesDeferredRevenueCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent" name="DueToRelatedPartiesDeferredRevenueNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_CostOfGoodsAndServicesSoldOperatingExpense" name="CostOfGoodsAndServicesSoldOperatingExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_InterestIncomeAndOtherIncomeExpensesNet" name="InterestIncomeAndOtherIncomeExpensesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_UnconsolidatedVariableInterestEntityInvestmentIncome" name="UnconsolidatedVariableInterestEntityInvestmentIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_DevelopmentAndOtherRevenueMember" name="DevelopmentAndOtherRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_DrugProductRevenueMember" name="DrugProductRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ProductRevenue" name="ProductRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_CollaborationServicesAndOtherRevenue" name="CollaborationServicesAndOtherRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_DrugProductRevenueFromRelatedParty" name="DrugProductRevenueFromRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_AstellasCollaborationAgreementMember" name="AstellasCollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" name="SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" name="AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_UnrealizedLossGainOnEquityInvestments" name="UnrealizedLossGainOnEquityInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" name="InvestmentLossInUnconsolidatedVariableInterestEntity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" name="IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" name="IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" name="IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" name="PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_RepaymentsOfFinanceLeaseLiabilities" name="RepaymentsOfFinanceLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock" name="CollaborativeArrangementAndRevenuesDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_AcquisitionAndVariableInterestEntityAbstract" name="AcquisitionAndVariableInterestEntityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_DescriptionOfOperationsPolicyPolicyTextBlock" name="DescriptionOfOperationsPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" name="BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" name="RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" name="RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock" name="CollaborativeArrangementAndRevenuesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ProductRevenuePolicyPolicyTextBlock" name="ProductRevenuePolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_DrugProductRevenuePolicyTextBlock" name="DrugProductRevenuePolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ContractWithCustomerMilestoneMethodTableTextBlock" name="ContractWithCustomerMilestoneMethodTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_UnitedStatesRestOfWorldAndChinaMember" name="UnitedStatesRestOfWorldAndChinaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AstraZenecaAgreementsMember" name="AstraZenecaAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ScheduleOfDrugProductRevenueTableTextBlock" name="ScheduleOfDrugProductRevenueTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" name="ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" name="ScheduleOfLeaseTermAndDiscountRateTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" name="ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" name="ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_AccountingPolicyLineItems" name="AccountingPolicyLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AccountingPolicyTable" name="AccountingPolicyTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_HiFiBiOAgreementMember" name="HiFiBiOAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ProfitSharePercent" name="ProfitSharePercent" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_DescriptionOfSalesReturn" name="DescriptionOfSalesReturn" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_InitialUpfrontPayment" name="InitialUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments" name="MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" name="ProceedsFromUpfrontNonContingentAndTimeBasedPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_PotentialMilestones" name="PotentialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_CommercialSalesMilestone" name="CommercialSalesMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_AdditionalConsiderationBasedOnNetSales" name="AdditionalConsiderationBasedOnNetSales" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" name="CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_ClinicalDevelopmentMilestonesMember" name="ClinicalDevelopmentMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_RegulatoryMilestonesMember" name="RegulatoryMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_PercentageOfFundingForCosts" name="PercentageOfFundingForCosts" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_DevelopmentAndRegulatoryApprovalMilestones" name="DevelopmentAndRegulatoryApprovalMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" name="ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_UnitedStatesAndRestOfWorldMember" name="UnitedStatesAndRestOfWorldMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_DeferredApprovalMilestoneMember" name="DeferredApprovalMilestoneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_DirectSalesMember" name="DirectSalesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_CommercialSalesAndOtherEventsMilestone" name="CommercialSalesAndOtherEventsMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" name="ProceedsFromUpfrontNonContingentAndNonRefundablePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" name="CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_CashConsiderationReceivedUnderCollaborationAgreement" name="CashConsiderationReceivedUnderCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" name="CoDevelopmentInformationSharingAndCommitteeServicesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ChinaPerformanceObligationMember" name="ChinaPerformanceObligationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" name="VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_SuppliesNet" name="SuppliesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" name="RevenueGrossFromContractWithCustomerExcludingAssessedTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax" name="RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_SalesToFalikangMember" name="SalesToFalikangMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_DiscountsAndRebatesMember" name="DiscountsAndRebatesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ProfitShareMember" name="ProfitShareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_NetTransferPriceMember" name="NetTransferPriceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_IncreaseInDeferredRevenueMember" name="IncreaseInDeferredRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_RebatesAndDiscountsMember" name="RebatesAndDiscountsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_GrossAccountsReceivableMember" name="GrossAccountsReceivableMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ContractLiabilitiesMember" name="ContractLiabilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_DeferredForFutureRecognitionMember" name="DeferredForFutureRecognitionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ContractWithCustomerLiabilityAdditions" name="ContractWithCustomerLiabilityAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_ContractWithCustomerLiabilityDeduction" name="ContractWithCustomerLiabilityDeduction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" name="ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_ContractWithCustomerLiabilityLineItems" name="ContractWithCustomerLiabilityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ContractWithCustomerLiabilityTable" name="ContractWithCustomerLiabilityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AstellasAgreementMember" name="AstellasAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_BeijingFalikangPharmaceuticalCoLtdMember" name="BeijingFalikangPharmaceuticalCoLtdMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_APIShipmentMember" name="APIShipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AcquisitionAndVariableInterestEntityLineItems" name="AcquisitionAndVariableInterestEntityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AcquisitionAndVariableInterestEntityTable" name="AcquisitionAndVariableInterestEntityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" name="BeijingKangdaYongfuPharmaceuticalCoLTDMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_FibroGenBeijingMember" name="FibroGenBeijingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AstraZenecaABMember" name="AstraZenecaABMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" name="EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_USGovernmentBondsMember" name="USGovernmentBondsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AgencyBondsMember" name="AgencyBondsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_BondAndMutualFundsMember" name="BondAndMutualFundsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_FinanceLeaseRightOfUseAssetsCost" name="FinanceLeaseRightOfUseAssetsCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_FinanceLeaseAccumulatedAmortization" name="FinanceLeaseAccumulatedAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_OperatingLeaseRightOfUseAssetsCost" name="OperatingLeaseRightOfUseAssetsCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_OperatingLeaseAccumulatedAmortization" name="OperatingLeaseAccumulatedAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_FinanceLeaseAndOperatingLeaseAssets" name="FinanceLeaseAndOperatingLeaseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_FinanceLeaseAndOperatingLeaseLiability" name="FinanceLeaseAndOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_LesseeFinanceLeaseExpirationPeriod" name="LesseeFinanceLeaseExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ShorensteinPropertiesLLCMember" name="ShorensteinPropertiesLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_LeaseAmendmentMember" name="LeaseAmendmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" name="BeijingEconomicTechnologicalDevelopmentAreaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" name="PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" name="LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ScheduledRentCommencementYearOptionOne" name="ScheduledRentCommencementYearOptionOne" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo" name="PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ScheduledRentCommencementYearOptionTwo" name="ScheduledRentCommencementYearOptionTwo" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_NumberOfOptionalRightsToExtendLease" name="NumberOfOptionalRightsToExtendLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" name="LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_LesseeOperatingLeaseExpirationPeriod" name="LesseeOperatingLeaseExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" name="NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" name="NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ScheduleOfLeasesLineItems" name="ScheduleOfLeasesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ScheduleOfLeasesTable" name="ScheduleOfLeasesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_WeightedAverageRemainingLeaseTermAbstract" name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_WeightedAverageDiscountRateAbstract" name="WeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AvailableForSaleSecuritiesContractualMaturityPeriod" name="AvailableForSaleSecuritiesContractualMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" name="PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="fgen_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AccruedPreclinicalAndClinicalTrialCurrent" name="AccruedPreclinicalAndClinicalTrialCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" name="AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_AccruedCoPromotionExpensesCurrent" name="AccruedCoPromotionExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_AccruedProfitShareCurrent" name="AccruedProfitShareCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_PropertyTaxesAndOtherCurrent" name="PropertyTaxesAndOtherCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" name="AccruedLongTermCoPromotionLiabilityNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_AstellasMember" name="AstellasMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_FalikangMember" name="FalikangMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_MiscellaneousReceivables" name="MiscellaneousReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_MaximumFutureMilestonePayments" name="MaximumFutureMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ManufactureAndSupplyOfRoxadustatMember" name="ManufactureAndSupplyOfRoxadustatMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ManufactureAndSupplyOfPamrevlumabMember" name="ManufactureAndSupplyOfPamrevlumabMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_OtherPurchasesMember" name="OtherPurchasesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" name="ResearchAndPreClinicalStageDevelopmentProgramsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_LicenseAgreementWithEluminexMember" name="LicenseAgreementWithEluminexMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_CommercialMilestone" name="CommercialMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments" name="FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>fgen-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-08-09T14:56:03.0123524+00:00 -->
<!-- Version            : 5.0.1.648 -->
<!-- Package ID         : eb9c0c47f0494648af9d850a5814e112 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="fgen-20210630.xsd#TemplateLink" roleURI="http://www.fibrogen.com/20210630/role/TemplateLink" />
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:href="fgen-20210630.xsd#Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RestrictedTimeDepositsNoncurrent" xlink:type="locator" xlink:label="fgen_RestrictedTimeDepositsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedProductDevelopmentCosts" xlink:type="locator" xlink:label="fgen_AccruedProductDevelopmentCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="fgen_AccruedProductDevelopmentCosts" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="fgen_RestrictedTimeDepositsNoncurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10280.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10290.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10300.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="10310.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10320.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="10330.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10340.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="fgen-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CostOfGoodsAndServicesSoldOperatingExpense" xlink:type="locator" xlink:label="fgen_CostOfGoodsAndServicesSoldOperatingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_InterestIncomeAndOtherIncomeExpensesNet" xlink:type="locator" xlink:label="fgen_InterestIncomeAndOtherIncomeExpensesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnconsolidatedVariableInterestEntityInvestmentIncome" xlink:type="locator" xlink:label="fgen_UnconsolidatedVariableInterestEntityInvestmentIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="fgen_UnconsolidatedVariableInterestEntityInvestmentIncome" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestExpense" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="fgen_InterestIncomeAndOtherIncomeExpensesNet" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="fgen_CostOfGoodsAndServicesSoldOperatingExpense" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="fgen-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" xlink:href="fgen-20210630.xsd#Role_StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnrealizedLossGainOnEquityInvestments" xlink:type="locator" xlink:label="fgen_UnrealizedLossGainOnEquityInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RepaymentsOfFinanceLeaseLiabilities" xlink:type="locator" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="fgen_RepaymentsOfFinanceLeaseLiabilities" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fgen_UnrealizedLossGainOnEquityInvestments" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="10200.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" order="10240.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10250.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10260.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10270.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" order="10280.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10290.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10300.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10310.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" order="10320.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10330.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" order="10340.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" order="10350.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="10360.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" xlink:type="locator" xlink:label="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CashConsiderationReceivedUnderCollaborationAgreement" xlink:type="locator" xlink:label="fgen_CashConsiderationReceivedUnderCollaborationAgreement" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_CashConsiderationReceivedUnderCollaborationAgreement" xlink:to="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_CashConsiderationReceivedUnderCollaborationAgreement" xlink:to="us-gaap_ContractWithCustomerLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FinanceLeaseAccumulatedAmortization" xlink:type="locator" xlink:label="fgen_FinanceLeaseAccumulatedAmortization" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FinanceLeaseRightOfUseAssetsCost" xlink:type="locator" xlink:label="fgen_FinanceLeaseRightOfUseAssetsCost" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_OperatingLeaseAccumulatedAmortization" xlink:type="locator" xlink:label="fgen_OperatingLeaseAccumulatedAmortization" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_OperatingLeaseRightOfUseAssetsCost" xlink:type="locator" xlink:label="fgen_OperatingLeaseRightOfUseAssetsCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FinanceLeaseAndOperatingLeaseAssets" xlink:type="locator" xlink:label="fgen_FinanceLeaseAndOperatingLeaseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FinanceLeaseAndOperatingLeaseLiability" xlink:type="locator" xlink:label="fgen_FinanceLeaseAndOperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_FinanceLeaseAndOperatingLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_FinanceLeaseAndOperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_FinanceLeaseAndOperatingLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_FinanceLeaseAndOperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_FinanceLeaseAndOperatingLeaseAssets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_FinanceLeaseAndOperatingLeaseAssets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="fgen_OperatingLeaseRightOfUseAssetsCost" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="fgen_OperatingLeaseAccumulatedAmortization" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="fgen_FinanceLeaseRightOfUseAssetsCost" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="fgen_FinanceLeaseAccumulatedAmortization" order="10100.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome" order="10040.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2" xlink:href="fgen-20210630.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CommercialPaperAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_Cash" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CommercialPaperAtCarryingValue" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfInventoryDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:type="locator" xlink:label="us-gaap_Supplies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_SuppliesNet" xlink:type="locator" xlink:label="fgen_SuppliesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="fgen_SuppliesNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_SuppliesNet" xlink:to="us-gaap_Supplies" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_SuppliesNet" xlink:to="us-gaap_ContractWithCustomerLiability" order="10050.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PropertyTaxesAndOtherCurrent" xlink:type="locator" xlink:label="fgen_PropertyTaxesAndOtherCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedProfitShareCurrent" xlink:type="locator" xlink:label="fgen_AccruedProfitShareCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedCoPromotionExpensesCurrent" xlink:type="locator" xlink:label="fgen_AccruedCoPromotionExpensesCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" xlink:type="locator" xlink:label="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedPreclinicalAndClinicalTrialCurrent" xlink:type="locator" xlink:label="fgen_AccruedPreclinicalAndClinicalTrialCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="fgen_AccruedPreclinicalAndClinicalTrialCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="fgen_AccruedCoPromotionExpensesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="fgen_AccruedProfitShareCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="fgen_PropertyTaxesAndOtherCurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" xlink:type="locator" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>fgen-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-08-09T14:56:03.0123524+00:00 -->
<!-- Version            : 5.0.1.648 -->
<!-- Package ID         : eb9c0c47f0494648af9d850a5814e112 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="fgen-20210630.xsd#TemplateLink" roleURI="http://www.fibrogen.com/20210630/role/TemplateLink" />
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="fgen-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnconsolidatedVariableInterestEntityInvestmentIncome" xlink:type="locator" xlink:label="fgen_UnconsolidatedVariableInterestEntityInvestmentIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_InterestIncomeAndOtherIncomeExpensesNet" xlink:type="locator" xlink:label="fgen_InterestIncomeAndOtherIncomeExpensesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CostOfGoodsAndServicesSoldOperatingExpense" xlink:type="locator" xlink:label="fgen_CostOfGoodsAndServicesSoldOperatingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DevelopmentAndOtherRevenueMember" xlink:type="locator" xlink:label="fgen_DevelopmentAndOtherRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10130.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DevelopmentAndOtherRevenueMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="fgen_CostOfGoodsAndServicesSoldOperatingExpense" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_TypeOfCostGoodOrServiceExtensibleList" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="fgen_InterestIncomeAndOtherIncomeExpensesNet" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="11900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_UnconsolidatedVariableInterestEntityInvestmentIncome" order="12060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="12220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="12300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical" xlink:href="fgen-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueFromRelatedParty" xlink:type="locator" xlink:label="fgen_DrugProductRevenueFromRelatedParty" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProductRevenue" xlink:type="locator" xlink:label="fgen_ProductRevenue" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborationServicesAndOtherRevenue" xlink:type="locator" xlink:label="fgen_CollaborationServicesAndOtherRevenue" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_CollaborationServicesAndOtherRevenue" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_ProductRevenue" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_DrugProductRevenueFromRelatedParty" order="10320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited" xlink:href="fgen-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" xlink:type="locator" xlink:label="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" xlink:type="locator" xlink:label="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfDrugProductRevenueTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfDrugProductRevenueTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerMilestoneMethodTableTextBlock" xlink:type="locator" xlink:label="fgen_ContractWithCustomerMilestoneMethodTableTextBlock" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_ContractWithCustomerMilestoneMethodTableTextBlock" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_ScheduleOfDrugProductRevenueTableTextBlock" order="11110.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments" xlink:type="locator" xlink:label="fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_InitialUpfrontPayment" xlink:type="locator" xlink:label="fgen_InitialUpfrontPayment" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DescriptionOfSalesReturn" xlink:type="locator" xlink:label="fgen_DescriptionOfSalesReturn" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="locator" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProfitSharePercent" xlink:type="locator" xlink:label="fgen_ProfitSharePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_HiFiBiOAgreementMember" xlink:type="locator" xlink:label="fgen_HiFiBiOAgreementMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccountingPolicyTable" xlink:type="locator" xlink:label="fgen_AccountingPolicyTable" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccountingPolicyLineItems" xlink:type="locator" xlink:label="fgen_AccountingPolicyLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_AccountingPolicyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_HiFiBiOAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_ProfitSharePercent" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_DescriptionOfSalesReturn" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_InitialUpfrontPayment" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="10660.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PercentageOfFundingForCosts" xlink:type="locator" xlink:label="fgen_PercentageOfFundingForCosts" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DevelopmentAndRegulatoryApprovalMilestones" xlink:type="locator" xlink:label="fgen_DevelopmentAndRegulatoryApprovalMilestones" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AdditionalConsiderationBasedOnNetSales" xlink:type="locator" xlink:label="fgen_AdditionalConsiderationBasedOnNetSales" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommercialSalesMilestone" xlink:type="locator" xlink:label="fgen_CommercialSalesMilestone" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PotentialMilestones" xlink:type="locator" xlink:label="fgen_PotentialMilestones" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RegulatoryMilestonesMember" xlink:type="locator" xlink:label="fgen_RegulatoryMilestonesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ClinicalDevelopmentMilestonesMember" xlink:type="locator" xlink:label="fgen_ClinicalDevelopmentMilestonesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_ClinicalDevelopmentMilestonesMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_RegulatoryMilestonesMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_PotentialMilestones" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CommercialSalesMilestone" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_AdditionalConsiderationBasedOnNetSales" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_DevelopmentAndRegulatoryApprovalMilestones" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_PercentageOfFundingForCosts" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11650.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommercialSalesAndOtherEventsMilestone" xlink:type="locator" xlink:label="fgen_CommercialSalesAndOtherEventsMilestone" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommercialSalesMilestone" xlink:type="locator" xlink:label="fgen_CommercialSalesMilestone" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PotentialMilestones" xlink:type="locator" xlink:label="fgen_PotentialMilestones" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DirectSalesMember" xlink:type="locator" xlink:label="fgen_DirectSalesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DeferredApprovalMilestoneMember" xlink:type="locator" xlink:label="fgen_DeferredApprovalMilestoneMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RegulatoryMilestonesMember" xlink:type="locator" xlink:label="fgen_RegulatoryMilestonesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ClinicalDevelopmentMilestonesMember" xlink:type="locator" xlink:label="fgen_ClinicalDevelopmentMilestonesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnitedStatesAndRestOfWorldMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesAndRestOfWorldMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_ClinicalDevelopmentMilestonesMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_RegulatoryMilestonesMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_DeferredApprovalMilestoneMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_DirectSalesMember" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_PotentialMilestones" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CommercialSalesMilestone" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CommercialSalesAndOtherEventsMilestone" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11430.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DevelopmentAndOtherRevenueMember" xlink:type="locator" xlink:label="fgen_DevelopmentAndOtherRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_ProductOrServiceAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DevelopmentAndOtherRevenueMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10740.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CashConsiderationReceivedUnderCollaborationAgreement" xlink:type="locator" xlink:label="fgen_CashConsiderationReceivedUnderCollaborationAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" xlink:type="locator" xlink:label="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ChinaPerformanceObligationMember" xlink:type="locator" xlink:label="fgen_ChinaPerformanceObligationMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" xlink:type="locator" xlink:label="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DevelopmentAndOtherRevenueMember" xlink:type="locator" xlink:label="fgen_DevelopmentAndOtherRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_ProductOrServiceAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DevelopmentAndOtherRevenueMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_ChinaPerformanceObligationMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="fgen_CashConsiderationReceivedUnderCollaborationAgreement" order="11000.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" xlink:type="locator" xlink:label="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" order="10360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_SuppliesNet" xlink:type="locator" xlink:label="fgen_SuppliesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnitedStatesAndRestOfWorldMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesAndRestOfWorldMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="fgen_SuppliesNet" order="10260.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_IncreaseInDeferredRevenueMember" xlink:type="locator" xlink:label="fgen_IncreaseInDeferredRevenueMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_NetTransferPriceMember" xlink:type="locator" xlink:label="fgen_NetTransferPriceMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProfitShareMember" xlink:type="locator" xlink:label="fgen_ProfitShareMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:type="locator" xlink:label="us-gaap_SalesReturnsAndAllowancesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DiscountsAndRebatesMember" xlink:type="locator" xlink:label="fgen_DiscountsAndRebatesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_SalesToFalikangMember" xlink:type="locator" xlink:label="fgen_SalesToFalikangMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DirectSalesMember" xlink:type="locator" xlink:label="fgen_DirectSalesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_DirectSalesMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_SalesToFalikangMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DiscountsAndRebatesMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_SalesReturnsAndAllowancesMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_ProfitShareMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_NetTransferPriceMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_IncreaseInDeferredRevenueMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax" order="10980.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DeferredForFutureRecognitionMember" xlink:type="locator" xlink:label="fgen_DeferredForFutureRecognitionMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractLiabilitiesMember" xlink:type="locator" xlink:label="fgen_ContractLiabilitiesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_GrossAccountsReceivableMember" xlink:type="locator" xlink:label="fgen_GrossAccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RebatesAndDiscountsMember" xlink:type="locator" xlink:label="fgen_RebatesAndDiscountsMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DiscountsAndRebatesMember" xlink:type="locator" xlink:label="fgen_DiscountsAndRebatesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DiscountsAndRebatesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_RebatesAndDiscountsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fgen_GrossAccountsReceivableMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fgen_ContractLiabilitiesMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DeferredForFutureRecognitionMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10340.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerLiabilityDeduction" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityDeduction" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerLiabilityAdditions" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityAdditions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasAgreementMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractLiabilitiesMember" xlink:type="locator" xlink:label="fgen_ContractLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DirectSalesMember" xlink:type="locator" xlink:label="fgen_DirectSalesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerLiabilityTable" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityTable" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerLiabilityLineItems" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_ContractWithCustomerLiabilityTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_ContractWithCustomerLiabilityTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_DirectSalesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_ContractWithCustomerLiabilityTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fgen_ContractLiabilitiesMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_ContractWithCustomerLiabilityTable" xlink:to="srt_StatementGeographicalAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasAgreementMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityAdditions" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityDeduction" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10720.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BeijingFalikangPharmaceuticalCoLtdMember" xlink:type="locator" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="fgen_BeijingFalikangPharmaceuticalCoLtdMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="10350.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_APIShipmentMember" xlink:type="locator" xlink:label="fgen_APIShipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TransactionTypeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="fgen_APIShipmentMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasAgreementMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10470.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureVariableInterestEntityAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaABMember" xlink:type="locator" xlink:label="fgen_AstraZenecaABMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FibroGenBeijingMember" xlink:type="locator" xlink:label="fgen_FibroGenBeijingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BeijingFalikangPharmaceuticalCoLtdMember" xlink:type="locator" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" xlink:type="locator" xlink:label="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AcquisitionAndVariableInterestEntityTable" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityTable" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="fgen_AcquisitionAndVariableInterestEntityTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="fgen_BeijingFalikangPharmaceuticalCoLtdMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_FibroGenBeijingMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fgen_AstraZenecaABMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BeijingFalikangPharmaceuticalCoLtdMember" xlink:type="locator" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AcquisitionAndVariableInterestEntityTable" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityTable" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="fgen_AcquisitionAndVariableInterestEntityTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="fgen_BeijingFalikangPharmaceuticalCoLtdMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BondAndMutualFundsMember" xlink:type="locator" xlink:label="fgen_BondAndMutualFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:type="locator" xlink:label="us-gaap_ForeignGovernmentDebtMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AgencyBondsMember" xlink:type="locator" xlink:label="fgen_AgencyBondsMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_USGovernmentBondsMember" xlink:type="locator" xlink:label="fgen_USGovernmentBondsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fgen_USGovernmentBondsMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fgen_AgencyBondsMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ForeignGovernmentDebtMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fgen_BondAndMutualFundsMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11400.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LesseeOperatingLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeOperatingLeaseExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduledRentCommencementYearOptionTwo" xlink:type="locator" xlink:label="fgen_ScheduledRentCommencementYearOptionTwo" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo" xlink:type="locator" xlink:label="fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduledRentCommencementYearOptionOne" xlink:type="locator" xlink:label="fgen_ScheduledRentCommencementYearOptionOne" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_NumberOfOptionalRightsToExtendLease" xlink:type="locator" xlink:label="fgen_NumberOfOptionalRightsToExtendLease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseOptionToExtend" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" xlink:type="locator" xlink:label="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LesseeFinanceLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" xlink:type="locator" xlink:label="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201901Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201901Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LeaseAmendmentMember" xlink:type="locator" xlink:label="fgen_LeaseAmendmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ShorensteinPropertiesLLCMember" xlink:type="locator" xlink:label="fgen_ShorensteinPropertiesLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_ShorensteinPropertiesLLCMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_2" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="fgen_LeaseAmendmentMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201901Member" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_LesseeFinanceLeaseExpirationPeriod" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseOptionToExtend" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_NumberOfOptionalRightsToExtendLease" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_ScheduledRentCommencementYearOptionOne" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_ScheduledRentCommencementYearOptionTwo" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiability" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_LesseeOperatingLeaseExpirationPeriod" order="11550.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" xlink:type="locator" xlink:label="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RepaymentsOfFinanceLeaseLiabilities" xlink:type="locator" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201901Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201901Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfLeasesTable" xlink:type="locator" xlink:label="fgen_ScheduleOfLeasesTable" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfLeasesLineItems" xlink:type="locator" xlink:label="fgen_ScheduleOfLeasesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fgen_ScheduleOfLeasesLineItems" xlink:to="fgen_ScheduleOfLeasesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_ScheduleOfLeasesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201901Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_ScheduleOfLeasesLineItems" xlink:to="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="fgen_RepaymentsOfFinanceLeaseLiabilities" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_ScheduleOfLeasesLineItems" xlink:to="fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_ScheduleOfLeasesLineItems" xlink:to="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10880.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_SuppliesNet" xlink:type="locator" xlink:label="fgen_SuppliesNet" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" xlink:type="locator" xlink:label="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AvailableForSaleSecuritiesContractualMaturityPeriod" xlink:type="locator" xlink:label="fgen_AvailableForSaleSecuritiesContractualMaturityPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionForeignMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_GeographicDistributionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionForeignMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="srt_StatementGeographicalAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_AvailableForSaleSecuritiesContractualMaturityPeriod" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_SuppliesNet" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10680.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BondAndMutualFundsMember" xlink:type="locator" xlink:label="fgen_BondAndMutualFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:type="locator" xlink:label="us-gaap_ForeignGovernmentDebtMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BondsMember" xlink:type="locator" xlink:label="us-gaap_BondsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_BondsMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ForeignGovernmentDebtMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fgen_BondAndMutualFundsMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="11050.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="fgen_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fgen_LaboratoryEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10560.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10900.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_MiscellaneousReceivables" xlink:type="locator" xlink:label="fgen_MiscellaneousReceivables" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueFromRelatedParty" xlink:type="locator" xlink:label="fgen_DrugProductRevenueFromRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_RevenueFromRelatedParties" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FalikangMember" xlink:type="locator" xlink:label="fgen_FalikangMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasMember" xlink:type="locator" xlink:label="fgen_AstellasMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_AstellasMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_FalikangMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fgen_DrugProductRevenueFromRelatedParty" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fgen_MiscellaneousReceivables" order="11080.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="locator" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_MaximumFutureMilestonePayments" xlink:type="locator" xlink:label="fgen_MaximumFutureMilestonePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" xlink:type="locator" xlink:label="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_OtherPurchasesMember" xlink:type="locator" xlink:label="fgen_OtherPurchasesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ManufactureAndSupplyOfPamrevlumabMember" xlink:type="locator" xlink:label="fgen_ManufactureAndSupplyOfPamrevlumabMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ManufactureAndSupplyOfRoxadustatMember" xlink:type="locator" xlink:label="fgen_ManufactureAndSupplyOfRoxadustatMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="fgen_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="fgen_CommitmentsAndContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fgen_CommitmentsAndContingenciesLineItems" xlink:to="fgen_CommitmentsAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="fgen_ManufactureAndSupplyOfRoxadustatMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="fgen_ManufactureAndSupplyOfPamrevlumabMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="fgen_OtherPurchasesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligation" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_CommitmentsAndContingenciesLineItems" xlink:to="fgen_MaximumFutureMilestonePayments" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber" order="10310.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureSubsequentEventAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommercialMilestone" xlink:type="locator" xlink:label="fgen_CommercialMilestone" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments" xlink:type="locator" xlink:label="fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LicenseAgreementWithEluminexMember" xlink:type="locator" xlink:label="fgen_LicenseAgreementWithEluminexMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_LicenseAgreementWithEluminexMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="fgen_CommercialMilestone" order="10410.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>fgen-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-08-09T14:56:03.0133517+00:00 -->
<!-- Version            : 5.0.1.648 -->
<!-- Package ID         : eb9c0c47f0494648af9d850a5814e112 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" xlink:type="locator" xlink:label="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" xlink:to="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease liability payments due after year four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after year four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RestrictedTimeDepositsNoncurrent" xlink:type="locator" xlink:label="fgen_RestrictedTimeDepositsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_RestrictedTimeDepositsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted time deposits noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RestrictedTimeDepositsNoncurrent" xlink:to="fgen_RestrictedTimeDepositsNoncurrent_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" />
    <link:label xml:lang="en-US" xlink:label="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity method investment in unconsolidated variable interest entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" xlink:to="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedProductDevelopmentCosts" xlink:type="locator" xlink:label="fgen_AccruedProductDevelopmentCosts" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedProductDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the long-term portion of the outstanding principal and accrued interest of advances in the form note agreements received by the entity to fund various product development efforts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedProductDevelopmentCosts" xlink:to="fgen_AccruedProductDevelopmentCosts_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net ($13,352 and $4,127 from related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets ($0 and $889 from related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RestrictedTimeDepositsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted time deposits</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RestrictedTimeDepositsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Time Deposits Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investment in unconsolidated variable interest entity</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment In Unconsolidated Variable Interest Entity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, stockholders&#8217; equity and non-controlling interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable ($0 and $1,118 to a related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities ($14 and $24 to a related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue ($10,699 and $2,907 to a related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liabilities, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedProductDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product development obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedProductDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Product Development Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current ($9,381 and $4,636 to a related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liabilities, non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at June 30, 2021, and December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.01 par value; 225,000 shares authorized at June 30, 2021, and December 31, 2020; 92,609 and 91,441 shares issued and outstanding at June 30, 2021, and December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, stockholders&#8217; equity and non-controlling interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DueToRelatedPartiesDeferredRevenueCurrent" xlink:type="locator" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Due to related parties deferred revenue current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DueToRelatedPartiesDeferredRevenueCurrent" xlink:to="fgen_DueToRelatedPartiesDeferredRevenueCurrent_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DueToRelatedPartiesDeferredRevenueNoncurrent" xlink:type="locator" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Due to related parties deferred revenue noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent" xlink:to="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable from related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets from related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due From Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable to related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities to related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue current to related party</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Deferred Revenue Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue non-current to related party</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Deferred Revenue Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CostOfGoodsAndServicesSoldOperatingExpense" xlink:type="locator" xlink:label="fgen_CostOfGoodsAndServicesSoldOperatingExpense" />
    <link:label xml:lang="en-US" xlink:label="fgen_CostOfGoodsAndServicesSoldOperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of goods and services sold operating expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CostOfGoodsAndServicesSoldOperatingExpense" xlink:to="fgen_CostOfGoodsAndServicesSoldOperatingExpense_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_InterestIncomeAndOtherIncomeExpensesNet" xlink:type="locator" xlink:label="fgen_InterestIncomeAndOtherIncomeExpensesNet" />
    <link:label xml:lang="en-US" xlink:label="fgen_InterestIncomeAndOtherIncomeExpensesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest income and other income (expenses), net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_InterestIncomeAndOtherIncomeExpensesNet" xlink:to="fgen_InterestIncomeAndOtherIncomeExpensesNet_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnconsolidatedVariableInterestEntityInvestmentIncome" xlink:type="locator" xlink:label="fgen_UnconsolidatedVariableInterestEntityInvestmentIncome" />
    <link:label xml:lang="en-US" xlink:label="fgen_UnconsolidatedVariableInterestEntityInvestmentIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unconsolidated variable interest entity investment income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_UnconsolidatedVariableInterestEntityInvestmentIncome" xlink:to="fgen_UnconsolidatedVariableInterestEntityInvestmentIncome_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DevelopmentAndOtherRevenueMember" xlink:type="locator" xlink:label="fgen_DevelopmentAndOtherRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_DevelopmentAndOtherRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and other revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DevelopmentAndOtherRevenueMember" xlink:to="fgen_DevelopmentAndOtherRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DevelopmentAndOtherRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Other Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DevelopmentAndOtherRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development And Other Revenue [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Revenue, Net [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Drug product revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DrugProductRevenueMember" xlink:to="fgen_DrugProductRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Drug Product Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Drug Product Revenue [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating costs and expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs And Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CostOfGoodsAndServicesSoldOperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of goods sold</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CostOfGoodsAndServicesSoldOperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Goods And Services Sold Operating Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost, Product and Service [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:to="us-gaap_TypeOfCostGoodOrServiceExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Cost Good Or Service Extensible List</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating costs and expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_InterestIncomeAndOtherIncomeExpensesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income and other income (expenses), net</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_InterestIncomeAndOtherIncomeExpensesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income And Other Income Expenses Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total interest and other, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Nonoperating Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for (benefit from) income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_UnconsolidatedVariableInterestEntityInvestmentIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment income in unconsolidated variable interest entity</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_UnconsolidatedVariableInterestEntityInvestmentIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unconsolidated Variable Interest Entity Investment Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share - basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of common shares used to calculate net loss per share - basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProductRevenue" xlink:type="locator" xlink:label="fgen_ProductRevenue" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product revenue from a related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ProductRevenue" xlink:to="fgen_ProductRevenue_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborationServicesAndOtherRevenue" xlink:type="locator" xlink:label="fgen_CollaborationServicesAndOtherRevenue" />
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborationServicesAndOtherRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognized from co-development services, manufacturing of clinical supplies, committee services and information services and other revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CollaborationServicesAndOtherRevenue" xlink:to="fgen_CollaborationServicesAndOtherRevenue_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueFromRelatedParty" xlink:type="locator" xlink:label="fgen_DrugProductRevenueFromRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenueFromRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Drug product revenue from related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DrugProductRevenueFromRelatedParty" xlink:to="fgen_DrugProductRevenueFromRelatedParty_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Astellas agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AstellasCollaborationAgreementMember" xlink:to="fgen_AstellasCollaborationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Astellas Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Astellas Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborationServicesAndOtherRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration services and other revenue from a related party</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborationServicesAndOtherRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Services And Other Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product revenue from a related party</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenueFromRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Drug product revenue from a related party</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenueFromRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Drug Product Revenue From Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale investments:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Available For Sale Securities Adjustment Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on investments, net of tax effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive income, net of taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" xlink:type="locator" xlink:label="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" />
    <link:label xml:lang="en-US" xlink:label="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued from stock plans net of payroll taxes paid shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" xlink:to="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" xlink:type="locator" xlink:label="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" />
    <link:label xml:lang="en-US" xlink:label="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital shares issued from stock plans net of payroll taxes paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" xlink:to="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling Interests [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in unrealized gain or loss on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign currency translation adjustments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued from stock plans, net of payroll taxes paid</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued from stock plans, net of payroll taxes paid, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued From Stock Plans Net Of Payroll Taxes Paid Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnrealizedLossGainOnEquityInvestments" xlink:type="locator" xlink:label="fgen_UnrealizedLossGainOnEquityInvestments" />
    <link:label xml:lang="en-US" xlink:label="fgen_UnrealizedLossGainOnEquityInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrealized loss (gain) on equity investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_UnrealizedLossGainOnEquityInvestments" xlink:to="fgen_UnrealizedLossGainOnEquityInvestments_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" />
    <link:label xml:lang="en-US" xlink:label="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment loss in unconsolidated variable interest entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" xlink:to="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" />
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease right-of-use assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease liabilities, current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:to="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in accrued interest for finance lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" xlink:to="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease liabilities, non-current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" xlink:to="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" />
    <link:label xml:lang="en-US" xlink:label="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment made for investment in unconsolidated variable interest entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" xlink:to="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RepaymentsOfFinanceLeaseLiabilities" xlink:type="locator" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayments of finance lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RepaymentsOfFinanceLeaseLiabilities" xlink:to="fgen_RepaymentsOfFinanceLeaseLiabilities_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of finance lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Right Of Use Asset Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net accretion of premium and discount on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_UnrealizedLossGainOnEquityInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized loss on equity investments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_UnrealizedLossGainOnEquityInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Loss Gain On Equity Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Investment loss in unconsolidated variable interest entity</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Loss In Unconsolidated Variable Interest Entity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss (gain) on disposal of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Disposition Of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense for acquired in-process research and development asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development In Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax benefit on unrealized gain on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Available For Sale Securities Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Realized loss on sales of available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest for finance lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Interest For Finance Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, non-current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities Non Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment made for investment in unconsolidated variable interest entity</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Made For Investment In Unconsolidated Variable Interest Entity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Available For Sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales of available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Available For Sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Maturity And Collections Of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayments of finance lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Finance Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayments of lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Debt And Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid for payroll taxes on restricted stock unit releases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Related To Tax Withholding For Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate change on cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Total cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Total cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement and revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock" xlink:to="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreements and Revenues</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement And Revenues Disclosure [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityAbstract" />
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition and variable interest entity abstract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:to="fgen_AcquisitionAndVariableInterestEntityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition And Variable Interest Entity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableInterestEntityDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Interest Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="us-gaap_VariableInterestEntityDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableInterestEntityDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases Of Lessee Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DescriptionOfOperationsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="fgen_DescriptionOfOperationsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_DescriptionOfOperationsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of operations policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DescriptionOfOperationsPolicyPolicyTextBlock" xlink:to="fgen_DescriptionOfOperationsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DescriptionOfOperationsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DescriptionOfOperationsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Operations Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" xlink:type="locator" xlink:label="fgen_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and principles of consolidation policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" xlink:to="fgen_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss) per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RisksAndUncertaintiesPolicyTextBlock" xlink:type="locator" xlink:label="fgen_RisksAndUncertaintiesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks and uncertainties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RisksAndUncertaintiesPolicyTextBlock" xlink:to="fgen_RisksAndUncertaintiesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Risks And Uncertainties Policy [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" xlink:type="locator" xlink:label="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued and adopted accounting guidance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" xlink:to="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued and Adopted Accounting Guidance</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued And Adopted Accounting Guidance Policy [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" xlink:type="locator" xlink:label="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting guidance not yet adopted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" xlink:to="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Guidance Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Guidance Not Yet Adopted Policy [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement and revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock" xlink:to="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Arrangements and Revenues</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement And Revenues Policy [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProductRevenuePolicyPolicyTextBlock" xlink:type="locator" xlink:label="fgen_ProductRevenuePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProductRevenuePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product revenue policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ProductRevenuePolicyPolicyTextBlock" xlink:to="fgen_ProductRevenuePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProductRevenuePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Revenue, Net</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProductRevenuePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Revenue Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenuePolicyTextBlock" xlink:type="locator" xlink:label="fgen_DrugProductRevenuePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Drug product revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DrugProductRevenuePolicyTextBlock" xlink:to="fgen_DrugProductRevenuePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Drug Product Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Drug Product Revenue Policy [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerMilestoneMethodTableTextBlock" xlink:type="locator" xlink:label="fgen_ContractWithCustomerMilestoneMethodTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerMilestoneMethodTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer milestone method.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractWithCustomerMilestoneMethodTableTextBlock" xlink:to="fgen_ContractWithCustomerMilestoneMethodTableTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:label xml:lang="en-US" xlink:label="country_JP_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Japan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JP" xlink:to="country_JP_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_JP_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">JAPAN</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_EuropeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Europe [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_EuropeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Europe [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">United States/Rest of World and China.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S./RoW and China [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">United States Rest Of World And China [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstraZenecaAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Astra Zeneca agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AstraZenecaAgreementsMember" xlink:to="fgen_AstraZenecaAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstraZenecaAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AstraZeneca Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AstraZenecaAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Astra Zeneca Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerMilestoneMethodTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of License Revenue and Development Revenue Recognized under Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerMilestoneMethodTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Milestone Method Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Roll-forward of Related Contract Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset And Liability Table [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfDrugProductRevenueTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfDrugProductRevenueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfDrugProductRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of drug product revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduleOfDrugProductRevenueTableTextBlock" xlink:to="fgen_ScheduleOfDrugProductRevenueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfDrugProductRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Drug Product Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfDrugProductRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Drug Product Revenue Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Equity Method Investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Values of Financial Assets Measured on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of lease assets and related lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" xlink:to="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Assets and Related Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Lease Assets And Related Lease Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental cash flow information related to leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Cash Flow Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of lease term and discount rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" xlink:to="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Term and Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Lease Term And Discount Rate Table [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of maturities of finance and operating leases liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" xlink:to="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Finance and Operating Leases Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Maturities Of Finance And Operating Leases Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash And Cash Equivalents Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Inventory Current Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued and Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Long-term Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Recorded Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of share based payment award stock options and employee stock purchase plan valuation assumptions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options And Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccountingPolicyLineItems" xlink:type="locator" xlink:label="fgen_AccountingPolicyLineItems" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccountingPolicyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_AccountingPolicyLineItems_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccountingPolicyTable" xlink:type="locator" xlink:label="fgen_AccountingPolicyTable" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccountingPolicyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccountingPolicyTable" xlink:to="fgen_AccountingPolicyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccountingPolicyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policy [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccountingPolicyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policy [Table]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_HiFiBiOAgreementMember" xlink:type="locator" xlink:label="fgen_HiFiBiOAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_HiFiBiOAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">HiFiBiO agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_HiFiBiOAgreementMember" xlink:to="fgen_HiFiBiOAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_HiFiBiOAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HiFiBiO Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_HiFiBiOAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Hi Fi Bi O Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccountingPolicyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policy [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccountingPolicyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policy [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProfitSharePercent" xlink:type="locator" xlink:label="fgen_ProfitSharePercent" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProfitSharePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit share percent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ProfitSharePercent" xlink:to="fgen_ProfitSharePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProfitSharePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Profit share percent</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProfitSharePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Share Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="locator" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of payment term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Performance Obligation Description Of Payment Terms</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DescriptionOfSalesReturn" xlink:type="locator" xlink:label="fgen_DescriptionOfSalesReturn" />
    <link:label xml:lang="en-US" xlink:label="fgen_DescriptionOfSalesReturn_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of sales return.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DescriptionOfSalesReturn" xlink:to="fgen_DescriptionOfSalesReturn_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DescriptionOfSalesReturn_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of sales return</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DescriptionOfSalesReturn_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Sales Return</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_InitialUpfrontPayment" xlink:type="locator" xlink:label="fgen_InitialUpfrontPayment" />
    <link:label xml:lang="en-US" xlink:label="fgen_InitialUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_InitialUpfrontPayment" xlink:to="fgen_InitialUpfrontPayment_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments" xlink:type="locator" xlink:label="fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum additional future option, clinical, regulatory, and commercial milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments" xlink:to="fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_InitialUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_InitialUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum additional future option, clinical, regulatory, and commercial milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Additional Future Option Clinical Regulatory And Commercial Milestone Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Liability</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" xlink:to="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PotentialMilestones" xlink:type="locator" xlink:label="fgen_PotentialMilestones" />
    <link:label xml:lang="en-US" xlink:label="fgen_PotentialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PotentialMilestones" xlink:to="fgen_PotentialMilestones_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommercialSalesMilestone" xlink:type="locator" xlink:label="fgen_CommercialSalesMilestone" />
    <link:label xml:lang="en-US" xlink:label="fgen_CommercialSalesMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of milestone payments related to commercial sales under the collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CommercialSalesMilestone" xlink:to="fgen_CommercialSalesMilestone_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AdditionalConsiderationBasedOnNetSales" xlink:type="locator" xlink:label="fgen_AdditionalConsiderationBasedOnNetSales" />
    <link:label xml:lang="en-US" xlink:label="fgen_AdditionalConsiderationBasedOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of additional consideration based on net sales of product as defined under a collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AdditionalConsiderationBasedOnNetSales" xlink:to="fgen_AdditionalConsiderationBasedOnNetSales_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" />
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" xlink:to="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEC Schedule, 12-09, Valuation Allowances and Reserves Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowances And Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEC Schedule, 12-09, Valuation Allowances and Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowances And Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ClinicalDevelopmentMilestonesMember" xlink:type="locator" xlink:label="fgen_ClinicalDevelopmentMilestonesMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ClinicalDevelopmentMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical development milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ClinicalDevelopmentMilestonesMember" xlink:to="fgen_ClinicalDevelopmentMilestonesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ClinicalDevelopmentMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical and Development Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ClinicalDevelopmentMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Development Milestones [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RegulatoryMilestonesMember" xlink:type="locator" xlink:label="fgen_RegulatoryMilestonesMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_RegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RegulatoryMilestonesMember" xlink:to="fgen_RegulatoryMilestonesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_RegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront, non-contingent and time-based payments received</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Upfront Non Contingent And Time Based Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PotentialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PotentialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Potential Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommercialSalesMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial sales milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommercialSalesMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Sales Milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AdditionalConsiderationBasedOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional consideration based on net sales description</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AdditionalConsiderationBasedOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Consideration Based On Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate consideration received excluding drug product revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Aggregate Consideration Excluding Drug Product Revenue</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PercentageOfFundingForCosts" xlink:type="locator" xlink:label="fgen_PercentageOfFundingForCosts" />
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageOfFundingForCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PercentageOfFundingForCosts" xlink:to="fgen_PercentageOfFundingForCosts_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DevelopmentAndRegulatoryApprovalMilestones" xlink:type="locator" xlink:label="fgen_DevelopmentAndRegulatoryApprovalMilestones" />
    <link:label xml:lang="en-US" xlink:label="fgen_DevelopmentAndRegulatoryApprovalMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DevelopmentAndRegulatoryApprovalMilestones" xlink:to="fgen_DevelopmentAndRegulatoryApprovalMilestones_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DevelopmentAndRegulatoryApprovalMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulatory approval milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DevelopmentAndRegulatoryApprovalMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development And Regulatory Approval Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageOfFundingForCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of joint development costs committed to fund</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageOfFundingForCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Funding For Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred Revenue</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" xlink:to="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnitedStatesAndRestOfWorldMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_UnitedStatesAndRestOfWorldMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">United states and rest of world.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_UnitedStatesAndRestOfWorldMember" xlink:to="fgen_UnitedStatesAndRestOfWorldMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_UnitedStatesAndRestOfWorldMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S./RoW [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_UnitedStatesAndRestOfWorldMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">United States And Rest Of World [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DeferredApprovalMilestoneMember" xlink:type="locator" xlink:label="fgen_DeferredApprovalMilestoneMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_DeferredApprovalMilestoneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred approval milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DeferredApprovalMilestoneMember" xlink:to="fgen_DeferredApprovalMilestoneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DeferredApprovalMilestoneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Approval Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DeferredApprovalMilestoneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Approval Milestone [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:label xml:lang="en-US" xlink:label="country_CN_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">China [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_CN_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CHINA</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DirectSalesMember" xlink:type="locator" xlink:label="fgen_DirectSalesMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_DirectSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DirectSalesMember" xlink:to="fgen_DirectSalesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DirectSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct Sales [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DirectSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Direct Sales [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront, non-contingent, non-refundable and time-based payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Upfront Non Contingent Non Refundable And Time Based Payments</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommercialSalesAndOtherEventsMilestone" xlink:type="locator" xlink:label="fgen_CommercialSalesAndOtherEventsMilestone" />
    <link:label xml:lang="en-US" xlink:label="fgen_CommercialSalesAndOtherEventsMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial sales and other events milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CommercialSalesAndOtherEventsMilestone" xlink:to="fgen_CommercialSalesAndOtherEventsMilestone_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" xlink:to="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" />
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement aggregate consideration for milestone and upfront payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" xlink:to="fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from upfront, non-contingent and non-refundable payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Upfront Non Contingent And Non Refundable Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommercialSalesAndOtherEventsMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial sales and other events milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommercialSalesAndOtherEventsMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Sales And Other Events Milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate consideration received for milestone and upfront payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Aggregate Consideration For Milestone And Upfront Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition Multiple Deliverable Arrangements [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Multiple Deliverable Arrangements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DevelopmentAndOtherRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Development Revenue [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Multiple Deliverable Arrangements [Line Items]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CashConsiderationReceivedUnderCollaborationAgreement" xlink:type="locator" xlink:label="fgen_CashConsiderationReceivedUnderCollaborationAgreement" />
    <link:label xml:lang="en-US" xlink:label="fgen_CashConsiderationReceivedUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CashConsiderationReceivedUnderCollaborationAgreement" xlink:to="fgen_CashConsiderationReceivedUnderCollaborationAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">License [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" xlink:type="locator" xlink:label="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Co development information sharing and committee services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" xlink:to="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Co-development, information sharing &amp; committee services [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Co Development Information Sharing And Committee Services [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ChinaPerformanceObligationMember" xlink:type="locator" xlink:label="fgen_ChinaPerformanceObligationMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ChinaPerformanceObligationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">China performance obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ChinaPerformanceObligationMember" xlink:to="fgen_ChinaPerformanceObligationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ChinaPerformanceObligationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">China performance obligation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ChinaPerformanceObligationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">China Performance Obligation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Revenue License And Development Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CashConsiderationReceivedUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CashConsiderationReceivedUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Consideration Received Under Collaboration Agreement</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" xlink:type="locator" xlink:label="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" />
    <link:label xml:lang="en-US" xlink:label="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Variable consideration payment received from estimated future co-development billing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" xlink:to="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remainder of transaction price, variable consideration from estimated future co-development billing</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Consideration Payment Received From Estimated Future Co Development Billing</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in revenue from changes to estimated variable consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_SuppliesNet" xlink:type="locator" xlink:label="fgen_SuppliesNet" />
    <link:label xml:lang="en-US" xlink:label="fgen_SuppliesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplies, net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_SuppliesNet" xlink:to="fgen_SuppliesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_SuppliesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unbilled co-development revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_SuppliesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplies Net</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue gross from contract with customer excluding assessed tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" xlink:to="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue gross transfer price from contract with customer excluding assessed tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax" xlink:to="fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Product [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_SalesToFalikangMember" xlink:type="locator" xlink:label="fgen_SalesToFalikangMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_SalesToFalikangMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales to Falikang.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_SalesToFalikangMember" xlink:to="fgen_SalesToFalikangMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_SalesToFalikangMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales To Falikang [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_SalesToFalikangMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales To Falikang [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DiscountsAndRebatesMember" xlink:type="locator" xlink:label="fgen_DiscountsAndRebatesMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_DiscountsAndRebatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Discounts and rebates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DiscountsAndRebatesMember" xlink:to="fgen_DiscountsAndRebatesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DiscountsAndRebatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discounts and Rebates [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DiscountsAndRebatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Discounts And Rebates [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:type="locator" xlink:label="us-gaap_SalesReturnsAndAllowancesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesReturnsAndAllowancesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Returns [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesReturnsAndAllowancesMember" xlink:to="us-gaap_SalesReturnsAndAllowancesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesReturnsAndAllowancesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Returns And Allowances [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProfitShareMember" xlink:type="locator" xlink:label="fgen_ProfitShareMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProfitShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ProfitShareMember" xlink:to="fgen_ProfitShareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProfitShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Profit Share [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProfitShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Share [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_NetTransferPriceMember" xlink:type="locator" xlink:label="fgen_NetTransferPriceMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_NetTransferPriceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net transfer price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_NetTransferPriceMember" xlink:to="fgen_NetTransferPriceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_NetTransferPriceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Transfer Price [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_NetTransferPriceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Transfer Price [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_IncreaseInDeferredRevenueMember" xlink:type="locator" xlink:label="fgen_IncreaseInDeferredRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseInDeferredRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in deferred revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_IncreaseInDeferredRevenueMember" xlink:to="fgen_IncreaseInDeferredRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseInDeferredRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in Deferred Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseInDeferredRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Deferred Revenue [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Gross From Contract With Customer Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross transfer price</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Gross Transfer Price From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RebatesAndDiscountsMember" xlink:type="locator" xlink:label="fgen_RebatesAndDiscountsMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_RebatesAndDiscountsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Rebates and discounts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RebatesAndDiscountsMember" xlink:to="fgen_RebatesAndDiscountsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_RebatesAndDiscountsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rebates and Discounts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RebatesAndDiscountsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Rebates And Discounts [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_GrossAccountsReceivableMember" xlink:type="locator" xlink:label="fgen_GrossAccountsReceivableMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_GrossAccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross accounts receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_GrossAccountsReceivableMember" xlink:to="fgen_GrossAccountsReceivableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_GrossAccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Accounts Receivable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_GrossAccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gross Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractLiabilitiesMember" xlink:type="locator" xlink:label="fgen_ContractLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract liabilities,</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractLiabilitiesMember" xlink:to="fgen_ContractLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract Liabilities [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DeferredForFutureRecognitionMember" xlink:type="locator" xlink:label="fgen_DeferredForFutureRecognitionMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_DeferredForFutureRecognitionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred for future recognition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DeferredForFutureRecognitionMember" xlink:to="fgen_DeferredForFutureRecognitionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DeferredForFutureRecognitionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Constrained for Future Recognition [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DeferredForFutureRecognitionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred For Future Recognition [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerLiabilityAdditions" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityAdditions" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability additions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractWithCustomerLiabilityAdditions" xlink:to="fgen_ContractWithCustomerLiabilityAdditions_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerLiabilityDeduction" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityDeduction" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityDeduction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability deduction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractWithCustomerLiabilityDeduction" xlink:to="fgen_ContractWithCustomerLiabilityDeduction_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer, liability, increase (decrease) from current translation and other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" xlink:to="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerLiabilityLineItems" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityLineItems" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityLineItems_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerLiabilityTable" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityTable" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract With Customer Liability [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractWithCustomerLiabilityTable" xlink:to="fgen_ContractWithCustomerLiabilityTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract With Customer Liability [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Astellas agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AstellasAgreementMember" xlink:to="fgen_AstellasAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Astellas Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Astellas Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract with Customer Liability [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Balance at December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Additions</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Additions</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityDeduction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deduction</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityDeduction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Deduction</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency Translation and Other</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Increase Decrease From Current Translation And Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized as Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">Balance at June 30, 2021</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Method Investment, Nonconsolidated Investee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Method Investment, Nonconsolidated Investee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BeijingFalikangPharmaceuticalCoLtdMember" xlink:type="locator" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Beijing Falikang Pharmaceutical Co. Ltd.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_BeijingFalikangPharmaceuticalCoLtdMember" xlink:to="fgen_BeijingFalikangPharmaceuticalCoLtdMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beijing Falikang Pharmaceutical Co Ltd</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Beijing Falikang Pharmaceutical Co Ltd [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions to gross accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allowance For Doubtful Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction [Domain]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_APIShipmentMember" xlink:type="locator" xlink:label="fgen_APIShipmentMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_APIShipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">API shipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_APIShipmentMember" xlink:to="fgen_APIShipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_APIShipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">API Shipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_APIShipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A P I Shipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Drug product revenue recognized</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityLineItems" />
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition and variable interest entity line items.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="fgen_AcquisitionAndVariableInterestEntityLineItems_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AcquisitionAndVariableInterestEntityTable" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityTable" />
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition and variable interest entity table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="fgen_AcquisitionAndVariableInterestEntityTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition And Variable Interest Entity [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition And Variable Interest Entity [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Acquiree [Domain]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" xlink:type="locator" xlink:label="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Beijing Kangda Yongfu Pharmaceutical Co., LTD.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" xlink:to="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Beijing Kangda Yongfu Pharmaceutical Co L T D [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FibroGenBeijingMember" xlink:type="locator" xlink:label="fgen_FibroGenBeijingMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_FibroGenBeijingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">FibroGen Beijing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FibroGenBeijingMember" xlink:to="fgen_FibroGenBeijingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_FibroGenBeijingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FibroGen Beijing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FibroGenBeijingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fibro Gen Beijing [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaABMember" xlink:type="locator" xlink:label="fgen_AstraZenecaABMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstraZenecaABMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">AstraZeneca AB.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AstraZenecaABMember" xlink:to="fgen_AstraZenecaABMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstraZenecaABMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AstraZenecaAB [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AstraZenecaABMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Astra Zeneca A B [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition And Variable Interest Entity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition And Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding shares acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Percentage Of Voting Interests Acquired</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" />
    <link:label xml:lang="en-US" xlink:label="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity method investment increase (decrease) from currency translation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" xlink:to="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Beijing Falikang Pharmaceutical Co. Ltd [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share of Net Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Equity Method Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency Translation</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Increase Decrease From Currency Translation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate bonds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_USGovernmentBondsMember" xlink:type="locator" xlink:label="fgen_USGovernmentBondsMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_USGovernmentBondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. government bonds.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_USGovernmentBondsMember" xlink:to="fgen_USGovernmentBondsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_USGovernmentBondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government bonds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_USGovernmentBondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Bonds [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AgencyBondsMember" xlink:type="locator" xlink:label="fgen_AgencyBondsMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_AgencyBondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agency bonds.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AgencyBondsMember" xlink:to="fgen_AgencyBondsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AgencyBondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agency bonds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AgencyBondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agency Bonds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset-backed securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:type="locator" xlink:label="us-gaap_ForeignGovernmentDebtMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignGovernmentDebtMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign government bonds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignGovernmentDebtMember" xlink:to="us-gaap_ForeignGovernmentDebtMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignGovernmentDebtMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Government Debt [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BondAndMutualFundsMember" xlink:type="locator" xlink:label="fgen_BondAndMutualFundsMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_BondAndMutualFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bond and mutual funds.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_BondAndMutualFundsMember" xlink:to="fgen_BondAndMutualFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_BondAndMutualFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bond and mutual funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_BondAndMutualFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bond And Mutual Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investments [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesMember" xlink:to="us-gaap_EquitySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets fair value disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of assets from level 1 to 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of assets from level 2 to 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level1 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of assets into level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of assets out of level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities fair value disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of liabilities from level 1 to 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level1 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of liabilities from level 2 to 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level2 To Level1 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of liabilities into level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of liabilities out of level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FinanceLeaseRightOfUseAssetsCost" xlink:type="locator" xlink:label="fgen_FinanceLeaseRightOfUseAssetsCost" />
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseRightOfUseAssetsCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease, right-of-use assets - cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FinanceLeaseRightOfUseAssetsCost" xlink:to="fgen_FinanceLeaseRightOfUseAssetsCost_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FinanceLeaseAccumulatedAmortization" xlink:type="locator" xlink:label="fgen_FinanceLeaseAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease accumulated amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FinanceLeaseAccumulatedAmortization" xlink:to="fgen_FinanceLeaseAccumulatedAmortization_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_OperatingLeaseRightOfUseAssetsCost" xlink:type="locator" xlink:label="fgen_OperatingLeaseRightOfUseAssetsCost" />
    <link:label xml:lang="en-US" xlink:label="fgen_OperatingLeaseRightOfUseAssetsCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease, right-of-use assets - cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_OperatingLeaseRightOfUseAssetsCost" xlink:to="fgen_OperatingLeaseRightOfUseAssetsCost_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_OperatingLeaseAccumulatedAmortization" xlink:type="locator" xlink:label="fgen_OperatingLeaseAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="fgen_OperatingLeaseAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease, accumulated amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_OperatingLeaseAccumulatedAmortization" xlink:to="fgen_OperatingLeaseAccumulatedAmortization_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FinanceLeaseAndOperatingLeaseAssets" xlink:type="locator" xlink:label="fgen_FinanceLeaseAndOperatingLeaseAssets" />
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAndOperatingLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease and operating lease assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FinanceLeaseAndOperatingLeaseAssets" xlink:to="fgen_FinanceLeaseAndOperatingLeaseAssets_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FinanceLeaseAndOperatingLeaseLiability" xlink:type="locator" xlink:label="fgen_FinanceLeaseAndOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAndOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease and operating lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FinanceLeaseAndOperatingLeaseLiability" xlink:to="fgen_FinanceLeaseAndOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseRightOfUseAssetsCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets - cost</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseRightOfUseAssetsCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Right Of Use Assets Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance lease right-of-use assets, net</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OperatingLeaseRightOfUseAssetsCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets - cost</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OperatingLeaseRightOfUseAssetsCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Assets Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OperatingLeaseAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OperatingLeaseAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating lease right-of-use assets, net</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAndOperatingLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease assets</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAndOperatingLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease And Operating Lease Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Finance lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Finance lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAndOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAndOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease And Operating Lease Liability</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LesseeFinanceLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, finance lease, expiration period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LesseeFinanceLeaseExpirationPeriod" xlink:to="fgen_LesseeFinanceLeaseExpirationPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ShorensteinPropertiesLLCMember" xlink:type="locator" xlink:label="fgen_ShorensteinPropertiesLLCMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ShorensteinPropertiesLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shorenstein properties LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ShorensteinPropertiesLLCMember" xlink:to="fgen_ShorensteinPropertiesLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ShorensteinPropertiesLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shorenstein Properties LLC [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ShorensteinPropertiesLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shorenstein Properties L L C [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LeaseAmendmentMember" xlink:type="locator" xlink:label="fgen_LeaseAmendmentMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_LeaseAmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease amendment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LeaseAmendmentMember" xlink:to="fgen_LeaseAmendmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_LeaseAmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LeaseAmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Amendment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201901Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201901Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201901Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 842 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201901Member" xlink:to="us-gaap_AccountingStandardsUpdate201901Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201901Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201901 [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" xlink:type="locator" xlink:label="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Beijing economic-technological development area.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" xlink:to="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beijing Economic-Technological Development Area [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Beijing Economic Technological Development Area [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, finance lease, initial lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Finance Lease Term Of Contract1</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, finance lease, expiration period</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Finance Lease Expiration Period</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" xlink:type="locator" xlink:label="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage increases on each anniversary of rent commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" xlink:to="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" />
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, finance lease, option to extend the additional lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" xlink:to="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduledRentCommencementYearOptionOne" xlink:type="locator" xlink:label="fgen_ScheduledRentCommencementYearOptionOne" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduledRentCommencementYearOptionOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent commencement year option one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduledRentCommencementYearOptionOne" xlink:to="fgen_ScheduledRentCommencementYearOptionOne_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo" xlink:type="locator" xlink:label="fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo" />
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage increases on anniversary of rent commencement date option two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo" xlink:to="fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduledRentCommencementYearOptionTwo" xlink:type="locator" xlink:label="fgen_ScheduledRentCommencementYearOptionTwo" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduledRentCommencementYearOptionTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Scheduled rent commencement year option two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduledRentCommencementYearOptionTwo" xlink:to="fgen_ScheduledRentCommencementYearOptionTwo_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_NumberOfOptionalRightsToExtendLease" xlink:type="locator" xlink:label="fgen_NumberOfOptionalRightsToExtendLease" />
    <link:label xml:lang="en-US" xlink:label="fgen_NumberOfOptionalRightsToExtendLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of optional rights to extend lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_NumberOfOptionalRightsToExtendLease" xlink:to="fgen_NumberOfOptionalRightsToExtendLease_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, finance lease, additional lease expiration period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" xlink:to="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, finance lease, existence of option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Finance Lease Existence Of Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, finance lease, additional lease expiration period</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Finance Lease Additional Lease Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage increases on each anniversary of rent commencement date 2023</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Increases On Each Anniversary Of Rent Commencement Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeFinanceLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, finance lease, option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseOptionToExtend" xlink:to="us-gaap_LesseeFinanceLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeFinanceLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Finance Lease Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_NumberOfOptionalRightsToExtendLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Optional rights to extend lease</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_NumberOfOptionalRightsToExtendLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Optional Rights To Extend Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, finance lease, option to extend the additional lease term</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Finance Lease Option To Extend Additional Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduledRentCommencementYearOptionOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent increase commencement year first option</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduledRentCommencementYearOptionOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scheduled Rent Commencement Year Option One</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage increases on each anniversary of rent commencement date 2028</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Increases On Anniversary Of Rent Commencement Date Option Two</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduledRentCommencementYearOptionTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent increase commencement year second option</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduledRentCommencementYearOptionTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scheduled Rent Commencement Year Option Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash payment related to lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LesseeOperatingLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeOperatingLeaseExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeOperatingLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, expiration period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LesseeOperatingLeaseExpirationPeriod" xlink:to="fgen_LesseeOperatingLeaseExpirationPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeOperatingLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, expiration period</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeOperatingLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease cost:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization of right-of-use assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest on lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sublease income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash right of use assets obtained in exchange for new lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" xlink:to="fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" xlink:type="locator" xlink:label="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" />
    <link:label xml:lang="en-US" xlink:label="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash increase decrease resulting from lease modification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" xlink:to="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfLeasesLineItems" xlink:type="locator" xlink:label="fgen_ScheduleOfLeasesLineItems" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeasesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduleOfLeasesLineItems" xlink:to="fgen_ScheduleOfLeasesLineItems_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfLeasesTable" xlink:type="locator" xlink:label="fgen_ScheduleOfLeasesTable" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeasesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduleOfLeasesTable" xlink:to="fgen_ScheduleOfLeasesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeasesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Leases [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeasesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Leases [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeasesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Leases [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeasesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Leases [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from operating leases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Interest Payment On Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing cash flows from finance leases</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash: Right-of-use assets obtained in exchange for new lease liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Right Of Use Assets Obtained In Exchange For New Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Finance Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash: Increase (decrease) resulting from lease modification:</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Increase Decrease Resulting From Lease Modification [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Finance lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Finance lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Finance lease liabilities, non-current</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_WeightedAverageRemainingLeaseTermAbstract" xlink:type="locator" xlink:label="fgen_WeightedAverageRemainingLeaseTermAbstract" />
    <link:label xml:lang="en-US" xlink:label="fgen_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted-average remaining lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_WeightedAverageRemainingLeaseTermAbstract" xlink:to="fgen_WeightedAverageRemainingLeaseTermAbstract_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_WeightedAverageDiscountRateAbstract" xlink:type="locator" xlink:label="fgen_WeightedAverageDiscountRateAbstract" />
    <link:label xml:lang="en-US" xlink:label="fgen_WeightedAverageDiscountRateAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted-average discount rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_WeightedAverageDiscountRateAbstract" xlink:to="fgen_WeightedAverageDiscountRateAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (years):</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_WeightedAverageDiscountRateAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate:</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_WeightedAverageDiscountRateAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liabilities Payments Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 (remaining six month period)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Remainder Of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Year Four</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beyond 2025</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due After Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 (remaining six month period)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Remainder Of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beyond 2025</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Cash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Cash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CommercialPaperAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperAtCarryingValue" xlink:to="us-gaap_CommercialPaperAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfInvestmentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographic Distribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicDistributionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographic Distribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicDistributionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionForeignMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicDistributionForeignMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign subsidiaries [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionForeignMember" xlink:to="us-gaap_GeographicDistributionForeignMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicDistributionForeignMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution Foreign [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government bonds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryAndGovernmentMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury And Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BondsMember" xlink:type="locator" xlink:label="us-gaap_BondsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agency bonds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BondsMember" xlink:to="us-gaap_BondsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bonds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Holding Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Holding Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AvailableForSaleSecuritiesContractualMaturityPeriod" xlink:type="locator" xlink:label="fgen_AvailableForSaleSecuritiesContractualMaturityPeriod" />
    <link:label xml:lang="en-US" xlink:label="fgen_AvailableForSaleSecuritiesContractualMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the maximum contractual maturity period for available-for-sale securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AvailableForSaleSecuritiesContractualMaturityPeriod" xlink:to="fgen_AvailableForSaleSecuritiesContractualMaturityPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AvailableForSaleSecuritiesContractualMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual maturities of available-for-sale investments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AvailableForSaleSecuritiesContractualMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Contractual Maturity Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other-than-temporary impairment loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Than Temporary Impairment Losses Investments Availableforsale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Raw Materials</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work-in-progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Work In Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Finished Goods</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total inventories</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" xlink:type="locator" xlink:label="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" />
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of pre-launch inventory capitalized of aggregate inventory balance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" xlink:to="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of pre-launch inventory capitalized of aggregate inventory balance</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Pre Launch Inventory Capitalized Of Aggregate Inventory Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:type="locator" xlink:label="us-gaap_Supplies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Supplies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unbilled contract assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Supplies" xlink:to="us-gaap_Supplies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Supplies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplies</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred revenues from associated contracts</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_SuppliesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net unbilled contract assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="fgen_LaboratoryEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LaboratoryEquipmentMember" xlink:to="fgen_LaboratoryEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machinery [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Machinery And Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in progress [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedPreclinicalAndClinicalTrialCurrent" xlink:type="locator" xlink:label="fgen_AccruedPreclinicalAndClinicalTrialCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedPreclinicalAndClinicalTrialCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to pre-clinical and clinical trial activities, including those performed by third parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedPreclinicalAndClinicalTrialCurrent" xlink:to="fgen_AccruedPreclinicalAndClinicalTrialCurrent_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" xlink:type="locator" xlink:label="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued contract liabilities to pharmaceutical distributors current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" xlink:to="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedCoPromotionExpensesCurrent" xlink:type="locator" xlink:label="fgen_AccruedCoPromotionExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedCoPromotionExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued co-promotion expenses - current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedCoPromotionExpensesCurrent" xlink:to="fgen_AccruedCoPromotionExpensesCurrent_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedProfitShareCurrent" xlink:type="locator" xlink:label="fgen_AccruedProfitShareCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedProfitShareCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued profit share current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedProfitShareCurrent" xlink:to="fgen_AccruedProfitShareCurrent_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PropertyTaxesAndOtherCurrent" xlink:type="locator" xlink:label="fgen_PropertyTaxesAndOtherCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_PropertyTaxesAndOtherCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property taxes and other current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PropertyTaxesAndOtherCurrent" xlink:to="fgen_PropertyTaxesAndOtherCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedPreclinicalAndClinicalTrialCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preclinical and clinical trial accruals</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedPreclinicalAndClinicalTrialCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Preclinical And Clinical Trial Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and related accruals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities to pharmaceutical distributors</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Contract Liabilities To Pharmaceutical Distributors Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedCoPromotionExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued co-promotion expenses - current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedCoPromotionExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Co Promotion Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedProfitShareCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Roxadustat profit share to AstraZeneca</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedProfitShareCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Profit Share Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PropertyTaxesAndOtherCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property taxes and other taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PropertyTaxesAndOtherCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Taxes And Other Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Profit share liability</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" xlink:type="locator" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued long term co promotion liability non current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" xlink:to="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued long-term co-promotion expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Long Term Co Promotion Liability Non Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax And Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Sundry Liabilities Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other long-term liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Selling, general and administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Employee Share Purchase Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Compensation Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average estimated fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasMember" xlink:type="locator" xlink:label="fgen_AstellasMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Astellas.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AstellasMember" xlink:to="fgen_AstellasMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Astellas [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Astellas [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FalikangMember" xlink:type="locator" xlink:label="fgen_FalikangMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_FalikangMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Falikang.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FalikangMember" xlink:to="fgen_FalikangMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_FalikangMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Falikang [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FalikangMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Falikang [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_RevenueFromRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue related to collaboration agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Accounts receivable from related party</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued liabilities to related party</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Deferred revenue</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_MiscellaneousReceivables" xlink:type="locator" xlink:label="fgen_MiscellaneousReceivables" />
    <link:label xml:lang="en-US" xlink:label="fgen_MiscellaneousReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Miscellaneous receivables.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_MiscellaneousReceivables" xlink:to="fgen_MiscellaneousReceivables_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Investment income</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity method investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding shares owned</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_MiscellaneousReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Miscellaneous receivables</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_MiscellaneousReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Miscellaneous Receivables</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_MaximumFutureMilestonePayments" xlink:type="locator" xlink:label="fgen_MaximumFutureMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="fgen_MaximumFutureMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum future milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_MaximumFutureMilestonePayments" xlink:to="fgen_MaximumFutureMilestonePayments_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="fgen_CommitmentsAndContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="fgen_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CommitmentsAndContingenciesLineItems" xlink:to="fgen_CommitmentsAndContingenciesLineItems_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="fgen_CommitmentsAndContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="fgen_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CommitmentsAndContingenciesTable" xlink:to="fgen_CommitmentsAndContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Category of Item Purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Purchase Commitment By Category Of Item Purchased [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Purchase Commitment, Category of Item Purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Purchase Commitment Category Of Item Purchased [Domain]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ManufactureAndSupplyOfRoxadustatMember" xlink:type="locator" xlink:label="fgen_ManufactureAndSupplyOfRoxadustatMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ManufactureAndSupplyOfRoxadustatMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacture and Supply of Roxadustat.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ManufactureAndSupplyOfRoxadustatMember" xlink:to="fgen_ManufactureAndSupplyOfRoxadustatMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ManufactureAndSupplyOfRoxadustatMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacture and Supply of Roxadustat [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ManufactureAndSupplyOfRoxadustatMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacture And Supply Of Roxadustat [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ManufactureAndSupplyOfPamrevlumabMember" xlink:type="locator" xlink:label="fgen_ManufactureAndSupplyOfPamrevlumabMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ManufactureAndSupplyOfPamrevlumabMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacture and supply of pamrevlumab.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ManufactureAndSupplyOfPamrevlumabMember" xlink:to="fgen_ManufactureAndSupplyOfPamrevlumabMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ManufactureAndSupplyOfPamrevlumabMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacture and Supply of Pamrevlumab [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ManufactureAndSupplyOfPamrevlumabMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacture And Supply Of Pamrevlumab [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_OtherPurchasesMember" xlink:type="locator" xlink:label="fgen_OtherPurchasesMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_OtherPurchasesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Purchases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_OtherPurchasesMember" xlink:to="fgen_OtherPurchasesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_OtherPurchasesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Purchases [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OtherPurchasesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Purchases [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" xlink:type="locator" xlink:label="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and pre-clinical stage development programs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" xlink:to="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Pre-Clinical Stage Development Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Pre Clinical Stage Development Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding non-cancelable purchase obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_MaximumFutureMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum future milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_MaximumFutureMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Future Milestone Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="locator" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Putative securities class action complaints filed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency New Claims Filed Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LicenseAgreementWithEluminexMember" xlink:type="locator" xlink:label="fgen_LicenseAgreementWithEluminexMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_LicenseAgreementWithEluminexMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement with Eluminex.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LicenseAgreementWithEluminexMember" xlink:to="fgen_LicenseAgreementWithEluminexMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_LicenseAgreementWithEluminexMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eluminex [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LicenseAgreementWithEluminexMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement With Eluminex [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommercialMilestone" xlink:type="locator" xlink:label="fgen_CommercialMilestone" />
    <link:label xml:lang="en-US" xlink:label="fgen_CommercialMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CommercialMilestone" xlink:to="fgen_CommercialMilestone_lbl" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments" xlink:type="locator" xlink:label="fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Future manufacturing clinical regulatory and commercial milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments" xlink:to="fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future manufacturing clinical regulatory and commercial milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Future Manufacturing Clinical Regulatory And Commercial Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommercialMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommercialMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>fgen-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-08-09T14:56:03.0133517+00:00 -->
<!-- Version            : 5.0.1.648 -->
<!-- Package ID         : eb9c0c47f0494648af9d850a5814e112 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/role/TemplateLink" xlink:href="fgen-20210630.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="fgen-20210630.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:href="fgen-20210630.xsd#Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedProductDevelopmentCosts" xlink:type="locator" xlink:label="fgen_AccruedProductDevelopmentCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RestrictedTimeDepositsNoncurrent" xlink:type="locator" xlink:label="fgen_RestrictedTimeDepositsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="fgen_RestrictedTimeDepositsNoncurrent" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="fgen_AccruedProductDevelopmentCosts" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_PreferredStockValue" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_CommonStockValue" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquity" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterest" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="fgen-20210630.xsd#Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DueToRelatedPartiesDeferredRevenueNoncurrent" xlink:type="locator" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DueToRelatedPartiesDeferredRevenueCurrent" xlink:type="locator" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="fgen_DueToRelatedPartiesDeferredRevenueCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="fgen-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnconsolidatedVariableInterestEntityInvestmentIncome" xlink:type="locator" xlink:label="fgen_UnconsolidatedVariableInterestEntityInvestmentIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_InterestIncomeAndOtherIncomeExpensesNet" xlink:type="locator" xlink:label="fgen_InterestIncomeAndOtherIncomeExpensesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CostOfGoodsAndServicesSoldOperatingExpense" xlink:type="locator" xlink:label="fgen_CostOfGoodsAndServicesSoldOperatingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DevelopmentAndOtherRevenueMember" xlink:type="locator" xlink:label="fgen_DevelopmentAndOtherRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DevelopmentAndOtherRevenueMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="fgen_CostOfGoodsAndServicesSoldOperatingExpense" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_TypeOfCostGoodOrServiceExtensibleList" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="fgen_InterestIncomeAndOtherIncomeExpensesNet" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_UnconsolidatedVariableInterestEntityInvestmentIncome" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical" xlink:href="fgen-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueFromRelatedParty" xlink:type="locator" xlink:label="fgen_DrugProductRevenueFromRelatedParty" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProductRevenue" xlink:type="locator" xlink:label="fgen_ProductRevenue" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborationServicesAndOtherRevenue" xlink:type="locator" xlink:label="fgen_CollaborationServicesAndOtherRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_CollaborationServicesAndOtherRevenue" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_ProductRevenue" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_DrugProductRevenueFromRelatedParty" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="fgen-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited" xlink:href="fgen-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" xlink:type="locator" xlink:label="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" xlink:type="locator" xlink:label="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" xlink:href="fgen-20210630.xsd#Role_StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RepaymentsOfFinanceLeaseLiabilities" xlink:type="locator" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnrealizedLossGainOnEquityInvestments" xlink:type="locator" xlink:label="fgen_UnrealizedLossGainOnEquityInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="fgen_UnrealizedLossGainOnEquityInvestments" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="fgen_RepaymentsOfFinanceLeaseLiabilities" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPolicies" xlink:href="fgen-20210630.xsd#Role_DisclosureSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenues" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenues" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenues">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntity" xlink:href="fgen-20210630.xsd#Role_DisclosureVariableInterestEntity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityDisclosureTextBlock" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:to="us-gaap_VariableInterestEntityDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="fgen-20210630.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeases" xlink:href="fgen-20210630.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponents" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="fgen-20210630.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureIncomeTaxes" xlink:href="fgen-20210630.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="fgen-20210630.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="fgen-20210630.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEvent" xlink:href="fgen-20210630.xsd#Role_DisclosureSubsequentEvent" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEvent">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:href="fgen-20210630.xsd#Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenuePolicyTextBlock" xlink:type="locator" xlink:label="fgen_DrugProductRevenuePolicyTextBlock" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProductRevenuePolicyPolicyTextBlock" xlink:type="locator" xlink:label="fgen_ProductRevenuePolicyPolicyTextBlock" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" xlink:type="locator" xlink:label="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" xlink:type="locator" xlink:label="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RisksAndUncertaintiesPolicyTextBlock" xlink:type="locator" xlink:label="fgen_RisksAndUncertaintiesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" xlink:type="locator" xlink:label="fgen_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DescriptionOfOperationsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="fgen_DescriptionOfOperationsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_DescriptionOfOperationsPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_RisksAndUncertaintiesPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_ProductRevenuePolicyPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_DrugProductRevenuePolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfDrugProductRevenueTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfDrugProductRevenueTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerMilestoneMethodTableTextBlock" xlink:type="locator" xlink:label="fgen_ContractWithCustomerMilestoneMethodTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_ContractWithCustomerMilestoneMethodTableTextBlock" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_ScheduleOfDrugProductRevenueTableTextBlock" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityTables" xlink:href="fgen-20210630.xsd#Role_DisclosureVariableInterestEntityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="fgen-20210630.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesTables" xlink:href="fgen-20210630.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="fgen-20210630.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments" xlink:type="locator" xlink:label="fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_InitialUpfrontPayment" xlink:type="locator" xlink:label="fgen_InitialUpfrontPayment" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DescriptionOfSalesReturn" xlink:type="locator" xlink:label="fgen_DescriptionOfSalesReturn" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="locator" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProfitSharePercent" xlink:type="locator" xlink:label="fgen_ProfitSharePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccountingPolicyLineItems" xlink:type="locator" xlink:label="fgen_AccountingPolicyLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_HiFiBiOAgreementMember" xlink:type="locator" xlink:label="fgen_HiFiBiOAgreementMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccountingPolicyTable" xlink:type="locator" xlink:label="fgen_AccountingPolicyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_AccountingPolicyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_HiFiBiOAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="fgen_AccountingPolicyLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_ProfitSharePercent" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_DescriptionOfSalesReturn" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_InitialUpfrontPayment" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PercentageOfFundingForCosts" xlink:type="locator" xlink:label="fgen_PercentageOfFundingForCosts" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DevelopmentAndRegulatoryApprovalMilestones" xlink:type="locator" xlink:label="fgen_DevelopmentAndRegulatoryApprovalMilestones" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AdditionalConsiderationBasedOnNetSales" xlink:type="locator" xlink:label="fgen_AdditionalConsiderationBasedOnNetSales" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommercialSalesMilestone" xlink:type="locator" xlink:label="fgen_CommercialSalesMilestone" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PotentialMilestones" xlink:type="locator" xlink:label="fgen_PotentialMilestones" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RegulatoryMilestonesMember" xlink:type="locator" xlink:label="fgen_RegulatoryMilestonesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ClinicalDevelopmentMilestonesMember" xlink:type="locator" xlink:label="fgen_ClinicalDevelopmentMilestonesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_ClinicalDevelopmentMilestonesMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_RegulatoryMilestonesMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_PotentialMilestones" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CommercialSalesMilestone" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_AdditionalConsiderationBasedOnNetSales" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_DevelopmentAndRegulatoryApprovalMilestones" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_PercentageOfFundingForCosts" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommercialSalesAndOtherEventsMilestone" xlink:type="locator" xlink:label="fgen_CommercialSalesAndOtherEventsMilestone" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommercialSalesMilestone" xlink:type="locator" xlink:label="fgen_CommercialSalesMilestone" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PotentialMilestones" xlink:type="locator" xlink:label="fgen_PotentialMilestones" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DirectSalesMember" xlink:type="locator" xlink:label="fgen_DirectSalesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DeferredApprovalMilestoneMember" xlink:type="locator" xlink:label="fgen_DeferredApprovalMilestoneMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RegulatoryMilestonesMember" xlink:type="locator" xlink:label="fgen_RegulatoryMilestonesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ClinicalDevelopmentMilestonesMember" xlink:type="locator" xlink:label="fgen_ClinicalDevelopmentMilestonesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnitedStatesAndRestOfWorldMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesAndRestOfWorldMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_ClinicalDevelopmentMilestonesMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_RegulatoryMilestonesMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_DeferredApprovalMilestoneMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_DirectSalesMember" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_PotentialMilestones" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CommercialSalesMilestone" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CommercialSalesAndOtherEventsMilestone" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DevelopmentAndOtherRevenueMember" xlink:type="locator" xlink:label="fgen_DevelopmentAndOtherRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DevelopmentAndOtherRevenueMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CashConsiderationReceivedUnderCollaborationAgreement" xlink:type="locator" xlink:label="fgen_CashConsiderationReceivedUnderCollaborationAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" xlink:type="locator" xlink:label="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ChinaPerformanceObligationMember" xlink:type="locator" xlink:label="fgen_ChinaPerformanceObligationMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" xlink:type="locator" xlink:label="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DevelopmentAndOtherRevenueMember" xlink:type="locator" xlink:label="fgen_DevelopmentAndOtherRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10050.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_ProductOrServiceAxis" order="10050.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DevelopmentAndOtherRevenueMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember_li0l2" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_ChinaPerformanceObligationMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="fgen_CashConsiderationReceivedUnderCollaborationAgreement" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" xlink:type="locator" xlink:label="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_SuppliesNet" xlink:type="locator" xlink:label="fgen_SuppliesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_UnitedStatesAndRestOfWorldMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesAndRestOfWorldMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="fgen_SuppliesNet" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_IncreaseInDeferredRevenueMember" xlink:type="locator" xlink:label="fgen_IncreaseInDeferredRevenueMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_NetTransferPriceMember" xlink:type="locator" xlink:label="fgen_NetTransferPriceMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ProfitShareMember" xlink:type="locator" xlink:label="fgen_ProfitShareMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:type="locator" xlink:label="us-gaap_SalesReturnsAndAllowancesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DiscountsAndRebatesMember" xlink:type="locator" xlink:label="fgen_DiscountsAndRebatesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_SalesToFalikangMember" xlink:type="locator" xlink:label="fgen_SalesToFalikangMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DirectSalesMember" xlink:type="locator" xlink:label="fgen_DirectSalesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember_li0l2" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_DirectSalesMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_SalesToFalikangMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DiscountsAndRebatesMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_SalesReturnsAndAllowancesMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_ProfitShareMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_NetTransferPriceMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_IncreaseInDeferredRevenueMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DeferredForFutureRecognitionMember" xlink:type="locator" xlink:label="fgen_DeferredForFutureRecognitionMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractLiabilitiesMember" xlink:type="locator" xlink:label="fgen_ContractLiabilitiesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_GrossAccountsReceivableMember" xlink:type="locator" xlink:label="fgen_GrossAccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RebatesAndDiscountsMember" xlink:type="locator" xlink:label="fgen_RebatesAndDiscountsMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DiscountsAndRebatesMember" xlink:type="locator" xlink:label="fgen_DiscountsAndRebatesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DiscountsAndRebatesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_RebatesAndDiscountsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fgen_GrossAccountsReceivableMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fgen_ContractLiabilitiesMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DeferredForFutureRecognitionMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerLiabilityDeduction" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityDeduction" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerLiabilityAdditions" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityAdditions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerLiabilityLineItems" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasAgreementMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractLiabilitiesMember" xlink:type="locator" xlink:label="fgen_ContractLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DirectSalesMember" xlink:type="locator" xlink:label="fgen_DirectSalesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ContractWithCustomerLiabilityTable" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="fgen_ContractWithCustomerLiabilityTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_DirectSalesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fgen_ContractLiabilitiesMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityTable" xlink:to="srt_StatementGeographicalAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasAgreementMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityTable" xlink:to="fgen_ContractWithCustomerLiabilityLineItems" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityAdditions" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityDeduction" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="us-gaap_ContractWithCustomerLiability_li0l2" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BeijingFalikangPharmaceuticalCoLtdMember" xlink:type="locator" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="fgen_BeijingFalikangPharmaceuticalCoLtdMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_APIShipmentMember" xlink:type="locator" xlink:label="fgen_APIShipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TransactionTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="fgen_APIShipmentMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasAgreementMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureVariableInterestEntityAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaABMember" xlink:type="locator" xlink:label="fgen_AstraZenecaABMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FibroGenBeijingMember" xlink:type="locator" xlink:label="fgen_FibroGenBeijingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BeijingFalikangPharmaceuticalCoLtdMember" xlink:type="locator" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" xlink:type="locator" xlink:label="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AcquisitionAndVariableInterestEntityTable" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityTable" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:to="fgen_AcquisitionAndVariableInterestEntityTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="fgen_BeijingFalikangPharmaceuticalCoLtdMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_FibroGenBeijingMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fgen_AstraZenecaABMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="fgen_AcquisitionAndVariableInterestEntityLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments_li0l2" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BeijingFalikangPharmaceuticalCoLtdMember" xlink:type="locator" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AcquisitionAndVariableInterestEntityTable" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityTable" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:to="fgen_AcquisitionAndVariableInterestEntityTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="fgen_BeijingFalikangPharmaceuticalCoLtdMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="fgen_AcquisitionAndVariableInterestEntityLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestments_li0l2" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BondAndMutualFundsMember" xlink:type="locator" xlink:label="fgen_BondAndMutualFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:type="locator" xlink:label="us-gaap_ForeignGovernmentDebtMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AgencyBondsMember" xlink:type="locator" xlink:label="fgen_AgencyBondsMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_USGovernmentBondsMember" xlink:type="locator" xlink:label="fgen_USGovernmentBondsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fgen_USGovernmentBondsMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fgen_AgencyBondsMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ForeignGovernmentDebtMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fgen_BondAndMutualFundsMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FinanceLeaseAndOperatingLeaseLiability" xlink:type="locator" xlink:label="fgen_FinanceLeaseAndOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FinanceLeaseAndOperatingLeaseAssets" xlink:type="locator" xlink:label="fgen_FinanceLeaseAndOperatingLeaseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_OperatingLeaseAccumulatedAmortization" xlink:type="locator" xlink:label="fgen_OperatingLeaseAccumulatedAmortization" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_OperatingLeaseRightOfUseAssetsCost" xlink:type="locator" xlink:label="fgen_OperatingLeaseRightOfUseAssetsCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FinanceLeaseAccumulatedAmortization" xlink:type="locator" xlink:label="fgen_FinanceLeaseAccumulatedAmortization" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FinanceLeaseRightOfUseAssetsCost" xlink:type="locator" xlink:label="fgen_FinanceLeaseRightOfUseAssetsCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_FinanceLeaseRightOfUseAssetsCost" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_FinanceLeaseAccumulatedAmortization" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_OperatingLeaseRightOfUseAssetsCost" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_OperatingLeaseAccumulatedAmortization" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_FinanceLeaseAndOperatingLeaseAssets" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_FinanceLeaseAndOperatingLeaseLiability" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LesseeOperatingLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeOperatingLeaseExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduledRentCommencementYearOptionTwo" xlink:type="locator" xlink:label="fgen_ScheduledRentCommencementYearOptionTwo" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo" xlink:type="locator" xlink:label="fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduledRentCommencementYearOptionOne" xlink:type="locator" xlink:label="fgen_ScheduledRentCommencementYearOptionOne" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_NumberOfOptionalRightsToExtendLease" xlink:type="locator" xlink:label="fgen_NumberOfOptionalRightsToExtendLease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseOptionToExtend" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" xlink:type="locator" xlink:label="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LesseeFinanceLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" xlink:type="locator" xlink:label="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201901Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201901Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LeaseAmendmentMember" xlink:type="locator" xlink:label="fgen_LeaseAmendmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ShorensteinPropertiesLLCMember" xlink:type="locator" xlink:label="fgen_ShorensteinPropertiesLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_ShorensteinPropertiesLLCMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="fgen_LeaseAmendmentMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201901Member" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_LesseeFinanceLeaseExpirationPeriod" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseOptionToExtend" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_NumberOfOptionalRightsToExtendLease" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_ScheduledRentCommencementYearOptionOne" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_ScheduledRentCommencementYearOptionTwo" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiability" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_LesseeOperatingLeaseExpirationPeriod" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_SubleaseIncome" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" xlink:type="locator" xlink:label="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_RepaymentsOfFinanceLeaseLiabilities" xlink:type="locator" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfLeasesLineItems" xlink:type="locator" xlink:label="fgen_ScheduleOfLeasesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201901Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201901Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ScheduleOfLeasesTable" xlink:type="locator" xlink:label="fgen_ScheduleOfLeasesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_ScheduleOfLeasesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ScheduleOfLeasesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201901Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ScheduleOfLeasesTable" xlink:to="fgen_ScheduleOfLeasesLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ScheduleOfLeasesLineItems" xlink:to="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="fgen_RepaymentsOfFinanceLeaseLiabilities" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ScheduleOfLeasesLineItems" xlink:to="fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ScheduleOfLeasesLineItems" xlink:to="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_WeightedAverageDiscountRateAbstract" xlink:type="locator" xlink:label="fgen_WeightedAverageDiscountRateAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_WeightedAverageRemainingLeaseTermAbstract" xlink:type="locator" xlink:label="fgen_WeightedAverageRemainingLeaseTermAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_WeightedAverageRemainingLeaseTermAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_WeightedAverageDiscountRateAbstract" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CommercialPaperAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_Cash" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CommercialPaperAtCarryingValue" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_SuppliesNet" xlink:type="locator" xlink:label="fgen_SuppliesNet" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" xlink:type="locator" xlink:label="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AvailableForSaleSecuritiesContractualMaturityPeriod" xlink:type="locator" xlink:label="fgen_AvailableForSaleSecuritiesContractualMaturityPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionForeignMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_GeographicDistributionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionForeignMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_AvailableForSaleSecuritiesContractualMaturityPeriod" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_SuppliesNet" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_BondAndMutualFundsMember" xlink:type="locator" xlink:label="fgen_BondAndMutualFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:type="locator" xlink:label="us-gaap_ForeignGovernmentDebtMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BondsMember" xlink:type="locator" xlink:label="us-gaap_BondsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_BondsMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ForeignGovernmentDebtMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fgen_BondAndMutualFundsMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfInventoryDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_InventoryNet" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_SuppliesNet" xlink:type="locator" xlink:label="fgen_SuppliesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:type="locator" xlink:label="us-gaap_Supplies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_Supplies" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="fgen_SuppliesNet" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="fgen_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fgen_LaboratoryEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_PropertyTaxesAndOtherCurrent" xlink:type="locator" xlink:label="fgen_PropertyTaxesAndOtherCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedProfitShareCurrent" xlink:type="locator" xlink:label="fgen_AccruedProfitShareCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedCoPromotionExpensesCurrent" xlink:type="locator" xlink:label="fgen_AccruedCoPromotionExpensesCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" xlink:type="locator" xlink:label="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedPreclinicalAndClinicalTrialCurrent" xlink:type="locator" xlink:label="fgen_AccruedPreclinicalAndClinicalTrialCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="fgen_AccruedPreclinicalAndClinicalTrialCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="fgen_AccruedCoPromotionExpensesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="fgen_AccruedProfitShareCurrent" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="fgen_PropertyTaxesAndOtherCurrent" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" xlink:type="locator" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_MiscellaneousReceivables" xlink:type="locator" xlink:label="fgen_MiscellaneousReceivables" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueFromRelatedParty" xlink:type="locator" xlink:label="fgen_DrugProductRevenueFromRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_RevenueFromRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FalikangMember" xlink:type="locator" xlink:label="fgen_FalikangMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_AstellasMember" xlink:type="locator" xlink:label="fgen_AstellasMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_AstellasMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_FalikangMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fgen_DrugProductRevenueFromRelatedParty" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fgen_MiscellaneousReceivables" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="locator" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_MaximumFutureMilestonePayments" xlink:type="locator" xlink:label="fgen_MaximumFutureMilestonePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="fgen_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" xlink:type="locator" xlink:label="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_OtherPurchasesMember" xlink:type="locator" xlink:label="fgen_OtherPurchasesMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ManufactureAndSupplyOfPamrevlumabMember" xlink:type="locator" xlink:label="fgen_ManufactureAndSupplyOfPamrevlumabMember" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_ManufactureAndSupplyOfRoxadustatMember" xlink:type="locator" xlink:label="fgen_ManufactureAndSupplyOfRoxadustatMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="fgen_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="fgen_CommitmentsAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="fgen_ManufactureAndSupplyOfRoxadustatMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="fgen_ManufactureAndSupplyOfPamrevlumabMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="fgen_OtherPurchasesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_CommitmentsAndContingenciesTable" xlink:to="fgen_CommitmentsAndContingenciesLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligation" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_CommitmentsAndContingenciesLineItems" xlink:to="fgen_MaximumFutureMilestonePayments" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail" xlink:href="fgen-20210630.xsd#Role_DisclosureSubsequentEventAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CommercialMilestone" xlink:type="locator" xlink:label="fgen_CommercialMilestone" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments" xlink:type="locator" xlink:label="fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_LicenseAgreementWithEluminexMember" xlink:type="locator" xlink:label="fgen_LicenseAgreementWithEluminexMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="fgen-20210630.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_LicenseAgreementWithEluminexMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="fgen_CommercialMilestone" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>fgen-10q_20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:fgen="http://www.fibrogen.com/20210630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fgen-20210630.xsd" xlink:type="simple"/>
    <context id="C_0000921299_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_0000921299_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0000921299_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0000921299_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenHiFiBiOAgreementMember_20210616_20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:HiFiBiOAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenHiFiBiOAgreementMember_20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:HiFiBiOAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20090228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-06-01</startDate>
            <endDate>2009-02-28</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-06-01</startDate>
            <endDate>2005-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-06-01</startDate>
            <endDate>2005-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-06-01</startDate>
            <endDate>2005-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20090228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-04-01</startDate>
            <endDate>2009-02-28</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2006-04-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-04-01</startDate>
            <endDate>2006-04-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-04-01</startDate>
            <endDate>2006-04-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-04-01</startDate>
            <endDate>2006-04-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-29</startDate>
            <endDate>2013-07-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-29</startDate>
            <endDate>2013-07-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-29</startDate>
            <endDate>2013-07-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenDeferredApprovalMilestoneMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:DeferredApprovalMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-29</startDate>
            <endDate>2013-07-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-29</startDate>
            <endDate>2013-07-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-29</startDate>
            <endDate>2013-07-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-29</startDate>
            <endDate>2013-07-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenCoDevelopmentInformationSharingAndCommitteeServicesMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:CoDevelopmentInformationSharingAndCommitteeServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenChinaPerformanceObligationMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:ChinaPerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DiscountsAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DiscountsAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DiscountsAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DiscountsAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenProfitShareMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ProfitShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenProfitShareMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ProfitShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenProfitShareMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ProfitShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenProfitShareMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ProfitShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNetTransferPriceMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:NetTransferPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNetTransferPriceMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:NetTransferPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNetTransferPriceMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:NetTransferPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNetTransferPriceMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:NetTransferPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenIncreaseInDeferredRevenueMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:IncreaseInDeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenIncreaseInDeferredRevenueMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:IncreaseInDeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenIncreaseInDeferredRevenueMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:IncreaseInDeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenIncreaseInDeferredRevenueMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:SalesToFalikangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:IncreaseInDeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DiscountsAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DiscountsAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DiscountsAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DiscountsAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:ContractLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:ContractLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:ContractLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:DirectSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:GrossAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:GrossAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:ContractLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:ContractLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDeferredForFutureRecognitionMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DeferredForFutureRecognitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDeferredForFutureRecognitionMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DeferredForFutureRecognitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fgen:APIShipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fgen:APIShipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAstraZenecaABMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fgen:BeijingKangdaYongfuPharmaceuticalCoLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">fgen:AstraZenecaABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FibroGenBeijingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenUSGovernmentBondsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:USGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenUSGovernmentBondsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:USGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenUSGovernmentBondsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:USGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenUSGovernmentBondsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:USGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenAgencyBondsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:AgencyBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenAgencyBondsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:AgencyBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenAgencyBondsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:AgencyBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenAgencyBondsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:AgencyBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:ShorensteinPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:ShorensteinPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fgen:LeaseAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:ShorensteinPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201901Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fgen:LeaseAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:ShorensteinPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201901Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fgen:LeaseAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:ShorensteinPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:BeijingEconomicTechnologicalDevelopmentAreaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:BeijingEconomicTechnologicalDevelopmentAreaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201901Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201901Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapGeographicDistributionAxis_us-gaapGeographicDistributionForeignMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapGeographicDistributionAxis_us-gaapGeographicDistributionForeignMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapBondsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fgen:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fgen:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FalikangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FalikangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FalikangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FalikangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FalikangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FalikangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfRoxadustatMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fgen:ManufactureAndSupplyOfRoxadustatMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfPamrevlumabMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fgen:ManufactureAndSupplyOfPamrevlumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenOtherPurchasesMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fgen:OtherPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenResearchAndPreClinicalStageDevelopmentProgramsMember_20210101_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fgen:ResearchAndPreClinicalStageDevelopmentProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_20210401_20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_20210501_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenLicenseAgreementWithEluminexMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:LicenseAgreementWithEluminexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-19</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenLicenseAgreementWithEluminexMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210719_20210719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:LicenseAgreementWithEluminexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-19</startDate>
            <endDate>2021-07-19</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_fgenSegment">
        <measure>fgen:Segment</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_fgenOption">
        <measure>fgen:Option</measure>
    </unit>
    <unit id="U_fgenPutativeClassAction">
        <measure>fgen:PutativeClassAction</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0000921299_20210101_20210630" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="C_0000921299_20210101_20210630" id="F_000003_2">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0000921299_20210101_20210630" id="F_000004">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0000921299_20210101_20210630" id="F_000007">0000921299</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0000921299_20210101_20210630" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:LesseeFinanceLeaseExistenceOfOptionToExtend
      contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601"
      id="F_000878">true</us-gaap:LesseeFinanceLeaseExistenceOfOptionToExtend>
    <dei:DocumentFiscalYearFocus contextRef="C_0000921299_20210101_20210630" id="F_000003">2021</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0000921299_20210630"
      id="F_000081"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0000921299_20201231"
      id="F_000082"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="C_0000921299_20210401_20210630" id="F_000153">us-gaap:ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="C_0000921299_20200401_20200630" id="F_000154">us-gaap:ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="C_0000921299_20210101_20210630" id="F_000155">us-gaap:ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="C_0000921299_20200101_20200630" id="F_000156">us-gaap:ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNetTransferPriceMember_20200101_20200630"
      decimals="-3"
      id="F_000702"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenIncreaseInDeferredRevenueMember_20200101_20200630"
      decimals="-3"
      id="F_000706"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20210630"
      decimals="-3"
      id="F_000802"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20210630"
      decimals="-3"
      id="F_000803"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20210630"
      decimals="-3"
      id="F_000804"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20210630"
      decimals="-3"
      id="F_000805"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0000921299_20210630" id="F_000938">P1Y3M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0000921299_20201231" id="F_000939">P2Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0000921299_20210630" id="F_000940">P7Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0000921299_20201231" id="F_000941">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210401_20210630"
      id="F_001102">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200401_20200630"
      id="F_001103">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630"
      id="F_001104">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200630"
      id="F_001105">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630"
      id="F_001122">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630"
      id="F_001123">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630"
      id="F_001124">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630"
      id="F_001125">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630"
      id="F_001126">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630"
      id="F_001127">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630"
      id="F_001128">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630"
      id="F_001129">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630"
      decimals="INF"
      id="F_001130"
      unitRef="U_xbrlipure">0.475</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630"
      decimals="INF"
      id="F_001131"
      unitRef="U_xbrlipure">0.495</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630"
      decimals="INF"
      id="F_001132"
      unitRef="U_xbrlipure">0.475</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630"
      decimals="INF"
      id="F_001133"
      unitRef="U_xbrlipure">0.495</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630"
      decimals="INF"
      id="F_001134"
      unitRef="U_xbrlipure">1.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630"
      decimals="INF"
      id="F_001135"
      unitRef="U_xbrlipure">0.771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630"
      decimals="INF"
      id="F_001136"
      unitRef="U_xbrlipure">1.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630"
      decimals="INF"
      id="F_001137"
      unitRef="U_xbrlipure">0.771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630"
      decimals="INF"
      id="F_001138"
      unitRef="U_xbrlipure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630"
      decimals="INF"
      id="F_001139"
      unitRef="U_xbrlipure">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630"
      decimals="INF"
      id="F_001140"
      unitRef="U_xbrlipure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630"
      decimals="INF"
      id="F_001141"
      unitRef="U_xbrlipure">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630"
      decimals="INF"
      id="F_001142"
      unitRef="U_xbrlipure">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630"
      decimals="INF"
      id="F_001143"
      unitRef="U_xbrlipure">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630"
      decimals="INF"
      id="F_001144"
      unitRef="U_xbrlipure">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630"
      decimals="INF"
      id="F_001145"
      unitRef="U_xbrlipure">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <dei:DocumentType contextRef="C_0000921299_20210101_20210630" id="F_000000">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="C_0000921299_20210101_20210630" id="F_000026">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="C_0000921299_20210101_20210630" id="F_000002">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="C_0000921299_20210101_20210630" id="F_000027">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0000921299_20210101_20210630" id="F_000017">001-36740</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0000921299_20210101_20210630" id="F_000006">FIBROGEN, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000921299_20210101_20210630" id="F_000018">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000921299_20210101_20210630" id="F_000019">77-0357827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000921299_20210101_20210630" id="F_000020">409 Illinois Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0000921299_20210101_20210630" id="F_000021">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000921299_20210101_20210630" id="F_000022">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000921299_20210101_20210630" id="F_000023">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000921299_20210101_20210630" id="F_000024">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000921299_20210101_20210630" id="F_000025">978-1200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0000921299_20210101_20210630" id="F_000015">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000921299_20210101_20210630" id="F_000005">FGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000921299_20210101_20210630" id="F_000016">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="C_0000921299_20210101_20210630" id="F_000012">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0000921299_20210101_20210630" id="F_000013">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0000921299_20210101_20210630" id="F_000009">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0000921299_20210101_20210630" id="F_000010">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000921299_20210101_20210630" id="F_000011">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="C_0000921299_20210101_20210630" id="F_000014">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0000921299_20210731"
      decimals="INF"
      id="F_000028"
      unitRef="U_xbrlishares">92621941</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000029"
      unitRef="U_iso4217USD">353361000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000030"
      unitRef="U_iso4217USD">678393000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000031"
      unitRef="U_iso4217USD">153851000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000032"
      unitRef="U_iso4217USD">8144000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">13352000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">4127000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000033"
      unitRef="U_iso4217USD">24266000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000034"
      unitRef="U_iso4217USD">41883000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">24530000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">16530000</us-gaap:InventoryNet>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">0</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">889000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">8458000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">10160000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">564466000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">755110000</us-gaap:AssetsCurrent>
    <fgen:RestrictedTimeDepositsNoncurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">2072000</fgen:RestrictedTimeDepositsNoncurrent>
    <fgen:RestrictedTimeDepositsNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">2072000</fgen:RestrictedTimeDepositsNoncurrent>
    <us-gaap:LongTermInvestments
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">105758000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">244000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">30670000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">33647000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">861000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">29606000</us-gaap:FinanceLeaseRightOfUseAsset>
    <fgen:EquityMethodInvestmentInUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">3083000</fgen:EquityMethodInvestmentInUnconsolidatedVariableInterestEntity>
    <fgen:EquityMethodInvestmentInUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">2728000</fgen:EquityMethodInvestmentInUnconsolidatedVariableInterestEntity>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">97091000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">2043000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">4617000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">1390000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">808618000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">826840000</us-gaap:Assets>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">0</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">1118000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">48988000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">24789000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">14000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">24000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">147801000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">118333000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <fgen:DueToRelatedPartiesDeferredRevenueCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">10699000</fgen:DueToRelatedPartiesDeferredRevenueCurrent>
    <fgen:DueToRelatedPartiesDeferredRevenueCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">2907000</fgen:DueToRelatedPartiesDeferredRevenueCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">25234000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">6547000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">23000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">12330000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">10718000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">1188000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">232764000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">163187000</us-gaap:LiabilitiesCurrent>
    <fgen:AccruedProductDevelopmentCosts
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">18277000</fgen:AccruedProductDevelopmentCosts>
    <fgen:AccruedProductDevelopmentCosts
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">18697000</fgen:AccruedProductDevelopmentCosts>
    <fgen:DueToRelatedPartiesDeferredRevenueNoncurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">9381000</fgen:DueToRelatedPartiesDeferredRevenueNoncurrent>
    <fgen:DueToRelatedPartiesDeferredRevenueNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">4636000</fgen:DueToRelatedPartiesDeferredRevenueNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">152865000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">138474000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">6000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">25391000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">94196000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">853000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">30659000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">38789000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000079"
      unitRef="U_iso4217USD">528767000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000080"
      unitRef="U_iso4217USD">385391000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000114"
      unitRef="U_iso4217USD_xbrlishares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0000921299_20210630"
      decimals="INF"
      id="F_000113"
      unitRef="U_iso4217USD_xbrlishares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000116"
      unitRef="U_xbrlishares">125000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0000921299_20210630"
      decimals="INF"
      id="F_000115"
      unitRef="U_xbrlishares">125000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000118"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000120"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0000921299_20210630"
      decimals="INF"
      id="F_000117"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_20210630"
      decimals="INF"
      id="F_000119"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000083"
      unitRef="U_iso4217USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000084"
      unitRef="U_iso4217USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000122"
      unitRef="U_iso4217USD_xbrlishares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0000921299_20210630"
      decimals="INF"
      id="F_000121"
      unitRef="U_iso4217USD_xbrlishares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000124"
      unitRef="U_xbrlishares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0000921299_20210630"
      decimals="INF"
      id="F_000123"
      unitRef="U_xbrlishares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000125"
      unitRef="U_xbrlishares">92609000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000127"
      unitRef="U_xbrlishares">92609000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000126"
      unitRef="U_xbrlishares">91441000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000128"
      unitRef="U_xbrlishares">91441000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000085"
      unitRef="U_iso4217USD">926000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">914000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">1443975000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">1399774000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">-4567000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">-4499000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">-1179754000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">-974011000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">260580000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">422178000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">19271000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000096"
      unitRef="U_iso4217USD">19271000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000097"
      unitRef="U_iso4217USD">279851000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000098"
      unitRef="U_iso4217USD">441449000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">808618000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">826840000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20210401_20210630"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20200401_20200630"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20210101_20210630"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20200101_20200630"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fgen:CollaborationServicesAndOtherRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">2645000</fgen:CollaborationServicesAndOtherRevenue>
    <fgen:CollaborationServicesAndOtherRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">4766000</fgen:CollaborationServicesAndOtherRevenue>
    <fgen:CollaborationServicesAndOtherRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">6256000</fgen:CollaborationServicesAndOtherRevenue>
    <fgen:CollaborationServicesAndOtherRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">9503000</fgen:CollaborationServicesAndOtherRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20210401_20210630"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">19641000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20200401_20200630"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">18957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20210101_20210630"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">34228000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20200101_20200630"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">38402000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fgen:ProductRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">11760000</fgen:ProductRevenue>
    <fgen:ProductRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">0</fgen:ProductRevenue>
    <fgen:ProductRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">22167000</fgen:ProductRevenue>
    <fgen:ProductRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">0</fgen:ProductRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20210401_20210630"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">13371000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200401_20200630"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">15693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20210101_20210630"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">28733000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20200630"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">20648000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fgen:DrugProductRevenueFromRelatedParty
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">-1974000</fgen:DrugProductRevenueFromRelatedParty>
    <fgen:DrugProductRevenueFromRelatedParty
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">8238000</fgen:DrugProductRevenueFromRelatedParty>
    <fgen:DrugProductRevenueFromRelatedParty
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">2056000</fgen:DrugProductRevenueFromRelatedParty>
    <fgen:DrugProductRevenueFromRelatedParty
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">8238000</fgen:DrugProductRevenueFromRelatedParty>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210401_20210630"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">-8648000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20200401_20200630"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">8238000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210101_20210630"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">-168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20200101_20200630"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">8238000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">24364000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">42888000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">62793000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">67288000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fgen:CostOfGoodsAndServicesSoldOperatingExpense
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">3078000</fgen:CostOfGoodsAndServicesSoldOperatingExpense>
    <fgen:CostOfGoodsAndServicesSoldOperatingExpense
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">3076000</fgen:CostOfGoodsAndServicesSoldOperatingExpense>
    <fgen:CostOfGoodsAndServicesSoldOperatingExpense
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">6479000</fgen:CostOfGoodsAndServicesSoldOperatingExpense>
    <fgen:CostOfGoodsAndServicesSoldOperatingExpense
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">4047000</fgen:CostOfGoodsAndServicesSoldOperatingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">122567000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">61414000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">197243000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">116315000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">32554000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">63535000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">63334000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">113138000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">158199000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">128025000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">267056000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">233500000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">-133835000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">-85137000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">-204263000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">-166212000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">355000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">651000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">856000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">1284000</us-gaap:InterestExpense>
    <fgen:InterestIncomeAndOtherIncomeExpensesNet
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">-363000</fgen:InterestIncomeAndOtherIncomeExpensesNet>
    <fgen:InterestIncomeAndOtherIncomeExpensesNet
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">644000</fgen:InterestIncomeAndOtherIncomeExpensesNet>
    <fgen:InterestIncomeAndOtherIncomeExpensesNet
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">-817000</fgen:InterestIncomeAndOtherIncomeExpensesNet>
    <fgen:InterestIncomeAndOtherIncomeExpensesNet
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">3810000</fgen:InterestIncomeAndOtherIncomeExpensesNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">-718000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">-7000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">-1673000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">2526000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">-134553000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">-85144000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">-205936000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">-163686000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">-3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">169000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">130000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">-25000</us-gaap:IncomeTaxExpenseBenefit>
    <fgen:UnconsolidatedVariableInterestEntityInvestmentIncome
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">562000</fgen:UnconsolidatedVariableInterestEntityInvestmentIncome>
    <fgen:UnconsolidatedVariableInterestEntityInvestmentIncome
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">0</fgen:UnconsolidatedVariableInterestEntityInvestmentIncome>
    <fgen:UnconsolidatedVariableInterestEntityInvestmentIncome
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">323000</fgen:UnconsolidatedVariableInterestEntityInvestmentIncome>
    <fgen:UnconsolidatedVariableInterestEntityInvestmentIncome
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">0</fgen:UnconsolidatedVariableInterestEntityInvestmentIncome>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">-133988000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">-85313000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">-205743000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">-163661000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0000921299_20210401_20210630"
      decimals="2"
      id="F_000201"
      unitRef="U_iso4217USD_xbrlishares">-1.45</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0000921299_20200401_20200630"
      decimals="2"
      id="F_000202"
      unitRef="U_iso4217USD_xbrlishares">-0.95</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0000921299_20210101_20210630"
      decimals="2"
      id="F_000203"
      unitRef="U_iso4217USD_xbrlishares">-2.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0000921299_20200101_20200630"
      decimals="2"
      id="F_000204"
      unitRef="U_iso4217USD_xbrlishares">-1.84</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000205"
      unitRef="U_xbrlishares">92276000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000206"
      unitRef="U_xbrlishares">89451000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000207"
      unitRef="U_xbrlishares">91983000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000208"
      unitRef="U_xbrlishares">88835000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">-133988000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">-85313000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">-205743000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">-163661000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">40000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">-1615000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">-30000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">-1334000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">17000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">-1129000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">-38000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">520000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">57000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">-2744000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">-68000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000236"
      unitRef="U_iso4217USD">-814000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">-133931000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">-88057000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000239"
      unitRef="U_iso4217USD">-205811000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">-164475000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="INF"
      id="F_000241"
      unitRef="U_xbrlishares">92080399</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">921000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">1420471000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">-4624000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">-1045766000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210331"
      decimals="-3"
      id="F_000246"
      unitRef="U_iso4217USD">19271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_20210331"
      decimals="-3"
      id="F_000247"
      unitRef="U_iso4217USD">390273000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">-133988000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630"
      decimals="-3"
      id="F_000253"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">-133988000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">17000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">17000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630"
      decimals="-3"
      id="F_000264"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">40000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630"
      decimals="-3"
      id="F_000267"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">40000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630"
      decimals="INF"
      id="F_000269"
      unitRef="U_xbrlishares">528530</fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630"
      decimals="-3"
      id="F_000270"
      unitRef="U_iso4217USD">5000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630"
      decimals="-3"
      id="F_000271"
      unitRef="U_iso4217USD">4503000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630"
      decimals="-3"
      id="F_000272"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630"
      decimals="-3"
      id="F_000273"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630"
      decimals="-3"
      id="F_000274"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">4508000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">19001000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000282"
      unitRef="U_iso4217USD">19001000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630"
      decimals="INF"
      id="F_000283"
      unitRef="U_xbrlishares">92608929</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630"
      decimals="-3"
      id="F_000284"
      unitRef="U_iso4217USD">926000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210630"
      decimals="-3"
      id="F_000285"
      unitRef="U_iso4217USD">1443975000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210630"
      decimals="-3"
      id="F_000286"
      unitRef="U_iso4217USD">-4567000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210630"
      decimals="-3"
      id="F_000287"
      unitRef="U_iso4217USD">-1179754000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210630"
      decimals="-3"
      id="F_000288"
      unitRef="U_iso4217USD">19271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000289"
      unitRef="U_iso4217USD">279851000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331"
      decimals="INF"
      id="F_000290"
      unitRef="U_xbrlishares">88895630</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331"
      decimals="-3"
      id="F_000291"
      unitRef="U_iso4217USD">889000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331"
      decimals="-3"
      id="F_000292"
      unitRef="U_iso4217USD">1319354000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331"
      decimals="-3"
      id="F_000293"
      unitRef="U_iso4217USD">1183000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331"
      decimals="-3"
      id="F_000294"
      unitRef="U_iso4217USD">-863068000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200331"
      decimals="-3"
      id="F_000295"
      unitRef="U_iso4217USD">19271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_20200331"
      decimals="-3"
      id="F_000296"
      unitRef="U_iso4217USD">477629000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630"
      decimals="-3"
      id="F_000297"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630"
      decimals="-3"
      id="F_000298"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630"
      decimals="-3"
      id="F_000299"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630"
      decimals="-3"
      id="F_000300"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630"
      decimals="-3"
      id="F_000301"
      unitRef="U_iso4217USD">-85313000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630"
      decimals="-3"
      id="F_000302"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000303"
      unitRef="U_iso4217USD">-85313000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630"
      decimals="-3"
      id="F_000304"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630"
      decimals="-3"
      id="F_000305"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630"
      decimals="-3"
      id="F_000306"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630"
      decimals="-3"
      id="F_000307"
      unitRef="U_iso4217USD">-1129000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630"
      decimals="-3"
      id="F_000308"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630"
      decimals="-3"
      id="F_000309"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000310"
      unitRef="U_iso4217USD">-1129000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630"
      decimals="-3"
      id="F_000311"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630"
      decimals="-3"
      id="F_000312"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630"
      decimals="-3"
      id="F_000313"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630"
      decimals="-3"
      id="F_000314"
      unitRef="U_iso4217USD">-1615000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630"
      decimals="-3"
      id="F_000315"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630"
      decimals="-3"
      id="F_000316"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000317"
      unitRef="U_iso4217USD">-1615000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630"
      decimals="INF"
      id="F_000318"
      unitRef="U_xbrlishares">1332663</fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630"
      decimals="-3"
      id="F_000319"
      unitRef="U_iso4217USD">13000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630"
      decimals="-3"
      id="F_000320"
      unitRef="U_iso4217USD">7914000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630"
      decimals="-3"
      id="F_000321"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630"
      decimals="-3"
      id="F_000322"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630"
      decimals="-3"
      id="F_000323"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000324"
      unitRef="U_iso4217USD">7927000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630"
      decimals="-3"
      id="F_000325"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">17644000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630"
      decimals="-3"
      id="F_000328"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630"
      decimals="-3"
      id="F_000329"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630"
      decimals="-3"
      id="F_000330"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000331"
      unitRef="U_iso4217USD">17644000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630"
      decimals="INF"
      id="F_000332"
      unitRef="U_xbrlishares">90228293</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630"
      decimals="-3"
      id="F_000333"
      unitRef="U_iso4217USD">902000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200630"
      decimals="-3"
      id="F_000334"
      unitRef="U_iso4217USD">1344912000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200630"
      decimals="-3"
      id="F_000335"
      unitRef="U_iso4217USD">-1561000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200630"
      decimals="-3"
      id="F_000336"
      unitRef="U_iso4217USD">-948381000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200630"
      decimals="-3"
      id="F_000337"
      unitRef="U_iso4217USD">19271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_20200630"
      decimals="-3"
      id="F_000338"
      unitRef="U_iso4217USD">415143000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000339"
      unitRef="U_xbrlishares">91440633</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000340"
      unitRef="U_iso4217USD">914000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000341"
      unitRef="U_iso4217USD">1399774000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000342"
      unitRef="U_iso4217USD">-4499000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000343"
      unitRef="U_iso4217USD">-974011000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231"
      decimals="-3"
      id="F_000344"
      unitRef="U_iso4217USD">19271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000345"
      unitRef="U_iso4217USD">441449000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630"
      decimals="-3"
      id="F_000346"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630"
      decimals="-3"
      id="F_000347"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630"
      decimals="-3"
      id="F_000348"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630"
      decimals="-3"
      id="F_000349"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630"
      decimals="-3"
      id="F_000350"
      unitRef="U_iso4217USD">-205743000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630"
      decimals="-3"
      id="F_000351"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000352"
      unitRef="U_iso4217USD">-205743000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630"
      decimals="-3"
      id="F_000353"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630"
      decimals="-3"
      id="F_000354"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630"
      decimals="-3"
      id="F_000355"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630"
      decimals="-3"
      id="F_000356"
      unitRef="U_iso4217USD">-38000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630"
      decimals="-3"
      id="F_000357"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630"
      decimals="-3"
      id="F_000358"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000359"
      unitRef="U_iso4217USD">-38000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630"
      decimals="-3"
      id="F_000360"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630"
      decimals="-3"
      id="F_000361"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630"
      decimals="-3"
      id="F_000362"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630"
      decimals="-3"
      id="F_000363"
      unitRef="U_iso4217USD">-30000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630"
      decimals="-3"
      id="F_000364"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630"
      decimals="-3"
      id="F_000365"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000366"
      unitRef="U_iso4217USD">-30000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630"
      decimals="INF"
      id="F_000367"
      unitRef="U_xbrlishares">1168296</fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630"
      decimals="-3"
      id="F_000368"
      unitRef="U_iso4217USD">12000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630"
      decimals="-3"
      id="F_000369"
      unitRef="U_iso4217USD">5816000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630"
      decimals="-3"
      id="F_000370"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630"
      decimals="-3"
      id="F_000371"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630"
      decimals="-3"
      id="F_000372"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000373"
      unitRef="U_iso4217USD">5828000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630"
      decimals="-3"
      id="F_000374"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630"
      decimals="-3"
      id="F_000375"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630"
      decimals="-3"
      id="F_000376"
      unitRef="U_iso4217USD">38385000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630"
      decimals="-3"
      id="F_000377"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630"
      decimals="-3"
      id="F_000378"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630"
      decimals="-3"
      id="F_000379"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000380"
      unitRef="U_iso4217USD">38385000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630"
      decimals="INF"
      id="F_000381"
      unitRef="U_xbrlishares">92608929</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630"
      decimals="-3"
      id="F_000382"
      unitRef="U_iso4217USD">926000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210630"
      decimals="-3"
      id="F_000383"
      unitRef="U_iso4217USD">1443975000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210630"
      decimals="-3"
      id="F_000384"
      unitRef="U_iso4217USD">-4567000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210630"
      decimals="-3"
      id="F_000385"
      unitRef="U_iso4217USD">-1179754000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210630"
      decimals="-3"
      id="F_000386"
      unitRef="U_iso4217USD">19271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000387"
      unitRef="U_iso4217USD">279851000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000388"
      unitRef="U_xbrlishares">87657489</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000389"
      unitRef="U_iso4217USD">877000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000390"
      unitRef="U_iso4217USD">1300725000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000391"
      unitRef="U_iso4217USD">-747000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000392"
      unitRef="U_iso4217USD">-784720000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191231"
      decimals="-3"
      id="F_000393"
      unitRef="U_iso4217USD">19271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000394"
      unitRef="U_iso4217USD">535406000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630"
      decimals="-3"
      id="F_000395"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630"
      decimals="-3"
      id="F_000396"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630"
      decimals="-3"
      id="F_000397"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630"
      decimals="-3"
      id="F_000398"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630"
      decimals="-3"
      id="F_000399"
      unitRef="U_iso4217USD">-163661000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630"
      decimals="-3"
      id="F_000400"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000401"
      unitRef="U_iso4217USD">-163661000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630"
      decimals="-3"
      id="F_000402"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630"
      decimals="-3"
      id="F_000403"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630"
      decimals="-3"
      id="F_000404"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630"
      decimals="-3"
      id="F_000405"
      unitRef="U_iso4217USD">520000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630"
      decimals="-3"
      id="F_000406"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630"
      decimals="-3"
      id="F_000407"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000408"
      unitRef="U_iso4217USD">520000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630"
      decimals="-3"
      id="F_000409"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630"
      decimals="-3"
      id="F_000410"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630"
      decimals="-3"
      id="F_000411"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630"
      decimals="-3"
      id="F_000412"
      unitRef="U_iso4217USD">-1334000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630"
      decimals="-3"
      id="F_000413"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630"
      decimals="-3"
      id="F_000414"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000415"
      unitRef="U_iso4217USD">-1334000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630"
      decimals="INF"
      id="F_000416"
      unitRef="U_xbrlishares">2570804</fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630"
      decimals="-3"
      id="F_000417"
      unitRef="U_iso4217USD">25000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630"
      decimals="-3"
      id="F_000418"
      unitRef="U_iso4217USD">9627000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630"
      decimals="-3"
      id="F_000419"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630"
      decimals="-3"
      id="F_000420"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630"
      decimals="-3"
      id="F_000421"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000422"
      unitRef="U_iso4217USD">9652000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630"
      decimals="-3"
      id="F_000423"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630"
      decimals="-3"
      id="F_000424"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630"
      decimals="-3"
      id="F_000425"
      unitRef="U_iso4217USD">34560000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630"
      decimals="-3"
      id="F_000426"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630"
      decimals="-3"
      id="F_000427"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630"
      decimals="-3"
      id="F_000428"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000429"
      unitRef="U_iso4217USD">34560000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630"
      decimals="INF"
      id="F_000430"
      unitRef="U_xbrlishares">90228293</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630"
      decimals="-3"
      id="F_000431"
      unitRef="U_iso4217USD">902000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200630"
      decimals="-3"
      id="F_000432"
      unitRef="U_iso4217USD">1344912000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200630"
      decimals="-3"
      id="F_000433"
      unitRef="U_iso4217USD">-1561000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200630"
      decimals="-3"
      id="F_000434"
      unitRef="U_iso4217USD">-948381000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200630"
      decimals="-3"
      id="F_000435"
      unitRef="U_iso4217USD">19271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_20200630"
      decimals="-3"
      id="F_000436"
      unitRef="U_iso4217USD">415143000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000437"
      unitRef="U_iso4217USD">-205743000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000438"
      unitRef="U_iso4217USD">-163661000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000439"
      unitRef="U_iso4217USD">5242000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000440"
      unitRef="U_iso4217USD">5737000</us-gaap:Depreciation>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000441"
      unitRef="U_iso4217USD">4393000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000442"
      unitRef="U_iso4217USD">5247000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000443"
      unitRef="U_iso4217USD">-767000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000444"
      unitRef="U_iso4217USD">22000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <fgen:UnrealizedLossGainOnEquityInvestments
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000445"
      unitRef="U_iso4217USD">-4000</fgen:UnrealizedLossGainOnEquityInvestments>
    <fgen:UnrealizedLossGainOnEquityInvestments
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000446"
      unitRef="U_iso4217USD">-15000</fgen:UnrealizedLossGainOnEquityInvestments>
    <fgen:InvestmentLossInUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000447"
      unitRef="U_iso4217USD">323000</fgen:InvestmentLossInUnconsolidatedVariableInterestEntity>
    <fgen:InvestmentLossInUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000448"
      unitRef="U_iso4217USD">0</fgen:InvestmentLossInUnconsolidatedVariableInterestEntity>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000449"
      unitRef="U_iso4217USD">-13000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000450"
      unitRef="U_iso4217USD">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000451"
      unitRef="U_iso4217USD">38385000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000452"
      unitRef="U_iso4217USD">34560000</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000453"
      unitRef="U_iso4217USD">25000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000454"
      unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000455"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000456"
      unitRef="U_iso4217USD">-138000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000457"
      unitRef="U_iso4217USD">-8000</us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000458"
      unitRef="U_iso4217USD">-258000</us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000459"
      unitRef="U_iso4217USD">-17868000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000460"
      unitRef="U_iso4217USD">-1903000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000461"
      unitRef="U_iso4217USD">7861000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000462"
      unitRef="U_iso4217USD">2016000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000463"
      unitRef="U_iso4217USD">-2231000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000464"
      unitRef="U_iso4217USD">-126874000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <fgen:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000465"
      unitRef="U_iso4217USD">1800000</fgen:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <fgen:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000466"
      unitRef="U_iso4217USD">-494000</fgen:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000467"
      unitRef="U_iso4217USD">3066000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000468"
      unitRef="U_iso4217USD">-3529000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000469"
      unitRef="U_iso4217USD">-1013000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000470"
      unitRef="U_iso4217USD">-1060000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000471"
      unitRef="U_iso4217USD">27745000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000472"
      unitRef="U_iso4217USD">-33331000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <fgen:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000473"
      unitRef="U_iso4217USD">295000</fgen:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent>
    <fgen:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000474"
      unitRef="U_iso4217USD">-170000</fgen:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000475"
      unitRef="U_iso4217USD">33078000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000476"
      unitRef="U_iso4217USD">48117000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <fgen:IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000477"
      unitRef="U_iso4217USD">-73000</fgen:IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities>
    <fgen:IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000478"
      unitRef="U_iso4217USD">-115000</fgen:IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities>
    <fgen:IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000479"
      unitRef="U_iso4217USD">1388000</fgen:IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent>
    <fgen:IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000480"
      unitRef="U_iso4217USD">-359000</fgen:IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000481"
      unitRef="U_iso4217USD">-8065000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000482"
      unitRef="U_iso4217USD">64317000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000483"
      unitRef="U_iso4217USD">-71527000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000484"
      unitRef="U_iso4217USD">90179000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000485"
      unitRef="U_iso4217USD">2215000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000486"
      unitRef="U_iso4217USD">1185000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <fgen:PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000487"
      unitRef="U_iso4217USD">0</fgen:PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity>
    <fgen:PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000488"
      unitRef="U_iso4217USD">1419000</fgen:PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecurities
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000489"
      unitRef="U_iso4217USD">266647000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecurities
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000490"
      unitRef="U_iso4217USD">38000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000491"
      unitRef="U_iso4217USD">4000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000492"
      unitRef="U_iso4217USD">10606000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000493"
      unitRef="U_iso4217USD">10610000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000494"
      unitRef="U_iso4217USD">201900000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000495"
      unitRef="U_iso4217USD">-254252000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">209864000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <fgen:RepaymentsOfFinanceLeaseLiabilities
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">5326000</fgen:RepaymentsOfFinanceLeaseLiabilities>
    <fgen:RepaymentsOfFinanceLeaseLiabilities
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000498"
      unitRef="U_iso4217USD">5992000</fgen:RepaymentsOfFinanceLeaseLiabilities>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000499"
      unitRef="U_iso4217USD">201000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000500"
      unitRef="U_iso4217USD">201000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000501"
      unitRef="U_iso4217USD">5928000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000502"
      unitRef="U_iso4217USD">6858000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000503"
      unitRef="U_iso4217USD">11756000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000504"
      unitRef="U_iso4217USD">16510000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000505"
      unitRef="U_iso4217USD">301000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000506"
      unitRef="U_iso4217USD">3459000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000507"
      unitRef="U_iso4217USD">446000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000508"
      unitRef="U_iso4217USD">-499000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000509"
      unitRef="U_iso4217USD">-325032000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000510"
      unitRef="U_iso4217USD">303003000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000511"
      unitRef="U_iso4217USD">678393000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000512"
      unitRef="U_iso4217USD">126266000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000513"
      unitRef="U_iso4217USD">353361000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000921299_20200630"
      decimals="-3"
      id="F_000514"
      unitRef="U_iso4217USD">429269000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000515">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Significant Accounting Policies&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description of Operations&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;FibroGen, Inc. (&#x201c;FibroGen&#x201d; or the &#x201c;Company&#x201d;) is headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#x2019;s Republic of China (&#x201c;China&#x201d;). FibroGen is a leading biopharmaceutical company developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (&#x201c;HIF&#x201d;) biology, 2-oxoglutarate enzymology, connective tissue growth factor (&#x201c;CTGF&#x201d;) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Roxadustat, FibroGen&#x2019;s most advanced product, is an oral small molecule inhibitor of HIF prolyl hydroxylase (&#x201c;HIF-PH&#x201d;) activity that is being commercialized in China (tradename: &#x7231;&#x745e;&#x5353;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;) for the treatment of anemia caused by chronic kidney disease (&#x201c;CKD&#x201d;) in dialysis and non-dialysis patients. EVRENZO&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; (roxadustat) is also being commercialized in Japan and has been approved in South Korea and Chile for the treatment of anemia associated with CKD in dialysis and non-dialysis patients. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2021, the Committee for Medicinal Products for Human Use of the European Medicines Agency (&#x201c;EMA&#x201d;) adopted a positive opinion, recommending the granting of Marketing Authorization Application (&#x201c;MAA&#x201d;) for the medicinal product Evrenzo (roxadustat), intended for the treatment of adult patients with symptomatic anemia associated with CKD. Our partner Astellas Pharma Inc. (&#x201c;Astellas&#x201d;) expects an approval decision on the MAA for roxadustat by the European Commission in August 2021. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2021, the United States (&#x201c;U.S.&#x201d;) Food and Drug Administration (&#x201c;FDA&#x201d;) Cardiovascular and Renal Drugs Advisory Committee (&#x201c;CRDAC&#x201d;) voted to recommend not approving roxadustat, an oral HIF-PH inhibitor, for the treatment of anemia due to CKD in adult patients. The CRDAC vote was 13 to 1 for non-dialysis dependent CKD patients, and 12 to 2 for dialysis-dependent CKD patients. While the FDA is not required to follow CRDAC's vote, the agency considers CRDAC's non-binding recommendations when making its decision. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 3 development in China for anemia associated with myelodysplastic syndromes. Roxadustat is in Phase 2 clinical development for chemotherapy-induced anemia. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pamrevlumab, a human monoclonal antibody targeting CTGF, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer and Duchenne muscular dystrophy.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation and Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed consolidated financial statements include the accounts of FibroGen, its wholly owned subsidiaries and its majority-owned subsidiaries, FibroGen Europe Oy and FibroGen China Anemia Holdings, Ltd. All inter-company transactions and balances have been eliminated in consolidation. For any variable interest entity for which FibroGen is not the primary beneficiary, the Company uses the equity method of accounting. The Company operates as one segment &#x2014; the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The unaudited condensed consolidated financial statements and related disclosures have been prepared in accordance with accounting principles generally accepted in the U.S. (&#x201c;U.S. GAAP&#x201d;) applicable to interim financial reporting and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) and, therefore, do not include all information and footnote disclosures normally included in the annual consolidated financial statements. The financial information included herein should be read in conjunction with the consolidated financial statements and related notes in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC for the year ended December&#160;31, 2020 (&#x201c;2020 Form 10-K&#x201d;). &lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue, specifically, estimates in variable consideration for drug product sales, and estimates in transaction price per unit for the China performance obligation (as defined and discussed under &lt;span style="font-style:italic;"&gt;Significant Accounting Policies&lt;/span&gt; below). On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates. In the Company&#x2019;s opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair statement of its financial position, results of operations and cash flows for the interim periods presented.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Loss per Share&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potential common shares that would have the effect of increasing diluted earnings per share are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings per share. Diluted weighted average shares excluded potential common shares related to stock options, restricted stock units and shares to be purchased under the employee stock purchase plan totaling 11.4 million and 9.2 million for the three months ended June&#160;30, 2021 and 2020, and totaling 9.4 million and 9.0 million for the six months ended June&#160;30, 2021 and 2020, respectively, as they were anti-dilutive.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s business is subject to risks and uncertainties, including those related to Severe Acute Respiratory Syndrome Coronavirus 2 and the resulting Coronavirus Disease (&#x201c;COVID-19&#x201d;) and the risk that we may not get approval of roxadustat in the U.S. for CKD anemia given the fact that the CRDAC voted to recommend not approving roxadustat in July 2021.&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#x2019;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, obtaining second source suppliers, &lt;span style="font-size:9.5pt;"&gt;regulatory approval from the FDA or other regulatory authorities, &lt;/span&gt;the results of clinical trials and the achievement of milestones, market acceptance of the Company&#x2019;s product candidates, competition from other products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued and Adopted Accounting Guidance&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2019-12, &lt;span style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;. This guidance simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step up in the tax basis of goodwill, and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. This guidance was effective for annual reporting periods beginning after December 15, 2020 including interim periods. The Company adopted this guidance on January 1, 2021, and the adoption of this guidance did not have material impact to the Company&#x2019;s condensed consolidated financial statements and related disclosures.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Guidance Not Yet Adopted&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the FASB issued ASU 2020-04, &lt;span style="font-style:italic;"&gt;Reference Rate Reform (Topic 848): &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt; (&#x201c;&lt;span style="font-style:italic;"&gt;ASU&lt;/span&gt;&lt;span style="font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-style:italic;"&gt;2020&lt;/span&gt;&lt;span style="font-style:italic;"&gt;-&lt;/span&gt;&lt;span style="font-style:italic;"&gt;04&lt;/span&gt;&lt;span style="font-style:italic;"&gt;&#x201d;&lt;/span&gt;)&lt;span style="font-style:italic;"&gt;,&lt;/span&gt; which provides companies with optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform. This guidance is effective as of March 12, 2020 through December 31, 2022. Subsequently in January 2021, the FASB issued ASU 2021-01, &lt;span style="font-style:italic;"&gt;Reference Rate Reform (Topic 848): Scope&lt;/span&gt;, which clarifies ASU 2020-04 and provides certain optional expedients that allow derivative instruments impacted by changes in the interest rate used for margining, discounting or contract price alignment to qualify for certain optional relief. ASU 2021-01 is effective in the same timeframe as ASU 2020-04. The relief offered by this guidance, if adopted, is available to companies for the period March 12, 2020 through December 31, 2022. &lt;span style="Background-color:#FFFFFF;"&gt;The Company has certain lease arrangements that are linked to LIBOR. The Company is in the process of evaluating options for transitioning away from LIBOR and expects to complete this analysis by the time LIBOR is phased out. The Company did not elect to apply any of the expedients or exceptions as of and for the period ended June 30, 2021 and is currently evaluating the impact on its consolidated financial statements and related disclosures upon adoption of this guidance.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant Accounting Policies&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the 2020 Form 10-K, except for the following:&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Product revenue, net &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue, net consists of revenues from sales of roxadustat commercial product to Beijing Falikang Pharmaceutical Co., Ltd. (&#x201c;Falikang&#x201d;), and directly to pharmaceutical distributors located in a few provinces in China that are not covered by Falikang. Falikang is jointly owned by AstraZeneca AB (&#x201c;AstraZeneca&#x201d;) and FibroGen Beijing. The Company is not the primary beneficiary of Falikang for accounting purposes, as AstraZeneca is the final decision maker for all the roxadustat commercialization activities, and the Company lacks the power criterion to direct the activities of Falikang (see Note 3, &lt;span style="font-style:italic;"&gt;Variable Interest Entity&lt;/span&gt;). &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Sales to Falikang&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Falikang became fully operational in January 2021, at which time FibroGen Beijing began selling roxadustat commercial product to Falikang. Falikang is FibroGen Beijing&#x2019;s primary customer in China and substantially all roxadustat product sales to distributors in China are made by Falikang. Falikang bears inventory risk once it receives and accepts the product from FibroGen Beijing, and is responsible for delivering product to its distributors.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The promises identified under the AstraZeneca China Agreement (as defined in Note 2, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;), including the license, co-development services and manufacturing of commercial supplies have been bundled into a single performance obligation (&#x201c;China performance obligation&#x201d;). Amounts of the transaction price allocable to this performance obligation under the Company&#x2019;s agreements with AstraZeneca as outlined in Note 2, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues,&lt;/span&gt; are deferred until control of the manufactured commercial product is transferred to AstraZeneca.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The initiation of roxadustat sales to Falikang marked the beginning of the China performance obligation&lt;span style="font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;"&gt; Revenue is recognized at a point in time when control of roxadustat commercial product is transferred to Falikang. Revenue is recognized based on the estimated transaction price per unit and actual quantity of product delivered during the reporting period. Specifically, the transaction price per unit is determined based on the overall transaction price over the total estimated sales quantity for the estimated performance period in which the Company believes those sales would occur. The price per unit is subject to reassessment on a quarterly basis, which may result in cumulative catch up adjustments due to changes in estimates.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The overall transaction price for FibroGen Beijing&#x2019;s product sales to Falikang includes the following elements of consideration: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Non-refundable upfront license fees; development, regulatory, and commercial milestone payments based on the China Agreement allocated to the China performance obligation;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Co-development billings resulting from the Company&#x2019;s research and development efforts, which are reimbursable under the China Agreement;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="text-decoration:none;Background-color:#auto;font-family:Noto Sans Symbols;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interim profit/loss share between FibroGen Beijing and AstraZeneca from April 1, 2020 through December 31, 2020; and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Net transfer price from product sales to Falikang from January 1, 2021 onwards. The net transfer price includes the following elements: &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;o&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Gross transfer price: The gross transfer price is based on a percentage of Falikang&#x2019;s net sales to its distributors, which takes into account Falikang&#x2019;s operating expenses and its payments to AstraZeneca for roxadustat sales and marketing efforts, capped at a percentage of Falikang&#x2019;s net roxadustat sales. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;o&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Profit share: The gross transfer price is then adjusted for an estimated amount to achieve the 50/50 profit share from current period roxadustat net sales in China. The adjustments to date have been a reduction to the transfer price and the related accounts receivable from Falikang.&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The non-refundable upfront license fees constitute a &lt;span style="color:#000000;"&gt;fixed consideration. The remainder of the above are variable consideration components, which may be constrained, and included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. The calculation of the above variable consideration includes key estimates such as total sales quantity, performance period, gross transfer price and profit share, which require a substantial degree of judgment.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Any net transfer price in excess of the revenue recognized is deferred, and will be recognized over future periods as the performance obligations are satisfied.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Direct Sales to Distributors&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company sells roxadustat in China directly to a number of pharmaceutical distributors located in a few provinces in China that are not covered by Falikang. These pharmaceutical distributors are the Company&#x2019;s customers. Hospitals order roxadustat through a distributor and the Company ships the product directly to the distributors. The delivery of roxadustat to a distributor represents a single performance obligation. Distributors are responsible for delivering product to end users, primarily hospitals. Distributors bear inventory risk once they receive and accept the product. Product revenue is recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The period between the transfer of control of the promised goods and when the Company receives payment is based on 60-day payment terms. As such, product revenue is not adjusted for the effects of a significant financing component.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue is recorded at the net sales prices which includes the following estimates of variable consideration:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Price adjustment: When China&#x2019;s National Healthcare Security Administration releases price guidance for roxadustat under the National Reimbursement Drug List, any channel inventories that have not been sold through by distributors, or to patients by hospitals and retailors, would be eligible for a price adjustment under the price protection. The price adjustment is calculated based on estimated channel inventory levels;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Contractual sales rebate: The contractual sales rebate is calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. The contractual sales rebate is recorded as a reduction to revenue at the point of sale to the distributor;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Non-key account hospital listing award: A one-time fixed-amount award is offered to a distributor who successfully lists the product with an eligible hospital, and who meets certain requirements. The Company considers this particular award to be an upfront payment to a customer within the definitions of Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/span&gt;(&#x201c;ASC 606&#x201d;). The non-key account hospital listing award is capitalized when the distributor meets eligibility requirements, and amortized as reduction to product revenue over future sales orders made by the distributor until exhausted;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="text-decoration:none;Background-color:#auto;font-family:Noto Sans Symbols;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other discounts and rebates, including key account hospital sales reba&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;t&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;e and transfer fee discount, are generally based on a percentage of eligible gross sales made by the distributor and recorded as a reduction to revenue at the point of sale to the distributor; and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Sales returns: Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product&#x2019;s expiration date.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The calculation of the above variable consideration is based on gross sales to the distributor, or estimated utilizing best available information from the distributor, maximum known exposures and other available information including estimated channel inventory levels and estimated sales made by the distributor to hospitals, which involve a substantial degree of judgment.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The above rebates and discounts all together are eligible to be applied against the distributor&#x2019;s future sales order, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible and in the same period that the related revenue is recorded. Due to the distributor&#x2019;s legal right to offset, at each balance sheet date, the liability for rebates and discounts are presented as reductions of gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The distributor&#x2019;s legal right of offset is calculated at the individual distributor level.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;License Acquisition Agreement&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 16, 2021, the Company entered into an exclusive license and option agreement with HiFiBiO Therapeutics (&#x201c;HiFiBiO&#x201d;) (&#x201c;HiFiBiO Agreement&#x201d;), pursuant to which the Company exclusively licensed all product candidates in HiFiBiO&#x2019;s Galectin-9 program and will have the sole right to develop them worldwide. The Company has also obtained exclusive options to license all product candidates in HiFiBiO&#x2019;s CXCR5 and CCR8 programs. Under the terms of the HiFiBiO Agreement, the Company will make a $25 million upfront payment to HiFiBiO, as well as payments upon option exercise. In addition, HiFiBiO may receive up to a total of an additional $1.1 billion in future option, clinical, regulatory, and commercial milestone payments across all three programs. HiFiBiO will also be eligible to receive royalties based upon worldwide net sales. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The acquisition of these licenses was accounted for as an asset acquisition. The initial upfront payment of $25.0 million related to the license and options acquisition meets the definition of an in-process research and development asset (&#x201c;IPR&amp;amp;D asset&#x201d;) under the ASC 730, &lt;span style="font-style:italic;"&gt;Research and Development&lt;/span&gt; (&#x201c;ASC 730&#x201d;). It relates to particular research and development projects and is determined to have no alternative future uses and thus have no separate economic value. Therefore, this upfront payment was recorded as a research and development expense during the three months ended June 30, 2021. As of June 30, 2021, this amount was not paid, and was included as accounts payable in the condensed consolidated balance sheet.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration payments will be evaluated and recognized when they become probable and reasonably estimable. The related IPR&amp;amp;D asset will only be capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, amounts allocated to IPR&amp;amp;D asset that have no alternative use will be expensed. As of June 30, 2021, all programs were at the early stage of development and the contingencies related to the milestone payments had not been resolved, therefore no contingent consideration was recognized. The Company will reassess the probability of future option payments and contingent payments on a quarterly basis.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <fgen:DescriptionOfOperationsPolicyPolicyTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000526">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description of Operations&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;FibroGen, Inc. (&#x201c;FibroGen&#x201d; or the &#x201c;Company&#x201d;) is headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#x2019;s Republic of China (&#x201c;China&#x201d;). FibroGen is a leading biopharmaceutical company developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (&#x201c;HIF&#x201d;) biology, 2-oxoglutarate enzymology, connective tissue growth factor (&#x201c;CTGF&#x201d;) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Roxadustat, FibroGen&#x2019;s most advanced product, is an oral small molecule inhibitor of HIF prolyl hydroxylase (&#x201c;HIF-PH&#x201d;) activity that is being commercialized in China (tradename: &#x7231;&#x745e;&#x5353;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;) for the treatment of anemia caused by chronic kidney disease (&#x201c;CKD&#x201d;) in dialysis and non-dialysis patients. EVRENZO&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; (roxadustat) is also being commercialized in Japan and has been approved in South Korea and Chile for the treatment of anemia associated with CKD in dialysis and non-dialysis patients. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2021, the Committee for Medicinal Products for Human Use of the European Medicines Agency (&#x201c;EMA&#x201d;) adopted a positive opinion, recommending the granting of Marketing Authorization Application (&#x201c;MAA&#x201d;) for the medicinal product Evrenzo (roxadustat), intended for the treatment of adult patients with symptomatic anemia associated with CKD. Our partner Astellas Pharma Inc. (&#x201c;Astellas&#x201d;) expects an approval decision on the MAA for roxadustat by the European Commission in August 2021. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2021, the United States (&#x201c;U.S.&#x201d;) Food and Drug Administration (&#x201c;FDA&#x201d;) Cardiovascular and Renal Drugs Advisory Committee (&#x201c;CRDAC&#x201d;) voted to recommend not approving roxadustat, an oral HIF-PH inhibitor, for the treatment of anemia due to CKD in adult patients. The CRDAC vote was 13 to 1 for non-dialysis dependent CKD patients, and 12 to 2 for dialysis-dependent CKD patients. While the FDA is not required to follow CRDAC's vote, the agency considers CRDAC's non-binding recommendations when making its decision. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 3 development in China for anemia associated with myelodysplastic syndromes. Roxadustat is in Phase 2 clinical development for chemotherapy-induced anemia. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pamrevlumab, a human monoclonal antibody targeting CTGF, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer and Duchenne muscular dystrophy.&lt;/p&gt;</fgen:DescriptionOfOperationsPolicyPolicyTextBlock>
    <fgen:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000527">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation and Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed consolidated financial statements include the accounts of FibroGen, its wholly owned subsidiaries and its majority-owned subsidiaries, FibroGen Europe Oy and FibroGen China Anemia Holdings, Ltd. All inter-company transactions and balances have been eliminated in consolidation. For any variable interest entity for which FibroGen is not the primary beneficiary, the Company uses the equity method of accounting. The Company operates as one segment &#x2014; the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The unaudited condensed consolidated financial statements and related disclosures have been prepared in accordance with accounting principles generally accepted in the U.S. (&#x201c;U.S. GAAP&#x201d;) applicable to interim financial reporting and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) and, therefore, do not include all information and footnote disclosures normally included in the annual consolidated financial statements. The financial information included herein should be read in conjunction with the consolidated financial statements and related notes in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC for the year ended December&#160;31, 2020 (&#x201c;2020 Form 10-K&#x201d;). &lt;/p&gt;
</fgen:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0000921299_20210101_20210630"
      decimals="INF"
      id="F_000563"
      unitRef="U_fgenSegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates contextRef="C_0000921299_20210101_20210630" id="F_000528">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue, specifically, estimates in variable consideration for drug product sales, and estimates in transaction price per unit for the China performance obligation (as defined and discussed under &lt;span style="font-style:italic;"&gt;Significant Accounting Policies&lt;/span&gt; below). On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates. In the Company&#x2019;s opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair statement of its financial position, results of operations and cash flows for the interim periods presented.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000529">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Loss per Share&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potential common shares that would have the effect of increasing diluted earnings per share are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings per share. Diluted weighted average shares excluded potential common shares related to stock options, restricted stock units and shares to be purchased under the employee stock purchase plan totaling 11.4 million and 9.2 million for the three months ended June&#160;30, 2021 and 2020, and totaling 9.4 million and 9.0 million for the six months ended June&#160;30, 2021 and 2020, respectively, as they were anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_20210401_20210630"
      decimals="-5"
      id="F_000564"
      unitRef="U_xbrlishares">11400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_20200401_20200630"
      decimals="-5"
      id="F_000565"
      unitRef="U_xbrlishares">9200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_20210101_20210630"
      decimals="-5"
      id="F_000566"
      unitRef="U_xbrlishares">9400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_20200101_20200630"
      decimals="-5"
      id="F_000567"
      unitRef="U_xbrlishares">9000000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <fgen:RisksAndUncertaintiesPolicyTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000530">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s business is subject to risks and uncertainties, including those related to Severe Acute Respiratory Syndrome Coronavirus 2 and the resulting Coronavirus Disease (&#x201c;COVID-19&#x201d;) and the risk that we may not get approval of roxadustat in the U.S. for CKD anemia given the fact that the CRDAC voted to recommend not approving roxadustat in July 2021.&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#x2019;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, obtaining second source suppliers, &lt;span style="font-size:9.5pt;"&gt;regulatory approval from the FDA or other regulatory authorities, &lt;/span&gt;the results of clinical trials and the achievement of milestones, market acceptance of the Company&#x2019;s product candidates, competition from other products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals.&lt;/p&gt;</fgen:RisksAndUncertaintiesPolicyTextBlock>
    <fgen:RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000531">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued and Adopted Accounting Guidance&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2019-12, &lt;span style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;. This guidance simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step up in the tax basis of goodwill, and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. This guidance was effective for annual reporting periods beginning after December 15, 2020 including interim periods. The Company adopted this guidance on January 1, 2021, and the adoption of this guidance did not have material impact to the Company&#x2019;s condensed consolidated financial statements and related disclosures.&lt;/p&gt;
</fgen:RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock>
    <fgen:RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000532">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Guidance Not Yet Adopted&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the FASB issued ASU 2020-04, &lt;span style="font-style:italic;"&gt;Reference Rate Reform (Topic 848): &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt; (&#x201c;&lt;span style="font-style:italic;"&gt;ASU&lt;/span&gt;&lt;span style="font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-style:italic;"&gt;2020&lt;/span&gt;&lt;span style="font-style:italic;"&gt;-&lt;/span&gt;&lt;span style="font-style:italic;"&gt;04&lt;/span&gt;&lt;span style="font-style:italic;"&gt;&#x201d;&lt;/span&gt;)&lt;span style="font-style:italic;"&gt;,&lt;/span&gt; which provides companies with optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform. This guidance is effective as of March 12, 2020 through December 31, 2022. Subsequently in January 2021, the FASB issued ASU 2021-01, &lt;span style="font-style:italic;"&gt;Reference Rate Reform (Topic 848): Scope&lt;/span&gt;, which clarifies ASU 2020-04 and provides certain optional expedients that allow derivative instruments impacted by changes in the interest rate used for margining, discounting or contract price alignment to qualify for certain optional relief. ASU 2021-01 is effective in the same timeframe as ASU 2020-04. The relief offered by this guidance, if adopted, is available to companies for the period March 12, 2020 through December 31, 2022. &lt;span style="Background-color:#FFFFFF;"&gt;The Company has certain lease arrangements that are linked to LIBOR. The Company is in the process of evaluating options for transitioning away from LIBOR and expects to complete this analysis by the time LIBOR is phased out. The Company did not elect to apply any of the expedients or exceptions as of and for the period ended June 30, 2021 and is currently evaluating the impact on its consolidated financial statements and related disclosures upon adoption of this guidance.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant Accounting Policies&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the 2020 Form 10-K, except for the following:&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Product revenue, net &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue, net consists of revenues from sales of roxadustat commercial product to Beijing Falikang Pharmaceutical Co., Ltd. (&#x201c;Falikang&#x201d;), and directly to pharmaceutical distributors located in a few provinces in China that are not covered by Falikang. Falikang is jointly owned by AstraZeneca AB (&#x201c;AstraZeneca&#x201d;) and FibroGen Beijing. The Company is not the primary beneficiary of Falikang for accounting purposes, as AstraZeneca is the final decision maker for all the roxadustat commercialization activities, and the Company lacks the power criterion to direct the activities of Falikang (see Note 3, &lt;span style="font-style:italic;"&gt;Variable Interest Entity&lt;/span&gt;). &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Sales to Falikang&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Falikang became fully operational in January 2021, at which time FibroGen Beijing began selling roxadustat commercial product to Falikang. Falikang is FibroGen Beijing&#x2019;s primary customer in China and substantially all roxadustat product sales to distributors in China are made by Falikang. Falikang bears inventory risk once it receives and accepts the product from FibroGen Beijing, and is responsible for delivering product to its distributors.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The promises identified under the AstraZeneca China Agreement (as defined in Note 2, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;), including the license, co-development services and manufacturing of commercial supplies have been bundled into a single performance obligation (&#x201c;China performance obligation&#x201d;). Amounts of the transaction price allocable to this performance obligation under the Company&#x2019;s agreements with AstraZeneca as outlined in Note 2, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues,&lt;/span&gt; are deferred until control of the manufactured commercial product is transferred to AstraZeneca.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The initiation of roxadustat sales to Falikang marked the beginning of the China performance obligation&lt;span style="font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;"&gt; Revenue is recognized at a point in time when control of roxadustat commercial product is transferred to Falikang. Revenue is recognized based on the estimated transaction price per unit and actual quantity of product delivered during the reporting period. Specifically, the transaction price per unit is determined based on the overall transaction price over the total estimated sales quantity for the estimated performance period in which the Company believes those sales would occur. The price per unit is subject to reassessment on a quarterly basis, which may result in cumulative catch up adjustments due to changes in estimates.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The overall transaction price for FibroGen Beijing&#x2019;s product sales to Falikang includes the following elements of consideration: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Non-refundable upfront license fees; development, regulatory, and commercial milestone payments based on the China Agreement allocated to the China performance obligation;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Co-development billings resulting from the Company&#x2019;s research and development efforts, which are reimbursable under the China Agreement;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="text-decoration:none;Background-color:#auto;font-family:Noto Sans Symbols;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interim profit/loss share between FibroGen Beijing and AstraZeneca from April 1, 2020 through December 31, 2020; and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Net transfer price from product sales to Falikang from January 1, 2021 onwards. The net transfer price includes the following elements: &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;o&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Gross transfer price: The gross transfer price is based on a percentage of Falikang&#x2019;s net sales to its distributors, which takes into account Falikang&#x2019;s operating expenses and its payments to AstraZeneca for roxadustat sales and marketing efforts, capped at a percentage of Falikang&#x2019;s net roxadustat sales. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;o&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Profit share: The gross transfer price is then adjusted for an estimated amount to achieve the 50/50 profit share from current period roxadustat net sales in China. The adjustments to date have been a reduction to the transfer price and the related accounts receivable from Falikang.&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The non-refundable upfront license fees constitute a &lt;span style="color:#000000;"&gt;fixed consideration. The remainder of the above are variable consideration components, which may be constrained, and included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. The calculation of the above variable consideration includes key estimates such as total sales quantity, performance period, gross transfer price and profit share, which require a substantial degree of judgment.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Any net transfer price in excess of the revenue recognized is deferred, and will be recognized over future periods as the performance obligations are satisfied.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Direct Sales to Distributors&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company sells roxadustat in China directly to a number of pharmaceutical distributors located in a few provinces in China that are not covered by Falikang. These pharmaceutical distributors are the Company&#x2019;s customers. Hospitals order roxadustat through a distributor and the Company ships the product directly to the distributors. The delivery of roxadustat to a distributor represents a single performance obligation. Distributors are responsible for delivering product to end users, primarily hospitals. Distributors bear inventory risk once they receive and accept the product. Product revenue is recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The period between the transfer of control of the promised goods and when the Company receives payment is based on 60-day payment terms. As such, product revenue is not adjusted for the effects of a significant financing component.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue is recorded at the net sales prices which includes the following estimates of variable consideration:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Price adjustment: When China&#x2019;s National Healthcare Security Administration releases price guidance for roxadustat under the National Reimbursement Drug List, any channel inventories that have not been sold through by distributors, or to patients by hospitals and retailors, would be eligible for a price adjustment under the price protection. The price adjustment is calculated based on estimated channel inventory levels;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Contractual sales rebate: The contractual sales rebate is calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. The contractual sales rebate is recorded as a reduction to revenue at the point of sale to the distributor;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Non-key account hospital listing award: A one-time fixed-amount award is offered to a distributor who successfully lists the product with an eligible hospital, and who meets certain requirements. The Company considers this particular award to be an upfront payment to a customer within the definitions of Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/span&gt;(&#x201c;ASC 606&#x201d;). The non-key account hospital listing award is capitalized when the distributor meets eligibility requirements, and amortized as reduction to product revenue over future sales orders made by the distributor until exhausted;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="text-decoration:none;Background-color:#auto;font-family:Noto Sans Symbols;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other discounts and rebates, including key account hospital sales reba&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;t&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;e and transfer fee discount, are generally based on a percentage of eligible gross sales made by the distributor and recorded as a reduction to revenue at the point of sale to the distributor; and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Sales returns: Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product&#x2019;s expiration date.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The calculation of the above variable consideration is based on gross sales to the distributor, or estimated utilizing best available information from the distributor, maximum known exposures and other available information including estimated channel inventory levels and estimated sales made by the distributor to hospitals, which involve a substantial degree of judgment.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The above rebates and discounts all together are eligible to be applied against the distributor&#x2019;s future sales order, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible and in the same period that the related revenue is recorded. Due to the distributor&#x2019;s legal right to offset, at each balance sheet date, the liability for rebates and discounts are presented as reductions of gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The distributor&#x2019;s legal right of offset is calculated at the individual distributor level.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;License Acquisition Agreement&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 16, 2021, the Company entered into an exclusive license and option agreement with HiFiBiO Therapeutics (&#x201c;HiFiBiO&#x201d;) (&#x201c;HiFiBiO Agreement&#x201d;), pursuant to which the Company exclusively licensed all product candidates in HiFiBiO&#x2019;s Galectin-9 program and will have the sole right to develop them worldwide. The Company has also obtained exclusive options to license all product candidates in HiFiBiO&#x2019;s CXCR5 and CCR8 programs. Under the terms of the HiFiBiO Agreement, the Company will make a $25 million upfront payment to HiFiBiO, as well as payments upon option exercise. In addition, HiFiBiO may receive up to a total of an additional $1.1 billion in future option, clinical, regulatory, and commercial milestone payments across all three programs. HiFiBiO will also be eligible to receive royalties based upon worldwide net sales. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The acquisition of these licenses was accounted for as an asset acquisition. The initial upfront payment of $25.0 million related to the license and options acquisition meets the definition of an in-process research and development asset (&#x201c;IPR&amp;amp;D asset&#x201d;) under the ASC 730, &lt;span style="font-style:italic;"&gt;Research and Development&lt;/span&gt; (&#x201c;ASC 730&#x201d;). It relates to particular research and development projects and is determined to have no alternative future uses and thus have no separate economic value. Therefore, this upfront payment was recorded as a research and development expense during the three months ended June 30, 2021. As of June 30, 2021, this amount was not paid, and was included as accounts payable in the condensed consolidated balance sheet.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration payments will be evaluated and recognized when they become probable and reasonably estimable. The related IPR&amp;amp;D asset will only be capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, amounts allocated to IPR&amp;amp;D asset that have no alternative use will be expensed. As of June 30, 2021, all programs were at the early stage of development and the contingencies related to the milestone payments had not been resolved, therefore no contingent consideration was recognized. The Company will reassess the probability of future option payments and contingent payments on a quarterly basis.&lt;/p&gt;</fgen:RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock>
    <fgen:ProfitSharePercent
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630"
      decimals="INF"
      id="F_000568"
      unitRef="U_xbrlipure">0.50</fgen:ProfitSharePercent>
    <us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms contextRef="C_0000921299_20210101_20210630" id="F_000569">The period between the transfer of control of the promised goods and when the Company receives payment is based on 60-day payment terms.</us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms>
    <fgen:DescriptionOfSalesReturn contextRef="C_0000921299_20210101_20210630" id="F_000570">Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product&#x2019;s expiration date.</fgen:DescriptionOfSalesReturn>
    <fgen:InitialUpfrontPayment
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenHiFiBiOAgreementMember_20210616_20210616"
      decimals="-6"
      id="F_000571"
      unitRef="U_iso4217USD">25000000</fgen:InitialUpfrontPayment>
    <fgen:MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenHiFiBiOAgreementMember_20210616_20210616"
      decimals="INF"
      id="F_000572"
      unitRef="U_iso4217USD">1100000000</fgen:MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments>
    <fgen:InitialUpfrontPayment
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenHiFiBiOAgreementMember_20210616_20210616"
      decimals="-5"
      id="F_000573"
      unitRef="U_iso4217USD">25000000.0</fgen:InitialUpfrontPayment>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenHiFiBiOAgreementMember_20210616"
      decimals="INF"
      id="F_000574"
      unitRef="U_iso4217USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <fgen:CollaborativeArrangementAndRevenuesDisclosureTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000516">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Collaboration Agreements and Revenues&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas Agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Japan Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2005, the Company entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (&#x201c;Japan Agreement&#x201d;). Under this agreement, Astellas paid license fees and other consideration totaling $40.1&#160;million (such amounts were fully received as of February 2009). Under the Japan Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $132.5&#160;million in potential milestone payments, comprised of (i)&#160;up to $22.5&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of July 2016), (ii)&#160;up to $95.0&#160;million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $15.0&#160;million in milestone payments upon the achievement of specified commercial sales milestone. The Japan Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range of the list price published by Japan&#x2019;s Ministry of Health, Labour and Welfare, adjusted for certain elements, after commercial launch. The aggregate amount of consideration received through June&#160;30, 2021 totals $105.1 million, excluding drug product revenue that is discussed separately below.&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#x201c;Japan Amendment&#x201d;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;active pharmaceutical ingredient (&#x201c;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;API&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x201d;)&lt;/span&gt;&lt;span style="font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;to Astellas &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;for the roxadustat commercial &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;purposes &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;in Japan&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. The commercial terms of the Japan Agreement relating to the transfer price for roxadustat for commercial use remain substantially the same, reflecting an adjustment for the manufacture of drug product by Astellas rather than FibroGen. The related drug product revenue, as described in details under &lt;/span&gt;&lt;span style="font-style:italic;"&gt;Drug Product Revenue&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; section below, was $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.0)&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;and $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;for the three &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;and six &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;months ended &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, 2021&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;respectively&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Europe Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2006, the Company entered into a separate collaboration agreement with Astellas for the development and commercialization of roxadustat for the treatment of anemia in Europe, the Middle East, the Commonwealth of Independent States and South Africa (&#x201c;Europe Agreement&#x201d;). Under the terms of the Europe Agreement, Astellas paid license fees and other upfront consideration totaling $320.0 million (such amounts were fully received as of February 2009). The Europe Agreement also provides for additional development and regulatory approval milestone payments up to $425.0&#160;million, comprised of (i)&#160;up to $90.0&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of 2012), (ii)&#160;up to $335.0&#160;million in milestone payments upon achievement of specified regulatory milestone events. Under the Europe Agreement, Astellas committed to fund 50% of joint development costs for Europe and North America, and all territory-specific costs. The Europe Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range. The aggregate amount of consideration received under the Europe Agreement through June&#160;30, 2021 totals $540.0 million, excluding drug product revenue that is discussed separately below.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Europe Agreement, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. During the first quarter of 2021, the Company entered into an Astellas EU Supply Agreement (&#x201c;EU Supply Agreement&#x201d;) under the Europe Agreement with Astellas to define general forecast, order, supply and payment terms for Astellas to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The Company shipped bulk drug product to Astellas as pre-commercial supply for process validation purposes during the first quarter of 2021. The Company recorded the consideration of $11.8 million from this shipment as deferred revenue as of June 30, 2021, as described in details under &lt;span style="font-style:italic;"&gt;Drug Product Revenue&lt;/span&gt; section below.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca Agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;U.S./Rest of World (&#x201c;RoW&#x201d;) Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective July 30, 2013, the Company entered into a collaboration agreement with AstraZeneca for the development and commercialization of roxadustat for the treatment of anemia in the U.S. and all other countries in the world, other than China, not previously licensed under the Astellas Europe and Astellas Japan Agreements (&#x201c;U.S./RoW Agreement&#x201d;). It also excludes China, which is covered by a separate agreement with AstraZeneca described below. Under the terms of the U.S./RoW Agreement, AstraZeneca paid upfront, non-contingent, non-refundable and time-based payments totaling $374.0 million (such amounts were fully received as of June 2016). Under the U.S./RoW Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $875.0 million in potential milestone payments, comprised of (i)&#160;up to $65.0 million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of April 2020), (ii)&#160;up to $325.0 million in milestone payments upon achievement of specified regulatory milestone events, (iii)&#160;up to $160.0&#160;million in milestone payments related to activity by potential competitors and (iv)&#160;up to approximately $325.0 million in milestone payments upon the achievement of specified commercial sales events. The aggregate amount of consideration received under the U.S./RoW Agreement through June&#160;30, 2021 totals $439.0 million, excluding drug product revenue that is discussed separately below.&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2020, the Company entered into Master Supply Agreement under the U.S./RoW Agreement with AstraZeneca (&#x201c;Master Supply Agreement&#x201d;) to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The Company shipped bulk drug product to AstraZeneca as commercial supply during 2020, and the first and second quarter of 2021. On July 15, 2021, the FDA CRDAC voted to recommend not approving roxadustat for the treatment of anemia due to CKD in adult patients. While the FDA is not required to follow the CRDAC&#x2019;s vote, the agency considers the CRDAC&#x2019;s non-binding recommendations when making its decision. The Company evaluated the impact of these developments in revising its estimates of variable consideration associated with drug product revenue. As a result, the Company updated the estimated transaction price, and recorded $11.2 million as deferred revenue as of June 30, 2021. See details under &lt;span style="font-style:italic;"&gt;Drug Product Revenue&lt;/span&gt; section below.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;China Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective July&#160;30, 2013, the Company (through its subsidiaries affiliated with China) entered into the China Agreement (&#x201c;China Agreement&#x201d;). Under the terms of the China Agreement, AstraZeneca agreed to pay upfront consideration totaling $28.2&#160;million (such amounts were fully received in 2014). Under the China Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $348.5 million in potential milestone payments, comprised of (i)&#160;up to $15.0 million in milestone payments upon achievement of specified clinical and development milestone events, (ii)&#160;up to $146.0 million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $187.5 million in milestone payments upon the achievement of specified commercial sales and other events. The China Agreement is structured as a 50/50 profit or loss share (as defined), which was amended under the China Amendment discussed below in the third quarter of 2020, and provides for joint development costs (including capital and equipment costs for construction of the manufacturing plant in China), to be shared equally during the development period. The aggregate amount of such consideration received for milestone and upfront payments through June&#160;30, 2021 totals $77.2 million.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;China Amendment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2020, FibroGen China and AstraZeneca (together with FibroGen China, the &#x201c;Parties&#x201d;) entered into the China Amendment, effective July 1, 2020, relating to the development and commercialization of roxadustat in China. While the responsibilities of the Parties under the China Agreement remain largely the same, certain changes were made. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the China Amendment, in September 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Falikang, which performs roxadustat distribution, as well as conduct sales and marketing through AstraZeneca. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the China Amendment, the interim period is defined as the period from April 1, 2020 to the time when Falikang is fully operational. Falikang became fully operational in January 2021. The calculation for profit or loss share related to sales of roxadustat in China has changed for the period from April 1, 2020 onwards. With effect from April 1, 2020, the Parties have changed the method under which commercial expenses incurred by AstraZeneca are calculated and billed. AstraZeneca&#x2019;s co-promotion expenses for their sales and marketing efforts are now subject to a cap of a percentage of net sales. Once AstraZeneca has been fully reimbursed for their sales and marketing costs under the cap, AstraZeneca will bill the co-promotion expenses based on actual costs on a prospective basis. In addition, the China Amendment has allowed for a higher cost of manufacturing incurred by FibroGen Beijing to be included in the profit or loss share calculation, subject to an annual cap, among other changes. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since Falikang became fully operational in January 2021, substantially all direct roxadustat product sales to distributors in China are made by Falikang, while FibroGen Beijing continues to sell roxadustat product directly in a few provinces in China. FibroGen Beijing manufactures and supplies commercial product to Falikang based on a gross transfer price, which is adjusted for the estimated profit share. In addition, AstraZeneca now bills the co-promotion expenses to Falikang and to FibroGen Beijing, respectively, for its services provided to the respective entity. Development costs continue to be shared 50/50 between the Parties.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the three and six months ended June&#160;30, 2021, the Company recognized $11.8 million and $22.2 million, respectively, of net product revenue from the sales to Falikang, as described in details under &lt;span style="font-style:italic;"&gt;Product Revenue, Net&lt;/span&gt; section below.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to sales to Falikang, during the three and six months ended June&#160;30, 2021, the Company recognized $1.6 million and 6.6 million, respectively, of net product revenue from sales directly to distributors in a few provinces in China, &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;as &lt;/span&gt;described as direct sales&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt; &lt;/span&gt;under &lt;span style="font-style:italic;"&gt;Product Revenue, Net&lt;/span&gt; section below.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;License Revenue and Development Revenue Recognized Under the Collaboration Agreements&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts recognized as license revenue and development revenue under the Japan Agreement with Astellas were as follows (in thousands):&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance Obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Japan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.68%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;164&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;327&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Japan Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&#160;at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,529&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,559&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total license and development&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;116,876&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;116,906&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The revenue recognized under the Japan Agreement for the three months ended June&#160;30, 2021 included immaterial revenue resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied or partially satisfied in previous periods. The Company does not expect material variable consideration from estimated future co-development billing beyond the development period in the transaction price related to the Japan Agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts recognized as license revenue and development revenue under the Europe Agreement with Astellas were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance Obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Europe&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,546&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,602&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,077&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,176&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Europe Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&#160;at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;487,951&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;487,951&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255,039&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.68%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total license and development&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;742,990&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;743,323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:2.5%;text-indent:-2.5%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The revenue recognized under the Europe Agreement for the three months ended June&#160;30, 2021 included an increase in revenue of $0.4 million resulting from changes to estimated variable consideration. The remainder of the transaction price related to the Europe Agreement includes $10.7 million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts recognized as revenue under the U.S./RoW and China Agreement with AstraZeneca were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance Obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S.&#160;/&#160;RoW&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;and China&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,993&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,969&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,305&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China performance obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;594&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement with AstraZeneca, along with any associated deferred revenue as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S.&#160;/&#160;RoW and China Agreements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&#160;at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.24%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;341,844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;341,844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.24%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Co-development, information sharing &amp;amp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;committee services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;582,743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,309&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;585,052&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.24%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China performance obligation *&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,167&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149,759&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;171,926&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.24%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total license and development&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;946,754&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;152,068&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;**&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,098,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;* &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;China performance obligation revenue is recognized as product revenue, as described in details under &lt;span style="font-style:italic;"&gt;Product Revenue, Net&lt;/span&gt; section below.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;**&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the consolidated balance sheets. As of June 30, 2021, deferred revenue included $146.8 million related to the U.S./RoW and China Agreement, which represents the net of $152.1 million of deferred revenue presented above and a $5.3 million unbilled co-development revenue under the China Amendment with AstraZeneca.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The revenue recognized under the U.S./RoW Agreement for the three months ended June&#160;30, 2021 included a reduction in revenue of $0.2 million resulting from changes to estimated variable consideration. The remainder of the transaction price related to the U.S./RoW Agreement and China Agreement includes $34.1 million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period, except for amounts allocated to the China performance obligation. The amount allocated to the U.S./RoW Agreement is expected to be recognized over the remaining development service period. The amount allocated to the China performance obligation is expected to be recognized as the Company transfers control of the commercial products to Falikang.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product Revenue, Net&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue, net from the sales of roxadustat commercial product in China was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct Sales:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,230&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,833&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,659&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discounts and rebates&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,095&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales returns&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct sales revenue, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,611&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,693&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,566&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales to Falikang:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross transfer price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,714&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Profit share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,636&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net transfer price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,141&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,479&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000702"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase in deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,381&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,312&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000706"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales to Falikang revenue, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,167&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total product revenue, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,371&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,693&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,733&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Direct Sales&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue from direct roxadustat product sales to distributors in China is recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products, net of various sales rebates and discounts. The total discounts and rebates were $0.6 million and $4.1 million for the three months ended June&#160;30, 2021 and 2020, and $1.2 million and $4.5 million for the six months ended June&#160;30, 2021 and 2020, respectively, which primarily consisted of the contractual sales rebate calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor.  &lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The rebates and discounts that the Company&#x2019;s pharmaceutical distributors have earned are eligible to be applied against future sales orders, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible in the same period that the related revenue is recorded. Due to the Company&#x2019;s legal right to offset, at each balance sheet date, the rebates and discounts are presented as reductions to gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The Company&#x2019;s legal right to offset is calculated at the individual distributor level. The following table includes a roll-forward of the contract liabilities (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deduction&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Translation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.6%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue - Direct sales - contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(883&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(183&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,793&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June&#160;30, 2021 and December&#160;31, 2020, the total contract liabilities were $13.8 million and $15.1 million, which were included in accrued and other current liabilities in the condensed consolidated balance sheet. The rebates and discounts reflected as reductions to gross accounts receivable for direct sales was $0.8 million and $0.5 million as of June 30, 2021 and December 31, 2020, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Sales to Falikang &#x2013; China Performance Obligation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since Falikang became fully operational in January 2021, substantially all direct roxadustat product sales to distributors in China are made by Falikang. FibroGen Beijing manufactures and supplies commercial product to Falikang. The net transfer price for FibroGen Beijing&#x2019;s product sales to Falikang is based on a gross transfer price, which is adjusted to account for the 50/50 profit share for the period.  &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The roxadustat sales to Falikang marked the beginning of the Company&#x2019;s China performance obligation under the Company&#x2019;s agreements with AstraZeneca&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt;.&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; Product revenue is based on the transaction price of the China performance obligation. &lt;/span&gt;&lt;span style="color:#000000;"&gt;Revenue is recognized when control of product is transferred to Falikang, &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;in an amount that &lt;/span&gt;&lt;span style="color:#000000;"&gt;reflects the allocation of the transaction price to the performance obligation satisfied during the reporting period&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;"&gt;Any net transfer price in excess of the revenue recognized is added to the deferred balance to date, and will &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;be recognized over future periods as the performance obligations are satisfied&lt;/span&gt;&lt;span style="color:#000000;"&gt;. During the three and six months ended June&#160;30, 2021, following updates to its estimates, the Company deferred $5.4 million and $9.3 million, respectively, from the net transfer price to Falikang, which was included in the related deferred revenue of the China performance obligation.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table includes a roll-forward of the related deferred revenue that is considered as a contract liability (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognized as Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue - AstraZeneca&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&#160;&#160;China performance obligation - deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(137,338&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34,588&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,167&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(149,759&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue includes amounts allocated to the China performance obligation under the AstraZeneca arrangement as revenue recognition associated with this unit of accounting is tied to the commercial launch of the products within China and to when the control of the manufactured commercial products is transferred to AstraZeneca. As of June&#160;30, 2021, approximately $6.3 million of the deferred revenue related to the China unit of accounting was included in short-term deferred revenue, which represents the amount of deferred revenue associated with the China unit of accounting that is expected to be recognized within the next 12 months, associated with the commercial sales in China.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reductions to gross accounts receivable related to product revenue to Falikang was $10.1 million as of June&#160;30, 2021.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug Product Revenue&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue from commercial-grade API or bulk drug product sales to AstraZeneca and Astellas was as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,056&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,674&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,224&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(168&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During three months ended June 30, 2021, the Company shipped bulk drug product to AstraZeneca as commercial supply under the terms of the Master Supply Agreement. Based on the above-mentioned FDA CRDAC&#x2019;s vote on July 15, 2021, the Company evaluated the impact of these developments in revising its estimates of variable consideration associated with drug product revenue. As a result, the Company updated the estimated transaction price, and recorded $11.2 million as deferred revenue as of June 30, 2021.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the three months ended June 30, 2021, the Company recorded a reduction of $2.0 million to the drug product revenue related to the API shipments fulfilled under the terms of the Japan Amendment with Astellas in 2018, due to a change in estimated variable consideration. Specifically, the change in estimated variable consideration was based on the API held by Astellas at June 30, 2021, adjusted to reflect the changes in the estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others. This amount was recorded under deferred revenue in the condensed consolidated balance sheet as of June 30, 2021. During the first quarter of 2021, the Company recorded $4.0 million drug product revenue related to the same API shipments for the change in estimated variable consideration based on the API held by Astellas at March 31, 2021, under the same methodology. This amount was unbilled to Astellas as of March 31, 2021, and was billed and received from Astellas during the second quarter of 2021.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the three months ended March 31, 2021, the Company shipped bulk drug product from process validation supplies for commercial purposes under the terms of the Europe Agreement and the EU Supply Agreement with Astellas. The Company recorded the consideration of $11.8 million from this shipment as deferred revenue as of June 30, 2021, due to a high degree of uncertainty associated with the final consideration. The deferred revenue will be recognized as and when uncertainty is resolved.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table includes a roll-forward of the above-mentioned deferred revenues that are considered as contract liabilities related to drug product (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognized as Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas - Japan Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas - Europe Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,759&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca - U.S.&#160;Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue - deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24,904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(30,888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:CollaborativeArrangementAndRevenuesDisclosureTextBlock>
    <fgen:CollaborativeArrangementAndRevenuesPolicyTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000533">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas Agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Japan Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2005, the Company entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (&#x201c;Japan Agreement&#x201d;). Under this agreement, Astellas paid license fees and other consideration totaling $40.1&#160;million (such amounts were fully received as of February 2009). Under the Japan Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $132.5&#160;million in potential milestone payments, comprised of (i)&#160;up to $22.5&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of July 2016), (ii)&#160;up to $95.0&#160;million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $15.0&#160;million in milestone payments upon the achievement of specified commercial sales milestone. The Japan Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range of the list price published by Japan&#x2019;s Ministry of Health, Labour and Welfare, adjusted for certain elements, after commercial launch. The aggregate amount of consideration received through June&#160;30, 2021 totals $105.1 million, excluding drug product revenue that is discussed separately below.&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#x201c;Japan Amendment&#x201d;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;active pharmaceutical ingredient (&#x201c;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;API&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x201d;)&lt;/span&gt;&lt;span style="font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;to Astellas &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;for the roxadustat commercial &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;purposes &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;in Japan&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. The commercial terms of the Japan Agreement relating to the transfer price for roxadustat for commercial use remain substantially the same, reflecting an adjustment for the manufacture of drug product by Astellas rather than FibroGen. The related drug product revenue, as described in details under &lt;/span&gt;&lt;span style="font-style:italic;"&gt;Drug Product Revenue&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; section below, was $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.0)&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;and $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;for the three &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;and six &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;months ended &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, 2021&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;respectively&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Europe Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2006, the Company entered into a separate collaboration agreement with Astellas for the development and commercialization of roxadustat for the treatment of anemia in Europe, the Middle East, the Commonwealth of Independent States and South Africa (&#x201c;Europe Agreement&#x201d;). Under the terms of the Europe Agreement, Astellas paid license fees and other upfront consideration totaling $320.0 million (such amounts were fully received as of February 2009). The Europe Agreement also provides for additional development and regulatory approval milestone payments up to $425.0&#160;million, comprised of (i)&#160;up to $90.0&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of 2012), (ii)&#160;up to $335.0&#160;million in milestone payments upon achievement of specified regulatory milestone events. Under the Europe Agreement, Astellas committed to fund 50% of joint development costs for Europe and North America, and all territory-specific costs. The Europe Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range. The aggregate amount of consideration received under the Europe Agreement through June&#160;30, 2021 totals $540.0 million, excluding drug product revenue that is discussed separately below.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Europe Agreement, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. During the first quarter of 2021, the Company entered into an Astellas EU Supply Agreement (&#x201c;EU Supply Agreement&#x201d;) under the Europe Agreement with Astellas to define general forecast, order, supply and payment terms for Astellas to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The Company shipped bulk drug product to Astellas as pre-commercial supply for process validation purposes during the first quarter of 2021. The Company recorded the consideration of $11.8 million from this shipment as deferred revenue as of June 30, 2021, as described in details under &lt;span style="font-style:italic;"&gt;Drug Product Revenue&lt;/span&gt; section below.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca Agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;U.S./Rest of World (&#x201c;RoW&#x201d;) Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective July 30, 2013, the Company entered into a collaboration agreement with AstraZeneca for the development and commercialization of roxadustat for the treatment of anemia in the U.S. and all other countries in the world, other than China, not previously licensed under the Astellas Europe and Astellas Japan Agreements (&#x201c;U.S./RoW Agreement&#x201d;). It also excludes China, which is covered by a separate agreement with AstraZeneca described below. Under the terms of the U.S./RoW Agreement, AstraZeneca paid upfront, non-contingent, non-refundable and time-based payments totaling $374.0 million (such amounts were fully received as of June 2016). Under the U.S./RoW Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $875.0 million in potential milestone payments, comprised of (i)&#160;up to $65.0 million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of April 2020), (ii)&#160;up to $325.0 million in milestone payments upon achievement of specified regulatory milestone events, (iii)&#160;up to $160.0&#160;million in milestone payments related to activity by potential competitors and (iv)&#160;up to approximately $325.0 million in milestone payments upon the achievement of specified commercial sales events. The aggregate amount of consideration received under the U.S./RoW Agreement through June&#160;30, 2021 totals $439.0 million, excluding drug product revenue that is discussed separately below.&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2020, the Company entered into Master Supply Agreement under the U.S./RoW Agreement with AstraZeneca (&#x201c;Master Supply Agreement&#x201d;) to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The Company shipped bulk drug product to AstraZeneca as commercial supply during 2020, and the first and second quarter of 2021. On July 15, 2021, the FDA CRDAC voted to recommend not approving roxadustat for the treatment of anemia due to CKD in adult patients. While the FDA is not required to follow the CRDAC&#x2019;s vote, the agency considers the CRDAC&#x2019;s non-binding recommendations when making its decision. The Company evaluated the impact of these developments in revising its estimates of variable consideration associated with drug product revenue. As a result, the Company updated the estimated transaction price, and recorded $11.2 million as deferred revenue as of June 30, 2021. See details under &lt;span style="font-style:italic;"&gt;Drug Product Revenue&lt;/span&gt; section below.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;China Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective July&#160;30, 2013, the Company (through its subsidiaries affiliated with China) entered into the China Agreement (&#x201c;China Agreement&#x201d;). Under the terms of the China Agreement, AstraZeneca agreed to pay upfront consideration totaling $28.2&#160;million (such amounts were fully received in 2014). Under the China Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $348.5 million in potential milestone payments, comprised of (i)&#160;up to $15.0 million in milestone payments upon achievement of specified clinical and development milestone events, (ii)&#160;up to $146.0 million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $187.5 million in milestone payments upon the achievement of specified commercial sales and other events. The China Agreement is structured as a 50/50 profit or loss share (as defined), which was amended under the China Amendment discussed below in the third quarter of 2020, and provides for joint development costs (including capital and equipment costs for construction of the manufacturing plant in China), to be shared equally during the development period. The aggregate amount of such consideration received for milestone and upfront payments through June&#160;30, 2021 totals $77.2 million.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;China Amendment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2020, FibroGen China and AstraZeneca (together with FibroGen China, the &#x201c;Parties&#x201d;) entered into the China Amendment, effective July 1, 2020, relating to the development and commercialization of roxadustat in China. While the responsibilities of the Parties under the China Agreement remain largely the same, certain changes were made. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the China Amendment, in September 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Falikang, which performs roxadustat distribution, as well as conduct sales and marketing through AstraZeneca. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the China Amendment, the interim period is defined as the period from April 1, 2020 to the time when Falikang is fully operational. Falikang became fully operational in January 2021. The calculation for profit or loss share related to sales of roxadustat in China has changed for the period from April 1, 2020 onwards. With effect from April 1, 2020, the Parties have changed the method under which commercial expenses incurred by AstraZeneca are calculated and billed. AstraZeneca&#x2019;s co-promotion expenses for their sales and marketing efforts are now subject to a cap of a percentage of net sales. Once AstraZeneca has been fully reimbursed for their sales and marketing costs under the cap, AstraZeneca will bill the co-promotion expenses based on actual costs on a prospective basis. In addition, the China Amendment has allowed for a higher cost of manufacturing incurred by FibroGen Beijing to be included in the profit or loss share calculation, subject to an annual cap, among other changes. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since Falikang became fully operational in January 2021, substantially all direct roxadustat product sales to distributors in China are made by Falikang, while FibroGen Beijing continues to sell roxadustat product directly in a few provinces in China. FibroGen Beijing manufactures and supplies commercial product to Falikang based on a gross transfer price, which is adjusted for the estimated profit share. In addition, AstraZeneca now bills the co-promotion expenses to Falikang and to FibroGen Beijing, respectively, for its services provided to the respective entity. Development costs continue to be shared 50/50 between the Parties.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the three and six months ended June&#160;30, 2021, the Company recognized $11.8 million and $22.2 million, respectively, of net product revenue from the sales to Falikang, as described in details under &lt;span style="font-style:italic;"&gt;Product Revenue, Net&lt;/span&gt; section below.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to sales to Falikang, during the three and six months ended June&#160;30, 2021, the Company recognized $1.6 million and 6.6 million, respectively, of net product revenue from sales directly to distributors in a few provinces in China, &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;as &lt;/span&gt;described as direct sales&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt; &lt;/span&gt;under &lt;span style="font-style:italic;"&gt;Product Revenue, Net&lt;/span&gt; section below.&lt;/p&gt;</fgen:CollaborativeArrangementAndRevenuesPolicyTextBlock>
    <fgen:ProceedsFromUpfrontNonContingentAndTimeBasedPayments
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20090228"
      decimals="-5"
      id="F_000575"
      unitRef="U_iso4217USD">40100000</fgen:ProceedsFromUpfrontNonContingentAndTimeBasedPayments>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630"
      decimals="-5"
      id="F_000576"
      unitRef="U_iso4217USD">132500000</fgen:PotentialMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630"
      decimals="-5"
      id="F_000577"
      unitRef="U_iso4217USD">22500000</fgen:PotentialMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630"
      decimals="-5"
      id="F_000578"
      unitRef="U_iso4217USD">95000000.0</fgen:PotentialMilestones>
    <fgen:CommercialSalesMilestone
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630"
      decimals="-5"
      id="F_000579"
      unitRef="U_iso4217USD">15000000.0</fgen:CommercialSalesMilestone>
    <fgen:AdditionalConsiderationBasedOnNetSales
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630"
      id="F_000580">the low 20% range of the list price</fgen:AdditionalConsiderationBasedOnNetSales>
    <fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-5"
      id="F_000581"
      unitRef="U_iso4217USD">105100000</fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630"
      decimals="-5"
      id="F_000582"
      unitRef="U_iso4217USD">-2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210630"
      decimals="-5"
      id="F_000583"
      unitRef="U_iso4217USD">2100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fgen:ProceedsFromUpfrontNonContingentAndTimeBasedPayments
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20090228"
      decimals="-5"
      id="F_000584"
      unitRef="U_iso4217USD">320000000.0</fgen:ProceedsFromUpfrontNonContingentAndTimeBasedPayments>
    <fgen:DevelopmentAndRegulatoryApprovalMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060430"
      decimals="-5"
      id="F_000585"
      unitRef="U_iso4217USD">425000000.0</fgen:DevelopmentAndRegulatoryApprovalMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430"
      decimals="-5"
      id="F_000586"
      unitRef="U_iso4217USD">90000000.0</fgen:PotentialMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430"
      decimals="-5"
      id="F_000587"
      unitRef="U_iso4217USD">335000000.0</fgen:PotentialMilestones>
    <fgen:PercentageOfFundingForCosts
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430"
      decimals="2"
      id="F_000588"
      unitRef="U_xbrlipure">0.50</fgen:PercentageOfFundingForCosts>
    <fgen:AdditionalConsiderationBasedOnNetSales
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630"
      id="F_000589">low 20% range</fgen:AdditionalConsiderationBasedOnNetSales>
    <fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-5"
      id="F_000590"
      unitRef="U_iso4217USD">540000000.0</fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630"
      decimals="-5"
      id="F_000591"
      unitRef="U_iso4217USD">11800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <fgen:ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000592"
      unitRef="U_iso4217USD">374000000.0</fgen:ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000593"
      unitRef="U_iso4217USD">875000000.0</fgen:PotentialMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000594"
      unitRef="U_iso4217USD">65000000.0</fgen:PotentialMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000595"
      unitRef="U_iso4217USD">325000000.0</fgen:PotentialMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenDeferredApprovalMilestoneMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000596"
      unitRef="U_iso4217USD">160000000.0</fgen:PotentialMilestones>
    <fgen:CommercialSalesMilestone
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000597"
      unitRef="U_iso4217USD">325000000.0</fgen:CommercialSalesMilestone>
    <fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-5"
      id="F_000598"
      unitRef="U_iso4217USD">439000000.0</fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630"
      decimals="-5"
      id="F_000599"
      unitRef="U_iso4217USD">11200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <fgen:ProceedsFromUpfrontNonContingentAndNonRefundablePayments
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000600"
      unitRef="U_iso4217USD">28200000</fgen:ProceedsFromUpfrontNonContingentAndNonRefundablePayments>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000601"
      unitRef="U_iso4217USD">348500000</fgen:PotentialMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000602"
      unitRef="U_iso4217USD">15000000.0</fgen:PotentialMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000603"
      unitRef="U_iso4217USD">146000000.0</fgen:PotentialMilestones>
    <fgen:CommercialSalesAndOtherEventsMilestone
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000604"
      unitRef="U_iso4217USD">187500000</fgen:CommercialSalesAndOtherEventsMilestone>
    <fgen:CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-5"
      id="F_000605"
      unitRef="U_iso4217USD">77200000</fgen:CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630"
      decimals="-5"
      id="F_000606"
      unitRef="U_iso4217USD">11800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630"
      decimals="-5"
      id="F_000607"
      unitRef="U_iso4217USD">22200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210401_20210630"
      decimals="-5"
      id="F_000608"
      unitRef="U_iso4217USD">1600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630"
      decimals="-5"
      id="F_000609"
      unitRef="U_iso4217USD">6600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fgen:ContractWithCustomerMilestoneMethodTableTextBlock
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_20210101_20210630"
      id="F_000536">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts recognized as license revenue and development revenue under the Japan Agreement with Astellas were as follows (in thousands):&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance Obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Japan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.68%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;164&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;327&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</fgen:ContractWithCustomerMilestoneMethodTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630"
      decimals="-3"
      id="F_000610"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630"
      decimals="-3"
      id="F_000611"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630"
      decimals="-3"
      id="F_000612"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630"
      decimals="-3"
      id="F_000613"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630"
      decimals="-3"
      id="F_000614"
      unitRef="U_iso4217USD">99000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630"
      decimals="-3"
      id="F_000615"
      unitRef="U_iso4217USD">164000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630"
      decimals="-3"
      id="F_000616"
      unitRef="U_iso4217USD">179000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630"
      decimals="-3"
      id="F_000617"
      unitRef="U_iso4217USD">327000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_20210101_20210630"
      id="F_000537">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Japan Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&#160;at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,529&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,559&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total license and development&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;116,876&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;116,906&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000618"
      unitRef="U_iso4217USD">100347000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000621"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000624"
      unitRef="U_iso4217USD">100347000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000619"
      unitRef="U_iso4217USD">16529000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000622"
      unitRef="U_iso4217USD">30000</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000625"
      unitRef="U_iso4217USD">16559000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000620"
      unitRef="U_iso4217USD">116876000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000623"
      unitRef="U_iso4217USD">30000</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000626"
      unitRef="U_iso4217USD">116906000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <fgen:ContractWithCustomerMilestoneMethodTableTextBlock
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20210101_20210630"
      id="F_000538">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts recognized as license revenue and development revenue under the Europe Agreement with Astellas were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance Obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Europe&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,546&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,602&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,077&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,176&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</fgen:ContractWithCustomerMilestoneMethodTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630"
      decimals="-3"
      id="F_000627"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630"
      decimals="-3"
      id="F_000628"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630"
      decimals="-3"
      id="F_000629"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630"
      decimals="-3"
      id="F_000630"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630"
      decimals="-3"
      id="F_000631"
      unitRef="U_iso4217USD">2546000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630"
      decimals="-3"
      id="F_000632"
      unitRef="U_iso4217USD">4602000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210101_20210630"
      decimals="-3"
      id="F_000633"
      unitRef="U_iso4217USD">6077000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20200630"
      decimals="-3"
      id="F_000634"
      unitRef="U_iso4217USD">9176000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20210101_20210630"
      id="F_000539">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Europe Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&#160;at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;487,951&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;487,951&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255,039&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.68%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total license and development&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;742,990&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;743,323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:2.5%;text-indent:-2.5%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000635"
      unitRef="U_iso4217USD">487951000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000638"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000641"
      unitRef="U_iso4217USD">487951000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000636"
      unitRef="U_iso4217USD">255039000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000639"
      unitRef="U_iso4217USD">333000</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000642"
      unitRef="U_iso4217USD">255372000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000637"
      unitRef="U_iso4217USD">742990000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000640"
      unitRef="U_iso4217USD">333000</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630"
      decimals="-3"
      id="F_000643"
      unitRef="U_iso4217USD">743323000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630"
      decimals="-5"
      id="F_000645"
      unitRef="U_iso4217USD">400000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20210401_20210630"
      decimals="-5"
      id="F_000644"
      unitRef="U_iso4217USD">10700000</fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling>
    <fgen:ContractWithCustomerMilestoneMethodTableTextBlock
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20210101_20210630"
      id="F_000540">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts recognized as revenue under the U.S./RoW and China Agreement with AstraZeneca were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance Obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S.&#160;/&#160;RoW&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;and China&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,993&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,969&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,305&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China performance obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;594&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</fgen:ContractWithCustomerMilestoneMethodTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630"
      decimals="-3"
      id="F_000646"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200401_20200630"
      decimals="-3"
      id="F_000647"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630"
      decimals="-3"
      id="F_000648"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20200630"
      decimals="-3"
      id="F_000649"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630"
      decimals="-3"
      id="F_000650"
      unitRef="U_iso4217USD">16993000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200401_20200630"
      decimals="-3"
      id="F_000651"
      unitRef="U_iso4217USD">13750000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630"
      decimals="-3"
      id="F_000652"
      unitRef="U_iso4217USD">27969000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20200630"
      decimals="-3"
      id="F_000653"
      unitRef="U_iso4217USD">28305000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630"
      decimals="-3"
      id="F_000654"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200401_20200630"
      decimals="-3"
      id="F_000655"
      unitRef="U_iso4217USD">441000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630"
      decimals="-3"
      id="F_000656"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20200630"
      decimals="-3"
      id="F_000657"
      unitRef="U_iso4217USD">594000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20210101_20210630"
      id="F_000541">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement with AstraZeneca, along with any associated deferred revenue as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S.&#160;/&#160;RoW and China Agreements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&#160;at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&#160;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.24%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;341,844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;341,844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.24%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Co-development, information sharing &amp;amp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;committee services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;582,743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,309&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;585,052&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.24%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China performance obligation *&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,167&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149,759&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;171,926&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.24%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total license and development&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;946,754&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;152,068&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;**&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,098,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;* &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;China performance obligation revenue is recognized as product revenue, as described in details under &lt;span style="font-style:italic;"&gt;Product Revenue, Net&lt;/span&gt; section below.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;**&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the consolidated balance sheets. As of June 30, 2021, deferred revenue included $146.8 million related to the U.S./RoW and China Agreement, which represents the net of $152.1 million of deferred revenue presented above and a $5.3 million unbilled co-development revenue under the China Amendment with AstraZeneca.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-3"
      id="F_000658"
      unitRef="U_iso4217USD">341844000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-3"
      id="F_000662"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-3"
      id="F_000666"
      unitRef="U_iso4217USD">341844000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenCoDevelopmentInformationSharingAndCommitteeServicesMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-3"
      id="F_000659"
      unitRef="U_iso4217USD">582743000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenCoDevelopmentInformationSharingAndCommitteeServicesMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-3"
      id="F_000663"
      unitRef="U_iso4217USD">2309000</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenCoDevelopmentInformationSharingAndCommitteeServicesMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-3"
      id="F_000667"
      unitRef="U_iso4217USD">585052000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenChinaPerformanceObligationMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-3"
      id="F_000660"
      unitRef="U_iso4217USD">22167000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenChinaPerformanceObligationMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-3"
      id="F_000664"
      unitRef="U_iso4217USD">149759000</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenChinaPerformanceObligationMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-3"
      id="F_000668"
      unitRef="U_iso4217USD">171926000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-3"
      id="F_000661"
      unitRef="U_iso4217USD">946754000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-3"
      id="F_000665"
      unitRef="U_iso4217USD">152068000</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-3"
      id="F_000669"
      unitRef="U_iso4217USD">1098822000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-5"
      id="F_000670"
      unitRef="U_iso4217USD">146800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-5"
      id="F_000671"
      unitRef="U_iso4217USD">152100000</us-gaap:ContractWithCustomerLiability>
    <fgen:SuppliesNet
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-5"
      id="F_000672"
      unitRef="U_iso4217USD">5300000</fgen:SuppliesNet>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210401_20210630"
      decimals="-5"
      id="F_000674"
      unitRef="U_iso4217USD">200000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20210401_20210630"
      decimals="-5"
      id="F_000673"
      unitRef="U_iso4217USD">34100000</fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling>
    <fgen:ProductRevenuePolicyPolicyTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000534">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product Revenue, Net&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue, net from the sales of roxadustat commercial product in China was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct Sales:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,230&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,833&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,659&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discounts and rebates&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,095&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales returns&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct sales revenue, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,611&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,693&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,566&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales to Falikang:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross transfer price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,714&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Profit share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,636&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net transfer price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,141&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,479&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000702"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase in deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,381&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,312&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000706"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales to Falikang revenue, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,167&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total product revenue, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,371&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,693&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,733&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Direct Sales&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue from direct roxadustat product sales to distributors in China is recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products, net of various sales rebates and discounts. The total discounts and rebates were $0.6 million and $4.1 million for the three months ended June&#160;30, 2021 and 2020, and $1.2 million and $4.5 million for the six months ended June&#160;30, 2021 and 2020, respectively, which primarily consisted of the contractual sales rebate calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor.  &lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The rebates and discounts that the Company&#x2019;s pharmaceutical distributors have earned are eligible to be applied against future sales orders, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible in the same period that the related revenue is recorded. Due to the Company&#x2019;s legal right to offset, at each balance sheet date, the rebates and discounts are presented as reductions to gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The Company&#x2019;s legal right to offset is calculated at the individual distributor level. The following table includes a roll-forward of the contract liabilities (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deduction&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Translation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.6%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue - Direct sales - contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(883&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(183&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,793&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June&#160;30, 2021 and December&#160;31, 2020, the total contract liabilities were $13.8 million and $15.1 million, which were included in accrued and other current liabilities in the condensed consolidated balance sheet. The rebates and discounts reflected as reductions to gross accounts receivable for direct sales was $0.8 million and $0.5 million as of June 30, 2021 and December 31, 2020, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Sales to Falikang &#x2013; China Performance Obligation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since Falikang became fully operational in January 2021, substantially all direct roxadustat product sales to distributors in China are made by Falikang. FibroGen Beijing manufactures and supplies commercial product to Falikang. The net transfer price for FibroGen Beijing&#x2019;s product sales to Falikang is based on a gross transfer price, which is adjusted to account for the 50/50 profit share for the period.  &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The roxadustat sales to Falikang marked the beginning of the Company&#x2019;s China performance obligation under the Company&#x2019;s agreements with AstraZeneca&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt;.&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; Product revenue is based on the transaction price of the China performance obligation. &lt;/span&gt;&lt;span style="color:#000000;"&gt;Revenue is recognized when control of product is transferred to Falikang, &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;in an amount that &lt;/span&gt;&lt;span style="color:#000000;"&gt;reflects the allocation of the transaction price to the performance obligation satisfied during the reporting period&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;"&gt;Any net transfer price in excess of the revenue recognized is added to the deferred balance to date, and will &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;be recognized over future periods as the performance obligations are satisfied&lt;/span&gt;&lt;span style="color:#000000;"&gt;. During the three and six months ended June&#160;30, 2021, following updates to its estimates, the Company deferred $5.4 million and $9.3 million, respectively, from the net transfer price to Falikang, which was included in the related deferred revenue of the China performance obligation.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table includes a roll-forward of the related deferred revenue that is considered as a contract liability (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognized as Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue - AstraZeneca&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&#160;&#160;China performance obligation - deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(137,338&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34,588&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,167&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(149,759&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue includes amounts allocated to the China performance obligation under the AstraZeneca arrangement as revenue recognition associated with this unit of accounting is tied to the commercial launch of the products within China and to when the control of the manufactured commercial products is transferred to AstraZeneca. As of June&#160;30, 2021, approximately $6.3 million of the deferred revenue related to the China unit of accounting was included in short-term deferred revenue, which represents the amount of deferred revenue associated with the China unit of accounting that is expected to be recognized within the next 12 months, associated with the commercial sales in China.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reductions to gross accounts receivable related to product revenue to Falikang was $10.1 million as of June&#160;30, 2021.&lt;/p&gt;</fgen:ProductRevenuePolicyPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000542">Product revenue, net from the sales of roxadustat commercial product in China was as follows (in thousands):
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct Sales:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,230&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,833&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,659&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discounts and rebates&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,095&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales returns&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct sales revenue, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,611&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,693&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,566&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales to Falikang:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross transfer price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,714&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Profit share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,636&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net transfer price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,141&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,479&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000702"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase in deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,381&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,312&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000706"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales to Falikang revenue, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,167&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total product revenue, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,371&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,693&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,733&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210401_20210630"
      decimals="-3"
      id="F_000675"
      unitRef="U_iso4217USD">2230000</fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax>
    <fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20200401_20200630"
      decimals="-3"
      id="F_000676"
      unitRef="U_iso4217USD">19833000</fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax>
    <fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630"
      decimals="-3"
      id="F_000677"
      unitRef="U_iso4217USD">7659000</fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax>
    <fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20200101_20200630"
      decimals="-3"
      id="F_000678"
      unitRef="U_iso4217USD">25205000</fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20210401_20210630"
      decimals="-3"
      id="F_000679"
      unitRef="U_iso4217USD">-618000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20200401_20200630"
      decimals="-3"
      id="F_000680"
      unitRef="U_iso4217USD">-4095000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20210101_20210630"
      decimals="-3"
      id="F_000681"
      unitRef="U_iso4217USD">-1181000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20200101_20200630"
      decimals="-3"
      id="F_000682"
      unitRef="U_iso4217USD">-4512000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20210401_20210630"
      decimals="-3"
      id="F_000683"
      unitRef="U_iso4217USD">-1000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20200401_20200630"
      decimals="-3"
      id="F_000684"
      unitRef="U_iso4217USD">-45000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20210101_20210630"
      decimals="-3"
      id="F_000685"
      unitRef="U_iso4217USD">88000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20200101_20200630"
      decimals="-3"
      id="F_000686"
      unitRef="U_iso4217USD">-45000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210401_20210630"
      decimals="-3"
      id="F_000687"
      unitRef="U_iso4217USD">1611000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20200401_20200630"
      decimals="-3"
      id="F_000688"
      unitRef="U_iso4217USD">15693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630"
      decimals="-3"
      id="F_000689"
      unitRef="U_iso4217USD">6566000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20200101_20200630"
      decimals="-3"
      id="F_000690"
      unitRef="U_iso4217USD">20648000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fgen:RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20210401_20210630"
      decimals="-3"
      id="F_000691"
      unitRef="U_iso4217USD">26714000</fgen:RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax>
    <fgen:RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20200401_20200630"
      decimals="-3"
      id="F_000692"
      unitRef="U_iso4217USD">0</fgen:RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax>
    <fgen:RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20210101_20210630"
      decimals="-3"
      id="F_000693"
      unitRef="U_iso4217USD">51115000</fgen:RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax>
    <fgen:RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20200101_20200630"
      decimals="-3"
      id="F_000694"
      unitRef="U_iso4217USD">0</fgen:RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenProfitShareMember_20210401_20210630"
      decimals="-3"
      id="F_000695"
      unitRef="U_iso4217USD">-9573000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenProfitShareMember_20200401_20200630"
      decimals="-3"
      id="F_000696"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenProfitShareMember_20210101_20210630"
      decimals="-3"
      id="F_000697"
      unitRef="U_iso4217USD">-19636000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenProfitShareMember_20200101_20200630"
      decimals="-3"
      id="F_000698"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNetTransferPriceMember_20210401_20210630"
      decimals="-3"
      id="F_000699"
      unitRef="U_iso4217USD">17141000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNetTransferPriceMember_20200401_20200630"
      decimals="-3"
      id="F_000700"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNetTransferPriceMember_20210101_20210630"
      decimals="-3"
      id="F_000701"
      unitRef="U_iso4217USD">31479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenIncreaseInDeferredRevenueMember_20210401_20210630"
      decimals="-3"
      id="F_000703"
      unitRef="U_iso4217USD">-5381000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenIncreaseInDeferredRevenueMember_20200401_20200630"
      decimals="-3"
      id="F_000704"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenIncreaseInDeferredRevenueMember_20210101_20210630"
      decimals="-3"
      id="F_000705"
      unitRef="U_iso4217USD">-9312000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20210401_20210630"
      decimals="-3"
      id="F_000707"
      unitRef="U_iso4217USD">11760000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20200401_20200630"
      decimals="-3"
      id="F_000708"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20210101_20210630"
      decimals="-3"
      id="F_000709"
      unitRef="U_iso4217USD">22167000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenSalesToFalikangMember_20200101_20200630"
      decimals="-3"
      id="F_000710"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20210401_20210630"
      decimals="-3"
      id="F_000711"
      unitRef="U_iso4217USD">13371000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200401_20200630"
      decimals="-3"
      id="F_000712"
      unitRef="U_iso4217USD">15693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20210101_20210630"
      decimals="-3"
      id="F_000713"
      unitRef="U_iso4217USD">28733000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20200630"
      decimals="-3"
      id="F_000714"
      unitRef="U_iso4217USD">20648000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20210401_20210630"
      decimals="-5"
      id="F_000715"
      unitRef="U_iso4217USD">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20200401_20200630"
      decimals="-5"
      id="F_000716"
      unitRef="U_iso4217USD">4100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20210101_20210630"
      decimals="-5"
      id="F_000717"
      unitRef="U_iso4217USD">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDiscountsAndRebatesMember_20200101_20200630"
      decimals="-5"
      id="F_000718"
      unitRef="U_iso4217USD">4500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000543">The following table includes a roll-forward of the contract liabilities (in thousands):
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deduction&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Translation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.6%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue - Direct sales - contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(883&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(183&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,793&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20201231"
      decimals="-3"
      id="F_000719"
      unitRef="U_iso4217USD">15137000</us-gaap:ContractWithCustomerLiability>
    <fgen:ContractWithCustomerLiabilityAdditions
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630"
      decimals="-3"
      id="F_000720"
      unitRef="U_iso4217USD">883000</fgen:ContractWithCustomerLiabilityAdditions>
    <fgen:ContractWithCustomerLiabilityDeduction
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630"
      decimals="-3"
      id="F_000721"
      unitRef="U_iso4217USD">2410000</fgen:ContractWithCustomerLiabilityDeduction>
    <fgen:ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210101_20210630"
      decimals="-3"
      id="F_000722"
      unitRef="U_iso4217USD">-183000</fgen:ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210630"
      decimals="-3"
      id="F_000723"
      unitRef="U_iso4217USD">13793000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20210101_20210630"
      decimals="-5"
      id="F_000727"
      unitRef="U_iso4217USD">13800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20200101_20201231"
      decimals="-5"
      id="F_000726"
      unitRef="U_iso4217USD">15100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20210101_20210630"
      decimals="-5"
      id="F_000725"
      unitRef="U_iso4217USD">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20200101_20201231"
      decimals="-5"
      id="F_000724"
      unitRef="U_iso4217USD">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDeferredForFutureRecognitionMember_20210401_20210630"
      decimals="-5"
      id="F_000728"
      unitRef="U_iso4217USD">5400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDeferredForFutureRecognitionMember_20210101_20210630"
      decimals="-5"
      id="F_000729"
      unitRef="U_iso4217USD">9300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630"
      id="F_000544">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table includes a roll-forward of the related deferred revenue that is considered as a contract liability (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognized as Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue - AstraZeneca&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&#160;&#160;China performance obligation - deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(137,338&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34,588&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,167&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(149,759&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-3"
      id="F_000730"
      unitRef="U_iso4217USD">137338000</us-gaap:ContractWithCustomerLiability>
    <fgen:ContractWithCustomerLiabilityAdditions
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630"
      decimals="-3"
      id="F_000731"
      unitRef="U_iso4217USD">34588000</fgen:ContractWithCustomerLiabilityAdditions>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630"
      decimals="-3"
      id="F_000732"
      unitRef="U_iso4217USD">22167000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-3"
      id="F_000733"
      unitRef="U_iso4217USD">149759000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-5"
      id="F_000734"
      unitRef="U_iso4217USD">6300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210630"
      decimals="-5"
      id="F_000735"
      unitRef="U_iso4217USD">10100000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <fgen:DrugProductRevenuePolicyTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000535">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug Product Revenue&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue from commercial-grade API or bulk drug product sales to AstraZeneca and Astellas was as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,056&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,674&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,224&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(168&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During three months ended June 30, 2021, the Company shipped bulk drug product to AstraZeneca as commercial supply under the terms of the Master Supply Agreement. Based on the above-mentioned FDA CRDAC&#x2019;s vote on July 15, 2021, the Company evaluated the impact of these developments in revising its estimates of variable consideration associated with drug product revenue. As a result, the Company updated the estimated transaction price, and recorded $11.2 million as deferred revenue as of June 30, 2021.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the three months ended June 30, 2021, the Company recorded a reduction of $2.0 million to the drug product revenue related to the API shipments fulfilled under the terms of the Japan Amendment with Astellas in 2018, due to a change in estimated variable consideration. Specifically, the change in estimated variable consideration was based on the API held by Astellas at June 30, 2021, adjusted to reflect the changes in the estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others. This amount was recorded under deferred revenue in the condensed consolidated balance sheet as of June 30, 2021. During the first quarter of 2021, the Company recorded $4.0 million drug product revenue related to the same API shipments for the change in estimated variable consideration based on the API held by Astellas at March 31, 2021, under the same methodology. This amount was unbilled to Astellas as of March 31, 2021, and was billed and received from Astellas during the second quarter of 2021.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the three months ended March 31, 2021, the Company shipped bulk drug product from process validation supplies for commercial purposes under the terms of the Europe Agreement and the EU Supply Agreement with Astellas. The Company recorded the consideration of $11.8 million from this shipment as deferred revenue as of June 30, 2021, due to a high degree of uncertainty associated with the final consideration. The deferred revenue will be recognized as and when uncertainty is resolved.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table includes a roll-forward of the above-mentioned deferred revenues that are considered as contract liabilities related to drug product (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognized as Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas - Japan Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas - Europe Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,759&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca - U.S.&#160;Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue - deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24,904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(30,888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:DrugProductRevenuePolicyTextBlock>
    <fgen:ScheduleOfDrugProductRevenueTableTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000545">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue from commercial-grade API or bulk drug product sales to AstraZeneca and Astellas was as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,056&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,674&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,224&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(168&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:ScheduleOfDrugProductRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630"
      decimals="-3"
      id="F_000736"
      unitRef="U_iso4217USD">-1974000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200401_20200630"
      decimals="-3"
      id="F_000737"
      unitRef="U_iso4217USD">8238000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210630"
      decimals="-3"
      id="F_000738"
      unitRef="U_iso4217USD">2056000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20200630"
      decimals="-3"
      id="F_000739"
      unitRef="U_iso4217USD">8238000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630"
      decimals="-3"
      id="F_000740"
      unitRef="U_iso4217USD">-6674000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200401_20200630"
      decimals="-3"
      id="F_000741"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210630"
      decimals="-3"
      id="F_000742"
      unitRef="U_iso4217USD">-2224000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20200630"
      decimals="-3"
      id="F_000743"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630"
      decimals="-3"
      id="F_000744"
      unitRef="U_iso4217USD">-8648000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200401_20200630"
      decimals="-3"
      id="F_000745"
      unitRef="U_iso4217USD">8238000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210630"
      decimals="-3"
      id="F_000746"
      unitRef="U_iso4217USD">-168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20200630"
      decimals="-3"
      id="F_000747"
      unitRef="U_iso4217USD">8238000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630"
      decimals="-5"
      id="F_000748"
      unitRef="U_iso4217USD">11200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630"
      decimals="-5"
      id="F_000749"
      unitRef="U_iso4217USD">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210101_20210331"
      decimals="-5"
      id="F_000750"
      unitRef="U_iso4217USD">4000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630"
      decimals="-5"
      id="F_000751"
      unitRef="U_iso4217USD">11800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210101_20210630"
      id="F_000546">The following table includes a roll-forward of the above-mentioned deferred revenues that are considered as contract liabilities related to drug product (in thousands):
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognized as Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas - Japan Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas - Europe Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,759&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca - U.S.&#160;Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue - deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24,904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(30,888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20201231"
      decimals="-3"
      id="F_000752"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiability>
    <fgen:ContractWithCustomerLiabilityAdditions
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210101_20210630"
      decimals="-3"
      id="F_000756"
      unitRef="U_iso4217USD">1974000</fgen:ContractWithCustomerLiabilityAdditions>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210101_20210630"
      decimals="-3"
      id="F_000760"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210630"
      decimals="-3"
      id="F_000764"
      unitRef="U_iso4217USD">1974000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20201231"
      decimals="-3"
      id="F_000753"
      unitRef="U_iso4217USD">5984000</us-gaap:ContractWithCustomerLiability>
    <fgen:ContractWithCustomerLiabilityAdditions
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210101_20210630"
      decimals="-3"
      id="F_000757"
      unitRef="U_iso4217USD">11759000</fgen:ContractWithCustomerLiabilityAdditions>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210101_20210630"
      decimals="-3"
      id="F_000761"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_20210630"
      decimals="-3"
      id="F_000765"
      unitRef="U_iso4217USD">17743000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-3"
      id="F_000754"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiability>
    <fgen:ContractWithCustomerLiabilityAdditions
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630"
      decimals="-3"
      id="F_000758"
      unitRef="U_iso4217USD">11171000</fgen:ContractWithCustomerLiabilityAdditions>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630"
      decimals="-3"
      id="F_000762"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-3"
      id="F_000766"
      unitRef="U_iso4217USD">11171000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20201231"
      decimals="-3"
      id="F_000755"
      unitRef="U_iso4217USD">5984000</us-gaap:ContractWithCustomerLiability>
    <fgen:ContractWithCustomerLiabilityAdditions
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210101_20210630"
      decimals="-3"
      id="F_000759"
      unitRef="U_iso4217USD">24904000</fgen:ContractWithCustomerLiabilityAdditions>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210101_20210630"
      decimals="-3"
      id="F_000763"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20210630"
      decimals="-3"
      id="F_000767"
      unitRef="U_iso4217USD">30888000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000517">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Variable Interest Entity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Falikang is a distribution entity jointly owned by AstraZeneca and FibroGen Beijing. FibroGen Beijing owns 51.1% of the outstanding shares of Falikang. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the guidance under ASC 810, &lt;span style="font-style:italic;"&gt;Consolidation&lt;/span&gt; (&#x201c;ASC 810&#x201d;), the Company concluded that Falikang qualifies as a variable interest entity (&#x201c;VIE&#x201d;). As Falikang is a distribution entity and AstraZeneca is the final decision maker for all the roxadustat commercialization activities, the Company lacks the power criterion while AstraZeneca meets both the power and economic criteria under the ASC 810, to direct the activities of Falikang that most significantly impact its performance. Therefore, the Company is not the primary beneficiary of this VIE for accounting purposes. As a result, the Company accounts for its investment in Falikang under the equity method, and Falikang is not consolidated into the Company&#x2019;s condensed consolidated financial statements. Accordingly, the Company records its total investments in Falikang as an equity method investment in an unconsolidated variable interest entity in the condensed consolidated balance sheet. In addition, the Company recognizes its proportionate share of the reported profits or losses of Falikang as investment gain or loss in unconsolidated variable interest entity in the condensed consolidated statement of operations, and as an adjustment to its investment in Falikang in the condensed consolidated balance sheet. Falikang has not incurred material profit or loss to date. The Company may provide shareholder loans to Falikang to meet necessary financial obligations as part of its operations. To date, these loans have been immaterial. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s&#160;equity&#160;method&#160;investment&#160;in Falikang was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Entity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ownership Percentage&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share of Net Income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Translation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Falikang&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,083&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Falikang is considered a related party to the Company. See Note 9, &lt;span style="font-style:italic;"&gt;Related Party Transactions&lt;/span&gt;, for related disclosures.&lt;/p&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAstraZenecaABMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20210630"
      decimals="3"
      id="F_000768"
      unitRef="U_xbrlipure">0.511</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000547">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s&#160;equity&#160;method&#160;investment&#160;in Falikang was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Entity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ownership Percentage&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share of Net Income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Translation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Falikang&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,083&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210630"
      decimals="3"
      id="F_000769"
      unitRef="U_xbrlipure">0.511</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20201231"
      decimals="-3"
      id="F_000770"
      unitRef="U_iso4217USD">2728000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210101_20210630"
      decimals="-3"
      id="F_000771"
      unitRef="U_iso4217USD">323000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <fgen:EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210101_20210630"
      decimals="-3"
      id="F_000772"
      unitRef="U_iso4217USD">32000</fgen:EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation>
    <us-gaap:EquityMethodInvestments
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210630"
      decimals="-3"
      id="F_000773"
      unitRef="U_iso4217USD">3083000</us-gaap:EquityMethodInvestments>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000518">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair values of the Company&#x2019;s financial assets that are measured on a recurring basis are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,099&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,099&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,568&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,568&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,284&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,284&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,490&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,490&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;233&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;233&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;267,428&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215,507&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;482,935&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bond and mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590,591&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;598,735&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s Level 2 investments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data and other observable inputs. There were no transfers of assets between levels during the three and six months ended June&#160;30, 2021. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s financial liabilities related to lease obligations as of June 30, 2021 and December 31, 2020 were $0.9 million and $1.1 million, respectively. The fair values of the Company&#x2019;s financial liabilities are carried at historical cost that were derived by using an income approach, which required Level 3 inputs such as discounted estimated future cash flows. There were no transfers of assets or liabilities between levels for any of the periods presented.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000548">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair values of the Company&#x2019;s financial assets that are measured on a recurring basis are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,099&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,099&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,568&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,568&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,284&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,284&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,490&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,490&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;233&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;233&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;267,428&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215,507&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;482,935&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bond and mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590,591&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;598,735&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210630"
      decimals="-3"
      id="F_000774"
      unitRef="U_iso4217USD">220627000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210630"
      decimals="-3"
      id="F_000775"
      unitRef="U_iso4217USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210630"
      decimals="-3"
      id="F_000776"
      unitRef="U_iso4217USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210630"
      decimals="-3"
      id="F_000777"
      unitRef="U_iso4217USD">220627000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630"
      decimals="-3"
      id="F_000778"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630"
      decimals="-3"
      id="F_000779"
      unitRef="U_iso4217USD">104483000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630"
      decimals="-3"
      id="F_000780"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630"
      decimals="-3"
      id="F_000781"
      unitRef="U_iso4217USD">104483000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630"
      decimals="-3"
      id="F_000782"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630"
      decimals="-3"
      id="F_000783"
      unitRef="U_iso4217USD">72099000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630"
      decimals="-3"
      id="F_000784"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630"
      decimals="-3"
      id="F_000785"
      unitRef="U_iso4217USD">72099000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenUSGovernmentBondsMember_20210630"
      decimals="-3"
      id="F_000786"
      unitRef="U_iso4217USD">46568000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenUSGovernmentBondsMember_20210630"
      decimals="-3"
      id="F_000787"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenUSGovernmentBondsMember_20210630"
      decimals="-3"
      id="F_000788"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenUSGovernmentBondsMember_20210630"
      decimals="-3"
      id="F_000789"
      unitRef="U_iso4217USD">46568000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenAgencyBondsMember_20210630"
      decimals="-3"
      id="F_000790"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenAgencyBondsMember_20210630"
      decimals="-3"
      id="F_000791"
      unitRef="U_iso4217USD">14284000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenAgencyBondsMember_20210630"
      decimals="-3"
      id="F_000792"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenAgencyBondsMember_20210630"
      decimals="-3"
      id="F_000793"
      unitRef="U_iso4217USD">14284000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630"
      decimals="-3"
      id="F_000794"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630"
      decimals="-3"
      id="F_000795"
      unitRef="U_iso4217USD">12490000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630"
      decimals="-3"
      id="F_000796"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630"
      decimals="-3"
      id="F_000797"
      unitRef="U_iso4217USD">12490000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630"
      decimals="-3"
      id="F_000798"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630"
      decimals="-3"
      id="F_000799"
      unitRef="U_iso4217USD">12151000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630"
      decimals="-3"
      id="F_000800"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630"
      decimals="-3"
      id="F_000801"
      unitRef="U_iso4217USD">12151000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630"
      decimals="-3"
      id="F_000806"
      unitRef="U_iso4217USD">233000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630"
      decimals="-3"
      id="F_000807"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630"
      decimals="-3"
      id="F_000808"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630"
      decimals="-3"
      id="F_000809"
      unitRef="U_iso4217USD">233000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630"
      decimals="-3"
      id="F_000810"
      unitRef="U_iso4217USD">267428000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630"
      decimals="-3"
      id="F_000811"
      unitRef="U_iso4217USD">215507000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630"
      decimals="-3"
      id="F_000812"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630"
      decimals="-3"
      id="F_000813"
      unitRef="U_iso4217USD">482935000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231"
      decimals="-3"
      id="F_000814"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231"
      decimals="-3"
      id="F_000815"
      unitRef="U_iso4217USD">8144000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231"
      decimals="-3"
      id="F_000816"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231"
      decimals="-3"
      id="F_000817"
      unitRef="U_iso4217USD">8144000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_000818"
      unitRef="U_iso4217USD">244000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_000819"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_000820"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_000821"
      unitRef="U_iso4217USD">244000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000822"
      unitRef="U_iso4217USD">590347000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000823"
      unitRef="U_iso4217USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000824"
      unitRef="U_iso4217USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000825"
      unitRef="U_iso4217USD">590347000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000826"
      unitRef="U_iso4217USD">590591000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000827"
      unitRef="U_iso4217USD">8144000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000828"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000829"
      unitRef="U_iso4217USD">598735000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_0000921299_20210630"
      decimals="INF"
      id="F_000830"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_0000921299_20210630"
      decimals="INF"
      id="F_000831"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_0000921299_20210101_20210630"
      decimals="INF"
      id="F_000832"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_0000921299_20210101_20210630"
      decimals="INF"
      id="F_000833"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0000921299_20210630"
      decimals="-5"
      id="F_000834"
      unitRef="U_iso4217USD">900000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0000921299_20201231"
      decimals="-5"
      id="F_000835"
      unitRef="U_iso4217USD">1100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_0000921299_20210630"
      decimals="INF"
      id="F_000836"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_0000921299_20210630"
      decimals="INF"
      id="F_000838"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_0000921299_20210630"
      decimals="INF"
      id="F_000840"
      unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="C_0000921299_20210630"
      decimals="INF"
      id="F_000842"
      unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_0000921299_20210101_20210630"
      decimals="INF"
      id="F_000844"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_0000921299_20210101_20210630"
      decimals="INF"
      id="F_000846"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_0000921299_20210101_20210630"
      decimals="INF"
      id="F_000848"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_0000921299_20210101_20210630"
      decimals="INF"
      id="F_000850"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000837"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000839"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000841"
      unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000843"
      unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_0000921299_20200101_20201231"
      decimals="INF"
      id="F_000845"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_0000921299_20200101_20201231"
      decimals="INF"
      id="F_000847"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_0000921299_20200101_20201231"
      decimals="INF"
      id="F_000849"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_0000921299_20200101_20201231"
      decimals="INF"
      id="F_000851"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000519">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Leases&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s lease assets and related lease liabilities were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Sheet Line Item&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets - cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,477&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,146&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease right-of-use assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets - cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,705&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,934&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,614&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,891&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;97,091&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,043&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;97,952&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,649&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities, current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,330&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,718&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,188&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,391&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;853&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,762&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s long-term property lease with Alexandria for its corporate headquarters in San Francisco, California, had an initial term of 15&#160;years, scheduled to expire in 2023. The original lease was accounted for as a finance lease upon adoption of ASC 842, &lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt; (&#x201c;ASC 842&#x201d;), at January 1, 2019. &lt;br/&gt;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 1, 2021, the Company entered into an amendment with Alexandria to extend the lease to 2028 (&#x201c;Lease Amendment&#x201d;). Under the terms of the Lease Amendment, the Company has two optional rights to each extend the lease for an additional five years. The lease contract provides for a fixed annual rent, with scheduled increases of two percent that occur on each anniversary of the rent commencement date through 2023, and with scheduled increases of three percent that occur on each anniversary of the rent commencement date through 2028. This lease requires the Company to pay all costs of ownership, operation, and maintenance of the premises, including without limitation all operating costs, insurance costs, and taxes. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Company determined that the Lease Amendment was a lease modification, effective June 1, 2021, and thus reassessed the lease classification, remeasured the related lease liability using an updated discount rate, and adjusted the related right-of-use asset under the lease modification guidance under the ASC 842. Accordingly, on June 1, 2021, the Company determined that the modified lease be accounted for as an operating lease, and therefore derecognized the previous finance lease right-of-use asset of $24.6 million and the related finance lease liability of $32.6 million, and recognized an operating lease right-of-use asset of $93.2 million and the related operating lease liability of $101.2 million. Starting June 1, 2021, the cash payment related to this lease was classified as an operating activity, the impact of which was approximately $1.1 million to the condensed consolidated statement of cash flow for the six months ended June 30, 2021. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the three months ended March 31, 2021, after FibroGen Beijing&#x2019;s previous long-term lease agreement expired, the Company entered into a new lease agreement with the landlord for the same pilot plant located in Beijing Yizhuang Biomedical Park of BDA. The new lease term is five year, scheduled to expire in 2026, and is treated as an operating lease. Accordingly, the Company recorded $3.4 million in the operating right-of-use assets and total operating lease liabilities, respectively. The lease contract provides for fixed quarterly rent payments, and require the Company to pay operating and maintenance costs.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease expense were as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Statement of Operations Line Item&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of goods sold;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,777&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,653&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,393&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;242&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;534&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of goods sold;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,744&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,162&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;564&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(275&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(306&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(598&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.12%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,488&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,136&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,607&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,262&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental cash flow information related to leases were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,246&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;433&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows from finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;628&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,010&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing cash flows from finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,326&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,992&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-cash: Right-of-use assets obtained in exchange for new lease liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,498&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-cash: Increase (decrease) resulting from lease modification:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24,654&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93,222&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities, current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,587&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,221&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,009&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease term and discount rate were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term (years):&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000938"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000939"&gt;2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000940"&gt;7.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000941"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities of lease liabilities as of June&#160;30, 2021 are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance&#160;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&#160;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021 (remaining six month period)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,534&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,517&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,454&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beyond 2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,881&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125,377&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,463&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,914&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000549">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s lease assets and related lease liabilities were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Sheet Line Item&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets - cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,477&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,146&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease right-of-use assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets - cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,705&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,934&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,614&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,891&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;97,091&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,043&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;97,952&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,649&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities, current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,330&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,718&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,188&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,391&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;853&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,762&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock>
    <fgen:FinanceLeaseRightOfUseAssetsCost
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000852"
      unitRef="U_iso4217USD">2007000</fgen:FinanceLeaseRightOfUseAssetsCost>
    <fgen:FinanceLeaseRightOfUseAssetsCost
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000853"
      unitRef="U_iso4217USD">50477000</fgen:FinanceLeaseRightOfUseAssetsCost>
    <fgen:FinanceLeaseAccumulatedAmortization
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000854"
      unitRef="U_iso4217USD">1146000</fgen:FinanceLeaseAccumulatedAmortization>
    <fgen:FinanceLeaseAccumulatedAmortization
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000855"
      unitRef="U_iso4217USD">20871000</fgen:FinanceLeaseAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000856"
      unitRef="U_iso4217USD">861000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000857"
      unitRef="U_iso4217USD">29606000</us-gaap:FinanceLeaseRightOfUseAsset>
    <fgen:OperatingLeaseRightOfUseAssetsCost
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000858"
      unitRef="U_iso4217USD">100705000</fgen:OperatingLeaseRightOfUseAssetsCost>
    <fgen:OperatingLeaseRightOfUseAssetsCost
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000859"
      unitRef="U_iso4217USD">3934000</fgen:OperatingLeaseRightOfUseAssetsCost>
    <fgen:OperatingLeaseAccumulatedAmortization
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000860"
      unitRef="U_iso4217USD">3614000</fgen:OperatingLeaseAccumulatedAmortization>
    <fgen:OperatingLeaseAccumulatedAmortization
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000861"
      unitRef="U_iso4217USD">1891000</fgen:OperatingLeaseAccumulatedAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000862"
      unitRef="U_iso4217USD">97091000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000863"
      unitRef="U_iso4217USD">2043000</us-gaap:OperatingLeaseRightOfUseAsset>
    <fgen:FinanceLeaseAndOperatingLeaseAssets
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000864"
      unitRef="U_iso4217USD">97952000</fgen:FinanceLeaseAndOperatingLeaseAssets>
    <fgen:FinanceLeaseAndOperatingLeaseAssets
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000865"
      unitRef="U_iso4217USD">31649000</fgen:FinanceLeaseAndOperatingLeaseAssets>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000866"
      unitRef="U_iso4217USD">23000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000867"
      unitRef="U_iso4217USD">12330000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000868"
      unitRef="U_iso4217USD">10718000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000869"
      unitRef="U_iso4217USD">1188000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000870"
      unitRef="U_iso4217USD">6000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000871"
      unitRef="U_iso4217USD">25391000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000872"
      unitRef="U_iso4217USD">94196000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000873"
      unitRef="U_iso4217USD">853000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <fgen:FinanceLeaseAndOperatingLeaseLiability
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000874"
      unitRef="U_iso4217USD">104943000</fgen:FinanceLeaseAndOperatingLeaseLiability>
    <fgen:FinanceLeaseAndOperatingLeaseLiability
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000875"
      unitRef="U_iso4217USD">39762000</fgen:FinanceLeaseAndOperatingLeaseLiability>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210630"
      id="F_000876">P15Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <fgen:LesseeFinanceLeaseExpirationPeriod
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210101_20210630"
      id="F_000877">2023</fgen:LesseeFinanceLeaseExpirationPeriod>
    <fgen:LesseeFinanceLeaseAdditionalLeaseExpirationPeriod
      contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601"
      id="F_000879">2028</fgen:LesseeFinanceLeaseAdditionalLeaseExpirationPeriod>
    <us-gaap:LesseeFinanceLeaseOptionToExtend
      contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601"
      id="F_000881">Under the terms of the Lease Amendment, the Company has two optional rights to each extend the lease for an additional five years.</us-gaap:LesseeFinanceLeaseOptionToExtend>
    <fgen:NumberOfOptionalRightsToExtendLease
      contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601"
      decimals="INF"
      id="F_000882"
      unitRef="U_fgenOption">2</fgen:NumberOfOptionalRightsToExtendLease>
    <fgen:LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm
      contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601"
      id="F_000883">P5Y</fgen:LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm>
    <fgen:PercentageIncreasesOnEachAnniversaryOfRentCommencementDate
      contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601"
      decimals="2"
      id="F_000880"
      unitRef="U_xbrlipure">0.02</fgen:PercentageIncreasesOnEachAnniversaryOfRentCommencementDate>
    <fgen:ScheduledRentCommencementYearOptionOne
      contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601"
      id="F_000884">2023</fgen:ScheduledRentCommencementYearOptionOne>
    <fgen:PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo
      contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601"
      decimals="2"
      id="F_000885"
      unitRef="U_xbrlipure">0.03</fgen:PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo>
    <fgen:ScheduledRentCommencementYearOptionTwo
      contextRef="C_0000921299_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601_20210601"
      id="F_000886">2028</fgen:ScheduledRentCommencementYearOptionTwo>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601"
      decimals="-5"
      id="F_000887"
      unitRef="U_iso4217USD">24600000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601"
      decimals="-5"
      id="F_000888"
      unitRef="U_iso4217USD">32600000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601"
      decimals="-5"
      id="F_000889"
      unitRef="U_iso4217USD">93200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210601"
      decimals="-5"
      id="F_000890"
      unitRef="U_iso4217USD">101200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_us-gaapLeaseContractualTermAxis_fgenLeaseAmendmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210101_20210630"
      decimals="-5"
      id="F_000891"
      unitRef="U_iso4217USD">1100000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20210331"
      id="F_000892">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <fgen:LesseeOperatingLeaseExpirationPeriod
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20210101_20210331"
      id="F_000893">2026</fgen:LesseeOperatingLeaseExpirationPeriod>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20210331"
      decimals="-5"
      id="F_000894"
      unitRef="U_iso4217USD">3400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20210331"
      decimals="-5"
      id="F_000895"
      unitRef="U_iso4217USD">3400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000550">
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease expense were as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Statement of Operations Line Item&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of goods sold;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,777&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,653&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,393&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;242&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;534&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of goods sold;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,744&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,162&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;564&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(275&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(306&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(598&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.12%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,488&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,136&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,607&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,262&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000896"
      unitRef="U_iso4217USD">1777000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000897"
      unitRef="U_iso4217USD">2653000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000898"
      unitRef="U_iso4217USD">4393000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000899"
      unitRef="U_iso4217USD">5247000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000900"
      unitRef="U_iso4217USD">242000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000901"
      unitRef="U_iso4217USD">534000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000902"
      unitRef="U_iso4217USD">627000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000903"
      unitRef="U_iso4217USD">1049000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000904"
      unitRef="U_iso4217USD">1744000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000905"
      unitRef="U_iso4217USD">255000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000906"
      unitRef="U_iso4217USD">2162000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000907"
      unitRef="U_iso4217USD">564000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000908"
      unitRef="U_iso4217USD">275000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000909"
      unitRef="U_iso4217USD">306000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000910"
      unitRef="U_iso4217USD">575000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000911"
      unitRef="U_iso4217USD">598000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_000912"
      unitRef="U_iso4217USD">3488000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_000913"
      unitRef="U_iso4217USD">3136000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000914"
      unitRef="U_iso4217USD">6607000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000915"
      unitRef="U_iso4217USD">6262000</us-gaap:LeaseCost>
    <fgen:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000551">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental cash flow information related to leases were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,246&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;433&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows from finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;628&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,010&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing cash flows from finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,326&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,992&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-cash: Right-of-use assets obtained in exchange for new lease liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,498&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-cash: Increase (decrease) resulting from lease modification:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24,654&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93,222&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities, current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,587&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,221&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,009&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000916"
      unitRef="U_iso4217USD">2246000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000917"
      unitRef="U_iso4217USD">433000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000918"
      unitRef="U_iso4217USD">628000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000919"
      unitRef="U_iso4217USD">1010000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <fgen:RepaymentsOfFinanceLeaseLiabilities
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000920"
      unitRef="U_iso4217USD">5326000</fgen:RepaymentsOfFinanceLeaseLiabilities>
    <fgen:RepaymentsOfFinanceLeaseLiabilities
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000921"
      unitRef="U_iso4217USD">5992000</fgen:RepaymentsOfFinanceLeaseLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000922"
      unitRef="U_iso4217USD">303000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000923"
      unitRef="U_iso4217USD">144000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_000924"
      unitRef="U_iso4217USD">3498000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_000925"
      unitRef="U_iso4217USD">5000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20210630"
      decimals="-3"
      id="F_000926"
      unitRef="U_iso4217USD">24654000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20200630"
      decimals="-3"
      id="F_000927"
      unitRef="U_iso4217USD">0</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20210630"
      decimals="-3"
      id="F_000928"
      unitRef="U_iso4217USD">93222000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20200630"
      decimals="-3"
      id="F_000929"
      unitRef="U_iso4217USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20210630"
      decimals="-3"
      id="F_000930"
      unitRef="U_iso4217USD">12587000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20200630"
      decimals="-3"
      id="F_000931"
      unitRef="U_iso4217USD">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20210630"
      decimals="-3"
      id="F_000932"
      unitRef="U_iso4217USD">9221000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20200630"
      decimals="-3"
      id="F_000933"
      unitRef="U_iso4217USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20210630"
      decimals="-3"
      id="F_000934"
      unitRef="U_iso4217USD">20009000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20200630"
      decimals="-3"
      id="F_000935"
      unitRef="U_iso4217USD">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20210630"
      decimals="-3"
      id="F_000936"
      unitRef="U_iso4217USD">91943000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201901Member_20200630"
      decimals="-3"
      id="F_000937"
      unitRef="U_iso4217USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <fgen:ScheduleOfLeaseTermAndDiscountRateTableTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000552">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease term and discount rate were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term (years):&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000938"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000939"&gt;2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000940"&gt;7.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000941"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:ScheduleOfLeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0000921299_20210630"
      decimals="4"
      id="F_000942"
      unitRef="U_xbrlipure">0.0455</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0000921299_20201231"
      decimals="4"
      id="F_000943"
      unitRef="U_xbrlipure">0.0439</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0000921299_20210630"
      decimals="4"
      id="F_000944"
      unitRef="U_xbrlipure">0.0475</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0000921299_20201231"
      decimals="4"
      id="F_000945"
      unitRef="U_xbrlipure">0.0474</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <fgen:ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000553">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities of lease liabilities as of June&#160;30, 2021 are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance&#160;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&#160;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021 (remaining six month period)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,534&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,517&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,454&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beyond 2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,881&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125,377&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,463&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,914&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000946"
      unitRef="U_iso4217USD">16000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000955"
      unitRef="U_iso4217USD">7534000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000947"
      unitRef="U_iso4217USD">11000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000956"
      unitRef="U_iso4217USD">15517000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000948"
      unitRef="U_iso4217USD">3000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000957"
      unitRef="U_iso4217USD">13454000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000949"
      unitRef="U_iso4217USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000958"
      unitRef="U_iso4217USD">16798000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000950"
      unitRef="U_iso4217USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000959"
      unitRef="U_iso4217USD">18193000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <fgen:FinanceLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000951"
      unitRef="U_iso4217USD">0</fgen:FinanceLeaseLiabilityPaymentsDueAfterYearFour>
    <fgen:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000960"
      unitRef="U_iso4217USD">53881000</fgen:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000952"
      unitRef="U_iso4217USD">30000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000961"
      unitRef="U_iso4217USD">125377000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000953"
      unitRef="U_iso4217USD">1000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000962"
      unitRef="U_iso4217USD">20463000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000954"
      unitRef="U_iso4217USD">29000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000963"
      unitRef="U_iso4217USD">104914000</us-gaap:OperatingLeaseLiability>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000520">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Balance Sheet Components&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;130,035&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,046&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,699&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;353,361&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;678,393&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At June&#160;30, 2021 and December&#160;31, 2020, a total of $85.1 million and $66.0 million, respectively, of the Company&#x2019;s cash and cash equivalents were held outside of the U.S. in its foreign subsidiaries to be used primarily for its China operations.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Investments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s investments consist of available-for-sale debt investments and marketable equity investments. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#x2019;s investments by major investments type are summarized in the tables below (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&#160;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&#160;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,499&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,589&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,568&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,284&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,489&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,490&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;233&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;259,534&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(71&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;259,609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&#160;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&#160;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bond and mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,147&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,272&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,388&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At June&#160;30, 2021, the available-for-sale investments had contractual maturities range from several months to two years. During the three and six months ended June&#160;30, 2021 and 2020, the Company did not recognize any other-than-temporary impairment loss.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Inventories&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,190&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Work-in-progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,799&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventories&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,530&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,530&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes inventory costs for FibroGen Beijing&#x2019;s production of roxadustat for commercial sales purposes. The Company started capitalizing pre-launch inventory costs in the second quarter of 2020 prior to regulatory approvals in the U.S. and other territories. As of June&#160;30, 2021 and December&#160;31, 2020, pre-launch inventory capitalized was 37% and 29% of the total inventory balance, respectively. The provision to write-down excess and obsolete inventory was immaterial for three and six months ended June&#160;30, 2021 and 2020.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unbilled contract assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,256&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,147&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenues from associated contracts&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,256&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,147&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net unbilled contract assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,309&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,807&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,160&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The unbilled contract assets as of June 30, 2021 of $5.3 million related to unbilled co-development revenue under the China Amendment with AstraZeneca. The unbilled contract assets as of December 31, 2020 were related to unbilled co-development revenue under the China Amendment with AstraZeneca. See Note 2, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;, for details.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,657&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,006&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,387&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,312&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,545&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,126&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,407&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;147,029&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,894&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(116,359&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(111,247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,670&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,647&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accrued and Other Current Liabilities &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preclinical and clinical trial accruals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,274&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and related accruals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,047&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities to pharmaceutical distributors&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,793&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued co-promotion expenses - current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,832&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,537&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Roxadustat profit share to AstraZeneca&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property taxes and other taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,471&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,869&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,900&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;147,801&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The profit share liability of $7.0 million to AstraZeneca as of June 30, 2021 and December 31, 2020 represented the profit/loss share between FibroGen Beijing and AstraZeneca that was calculated for the interim period pursuant to the China Amendment. This liability correspondingly reduced the deferred revenue related to the performance obligation in accordance with the China Amendment.&lt;span style="font-weight:bold;color:#FF0000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Other Long-term Liabilities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other long-term liabilities consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued long-term co-promotion expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,424&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other long-term tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,985&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,469&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,690&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other long-term liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,659&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,789&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000554">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;130,035&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,046&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,699&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;353,361&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;678,393&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:Cash
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000964"
      unitRef="U_iso4217USD">130035000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000965"
      unitRef="U_iso4217USD">88046000</us-gaap:Cash>
    <us-gaap:CommercialPaperAtCarryingValue
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000966"
      unitRef="U_iso4217USD">2699000</us-gaap:CommercialPaperAtCarryingValue>
    <us-gaap:CommercialPaperAtCarryingValue
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000967"
      unitRef="U_iso4217USD">0</us-gaap:CommercialPaperAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000968"
      unitRef="U_iso4217USD">220627000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000969"
      unitRef="U_iso4217USD">590347000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000970"
      unitRef="U_iso4217USD">353361000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000971"
      unitRef="U_iso4217USD">678393000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000921299_us-gaapGeographicDistributionAxis_us-gaapGeographicDistributionForeignMember_20210630"
      decimals="-5"
      id="F_000972"
      unitRef="U_iso4217USD">85100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000921299_us-gaapGeographicDistributionAxis_us-gaapGeographicDistributionForeignMember_20201231"
      decimals="-5"
      id="F_000973"
      unitRef="U_iso4217USD">66000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000555">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s investments consist of available-for-sale debt investments and marketable equity investments. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#x2019;s investments by major investments type are summarized in the tables below (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&#160;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&#160;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,499&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,589&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,568&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,284&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,489&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,490&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;233&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;259,534&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(71&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;259,609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&#160;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&#160;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bond and mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,147&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,272&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,388&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630"
      decimals="-3"
      id="F_000974"
      unitRef="U_iso4217USD">104499000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630"
      decimals="-3"
      id="F_000985"
      unitRef="U_iso4217USD">27000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630"
      decimals="-3"
      id="F_000996"
      unitRef="U_iso4217USD">43000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20210630"
      decimals="-3"
      id="F_001007"
      unitRef="U_iso4217USD">104483000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630"
      decimals="-3"
      id="F_000975"
      unitRef="U_iso4217USD">69400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630"
      decimals="-3"
      id="F_000986"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630"
      decimals="-3"
      id="F_000997"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20210630"
      decimals="-3"
      id="F_001008"
      unitRef="U_iso4217USD">69400000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210630"
      decimals="-3"
      id="F_000976"
      unitRef="U_iso4217USD">46589000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210630"
      decimals="-3"
      id="F_000987"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210630"
      decimals="-3"
      id="F_000998"
      unitRef="U_iso4217USD">21000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210630"
      decimals="-3"
      id="F_001009"
      unitRef="U_iso4217USD">46568000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapBondsMember_20210630"
      decimals="-3"
      id="F_000977"
      unitRef="U_iso4217USD">14288000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapBondsMember_20210630"
      decimals="-3"
      id="F_000988"
      unitRef="U_iso4217USD">2000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapBondsMember_20210630"
      decimals="-3"
      id="F_000999"
      unitRef="U_iso4217USD">6000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapBondsMember_20210630"
      decimals="-3"
      id="F_001010"
      unitRef="U_iso4217USD">14284000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630"
      decimals="-3"
      id="F_000978"
      unitRef="U_iso4217USD">12489000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630"
      decimals="-3"
      id="F_000989"
      unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630"
      decimals="-3"
      id="F_001000"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20210630"
      decimals="-3"
      id="F_001011"
      unitRef="U_iso4217USD">12490000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630"
      decimals="-3"
      id="F_000979"
      unitRef="U_iso4217USD">12151000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630"
      decimals="-3"
      id="F_000990"
      unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630"
      decimals="-3"
      id="F_001001"
      unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630"
      decimals="-3"
      id="F_001012"
      unitRef="U_iso4217USD">12151000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630"
      decimals="-3"
      id="F_000980"
      unitRef="U_iso4217USD">118000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630"
      decimals="-3"
      id="F_000991"
      unitRef="U_iso4217USD">115000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630"
      decimals="-3"
      id="F_001002"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630"
      decimals="-3"
      id="F_001013"
      unitRef="U_iso4217USD">233000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000981"
      unitRef="U_iso4217USD">259534000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_000992"
      unitRef="U_iso4217USD">146000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001003"
      unitRef="U_iso4217USD">71000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001014"
      unitRef="U_iso4217USD">259609000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231"
      decimals="-3"
      id="F_000982"
      unitRef="U_iso4217USD">8147000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231"
      decimals="-3"
      id="F_000993"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231"
      decimals="-3"
      id="F_001004"
      unitRef="U_iso4217USD">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231"
      decimals="-3"
      id="F_001015"
      unitRef="U_iso4217USD">8144000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_000983"
      unitRef="U_iso4217USD">125000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_000994"
      unitRef="U_iso4217USD">119000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_001005"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_001016"
      unitRef="U_iso4217USD">244000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000984"
      unitRef="U_iso4217USD">8272000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000995"
      unitRef="U_iso4217USD">119000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001006"
      unitRef="U_iso4217USD">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001017"
      unitRef="U_iso4217USD">8388000</us-gaap:AvailableForSaleSecurities>
    <fgen:AvailableForSaleSecuritiesContractualMaturityPeriod
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_20210101_20210630"
      id="F_001018">P2Y</fgen:AvailableForSaleSecuritiesContractualMaturityPeriod>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
      contextRef="C_0000921299_20210101_20210630"
      decimals="INF"
      id="F_001019"
      unitRef="U_iso4217USD">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
      contextRef="C_0000921299_20210401_20210630"
      decimals="INF"
      id="F_001020"
      unitRef="U_iso4217USD">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000556">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,190&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Work-in-progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,799&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventories&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,530&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,530&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001021"
      unitRef="U_iso4217USD">1190000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001022"
      unitRef="U_iso4217USD">2303000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001023"
      unitRef="U_iso4217USD">15541000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001024"
      unitRef="U_iso4217USD">8114000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001025"
      unitRef="U_iso4217USD">7799000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001026"
      unitRef="U_iso4217USD">6113000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001027"
      unitRef="U_iso4217USD">24530000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001028"
      unitRef="U_iso4217USD">16530000</us-gaap:InventoryNet>
    <fgen:PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance
      contextRef="C_0000921299_20210630"
      decimals="2"
      id="F_001029"
      unitRef="U_xbrlipure">0.37</fgen:PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance>
    <fgen:PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance
      contextRef="C_0000921299_20201231"
      decimals="2"
      id="F_001030"
      unitRef="U_xbrlipure">0.29</fgen:PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000557">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unbilled contract assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,256&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,147&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenues from associated contracts&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,256&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,147&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net unbilled contract assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,309&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,807&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,160&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:Supplies
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001031"
      unitRef="U_iso4217USD">5256000</us-gaap:Supplies>
    <us-gaap:Supplies
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001032"
      unitRef="U_iso4217USD">2147000</us-gaap:Supplies>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001033"
      unitRef="U_iso4217USD">5256000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001034"
      unitRef="U_iso4217USD">2147000</us-gaap:ContractWithCustomerLiability>
    <fgen:SuppliesNet
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001035"
      unitRef="U_iso4217USD">0</fgen:SuppliesNet>
    <fgen:SuppliesNet
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001036"
      unitRef="U_iso4217USD">0</fgen:SuppliesNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001037"
      unitRef="U_iso4217USD">7149000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001038"
      unitRef="U_iso4217USD">8353000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001039"
      unitRef="U_iso4217USD">1309000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001040"
      unitRef="U_iso4217USD">1807000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001041"
      unitRef="U_iso4217USD">8458000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001042"
      unitRef="U_iso4217USD">10160000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <fgen:SuppliesNet
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-5"
      id="F_001043"
      unitRef="U_iso4217USD">5300000</fgen:SuppliesNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000558">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,657&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,006&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,387&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,312&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,545&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,126&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,407&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;147,029&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,894&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(116,359&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(111,247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,670&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,647&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210630"
      decimals="-3"
      id="F_001044"
      unitRef="U_iso4217USD">102657000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_001045"
      unitRef="U_iso4217USD">102006000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20210630"
      decimals="-3"
      id="F_001046"
      unitRef="U_iso4217USD">19247000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20201231"
      decimals="-3"
      id="F_001047"
      unitRef="U_iso4217USD">18143000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20210630"
      decimals="-3"
      id="F_001048"
      unitRef="U_iso4217USD">8387000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20201231"
      decimals="-3"
      id="F_001049"
      unitRef="U_iso4217USD">8312000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210630"
      decimals="-3"
      id="F_001050"
      unitRef="U_iso4217USD">9205000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231"
      decimals="-3"
      id="F_001051"
      unitRef="U_iso4217USD">9545000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210630"
      decimals="-3"
      id="F_001052"
      unitRef="U_iso4217USD">6126000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231"
      decimals="-3"
      id="F_001053"
      unitRef="U_iso4217USD">6128000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20210630"
      decimals="-3"
      id="F_001054"
      unitRef="U_iso4217USD">1407000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231"
      decimals="-3"
      id="F_001055"
      unitRef="U_iso4217USD">760000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001056"
      unitRef="U_iso4217USD">147029000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001057"
      unitRef="U_iso4217USD">144894000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001058"
      unitRef="U_iso4217USD">116359000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001059"
      unitRef="U_iso4217USD">111247000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001060"
      unitRef="U_iso4217USD">30670000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001061"
      unitRef="U_iso4217USD">33647000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000559">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preclinical and clinical trial accruals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,274&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and related accruals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,047&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities to pharmaceutical distributors&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,793&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued co-promotion expenses - current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,832&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,537&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Roxadustat profit share to AstraZeneca&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property taxes and other taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,471&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,869&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,900&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;147,801&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <fgen:AccruedPreclinicalAndClinicalTrialCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001062"
      unitRef="U_iso4217USD">65274000</fgen:AccruedPreclinicalAndClinicalTrialCurrent>
    <fgen:AccruedPreclinicalAndClinicalTrialCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001063"
      unitRef="U_iso4217USD">44113000</fgen:AccruedPreclinicalAndClinicalTrialCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001064"
      unitRef="U_iso4217USD">18047000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001065"
      unitRef="U_iso4217USD">22800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <fgen:AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001066"
      unitRef="U_iso4217USD">13793000</fgen:AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent>
    <fgen:AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001067"
      unitRef="U_iso4217USD">15137000</fgen:AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent>
    <fgen:AccruedCoPromotionExpensesCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001068"
      unitRef="U_iso4217USD">20832000</fgen:AccruedCoPromotionExpensesCurrent>
    <fgen:AccruedCoPromotionExpensesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001069"
      unitRef="U_iso4217USD">11537000</fgen:AccruedCoPromotionExpensesCurrent>
    <fgen:AccruedProfitShareCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001070"
      unitRef="U_iso4217USD">7007000</fgen:AccruedProfitShareCurrent>
    <fgen:AccruedProfitShareCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001071"
      unitRef="U_iso4217USD">7007000</fgen:AccruedProfitShareCurrent>
    <fgen:PropertyTaxesAndOtherCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001072"
      unitRef="U_iso4217USD">10344000</fgen:PropertyTaxesAndOtherCurrent>
    <fgen:PropertyTaxesAndOtherCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001073"
      unitRef="U_iso4217USD">5970000</fgen:PropertyTaxesAndOtherCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001074"
      unitRef="U_iso4217USD">7471000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001075"
      unitRef="U_iso4217USD">4869000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001076"
      unitRef="U_iso4217USD">5033000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001077"
      unitRef="U_iso4217USD">6900000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001078"
      unitRef="U_iso4217USD">147801000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001079"
      unitRef="U_iso4217USD">118333000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630"
      decimals="-5"
      id="F_001080"
      unitRef="U_iso4217USD">7000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-5"
      id="F_001081"
      unitRef="U_iso4217USD">7000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000560">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other long-term liabilities consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&#160;30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued long-term co-promotion expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,424&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other long-term tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,985&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,469&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,690&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other long-term liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,659&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,789&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <fgen:AccruedLongTermCoPromotionLiabilityNonCurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001082"
      unitRef="U_iso4217USD">19205000</fgen:AccruedLongTermCoPromotionLiabilityNonCurrent>
    <fgen:AccruedLongTermCoPromotionLiabilityNonCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001083"
      unitRef="U_iso4217USD">27424000</fgen:AccruedLongTermCoPromotionLiabilityNonCurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001084"
      unitRef="U_iso4217USD">8985000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001085"
      unitRef="U_iso4217USD">8675000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001086"
      unitRef="U_iso4217USD">2469000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001087"
      unitRef="U_iso4217USD">2690000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0000921299_20210630"
      decimals="-3"
      id="F_001088"
      unitRef="U_iso4217USD">30659000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001089"
      unitRef="U_iso4217USD">38789000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000521">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense was recorded directly to research and development and selling, general and administrative expense as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,681&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,780&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,903&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,417&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,320&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,864&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,001&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,385&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,560&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used to estimate the fair value of stock options granted and purchases under the Company&#x2019;s 2014 Employee Share Purchase Plan (&#x201c;ESPP&#x201d;) using the Black-Scholes option valuation model were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001102"&gt;5.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001103"&gt;5.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001104"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001105"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average estimated fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25.38&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;ESPPs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001122"&gt;0.5 - 2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001123"&gt;0.5 - 2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001124"&gt;0.5 - 2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001125"&gt;0.5 - 2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47.5 - 104.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49.5 - 77.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47.5 - 104.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49.5 - 77.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0 - 2.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2 - 2.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0 - 2.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2 - 2.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average estimated fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.82&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.69&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000561">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense was recorded directly to research and development and selling, general and administrative expense as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,681&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,780&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,903&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,417&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,320&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,864&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,001&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,385&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,560&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210401_20210630"
      decimals="-3"
      id="F_001090"
      unitRef="U_iso4217USD">10681000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200401_20200630"
      decimals="-3"
      id="F_001091"
      unitRef="U_iso4217USD">10780000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210630"
      decimals="-3"
      id="F_001092"
      unitRef="U_iso4217USD">22903000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200630"
      decimals="-3"
      id="F_001093"
      unitRef="U_iso4217USD">21417000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210401_20210630"
      decimals="-3"
      id="F_001094"
      unitRef="U_iso4217USD">8320000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200401_20200630"
      decimals="-3"
      id="F_001095"
      unitRef="U_iso4217USD">6864000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210630"
      decimals="-3"
      id="F_001096"
      unitRef="U_iso4217USD">15482000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20200630"
      decimals="-3"
      id="F_001097"
      unitRef="U_iso4217USD">13143000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_20210401_20210630"
      decimals="-3"
      id="F_001098"
      unitRef="U_iso4217USD">19001000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_20200401_20200630"
      decimals="-3"
      id="F_001099"
      unitRef="U_iso4217USD">17644000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_20210101_20210630"
      decimals="-3"
      id="F_001100"
      unitRef="U_iso4217USD">38385000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_20200101_20200630"
      decimals="-3"
      id="F_001101"
      unitRef="U_iso4217USD">34560000</us-gaap:AllocatedShareBasedCompensationExpense>
    <fgen:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000562">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used to estimate the fair value of stock options granted and purchases under the Company&#x2019;s 2014 Employee Share Purchase Plan (&#x201c;ESPP&#x201d;) using the Black-Scholes option valuation model were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001102"&gt;5.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001103"&gt;5.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001104"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001105"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average estimated fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25.38&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;ESPPs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001122"&gt;0.5 - 2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001123"&gt;0.5 - 2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001124"&gt;0.5 - 2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001125"&gt;0.5 - 2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47.5 - 104.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49.5 - 77.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47.5 - 104.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49.5 - 77.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0 - 2.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2 - 2.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0 - 2.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2 - 2.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average estimated fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.82&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.69&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210401_20210630"
      decimals="3"
      id="F_001106"
      unitRef="U_xbrlipure">0.634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200401_20200630"
      decimals="3"
      id="F_001107"
      unitRef="U_xbrlipure">0.692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630"
      decimals="3"
      id="F_001108"
      unitRef="U_xbrlipure">0.594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200630"
      decimals="3"
      id="F_001109"
      unitRef="U_xbrlipure">0.684</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210401_20210630"
      decimals="3"
      id="F_001110"
      unitRef="U_xbrlipure">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200401_20200630"
      decimals="3"
      id="F_001111"
      unitRef="U_xbrlipure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630"
      decimals="3"
      id="F_001112"
      unitRef="U_xbrlipure">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200630"
      decimals="3"
      id="F_001113"
      unitRef="U_xbrlipure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210401_20210630"
      decimals="2"
      id="F_001114"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200401_20200630"
      decimals="2"
      id="F_001115"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630"
      decimals="2"
      id="F_001116"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200630"
      decimals="2"
      id="F_001117"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210401_20210630"
      decimals="2"
      id="F_001118"
      unitRef="U_iso4217USD_xbrlishares">11.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200401_20200630"
      decimals="2"
      id="F_001119"
      unitRef="U_iso4217USD_xbrlishares">21.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630"
      decimals="2"
      id="F_001120"
      unitRef="U_iso4217USD_xbrlishares">25.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200630"
      decimals="2"
      id="F_001121"
      unitRef="U_iso4217USD_xbrlishares">17.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630"
      decimals="2"
      id="F_001146"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630"
      decimals="2"
      id="F_001147"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630"
      decimals="2"
      id="F_001148"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630"
      decimals="2"
      id="F_001149"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210401_20210630"
      decimals="2"
      id="F_001150"
      unitRef="U_iso4217USD_xbrlishares">13.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200401_20200630"
      decimals="2"
      id="F_001151"
      unitRef="U_iso4217USD_xbrlishares">17.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20210630"
      decimals="2"
      id="F_001152"
      unitRef="U_iso4217USD_xbrlishares">14.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20200630"
      decimals="2"
      id="F_001153"
      unitRef="U_iso4217USD_xbrlishares">18.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000522">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Income Taxes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision for (benefit from) income tax for the three and six months ended June 30, 2021 were primarily due to foreign taxes. Provision for (benefit from) income tax for the three and six months ended June 30, 2020 were primarily due to the tax effect arising from other comprehensive income related to available-for-sale securities, and foreign taxes.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based upon the weight of available evidence, which includes its historical operating performance, reported cumulative net losses since inception, the Company has established and continues to maintain a full valuation allowance against its net deferred tax assets as it does not currently believe that realization of those assets is more likely than not.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000523">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Related Party Transactions &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas is an equity investor in the Company and is considered a related party. The Company recorded revenue related to collaboration agreements with Astellas of $2.6 million and $4.8 million for the three months ended June 30, 2021 and 2020, and $6.3 million and $9.5 million for the six months ended June&#160;30, 2021 and 2020, respectively. The Company also recorded drug product revenue from Astellas of $(2.0) million and $8.2 million for the three months ended June 30, 2021 and 2020, and $2.1 million and $8.2 million for the six months ended June&#160;30, 2021 and 2020, respectively. See Note 2, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;, for details.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s expense related to collaboration agreements with Astellas was immaterial for each of the three and six months ended June 30, 2021 and 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June&#160;30, 2021 and December&#160;31, 2020, accounts receivable from Astellas were $2.6&#160;million and $4.1&#160;million, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June&#160;30, 2021 and December&#160;31, 2020, total deferred revenue from Astellas was $20.1&#160;million and $7.5&#160;million, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June 30, 2021, the amount due to Astellas was immaterial. As of December&#160;31, 2020, amount due to Astellas was $1.1&#160;million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Falikang, an entity jointly owned by FibroGen Beijing and AstraZeneca is an unconsolidated VIE accounted for as an equity method investment, and considered as a related party to the Company. FibroGen Beijing owns 51.1% of Falikang&#x2019;s equity. See Note 3, &lt;span style="font-style:italic;"&gt;Variable Interest Entity&lt;/span&gt;, for details. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the three and six months ended June&#160;30, 2021, the net product revenue from Falikang was $11.8 million and $22.2 million, respectively. See Note 2, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;, for details.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the three and six months ended June&#160;30, 2021, the investment income in Falikang was $0.6 million and $0.3 million, respectively. As of June&#160;30, 2021 and December&#160;31, 2020, the Company&#x2019;s equity method investment in Falikang was $3.1 million and $2.7 million, respectively. See Note 3, &lt;span style="font-style:italic;"&gt;Variable Interest Entity&lt;/span&gt;, for details.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June&#160;30, 2021, accounts receivable, net, from Falikang was of $10.8 million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June&#160;30, 2021, there was no miscellaneous receivables from Falikang. As of December&#160;31, 2020, prepaid expenses and other current assets included miscellaneous receivables from Falikang of $0.9 million.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210401_20210630"
      decimals="-5"
      id="F_001154"
      unitRef="U_iso4217USD">2600000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200401_20200630"
      decimals="-5"
      id="F_001155"
      unitRef="U_iso4217USD">4800000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20210630"
      decimals="-5"
      id="F_001156"
      unitRef="U_iso4217USD">6300000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20200630"
      decimals="-5"
      id="F_001157"
      unitRef="U_iso4217USD">9500000</us-gaap:RevenueFromRelatedParties>
    <fgen:DrugProductRevenueFromRelatedParty
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20210401_20210630"
      decimals="-5"
      id="F_001158"
      unitRef="U_iso4217USD">-2000000.0</fgen:DrugProductRevenueFromRelatedParty>
    <fgen:DrugProductRevenueFromRelatedParty
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200401_20200630"
      decimals="-5"
      id="F_001159"
      unitRef="U_iso4217USD">8200000</fgen:DrugProductRevenueFromRelatedParty>
    <fgen:DrugProductRevenueFromRelatedParty
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20210101_20210630"
      decimals="-5"
      id="F_001160"
      unitRef="U_iso4217USD">2100000</fgen:DrugProductRevenueFromRelatedParty>
    <fgen:DrugProductRevenueFromRelatedParty
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200101_20200630"
      decimals="-5"
      id="F_001161"
      unitRef="U_iso4217USD">8200000</fgen:DrugProductRevenueFromRelatedParty>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210630"
      decimals="-5"
      id="F_001162"
      unitRef="U_iso4217USD">2600000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231"
      decimals="-5"
      id="F_001163"
      unitRef="U_iso4217USD">4100000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210630"
      decimals="-5"
      id="F_001165"
      unitRef="U_iso4217USD">20100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231"
      decimals="-5"
      id="F_001166"
      unitRef="U_iso4217USD">7500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231"
      decimals="-5"
      id="F_001164"
      unitRef="U_iso4217USD">1100000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210101_20210630"
      decimals="3"
      id="F_001171"
      unitRef="U_xbrlipure">0.511</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210401_20210630"
      decimals="-5"
      id="F_001174"
      unitRef="U_iso4217USD">11800000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20210630"
      decimals="-5"
      id="F_001175"
      unitRef="U_iso4217USD">22200000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210401_20210630"
      decimals="-5"
      id="F_001167"
      unitRef="U_iso4217USD">-600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210101_20210630"
      decimals="-5"
      id="F_001168"
      unitRef="U_iso4217USD">-300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210630"
      decimals="-5"
      id="F_001169"
      unitRef="U_iso4217USD">3100000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20201231"
      decimals="-5"
      id="F_001170"
      unitRef="U_iso4217USD">2700000</us-gaap:EquityMethodInvestments>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210630"
      decimals="-5"
      id="F_001176"
      unitRef="U_iso4217USD">10800000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <fgen:MiscellaneousReceivables
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20210630"
      decimals="INF"
      id="F_001172"
      unitRef="U_iso4217USD">0</fgen:MiscellaneousReceivables>
    <fgen:MiscellaneousReceivables
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20201231"
      decimals="-5"
      id="F_001173"
      unitRef="U_iso4217USD">900000</fgen:MiscellaneousReceivables>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000524">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.&lt;span style="margin-left:36pt;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contract Obligations &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June&#160;30, 2021, the Company had outstanding total non-cancelable purchase obligations of $81.9 million, including $29.6 million for manufacture and supply of roxadustat, $47.3 million for manufacture and supply of pamrevlumab, and $5.0 million for other purchases. The Company expects to fulfill our commitments under these agreements in the normal course of business, and as such, no liability has been recorded. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Some of the Company&#x2019;s license agreements provide for periodic maintenance fees over specified time periods, as well as payments by the Company upon the achievement of development, regulatory and commercial milestones. As of June 30, 2021, future milestone payments for research and pre-clinical stage development programs consisted of up to approximately $359.2 million in total potential future milestone payments under the Company&#x2019;s license agreements with HiFiBiO (for Galectin-9), Medarex, Inc. and others. These milestone payments generally become due and payable only upon the achievement of certain developmental, clinical, regulatory and/or commercial milestones. The event triggering such payment or obligation has not yet occurred.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Legal Proceedings&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, the Company is a party to various legal actions, both inside and outside the U.S., arising in the ordinary course of its business or otherwise. The Company accrues amounts, to the extent they can be reasonably estimated, that the Company believes will result in a probable loss (including, among other things, probable settlement value), to adequately address any liabilities related to legal proceedings and other loss contingencies. A loss or a range of loss is disclosed when it is reasonably possible that a material loss will incur and can be estimated, or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company did not have material accruals for any currently active legal action in its condensed consolidated balance sheets as of June&#160;30, 2021, as it could not predict the ultimate outcome of these matters, or reasonably estimate the potential exposure. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2021, three putative securities class action complaints were filed against FibroGen and certain of its current and former executive officers (collectively, the &#x201c;Defendants&#x201d;) in the U.S. District Court for the Northern District of California. The lawsuits allege that Defendants violated the Securities Exchange Act of 1934 by making materially false and misleading statements regarding FibroGen&#x2019;s Phase 3 clinical studies data and prospects for FDA approval between November 2019 and December 2020. Plaintiffs seek to represent a class of persons or entities that purchased FibroGen securities between November 8, 2019 and April 6, 2021. In May 2021, two additional putative securities class action complaints were filed against Defendants alleging the same claims. One of the lawsuits alleges that Defendants made materially false and misleading statements between October 2017 and December 2020 and seeks to represent a class of persons or entities that purchased FibroGen securities between October 18, 2017 and April 6, 2021. The other lawsuit alleges that Defendants made materially false and misleading statements between December 2018 and February 2020 and seeks to represent a class of persons or entities that purchased FibroGen securities between December 20, 2018 and April 6, 2021. All plaintiffs seek unspecified monetary damages and other relief. Motions for lead plaintiff were filed on June 11, 2021 and a hearing on the motion is scheduled for August 19, 2021. Once a lead plaintiff is appointed by the Court, the Company expects to receive an amended consolidated complaint. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 30, 2021, a purported shareholder derivative complaint was filed in the U.S. District Court for the Northern District of California.&#160;The complaint names as defendants ten of the Company&#x2019;s officers and directors, as well as the Company as nominal defendant, and asserts state and federal claims based on some of the same alleged misstatements as the securities class action complaints.&#160;The complaint seeks unspecified damages, attorneys&#x2019; fees, and other costs.&#160;The Company and individual defendants have not yet been served.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company believes that the claims are without merit and it intends to vigorously defend against them. However, any litigation is inherently uncertain, and any judgment or injunctive relief entered against FibroGen or any adverse settlement could materially and adversely impact its business, results of operations, financial condition, and prospects.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Indemnification Agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into standard indemnification arrangements in the ordinary course of business, including for example, service, manufacturing and collaboration agreements. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, including in connection with intellectual property infringement claims by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the extent permissible under applicable law. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these arrangements is minimal.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="C_0000921299_20210630"
      decimals="-5"
      id="F_001177"
      unitRef="U_iso4217USD">81900000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfRoxadustatMember_20210630"
      decimals="-5"
      id="F_001178"
      unitRef="U_iso4217USD">29600000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfPamrevlumabMember_20210630"
      decimals="-5"
      id="F_001179"
      unitRef="U_iso4217USD">47300000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenOtherPurchasesMember_20210630"
      decimals="-5"
      id="F_001180"
      unitRef="U_iso4217USD">5000000.0</us-gaap:ContractualObligation>
    <fgen:MaximumFutureMilestonePayments
      contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenResearchAndPreClinicalStageDevelopmentProgramsMember_20210101_20210630"
      decimals="-5"
      id="F_001181"
      unitRef="U_iso4217USD">359200000</fgen:MaximumFutureMilestonePayments>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="C_0000921299_20210401_20210430"
      decimals="INF"
      id="F_001182"
      unitRef="U_fgenPutativeClassAction">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="C_0000921299_20210501_20210531"
      decimals="INF"
      id="F_001183"
      unitRef="U_fgenPutativeClassAction">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0000921299_20210101_20210630" id="F_000525">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.&lt;span style="margin-left:36pt;"&gt;Subsequent Event&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Outcome of FDA Advisory Committee Review &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 15, 2021, the FDA CRDAC voted to recommend not approving roxadustat for the treatment of anemia due to CKD in adult patients. While the FDA is not required to follow the CRDAC&#x2019;s vote, the agency considers the CRDAC&#x2019;s non-binding recommendations when making its decision.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluated this subsequent event and concluded that it required adjustment and disclosure in the condensed consolidated financial statements, specifically to the drug product revenue related the bulk drug product shipments to AstraZeneca as commercial supply under the terms of the Master Supply Agreement. As a result, the Company recorded $11.2 million as deferred revenue as of June 30, 2021. See Note 2, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;, for details. &lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;License Agreement with Eluminex&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 19, 2021, Eluminex Biosciences (Suzhou) Limited (&#x201c;Eluminex&#x201d;), an ophthalmology-focused biotechnology company headquartered in Suzhou, China with a US-subsidiary office in San Francisco Bay Area, California, exclusively licensed global rights from FibroGen, Inc. for the development and commercialization of an investigational biosynthetic cornea derived from recombinant human collagen Type III intended to treat patients with corneal blindness.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the agreement, Eluminex will make an $8 million upfront payment to FibroGen. In addition, FibroGen may receive up to a total of $64 million in future manufacturing, clinical, regulatory, and commercial milestone payments for the biosynthetic cornea program, as well as $36 million in commercial milestones for the first recombinant collagen III product that is not the biosynthetic cornea. FibroGen will also be eligible to receive &lt;span style="color:#000000;"&gt;mid single-digit to low double-digit&lt;/span&gt; royalties based upon worldwide net sales&lt;span style="color:#000000;"&gt; of cornea products, and low single-digit to mid single-digit royalties based upon worldwide net sales of other recombinant human collagen type III products that are not cornea products&lt;/span&gt;.&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210630"
      decimals="-5"
      id="F_001184"
      unitRef="U_iso4217USD">11200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <fgen:CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments
      contextRef="C_0000921299_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenLicenseAgreementWithEluminexMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210719"
      decimals="-6"
      id="F_001185"
      unitRef="U_iso4217USD">8000000</fgen:CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments>
    <fgen:FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments
      contextRef="C_0000921299_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenLicenseAgreementWithEluminexMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210719_20210719"
      decimals="-6"
      id="F_001186"
      unitRef="U_iso4217USD">64000000</fgen:FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments>
    <fgen:CommercialMilestone
      contextRef="C_0000921299_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenLicenseAgreementWithEluminexMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210719_20210719"
      decimals="-6"
      id="F_001187"
      unitRef="U_iso4217USD">36000000</fgen:CommercialMilestone>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449255089432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FGEN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FIBROGEN, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0357827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">409 Illinois Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">978-1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,621,941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449182568504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 353,361<span></span>
</td>
<td class="nump">$ 678,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">153,851<span></span>
</td>
<td class="nump">8,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net ($13,352 and $4,127 from related parties)</a></td>
<td class="nump">24,266<span></span>
</td>
<td class="nump">41,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">24,530<span></span>
</td>
<td class="nump">16,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets ($0 and $889 from related parties)</a></td>
<td class="nump">8,458<span></span>
</td>
<td class="nump">10,160<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">564,466<span></span>
</td>
<td class="nump">755,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RestrictedTimeDepositsNoncurrent', window );">Restricted time deposits</a></td>
<td class="nump">2,072<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">105,758<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">30,670<span></span>
</td>
<td class="nump">33,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">29,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity', window );">Equity method investment in unconsolidated variable interest entity</a></td>
<td class="nump">3,083<span></span>
</td>
<td class="nump">2,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">97,091<span></span>
</td>
<td class="nump">2,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,617<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">808,618<span></span>
</td>
<td class="nump">826,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable ($0 and $1,118 to a related party)</a></td>
<td class="nump">48,988<span></span>
</td>
<td class="nump">24,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other current liabilities ($14 and $24 to a related party)</a></td>
<td class="nump">147,801<span></span>
</td>
<td class="nump">118,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue ($10,699 and $2,907 to a related party)</a></td>
<td class="nump">25,234<span></span>
</td>
<td class="nump">6,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">12,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">10,718<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">232,764<span></span>
</td>
<td class="nump">163,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedProductDevelopmentCosts', window );">Product development obligations</a></td>
<td class="nump">18,277<span></span>
</td>
<td class="nump">18,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current ($9,381 and $4,636 to a related party)</a></td>
<td class="nump">152,865<span></span>
</td>
<td class="nump">138,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, non-current</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">25,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">94,196<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">30,659<span></span>
</td>
<td class="nump">38,789<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">528,767<span></span>
</td>
<td class="nump">385,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at June 30, 2021, and December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 225,000 shares authorized at June 30, 2021, and December 31, 2020; 92,609 and 91,441 shares issued and outstanding at June 30, 2021, and December 31, 2020</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,443,975<span></span>
</td>
<td class="nump">1,399,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,567)<span></span>
</td>
<td class="num">(4,499)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,179,754)<span></span>
</td>
<td class="num">(974,011)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">260,580<span></span>
</td>
<td class="nump">422,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="nump">19,271<span></span>
</td>
<td class="nump">19,271<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">279,851<span></span>
</td>
<td class="nump">441,449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, stockholders&#8217; equity and non-controlling interests</a></td>
<td class="nump">$ 808,618<span></span>
</td>
<td class="nump">$ 826,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedProductDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the long-term portion of the outstanding principal and accrued interest of advances in the form note agreements received by the entity to fund various product development efforts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedProductDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment in unconsolidated variable interest entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RestrictedTimeDepositsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted time deposits noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RestrictedTimeDepositsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449182053944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from related parties</a></td>
<td class="nump">$ 13,352<span></span>
</td>
<td class="nump">$ 4,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Prepaid expenses and other current assets from related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable to related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accrued and other current liabilities to related party</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DueToRelatedPartiesDeferredRevenueCurrent', window );">Deferred revenue current to related party</a></td>
<td class="nump">10,699<span></span>
</td>
<td class="nump">2,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DueToRelatedPartiesDeferredRevenueNoncurrent', window );">Deferred revenue non-current to related party</a></td>
<td class="nump">$ 9,381<span></span>
</td>
<td class="nump">$ 4,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">225,000,000<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">92,609,000<span></span>
</td>
<td class="nump">91,441,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">92,609,000<span></span>
</td>
<td class="nump">91,441,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DueToRelatedPartiesDeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due to related parties deferred revenue current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DueToRelatedPartiesDeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DueToRelatedPartiesDeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due to related parties deferred revenue noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DueToRelatedPartiesDeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449182066408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 24,364<span></span>
</td>
<td class="nump">$ 42,888<span></span>
</td>
<td class="nump">$ 62,793<span></span>
</td>
<td class="nump">$ 67,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CostOfGoodsAndServicesSoldOperatingExpense', window );">Cost of goods sold</a></td>
<td class="nump">$ 3,078<span></span>
</td>
<td class="nump">$ 3,076<span></span>
</td>
<td class="nump">$ 6,479<span></span>
</td>
<td class="nump">$ 4,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList', window );">Cost, Product and Service [Extensible List]</a></td>
<td class="text">Product Revenue, Net [Member]<span></span>
</td>
<td class="text">Product Revenue, Net [Member]<span></span>
</td>
<td class="text">Product Revenue, Net [Member]<span></span>
</td>
<td class="text">Product Revenue, Net [Member]<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 122,567<span></span>
</td>
<td class="nump">$ 61,414<span></span>
</td>
<td class="nump">$ 197,243<span></span>
</td>
<td class="nump">$ 116,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">32,554<span></span>
</td>
<td class="nump">63,535<span></span>
</td>
<td class="nump">63,334<span></span>
</td>
<td class="nump">113,138<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">158,199<span></span>
</td>
<td class="nump">128,025<span></span>
</td>
<td class="nump">267,056<span></span>
</td>
<td class="nump">233,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(133,835)<span></span>
</td>
<td class="num">(85,137)<span></span>
</td>
<td class="num">(204,263)<span></span>
</td>
<td class="num">(166,212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Interest and other, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(355)<span></span>
</td>
<td class="num">(651)<span></span>
</td>
<td class="num">(856)<span></span>
</td>
<td class="num">(1,284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_InterestIncomeAndOtherIncomeExpensesNet', window );">Interest income and other income (expenses), net</a></td>
<td class="num">(363)<span></span>
</td>
<td class="nump">644<span></span>
</td>
<td class="num">(817)<span></span>
</td>
<td class="nump">3,810<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Total interest and other, net</a></td>
<td class="num">(718)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(1,673)<span></span>
</td>
<td class="nump">2,526<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(134,553)<span></span>
</td>
<td class="num">(85,144)<span></span>
</td>
<td class="num">(205,936)<span></span>
</td>
<td class="num">(163,686)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_UnconsolidatedVariableInterestEntityInvestmentIncome', window );">Investment income in unconsolidated variable interest entity</a></td>
<td class="nump">562<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (133,988)<span></span>
</td>
<td class="num">$ (85,313)<span></span>
</td>
<td class="num">$ (205,743)<span></span>
</td>
<td class="num">$ (163,661)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted</a></td>
<td class="num">$ (1.45)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (2.24)<span></span>
</td>
<td class="num">$ (1.84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares used to calculate net loss per share - basic and diluted</a></td>
<td class="nump">92,276<span></span>
</td>
<td class="nump">89,451<span></span>
</td>
<td class="nump">91,983<span></span>
</td>
<td class="nump">88,835<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember', window );">Development and Other Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">19,641<span></span>
</td>
<td class="nump">18,957<span></span>
</td>
<td class="nump">34,228<span></span>
</td>
<td class="nump">38,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">13,371<span></span>
</td>
<td class="nump">15,693<span></span>
</td>
<td class="nump">28,733<span></span>
</td>
<td class="nump">20,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="num">$ (8,648)<span></span>
</td>
<td class="nump">$ 8,238<span></span>
</td>
<td class="num">$ (168)<span></span>
</td>
<td class="nump">$ 8,238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CostOfGoodsAndServicesSoldOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of goods and services sold operating expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CostOfGoodsAndServicesSoldOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_InterestIncomeAndOtherIncomeExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest income and other income (expenses), net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_InterestIncomeAndOtherIncomeExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_UnconsolidatedVariableInterestEntityInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unconsolidated variable interest entity investment income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_UnconsolidatedVariableInterestEntityInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of cost from product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121551570&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfCostGoodOrServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449173319496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - Astellas Agreement [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CollaborationServicesAndOtherRevenue', window );">Collaboration services and other revenue from a related party</a></td>
<td class="nump">$ 2,645<span></span>
</td>
<td class="nump">$ 4,766<span></span>
</td>
<td class="nump">$ 6,256<span></span>
</td>
<td class="nump">$ 9,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProductRevenue', window );">Product revenue from a related party</a></td>
<td class="nump">11,760<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,167<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DrugProductRevenueFromRelatedParty', window );">Drug product revenue from a related party</a></td>
<td class="num">$ (1,974)<span></span>
</td>
<td class="nump">$ 8,238<span></span>
</td>
<td class="nump">$ 2,056<span></span>
</td>
<td class="nump">$ 8,238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CollaborationServicesAndOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized from co-development services, manufacturing of clinical supplies, committee services and information services and other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CollaborationServicesAndOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DrugProductRevenueFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Drug product revenue from related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DrugProductRevenueFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ProductRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product revenue from a related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ProductRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449177384616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (133,988)<span></span>
</td>
<td class="num">$ (85,313)<span></span>
</td>
<td class="num">$ (205,743)<span></span>
</td>
<td class="num">$ (163,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">40<span></span>
</td>
<td class="num">(1,615)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="num">(1,334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Available-for-sale investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments, net of tax effect</a></td>
<td class="nump">17<span></span>
</td>
<td class="num">(1,129)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of taxes</a></td>
<td class="nump">57<span></span>
</td>
<td class="num">(2,744)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="num">(814)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (133,931)<span></span>
</td>
<td class="num">$ (88,057)<span></span>
</td>
<td class="num">$ (205,811)<span></span>
</td>
<td class="num">$ (164,475)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449261784744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Noncontrolling Interests [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 535,406<span></span>
</td>
<td class="nump">$ 877<span></span>
</td>
<td class="nump">$ 1,300,725<span></span>
</td>
<td class="num">$ (747)<span></span>
</td>
<td class="num">$ (784,720)<span></span>
</td>
<td class="nump">$ 19,271<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,657,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(163,661)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(163,661)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized gain or loss on investments</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">520<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1,334)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,334)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid', window );">Shares issued from stock plans, net of payroll taxes paid</a></td>
<td class="nump">9,652<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">9,627<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares', window );">Shares issued from stock plans, net of payroll taxes paid, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,570,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">34,560<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">34,560<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">415,143<span></span>
</td>
<td class="nump">$ 902<span></span>
</td>
<td class="nump">1,344,912<span></span>
</td>
<td class="num">(1,561)<span></span>
</td>
<td class="num">(948,381)<span></span>
</td>
<td class="nump">19,271<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,228,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">477,629<span></span>
</td>
<td class="nump">$ 889<span></span>
</td>
<td class="nump">1,319,354<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
<td class="num">(863,068)<span></span>
</td>
<td class="nump">19,271<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,895,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(85,313)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(85,313)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized gain or loss on investments</a></td>
<td class="num">(1,129)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,129)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1,615)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,615)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid', window );">Shares issued from stock plans, net of payroll taxes paid</a></td>
<td class="nump">7,927<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">7,914<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares', window );">Shares issued from stock plans, net of payroll taxes paid, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,332,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">17,644<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">17,644<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">415,143<span></span>
</td>
<td class="nump">$ 902<span></span>
</td>
<td class="nump">1,344,912<span></span>
</td>
<td class="num">(1,561)<span></span>
</td>
<td class="num">(948,381)<span></span>
</td>
<td class="nump">19,271<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,228,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">441,449<span></span>
</td>
<td class="nump">$ 914<span></span>
</td>
<td class="nump">1,399,774<span></span>
</td>
<td class="num">(4,499)<span></span>
</td>
<td class="num">(974,011)<span></span>
</td>
<td class="nump">19,271<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,440,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(205,743)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(205,743)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized gain or loss on investments</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid', window );">Shares issued from stock plans, net of payroll taxes paid</a></td>
<td class="nump">5,828<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">5,816<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares', window );">Shares issued from stock plans, net of payroll taxes paid, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,168,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">38,385<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">38,385<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">279,851<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
<td class="nump">1,443,975<span></span>
</td>
<td class="num">(4,567)<span></span>
</td>
<td class="num">(1,179,754)<span></span>
</td>
<td class="nump">19,271<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,608,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">390,273<span></span>
</td>
<td class="nump">$ 921<span></span>
</td>
<td class="nump">1,420,471<span></span>
</td>
<td class="num">(4,624)<span></span>
</td>
<td class="num">(1,045,766)<span></span>
</td>
<td class="nump">19,271<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,080,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(133,988)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(133,988)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized gain or loss on investments</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid', window );">Shares issued from stock plans, net of payroll taxes paid</a></td>
<td class="nump">4,508<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">4,503<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares', window );">Shares issued from stock plans, net of payroll taxes paid, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">528,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">19,001<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">19,001<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 279,851<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
<td class="nump">$ 1,443,975<span></span>
</td>
<td class="num">$ (4,567)<span></span>
</td>
<td class="num">$ (1,179,754)<span></span>
</td>
<td class="nump">$ 19,271<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,608,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital shares issued from stock plans net of payroll taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued from stock plans net of payroll taxes paid shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449254773480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (205,743)<span></span>
</td>
<td class="num">$ (163,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">5,242<span></span>
</td>
<td class="nump">5,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use assets</a></td>
<td class="nump">4,393<span></span>
</td>
<td class="nump">5,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of premium and discount on investments</a></td>
<td class="nump">767<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_UnrealizedLossGainOnEquityInvestments', window );">Unrealized loss on equity investments</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_InvestmentLossInUnconsolidatedVariableInterestEntity', window );">Investment loss in unconsolidated variable interest entity</a></td>
<td class="num">(323)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss (gain) on disposal of property and equipment</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">38,385<span></span>
</td>
<td class="nump">34,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Expense for acquired in-process research and development asset</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Tax benefit on unrealized gain on available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Realized loss on sales of available-for-sale securities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">17,868<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(7,861)<span></span>
</td>
<td class="num">(2,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,231<span></span>
</td>
<td class="nump">126,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(1,800)<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(3,066)<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,013)<span></span>
</td>
<td class="num">(1,060)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">27,745<span></span>
</td>
<td class="num">(33,331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">295<span></span>
</td>
<td class="num">(170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">33,078<span></span>
</td>
<td class="nump">48,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities', window );">Accrued interest for finance lease liabilities</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">1,388<span></span>
</td>
<td class="num">(359)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(8,065)<span></span>
</td>
<td class="nump">64,317<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(71,527)<span></span>
</td>
<td class="nump">90,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,215)<span></span>
</td>
<td class="num">(1,185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity', window );">Payment made for investment in unconsolidated variable interest entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of available-for-sale securities</a></td>
<td class="num">(266,647)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities', window );">Proceeds from sales of available-for-sale securities</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">10,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">10,610<span></span>
</td>
<td class="nump">201,900<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(254,252)<span></span>
</td>
<td class="nump">209,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RepaymentsOfFinanceLeaseLiabilities', window );">Repayments of finance lease liabilities</a></td>
<td class="num">(5,326)<span></span>
</td>
<td class="num">(5,992)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Repayments of lease obligations</a></td>
<td class="num">(201)<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Cash paid for payroll taxes on restricted stock unit releases</a></td>
<td class="num">(5,928)<span></span>
</td>
<td class="num">(6,858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">11,756<span></span>
</td>
<td class="nump">16,510<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">3,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate change on cash and cash equivalents</a></td>
<td class="nump">446<span></span>
</td>
<td class="num">(499)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(325,032)<span></span>
</td>
<td class="nump">303,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash and cash equivalents at beginning of period</a></td>
<td class="nump">678,393<span></span>
</td>
<td class="nump">126,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash and cash equivalents at end of period</a></td>
<td class="nump">$ 353,361<span></span>
</td>
<td class="nump">$ 429,269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accrued interest for finance lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease liabilities, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease liabilities, non-current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_InvestmentLossInUnconsolidatedVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment loss in unconsolidated variable interest entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_InvestmentLossInUnconsolidatedVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment made for investment in unconsolidated variable interest entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RepaymentsOfFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments of finance lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RepaymentsOfFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_UnrealizedLossGainOnEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized loss (gain) on equity investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_UnrealizedLossGainOnEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449173295656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Significant Accounting Policies</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc. (&#8220;FibroGen&#8221; or the &#8220;Company&#8221;) is headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#8217;s Republic of China (&#8220;China&#8221;). FibroGen is a leading biopharmaceutical company developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (&#8220;HIF&#8221;) biology, 2-oxoglutarate enzymology, connective tissue growth factor (&#8220;CTGF&#8221;) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat, FibroGen&#8217;s most advanced product, is an oral small molecule inhibitor of HIF prolyl hydroxylase (&#8220;HIF-PH&#8221;) activity that is being commercialized in China (tradename: &#29233;&#29790;&#21331;<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>) for the treatment of anemia caused by chronic kidney disease (&#8220;CKD&#8221;) in dialysis and non-dialysis patients. EVRENZO<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (roxadustat) is also being commercialized in Japan and has been approved in South Korea and Chile for the treatment of anemia associated with CKD in dialysis and non-dialysis patients. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2021, the Committee for Medicinal Products for Human Use of the European Medicines Agency (&#8220;EMA&#8221;) adopted a positive opinion, recommending the granting of Marketing Authorization Application (&#8220;MAA&#8221;) for the medicinal product Evrenzo (roxadustat), intended for the treatment of adult patients with symptomatic anemia associated with CKD. Our partner Astellas Pharma Inc. (&#8220;Astellas&#8221;) expects an approval decision on the MAA for roxadustat by the European Commission in August 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) Cardiovascular and Renal Drugs Advisory Committee (&#8220;CRDAC&#8221;) voted to recommend not approving roxadustat, an oral HIF-PH inhibitor, for the treatment of anemia due to CKD in adult patients. The CRDAC vote was 13 to 1 for non-dialysis dependent CKD patients, and 12 to 2 for dialysis-dependent CKD patients. While the FDA is not required to follow CRDAC's vote, the agency considers CRDAC's non-binding recommendations when making its decision. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 3 development in China for anemia associated with myelodysplastic syndromes. Roxadustat is in Phase 2 clinical development for chemotherapy-induced anemia. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab, a human monoclonal antibody targeting CTGF, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer and Duchenne muscular dystrophy.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation and Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements include the accounts of FibroGen, its wholly owned subsidiaries and its majority-owned subsidiaries, FibroGen Europe Oy and FibroGen China Anemia Holdings, Ltd. All inter-company transactions and balances have been eliminated in consolidation. For any variable interest entity for which FibroGen is not the primary beneficiary, the Company uses the equity method of accounting. The Company operates as one segment &#8212; the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited condensed consolidated financial statements and related disclosures have been prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;) applicable to interim financial reporting and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and, therefore, do not include all information and footnote disclosures normally included in the annual consolidated financial statements. The financial information included herein should be read in conjunction with the consolidated financial statements and related notes in the Company&#8217;s Annual Report on Form 10-K filed with the SEC for the year ended December&#160;31, 2020 (&#8220;2020 Form 10-K&#8221;). </p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue, specifically, estimates in variable consideration for drug product sales, and estimates in transaction price per unit for the China performance obligation (as defined and discussed under <span style="font-style:italic;">Significant Accounting Policies</span> below). On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates. In the Company&#8217;s opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair statement of its financial position, results of operations and cash flows for the interim periods presented.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential common shares that would have the effect of increasing diluted earnings per share are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings per share. Diluted weighted average shares excluded potential common shares related to stock options, restricted stock units and shares to be purchased under the employee stock purchase plan totaling 11.4 million and 9.2 million for the three months ended June&#160;30, 2021 and 2020, and totaling 9.4 million and 9.0 million for the six months ended June&#160;30, 2021 and 2020, respectively, as they were anti-dilutive.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s business is subject to risks and uncertainties, including those related to Severe Acute Respiratory Syndrome Coronavirus 2 and the resulting Coronavirus Disease (&#8220;COVID-19&#8221;) and the risk that we may not get approval of roxadustat in the U.S. for CKD anemia given the fact that the CRDAC voted to recommend not approving roxadustat in July 2021.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, obtaining second source suppliers, <span style="font-size:9.5pt;">regulatory approval from the FDA or other regulatory authorities, </span>the results of clinical trials and the achievement of milestones, market acceptance of the Company&#8217;s product candidates, competition from other products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued and Adopted Accounting Guidance</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span>. This guidance simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step up in the tax basis of goodwill, and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. This guidance was effective for annual reporting periods beginning after December 15, 2020 including interim periods. The Company adopted this guidance on January 1, 2021, and the adoption of this guidance did not have material impact to the Company&#8217;s condensed consolidated financial statements and related disclosures.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Guidance Not Yet Adopted</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued ASU 2020-04, <span style="font-style:italic;">Reference Rate Reform (Topic 848): </span><span style="font-style:italic;color:#000000;">Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span> (&#8220;<span style="font-style:italic;">ASU</span><span style="font-style:italic;"> </span><span style="font-style:italic;">2020</span><span style="font-style:italic;">-</span><span style="font-style:italic;">04</span><span style="font-style:italic;">&#8221;</span>)<span style="font-style:italic;">,</span> which provides companies with optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform. This guidance is effective as of March 12, 2020 through December 31, 2022. Subsequently in January 2021, the FASB issued ASU 2021-01, <span style="font-style:italic;">Reference Rate Reform (Topic 848): Scope</span>, which clarifies ASU 2020-04 and provides certain optional expedients that allow derivative instruments impacted by changes in the interest rate used for margining, discounting or contract price alignment to qualify for certain optional relief. ASU 2021-01 is effective in the same timeframe as ASU 2020-04. The relief offered by this guidance, if adopted, is available to companies for the period March 12, 2020 through December 31, 2022. <span style="Background-color:#FFFFFF;">The Company has certain lease arrangements that are linked to LIBOR. The Company is in the process of evaluating options for transitioning away from LIBOR and expects to complete this analysis by the time LIBOR is phased out. The Company did not elect to apply any of the expedients or exceptions as of and for the period ended June 30, 2021 and is currently evaluating the impact on its consolidated financial statements and related disclosures upon adoption of this guidance.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Significant Accounting Policies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the 2020 Form 10-K, except for the following:</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product revenue, net </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue, net consists of revenues from sales of roxadustat commercial product to Beijing Falikang Pharmaceutical Co., Ltd. (&#8220;Falikang&#8221;), and directly to pharmaceutical distributors located in a few provinces in China that are not covered by Falikang. Falikang is jointly owned by AstraZeneca AB (&#8220;AstraZeneca&#8221;) and FibroGen Beijing. The Company is not the primary beneficiary of Falikang for accounting purposes, as AstraZeneca is the final decision maker for all the roxadustat commercialization activities, and the Company lacks the power criterion to direct the activities of Falikang (see Note 3, <span style="font-style:italic;">Variable Interest Entity</span>). </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales to Falikang</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang became fully operational in January 2021, at which time FibroGen Beijing began selling roxadustat commercial product to Falikang. Falikang is FibroGen Beijing&#8217;s primary customer in China and substantially all roxadustat product sales to distributors in China are made by Falikang. Falikang bears inventory risk once it receives and accepts the product from FibroGen Beijing, and is responsible for delivering product to its distributors.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promises identified under the AstraZeneca China Agreement (as defined in Note 2, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>), including the license, co-development services and manufacturing of commercial supplies have been bundled into a single performance obligation (&#8220;China performance obligation&#8221;). Amounts of the transaction price allocable to this performance obligation under the Company&#8217;s agreements with AstraZeneca as outlined in Note 2, <span style="font-style:italic;">Collaboration Agreements and Revenues,</span> are deferred until control of the manufactured commercial product is transferred to AstraZeneca.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initiation of roxadustat sales to Falikang marked the beginning of the China performance obligation<span style="font-style:italic;">.</span><span style="color:#000000;"> Revenue is recognized at a point in time when control of roxadustat commercial product is transferred to Falikang. Revenue is recognized based on the estimated transaction price per unit and actual quantity of product delivered during the reporting period. Specifically, the transaction price per unit is determined based on the overall transaction price over the total estimated sales quantity for the estimated performance period in which the Company believes those sales would occur. The price per unit is subject to reassessment on a quarterly basis, which may result in cumulative catch up adjustments due to changes in estimates.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The overall transaction price for FibroGen Beijing&#8217;s product sales to Falikang includes the following elements of consideration: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Non-refundable upfront license fees; development, regulatory, and commercial milestone payments based on the China Agreement allocated to the China performance obligation;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Co-development billings resulting from the Company&#8217;s research and development efforts, which are reimbursable under the China Agreement;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:Noto Sans Symbols;"/><span style="color:#000000;"/><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interim profit/loss share between FibroGen Beijing and AstraZeneca from April 1, 2020 through December 31, 2020; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Net transfer price from product sales to Falikang from January 1, 2021 onwards. The net transfer price includes the following elements: </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Gross transfer price: The gross transfer price is based on a percentage of Falikang&#8217;s net sales to its distributors, which takes into account Falikang&#8217;s operating expenses and its payments to AstraZeneca for roxadustat sales and marketing efforts, capped at a percentage of Falikang&#8217;s net roxadustat sales. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Profit share: The gross transfer price is then adjusted for an estimated amount to achieve the 50/50 profit share from current period roxadustat net sales in China. The adjustments to date have been a reduction to the transfer price and the related accounts receivable from Falikang.&#160;&#160;</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The non-refundable upfront license fees constitute a <span style="color:#000000;">fixed consideration. The remainder of the above are variable consideration components, which may be constrained, and included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. The calculation of the above variable consideration includes key estimates such as total sales quantity, performance period, gross transfer price and profit share, which require a substantial degree of judgment.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any net transfer price in excess of the revenue recognized is deferred, and will be recognized over future periods as the performance obligations are satisfied.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Direct Sales to Distributors</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells roxadustat in China directly to a number of pharmaceutical distributors located in a few provinces in China that are not covered by Falikang. These pharmaceutical distributors are the Company&#8217;s customers. Hospitals order roxadustat through a distributor and the Company ships the product directly to the distributors. The delivery of roxadustat to a distributor represents a single performance obligation. Distributors are responsible for delivering product to end users, primarily hospitals. Distributors bear inventory risk once they receive and accept the product. Product revenue is recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The period between the transfer of control of the promised goods and when the Company receives payment is based on 60-day payment terms. As such, product revenue is not adjusted for the effects of a significant financing component.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is recorded at the net sales prices which includes the following estimates of variable consideration:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Price adjustment: When China&#8217;s National Healthcare Security Administration releases price guidance for roxadustat under the National Reimbursement Drug List, any channel inventories that have not been sold through by distributors, or to patients by hospitals and retailors, would be eligible for a price adjustment under the price protection. The price adjustment is calculated based on estimated channel inventory levels;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Contractual sales rebate: The contractual sales rebate is calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. The contractual sales rebate is recorded as a reduction to revenue at the point of sale to the distributor;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Non-key account hospital listing award: A one-time fixed-amount award is offered to a distributor who successfully lists the product with an eligible hospital, and who meets certain requirements. The Company considers this particular award to be an upfront payment to a customer within the definitions of Accounting Standards Codification (&#8220;ASC&#8221;) 606, <span style="font-style:italic;">Revenue from Contracts with Customers </span>(&#8220;ASC 606&#8221;). The non-key account hospital listing award is capitalized when the distributor meets eligibility requirements, and amortized as reduction to product revenue over future sales orders made by the distributor until exhausted;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:Noto Sans Symbols;"/><span style="color:#000000;"/><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other discounts and rebates, including key account hospital sales reba</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e and transfer fee discount, are generally based on a percentage of eligible gross sales made by the distributor and recorded as a reduction to revenue at the point of sale to the distributor; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Sales returns: Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product&#8217;s expiration date.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The calculation of the above variable consideration is based on gross sales to the distributor, or estimated utilizing best available information from the distributor, maximum known exposures and other available information including estimated channel inventory levels and estimated sales made by the distributor to hospitals, which involve a substantial degree of judgment.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above rebates and discounts all together are eligible to be applied against the distributor&#8217;s future sales order, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible and in the same period that the related revenue is recorded. Due to the distributor&#8217;s legal right to offset, at each balance sheet date, the liability for rebates and discounts are presented as reductions of gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The distributor&#8217;s legal right of offset is calculated at the individual distributor level.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Acquisition Agreement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 16, 2021, the Company entered into an exclusive license and option agreement with HiFiBiO Therapeutics (&#8220;HiFiBiO&#8221;) (&#8220;HiFiBiO Agreement&#8221;), pursuant to which the Company exclusively licensed all product candidates in HiFiBiO&#8217;s Galectin-9 program and will have the sole right to develop them worldwide. The Company has also obtained exclusive options to license all product candidates in HiFiBiO&#8217;s CXCR5 and CCR8 programs. Under the terms of the HiFiBiO Agreement, the Company will make a $25 million upfront payment to HiFiBiO, as well as payments upon option exercise. In addition, HiFiBiO may receive up to a total of an additional $1.1 billion in future option, clinical, regulatory, and commercial milestone payments across all three programs. HiFiBiO will also be eligible to receive royalties based upon worldwide net sales. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The acquisition of these licenses was accounted for as an asset acquisition. The initial upfront payment of $25.0 million related to the license and options acquisition meets the definition of an in-process research and development asset (&#8220;IPR&amp;D asset&#8221;) under the ASC 730, <span style="font-style:italic;">Research and Development</span> (&#8220;ASC 730&#8221;). It relates to particular research and development projects and is determined to have no alternative future uses and thus have no separate economic value. Therefore, this upfront payment was recorded as a research and development expense during the three months ended June 30, 2021. As of June 30, 2021, this amount was not paid, and was included as accounts payable in the condensed consolidated balance sheet.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration payments will be evaluated and recognized when they become probable and reasonably estimable. The related IPR&amp;D asset will only be capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, amounts allocated to IPR&amp;D asset that have no alternative use will be expensed. As of June 30, 2021, all programs were at the early stage of development and the contingencies related to the milestone payments had not been resolved, therefore no contingent consideration was recognized. The Company will reassess the probability of future option payments and contingent payments on a quarterly basis.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449182553144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock', window );">Collaboration Agreements and Revenues</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaboration Agreements and Revenues</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Astellas Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Japan Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2005, the Company entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (&#8220;Japan Agreement&#8221;). Under this agreement, Astellas paid license fees and other consideration totaling $40.1&#160;million (such amounts were fully received as of February 2009). Under the Japan Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $132.5&#160;million in potential milestone payments, comprised of (i)&#160;up to $22.5&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of July 2016), (ii)&#160;up to $95.0&#160;million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $15.0&#160;million in milestone payments upon the achievement of specified commercial sales milestone. The Japan Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range of the list price published by Japan&#8217;s Ministry of Health, Labour and Welfare, adjusted for certain elements, after commercial launch. The aggregate amount of consideration received through June&#160;30, 2021 totals $105.1 million, excluding drug product revenue that is discussed separately below.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#8220;Japan Amendment&#8221;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">active pharmaceutical ingredient (&#8220;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">API</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</span><span style="font-weight:bold;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to Astellas </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the roxadustat commercial </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">purposes </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in Japan</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The commercial terms of the Japan Agreement relating to the transfer price for roxadustat for commercial use remain substantially the same, reflecting an adjustment for the manufacture of drug product by Astellas rather than FibroGen. The related drug product revenue, as described in details under </span><span style="font-style:italic;">Drug Product Revenue</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> section below, was $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.0)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the three </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and six </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">months ended </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respectively</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Europe Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2006, the Company entered into a separate collaboration agreement with Astellas for the development and commercialization of roxadustat for the treatment of anemia in Europe, the Middle East, the Commonwealth of Independent States and South Africa (&#8220;Europe Agreement&#8221;). Under the terms of the Europe Agreement, Astellas paid license fees and other upfront consideration totaling $320.0 million (such amounts were fully received as of February 2009). The Europe Agreement also provides for additional development and regulatory approval milestone payments up to $425.0&#160;million, comprised of (i)&#160;up to $90.0&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of 2012), (ii)&#160;up to $335.0&#160;million in milestone payments upon achievement of specified regulatory milestone events. Under the Europe Agreement, Astellas committed to fund 50% of joint development costs for Europe and North America, and all territory-specific costs. The Europe Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range. The aggregate amount of consideration received under the Europe Agreement through June&#160;30, 2021 totals $540.0 million, excluding drug product revenue that is discussed separately below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Europe Agreement, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. During the first quarter of 2021, the Company entered into an Astellas EU Supply Agreement (&#8220;EU Supply Agreement&#8221;) under the Europe Agreement with Astellas to define general forecast, order, supply and payment terms for Astellas to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The Company shipped bulk drug product to Astellas as pre-commercial supply for process validation purposes during the first quarter of 2021. The Company recorded the consideration of $11.8 million from this shipment as deferred revenue as of June 30, 2021, as described in details under <span style="font-style:italic;">Drug Product Revenue</span> section below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">U.S./Rest of World (&#8220;RoW&#8221;) Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective July 30, 2013, the Company entered into a collaboration agreement with AstraZeneca for the development and commercialization of roxadustat for the treatment of anemia in the U.S. and all other countries in the world, other than China, not previously licensed under the Astellas Europe and Astellas Japan Agreements (&#8220;U.S./RoW Agreement&#8221;). It also excludes China, which is covered by a separate agreement with AstraZeneca described below. Under the terms of the U.S./RoW Agreement, AstraZeneca paid upfront, non-contingent, non-refundable and time-based payments totaling $374.0 million (such amounts were fully received as of June 2016). Under the U.S./RoW Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $875.0 million in potential milestone payments, comprised of (i)&#160;up to $65.0 million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of April 2020), (ii)&#160;up to $325.0 million in milestone payments upon achievement of specified regulatory milestone events, (iii)&#160;up to $160.0&#160;million in milestone payments related to activity by potential competitors and (iv)&#160;up to approximately $325.0 million in milestone payments upon the achievement of specified commercial sales events. The aggregate amount of consideration received under the U.S./RoW Agreement through June&#160;30, 2021 totals $439.0 million, excluding drug product revenue that is discussed separately below.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the Company entered into Master Supply Agreement under the U.S./RoW Agreement with AstraZeneca (&#8220;Master Supply Agreement&#8221;) to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The Company shipped bulk drug product to AstraZeneca as commercial supply during 2020, and the first and second quarter of 2021. On July 15, 2021, the FDA CRDAC voted to recommend not approving roxadustat for the treatment of anemia due to CKD in adult patients. While the FDA is not required to follow the CRDAC&#8217;s vote, the agency considers the CRDAC&#8217;s non-binding recommendations when making its decision. The Company evaluated the impact of these developments in revising its estimates of variable consideration associated with drug product revenue. As a result, the Company updated the estimated transaction price, and recorded $11.2 million as deferred revenue as of June 30, 2021. See details under <span style="font-style:italic;">Drug Product Revenue</span> section below.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective July&#160;30, 2013, the Company (through its subsidiaries affiliated with China) entered into the China Agreement (&#8220;China Agreement&#8221;). Under the terms of the China Agreement, AstraZeneca agreed to pay upfront consideration totaling $28.2&#160;million (such amounts were fully received in 2014). Under the China Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $348.5 million in potential milestone payments, comprised of (i)&#160;up to $15.0 million in milestone payments upon achievement of specified clinical and development milestone events, (ii)&#160;up to $146.0 million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $187.5 million in milestone payments upon the achievement of specified commercial sales and other events. The China Agreement is structured as a 50/50 profit or loss share (as defined), which was amended under the China Amendment discussed below in the third quarter of 2020, and provides for joint development costs (including capital and equipment costs for construction of the manufacturing plant in China), to be shared equally during the development period. The aggregate amount of such consideration received for milestone and upfront payments through June&#160;30, 2021 totals $77.2 million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Amendment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, FibroGen China and AstraZeneca (together with FibroGen China, the &#8220;Parties&#8221;) entered into the China Amendment, effective July 1, 2020, relating to the development and commercialization of roxadustat in China. While the responsibilities of the Parties under the China Agreement remain largely the same, certain changes were made. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the China Amendment, in September 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Falikang, which performs roxadustat distribution, as well as conduct sales and marketing through AstraZeneca. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the China Amendment, the interim period is defined as the period from April 1, 2020 to the time when Falikang is fully operational. Falikang became fully operational in January 2021. The calculation for profit or loss share related to sales of roxadustat in China has changed for the period from April 1, 2020 onwards. With effect from April 1, 2020, the Parties have changed the method under which commercial expenses incurred by AstraZeneca are calculated and billed. AstraZeneca&#8217;s co-promotion expenses for their sales and marketing efforts are now subject to a cap of a percentage of net sales. Once AstraZeneca has been fully reimbursed for their sales and marketing costs under the cap, AstraZeneca will bill the co-promotion expenses based on actual costs on a prospective basis. In addition, the China Amendment has allowed for a higher cost of manufacturing incurred by FibroGen Beijing to be included in the profit or loss share calculation, subject to an annual cap, among other changes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since Falikang became fully operational in January 2021, substantially all direct roxadustat product sales to distributors in China are made by Falikang, while FibroGen Beijing continues to sell roxadustat product directly in a few provinces in China. FibroGen Beijing manufactures and supplies commercial product to Falikang based on a gross transfer price, which is adjusted for the estimated profit share. In addition, AstraZeneca now bills the co-promotion expenses to Falikang and to FibroGen Beijing, respectively, for its services provided to the respective entity. Development costs continue to be shared 50/50 between the Parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three and six months ended June&#160;30, 2021, the Company recognized $11.8 million and $22.2 million, respectively, of net product revenue from the sales to Falikang, as described in details under <span style="font-style:italic;">Product Revenue, Net</span> section below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to sales to Falikang, during the three and six months ended June&#160;30, 2021, the Company recognized $1.6 million and 6.6 million, respectively, of net product revenue from sales directly to distributors in a few provinces in China, <span style="Background-color:#FFFFFF;color:#000000;">as </span>described as direct sales<span style="Background-color:#FFFFFF;color:#000000;"> </span>under <span style="font-style:italic;">Product Revenue, Net</span> section below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">License Revenue and Development Revenue Recognized Under the Collaboration Agreements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts recognized as license revenue and development revenue under the Japan Agreement with Astellas were as follows (in thousands):&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.68%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">327</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Japan Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,529</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,559</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,876</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,906</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue recognized under the Japan Agreement for the three months ended June&#160;30, 2021 included immaterial revenue resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied or partially satisfied in previous periods. The Company does not expect material variable consideration from estimated future co-development billing beyond the development period in the transaction price related to the Japan Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts recognized as license revenue and development revenue under the Europe Agreement with Astellas were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,546</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,602</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,077</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,176</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Europe Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,951</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,951</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255,039</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255,372</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.68%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">742,990</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">743,323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:2.5%;text-indent:-2.5%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue recognized under the Europe Agreement for the three months ended June&#160;30, 2021 included an increase in revenue of $0.4 million resulting from changes to estimated variable consideration. The remainder of the transaction price related to the Europe Agreement includes $10.7 million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts recognized as revenue under the U.S./RoW and China Agreement with AstraZeneca were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.&#160;/&#160;RoW</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and China</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,993</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,750</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,969</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,305</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China performance obligation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">441</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">594</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement with AstraZeneca, along with any associated deferred revenue as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U.S.&#160;/&#160;RoW and China Agreements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.24%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">341,844</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">341,844</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.24%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-development, information sharing &amp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;committee services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">582,743</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,309</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">585,052</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.24%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China performance obligation *</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,167</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,759</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,926</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.24%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">946,754</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152,068</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,098,822</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* </span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">China performance obligation revenue is recognized as product revenue, as described in details under <span style="font-style:italic;">Product Revenue, Net</span> section below.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the consolidated balance sheets. As of June 30, 2021, deferred revenue included $146.8 million related to the U.S./RoW and China Agreement, which represents the net of $152.1 million of deferred revenue presented above and a $5.3 million unbilled co-development revenue under the China Amendment with AstraZeneca.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue recognized under the U.S./RoW Agreement for the three months ended June&#160;30, 2021 included a reduction in revenue of $0.2 million resulting from changes to estimated variable consideration. The remainder of the transaction price related to the U.S./RoW Agreement and China Agreement includes $34.1 million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period, except for amounts allocated to the China performance obligation. The amount allocated to the U.S./RoW Agreement is expected to be recognized over the remaining development service period. The amount allocated to the China performance obligation is expected to be recognized as the Company transfers control of the commercial products to Falikang.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Product Revenue, Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue, net from the sales of roxadustat commercial product in China was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Direct Sales:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,230</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,833</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,659</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,205</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discounts and rebates</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(618</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,095</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,181</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,512</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales returns</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct sales revenue, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,611</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,693</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,566</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,648</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sales to Falikang:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross transfer price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,714</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,115</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Profit share</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,573</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,636</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net transfer price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,141</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,479</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000702">&#160;</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,381</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,312</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000706">&#160;</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales to Falikang revenue, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,760</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,167</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total product revenue, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,371</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,693</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,733</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,648</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Direct Sales</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue from direct roxadustat product sales to distributors in China is recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products, net of various sales rebates and discounts. The total discounts and rebates were $0.6 million and $4.1 million for the three months ended June&#160;30, 2021 and 2020, and $1.2 million and $4.5 million for the six months ended June&#160;30, 2021 and 2020, respectively, which primarily consisted of the contractual sales rebate calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor.  </p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rebates and discounts that the Company&#8217;s pharmaceutical distributors have earned are eligible to be applied against future sales orders, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible in the same period that the related revenue is recorded. Due to the Company&#8217;s legal right to offset, at each balance sheet date, the rebates and discounts are presented as reductions to gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The Company&#8217;s legal right to offset is calculated at the individual distributor level. The following table includes a roll-forward of the contract liabilities (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deduction</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Currency</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Translation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.6%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue - Direct sales - contract liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(883</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,410</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(183</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,793</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021 and December&#160;31, 2020, the total contract liabilities were $13.8 million and $15.1 million, which were included in accrued and other current liabilities in the condensed consolidated balance sheet. The rebates and discounts reflected as reductions to gross accounts receivable for direct sales was $0.8 million and $0.5 million as of June 30, 2021 and December 31, 2020, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales to Falikang &#8211; China Performance Obligation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since Falikang became fully operational in January 2021, substantially all direct roxadustat product sales to distributors in China are made by Falikang. FibroGen Beijing manufactures and supplies commercial product to Falikang. The net transfer price for FibroGen Beijing&#8217;s product sales to Falikang is based on a gross transfer price, which is adjusted to account for the 50/50 profit share for the period.  </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The roxadustat sales to Falikang marked the beginning of the Company&#8217;s China performance obligation under the Company&#8217;s agreements with AstraZeneca</span><span style="font-style:italic;Background-color:#FFFFFF;">.</span><span style="Background-color:#FFFFFF;"> Product revenue is based on the transaction price of the China performance obligation. </span><span style="color:#000000;">Revenue is recognized when control of product is transferred to Falikang, </span><span style="Background-color:#FFFFFF;">in an amount that </span><span style="color:#000000;">reflects the allocation of the transaction price to the performance obligation satisfied during the reporting period</span><span style="Background-color:#FFFFFF;">. </span><span style="color:#000000;">Any net transfer price in excess of the revenue recognized is added to the deferred balance to date, and will </span><span style="Background-color:#FFFFFF;">be recognized over future periods as the performance obligations are satisfied</span><span style="color:#000000;">. During the three and six months ended June&#160;30, 2021, following updates to its estimates, the Company deferred $5.4 million and $9.3 million, respectively, from the net transfer price to Falikang, which was included in the related deferred revenue of the China performance obligation.</span> </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes a roll-forward of the related deferred revenue that is considered as a contract liability (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognized as Revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue - AstraZeneca</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;China performance obligation - deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(137,338</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,588</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,167</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(149,759</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue includes amounts allocated to the China performance obligation under the AstraZeneca arrangement as revenue recognition associated with this unit of accounting is tied to the commercial launch of the products within China and to when the control of the manufactured commercial products is transferred to AstraZeneca. As of June&#160;30, 2021, approximately $6.3 million of the deferred revenue related to the China unit of accounting was included in short-term deferred revenue, which represents the amount of deferred revenue associated with the China unit of accounting that is expected to be recognized within the next 12 months, associated with the commercial sales in China.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reductions to gross accounts receivable related to product revenue to Falikang was $10.1 million as of June&#160;30, 2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Drug Product Revenue<span style="font-weight:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue from commercial-grade API or bulk drug product sales to AstraZeneca and Astellas was as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,974</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,056</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,674</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,224</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,648</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(168</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During three months ended June 30, 2021, the Company shipped bulk drug product to AstraZeneca as commercial supply under the terms of the Master Supply Agreement. Based on the above-mentioned FDA CRDAC&#8217;s vote on July 15, 2021, the Company evaluated the impact of these developments in revising its estimates of variable consideration associated with drug product revenue. As a result, the Company updated the estimated transaction price, and recorded $11.2 million as deferred revenue as of June 30, 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended June 30, 2021, the Company recorded a reduction of $2.0 million to the drug product revenue related to the API shipments fulfilled under the terms of the Japan Amendment with Astellas in 2018, due to a change in estimated variable consideration. Specifically, the change in estimated variable consideration was based on the API held by Astellas at June 30, 2021, adjusted to reflect the changes in the estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others. This amount was recorded under deferred revenue in the condensed consolidated balance sheet as of June 30, 2021. During the first quarter of 2021, the Company recorded $4.0 million drug product revenue related to the same API shipments for the change in estimated variable consideration based on the API held by Astellas at March 31, 2021, under the same methodology. This amount was unbilled to Astellas as of March 31, 2021, and was billed and received from Astellas during the second quarter of 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2021, the Company shipped bulk drug product from process validation supplies for commercial purposes under the terms of the Europe Agreement and the EU Supply Agreement with Astellas. The Company recorded the consideration of $11.8 million from this shipment as deferred revenue as of June 30, 2021, due to a high degree of uncertainty associated with the final consideration. The deferred revenue will be recognized as and when uncertainty is resolved.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes a roll-forward of the above-mentioned deferred revenues that are considered as contract liabilities related to drug product (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognized as Revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - Japan Agreement</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,974</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,974</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - Europe Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,984</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,759</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,743</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca - U.S.&#160;Agreement</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue - deferred revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,984</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,904</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,888</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement and revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449173327576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AcquisitionAndVariableInterestEntityAbstract', window );"><strong>Acquisition And Variable Interest Entity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entity</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Variable Interest Entity</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang is a distribution entity jointly owned by AstraZeneca and FibroGen Beijing. FibroGen Beijing owns 51.1% of the outstanding shares of Falikang. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the guidance under ASC 810, <span style="font-style:italic;">Consolidation</span> (&#8220;ASC 810&#8221;), the Company concluded that Falikang qualifies as a variable interest entity (&#8220;VIE&#8221;). As Falikang is a distribution entity and AstraZeneca is the final decision maker for all the roxadustat commercialization activities, the Company lacks the power criterion while AstraZeneca meets both the power and economic criteria under the ASC 810, to direct the activities of Falikang that most significantly impact its performance. Therefore, the Company is not the primary beneficiary of this VIE for accounting purposes. As a result, the Company accounts for its investment in Falikang under the equity method, and Falikang is not consolidated into the Company&#8217;s condensed consolidated financial statements. Accordingly, the Company records its total investments in Falikang as an equity method investment in an unconsolidated variable interest entity in the condensed consolidated balance sheet. In addition, the Company recognizes its proportionate share of the reported profits or losses of Falikang as investment gain or loss in unconsolidated variable interest entity in the condensed consolidated statement of operations, and as an adjustment to its investment in Falikang in the condensed consolidated balance sheet. Falikang has not incurred material profit or loss to date. The Company may provide shareholder loans to Falikang to meet necessary financial obligations as part of its operations. To date, these loans have been immaterial. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s&#160;equity&#160;method&#160;investment&#160;in Falikang was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Entity</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership Percentage</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share of Net Income</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Currency</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Translation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,728</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,083</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang is considered a related party to the Company. See Note 9, <span style="font-style:italic;">Related Party Transactions</span>, for related disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AcquisitionAndVariableInterestEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition and variable interest entity abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AcquisitionAndVariableInterestEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449182181224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value Measurements</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company&#8217;s financial assets that are measured on a recurring basis are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,483</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,483</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,099</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,099</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,568</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,568</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agency bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,284</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,284</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,490</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,490</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign government bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,151</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,151</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267,428</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,507</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">482,935</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590,591</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598,735</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Level 2 investments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data and other observable inputs. There were no transfers of assets between levels during the three and six months ended June&#160;30, 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial liabilities related to lease obligations as of June 30, 2021 and December 31, 2020 were $0.9 million and $1.1 million, respectively. The fair values of the Company&#8217;s financial liabilities are carried at historical cost that were derived by using an income approach, which required Level 3 inputs such as discounted estimated future cash flows. There were no transfers of assets or liabilities between levels for any of the periods presented.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449181683864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Leases</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s lease assets and related lease liabilities were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Line Item</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets - cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,477</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,146</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,871</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,606</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets - cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,705</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,934</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,614</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,891</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,091</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,043</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,952</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,649</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,330</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,718</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,188</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,391</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, non-current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,196</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">853</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,943</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,762</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s long-term property lease with Alexandria for its corporate headquarters in San Francisco, California, had an initial term of 15&#160;years, scheduled to expire in 2023. The original lease was accounted for as a finance lease upon adoption of ASC 842, <span style="font-style:italic;">Leases</span> (&#8220;ASC 842&#8221;), at January 1, 2019. <br/></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 1, 2021, the Company entered into an amendment with Alexandria to extend the lease to 2028 (&#8220;Lease Amendment&#8221;). Under the terms of the Lease Amendment, the Company has two optional rights to each extend the lease for an additional five years. The lease contract provides for a fixed annual rent, with scheduled increases of two percent that occur on each anniversary of the rent commencement date through 2023, and with scheduled increases of three percent that occur on each anniversary of the rent commencement date through 2028. This lease requires the Company to pay all costs of ownership, operation, and maintenance of the premises, including without limitation all operating costs, insurance costs, and taxes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company determined that the Lease Amendment was a lease modification, effective June 1, 2021, and thus reassessed the lease classification, remeasured the related lease liability using an updated discount rate, and adjusted the related right-of-use asset under the lease modification guidance under the ASC 842. Accordingly, on June 1, 2021, the Company determined that the modified lease be accounted for as an operating lease, and therefore derecognized the previous finance lease right-of-use asset of $24.6 million and the related finance lease liability of $32.6 million, and recognized an operating lease right-of-use asset of $93.2 million and the related operating lease liability of $101.2 million. Starting June 1, 2021, the cash payment related to this lease was classified as an operating activity, the impact of which was approximately $1.1 million to the condensed consolidated statement of cash flow for the six months ended June 30, 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2021, after FibroGen Beijing&#8217;s previous long-term lease agreement expired, the Company entered into a new lease agreement with the landlord for the same pilot plant located in Beijing Yizhuang Biomedical Park of BDA. The new lease term is five year, scheduled to expire in 2026, and is treated as an operating lease. Accordingly, the Company recorded $3.4 million in the operating right-of-use assets and total operating lease liabilities, respectively. The lease contract provides for fixed quarterly rent payments, and require the Company to pay operating and maintenance costs.</p>

<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense were as follows (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of Operations Line Item</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease cost:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,777</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,653</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,393</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,247</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">534</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,049</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,744</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,162</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(275</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(306</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(575</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(598</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.12%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,488</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,136</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,607</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,262</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to leases were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,246</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">433</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from finance leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,010</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows from finance leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,326</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,992</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-cash: Right-of-use assets obtained in exchange for new lease liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,498</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-cash: Increase (decrease) resulting from lease modification:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,654</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,222</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,587</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,221</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,009</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, non-current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,943</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease term and discount rate were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (years):</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000938">1.3</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000939">2.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000940">7.3</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000941">1.8</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.55</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.39</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.74</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of lease liabilities as of June&#160;30, 2021 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance&#160;Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating&#160;Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 (remaining six month period)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,534</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,517</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,454</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,798</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,193</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beyond 2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,881</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,377</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,463</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,914</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449183261176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Balance Sheet Components</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130,035</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,046</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,699</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353,361</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">678,393</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June&#160;30, 2021 and December&#160;31, 2020, a total of $85.1 million and $66.0 million, respectively, of the Company&#8217;s cash and cash equivalents were held outside of the U.S. in its foreign subsidiaries to be used primarily for its China operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s investments consist of available-for-sale debt investments and marketable equity investments. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#8217;s investments by major investments type are summarized in the tables below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,499</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,483</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,400</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,400</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,589</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,568</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agency bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,288</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,284</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,489</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,490</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign government bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,151</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,151</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259,534</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259,609</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,147</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,272</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,388</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June&#160;30, 2021, the available-for-sale investments had contractual maturities range from several months to two years. During the three and six months ended June&#160;30, 2021 and 2020, the Company did not recognize any other-than-temporary impairment loss.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inventories</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,190</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,303</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in-progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,541</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,114</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,799</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,113</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,530</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,530</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes inventory costs for FibroGen Beijing&#8217;s production of roxadustat for commercial sales purposes. The Company started capitalizing pre-launch inventory costs in the second quarter of 2020 prior to regulatory approvals in the U.S. and other territories. As of June&#160;30, 2021 and December&#160;31, 2020, pre-launch inventory capitalized was 37% and 29% of the total inventory balance, respectively. The provision to write-down excess and obsolete inventory was immaterial for three and six months ended June&#160;30, 2021 and 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unbilled contract assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,256</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,147</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues from associated contracts</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,256</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,147</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unbilled contract assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,149</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,353</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,309</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,807</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,458</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,160</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unbilled contract assets as of June 30, 2021 of $5.3 million related to unbilled co-development revenue under the China Amendment with AstraZeneca. The unbilled contract assets as of December 31, 2020 were related to unbilled co-development revenue under the China Amendment with AstraZeneca. See Note 2, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,657</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,006</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,247</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,143</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,387</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,312</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,205</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,545</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,126</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,128</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,407</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">760</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,029</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,894</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(116,359</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(111,247</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,670</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,647</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued and Other Current Liabilities </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical trial accruals</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,274</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,113</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related accruals</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,047</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,800</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities to pharmaceutical distributors</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,793</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued co-promotion expenses - current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,832</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,537</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat profit share to AstraZeneca</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property taxes and other taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,344</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,970</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional services</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,471</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,869</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,033</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,900</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued and other current liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,801</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,333</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The profit share liability of $7.0 million to AstraZeneca as of June 30, 2021 and December 31, 2020 represented the profit/loss share between FibroGen Beijing and AstraZeneca that was calculated for the interim period pursuant to the China Amendment. This liability correspondingly reduced the deferred revenue related to the performance obligation in accordance with the China Amendment.<span style="font-weight:bold;color:#FF0000;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Long-term Liabilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued long-term co-promotion expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,205</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,424</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,985</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,675</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,469</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,690</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other long-term liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,659</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,789</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449181636648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock-Based Compensation</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was recorded directly to research and development and selling, general and administrative expense as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,681</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,780</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,903</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,417</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,320</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,864</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,482</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,143</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,001</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,385</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,560</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to estimate the fair value of stock options granted and purchases under the Company&#8217;s 2014 Employee Share Purchase Plan (&#8220;ESPP&#8221;) using the Black-Scholes option valuation model were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001102">5.6</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001103">5.5</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001104">5.7</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001105">5.7</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average estimated fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.91</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.72</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.38</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ESPPs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001122">0.5 - 2.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001123">0.5 - 2.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001124">0.5 - 2.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001125">0.5 - 2.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.5 - 104.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.5 - 77.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.5 - 104.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.5 - 77.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0 - 2.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2 - 2.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0 - 2.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2 - 2.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average estimated fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.60</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.82</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.69</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449182364776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.</span></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for (benefit from) income tax for the three and six months ended June 30, 2021 were primarily due to foreign taxes. Provision for (benefit from) income tax for the three and six months ended June 30, 2020 were primarily due to the tax effect arising from other comprehensive income related to available-for-sale securities, and foreign taxes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon the weight of available evidence, which includes its historical operating performance, reported cumulative net losses since inception, the Company has established and continues to maintain a full valuation allowance against its net deferred tax assets as it does not currently believe that realization of those assets is more likely than not.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449181734808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.</span></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Related Party Transactions </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas is an equity investor in the Company and is considered a related party. The Company recorded revenue related to collaboration agreements with Astellas of $2.6 million and $4.8 million for the three months ended June 30, 2021 and 2020, and $6.3 million and $9.5 million for the six months ended June&#160;30, 2021 and 2020, respectively. The Company also recorded drug product revenue from Astellas of $(2.0) million and $8.2 million for the three months ended June 30, 2021 and 2020, and $2.1 million and $8.2 million for the six months ended June&#160;30, 2021 and 2020, respectively. See Note 2, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s expense related to collaboration agreements with Astellas was immaterial for each of the three and six months ended June 30, 2021 and 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021 and December&#160;31, 2020, accounts receivable from Astellas were $2.6&#160;million and $4.1&#160;million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021 and December&#160;31, 2020, total deferred revenue from Astellas was $20.1&#160;million and $7.5&#160;million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2021, the amount due to Astellas was immaterial. As of December&#160;31, 2020, amount due to Astellas was $1.1&#160;million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang, an entity jointly owned by FibroGen Beijing and AstraZeneca is an unconsolidated VIE accounted for as an equity method investment, and considered as a related party to the Company. FibroGen Beijing owns 51.1% of Falikang&#8217;s equity. See Note 3, <span style="font-style:italic;">Variable Interest Entity</span>, for details. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three and six months ended June&#160;30, 2021, the net product revenue from Falikang was $11.8 million and $22.2 million, respectively. See Note 2, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three and six months ended June&#160;30, 2021, the investment income in Falikang was $0.6 million and $0.3 million, respectively. As of June&#160;30, 2021 and December&#160;31, 2020, the Company&#8217;s equity method investment in Falikang was $3.1 million and $2.7 million, respectively. See Note 3, <span style="font-style:italic;">Variable Interest Entity</span>, for details.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021, accounts receivable, net, from Falikang was of $10.8 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021, there was no miscellaneous receivables from Falikang. As of December&#160;31, 2020, prepaid expenses and other current assets included miscellaneous receivables from Falikang of $0.9 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449181990840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.<span style="margin-left:36pt;">Commitments and Contingencies</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Obligations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021, the Company had outstanding total non-cancelable purchase obligations of $81.9 million, including $29.6 million for manufacture and supply of roxadustat, $47.3 million for manufacture and supply of pamrevlumab, and $5.0 million for other purchases. The Company expects to fulfill our commitments under these agreements in the normal course of business, and as such, no liability has been recorded. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the Company&#8217;s license agreements provide for periodic maintenance fees over specified time periods, as well as payments by the Company upon the achievement of development, regulatory and commercial milestones. As of June 30, 2021, future milestone payments for research and pre-clinical stage development programs consisted of up to approximately $359.2 million in total potential future milestone payments under the Company&#8217;s license agreements with HiFiBiO (for Galectin-9), Medarex, Inc. and others. These milestone payments generally become due and payable only upon the achievement of certain developmental, clinical, regulatory and/or commercial milestones. The event triggering such payment or obligation has not yet occurred.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Legal Proceedings</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company is a party to various legal actions, both inside and outside the U.S., arising in the ordinary course of its business or otherwise. The Company accrues amounts, to the extent they can be reasonably estimated, that the Company believes will result in a probable loss (including, among other things, probable settlement value), to adequately address any liabilities related to legal proceedings and other loss contingencies. A loss or a range of loss is disclosed when it is reasonably possible that a material loss will incur and can be estimated, or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not have material accruals for any currently active legal action in its condensed consolidated balance sheets as of June&#160;30, 2021, as it could not predict the ultimate outcome of these matters, or reasonably estimate the potential exposure. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2021, three putative securities class action complaints were filed against FibroGen and certain of its current and former executive officers (collectively, the &#8220;Defendants&#8221;) in the U.S. District Court for the Northern District of California. The lawsuits allege that Defendants violated the Securities Exchange Act of 1934 by making materially false and misleading statements regarding FibroGen&#8217;s Phase 3 clinical studies data and prospects for FDA approval between November 2019 and December 2020. Plaintiffs seek to represent a class of persons or entities that purchased FibroGen securities between November 8, 2019 and April 6, 2021. In May 2021, two additional putative securities class action complaints were filed against Defendants alleging the same claims. One of the lawsuits alleges that Defendants made materially false and misleading statements between October 2017 and December 2020 and seeks to represent a class of persons or entities that purchased FibroGen securities between October 18, 2017 and April 6, 2021. The other lawsuit alleges that Defendants made materially false and misleading statements between December 2018 and February 2020 and seeks to represent a class of persons or entities that purchased FibroGen securities between December 20, 2018 and April 6, 2021. All plaintiffs seek unspecified monetary damages and other relief. Motions for lead plaintiff were filed on June 11, 2021 and a hearing on the motion is scheduled for August 19, 2021. Once a lead plaintiff is appointed by the Court, the Company expects to receive an amended consolidated complaint. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 30, 2021, a purported shareholder derivative complaint was filed in the U.S. District Court for the Northern District of California.&#160;The complaint names as defendants ten of the Company&#8217;s officers and directors, as well as the Company as nominal defendant, and asserts state and federal claims based on some of the same alleged misstatements as the securities class action complaints.&#160;The complaint seeks unspecified damages, attorneys&#8217; fees, and other costs.&#160;The Company and individual defendants have not yet been served.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that the claims are without merit and it intends to vigorously defend against them. However, any litigation is inherently uncertain, and any judgment or injunctive relief entered against FibroGen or any adverse settlement could materially and adversely impact its business, results of operations, financial condition, and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Indemnification Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into standard indemnification arrangements in the ordinary course of business, including for example, service, manufacturing and collaboration agreements. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, including in connection with intellectual property infringement claims by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the extent permissible under applicable law. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these arrangements is minimal.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449182403112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.<span style="margin-left:36pt;">Subsequent Event</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Outcome of FDA Advisory Committee Review </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 15, 2021, the FDA CRDAC voted to recommend not approving roxadustat for the treatment of anemia due to CKD in adult patients. While the FDA is not required to follow the CRDAC&#8217;s vote, the agency considers the CRDAC&#8217;s non-binding recommendations when making its decision.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluated this subsequent event and concluded that it required adjustment and disclosure in the condensed consolidated financial statements, specifically to the drug product revenue related the bulk drug product shipments to AstraZeneca as commercial supply under the terms of the Master Supply Agreement. As a result, the Company recorded $11.2 million as deferred revenue as of June 30, 2021. See Note 2, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details. </p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Agreement with Eluminex</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 19, 2021, Eluminex Biosciences (Suzhou) Limited (&#8220;Eluminex&#8221;), an ophthalmology-focused biotechnology company headquartered in Suzhou, China with a US-subsidiary office in San Francisco Bay Area, California, exclusively licensed global rights from FibroGen, Inc. for the development and commercialization of an investigational biosynthetic cornea derived from recombinant human collagen Type III intended to treat patients with corneal blindness.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, Eluminex will make an $8 million upfront payment to FibroGen. In addition, FibroGen may receive up to a total of $64 million in future manufacturing, clinical, regulatory, and commercial milestone payments for the biosynthetic cornea program, as well as $36 million in commercial milestones for the first recombinant collagen III product that is not the biosynthetic cornea. FibroGen will also be eligible to receive <span style="color:#000000;">mid single-digit to low double-digit</span> royalties based upon worldwide net sales<span style="color:#000000;"> of cornea products, and low single-digit to mid single-digit royalties based upon worldwide net sales of other recombinant human collagen type III products that are not cornea products</span>.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449178221832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DescriptionOfOperationsPolicyPolicyTextBlock', window );">Description of Operations</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc. (&#8220;FibroGen&#8221; or the &#8220;Company&#8221;) is headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#8217;s Republic of China (&#8220;China&#8221;). FibroGen is a leading biopharmaceutical company developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (&#8220;HIF&#8221;) biology, 2-oxoglutarate enzymology, connective tissue growth factor (&#8220;CTGF&#8221;) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat, FibroGen&#8217;s most advanced product, is an oral small molecule inhibitor of HIF prolyl hydroxylase (&#8220;HIF-PH&#8221;) activity that is being commercialized in China (tradename: &#29233;&#29790;&#21331;<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>) for the treatment of anemia caused by chronic kidney disease (&#8220;CKD&#8221;) in dialysis and non-dialysis patients. EVRENZO<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (roxadustat) is also being commercialized in Japan and has been approved in South Korea and Chile for the treatment of anemia associated with CKD in dialysis and non-dialysis patients. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2021, the Committee for Medicinal Products for Human Use of the European Medicines Agency (&#8220;EMA&#8221;) adopted a positive opinion, recommending the granting of Marketing Authorization Application (&#8220;MAA&#8221;) for the medicinal product Evrenzo (roxadustat), intended for the treatment of adult patients with symptomatic anemia associated with CKD. Our partner Astellas Pharma Inc. (&#8220;Astellas&#8221;) expects an approval decision on the MAA for roxadustat by the European Commission in August 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) Cardiovascular and Renal Drugs Advisory Committee (&#8220;CRDAC&#8221;) voted to recommend not approving roxadustat, an oral HIF-PH inhibitor, for the treatment of anemia due to CKD in adult patients. The CRDAC vote was 13 to 1 for non-dialysis dependent CKD patients, and 12 to 2 for dialysis-dependent CKD patients. While the FDA is not required to follow CRDAC's vote, the agency considers CRDAC's non-binding recommendations when making its decision. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 3 development in China for anemia associated with myelodysplastic syndromes. Roxadustat is in Phase 2 clinical development for chemotherapy-induced anemia. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab, a human monoclonal antibody targeting CTGF, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer and Duchenne muscular dystrophy.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation and Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements include the accounts of FibroGen, its wholly owned subsidiaries and its majority-owned subsidiaries, FibroGen Europe Oy and FibroGen China Anemia Holdings, Ltd. All inter-company transactions and balances have been eliminated in consolidation. For any variable interest entity for which FibroGen is not the primary beneficiary, the Company uses the equity method of accounting. The Company operates as one segment &#8212; the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited condensed consolidated financial statements and related disclosures have been prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;) applicable to interim financial reporting and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and, therefore, do not include all information and footnote disclosures normally included in the annual consolidated financial statements. The financial information included herein should be read in conjunction with the consolidated financial statements and related notes in the Company&#8217;s Annual Report on Form 10-K filed with the SEC for the year ended December&#160;31, 2020 (&#8220;2020 Form 10-K&#8221;). </p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue, specifically, estimates in variable consideration for drug product sales, and estimates in transaction price per unit for the China performance obligation (as defined and discussed under <span style="font-style:italic;">Significant Accounting Policies</span> below). On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates. In the Company&#8217;s opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair statement of its financial position, results of operations and cash flows for the interim periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) per Share</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential common shares that would have the effect of increasing diluted earnings per share are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings per share. Diluted weighted average shares excluded potential common shares related to stock options, restricted stock units and shares to be purchased under the employee stock purchase plan totaling 11.4 million and 9.2 million for the three months ended June&#160;30, 2021 and 2020, and totaling 9.4 million and 9.0 million for the six months ended June&#160;30, 2021 and 2020, respectively, as they were anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s business is subject to risks and uncertainties, including those related to Severe Acute Respiratory Syndrome Coronavirus 2 and the resulting Coronavirus Disease (&#8220;COVID-19&#8221;) and the risk that we may not get approval of roxadustat in the U.S. for CKD anemia given the fact that the CRDAC voted to recommend not approving roxadustat in July 2021.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, obtaining second source suppliers, <span style="font-size:9.5pt;">regulatory approval from the FDA or other regulatory authorities, </span>the results of clinical trials and the achievement of milestones, market acceptance of the Company&#8217;s product candidates, competition from other products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock', window );">Recently Issued and Adopted Accounting Guidance</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued and Adopted Accounting Guidance</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span>. This guidance simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step up in the tax basis of goodwill, and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. This guidance was effective for annual reporting periods beginning after December 15, 2020 including interim periods. The Company adopted this guidance on January 1, 2021, and the adoption of this guidance did not have material impact to the Company&#8217;s condensed consolidated financial statements and related disclosures.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock', window );">Recently Issued Accounting Guidance Not Yet Adopted</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Guidance Not Yet Adopted</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued ASU 2020-04, <span style="font-style:italic;">Reference Rate Reform (Topic 848): </span><span style="font-style:italic;color:#000000;">Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span> (&#8220;<span style="font-style:italic;">ASU</span><span style="font-style:italic;"> </span><span style="font-style:italic;">2020</span><span style="font-style:italic;">-</span><span style="font-style:italic;">04</span><span style="font-style:italic;">&#8221;</span>)<span style="font-style:italic;">,</span> which provides companies with optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform. This guidance is effective as of March 12, 2020 through December 31, 2022. Subsequently in January 2021, the FASB issued ASU 2021-01, <span style="font-style:italic;">Reference Rate Reform (Topic 848): Scope</span>, which clarifies ASU 2020-04 and provides certain optional expedients that allow derivative instruments impacted by changes in the interest rate used for margining, discounting or contract price alignment to qualify for certain optional relief. ASU 2021-01 is effective in the same timeframe as ASU 2020-04. The relief offered by this guidance, if adopted, is available to companies for the period March 12, 2020 through December 31, 2022. <span style="Background-color:#FFFFFF;">The Company has certain lease arrangements that are linked to LIBOR. The Company is in the process of evaluating options for transitioning away from LIBOR and expects to complete this analysis by the time LIBOR is phased out. The Company did not elect to apply any of the expedients or exceptions as of and for the period ended June 30, 2021 and is currently evaluating the impact on its consolidated financial statements and related disclosures upon adoption of this guidance.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Significant Accounting Policies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the 2020 Form 10-K, except for the following:</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product revenue, net </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue, net consists of revenues from sales of roxadustat commercial product to Beijing Falikang Pharmaceutical Co., Ltd. (&#8220;Falikang&#8221;), and directly to pharmaceutical distributors located in a few provinces in China that are not covered by Falikang. Falikang is jointly owned by AstraZeneca AB (&#8220;AstraZeneca&#8221;) and FibroGen Beijing. The Company is not the primary beneficiary of Falikang for accounting purposes, as AstraZeneca is the final decision maker for all the roxadustat commercialization activities, and the Company lacks the power criterion to direct the activities of Falikang (see Note 3, <span style="font-style:italic;">Variable Interest Entity</span>). </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales to Falikang</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang became fully operational in January 2021, at which time FibroGen Beijing began selling roxadustat commercial product to Falikang. Falikang is FibroGen Beijing&#8217;s primary customer in China and substantially all roxadustat product sales to distributors in China are made by Falikang. Falikang bears inventory risk once it receives and accepts the product from FibroGen Beijing, and is responsible for delivering product to its distributors.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promises identified under the AstraZeneca China Agreement (as defined in Note 2, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>), including the license, co-development services and manufacturing of commercial supplies have been bundled into a single performance obligation (&#8220;China performance obligation&#8221;). Amounts of the transaction price allocable to this performance obligation under the Company&#8217;s agreements with AstraZeneca as outlined in Note 2, <span style="font-style:italic;">Collaboration Agreements and Revenues,</span> are deferred until control of the manufactured commercial product is transferred to AstraZeneca.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initiation of roxadustat sales to Falikang marked the beginning of the China performance obligation<span style="font-style:italic;">.</span><span style="color:#000000;"> Revenue is recognized at a point in time when control of roxadustat commercial product is transferred to Falikang. Revenue is recognized based on the estimated transaction price per unit and actual quantity of product delivered during the reporting period. Specifically, the transaction price per unit is determined based on the overall transaction price over the total estimated sales quantity for the estimated performance period in which the Company believes those sales would occur. The price per unit is subject to reassessment on a quarterly basis, which may result in cumulative catch up adjustments due to changes in estimates.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The overall transaction price for FibroGen Beijing&#8217;s product sales to Falikang includes the following elements of consideration: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Non-refundable upfront license fees; development, regulatory, and commercial milestone payments based on the China Agreement allocated to the China performance obligation;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Co-development billings resulting from the Company&#8217;s research and development efforts, which are reimbursable under the China Agreement;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:Noto Sans Symbols;"/><span style="color:#000000;"/><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interim profit/loss share between FibroGen Beijing and AstraZeneca from April 1, 2020 through December 31, 2020; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Net transfer price from product sales to Falikang from January 1, 2021 onwards. The net transfer price includes the following elements: </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Gross transfer price: The gross transfer price is based on a percentage of Falikang&#8217;s net sales to its distributors, which takes into account Falikang&#8217;s operating expenses and its payments to AstraZeneca for roxadustat sales and marketing efforts, capped at a percentage of Falikang&#8217;s net roxadustat sales. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Profit share: The gross transfer price is then adjusted for an estimated amount to achieve the 50/50 profit share from current period roxadustat net sales in China. The adjustments to date have been a reduction to the transfer price and the related accounts receivable from Falikang.&#160;&#160;</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The non-refundable upfront license fees constitute a <span style="color:#000000;">fixed consideration. The remainder of the above are variable consideration components, which may be constrained, and included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. The calculation of the above variable consideration includes key estimates such as total sales quantity, performance period, gross transfer price and profit share, which require a substantial degree of judgment.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any net transfer price in excess of the revenue recognized is deferred, and will be recognized over future periods as the performance obligations are satisfied.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Direct Sales to Distributors</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells roxadustat in China directly to a number of pharmaceutical distributors located in a few provinces in China that are not covered by Falikang. These pharmaceutical distributors are the Company&#8217;s customers. Hospitals order roxadustat through a distributor and the Company ships the product directly to the distributors. The delivery of roxadustat to a distributor represents a single performance obligation. Distributors are responsible for delivering product to end users, primarily hospitals. Distributors bear inventory risk once they receive and accept the product. Product revenue is recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The period between the transfer of control of the promised goods and when the Company receives payment is based on 60-day payment terms. As such, product revenue is not adjusted for the effects of a significant financing component.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is recorded at the net sales prices which includes the following estimates of variable consideration:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Price adjustment: When China&#8217;s National Healthcare Security Administration releases price guidance for roxadustat under the National Reimbursement Drug List, any channel inventories that have not been sold through by distributors, or to patients by hospitals and retailors, would be eligible for a price adjustment under the price protection. The price adjustment is calculated based on estimated channel inventory levels;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Contractual sales rebate: The contractual sales rebate is calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. The contractual sales rebate is recorded as a reduction to revenue at the point of sale to the distributor;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Non-key account hospital listing award: A one-time fixed-amount award is offered to a distributor who successfully lists the product with an eligible hospital, and who meets certain requirements. The Company considers this particular award to be an upfront payment to a customer within the definitions of Accounting Standards Codification (&#8220;ASC&#8221;) 606, <span style="font-style:italic;">Revenue from Contracts with Customers </span>(&#8220;ASC 606&#8221;). The non-key account hospital listing award is capitalized when the distributor meets eligibility requirements, and amortized as reduction to product revenue over future sales orders made by the distributor until exhausted;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:Noto Sans Symbols;"/><span style="color:#000000;"/><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other discounts and rebates, including key account hospital sales reba</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e and transfer fee discount, are generally based on a percentage of eligible gross sales made by the distributor and recorded as a reduction to revenue at the point of sale to the distributor; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Noto Sans Symbols;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#9679;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Sales returns: Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product&#8217;s expiration date.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The calculation of the above variable consideration is based on gross sales to the distributor, or estimated utilizing best available information from the distributor, maximum known exposures and other available information including estimated channel inventory levels and estimated sales made by the distributor to hospitals, which involve a substantial degree of judgment.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above rebates and discounts all together are eligible to be applied against the distributor&#8217;s future sales order, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible and in the same period that the related revenue is recorded. Due to the distributor&#8217;s legal right to offset, at each balance sheet date, the liability for rebates and discounts are presented as reductions of gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The distributor&#8217;s legal right of offset is calculated at the individual distributor level.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Acquisition Agreement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 16, 2021, the Company entered into an exclusive license and option agreement with HiFiBiO Therapeutics (&#8220;HiFiBiO&#8221;) (&#8220;HiFiBiO Agreement&#8221;), pursuant to which the Company exclusively licensed all product candidates in HiFiBiO&#8217;s Galectin-9 program and will have the sole right to develop them worldwide. The Company has also obtained exclusive options to license all product candidates in HiFiBiO&#8217;s CXCR5 and CCR8 programs. Under the terms of the HiFiBiO Agreement, the Company will make a $25 million upfront payment to HiFiBiO, as well as payments upon option exercise. In addition, HiFiBiO may receive up to a total of an additional $1.1 billion in future option, clinical, regulatory, and commercial milestone payments across all three programs. HiFiBiO will also be eligible to receive royalties based upon worldwide net sales. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The acquisition of these licenses was accounted for as an asset acquisition. The initial upfront payment of $25.0 million related to the license and options acquisition meets the definition of an in-process research and development asset (&#8220;IPR&amp;D asset&#8221;) under the ASC 730, <span style="font-style:italic;">Research and Development</span> (&#8220;ASC 730&#8221;). It relates to particular research and development projects and is determined to have no alternative future uses and thus have no separate economic value. Therefore, this upfront payment was recorded as a research and development expense during the three months ended June 30, 2021. As of June 30, 2021, this amount was not paid, and was included as accounts payable in the condensed consolidated balance sheet.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration payments will be evaluated and recognized when they become probable and reasonably estimable. The related IPR&amp;D asset will only be capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, amounts allocated to IPR&amp;D asset that have no alternative use will be expensed. As of June 30, 2021, all programs were at the early stage of development and the contingencies related to the milestone payments had not been resolved, therefore no contingent consideration was recognized. The Company will reassess the probability of future option payments and contingent payments on a quarterly basis.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock', window );">Collaboration Arrangements and Revenues</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Astellas Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Japan Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2005, the Company entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (&#8220;Japan Agreement&#8221;). Under this agreement, Astellas paid license fees and other consideration totaling $40.1&#160;million (such amounts were fully received as of February 2009). Under the Japan Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $132.5&#160;million in potential milestone payments, comprised of (i)&#160;up to $22.5&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of July 2016), (ii)&#160;up to $95.0&#160;million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $15.0&#160;million in milestone payments upon the achievement of specified commercial sales milestone. The Japan Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range of the list price published by Japan&#8217;s Ministry of Health, Labour and Welfare, adjusted for certain elements, after commercial launch. The aggregate amount of consideration received through June&#160;30, 2021 totals $105.1 million, excluding drug product revenue that is discussed separately below.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#8220;Japan Amendment&#8221;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">active pharmaceutical ingredient (&#8220;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">API</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</span><span style="font-weight:bold;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to Astellas </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the roxadustat commercial </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">purposes </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in Japan</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The commercial terms of the Japan Agreement relating to the transfer price for roxadustat for commercial use remain substantially the same, reflecting an adjustment for the manufacture of drug product by Astellas rather than FibroGen. The related drug product revenue, as described in details under </span><span style="font-style:italic;">Drug Product Revenue</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> section below, was $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.0)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the three </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and six </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">months ended </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respectively</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Europe Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2006, the Company entered into a separate collaboration agreement with Astellas for the development and commercialization of roxadustat for the treatment of anemia in Europe, the Middle East, the Commonwealth of Independent States and South Africa (&#8220;Europe Agreement&#8221;). Under the terms of the Europe Agreement, Astellas paid license fees and other upfront consideration totaling $320.0 million (such amounts were fully received as of February 2009). The Europe Agreement also provides for additional development and regulatory approval milestone payments up to $425.0&#160;million, comprised of (i)&#160;up to $90.0&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of 2012), (ii)&#160;up to $335.0&#160;million in milestone payments upon achievement of specified regulatory milestone events. Under the Europe Agreement, Astellas committed to fund 50% of joint development costs for Europe and North America, and all territory-specific costs. The Europe Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range. The aggregate amount of consideration received under the Europe Agreement through June&#160;30, 2021 totals $540.0 million, excluding drug product revenue that is discussed separately below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Europe Agreement, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. During the first quarter of 2021, the Company entered into an Astellas EU Supply Agreement (&#8220;EU Supply Agreement&#8221;) under the Europe Agreement with Astellas to define general forecast, order, supply and payment terms for Astellas to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The Company shipped bulk drug product to Astellas as pre-commercial supply for process validation purposes during the first quarter of 2021. The Company recorded the consideration of $11.8 million from this shipment as deferred revenue as of June 30, 2021, as described in details under <span style="font-style:italic;">Drug Product Revenue</span> section below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">U.S./Rest of World (&#8220;RoW&#8221;) Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective July 30, 2013, the Company entered into a collaboration agreement with AstraZeneca for the development and commercialization of roxadustat for the treatment of anemia in the U.S. and all other countries in the world, other than China, not previously licensed under the Astellas Europe and Astellas Japan Agreements (&#8220;U.S./RoW Agreement&#8221;). It also excludes China, which is covered by a separate agreement with AstraZeneca described below. Under the terms of the U.S./RoW Agreement, AstraZeneca paid upfront, non-contingent, non-refundable and time-based payments totaling $374.0 million (such amounts were fully received as of June 2016). Under the U.S./RoW Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $875.0 million in potential milestone payments, comprised of (i)&#160;up to $65.0 million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of April 2020), (ii)&#160;up to $325.0 million in milestone payments upon achievement of specified regulatory milestone events, (iii)&#160;up to $160.0&#160;million in milestone payments related to activity by potential competitors and (iv)&#160;up to approximately $325.0 million in milestone payments upon the achievement of specified commercial sales events. The aggregate amount of consideration received under the U.S./RoW Agreement through June&#160;30, 2021 totals $439.0 million, excluding drug product revenue that is discussed separately below.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the Company entered into Master Supply Agreement under the U.S./RoW Agreement with AstraZeneca (&#8220;Master Supply Agreement&#8221;) to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The Company shipped bulk drug product to AstraZeneca as commercial supply during 2020, and the first and second quarter of 2021. On July 15, 2021, the FDA CRDAC voted to recommend not approving roxadustat for the treatment of anemia due to CKD in adult patients. While the FDA is not required to follow the CRDAC&#8217;s vote, the agency considers the CRDAC&#8217;s non-binding recommendations when making its decision. The Company evaluated the impact of these developments in revising its estimates of variable consideration associated with drug product revenue. As a result, the Company updated the estimated transaction price, and recorded $11.2 million as deferred revenue as of June 30, 2021. See details under <span style="font-style:italic;">Drug Product Revenue</span> section below.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective July&#160;30, 2013, the Company (through its subsidiaries affiliated with China) entered into the China Agreement (&#8220;China Agreement&#8221;). Under the terms of the China Agreement, AstraZeneca agreed to pay upfront consideration totaling $28.2&#160;million (such amounts were fully received in 2014). Under the China Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $348.5 million in potential milestone payments, comprised of (i)&#160;up to $15.0 million in milestone payments upon achievement of specified clinical and development milestone events, (ii)&#160;up to $146.0 million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $187.5 million in milestone payments upon the achievement of specified commercial sales and other events. The China Agreement is structured as a 50/50 profit or loss share (as defined), which was amended under the China Amendment discussed below in the third quarter of 2020, and provides for joint development costs (including capital and equipment costs for construction of the manufacturing plant in China), to be shared equally during the development period. The aggregate amount of such consideration received for milestone and upfront payments through June&#160;30, 2021 totals $77.2 million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Amendment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, FibroGen China and AstraZeneca (together with FibroGen China, the &#8220;Parties&#8221;) entered into the China Amendment, effective July 1, 2020, relating to the development and commercialization of roxadustat in China. While the responsibilities of the Parties under the China Agreement remain largely the same, certain changes were made. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the China Amendment, in September 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Falikang, which performs roxadustat distribution, as well as conduct sales and marketing through AstraZeneca. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the China Amendment, the interim period is defined as the period from April 1, 2020 to the time when Falikang is fully operational. Falikang became fully operational in January 2021. The calculation for profit or loss share related to sales of roxadustat in China has changed for the period from April 1, 2020 onwards. With effect from April 1, 2020, the Parties have changed the method under which commercial expenses incurred by AstraZeneca are calculated and billed. AstraZeneca&#8217;s co-promotion expenses for their sales and marketing efforts are now subject to a cap of a percentage of net sales. Once AstraZeneca has been fully reimbursed for their sales and marketing costs under the cap, AstraZeneca will bill the co-promotion expenses based on actual costs on a prospective basis. In addition, the China Amendment has allowed for a higher cost of manufacturing incurred by FibroGen Beijing to be included in the profit or loss share calculation, subject to an annual cap, among other changes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since Falikang became fully operational in January 2021, substantially all direct roxadustat product sales to distributors in China are made by Falikang, while FibroGen Beijing continues to sell roxadustat product directly in a few provinces in China. FibroGen Beijing manufactures and supplies commercial product to Falikang based on a gross transfer price, which is adjusted for the estimated profit share. In addition, AstraZeneca now bills the co-promotion expenses to Falikang and to FibroGen Beijing, respectively, for its services provided to the respective entity. Development costs continue to be shared 50/50 between the Parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three and six months ended June&#160;30, 2021, the Company recognized $11.8 million and $22.2 million, respectively, of net product revenue from the sales to Falikang, as described in details under <span style="font-style:italic;">Product Revenue, Net</span> section below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to sales to Falikang, during the three and six months ended June&#160;30, 2021, the Company recognized $1.6 million and 6.6 million, respectively, of net product revenue from sales directly to distributors in a few provinces in China, <span style="Background-color:#FFFFFF;color:#000000;">as </span>described as direct sales<span style="Background-color:#FFFFFF;color:#000000;"> </span>under <span style="font-style:italic;">Product Revenue, Net</span> section below.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProductRevenuePolicyPolicyTextBlock', window );">Product Revenue, Net</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Product Revenue, Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue, net from the sales of roxadustat commercial product in China was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Direct Sales:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,230</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,833</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,659</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,205</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discounts and rebates</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(618</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,095</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,181</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,512</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales returns</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct sales revenue, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,611</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,693</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,566</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,648</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sales to Falikang:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross transfer price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,714</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,115</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Profit share</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,573</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,636</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net transfer price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,141</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,479</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000702">&#160;</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,381</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,312</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000706">&#160;</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales to Falikang revenue, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,760</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,167</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total product revenue, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,371</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,693</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,733</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,648</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Direct Sales</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue from direct roxadustat product sales to distributors in China is recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products, net of various sales rebates and discounts. The total discounts and rebates were $0.6 million and $4.1 million for the three months ended June&#160;30, 2021 and 2020, and $1.2 million and $4.5 million for the six months ended June&#160;30, 2021 and 2020, respectively, which primarily consisted of the contractual sales rebate calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor.  </p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rebates and discounts that the Company&#8217;s pharmaceutical distributors have earned are eligible to be applied against future sales orders, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible in the same period that the related revenue is recorded. Due to the Company&#8217;s legal right to offset, at each balance sheet date, the rebates and discounts are presented as reductions to gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The Company&#8217;s legal right to offset is calculated at the individual distributor level. The following table includes a roll-forward of the contract liabilities (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deduction</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Currency</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Translation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.6%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue - Direct sales - contract liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(883</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,410</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(183</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,793</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021 and December&#160;31, 2020, the total contract liabilities were $13.8 million and $15.1 million, which were included in accrued and other current liabilities in the condensed consolidated balance sheet. The rebates and discounts reflected as reductions to gross accounts receivable for direct sales was $0.8 million and $0.5 million as of June 30, 2021 and December 31, 2020, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales to Falikang &#8211; China Performance Obligation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since Falikang became fully operational in January 2021, substantially all direct roxadustat product sales to distributors in China are made by Falikang. FibroGen Beijing manufactures and supplies commercial product to Falikang. The net transfer price for FibroGen Beijing&#8217;s product sales to Falikang is based on a gross transfer price, which is adjusted to account for the 50/50 profit share for the period.  </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The roxadustat sales to Falikang marked the beginning of the Company&#8217;s China performance obligation under the Company&#8217;s agreements with AstraZeneca</span><span style="font-style:italic;Background-color:#FFFFFF;">.</span><span style="Background-color:#FFFFFF;"> Product revenue is based on the transaction price of the China performance obligation. </span><span style="color:#000000;">Revenue is recognized when control of product is transferred to Falikang, </span><span style="Background-color:#FFFFFF;">in an amount that </span><span style="color:#000000;">reflects the allocation of the transaction price to the performance obligation satisfied during the reporting period</span><span style="Background-color:#FFFFFF;">. </span><span style="color:#000000;">Any net transfer price in excess of the revenue recognized is added to the deferred balance to date, and will </span><span style="Background-color:#FFFFFF;">be recognized over future periods as the performance obligations are satisfied</span><span style="color:#000000;">. During the three and six months ended June&#160;30, 2021, following updates to its estimates, the Company deferred $5.4 million and $9.3 million, respectively, from the net transfer price to Falikang, which was included in the related deferred revenue of the China performance obligation.</span> </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes a roll-forward of the related deferred revenue that is considered as a contract liability (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognized as Revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue - AstraZeneca</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;China performance obligation - deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(137,338</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,588</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,167</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(149,759</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue includes amounts allocated to the China performance obligation under the AstraZeneca arrangement as revenue recognition associated with this unit of accounting is tied to the commercial launch of the products within China and to when the control of the manufactured commercial products is transferred to AstraZeneca. As of June&#160;30, 2021, approximately $6.3 million of the deferred revenue related to the China unit of accounting was included in short-term deferred revenue, which represents the amount of deferred revenue associated with the China unit of accounting that is expected to be recognized within the next 12 months, associated with the commercial sales in China.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reductions to gross accounts receivable related to product revenue to Falikang was $10.1 million as of June&#160;30, 2021.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DrugProductRevenuePolicyTextBlock', window );">Drug Product Revenue</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Drug Product Revenue<span style="font-weight:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue from commercial-grade API or bulk drug product sales to AstraZeneca and Astellas was as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,974</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,056</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,674</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,224</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,648</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(168</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During three months ended June 30, 2021, the Company shipped bulk drug product to AstraZeneca as commercial supply under the terms of the Master Supply Agreement. Based on the above-mentioned FDA CRDAC&#8217;s vote on July 15, 2021, the Company evaluated the impact of these developments in revising its estimates of variable consideration associated with drug product revenue. As a result, the Company updated the estimated transaction price, and recorded $11.2 million as deferred revenue as of June 30, 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended June 30, 2021, the Company recorded a reduction of $2.0 million to the drug product revenue related to the API shipments fulfilled under the terms of the Japan Amendment with Astellas in 2018, due to a change in estimated variable consideration. Specifically, the change in estimated variable consideration was based on the API held by Astellas at June 30, 2021, adjusted to reflect the changes in the estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others. This amount was recorded under deferred revenue in the condensed consolidated balance sheet as of June 30, 2021. During the first quarter of 2021, the Company recorded $4.0 million drug product revenue related to the same API shipments for the change in estimated variable consideration based on the API held by Astellas at March 31, 2021, under the same methodology. This amount was unbilled to Astellas as of March 31, 2021, and was billed and received from Astellas during the second quarter of 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2021, the Company shipped bulk drug product from process validation supplies for commercial purposes under the terms of the Europe Agreement and the EU Supply Agreement with Astellas. The Company recorded the consideration of $11.8 million from this shipment as deferred revenue as of June 30, 2021, due to a high degree of uncertainty associated with the final consideration. The deferred revenue will be recognized as and when uncertainty is resolved.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes a roll-forward of the above-mentioned deferred revenues that are considered as contract liabilities related to drug product (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognized as Revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - Japan Agreement</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,974</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,974</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - Europe Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,984</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,759</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,743</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca - U.S.&#160;Agreement</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue - deferred revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,984</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,904</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,888</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and principles of consolidation policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement and revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DescriptionOfOperationsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of operations policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DescriptionOfOperationsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DrugProductRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Drug product revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DrugProductRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ProductRevenuePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product revenue policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ProductRevenuePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting guidance not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently issued and adopted accounting guidance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449174252872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net</a></td>
<td class="text">Product revenue, net from the sales of roxadustat commercial product in China was as follows (in thousands):
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Direct Sales:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,230</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,833</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,659</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,205</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discounts and rebates</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(618</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,095</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,181</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,512</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales returns</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct sales revenue, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,611</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,693</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,566</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,648</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sales to Falikang:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross transfer price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,714</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,115</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Profit share</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,573</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,636</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net transfer price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,141</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,479</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000702">&#160;</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,381</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,312</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000706">&#160;</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales to Falikang revenue, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,760</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,167</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total product revenue, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,371</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,693</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,733</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,648</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Roll-forward of Related Contract Liabilities</a></td>
<td class="text">The following table includes a roll-forward of the contract liabilities (in thousands):
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deduction</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Currency</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Translation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.6%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue - Direct sales - contract liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(883</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,410</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(183</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,793</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ScheduleOfDrugProductRevenueTableTextBlock', window );">Schedule of Drug Product Revenue</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue from commercial-grade API or bulk drug product sales to AstraZeneca and Astellas was as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,974</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,056</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,674</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,224</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,648</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(168</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Roll-forward of Related Contract Liabilities</a></td>
<td class="text">The following table includes a roll-forward of the above-mentioned deferred revenues that are considered as contract liabilities related to drug product (in thousands):
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognized as Revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - Japan Agreement</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,974</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,974</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - Europe Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,984</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,759</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,743</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca - U.S.&#160;Agreement</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue - deferred revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,984</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,904</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,888</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Roll-forward of Related Contract Liabilities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes a roll-forward of the related deferred revenue that is considered as a contract liability (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognized as Revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue - AstraZeneca</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;China performance obligation - deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(137,338</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,588</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,167</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(149,759</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerMilestoneMethodTableTextBlock', window );">Summary of License Revenue and Development Revenue Recognized under Agreement</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts recognized as license revenue and development revenue under the Japan Agreement with Astellas were as follows (in thousands):&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.68%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">327</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Japan Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,529</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,559</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,876</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,906</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerMilestoneMethodTableTextBlock', window );">Summary of License Revenue and Development Revenue Recognized under Agreement</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts recognized as license revenue and development revenue under the Europe Agreement with Astellas were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,546</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,602</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,077</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,176</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Europe Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,951</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,951</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255,039</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255,372</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.68%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">742,990</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">743,323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:2.5%;text-indent:-2.5%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember', window );">U.S./RoW and China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerMilestoneMethodTableTextBlock', window );">Summary of License Revenue and Development Revenue Recognized under Agreement</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts recognized as revenue under the U.S./RoW and China Agreement with AstraZeneca were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.&#160;/&#160;RoW</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and China</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,993</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,750</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,969</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,305</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China performance obligation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">441</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">594</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement with AstraZeneca, along with any associated deferred revenue as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U.S.&#160;/&#160;RoW and China Agreements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160;2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.24%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">341,844</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">341,844</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.24%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-development, information sharing &amp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;committee services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">582,743</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,309</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">585,052</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.24%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China performance obligation *</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,167</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,759</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,926</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.24%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">946,754</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152,068</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,098,822</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* </span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">China performance obligation revenue is recognized as product revenue, as described in details under <span style="font-style:italic;">Product Revenue, Net</span> section below.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the consolidated balance sheets. As of June 30, 2021, deferred revenue included $146.8 million related to the U.S./RoW and China Agreement, which represents the net of $152.1 million of deferred revenue presented above and a $5.3 million unbilled co-development revenue under the China Amendment with AstraZeneca.</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ContractWithCustomerMilestoneMethodTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer milestone method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ContractWithCustomerMilestoneMethodTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ScheduleOfDrugProductRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of drug product revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ScheduleOfDrugProductRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449182269064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AcquisitionAndVariableInterestEntityAbstract', window );"><strong>Acquisition And Variable Interest Entity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Summary of Equity Method Investment</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s&#160;equity&#160;method&#160;investment&#160;in Falikang was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Entity</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership Percentage</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share of Net Income</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Currency</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Translation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,728</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,083</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AcquisitionAndVariableInterestEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition and variable interest entity abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AcquisitionAndVariableInterestEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449182553144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Values of Financial Assets Measured on Recurring Basis</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company&#8217;s financial assets that are measured on a recurring basis are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,483</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,483</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,099</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,099</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,568</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,568</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agency bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,284</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,284</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,490</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,490</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign government bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,151</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,151</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267,428</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,507</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">482,935</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590,591</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598,735</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449171605240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock', window );">Schedule of Lease Assets and Related Lease Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s lease assets and related lease liabilities were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Line Item</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets - cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,477</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,146</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,871</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,606</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets - cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,705</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,934</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,614</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,891</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,091</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,043</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,952</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,649</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,330</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,718</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,188</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,391</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, non-current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,196</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">853</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,943</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,762</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense were as follows (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of Operations Line Item</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease cost:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,777</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,653</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,393</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,247</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">534</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,049</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.92%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,744</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,162</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(275</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(306</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(575</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(598</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.92%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.12%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,488</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,136</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,607</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,262</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to leases were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,246</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">433</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from finance leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,010</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows from finance leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,326</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,992</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-cash: Right-of-use assets obtained in exchange for new lease liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,498</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-cash: Increase (decrease) resulting from lease modification:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,654</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,222</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,587</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,221</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,009</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, non-current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,943</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock', window );">Schedule of Lease Term and Discount Rate</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease term and discount rate were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (years):</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000938">1.3</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000939">2.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000940">7.3</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000941">1.8</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.55</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.39</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.74</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock', window );">Schedule of Maturities of Finance and Operating Leases Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of lease liabilities as of June&#160;30, 2021 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance&#160;Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating&#160;Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 (remaining six month period)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,534</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,517</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,454</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,798</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,193</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beyond 2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,881</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,377</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,463</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,914</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of lease assets and related lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of lease term and discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of maturities of finance and operating leases liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental cash flow information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449181781208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130,035</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,046</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,699</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353,361</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">678,393</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s investments consist of available-for-sale debt investments and marketable equity investments. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#8217;s investments by major investments type are summarized in the tables below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,499</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,483</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,400</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,400</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,589</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,568</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agency bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,288</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,284</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,489</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,490</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign government bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,151</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,151</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259,534</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259,609</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,147</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,272</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,388</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,190</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,303</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in-progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,541</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,114</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,799</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,113</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,530</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,530</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unbilled contract assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,256</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,147</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues from associated contracts</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,256</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,147</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unbilled contract assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,149</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,353</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,309</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,807</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,458</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,160</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,657</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,006</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,247</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,143</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,387</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,312</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,205</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,545</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,126</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,128</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,407</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">760</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,029</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,894</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(116,359</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(111,247</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,670</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,647</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued and Other Current Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical trial accruals</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,274</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,113</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related accruals</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,047</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,800</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities to pharmaceutical distributors</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,793</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued co-promotion expenses - current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,832</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,537</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat profit share to AstraZeneca</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property taxes and other taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,344</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,970</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional services</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,471</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,869</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,033</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,900</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued and other current liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,801</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,333</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of Other Long-term Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued long-term co-promotion expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,205</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,424</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,985</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,675</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,469</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,690</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other long-term liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,659</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,789</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449182196744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Recorded Stock-Based Compensation Expense</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was recorded directly to research and development and selling, general and administrative expense as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,681</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,780</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,903</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,417</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,320</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,864</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,482</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,143</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,001</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,385</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,560</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to estimate the fair value of stock options granted and purchases under the Company&#8217;s 2014 Employee Share Purchase Plan (&#8220;ESPP&#8221;) using the Black-Scholes option valuation model were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001102">5.6</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001103">5.5</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001104">5.7</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001105">5.7</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average estimated fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.91</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.72</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.38</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ESPPs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001122">0.5 - 2.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001123">0.5 - 2.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001124">0.5 - 2.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001125">0.5 - 2.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.5 - 104.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.5 - 77.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.5 - 104.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.5 - 77.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0 - 2.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2 - 2.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0 - 2.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2 - 2.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average estimated fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.60</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.82</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.69</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based payment award stock options and employee stock purchase plan valuation assumptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449255048472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Detail)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms', window );">Description of payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The period between the transfer of control of the promised goods and when the Company receives payment is based on 60-day payment terms.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DescriptionOfSalesReturn', window );">Description of sales return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product&#8217;s expiration date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProfitSharePercent', window );">Profit share percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_HiFiBiOAgreementMember', window );">HiFiBiO Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_InitialUpfrontPayment', window );">Initial upfront payment</a></td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments', window );">Maximum additional future option, clinical, regulatory, and commercial milestone payments</a></td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccountingPolicyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccountingPolicyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DescriptionOfSalesReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of sales return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DescriptionOfSalesReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_InitialUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_InitialUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum additional future option, clinical, regulatory, and commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ProfitSharePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit share percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ProfitSharePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_HiFiBiOAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_HiFiBiOAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449183333032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">35 Months Ended</th>
<th class="th" colspan="1">45 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2006</div></th>
<th class="th"><div>Jun. 30, 2005</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2009</div></th>
<th class="th"><div>Feb. 28, 2009</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,364<span></span>
</td>
<td class="nump">$ 42,888<span></span>
</td>
<td class="nump">$ 62,793<span></span>
</td>
<td class="nump">$ 67,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,648)<span></span>
</td>
<td class="nump">$ 8,238<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="nump">$ 8,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments', window );">Upfront, non-contingent and time-based payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CommercialSalesMilestone', window );">Commercial sales milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AdditionalConsiderationBasedOnNetSales', window );">Additional consideration based on net sales description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the low 20% range of the list price<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue', window );">Aggregate consideration received excluding drug product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Japan [Member] | Clinical and Development Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Japan [Member] | Regulatory Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Japan [Member] | Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments', window );">Upfront, non-contingent and time-based payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AdditionalConsiderationBasedOnNetSales', window );">Additional consideration based on net sales description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">low 20% range<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue', window );">Aggregate consideration received excluding drug product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DevelopmentAndRegulatoryApprovalMilestones', window );">Development and regulatory approval milestones</a></td>
<td class="nump">$ 425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PercentageOfFundingForCosts', window );">Percentage of joint development costs committed to fund</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Europe [Member] | Clinical and Development Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Europe [Member] | Regulatory Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="nump">$ 335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Europe [Member] | Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AdditionalConsiderationBasedOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional consideration based on net sales of product as defined under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AdditionalConsiderationBasedOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CommercialSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payments related to commercial sales under the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CommercialSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DevelopmentAndRegulatoryApprovalMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DevelopmentAndRegulatoryApprovalMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PercentageOfFundingForCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PercentageOfFundingForCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PotentialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PotentialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_ClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_ClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449254285960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 30, 2013</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,364<span></span>
</td>
<td class="nump">$ 42,888<span></span>
</td>
<td class="nump">62,793<span></span>
</td>
<td class="nump">$ 67,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,371<span></span>
</td>
<td class="nump">15,693<span></span>
</td>
<td class="nump">28,733<span></span>
</td>
<td class="nump">20,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,648)<span></span>
</td>
<td class="nump">8,238<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="nump">8,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,674)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,224)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments', window );">Upfront, non-contingent, non-refundable and time-based payments</a></td>
<td class="nump">$ 374,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="nump">875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CommercialSalesMilestone', window );">Commercial sales milestone</a></td>
<td class="nump">325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue', window );">Aggregate consideration received excluding drug product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW [Member] | Clinical and Development Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW [Member] | Regulatory Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="nump">325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW [Member] | Deferred Approval Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="nump">348,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments', window );">Proceeds from upfront, non-contingent and non-refundable payments</a></td>
<td class="nump">28,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CommercialSalesAndOtherEventsMilestone', window );">Commercial sales and other events milestone</a></td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments', window );">Aggregate consideration received for milestone and upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | China [Member] | Product Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | China [Member] | Clinical and Development Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | China [Member] | Regulatory Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="nump">$ 146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_DirectSalesMember', window );">Direct Sales [Member] | Product Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,611<span></span>
</td>
<td class="nump">$ 15,693<span></span>
</td>
<td class="nump">6,566<span></span>
</td>
<td class="nump">$ 20,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_DirectSalesMember', window );">Direct Sales [Member] | China [Member] | Product Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement aggregate consideration for milestone and upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CommercialSalesAndOtherEventsMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial sales and other events milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CommercialSalesAndOtherEventsMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CommercialSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payments related to commercial sales under the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CommercialSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PotentialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PotentialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_ClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_ClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_DeferredApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_DeferredApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_DirectSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_DirectSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449254656456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 24,364<span></span>
</td>
<td class="nump">$ 42,888<span></span>
</td>
<td class="nump">$ 62,793<span></span>
</td>
<td class="nump">$ 67,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember', window );">Development Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">19,641<span></span>
</td>
<td class="nump">18,957<span></span>
</td>
<td class="nump">34,228<span></span>
</td>
<td class="nump">38,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | License Revenue [Member] | Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Development Revenue [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">2,546<span></span>
</td>
<td class="nump">4,602<span></span>
</td>
<td class="nump">6,077<span></span>
</td>
<td class="nump">9,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 16,993<span></span>
</td>
<td class="nump">$ 13,750<span></span>
</td>
<td class="nump">$ 27,969<span></span>
</td>
<td class="nump">$ 28,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449255355992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">$ 5,256<span></span>
</td>
<td class="nump">$ 2,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">116,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">116,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Japan [Member] | Development Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">16,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">16,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Japan [Member] | License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">100,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">100,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">742,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">743,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Europe [Member] | Development Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">255,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">255,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Europe [Member] | License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">487,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">487,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">149,759<span></span>
</td>
<td class="nump">$ 137,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW and China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">946,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">152,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">1,098,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">341,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">341,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | Co-development, information sharing &amp; committee services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">582,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">2,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">585,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | China performance obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">22,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">149,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">$ 171,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CashConsiderationReceivedUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_ChinaPerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_ChinaPerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449265898408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling', window );">Remainder of transaction price, variable consideration from estimated future co-development billing</a></td>
<td class="nump">$ 10.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member] | Astellas Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Changes in revenue from changes to estimated variable consideration</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember', window );">U.S./RoW and China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling', window );">Remainder of transaction price, variable consideration from estimated future co-development billing</a></td>
<td class="nump">34.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember', window );">U.S./RoW and China [Member] | AstraZeneca Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Changes in revenue from changes to estimated variable consideration</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable consideration payment received from estimated future co-development billing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449254721800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current ($9,381 and $4,636 to a related party)</a></td>
<td class="nump">$ 152,865<span></span>
</td>
<td class="nump">$ 138,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">5,256<span></span>
</td>
<td class="nump">2,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SuppliesNet', window );">Net unbilled co-development revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">149,759<span></span>
</td>
<td class="nump">$ 137,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SuppliesNet', window );">Net unbilled co-development revenue</a></td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current ($9,381 and $4,636 to a related party)</a></td>
<td class="nump">146,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">152,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SuppliesNet', window );">Net unbilled co-development revenue</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_SuppliesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplies, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_SuppliesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449181933928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Summary of Product Revenue, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 24,364<span></span>
</td>
<td class="nump">$ 42,888<span></span>
</td>
<td class="nump">$ 62,793<span></span>
</td>
<td class="nump">$ 67,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DiscountsAndRebatesMember', window );">Discounts and Rebates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">13,371<span></span>
</td>
<td class="nump">15,693<span></span>
</td>
<td class="nump">28,733<span></span>
</td>
<td class="nump">20,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net [Member] | Direct Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax', window );">Gross revenue</a></td>
<td class="nump">2,230<span></span>
</td>
<td class="nump">19,833<span></span>
</td>
<td class="nump">7,659<span></span>
</td>
<td class="nump">25,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,611<span></span>
</td>
<td class="nump">15,693<span></span>
</td>
<td class="nump">6,566<span></span>
</td>
<td class="nump">20,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net [Member] | Direct Sales [Member] | Discounts and Rebates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="num">(618)<span></span>
</td>
<td class="num">(4,095)<span></span>
</td>
<td class="num">(1,181)<span></span>
</td>
<td class="num">(4,512)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net [Member] | Direct Sales [Member] | Sales Returns [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net [Member] | Sales To Falikang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">11,760<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,167<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax', window );">Gross transfer price</a></td>
<td class="nump">26,714<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">51,115<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net [Member] | Sales To Falikang [Member] | Profit Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="num">(9,573)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,636)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net [Member] | Sales To Falikang [Member] | Net Transfer Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">17,141<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,479<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net [Member] | Sales To Falikang [Member] | Increase in Deferred Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="num">$ (5,381)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (9,312)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue gross from contract with customer excluding assessed tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue gross transfer price from contract with customer excluding assessed tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DiscountsAndRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DiscountsAndRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_DirectSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_DirectSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_SalesToFalikangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_SalesToFalikangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_ProfitShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_ProfitShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_NetTransferPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_NetTransferPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_IncreaseInDeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_IncreaseInDeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449261830632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Product Revenue, Net - Additional Information 1 (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 24,364<span></span>
</td>
<td class="nump">$ 42,888<span></span>
</td>
<td class="nump">$ 62,793<span></span>
</td>
<td class="nump">$ 67,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DiscountsAndRebatesMember', window );">Discounts and Rebates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_RebatesAndDiscountsMember', window );">Rebates and Discounts [Member] | Gross Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_RebatesAndDiscountsMember', window );">Rebates and Discounts [Member] | Contract Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DeferredForFutureRecognitionMember', window );">Constrained for Future Recognition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DiscountsAndRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DiscountsAndRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_RebatesAndDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_RebatesAndDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=fgen_GrossAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=fgen_GrossAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=fgen_ContractLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=fgen_ContractLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DeferredForFutureRecognitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DeferredForFutureRecognitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449254956488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Roll-forward of Related Contract Liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityLineItems', window );"><strong>Contract with Customer Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="num">$ (2,147)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at June 30, 2021</a></td>
<td class="num">(5,256)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityLineItems', window );"><strong>Contract with Customer Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="num">(137,338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="num">(34,588)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized as Revenue</a></td>
<td class="nump">22,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at June 30, 2021</a></td>
<td class="num">(149,759)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net [Member] | Direct Sales [Member] | Contract Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityLineItems', window );"><strong>Contract with Customer Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="num">(15,137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="num">(883)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityDeduction', window );">Deduction</a></td>
<td class="nump">2,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther', window );">Currency Translation and Other</a></td>
<td class="num">(183)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at June 30, 2021</a></td>
<td class="num">(13,793)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityLineItems', window );"><strong>Contract with Customer Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="num">(5,984)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="num">(24,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized as Revenue</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at June 30, 2021</a></td>
<td class="num">(30,888)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member] | AstraZeneca Agreements [Member] | U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityLineItems', window );"><strong>Contract with Customer Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="num">(11,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized as Revenue</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at June 30, 2021</a></td>
<td class="num">(11,171)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member] | Astellas Agreement [Member] | Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityLineItems', window );"><strong>Contract with Customer Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="num">(1,974)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized as Revenue</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at June 30, 2021</a></td>
<td class="num">(1,974)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member] | Astellas Agreement [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityLineItems', window );"><strong>Contract with Customer Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="num">(5,984)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="num">(11,759)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized as Revenue</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at June 30, 2021</a></td>
<td class="num">$ (17,743)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability additions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ContractWithCustomerLiabilityDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability deduction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ContractWithCustomerLiabilityDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer, liability, increase (decrease) from current translation and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ContractWithCustomerLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ContractWithCustomerLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_DirectSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_DirectSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=fgen_ContractLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=fgen_ContractLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449254573048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Deferred Revenue - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 5,256<span></span>
</td>
<td class="nump">$ 2,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net [Member] | Beijing Falikang Pharmaceutical Co Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Reductions to gross accounts receivable</a></td>
<td class="nump">10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">149,759<span></span>
</td>
<td class="nump">$ 137,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=fgen_BeijingFalikangPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=fgen_BeijingFalikangPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449178181112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">$ 24,364<span></span>
</td>
<td class="nump">$ 42,888<span></span>
</td>
<td class="nump">$ 62,793<span></span>
</td>
<td class="nump">$ 67,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="num">(8,648)<span></span>
</td>
<td class="nump">8,238<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="nump">8,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member] | Astellas Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="num">(1,974)<span></span>
</td>
<td class="nump">8,238<span></span>
</td>
<td class="nump">2,056<span></span>
</td>
<td class="nump">8,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member] | AstraZeneca Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="num">$ (6,674)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2,224)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449182266104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Drug Product Revenue - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred Revenue</a></td>
<td class="nump">$ 25,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue recognized</a></td>
<td class="nump">24,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,888<span></span>
</td>
<td class="nump">62,793<span></span>
</td>
<td class="nump">$ 67,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred Revenue</a></td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue recognized</a></td>
<td class="num">(8,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,238<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="nump">8,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member] | Astellas Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue recognized</a></td>
<td class="num">(1,974)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,238<span></span>
</td>
<td class="nump">2,056<span></span>
</td>
<td class="nump">$ 8,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member] | Europe [Member] | Astellas Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred Revenue</a></td>
<td class="nump">11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member] | API Shipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue recognized</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=fgen_APIShipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=fgen_APIShipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449177406600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entity - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember', window );">Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | Beijing Falikang Pharmaceutical Co Ltd | FibroGen Beijing [Member] | AstraZenecaAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AcquisitionAndVariableInterestEntityLineItems', window );"><strong>Acquisition And Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of outstanding shares acquired</a></td>
<td class="nump">51.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AcquisitionAndVariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition and variable interest entity line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AcquisitionAndVariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=fgen_BeijingFalikangPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=fgen_BeijingFalikangPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_FibroGenBeijingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_FibroGenBeijingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=fgen_AstraZenecaABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=fgen_AstraZenecaABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449181632504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entity - Summary of Equity Method Investment (Detail) - Beijing Falikang Pharmaceutical Co. Ltd [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AcquisitionAndVariableInterestEntityLineItems', window );"><strong>Acquisition And Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership Percentage</a></td>
<td class="nump">51.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning balance</a></td>
<td class="nump">$ 2,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of Net Income</a></td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation', window );">Currency Translation</a></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending balance</a></td>
<td class="nump">$ 3,083<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AcquisitionAndVariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition and variable interest entity line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AcquisitionAndVariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment increase (decrease) from currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=fgen_BeijingFalikangPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=fgen_BeijingFalikangPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449177641112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">$ 259,609<span></span>
</td>
<td class="nump">$ 8,388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">104,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">69,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">12,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember', window );">Foreign government bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">12,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=fgen_BondAndMutualFundsMember', window );">Bond and mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of financial assets</a></td>
<td class="nump">482,935<span></span>
</td>
<td class="nump">598,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">220,627<span></span>
</td>
<td class="nump">590,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">104,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">72,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | U.S. government bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">46,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Agency bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">14,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Asset-backed securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">12,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Foreign government bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">12,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Bond and mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Equity investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of financial assets</a></td>
<td class="nump">267,428<span></span>
</td>
<td class="nump">590,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">220,627<span></span>
</td>
<td class="nump">590,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | U.S. government bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">46,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Agency bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Asset-backed securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Foreign government bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Bond and mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Equity investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of financial assets</a></td>
<td class="nump">215,507<span></span>
</td>
<td class="nump">8,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">104,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">72,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | U.S. government bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Agency bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">14,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Asset-backed securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">12,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Foreign government bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">12,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Bond and mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Equity investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | U.S. government bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Agency bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Asset-backed securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Foreign government bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Bond and mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Equity investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=fgen_BondAndMutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=fgen_BondAndMutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=fgen_USGovernmentBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=fgen_USGovernmentBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=fgen_AgencyBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=fgen_AgencyBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449181856824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Transfers of assets from level 1 to 2</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Transfers of assets from level 2 to 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfers of assets into level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers of assets out of level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities fair value disclosure</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Transfers of liabilities from level 1 to 2</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Transfers of liabilities from level 2 to 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Transfers of liabilities into level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfers of liabilities out of level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449255163576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_FinanceLeaseRightOfUseAssetsCost', window );">Right-of-use assets - cost</a></td>
<td class="nump">$ 2,007<span></span>
</td>
<td class="nump">$ 50,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_FinanceLeaseAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,146)<span></span>
</td>
<td class="num">(20,871)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets, net</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">29,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_OperatingLeaseRightOfUseAssetsCost', window );">Right-of-use assets - cost</a></td>
<td class="nump">100,705<span></span>
</td>
<td class="nump">3,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_OperatingLeaseAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(3,614)<span></span>
</td>
<td class="num">(1,891)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">97,091<span></span>
</td>
<td class="nump">2,043<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_FinanceLeaseAndOperatingLeaseAssets', window );">Total lease assets</a></td>
<td class="nump">97,952<span></span>
</td>
<td class="nump">31,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">12,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">10,718<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">25,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">94,196<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_FinanceLeaseAndOperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 104,943<span></span>
</td>
<td class="nump">$ 39,762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_FinanceLeaseAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_FinanceLeaseAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_FinanceLeaseAndOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease and operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_FinanceLeaseAndOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_FinanceLeaseAndOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease and operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_FinanceLeaseAndOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_FinanceLeaseRightOfUseAssetsCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease, right-of-use assets - cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_FinanceLeaseRightOfUseAssetsCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_OperatingLeaseAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease, accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_OperatingLeaseAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_OperatingLeaseRightOfUseAssetsCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease, right-of-use assets - cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_OperatingLeaseRightOfUseAssetsCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449176213144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 01, 2021 </div>
<div>USD ($) </div>
<div>Option</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payment related to lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,246<span></span>
</td>
<td class="nump">$ 433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201901Member', window );">ASC 842 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,654<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,222<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_ShorensteinPropertiesLLCMember', window );">Shorenstein Properties LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Lessee, finance lease, initial lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_LesseeFinanceLeaseExpirationPeriod', window );">Lessee, finance lease, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_ShorensteinPropertiesLLCMember', window );">Shorenstein Properties LLC [Member] | Lease Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend', window );">Lessee, finance lease, existence of option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod', window );">Lessee, finance lease, additional lease expiration period</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate', window );">Percentage increases on each anniversary of rent commencement date 2023</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseOptionToExtend', window );">Lessee, finance lease, option to extend</a></td>
<td class="text">Under the terms of the Lease Amendment, the Company has two optional rights to each extend the lease for an additional five years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_NumberOfOptionalRightsToExtendLease', window );">Optional rights to extend lease | Option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm', window );">Lessee, finance lease, option to extend the additional lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ScheduledRentCommencementYearOptionOne', window );">Rent increase commencement year first option</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo', window );">Percentage increases on each anniversary of rent commencement date 2028</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ScheduledRentCommencementYearOptionTwo', window );">Rent increase commencement year second option</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_ShorensteinPropertiesLLCMember', window );">Shorenstein Properties LLC [Member] | Lease Amendment [Member] | ASC 842 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">$ 24,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liability</a></td>
<td class="nump">32,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">93,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 101,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payment related to lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_BeijingEconomicTechnologicalDevelopmentAreaMember', window );">Beijing Economic-Technological Development Area [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_LesseeOperatingLeaseExpirationPeriod', window );">Lessee, operating lease, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, finance lease, additional lease expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_LesseeFinanceLeaseExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, finance lease, expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_LesseeFinanceLeaseExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, finance lease, option to extend the additional lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_LesseeOperatingLeaseExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_LesseeOperatingLeaseExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_NumberOfOptionalRightsToExtendLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of optional rights to extend lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_NumberOfOptionalRightsToExtendLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage increases on anniversary of rent commencement date option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage increases on each anniversary of rent commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ScheduledRentCommencementYearOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent commencement year option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ScheduledRentCommencementYearOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ScheduledRentCommencementYearOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Scheduled rent commencement year option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ScheduledRentCommencementYearOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's finance lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201901Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201901Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_ShorensteinPropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_ShorensteinPropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=fgen_LeaseAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=fgen_LeaseAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_BeijingEconomicTechnologicalDevelopmentAreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_BeijingEconomicTechnologicalDevelopmentAreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449181164440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 1,777<span></span>
</td>
<td class="nump">$ 2,653<span></span>
</td>
<td class="nump">$ 4,393<span></span>
</td>
<td class="nump">$ 5,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="nump">627<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">1,744<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">2,162<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(275)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
<td class="num">(575)<span></span>
</td>
<td class="num">(598)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 3,488<span></span>
</td>
<td class="nump">$ 3,136<span></span>
</td>
<td class="nump">$ 6,607<span></span>
</td>
<td class="nump">$ 6,262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449255117144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 2,246<span></span>
</td>
<td class="nump">$ 433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">628<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RepaymentsOfFinanceLeaseLiabilities', window );">Financing cash flows from finance leases</a></td>
<td class="nump">5,326<span></span>
</td>
<td class="nump">5,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract', window );"><strong>Non-cash: Right-of-use assets obtained in exchange for new lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">3,498<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract', window );"><strong>Non-cash: Increase (decrease) resulting from lease modification:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="num">(861)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29,606)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">97,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current</a></td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,330)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">10,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, non-current</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">94,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201901Member', window );">ASC 842 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract', window );"><strong>Non-cash: Increase (decrease) resulting from lease modification:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="num">(24,654)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">93,222<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current</a></td>
<td class="num">(12,587)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">9,221<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, non-current</a></td>
<td class="num">(20,009)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">$ 91,943<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash increase decrease resulting from lease modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash right of use assets obtained in exchange for new lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RepaymentsOfFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments of finance lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RepaymentsOfFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201901Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201901Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449171542872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Lease Term and Discount Rate (Detail)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted-average remaining lease term (years):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted-average discount rate:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">4.55%<span></span>
</td>
<td class="nump">4.39%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.74%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average remaining lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449254696040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (remaining six month period)</a></td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour', window );">Beyond 2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (remaining six month period)</a></td>
<td class="nump">7,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">15,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">13,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">16,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">18,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Beyond 2025</a></td>
<td class="nump">53,881<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">125,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(20,463)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 104,914<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449171537368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash And Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 130,035<span></span>
</td>
<td class="nump">$ 88,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaperAtCarryingValue', window );">Commercial paper</a></td>
<td class="nump">2,699<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">220,627<span></span>
</td>
<td class="nump">590,347<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 353,361<span></span>
</td>
<td class="nump">$ 678,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaperAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaperAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449178074344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 353,361,000<span></span>
</td>
<td class="nump">$ 353,361,000<span></span>
</td>
<td class="nump">$ 678,393,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Other-than-temporary impairment loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance', window );">Percentage of pre-launch inventory capitalized of aggregate inventory balance</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SuppliesNet', window );">Net unbilled co-development revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Profit share liability</a></td>
<td class="nump">25,234,000<span></span>
</td>
<td class="nump">25,234,000<span></span>
</td>
<td class="nump">6,547,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SuppliesNet', window );">Net unbilled co-development revenue</a></td>
<td class="nump">5,300,000<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Profit share liability</a></td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AvailableForSaleSecuritiesContractualMaturityPeriod', window );">Contractual maturities of available-for-sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember', window );">Foreign subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 85,100,000<span></span>
</td>
<td class="nump">$ 85,100,000<span></span>
</td>
<td class="nump">$ 66,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AvailableForSaleSecuritiesContractualMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum contractual maturity period for available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AvailableForSaleSecuritiesContractualMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of pre-launch inventory capitalized of aggregate inventory balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_SuppliesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplies, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_SuppliesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449177444600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 259,534<span></span>
</td>
<td class="nump">$ 8,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">259,609<span></span>
</td>
<td class="nump">8,388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">104,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">104,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">69,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">69,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">46,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">46,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_BondsMember', window );">Agency bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">14,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">14,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">12,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">12,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember', window );">Foreign government bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">12,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">12,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=fgen_BondAndMutualFundsMember', window );">Bond and mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_BondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_BondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=fgen_BondAndMutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=fgen_BondAndMutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449173873944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsAbstract', window );"><strong>Schedule Of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 1,190<span></span>
</td>
<td class="nump">$ 2,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-progress</a></td>
<td class="nump">15,541<span></span>
</td>
<td class="nump">8,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">7,799<span></span>
</td>
<td class="nump">6,113<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 24,530<span></span>
</td>
<td class="nump">$ 16,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449173312472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Unbilled contract assets</a></td>
<td class="nump">$ 5,256<span></span>
</td>
<td class="nump">$ 2,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenues from associated contracts</a></td>
<td class="num">(5,256)<span></span>
</td>
<td class="num">(2,147)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SuppliesNet', window );">Net unbilled contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid assets</a></td>
<td class="nump">7,149<span></span>
</td>
<td class="nump">8,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,309<span></span>
</td>
<td class="nump">1,807<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 8,458<span></span>
</td>
<td class="nump">$ 10,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_SuppliesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplies, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_SuppliesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449255315880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 147,029<span></span>
</td>
<td class="nump">$ 144,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(116,359)<span></span>
</td>
<td class="num">(111,247)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">30,670<span></span>
</td>
<td class="nump">33,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">102,657<span></span>
</td>
<td class="nump">102,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fgen_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">19,247<span></span>
</td>
<td class="nump">18,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">8,387<span></span>
</td>
<td class="nump">8,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">9,205<span></span>
</td>
<td class="nump">9,545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">6,126<span></span>
</td>
<td class="nump">6,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,407<span></span>
</td>
<td class="nump">$ 760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fgen_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fgen_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449176204280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedPreclinicalAndClinicalTrialCurrent', window );">Preclinical and clinical trial accruals</a></td>
<td class="nump">$ 65,274<span></span>
</td>
<td class="nump">$ 44,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related accruals</a></td>
<td class="nump">18,047<span></span>
</td>
<td class="nump">22,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent', window );">Contract liabilities to pharmaceutical distributors</a></td>
<td class="nump">13,793<span></span>
</td>
<td class="nump">15,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedCoPromotionExpensesCurrent', window );">Accrued co-promotion expenses - current</a></td>
<td class="nump">20,832<span></span>
</td>
<td class="nump">11,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedProfitShareCurrent', window );">Roxadustat profit share to AstraZeneca</a></td>
<td class="nump">7,007<span></span>
</td>
<td class="nump">7,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PropertyTaxesAndOtherCurrent', window );">Property taxes and other taxes</a></td>
<td class="nump">10,344<span></span>
</td>
<td class="nump">5,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">7,471<span></span>
</td>
<td class="nump">4,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">5,033<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 147,801<span></span>
</td>
<td class="nump">$ 118,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedCoPromotionExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued co-promotion expenses - current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedCoPromotionExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued contract liabilities to pharmaceutical distributors current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedPreclinicalAndClinicalTrialCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to pre-clinical and clinical trial activities, including those performed by third parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedPreclinicalAndClinicalTrialCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedProfitShareCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued profit share current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedProfitShareCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PropertyTaxesAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property taxes and other current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PropertyTaxesAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449255276056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Other Long-term Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrentAbstract', window );"><strong>Other Liabilities Noncurrent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedLongTermCoPromotionLiabilityNonCurrent', window );">Accrued long-term co-promotion expenses</a></td>
<td class="nump">$ 19,205<span></span>
</td>
<td class="nump">$ 27,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Other long-term tax liabilities</a></td>
<td class="nump">8,985<span></span>
</td>
<td class="nump">8,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">2,469<span></span>
</td>
<td class="nump">2,690<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">$ 30,659<span></span>
</td>
<td class="nump">$ 38,789<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedLongTermCoPromotionLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued long term co promotion liability non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedLongTermCoPromotionLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449181495480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 19,001<span></span>
</td>
<td class="nump">$ 17,644<span></span>
</td>
<td class="nump">$ 38,385<span></span>
</td>
<td class="nump">$ 34,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">10,681<span></span>
</td>
<td class="nump">10,780<span></span>
</td>
<td class="nump">22,903<span></span>
</td>
<td class="nump">21,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 8,320<span></span>
</td>
<td class="nump">$ 6,864<span></span>
</td>
<td class="nump">$ 15,482<span></span>
</td>
<td class="nump">$ 13,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449255186824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">63.40%<span></span>
</td>
<td class="nump">69.20%<span></span>
</td>
<td class="nump">59.40%<span></span>
</td>
<td class="nump">68.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value</a></td>
<td class="nump">$ 11.91<span></span>
</td>
<td class="nump">$ 21.72<span></span>
</td>
<td class="nump">$ 25.38<span></span>
</td>
<td class="nump">$ 17.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">2014 Employee Share Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">47.50%<span></span>
</td>
<td class="nump">49.50%<span></span>
</td>
<td class="nump">47.50%<span></span>
</td>
<td class="nump">49.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">104.20%<span></span>
</td>
<td class="nump">77.10%<span></span>
</td>
<td class="nump">104.20%<span></span>
</td>
<td class="nump">77.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value</a></td>
<td class="nump">$ 13.60<span></span>
</td>
<td class="nump">$ 17.82<span></span>
</td>
<td class="nump">$ 14.69<span></span>
</td>
<td class="nump">$ 18.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">2014 Employee Share Purchase Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">2014 Employee Share Purchase Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449255332472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from related party</a></td>
<td class="nump">$ 13,352,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,352,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,127,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accrued liabilities to related party</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">5,256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,147,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_AstellasMember', window );">Astellas [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DrugProductRevenueFromRelatedParty', window );">Drug product revenue from a related party</a></td>
<td class="num">(2,000,000.0)<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_AstellasMember', window );">Astellas [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue related to collaboration agreements</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from related party</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accrued liabilities to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_FalikangMember', window );">Falikang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from related party</a></td>
<td class="nump">10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Investment income</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Percentage of outstanding shares owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_MiscellaneousReceivables', window );">Miscellaneous receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_FalikangMember', window );">Falikang [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue related to collaboration agreements</a></td>
<td class="nump">$ 11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DrugProductRevenueFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Drug product revenue from related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DrugProductRevenueFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_MiscellaneousReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_MiscellaneousReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_AstellasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_AstellasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_FalikangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_FalikangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449178067464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2021 </div>
<div>PutativeClassAction</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>PutativeClassAction</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Outstanding non-cancelable purchase obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Putative securities class action complaints filed | PutativeClassAction</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ManufactureAndSupplyOfRoxadustatMember', window );">Manufacture and Supply of Roxadustat [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Outstanding non-cancelable purchase obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ManufactureAndSupplyOfPamrevlumabMember', window );">Manufacture and Supply of Pamrevlumab [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Outstanding non-cancelable purchase obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_OtherPurchasesMember', window );">Other Purchases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Outstanding non-cancelable purchase obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember', window );">Research and Pre-Clinical Stage Development Programs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_MaximumFutureMilestonePayments', window );">Maximum future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 359.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_MaximumFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum future milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_MaximumFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ManufactureAndSupplyOfRoxadustatMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ManufactureAndSupplyOfRoxadustatMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ManufactureAndSupplyOfPamrevlumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ManufactureAndSupplyOfPamrevlumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_OtherPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_OtherPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140449255210216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 19, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,234<span></span>
</td>
<td class="nump">$ 6,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Eluminex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments', window );">Aggregate consideration received for milestone and upfront payments</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments', window );">Future manufacturing clinical regulatory and commercial milestone payments</a></td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CommercialMilestone', window );">Commercial milestone</a></td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement aggregate consideration for milestone and upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CommercialMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CommercialMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future manufacturing clinical regulatory and commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_LicenseAgreementWithEluminexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_LicenseAgreementWithEluminexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M ]>T 3S?"J%>;_17U/&K^<U_ 5!+ P04    " ",@0E3/KJQSKX#  #7#0
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M9MT>ACTH-A,+M2U/DI/V[T?)CI?$:=9U+]'M')*'8D3W-UP\RA1 D:<\*^3
M2I4J;VQ;QBGD5%[R$@H\67*14X5+L;)E*8 FAI1GMN<XD9U35EC#OMF;B6&?
M5RIC!<P$D56>4_$\AHQO!I9K;3?NV2I5>L,>]DNZ@CFHAW(F<&6W5A*60R$9
M+XB Y< :N3>WH<8;P#<&&[DS)UK)@O-'O?B4#"Q'!P09Q$I;H#BL80)9I@UA
M&+\:FU;K4A-WYUOK'XQVU+*@$B8\^\X2E0ZL*XLDL*15IN[YYB,T>DR ,<^D
M^26;!NM8)*ZDXGE#Q@AR5M0C?6KRL$- .\<)7D/P#@G!"P2_(?BO]1 TA."U
M'L*&8*3;M7:3N"E5=-@7?$.$1J,U/3'9-VS,%RMTG<R5P%.&/#6<\"+!6X>$
MX$SRC"54X6*N<,!R4)+P)?E2@J#Z7B4Y>RAHE3#$G).S&14(24&QF&;GY(*,
MI,(KIY*,5@(,G_RX@WP!XB>>/LRGY.S=.7E'6$&^IKR2M$ADWU:H0T=CQTW,
MXSIF[X68?7+'T:TDMQA[<H0_/<V/3O!MS%^;1&^;Q+%WTN#GJK@DOO.>>([G
M'HEG\GJZ<TS._WF_?;/WO63X;47YQE[P8D5A!2QX73!$@EBS&"3!JR8<:T7@
MZ[*&H@*R%#PG%)>9*;F2"O5\K!AJ=Y%QIY^]]="+@K!OKW<SW 4%O2C:!TV[
MH,@+#T"W7=!UZ/@M:"\G09N3X&1.9H(G5:S^67IM-=R)Q75[D7.@O8LZ0$R[
M",]SH]Z!\E-V]F2'K>SPI.RIJ%:D?*/VL',/%^YU+SC0WD5=>?[5@?PNR',Z
M]_X72W4"[)V7-@>Q,BU.DIA7A:K_(NUNVT5'IGD<[(_=FXE[9'^*7;=NDG_,
MURW[CHH5PQ<X@R6Z<BY[&+"HVV"]4+PT[_R"*^P:9IKBEP,(#<#S)>=JN] .
MVF^1X6]02P,$%     @ C($)4R]4RRN; P  D@L  !@   !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6RE5MMNVS@0_15"Z$,"U-%=E@/;@&-[L2V:-FB:]F&Q
M#[1%6=I2I)>D[;1?WR&EJ+9,"\'NB\7+.3.<P_%PQ@<NOLN"$(6>*\KDQ"F4
MVMZZKEP7I,+RAF\)@YV<BPHKF(J-*[>"X,R0*NH&GI>X%2Z9,QV;M0<Q'?.=
MHB4C#P+)755A\>..4'Z8.+[SLO"YW!1*+[C3\19OR"-13]L' 3.WM9*5%6&R
MY P)DD^<F7^[]#U-,(BO)3G(HS'2H:PX_ZXG[[*)X^D3$4K62IO \-F3.:%4
M6X)S_-L8=5J?FG@\?K'^APD>@EEA2>:<?BLS54R<U$$9R?&.JL_\\"=I HJU
MO36GTORB0X/U'+3>2<6KA@PGJ$I6?_%S(\01 >S8"4%#"+J$Z (A; CA:SU$
M#2%ZK8>X(9C0W3IV(]P"*SP="WY 0J/!FAX8]0T;]"J93I1')6"W!)Z:SCG+
MX-I)AF D.2TSK&#RJ. #^: DXCEL59"%A4Z//4$?N)3HZHGA758"]AH-T-/C
M EV]N49O4,G0EX+O)&:9'+L*3JC]N.OF-'?U:8(+IPG1/6>JD&@)I\HL_$4_
M/^GANZ!,*T_P(L]=T&OP_8[=H-![BP(O\"WGF;^>[MG"^7_>E__9^XD889LK
MH;$77K#7)@7ZE*-W;,TK@F8LZZ1'L_'7;"65@#KP=X_GJ/4<&<_1!<\?H6)2
M2#M;1M7,Q#!U6=Q/!WX8CM)T[.Z/;\J"2^/0#T]A"PLL\.)AU,$M;6Z3,$G\
M%G<2:=Q&&O=J_$D51*#UB:)EK>B55N#ZMD?.I'62],H))18**(/Z(@1AZQ\(
M+HI)BNO2G?T#9<?\]VURUY;CH[@CKZ/T.02D\>..T!94V+&TM%D*P\@N\;"-
M?M@K\6R/2XI7E S@G1U(3+7">]+$W*=OVGI(>_5]8O!FT_(G%-(-O-7-S2$0
M]\C16\0@JZ&Z*OR,2)[#RVG3.SV3P!]V]#Z'#'P_&'7TMJ#"SG]D>8Z) \^N
M]JC58M2KQ>6$/A: 6'-M='Z<;NSGD$$PC*).[!94THW=@DG]"ZGF>[^?5Z\W
M_-/:>*F&-4;.BECH=\*U =/4Z\JRL.&@C*5^Q^#2ZCF)HF'<B=P]ZC$J(C:F
MN9-PL3NFZB>D76T;R)EIFSKK=_[MW+>L+W3#:7J:W^;K;O4>BTW))*(D!U?>
MS1 N2=0-8#U1?&LZG!57T"^980%-,Q$: /LYY^IEHAVT;?CT%U!+ P04
M" ",@0E30FG56_0'   :,   &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;,6;66_;1A#'O\I"Z$,"1!'WX%78!AH=;(L>0=VT#T4?&&EML>&ADI2=]--W
M2,NBN#O<I1T[>8EU_&=V])\]?B*5L]NB_%!MI:S)QRS-J_/)MJYWW\YFU7HK
ML[AZ7>QD#N]<%646U_"TO)Y5NU+&FS8H2V?,<;Q9%B?YY.*L?>UM>7%6[.LT
MR>7;DE3[+(O+3V]D6MR>3^CD_H7?DNMMW;PPNSC;Q=?R4M;O=F]+>#8[9MDD
MF<RKI,A)*:_.)]_1;R/1!K2*/Q)Y6YT\)LU'>5\4'YHG/VS.)TY3D4SENFY2
MQ/#G1LYEFC:9H(Y_#TDGQS&;P-/']]E7[8>'#_,^KN2\2/],-O7V?!),R$9>
MQ?NT_JVX_5X>/I#;Y%L7:=7^2VX/6F="UONJ+K)#,%20)?G=W_CCP8B3 ,H'
M M@A@"D!C T$\$, 5P*X-Q @#@%""7#=@0#W$."J)84# =XAP%-+$@,!_B'
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M-;[7,'X8Y-:\&G OAT&VYG+#89&MM %\OY)R>/Z@?^#X=LGU_P%02P,$%
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MDWN-Q&T#VFYG@?G@J:_AB9R!<'YBS$/UF:88\BDFP4\$'IPWN>VN$-H09E;
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MDWY9:SIZ <_I(GC\0 ND7^>_^!=02P,$%     @ C($)4\#Q87==&0  568
M !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL[5U;<]M&LG[GKT!I=;:D
M%$01X#UV7"5;R:YSDHW+<M95>^H\@,"0G!@$&%PD:W_]Z>ZYXT)1LK+QPWFQ
M21"8Z>GK-]T]T,N[O/A4;AFKO,^[-"N_.]E6U?[;R\LRWK)=5 [S/<O@EW5>
M[*(*OA:;RW)?L"BAAW;I93@:S2YW$<].7KVD:^^*5R_SNDIYQMX57EGO=E%Q
M_YJE^=UW)\&)NO">;[857KA\]7(?;=@-JW[=ORO@VZ4>)>$[EI4\S[R"K;\[
MN0J^?3W!^^F&?W)V5UJ?/5S)*L\_X9>WR7<G(R2(I2RN<(0(_KME;UB:XD!
MQN]RS!,])3YH?U:C_T!KA[6LHI*]R=.//*FVWYTL3KR$K:,ZK=[G=W]G<CU3
M'"_.TY+^]>[$O?/EB1?7997OY,- P8YGXO_HL^2#]<!BU/- *!\(B6XQ$5%Y
M'571JY=%?N<5>#>,AA]HJ?0T$,<S%,I-5<"O')ZK7L%JTFB5%Q'QZ&I3, 8L
MKTHORA+O/;ME6<W*EY<53(4/7,9RV-=BV+!GV)GW<YY5V]+[/DM8XCY_"21J
M.D-%Y^OPX( _UMG0&X]\+QR%P8'QQGK=8QIOW#/>+\4FROB_Q;+?Y%F9ISR1
M3("5ORM8"6P0%WY9>S_P+,IB'J7>#5R4+/J?JU59%:!7_WN H(DF:$($39Y;
M$(>'#;WAX*BAO:NR MN(2ON&'Z-]9#WAO<T\$ 0#(8RFOE=M&;!N![?<>_ K
M*UCB\:S*O<B+G2DC/< =K[9F)O I-$@"-*3YGNY FN)\MV,%LEM)Z&Q55UZ6
M5Z#Z6;T&EM<%._?RM5?DGZ,$S"2J]&@5.*>*QH+?HXSM> 1DR;6<_?4OBS <
MO6BLC*X&+\Z'WJ^@L#@.+PW9OB%Y'_'$2WD,;HEY:\8$$W.8MP"RP5?!TX+D
M*J^ _FSCG4Y&PP!L-TUI)64=;[UHE]?(X#M@FK>NT_0>/%S,P$$E'LP"A/_
M5D4-;A)YO;3H8DVAN') LM,R]UC*-WR5 C=R-;*W+O*=64F$<H%!-J#/Q*G]
M'IC)P=$QH.8T&(?#J:8:^+?/*Y@-30 N,G!,H ?[Z)X4Q4>1[0M> ODPU!D_
M]^H]3GT:-D9I/PMWDG?><M ");9RSV*^YC!<##SD,<R*?+85Q8R$&@SC',O9
M'^L4N1K,SGV@U)"ZG Y'7T0J\+).HRH'H36)\XE\F$U/UV3WD9.CK/MYI>W&
M*R-XWHPR]#ZT-4=H"I!Q"UHKK9&3%>LY,>"!2#,O WP@QH09X9&DCBOO#!@*
M$1!<3G*.1"-Q$.6!N?_E%5&V(;VBB[RLX"DP&V]?K^#;%D9=W0N"T/:"^8O2
M^QDD#0[U'I_Z.XO2:NM[/X$7J0OBWD>6KJ." 2N3W\#B802D.&9%!=@#%)Y)
M58S6%1FCYD4:U5F\%2PP*B\4!>=R[59K2[4M\GJS%1Y/A1YAUB4(;#0U5NU[
M['.<U@F:>U+4&\VA0GA7& L<%-AFPDL(ZLC3DNVC0@A_A=!HB,X5M'+A0[!9
M%?G?6$:KUO;J>ECX$9:;D!CA>X=?$'-&*8QM.7>XUW*AMOMTZ";.MKRP\:(X
MG^M)%37=GE3]:BWN+J]35%GP*<0AES!<>EGO]VB^AD:!X;S]-@) %K.Z(L\
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M02#3684(JI39J]N>Y-712WM<]DJ!R"?#IK9&/P"<)N/E,P,G2NJ$HP,N_F=
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M-!*0!YU,7] #.%ONMJW>]S;%,OCU<,X4LZT6I(+A>369O$8H,?2N(-!U:*&
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MZG%-B1R@1%E5?ZY4RD&XD<^5%X32L_F=,[6.E9F&:($BCX.(%B=;I\6M,$_
M,;!?"]IYEK3SY.AUUU%T46G0:[C8% C \"5X@$#:)Z<U\'#//EJOW?B/I6_5
MC.0G_.5\0KYCX8?@47#;,IK.]'>+VL'9S)_1S3K=&/IA:%_H8A1MB2@Q:,]R
M%LSL"SHT'LYPN:'NRXZI&S_F'+/M.<T_]%[;F(Q*;!?X V@27-;'U)WCX'AW
MQYGV_S_"W3:[)C1Z3,MYT:P48GDPM([=*LS79<8-1XSVJUYP1 ?"UJ)BVJ,M
MC3=Q-MH+N7J]J'SG0"0KDX18'RQ,WLA7J.'V4"SZ^*?)F3B["%S8EJ6)\TK*
M)E+QG=V61/G6U#H98.8GX]-.KBI8M@$6[, AX2F]+-&!PHF\%A&^-1@=3Q*=
M, "W*TTXCF#/0_A0G7\VC]]S7*#&LHT7<_:,8 XC4;:>*UQ$+-3J)>3?4?@_
M.C?RH.(?\9HU8V;V.XB.T6O*R3:46^Z4'Z%51VG4SU$!*$2B9OC7F X1(4X6
MYFF^N6_S6W<H--Z&!MQH#DO[--1R\8#T0O+4L_/:;6M3V??RD</^ISGU<4&(
MB.AX69M.NC3>1:M?XM;C:]JO3Y2-UUWOV',<T9_SUC?M]/#L(3R#M.%M@.%%
M*:.Z[\2%:YZ);&>S2Z,U;<<V/1*)+8+_]D24!0'+O)65D,=N-IL!OTF+K!'1
M*4AGV]F9M;6,TU&9_\QV5!O&1;/QWNEOL[!AQT5KD%8/]=G47RXF5,0/Q"[4
M*H7/J=_MW$:6, ;U_YD1S.V!'\R=$K>^THG*N_?+BA[X&$[\Y:BU*N#- O?0
M77]5XM+Z4Q]@JQOZ@R:E>!V?^*L?^JJG_F;*E?A3(>9V\0=7P)%L>(85ES4\
M.AK.IR>B[J*^5/F>_G#(*J^J?$<?MPSV%07> +^O<X"5\@M.H/^2S*O_ U!+
M P04    " ",@0E3(L!?P2D#  "I!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6RM56UOTS 0_IY?<0HO FEJTF1C9;25VL)@2(-JY44"\<%)KHV9
M8P?;H>N_Y^RDH0BZ3WQ);-_=<\]SOES&6Z5O38EHX:X2TDS"TMKZ(HI,7F+%
MS$#5*,FR5KIBEK9Z$YE:(RM\4"6B)(Z?117C,IR._=E23\>JL8)+7&HP354Q
MO9NC4-M). SW!S=\4UIW$$W'-=O@"NW'>JEI%_4H!:]0&JXD:%Q/PMGP8G[J
M_+W#)XY;<[ &IR13ZM9MKHI)&#M"*#"W#H'1ZR<N4 @'1#1^=)AAG](%'J[W
MZ)=>.VG)F,&%$I]Y8<M). JAP#5KA+U1VS?8Z3ES>+D2QC]AV_J>)2'DC;&J
MZH*)0<5E^V9W71T. D;QD8"D"T@\[S:19_F2638=:[4%[;P)S2V\5!]-Y+AT
ME[*RFJR<XNST$].<90+A2EK4:"R\DI;;W3BRA.Y\HKQ#FK=(R1&D9W"MI"T-
M 118_!D?$:N>6K*G-D_N!7S;R &D\0DD<3*\!R_MI:8>+SV"-\M_--QPWPPS
M6< QZ?!UEAFKJ5^^W9/UM,]ZZK.>_H<"WX^4#H*CE"^9X+=,;H ;8%!PXL^S
MQDO%UN.[XM**':BMQ *R'<R<QB\H,6? J!R7/-/J-4J8(__.Y6;PUXF+-7 V
M' P?@5J#+1'H,S>6HIW5E(PH.<N>S0"6C38-DQ:L\OZ;AA=,Y@@--8F&V6H!
MHR%=\4))HP39/.4/Y+E05<WD[O&#43(\?V$ Z?)(1H6V5 5P^9/4TW"PM/RM
M?LM(OH&U$C1L##PA&[DWAAB:IQ=!6ZS@/95 FY+7L$2=$P9-GV#.A"?&++S$
M'*N,Z*5#WWQQL'+2G+)W-":O9*XJ#!:-UBCS'7S03!KAF1^B4/MBW[[!GF+@
MRA<\"AX&R<EY,J)WFJ3^Z1XG\2@-#N\RI[IPJA1=&:,92%EH53--E>@JVM5I
M "M$>*<LPO,3N.D\E][3$V1^"II_=71T,#XJU!L_)%WN1MIVDO2G_1R>M>/G
MMWL[Q*^9WG!J$H%K"HT'YV<AZ'8PMANK:C^,,F5IM/EE2?\2U,Z![&M%$KJ-
M2]#_G::_ %!+ P04    " ",@0E3^(88VSX%   [#   &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6RE%]ENXS;PW5\Q4!=%"VAM699C.TT,)-E=M$47
M6.S5AZ(/M#2VV%"DEJ3B=;^^,]01Y]P6?8A%#N>^<[8W]MJ5B!Z^5DJ[\ZCT
MOCZ=3%Q>8B7<V-2HZ65K;"4\7>UNXFJ+H@A$E9JD27(RJ834T?HLP-[9]9EI
MO)(:WUEP354)>[A$9?;GT33J >_EKO0,F*S/:K'##^@_U>\LW28#ET)6J)TT
M&BQNSZ.+Z>EEQO@!X;/$O3LZ UNR,>::+[\4YU'""J'"W#,'09\;O$*EF!&I
M\:7C&0TBF?#XW'-_$VPG6S;"X951O\O"E^?1,H("MZ)1_KW9_XR=/7/FEQOE
MPB_L6]Q9%D'>.&^JCI@TJ*1NO^)KYX<C@F7R!$':$:1![U90T/*5\&)]9LT>
M+&,3-SX$4P,U*2<U!^6#M_0JB<ZOWPAIX;-0#<);%*ZQ2![W[FSBB3FC3/*.
MT67+*'V"T0F\-=J7#E[K HN[]!-2:M L[36[3)]E^&NCQS!+8DB3=/H,O]E@
MZ2SPFWW;TE?2Y<JPL0[^N-@X;RDY_GQ&1C;(R(*,[/][\UE&7(JGKA8YGD=4
M:P[M#4;K;#QZ0@!\+!&V_';#;P[,%CR!KDQ5"WWX_KME.EW\Y& KM="Y% J$
M<TATOA0>A$6H6FX%<*50M>6-M5+O...E"QB"R(VB(G;P@]1$:1HG=.%^/!U1
MJ' (U>@WO$$%_3?MOK/11^.%&E&6X($RV%Y3Q]DVQ&#T8I2F27R2+N@45$U_
MNG/J7Z^,K8T5'F%CF*['F"99G"UG#^YD?84VF%N+&NV L$CC9+6Z?_TT_C"&
MG;E!J]FIG9#L))Z?+ ?<_MN!+W:H\\-]?;(X76;WKQ?L\9<;D5^3EQT[6'J)
M1U1IG*V2^U=J/=18]$.]CO"F\^G]Z^LOC?0'D/H&G0\I,DIGLP=6,*P-"WGY
M9!%GZ9)/TWD\3^Y&(UNF\6HV'[W"'*L-6IA-0[B3;X3[DI0%2A.H&M]0(/J(
MWW)>QM,L>P3RF E9]M $@CV24_-5$L^RQ0/T'MY;S??Y:OJH'O/5,EZ0S1\?
MJ:3.VF/U0I6$^BN@<5P\OI2V>%D+2W;45N8,<Z:Q.;IQ*-D!2 4N"0J-ETK^
MC<2VH-YO#^ \.4_8(C 689!5ID#E8L+)55.$(C6^Y*NIL/5U\,1+GE;D_+JV
M1M P)Q(:XK O95Z"4 H<)9;<REQ04DE=-YT)9L/JB(W"&%!2&[%02.H(7AV
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MG4Q.1"YG:5/83WKU5]G*,R1\F2YJ_B]6[FR(PUE36UVVP."@5)5[I@^M'GH
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M+12 *I7Z8I'"-RL< F_@ENGIF0B'XE&F!L)1@<Z; BYLM9 /2X7< )0(Z'C
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M<!0>.R2-'6*KKQV(-XTA!KDP<%[;.OQ3:L!?O G%&=Q0O%7W1O]%5N)&JM\
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MP*FV#"BMR+*A$AXM)0NZQPK$L;]N'Y666$-_G_$D'3U)K2?I#R#]/%+A.Z?
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M$5D=HBN;S="@U#;]E?O&#X,-YR>/;%@V&Y:L=SJ(M7PGH[RZ]&XG/*V&-/K
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M>?L@*G_]R_ER\>IUP,8,9#@ZO?)NJW/%!E;*:Y?K3! 51V4I8J)0 (/;0O,
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M8 (,JCU.X>-<48"&/?(#S3%3+9CND$B$F'IY\OJ=*I3-)4[F!XO7W[8\0.1
M;2 H#=ZZ 1E$CAF]^]EY@KOMWT.=&VDT%E@M$PZ,W(6:= 1#JW6#M/X\L=6N
MR2DL_M1[YOL]&A-*D^LD=W%Q>D:%N)2?B:9:)"$:!7"46*W4P6 08]Z%KYN*
M P*7GA^V+NSJTQTW;J=B4$+!'S@=P))-@74A]4)D]>V[ZU0W01O(L;BC;N5G
M]!/E"BY?GBPN>-,[E;5/EFA-[SBHNBC0]2CUF=C#JXKJ.(6LP0 U;0@2-X^(
M'M:S&]A=;9>6]R 88.B>'N?37I4$PY<I#1B8'^2AA>6.2"_7!#[BLO\.GX.8
M<JBY849,@T1&08XNP8(?;=?.'0$CW$-&"4+^3^+<^N%C%ET3CE?WPY$:980A
M_*_BT)Z_2'%X]5 <*#.:6I'<\-6],#!Z<<[K;]4*G.L/_R<W#!28]DH<^>$:
MQ:0Z2H_:]KTYJKB*I',N2TGNZ8NLIZZ@F&' 3B,7Y2?YHY<W1"G@RQ5AL4A'
MIS%$;-!*DP.;WK!TJ=Q DVRC\IIVDMSK>HTA#!S4ZOV1ZHT\/H]:L:IR-&[D
M_=  RAQW;(/I"M534<JA9"--Z(Y@7-JZE*,C80$ ,*AI%(D*)(R%88.V>>,,
M=>+XI[<IE;O]8H<*F%SQM9B]EVVA.]?=O,<MBN)C@UM7D"@&N88/T%V/1Z^A
MN[A-+C515">_'2,#ZF!(\$_%3^4T"S1\P_=3'/LPF".9D%*Z<1(-DJ<Y^<\)
M\-@#*9.&R&T "T4CK+/J$!K[>0:=#H"<N1"/YF]ZJ6VN,<S60[-#:J/:J8&'
M9;A@2X/#KP]US%U?US@$(.$)#)V.0)>@4\M ?2&-R#EC<JO7SF.& -;2P1W%
M0U Y$^_=#K+]M.F.8SO/:)K^85!JXVK;]"A-J+#V]SI?MW.0MK]C!6,T)3)Q
M#/8^T.\T':+,<6@8->^IG1N0(Y^4UN&;AC, W>'<,FW&!R8X!X:3S8!4:+H@
MT'QG85-)G(X; "J>N2HMPILE@Z_[J79T>4*&D"_@2[XZ0O=!T1SME9Z'@-&E
MR0,S5Z]W?W]$2:KV$M##)$C11S)-!W=!M"9=.1@C5\XW!W;*HB&!^%K2,.;:
M&YR!.D?C9:LX@98(AC#H2]/?Y9#@ALQTN6+-24"_,>?QE+*).1I3A:+[GZ+@
M>#,8TO3;<N;QUL/0?$UY:&USB\W7"01>[FSK-)(AKI$T+\@7#50:0C@PEC 1
M^D9TD@!44)#)"LWDE6VL,VY]2'F%@);]5' OEH/KK^%U!-2H%.O$9]($+XO8
M7)4T_;GK6+*3,DYENB5H4X,A]<3IR1DQ]*2::*;E6V:#$OV?QZ2+):- #T0?
MGA+2YN=P+NX$TRV"(B^G::FQ37NFZ)I[B0:Q7"ZZ$^@ZH=-R=%\ )Q)'\Y2:
M+II08@V,Y[%?[I*W2KG795T.AK%^D&TNKKK[HJ'1B4'X*H(]PJ,]1@PUOM\<
M)6NZM<D5@4+30*CN1\P20_:X9HHGT0VA=KTO^X/XK 7HX(;AS\#&MX>R(;1Q
MT@[X?W 1@-X1D> ;CQ[,Q[;!)*PVLX=N^>>#WU50/=;\ZQ&-Y?!T^HFE>]K]
M0'6=?I?IEZ=?MSY(CPF![JD*;#V9O7HQ$3[]8I2^1%?QKS0KA_I9\D<T:X@)
M+<#[PB'4S1<ZH/O9[NK?4$L#!!0    ( (R!"5.JI=Z%AP4  /D+   9
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MD]K$POK8!!91A"]L-6869Y3HK='9V<PXY0JC+(G0+ "Q3[$&QYDIE$4"(9(
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MJT;I'K"NAGU8K@=;0.*Q 8G'6Y'=FQ@%'4B_0DKRFBT 3GP%*&.6 FZBKR]
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M'!,AX%S3&7[)WZ!,L2)H!M)JRZ::87BA!8;8N"JS8@VA,[^I'PD@4((E%C6
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MSC8NF=VB> *SMUA-Q:0B:"VI);L='E\'A2V+87H!F,UH"$#XN5&)@2BS06T
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MS:='-W&V8X6M%<7Y?$NJJ>FWI/I;9W%<*6;OR2D&ES!N%*'N/(=&ONJH7:P
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MC,<V8SS>FNKMZTGKS1@_?ACN=^O-GUMV'BSP#]/3*5T 0]W63H.!_.8LYUS
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M965T,C$N>&ULW5IM;]LX$OZN7T'XBD52,+:H=V63 'G9O>NBO0V2["UPA_M
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MB!7^FZB'D >C@4[O$[I,TJ1(F!P+NDGI*I>>RBV-V/D,DJ5DXI'-+AX@WJK
M2<!8A::,)(_2,@8[4HC H48J/*-&F[33YB#HKFBJ609"]P;(*%N"O\&U2,?1
M91PGFGB,&Z9L#47CN@07Y]%GI,DOK=A-!<JO,*;HRVM"5+.ML4<EZ 0-HN%D
M5%UPVA'XD=@^8 ;*06#K@H4=8NJ7=<41N-T';Q^C"?>ZK7O=2??>P_(E+L'
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M=R[Z(>BFR)N!51M?6$MEJ4Q]MZ!W$;4SH/654G8_< +M2SO^"U!+ P04
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M^[UUW8SK'^+-TKMG:L.%)@6L434<CE./J&:1-(21E1O>2VEP%;CK%G<O*"N
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MPJ6%I5M^LN77+)1;?OB>2;,3+T0)R0=>+CC6*U$K(%-'4W1)2\HSAF<V_3\
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MK&73EJKA6B[.#BZ\UY>>2QOLBE]*>=]NC3FY,E?J"SW\7)P=N&21K&1N2(3
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MGQG [S,!Q5^>9!M4_X?A]']02P,$%     @ C($)4T250XME!@  0B8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,CDN>&ULS5I1;YM($/XK*ZL/K=3$L+N
M73F64KO)Y72MHJ2Y2E?=PP;6-BJPOF6=M*?[\;=@PF(6%AS[P2\)X)EAAN]C
MOAU@\LSXCW1%J0 _XRA)+P8K(=8?AL/47]&8I.=L31/YRX+QF BYRY?#=,TI
M"7*G.!I"RW*',0F3P722'[OETPG;B"A,Z"T'Z2:."?_UD4;L^6)@#UX.W(7+
ME<@.#*>3-5G2>RH>UK=<[@W+*$$8TR0-60(X75P,+NT/UP[*''*+/T/ZG%:V
M05;*(V,_LIV;X&)@91G1B/HB"T'DOR<ZHU&419)Y_%,$'93GS!RKVR_1K_+B
M93&/)*4S%GT+ [&Z&(P&(* +LHG$'7O^C18%.5D\GT5I_A<\%[;6 /B;5+"X
M<)89Q&&R_4]^%A>BXF#C%@=8.,"^#JAP0'T=<.& ^SHXA8/3U\$M'-R^#E[A
MX.5@;:]N#LV<"#*=</8,>&8MHV4;.;ZYMT0D3#(JW@LN?PVEGYA*""/RR#C)
MB7&YY)1*HHD4D"0 =_2))AN:@C-PF0I._J()]4G52OX0!&'F2R)PDVQOC2R2
M#=[.J2!A]$[:/-S/P=LW[\ ;$";@ZXIM4AD]G0R%+"!+8^@7R7[<)@M;DOU]
M$YT#9+T'T+)1@_NLRSUY<8=V@_N\O[O5X/[IL+-?'7;V:[/[G/K2W6YR'TK*
ME+R!)6]@'@]U\^:)@DO.2;*L,.<+2\[\-A/P56ZF).]%*?C^APP-;@2-T[\-
MB:$R,90GAEL+75#.:4G>)IIL([AYA*Q7/TVA Q&>#)^J</:RNM:M7 =[I=%.
M#;BL 1MK*%*7K=YGRR3\EP9-56QC.-7\,')K^<VQEA^&H]&H5JL>RX7>&.U:
M7>FQ7 ]68NT4ZY3%.L9B;SD+-KYXP>L]^"(%^/MG&C]2;B*$6\9W3XNI7IF8
M=P24/0T9&R'/KJ'<8.6X=?P^Z59PY*$ZR@U6EHM;4!Z5Q8[,MR7?+$$-ZCXH
MC\OXX]-"V;:4PEH'=Z0BQ Z MEQ.U@#L--M-L;((L(] Q2)(]>QGHRHS"A75
MS480U3M.4S#;K5E==<7:K5>)EPV-];:L9E[X"/X#K^6KK73*1B?&6"4_MEE_
M>C%6EXQ&QG:9[::H1,,VJT9/QCHZR5S7JVMD@YE61T,D""&N\]44:;=4I5^V
M>R!9'\[OSX=W[%LO@BIYLKT3(Z@2$]NL)@_K!6>)> ^2/(E$A/*\+_MREMTD
M 7F,:)ZGD)/S63:M!F!-?N7Y-TX>(VUQ@SQLM3)5"9,]-J]OF)#G#.5\%(<1
ME0.=O!3&1,9ZR_.<UD2@TB%HUJ$9BV/*_2R3E,A,5#Y-:4!=:A TI*&T!IJU
MYG(I.;PD@@()7!H&M)@]Y9U,)8L"0'_ZT2:0B((@:\+KH@GS]EX$=97 :&QI
MS:C;;K>FRC!TJ)YHMZ@\-I-A0E_"D=%T+LN+V#J_>3Z71.EQ0T.E./#$% <J
MQ8%FQ=GW)H$- XN!G$I6H%E67@?D'5UN(B(8_[4G=$H#X(D-,5#)!#2/,7M#
MI\\7QL:B1 &:1>%UV)5KG<NU[#1/LHS](%0Z $]L0D%*&9!9&?:%$#6,(:[5
M"B%2VH ZM*$3PMDJ3$@?8)!JWNC4'F55GF69'V;M#0S2[RT\<EJ!4?T9'3X1
M(+TG>[H&][*Z1OJC)J^=7ZJ]H\YG33ZE00KD\C$&F^959(YZ;2%IO.CZFA^.
M6D<<I'H^,J_[M?5:EA<3*\I!!H+H6, 5T7=NTGPAV9*7:OC(W/ [%W +QBM\
MS;(NKK3I,LZ0K@N>IP^4G6:[52GU0&;UZ#=0%D$,D^*\P01CNUY%9YRK!A-G
MC%O*5"J$S-/(OAU6'GCM UJL] =;I]6!L5(D?(PG8U@?+&Q[I'&WP0S"5NYB
MI6#XT/%# _4XLP=62H9/;/; E9<MQYT]<,,CK?;U*U;BA ^=/3047SMX8"5"
M^,0&#ZQT"!]W\"C"5=<4-G;;@5/2@3O>;82R.PAPGXOT,1JGZN;XQ&8*1_5T
MQSQ3]&N<3M,D8=??;A56.\@UO-YJ".8ZKEO3U89@AO=;CE(*QZP4;2PXFIXZ
M2@^<$YMH'*4#CGFBZ4D+_:UZ-F#6\6YX]^YJM_.P\G%,]G759\*7H2PMH@OI
M9IU[DB]\^\'2=D>P=?Z]S",3@L7YYHH2N<S-#.3O"R8;3[&3?8)3?C8V_1]0
M2P,$%     @ C($)4V!I)MBF!   >1@  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S N>&ULQ5G+;MLX%/T5PNBB!=I(I-Z!8R"Q-)@6#1 DS11H,0O:HFVA
MDN@AZ;@=S,</]; HRS+EQ@MO8HDZYY*7YY)'8L9;RG[P%2$"_,S2G-^,5D*L
MKPV#SU<DP_R*KDDNGRPHR["0MVQI\#4C."Y)66H@TW2-#"?Y:#(NVQ[89$PW
M(DUR\L  WV099K_N2$JW-R,XVC4\)LN5*!J,R7B-E^2)B.?U Y-W1A,E3C*2
M\X3F@)'%S>@67D=622@1?R5DRUO7H$AE1NF/XN9C?#,RBQ&1E,Q%$0++GQ<R
M)6E:1)+C^*<..FKZ+(CMZUWT/\KD93(SS,F4IE^36*QN1OX(Q&2!-ZEXI-L_
M29V04\2;TY27?\&VQIHC,-]P0;.:+$>0)7GUBW_6$]$BR#C]!%034)=@'R%8
M-<$ZM0>[)MBG]N#4A#)UH\J]G+@0"SP9,[H%K$#+:,5%.?LE6\Y7DA>%\B28
M?)I(GIC("4[QC#)<RG:[9(3(,A <X#P&C^2%Y!O"P0?P5!42H OP.9G+0B&[
MIR4RE-<I71?4IOV1S.DR3_XE,=CD,6$J.G@;$H&3])T,_/P4@K=OWH$W(,G!
MEQ7=<!F/CPTADRN&:,SK1.ZJ1-"11"QP3W.QXB"2?<4]_%#/=S5\0TYJ,[-H
M-[-W2!OPTR:_ I;Y'B 3P9[Q3$^GFWWIG-=[].K>]R;#:LK,*N-91^)U:J(H
MMO?@7B[F9)V2#S%)Y6[!\"PEX)8QG"_K(OS^6<8!'P7)^-^:4=C-*.QR%/:1
M47RA J=R>RO'TE=B%=TMZ<46^S)!MN7:8^.E+=PARD:^[^^CPD.4B[S VD=%
M/2@/M6+MY>DT>3K:/+LK]/L]R6:$Z:;0;4*[%Q32:T;AG2=D17=:TVIV1!Q$
MA(.(2(?8R\MO\O*U>?5MHR>(%S3A@PN*!TWE.>9Y\M7\]LS"P+5A1\,^F!\X
M7D?('IAE(]19L%$?S+=-U"\I;#DLU&9[RX5\#\*\Y7\[3<%_!V[:>O0)KW%^
MBOX0J;&@2U: L@-HG5D!UN *'H:$PY!("]G/3MD,U/O,JQ6/-DQ^ IPDN?("
MZ%Q2<F4<T#U3<G=8\D%(. R)M)#][)0A0;TCZ277[>N_M="5D4#_DJHKQX'!
MF:H'!V($05?V0PSLOI6%?2 OZ$I_"+*0UR\^4GZ&]'YVEOBGKWFD+ ?!"ZJ/
ME-T@=)[Z-;^M!W)LMZ-_#\IV6\9<?Q =HES3Z[P,1#VH 'KND1)0AH;TAB9+
M@.%O)"=SW/Z*;ND\724Y/DEFY3/(OJ3,RF*0_GMC6&9G<&OO@=C=%[YP.$[4
M W$"^XB\RKR0WKR&Y=6X^O/5TY7Q2+^6)R6GEX'R'N1=L@R4YR#]U\MP&?C#
M93 ("8<AD1:RGYUR,J1WLN$2&-CH7U<&EG(AR[Q@&5C*?"S]]\Y@&=1\=\_.
M@^[1R+0/9GE.MQQZ8,@+W*[S]\%\RW0Z96&TCE(SPI;E&38'<[K)177<U;0V
MY^2WY>EPI_T.7D]A3WL(KZ/J%%R%KP[E[S%;)CD'*5G(KLPK3Y8OJ\ZYJQM!
MU^5![HP*0;/R<D5P3%@!D,\7E(K=3=%!\]^&R?]02P,$%     @ C($)4_=+
M8064!0  :R   !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULQ9IM;YLX
M',"_BA5-ITW:"GX"LDLC=>F=MFG557VX23?MA4/<! UPSG;:G70?_@RAF)2'
M<84I;UHP_)___=G8G3T(^4UM.-?@>Q*GZG2RT7K[UG%4N.$)4R=BRU/SY$[(
MA&ES*]>.VDK.5KE0$CO(=3TG85$ZF<_RL4LYGXF=CJ.47TJ@=DG"Y#_O>"P>
M3B=P\CAP%:TW.AMPYK,M6_-KKF^WE]+<.:66593P5$4B!9+?G4[.X-L%]3*!
M_(T_(_Z@*M<@"V4IQ+?LYL/J=.)F'O&8ASI3P<RO>[[@<9QI,G[\72B=E#8S
MP>KUH_;?\^!-,$NF^$+$GZ.5WIQ.@@E8\3NVB_65>'C/BX!HIB\4L<I_@H?B
M77<"PIW2(BF$C0=)E.Y_L^]%(BH"D+0(H$( ]17 A0#. ]U[EH=USC2;SZ1X
M #)[VVC++O+<Y-(FFBC-RGBMI7D:&3D]-^'';"DDRY-ZMI:<FR)I!5BZ E?\
MGJ<[KL ;<"-9JM@^]9<R"KEY&#/-5T +L!"FK"M>*+GB(3>E6>4JSL)0[#)]
M^U&VC#DXBV,1/LI><IDW8VI4_K&,HW6NQ-B/1;HVR= ;<*:4"*-<X)S?<2EY
MZ1IX><XUB^)7QL7;ZW/P\L4K\ )$*;C9B)TR#JB9HTV:LF"=L$C)NWU*4$M*
M/N[2$X#=UP"Y"#:(+[K%SWEHQ&$N[AZ*.Z8X985062&4Z\,M^AXC-0D4ZS3*
MLO,:7)@NC;8Q?[/BL<FUW.=5FB*MB_I]^63T@ ^:)^IKAQ>X] +G7I#6J X3
MWY36O08OUY#AXWY.$?5FSGTU>?67$"1^^=*!<Z1TCG0Z=Z:TX0!3MG_!EPN>
M++G\"OX%']F6I>5 1RYH:8X>L2)>Z877&?1BE^S,7Z"QU563O0Y:23>$7N![
MS0GW2]O^X&[P:Y:QVVPU**T&G59OA&;Q(6R:# =-(4_=EI"GI?'I:#UF!LY-
M8F*QS=][[)<>+0A=RVWWB$T(*_,''*$-"R4'1?$HFC;7!%HV0C2X$0L5?3H1
M6AS";A[V[,5"RY.X:5O<%GAP/.*9@4]FPDX5_U^=:&D(CXE#:'D(QP B;""B
MZ^*V*0A:),+A3(1U*+9UHH4B'(6*L &+77%;+L(A8/QM)\TG1Y^&0Q9]Z)CH
M0Q9]: STH3KZ?(*FTY;"H\JZ<#C[4 /[,&ZQ;.&'1H$?JL//)QBC-ON6?F@(
M_9ZTW/,G8V01B(Z)0&01B,9 (*HC$%'JXI99"5D$HN$(1 WKPM:.M!!$HT 0
MU2%H(L<^:K%O(8A&A.#S)F1L^8B/R4=L^8C'X".N\Y$$_I3"YII@RT<\G(^X
MSL<6+N/*E_(H=,1U.G;&;>F(?TA'R?[B*0]9=4.G3XM9X.%C @];X.%NX/6J
M<<.*CTS]RB*\V)GP:EL3$/L8!RT%L5C$W5C\04$,#FY/KD^<*_$YWS);;**4
M]2J7Q2,.CEDNBTG<C<F>1)C6"C8EGD])RRZ1!2-Q!W=+H>*@6RARO98N():&
MI)N&/;% &KZ4W6D0H)8YBE@>DFX>#FK#Y\U9Q$*3X"-V**GL)';#LU^'%DH.
M%C$$!J2M0RU7"1W>H;3OG$4L1TDW1_LV9QVEG7%;1)*?B$CS="%,CY2+_-<@
M2O<G7-EYA-HP&:5K\ M+MK^"4"1)I#7G0'%Y;UJZU\Q(+&K),5%++&K)&*@E
M==32 )FOM.:"4HM:.ARUM(Y:A-V6KQ!J04M' 2VM@Y8&U*4MG*66L_3G<G8_
ML*V<BXGR7*S7,8:%+CTF=*F%+AT#NK0.782@U[*!12NG.<.92^O,?;*&/#1N
MP4M' 2]M6)OZ<(J>'FHXE9/@[!C^@LEUE"H0\SLCZ)[X)@*Y/]G>WVBQS0^'
MET)KD>27&\Z,*]D+YOF=$/KQ)CMO+O^_8/X?4$L#!!0    ( (R!"5-XRL%J
M0@,  )D*   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;,U6VV[;.!#]
ME8'0AQ9(K(N=6V$;<)(N-L4:"&RD!;;H RV-):(4J9*4W5WLQW=(R;):V$:V
M+^F+)8XXAV?F#,<SWBK]Q12(%KZ50II)4%A;O0U#DQ98,C-0%4KZLE:Z9):6
M.@]-I9%EWJD481)%EV')N RF8V][U-.QJJW@$A\UF+HLF?[G%H7:3H(XV!D6
M/"^L,X33<<5R7*)]JAXUK<(.)>,E2L.5!(WK23"+W][&(^?@=WS@N#6]=W"A
MK)3ZXA8/V22('",4F%H'P>BQP3L4PB$1CZ\M:-"=Z1S[[SOT/WSP%,R*&;Q3
MXB//;#$)K@/(<,UJ81=J^R>V 5TXO%0)XW]AV^Z- DAK8U79.A.#DLOFR;ZU
MB>@Y)/$1AZ1U2#SOYB#/\IY9-AUKM07M=A.:>_&A>F\BQZ5396DU?>7D9Z<4
MC6 KI9G/T2S7B)1S:X#)#!:X05FC@7-8-JJ!6N^L]$Q5+OF_F,&3S%"#+1".
MXIW#+,NXLS(!#[*I)[=G!*_OT3(NWL KX!+F7 BRFW%H*3[',DS;6&Z;6)(C
ML0QAKJ0M#+PC.MF/_B'EI4M.LDO.;7(2\'TM!S",SB")DOAI>0^O7[TY 3OL
M<C[TL*,CL.]J3;<*/LVQ7*'^? )QU"&./.+P".)/DKB\GL&<"I-7 L\S%%3Y
MFJT$PDQK)O-6DT]_$0X\6"S-*187'8N+DW$MT+4!5PE4)9;.,:RY>I7F*9[!
MAFGN2:0D+Z=]30&LM2H!C>54$%1+Z]K6VNTAWAOJ&I7C"BM7%3(_5!0-J1M/
MRC6AS32.!E?C<',@E,LNE,O_(Q'\!S-CJ74PLZ_IYPAXU9UW]8("7G<LKD]&
M?5<X:.-NH6X)>7'2UFY53Z?#:AX2J#GTNB=0-!@=UN>F8WISDNG38#D(%^JC
M;U-W!9?L.6K$T;XK1B^H1]SKSO'O>*5:5GW)AJ-!?%BS.-E'D_RJ:LT-T^QO
ME)BR_A_'<W3==]YX^)*Z[OMU/'J)F]:>>O/#54M^DBWL30LEZMS/1(; :VF;
MP:&S=G/7K)DV]MN;H6W.=,ZE 8%K<J6N2[U8-W-0L["J\K/'2EF:9/QK0;,C
M:K>!OJ^5LKN%.Z";1J?? 5!+ P04    " ",@0E3#8PNA(L#  "7"P  &0
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M?&&[WZ%TJ*?U12P5YA?M2EG'0E$N),M*L+(@2VCQ3WZ6@6@ E)YV@%L"W&.
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M5XF6%RUW,9%L97K*.9.J0S7#I?I, :X-U/,%8W([T0ZJ#Y_A7U!+ P04
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M**)^<,:*@:VRXS-'/DT3D;^IEJ/E$7V<'4QKXQ-\-\4MXP_X;I8?P"OZ_/\
M>518A7))(UC*J8S;GK0=RX_8^8V@F^R$MZ!"GA>SRS60 )@*D+\O*17[&S5!
M^4?'Z']02P,$%     @ C($)4U%"U#U. @  Z@0  !D   !X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL?51A;],P$/TKITA(((TF35M 4UNIW1@,-JG:8 @F
M/KC))3%U[,Z^T$WBQW-VTZB(M5]BG^_>NW?GG,<;8U>N0B1XK)5VDZ@B6I_&
ML<LJK(7KF35J]A3&UH+8M&7LUA9%'D"UBM,D>1/70NIH.@YG"SL=FX:4U+BP
MX)JZ%O9ICLIL)E$_VAW<R+(B?Q!/QVM1XBW2U_7"LA5W++FL43MI-%@L)M&L
M?SH?^O@0<"=QX_;VX"M9&K/RQF4^B1(O"!5FY!D$+[_Q#)7R1"SCH>6,NI0>
MN+_?L5^$VKF6I7!X9M0WF5,UB=Y%D&,A&D4W9O,1VWI&GB\SRH4O;-K8)(*L
M<63J%LP*:JFWJWAL^[ 'Z \/ -(6D ;=VT1!Y;D@,1U;LP'KHYG-;T*I <WB
MI/:7<DN6O9)Q-+T35HJE0KC4A!8=P7M-DI[@-<SR7/K."<7.[?7[/KX\1Q)2
MO1K'Q/D]2YRUN>;;7.F!7)\:W8-!<@)IDO;_A<<LN].>=MK3P#<\P#='^4OJ
M$CX+7>8"OAM=%@TL*L%2,VQ(9BS]S/1.X.K+.=Q?8[U$^Q/^P YX(91<,?A_
M#%Q1SH$7<FG-!]0=8H]DYLB*'Z@Q$[-YYSA2UJ K:Q#*&APH:Y8]--*%UL-,
MYW#PBNZO& F7A+4[EG?8Y1T>;><";8::>!3!%, #[$CHW%?MN#WH>()8F,7\
MN9L_3CWJ]_K)B^<TQGN_KG\%KH4MI7:@L&"FI/=V%('=3M;6(+,.?_/2$,]&
MV%;\&*'U >POC*&=X0>D>]ZF?P%02P,$%     @ C($)4UNM+MS% @  Q@8
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MPX1^-*A= .VOE+*'B1,H?UW#7U!+ P04    " ",@0E3T=4[4;8(  "@5
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M/5U"GTFD"8#[F1!Z.S )ZLYU^!]02P,$%     @ C($)4TQ(1$-: P  X@L
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M,8%DL3,M!EJLW&YP*K396[K3I=G-$VDGF/MS(?3KP&XPR_\'P[]02P,$%
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MR@+P_59*\_1@%=3_%%C\#5!+ P04    " ",@0E3E?7,4&(%   X'@  &0
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M85DU;-5$BZWM2%9"8W]CAQDVN2 - )^OA="O$Y.@:9LG_P)02P,$%     @
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M<VAE971S+W-H965T-C N>&ULM5AM;]LV$/XKA+$"+;!&(O5B)W ,)'&,I5B
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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MEW\</SSSUM3=(9\-?S*:O0%02P$"% ,4    " ",@0E3!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M (R!"5/U<8TG[@   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( (R!"5.97)PC$ 8  )PG   3
M  "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ C($)4Y"C
M//@W!0  ;!4  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( (R!"5,=>%U+>P<  $$?   8
M  " @7H-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " ",
M@0E3/KJQSKX#  #7#0  &               @($K%0  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ C($)4XV.K:NS!@  D!T  !@
M         ("!'QD  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( (R!"5.QK1]9[P(  )<(   8              " @0@@  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " ",@0E3+U3+*YL#  "2"P
M&               @($M(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ C($)4T)IU5OT!P  &C   !@              ("!_B8  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( (R!"5-B]'FX)P@
M &DB   8              " @2@O  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " ",@0E3#CF5,>P6  "I/P  &               @(&%
M-P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ C($)4\#Q
M87==&0  568  !D              ("!ITX  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " ",@0E3(L!?P2D#  "I!@  &0
M    @($[:   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M (R!"5/XAAC;/@4  #L,   9              " @9MK  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ C($)4[UCN7[&"0  IAH  !D
M             ("!$'$  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " ",@0E3\,=F&Y$)  "$&   &0              @($->P  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( (R!"5-O^072& 0
M .,)   9              " @=6$  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ C($)4]WJ/88R P  "P<  !D              ("!
M)(D  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " ",@0E3
MF)1SE%P$  !0#0  &0              @(&-C   >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( (R!"5-93P"3HPH  ,(;   9
M      " @2"1  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ C($)4ZJEWH6'!0  ^0L  !D              ("!^IL  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " ",@0E3.\%\,:\G   >D@
M&0              @(&XH0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( (R!"5.%EZ5K#0D  -,D   9              " @9[)  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ C($)4X8Q]R:?
M @  =04  !D              ("!XM(  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " ",@0E3%5>@3V$#  #9!P  &0
M@(&XU0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( (R!
M"5/1VS8TE@8  $H3   9              " @5#9  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ C($)4Z(8RQF)!P  KQ0  !D
M         ("!'>   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    " ",@0E3HYYYTTX$  #C"@  &0              @('=YP  >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( (R!"5-LG7 S1 0  ",-
M   9              " @6+L  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ C($)4X"+NYHC!@  SR   !D              ("!W?
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " ",@0E31)5#
MBV4&  !")@  &0              @($W]P  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( (R!"5-@:2;8I@0  'D8   9
M  " @=/]  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
MC($)4_=+8064!0  :R   !D              ("!L (! 'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " ",@0E3>,K!:D(#  "9"@  &0
M            @(%[" $ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( (R!"5,-C"Z$BP,  )<+   9              " @?0+ 0!X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ C($)4]/<W!+X!
M1AD  !D              ("!M@\! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " ",@0E3"2M.FK8#  "T#@  &0              @('E
M% $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( (R!"5,D
MB)T]U@0  &@7   9              " @=(8 0!X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ C($)4YI:P6D# P  L D  !D
M     ("!WQT! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (R!"5/1U3M1M@@  *!4   9              "
M@3XN 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ C($)
M4W P0>;^ @  Q0H  !D              ("!*S<! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    " ",@0E33$A$0UH#  #B"P  &0
M        @(%@.@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( (R!"5/I9VT!K@4  !0;   9              " @?$] 0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ C($)4U,D8N N P  1@H
M !D              ("!UD,! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    " ",@0E3?6#)@YH$  #O$@  &0              @($[1P$
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( (R!"5.8QKVD
M=@(  (4'   9              " @0Q, 0!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ C($)4[ 8EUL] P  *PP  !D
M ("!N4X! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " ",
M@0E3!UX>\XD"  !W!@  &0              @($M4@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( (R!"5-"0KL1* 0  " 0   9
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M970U-2YX;6Q02P$"% ,4    " ",@0E3.A4YVGD#   U"@  &0
M    @(&#: $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M (R!"5,?I]WBE0(  )\&   9              " @3-L 0!X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L! A0#%     @ C($)4]5J$!=, P  0@L  !D
M             ("!_VX! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M% ,4    " ",@0E3EV$#1O0$  #=&0  &0              @(&"<@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( (R!"5/!0"!-G00
M -<4   9              " @:UW 0!X;"]W;W)K<VAE971S+W-H965T-C N
M>&UL4$L! A0#%     @ C($)4[9^,:RF P  J0P  !D              ("!
M@7P! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " ",@0E3
M9I=SSO<"  #0"   &0              @(%>@ $ >&PO=V]R:W-H965T<R]S
M:&5E=#8R+GAM;%!+ 0(4 Q0    ( (R!"5,.8)5M&@,  &81   -
M      "  8R# 0!X;"]S='EL97,N>&UL4$L! A0#%     @ C($)4Y>*NQS
M    $P(   L              ( !T88! %]R96QS+RYR96QS4$L! A0#%
M  @ C($)4W+@97R@!   B"D   \              ( !NH<! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( (R!"5-W2W&%!@(  /$D   :
M  "  8>, 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M (R!"5/_)Z=UXP$  &PD   3              "  <6. 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !& $8 (1,  -F0 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>371</ContextCount>
  <ElementCount>398</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>82</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statement of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Collaboration Agreements and Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenues</Role>
      <ShortName>Collaboration Agreements and Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Variable Interest Entity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntity</Role>
      <ShortName>Variable Interest Entity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Collaboration Agreements and Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables</Role>
      <ShortName>Collaboration Agreements and Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenues</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Variable Interest Entity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityTables</Role>
      <ShortName>Variable Interest Entity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Collaboration Agreements and Revenues - Astellas Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Astellas Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Collaboration Agreements and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail</Role>
      <ShortName>Collaboration Agreements and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Collaboration Agreements and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Collaboration Agreements and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail</Role>
      <ShortName>Collaboration Agreements and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Collaboration Agreements and Revenues - Summary of Product Revenue, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Summary of Product Revenue, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Collaboration Agreements and Revenues - Product Revenue, Net - Additional Information 1 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail</Role>
      <ShortName>Collaboration Agreements and Revenues - Product Revenue, Net - Additional Information 1 (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Collaboration Agreements and Revenues - Roll-forward of Related Contract Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Roll-forward of Related Contract Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Collaboration Agreements and Revenues - Deferred Revenue - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Deferred Revenue - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Collaboration Agreements and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Collaboration Agreements and Revenues - Drug Product Revenue - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Drug Product Revenue - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Variable Interest Entity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail</Role>
      <ShortName>Variable Interest Entity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Variable Interest Entity - Summary of Equity Method Investment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail</Role>
      <ShortName>Variable Interest Entity - Summary of Equity Method Investment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Leases - Components of Lease Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail</Role>
      <ShortName>Leases - Components of Lease Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail</Role>
      <ShortName>Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Leases - Schedule of Lease Term and Discount Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail</Role>
      <ShortName>Leases - Schedule of Lease Term and Discount Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Balance Sheet Components - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail</Role>
      <ShortName>Balance Sheet Components - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail</Role>
      <ShortName>Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Balance Sheet Components - Schedule of Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Balance Sheet Components - Schedule of Other Long-term Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Other Long-term Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Stock-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Stock-Based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="fgen-10q_20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Subsequent Event - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail</Role>
      <ShortName>Subsequent Event - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="fgen-10q_20210630.htm">fgen-10q_20210630.htm</File>
    <File>fgen-20210630.xsd</File>
    <File>fgen-20210630_cal.xml</File>
    <File>fgen-20210630_def.xml</File>
    <File>fgen-20210630_lab.xml</File>
    <File>fgen-20210630_pre.xml</File>
    <File>fgen-ex101_15.htm</File>
    <File>fgen-ex102_408.htm</File>
    <File>fgen-ex211_16.htm</File>
    <File>fgen-ex311_9.htm</File>
    <File>fgen-ex312_8.htm</File>
    <File>fgen-ex321_7.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fgen-10q_20210630.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 371,
   "dts": {
    "calculationLink": {
     "local": [
      "fgen-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "fgen-20210630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "fgen-10q_20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fgen-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fgen-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "fgen-20210630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 540,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 45,
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 51
   },
   "keyCustom": 91,
   "keyStandard": 307,
   "memberCustom": 42,
   "memberStandard": 39,
   "nsprefix": "fgen",
   "nsuri": "http://www.fibrogen.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:CollaborativeArrangementAndRevenuesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Collaboration Agreements and Revenues",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenues",
     "shortName": "Collaboration Agreements and Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:CollaborativeArrangementAndRevenuesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Variable Interest Entity",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntity",
     "shortName": "Variable Interest Entity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Fair Value Measurements",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Leases",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Balance Sheet Components",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Stock-Based Compensation",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Income Taxes",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Related Party Transactions",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Commitments and Contingencies",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Subsequent Event",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:DescriptionOfOperationsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:DescriptionOfOperationsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "fgen:ProductRevenuePolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Collaboration Agreements and Revenues (Tables)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
     "shortName": "Collaboration Agreements and Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "fgen:ProductRevenuePolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Variable Interest Entity (Tables)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityTables",
     "shortName": "Variable Interest Entity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Leases (Tables)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "fgen:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_fgenSegment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "fgen:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_fgenSegment",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210401_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Collaboration Agreements and Revenues - Astellas Agreements - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
     "shortName": "Collaboration Agreements and Revenues - Astellas Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "fgen:CollaborativeArrangementAndRevenuesPolicyTextBlock",
       "fgen:CollaborativeArrangementAndRevenuesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20090228",
      "decimals": "-5",
      "lang": null,
      "name": "fgen:ProceedsFromUpfrontNonContingentAndTimeBasedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Collaboration Agreements and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
     "shortName": "Collaboration Agreements and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730",
      "decimals": "-5",
      "lang": null,
      "name": "fgen:ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DueFromRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210401_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Collaboration Agreements and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
     "shortName": "Collaboration Agreements and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ContractWithCustomerMilestoneMethodTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
     "shortName": "Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210630",
      "decimals": "-3",
      "lang": null,
      "name": "fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20210401_20210630",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Collaboration Agreements and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
     "shortName": "Collaboration Agreements and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20210401_20210630",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail",
     "shortName": "Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210630",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210401_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Collaboration Agreements and Revenues - Summary of Product Revenue, Net (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail",
     "shortName": "Collaboration Agreements and Revenues - Summary of Product Revenue, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "fgen:ProductRevenuePolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_fgenDirectSalesMember_20210401_20210630",
      "decimals": "-3",
      "lang": null,
      "name": "fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210401_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Collaboration Agreements and Revenues - Product Revenue, Net - Additional Information 1 (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
     "shortName": "Collaboration Agreements and Revenues - Product Revenue, Net - Additional Information 1 (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20210101_20210630",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Collaboration Agreements and Revenues - Roll-forward of Related Contract Liabilities (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
     "shortName": "Collaboration Agreements and Revenues - Roll-forward of Related Contract Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20210101_20210630",
      "decimals": "-3",
      "lang": null,
      "name": "fgen:ContractWithCustomerLiabilityAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Collaboration Agreements and Revenues - Deferred Revenue - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
     "shortName": "Collaboration Agreements and Revenues - Deferred Revenue - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210630",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210401_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Collaboration Agreements and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
     "shortName": "Collaboration Agreements and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Collaboration Agreements and Revenues - Drug Product Revenue - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
     "shortName": "Collaboration Agreements and Revenues - Drug Product Revenue - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20210401_20210630",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210401_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210401_20210630",
      "decimals": "-3",
      "lang": null,
      "name": "fgen:CostOfGoodsAndServicesSoldOperatingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAstraZenecaABMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20210630",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Variable Interest Entity - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail",
     "shortName": "Variable Interest Entity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAstraZenecaABMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20210630",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210630",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Variable Interest Entity - Summary of Equity Method Investment (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail",
     "shortName": "Variable Interest Entity - Summary of Equity Method Investment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20210630",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecurities",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:FinanceLeaseRightOfUseAssetsCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail",
     "shortName": "Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:FinanceLeaseRightOfUseAssetsCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20210630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeaseTermOfContract1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210401_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Leases - Components of Lease Expense (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail",
     "shortName": "Leases - Components of Lease Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210401_20210630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FinanceLeaseInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail",
     "shortName": "Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FinanceLeaseInterestPaymentOnLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfLeaseTermAndDiscountRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Leases - Schedule of Lease Term and Discount Rate (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail",
     "shortName": "Leases - Schedule of Lease Term and Discount Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfLeaseTermAndDiscountRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:CollaborationServicesAndOtherRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20210401_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:CollaborationServicesAndOtherRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail",
     "shortName": "Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Balance Sheet Components - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
     "shortName": "Balance Sheet Components - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210401_20210630",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
     "shortName": "Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Balance Sheet Components - Schedule of Inventory (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail",
     "shortName": "Balance Sheet Components - Schedule of Inventory (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Supplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
     "shortName": "Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Supplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:AccruedPreclinicalAndClinicalTrialCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:AccruedPreclinicalAndClinicalTrialCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:AccruedLongTermCoPromotionLiabilityNonCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Balance Sheet Components - Schedule of Other Long-term Liabilities (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Other Long-term Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:AccruedLongTermCoPromotionLiabilityNonCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210401_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Stock-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210401_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210401_20210630",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Stock-Based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail",
     "shortName": "Stock-Based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210401_20210630",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210401_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210401_20210630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Related Party Transactions - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
     "shortName": "Related Party Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20210401_20210630",
      "decimals": "-5",
      "lang": null,
      "name": "fgen:DrugProductRevenueFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Subsequent Event - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail",
     "shortName": "Subsequent Event - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenLicenseAgreementWithEluminexMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210719",
      "decimals": "-6",
      "lang": null,
      "name": "fgen:CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Changes in Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statement of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Significant Accounting Policies",
     "role": "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10q_20210630.htm",
      "contextRef": "C_0000921299_20210101_20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 82,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China [Member]"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan [Member]"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S. [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "fgen_APIShipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "API shipment.",
        "label": "A P I Shipment [Member]",
        "terseLabel": "API Shipment [Member]"
       }
      }
     },
     "localname": "APIShipmentMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AccountingPolicyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policy.",
        "label": "Accounting Policy [Line Items]",
        "terseLabel": "Accounting Policy [Line Items]"
       }
      }
     },
     "localname": "AccountingPolicyLineItems",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_AccountingPolicyTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policy.",
        "label": "Accounting Policy [Table]",
        "terseLabel": "Accounting Policy [Table]"
       }
      }
     },
     "localname": "AccountingPolicyTable",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_AccruedCoPromotionExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued co-promotion expenses - current.",
        "label": "Accrued Co Promotion Expenses Current",
        "terseLabel": "Accrued co-promotion expenses - current"
       }
      }
     },
     "localname": "AccruedCoPromotionExpensesCurrent",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued contract liabilities to pharmaceutical distributors current.",
        "label": "Accrued Contract Liabilities To Pharmaceutical Distributors Current",
        "terseLabel": "Contract liabilities to pharmaceutical distributors"
       }
      }
     },
     "localname": "AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AccruedLongTermCoPromotionLiabilityNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued long term co promotion liability non current.",
        "label": "Accrued Long Term Co Promotion Liability Non Current",
        "terseLabel": "Accrued long-term co-promotion expenses"
       }
      }
     },
     "localname": "AccruedLongTermCoPromotionLiabilityNonCurrent",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AccruedPreclinicalAndClinicalTrialCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to pre-clinical and clinical trial activities, including those performed by third parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Preclinical And Clinical Trial Current",
        "terseLabel": "Preclinical and clinical trial accruals"
       }
      }
     },
     "localname": "AccruedPreclinicalAndClinicalTrialCurrent",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AccruedProductDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10120.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the long-term portion of the outstanding principal and accrued interest of advances in the form note agreements received by the entity to fund various product development efforts.",
        "label": "Accrued Product Development Costs",
        "terseLabel": "Product development obligations"
       }
      }
     },
     "localname": "AccruedProductDevelopmentCosts",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AccruedProfitShareCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued profit share current.",
        "label": "Accrued Profit Share Current",
        "terseLabel": "Roxadustat profit share to AstraZeneca"
       }
      }
     },
     "localname": "AccruedProfitShareCurrent",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AcquisitionAndVariableInterestEntityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition and variable interest entity abstract.",
        "label": "Acquisition And Variable Interest Entity [Abstract]"
       }
      }
     },
     "localname": "AcquisitionAndVariableInterestEntityAbstract",
     "nsuri": "http://www.fibrogen.com/20210630",
     "xbrltype": "stringItemType"
    },
    "fgen_AcquisitionAndVariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition and variable interest entity line items.",
        "label": "Acquisition And Variable Interest Entity [Line Items]",
        "terseLabel": "Acquisition And Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "AcquisitionAndVariableInterestEntityLineItems",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_AcquisitionAndVariableInterestEntityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition and variable interest entity table.",
        "label": "Acquisition And Variable Interest Entity [Table]",
        "terseLabel": "Acquisition And Variable Interest Entity [Table]"
       }
      }
     },
     "localname": "AcquisitionAndVariableInterestEntityTable",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_AdditionalConsiderationBasedOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional consideration based on net sales of product as defined under a collaboration agreement.",
        "label": "Additional Consideration Based On Net Sales",
        "terseLabel": "Additional consideration based on net sales description"
       }
      }
     },
     "localname": "AdditionalConsiderationBasedOnNetSales",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital shares issued from stock plans net of payroll taxes paid.",
        "label": "Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid",
        "terseLabel": "Shares issued from stock plans, net of payroll taxes paid"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AgencyBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency bonds.",
        "label": "Agency Bonds [Member]",
        "terseLabel": "Agency bonds [Member]"
       }
      }
     },
     "localname": "AgencyBondsMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AstellasAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Astellas agreement.",
        "label": "Astellas Agreement [Member]",
        "terseLabel": "Astellas Agreement [Member]"
       }
      }
     },
     "localname": "AstellasAgreementMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AstellasCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Astellas agreements.",
        "label": "Astellas Collaboration Agreement [Member]",
        "terseLabel": "Astellas Agreement [Member]"
       }
      }
     },
     "localname": "AstellasCollaborationAgreementMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AstellasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Astellas.",
        "label": "Astellas [Member]",
        "terseLabel": "Astellas [Member]"
       }
      }
     },
     "localname": "AstellasMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AstraZenecaABMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca AB.",
        "label": "Astra Zeneca A B [Member]",
        "terseLabel": "AstraZenecaAB [Member]"
       }
      }
     },
     "localname": "AstraZenecaABMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AstraZenecaAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Astra Zeneca agreements.",
        "label": "Astra Zeneca Agreements [Member]",
        "terseLabel": "AstraZeneca Agreements [Member]"
       }
      }
     },
     "localname": "AstraZenecaAgreementsMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AvailableForSaleSecuritiesContractualMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum contractual maturity period for available-for-sale securities.",
        "label": "Available For Sale Securities Contractual Maturity Period",
        "terseLabel": "Contractual maturities of available-for-sale investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContractualMaturityPeriod",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "fgen_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and principles of consolidation policy.",
        "label": "Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_BeijingEconomicTechnologicalDevelopmentAreaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beijing economic-technological development area.",
        "label": "Beijing Economic Technological Development Area [Member]",
        "terseLabel": "Beijing Economic-Technological Development Area [Member]"
       }
      }
     },
     "localname": "BeijingEconomicTechnologicalDevelopmentAreaMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_BeijingFalikangPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beijing Falikang Pharmaceutical Co. Ltd.",
        "label": "Beijing Falikang Pharmaceutical Co Ltd [Member]",
        "terseLabel": "Beijing Falikang Pharmaceutical Co Ltd",
        "verboseLabel": "Beijing Falikang Pharmaceutical Co. Ltd [Member]"
       }
      }
     },
     "localname": "BeijingFalikangPharmaceuticalCoLtdMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beijing Kangda Yongfu Pharmaceutical Co., LTD.",
        "label": "Beijing Kangda Yongfu Pharmaceutical Co L T D [Member]",
        "terseLabel": "Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member]"
       }
      }
     },
     "localname": "BeijingKangdaYongfuPharmaceuticalCoLTDMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_BondAndMutualFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond and mutual funds.",
        "label": "Bond And Mutual Funds [Member]",
        "terseLabel": "Bond and mutual funds [Member]"
       }
      }
     },
     "localname": "BondAndMutualFundsMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_CashConsiderationReceivedUnderCollaborationAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition.",
        "label": "Cash Consideration Received Under Collaboration Agreement",
        "totalLabel": "Total Consideration"
       }
      }
     },
     "localname": "CashConsiderationReceivedUnderCollaborationAgreement",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_ChinaPerformanceObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "China performance obligation.",
        "label": "China Performance Obligation [Member]",
        "terseLabel": "China performance obligation [Member]"
       }
      }
     },
     "localname": "ChinaPerformanceObligationMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_ClinicalDevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical development milestone.",
        "label": "Clinical Development Milestones [Member]",
        "terseLabel": "Clinical and Development Milestone [Member]"
       }
      }
     },
     "localname": "ClinicalDevelopmentMilestonesMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co development information sharing and committee services.",
        "label": "Co Development Information Sharing And Committee Services [Member]",
        "terseLabel": "Co-development, information sharing &amp; committee services [Member]"
       }
      }
     },
     "localname": "CoDevelopmentInformationSharingAndCommitteeServicesMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_CollaborationServicesAndOtherRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognized from co-development services, manufacturing of clinical supplies, committee services and information services and other revenue.",
        "label": "Collaboration Services And Other Revenue",
        "terseLabel": "Collaboration services and other revenue from a related party"
       }
      }
     },
     "localname": "CollaborationServicesAndOtherRevenue",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue.",
        "label": "Collaborative Arrangement Aggregate Consideration Excluding Drug Product Revenue",
        "terseLabel": "Aggregate consideration received excluding drug product revenue"
       }
      }
     },
     "localname": "CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement aggregate consideration for milestone and upfront payments.",
        "label": "Collaborative Arrangement Aggregate Consideration For Milestone And Upfront Payments",
        "terseLabel": "Aggregate consideration received for milestone and upfront payments"
       }
      }
     },
     "localname": "CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and revenues.",
        "label": "Collaborative Arrangement And Revenues Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements and Revenues"
       }
      }
     },
     "localname": "CollaborativeArrangementAndRevenuesDisclosureTextBlock",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and revenues.",
        "label": "Collaborative Arrangement And Revenues Policy [Text Block]",
        "terseLabel": "Collaboration Arrangements and Revenues"
       }
      }
     },
     "localname": "CollaborativeArrangementAndRevenuesPolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_CommercialMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestone.",
        "label": "Commercial Milestone",
        "terseLabel": "Commercial milestone"
       }
      }
     },
     "localname": "CommercialMilestone",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_CommercialSalesAndOtherEventsMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial sales and other events milestone.",
        "label": "Commercial Sales And Other Events Milestone",
        "terseLabel": "Commercial sales and other events milestone"
       }
      }
     },
     "localname": "CommercialSalesAndOtherEventsMilestone",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_CommercialSalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of milestone payments related to commercial sales under the collaborative agreement.",
        "label": "Commercial Sales Milestone",
        "terseLabel": "Commercial sales milestone"
       }
      }
     },
     "localname": "CommercialSalesMilestone",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_ContractLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract liabilities,",
        "label": "Contract Liabilities [Member]",
        "terseLabel": "Contract Liabilities [Member]"
       }
      }
     },
     "localname": "ContractLiabilitiesMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability additions.",
        "label": "Contract With Customer Liability Additions",
        "negatedLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ContractWithCustomerLiabilityDeduction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability deduction.",
        "label": "Contract With Customer Liability Deduction",
        "terseLabel": "Deduction"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDeduction",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer, liability, increase (decrease) from current translation and other.",
        "label": "Contract With Customer Liability Increase Decrease From Current Translation And Other",
        "terseLabel": "Currency Translation and Other"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ContractWithCustomerLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability.",
        "label": "Contract With Customer Liability [Line Items]",
        "terseLabel": "Contract with Customer Liability [Line Items]"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityLineItems",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_ContractWithCustomerLiabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer Liability [Table]",
        "label": "Contract With Customer Liability [Table]",
        "terseLabel": "Contract With Customer Liability [Table]"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityTable",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_ContractWithCustomerMilestoneMethodTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer milestone method.",
        "label": "Contract With Customer Milestone Method Table [Text Block]",
        "terseLabel": "Summary of License Revenue and Development Revenue Recognized under Agreement"
       }
      }
     },
     "localname": "ContractWithCustomerMilestoneMethodTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_CostOfGoodsAndServicesSoldOperatingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of goods and services sold operating expense.",
        "label": "Cost Of Goods And Services Sold Operating Expense",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldOperatingExpense",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail": {
       "order": 10010.0,
       "parentTag": "fgen_CashConsiderationReceivedUnderCollaborationAgreement",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date.",
        "label": "Cumulative Revenue License And Development Revenue Recognized",
        "terseLabel": "Cumulative Revenue"
       }
      }
     },
     "localname": "CumulativeRevenueLicenseAndDevelopmentRevenueRecognized",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_DeferredApprovalMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred approval milestone.",
        "label": "Deferred Approval Milestone [Member]",
        "terseLabel": "Deferred Approval Milestone [Member]"
       }
      }
     },
     "localname": "DeferredApprovalMilestoneMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_DeferredForFutureRecognitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred for future recognition.",
        "label": "Deferred For Future Recognition [Member]",
        "terseLabel": "Constrained for Future Recognition [Member]"
       }
      }
     },
     "localname": "DeferredForFutureRecognitionMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_DescriptionOfOperationsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of operations policy.",
        "label": "Description Of Operations Policy Policy [Text Block]",
        "terseLabel": "Description of Operations"
       }
      }
     },
     "localname": "DescriptionOfOperationsPolicyPolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_DescriptionOfSalesReturn": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of sales return.",
        "label": "Description Of Sales Return",
        "terseLabel": "Description of sales return"
       }
      }
     },
     "localname": "DescriptionOfSalesReturn",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_DevelopmentAndOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and other revenue.",
        "label": "Development And Other Revenue [Member]",
        "terseLabel": "Development and Other Revenue [Member]",
        "verboseLabel": "Development Revenue [Member]"
       }
      }
     },
     "localname": "DevelopmentAndOtherRevenueMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_DevelopmentAndRegulatoryApprovalMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement.",
        "label": "Development And Regulatory Approval Milestones",
        "terseLabel": "Development and regulatory approval milestones"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryApprovalMilestones",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_DirectSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct sales.",
        "label": "Direct Sales [Member]",
        "terseLabel": "Direct Sales [Member]"
       }
      }
     },
     "localname": "DirectSalesMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_DiscountsAndRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discounts and rebates.",
        "label": "Discounts And Rebates [Member]",
        "terseLabel": "Discounts and Rebates [Member]"
       }
      }
     },
     "localname": "DiscountsAndRebatesMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_DrugProductRevenueFromRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug product revenue from related party.",
        "label": "Drug Product Revenue From Related Party",
        "terseLabel": "Drug product revenue from a related party"
       }
      }
     },
     "localname": "DrugProductRevenueFromRelatedParty",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_DrugProductRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug product revenue.",
        "label": "Drug Product Revenue [Member]",
        "terseLabel": "Drug Product Revenue [Member]"
       }
      }
     },
     "localname": "DrugProductRevenueMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_DrugProductRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug product revenue.",
        "label": "Drug Product Revenue Policy [Text Block]",
        "terseLabel": "Drug Product Revenue"
       }
      }
     },
     "localname": "DrugProductRevenuePolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_DueToRelatedPartiesDeferredRevenueCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due to related parties deferred revenue current.",
        "label": "Due To Related Parties Deferred Revenue Current",
        "terseLabel": "Deferred revenue current to related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesDeferredRevenueCurrent",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_DueToRelatedPartiesDeferredRevenueNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due to related parties deferred revenue noncurrent.",
        "label": "Due To Related Parties Deferred Revenue Noncurrent",
        "terseLabel": "Deferred revenue non-current to related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesDeferredRevenueNoncurrent",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10270.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment in unconsolidated variable interest entity.",
        "label": "Equity Method Investment In Unconsolidated Variable Interest Entity",
        "terseLabel": "Equity method investment in unconsolidated variable interest entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentInUnconsolidatedVariableInterestEntity",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment increase (decrease) from currency translation.",
        "label": "Equity Method Investment Increase Decrease From Currency Translation",
        "terseLabel": "Currency Translation"
       }
      }
     },
     "localname": "EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_FalikangMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Falikang.",
        "label": "Falikang [Member]",
        "terseLabel": "Falikang [Member]"
       }
      }
     },
     "localname": "FalikangMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_FibroGenBeijingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FibroGen Beijing.",
        "label": "Fibro Gen Beijing [Member]",
        "terseLabel": "FibroGen Beijing [Member]"
       }
      }
     },
     "localname": "FibroGenBeijingMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_FinanceLeaseAccumulatedAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10100.0,
       "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease accumulated amortization.",
        "label": "Finance Lease Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FinanceLeaseAccumulatedAmortization",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_FinanceLeaseAndOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease and operating lease assets.",
        "label": "Finance Lease And Operating Lease Assets",
        "totalLabel": "Total lease assets"
       }
      }
     },
     "localname": "FinanceLeaseAndOperatingLeaseAssets",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_FinanceLeaseAndOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease and operating lease liability.",
        "label": "Finance Lease And Operating Lease Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseAndOperatingLeaseLiability",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_FinanceLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10120.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease liability payments due after year four.",
        "label": "Finance Lease Liability Payments Due After Year Four",
        "terseLabel": "Beyond 2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_FinanceLeaseRightOfUseAssetsCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10090.0,
       "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease, right-of-use assets - cost.",
        "label": "Finance Lease Right Of Use Assets Cost",
        "terseLabel": "Right-of-use assets - cost"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetsCost",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future manufacturing clinical regulatory and commercial milestone payments.",
        "label": "Future Manufacturing Clinical Regulatory And Commercial Milestone Payments",
        "terseLabel": "Future manufacturing clinical regulatory and commercial milestone payments"
       }
      }
     },
     "localname": "FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_GrossAccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross accounts receivable.",
        "label": "Gross Accounts Receivable [Member]",
        "terseLabel": "Gross Accounts Receivable [Member]"
       }
      }
     },
     "localname": "GrossAccountsReceivableMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_HiFiBiOAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HiFiBiO agreement.",
        "label": "Hi Fi Bi O Agreement [Member]",
        "terseLabel": "HiFiBiO Agreement [Member]"
       }
      }
     },
     "localname": "HiFiBiOAgreementMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10340.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accrued interest for finance lease liabilities.",
        "label": "Increase Decrease In Accrued Interest For Finance Lease Liabilities",
        "terseLabel": "Accrued interest for finance lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10320.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease liabilities, current.",
        "label": "Increase Decrease In Operating Lease Liabilities Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10350.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease liabilities, non-current.",
        "label": "Increase Decrease In Operating Lease Liabilities Non Current",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10280.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease right-of-use assets.",
        "label": "Increase Decrease In Operating Lease Right Of Use Assets",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_IncreaseInDeferredRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in deferred revenue.",
        "label": "Increase In Deferred Revenue [Member]",
        "terseLabel": "Increase in Deferred Revenue [Member]"
       }
      }
     },
     "localname": "IncreaseInDeferredRevenueMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_InitialUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment.",
        "label": "Initial Upfront Payment",
        "terseLabel": "Initial upfront payment"
       }
      }
     },
     "localname": "InitialUpfrontPayment",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_InterestIncomeAndOtherIncomeExpensesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10070.0,
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income and other income (expenses), net.",
        "label": "Interest Income And Other Income Expenses Net",
        "terseLabel": "Interest income and other income (expenses), net"
       }
      }
     },
     "localname": "InterestIncomeAndOtherIncomeExpensesNet",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_InvestmentLossInUnconsolidatedVariableInterestEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment loss in unconsolidated variable interest entity.",
        "label": "Investment Loss In Unconsolidated Variable Interest Entity",
        "negatedLabel": "Investment loss in unconsolidated variable interest entity"
       }
      }
     },
     "localname": "InvestmentLossInUnconsolidatedVariableInterestEntity",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_LeaseAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease amendment.",
        "label": "Lease Amendment [Member]",
        "terseLabel": "Lease Amendment [Member]"
       }
      }
     },
     "localname": "LeaseAmendmentMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, finance lease, additional lease expiration period.",
        "label": "Lessee Finance Lease Additional Lease Expiration Period",
        "terseLabel": "Lessee, finance lease, additional lease expiration period"
       }
      }
     },
     "localname": "LesseeFinanceLeaseAdditionalLeaseExpirationPeriod",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "fgen_LesseeFinanceLeaseExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, finance lease, expiration period.",
        "label": "Lessee Finance Lease Expiration Period",
        "terseLabel": "Lessee, finance lease, expiration period"
       }
      }
     },
     "localname": "LesseeFinanceLeaseExpirationPeriod",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, finance lease, option to extend the additional lease term.",
        "label": "Lessee Finance Lease Option To Extend Additional Lease Term",
        "terseLabel": "Lessee, finance lease, option to extend the additional lease term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "fgen_LesseeOperatingLeaseExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, expiration period.",
        "label": "Lessee Operating Lease Expiration Period",
        "terseLabel": "Lessee, operating lease, expiration period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExpirationPeriod",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "fgen_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year four.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "terseLabel": "Beyond 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_LicenseAgreementWithEluminexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement with Eluminex.",
        "label": "License Agreement With Eluminex [Member]",
        "terseLabel": "Eluminex [Member]"
       }
      }
     },
     "localname": "LicenseAgreementWithEluminexMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_ManufactureAndSupplyOfPamrevlumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacture and supply of pamrevlumab.",
        "label": "Manufacture And Supply Of Pamrevlumab [Member]",
        "terseLabel": "Manufacture and Supply of Pamrevlumab [Member]"
       }
      }
     },
     "localname": "ManufactureAndSupplyOfPamrevlumabMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_ManufactureAndSupplyOfRoxadustatMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacture and Supply of Roxadustat.",
        "label": "Manufacture And Supply Of Roxadustat [Member]",
        "terseLabel": "Manufacture and Supply of Roxadustat [Member]"
       }
      }
     },
     "localname": "ManufactureAndSupplyOfRoxadustatMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum additional future option, clinical, regulatory, and commercial milestone payments.",
        "label": "Maximum Additional Future Option Clinical Regulatory And Commercial Milestone Payments",
        "terseLabel": "Maximum additional future option, clinical, regulatory, and commercial milestone payments"
       }
      }
     },
     "localname": "MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_MaximumFutureMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum future milestone payments.",
        "label": "Maximum Future Milestone Payments",
        "terseLabel": "Maximum future milestone payments"
       }
      }
     },
     "localname": "MaximumFutureMilestonePayments",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_MiscellaneousReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Miscellaneous receivables.",
        "label": "Miscellaneous Receivables",
        "terseLabel": "Miscellaneous receivables"
       }
      }
     },
     "localname": "MiscellaneousReceivables",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_NetTransferPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net transfer price.",
        "label": "Net Transfer Price [Member]",
        "terseLabel": "Net Transfer Price [Member]"
       }
      }
     },
     "localname": "NetTransferPriceMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash increase decrease resulting from lease modification.",
        "label": "Non Cash Increase Decrease Resulting From Lease Modification [Abstract]",
        "terseLabel": "Non-cash: Increase (decrease) resulting from lease modification:"
       }
      }
     },
     "localname": "NonCashIncreaseDecreaseResultingFromLeaseModificationAbstract",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash right of use assets obtained in exchange for new lease liabilities.",
        "label": "Non Cash Right Of Use Assets Obtained In Exchange For New Lease Liabilities [Abstract]",
        "terseLabel": "Non-cash: Right-of-use assets obtained in exchange for new lease liabilities:"
       }
      }
     },
     "localname": "NonCashRightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_NumberOfOptionalRightsToExtendLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of optional rights to extend lease.",
        "label": "Number Of Optional Rights To Extend Lease",
        "terseLabel": "Optional rights to extend lease"
       }
      }
     },
     "localname": "NumberOfOptionalRightsToExtendLease",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "fgen_OperatingLeaseAccumulatedAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease, accumulated amortization.",
        "label": "Operating Lease Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "OperatingLeaseAccumulatedAmortization",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_OperatingLeaseRightOfUseAssetsCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease, right-of-use assets - cost.",
        "label": "Operating Lease Right Of Use Assets Cost",
        "terseLabel": "Right-of-use assets - cost"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetsCost",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_OtherPurchasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Purchases.",
        "label": "Other Purchases [Member]",
        "terseLabel": "Other Purchases [Member]"
       }
      }
     },
     "localname": "OtherPurchasesMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made for investment in unconsolidated variable interest entity.",
        "label": "Payment Made For Investment In Unconsolidated Variable Interest Entity",
        "negatedLabel": "Payment made for investment in unconsolidated variable interest entity"
       }
      }
     },
     "localname": "PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage increases on anniversary of rent commencement date option two.",
        "label": "Percentage Increases On Anniversary Of Rent Commencement Date Option Two",
        "terseLabel": "Percentage increases on each anniversary of rent commencement date 2028"
       }
      }
     },
     "localname": "PercentageIncreasesOnAnniversaryOfRentCommencementDateOptionTwo",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage increases on each anniversary of rent commencement date.",
        "label": "Percentage Increases On Each Anniversary Of Rent Commencement Date",
        "terseLabel": "Percentage increases on each anniversary of rent commencement date 2023"
       }
      }
     },
     "localname": "PercentageIncreasesOnEachAnniversaryOfRentCommencementDate",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "fgen_PercentageOfFundingForCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs.",
        "label": "Percentage Of Funding For Costs",
        "terseLabel": "Percentage of joint development costs committed to fund"
       }
      }
     },
     "localname": "PercentageOfFundingForCosts",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of pre-launch inventory capitalized of aggregate inventory balance.",
        "label": "Percentage Of Pre Launch Inventory Capitalized Of Aggregate Inventory Balance",
        "terseLabel": "Percentage of pre-launch inventory capitalized of aggregate inventory balance"
       }
      }
     },
     "localname": "PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "fgen_PotentialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement.",
        "label": "Potential Milestones",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "PotentialMilestones",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.",
        "label": "Proceeds From Upfront Non Contingent And Non Refundable Payments",
        "terseLabel": "Proceeds from upfront, non-contingent and non-refundable payments"
       }
      }
     },
     "localname": "ProceedsFromUpfrontNonContingentAndNonRefundablePayments",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration.",
        "label": "Proceeds From Upfront Non Contingent And Time Based Payments",
        "terseLabel": "Upfront, non-contingent and time-based payments received"
       }
      }
     },
     "localname": "ProceedsFromUpfrontNonContingentAndTimeBasedPayments",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.",
        "label": "Proceeds From Upfront Non Contingent Non Refundable And Time Based Payments",
        "terseLabel": "Upfront, non-contingent, non-refundable and time-based payments"
       }
      }
     },
     "localname": "ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ProductRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product revenue from a related party.",
        "label": "Product Revenue",
        "terseLabel": "Product revenue from a related party"
       }
      }
     },
     "localname": "ProductRevenue",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ProductRevenuePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product revenue policy.",
        "label": "Product Revenue Policy Policy [Text Block]",
        "terseLabel": "Product Revenue, Net"
       }
      }
     },
     "localname": "ProductRevenuePolicyPolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_ProfitShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit share.",
        "label": "Profit Share [Member]",
        "terseLabel": "Profit Share [Member]"
       }
      }
     },
     "localname": "ProfitShareMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_ProfitSharePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit share percent.",
        "label": "Profit Share Percent",
        "terseLabel": "Profit share percent"
       }
      }
     },
     "localname": "ProfitSharePercent",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "fgen_PropertyTaxesAndOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property taxes and other current.",
        "label": "Property Taxes And Other Current",
        "terseLabel": "Property taxes and other taxes"
       }
      }
     },
     "localname": "PropertyTaxesAndOtherCurrent",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_RebatesAndDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rebates and discounts.",
        "label": "Rebates And Discounts [Member]",
        "terseLabel": "Rebates and Discounts [Member]"
       }
      }
     },
     "localname": "RebatesAndDiscountsMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently issued accounting guidance not yet adopted.",
        "label": "Recently Issued Accounting Guidance Not Yet Adopted Policy [Text Block]",
        "terseLabel": "Recently Issued Accounting Guidance Not Yet Adopted"
       }
      }
     },
     "localname": "RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently issued and adopted accounting guidance.",
        "label": "Recently Issued And Adopted Accounting Guidance Policy [Text Block]",
        "terseLabel": "Recently Issued and Adopted Accounting Guidance"
       }
      }
     },
     "localname": "RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone.",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestone [Member]"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_RepaymentsOfFinanceLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments of finance lease liabilities.",
        "label": "Repayments Of Finance Lease Liabilities",
        "negatedLabel": "Repayments of finance lease liabilities",
        "terseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "RepaymentsOfFinanceLeaseLiabilities",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and pre-clinical stage development programs.",
        "label": "Research And Pre Clinical Stage Development Programs [Member]",
        "terseLabel": "Research and Pre-Clinical Stage Development Programs [Member]"
       }
      }
     },
     "localname": "ResearchAndPreClinicalStageDevelopmentProgramsMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_RestrictedTimeDepositsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10230.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted time deposits noncurrent.",
        "label": "Restricted Time Deposits Noncurrent",
        "terseLabel": "Restricted time deposits"
       }
      }
     },
     "localname": "RestrictedTimeDepositsNoncurrent",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue gross from contract with customer excluding assessed tax.",
        "label": "Revenue Gross From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Gross revenue"
       }
      }
     },
     "localname": "RevenueGrossFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue gross transfer price from contract with customer excluding assessed tax.",
        "label": "Revenue Gross Transfer Price From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Gross transfer price"
       }
      }
     },
     "localname": "RevenueGrossTransferPriceFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and uncertainties.",
        "label": "Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_SalesToFalikangMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales to Falikang.",
        "label": "Sales To Falikang [Member]",
        "terseLabel": "Sales To Falikang [Member]"
       }
      }
     },
     "localname": "SalesToFalikangMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_ScheduleOfDrugProductRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of drug product revenue.",
        "label": "Schedule Of Drug Product Revenue Table [Text Block]",
        "terseLabel": "Schedule of Drug Product Revenue"
       }
      }
     },
     "localname": "ScheduleOfDrugProductRevenueTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of lease assets and related lease liabilities.",
        "label": "Schedule Of Lease Assets And Related Lease Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Lease Assets and Related Lease Liabilities"
       }
      }
     },
     "localname": "ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of lease term and discount rate.",
        "label": "Schedule Of Lease Term And Discount Rate Table [Text Block]",
        "terseLabel": "Schedule of Lease Term and Discount Rate"
       }
      }
     },
     "localname": "ScheduleOfLeaseTermAndDiscountRateTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_ScheduleOfLeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of leases.",
        "label": "Schedule Of Leases [Line Items]",
        "terseLabel": "Schedule Of Leases [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfLeasesLineItems",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_ScheduleOfLeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of leases.",
        "label": "Schedule Of Leases [Table]",
        "terseLabel": "Schedule Of Leases [Table]"
       }
      }
     },
     "localname": "ScheduleOfLeasesTable",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of maturities of finance and operating leases liabilities.",
        "label": "Schedule Of Maturities Of Finance And Operating Leases Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Maturities of Finance and Operating Leases Liabilities"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of share based payment award stock options and employee stock purchase plan valuation assumptions.",
        "label": "Schedule Of Share Based Payment Award Stock Options And Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental cash flow information related to leases.",
        "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_ScheduledRentCommencementYearOptionOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent commencement year option one.",
        "label": "Scheduled Rent Commencement Year Option One",
        "terseLabel": "Rent increase commencement year first option"
       }
      }
     },
     "localname": "ScheduledRentCommencementYearOptionOne",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "fgen_ScheduledRentCommencementYearOptionTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scheduled rent commencement year option two.",
        "label": "Scheduled Rent Commencement Year Option Two",
        "terseLabel": "Rent increase commencement year second option"
       }
      }
     },
     "localname": "ScheduledRentCommencementYearOptionTwo",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued from stock plans net of payroll taxes paid shares.",
        "label": "Shares Issued From Stock Plans Net Of Payroll Taxes Paid Shares",
        "terseLabel": "Shares issued from stock plans, net of payroll taxes paid, Shares"
       }
      }
     },
     "localname": "SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "fgen_ShorensteinPropertiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shorenstein properties LLC.",
        "label": "Shorenstein Properties L L C [Member]",
        "terseLabel": "Shorenstein Properties LLC [Member]"
       }
      }
     },
     "localname": "ShorensteinPropertiesLLCMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_SuppliesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplies, net.",
        "label": "Supplies Net",
        "terseLabel": "Net unbilled co-development revenue",
        "totalLabel": "Net unbilled contract assets"
       }
      }
     },
     "localname": "SuppliesNet",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_USGovernmentBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. government bonds.",
        "label": "U S Government Bonds [Member]",
        "terseLabel": "U.S. government bonds [Member]"
       }
      }
     },
     "localname": "USGovernmentBondsMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_UnconsolidatedVariableInterestEntityInvestmentIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10030.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unconsolidated variable interest entity investment income.",
        "label": "Unconsolidated Variable Interest Entity Investment Income",
        "terseLabel": "Investment income in unconsolidated variable interest entity"
       }
      }
     },
     "localname": "UnconsolidatedVariableInterestEntityInvestmentIncome",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_UnitedStatesAndRestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United states and rest of world.",
        "label": "United States And Rest Of World [Member]",
        "terseLabel": "U.S./RoW [Member]"
       }
      }
     },
     "localname": "UnitedStatesAndRestOfWorldMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_UnitedStatesRestOfWorldAndChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States/Rest of World and China.",
        "label": "United States Rest Of World And China [Member]",
        "terseLabel": "U.S./RoW and China [Member]"
       }
      }
     },
     "localname": "UnitedStatesRestOfWorldAndChinaMember",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_UnrealizedLossGainOnEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized loss (gain) on equity investments.",
        "label": "Unrealized Loss Gain On Equity Investments",
        "negatedLabel": "Unrealized loss on equity investments"
       }
      }
     },
     "localname": "UnrealizedLossGainOnEquityInvestments",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable consideration payment received from estimated future co-development billing.",
        "label": "Variable Consideration Payment Received From Estimated Future Co Development Billing",
        "terseLabel": "Remainder of transaction price, variable consideration from estimated future co-development billing"
       }
      }
     },
     "localname": "VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average discount rate.",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted-average discount rate:"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average remaining lease term.",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted-average remaining lease term (years):"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.fibrogen.com/20210630",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r235",
      "r237",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r422",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r235",
      "r237",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r422",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r150",
      "r214",
      "r217",
      "r368",
      "r421",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r150",
      "r214",
      "r217",
      "r368",
      "r421",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r224",
      "r235",
      "r237",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r422",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r224",
      "r235",
      "r237",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r422",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r151",
      "r152",
      "r214",
      "r218",
      "r424",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r151",
      "r152",
      "r214",
      "r218",
      "r424",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201901Member": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-01 Leases (Topic 842): Codification Improvements.",
        "label": "Accounting Standards Update201901 [Member]",
        "terseLabel": "ASC 842 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201901Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10170.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable ($0 and $1,118 to a related party)"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r40",
      "r99",
      "r351",
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Related Parties Current",
        "terseLabel": "Accounts payable to related party"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r23",
      "r154",
      "r155"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10320.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable, net ($13,352 and $4,127 from related parties)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r47",
      "r99",
      "r350",
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable Related Parties Current",
        "positiveLabel": "Accounts receivable from related party",
        "terseLabel": "Accounts receivable from related parties"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion Amortization Of Discounts And Premiums Investments",
        "negatedLabel": "Net accretion of premium and discount on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10180.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities And Other Liabilities",
        "terseLabel": "Accrued and other current liabilities ($14 and $24 to a related party)"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "totalLabel": "Total accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r42"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r38",
      "r195"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r60",
      "r62",
      "r63",
      "r409",
      "r433",
      "r437"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10090.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r59",
      "r63",
      "r64",
      "r106",
      "r107",
      "r108",
      "r297",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r24",
      "r259"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r256",
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r272",
      "r273",
      "r274",
      "r275",
      "r370",
      "r371",
      "r372",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r238",
      "r240",
      "r262",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r240",
      "r250",
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r156",
      "r179",
      "r180",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Allowance For Doubtful Accounts Receivable",
        "terseLabel": "Reductions to gross accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti-dilutive shares outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r163",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset Backed Securities [Member]",
        "terseLabel": "Asset-backed securities [Member]"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r95",
      "r138",
      "r142",
      "r148",
      "r171",
      "r293",
      "r298",
      "r316",
      "r387",
      "r407"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r54",
      "r95",
      "r171",
      "r293",
      "r298",
      "r316"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10220.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "terseLabel": "Total fair value of financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available For Sale Securities",
        "terseLabel": "Fair Value",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Gross Unrealized Holding Gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Gross Unrealized Holding Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available For Sale Securities Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10240.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.",
        "label": "Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments",
        "negatedLabel": "Realized loss on sales of available-for-sale securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r241",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security, in which the authorized issuer owes the holder a debt and is obliged to repay the principal and interest (the coupon).",
        "label": "Bonds [Member]",
        "terseLabel": "Agency bonds [Member]"
       }
      }
     },
     "localname": "BondsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r234",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r234",
      "r236",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition Percentage Of Voting Interests Acquired",
        "terseLabel": "Percentage of outstanding shares acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r286",
      "r287",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination Contingent Consideration Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r35",
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash And Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r35",
      "r92"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10300.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Total cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure",
        "terseLabel": "Assets fair value disclosure"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r87",
      "r92",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Total cash and cash equivalents at end of period",
        "periodStartLabel": "Total cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r87",
      "r317"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperAtCarryingValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Commercial Paper At Carrying Value",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r45",
      "r202",
      "r393",
      "r414"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.01 par value; 225,000 shares authorized at June 30, 2021, and December 31, 2020; 92,609 and 91,441 shares issued and outstanding at June 30, 2021, and December 31, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r67",
      "r69",
      "r70",
      "r77",
      "r398",
      "r418"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction in progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract With Customer Asset And Liability Table [Text Block]",
        "terseLabel": "Roll-forward of Related Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r208",
      "r209",
      "r215"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10050.0,
       "parentTag": "fgen_SuppliesNet",
       "weight": -1.0
      },
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail": {
       "order": 10020.0,
       "parentTag": "fgen_CashConsiderationReceivedUnderCollaborationAgreement",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "negatedLabel": "Deferred revenues from associated contracts",
        "negatedPeriodEndLabel": "Balance at June 30, 2021",
        "negatedPeriodStartLabel": "Balance at December 31, 2020",
        "positiveLabel": "Deferred revenue",
        "terseLabel": "Deferred Revenue",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.",
        "label": "Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized",
        "terseLabel": "Changes in revenue from changes to estimated variable consideration"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r208",
      "r209",
      "r215"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10190.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "positiveLabel": "Profit share liability",
        "terseLabel": "Deferred revenue ($10,699 and $2,907 to a related party)",
        "verboseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r208",
      "r209",
      "r215"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10130.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Deferred revenue, net of current ($9,381 and $4,636 to a related party)"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract With Customer Liability Revenue Recognized",
        "terseLabel": "Recognized as Revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Outstanding non-cancelable purchase obligations"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds [Member]"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.",
        "label": "Deferred Tax And Other Liabilities Noncurrent",
        "terseLabel": "Other long-term tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r90",
      "r193"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation Of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation Of Revenue [Line Items]",
        "terseLabel": "Disaggregation Of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r214",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue [Table]",
        "terseLabel": "Disaggregation Of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue Table [Text Block]",
        "terseLabel": "Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r4",
      "r14",
      "r22",
      "r97",
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due From Related Parties Current",
        "terseLabel": "Prepaid expenses and other current assets from related parties"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r40",
      "r99",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due To Related Parties Current",
        "terseLabel": "Accrued and other current liabilities to related party",
        "verboseLabel": "Accrued liabilities to related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share - basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Income (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10040.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "terseLabel": "Effect of exchange rate change on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Payroll and related accruals"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee stock options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r110",
      "r117",
      "r119",
      "r124",
      "r176",
      "r206",
      "r207",
      "r256",
      "r257",
      "r258",
      "r274",
      "r275",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r0",
      "r95",
      "r171",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r0",
      "r95",
      "r171",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment Ownership Percentage",
        "terseLabel": "Ownership Percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r36",
      "r139",
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Text Block]",
        "terseLabel": "Summary of Equity Method Investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r15",
      "r18",
      "r168",
      "r405",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity investments [Member]"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value Assets Level1 To Level2 Transfers Amount",
        "terseLabel": "Transfers of assets from level 1 to 2"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value Assets Level2 To Level1 Transfers Amount",
        "terseLabel": "Transfers of assets from level 2 to 1"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value Assets Measured On Recurring Basis [Text Block]",
        "terseLabel": "Fair Values of Financial Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r308",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r307",
      "r308",
      "r310",
      "r311",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r225",
      "r226",
      "r231",
      "r233",
      "r308",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r225",
      "r226",
      "r231",
      "r233",
      "r308",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r308",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value Liabilities Level1 To Level2 Transfers Amount",
        "terseLabel": "Transfers of liabilities from level 1 to 2"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value Liabilities Level2 To Level1 Transfers Amount",
        "terseLabel": "Transfers of liabilities from level 2 to 1"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3",
        "terseLabel": "Transfers of liabilities into level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3",
        "terseLabel": "Transfers of liabilities out of level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3",
        "terseLabel": "Transfers of assets into level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3",
        "terseLabel": "Transfers of assets out of level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r313",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r332",
      "r337",
      "r346"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r333",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease Interest Payment On Liability",
        "terseLabel": "Operating cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Liabilities Payments Due [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r331",
      "r345"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": {
       "order": 10040.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease Liability",
        "terseLabel": "Finance lease liability",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "fgen_FinanceLeaseAndOperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10200.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease Liability Current",
        "negatedLabel": "Finance lease liabilities, current",
        "terseLabel": "Finance lease liabilities, current",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "fgen_FinanceLeaseAndOperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10140.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease Liability Noncurrent",
        "negatedLabel": "Finance lease liabilities, non-current",
        "terseLabel": "Finance lease liabilities, non-current",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease Liability Payments Due",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10110.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10100.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10090.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease Liability Payments Remainder Of Fiscal Year",
        "terseLabel": "2021 (remaining six month period)"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": {
       "order": 10030.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10050.0,
       "parentTag": "fgen_FinanceLeaseAndOperatingLeaseAssets",
       "weight": 1.0
      },
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10260.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease Right Of Use Asset",
        "negatedLabel": "Finance lease right-of-use assets",
        "terseLabel": "Finance lease right-of-use assets",
        "totalLabel": "Finance lease right-of-use assets, net"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r332",
      "r337",
      "r346"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      },
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease Right Of Use Asset Amortization",
        "terseLabel": "Amortization of finance lease right-of-use assets",
        "verboseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r343",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r342",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r190",
      "r191",
      "r369",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r187",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignGovernmentDebtMember": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities (such as bonds) issued by a national, local, or municipal government not within the country of domicile of the entity.",
        "label": "Foreign Government Debt [Member]",
        "terseLabel": "Foreign government bonds [Member]"
       }
      }
     },
     "localname": "ForeignGovernmentDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r90",
      "r192",
      "r197"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain Loss On Disposition Of Assets",
        "negatedLabel": "Loss (gain) on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicDistributionAxis": {
     "auth_ref": [
      "r182",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.",
        "label": "Geographic Distribution [Axis]",
        "terseLabel": "Geographic Distribution"
       }
      }
     },
     "localname": "GeographicDistributionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeographicDistributionDomain": {
     "auth_ref": [
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.",
        "label": "Geographic Distribution [Domain]",
        "terseLabel": "Geographic Distribution"
       }
      }
     },
     "localname": "GeographicDistributionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicDistributionForeignMember": {
     "auth_ref": [
      "r183",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation of business activity identified as foreign.",
        "label": "Geographic Distribution Foreign [Member]",
        "terseLabel": "Foreign subsidiaries [Member]"
       }
      }
     },
     "localname": "GeographicDistributionForeignMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r73",
      "r138",
      "r141",
      "r144",
      "r147",
      "r149",
      "r386",
      "r395",
      "r401",
      "r419"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r74",
      "r90",
      "r136",
      "r169",
      "r394",
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income Loss From Equity Method Investments",
        "negatedTerseLabel": "Investment income",
        "terseLabel": "Share of Net Income"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r276",
      "r278",
      "r280",
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r118",
      "r119",
      "r137",
      "r268",
      "r277",
      "r279",
      "r420"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "terseLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10300.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10250.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10310.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10330.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10260.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase Decrease In Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10360.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase Decrease In Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10290.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase Decrease In Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10270.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r72",
      "r135",
      "r326",
      "r327",
      "r399"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10060.0,
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10050.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income Expense Nonoperating Net",
        "totalLabel": "Total interest and other, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory Finished Goods",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r52"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10330.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Raw Materials",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory Work In Process",
        "terseLabel": "Work-in-progress"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r344",
      "r346"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Cost [Abstract]",
        "terseLabel": "Finance lease cost:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases Of Lessee Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend finance lease.",
        "label": "Lessee Finance Lease Existence Of Option To Extend",
        "terseLabel": "Lessee, finance lease, existence of option to extend"
       }
      }
     },
     "localname": "LesseeFinanceLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeFinanceLeaseOptionToExtend": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's finance lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Finance Lease Option To Extend",
        "terseLabel": "Lessee, finance lease, option to extend"
       }
      }
     },
     "localname": "LesseeFinanceLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Finance Lease Term Of Contract1",
        "terseLabel": "Lessee, finance lease, initial lease term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year",
        "terseLabel": "2021 (remaining six month period)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Lessee, operating lease, lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r41",
      "r95",
      "r143",
      "r171",
      "r294",
      "r298",
      "r299",
      "r316"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r95",
      "r171",
      "r316",
      "r390",
      "r412"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities, stockholders\u2019 equity and non-controlling interests"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities, stockholders\u2019 equity and non-controlling interests"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r43",
      "r95",
      "r171",
      "r294",
      "r298",
      "r299",
      "r316"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10110.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities Fair Value Disclosure",
        "terseLabel": "Liabilities fair value disclosure"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License Revenue [Member]",
        "verboseLabel": "License [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10240.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of items purchased under a long-term purchase commitment.",
        "label": "Long Term Purchase Commitment By Category Of Item Purchased [Axis]",
        "terseLabel": "Category of Item Purchased"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.",
        "label": "Long Term Purchase Commitment Category Of Item Purchased [Domain]",
        "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency New Claims Filed Number",
        "terseLabel": "Putative securities class action complaints filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery And Equipment [Member]",
        "terseLabel": "Machinery [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r48",
      "r95",
      "r171",
      "r316",
      "r389",
      "r411"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Minority Interest",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds At Carrying Value",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r87",
      "r88",
      "r91"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r65",
      "r68",
      "r75",
      "r91",
      "r95",
      "r109",
      "r113",
      "r114",
      "r115",
      "r116",
      "r118",
      "r119",
      "r120",
      "r138",
      "r141",
      "r144",
      "r147",
      "r149",
      "r171",
      "r316",
      "r396",
      "r416"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r207",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "terseLabel": "Interest and other, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs And Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10090.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r138",
      "r141",
      "r144",
      "r147",
      "r149"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10040.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r338",
      "r346"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Payments Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "fgen_FinanceLeaseAndOperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10210.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liabilities, current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10040.0,
       "parentTag": "fgen_FinanceLeaseAndOperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10150.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r334",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Operating cash flows from operating leases",
        "verboseLabel": "Cash payment related to lease"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10060.0,
       "parentTag": "fgen_FinanceLeaseAndOperatingLeaseAssets",
       "weight": 1.0
      },
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10280.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "totalLabel": "Operating lease right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r343",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r342",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r42"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10290.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Available For Sale Securities Adjustment Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Available-for-sale investments:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r57",
      "r58",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax",
        "terseLabel": "Change in unrealized gain or loss on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r57",
      "r58",
      "r61"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10230.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Loss Available For Sale Securities Tax",
        "terseLabel": "Tax benefit on unrealized gain on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax",
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r66",
      "r69",
      "r71",
      "r76",
      "r206",
      "r318",
      "r323",
      "r324",
      "r397",
      "r417"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income Loss Net Of Tax",
        "totalLabel": "Other comprehensive income, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r57",
      "r60"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 10040.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized gain (loss) on investments, net of tax effect"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10160.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Total other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Noncurrent [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Other Long-term Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "auth_ref": [
      "r19",
      "r388",
      "r408"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.",
        "label": "Other Sundry Liabilities Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Other Than Temporary Impairment Losses Investments Availableforsale Securities",
        "terseLabel": "Other-than-temporary impairment loss"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Cash paid for payroll taxes on restricted stock unit releases"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecurities": {
     "auth_ref": [
      "r82",
      "r158"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.",
        "label": "Payments To Acquire Available For Sale Securities",
        "negatedLabel": "Purchases of available-for-sale securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at June 30, 2021, and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r33",
      "r34"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10340.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets ($0 and $889 from related parties)",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense And Other Assets Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r8",
      "r185",
      "r186"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense Current",
        "terseLabel": "Prepaid assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds From Sale Maturity And Collections Of Investments",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r80",
      "r158"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.",
        "label": "Proceeds From Sale Of Available For Sale Securities",
        "terseLabel": "Proceeds from sales of available-for-sale securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product Revenue, Net [Member]",
        "verboseLabel": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r65",
      "r68",
      "r86",
      "r95",
      "r109",
      "r118",
      "r119",
      "r138",
      "r141",
      "r144",
      "r147",
      "r149",
      "r171",
      "r292",
      "r295",
      "r296",
      "r302",
      "r303",
      "r316",
      "r401"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r38",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r37",
      "r194"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r196",
      "r413"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10250.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r16",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r16",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r232",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r232",
      "r349",
      "r352",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r347",
      "r348",
      "r350",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.",
        "label": "Repayments Of Debt And Capital Lease Obligations",
        "negatedLabel": "Repayments of lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r265",
      "r467"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10110.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10220.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research And Development In Process",
        "terseLabel": "Expense for acquired in-process research and development asset"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r207",
      "r259",
      "r410",
      "r432",
      "r437"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10100.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r110",
      "r117",
      "r119",
      "r176",
      "r256",
      "r257",
      "r258",
      "r274",
      "r275",
      "r428",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r133",
      "r134",
      "r140",
      "r145",
      "r146",
      "r150",
      "r151",
      "r153",
      "r213",
      "r214",
      "r368"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10080.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "positiveVerboseLabel": "Drug product revenue recognized",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r78",
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue From Related Parties",
        "terseLabel": "Revenue related to collaboration agreements"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.",
        "label": "Revenue Performance Obligation Description Of Payment Terms",
        "terseLabel": "Description of payment term"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue Recognition Multiple Deliverable Arrangements [Line Items]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.",
        "label": "Revenue Recognition Multiple Deliverable Arrangements [Table]",
        "terseLabel": "Revenue Recognition Multiple Deliverable Arrangements [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r341",
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Finance Lease Liability",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r341",
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns And Allowances [Member]",
        "terseLabel": "Sales Returns [Member]"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]",
        "terseLabel": "Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r161",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule Of Available For Sale Securities [Table]",
        "terseLabel": "Schedule Of Available For Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule Of Cash And Cash Equivalents Table [Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r240",
      "r249",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r240",
      "r249",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Schedule of Recorded Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r13",
      "r30",
      "r31",
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule Of Inventory Current Table [Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Investments [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r38",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r98",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r241",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10120.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling General And Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average estimated fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r239",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r244",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r18",
      "r391",
      "r392",
      "r406"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10310.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r46",
      "r106",
      "r107",
      "r108",
      "r110",
      "r117",
      "r119",
      "r124",
      "r176",
      "r206",
      "r207",
      "r256",
      "r257",
      "r258",
      "r274",
      "r275",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Income And Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r124",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Stock Compensation Plan [Member]",
        "terseLabel": "2014 Employee Share Purchase Plan [Member]"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r27",
      "r28",
      "r95",
      "r157",
      "r171",
      "r316"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r95",
      "r106",
      "r107",
      "r108",
      "r110",
      "r117",
      "r171",
      "r176",
      "r207",
      "r256",
      "r257",
      "r258",
      "r274",
      "r275",
      "r290",
      "r291",
      "r301",
      "r316",
      "r318",
      "r319",
      "r324",
      "r429",
      "r430"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r339",
      "r346"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r325",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r325",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r325",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r325",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r355",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Supplies": {
     "auth_ref": [
      "r6",
      "r8",
      "r184",
      "r186"
     ],
     "calculation": {
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10040.0,
       "parentTag": "fgen_SuppliesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Supplies",
        "terseLabel": "Unbilled contract assets"
       }
      }
     },
     "localname": "Supplies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r272",
      "r273",
      "r274",
      "r275",
      "r370",
      "r371",
      "r372",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfCostGoodOrServiceExtensibleList": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of cost from product sold and service rendered.",
        "label": "Type Of Cost Good Or Service Extensible List",
        "terseLabel": "Cost, Product and Service [Extensible List]"
       }
      }
     },
     "localname": "TypeOfCostGoodOrServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r225",
      "r402",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "U S Treasury And Government [Member]",
        "terseLabel": "U.S. government bonds [Member]"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "Valuation Allowances And Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "Valuation Allowances And Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail",
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "terseLabel": "Variable Interest Entity"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureVariableInterestEntity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity Ownership Percentage",
        "terseLabel": "Percentage of outstanding shares owned"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted average number of common shares used to calculate net loss per share - basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6283291-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r468": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r469": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r471": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r472": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r473": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(7)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001564590-21-042639-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-042639-xbrl.zip
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M4?!';P6[A,+U,V8"O81G9&![9%TC0_]!+ZX^]B]DN-R0[!J&]9-I'08$?D3
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M2=#B&Z]6K^Q-@E#)83P%_!LNZ1U9$B ?<K-*@+ ,[$> ;6OC5Z?E:6VJP:[
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MX*?F26+!;P6)!3]6Y,A2+E6I2'4\N46"HA49"*P&"R1D8M3T@-")=)#$NMQ
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M$-SO -?AB Q>0LL=C.^<\Y?@MB^8KSGG+\&M1S  <\Y?9;&_@*T*6W+$3D]
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M%C]=L708>)MY%^I3>YL@U,()-7B;>1?J4WN;(-3""35XF\((-<A@OF40V+T
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M\65@MP4JMLV:/8,]H"G!+X8[14_ 8;NM$+#8)A:[=R:8!'\NPCF+^_%3W'(
M\VQBGM I) \$]PS=9(>]#1WTC$.GDO S"=&T4/4*^W%9FG4KG^GFFKK'MM\X
MLSVX#C=J>P:R[2ZWOM<X9XJ1316!M\8QMP<?"^Y;&0'[VFZ"L^KMUT_!P"=P
M6.N'-\GY>C:"A6V<(E*W]\(V$B]L(Q0G.W0D(.[0J)"3V*,O(-2:&ED/F(PM
M,KVV"->(=NCT729=-[K*3B!8G"#ZN^Y,^M3>TDW\NAHX&+I/-O[3I??T7^B_
M(OM'5R^'541+[N11,VR8<&CK:-R4L\Q_9T!D7T^]3>93V$:M<[ES'-LH=P(#
MD@.2LU4]A65G-_44?B*=>OKT07^])-BVJ"6,;?8G_I<)1AJ?[Z</FO["_CN3
M;&=N4#:<(O*LF^=/EN-8T\OJS/GH_\6Q9OQ7]NYSW60\>%G]Z\<Q_=JYK?\7
M7\KTXMGGO_TB-ZL?/WV8K;R5FMGX?(+UYXES6:?W/5F$#B#XRI7E/AE84BZ4
M!KTV0YJFF\_!17DYA&2#&J.I;LPO1Y3;;.D._Y0>K2DRPP.N"C9B/JKZED'Q
MAY"A/YN7E,<=3,)OK<=^-NX[/[UI/5F&%EZ.-KW][95C([DTJ00BPWNYPT+R
M3"3I7TWLW?6"B$YUPZ7DWWCV^=O=8-2_DH:C[J@_W'E>R=;O%/,:]GO?'@>C
M07\H=>^NI/[_]/[>O?O:EWKWM[>#X7!P?W?<R2J'G.SOR)Y01G<LLR)=7?0N
M)*7:J'?>GN"J\ PM0]>DZD4KK>SXOQIX3&63KH?_._&$E?[AK?4*+5@SK;@U
M#RUN:W1Q9Q3L563C&!)N(-?U)WN&S)79K-'Y[#/]4?I$50+]]<Z=4G6B<I/L
MFIMDU>J99")FG6A8IZ"GNE/?.CB3?#7SB,=QKN1JD$FNGO^3*Y[E5SY_^L &
M][D,S/,?UZ;VVCPC.=]-K^TEY^]N$?DAW9OXO3\K:B4$\_*FQ);O([-T/SF(
M:4*/2+^>4891L6%0TJJ4,(O??4+QW_WW^&156=)T9N/+X(>/TD]=<R9T%G0%
MO"]P2\71I!?^;;JTUFSQ&N_F^D6C_M>//R>Z@\_9M]FD?Q(T.TMFVVS!T2%^
MMK#T;2 -YU-*BQ7:A*4P[9*OB.HIQ[$)"Y1F'!;\TZ6&+";&_!'/+.(D@@6)
M#08YOY[I='34YZ$\;AE/R# LY\EZ97+5:=4;'[< QZ</CA;#&RF(GMD*[BBB
M"D>.*-'#TG[V^9_?NH^C_N/-'])C_^'^<20]?'L<?NO>C:31O40MCQ$U+R2Y
M)MT_2G+CG?9>NK^61G_O2R&C9&&0='LC=EGNU.KK*TC_1=B_F"1_CKH$A[(Z
MCP!DU$N4J)<H_1FPJ>1Y3!)UI["V1?$I<<S^P)_M>YY8:E:_U.C34_KL1$/S
M.75[L7GV^3?7Q)X>J54K$GLNRO;'\06.0)7[QR*J%;;NM=AU3V*OQ^)[=DKE
M)*/8J%):L>8E>ZG.DD:'TBGUC'1*8HH?7J.,'KMWPP'7"QFKC QTQ1XNTQ%U
MA;/@OT!9C(E%G:2(+Z5AE1?[6>:E2X=/6,AHX0YD^V^?/R7'.NTX8L9T+*?Y
M"!S *PEL%IF6QCK5/J;+PL*7F\T$>07 ^CPR?$V?O.,/)O.1Z=O.:\U6O9I<
M\0OL(==.%5Y1ZH<,A&TV')M1CGC$S_S\>-.YHU>2<<7UX,OC_=?^744:W/4N
M4MN$.0@Y]%^1ZO"UDZRQ1!9K)B%;LF=890DO3=)-27=L29UP>_Y]864C??Z@
MN0O?9Q@P6!F_;PZD-=Z].5XBU[$^[F'(>ZNV>&M 9TZT:HCPCWP1V%]\<[\3
M9^Q_/-M7QL),PWY?)1[[P\G$;K-J:T>!;&!20V/FVQI#A[JQ/<LU'3+O65IZ
M?YB;Z:PD'<^(]<*^R1SB*VR@G]0WCH.\&!-]&\EK6TBNG)3BR5.4":<.W+XC
MMW>BW#Y"KP._TD+E')_&JFNUSJNU1JNMM+8Q\@<?PHH*9)Q\!TW#ON-P)%$7
MCE>%2+^Y1+<UG=>>4GLB T-)W+FOP#)? O*,3/V__/?WF0!F31# W&!)M<N#
MDD<0I<'%X\7P0NI/9X8U9]5219:=%827[JR+]S' O#'<!6;ZB<ST4EHI2C5J
MI70UC6#;]O]SHYM83F:AU*L=:6 8NFGIMC1T",;.X6WNTAC8XD_T$+9G.:53
MWBB=/?KC/1E9/\UDLCE$IG1-1Z7JMFJM2V5E<UQ:438.A=O)]^2!NMJZJ2:,
M1O:Z  T@)'L)26TC9SY8MH.,?^NSQ-&DSYVZW&@?V\$NL@O@DX1%XA\(Q0E]
MA@RI_XI5E^WKE.['U&+&]@%\RV([DD5F&2JX$I/<1/[3UA1@?&F%, FKS1A7
M#V,<T_U=@E%R5*.@MHYI[[?H_$;XJS>6BHR'"1U_FJAEI]4^EY5JBE1TAEL9
M#LJNRYSLWWYI*W+KHRTYV, SMF)^WK\B4> S7";,$J($I"NHX<MR9AQK:Y3S
M"N.V5915#TF](55$1'=T^D8O48P)UJ292VR798P=2Z)W\(".K+Q[>L_4&*OL
MZ:I.A'Z)&';#M$/SCMF]==0B1RG,+HT+N?577_UTJA?MVGHD9J7846G[=X24
MWLH-M?JVJTH[?'63P16NL?0GSE?:#HF)](NW]^2CM"I*6^_A$]YZAR<QL;><
M5B\?5E9&NF/PD@J,U(FDLI8<6\H<@39'I0U!7+UX5;9 %D'(<N<7(7&)P:_J
MA.U"EZ@V^3G1Z5^6*F<7%S,/Y,N*6 EH<XPM2_**2>P;#7-9>>*8F##T94VG
ME /XX?,5Z2_5BZHLS1!A9'9W+5+) RL<3I(%8X[J"G/X2.P!<<(2S:_].V"
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M"7<.6;:;?.NCOUHY'7T*>@6_?UD.V0_L;%^#H-#RA'V$=M]1EZ&I]D"5V;9
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MR6";7UG1"5)Y$3%U;A?950:)8:2D7]3I"W:%N0)T@^G=_VMP=2YWH*T+ #<
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MD-8ZC[/X;[@"J2(QV/2W!;''Z3>\@M'RU"9]95%GDS<K\%N+TM4HK[T*=4D
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M00<@R_":FXUUDX(0>X+@F44<.L]X"XQ@U@5]T;&BXK=7^^FW3?O)LBJ!:[P
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MKGK PIJ+QB1$>3'Q3W;&_ LVK%EP1%0H/<!>X7G!WFZWE60L-FS\D_G, %(
M4@!2 %([@]2U_D2LK]B4WG$T>2_=^J[F*#A*<RY=>:#$/<V>=5&1;ASM0GK'
M25/]N'C#%ZS_ATZ1_UG^^-X__'@5Q0AF7JGJ)4"Y93?GR0G]A6WZU;AC.46\
MJ,0KUZ,W>!XG?=A=E"K[>VOYJWAT+ZA.9F=0\0/FY_S/ADY]5HU="'NO )(
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M:/1:/%X#D2_$,?'-BW8CQRL/ E!V,D  )87*BYP4O[_*2^]O-"N->G:GJH+
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MN'KEP>K!O7ZY(K<ZE59#G S%3I 1AO-2P4;J<  HVC*@-RC:W)"*QQ% SQY
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MX,:9V22RFZV* CZI>.PF2H>2<B>M!:U8 GL&3B4K+QF@N9JPI $)$8,,H!^
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M9$GQTJ2@KB$[75HR@+I.M1NYMKX;.8"YG8["?J,QY&*7<:TASO%/(,C[=N0
M#58LZ"P;XPM*!M!@J318?2\-]D:KQH4&:S9DT&"B<0MH,(#.4C*^H&0 #99*
M@S7V],&V=D\,-1(6YYP_$&308 "=969\0<D &BR5!HN<,I_0!]O[M#RYHK3K
MH-Y$8Z4,FACNFT1>25 >X=S:'"4R==YO=+G++?C#.S_#:;\_Z;XW.' X'Z48
M<)YP/DBUVM!Y+VJ!_;-J_[0"^V?\C,V%\>/U<^Z:VCU#5^^WX/S@.^QD<N9>
M*,<JT*D'<%BPD$<A@$;- 4R#1LT-J4"C[D:^Y JUG;U"W3G36\\ND !ZM+BH
M ,I4'%J ,LT_J4"9'LP][1S"/=WIS+Y0^ED6YQ!;4*O@G@I/!D%A&C1J;D@%
M&O5 [FF[>@CW=.\D>*W2EJN@9'/!<Z)LZ3UV>EQI7=0:8I-F9#G(D/1LF\!F
M0R>PC82N'MOE:&,PGO)!RQV//P;K*OMX15O>5$ZX8E/=6:85')V<?3J]);>%
MJ2<$4TK(&GK0R3G <=#)Q:$EZ.33Z60E>YW\1D8^1B>#1LX%>X%&%H(,@J(X
M:.3BT!(T\NDT\L;67?MXR3ME]7?<DM=L95>1#@H;%#8H;%#80$M0V$+0-[F^
MWMBH;!\/>N^B :724,1I# -J&@Z&S1<%A*CT@J8]IZZ%W*A)2PY00M!I1Z.G
MW :-H+0K6\L<4<D &@8T#- )-$SQ: <:1@PR@(8!#0-T @U3/-J!AA&##*!A
M0,, G4##%(]VH&$*=R)N/ 7""_ED&=J>)$F[_C>6;4M/F-Z'@Z[1#GK%MG#U
M#J#SH=%]><D QUFDJJR-.9")01P#O6MB37OT0[KITA6_]RIU+-/^PK'0NV_$
MD+#_2H='32G=1&0^</#4OK-,5LM#+,.@CP;%/YEL6]VM(+=6KS0:XI3D GB<
MNOH6M*9@RUXRQA>4#* U4VG-F$.@3J0U=]Q8NI/6;#<J<H8=H0$[0&GF=,4%
M1>NR,;Z@9 "EF4IIMH11FEGN_52JC4JG)LZV$@ /T)H UV5F?$') %KS_[+W
MMLUM(TFV\%]!>&;W:4=0:KZ_V#L=(<MRMV:[):\ES]Y[OTR 1%%$-P2P 5"V
M^M<_654 " HD14*@F !.[&Q;$DD0J).5)S,K7W*QYI -:VZOP-PS0-OO-/I#
ML"8["64PQOB !\W\)Q9_]KT'.Y"J@=YJ_# 6KIC:H3&EK?ZVD.-GI)PA'08P
MP+KA8=V,UELW9+5$/2(^: 58] !A-J,CL*]?ZJZ#T*JE2>LF^$QA *'E:'PT
M:A;"9[O.[VWU1R R;D+#=#^#S2#]]84!;):'S=8,I\GEG6T];4TE[?*9Z(?]
MS'L_@\T@_?6% 6R6)]@X6C/7)9=SMM,Q:"I#J =:XR8]!1QS%M/_]_7&T?(_
M^[QT'T00WM.-Q2>=MMS6M!G5>IBAD-C0I\:.D/A5>"DT\>C_+N?STGW:X2,&
M&/!!B&.^"N83E .JU28D+T*KTI;>_H9>,BYH>B?<=U]7&.1?$8'$.6\72J<N
MJ4?;A"\Z;TXLOUZ_S2;##>,&^*H(,"L?+$K*K J.88S&-N"JCU3YB/4HZ.W/
MJ]T#\^KV<^]T8OE?PO<L,YA)&1S2Y]^#9\L@<J!9T&RI:190E9IGR^+ ]@[N
MP.YV)-]I\^FA519BK:.* +/RP:*DS%I#>[1"Q%H2![9_< =VUR&U<&!+*7)<
MQM)N2QZPO 6)L=$^/3CCIE?WB!VZKT1H.%YPM)+H+=;/ZV%1$>OGJ*,YMH%7
MR\##W]G!N./DCD*0K'10(D?^9*:!&RG>93>:U^SNW6F,AD,V696;+*:-RK]6
M.N1HA=V@9=!R-;$$+8.6E[2<Z1"W!RT7W#Z\T^+3606L#%9F#P-8N3I8@I7!
MRDM6SG0VV\M9+K8_^: +6BZ'H(&66<  6JX.EJ!ET'),R^3FOLA9+K@!>K\%
M6BZ%H.W4+N#>MBQ'E',"=_]TV.,- =-4+30B.G8NHUQ46#E,<<J:.C!CRH)=
MW7H"<84!# .& 4Y@F.IA!X;A 0,8!@P#G, PU<,.#,,#!C ,& 8X@6&JAQT8
MIG)3@IDC$)>[&G/A&\',](5Q8HS-P)X8IFL9ENTL0F&QRWJ #8#._C5.]ZDW
M>>^6J?/O[V/?L95*"U:R=C*#J"Y,WZ7%#CX+_T:^_8-4?V>N]5$KO[RUJ.UE
M&L]/K=,N!G>P$R2,"0:OU5+PP6L<47DAKV4F4KV(US87<Z9YK7DZ J^Q$R3P
M&GBMEH(/7N.(R@MYK5.PO[:I'#+-:^W3=A>\QDV0P&O@M5H*/GB-(RHOY+5N
MP?[:IGK"U3CD$+S&3I!0$7AT"+@F!,"^0!Y&;6& D<$6&NP0'C" 'R#]M84!
M_, 6&NP0'C" 'R#]M84!_, 6&NP0'C" 'R#]M84!_, 6&NP05,*]+@+&_ZIK
M"<LP'X1OW@G#7=R/A6]X4V/BW=][KJZ/"XQ%0&\*/6-B.I.%8X9"PE;59=&"
MJ?]KN*@6Y(L1OV6OO0YG 0.LG*W3O3>EY_2>IN?$_'"FZ>%*L</U5*7J7"_"
M("052  45#WX=,;WQN;?HW:C/>@CJ8>;R#'5!N!"2']]80 7YN+"_FMPX?;Q
MD;M-C1PUNCT^<S"@#7AK W AI+^^,( +<W'AX'7\PFU#&W?S"UN-T9#/J$9H
M ][: %P(Z:\O#.#"7%PX?!V_<-NDQ-W\PF%CV$&CFBTBI\4JEJIM O@:A]X_
MAN;8$?17RW[8M $G]#C"3S]\>[YN0ZX\_7_LL\'2-WB F]"K9H=TI<D+]_T>
M:WX[$X8YF7CW<]-])"&D5T+Z-GF4:[J&38]SYYN.,3?]4)Y\AS,1"%(%YL*R
MY=DX;51ZB$#_I";-FO+/4]LUW8E-'Z0M'HI[>LY@KV5K%0U>T;+:BQYGYL?/
M,R<%=S+VA?G'B3FEQWEG.M_,1U*0/^ZW7_D\XW^9QLR7*OAOM]?G]"MI(7<%
M/5*MGF]*W?F.U*$@4J"+D4S)W2JEY5RJ<06]_"CM7_.GO7,CUFZ56#NM;LF=
MI&N_;XI6<^PYUMY(Y%WV3Y<?OES_?''5,"ZOSD\/M6V.\&3*5#B_OOIX<75S
M\?'?]-/-]:^7'\]NZ9>;6_KGMXNKVQOZ^V^?OUR\^2EYIY%^I[%\IW']R=!O
M_H7>=_FO"^/7ZYN;G1>,OR3\<.F2QO46 9E)P=LJ/=C7F$$R3U4B_;AB#D2F
MB;)4HFD+_WA#YNE$.(XTWXA;D]\C@T_]OO+8[\Q%Z+V/9C606>:8\T"\BW]X
M;T1F8;,9N>:9;,"#9V@FV7^C?F:>]\JD^?0\[XU>TZYR^[P-RT(,CI$R&X=K
MV@SQ2*N634[&<!<GHU!HZ$ZD.?*/-_TW##*;VYW307L[=/&BU0:V6S([A?$;
MO3@+C NZ/<OXY\(5&LU.LW'DO?8Z7CD/**#<R@4-E!MWV&[L[YQ5VZ[;K,XJ
M<%,M3KVM;X9 @:LX0Y-P59L#5[6:*UPE5W@M48',4KC*E!10%CM8^&G"7-L)
MJA*JLC*XRHP%J$IVL/!3E="$T(25QA5&(TM8^&E"&(U0E;57E3 :^<%2AO9,
MHT/4;^RR_*^0/W05-1[BE[&M^ OU&K5)E,< L+AB1I)[O2MF=AL EJZ8:;>>
M5LR09KMT)]Z]^)74VTN:!<4SOG:KB&EU.HW1<(B2&&XRQ7'&)2@.@@^* \7M
M1G'M%U#<]AY ^U'<L-?HM-  @9U(@>' <+44?# <1U1R,%SG14[<MLX^^S%<
MN]EK#+J@.'8R!8H#Q=52\$%Q'%')07'=%SEQVQKV[!FG['<:_3Y:NK*3J;<O
M/PP]6.;!H0Y#V2S^=3@3OIQ*,_?%3+B!_2 ,6^U.XP=Y3/KV';^!3C! ,$>K
MMC# "F$+#78(#QC #Y#^VL( ?F +#78(#QC #Y#^VL( ?F +#78(#QC #Y#^
MVL( ?F +#79(Y4KE6IW3 6\0/GD^7<PU)@O?%^[D49=M.JIUOV%:OR^",)G1
MP.L8%32.T^O:P@ :WSJ&:D.N2N]IKHHZ'C]/GXXO4U<BS7@>*<9;>4_ZF\Y<
MZW:I)<\2)7DEPNOIK?G]1<5Y24)+MXE<%FXBQU0;@ LA_?6% 5R8*W&SSX$,
MBRSC:S7Z+8QN9">:*'& GJZEX#.% 729BRX''.ARQYK )2=VX$2R$SX0(C1Q
M+06?*0P@Q%R$..1 B(56$#8ZG2[HDIMH5KM^D/\)\=F#:3MR=O$)O?4DH-UB
MV.Z#B,Z%43]8+A9%]DJU88 QPQ8:[! >,( ?(/VUA0'\P!8:[! >,( ?(/VU
MA0'\P!8:[! >,( ?(/VUA0'\P!8:[)#CU ^N' 7EFS^Z%RSMP6FGQQN:KZXO
M:.W_$I9Q9]INU&O2\-STT5'#<$5H>%,C-+\;8CH5D_!8AZTO'[9=[8W%Y>![
MEPFP-=>!+* :K0ST?1%:E;8D]L^Z&>V:=;-4P;]XCD3I9U+$,A7GVKT1DX5O
MA[8(SGP[H)<^TJ_NW6?AVYY5;!%C:\ FH8;ET&(VDGA<10+^Y8,%^+?\4(%_
M#Y7V*LF. P$76SA)5P5/ET)BCU8\ HHN@=X'19<&*E#TP2BZQ8.B]R_6'(*$
M2R&3(&$6,##5["#ATD %$CY0G+K3YL'!S]2')M3;:_-IE #N?8U3_Y>F8;SV
MJ3]S6#8/FDP?\XO<?82+@0N6$_<,IA@;N:AKB1BF53FP7#6M#@LG;*\5VZNS
M3V>.8L_[>\6=]Q>D\6%&,=0:8&,^6("-:X EV/AXQQ'=XNFXR-/_=F/0+:[M
M%5B;Y<$#"+L&2AZ$71TL0=C'(^R]Q@0=*!>@7UPN "@9E Q*!B4#2U R"WQS
M4/)>PXH*;1V]I.1A"VYR.02L@);1AVP*8'F+L2.,]NG!Z3F]L&//L5X(45X\
M5O:I(7L!,$R@?#U4V.P3IEEY.8RF%?!J:33]G1V,^>RE?$C"7EJUES+3JM:8
M2H6<_.]7:-CI-$:=%OM,RXU44"N-PK'* 23-1;N#I$'2(.D7D71F@E9NDBXR
M'V X;#0+3.,#1X.CP='@Z-)@"8X&1R\Y.M-O[P6.]$XI +OE[#5[C6$+CG0Y
MQ XDS0(&D'1UL 1)@Z03DNYF>O*]P)$N<)YTO]OH#GH@Z5*(W;J<@1]#.?>8
M_FK9#YLVX(0>1?CI!V_/UVW(E2?_CWV>-,U<![@)O6!V2%>:O!" /9;[=B8,
M<R+[!9CN(PDJO1+2MY'@&::<$A"*.]]T#))$W3M@)@)!FL!<6"23EMS#]!"!
M_DDI6E/^>6J[ICNQZ8-!2']08P8.M&P'Q*Y5]%T4O5?ZT>/,_/AYYN:=.!G[
MPOSCQ)S2X[PSG6_F8_#&^'$_A<'G&?_+-&:^I(B_W5Z?TZ^D!MT5]$CC>[XI
M-?H[4M+"=VRZ& FV5!E29,\ES2CYDQ\E)6+^]%0*<BV'?N0MLG7 1=Y;G/>[
MB72FTFOE)GVZ_/#E^N>+JX9Q>75^>JA]>H0G4P;2^?75QXNKFXN/_Z:?;JY_
MO?QX=DN_W-S2/[]=7-W>_/OB?[Y>WO[?-S\E[S32[S26[S2N/QGGOYQ=_7QQ
M0TMEZ,]52!!^N'2)9KQ%8+I6T##$]XD@>RB824HB=C'?5NE9O\9,>JBGRJ5/
M(C-+65V1D?J/-V2%3X3C2#.4[(3D]\C 5;^O*+YWYB+TWD<F+IF7CCD/Q+OX
MA_=&9 8WF]$0OTQBZ&LE[PY.^]TCEFZ4-A)35.%,YYBKS\;O68L%W9TT6O[Q
MIMU_PZ#R8C Z'0UWZ].X,5"RJS(K)JE:X36,X=J*;%Z[Q?,-Z43=DI4JC-_H
M33-#=T9$30([L'9O6E@&\JGPK@(S<08BH246K-1NGG:'!14$<MI@?1D(/ARR
MY][]O>=J?&]";_+'T?F*%0\=>/7Y*;A<^X8K.1T#O:6Q_HI:,3[T'.Z"9(T0
M.J.5DC%ATRD@L%*>Q_YLVA;=V-%5>2E=#ZC\&BH*;JJ\U5SQ",'*>^C\R61Q
MOW#D"72ME+[JP5&K)U[)*P+9,42H1&0'3<J>%$>GS3Z0+( 3H2>9X0,]63GT
MH"=+B.25Y];,@G9#WW,<$B/P D-\P M K["-]6+HL/->%[MAL3P.^,!I+*%!
M]E5YDGZ0?<4$B*/XEUOJK5],534\=;R1Y2S''L(,EBJ'\H/G!8U9>XUY=D_@
MA-"8#*'AIS&A$,NE$(?/8%=#?7=NSF4O$"@\AMA X94-'%X*[TF.)S2> D[W
M!S-^D*/#CCW-$7H/>J\*X/#2>ZN>+]2>PNVCF-H3&YXM1VR@\,H&#A0>>]PN
MY0.)(,3Q!T=TH/+*!@Y4'GO<;CV$\G@B4V!.TN$F$^@TI8KFN'PP'=.=",,,
MC=],?S(S.JW&WJUTR_*P6MST?PTY@X;=_ 3-O165-;ZC1X[4XW_W)6?3=O1@
M*.BD:RY#/XZ"S):1']_'OF.K+LS!RLR/UM.9'SJU[7H1!J'IRI7>,NDC^LQ-
M/"3@XL^%'3[*ZGZZ23<,SK[;0?PFW:],=2K[3=R/A:]G>'4ZK?1XD,NK3]O&
M@OPT:C>:PV:C,QJQF0<"M<!:+1R($+'JD'W.<[3 AMO8<,, K':&#"5=S<C>
M%7Z@R>W2G3@+N>2?/5]>]2P,?7N\4+WV;[TKSY5D&57FQI'25V50-6 K&9XU
M:O.9;@EEP5ME@R@A^W4D2IF]"J+<BR@[K(GRS(J;Q\I^JI=NE(O[#&GN-HRR
MT6TW&]T!6)6;$'/5[V!5R'[]6'6DCKQJS:HY!C!W>=/JLA>A:EF[9CKT<W[I
M7H.?NXU^NPN>92;6N5/[0;&@V/*BP(]B$>'-0[$]UA3[182F[0KKPO1=NGI0
M*)^V&LUNKS'H]\&IS.08G I.K:'8@U,9@K(_I?994^KZBQ<2"QXUV@@$LQ-@
MKKH=C K9!Z."47=@U,&K,^J+B+ S:A(3=L"$S 2/4</F5R^.XH+!E0@-QPN.
M5BP->X37JM== [%  49)#J-D^-0H(=6F3WUEQZ_#YCAWFRW]0[_3W&:B_"5\
MSS*#F92\(7W[^\)L$FB$2FL$L"%DOZXH@ USL.$(; B-4%6- #:$[-<5!=0#
M[<^&O>9KL.$.93U@QJK((%/M &:$[-<5!=3TY&#&3'^E@S#C?I4Y8,FJR"-3
M30&6A.S7%05$4W.4Y?0RG9<.09/;JFNV<>*>93:=3F,T'((KF4GET692@29Y
MK7J]Q)XI"J#)',YDINW2(5CR^8(9^(]5$4&FR@'$"-FO*PH@QCS^8Z9STJ[,
M".>O%IO];2%5,*4;$<1E^<]GIGLG#%MN95_0<O\E+./.I-\]_P##@K@\]LJX
M(%D%9) RL]T'LJ>E%9Z[* A%RBA2!@HPO(X?D<BTT]IT_BS-L+,'TW9D@?(G
MS[\AB^E&3!:^'=HB.+-^7VB=2';;]?36_%[U#&HHDTHK$Q I9+^N*(!(<Q!I
MIHD6B!3*!,H$1 K9KRT**$7*0:29WEG,B+0454Q0+)56+"!5R'Y=44 54PY2
MS?1^XD:JQ15 I<[R!^!39I++5*> 3R'[=44!T=X<?)KI'L6,3_-62L$[+9/<
M,M4H8%/(?EU1 )ONSZ;]3/<I9FQ:AHHJZ)5*ZQ5P*F2_KBB 4W-P:J9OU2MP
M*F*S998Q3!LZ/@:T_^ABKD';SQ?NY-%0'W-,N4'J4F=E)BH'0Y>.K@)XK'K=
M%3$+%&"&Y3##,GW1MIEAD?8_CY3_K;PG_4UGKG6[9(+Z)8E#M51:M8!6(?MU
M10&TFH-6,XW40*NLA!JJA04*H%7(?DU10.U5#EK-=&%C3:NEJ,2"FJFTF@'%
M0O;KB@(JL7)0[%X-MXY/L8>HR^HVP:[,Y)BIA@&[0O;KB@+BPCG8=:\N7$=G
M5]Y56M OE=8OX%;(?EU1 +?FX-:]&G,=G5O+4+,%+5-I+0.&A>S7%04P; Z&
MW:M+UT$8%E'<,DM<@15<F)25$X.;F4F&IF$'P4)8QM3W[NDAO<D?=:G>FCOT
MD8;ABM#PIL;<?)06N!&:WT50FR4P;8M?,2N,4900UQ0%&*/;C-'O8]^Q T5;
M*]9HTN-N>B?<=YK7+A6M?2)64]GLGZ6R5V;E9ZWH;Z6>E]EX-]'UCI$_?WGU
M:=NTUY]Z[6&CURG.?(7VJ+3V '-"]NN* IAS_S#.H+E"G,OX2W#K;4A9WY-<
MCU>6M@S_]$"?S 25J0H!?4+VZXH"BM!RT&>K)/198/G9JH.:/F1I])H=,"TS
MF6:J;<"TD/VZHH!:M!Q,VRX+TQ97A89F[&42::;*!D0+V:\K"H@(YR#:3DF(
MEG=!&C1+I34+6!6R7U<4P*HY6+5;$E8M0RD:]$NE]0NX%;)?5Q3 K3FXM7=$
M;BWNZ'0(?F0FB8R&C*W4HQECS[>$'Z]QX#FV9>@WZAE<<Y)N-ZPN,&J[GHS-
M0%BT,^_GP@V2J6/'J.E,VRVU!X=ID7=K.S3QNM5;O[% 2MM A8 %.REM)V4:
MSNUL*BE5>Y[2M%_$GPL[H-6_$?Z#/1&?A6][UA<Q\>Y<=95_F<Y"8"3)3KRQ
M.VE .X'2:P<%*+WT2('2#T3IF3YWH'10.EOY!J4#"E!Z-9#2Y6*@],(I/=-8
MKR24_AHE9JU1H]EL@>S+(/D@>T !LJ\&4J-GSQU!]KG(?E16LB];E1NHOK):
M"U3/!@I0?>F10JC^,%0_;):4ZGG7V8'7*ZNBP.MLH "OEQXI\/J!>+U54EXO
M0Z4?V+VRB@KLS@8*L'OID0*['XC=VXS8'6?HH.BC#<G;5H%H>8NQ(XSVZ<$)
M.[W 8\^Q7H947E@^F([I3H1AAL8_%ZXP.LW& >;%\7C6E6EQ4O$<JRIYB\%8
M-_ECVKP@I<3EBJXU/[8A!WN2#92K]N1AT:RIP;EAE-VP\]3BU,TJKA=A$)JN
MA.NP-1A[#J@;M1O]YK Q:H_8]*_89%)NI DHG%J1.*  C1<,Y=_9H0@&/U;(
MJ)LA<$FQ,_(6A!]H0KYT)\Y"XO;9\^55S\+0M\>+T*3%O_76G\R\*NNOSL\;
MM?L@]S((*\@=4(#<ZT#NZ>)+D/OKD7N/-;GO4(.9^]BHT>UV&J,!GUFZL 38
MT@\L 390P!*HM"6P6ID)2R OLC_L;PIDVBGR,@7VJ]!<Y_\KT3[9O85U?P#;
MH RR_A9F 0,48!94!DI^9@&B_T<S"S(M&5F9!=NJ.5]L [0:K<&H,>AU80>4
M0;AA!W!  79 9:"$'5!5.V!_,R#3QI&5&?!\\><+RDO:@^+*2V  5)9Z8 6P
M@0)6 *P 6 $'L (R_1T/;@6\B+S;Y+X/>V#O4D@CH_&4F_E#UXN^!@9;"^TD
M/JUF#! ;WC[<NK_:#&TL^ZJY="0-!!@R]@Z0.#X2V! \8  =0/IK"P/H@ L2
MV! \8  =0/IK"X,NG@(2QT<"&X('#* #2']M8= 5-$#B^$A@0_"  70 Z:\M
M# @6<4$"&X('#* #2']M80 =<$$"&X('#* #2']M80 =<$$"&^)HHV!>/=LW
MO98LIK[\9OJ3F=%IU6?L2Y-=4<N!#!%.R\]OS8^F=)E46+! 84<CI*:56!OF
MJHR:1YVKTFQV.JU]YJH,AXWAJ-?H=YILJK&@%EBKA=?SS+'JM95]KL7-8,-]
MZI)'F:'UK+J3[,:@JS-*AD,^ \B@+'BK;! E9+^.1+E3WCN(,DV4F?GOK(CR
MS'IFWL=:TMRQEV>G-6IT&/7RA&;AK=_!JI#]^K'JCN4#8-4TJV9G7+-BU7U&
M9[R$85O##MB5F3!SU?-@5\A^_=@5P=T<(RA&O"=0;QY!L3[$N]<(BF&_TVCV
MAZ!59E)\M%D38%1>JUXOL0>C,@1E?T+E/?7YN6$.+W!1>0US@%;AK=O!J)!]
M,"H8=0=&??WAR2\BPNY@T.BWD6'$3? P ^'X&%R)T'"\(.!7(@A[I%:%F4 !
M1LF+C)+,Z&92;?J\]U?2;X=-;NXV6_J'9V8W_25\SS*#F92\(7W[^\)L$FB$
M2FL$L"%DOZXH@ USL&%F@C'8$!JA*AH!; C9KRL** 3*P8:92;Z'8,,=ZGG
MC%610:;: <P(V:\K"BCFV9L9.\U,8Z6#,.-^-3E@R:K((U-- 9:$[-<5!413
M]R_*Z30S+9<.09/;:FNV<>*>13:]1J=57.DJU,61:VS DI72SS43>Z8H@"5S
M^)*9=DN'(,GGZV7@/E9%!)DJ!Q C9+^N*( 8\[B/F99)NS(C?+\Z[/6WA=3
ME&XR$)?E/Y^9[ITP;+F3?4'+_9>PC#N3?O?\ \P(XO+8*U."9 V00;K,=A_(
MG)9&>.Z2()0HHT09*,#N.GY (M-*:]/IL[3"SAY,VY'ER9\\_X8,IALQ6?AV
M:(O@S/I]H74BF6W7TUOS>]7SIZ%,*JU,0*20_;JB "+-0:29%EH@4B@3*!,0
M*62_MBB@$"D'D68Z9S$CTE+4,$&Q5%JQ@%0A^W5% 35,>8[7,ZV?N+%J<?5/
M^YWWMQHM]+UD)^$8IP!E7T.Q9XH" L(Y_-A,>REFC)NWE H.;)GDEJE& 9M"
M]NN* M@T!YMFVE,Q8],RU%Q!KU1:KX!3(?MU10&<FB,HW,ITMGH%4D7XM@9:
MHIAJ+4PLRKG\M$/I8JY!&]07[N314!]S3+DWZE*M929*"8.;2F4CH&*VTBC
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MJ? /^).;I#+5(>!/R'Y=44 UV_[\V6Z6A#\+K&/;>,HR:(Q:73 M,YEFJFW
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M.X #"K #*@,E[("JV@'[FP&9-HZLS(#GBS]SGQ.,&NU!"P9 &:0:AP2  E8
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MP:@[,.KKSTE^$1'V.KU&M]D'$S(3O (+H XW+N?UQAT<!8,K$1J.%P3L)MS
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M>*QZW14Q"Q1@A^6PPS*=T;;989'V/X^4_ZV\)_U-9ZYUNV2"^J6)0[546K6
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M4I_5.E-/M7(R^Y$NG&-S=!BJI-ZJ2CI=TV\D5DJQT1Q9BEFV#5867V=^K.;
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M%_\J*._F5'**I''A54Y<)<OV_IQCQRY;V=0Y_Z1 8"AB#1%<7"3K_?2_GAD
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M*Q<^EUNF^PW^[:TL8K:R]F$L*R5L1QYE\Q()// "VX=(5%JYSKUDL%7S*#S
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M3RGSTMB:;)!^+-A61=;\[$)N;7?Q[E"<0*%0F<:9_GIO+4^_ YOC^OYY%:[
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M89QI%W?Y.*R09E'<.H?I8%ICG4,G2TJ%,8K*Q0_GN#6)48!HT()10&M$A5'
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MNBUYP79K/TE,8]GSP%CO/:JO])=/N@>_2]_XF^*ZQY'T1@?,E4 =Z+OTI?-
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M>R[$;=3^_HH!<;L*;F<Z6O>]H* J;A>F0F;J0%XL$,5%LQ51_1BB.&I_?\6
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MA4"-VM]?,2!05P'JA5A W5B%0C6@OLP!!;JNCKLN!&[4_OZ* 8&[ G"KLEC
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M_MJ3","9*?T>; B'24T>2'1R(XD"9@$\*FW$QY6UT4$7P(N".BQ!)R@C&D"
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M0&U]XMY+6]<!@_6?PDS3H^6OI6N;_- W)CR(VJ!D^1X8K[MUP*Z)M":Z^=]
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M<RS3D,(+)<'QJ<:1HWB#5EE'-"2_6E=[95/_E2,\!0-ZF^!+H8R E<!K R<
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MO#TV::+B-3ZRD_17G0V$<WEB[$S>>*L8NP"\6QUE=^1NOT?HATW&J&I=-@=
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MWW)X(IDC2CY.II8S8^Q;:.U2[4)[CMF5GMQ M .8U!VWNA/8D?17F T$=CG
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MV'#BAND7?%!PRN0F'$#(E%9?X$"W6U?PV1^" 0QL./5 C6"@?"DG&*!P@'
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M:_HF\V2QLL577&'AC\+1$0&<%$R!/9QRX9TYMB=4D)C8JJ(S60*3J8\YQ:S
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MZ,FO6_"E9 CM05K_(K6#U8)4N3:;>1$11&)?3C?#.-["71=F>=F&^6@:09H
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M^8D[GO3F+OA[[ 1OI<\F.)E@2=]$9>_XZKCH+:8_.=,Q(+4U$8F"VLC1 P[
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MQ4S,<^CE\YC:B7N4PK8<7>,,"$>V)&@48P>\3B0(\0XG44D-NVQ,WENVL%V
M9R*C"#Z^4_1J40O:9&I%G/?6OQ<$;JN6*L8.0$!L#@-?!'#B5N%JP@1SA'&R
M!%<D88H5)9M]1XX..8\,R;S3VXMTRS=]#B$1Y[X!2>/5)-SSF&@&$&UQXECE
M4.6OK^7H!W@/28E4="-L#=N;UG!Z<YA.;;'@T,H;..)-DB()+38];K&P/WEB
M-%::D"$O:^M1>_H\?1%ML(U8EJR"'XHFK%I=@(405PE>T'V(!M(O;MF.6Y7#
M(#_9>"O&\P1BN)$6M1["5^+-G1K?[QSJ@<V%!4*6I_!(>R]LF8BZA'FJ'2Z-
M=<()W9KT9NWT#FQ'>AJ;8C#++/J*'(JBB)KCW'UT,UFD'Y>JUFK-":5RCF&\
MBX0_;+5(/#'Q')ZZ%FE0BP/LO.MLF3%(]@($DVG4".TOD;L44W73U8,)[['E
MNO5":5X%5KX^SCLQUB-Z^")!0MW.TF2QLSM%H;DL+AB52(G7V92P"2>B&K,B
MFQE,C6A7K[=6 ;G8\V8IL>DF>9PP=S*_:;3'(-G]*> D%@S#$7=SQ"[PJ?^B
M_S+I0>&MLR\Z+^=A1S1\%9;(1_"*_B$^RLO>8.G>W";$'G?:+(A]VYP(*;V.
M>U:VLQ8AV\#F@O#S=V=A-Q573TO31<=GV/-BBAW<?+?)*TAPO,[XA^]WUU\_
MWD$(_,?';W]<?_SSF-OH. @ 6[,EUG35=+%8*F*P3*E5(%GZR)X[#@ACS92E
M6^9,+98TLX&,!4/0!9%($A7<V(\5OR7AFA2M+=PCQV\[-)TI;Z 'B0,IU$74
M'4TG""%JWKX_+\"*SZ2I.64\BR6L.4]$ _EKX<8FKGW:5-S1"Q\:SM(#99IR
M40_G''%GU/5-T54LC6=3Y]G4. L#/<0N@1#)F_SK^E/BAL.J>3D;8M2:\^P\
M6(&ON5S[F/WW;!+]*>[*?^3.&5AQ)CVXSA/0^<5]+^]_7W)C\<KQYNIT,5I,
M\G@4*FG:MA/MBIMP0#73J?DEC8]\)\W0=7C2'<"!:5Z$VV*,IWO<>PF_I89-
M"H?#\?R84$:<\I:C@Z8<OI?.FW"? K@%P9+%B3DVAZ8O.N\EX#7_CC6S0"X,
MUWF>67R_>TH4:K?_F@=EG,M\ZE]<YQ@R+EYIB0TU,%(->".@&$1\Y^"YJGVU
MV7S/_^WV&_Q?I=E4WO_J!0D;YI3KM7]YSR6^-@X)IZA ]$<NPR E48(>N"4R
MK=W6^U_?P5TNWJ[MA16>CT S?>PZ(&[23].PV2R6D+F8_N<J/>( [$28-=-$
M%ZY=2SZ8=])^_./;QZ__=U/@NTAOYBV^;P4SPS+1<G+_6^-)<+[ 9!QCV"L<
MV4,G &W\#V!T.+'@4O@<ZX@%IL6!!_AQUBKJ(-Z$%MOK5O2)Z%4Y5^N-UB^(
MU.TZVCB],"TX:D3G%/P2VJ-P2%58BN(?_TO4J[Y[R:;5CP'?G@2??4D,V"#L
MG4Z2*U\&<T4SG"DGOL8###.<T0$ $9T=$?50QQ,&'EPM<J%&/*?XDXE?!L!S
MQXU[> :A!^>G4Z!?!O,'QL(P25XG+FE^? 3/\6]G02#E>>/.<BE:Z#2/0'<&
MWKW#LV+Z&BFK2S<<N@#,;7"]DQ,8;P5RAHU+\?+C/R;O$.\KU^SY!(ZXH3S>
MX0[O' ZUG#?01SF?A$&I9#&(?+3U/6RA/6;<N(XZX>:"_-T6V8<[[M=Z"5GY
MWO*$I)\<QPAG2/ &\('!-PGQAN\%.?IT-9>C2SY'!2@/$1G/(H7=PER<^ V\
M9;LY$K,;;QH0]]EB!X2< %V(5G. DW?8''$?[V,02Q%;\)4FOUX1-UTP?@:;
M,L%B<;/X'J'+H:C\2VK8(AU]H;;\"YOOR-AX-T8!.S&.6NCGSE*X,3P[SB?M
M<::G*XCZD3 )<8$I_NJ+;X2N3CA";*E5F\S@<F/F0;#I<>/GS6QPM"8IE?MR
M=3</'%8L65V^9/Y<?<PF3A@(S$*OGB.'6,QQ<^]V81QXU ,R<6Q'MT0+*H>]
M(9!6@J#D(40]'F/(F_!ZJ66 H- !;1P#EZ:!!4_B(:(();B:Q^RZODW"&!F4
MU];Y+7A_CX@N0G,9 %,@*I(F060)00!\D*;Q'.^OOES-N9[ATW%WHC0;U(F"
MK!/E./-5V8U*9:SB.LG.QZQ"L:P[OMF<%V-YU>D;\Z:F&X["OHL@!B0,0EWM
MT70##Q D+J&%:6YA+E-_OWH1!Z-ZU<N;/ZZO:DH?U:)B\UWDENO2MLE$W2C)
MP5\QQ3GRQBF2>0Y%@^\"F$H\&#"341;Z7)QDX3+K$+>!YC!79"JT<,(Q'VP
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MWE05@U61&&()7=6SLKJ<G$Y5JD07Q+-](.OU0V>]-*VR7[G(%'J<?UV)6QI
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MU^6::N3L\];H?N26K8V&H/9-4? ?FGK?%]1;7%%2L:J]? -^=B+/T*CC]&[
M,WNS\>B^^D/!MJU>T)"S;8,'W 3CC-M7B"H(F[9=U<QD$_@J<[O9^28.%',5
M96@*KK(I<%6GVQJ5M I7>"-1,9F5C_)HVQVF+'*PT+"$[=$3U8E-)9O*QN"*
MVQ785)*#A8:I9*>1+:$QN++32!(6"I:PW3KOL=/(II)-)3N-A&$AE!+>JF]9
MEM@85:F6OK:;/>7;FXU"042='@4F&MBMCD&0G*K]TF$:.X$;6_DI2KC=<2$C
M?:LW'E7D_$1/=\S>:;&-4^:>Z_KR'D N/WQH?[@\%J<<"8$C["?]HK8"X];9
M3\5.YRU*41T&FPBE.1 \C<6?;]&/8XF>MN9DMK0^'PRVBB$?A*+$YNJXGD.0
M.6/#*E('&%39E9>=I=](&)@@Z&+#*D("AN>)'WC96?KK  ,3!%UL6$4HP*!K
M\+SL+/U&PL $01<;XU5D[Y+0<;<9- F$+WBA3RKWK0,==6-!D]:=ZGX.PVS0
M"WH(,$.?7-@]JSOHT</&,.V@:J2X",32S]Q@*#?T;&LT&M'#QC#MH&JD.&Y@
MZ6=N,)0;!K8U/._2P\8P[2!JI+CTP]+/W& L-PPMF^.&RF$PN1&(# B?BNLB
M)F&<Z"LD\.+6();&M 21 8/+T0P#<_>]V'3Z(ZMS?DX/'-81$C!P08BEWUP8
MF"& (>R1U;;[],!A'2$! \<0+/WFPL ,<7)A#X96NS^@!P[K" 48N#C$TF\P
M#,P0P!#=KM5O[WTB*>L(O1(1-P;M"\*?,A%^&.]=#N(=?KR+@V%@HGX.;$X[
MP-3GO)FC<B ('JK+I2 6?'-A8'8 =ACUK6Z'=X%7C0-%<N#0@07?6!B8'( <
M[';?&O:8':H&@AX[< 6(!=]@&)@=,+$TZ%J#067W=[*2;&(';A"JK/I3ND3K
M3(R=V)NH7B'7\]-$NMPJ1(D[*EQVPZS3M@[?"A%@]D;V;O6V[0!GY:@ZL*N2
M%>[6A!JM"$P3)&!@FB )RVF[=<XT434*%&GBWKNLFZ<(3!,D8&":( G+J=VR
MMQU!S<I1-4UPHQ"S0J,%GUF!)"RGG=:(6:%J% Y3'N+FH&HX@O?W-6SK@&'6
MARH,._(S0\$:80@,W S$TF\N#,P'9*!@&$C P/$!2[^Y,# ?D(&"8:  @]&E
M')9^TV%@/B #A?$P;"OB5(<)%W'H%'%*)>4)+*2,&E539J/$,#!-UP$*AH$$
M#%S68>DW%P;F S)0, PD8."R#DN_N3 P'Y"!@F&@  .7=5CZ#8:!^8 ,%,;#
M4%E99Z6&(\9AY,HH7^0X]#U7Z \*-;.%$\%J&H7,,6L]Y3!M/RRX /3LZ.P.
MC>$VK0)L-*4S/E3Q86SH8J.*1>P!D,""]80N-LPQM/%A;.AB\X3(IO%8P.A@
MY@"&?4(A)=-]T,SE"WF$"+0,P#CTW4U0*KA&.5KW KLG;+^G@=30==N6L-MV
M9?<?D#1U-$"B8.=T8:4R.T<8"#9RU&%[)R=R/I919N@ZRM"UV="1 XI0$>%Q
MO2$-5AZJ];5CM8HP"M57.1F# Q3]63M8.PS$X'D:1GC-6>YI8W"\K6", ^L"
M;0R>ITF$\)H7.:D!A9R4?=X:F!0RGWJ!2&9A&CN!&].[[-QPD[1W2JEV5PKO
M@L CJH7[0O"KXSO!1(JO,RD3>O<G\)DC-+2 =\S3@(%[2,A P3"0@('/'&'I
M-Q<&Y@,R4# ,)&#@,T=8^LV%@?F #!0, P48^,P1EGZ#86 ^( .%\3#P?<!'
M!^'2B6?""5PQP7_(?Z<>+#H,,^;3Y2O'ANI^#./M% T8F+G)0,$PD("!*STL
M_>;"P'Q !@J&@00,7.EAZ7]^&%[00^#Q/841OJM1T7.WW[6Z@\H.1&'UH&VE
MN.S#TL_D8"HY#(8CJWO>I0>.8>IQP!I0[?I[R(#P=19&\%D9S54ER ]A%=1/
M7G MXV3^E'(0-_X0870N6S<<!D[_D8&"82 ! Y>#6/K-A8'Y@ P4# ,)&+@<
MQ-)O+@R<]CNYL/OGUJ!]3@\<UA$*,'!-B*7?8!B8(4XN1E9W-*('C?$:PJU!
M1P?A[60""YG$(I(3Z5T[8U]R4U#EJ/"^#H:!LWYU@()A( $#5X%8^LV%@?F
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M0]OUA#NNJL= L;TQFG% %K_\\*']X?)8+'X !,C<O+7A%IO76Q1C[KFN+ZM
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MGGV78-TF:BH")'WA(68^? G-DG/C1&XV0!#'3>.3X-5X2($//@P%'.<+ _5
M"]R-H[[QDIF8R"AQ8/R1_'<**H(#CL4<],Y-(_4DF!<LAA>Z+?$Q6R*P!S"C
M?X.=!W<$UT<#!VJ.IB)"A!W4IY+  73P1U3+S#+@@W(%C:2>*/PZFQ&^>1ZZ
MWM2;*%L2XUMV6T*T^V#M83! .$K:\%4%&GK681J)Q<P!JSB1 -=$ZTYA$%IU
MMO%W" _>F4Y1&Z+,:L;I8N%[\,,DG,]!T+W2"2+E:^\+P7,R<79%ND#XU#@
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M"YN.FM('*&RZ:DJ_JV(X!OAM*L^[-H[;'#U=="%%8Z-_7K4-OY8U^#>@7-Y
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MR['_^G!PV]O?<:5NX@=LSQ6ZQ K&-G]RLFRGI?<9'RR?C(&%YP)=U-G2Z<%
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MMWIVBS'4"F=0$Z<;T-F<P]ND*C0YGJR2@WW20 ;UI>A@WC]B.CSIH@/>#.Z
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MS=WE7K-KNO0+04NSTQ9Y[I6!2C9T3?F[&Q\\L-W7P.0HN /6 H,+R':> !@
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MYQRM(6S0N(>8%)NQ4#1#AY0Y$Y1="5+)7,?'J8>HSF7#\5<FS8(_&% LH%A
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MF,LDP&V VP"W 6YO!+>N1LXH<*2ZZ;&2C9D)J[%0:G<?U+R .P%W N[<#'<
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M( /G7?-#?_SYW2!J])&3$\^@IY6S\6YD5*G_%-6+*OY(+AWR_F$[%;3B087
MQ?'D)8H5&<Z-T8?E_TW5< U8KX+32(?1)B-0X[)*2EI%.$!2&B;4'IK./.]&
MO$=CRR_#LR'^^^1?+^'PQ%S&5DZPU/U$]TRSE7>I*#1@3]K4O*QHH>P:;#ZE
MN1!;1'$!%P8]9.ROIR@#[5)6B!K GGAQ95$RZB';D/=>&F=I1Q;UI9_'=&4L
M',4;<4'N5W+H(A5T_*)]9,KZ\8:1D08N).&LCO7*![Y=P3OA6@[L%_%N)GA[
M,,Q28K?8N+H<SPBWM'=;NII.[5HSO+"H&ZK7JJ*$P]6SF-&=7MBN&EG5'S&^
M,="YT?@N]-9'F8A3 B_5R.%IZXD&1O3E=W_$T(;GJ:1U#CC)7C^-E"P@6X1)
M]W!_4-]LT1OQ2%4[EMW-;YO[T$\W.=^X!0 ,?6 &MA&7L3]3T? 8K!\>Z-&;
MZI =N7V=3$>)=$A%9[LW#WUPF2 DWJ'Q<!RI!$B"[;/36&^%P_,8AEG4I:J!
MY[W"(_;QZB1]_3RJE;.W<GT=A+47^+9JSK>)ZLU@">YZ)0CORGLV6@E\6S?D
M>%K6MCB#MNE'MBX$#9 DT=^./0&W(.;Q1X'!N2%8C-I"0NR(8M,O7AM&K_UZ
MP/G"!.!8$_ ^R663IMIOO4ZTZB77'G"_ DAOA7SM"Q&O5',8[>R"^$+.%UAC
M0KJEJ1%C>])4JG4))JW,;;9LUCHA#C5&>E.8JW7@*R$#$"*L;1K]\JJ@!AQX
M030#19#1";0C$U+3E4CK[#$6A/X5)ZQ*/K*A@ADR%,75)7A.94>!27#(.BXP
M1\%1:U=LV2BR;"X &4P[$NP34$SB86 / E%2SH!=)K 8FHPKIK2S(1&Z*1*.
MTMHL M%O'J>V I82?HBGUV+S2H>".2R_HO)&O%]QZ=5#>M?:YA29!6<EB+^E
M50UT*,T/FR*W8$RYF[+^6?OY!J92B\L_==>%AJ1LMTF(7CF%(+UD1R 4&VN9
MDAJOB[UF\'*!S$OFIBXR\O.O.B57M\2"(P!M0^DRT0;!^%G$T*P^%)8O0;JP
M.1,),!> YJS_\2.Y=DK!X:&31,U$ABD?$T%7!TNF]6Q6LFV:3'W]8E6-8[A'
MK_!YI9QL(BN3P;+9T,5:$JF3>.K6[$_7B@\=R'8%_J:=B'9S:%J2"?#2_QM^
MC?E=A+JUD'X=TJ]#^K5+O^8N!V2Q&3&TZH>V9B3'#M#?P1Y':YTU-1 3<I#^
M:'.V*'7ELQ/M)**PC5$C7N#\CR!0BR0CX8L&X+@((UH"T 6@"T!W8Z#+*^J(
M"?C$:;0M_Y<T40L\[)2>_QTYV8TVVS(%6A%:5'YAQ93 R9[O %,!I@),!9BZ
MV3A>/YK(S;=\;X6+^#(>S='&6V3DKB!XPUXWNC*J\2@N74I8/W/AZTPF(D>?
MRF.CA^EPL?E#F#P54"R@6$"QFZ$8M<SC&)R>SB)M[IES(+;R6281IOL;GZ!R
MR14MCZW+W&P\.ZUMK=G*5+T 8@'$ H@%$+L1B)ED$57Y\&5")@[& K@$< G@
M$L#E1N#B@O3S&%.$<DK?=-V6=2OJ@"T!6P*V!&RY$;:8U'#R"149J2VV^@<0
MIO2P)@!, )@ , %@;N:DQEPP,[)7Q\BP,X@H%;:S8,1)X@66E*[-3Z=RJ59:
MMS:N;@!*V]+\X3 T?^A_\X<O<<BM5P8A&X1L$+)!R&+"2K.J<]V,*4H:/\=@
MKL3T;4X:!\5_J4OL8NNRG.,A4I>M(@O9*0&3 B8%3+HA)IFZV:)L]">@4(E7
MLZ&2F4AK'G#JQVBYX1TEJF")J<V@"]WC R %0 J =&- RN.J+GF,&O8RP'I.
M5U# N1^-W)'.[)!!-,F* @L6L%' '/XKXK*:_5[''S'SI%)U#KO5A>TIE0A6
M>K1EDE!735?&, &]S#30Y=)LAW(#TU]TZ:8R8P7] O;KE6_I/L!F%B55:'Q.
MG_M^=RM\WUU[2^VBTD)/2,3VKV.1BPD<&K:!A1.*LR4VX^5N6$O=M#3V"ERQ
M*VY6*SU2-,<*35,-; 8,8%']P!21*W%9'?!8CP65I:LS!9:5W"T^]][+2T-J
M8^=7/73.:R$]%_#D5/&B8#EJ^-<-[HKFU;]BEU=Q+EQG&-U<.^*1L^=>_PC=
M8=M=5E5C 20>..D6\$;8WL3\BBJ)$E%2HQ61IXM"4DLPU_=<<7.^\8[W*[JA
M-<VK,=_MH@-U^69N&MB6OTBT5S6V800B_2Q2F6!?A>B8ZW9MN^>?CTVW9V98
M;7[9T<%-UMVYC'6[&!<6Q.MW?^S8P<#[LST<[@$P@?/FXZ'^(;KML%<$OM)
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M7Q:?W\+/-M%-CJ.%[BR<=3,%D&@]'KBE#<S#I90,)(Z?^ 7+;,<-Q_+H&GO
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M<PI$&-1T-<F2)>82L./(1"UUPY1DY3[UN8@CE#M[*2DG45$[(ALS-4@-MXM
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M!BV]]E9LUDA@D.J@.=H\YHA//I&\_Z97C'C<*SVB1RRB_,*X0O=WB-H^PS/
M.W5L$RQ\AB%-"@H"[ST/(Q=78RWCF:25+MS8^">L")I)8+((((DXQ*&_)TI:
M#G=(U_N*?V6BQ.R"2T+<#LSTZ/(A@] /_M  KQNM#A&!CR89/ T7H;HI]@@N
M80V'E:I*OSG:LXP#LR*OC;<B08SHFDE2(V#SPV'_R5G(B276FQBUF/?Z_ CK
M?YU;=YQXEA@3<RG@*\TRVSEE\/1Z1(L;$:V,\8 X8V?3I[(6/L[=EQ>!=,P;
M\I>9SC9.=\F"42P@K",X'DOI(4_*\>JD[376[QJ23G,;FLX[9Q8Y3E2)#.M8
MZ%+@AI:?*?:4-N["A>N+;F4K9:5%[M:QU>^1WXB[*ZKE.4B"FK\7<);JK_9Y
M%B8C;F.5]YR)\+0QG$@U\B:@:<A5HZ:8/-GQ[4E%&%%]M=:9@ 1N&;F.,Z3O
M:0V4YH"-TVU?S\*9T^H>]Y)%GU[EU";+MXNQ2)L[+;2DO$G!*8<P3^&N;UU6
M#L/Y4_)A).Y]K7AUR&1KM-JV5V9BHLXG4+R7'4>=,1 5I)ZG0_3AB=Q&]>"
M9I3KLY6?-DVN#CA^C,=]9<D64EE2@UV*KVCQI6 SO6/MZ;[1(G&KNWZDT$+
M<"A,WL1 8;DO\K.JKKH&8UX,&CB( TVH24<?9&P%Z=5PEW$R$#F91B8-N*(F
MU+$/J1+2D,B0G$^^^@BK7@ RS# A1E^1<V<B0K(*P48V6 ?40G0+C3RVJ^91
M&GNI&O=1<QFJ5$E3_5>0=^F!2\Z=#."6IV+5DYDM\$I?*;0 XW&=*U66YU\*
MUT*N%,XE,SRAC%4B^&(/K4NAAI;U'7]/YSQANE/O<.Q$SK?N(G<<%MU6)8'*
M*!^_1*_5#\K&2H,Q&]-^>:\XV"6>%FN*.XS9(P[$_\0PYLKX$!4_/M3/^=;?
M\G=#I+-!\<0^29#DUTB='B<O$*KT/D.S+TWPS2 PPC/"D<"'??/R!3S(;?/L
M:* !<&":/H>SM*Z*G!'$57E6L2/C60J0QPH/3AZ9,"&O_[S#[61+]E\E(2B_
M@T\0WQ=.Y-L,_/OCY$UDEZR)%%=T6]J[1(RJ$B1MX.?5O*^8-8?F%]3LJG*<
M/S,Q&F5)P7Q+KP)1"'.$L S.VY'RJ_6]-T%ZFN\J^J!%)U+%%H]0 ON-L4#-
MLM[MX_[:PP0:QL@P%L4>13XBX"2<\IG[H3I.'CWY_-&G3YXD]W#)!)'Q?_$7
M_)E0;"J&@9CZR;+>PVH7&'SU^&#+9$6"YXIW?_+@P2>/GGP:OQM_<?#=NTW5
M5@U[#?AFST83C> X>:=5K'2>XBH//NIAR9)G< S5>L8_]8?[&FMX\7V=: DJ
MH/WL2UPIN<$@<NF$4P4N?H3["K$96E;@I2#XXT6^J*NOG?8EX#2DHPX.X%&N
MW%*&40KLX:<:V2]A@/H7!NGIW><(^)Y)K]&RPW\A-Q+I_H#YNG8874/;% U\
M0>(!$7A%9W#&%I)B[6_*-K:$",NWSB>+0_*4W%*WTL=X1.(Z * 4JXJ/DHX@
MDHTSIQ*OKSDH 3#F<KK48B+T8WHVJ8KR[-R#_?*:($VU:X<5Q7=)"/0SJA$)
M*ZT0$8F2Z9'@MB! AX$*!!0@]G=!_V<MVVRB'9KI"H X,'? 02.%V\_?L<&,
MMTM) EIP]2G-*1QGW$PB*_9-VZAJ0&!$0SEN0D3M$ U"3MG(P+/&9PF\X*=<
M."&UN/C.X[/4M-Z"H<9#D=&)Y=4?_X@O=,>SC)_-6<8YR_C19!E?$Z6N=&&J
MRG[BALR4F&%XPJV6Z$XCX9W ;=4#Q'A6$R*U:,2HQG:E@A@D,6SKBRA%)<!T
M_/@VPO/$U;6DPQ:]OJ>H4FN%>Y! ^AB2>8-=D]"=%C5+X9X- %^C#1KHPT6&
M('2N-C<(05QP*C[C<)T)@+LAFK1C)T+77%E\1L%=U^\Z>PQV7K,#YTTB$:9Z
M&\V^1FMJG.^9P\=P^,0KX&;Q\0SF ;/*#9X6H;AJ%XX:-8IIL)S#255-5U)L
MC8'/!;7W2R[RJN@7JEE"3S;P3#I%0QN,!6I"8'(JS-'K?B50WM0"K4:N:KPM
M9+*X,VUVE*U6F!(3YOU>'C"E6K\M(XTN7&##'93QAT."AY+#J(8J>K0R3H,3
M4PQ:3ISHF#_K*O#373)"KAOKQ(TO,NYWBE:O+Y^KZK.LE.2E4-S"8PR*78F&
MP,7!5147K@^8FZI=%V-0KQ%"^/R]S06E7ZK/R<4%?3Z&"HSPLUY]GA:+$TFF
MYTK<!K%P@&3DIC(@C920YSE61;3WJ:K#XN#Z)]K3WL4\<'T6N+MK\+R3Z#&G
MX!CM&*- +&!=$LA"JR6VA? V8#S1Q(Q78#F<8<6'9_OK RT-+XS'64X'?/VV
MM)L:0>M8@,"T9S_[AF=>]5U6=7$PWW/;;0E?>R3! US1=WBF<:(:V<%?*N)8
M8[ZF.YZF]FAQ74EFR=II-XUL+YRG 0:D!!P,(K%-0#/3P$'%@V![5M6RPR=E
MO:Z;Q\D/56F>$R,$L@5\MRJU!28UB=?-4S3&SL=-A@'MU+1P5H0U\TMH+U9/
M[QF7I4A@!NPTAQC>Y&=PUIL5]UVC(1]-CID+>^#@5_NLH'3L/E3<@? [-V\C
M<20 X<P P*/WA?KC:9!*#UBA<@I70 -'ZVLQ6([KWSNM<&W_(8G<43V_'&.M
M]4Q] 81:2TL?M*0#L<@*V&XVFI0&)$XK3-3\1 @<!MD''E2I !B'V_=DH4+A
M8Y.=CL>.6)0],L\4U^1$BV1*<7N2D80@Q1F9,M<5A21&L/UB'=F&W,.)$_\C
MKU%21%]"X',19I[O!F7S7=,K6N-$4"\O%&!%TM&V%?B-+V.TZV^\)[9;D!_
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MI:'9,!WC]4C881!,Z?NH"FP%_UFJX_0ZE*AG?4&6#M.>CQ Z8-TOJ'FB7 E
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M[9DP,)?0KJ749Q28YQ![2VV-=Q4'.C7>/DNE62K-4FF62O^65+*Q"8FL(.Q
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MI5%V@@0@_J]K4(P/VR88-F%.G^>M$C#C8IJT<Q"'E-O!+0\F:# ]&26&PK9
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M=D5Q7>PBNLAG<52TY%-A+0(<"23HH"=EQX$S;0P=V@AFPT0_[XASQSA0@S8
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M4617.#427]LR:P:ODW$C)$]?7%=8ERYDKD)1$T*>?51<I1&.5GN)D;@.M%E
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M>_D9G92-=/;)Y+?[RL@O02%<JN85Y2PIO&4:!,+1U4AZ7'JG!Q$ET/PXRQ1
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M-L)^-WX+E2.HUJPM-'4G52R1"8U(]*P6H#/3SB^1^50FPN3RC!\0-]AK*(2
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M D[@3EQP5V/BEA>V-/QVTA=&;MISYF2RN,-,D@X73?$\@D5%H9&XV*"2A"V
MEGL \ ?HSXTL&8:D,TQ52?V'D+X_\2^,<TL/]($ASQ#NXOCPZ#E]$GYX,;(?
MT2O<<W&Z5@V'845F71;;;;Q^.06S3W&ZUHX1_X[R<J8MF_E2P==&<=! .J;+
MP/5Q[ZHS[AK#;>3DT_71C0FY=CX'1P:\I8S!L#@=5O.AE);X6$;%A&J4D@)T
M":OHY&Y19HU6A>A?Z3 ;J^9:J4YFA%YJY.FOSE'VG(?25U6HRUA#ULG=#\A
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M\R?TG4'HTNX5/X^/PN1FGYR':<OVH$YY?'3TV]'3=6<MVW&=I1E<7%'-T"]
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MBH,:]4[8;+A=:KAJL1UOGC4)HA<2]V73[39&DY!6P^:^M-IN(+0R'HMZ[DM
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M- W3AY!!I0PZCC+>/Y(L+!L]XE//\[/Y=.?XWG5X[BS\V G26!=K*T0EF+-
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MLLUP0>A"R_>'F4/8)D;]&3R?^W&,T/H@*\JX_ @#^.-U@C\&#,"  >@'!F"
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M62:O =--5;:F9]V6]2JH7SV69=. 9>TSSG9-B^D=I.$:9^F@2-N\ND0'9=,
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MSEJ=C_@.$6:"Z)Q)G=&(015EJC"4#&BY;LZ6,BV3%0VHI=QC<Y^2: E?3L
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M=US)MNR>WG;O[IPHZ]&C.;)+5Y*[SV['C0FJ"B5Q!D74D"S9FD]_\2()LOC
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M)=,UF\0ZJ5@%P0ZJ4W7_#=//%##$ZEH-%R]IRKK#^OX3Z,Y/;Z?;P@CU#"_
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MFG] FF=]JA0M'O!6XN#A6?6*+VBQQC!,4!-0;*;6>8"'E' #OU&V@/%5[[I
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MT4R\I<1_%#OYG9ASYPJ]8@OV&;\0<)[E\986GM8/OIGL0(P)_)Q&22Z6]L6
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MD)3YD6C.3EF!@A<HF3D(&)/MHK M$V%U=VS[I";'G(=6H$>W@^KGN84(@,D
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M&,P0=G-?=W0QZ0.,_QHG#T57W^O'*-U&*[C/XU6$3O%5OM8\#% G:+@_K<K
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MTY)0WA-"FQ/Y49Q2CBGK8@G^FW'ZQ' 0#',^TK*(_4#=C+A8.4PD/3?T6U1
M\"LFQ,BO28I\@@$1/14_HA]/"$NJ/<*=#(<($YY"VD[Q#2"<;&'ZNP_GM/H^
M@<TL<[CT>MACQ>U"Z3VD5_RT"XA^0UBP5U^KQYUQJG.1QP:7:9YMQM6)MXMG
MM:I+B++!4Q=L2 4B22SA,AZ9]$2CP?9@FF;Z9$+<8PI0>=/'W+S[*4TUX3[*
MCLV4]C#C?.NK2%=>FN(HB&?F-JS2*29%*+_%^0NQ79TKOF,4IN8W;8I.3>?
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M# /OAW26PK"A,#[V8'&_*N@\>V\O"=C_US":]C$UXR1U:UPFDY0L$689<>
MW4&C-'*,TJ3#P@'*3FRM8@0RF![CT)M'!-7@PGK*\QN:CFA6H4.9+=J[C LU
M;0$V1FEJ=ZT^RH[ZF_GA*8KPG#4W&U:6WU @"04@_$5K7>5RCIGF)$[\P[5K
MG/5N"TI0SENV22M"/QQ(RW><N<T\'F/D*QJC&&S0:W5 !YP1\8]R*E.M8H2)
MG2R5\M 6*J\PW4O+S6I0WW!B>+RE2G7:CKD:%Z?'8+0.!9#9DSX%"^I]@0HE
MD)#_>73B888Z-M?['/T"V5PIN3V1(31_:D"%VL048I"Z@S1"#HDU0^_Z5FK@
MV$[Y%#2ZGEC3M>U( \U5&6@Z-B"M;6?-.<[VQ$UC*>7=W(RLV%/372C[%;WR
M7X-WL:_4:7$Z<4:=IGFT4>7AJDMV;;5Y\.Y?>JP-*S95[5H@+%VR>AN"<)6V
M-[OGD27V;%Z*)$I/DWUPG-;$F7Z ]N7OW*B U)[(1Q7F.R"-Q(MST_8;*_FD
MJ^T/W(KL2E'=<9]P48CPPC?ZV2G9YR"CIZA[FB"Q5=LU8L& _.OQ[1F&>)O0
MY].>8!IC\KDLSR8T%;<J@(UNU18%<MNNO*HA*24MCSB9K$ 6%M32TN_5\@(N
M,& 2^]KAW(6%=K9#MP[\15HC\L 0'3U-'>(]?,F#G#4*O2\%U>W)/DAFRD/)
MO63M1QG.#%3<@&#G1VQ000IKJ,YC5- ((,LT6.\9MGYK]1%"UH%QU4Y]G0[3
MWTA=07U>8S/N-LLT37^&&22X[:Z3Z L\0H39!?.R:%"_#9H2.7.@%,@[*$(L
MF;)#XJAFZUE3-!TDL8%*5X ::@%&=[LDCM7CB@MU3'N!B-#<_@D3F+)+,]?1
M/DYH475 CXA%I:Z^UVD2GK *T&%D!],C3#>X7FUR 3Z!+1>!^630$,(SMS0#
M'4_2^:H 1@UD0<F:=W9I EN5LB_DOW96OO<F[1&MLYY^+<F2* YVI*A$5YN.
MM7Z:DM'QO&MS O+GGH(3^_'UKR"-/C6_1N7UL&&C*VOLN.)F%>H+L[PR?%G?
M<5*R-S?EH5Q &'4KN(S"6K6BBA0GE"4J<; ?:_@Q2I;C\&<924(9Z[*DPX^
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M5*##&KKT&"8Q13&':4Q.BK@LDQ3WS>CGYPDV4F %;@[3EU'NCLZP1C*6D5T
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M&6X+1%$_L3/D,Z[:K0:L\#+M-CJ=MYO>K^4)FBP8J$J TDJT\M;PN=EZU=W
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MEYO&Q%1KTV.W 8#MOHYX&)O9DE\ &I&'+*];I\$0UB<3SE8#169#;:N*4_U
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MJ?:.YK"97:($<&K%E#4.G-D5C2# R:OH&9HGX^6AY!7' 1TOC0:/? [C>*M
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MB0-+Q)UF530DO:DKY.%EUJPX$]/+)<&KG(069Q)"4J/'-7F:["]O\G2A2+(
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MTR+*X8/K$%6TU)WC*\N>UYZQ9D=8< A%)V)GGS944$&4N]EG5Z]N$#(H-Z=
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M9APFT9BY'?^,'R@ "\M&41BWX-ITP\5$GGNY4;34K*;W!5XC>I/&"E8S(2)
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MZF<_('K&XZ+P<BUTE0^M)9\+>1[K8HY\1&(?T)FS8$4@J=0,W17:F(WAF85
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MR51XL(OFWU,Q&.A_ZY/A5W8\^(Z8)O*M_LL[D R#= R4 @8<?2'&/V@OZ,M
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M4MNH6&3M;!;T29$%VT;M@DAV_$1-PNF+Q"<IB^J6)U$J)BQ+[^%SJ C',DG
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MW,>YX.J/\$9%[U=*5;E?$]WI:52QM&?KBTMQ$%O(,OMJ@<Q\4AE[$=+%TH[
MNEMD3%ASE099K FVX$$WEMY$X!V#>_JOS(_9!2>"A U311\GZJLB<&XO:'BW
MWA%'+N>IB,4(>/MXUV&@7M&MV8!64 9BR4'H*A?FG? #6H[Q2?+3UL3XIQ>6
M*_3$N$*WRM.L?&A[E^?J7 SU4#* 29*[=!"+>V<0W8?DV8QB<JE.X599<?>6
M4Z&X=^@B+UG4-J^8YBZNI35%*%3<1/U<<>-%<.=5,B@#W$.)"%H1/^!LAEG
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M3^&N7A=*9+0ZX9HZQ*975>*<"M28L)/CS5C$4\XT_83%.T+GOS,!S$GZ7-^
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M]RHV5=A0Z-B7Q]6OJYON%H:+8EWMK7"R?.#JTZIF^P,U8M;%O.<,T,F!)>3
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M:*ZNF%B'YGI6:*Z-%MME82?ZP-;1QZOT9]0GV\F/Q[CG.C_#)F))E$;P4:O
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M0ZZE!J-_B67 =*%TJNSB2<2%%GI![#KDS3>I%L;FY8QJ:H;G<_G:2"<K,,!
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M7.49(9(Q@=Z&:B<4+F%( 5;+Y6+3NCX&.J?RZ@!YDHF"V5":25Z4P.0!96&
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MJ&G9C?1=4O;E>,-*'6!],;,1W\BMH<XJ<FL2+Q8\L*V0KZG 5%& J:LQM_V
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M)4G".H0&A$]9=H05I!?^ P_JC#MD0PF/M/M$2^PEOZ1^ @O)\<[<#SA&H<#
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M Y_9Z-R@@D+W5HG/^% V)3X3.@W$Y_A*Z9 ($55U.50Q'#O&-_,@$R(_4GM
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M/ 0)Q3]=/L5_0MM!:Q&_'[3X'L_<I!=,MH27*=Q7E3.210*T*&T!&R(*8R&
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MF#I5>Q G3NU&A]42+!\0!GM[=0V*)\E)2<$\ZMC?\''A^DY4CI8>EF+)A^+
M"E'0A2.-?B2)V0UMJ>UO("A</IXB=-W,BJ@VM_JDM-8"20UFFM&YL,$LRB4C
M18G6 5[%LS,.8X0/POTX=)_42F:\$B.!A6_-?=#IU*#JR7=&7TL->U+:8Q4
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M7#4-CX&K8_Z7SL35,3]/S[LZ9E?'[.J8G8/SO#+FDUZFK4J6#% T"H)T33%
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MZ+WAZXS#/Q>@\-&"5G:]I&(@+B!X3N$0DMV>B 6U"-7Z/.<W7/IS=@Y]SI6
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M-"FP(\@0$>$**.HK_)Y4];-N)Q &Z=H(;\U""COA'"D -9=WS@VH(9;QDE1
MROU4B#\EY60BEF(NN0KE%.O&1@]-\5$&MC$2M)S)AA]&A<(TVCQPMV<6V-Y+
M  >Q@P'H.@8X$_/L3<RS[;R&Z(A>IVNC11RT)Y/.9%CM+)3;F/65G</.B_KD
MB.0^K+GVNY9CY41DA71'5J.7Z5>JXVQ*PJ+?]XW(3HQ:@=U(14@%/D62P7?7
MM#$JJ1XK3R11;( ^B$!'E+DI< 3U7 L'X0VPDP5@_SR?.[ NLW5&=BZU(*![
MY')@X3U1.!:(!92UL*V OW DZJKV\TI[6W6\_11S6]M4.2+F,OF27U1QB^8D
M7\W4:K->P:=>:4_N)?CEG4G'"C?CW_IVWESXK=NQP]3:X*X.!P-;%Q;Z;62!
MAZK?QIU.S?O@MVZ5WI?):R?]_J!M'TM_,ASUJ^*=/?+Q>-2=V#SR?@\F-QA5
MXPNYQJ@O&AYVBTF<\8MBX-PNONPNOGWWX?H#YKT^N8S74=BXQVEYC\\TXX7F
M=;_?'PT'6ZSK^BIC:[=/_*9'DT'?]KUWP9COMJVQTFY_!+)L8O, NMW.I-MM
MVU[&/TT.%_;];;5(\"&_^AO$(1W6N/]0X,2D* TB>XIEKF %/L08TH"!+-',
M5&6VZN]+?X-F6VXY"SAE$5E*;+%R4 (#)=C0J^)'^)O<AX E>(7&8XM:C21B
M ;/B[A[4>B018)N28%SQ>BBCV%]B=TXRS1[ASYM7"WP='+\0#<<YBL D]2[^
MW^Z@!6N!_^\2&=/%5VFA^8)[J-IG<EC=17F<KME#UYQO(G'0&4RZ/7N'Q\Z@
MUQW459Z!&JJON+5VTQCT!YW1J-<^F&;8\O1R'\4C5AXZXJW5AX\P"0PX%+(%
M*ZI"YCP4OZ?2P@G[0CV(O*%$>14^<&2>HRL8MX]4C$5=RL5YE=J\6GW%T-R$
MJ8_FK/%VU%_X2@>$[PX<$-X!X1T0W@'A'1#^*S>RL)6%%[H$?Z8]/J3M8%B<
MAX%H8'@>J3:^BC?W%8PKY=7]O;%'M\^W*+\)-B+^TO3+G$RNQI/BMUGX'#NC
MJ_Y_>VU^?(6?NX.KR63;[\.KWGC+[[WV5:=K_/XW'H0<"0P69@R3ZO]%?_/+
M8#X/!8B>'WZ\^>7G7S[^C[_\/S^\>3.\O?U++M!I45ZA5/O[X*H/>Z#^])'.
M2_%OGZ4<4/_^(9?C<OE)5*1Q&,R]]M5H ,:PVFIU@10O6Z^AX6R]@M2)_9(Z
M,6<MA;&H(/E/&@/^NZB3\ ^5#ZKV4#=26OMJ*!9/(%+HX^]T7E?L?OF!IH9[
M6SPU6T[*F]O;Z[=#=U(.>U*JJBRW,ZI*VVW+5]H6XSN4<,R]/^D=/N";FX_C
MD@'BSL$YGH/_>?-QT.@@D _@3L%W>0H^BE4(/AS%QFK/@EU]\[%PA^ 9A^!Y
M)MP!XPZU3M96Q>#V_GO8>XI7NGUV^^SVN=D^=]KC\DZ_ZG2Z5X,CWFY6X0Z:
M<"0@@&.%)IQM <IPT.U/>OTM,+AZ4MSA_J2X%9Z[(!3I&AG@\BC:"\;6'83I
MR,_HMCB=$YQ',ZH+__)<!>=@/)R,>VU;-<&HBQ#AG@VWBQW?^OTJW(M^&O9'
M8VLI <CHP;C;L<&'![UQ?]!NQO]0Z7#TW_WEZO6;2L,<)8NM,KC\D*NO.;\2
M1 I+K@FNH>!0B,25>D0"GU);DAGT/9:B4Z%<7B+GS^X#\< AH6)57KDH$/Y2
MJ F40+ B1"L?"CR4'YF_JU)TA_@LJOXJ%V$W+JD^GM3L\&JT+;4ZZEUU>UM^
M[\#CQT^G7GLN]7IFJ5?Z:%7V]4GAE7]2JX:!79?X^:Y#_A_B*Y?P.\-]SWW+
MVX?:V+[+]9W# :BF=UR*[R7W_MMXI9UMG_@9;JK=U?Y.DSIGN\OGE=%Q$OL9
MV_ZJ?579]V\MM+ON<W9"^^QVV0EMM^VG:F;WW+?L)/;9[;*3V&[;&VY[=W U
M'E0VOM>^Z@V^L>CNNX_:B>ZSVV4GNMVVG[SH'KB/VHGNL]ME)[K=MK^(Z&X
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M-*_D&H=H)#W$N+CZ=8LX#.-'="/0GPA6]'S2$*7M@&&E,9K^*5SIIW$$K][
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MH-\;MCM5@F(*SPXGW7:WSH@"^ZH"J,SMJ_UMJ+)S^-LJ72<"U)B*VMW$Z?K
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M58@ 3$7H+3-DJPXEVDLW'='%2PS=TA "M/QAT:;8NU6W7-E00O]>A'2["49
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M,(Y@IL.85H&^3*_"'M*J&"$4L\AD>(4WK!#8(4CT<0P>KZX0CCSBJ/D3,88
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M.)AKJ\M5IPK9I+W)O8:FNL8\&TRP:96\[G"[1QNJ/<J!BME'ZMJ$:2AY2.@
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M@<PID_[=>9I';=8[3_,4A/]Y)0]V<@MOP$>+*<9Y^R5(U\BZ2=+NU_C1WAG
MDB.0H$L%R"&B?WXJABOG&=9&)'=^!(.<MVC1YQ2TA/<1DI(K)+R[.)Y[&FV9
M@W1#_U$+YC^R)$CG@08,RGBO[.^F7JN8+Q"+M,BH8YB:Y0KGQ<'#;'T?)](=
MY1<1?8$.7%,]!Z('5=N9-85<">?+3TA3D0>A9Z!9-M@G *^;8AD-<JWXJ1P=
M?.F2NP,AO-E,T2?XA!Y=8^347QLH*T,=Y!6(!5SS7>)SE88G6T"G_"?=\TXW
M '%,XD?]Q3HE<A)*Y*S"E3LID>N"*/TA8 FN)5@S-8*@4% E*+,9WKF'R*:
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M1"#I0+11,26H]8)11?**;#JNO,QYYT%0"B2XQX8F]58:/0]D)&/!9F U*4-
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M.M.WT]_2UVM1:+.Y3BT*O0Y1Z'TE5SQ*%$J+:R(I'>D"CD\3@EB>,9+K?DC
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M.V!EIQ2:'H?6+_6*EZWXZ.QX^/EL=#(Z(MG/D.->(;6L+0?/:SEHM]KOU7+
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M6;#[(I4%7]OR7 \O/UN#LV,+_S$Z&UR/SL_>=]&[33$C_$S#0?<E"MMMC*D
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ME]FAR09-AFVN&$[BM#1IZ\C/Q_2E0]>Y_2@9_V466RG8BEZ#T-]44C^O@1)
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MG=;!RF!VJ[SU$2>)0HB<=6G3#TJ**PU]JJ#;LL).3EIB\WYI^%2<BES2^:_
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MR( ?Y'90>A"%,(=BGC =KN-]=GMUO$\=[U/'^]3Q/AL6[[/1HLTZY 8*VN4
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M1L[U"3/+FS-LHTO3[J;,(^;FT(D/ T=@74 W%)3YIEQ+F:UGHU7V5N"B<1%
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MOT?6"/^=*WDIF>/=8 .>^"Y"!XYV"RZ(IJ_Z'$)O"[AG++<E4CR+E7AFIU_
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M7ZD$?<)V@.W3(*"C?@7R"CF6HF*83[D 3'<WY'0K93*+E'UAVY/M1KI=]//
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MW5YV1",76.CE;3#N\'O;#4 8+D31[J8BX%$!?%,!?X 7S6B3W<XK[U>0X-$
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M55\56 <WZ04%['M@Z>&#L,]B#<,<RMN++]+CK/WA?)RU/]#_#U!+ P04
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M+FAT;5!+ 0(4 Q0    ( (R!"5/SXZS3&1H  !0Q 0 1              "
M 0>$ P!F9V5N+3(P,C$P-C,P+GAS9%!+ 0(4 Q0    ( (R!"5.YW'S)IQ0
M #Q( 0 5              "  4^> P!F9V5N+3(P,C$P-C,P7V-A;"YX;6Q0
M2P$"% ,4    " ",@0E3WS-[<S<T  #:! 0 %0              @ $ILP,
M9F=E;BTR,#(Q,#8S,%]D968N>&UL4$L! A0#%     @ C($)4X<C2@8MAP
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M>#$P,E\T,#@N:'1M4$L! A0#%     @ C($)4PW6#487 P  5!8  !$
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-  P !@,  'M[!@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
